id,overall_status,study_type,phase,sponsors,sponsors_class,start_date,completion_date,primary_completion_date,primary_purpose,enrollment,condition,location_countries,gender,age,intervention,primary_outcome,title
NCT00571389,Recruiting,Observational,,"BioCytics, Inc.",Industry,7-Nov-21,25-Feb-21,25-Feb-21,CASE-ONLY,1000,"SOLID TUMOR, ADULT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,,"A Study to Facilitate Development of an Ex-Vivo Device Platform for Circulating Tumor Cell and Immune Cell Harvesting, Banking, and Apoptosis-Viability Assay"
NCT01306084,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,15-Mar-11,,,OTHER,1000,ANOGENITAL HERPES,UNITED STATES,ALL,"Child, Adult, Older Adult",,"SAMPLE COLLECTION, ANALYSIS OF IMMUNE FUNCTION, OR REVIEW OF TISSUE BX OR CLINICAL RPTS FROM OUTSIDE LABS IN DESIGNATED POP. W/ VIRAL, SUSPECTED, OR RECOVERED FROM A VIRAL INFECTION OR A CLOSE CONTACT OF PEOPLE W/OR SUSPECTED TO HAVE A VIRAL INF...",Viral Infections in Healthy and Immunocompromised Hosts
NCT02735707,Recruiting,Interventional,Phase 4,MJM Bonten,Other,11-Apr-16,23-Dec-21,21-Dec-21,TREATMENT,7100,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID",AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",FIXED-DURATION HYDROCORTISONE,ALL-CAUSE MORTALITY,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"
NCT02765191,Recruiting,Interventional,Not Applicable,Uppsala University,Other,16-Apr-21,25-Oct-21,21-Oct-21,OTHER,20,"SEPSIS, SEVERE",SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",PLASMA EXPANSION WITH RINGER'S ACETATE,CHANGE IN RENAL BLOOD FLOW AND RENAL OXYGENATION AFTER STANDARDIZED PLASMA EXPANSION WITH FLUID BOLUS,MR-Evaluation of Renal Function In Septic Patients
NCT02788903,"Active, not recruiting",Observational,,Milton S. Hershey Medical Center,Other,16-Mar-21,21-Feb-21,21-Feb-21,COHORT,2000000,OBESITY,,ALL,"18 Years and older   (Adult, Older Adult)",WEIGHT COUNSELING,WEIGHT CHANGE,A Patient-Centered PaTH to Addressing Diabetes: Impact of State Health Policies on Diabetes Outcomes and Disparities
NCT03042143,Recruiting,Interventional,Phase 1/Phase 2,Belfast Health and Social Care Trust,Other,7-Jan-19,22-Oct-21,20-Sep-21,TREATMENT,75,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",HUMAN UMBILICAL CORD DERIVED CD362 ENRICHED MSCS,OXYGENATION INDEX (OI),"Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)"
NCT03183570,Recruiting,Interventional,Early Phase 1,Stanford University,Other,8-Nov-17,14-Apr-23,14-Apr-22,DIAGNOSTIC,30,IDIOPATHIC PULMONARY FIBROSIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",[18F]FP-R01-MG-F2,"SUV MAX COMPARISON : IPF VERSUS HEALTHY LUNG, PSC VERSUS HEALTHY LIVER, COVID19 VERSUS HEALTHY LUNG","Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CT"
NCT03188796,Recruiting,Interventional,Phase 3,Medical University of Graz,Other,10-Oct-17,23-Feb-21,22-Dec-21,TREATMENT,2400,CRITICAL ILLNESS,AUSTRIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CHOLECALCIFEROL,28-DAY MORTALITY,"The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)"
NCT03226886,Recruiting,Observational,,Royal Marsden NHS Foundation Trust,Other,5-Feb-12,1-Sep-23,1-Sep-23,OTHER,360,RENAL CELL CARCINOMA,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,TO VALIDATE ITH INDEX AND WGII AS STAGE AND GRADE INDEPENDENT PROGNOSTIC MARKERS OF PROGRESSION FREE SURVIVAL IN PATIENTS WITH CCRCC MUTATION IN A GENE OF INTEREST,TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)) CAPTURE: COVID-19 Antiviral Response in a Pan-tumour Immune Study
NCT03256773,Recruiting,Observational,,University of Alabama at Birmingham,Other,15-Apr-16,31-Dec-22,31-Dec-21,COHORT,60,CYSTIC FIBROSIS,UNITED STATES,ALL,"14 Years and older   (Child, Adult, Older Adult)",,FEASIBILITY OF UOCT PROBE,Imaging of Human Epithelial Airway Using a High Resolution Micro OCT Catheter (Functional Anatomic Imaging of CF Patients With Early Lung Disease Using Micro OCT)
NCT03305341,"Active, not recruiting",Interventional,Early Phase 1,"Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair",Industry,18-Jul-20,28-Jun-21,28-Jun-21,TREATMENT,20,COVID,UNITED STATES,ALL,"22 Years to 72 Years   (Adult, Older Adult)",COVID-19 THERAPEUTIC BIOLOGICS - SPIKE-GM-CSF PROTEIN LACTATED RINGER'S INJECTION,NUMBER OF PARTICIPANTS WITH MODERATE COVID-19:,"Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients."
NCT03331445,Recruiting,Interventional,Phase 2,Chris Miller,Industry,24-Oct-17,31-Mar-21,31-Dec-20,TREATMENT,20,RESPIRATORY TRACT INFECTIONS,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",NITRIC OXIDE 0.5 % / NITROGEN 99.5 % GAS FOR INHALATION,MEASURE THE SAFETY OF 160PPM INHALED NITRIC OXIDE DELIVERY IN NTM SUBJECTS,"An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults & Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections"
NCT03348670,"Active, not recruiting",Interventional,Early Phase 1,"Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair",Industry,20-Jul-20,28-Jun-21,28-Jun-21,TREATMENT,20,COVID,UNITED STATES,ALL,"22 Years to 72 Years   (Adult, Older Adult)",COVID-19 THERAPEUTIC BIOLOGICS - SPIKE-GM-CSF PROTEIN LACTATED RINGER'S INJECTION,TEST MACROPHAGE MIGRATION INHIBITORY FACTOR (MMIF),"Conducting an Initial Small, Controlled Clinical Trial to Assess for COVID-19 Therapeutic Biologics Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients."
NCT03376854,Recruiting,Interventional,Phase 2,"University of Maryland, Baltimore",Other,1-May-18,31-Dec-20,30-Nov-20,TREATMENT,20,"RESPIRATORY DISTRESS SYNDROME, ADULT",UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYPOTHERMIA,TARGETED TEMPERATURE COMPLIANCE,Pilot Randomized Clinical Trial of Therapeutic Hypothermia Plus Neuromuscular Blockade vs. Standard of Care in COVID-19 Patients With Moderate to Severe ARDS - the Cooling to Help Injured Lungs (CHILL) Pilot Study
NCT03452774,Recruiting,Observational [Patient Registry],,"Massive Bio, Inc.",Industry,1-Jan-18,22-Dec-21,21-Dec-21,COHORT,1500,"CANCER, METASTATIC",UNITED STATES,ALL,"Child, Adult, Older Adult",CLINICAL TRIAL MATCHING,PROPORTION OF PATIENTS ELIGIBLE FOR CTE VERSUS ACTUAL CTE,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03474965,Recruiting,Interventional,Phase 2,Novartis Pharmaceuticals,Industry,1-Oct-18,20-Nov-24,5-Jun-23,TREATMENT,100,SICKLE CELL DISEASE (SCD),BELGIUM,ALL,6 Months to 17 Years   (Child),CRIZANLIZUMAB,PK (AUCD15) AFTER 1ST DOSE,"A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis"
NCT03680274,Recruiting,Interventional,Phase 3,Université de Sherbrooke,Other,8-Nov-18,31-Dec-22,31-Dec-21,TREATMENT,800,SEPSIS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN C,NUMBER OF DECEASED PARTICIPANTS OR WITH PERSISTENT ORGAN DYSFUNCTION,Lessening Organ Dysfunction With VITamin C (LOVIT)
NCT03708718,Recruiting,Interventional,Phase 2,Prof. Ariane herrick,Other,21-Dec-17,21-Sep-21,21-Jun-21,TREATMENT,72,SYSTEMIC SCLEROSIS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PREDNISOLONE 5 MG,HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI),"A Phase II Randomised Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis (Initially Double-blind, Then Switched to Open-label Because of Covid-19)"
NCT03738774,Recruiting,Observational,,Vanderbilt University Medical Center,Other,2-Jan-19,22-Jul-21,21-Dec-21,COHORT,200,POST INTENSIVE CARE SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF DEATHS OR HOSPITAL READMISSIONS WITHIN THREE MONTHS OF DISCHARGE,Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)
NCT03808922,Recruiting,Interventional,Phase 3,"Ansun Biopharma, Inc.",Industry,23-May-19,28-Dec-21,30-Apr-21,TREATMENT,274,LOWER RESPIRATORY TRACT INFECTION,AUSTRALIA,ALL,"Child, Adult, Older Adult",DAS181,PERCENT OF SUBJECTS WHO RETURN TO ROOM AIR (RTRA) (MAIN STUDY),A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
NCT03852537,"Active, not recruiting",Interventional,Phase 1,Mayo Clinic,Other,2-Dec-19,15-Mar-21,17-Nov-20,TREATMENT,44,PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,FEASIBILITY OF THE TIMELY INITIATION OF CORTICOSTEROIDS AND IMPLEMENTATION OF BIOMARKER-TITRATED CORTICOSTEROID DOSING: PERCENTAGE OF ELIGIBLE PATIENTS ADHERED TO THE TIMELY INITIATION,SMART Trial: Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
NCT03871491,Recruiting,Interventional,Phase 3,NICHD Global Network for Women's and Children's Health,Other,1-Sep-20,1-Sep-23,1-Sep-23,PREVENTION,34000,MATERNAL DEATH,BANGLADESH,FEMALE,18 Years to 45 Years   (Adult),AZITHROMYCIN,MATERNAL: INCIDENCE OF MATERNAL DEATH OR SEPSIS WITHIN 6 WEEKS (42 DAYS) POST-DELIVERY IN INTERVENTION VS. PLACEBO GROUP.,Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial
NCT03891420,Recruiting,Interventional,Phase 1,BioCryst Pharmaceuticals,Industry,9-Apr-20,31-May-21,31-May-21,TREATMENT,132,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",GALIDESIVIR,NUMBER OF SUBJECTS WITH TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS,"A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19"
NCT03907891,Recruiting,Interventional,Not Applicable,University of Illinois at Chicago,Other,1-Aug-19,23-May-21,23-May-21,TREATMENT,225,ISCHEMIC HEART DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MOTIVATIONAL SOCIAL SUPPORT FROM NURSE,ACTIGRAPH GT9X LINK ACCELEROMETER,A Randomized Controlled Trial to Reduce Hopelessness Through Enhanced Physical Activity in Adults With Ischemic Heart Disease
NCT03944447,Recruiting,Interventional,Phase 2,"OMNI Medical Services, LLC",Other,1-Dec-18,31-Dec-25,31-Dec-25,TREATMENT,200000,CHRONIC PAIN,UNITED STATES,ALL,"7 Years and older   (Child, Adult, Older Adult)","CANNABIS, MEDICAL",PREVENTION OF COVID-19,Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
NCT03963622,Recruiting,Interventional,Not Applicable,Unity Health Toronto,Other,23-Nov-20,22-Nov-21,22-May-21,TREATMENT,740,ARDS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",RESPIRATORY MECHANICS,ALL-CAUSE 60-DAY MORTALITY,Careful Ventilation in Acute Respiratory Distress Syndrome
NCT04025580,Recruiting,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,2-Oct-19,31-Dec-25,31-Dec-25,BASIC SCIENCE,300,HEALTHY VOLUNTEER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FLUCELVAX,MICRONEUTRALIZATION TITERS,Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
NCT04061382,Recruiting,Observational,,University of Oxford,Other,15-Oct-19,30-Jun-21,31-Mar-21,OTHER,3800,SEROGROUP C MENINGOCOCCAL MENINGITIS,UNITED KINGDOM,ALL,"up to 24 Years   (Child, Adult)",VENEPUNCTURE,FEASIBILITY OF DEVELOPING AN ENGLAND BASED SERO-EPIDEMIOLOGICAL PROGRAMME IN 0-24 YEAR OLDS,Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020
NCT04107402,Recruiting,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,15-Mar-19,15-Mar-24,15-Nov-21,BASIC SCIENCE,150,SEPTIC SHOCK,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)","ASSESSMENT OF COAGULOPATHY, PLATELETS ACTIVATION AND PLATELETS-NEUTROPHILS INTERPLAY",PLATELETS ACETYL-COA CARBOXYLASE PHOSPHORYLATION RATE,Prospective Evaluation of PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock Patients. Impact of Platelets Metabolism to Inflammatory Response.
NCT04148430,Recruiting,Interventional,Phase 2,Memorial Sloan Kettering Cancer Center,Other,30-Oct-19,22-Oct-21,22-Oct-21,TREATMENT,90,B CELL ALL,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,ARM 1 (CAR T CELL GROUP) RATE OF SEVERE NEUROTOXICITIES,A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells And to Treat Systemic Inflammation Associated With COVID-19
NCT04160975,Completed,Interventional,Not Applicable,Harvard University,Other,20-Dec-19,19-Feb-21,19-Feb-21,HEALTH SERVICES RESEARCH,2902,"FLU, HUMAN",UNITED STATES,MALE,18 Years to 51 Years   (Adult),VIDEO ABOUT SAFETY AND EFFECTIVENESS OF ADULT SEASONAL FLU VACCINATION,POSTERIOR BELIEFS ABOUT THE RISK/BENEFITS OF THE FLU SHOT,Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
NCT04169542,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,21-May-19,31-Mar-22,31-Mar-22,COHORT,600,BREAST DUCTAL CARCINOMA IN SITU,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ADMINISTRATION,PREVALENCE OF FINANCIAL TOXICITY,"Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain"
NCT04233268,Recruiting,Observational,,Cambridge University Hospitals NHS Foundation Trust,Other,6-Apr-20,28-Feb-25,28-Feb-23,COHORT,250,LOWER RESPIRATORY TRACT INFECTION,UNITED KINGDOM,ALL,up to 16 Years   (Child),RAPID PATHOGEN DETECTION,PERFORMANCE OF THE NOVEL PATHOGEN DETECTION ASSAY,RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study
NCT04240886,Recruiting,Interventional,Phase 2,Amplyx Pharmaceuticals,Industry,4-Jan-20,21-Oct-21,21-Jul-21,TREATMENT,50,INVASIVE FUNGAL INFECTIONS,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",FOSMANOGEPIX,ALL-CAUSE MORTALITY,"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds"
NCT04244591,Completed,Interventional,Phase 2/Phase 3,Peking Union Medical College Hospital,Other,26-Jan-20,13-Apr-20,13-Apr-20,TREATMENT,80,COVID INFECTIONS,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE THERAPY,LOWER MURRAY LUNG INJURY SCORE,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial"
NCT04245631,Recruiting,Observational,,Beijing Ditan Hospital,Other,1-Jan-20,31-Dec-20,31-Dec-20,COHORT,50,NEW CORONAVIRUS,CHINA,ALL,"1 Year to 90 Years   (Child, Adult, Older Adult)",RECOMBINASE AIDED AMPLIFICATION (RAA) ASSAY,DETECTION SENSITIVITY IS GREATER THAN 95%,"Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV"
NCT04247620,Enrolling by invitation,Interventional,Not Applicable,Baylor College of Medicine,Other,15-Dec-20,24-Jun-21,24-Jun-21,SUPPORTIVE CARE,186,TYPE 1 DIABETES,UNITED STATES,ALL,"17 Years to 35 Years   (Child, Adult)",DIABETTER TOGETHER,GLYCEMIC CONTROL (HBA1C),"DiaBetter Together: A Strengths-based, Peer Mentor Transition RCT for Young Adults With Type 1 Diabetes"
NCT04251767,Withdrawn,Interventional,Not Applicable,The Second Hospital of Nanjing Medical University,Other,5-Feb-20,30-Apr-20,30-Apr-20,TREATMENT,0,COVID COMPLICATED WITH REFRACTORY INTESTINAL INFECTIONS,CHINA,ALL,"14 Years to 70 Years   (Child, Adult, Older Adult)",WASHED MICROBIOTA TRANSPLANTATION,NUMBER OF PARTICIPANTS WITH IMPROVEMENT FROM SEVERE TYPE TO COMMON TYPE,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study"
NCT04251871,Recruiting,Interventional,Not Applicable,Beijing 302 Hospital,Other,22-Jan-20,22-Jan-21,22-Jan-21,TREATMENT,150,PNEUMONIA CAUSED BY HUMAN CORONAVIRUS (DISORDER),CHINA,ALL,"14 Years to 80 Years   (Child, Adult, Older Adult)","CONVENTIONAL MEDICINES (OXYGEN THERAPY, ALFA INTERFERON VIA AEROSOL INHALATION, AND LOPINAVIR/RITONAVIR) AND TRADITIONAL CHINESE MEDICINES (TCMS) GRANULES",THE INCIDENTS OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) DEVELOPMENT,"Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial"
NCT04252118,Recruiting,Interventional,Phase 1,Beijing 302 Hospital,Other,27-Jan-20,21-Dec-21,20-Dec-21,TREATMENT,20,COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MSCS,SIZE OF LESION AREA BY CHEST RADIOGRAPH OR CT,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19
NCT04252274,Recruiting,Interventional,Phase 3,Shanghai Public Health Clinical Center,Other,30-Jan-20,31-Dec-20,31-Aug-20,TREATMENT,30,"PNEUMONIA, PNEUMOCYSTIS",CHINA,ALL,"Child, Adult, Older Adult",DARUNAVIR AND COBICISTAT,"THE VIROLOGICAL CLEARANCE RATE OF THROAT SWABS, SPUTUM, OR LOWER RESPIRATORY TRACT SECRETIONS AT DAY 7",Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
NCT04252664,Suspended,Interventional,Phase 3,Capital Medical University,Other,12-Feb-20,27-Apr-20,10-Apr-20,TREATMENT,308,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,TIME TO CLINICAL RECOVERYTIME TO CLINICAL RECOVERY (TTCR),"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19."
NCT04254874,Recruiting,Interventional,Phase 4,Tongji Hospital,Other,1-Feb-20,1-Jul-20,1-Jun-20,TREATMENT,100,2019-NCOV,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",ABIDOL HYDROCHLORIDE,RATE OF DISEASE REMISSION,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia."
NCT04255017,Recruiting,Interventional,Phase 4,Tongji Hospital,Other,1-Feb-20,1-Jul-20,1-Jun-20,TREATMENT,400,2019-NCOV,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",ABIDOL HYDROCHLORIDE,RATE OF DISEASE REMISSION,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia."
NCT04255940,Recruiting,Observational,,Qilu Hospital of Shandong University,Other,20-Jan-20,30-Apr-20,30-Apr-20,CASE-ONLY,12000,CARDIOVASCULAR DEATH; MAJOR ADVERSE CARDIOVASCULAR EVENTS,CHINA,ALL,"Child, Adult, Older Adult",,CARDIOVASCULAR DEATH,Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China
NCT04256395,Completed,Observational,,Beijing Tsinghua Chang Gung Hospital,Other,1-Feb-20,1-Jul-20,1-Jul-20,OTHER,102456,SUSCEPTIBILITY TO VIRAL AND MYCOBACTERIAL INFECTION,CHINA,ALL,"Child, Adult, Older Adult",MOBILE INTERNET SURVEY ON SELF-TEST,POSITIVE NUMBER DIAGNOSED BY NATIONAL GUIDELINE IN THE EVALUATED POPULATION,Registry Study on the Efficacy of a Self-test and Self-alert Applet in Detecting Susceptible Infection of COVID-19 --a Population Based Mobile Internet Survey
NCT04257656,Terminated,Interventional,Phase 3,Capital Medical University,Other,6-Feb-20,10-Apr-20,30-Mar-20,TREATMENT,237,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,TIME TO CLINICAL IMPROVEMENT (TTCI) [CENSORED AT DAY 28],"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19."
NCT04259892,Recruiting,Observational,,"Institut National de la Santé Et de la Recherche Médicale, France",Other,4-Feb-20,4-Feb-21,4-Oct-20,COHORT,345,CORONAVIRUS,FRANCE,ALL,"Child, Adult, Older Adult",2019-NCOV PCR,"TIME TO SARS-COV-2 NASOPHARYNGEAL EXCRETION, FROM THE DAY OF THE FIRST HIGH/MODERATE RISK CONTACT TO 12 DAYS AFTER THE LAST HIGH/MODERATE RISK CONTACT WITH A LABORATORY-CONFIRMED SARS-COV-2 CASE.",Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection
NCT04260308,Recruiting,Observational,,Huazhong University of Science and Technology,Other,3-Feb-20,20-Apr-20,15-Apr-20,CASE-ONLY,30000,VIRUS; PNEUMONIA,CHINA,ALL,"Child, Adult, Older Adult",,GHQ-12(GENERAL HEALTH QUESTIONNAIRE-12),"A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia in Wuhan, China"
NCT04260594,Not yet recruiting,Interventional,Phase 4,Jieming QU,Other,7-Feb-20,30-Dec-20,1-Jul-20,TREATMENT,380,2019-NCOV,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ARBIDOL,VIRUS NEGATIVE CONVERSION RATE IN THE FIRST WEEK,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov)."
NCT04261270,Recruiting,Interventional,Phase 3,Tongji Hospital,Other,1-Feb-20,1-Jul-20,1-May-20,TREATMENT,60,2019-NCOV PNEUMONIA,CHINA,ALL,18 Years to 55 Years   (Adult),ASC09F+OSELTAMIVIR,RATE OF COMPREHENSIVE ADVERSE OUTCOME,"A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia"
NCT04261426,Not yet recruiting,Interventional,Phase 2/Phase 3,Peking Union Medical College Hospital,Other,10-Feb-20,30-Jun-20,30-Apr-20,TREATMENT,80,2019-NCOV,,ALL,"18 Years and older   (Adult, Older Adult)",INTRAVENOUS IMMUNOGLOBULIN,CLINICAL IMPROVEMENT BASED ON THE 7-POINT SCALE,"A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia"
NCT04261517,Completed,Interventional,Phase 3,Shanghai Public Health Clinical Center,Other,6-Feb-20,25-Feb-20,25-Feb-20,TREATMENT,30,"PNEUMONIA, PNEUMOCYSTIS",CHINA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"THE VIROLOGICAL CLEARANCE RATE OF THROAT SWABS, SPUTUM, OR LOWER RESPIRATORY TRACT SECRETIONS AT DAY 3",Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
NCT04261907,Not yet recruiting,Interventional,Not Applicable,First Affiliated Hospital of Zhejiang University,Other,7-Feb-20,30-Jun-20,31-May-20,TREATMENT,160,2019-NCOV,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ASC09/RITONAVIR GROUP,THE INCIDENCE OF COMPOSITE ADVERSE OUTCOME,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection"
NCT04262921,Recruiting,Observational,,"Institut National de la Santé Et de la Recherche Médicale, France",Other,8-Feb-20,7-Aug-23,7-Aug-20,OTHER,5000,CORONAVIRUS INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",,CLINICAL FEATURES,Clinical Characterisation Protocol for Severe Emerging Infections
NCT04263402,Recruiting,Interventional,Phase 4,Tongji Hospital,Other,1-Feb-20,1-Jul-20,1-Jun-20,TREATMENT,100,2019-NCOV SEVERE PNEUMONIA,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,RATE OF DISEASE REMISSION,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia"
NCT04264533,Terminated,Interventional,Phase 2,ZhiYong Peng,Other,14-Feb-20,29-Mar-20,2-Mar-20,TREATMENT,56,VITAMIN C,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",VC,VENTILATION-FREE DAYS,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial
NCT04264858,Not yet recruiting,Interventional,Not Applicable,"Wuhan Union Hospital, China",Other,17-Mar-20,31-May-20,30-Apr-20,TREATMENT,10,2019-NCOV,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",IMMUNOGLOBULIN OF CURED PATIENTS,TIME TO CLINICAL IMPROVEMENT (TTCI),An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients
NCT04268537,Not yet recruiting,Interventional,Phase 2,"Southeast University, China",Other,10-Feb-20,31-Oct-20,30-Apr-20,TREATMENT,120,"2019 NCOV, PD-1",,ALL,"18 Years and older   (Adult, Older Adult)",PD-1 BLOCKING ANTIBODY+STANDARD TREATMENT,LUNG INJURY SCORE,Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients
NCT04269525,Recruiting,Interventional,Phase 2,ZhiYong Peng,Other,6-Feb-20,30-Dec-20,1-Dec-20,PREVENTION,16,"PNEUMONIA, VIRAL",CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",UC-MSCS,OXYGENATION INDEX,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection
NCT04270383,Not yet recruiting,Observational,,Beijing Children's Hospital,Other,15-Feb-20,31-Dec-20,31-Dec-20,COHORT,500,2019-NCOV,CHINA,ALL,"up to 18 Years   (Child, Adult)",,THE CURE RATE OF 2019-NCOV.,A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
NCT04272710,Withdrawn,Observational,,Chongqing Medical University,Other,25-Jan-20,30-Apr-20,31-Mar-20,COHORT,0,2019-NCOV,CHINA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,OCCUPANCY RATE IN THE INTENSIVE CARE UNIT (ICU),Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
NCT04273321,Completed,Interventional,Not Applicable,Beijing Chao Yang Hospital,Other,14-Feb-20,15-Apr-20,15-Apr-20,TREATMENT,86,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,THE INCIDENCE OF TREATMENT FAILURE IN 14 DAYS,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails
NCT04273529,Not yet recruiting,Interventional,Phase 2,First Affiliated Hospital of Wenzhou Medical University,Other,20-Feb-20,30-Jun-20,30-May-20,TREATMENT,100,COVID THALIDOMIDE,,ALL,"18 Years and older   (Adult, Older Adult)",THALIDOMIDE,TIME TO CLINICAL RECOVERYTIME TO CLINICAL RECOVERY (TTCR),"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study"
NCT04273581,Not yet recruiting,Interventional,Phase 2,First Affiliated Hospital of Wenzhou Medical University,Other,18-Feb-20,30-May-20,30-Apr-20,TREATMENT,40,COVID THALIDOMIDE,,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,TIME TO CLINICAL IMPROVEMENT (TTCI),"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study"
NCT04273646,Not yet recruiting,Interventional,Not Applicable,"Wuhan Union Hospital, China",Other,20-Apr-20,15-Feb-22,30-Jun-20,TREATMENT,48,2019 NOVEL CORONAVIRUS PNEUMONIA,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",UC-MSCS,PNEUMONIA SEVERITY INDEX,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19
NCT04273763,"Active, not recruiting",Interventional,Not Applicable,Second Affiliated Hospital of Wenzhou Medical University,Other,16-Feb-20,1-Jun-20,10-May-20,TREATMENT,18,NOVEL CORONAVIRUS PNEUMONIA,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BROMHEXINE HYDROCHLORIDE TABLETS,TIME TO CLINICAL RECOVERY AFTER TREATMENT,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
NCT04274322,"Active, not recruiting",Observational,,Peking University Third Hospital,Other,19-Feb-20,20-Jul-21,4-Apr-20,COHORT,117,CRITICALLY ILL,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",NUTRITION SUPPORT,28-DAY ALL CAUSE MORTALITY,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC)
NCT04275245,Recruiting,Interventional,Phase 1/Phase 2,Tang-Du Hospital,Other,3-Feb-20,31-Dec-20,31-Dec-20,TREATMENT,20,2019-NCOVS INFECTION PNEUMONIA,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",MEPLAZUMAB FOR INJECTION,2019 NCOV NUCLEIC ACID DETECTION,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia"
NCT04275388,Not yet recruiting,Observational,,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,Industry,15-May-20,14-Dec-21,14-Jul-20,COHORT,426,2019 NOVEL CORONAVIRUS PNEUMONIA,,ALL,"up to 100 Years   (Child, Adult, Older Adult)",XIYANPING INJECTION,CLINICAL RECOVERY TIME,Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)
NCT04275414,Completed,Interventional,Phase 2,Qilu Hospital of Shandong University,Other,15-Feb-20,2-May-20,5-Apr-20,TREATMENT,27,CORONAVIRUS INFECTION,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BEVACIZUMAB INJECTION,PARTIAL ARTERIAL OXYGEN PRESSURE (PAO2) TO FRACTION OF INSPIRATION O2 (FIO2) RATIO,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP)
NCT04275947,Recruiting,Observational,,Chinese Alliance Against Lung Cancer,Other,14-Feb-20,31-May-20,30-Apr-20,COHORT,450,COVID,CHINA,ALL,"18 Years to 90 Years   (Adult, Older Adult)","NCAPP, A CELL PHONE-BASED AUTO-DIAGNOSIS SYSTEM",ACCURACY OF NCAPP COVID-19 RISK DIAGNOSTIC MODEL,"The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp"
NCT04276688,Completed,Interventional,Phase 2,The University of Hong Kong,Other,10-Feb-20,31-Mar-20,30-Mar-20,TREATMENT,127,NOVEL CORONAVIRUS INFECTION,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",LOPINAVIR/RITONAVIR,TIME TO NEGATIVE NPS,"An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection"
NCT04276896,Recruiting,Interventional,Phase 1/Phase 2,Shenzhen Geno-Immune Medical Institute,Other,24-Mar-20,31-Dec-24,31-Jul-23,TREATMENT,100,PATHOGEN INFECTION COVID INFECTION,CHINA,ALL,"6 Months to 80 Years   (Child, Adult, Older Adult)",INJECTION AND INFUSION OF LV-SMENP-DC VACCINE AND ANTIGEN-SPECIFIC CTLS,CLINICAL IMPROVEMENT BASED ON THE 7-POINT SCALE,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus
NCT04276987,Completed,Interventional,Phase 1,Ruijin Hospital,Other,15-Feb-20,31-Jul-20,31-May-20,TREATMENT,24,CORONAVIRUS,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",MSCS-DERIVED EXOSOMES,ADVERSE REACTION (AE) AND SEVERE ADVERSE REACTION (SAE),A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia
NCT04278404,Recruiting,Observational,,Duke University,Other,5-Mar-20,24-Apr-24,24-Apr-24,OTHER,5000,CORONAVIRUS INFECTION (COVID),CANADA,ALL,"up to 20 Years   (Child, Adult)","THE POP02 STUDY IS COLLECTING BODILY FLUID SAMPLES (I.E., WHOLE BLOOD, EFFLUENT SAMPLES) OF CHILDREN PRESCRIBED THE FOLLOWING DRUGS OF INTEREST PER STANDARD OF CARE:",CLEARANCE (CL) OR APPARENT ORAL CLEARANCE (CL/F) AS MEASURED BY PK SAMPLING,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs"
NCT04278963,Suspended,Interventional,Phase 2/Phase 3,China Academy of Chinese Medical Sciences,Other,27-Feb-20,21-Jan-21,21-Jan-21,TREATMENT,300,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",YINHU QINGWEN DECOCTION,MEAN CLINICAL RECOVERY TIME (HOURS),"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19"
NCT04279197,Recruiting,Interventional,Phase 2,ShuGuang Hospital,Other,23-Apr-20,21-Dec-21,21-Dec-21,TREATMENT,160,PULMONARY FIBROSIS DUE TO COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",FUZHENG HUAYU TABLET,THE IMPROVEMENT PROPORTION OF PULMONARY FIBROSIS,The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: a Multicenter Randomized Controlled Trial
NCT04279782,Recruiting,Observational,,"Third Affiliated Hospital, Sun Yat-Sen University",Other,20-Jan-20,28-Feb-21,31-Jan-21,COHORT,100,CORONAVIRUS,CHINA,ALL,"Child, Adult, Older Adult",COMPREHENSIVE TREATMENT,SURVIVAL RATE,Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit
NCT04279795,Recruiting,Observational,,"Third Affiliated Hospital, Sun Yat-Sen University",Other,20-Jan-20,28-Feb-21,31-Jan-21,COHORT,20,CORONAVIRUS,CHINA,ALL,"Child, Adult, Older Adult",,POSITIVE RATE OF 2019 NOVEL CORONAVIRUS RNA,Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients
NCT04279899,Recruiting,Observational,,Children's Hospital of Fudan University,Other,1-Feb-20,31-Dec-20,30-Nov-20,CASE-ONLY,100,NEONATAL INFECTION,CHINA,ALL,up to 28 Days   (Child),,THE DEATH OF NEWBORNS WITH COVID-19,A Multicenter Observational Study of the Perinatal-neonatal Population With or With Risk of COVID-19 in China
NCT04280224,Recruiting,Interventional,Phase 1,Xinxiang medical university,Other,15-Feb-20,30-Dec-20,30-Sep-20,TREATMENT,30,NOVEL CORONAVIRUS PNEUMONIA,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",NK CELLS,IMPROVEMENT OF CLINICAL SYMPTOMS INCLUDING DURATION OF FEVER,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus
NCT04280588,Withdrawn,Interventional,Phase 2,First Affiliated Hospital of Fujian Medical University,Other,22-Feb-20,1-Jul-20,1-Jul-20,TREATMENT,0,CORONAVIRUS DISEASE (COVID),CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FINGOLIMOD 0.5 MG,THE CHANGE OF PNEUMONIA SEVERITY ON X-RAY IMAGES,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)
NCT04280705,Completed,Interventional,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,21-Feb-20,21-May-20,21-May-20,TREATMENT,1062,COVID,DENMARK,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PLACEBO,TIME TO RECOVERY,"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults"
NCT04280913,Withdrawn,Observational,,Guangzhou Institute of Respiratory Disease,Other,22-Feb-20,31-Mar-20,31-Mar-20,COHORT,0,CORONAVIRUS DISEASE 2019,CHINA,ALL,"Child, Adult, Older Adult",RETROSPECTIVE ANALYSIS,TIME TO NEGATIVE CONVERSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,Clinical Outcomes of Hospitalized Patients With Coronavirus Disease 2019
NCT04281693,Not yet recruiting,Interventional,Not Applicable,Affiliated Hospital to Academy of Military Medical Sciences,Other,20-Feb-21,20-Mar-21,20-Mar-21,SCREENING,230,NOVEL CORONAVIRUS INFECTION PNEUMONIA,CHINA,ALL,"Child, Adult, Older Adult",STANDARD SCREENING STRATEGY,SCREENING ACCURACY,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection
NCT04282135,Completed,Observational,,Klinikum Bayreuth GmbH,Industry,15-Feb-20,30-Jun-20,8-May-20,CASE-CONTROL,76,INFLUENZA,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",MCC IMS,CLUSTER ANALYSIS OF MCC IMS SPECTRA.,Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling
NCT04283461,"Active, not recruiting",Interventional,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NIH,16-Mar-20,22-Nov-22,22-Nov-22,PREVENTION,120,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",MRNA-1273,FREQUENCY OF SOLICITED LOCAL REACTOGENICITY ADVERSE EVENTS (AES),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults"
NCT04284046,Completed,Observational,,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",Other,31-Jan-20,18-Feb-20,18-Feb-20,COHORT,39,CT SCORES PREDICT MORTALITY IN 2019-NCOV PNEUMONIA,CHINA,ALL,"Child, Adult, Older Adult",CT SCORE,7-DAY MORTALITY,CT Scores Predict Mortality in 2019-nCoV Pneumonia
NCT04285190,Withdrawn,Interventional,Not Applicable,"Tasly Pharmaceuticals, Inc.",Industry,26-Feb-20,20-Apr-20,15-Apr-20,TREATMENT,0,CORONAVIRUS DISEASE 2019,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",T89,THE TIME TO OXYGEN SATURATION RECOVERY TO NORMAL LEVEL (≥97%),A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)
NCT04285801,Completed,Observational,,Chinese University of Hong Kong,Other,14-Feb-20,25-Feb-20,25-Feb-20,CASE-ONLY,8,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",,28 DAY MORTALITY,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study
NCT04286503,Not yet recruiting,Interventional,Phase 4,Beijing YouAn Hospital,Other,23-Feb-20,28-Feb-21,28-Feb-21,TREATMENT,520,NOVEL CORONAVIRUS INFECTIOUS DISEASE (COVID),,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CARRIMYCIN,FEVER TO NORMAL TIME (DAY),"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study"
NCT04287686,Withdrawn,Interventional,Not Applicable,The First Affiliated Hospital of Guangzhou Medical University,Other,20-Feb-21,20-Apr-21,20-Apr-21,TREATMENT,0,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RECOMBINANT HUMAN ANGIOTENSIN-CONVERTING ENZYME 2 (RHACE2),TIME COURSE OF BODY TEMPERATURE (FEVER),"A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19"
NCT04288102,Completed,Interventional,Phase 2,Beijing 302 Hospital,Other,5-Mar-20,9-Jul-20,12-May-20,TREATMENT,100,CORONA VIRUS DISEASE 2019(COVID),CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",UC-MSCS,CHANGE IN LESION PROPORTION (%) OF FULL LUNG VOLUME FROM BASELINE TO DAY 28.,"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients"
NCT04288713,Available,Expanded Access,,Hudson Medical,Other,,,,,,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",ECULIZUMAB,,Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.
NCT04290780,Recruiting,Observational,,Hospices Civils de Lyon,Other,9-Mar-20,31-Dec-21,31-Dec-21,COHORT,300,INFECTION VIRAL,FRANCE,ALL,"Child, Adult, Older Adult",NOSOCOMIAL INFECTION/HOSPITAL ACQUIRED INFECTION,NOSOCOMIAL INFECTION,Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus
NCT04290858,Withdrawn,Interventional,Phase 2,Xijing Hospital,Other,1-Mar-20,1-Feb-22,1-Mar-21,TREATMENT,0,CORONAVIRUS INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE,REDUCTION IN THE INCIDENCE OF INTUBATION AND MECHANICAL VENTILATION,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial
NCT04290871,Withdrawn,Interventional,Phase 2,Xijing Hospital,Other,23-Mar-20,1-Mar-22,1-Mar-21,TREATMENT,0,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE GAS,SARS-FREE PATIENTS AT 14 DAYS,Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.
NCT04291053,Not yet recruiting,Interventional,Phase 2/Phase 3,Tongji Hospital,Other,1-Apr-20,1-Sep-20,1-Aug-20,TREATMENT,550,COVID,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HUAIER GRANULE,MORTALITY RATE,"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study"
NCT04291729,Completed,Interventional,Phase 4,The Ninth Hospital of Nanchang,Other,17-Feb-20,19-Mar-20,19-Mar-20,TREATMENT,11,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",GANOVO+RITONAVIR+/-INTERFERON NEBULIZATION,RATE OF COMPOSITE ADVERSE OUTCOMES,An Open Clinical Trial to Evaluate Ganovo（Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
NCT04292327,"Active, not recruiting",Observational,,Fujian Provincial Hospital,Other,1-Jan-20,31-Jul-20,30-Apr-20,OTHER,400,PNEUMONIA CAUSED BY HUMAN CORONAVIRUS,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,MORTALITY,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)
NCT04292340,Recruiting,Observational,,Shanghai Public Health Clinical Center,Other,1-Feb-20,31-Dec-20,31-Jul-20,CASE-ONLY,15,CORONAVIRUS,CHINA,ALL,"Child, Adult, Older Adult",,"THE VIROLOGICAL CLEARANCE RATE OF THROAT SWABS, SPUTUM, OR LOWER RESPIRATORY TRACT SECRETIONS AT DAY 1",The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study
NCT04292730,Completed,Interventional,Phase 3,Gilead Sciences,Industry,15-Mar-20,26-Jun-20,29-Apr-20,TREATMENT,1113,COVID,CHINA,ALL,"12 Years and older   (Child, Adult, Older Adult)",REMDESIVIR,PART A: PERCENTAGE OF PARTICIPANTS IN EACH CLINICAL STATUS CATEGORY AS ASSESSED BY A 7-POINT ORDINAL SCALE ON DAY 11,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment
NCT04292899,Completed,Interventional,Phase 3,Gilead Sciences,Industry,6-Mar-20,30-Jun-20,9-Apr-20,TREATMENT,4891,COVID,CHINA,ALL,"12 Years and older   (Child, Adult, Older Adult)",REMDESIVIR,PART A: PERCENTAGE OF PARTICIPANTS IN EACH CLINICAL STATUS CATEGORY AS ASSESSED BY A 7-POINT ORDINAL SCALE ON DAY 14,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
NCT04292964,Completed,Observational,,Chongqing Medical University,Other,1-Mar-20,13-Mar-20,13-Mar-20,COHORT,201,SARS-COV2,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",,ALL-CAUSE MORTALITY,Prognostic Factors of Patients With COVID-19
NCT04293692,Withdrawn,Interventional,Not Applicable,Puren Hospital Affiliated to Wuhan University of Science and Technology,Other,24-Feb-20,25-Feb-20,25-Feb-20,TREATMENT,0,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",UC-MSCS,SIZE OF LESION AREA BY CHEST IMAGING,Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus
NCT04293887,Not yet recruiting,Interventional,Early Phase 1,Tongji Hospital,Other,1-Mar-20,30-Jun-20,30-May-20,TREATMENT,328,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT HUMAN INTERFERON Α1Β,THE INCIDENCE OF SIDE EFFECTS,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan"
NCT04295551,Not yet recruiting,Interventional,Not Applicable,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,Industry,14-Mar-20,14-Apr-21,14-Jul-20,TREATMENT,80,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",LOPINAVIR / RITONAVIR TABLETS COMBINED WITH XIYANPING INJECTION,CLINICAL RECOVERY TIME,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
NCT04296643,Recruiting,Interventional,Not Applicable,McMaster University,Other,1-Apr-20,1-Apr-21,1-Feb-21,PREVENTION,576,CORONAVIRUS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",MEDICAL MASK,RT-PCR CONFIRMED COVID-19 INFECTION,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial
NCT04298060,Not yet recruiting,Interventional,Phase 2,"Ansun Biopharma, Inc.",Industry,20-Jul-21,22-Sep-21,21-Mar-21,TREATMENT,280,INFLUENZA INFECTION,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",DAS181,PERCENT OF SUBJECTS WHO HAVE RETURNED TO ROOM AIR,A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection
NCT04298814,Withdrawn,Observational,,Tongji Hospital,Other,7-Aug-20,30-Dec-20,30-Dec-20,CASE-ONLY,0,COVID,CHINA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",SEVERE COVID-19 PNEUMONIA WITH ET,SUCCESS RATE OF INTUBATION,Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia
NCT04299152,Not yet recruiting,Interventional,Phase 2,Tianhe Stem Cell Biotechnologies Inc.,Industry,10-Nov-20,10-Nov-21,9-Oct-21,TREATMENT,20,SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PNEUMONIA,,ALL,18 Years to 60 Years   (Adult),STEM CELL EDUCATOR-TREATED MONONUCLEAR CELLS APHERESIS,DETERMINE THE NUMBER OF COVID-19 PATIENTS WHO WERE UNABLE TO COMPLETE SCE THERAPY,Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04299724,Recruiting,Interventional,Phase 1,Shenzhen Geno-Immune Medical Institute,Other,15-Feb-20,31-Dec-24,31-Jul-23,TREATMENT,100,TREAT AND PREVENT COVID INFECTION,CHINA,ALL,"6 Months to 80 Years   (Child, Adult, Older Adult)",PATHOGEN-SPECIFIC AAPC,FREQUENCY OF VACCINE EVENTS,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
NCT04302519,Not yet recruiting,Interventional,Early Phase 1,"CAR-T (Shanghai) Biotechnology Co., Ltd.",Industry,5-Mar-20,30-Jul-21,30-Jun-21,TREATMENT,24,COVID,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",DENTAL PULP MESENCHYMAL STEM CELLS,DISPPEAR TIME OF GROUND-GLASS SHADOW IN THE LUNGS,Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
NCT04302688,Completed,Observational,,Renmin Hospital of Wuhan University,Other,10-Dec-19,4-Mar-20,10-Feb-20,OTHER,669,PNEUMONITIS,CHINA,ALL,"Child, Adult, Older Adult",,SURVIVAL STATUS,Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram
NCT04302766,Available,Expanded Access,,U.S. Army Medical Research and Development Command,U.S. Fed,,,,,,CORONAVIRUS DISEASE 2019,,ALL,"Child, Adult, Older Adult",REMDESIVIR,,Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™)
NCT04303299,Recruiting,Interventional,Phase 3,Rajavithi Hospital,Other,19-Aug-20,31-Dec-21,31-Dec-21,TREATMENT,320,SARS-COV2 INFECTIONS,THAILAND,ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",ORAL,SARS-COV-2 ERADICATION TIME,"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19"
NCT04303507,Recruiting,Interventional,Not Applicable,University of Oxford,Other,29-Apr-20,21-Apr-21,21-Apr-21,PREVENTION,40000,COVID,INDONESIA,ALL,"16 Years and older   (Child, Adult, Older Adult)",CHLOROQUINE OR HYDROXYCHLOROQUINE,NUMBER OF SYMPTOMATIC COVID-19 INFECTIONS,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)"
NCT04304053,Completed,Interventional,Phase 3,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Other,18-Mar-20,15-Jun-20,15-Jun-20,PREVENTION,2300,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TREATMENT AND PROPHYLAXIS,STUDY 1- CLINICAL AND VIROLOGICAL OUTCOME IN EXPOSED CONTACTS,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)
NCT04304313,Recruiting,Interventional,Phase 3,Tongji Hospital,Other,9-Feb-20,9-Nov-20,1-Mar-20,TREATMENT,10,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",SILDENAFIL CITRATE TABLETS,RATE OF DISEASE REMISSION,A Pilot Study of Sildenafi in the Treatment of COVID-19
NCT04304690,"Active, not recruiting",Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,16-Mar-20,16-Oct-21,16-May-21,OTHER,1000,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",BLOOD SAMPLE,QUANTIFY THE PROPORTION OF PATIENTS WITH DOCUMENTED SARS-COV2 INFECTION AMONG MEDICAL AND PARAMEDICAL STAFF,"COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic"
NCT04305106,Recruiting,Interventional,Not Applicable,Qilu Hospital of Shandong University,Other,17-Mar-20,31-Jul-20,30-Jun-20,TREATMENT,140,COVID PNEUMONIA,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BEVACIZUMAB,THE TIME FROM RANDOMIZATION TO CLINICAL IMPROVEMENT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial
NCT04305457,"Active, not recruiting",Interventional,Phase 2,Massachusetts General Hospital,Other,21-Mar-20,1-Apr-22,1-Apr-21,TREATMENT,70,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE,REDUCTION IN THE INCIDENCE OF PATIENTS WITH MILD/MODERATE COVID-19 REQUIRING INTUBATION AND MECHANICAL VENTILATION,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial
NCT04305574,Completed,Observational,,Jean Liu,Other,7-Mar-20,21-Apr-20,21-Apr-20,COHORT,1145,CORONAVIRUS,SINGAPORE,ALL,"21 Years and older   (Adult, Older Adult)",USE OF SOCIAL MEDIA DURING COVID-19,"DEPRESSION, ANXIETY AND STRESS SCALE",Getting it Right: Towards Responsible Social Media Use During a Pandemic
NCT04306055,Completed,Interventional,Not Applicable,Guangzhou Blood Center,Other,13-Mar-20,3-Apr-20,13-Mar-20,HEALTH SERVICES RESEARCH,19491,BLOOD DONATION,CHINA,ALL,18 Years to 60 Years   (Adult),QUESTIONNAIRE WITH PRECAUTION INFORMATION,DIFFERENCES OF ATTITUDE ABOUT BLOOD DONATION TOWARDS DIFFERENT QUESTIONNAIRES,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China"
NCT04306393,Recruiting,Interventional,Phase 2,Massachusetts General Hospital,Other,21-Mar-20,21-Mar-22,21-Mar-21,TREATMENT,200,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",NITRIC OXIDE GAS,CHANGE OF ARTERIAL OXYGENATION AT 48 HOURS FROM ENROLLMENT,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.
NCT04306497,Completed,Observational,,"Jiangsu Famous Medical Technology Co., Ltd.",Industry,22-Jan-20,30-May-20,30-Apr-20,COHORT,340,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TCM PRESCRIPTIONS,THE RELIEF OF MAIN SYMPTOMS/ DISAPPEARANCE RATE OF TIME,Clinical Trial of TCM Differentiation and Treatment Protocol of COVID-19 in Jiangsu Province
NCT04306705,Recruiting,Observational,,Tongji Hospital,Other,20-Feb-20,20-Jun-20,30-May-20,COHORT,120,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TOCILIZUMAB,PROPORTION OF PARTICIPANTS WITH NORMALIZATION OF FEVER AND OXYGEN SATURATION THROUGH DAY 14,A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19
NCT04307459,Recruiting,Observational,,University of Milan,Other,19-Mar-20,31-Dec-20,1-Sep-20,COHORT,50,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OPERATING PROCEDURES,REAL LIFE DATA OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) INFECTION,Acute Respiratory Failure and Continuous Positive Airway Pressure Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: a Real Life Evaluation
NCT04307693,Terminated,Interventional,Phase 2,Asan Medical Center,Other,11-Mar-20,30-Apr-20,30-Apr-20,TREATMENT,65,COVID,"KOREA, REPUBLIC OF",ALL,"16 Years to 99 Years   (Child, Adult, Older Adult)",LOPINAVIR/RITONAVIR,VIRAL LOAD,Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
NCT04308187,Not yet recruiting,Observational [Patient Registry],,"University Hospital, Clermont-Ferrand",Other,11-Mar-20,22-Mar-21,22-Mar-21,COHORT,50000,"STRESS, PSYCHOLOGICAL",FRANCE,ALL,"Child, Adult, Older Adult",,STRESS,The COVISTRESS Study: Influence of the COvid-19 Epidemic on STRESS
NCT04308317,Enrolling by invitation,Interventional,Phase 4,Henan Provincial People's Hospital,Other,5-Mar-20,1-May-21,1-Mar-21,TREATMENT,60,"CORONA VIRUS DISEASE 2019,COVID",CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",TETRANDRINE,SURVIVAL RATE,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19
NCT04308668,Completed,Interventional,Phase 3,University of Minnesota,Other,17-Mar-20,20-May-20,20-May-20,TREATMENT,1309,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,INCIDENCE OF COVID19 DISEASE AMONG THOSE WHO ARE ASYMPTOMATIC AT BASELINE,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial
NCT04310228,Recruiting,Interventional,Not Applicable,Peking University First Hospital,Other,8-Mar-20,20-May-21,20-May-21,TREATMENT,150,COVID,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",FAVIPIRAVIR COMBINED WITH TOCILIZUMAB,CLINICAL CURE RATE,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study"
NCT04310865,Suspended,Interventional,Phase 2/Phase 3,Zhong Wang,Other,20-Nov-21,30-Jun-21,30-Mar-21,PREVENTION,116,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",YINHU QINGWEN GRANULA,CHANGES IN THE RATIO OF PAO2 TO FIO2 FROM BASELINE,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19"
NCT04311177,Completed,Interventional,Phase 2,University of Minnesota,Other,9-Apr-20,1-Feb-21,1-Feb-21,TREATMENT,580,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,HOSPITAL ADMISSION,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
NCT04311398,Not yet recruiting,Observational,,Huashan Hospital,Other,13-May-20,1-Dec-20,1-Jun-20,COHORT,100,COVID,CHINA,ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",NEW QIASTAT-DX FULLY AUTOMATIC MULTIPLE PCR DETECTION PLATFORM,SENSITIVITY， SPECTIVITY TURNAROUND TIME OF THE NEW QIASTAT-DX FULLY AUTOMATIC MULTIPLE PCR DETECTION PLATFORM,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System
NCT04311697,Completed,Interventional,Phase 2/Phase 3,"NeuroRx, Inc.",Industry,15-May-20,22-Feb-21,22-Feb-21,TREATMENT,196,CRITICAL COVID WITH RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",AVIPTADIL BY INTRAVENOUS INFUSION + STANDARD OF CARE,RESOLUTION OF RESPIRATORY FAILURE (COMPOSITE ENDPOINT),ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure
NCT04312009,Completed,Interventional,Phase 2,University of Minnesota,Other,13-Apr-20,1-Feb-21,1-Feb-21,TREATMENT,200,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,DIFFERENCE IN ESTIMATED (PEEP ADJUSTED) P/F RATIO AT 7 DAYS,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization
NCT04312100,Recruiting,Observational,,Henan Provincial People's Hospital,Other,1-Feb-20,21-Feb-21,20-Oct-21,COHORT,30,CORONAVIRUS DISEASE-2019,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",OXYGEN TREATMENT,INCIDENCE OF RESPIRATORY FAILURE,Sequential Oxygen Therapy Strategy for Patients With COVID-19
NCT04312243,Recruiting,Interventional,Phase 2,Massachusetts General Hospital,Other,7-Apr-20,7-Apr-22,7-Apr-21,PREVENTION,470,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",INHALED NITRIC OXIDE GAS,COVID-19 DIAGNOSIS,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers
NCT04312464,Enrolling by invitation,Observational,,"Wuhan Union Hospital, China",Other,1-Jan-20,18-Mar-20,15-Mar-20,CASE-CONTROL,500,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",NON,THE MYOCARDIAL INJURY INCIDENCE,Retrospective Study of Myocardial Damage in COVID-19
NCT04312997,Recruiting,Interventional,Phase 2,"Pulmotect, Inc.",Industry,16-Jun-20,21-May-21,21-Apr-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PUL-042 INHALATION SOLUTION,SEVERITY OF COVID-19,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
NCT04313023,Recruiting,Interventional,Phase 2,"Pulmotect, Inc.",Industry,9-Jun-20,21-Jun-21,21-May-21,PREVENTION,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PUL-042 INHALATION SOLUTION,SEVERITY OF COVID-19,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
NCT04313127,"Active, not recruiting",Interventional,Phase 1,CanSino Biologics Inc.,Industry,16-Mar-20,20-Dec-22,30-Dec-20,PREVENTION,108,COVID,CHINA,ALL,18 Years to 60 Years   (Adult),RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),SAFETY INDEXES OF ADVERSE REACTIONS,"A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old"
NCT04313322,Recruiting,Interventional,Phase 1,Stem Cells Arabia,Other,16-Mar-20,30-Sep-20,30-Jun-20,TREATMENT,5,USE OF STEM CELLS FOR COVID TREATMENT,JORDAN,ALL,"18 Years and older   (Adult, Older Adult)",WJ-MSCS,CLINICAL OUTCOME,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
NCT04313946,Recruiting,Observational,,Professor Adrian Covic,Other,18-Mar-20,18-Aug-20,16-Aug-20,ECOLOGIC OR COMMUNITY,200,COVID,ITALY,ALL,"Child, Adult, Older Adult",SCANNING CHEST X-RAYS AND PERFORMING AI ALGORITHMS ON IMAGES,COVID-19 POSITIVE X-RAYS,The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations
NCT04314232,Recruiting,Observational,,"University Hospital, Akershus",Other,18-Mar-20,31-Dec-21,31-Dec-21,COHORT,200,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PARTICIPANTS WITH ICU ADMISSION OR DEATH,"Changes in Organ Specific Biomarkers, Virus Expression and Prognosis of Covid-19"
NCT04315298,Completed,Interventional,Phase 2/Phase 3,Regeneron Pharmaceuticals,Industry,18-Mar-20,2-Sep-20,24-Jul-20,TREATMENT,1912,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB,PERCENT CHANGE IN C-REACTIVE PROTEIN (CRP) LEVELS IN PATIENTS WITH SERUM IL-6 LEVEL GREATER THAN THE UPPER LIMIT OF NORMAL,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19"
NCT04315480,"Active, not recruiting",Interventional,Phase 2,Università Politecnica delle Marche,Other,12-Mar-20,20-May-21,9-Apr-20,TREATMENT,38,SARS PNEUMONIA,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",TOCILIZUMAB,ARREST IN DETERIORATION OF PULMONARY FUNCTION,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia
NCT04315870,Recruiting,Observational [Patient Registry],,Federico II University,Other,1-Jan-20,30-Apr-20,20-Apr-20,COHORT,20,INFECTION VIRAL,ITALY,FEMALE,18 Years to 50 Years   (Adult),PREGNANT WOMEN WITH LABORATORY-CONFIRMED 2019-N-COV,MATERNAL AND PERINATAL OUTCOMES,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy
NCT04315896,"Active, not recruiting",Interventional,Phase 3,"National Institute of Respiratory Diseases, Mexico",Other,14-Apr-20,15-Aug-20,1-Jul-20,TREATMENT,500,COVID,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,ALL-CAUSE HOSPITAL MORTALITY,Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)
NCT04315948,"Active, not recruiting",Interventional,Phase 3,"Institut National de la Santé Et de la Recherche Médicale, France",Other,22-Mar-20,23-Mar-21,23-Mar-21,TREATMENT,3100,CORONAVIRUS INFECTION,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,PERCENTAGE OF SUBJECTS REPORTING EACH SEVERITY RATING ON A 7-POINT ORDINAL SCALE,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults"
NCT04315987,Not yet recruiting,Interventional,Phase 2,Azidus Brasil,Industry,20-Jun-21,20-Aug-21,20-Aug-21,TREATMENT,90,COVID PNEUMONIA,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",NESTACELL®,CHANGE IN CLINICAL CONDITION,Exploratory Clinical Study to Assess the Efficacy of NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
NCT04316299,Completed,Observational,,Zhenhua Zen,Other,26-Feb-20,8-Mar-20,28-Feb-20,CASE-CONTROL,287,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF ACUTE KIDNEY INJURY,"Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study"
NCT04316377,"Active, not recruiting",Interventional,Phase 4,"University Hospital, Akershus",Other,25-Mar-20,3-Mar-25,25-May-20,TREATMENT,53,CORONAVIRUS INFECTION,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,RATE OF DECLINE IN SARS-COV-2 VIRAL LOAD,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection
NCT04316728,Not yet recruiting,Interventional,Not Applicable,"Centro Studi Internazionali, Italy",Other,20-Mar-21,20-Nov-21,20-Sep-21,DIAGNOSTIC,200,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",VIVADIAG™ COVID-19 LGM/IGG RAPID TEST,NUMBER OF PATIENTS WITH CONSTANT NEGATIVE RESULTS,Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19
NCT04316884,Recruiting,Observational,,Uppsala University,Other,12-Mar-20,31-Dec-21,31-Dec-20,COHORT,100,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",,ACUTE KIDNEY INJURY,Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19
NCT04316949,Recruiting,Observational,,University of Bologna,Other,20-Mar-20,31-May-20,30-Apr-20,COHORT,350,SARS-COV2 PNEUMONIA,ITALY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,RESPIRATORY FAILURE,Predictors of Respiratory Failure Requiring ICU Admission Among Hospitalized Patients With SARS-Cov-2 Infection
NCT04317040,Completed,Interventional,Phase 3,"OncoImmune, Inc.",Industry,8-Apr-20,30-Jan-21,23-Oct-20,TREATMENT,243,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CD24FC,IMPROVEMENT OF COVID-19 DISEASE STATUS,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment"
NCT04317092,"Active, not recruiting",Interventional,Phase 2,"National Cancer Institute, Naples",Other,19-Mar-20,19-Dec-22,19-Dec-20,TREATMENT,400,COVID PNEUMONIA,ITALY,ALL,"Child, Adult, Older Adult",TOCILIZUMAB INJECTION,LETHALITY RATE TWO WEEKS AFTER REGISTRATION,Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia
NCT04318015,Recruiting,Interventional,Phase 3,"National Institute of Respiratory Diseases, Mexico",Other,14-Apr-20,31-Mar-21,31-Dec-20,PREVENTION,400,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,SYMPTOMATIC COVID-19 INFECTION RATE,Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)
NCT04318301,Completed,Observational,,Zhenhua Zen,Other,21-Mar-20,30-Mar-20,28-Mar-20,CASE-CONTROL,275,COVID,CHINA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,RATE OF DEATH,"Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study"
NCT04318314,Recruiting,Observational [Patient Registry],,"University College, London",Other,18-Mar-20,31-Dec-21,31-Dec-20,COHORT,400,HEALTH CARE WORKER PATIENT TRANSMISSION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COPAN SWABBING AND BLOOD SAMPLE COLLECTION,SEROCONVERSION TO SARS-COV-2 POSITIVITY,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2
NCT04318366,Recruiting,Observational,,Università Vita-Salute San Raffaele,Other,19-Mar-20,19-Mar-22,19-Mar-22,COHORT,1000,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL STUDY,"CHARACTERIZE PATIENTS WITH SARS-COV-2 INFECTION AND TO CREATE A BIOBANK TO IDENTIFY PREDICTORS OF DISEASE SEVERITY, MORTALITY AND TREATMENT RESPONSE","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response"
NCT04318418,Completed,Observational,,Neuromed IRCCS,Other,23-Mar-20,30-Jun-20,10-May-20,COHORT,3400,COVID,ITALY,ALL,"Child, Adult, Older Adult",,SEVERE COVID-19,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19"
NCT04318431,Completed,Interventional,Not Applicable,Centre Hospitalier Intercommunal Creteil,Other,14-Apr-20,1-Jun-20,12-May-20,DIAGNOSTIC,605,COVID,FRANCE,ALL,up to 15 Years   (Child),DATA COLLECTION AND RHINOPHARYNGEAL SWAB,PROPORTION OF ASYMPTOMATIC CHILDREN OR CHILDREN WITH MILD RESPIRATORY SYMPTOMS,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care."
NCT04318444,Recruiting,Interventional,Phase 2/Phase 3,Columbia University,Other,29-Mar-20,22-Mar-21,21-Mar-21,PREVENTION,1600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"NUMBER OF PARTICIPANTS WITH SYMPTOMATIC, LAB-CONFIRMED COVID-19.",Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial
NCT04319016,Recruiting,Observational [Patient Registry],,Federico II University,Other,1-Jan-20,1-May-20,30-Apr-20,COHORT,200,INFECTION VIRAL,ITALY,FEMALE,"Child, Adult, Older Adult",PREGNANT WOMEN WITH LABORATORY-CONFIRMED 2019-N-COV,MATERNAL AND PERINATAL OUTCOMES,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy
NCT04319172,Recruiting,Observational,,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Other,12-Mar-20,21-Apr-21,21-Mar-21,COHORT,50,TRANSPLANT RECIPIENT,SPAIN,ALL,"16 Years and older   (Child, Adult, Older Adult)",,INCIDENCE OF CORONAVIRUS INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients
NCT04319211,Not yet recruiting,Observational,,Istanbul University-Cerrahpasa,Other,25-Mar-20,20-Jul-20,15-May-20,CASE-ONLY,200,HEALTHY PEOPLE,TURKEY,ALL,18 Years to 55 Years   (Adult),"DETERMINATION OF PHYSICAL ACTIVITY, QUALITY OF LIFE, STRESS LEVELS OF ISOLATED PEOPLE AT HOME WITH THE DANGER OF CORONAVIRUS.",INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE (IPAQ),"Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease"
NCT04319315,Recruiting,Observational,,Assiut University,Other,11-Mar-20,16-Apr-20,1-Apr-20,OTHER,400,COVID,EGYPT,ALL,"25 Years to 65 Years   (Adult, Older Adult)",SURVEY,NUMBER OF PHYSICIANS AFFECTED BY SOCIAL MEDIA MEASURED BY ONLINE SURVEY DESIGNED TO MEASURE THE INFLUENCE OF SOCIAL MEDIA ON MEDICAL PRACTICE,Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak
NCT04319445,"Active, not recruiting",Interventional,Not Applicable,Wake Forest University Health Sciences,Other,22-Mar-20,21-Jun-21,31-Aug-20,OTHER,233,MIGRAINE DISORDERS,UNITED STATES,ALL,"Child, Adult, Older Adult",MINDFULNESS SESSION(S),HELPFULNESS OF THE SESSION,Mindfulness During COVID-19 - Remote Mindfulness Sessions
NCT04319731,Recruiting,Interventional,Early Phase 1,University of Utah,Other,20-Mar-20,20-Mar-21,20-Mar-21,TREATMENT,10,SARS COV-2 INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HUMAN AMNIOTIC FLUID,VENTILATOR FREE DAYS,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
NCT04320017,Recruiting,Observational,,Groupe Hospitalier Pitie-Salpetriere,Other,20-Mar-20,20-May-20,20-May-20,COHORT,500,COVID,FRANCE,ALL,"16 Years and older   (Child, Adult, Older Adult)","ELECTROCARDIOGRAM, TRANSTHORACIC ECHOCARDIOGRAPHY AND CLINICO-BIOLOGICAL PARAMETERS IN ROUTINE CARE",INCIDENCE OF ACUTE MYOCARDIAL EVENTS IN COVID-19 POPULATION AT BASELINE AND DURING HOSPITAL STAY,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19
NCT04320056,Recruiting,Interventional,Not Applicable,Laval University,Other,20-Apr-20,31-Oct-21,30-Apr-21,OTHER,216,CORONAVIRUS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD ADMINISTRATION OF OXYGEN FLOW,THE NUMBER OF INTERVENTIONS,Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)
NCT04320238,Recruiting,Interventional,Phase 3,Shanghai Jiao Tong University School of Medicine,Other,21-Jan-20,20-Jun-21,20-May-21,PREVENTION,2944,2019 NOVEL CORONAVIRUS INFECTION,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",RECOMBINANT HUMAN INTERFERON ALPHA-1B,NEW-ONSET COVID-19,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area
NCT04320277,Not yet recruiting,Interventional,Phase 2/Phase 3,Hospital of Prato,Other,16-May-20,30-Jul-20,30-Jun-20,TREATMENT,200,PHARMACOLOGICAL ACTION,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BARICITINIB,THE PERCENTAGE OF PATIENTS REQUIRING TRANSFER TO ICU AS COMPARED WITH THE RATE OF TRANSFERS OBSERVED IN CONTROLS.,"Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study"
NCT04320472,"Active, not recruiting",Observational [Patient Registry],,Ictal Group,Other,23-Mar-20,31-Dec-20,30-Sep-20,COHORT,250,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",FOLLOW UP,PREVALENCE,Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection
NCT04320511,Recruiting,Observational,,William Beaumont Hospitals,Other,24-Jun-20,22-Jun-21,21-Jun-21,COHORT,25,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CT-V,"PREDICTIVE ASSOCIATION BETWEEN CT-V, PBM SCORE AND DISEASE PROGRESSION","COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2"
NCT04320615,Completed,Interventional,Phase 3,Hoffmann-La Roche,Industry,3-Apr-20,28-Jul-20,24-Jun-20,TREATMENT,450,COVID PNEUMONIA,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB (TCZ),CLINICAL STATUS ASSESSED USING A 7-CATEGORY ORDINAL SCALE,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia"
NCT04320732,Recruiting,Observational,,Oslo University Hospital,Other,27-Mar-20,20-Mar-30,27-Mar-22,CASE-CONTROL,250000,CORONAVIRUS,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION OF BEHAVIOR AND COVID-19 INFECTION WILL BE CONDUCTED.,RATE OF COVID-19 INFECTION,Risk Factors for Community- and Workplace Transmission of COVID-19
NCT04320862,Recruiting,Observational,,Duke University,Other,3-Apr-20,31-Dec-21,31-Dec-21,COHORT,200000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,NUMBER OF PARTICIPANTS WHO EXPERIENCE INPATIENT ADMISSION,Pandemic Response Network: Duke Community Health Watch
NCT04320953,Completed,Interventional,Not Applicable,Changhai Hospital,Other,16-Mar-20,9-Apr-20,26-Mar-20,OTHER,5,GASTROINTESTINAL DISEASE,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",NON-CONTACT MCE SYSTEM,TECHNICAL SUCCESS,Non-contact Endoscopy at Covid-19 Outbreak
NCT04321096,"Active, not recruiting",Interventional,Phase 1/Phase 2,University of Aarhus,Other,4-Apr-20,1-May-21,31-Jan-21,TREATMENT,580,CORONAVIRUS INFECTION,DENMARK,ALL,"18 Years to 110 Years   (Adult, Older Adult)",CAMOSTAT MESILATE,COHORT 1: DAYS TO CLINICAL IMPROVEMENT FROM STUDY ENROLMENT,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial"
NCT04321174,Recruiting,Interventional,Phase 3,Darrell Tan,Other,17-Apr-20,31-Mar-22,31-Mar-21,PREVENTION,1220,CORONAVIRUS INFECTION,CANADA,ALL,"18 Months and older   (Child, Adult, Older Adult)",LOPINAVIR/RITONAVIR,MICROBIOLOGIC EVIDENCE OF INFECTION,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
NCT04321265,Recruiting,Observational,,"Heinrich-Heine University, Duesseldorf",Other,19-Mar-20,21-Dec-21,21-Sep-21,COHORT,4000,COVID,DENMARK,ALL,70 Years and older   (Older Adult),,SURVIVAL,Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients
NCT04321278,Completed,Interventional,Phase 3,Hospital Israelita Albert Einstein,Other,28-Mar-20,14-Jun-20,14-Jun-20,TREATMENT,440,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE + AZITHROMYCIN,EVALUATION OF THE CLINICAL STATUS,Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients
NCT04321369,Completed,Observational,,Dr. Deneen Vojta,Industry,9-Mar-20,23-Mar-20,23-Mar-20,CASE-ONLY,533,"INFECTIONS, RESPIRATORY",UNITED STATES,ALL,"Child, Adult, Older Adult",TESTING SENSITIVITY FOR SARS-COV-2 VIRUS IN SYMPTOMATIC INDIVIDUALS,ACCURACY OF PATIENT ADMINISTERED TESTS,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals
NCT04321421,Completed,Interventional,Not Applicable,Foundation IRCCS San Matteo Hospital,Other,17-Mar-20,7-May-20,28-Apr-20,TREATMENT,49,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HYPERIMMUNE PLASMA,DEATH,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19
NCT04321616,Recruiting,Interventional,Phase 2/Phase 3,Oslo University Hospital,Other,28-Mar-20,20-Nov-21,20-Aug-21,TREATMENT,700,SARS-COV INFECTION,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,IN-HOSPITAL MORTALITY,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients
NCT04321811,"Active, not recruiting",Observational [Patient Registry],,xCures,Industry,21-Mar-20,20-Mar-22,9-Feb-21,COHORT,100000,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","OBSERVATION OF PATIENTS WITH KNOWN, SUSPECTED, OR AT RISK FOR COVID-19 INFECTION",DEFINE NATURAL SYMPTOM COURSE,A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19)
NCT04321928,Recruiting,Interventional,Not Applicable,University of Pecs,Other,1-Apr-20,21-Aug-21,21-Apr-21,PREVENTION,7576,SARS-COV2,HUNGARY,ALL,"60 Years and older   (Adult, Older Adult)",PERSONALIZED HEALTH EDUCATION,"PRIMARY COMPOSITE RATE OF INTENSIVE CARE UNIT (ICU) ADMISSION, 48 HOURS OF HOSPITAL ADMISSION, DEATH IN COVID-19 POSITIVE CASES",Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)
NCT04321993,Recruiting,Interventional,Phase 2,Lisa Barrett,Other,17-Apr-20,22-Mar-21,22-Feb-21,TREATMENT,800,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",BARICITINIB (JANUS KINASE INHIBITOR),CLINICAL STATUS OF SUBJECT AT DAY 15 (ON A 7 POINT ORDINAL SCALE).,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
NCT04322123,"Active, not recruiting",Interventional,Phase 3,Hospital do Coracao,Other,1-Apr-20,30-Aug-20,30-Aug-20,TREATMENT,630,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE ORAL PRODUCT,EVALUATION OF THE CLINICAL STATUS,"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients"
NCT04322188,Completed,Observational,,A.O. Ospedale Papa Giovanni XXIII,Other,19-Mar-20,8-May-20,8-May-20,COHORT,220,SEVERE ACUTE RESPIRATORY SYNDROME (ARDS) SECONDARY TO SARS-COV2 INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY IN SILTUXIMAB TREATED PATIENTS,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
NCT04322279,Recruiting,Observational,,"Institut National de la Santé Et de la Recherche Médicale, France",Other,9-Mar-20,1-Jun-21,1-Mar-21,COHORT,300,CORONAVIRUS,FRANCE,ALL,"Child, Adult, Older Adult",SEROLOGY,PROPORTION OF SUBJECTS WITH SARS-COV-2 POSITIVE SEROLOGY AT DAY 30 FOLLOWING THE LAST HIGH/MODERATE RISK CONTACT WITH A LABORATORY-CONFIRMED SARS-COV-2 CASE.,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. (CoV-CONTACT-SERO)
NCT04322344,Recruiting,Interventional,Phase 2/Phase 3,University of Catanzaro,Other,23-Mar-20,30-Dec-20,30-Jun-20,SUPPORTIVE CARE,120,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ESCIN,MORTALITY RATE,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients
NCT04322396,Completed,Interventional,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",Other,6-Apr-20,2-Feb-21,2-Feb-21,TREATMENT,117,VIRUS DISEASES,DENMARK,ALL,"Child, Adult, Older Adult",AZITHROMYCIN,NUMBER OF DAYS ALIVE AND DISCHARGED FROM HOSPITAL WITHIN 14 DAYS,"Proactive Protection With Azithromycin and Hydroxychloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19"
NCT04322487,Recruiting,Observational,,Catholic University of the Sacred Heart,Other,8-Apr-20,15-Jan-21,31-Dec-20,CASE-ONLY,100,CORONAVIRUS,ITALY,ALL,"Child, Adult, Older Adult",LUNG ULTRASOUND,LUNG ULTRASOUND GRADING SYSTEM FOR COVID-19 PNEUMONIA,"Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method"
NCT04322513,Recruiting,Observational,,University of Catanzaro,Other,24-Mar-20,30-Dec-20,30-Jun-20,CASE-CONTROL,110,CORONAVIRUS,ITALY,ALL,"14 Years to 75 Years   (Child, Adult, Older Adult)",BIOMARKERS EXPRESSION,BIOMARKERS EXPRESSION,Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection
NCT04322565,Recruiting,Interventional,Phase 2,Azienda Ospedaliero-Universitaria di Parma,Other,20-Apr-20,21-Dec-20,20-Dec-20,TREATMENT,310,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COLCHICINE,CLINICAL IMPROVEMENT,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia
NCT04322682,Completed,Interventional,Phase 3,Montreal Heart Institute,Other,23-Mar-20,21-Jan-21,21-Jan-21,TREATMENT,4506,CORONAVIRUS INFECTION,BRAZIL,ALL,"40 Years and older   (Adult, Older Adult)",COLCHICINE,NUMBER OF PARTICIPANTS WHO DIE OR REQUIRE HOSPITALIZATION DUE TO COVID-19 INFECTION,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
NCT04322773,Terminated,Interventional,Phase 2,Marius Henriksen,Other,5-Apr-20,8-Oct-20,8-Oct-20,TREATMENT,20,CORONA VIRUS DISEASE,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",ROACTEMRA IV,TIME TO INDEPENDENCE FROM SUPPLEMENTARY OXYGEN THERAPY,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial"
NCT04322786,"Active, not recruiting",Observational,,"University College, London",Other,1-Jan-98,31-Mar-21,31-May-16,CASE-CONTROL,1302508,"COVID, CORONAVIRUS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, INFLUENZA, ELECTRONIC HEALTH RECORDS, EPIDEMIOLOGY, COMORBIDITY, INCIDENCE, UNITED KINGDOM",,ALL,"18 Years and older   (Adult, Older Adult)",ACE INHIBITOR,INCIDENCE OF INFLUENZA,"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals."
NCT04323228,Recruiting,Interventional,Phase 2/Phase 3,King Saud University,Other,1-Sep-20,30-Dec-20,1-Dec-20,SUPPORTIVE CARE,40,COVID,SAUDI ARABIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ORAL SUPPLEMENT ENRICHED IN ANTIOXIDANTS,CHANGE FROM BASELINE SCORE OF NUTRITION RISK SCREENING-2002 (NRS-2002) AT END OF THE TRIAL,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial
NCT04323332,Not yet recruiting,Interventional,Phase 3,Xiyuan Hospital of China Academy of Chinese Medical Sciences,Other,20-Mar-21,20-Apr-21,20-Mar-21,TREATMENT,50,COVID,CHINA,ALL,"up to 85 Years   (Child, Adult, Older Adult)",TRADITIONAL CHINESE MEDICINE PRESCRIPTION,LENGTH OF HOSPITAL STAY (DAYS),A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19
NCT04323345,Recruiting,Interventional,Phase 3,Misr University for Science and Technology,Other,15-Apr-20,15-Jan-21,15-Dec-20,TREATMENT,1000,COVID,EGYPT,ALL,"5 Years to 75 Years   (Child, Adult, Older Adult)",NATURAL HONEY,RATE OF RECOVERY FROM POSITIVE TO NEGATIVE SWAPS,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial"
NCT04323514,Recruiting,Interventional,Not Applicable,University of Palermo,Other,13-Mar-20,13-Mar-21,13-Mar-21,TREATMENT,500,HOSPITALIZED PATIENTS WITH COVID PNEUMONIA,ITALY,ALL,"Child, Adult, Older Adult",VITAMIN C,IN-HOSPITAL MORTALITY,Use of Ascorbic Acid in Patients With COVID 19
NCT04323527,Completed,Interventional,Phase 2,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Other,23-Mar-20,7-Jun-20,7-May-20,TREATMENT,278,SARS-COV INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE DIPHOSPHATE,MORTALITY RATE REDUCTION OF 50% BY DAY 28,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial"
NCT04323592,Completed,Observational [Patient Registry],,University of Trieste,Other,23-Mar-20,10-May-20,10-May-20,COHORT,173,SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PNEUMONIA,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",METHYLPREDNISOLONE,"COMPOSITE PRIMARY END-POINT: ADMISSION TO ICU, NEED FOR INVASIVE MECHANICAL VENTILATION (MV), OR ALL-CAUSE DEATH BY DAY 28",Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
NCT04323631,Withdrawn,Interventional,Early Phase 1,Rambam Health Care Campus,Other,30-Apr-20,30-Apr-20,30-Apr-20,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,NUMBER PATIENTS DEVELOPING SEVERE INFECTION OR DEATH,Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
NCT04323644,Recruiting,Observational,,University of Birmingham,Other,1-Jan-20,30-Sep-20,30-Sep-20,COHORT,1000,COVID,SPAIN,ALL,"Child, Adult, Older Adult",SURGERY,30-DAY MORTALITY,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)
NCT04323761,Approved for marketing,Expanded Access,,Gilead Sciences,Industry,,,,,,SARS-COV2 INFECTION,AUSTRALIA,ALL,"12 Years and older   (Child, Adult, Older Adult)",REMDESIVIR,,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection
NCT04323787,Recruiting,Observational,,Mayo Clinic,Other,30-Mar-20,30-Apr-21,30-Apr-21,COHORT,50000,CORONAVIRUS,UNITED STATES,ALL,"Child, Adult, Older Adult",OBSERVATIONAL,ICU AND HOSPITAL MORTALITY OF COVID-19 PATIENTS,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)
NCT04323800,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,10-Jun-20,23-Jan-21,31-Dec-22,TREATMENT,500,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTI- SARS-COV-2 PLASMA,EFFICACY OF TREATMENT AT DAY 28,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19"
NCT04323839,Enrolling by invitation,Observational [Patient Registry],,"University of California, San Francisco",Other,20-Mar-20,31-Mar-24,31-Mar-24,COHORT,2000,PREGNANCY,UNITED STATES,FEMALE,"13 Years and older   (Child, Adult, Older Adult)",PREGNANT WOMEN UNDER INVESTIGATION FOR CORONAVIRUS OR DIAGNOSED WITH COVID-19,CLINICAL PRESENTATION,PRIORITY (Pregnancy Coronavirus Outcomes Registry)
NCT04323878,Recruiting,Observational,,Mario Negri Institute for Pharmacological Research,Other,1-Jun-20,21-Dec-21,21-Mar-21,COHORT,3000,EARLY CPAP VENTILATION IN COVID PATIENTS,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,DEATH OR NEED OF INTUBATION,EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.
NCT04324021,Terminated,Interventional,Phase 2/Phase 3,Swedish Orphan Biovitrum,Industry,2-Apr-20,13-Nov-20,13-Nov-20,TREATMENT,16,SARS-COV2,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",EMAPALUMAB,TREATMENT SUCCESS,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection."
NCT04324047,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,27-Mar-20,31-Dec-21,27-Mar-21,COHORT,1000,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,SURVIVAL,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients
NCT04324073,"Active, not recruiting",Interventional,Phase 2/Phase 3,Assistance Publique - Hôpitaux de Paris,Other,27-Mar-20,31-Dec-21,27-Mar-21,TREATMENT,239,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB,SURVIVAL WITHOUT NEEDS OF VENTILATOR UTILIZATION AT DAY 14.,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
NCT04324190,Recruiting,Interventional,Not Applicable,Gunther Meinlschmidt,Other,8-Apr-20,21-Dec-21,20-Jun-21,TREATMENT,600,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",GUIDED ONLINE SUPPORT PROGRAM,CHANGE IN SHORT-FORM-36 (SF-36) HEALTH SURVEY - MENTAL HEALTH COMPONENT SUMMARY SCORE,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic
NCT04324463,Recruiting,Interventional,Phase 3,Population Health Research Institute,Other,21-Apr-20,30-Jun-21,31-Dec-20,TREATMENT,4000,CORONAVIRUS,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,OUTPATIENT TRIAL - COLCHICINE VS. CONTROL AND ASPIRIN VS. CONTROL,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial"
NCT04324489,Completed,Interventional,Not Applicable,Renmin Hospital of Wuhan University,Other,6-Mar-20,30-Apr-20,16-Apr-20,TREATMENT,4,COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DAS181,IMPROVED CLINICAL STATUS,DAS181 for Severe COVID-19: Compassionate Use
NCT04324528,Recruiting,Interventional,Not Applicable,Dr. Alexander Supady,Other,27-Mar-20,26-Nov-20,26-Sep-20,TREATMENT,30,CORONAVIRUS,GERMANY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VV-ECMO + CYTOKINE ADSORPTION (CYTOSORB ADSORBER),INTERLEUKIN-6 (IL-6) LEVEL AFTER 72 HOURS,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
NCT04324606,"Active, not recruiting",Interventional,Phase 1/Phase 2,University of Oxford,Other,23-Apr-20,21-Oct-21,21-Oct-21,TREATMENT,1090,CORONAVIRUS,UNITED KINGDOM,ALL,18 Years to 55 Years   (Adult),CHADOX1 NCOV-19,ASSESS EFFICACY OF THE CANDIDATE CHADOX1 NCOV-19 AGAINST COVID-19: NUMBER OF VIROLOGICALLY CONFIRMED (PCR POSITIVE) SYMPTOMATIC CASES,"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers"
NCT04324684,Completed,Observational,,Catholic University of the Sacred Heart,Other,31-Mar-20,7-May-20,7-May-20,CASE-CONTROL,198,"PNEUMONIA, VIRAL",ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,RATE OF RECOVERY,Time of Recovery and Prognostic Factors of COVID-19 Pneumonia
NCT04324736,Completed,Observational,,Nantes University Hospital,Other,10-Mar-20,31-Dec-20,10-Apr-20,COHORT,5309,CORONAVIRUS,FRANCE,ALL,"Child, Adult, Older Adult",NO INTERVENTIONAL STUDY,ASSESS THE PREVALENCE OF SEVERE FORMS AMONG HOSPITALIZED PATIENTS WITH DIABÈTES AND COVID-19,"""Coronavirus SARS-CoV2 and Diabetes Outcomes"" : CORONADO"
NCT04324866,Not yet recruiting,Observational,,Universita di Verona,Other,1-Apr-20,20-Dec-21,20-Nov-21,COHORT,300,CORONAVIRUS INFECTION,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",NASOPHARYNGEAL SWAB,POINT PREVALENCE OF COVID-19 INFECTION,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
NCT04324996,Recruiting,Interventional,Phase 1/Phase 2,Chongqing Public Health Medical Center,Other,21-Feb-20,31-Aug-22,20-Feb-22,TREATMENT,90,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)","NK CELLS,IL15-NK CELLS,NKG2D CAR-NK CELLS,ACE2 CAR-NK CELLS,NKG2D-ACE2 CAR-NK CELLS",CLINICAL RESPONSE,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19
NCT04325048,Recruiting,Observational [Patient Registry],,Cordio Medical,Industry,23-Apr-20,21-Sep-21,21-Jun-21,COHORT,5000,CORONAVIRUS INFECTION,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",CORDIO APP,VOICE ANAYSIS,Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID-19
NCT04325061,Terminated,Interventional,Phase 4,Dr. Negrin University Hospital,Other,3-Apr-20,19-Jun-20,19-Jun-20,TREATMENT,19,ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,60-DAY MORTALITY,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19
NCT04325412,Recruiting,Observational [Patient Registry],,UMC Utrecht,Other,23-Mar-20,23-Jun-21,23-Mar-21,COHORT,1000,COVID; CARDIOVASCULAR DISEASES,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,THE INCIDENCE OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH COVID-19,Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY
NCT04325633,Terminated,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,24-Apr-20,15-Dec-20,15-Dec-20,TREATMENT,30,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",1: NAPROXEN,MORTALITY ALL CAUSES AT DAY30,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
NCT04325646,Recruiting,Observational,,Institut Pasteur,Industry,13-Mar-20,28-Feb-23,28-Feb-21,COHORT,2000,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),FRANCE,ALL,"5 Years and older   (Child, Adult, Older Adult)",HUMAN BIOLOGICAL SAMPLES,PRESENCE OF SPECIFIC ANTI-SARS-COV-2 ANTIBODIES IN THE DIFFERENT STUDY GROUPS.,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples
NCT04325672,Withdrawn,Interventional,Phase 2,Mayo Clinic,Other,1-Apr-20,31-Dec-22,31-Dec-22,BASIC SCIENCE,0,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,RNA IN SARS-COV-2,"Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19"
NCT04325867,Recruiting,Interventional,Not Applicable,Professor Adrian Covic,Other,31-Mar-20,1-Oct-20,1-Oct-20,HEALTH SERVICES RESEARCH,200,ANGINA PECTORIS,ROMANIA,ALL,"Child, Adult, Older Adult",TELE-MEDICINE PLATFORM,PROVIDING A SPECIAL ELECTRONIC PLATFORM (E-HEALTH) FOR REMOTE MANAGING CARDIOVASCULAR OUTPATIENTS,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic"
NCT04325893,Terminated,Interventional,Phase 3,"University Hospital, Angers",Other,1-Apr-20,18-Jun-20,18-Jun-20,TREATMENT,259,CORONAVIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"NUMBER OF DEATH FROM ANY CAUSE, OR THE NEED FOR INTUBATION AND MECHANICAL VENTILATION DURING THE 14 DAYS FOLLOWING INCLUSION AND START OF TREATMENT.","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study"
NCT04325906,Recruiting,Interventional,Not Applicable,Rush University Medical Center,Other,2-Apr-20,30-Jun-21,30-Mar-21,TREATMENT,346,PRONE POSITIONING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HIGH FLOW NASAL CANNULA (HFNC),TREATMENT FAILURE,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS
NCT04325919,Recruiting,Observational,,Chinese University of Hong Kong,Other,24-Feb-20,17-Jun-21,28-Feb-21,CASE-CONTROL,170,CORONAVIRUS INFECTION,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,CLINICAL,"Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)"
NCT04326036,Recruiting,Interventional,Early Phase 1,"Black Tie Medical, Inc.",Industry,25-Mar-20,31-Dec-21,1-Nov-21,TREATMENT,10,PULMONARY ALVEOLAR PROTEINOSIS,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MICROCANNULA HARVEST ADIPOSE DERIVED TISSUE STROMAL VASCULAR FRACTION (TSVF),INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection
NCT04326075,Recruiting,Interventional,Not Applicable,Mario Negri Institute for Pharmacological Research,Other,1-Dec-20,31-May-21,31-Mar-21,TREATMENT,900,CPAP VENTILATION,ITALY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CPAP TREATMENT,DEATH OR NEED OF INTUBATION,EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial
NCT04326114,Not yet recruiting,Interventional,Not Applicable,Universidad Complutense de Madrid,Other,26-Jul-20,20-Dec-20,15-Dec-20,PREVENTION,240,"DISEASE, INFECTIOUS",,ALL,"18 Years and older   (Adult, Older Adult)",INSPIRATORY TRAINING DEVICE,COVID-19 DISEASE DIAGNOSIS,Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial
NCT04326309,Recruiting,Observational,,HealthMode Inc.,Industry,25-Mar-20,25-Sep-22,25-Sep-22,COHORT,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,DATASET SIZE,Audio Data Collection for Identification and Classification of Coughing
NCT04326387,Recruiting,Observational,,CCTU- Cancer Theme,Other,6-Apr-20,7-Oct-21,7-Apr-21,COHORT,200,ACUTE DISEASE,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",SAMBA II (DIAGNOSTIC FOR THE REAL WORLD),SAMBA COVID-19 POC PCR TEST,Evaluation of Novel Diagnostic Tests for 2019-nCOV
NCT04326426,Enrolling by invitation,Interventional,Phase 3,Vanda Pharmaceuticals,Industry,13-Apr-20,31-Aug-20,1-Aug-20,TREATMENT,300,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",TRADIPITANT,TIME TO IMPROVEMENT ON A 7-POINT ORDINAL SCALE AS COMPARED TO BASELINE,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection"
NCT04326452,Recruiting,Interventional,Not Applicable,TMC HealthCare,Other,27-Mar-20,27-Mar-21,27-Mar-21,TREATMENT,30,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIDIRECTIONAL OXYGENATION MOUTHPIECE,PULSE OXIMETRY LEVEL,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection
NCT04326725,"Active, not recruiting",Observational,,Istinye University,Other,20-Mar-20,1-Sep-20,1-Jul-20,CASE-CONTROL,80,PNEUMONITIS,TURKEY,ALL,"20 Years to 90 Years   (Adult, Older Adult)",PLAQUENIL 200MG TABLET,PROTECTION AGAINST COVID-19,"Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study"
NCT04326790,Recruiting,Interventional,Phase 2,National and Kapodistrian University of Athens,Other,3-Apr-20,30-Sep-20,31-Aug-20,TREATMENT,180,CORONA VIRUS DISEASE 19 (COVID),GIBRALTAR,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,CLINICAL DETERIORATION IN THE SEMIQUANTITATIVE ORDINAL SCALE SUGGESTED BY THE WHO R&D COMMITTEE,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention
NCT04326920,"Active, not recruiting",Interventional,Phase 4,"University Hospital, Ghent",Other,24-Mar-20,31-Mar-21,31-Jan-21,TREATMENT,80,COVID,BELGIUM,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SARGRAMOSTIM,IMPROVEMENT IN OXYGENATION AT A DOSE OF 250 MCG DAILY DURING 5 DAYS IMPROVES OXYGENATION IN COVID-19 PATIENTS WITH ACUTE HYPOXIC RESPIRATORY FAILURE,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure."
NCT04327180,Recruiting,Observational,,"University Hospital, Lille",Other,30-Mar-20,21-Sep-21,21-Sep-21,COHORT,500,INFECTION VIRAL,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CORRELATION BETWEEN NASAL AND DEEP PCR POSITIVITY FOR COVID-19 PATIENTS PERFORMED AND ALL PREDICTORS FOR COVID-19 PATIENTS PERFORMED WITHIN 24 HOURS OF ADMISSION TO ICU,PCR-COVID-19 Predictors of Positivity in Patients Admitted to ICU for Respiratory Infection: A Prospective Observational Cohort Study
NCT04327206,Recruiting,Interventional,Phase 3,Murdoch Childrens Research Institute,Other,30-Mar-20,30-Mar-22,30-Jun-21,PREVENTION,10078,CORONAVIRUS DISEASE 2019 (COVID),AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",BCG VACCINE,COVID-19 DISEASE INCIDENCE,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial
NCT04327349,Enrolling by invitation,Interventional,Not Applicable,Mazandaran University of Medical Sciences,Other,28-Mar-20,30-Sep-20,20-May-20,TREATMENT,30,CORONAVIRUS INFECTION,"IRAN, ISLAMIC REPUBLIC OF",ALL,"30 Years to 70 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,MORTALITY CHANGES IN DAY 10,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
NCT04327388,Completed,Interventional,Phase 3,Sanofi,Industry,28-Mar-20,2-Sep-20,30-Jul-20,TREATMENT,420,CORONAVIRUS INFECTION,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB SAR153191,TIME TO IMPROVEMENT OF 2 POINTS IN CLINICAL STATUS ASSESSMENT FROM BASELINE USING THE 7-POINT ORDINAL SCALE,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19"
NCT04327401,Terminated,Interventional,Phase 3,Hospital Sirio-Libanes,Other,13-Apr-20,22-Jul-20,22-Jul-20,TREATMENT,299,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,VENTILATOR-FREE DAYS,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)"
NCT04327479,Recruiting,Observational [Patient Registry],,"University Hospital, Essen",Other,26-Mar-20,25-Mar-26,25-Mar-26,COHORT,728,CARDIOVASCULAR DISEASES,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ASSESSMENT OF CARDIOVASCULAR DISEASES AND CARDIOVASCULAR RISK FACTORS,ALL-CAUSE MORTALITY,Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
NCT04327505,Recruiting,Interventional,Phase 2/Phase 3,Karolinska Institutet,Other,3-Jun-20,31-Dec-22,31-Dec-21,TREATMENT,200,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),GERMANY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",HYPERBARIC OXYGEN,ICU ADMISSION,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19"
NCT04327531,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,26-Mar-20,28-May-20,22-May-20,ECOLOGIC OR COMMUNITY,200,COVID,TURKEY,ALL,25 Years to 55 Years   (Adult),TURKISH PHYSICIANS,EVALUATION OF COVID-19 KNOWLEDGE LEVEL OF TURKISH PHYSICIANS,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study"
NCT04327570,Recruiting,Observational [Patient Registry],,Universitaire Ziekenhuizen Leuven,Other,27-Mar-20,30-Sep-20,30-Sep-20,OTHER,100,CORONAVIRUS INFECTION,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT SAMPLING,CLINICAL FEATURES,In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2
NCT04327674,Recruiting,Observational [Patient Registry],,University of Aarhus,Other,14-Mar-20,15-May-20,15-May-20,COHORT,375,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,FLUS FINDINGS AND RESPIRATORY FAILURE,The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19
NCT04327804,Recruiting,Observational,,Dr. Deneen Vojta,Industry,25-Mar-20,10-Apr-20,3-Apr-20,CASE-ONLY,120,SARS-COV INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",ODD/EVEN BIRTH YEAR INTERVENTION GROUPS,DETECTION OF SARS-COV-2 VIRUS,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
NCT04328012,Recruiting,Interventional,Phase 2/Phase 3,Bassett Healthcare,Other,6-Apr-20,1-Aug-21,1-Jun-21,TREATMENT,100,SARS-COV2 INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES COVID-19 ORDINAL SEVERITY SCALE (NCOSS),Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)
NCT04328129,Recruiting,Interventional,Not Applicable,Institut Pasteur,Industry,23-Mar-20,23-Mar-22,23-Mar-22,SCREENING,1300,CORONAVIRUS INFECTION,FRENCH GUIANA,ALL,"Child, Adult, Older Adult",HUMAN BIOLOGICAL SAMPLES,EVALUATION OF THE EXTENT OF THE VIRUS TRANSMISSION WITHIN HOUSEHOLDS,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions
NCT04328272,Not yet recruiting,Interventional,Phase 3,Prof. Dr. Umar Farooq,Other,28-Mar-20,28-Jun-20,28-May-20,TREATMENT,75,COVID,PAKISTAN,ALL,18 Years to 50 Years   (Adult),HYDROXYCHLOROQUINE 200 MG ORAL TABLET,NATIONAL EARLY WARNING SCORE EQUAL TO ZERO,Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study
NCT04328285,"Active, not recruiting",Interventional,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Other,14-Apr-20,30-Mar-21,30-Mar-21,PREVENTION,1200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,OCCURRENCE OF AN SYMPTOMATIC OR ASYMPTOMATIC SARS-COV-2 INFECTION AMONG HEALTHCARE WORKERS (HCWS),Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial
NCT04328441,"Active, not recruiting",Interventional,Phase 3,UMC Utrecht,Other,25-Mar-20,30-Apr-21,31-Mar-21,PREVENTION,1500,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",BCG VACCINE,HEALTH CARE WORKERS ABSENTEEISM,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial."
NCT04328454,Recruiting,Observational,,Shanghai 10th People's Hospital,Other,30-Jan-20,15-Apr-20,2-Apr-20,COHORT,120,CORONAVIRUS,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",RETROSPECTIVE ANALYSIS,TIME TO NEGATIVE CONVERSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province
NCT04328467,"Active, not recruiting",Interventional,Phase 3,University of Minnesota,Other,6-Apr-20,20-Aug-21,20-Aug-21,TREATMENT,1500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COVID-19-FREE SURVIVAL,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial
NCT04328480,Recruiting,Interventional,Phase 3,Estudios Clínicos Latino América,Other,17-Apr-20,30-Mar-21,30-Mar-21,TREATMENT,1200,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,COMPOSITE OUTCOME: NEW REQUIREMENT FOR MECHANICAL VENTILATION OR DEATH,The ECLA PHRI COLCOVID Trial
NCT04328493,Recruiting,Interventional,Phase 2,"Oxford University Clinical Research Unit, Vietnam",Other,7-Apr-20,1-Apr-22,1-Apr-21,TREATMENT,250,SARS-COV2 INFECTION,VIETNAM,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE PHOSPHATE,VIRAL CLEARANCE TIME,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam
NCT04328961,Completed,Interventional,Phase 2/Phase 3,University of Washington,Other,31-Mar-20,8-Oct-20,24-Sep-20,PREVENTION,829,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,POLYMERASE CHAIN REACTION (PCR) CONFIRMED SARS-COV-2 INFECTION,"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study"
NCT04329195,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,9-Apr-20,9-Aug-20,9-May-20,TREATMENT,554,HISTORY OF CARDIOVASCULAR DISEASE TREATED WITH RAS BLOCKERS AND WITH SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",1: DISCONTINUATION OF RAS BLOCKER THERAPY,"TIME TO CLINICAL IMPROVEMENT FROM DAY 0 TO DAY 28 (IMPROVEMENT OF TWO POINTS ON A SEVEN-CATEGORY ORDINAL SCALE, OR LIVE DISCHARGE FROM THE HOSPITAL, WHICHEVER COMES FIRST)",ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study
NCT04329507,Recruiting,Observational,,NHS Lothian,Other,25-Mar-20,25-Mar-21,25-Mar-21,COHORT,200,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BREATH TEST,"TO PERFORM A STUDY IN PATIENTS WITH CLINICAL FEATURES OF PNEUMONIA/CHEST INFECTION TO IDENTIFY A SIGNATURE OF COVID-19 PNEUMONIA IN PATIENTS EXPOSED TO SARS-COV-2, COMPARED TO UNEXPOSED PATIENTS OR THOSE WITHOUT.",Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)
NCT04329533,Completed,Interventional,Not Applicable,University of Arizona,Other,13-Apr-20,1-Nov-20,1-Nov-20,SUPPORTIVE CARE,101,PERCEIVED STRESS,UNITED STATES,FEMALE,"18 Years to 99 Years   (Adult, Older Adult)","""CALM"" IS A MINDFULNESS MEDITATION MOBILE APP",PERCEIVED STRESS SCALE,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial
NCT04329546,Recruiting,Observational,,"University Hospital, Geneva",Other,27-Mar-20,31-Mar-22,31-Jan-22,COHORT,250,SARS-COV2 VIRAL KINETICS AND HOST IMMUNE RESPONSES,SWITZERLAND,ALL,"Child, Adult, Older Adult",NA (NO INTERVENTION),IMMUNOGENICITY PRIMARY OUTCOME: GEOMETRIC MEAN ANTIBODY CONCENTRATION OF TOTAL IGG ANTIBODIES TO SARS-COV-2 ASSESSED BY ELISA AT 28 DAYS,How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study
NCT04329559,Completed,Observational [Patient Registry],,Hepatopancreatobiliary Surgery Institute of Gansu Province,Other,30-Mar-20,10-Feb-21,10-Feb-21,COHORT,21,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",,ALL-CAUSE MORTALITY OF COVID-19 PATIENTS WITH LIVER CIRRHOSIS,Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study
NCT04329572,Suspended,Interventional,Early Phase 1,Azidus Brasil,Industry,23-Apr-20,30-Jun-20,31-May-20,TREATMENT,400,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,"EVOLUTION OF ACUTE RESPIRATORY SYNDROME, OXYGEN SATURATION HEMODYNAMIC STABILITY","Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus"
NCT04329611,Terminated,Interventional,Phase 3,Dr. Michael Hill,Other,13-Apr-20,20-Jul-20,20-Jul-20,TREATMENT,148,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"COMPOSITE OF HOSPITALIZATION, INVASIVE MECHANICAL VENTILATION OR DEATH WITHIN 30 DAYS","A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease."
NCT04329650,Recruiting,Interventional,Phase 2,Judit Pich Martínez,Other,15-Apr-20,20-May-20,20-May-20,TREATMENT,200,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",SILTUXIMAB,PROPORTION OF PATIENTS REQUIRING ICU ADMISSION AT ANY TIME WITHIN THE STUDY PERIOD.,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia"
NCT04329832,"Active, not recruiting",Interventional,Phase 2,"Intermountain Health Care, Inc.",Other,30-Mar-20,31-Dec-21,18-Dec-20,TREATMENT,85,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COVID ORDINAL OUTCOMES SCALE AT 14 DAYS,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial
NCT04329897,Completed,Interventional,Not Applicable,University of Iowa,Other,5-Apr-20,1-Jun-20,15-May-20,SUPPORTIVE CARE,90,HIP OSTEOARTHRITIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SOFTWARE MESSAGING,CHANGE IN REPORTED PAIN INTENSITY SCORE (PROMIS PAIN INTENSITY 3A) PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM PAIN INTENSITY (PROMIS) 3A SHORT FORM SCORES COLLECTED FROM ALL PARTICIPATING SUBJECTS.,Acceptance and Commitment Therapy Delivered by Automated Software Messaging
NCT04329923,Terminated,Interventional,Phase 2,"Ravi Amaravadi, MD",Other,9-Apr-20,13-Nov-20,11-Nov-20,TREATMENT,173,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE 400 MG TWICE A DAY,TIME TO RELEASE FROM QUARANTINE TIME,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
NCT04330144,Not yet recruiting,Interventional,Phase 3,Gangnam Severance Hospital,Other,1-Apr-20,30-Mar-22,30-Mar-21,PREVENTION,2486,CONTACT PERSON FROM COVID CONFIRMED PATIENT,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE AS POST EXPOSURE PROPHYLAXIS,THE RATE OF COVID-19,A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)
NCT04330261,Recruiting,Observational,,University of Calgary,Other,18-Mar-20,17-Mar-22,17-Mar-21,COHORT,12500,COVID,CANADA,ALL,"up to 18 Years   (Child, Adult)",EXPOSURE (NOT INTERVENTION) - SARS-COV-2 INFECTION,CLINICAL CHARACTERISTICS OF CHILDREN WITH SARS-COV-2,Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments
NCT04330300,Suspended,Interventional,Phase 4,"National University of Ireland, Galway, Ireland",Other,30-Apr-20,1-Dec-21,31-Jul-21,PREVENTION,2414,HYPERTENSION,IRELAND,ALL,"60 Years and older   (Adult, Older Adult)",THIAZIDE OR THIAZIDE-LIKE DIURETICS,"NUMBER OF COVID-19 POSITIVE PARTICIPANTS WHO DIE, REQUIRE INTUBATION IN ICU, OR REQUIRE HOSPITALIZATION FOR NON-INVASIVE VENTILATION (NIV)",The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial
NCT04330495,Not yet recruiting,Interventional,Phase 4,Instituto de Investigación Marqués de Valdecilla,Other,6-Apr-20,6-Nov-20,6-Nov-20,PREVENTION,800,COVID,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HIDROXICLOROQUINA,INCIDENCE RATE OF NEW COVID-19 CASES IN BOTH ARMS,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection"
NCT04330521,Recruiting,Observational,,Stanford University,Other,8-Apr-20,22-May-21,22-May-21,COHORT,50,CANCER,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,NUMBER OF PARTICIPANTS WHO FILL OUT THE SURVEY AND PARTICIPATE IN THE SEMI-STRUCTURED INTERVIEWS.,Impact of the Coronavirus (COVID-19) on Patients With Cancer
NCT04330586,Recruiting,Interventional,Phase 2,Korea University Guro Hospital,Other,1-Apr-20,31-Mar-21,31-Mar-21,TREATMENT,66,COVID,"KOREA, REPUBLIC OF",ALL,"18 Years to 80 Years   (Adult, Older Adult)",CICLESONIDE METERED DOSE INHALER [ALVESCO],RATE OF SARS-COV-2 ERADICATION AT DAY 14 FROM STUDY ENROLLMENT,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
NCT04330599,Recruiting,Observational,,Queen Mary University of London,Other,1-May-20,1-Apr-25,1-Apr-25,COHORT,12000,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",,INCIDENCE OF CONFIRMED COVID-19,Longitudinal Population-based Observational Study of COVID-19 in the UK Population
NCT04330638,"Active, not recruiting",Interventional,Phase 3,"University Hospital, Ghent",Other,3-Apr-20,21-Mar-21,21-Jan-21,TREATMENT,342,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",USUAL CARE,TIME TO CLINICAL IMPROVEMENT,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome"
NCT04330690,Recruiting,Interventional,Phase 2,Sunnybrook Health Sciences Centre,Other,18-Mar-20,18-May-22,18-Mar-22,TREATMENT,2900,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON BETA-1A,EFFICACY OF INTERVENTIONS AS ASSESSED BY ALL-CAUSE MORTALITY,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)"
NCT04331054,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,13-Apr-20,13-Jan-22,13-Jan-22,TREATMENT,436,COVID INFECTION,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",2: USUAL PRACTICE + SYMBICORT RAPIHALER,TIME (IN DAYS) TO CLINICAL IMPROVEMENT WITHIN 30 DAYS AFTER RANDOMIZATION,Protective Role of Inhaled Steroids for Covid-19 Infection
NCT04331106,Recruiting,Observational,,"Charite University, Berlin, Germany",Other,27-Mar-20,22-Apr-21,22-Apr-21,COHORT,7500,ANXIETY RELATED TO THE COVID PANDEMIC,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE QUESTIONNAIRE,CHARACTERISTICS OF COVID-19-RELATED ANXIETY,Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany
NCT04331171,Recruiting,Observational [Patient Registry],,Weprom,Other,17-Mar-20,15-Nov-20,15-Nov-20,COHORT,12000000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",WEB APPLICATION USERS,TO ASSESS OF THE EVOLUTION OF THE NUMBER OF CALLS TO EMERGENCY SERVICE WITHIN 12 DAYS AFTER THE LAUNCH OF THE APPLICATION HTTPS://WWW.MALADIECORONAVIRUS.FR/,Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage
NCT04331366,Completed,Interventional,Not Applicable,Emory University,Other,8-Apr-20,31-Aug-20,31-Aug-20,SUPPORTIVE CARE,2,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GO2 PEEP MOUTHPIECE,OXYGEN SATURATION BY PULSE OXIMETRY,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19
NCT04331470,Recruiting,Interventional,Phase 2/Phase 3,Fasa University of Medical Sciences,Other,4-Apr-20,20-May-20,20-Apr-20,TREATMENT,30,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"15 Years to 100 Years   (Child, Adult, Older Adult)",LEVAMISOLE PILL + BUDESONIDE+FORMOTEROL INHALER,CLEAR CHEST CT-SCAN,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease
NCT04331509,Recruiting,Observational,,King's College London,Other,23-Mar-20,23-Mar-22,23-Mar-22,COHORT,10000000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,PHYSICAL HEALTH SYMPTOMS,COVID-19 Symptom Tracker
NCT04331574,Recruiting,Observational [Patient Registry],,Societa Italiana dell'Ipertensione Arteriosa,Other,10-Mar-20,30-Apr-20,10-Apr-20,CASE-ONLY,2000,COVID,ITALY,ALL,"18 Years to 120 Years   (Adult, Older Adult)",,NUMBERS OF COVID-19 PATIENTS ENROLLED THAT USE ACE INHIBITORS AND/OR ANGIOTENSIN RECEPTOR BLOCKERS (ARB) AS ANTIHYPERTENSIVE AGENTS,Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19
NCT04331600,Completed,Interventional,Phase 4,Wroclaw Medical University,Other,16-Apr-20,17-Dec-20,17-Dec-20,TREATMENT,16,COVID,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE PHOSPHATE,COVID-19-RELATED HOSPITALIZATION OR ALL-CAUSE DEATH,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications"
NCT04331613,Recruiting,Interventional,Phase 1/Phase 2,Chinese Academy of Sciences,Other,27-Jan-20,20-Dec-21,20-Dec-21,TREATMENT,9,COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CASTEM,ADVERSE REACTION (AE) AND SEVERE ADVERSE REACTION (SAE),Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)
NCT04331665,Not yet recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,20-Apr-20,31-Jan-21,30-Oct-20,TREATMENT,64,COVID,CANADA,ALL,"12 Years and older   (Child, Adult, Older Adult)",RUXOLITINIB,PROPORTION OF PATIENTS WITH COVID-19 PNEUMONIA WHO BECOME CRITICALLY ILL (DEFINED AS REQUIRING MECHANICAL VENTILATION AND/OR FIO2 OF 60% OF MORE),A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia
NCT04331795,Completed,Interventional,Phase 2,University of Chicago,Other,4-Apr-20,5-Jun-20,5-Jun-20,TREATMENT,32,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,CLINICAL RESPONSE,Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis
NCT04331808,"Active, not recruiting",Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,30-Mar-20,31-Dec-21,31-Mar-21,TREATMENT,228,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,SURVIVAL WITHOUT NEEDS OF VENTILATOR UTILIZATION AT DAY 14. GROUP 1,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)
NCT04331834,Completed,Interventional,Phase 3,Barcelona Institute for Global Health,Other,3-Apr-20,31-Dec-20,25-Jun-20,PREVENTION,275,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CONFIRMED CASES OF A COVID-19,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial"
NCT04331886,Recruiting,Observational,,"Target PharmaSolutions, Inc.",Industry,13-Apr-20,21-Mar-21,21-Mar-21,COHORT,5000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NATURAL HISTORY OF COVID-19: CHARACTERISTICS OF COVID-19,An Observational Study of Patients With Coronavirus Disease 2019
NCT04331899,"Active, not recruiting",Interventional,Phase 2,Stanford University,Other,24-Apr-20,21-May-21,14-Aug-20,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PEGINTERFERON LAMBDA-1A,DURATION OF VIRAL SHEDDING OF SARS-COV-2 BY QRT-PCR,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19"
NCT04332016,Recruiting,Observational,,"University Hospital, Bordeaux",Other,2-Apr-20,23-Mar-21,23-Mar-21,CASE-ONLY,2000,INFECTION VIRAL,FRANCE,ALL,"up to 100 Years   (Child, Adult, Older Adult)",BIOLOGICAL SAMPLES COLLECTION,COVID-19 DESEASE DESCRIPTION,Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).
NCT04332042,Not yet recruiting,Interventional,Phase 2,Università Politecnica delle Marche,Other,10-Apr-20,10-Jul-20,20-Jun-20,TREATMENT,50,SARS-COV2 RELATED INTERSTITIAL PNEUMONIA,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TOFACITINIB,NEED OF MECHANICAL VENTILATION,TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia
NCT04332081,Terminated,Interventional,Not Applicable,NYU Langone Health,Other,6-Apr-20,29-May-20,29-May-20,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN THERAPY (HBOT),MORTALITY,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19
NCT04332094,Recruiting,Interventional,Phase 2,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Other,2-Apr-20,20-Oct-21,20-Sep-21,TREATMENT,276,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,IN-HOSPITAL MORTALITY,"Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)"
NCT04332107,Recruiting,Interventional,Phase 3,Thomas M. Lietman,Other,22-May-20,30-Dec-21,30-Sep-21,TREATMENT,2271,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AZITHROMYCIN,DAY 14 BINARY ASSESSMENT OF SYMPTOMS,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19
NCT04332380,Completed,Interventional,Phase 2,Universidad del Rosario,Other,1-May-20,28-Jul-20,28-Jul-20,TREATMENT,10,CORONAVIRUS,COLOMBIA,ALL,18 Years to 60 Years   (Adult),PLASMA,CHANGE IN VIRAL LOAD,Convalescent Plasma for Patients With COVID-19: A Pilot Study
NCT04332666,Not yet recruiting,Interventional,Phase 2/Phase 3,Erasme University Hospital,Other,30-Sep-20,15-Jun-21,30-Dec-20,TREATMENT,60,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN 1-7,VENTILATOR FREE DAYS,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial"
NCT04332835,Completed,Interventional,Phase 2/Phase 3,Universidad del Rosario,Other,8-Aug-20,15-Nov-20,31-Oct-20,TREATMENT,92,CORONAVIRUS,COLOMBIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",PLASMA,CHANGE IN VIRAL LOAD,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study"
NCT04332913,Recruiting,Observational,,University of L'Aquila,Other,1-Apr-20,31-Mar-21,31-Dec-20,COHORT,30,COVID PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,PERCENTAGE OF PATIENTS WITH COMPLETE RECOVERY DEFINED AS FEVER DISAPPEARANCE AND RETURN TO NORMAL PERIPHERAL OXYGEN SATURATION VALUES (SPO2) AFTER 14 DAYS FROM THE END OF TREATMENT WITH TOCILIZUMAB.,Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study
NCT04332991,Completed,Interventional,Phase 3,Massachusetts General Hospital,Other,2-Apr-20,23-Jul-20,19-Jun-20,TREATMENT,479,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COVID ORDINAL OUTCOMES SCALE ON DAY 15,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
NCT04333225,Completed,Interventional,Phase 2,Baylor Research Institute,Other,3-Apr-20,30-Jun-20,30-Jun-20,PREVENTION,228,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,RATE OF COVID-19 POSITIVE CONVERSION,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures
NCT04333251,Not yet recruiting,Interventional,Phase 1,Baylor Research Institute,Other,1-Apr-20,31-Dec-22,31-Dec-22,TREATMENT,115,"PNEUMONIA, INTERSTITIAL",,ALL,"18 Years and older   (Adult, Older Adult)",HIGH-TITER ANTI-SARS-COV-2 PLASMA,REDUCTION IN OXYGEN AND VENTILATION SUPPORT,Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19
NCT04333355,Terminated,Interventional,Phase 1,Hospital San Jose Tec de Monterrey,Other,8-May-20,20-Aug-20,20-Aug-20,TREATMENT,12,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,SIDE EFFECTS,Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection
NCT04333368,"Active, not recruiting",Interventional,Phase 1/Phase 2,Assistance Publique - Hôpitaux de Paris,Other,6-Apr-20,6-Apr-22,30-Jan-21,TREATMENT,47,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",UMBILICAL CORD WHARTON'S JELLY-DERIVED HUMAN,RESPIRATORY EFFICACY EVALUATED BY THE INCREASE IN PAO2/FIO2 RATIO FROM BASELINE TO DAY 7 IN THE EXPERIMENTAL GROUP COMPARED WITH THE PLACEBO GROUP,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS
NCT04333407,Recruiting,Interventional,Not Applicable,Imperial College London,Other,3-Apr-20,30-Mar-21,30-Mar-21,TREATMENT,3170,COVID,UNITED KINGDOM,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ASPIRIN 75MG,ALL-CAUSE MORTALITY AT 30 DAYS AFTER ADMISSION,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.
NCT04333420,Recruiting,Interventional,Phase 2/Phase 3,InflaRx GmbH,Industry,31-Mar-20,31-Aug-21,31-May-21,TREATMENT,390,SEVERE COVID PNEUMONIA,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",SOC + IFX-1,MORTALITY,"A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia"
NCT04333472,Recruiting,Interventional,Phase 2,Can-Fite BioPharma,Industry,6-Jan-21,6-Jul-21,6-Mar-21,TREATMENT,40,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",PICLIDENOSON,PROPORTION OF SUBJECTS ALIVE AND FREE OF RESPIRATORY FAILURE,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial"
NCT04333550,Recruiting,Interventional,Phase 1/Phase 2,Kermanshah University of Medical Sciences,Other,20-Apr-21,21-Mar-21,20-Sep-21,TREATMENT,50,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"3 Years to 99 Years   (Child, Adult, Older Adult)",DEFEROXAMINE,MORTALITY RATE,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations
NCT04333589,Recruiting,Interventional,Not Applicable,Peking University First Hospital,Other,1-Apr-20,15-Sep-20,1-Jun-20,TREATMENT,210,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FAVIPIRAVIR,VIRAL NUCLEIC ACID TEST NEGATIVE CONVERSION RATE,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive"
NCT04333628,Terminated,Interventional,Phase 2/Phase 3,"HaEmek Medical Center, Israel",Other,1-Jun-20,1-Sep-20,1-Sep-20,TREATMENT,5,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE,CHANGE IN VIRUS DURATION (VIRAL SHEDDING),"Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial"
NCT04333654,Terminated,Interventional,Phase 1,Sanofi,Industry,12-Apr-20,26-May-20,26-May-20,TREATMENT,8,CORONAVIRUS INFECTION,BELGIUM,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SAR321068,CHANGE FROM BASELINE TO DAY 3 IN NASOPHARYNGEAL SARS-COV-2 VIRAL LOAD (IF QUANTITATIVE PCR IS AVAILABLE),"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19"
NCT04333693,Not yet recruiting,Observational [Patient Registry],,Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery,Other,1-Apr-20,1-Nov-20,1-Oct-20,COHORT,50,VASCULAR SURGICAL PROCEDURES,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",VASCULAR SURGERY,30-DAYS MORTALITY,Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study (Covid-VAS)
NCT04333732,Recruiting,Interventional,Phase 3,Washington University School of Medicine,Other,4-Sep-20,21-Aug-21,21-Aug-21,PREVENTION,30000,COVID,GHANA,ALL,"18 Years and older   (Adult, Older Adult)",MR OR M-M-R II ® VACCINE,SYMPTOMATIC COVID-19,"An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults"
NCT04333849,Completed,Observational,,"University Hospital, Angers",Other,25-Mar-20,11-May-20,11-May-20,COHORT,132,CORONAVIRUS,FRANCE,ALL,70 Years and older   (Older Adult),,"PREFERRED MEANS OF COMMUNICATION FOR ELDERLY PEOPLE IN ISOLATION, HOSPITALIZED IN THE ACUTE CARE GERIATRIC UNIT OR RESIDING AT ST NICOLAS NURSING HOME (ANGERS UH).",Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19
NCT04333862,Recruiting,Observational,,"University Hospital Inselspital, Berne",Other,19-Mar-20,31-Jan-22,31-Jan-22,COHORT,500,SARS-COV2,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",,FRACTION OF HEALTHCARE WORKERS INFECTED WITH SARS-COV-2,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy
NCT04333875,"Active, not recruiting",Observational [Patient Registry],,"University Hospital Inselspital, Berne",Other,20-Mar-20,20-Dec-21,20-Dec-21,COHORT,71,AORTIC VALVE STENOSIS,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",TAVR OR SAVR,"COMPOSITE OF ALL-CAUSE MORTALITY, DISABLING AND NON-DISABLING STROKE, AND HOSPITALIZATION FOR HEART FAILURE",Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis - a Collateral Effect of the SARS-CoV-2 Pandemic (AS DEFER)
NCT04333914,Recruiting,Interventional,Phase 2,Centre Leon Berard,Other,15-Apr-20,21-Aug-21,21-Jun-21,TREATMENT,219,SARS-COV2 (COVID) INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AUTOPHAGY INHIBITOR (GNS651),28-DAY SURVIVAL RATE,"A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection."
NCT04333953,Recruiting,Observational [Patient Registry],,University of Missouri-Columbia,Other,1-Apr-20,1-Oct-20,1-Oct-20,CASE-ONLY,500,HIV/AIDS,UNITED STATES,ALL,"Child, Adult, Older Adult",NO INTERVENTION,MORTALITY,Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2
NCT04334005,Not yet recruiting,Interventional,Not Applicable,Universidad de Granada,Other,10-Apr-20,30-Jun-20,30-Jun-20,TREATMENT,200,PATIENTS INFECTED WITH COVID,SPAIN,ALL,"40 Years to 70 Years   (Adult, Older Adult)",VITAMIN D,COMPOSITE OF CUMULATIVE DEATH (I.E. MORTALITY) FOR ALL CAUSES AND FOR SPECIFIC CAUSES.,Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19
NCT04334044,Recruiting,Interventional,Phase 1/Phase 2,Grupo Cooperativo de Hemopatías Malignas,Other,1-Sep-20,1-May-21,1-Mar-21,TREATMENT,20,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB ORAL TABLET,RECOVERY OF PNEUMONIA,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib
NCT04334148,Completed,Interventional,Phase 3,Adrian Hernandez,Other,22-Apr-20,9-Jan-21,9-Jan-21,PREVENTION,1363,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,NUMBER OF PARTICIPANTS WITH CLINICAL INFECTION WITH COVID-19 INFECTION,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)
NCT04334252,Completed,Observational,,Jessa Hospital,Other,17-Apr-20,20-Dec-20,20-Dec-20,COHORT,528,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PREVALENCE OF SYMPTOMS,Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence
NCT04334265,Recruiting,Interventional,Not Applicable,Peking University First Hospital,Other,1-Apr-20,1-Dec-20,1-Jun-20,TREATMENT,750,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ANLUOHUAXIAN,CHANGES IN HIGH-RESOLUTION COMPUTER TOMOGRAPHY OF THE LUNG,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study"
NCT04334291,Completed,Observational [Patient Registry],,IVAN J NUÑEZ GIL,Other,23-Mar-20,31-May-20,1-May-20,COHORT,8168,COVID,SPAIN,ALL,"Child, Adult, Older Adult",OBSERVATIONAL (REGISTRY),DEATH,International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19)
NCT04334382,Recruiting,Interventional,Phase 3,"Intermountain Health Care, Inc.",Other,2-Apr-20,31-Dec-21,31-Dec-20,TREATMENT,1550,COVID,UNITED STATES,ALL,"45 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,HOSPITALIZATION WITHIN 14 DAYS OF ENROLLMENT,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial
NCT04334434,Completed,Interventional,Not Applicable,"Kubra Koce, MSc PT",Other,30-Jul-20,15-Dec-20,15-Sep-20,PREVENTION,30,TELEREHABILITATION,TURKEY,ALL,65 Years and older   (Older Adult),TELEREHABILITATION,PHYSICAL ACTIVITY SCALE FOR THE ELDERLY,Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic
NCT04334460,"Active, not recruiting",Interventional,Phase 2,Blade Therapeutics,Industry,4-May-20,21-Nov-21,11-Nov-20,TREATMENT,120,SARS-COV2,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",BLD-2660,TIME TO RECOVERY,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment"
NCT04334512,Recruiting,Interventional,Phase 2,ProgenaBiome,Other,22-Jun-20,21-Sep-21,21-Jun-21,TREATMENT,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,THE RATE OF RECOVERY OF MILD OR MODERATE COVID-19 IN PATIENTS USING QUINTUPLE THERAPY,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection"
NCT04334629,Recruiting,Interventional,Phase 4,King's College London,Other,26-May-20,25-Sep-21,25-May-21,TREATMENT,230,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",IBUPROFEN,DISEASE PROGRESSION,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial"
NCT04334850,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-20,20-Aug-21,20-Jul-21,TREATMENT,194,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COMBINED USE OF A RESPIRATORY BROAD PANEL MULTIPLEX PCR AND PROCALCITONIN,NUMBER OF ANTIBIOTIC FREE DAYS,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial"
NCT04334876,Not yet recruiting,Observational,,Indiana University,Other,1-Apr-20,1-Jan-21,1-Nov-20,ECOLOGIC OR COMMUNITY,340,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 IGG ANTIBODY TESTING KIT,VALIDATION OF SARS-COV-2 IGG ANTIBODY TEST,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis
NCT04334928,Recruiting,Interventional,Phase 3,Plan Nacional sobre el Sida (PNS),Other,15-Apr-20,31-Dec-20,31-Dec-20,PREVENTION,4000,CORONAVIRUS INFECTION,SPAIN,ALL,"18 Years to 70 Years   (Adult, Older Adult)",EMTRICITABINE/TENOFOVIR DISOPROXIL,NUMBER OF CONFIRMED SYMPTOMATIC INFECTIONS OF SARS-COV-2 (COVID-19),Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo
NCT04334954,"Active, not recruiting",Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,26-Aug-20,31-Mar-22,31-Mar-22,CASE-ONLY,11363,SARS-COV2 VIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PEOPLE WITH DETECTABLE ANTIBODIES TO SARS-COV2,SARS-COV2 Pandemic Serosurvey and Blood Sampling
NCT04334967,Suspended,Interventional,Phase 4,Providence Health & Services,Other,30-Mar-20,27-May-22,27-May-21,TREATMENT,13,COVID,UNITED STATES,ALL,"45 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TOTAL HOSPITALIZATION,Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment
NCT04334980,Recruiting,Interventional,Phase 1,Symvivo Corporation,Industry,2-Nov-20,28-Feb-22,8-Feb-22,PREVENTION,24,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",BACTRL-SPIKE,FREQUENCY OF ADVERSE EVENTS,"A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults"
NCT04335019,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-21,20-May-21,20-Apr-21,OTHER,300,2019-NCOV (COVID),,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY ULTRASOUND,ASSOCIATION OF PULMONARY LESIONS ON ULTRASOUND ON D0 CLASSIFIED ACCORDING TO THREE STAGES OF SEVERITY,Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +
NCT04335032,Not yet recruiting,Interventional,Phase 3,S.L.A. Pharma AG,Industry,9-Nov-20,31-Jul-21,13-Jul-21,TREATMENT,284,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",EICOSAPENTAENOIC ACID GASTRO-RESISTANT CAPSULES,EVALUATION OF EPA-FFA EFFICACY COMPARED TO PLACEBO,"A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2"
NCT04335071,Terminated,Interventional,Phase 2,"University Hospital Inselspital, Berne",Other,26-Apr-20,27-Sep-20,27-Sep-20,TREATMENT,5,SARS-COV2 INFECTION,SWITZERLAND,ALL,"30 Years to 80 Years   (Adult, Older Adult)",TOCILIZUMAB (TCZ),NUMBER OF PATIENTS WITH ICU ADMISSION,"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)"
NCT04335084,Recruiting,Interventional,Phase 2,ProgenaBiome,Other,22-Jun-20,21-Dec-21,21-Dec-21,PREVENTION,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PREVENTION OF COVID-19 SYMPTOMS AS RECORDED IN A DAILY DIARY,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection"
NCT04335097,Recruiting,Interventional,Not Applicable,Lars Wik,Other,22-Apr-20,20-Dec-25,8-Apr-21,SUPPORTIVE CARE,214,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",BIOSENSORS,STOP HOME ISOLATION,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study"
NCT04335123,Completed,Interventional,Phase 1,University of Kansas Medical Center,Other,4-Apr-20,17-Aug-20,21-Jun-20,TREATMENT,34,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AS ASSESSED BY PROTOCOL DEFINITION OF AE,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19
NCT04335136,Completed,Interventional,Phase 2,Apeiron Biologics,Industry,30-Apr-20,26-Dec-20,26-Dec-20,TREATMENT,200,COVID,AUSTRIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RHACE2 APN01,ALL CAUSE-DEATH OR INVASIVE MECHANICAL VENTILATION,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
NCT04335162,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,28-Feb-20,31-Aug-21,31-Aug-21,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DETERMINE THE INCIDENCE OF CARDIOMYOPATHIES AND VENOUS THROMBOEMBOLISM,Cardiovascular Complications in Patients With COVID-19
NCT04335188,Recruiting,Observational,,IHF GmbH - Institut für Herzinfarktforschung,Other,6-Apr-20,30-Sep-21,31-Jul-21,OTHER,4000,COVID,GERMANY,ALL,"Child, Adult, Older Adult",PROSPECTIVE OBERSERVATIONAL REGISTRY,CHEST X-RAY,"COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study"
NCT04335201,Recruiting,Interventional,Phase 2,IRCCS San Raffaele,Other,20-May-20,31-Aug-21,20-Jun-21,TREATMENT,50,PATIENTS WITH COVID PNEUMONIA WILL ALLOW TO DETECT AN ABSOLUTE REDUCTION IN THE RATE OF RESPIRATORY-FAILURE,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",DEFIBROTIDE INJECTION,TO ABLE TO REDUCE THE PROGRESSION OF ACUTE RESPIRATORY FAILURE,Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia
NCT04335279,Completed,Interventional,Not Applicable,Lady Davis Institute,Other,9-Apr-20,24-Jul-20,3-Jun-20,SUPPORTIVE CARE,172,SCLERODERMA,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SPIN-CHAT PROGRAM,ANXIETY: PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) ANXIETY 4A V1.0,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients
NCT04335305,Recruiting,Interventional,Phase 2,MedSIR,Other,9-Apr-20,30-Jun-21,31-Dec-20,TREATMENT,24,COVID,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TOCILIZUMAB,PERCENTAGE OF PATIENTS WITH NORMALIZATION OF SPO2 ≥96% ON ROOM AIR (MEASURED WITHOUT ANY RESPIRATORY SUPPORT FOR AT LEAST 15 MINUTES,"A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia"
NCT04335552,Terminated,Interventional,Phase 2,Duke University,Other,17-Apr-20,26-Jun-20,17-Jun-20,TREATMENT,11,SARS-COV2,UNITED STATES,ALL,"12 Years and older   (Child, Adult, Older Adult)",STANDARD OF CARE,WORLD HEALTH ORGANIZATION (WHO) ORDINAL SCALE MEASURED AT 14 DAYS AFTER ENROLLMENT,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection"
NCT04335630,Recruiting,Observational,,Memorial Hermann Health System,Other,30-Mar-20,22-Mar-21,21-Mar-21,CASE-CONTROL,500,CARDIOVASCULAR DISEASES,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","ELECTROCARDIOGRAM, TELEMETRY, ECHOCARDIOGRAM, LABORATORY VALUES","PREVALENCE OF CARDIOMYOPATHY, MYOCARDIAL INFARCTION, HEART FAILURE, CLINICALLY SIGNIFICANT ARRHYTHMIAS, CARDIOGENIC SHOCK OR CARDIAC ARREST.",Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019
NCT04335747,Recruiting,Observational,,Salome Kristensen,Other,23-Apr-20,1-Sep-21,1-Aug-21,COHORT,333,RHEUMATOID ARTHRITIS,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 INFECTION,DISEASE ACTIVITY,COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
NCT04335773,Recruiting,Observational [Patient Registry],,"University Hospital, Akershus",Other,3-Apr-20,31-Dec-30,31-Dec-30,CASE-CONTROL,350,PEDIATRIC RESPIRATORY DISEASES,NORWAY,ALL,"up to 18 Years   (Child, Adult)",,RISK FACTORS FOR SEVERE INFECTION,"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology"
NCT04335786,Recruiting,Interventional,Phase 4,Radboud University,Other,17-Apr-20,21-Dec-21,20-Dec-21,TREATMENT,651,ACUTE RESPIRATORY DISTRESS SYNDROME,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",VALSARTAN (DIOVAN),"FIRST OCCURRENCE OF INTENSIVE CARE UNIT ADMISSION, MECHANICAL VENTILATION OR DEATH","PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease"
NCT04335851,Completed,Interventional,Not Applicable,Biruni University,Other,6-Apr-20,3-Jun-20,15-May-20,TREATMENT,68,SOCIAL ISOLATION,TURKEY,ALL,18 Years to 35 Years   (Adult),VIDEO BASED AEROBIC EXERCISE,WORLD HEALTH ORGANIZATION QUALITY OF LIFE QUESTIONNAIRE BREF,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation
NCT04336215,Recruiting,Observational,,"Rutgers, The State University of New Jersey",Other,7-Apr-20,21-Oct-21,1-May-21,COHORT,750,CORONAVIRUS,UNITED STATES,ALL,"20 Years and older   (Adult, Older Adult)",NON-INTERVENTIONAL,PREVALENCE,"Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers"
NCT04336254,Recruiting,Interventional,Phase 1/Phase 2,Renmin Hospital of Wuhan University,Other,6-Apr-20,31-Mar-21,31-Dec-20,TREATMENT,20,COVID,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ALLOGENEIC HUMAN DENTAL PULP STEM CELLS (BSH BTC & UTOOTH BTC),TTCI,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial"
NCT04336332,"Active, not recruiting",Interventional,Phase 2,"Rutgers, The State University of New Jersey",Other,1-Apr-20,30-Apr-21,30-Apr-21,TREATMENT,160,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE + AZITHROMYCIN,CHANGES IN PATIENTS VIRAL LOAD,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
NCT04336345,Completed,Observational [Patient Registry],,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,1-Apr-20,4-Jun-20,30-Apr-20,COHORT,150,CORONAVIRUS INFECTION,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",,HOSPITAL MORTALITY,Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study)
NCT04336384,Completed,Observational,,"University Hospital, Montpellier",Other,1-Mar-20,30-Dec-20,1-Dec-20,COHORT,5000,CONGENITAL HEART DISEASE,FRANCE,ALL,"Child, Adult, Older Adult",,PREVALENCE OF COVID-19 INFECTION IN THE OVERALL CHD POPULATION,Impact of Covid-19 in Congenital Heart Disease - COVID-CHD
NCT04336410,"Active, not recruiting",Interventional,Phase 1,Inovio Pharmaceuticals,Industry,3-Apr-20,22-Jan-21,22-Jan-21,PREVENTION,120,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INO-4800,PERCENTAGE OF PARTICIPANTS WITH ADVERSE EVENTS (AES),"Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers"
NCT04336462,Recruiting,Interventional,Not Applicable,Shanghai Asclepius Meditec Inc.,Industry,15-Feb-20,1-Aug-20,21-Feb-20,TREATMENT,100,COVID,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",OXYHYDROGEN,RECOVERY TIME,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19"
NCT04336657,Recruiting,Observational,,Assiut University,Other,20-Apr-21,20-May-21,20-May-21,ECOLOGIC OR COMMUNITY,100,COVID,EGYPT,ALL,"8 Years to 80 Years   (Child, Adult, Older Adult)",QUESTIONNAIRE,MEASURE FREQUENCY OF PEOPLE SUFFERED FROM UNUSUAL FLU-LIKE SYMPTOMS BEFORE DECEMBER 2019,COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?
NCT04336748,Not yet recruiting,Interventional,Phase 3,Medical University of Vienna,Other,20-Apr-21,20-Aug-21,20-Jul-21,PREVENTION,440,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,SYMPTOMATIC OR ASYMPTOMATIC SARS-COV-2 INFECTION CONFIRMED BY PCR,"Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial"
NCT04336761,Recruiting,Observational,,"University Hospital, Lille",Other,15-Apr-20,21-Jan-21,21-Jan-21,COHORT,914,CORONAVIRUS,FRANCE,ALL,"up to 18 Years   (Child, Adult)",NASOPHARYNGEAL SWAB,PREVALENCE OF POSITIVITY OF COVID-19 VIRUS MEASURED BY RT-PCR,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France
NCT04336774,Withdrawn,Interventional,Not Applicable,Duke University,Other,20-Jul-21,9-Nov-20,1-Nov-20,DIAGNOSTIC,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAPTION AI,PERCENT OF PATIENT ECHOS THAT ARE NOT INTERPRETABLE,Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19
NCT04336787,Not yet recruiting,Observational,,Istanbul Kültür University,Other,12-Apr-20,10-Jun-20,10-May-20,ECOLOGIC OR COMMUNITY,100,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),SURVEY,INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE,"Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The Covıd-19 Quarantine Period"
NCT04336904,"Active, not recruiting",Interventional,Phase 3,Giuliano Rizzardini,Other,25-Mar-20,20-Jul-21,20-Jul-21,TREATMENT,100,COVID,ITALY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",FAVIPIRAVIR,TIME FROM RANDOMIZATION TO CLINICAL RECOVERY,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type"
NCT04336956,Recruiting,Observational [Patient Registry],,Centre Hospitalier Intercommunal Creteil,Other,7-Apr-20,30-Jun-21,30-Jun-21,COHORT,250,COVID,FRANCE,ALL,"up to 18 Years   (Child, Adult)",HOSPITALIZED CHILDREN WITH COVID19,PERCENTAGE OF CHILDREN WITH SEVERE OR CRITICAL FORM.,Covid-19 Pediatric Observatory
NCT04337008,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,3-Apr-20,31-Jul-20,3-Jun-20,DIAGNOSTIC,50,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD DRAW,OVERACTIVITY OF THE RENIN / ALDOSTERONE SYSTEM,Renin Angiotensin System - CoronaVirus
NCT04337047,Completed,Observational,,Wefight,Industry,31-Mar-20,3-May-20,30-Apr-20,COHORT,2000,"STRESS, PSYCHOLOGICAL",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ASSESMENT,QUANTIFY AND QUALIFY DISTRESS OVER A LARGE POPULATION IN TIMES OF PANDEMIC CRISIS.,Distress During the COVID-19 Pandemic in France: a National Assessment of At-risk Populations
NCT04337151,Recruiting,Observational,,Royal National Orthopaedic Hospital NHS Trust,Other,20-Apr-21,21-Mar-21,21-Jan-21,CASE-CONTROL,100,MAGEC ROD,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",MAGEC SPINE ROD,TITANIUM LEVEL,Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment
NCT04337190,Recruiting,Observational,,"University Hospital, Angers",Other,3-Apr-20,6-Dec-20,6-Oct-20,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,ACE2 LEVEL CHANGE OVER TIME,Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2)
NCT04337320,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,15-Mar-20,30-May-20,25-May-20,COHORT,40,COVID,TURKEY,ALL,up to 15 Minutes   (Child),NEWBORNS FROM COVID 19 POSITIVE MOTHERS,EVALUATION OF APGAR STATUS OF NEWBORNS FROM COVID 19 POSITIVE MOTHERS,Maternal And Neonatal Outcome of Pregnant Patients With COVID-19
NCT04337346,Completed,Observational [Patient Registry],,Kanuni Sultan Suleyman Training and Research Hospital,Other,5-Apr-20,25-Apr-20,20-Apr-20,CASE-CONTROL,80,ENDOMETRIOSIS,TURKEY,FEMALE,18 Years to 45 Years   (Adult),,COVID 19 ANXIETY LEVELS IN ENDOMETRIOSIS PATIENTS,Endometriosis Patients Covid 19 Anxiety
NCT04337359,No longer available,Expanded Access,,Novartis Pharmaceuticals,Industry,,,,,,SEVERE/VERY SEVERE COVID ILLNESS,,ALL,"6 Years to 90 Years   (Child, Adult, Older Adult)",RUXOLITINIB,,Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness
NCT04337424,Completed,Observational,,"University Hospital, Montpellier",Other,13-Apr-20,7-Oct-20,7-Oct-20,CASE-CONTROL,627,SARS-COV2,FRANCE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",SAMPLING SALIVARY,SPECIFIC DETECTION OF SARS-COV-2 SPECIFIC RNA,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2
NCT04337489,Not yet recruiting,Observational,,Imperial College London,Other,28-Jul-20,1-Apr-21,1-Apr-21,COHORT,200,CORONAVIRUS,,ALL,"18 Years to 95 Years   (Adult, Older Adult)",SENSIUMVITALS WEARABLE SENSOR,DETERIORATION RESULTING IN HEALTHCARE REVIEW,REmote MOniToring usE in Suspected Cases of COVID-19 (Coronavirus): REMOTE-COVID Trial
NCT04337502,Completed,Observational,,Maastricht University,Other,23-Dec-19,3-Mar-20,20-Jan-20,COHORT,300,CORONAVIRUS,CHINA,ALL,"Child, Adult, Older Adult",MACHINE LEARNING MODEL,PREDICTIVE PERFORMANCE,A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients
NCT04337541,Completed,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,2-Apr-20,2-Jun-20,2-Jun-20,PREVENTION,6000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",SURGICAL FACIAL MASK,"THE PRIMARY ENDPOINT IS THE DIFFERENCE IN SARS-COV-2 INFECTION BETWEEN THE TWO GROUPS AFTER 1 MONTHS AND IS A COMBINED ENDPOINT CONSISTING OF PRIMARY OUTCOME COMPONENTS 1, 2 AND/OR 3:",Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System
NCT04337762,Recruiting,Observational,,Beat COVID LLC,Industry,6-Apr-20,21-Jul-21,20-Dec-21,CASE-CONTROL,100000,COVID,UNITED STATES,ALL,"18 Years to 110 Years   (Adult, Older Adult)",,HEALTH OUTCOMES,A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression
NCT04337788,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Limoges",Other,20-May-21,20-Sep-21,20-Jul-21,PREVENTION,200,CORONAVIRUS INFECTION,,ALL,75 Years and older   (Older Adult),TELEHEALTH APPLICATIONS,IMPACT OF GERONTOLOGICAL TELEMONITORING ON HEALTHCARE MANAGEMENT FOR OLDER ADULTS LIVING IN NURSING HOMES WITH SYMPTOMS OF CONFIRMED OR PROBABLE COVID-19 DISEASE (DEATH WITHIN 30 DAYS).,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease
NCT04337918,Completed,Interventional,Phase 2,Sanotize Research and Development corp.,Industry,8-May-20,2-Feb-21,31-Jan-21,PREVENTION,143,CORONAVIRUS INFECTION,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",NORS (NITRIC OXIDE RELEASING SOLUTION),PREVENTION STUDY: MEASURE THE EFFECT OF NORS ON THE PREVENTION OF COVID-19 INFECTION AMONG HEALTH CARE PROFESSIONALS AT RISK OF EXPOSURE TO COVID-19,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection"
NCT04337983,Recruiting,Observational,,Bicetre Hospital,Other,13-Mar-20,21-Apr-21,20-Oct-21,COHORT,200,CORONAVIRUS,FRANCE,ALL,"Child, Adult, Older Adult",TRANSPULMONARY THERMODILUTION,BODY TEMPERATURE,Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study
NCT04337996,Completed,Interventional,Not Applicable,Tourcoing Hospital,Other,13-Jul-20,13-Jan-21,13-Jan-21,DIAGNOSTIC,8,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 DIAGNOSTIC TEST,COMPARISON OF THE PROPORTION OF PATIENTS CLASSIFIED AS COVID-19 POSITIVE ACCORDING TO THE 2 STRATEGIES,Dynamic Evaluation of COVID-19 Diagnostic Tests
NCT04338009,Enrolling by invitation,Interventional,Not Applicable,University of Pennsylvania,Other,31-Mar-20,31-Dec-20,31-Dec-20,TREATMENT,152,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DISCONTINUATION OF ARB/ACEI,HIERARCHICAL COMPOSITE ENDPOINT,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019
NCT04338074,Recruiting,Interventional,Phase 2,University of Alabama at Birmingham,Other,1-Jun-20,31-Dec-21,15-Dec-21,TREATMENT,100,COVID,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",TRANEXAMIC ACID TABLETS,HOSPITALIZATION,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients
NCT04338100,Not yet recruiting,Observational,,"University Hospital, Angers",Other,6-Apr-20,29-Jan-21,29-Dec-20,CASE-ONLY,300,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",FOLLOW-UP AT 14 DAYS,RISK OF UNFAVOURABLE OUTCOME AT D14,Point Of Care UltraSonography to Perform Risk-stratification of Patients With Suspected or Confirmed COVID-19 - POCUSCO Study
NCT04338126,Not yet recruiting,Interventional,Phase 2,University of Alabama at Birmingham,Other,30-Sep-21,31-Dec-21,15-Dec-21,TREATMENT,60,COVID,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",TRANEXAMIC ACID,ADMISSION TO INTENSIVE CARE UNIT,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Inpatients
NCT04338347,No longer available,Expanded Access,,Capricor Inc.,Industry,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAP-1002 ALLOGENEIC CARDIOSPHERE-DERIVED CELLS,,CAP-1002 Treatment in Patients With Severe COVID-19 and in Critical Condition as Indicated by Life Support Measurements
NCT04338360,Approved for marketing,Expanded Access,,Mayo Clinic,Other,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,,Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04338568,Recruiting,Interventional,Not Applicable,Hasselt University,Other,16-Apr-20,30-Dec-20,30-Nov-20,DIAGNOSTIC,50,COVID PNEUMONIA,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND,ACCURACY OF THE DIAGNOSIS OF INTERSTITIAL SYNDROME BY LUNG ULTRASOUND,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia
NCT04338672,Recruiting,Observational,,Sheba Medical Center,Other,5-Apr-20,1-Apr-22,1-Apr-21,COHORT,10000,"EMERGENCY SERVICE, HOSPITAL",ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PANDEMIC,RATES OF EMERGENCY VISITS NEEDING SURGICAL CONSULT,The Impact of the Coronavirus Disease 2019 (Covid-19) Outbreak on Emergency Room Attendances of Surgical Patients at a Tertiary Medical Center
NCT04338698,Recruiting,Interventional,Phase 3,Shehnoor Azhar,Other,22-Apr-20,30-Nov-20,1-Sep-20,TREATMENT,500,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,LABORATORY RESULT,Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment
NCT04338802,Not yet recruiting,Interventional,Phase 2,Huilan Zhang,Other,2-Apr-20,1-Aug-20,4-May-20,TREATMENT,96,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NINTEDANIB 150 MG,CHANGES IN FORCED VITAL CAPACITY (FVC),"Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study"
NCT04338828,"Active, not recruiting",Interventional,Phase 2,Massachusetts General Hospital,Other,18-Apr-20,22-Apr-21,21-Apr-21,TREATMENT,47,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE GAS,RATES OF RETURN VISITS TO THE ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department
NCT04338841,Completed,Interventional,Not Applicable,"University Hospital, Angers",Other,9-Apr-20,17-Jun-20,17-Jun-20,TREATMENT,3133,CORONAVIRUS INFECTION,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",HOME-COV RULE IMPLEMENTATION,THE COMPOSITE RATE OF ADVERSE OUTCOMES,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study
NCT04338906,Withdrawn,Interventional,Phase 4,"Heinrich-Heine University, Duesseldorf",Other,20-May-21,21-Dec-21,21-Dec-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,NOT HOSPITALIZED,Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection
NCT04338932,Completed,Observational,,Jessa Hospital,Other,17-Apr-20,15-May-20,15-May-20,COHORT,12,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,THE PREVALENCE OF A DVT IN PATIENTS AT THE ICU.,COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study
NCT04338945,Completed,Observational,,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,Other,15-Mar-20,1-May-20,15-Apr-20,COHORT,800,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",COVID-SURGRES QUESTIONAIRE,MEASURE OF THE IMPACT OF COVID EMERGENCY ON SURGICAL SPECIALIST TRAINING PROGRAMS,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey
NCT04338958,Recruiting,Interventional,Phase 2,University of Jena,Other,22-Apr-20,31-Jul-21,31-Jul-21,TREATMENT,200,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB,OVERALL RESPONSE RATE IN REVERSAL OF HYPERINFLAMMATION,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation
NCT04339322,Not yet recruiting,Observational,,Assiut University,Other,1-May-20,30-Jul-20,30-Jul-20,COHORT,200,CHARACTERISTICS DISEASES,,ALL,"Child, Adult, Older Adult",FOLLOW UP,DEMOGRAPHICS OF CORONAVIRUS DISEASE 2019 (COVID-19) IN THE COHORT GROUP,Characteristics and Outcome of COVID-19 Among Egyptian Patients
NCT04339387,Completed,Observational,,Brigham and Women's Hospital,Other,1-Mar-20,26-Apr-20,26-Apr-20,COHORT,1326,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SUITABLE FOR DISCHARGE,COVID-19 Risk Stratification
NCT04339426,Recruiting,Interventional,Phase 2,HonorHealth Research Institute,Other,20-Apr-20,21-Dec-21,21-Jul-21,TREATMENT,25,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",ATOVAQUONE/AZITHROMYCIN,VIROLOGY CURE RATE,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection"
NCT04339608,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,2-Apr-20,30-Jun-20,30-May-20,COHORT,10000,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 POSITIVE CASE,"A Prospective, Longitudinal, Observational Study of Healthcare Workers and the General Population to Watch for Flu-like Symptoms in Suspicion of COVID 19"
NCT04339634,"Active, not recruiting",Observational,,Tabula Rasa HealthCare,Industry,7-Apr-20,6-Apr-21,7-Jul-20,COHORT,12123,COVID,UNITED STATES,ALL,"55 Years and older   (Adult, Older Adult)",SIMULATION OF REPURPOSED DRUGS FOR COVID-19,TO DETERMINE THE MEDICATION RISK SCORE OF DE-IDENTIFIED PACE'S PARTICIPANTS USING THEIR CURRENT DRUG REGIMEN.,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy
NCT04339660,Recruiting,Interventional,Phase 1/Phase 2,Puren Hospital Affiliated to Wuhan University of Science and Technology,Other,1-Feb-20,30-Jun-20,30-Jun-20,TREATMENT,30,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",UC-MSCS,THE IMMUNE FUNCTION (TNF-Α 、IL-1Β、IL-6、TGF-Β、IL-8、PCT、CRP),Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
NCT04339686,Recruiting,Observational,,Poitiers University Hospital,Other,20-Apr-20,20-Nov-21,20-Sep-21,COHORT,56000,THE GOLD STANDARD FOR CURRENT SARS COV2 DETECTION IS RT-PCR,FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",THORACIC CT SCAN,DIAGNOSTIC PERFORMANCE OF CHEST CT IN SCREENING FOR PULMONARY LESIONS IN CLINICAL SUSPICIONS OF COVID.,Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening. Comparison to Virological Testing and Multiparametric Gold Standard
NCT04339712,Completed,Interventional,Phase 2,Hellenic Institute for the Study of Sepsis,Other,2-Apr-20,8-Jan-21,1-Dec-20,TREATMENT,102,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,CHANGE OF BASELINE TOTAL SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORE,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial
NCT04339790,"Active, not recruiting",Observational,,National Institute of Mental Health (NIMH),NIH,7-Apr-20,1-Apr-22,1-Apr-22,COHORT,10000,HEALTHY VOLUNTEER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NIMH COVID STUDY SURVEY - ADULT RESPONSES,Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers
NCT04339816,Terminated,Interventional,Phase 3,"Frantisek Duska, MD, PhD",Other,13-May-20,4-Nov-20,4-Nov-20,TREATMENT,3,COVID,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",AZITHROMYCIN,PROPORTION OF ALIVE PATIENTS FREE OFF MECHANICAL VENTILATION,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial
NCT04339842,Completed,Observational,,Eliz Arter,Other,10-Apr-20,31-May-20,31-May-20,CASE-ONLY,673,HEALTH BEHAVIOR,CYPRUS,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ASSESSMENT OF DIETARY CHANGES IN ADULTS IN THE QUARANTINE,CHANGES IN THE EATING HABITS OF ADULTS DURING THE QUARANTINE,Eating Habits of Adults During the Quarantine
NCT04339881,Completed,Observational [Patient Registry],,Assistance Publique - Hôpitaux de Paris,Other,17-Apr-20,12-Jul-20,10-Jul-20,OTHER,2523,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",,UNDERSTANDING THE DISSEMINATION OF SARS COV2 IN HOSPITAL,NOsocomial Dissemination Risk of SARS-Cov2
NCT04339998,Recruiting,Observational,,University of Minnesota,Other,15-Apr-20,20-Oct-21,20-Oct-21,COHORT,500,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",POINT-OF-CARE ULTRASONOGRAPHY (POCUS),POCUS SCORE - LUNGS,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
NCT04340050,Completed,Interventional,Early Phase 1,University of Chicago,Other,10-Apr-20,23-Dec-20,23-Dec-20,TREATMENT,10,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 CONVALESCENT PLASMA,"FEASIBILITY OF PERFORMING STUDY PATHWAY CONSISTING OF CONSENTING CONVALESCENT DONORS, HARVESTING CONVALESCENT PLASMA, APPLICATION FOR FDA EIND AND ADMINISTERING CONVALESCENT PLASMA TO THE PATIENTS",Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center
NCT04340219,Completed,Observational,,"University Hospital, Ghent",Other,30-Mar-20,18-Sep-20,10-Apr-20,COHORT,394,CANCER,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY ADMINISTRATION,DISTRESS AT BASELINE MEASURED BY THE COVID-19 PERITRAUMATIC DISTRESS INDEX (CPDI); IN TERMS OF PROPORTIONS (0-28 VS ≥ 29).,"A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)"
NCT04340232,Not yet recruiting,Interventional,Phase 2/Phase 3,"University of Colorado, Denver",Other,21-Mar-21,21-Oct-21,21-Aug-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",BARICITINIB,PHASE 2: CUMULATIVE INCIDENCE OF GRADE 3 AND 4 ADVERSE EVENTS (AES),Safety and Efficacy of Baricitinib for COVID-19
NCT04340349,Enrolling by invitation,Interventional,Early Phase 1,Instituto Nacional de Rehabilitacion,Other,11-May-20,15-Apr-21,20-Mar-21,PREVENTION,280,HYDROXYCHLOROQUINE,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,POLYMERASE CHAIN REACTION ASSAY (PCR) NEGATIVE AT DAY 0 PLUS NEGATIVE SEROLOGICAL PANEL FOR COVID-19 ANTIBODIES AT ENROLMENT.,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)
NCT04340414,Recruiting,Interventional,Not Applicable,Peking Union Medical College Hospital,Other,20-Feb-20,15-Oct-20,15-Aug-20,TREATMENT,10,COVID,CHINA,ALL,"14 Years and older   (Child, Adult, Older Adult)",LOW FLOW ECMO DRIVING BY CVVH MACHINE,PACO2,Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation（CO2 Removal） Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)
NCT04340466,Completed,Observational [Patient Registry],,Centre Hospitalier Universitaire de Nīmes,Other,3-Apr-20,3-Jul-20,3-Jul-20,COHORT,1003,"PNEUMONIA, VIRAL",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,MORTALITY AT DAY 28,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study
NCT04340479,Recruiting,Observational [Patient Registry],,"University of Colorado, Denver",Other,30-Jul-20,22-May-21,22-May-21,COHORT,20,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",ULTRASOUND LUNG IMAGING AS PART OF FAST+ EVALUATION,CORRELATION OF FAST+ PULMONARY FINDINGS WITH ACTIVE COVID INFECTION,The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation
NCT04340544,Terminated,Interventional,Phase 2,University Hospital Tuebingen,Other,22-Apr-20,12-Oct-20,12-Oct-20,TREATMENT,17,COVID,GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,DIFFERENCE IN TIME TO RESOLUTION OF CLINICAL SIGNS AND SYMPTOMS OF MILD COVID-19 TREATED WITH HYDROXYCHLOROQUINE OR PLACEBO AS ASSESSED BY DAILY SELF-ASSESSMENT,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease
NCT04340557,Recruiting,Interventional,Phase 4,Sharp HealthCare,Other,27-Mar-20,31-Dec-20,6-Oct-20,PREVENTION,200,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,MECHANICAL VENTILATION,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection
NCT04340921,Recruiting,Observational,,Barts & The London NHS Trust,Other,14-May-20,10-Nov-21,10-Nov-21,COHORT,140,CARDIOVASCULAR DISEASE ACUTE,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 EXPOSURE,T-CELL IMMUNOPHENOTYPE,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury
NCT04341012,Recruiting,Observational,,Mayo Clinic,Other,10-Sep-19,31-Dec-21,31-Dec-21,COHORT,120,LIVER DISEASES,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COLLECTION OF BREATH SAMPLE,BREATH VOLATILE ORGANIC COMPOUND PROFILES,Development of a Breath Analysis Test for Disease Diagnosis and Prognosis
NCT04341038,Recruiting,Interventional,Phase 3,Hospital Universitari de Bellvitge,Other,1-Apr-20,1-Jul-20,1-Jun-20,TREATMENT,84,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TACROLIMUS,TIME TO REACH CLINICAL STABILITY,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19
NCT04341103,Not yet recruiting,Observational,,CareDx,Industry,1-Apr-20,1-Mar-21,1-Dec-20,CASE-ONLY,500,SOLID ORGAN TRANSPLANT REJECTION,,ALL,"Child, Adult, Older Adult",,ASSESSING THE UTILITY OF ALLOSURE DD-CFDNA TO GUIDE CLINICAL IMMUNE-OPTIMIZATION FOR TRANSPLANT PATIENTS WITH COVID-19,AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience
NCT04341116,Recruiting,Interventional,Phase 2/Phase 3,I-Mab Biopharma Co. Ltd.,Industry,11-Apr-20,21-Dec-21,21-Dec-21,TREATMENT,384,CORONAVIRUS DISEASE 2019 COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TJ003234,PROPORTION (%) OF SUBJECTS RECOVERED,"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)"
NCT04341142,Recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,9-Apr-20,9-Apr-24,9-Apr-23,DIAGNOSTIC,550,COV2 POSITIVE CAREGIVERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TESTS WILL BE APPLIED ON PATIENTS BLOOD SAMPLING,THE POSITIVITY (YES/NO) OF THE SEROLOGICAL TEST.,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER
NCT04341168,Not yet recruiting,Observational,,University Hospital of Cologne,Other,20-Apr-21,20-Oct-21,20-Oct-21,COHORT,160,COVID,GERMANY,ALL,"Child, Adult, Older Adult",THIS STUDY IS NON- INTERVENTIONAL,CLINICAL COURSE OF COVID-19,"Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults"
NCT04341207,Recruiting,Interventional,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",Other,3-Apr-20,22-Apr-21,22-Apr-21,TREATMENT,1000,CANCER & COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PREVALENCE AND THE 3-MONTHS INCIDENCE OF SARS-COV-2 IN CANCER PATIENTS,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients
NCT04341285,Not yet recruiting,Interventional,Not Applicable,University Hospital Tuebingen,Other,1-Aug-20,1-May-22,1-Apr-22,TREATMENT,200,"ARDS, HUMAN",GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ECMO IMPLANTATION,28 DAY ALL CAUSE MORTALITY,Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)
NCT04341389,"Active, not recruiting",Interventional,Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Other,12-Apr-20,31-Jan-21,31-Jan-21,PREVENTION,508,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),OCCURRENCE OF ADVERSE REACTIONS,"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years"
NCT04341415,Recruiting,Interventional,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,Other,9-Apr-20,21-Mar-21,21-Mar-21,TREATMENT,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AURICULAR NEUROMODULATION,COMPARISON OF THE PERCENTAGE OF CLINICALLY IMPROVED INPATIENTS BETWEEN D0 AND D14,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.
NCT04341441,Terminated,Interventional,Phase 3,Henry Ford Health System,Other,7-Apr-20,15-Dec-20,15-Dec-20,PREVENTION,624,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE - DAILY DOSING,TO DETERMINE IF THE USE OF HYDROXYCHLOROQUINE AS PREVENTIVE THERAPY DECREASES THE RATE OF ACQUISITION OF SARS-COV 2 INFECTIONS AND CLINICAL COVID-19 DISEASE IN STUDY PARTICIPANTS FOR EACH RANDOMIZED TREATMENT ARM AS COMPARED TO PLACEBO.,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study
NCT04341480,"Active, not recruiting",Observational,,Tongji Hospital,Other,1-Jul-20,10-Jan-21,10-Dec-20,COHORT,305,GYNECOLOGICAL CANCER,CHINA,FEMALE,"18 Years to 80 Years   (Adult, Older Adult)",CHEMOTHERAPY,SARS-COV-2 INFECTION,"The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study"
NCT04341493,Recruiting,Interventional,Phase 4,Hugo Mendieta Zeron,Other,6-Apr-20,30-Dec-20,30-Aug-20,TREATMENT,86,CORONAVIRUS INFECTION,MEXICO,ALL,"5 Years and older   (Child, Adult, Older Adult)",NITAZOXANIDE 500 MG,MECHANICAL VENTILATION REQUIREMENT,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome
NCT04341506,Recruiting,Observational,,Northwestern Medicine,Other,8-Sep-20,15-Dec-21,15-Jul-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NON-CONTACT ECG,ECG CHANGES ASSOCIATED WITH COVID-19,Evaluating Non-contact ECG Sensor System for Early Detection of COVID19
NCT04341519,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,6-Apr-20,31-Dec-21,30-Nov-20,COHORT,1464,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PTSD,PTSD FAMILY MEMBERS SUP 22,"""Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers"" ""Impact Psychologique de l'épidémie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation"" ""BURDENCOV"""
NCT04341584,Completed,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,8-Apr-20,25-Jul-20,10-May-20,TREATMENT,161,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,SURVIVAL WITHOUT NEEDS OF VENTILATOR UTILIZATION AT DAY 14,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19"
NCT04341610,Withdrawn,Interventional,Phase 1/Phase 2,"Rigshospitalet, Denmark",Other,20-Apr-20,30-Apr-21,30-Jan-21,TREATMENT,0,RESPIRATORY TRACT DISEASES,DENMARK,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STEM CELL PRODUCT,CHANGES IN CLINICAL CRITICAL TREATMENT INDEX,"Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study"
NCT04341675,Recruiting,Interventional,Phase 2,University of Cincinnati,Other,24-Apr-20,20-Sep-21,20-Jul-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SIROLIMUS,PROPORTION OF PATIENTS WHO ARE ALIVE AND FREE FROM ADVANCED RESPIRATORY SUPPORT MEASURES AT DAY 28.,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)
NCT04341688,Not yet recruiting,Interventional,Not Applicable,Aga Khan University,Other,1-Feb-21,31-Jul-21,30-Jun-21,SUPPORTIVE CARE,50,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",GARGLE/MOUTHWASH,INTRAORAL VIRAL LOAD,"A Double Blind, Randomized Controlled Pilot Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed COVID-19 Patients: GARGLES STUDY"
NCT04341714,Recruiting,Observational,,Pierre and Marie Curie University,Other,16-Mar-20,15-Jun-20,30-May-20,COHORT,450,"EFFICACY, SELF",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SATISFACTION EVALUATION,EFFICIENCY OF THE TELEPHONE CONSULTATION,Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic
NCT04341727,Suspended,Interventional,Phase 3,Washington University School of Medicine,Other,4-Apr-20,1-Aug-21,1-Apr-21,TREATMENT,500,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,HOURS TO RECOVERY,"WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection"
NCT04341766,Completed,Observational [Patient Registry],,Centre Hospitalier Intercommunal Creteil,Other,31-Mar-20,30-Jun-20,27-May-20,COHORT,106,"PNEUMONIA, VIRAL",FRANCE,ALL,"18 Years to 105 Years   (Adult, Older Adult)",NO SPECIAL INTERVENTION,CHARACTERISTICS OF PULMONARY ULTRASOUND FOR COVID-19 PATIENTS,Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19
NCT04341792,Recruiting,Observational,,"University Hospital, Lille",Other,11-Apr-20,21-Apr-21,21-Apr-21,COHORT,1000,INFECTION VIRAL,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF SECONDARY AGGRAVATION,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic
NCT04341870,Suspended,Interventional,Phase 2/Phase 3,Assistance Publique - Hôpitaux de Paris,Other,11-Apr-20,20-Aug-21,8-May-20,TREATMENT,27,COVID,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SARILUMAB,"NEED FOR VENTILATION (INCLUDING INVASIVE AND NON INVASIVE VENTILATION), INTENSIVE CARE OR DEATH","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial"
NCT04341922,"Active, not recruiting",Interventional,Not Applicable,Karolinska Institutet,Other,9-May-20,10-Sep-21,20-Aug-20,TREATMENT,670,DYSFUNCTIONAL WORRY,SWEDEN,ALL,"16 Years and older   (Child, Adult, Older Adult)",INTERNET-DELIVERED COGNITIVE BEHAVIOR THERAPY (ICBT) FOR DYSFUNCTIONAL WORRY RELATED TO THE COVID-19 PANDEMIC,• COVID-19-ADAPTED VERSION OF THE SELF-RATED GENERALIZED ANXIETY DISORDER SCALE-7 (GAD-7),Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial
NCT04341935,Not yet recruiting,Interventional,Phase 4,University of Miami,Other,30-Jun-21,30-Dec-21,30-Dec-21,TREATMENT,20,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LINAGLIPTIN,CHANGES IN GLUCOSE LLEVELS,Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes
NCT04342104,Recruiting,Observational,,Hospital General Universitario Morales Meseguer,Other,1-Apr-20,15-Nov-21,31-Jul-21,COHORT,100,RESPIRATORY FAILURE,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MONITORING FOR AGGRAVATION,HACOR SCORE EFFICACY,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure
NCT04342156,Withdrawn,Interventional,Phase 3,Tan Tock Seng Hospital,Other,20-Apr-21,20-Oct-21,20-Aug-21,PREVENTION,0,CORONAVIRUS INFECTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE 200 MILLIGRAM (MG) TAB,POSITIVE SEROLOGY OR REVERSE TRANSCRIPTASE (RT-PCR) FOR COVID-19 UP UNTIL DAY 28.,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT)
NCT04342169,Recruiting,Interventional,Phase 2,University of Utah,Other,4-Apr-20,22-Apr-21,21-Apr-21,TREATMENT,400,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,DURATION OF VIRAL SHEDDING,Hydroxychloroquine for Outpatients With Confirmed COVID-19
NCT04342182,"Active, not recruiting",Interventional,Phase 2/Phase 3,Erasmus Medical Center,Other,8-Apr-20,31-Jul-21,1-Jul-21,TREATMENT,426,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,OVERALL MORTALITY UNTIL DISCHARGE FROM THE HOSPITAL OR A MAXIMUM OF 60 DAYS AFTER ADMISSION WHICHEVER COMES FIRST,Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19
NCT04342195,Recruiting,Observational,,Columbia University,Other,25-Mar-20,21-Mar-21,21-Mar-21,CASE-ONLY,50,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",BLOOD DRAW,NUMBER OF ANTIBODIES AGAINST CORONAVIRUSES ISOLATED AND IDENTIFIED FROM PATIENT SAMPLES,Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19
NCT04342208,Not yet recruiting,Observational,,Istanbul University-Cerrahpasa,Other,10-Apr-20,1-Jul-20,1-Jun-20,CASE-ONLY,500,MUSCULOSKELETAL PAIN,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,THE RAPID OFFICE STRAIN ASSESSMENT (ROSA),Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak
NCT04342221,Recruiting,Interventional,Phase 3,University Hospital Tuebingen,Other,29-Mar-20,22-Feb-21,21-Mar-21,TREATMENT,220,"COVID, HYDROXYCHLOROQUINE SULFATE",GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,EFFECT OF HCQ ON IN VIVO VIRAL CLEARANCE,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19
NCT04342637,Completed,Observational,,Al-Azhar University,Other,10-Apr-20,1-May-20,25-Apr-20,COHORT,163,COVID,EGYPT,ALL,"30 Years to 70 Years   (Adult, Older Adult)",PRACTICE DETAILS,EFFECT OF GI SOCIETIES RECOMMENDATIONS ON PREVENTION OF SARS-COV-2 INFECTION,Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey
NCT04342650,Completed,Interventional,Phase 2,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Other,8-Apr-20,8-Jun-20,14-May-20,TREATMENT,152,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE DIPHOSPHATE,PROPORTION OF PATIENTS WITH ONSET OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS),"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial"
NCT04342663,Completed,Interventional,Phase 2,Washington University School of Medicine,Other,10-Apr-20,12-Dec-20,20-Aug-20,TREATMENT,152,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FLUVOXAMINE,TIME TO CLINICAL WORSENING,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection"
NCT04342689,Recruiting,Interventional,Phase 2/Phase 3,Yale University,Other,3-Jun-20,1-Jun-21,1-Jun-21,TREATMENT,1500,COVID,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",DIETARY SUPPLEMENT CONTAINING RESISTANT STARCH,RATES OF HOSPITALIZATION FOR A COVID-19 RELATED COMPLICATION (PHASE 3),The Role of Resistant Starch in COVID-19 Infection
NCT04342702,"Active, not recruiting",Observational,,Second Affiliated Hospital of Wenzhou Medical University,Other,16-Mar-20,21-Mar-21,21-Mar-21,COHORT,504,FOLLOW-UP,CHINA,ALL,"Child, Adult, Older Adult",,36-ITEM SHORT FORM SURVEY INSTRUMENT (SF-36),A Study on the Prospective Cohort Library of Novel Coronavirus Pneumonia in Southeran
NCT04342728,Completed,Interventional,Not Applicable,The Cleveland Clinic,Other,8-Apr-20,11-Feb-21,30-Dec-20,SUPPORTIVE CARE,214,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ASCORBIC ACID,SYMPTOM REDUCTION,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study"
NCT04342806,Recruiting,Observational [Patient Registry],,Duke University,Other,10-Apr-20,31-Dec-99,31-Dec-99,COHORT,100000,HEALTH CARE WORKER (HCW),UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",,"NUMBER AND PERCENT OF PARTICIPANTS WHO ENROLL IN THE HERO REGISTRY STUDY BY GEOGRAPHIC REGION, AGE, COVID-19 RISK FACTORS, AND PAST COVID-19 DIAGNOSIS",Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study
NCT04342884,Recruiting,Observational,,Wake Forest University Health Sciences,Other,8-Apr-20,21-Dec-21,21-Dec-21,COHORT,150000,CORONAVIRUS,UNITED STATES,ALL,"Child, Adult, Older Adult",,SEROPREVALENCE OF SARS-COV-2 INFECTION IN THE GENERAL POPULATION OF NORTH CAROLINA,"A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records"
NCT04342897,Terminated,Interventional,Phase 2,Eli Lilly and Company,Industry,20-Apr-20,12-Oct-20,12-Oct-20,TREATMENT,95,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LY3127804,NUMBER OF VENTILATOR FREE DAYS,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19"
NCT04343001,Withdrawn,Interventional,Phase 3,London School of Hygiene and Tropical Medicine,Other,20-Oct-21,21-Aug-21,21-Apr-21,TREATMENT,0,COVID,NIGERIA,ALL,"40 Years and older   (Adult, Older Adult)",ASPIRIN,DEATH,"Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial"
NCT04343053,"Active, not recruiting",Interventional,Not Applicable,University Hospital of Ferrara,Other,8-Apr-20,9-Jun-21,9-Jun-20,DIAGNOSTIC,54,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 INFECTION,ON-TREATMENT PLATELET REACTIVITY,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection"
NCT04343092,Completed,Interventional,Phase 1,University of Baghdad,Other,18-Apr-20,1-Jun-20,31-May-20,TREATMENT,16,COVID,IRAQ,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN (IVM),NUMBER OF CURED PATIENTS,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial)
NCT04343144,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,15-Apr-20,30-Sep-20,31-Jul-20,TREATMENT,92,COVID- INFECTION WITH SARS-COV2 VIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NIVOLUMAB INJECTION,TIME TO CLINICAL IMPROVEMENT,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial
NCT04343183,Not yet recruiting,Interventional,Not Applicable,Ochsner Health System,Other,20-Apr-21,20-Jun-21,20-Jun-21,TREATMENT,48,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN THERAPY,DECREASE INCIDENCE OF INTUBATION BY 30% OR GREATER,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection
NCT04343248,Recruiting,Interventional,Phase 3,Romark Laboratories L.C.,Industry,12-May-20,30-Jun-21,30-Jun-21,PREVENTION,800,COVID,UNITED STATES,ALL,"55 Years to 120 Years   (Adult, Older Adult)",NITAZOXANIDE,SYMPTOMATIC LABORATORY-CONFIRMED COVID-19,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)"
NCT04343261,Completed,Interventional,Phase 2,Saint Francis Care,Other,10-Apr-20,13-Aug-20,23-Jul-20,TREATMENT,48,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2),UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,MORTALITY,Convalescent Plasma in the Treatment of COVID 19
NCT04343339,Completed,Observational,,"University Hospital, Montpellier",Other,8-Apr-20,30-Sep-20,30-Jul-20,COHORT,100,"ADDICTION, SUBSTANCE",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,EVOLUTION OF CONSUMPTION,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE
NCT04343404,Completed,Observational,,"University Hospital, Strasbourg, France",Other,1-Apr-20,15-Apr-20,15-Apr-20,CASE-ONLY,100,RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE DESCRIPTION OF COVID-19 PATIENTS RECEIVING RESPIRATORY ECMO-VV SUPPLEMENTATION AND WHAT HAPPENS TO THEM,STUDY ECMO-COVID-19 : Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19
NCT04343651,"Active, not recruiting",Interventional,Phase 2,"CytoDyn, Inc.",Industry,1-Apr-20,31-Aug-20,21-Jul-20,TREATMENT,86,CORONAVIRUS DISEASE 2019,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PLACEBOS,"CLINICAL IMPROVEMENT AS ASSESSED BY CHANGE IN TOTAL SYMPTOM SCORE (FOR FEVER, MYALGIA, DYSPNEA AND COUGH)","A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)"
NCT04343664,Not yet recruiting,Observational [Patient Registry],,Tjhin Wiguna,Other,1-Feb-21,31-Dec-21,1-Nov-21,ECOLOGIC OR COMMUNITY,10000,MENTAL STRESS,INDONESIA,ALL,"4 Years and older   (Child, Adult, Older Adult)",,DEPRESSION,Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia
NCT04343690,Withdrawn,Interventional,Not Applicable,Duke University,Other,27-Mar-20,1-May-20,1-May-20,OTHER,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CRISIS MANAGEMENT COACHING,CHANGE IN STRESS LEVEL AS MEASURED BY SURVEY,Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis
NCT04343729,"Active, not recruiting",Interventional,Phase 2,Fundação de Medicina Tropical Dr. Heitor Vieira Dourado,Other,18-Apr-20,20-Sep-21,16-Jun-20,TREATMENT,416,SARS-COV INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE SODIUM SUCCINATE,MORTALITY RATE AT DAY 28,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial."
NCT04343742,Recruiting,Observational,,Genesis Foundation,Other,1-Apr-20,1-Jun-20,7-Apr-20,CASE-ONLY,20,COVID,COLOMBIA,ALL,"Child, Adult, Older Adult",CHLORINE DIOXIDE 3000 PPM,NEGATIVE TESTING OF COVID19,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19
NCT04343755,"Active, not recruiting",Interventional,Phase 2,Hackensack Meridian Health,Other,9-Apr-20,21-Apr-21,21-Apr-21,TREATMENT,52,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,FOR PATIENTS HOSPITALIZED FOR COVID-19 BUT NOT INTUBATED,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
NCT04343768,Completed,Interventional,Phase 2,Shahid Beheshti University of Medical Sciences,Other,9-Apr-20,27-Apr-20,27-Apr-20,TREATMENT,60,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TIME TO CLINICAL IMPROVEMENT,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial"
NCT04343781,Completed,Observational,,"University Hospital, Angers",Other,22-Mar-20,5-Apr-20,5-Apr-20,COHORT,353,SARS-COV2,FRANCE,ALL,70 Years and older   (Older Adult),OBSERVATION,SYMPTOMS OF COVID-19 IN OLDER PATIENTS,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19
NCT04343794,Recruiting,Interventional,Not Applicable,The University of Hong Kong,Other,1-Apr-20,31-Jan-22,31-Dec-21,DIAGNOSTIC,200,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",BIOVITALS,TIME TO DIAGNOSIS OF COVID-19 BY RT-PCR IN SUBJECTS,Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19
NCT04343898,"Active, not recruiting",Observational,,Brigham and Women's Hospital,Other,1-Apr-20,1-Aug-22,1-Aug-20,COHORT,5220,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,28-DAY MORTALITY,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19
NCT04343963,Recruiting,Interventional,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,4-Apr-20,30-Apr-21,30-Sep-20,TREATMENT,436,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",PYRIDOSTIGMINE BROMIDE,CRITICAL CONDITION OR DEATH,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection
NCT04343976,Enrolling by invitation,Interventional,Phase 2,Raymond Chung,Other,22-Jun-20,30-Sep-21,1-Apr-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PEGYLATED INTERFERON LAMBDA,UNDETECTABLE COVID PCR AT DAY 7,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19
NCT04343989,"Active, not recruiting",Interventional,Phase 2,NYU Langone Health,Other,31-Mar-20,30-Jan-21,30-Jan-21,TREATMENT,90,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLAZAKIZUMAB 25 MG,CUMULATIVE INCIDENCE OF SERIOUS ADVERSE EVENTS ASSOCIATED WITH CLAZAKIZUMAB OR PLACEBO,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04344002,Recruiting,Observational [Patient Registry],,Spanish Lung Cancer Group,Other,21-Apr-20,30-Jun-21,30-Jun-21,COHORT,200,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,CLINICAL DATA OF LUNG CANCER PATIENTS WITH COVID-19 DIAGNOSES,Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease
NCT04344015,Recruiting,Interventional,Not Applicable,Thomas Jefferson University,Other,13-Apr-20,12-Apr-21,12-Apr-21,OTHER,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PLASMA DONATION,NUMBER OF PATIENTS WHO SCREEN ELIGIBLE FOR DONATION,Collection of COVID-19 Convalescent Plasma
NCT04344041,Recruiting,Interventional,Phase 3,"University Hospital, Angers",Other,15-Apr-20,21-May-21,21-May-21,TREATMENT,260,CORONAVIRUS,FRANCE,ALL,65 Years and older   (Older Adult),"CHOLECALCIFEROL 200,000 IU","NUMBER OF DEATH OF ANY CAUSE, DURING THE 14 DAYS FOLLOWING THE INCLUSION AND INTERVENTION.",COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)
NCT04344080,Recruiting,Interventional,Not Applicable,Universitätsklinikum Hamburg-Eppendorf,Other,1-Apr-20,21-Feb-21,20-Dec-21,TREATMENT,24,COVID,GERMANY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CYTOSORB-THERAPY,PERCENTAGE OF PATIENTS WITH A SIGNIFICANT STABILIZATION OF HEMODYNAMICS FOR AT LEAST 24 HOURS,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
NCT04344106,Recruiting,Interventional,Not Applicable,ELHARRAR Xavier,Other,1-Apr-20,1-May-20,15-Apr-20,SUPPORTIVE CARE,25,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,"PROPORTION OF ""RESPONDER"" PATIENTS TO PRONE POSITION",Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)
NCT04344119,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,9-Apr-20,30-Apr-21,30-Apr-21,CASE-ONLY,30,SKIN MANIFESTATIONS,FRANCE,ALL,"up to 90 Years   (Child, Adult, Older Adult)",,CLINICAL SKIN MANIFESTATIONS,Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains
NCT04344145,Completed,Observational,,Université Libre de Bruxelles,Other,16-Apr-20,29-May-20,25-May-20,CASE-CONTROL,693,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,BURNOUT,"Burnout, Emotional Distress and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population"
NCT04344171,Recruiting,Observational,,ClarData,Other,30-Mar-20,30-Jun-23,31-Dec-22,COHORT,5000,COVID,GERMANY,ALL,"Child, Adult, Older Adult",,OUTCOME COMPARISON BETWEEN DIFFERENT ANTIVIRAL THERAPIES,CovidDB: The Covid-19 Inpatient Database
NCT04344184,Recruiting,Interventional,Phase 2,Virginia Commonwealth University,Other,18-Dec-20,21-May-21,21-May-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",L-ASCORBIC ACID,CHANGE IN COVID DISEASE STATUS,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
NCT04344197,Completed,Observational,,University of Rome Tor Vergata,Other,2-Apr-20,15-Apr-20,8-Apr-20,OTHER,1200,SURGERY,ITALY,ALL,"Child, Adult, Older Adult",GLOBAL SURVEY,OVERVIEW OF SURGICAL MANAGEMENT ON PREVENTIVE MEASURES OF HOSPITAL INFECTION SPREAD DURING COVID 19,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey"
NCT04344210,Completed,Interventional,Not Applicable,Federal University of Rio Grande do Sul,Other,17-Apr-20,20-Sep-20,20-Sep-20,SUPPORTIVE CARE,149,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TELE-INTERVENTIONS RELATED TO DIABETES MANAGEMENT AND MENTAL WELL-BEING,VARIATION IN HBA1C LEVELS,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial
NCT04344236,Recruiting,Interventional,Phase 2,NYU Langone Health,Other,9-Apr-20,9-May-20,1-May-20,TREATMENT,48,COVID,UNITED STATES,ALL,"18 Years to 79 Years   (Adult, Older Adult)",SALINE ORAL/NASAL RINSE,VIRAL LOAD (AND/OR CYCLE TIME TO PCR AS A PROXY FOR QUANTITATIVE VIRAL LOAD) IN THE NASOPHARYNX AND OROPHARYNX,"A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19"
NCT04344249,Recruiting,Observational [Patient Registry],,Nantes University Hospital,Other,10-Apr-20,1-Sep-21,30-Sep-20,COHORT,850,IBD,FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,IGG AND IGM ANTI SARS-COV-2,Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic
NCT04344288,Terminated,Interventional,Phase 2,Hospices Civils de Lyon,Other,21-Apr-20,18-Aug-20,18-Aug-20,TREATMENT,11,VIRAL PNEUMONIA HUMAN CORONAVIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PREDNISONE,NUMBER OF PATIENTS WITH A THEORETICAL RESPIRATORY INDICATION FOR TRANSFER TO INTENSIVE CARE UNIT EVALUATED BY A SPO2 <90% STABILIZED AT REST AND UNDER NOT MORE THAN 5 L / MIN OF SUPPLEMENTAL OXYGEN USING MEDIUM CONCENTRATION MASK.,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
NCT04344327,Completed,Observational,,French Cardiology Society,Other,10-Apr-20,21-Apr-20,21-Apr-20,COHORT,2878,INFECTION VIRAL,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DEATH RATE,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF
NCT04344379,Suspended,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,17-Apr-20,15-Jul-20,30-Jun-20,PREVENTION,122,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TO ASSESS THE IMPACT OF HYDROXYCHLOROQUINE AND AZITHROMYCIN ON THE PREVENTION OF SARS-COV-2 CONTAMINATION IN HOSPITAL WORKERS EXPOSED TO 40 DAYS OF TREATMENT.,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus
NCT04344431,Recruiting,Interventional,Phase 2/Phase 3,Direction Centrale du Service de Santé des Armées,Other,14-Apr-20,22-Apr-21,22-Apr-21,TREATMENT,100,COVID,FRANCE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",HYPERBARIC OXYGEN TREATMENT (HBOT) I.E. INHALATION OF PRESSURIZED OXYGEN DELIVERED BY A HYPERBARIC CHAMBER (DRUG/DEVICE),TIME TO NORMALIZE THE OXYGEN REQUIREMENT (OXYGENO-DEPENDENCE),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)
NCT04344444,"Active, not recruiting",Interventional,Phase 3,LCMC Health,Other,13-Apr-20,10-Dec-21,10-Apr-21,TREATMENT,600,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,MOST SEVERE OUTCOME,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial
NCT04344457,Recruiting,Interventional,Phase 1/Phase 2,"Perseverance Research Center, LLC",Other,16-Apr-20,30-Sep-20,20-Jun-20,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,IMPROVEMENT OF CLINICAL STATUS,"An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms"
NCT04344509,Not yet recruiting,Observational,,Poitiers University Hospital,Other,20-Jun-21,20-Dec-21,20-Sep-21,CASE-CONTROL,10000,VENTILATOR ASSOCIATED PNEUMONIA,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",BACTERIAL SPECIES ISOLATED,PREVALENCE OF THE MICROORGANISMS RESPONSIBLE FOR VAP AMONG PATIENTS INFECTED OR NOT BY THE SARS-COV-2,Microbial Etiology of Ventilator-associated Pneumonia (VAP) in COVID-19 Infected Patients
NCT04344535,Enrolling by invitation,Interventional,Phase 1/Phase 2,Stony Brook University,Other,8-Apr-20,31-Aug-21,30-Apr-21,TREATMENT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,28 DAY VENTILATOR FREE DAYS,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection
NCT04344548,Not yet recruiting,Interventional,Phase 1/Phase 2,Universidad Nacional de Colombia,Other,13-Apr-20,10-Nov-20,10-Jun-20,TREATMENT,10,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",ALLOGENEIC NK TRANSFER,ADVERSE EFFECTS AND SAFETY,Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia
NCT04344561,Recruiting,Interventional,Not Applicable,Johns Hopkins University,Other,25-May-20,1-May-21,1-May-21,TREATMENT,70,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",POSTURAL POSITIONING,INCIDENCE OF MECHANICAL VENTILATION,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)
NCT04344587,Enrolling by invitation,Interventional,Not Applicable,Boston University,Other,23-Apr-20,21-Apr-21,21-Apr-21,SUPPORTIVE CARE,560,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",SELF-PRONE POSITION RECOMMENDATION,CHANGE IN RESPIRATORY STATUS,Awake Prone Position for Early Hypoxemia in COVID-19
NCT04344600,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,29-May-20,21-Dec-21,21-Jun-21,PREVENTION,164,SARS-COV2,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PEGINTERFERON LAMBDA ALFA-1A SUBCUTANEOUS INJECTION,PROPORTION OF PARTICIPANTS WITH NO EVIDENCE OF SARS-COV-2 INFECTION,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection
NCT04344665,"Active, not recruiting",Interventional,Not Applicable,Population Health Research Institute,Other,23-Apr-20,21-Jan-21,28-Oct-20,PREVENTION,905,SURGERY,CANADA,ALL,"40 Years and older   (Adult, Older Adult)",VIRTUAL CARE AND REMOTE AUTOMATED MONITORING,DAYS ALIVE AT HOME,Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial
NCT04344730,"Active, not recruiting",Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,10-Apr-20,31-Dec-21,31-Dec-21,TREATMENT,550,ACUTE HYPOXEMIC RESPIRATORY FAILURE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE INJECTION,THE TIME-TO-DEATH FROM ALL CAUSES,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS
NCT04344756,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-20,30-Sep-20,31-Jul-20,TREATMENT,808,COVID PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TINZAPARIN OR UNFRACTIONATED HEPARIN,SURVIVAL WITHOUT VENTILATION (VNI OR MECHANICAL VENTILATION),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial
NCT04344782,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,15-Apr-20,30-Nov-20,30-Sep-20,TREATMENT,130,COVID PNEUMONIA,,ALL,"18 Years and older   (Adult, Older Adult)",BEVACIZUMAB INJECTION,PROPORTION OF SURVIVING PATIENTS WITHOUT NEED FOR INTUBATION FOR RESPIRATORY SUPPORT,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial
NCT04344834,Not yet recruiting,Observational,,Assiut University,Other,20-May-21,20-Oct-21,20-Oct-21,ECOLOGIC OR COMMUNITY,300,MENTAL HEALTH ISSUE,,ALL,"Child, Adult, Older Adult",ONLINE QUESTIONNAIRE,DEPRESSION,Impact of Covid-19 on Egyptian Population Mental Health
NCT04344912,Recruiting,Observational [Patient Registry],,Assistance Publique - Hôpitaux de Paris,Other,20-Mar-20,20-Aug-21,20-Jun-21,COHORT,500,ACUTE CORONARY SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION,INCIDENCE OF RECURRENT MAJOR CARDIOVASCULAR EVENTS (MACE) AND URGENT REHOSPITALIZATION,Impact of COVID19 Outbreak in Cardiac Patients Admitted in Intensive Care Unit : the CCU-COVID19 Study
NCT04344925,Terminated,Observational,,Lawson Health Research Institute,Other,18-Apr-20,27-Nov-20,27-Nov-20,COHORT,21,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",AEROSOL-REDUCING MASK,TOTAL LEAK VOLUME OF NON INVASIVE VENTILATION MASK,Non-invasive Positive Pressure Ventilation Mask to Minimize Mask Leak and Potential Aerosolization Leading to Spread of Virus Such as COVID-19: A Non-inferiority Trial
NCT04344938,Not yet recruiting,Observational,,Assiut University,Other,20-Apr-21,20-Jul-21,20-Jun-21,ECOLOGIC OR COMMUNITY,874,COVID PANDEMIC FROM ETHICAL VIEW,,ALL,18 Years to 60 Years   (Adult),QUESTIONNAIR ABOUT EMERGING LEGAL AND EHICAL DISPUTES OVER PATIENT CONFIDENTIALITY,EVALUATE THE ETHICAL REQUIREMENT OF CONTROLLED DISRUPTS OF PATIENTS IN CASE OF INFECTIOUS DISEASE PANDEMIC,Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality
NCT04344951,Recruiting,Interventional,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Industry,6-Apr-20,30-Apr-21,1-Apr-21,PREVENTION,60,"PNEUMONIA, VIRAL",GREECE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",UNIKINON (CHLOROQUINE PHOSPHATE) 200MG TABLETS,50% REDUCTION IN SYMPTOM SCORE FOR PATIENTS WITH LOWER RESPIRATORY TRACT INFECTION,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial"
NCT04344964,Completed,Observational,,Austin Health,Other,15-Apr-20,3-Jul-20,29-May-20,CASE-CONTROL,186,COLON POLYP,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",NONE - NA,FAILED TO ATTEND PATIENTS,Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital
NCT04344977,"Active, not recruiting",Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1-Jun-20,1-Apr-25,1-Jul-24,CASE-ONLY,1500,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,IDENTIFICATION OF ELIGIBLE DONORS AND COLLECTION OF ANTI-SARS-COV-2 IMMUNE PLASMA,A Pilot Study for Collection of Anti-SARS-CoV-2 Immune Plasma
NCT04345159,Completed,Observational,,Fondation Ophtalmologique Adolphe de Rothschild,Other,17-Apr-20,30-Nov-20,30-Nov-20,COHORT,572,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE BY PHONE CALL,ADJUSTED ODDS RATIO,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
NCT04345276,Completed,Interventional,Phase 4,Huoshenshan Hospital,Other,18-Mar-20,15-Apr-20,15-Apr-20,TREATMENT,10,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",DANOPREVIR+RITONAVIR,RATE OF COMPOSITE ADVERSE OUTCOMES,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection
NCT04345289,Recruiting,Interventional,Phase 3,Thomas Benfield,Other,1-May-20,15-Jun-21,15-Jun-21,TREATMENT,1100,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT ANTI-SARS-COV-2 PLASMA,ALL-CAUSE MORTALITY OR NEED OF INVASIVE MECHANICAL VENTILATION,"Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial"
NCT04345315,Recruiting,Observational,,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,Other,27-Mar-20,22-Mar-21,21-Mar-21,COHORT,500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TEST,EPIDEMIOLOGY,Correlative Study on Cancer Patients and Healthcare Professionals Exposed to SARS-CoV-2 Infection
NCT04345406,Not yet recruiting,Interventional,Phase 3,Tanta University,Other,15-Apr-20,1-Dec-29,1-Dec-29,TREATMENT,60,COVID,EGYPT,ALL,"Child, Adult, Older Adult",ACEIS,NUMBER OF PATIENTS WITH VIROLOGICAL CURE,Randomized Trial of ACEIs in Treatment of COVID-19
NCT04345419,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,16-Jun-20,29-Dec-21,29-Dec-21,TREATMENT,120,COVID,EGYPT,ALL,"Child, Adult, Older Adult",CHLOROQUINE OR HYDROXYCHLOROQUINE,NUMBER OF PATIENTS WITH IMPROVEMENT OR MORTALITY,Remdesivir in COVID-19 Treatment: A Randomised Trial
NCT04345445,Not yet recruiting,Interventional,Phase 3,University of Malaya,Other,15-Apr-20,31-Oct-20,31-Oct-20,TREATMENT,310,COVID,MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,THE PROPORTION OF PATIENTS REQUIRING MECHANICAL VENTILATION,"An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression"
NCT04345510,Not yet recruiting,Observational,,German Cancer Research Center,Other,20-Apr-20,31-Dec-20,31-May-20,COHORT,500,COVID INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 INFECTION,Testing for COVID-19 Infection in Asymptomatic Persons
NCT04345523,Recruiting,Interventional,Phase 2,Cristina Avendaño Solá,Other,3-Apr-20,21-Apr-21,21-Feb-21,TREATMENT,278,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD AND DERIVATIVES.,"CATEGORY CHANGES IN THE ""7-ORDINAL SCALE""","Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients"
NCT04345536,Recruiting,Observational [Patient Registry],,Oslo University Hospital,Other,15-Mar-20,1-May-22,1-Jan-22,COHORT,400,COVID,NORWAY,ALL,"Child, Adult, Older Adult",,MORTALITY,Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital
NCT04345549,Completed,Interventional,Not Applicable,Aarogyam UK,Other,26-Feb-20,30-Mar-20,30-Mar-20,SUPPORTIVE CARE,18,FLU LIKE SYMPTOM,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),INDIVIDUALISED AYURVEDA,TIME TO ACHIEVE AFEBRILE,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak
NCT04345601,Recruiting,Interventional,Phase 1/Phase 2,Baylor College of Medicine,Other,21-Jan-21,22-Oct-21,22-Oct-21,TREATMENT,30,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,TREATMENT-RELATED SERIOUS ADVERSE EVENTS (TSAES),"Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled Study"
NCT04345614,Recruiting,Interventional,Phase 2,"CalciMedica, Inc.",Industry,8-Apr-20,21-Apr-21,21-Mar-21,TREATMENT,400,PNEUMONIA,PUERTO RICO,ALL,"18 Years and older   (Adult, Older Adult)",AUXORA,NUMBER OF DAYS FROM THE START OF THE FIRST INFUSION OF STUDY DRUG (SFISD) TO RECOVERY,"A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)"
NCT04345640,Recruiting,Observational,,"Institute of Liver and Biliary Sciences, India",Other,10-Apr-20,31-Dec-20,31-Dec-20,COHORT,1000,LIVER CIRRHOSES,INDIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NO INTERVENTION,SPONTANEOUS RECOVERY OR DEATH IN BOTH GROUPS,The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver - The Pan Asia-Pacific Prospective Multi-centre Observational Study (APCOLIS STUDY)
NCT04345653,"Active, not recruiting",Interventional,Phase 2,Hackensack Meridian Health,Other,14-Apr-20,8-Apr-21,5-Jun-20,PREVENTION,44,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE (HCQ),RECRUITMENT FEASIBILITY,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers"
NCT04345679,Recruiting,Interventional,Early Phase 1,Orthosera Kft.,Other,14-Apr-20,1-Sep-21,1-Jun-21,TREATMENT,20,COVID,HUNGARY,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 CONVALESCENT PLASMA,CHANGING OF VIRAL LOAD OF SARS-COV2,Anti COVID-19 Convalescent Plasma Therapy
NCT04345692,Terminated,Interventional,Phase 3,Queen's Medical Centre,Other,26-Mar-20,31-Aug-20,31-Aug-20,TREATMENT,17,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,I. CLINICAL STATUS,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients"
NCT04345848,Recruiting,Interventional,Phase 3,"University Hospital, Geneva",Other,28-Apr-20,31-Mar-21,31-Mar-21,TREATMENT,200,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,"COMPOSITE OUTCOME OF ARTERIAL OR VENOUS THROMBOSIS, DISSEMINATED INTRAVASCULAR COAGULATION AND ALL-CAUSE MORTALITY","Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Multicentric Randomized, Open-label Clinical Trial"
NCT04345861,Terminated,Interventional,Phase 2/Phase 3,"University Hospital, Montpellier",Other,11-Apr-20,8-Jun-20,8-Jun-20,TREATMENT,7,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE + PLACEBO,TIME TO CLINICAL IMPROVEMENT OF AT LEAST 1 LEVEL ON THE ORDINAL SCALE BETWEEN DAY 1 (DAY OF THE FIRST ADMINISTRATION OF STUDY DRUG) TO DAY 11 (DAY AFTER LAST DAY OF TREATMENT).,Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia
NCT04345887,Not yet recruiting,Interventional,Phase 4,Istanbul University-Cerrahpasa,Other,21-Apr-20,21-Oct-20,21-Jul-20,TREATMENT,60,"RESPIRATORY DISTRESS SYNDROME, ADULT",TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",SPIRONOLACTONE 100MG,P/F RATIO,The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients
NCT04345991,Recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,15-Apr-20,1-Jun-20,15-May-20,TREATMENT,120,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TRANSFUSION OF COVID-19 CONVALESCENT PLASMA,SURVIVAL WITHOUT NEEDS OF VENTILATOR UTILIZATION OR USE OF IMMUNOMODULATORY DRUGS,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS
NCT04346017,Recruiting,Interventional,Not Applicable,Francis Corazza,Other,20-Mar-20,20-Dec-21,20-Dec-21,BASIC SCIENCE,200,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",CYTOKINES DOSAGE,IL6 CONCENTRATION,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome
NCT04346043,Not yet recruiting,Observational,,Ain Shams University,Other,20-Apr-20,1-Dec-20,1-Oct-20,CASE-ONLY,100,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,DOMINANT VIRAL GENOME STRAIN,Strain Study: To Access the Egyptian COVID-19 Whole Genome (Dominant Strain) by Next Generation Sequencing (NGS) and Compare to the International Worldwide Database
NCT04346056,Recruiting,Observational,,Ain Shams University,Other,14-Apr-20,1-Dec-20,1-Oct-20,COHORT,500,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"1 Year to 80 Years   (Child, Adult, Older Adult)",,EXPLORING THE PRESENCE OF COVID-19,Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR
NCT04346082,Not yet recruiting,Interventional,Not Applicable,Chinese University of Hong Kong,Other,1-Aug-20,30-Jul-21,30-Jul-21,TREATMENT,30,STRESS,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE MINDFULNESS GROUP,RATE OF RECRUITMENT,Feasibility and Acceptability of Online Based Mindfulness Interventions to Relieve Distress During COVID-19 Outbreak in a Chinese Population: a Proof-of-concept Trial
NCT04346121,Completed,Observational,,Nantes University Hospital,Other,28-Apr-20,29-Jun-20,29-Jun-20,COHORT,132,PATIENT SAFETY,FRANCE,ALL,"Child, Adult, Older Adult","GPS REPORTS OF POTENTIAL PATIENT SAFETY INCIDENTS, NON-COVID-19 RELATED","DESCRIBE PATIENT SAFETY INCIDENTS (TYPES, SEVERITY, CONTRIBUTING AND CORRECTING FACTORS) - 1000 PSI REQUIRED",Non-COVID Patient-safety Incidents Reported by General Practitioners in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study.
NCT04346147,Recruiting,Interventional,Phase 2,Hospital Universitario de Fuenlabrada,Other,7-May-20,21-Sep-21,21-Jun-21,TREATMENT,165,COVID PNEUMONIA,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",IMATINIB TABLETS,TIME TO CLINICAL IMPROVEMENT,"Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia"
NCT04346160,Not yet recruiting,Observational,,G. d'Annunzio University,Other,14-Apr-20,30-Apr-20,30-Apr-20,CASE-CONTROL,25,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SCHIRMER TEST I,VIRUS MOLECULAR ANALYSIS,Tear Fluid miRNA Analysis in Sars-Cov2 Conjunctivitis
NCT04346186,Enrolling by invitation,Observational,,Herlev Hospital,Other,15-Apr-20,1-Aug-21,1-Oct-20,COHORT,30000,COVID,DENMARK,ALL,"Child, Adult, Older Adult",IGM AND IGG DIAGNOSTIC KITS TO SARS-COV-2,POSITIVE IGM/IGG TESTS,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff
NCT04346199,Completed,Interventional,Phase 2,AstraZeneca,Industry,12-Jun-20,17-Nov-20,17-Nov-20,TREATMENT,177,COVID,ARGENTINA,ALL,"18 Years to 130 Years   (Adult, Older Adult)",ACALABRUTINIB,SUBJECT ALIVE AND FREE OF RESPIRATORY FAILURE,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19"
NCT04346212,Recruiting,Observational,,Hospital de Mataró,Other,14-Apr-20,21-Jan-21,20-Dec-21,COHORT,300,OROPHARYNGEAL DYSPHAGIA,SPAIN,ALL,"Child, Adult, Older Adult",SWALLOWING EVALUATION WITH THE EAT-10 AND THE VOLUME-VISCOSITY SWALLOWING TEST (V-VST),CHANGES IN THE PREVALENCE OF OROPHARYNGEAL DYSPHAGIA,Oropharyngeal Dysphagia and Malnutrition in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment and Follow up in Patients Admitted by COVID-19 at the Consorci Sanitari Del Maresme
NCT04346264,Enrolling by invitation,Observational,,Ludwig Boltzmann Institute for Lung Health,Other,27-Apr-20,30-Sep-20,1-Jun-20,COHORT,5500,VIRUS DISEASES,AUSTRIA,ALL,"6 Years to 85 Years   (Child, Adult, Older Adult)",NO INTERVENTION PLANNED DUE TO THE OBSERVATIONAL STUDY DESIGN ONLY A DIAGNOSTIC TESTING,PREVALENCE OF SARS-COV-2 ANTIBODY TITRES,CoVid-19 - Infection and Antibody Formation in the Viennese Population - Data From the Vienna Health Study LEAD
NCT04346277,Available,Expanded Access,,Implicit Bioscience,Industry,,,,,,COVID,ITALY,ALL,"18 Years to 70 Years   (Adult, Older Adult)","IC14, A MONOCLONAL ANTIBODY AGAINST CD14",,Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)
NCT04346329,Not yet recruiting,Interventional,Phase 3,Universidad Nacional de Colombia,Other,20-Apr-20,1-Oct-20,1-Jun-20,PREVENTION,86,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,ADVERSE EFFECTS,Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2
NCT04346342,Completed,Observational,,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,6-Mar-20,1-Sep-20,1-Sep-20,COHORT,1122,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,VENTILATION MODE,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID) - an Observational Study of Invasively Ventilated Patients in the Netherlands
NCT04346355,Terminated,Interventional,Phase 2,Azienda Unità Sanitaria Locale Reggio Emilia,Other,31-Mar-20,6-Jun-20,6-Jun-20,TREATMENT,126,COVID PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,ENTRY INTO INTENSIVE CARE WITH INVASIVE MECHANICAL VENTILATION OR DEATH FROM ANY CAUSE OR CLINICAL AGGRAVATION,An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia
NCT04346368,Not yet recruiting,Interventional,Phase 1/Phase 2,Guangzhou Institute of Respiratory Disease,Other,20-Apr-21,20-Dec-21,20-Dec-21,TREATMENT,20,CORONAVIRUS DISEASE 2019 (COVID),CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BM-MSCS,CHANGES OF OXYGENATION INDEX (PAO2/FIO2),Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial
NCT04346420,Completed,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,9-Apr-20,1-May-20,1-May-20,SUPPORTIVE CARE,12,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD INTERFACE,CHANGE IN O2 OUTPUT,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19
NCT04346446,Completed,Interventional,Phase 2,"Institute of Liver and Biliary Sciences, India",Other,20-Apr-20,30-May-20,30-May-20,TREATMENT,29,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA TRANSFUSION,PROPORTION OF PATIENTS REMAINING FREE OF MECHANICAL VENTILATION IN BOTH GROUPS,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial
NCT04346589,Recruiting,Interventional,Not Applicable,A.O. Ospedale Papa Giovanni XXIII,Other,15-Apr-20,20-Aug-21,20-Aug-21,TREATMENT,10,"PNEUMONIA, VENTILATOR-ASSOCIATED",ITALY,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-CORONAVIRUS ANTIBODIES (IMMUNOGLOBULINS)OBTAINED WITH DFPP FROM CONVALESCENT PATIENTS,NUMBER OF MECHANICAL VENTILATION DAYS.,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)
NCT04346602,Recruiting,Observational,,Jilin University,Other,1-Feb-20,1-Dec-20,1-Jun-20,COHORT,132,COVID-2019,CHINA,ALL,"1 Year to 80 Years   (Child, Adult, Older Adult)",ALL TREATMENT ABOUT COVID-2019,FEVER,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019
NCT04346615,Recruiting,Interventional,Phase 2/Phase 3,"Biohaven Pharmaceuticals, Inc.",Industry,25-Apr-20,21-Jul-21,21-Jul-21,TREATMENT,120,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ZAVEGEPANT (BHV-3500),"TO COMPARE THE EFFICACY OF ZAVEGEPANT (BHV-3500) TO PLACEBO IN SUBJECTS HOSPITALIZED WITH COVID-19 INFECTION REQUIRING SUPPLEMENTAL OXYGEN, USING A SIX-POINT RATING SCALE AT DAY 15. .","BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen"
NCT04346628,Enrolling by invitation,Interventional,Phase 2,Stanford University,Other,12-Jul-20,21-Jul-21,21-Jul-21,TREATMENT,120,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,TIME UNTIL CESSATION OF ORAL SHEDDING OF SARS-COV-2 VIRUS,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19"
NCT04346667,Recruiting,Interventional,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Other,14-Apr-20,30-Jun-21,30-May-20,TREATMENT,400,SARS-COV2,PAKISTAN,ALL,20 Years to 50 Years   (Adult),HYDROXYCHLOROQUINE SULFATE REGULAR DOSE,RT-PCR NEGATIVE STATUS,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
NCT04346693,Completed,Interventional,Phase 3,Burnasyan Federal Medical Biophysical Center,Other,8-Apr-20,20-Nov-20,1-Nov-20,TREATMENT,320,ACUTE RESPIRATORY TRACT INFECTION,RUSSIAN FEDERATION,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STANDARD THERAPY RECOMMENDED BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION.,THE CHANGE OF VIRAL LOAD IN PATIENTS WITH SARS-COVID-19.,An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)
NCT04346797,Recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,16-Apr-20,31-Dec-20,30-Sep-20,TREATMENT,120,SARS-COV2,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ECULIZUMAB,SURVIVAL WITHOUT NEEDS OF INTUBATION AT DAY 14,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort"
NCT04346810,Not yet recruiting,Observational,,Hôpital Raymond Poincaré,Other,15-Apr-20,1-Sep-20,15-Aug-20,ECOLOGIC OR COMMUNITY,100,COVID,,ALL,"Child, Adult, Older Adult",PATIENT MANAGEMENT SUFFERING OF CORONAVIRUS INFECTION,STRESS IN A RECOVERY ROOM TRANSFORMED INTO AN INTENSIVE CARE UNIT VERSUS A CONVENTIONAL INTENSIVE CARE UNIT,Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit
NCT04346927,Not yet recruiting,Interventional,Not Applicable,Yasemin Çırak,Other,10-Aug-20,30-Nov-20,10-Oct-20,TREATMENT,30,TELEREHABILITATION,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",TELEREHABILITATION,VISUAL ANALOGUE SCALE,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home
NCT04346940,Not yet recruiting,Interventional,Not Applicable,Istinye University,Other,10-Aug-20,30-Nov-20,10-Oct-20,TREATMENT,30,TELEREHABILITATION,,ALL,"60 Years and older   (Adult, Older Adult)",TELEREHABILITATION,STANDARDIZED MINI MENTAL TEST,The Effectiveness of Telerehabilitation-Based Exercises in Elderly People Under Social Isolation Process Due to Coronavirus
NCT04346953,Not yet recruiting,Interventional,Not Applicable,Istinye University,Other,20-Aug-20,30-Nov-20,1-Oct-20,PREVENTION,128,HEALTHY LIFESTYLE,,ALL,40 Years to 60 Years   (Adult),VIDEO BASED EXERCISE,INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE - SHORT FORM,Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic
NCT04346966,Not yet recruiting,Interventional,Not Applicable,Istinye University,Other,20-Aug-20,20-Nov-20,20-Oct-20,PREVENTION,128,SOCIAL ISOLATION,,ALL,18 Years to 40 Years   (Adult),STUDY GROUP,INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE (SHORT FORM),The Effectiveness of Video-Based Exercises in Young Adults Under Social Isolation Process Due to Coronavirus
NCT04346979,Not yet recruiting,Interventional,Not Applicable,Istinye University,Other,1-Aug-20,1-Nov-20,1-Oct-20,TREATMENT,50,TELEREHABILITATION,,FEMALE,"45 Years to 65 Years   (Adult, Older Adult)",TELEREHABILITATION-BASED,THE BRIEF RESILIENCE SCALE,"The Effect of Telerehabilitation Based Yoga and Mindfulness Home Program on Psychological Resilience, Body Awareness and Physical Activity in Postmenopausal Women Having Social Isolation"
NCT04347031,Completed,Interventional,Phase 2/Phase 3,Burnasyan Federal Medical Biophysical Center,Other,8-Apr-20,20-Nov-20,1-Nov-20,TREATMENT,320,"PNEUMONIA, VIRAL",RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),MEFLOQUINE,1ST PRIMARY ENDPOINT FOR GROUP 1,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19"
NCT04347070,"Active, not recruiting",Observational,,"University Hospital, Montpellier",Other,1-Apr-17,1-Dec-22,1-Sep-20,COHORT,150,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PHSYIOTHERAPY,TIME OF PHYSIOTHERAPY,"Implementation of Physiotherapy on COVID-19 Patients in Intensive Care Units : a Retrospective, Multicentric, International Study"
NCT04347174,Completed,Interventional,Not Applicable,Cadila Pharnmaceuticals,Industry,30-Apr-20,21-Aug-20,10-Aug-20,TREATMENT,40,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",SUSPENSION OF HEAT KILLED (AUTOCLAVED) MYCOBACTERIUM W,7-CATEGORY ORDINAL SCALE THAT RANGES FROM 1 (NOT HOSPITALIZED WITH RESUMPTION OF NORMAL ACTIVITIES) TO 7 (DEATH),A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection
NCT04347226,Recruiting,Interventional,Phase 2,Matthew Dallos,Other,16-Apr-20,22-Sep-21,21-Sep-21,TREATMENT,138,SOLID TUMOR,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BMS-986253,TIME TO IMPROVEMENT IN THE 7-POINT ORDINAL SCALE,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19
NCT04347239,Recruiting,Interventional,Phase 2,"CytoDyn, Inc.",Industry,15-Apr-20,1-Apr-21,31-Dec-20,TREATMENT,390,CORONAVIRUS DISEASE 2019,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBOS,ALL-CAUSE MORTALITY AT DAY 28,"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)"
NCT04347278,Recruiting,Observational [Patient Registry],,Instituto de Investigación Marqués de Valdecilla,Other,22-Apr-20,1-Jan-21,15-Oct-20,OTHER,1000,SARS-COV2,SPAIN,ALL,"1 Year to 100 Years   (Child, Adult, Older Adult)",PATIENTS WITH THE TREATMENT AGAINS COVID19,EFFECTIVENESS OF CURRENT DRUG TREATMENTS FOR HOSPITALIZED PATIENTS WITH SARS-COV-2 INFECTION (COVID-19 PATIENTS) IN ROUTINE CLINICAL PRACTICE,Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry
NCT04347369,Recruiting,Observational,,Xinqiao Hospital of Chongqing,Other,17-Jan-20,31-Dec-20,30-Aug-20,CASE-ONLY,1000,COVID DISEASE,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",OTHER,DISCRIMINATION,a Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
NCT04347382,Completed,Interventional,Phase 3,Sohaib Ashraf,Other,30-Apr-20,30-Aug-20,30-Aug-20,TREATMENT,313,CORONAVIRUS INFECTION,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",HONEY,DAYS REQUIRED TO GET A POSITIVE COVID-19 PCR TO NEGATIVE,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan"
NCT04347408,Recruiting,Observational,,"Queen's University, Belfast",Other,6-May-20,13-Dec-20,13-Dec-20,COHORT,1000,COVID,UNITED KINGDOM,ALL,2 Years to 15 Years   (Child),COVID-19 ANTIBODY TESTING (IGG AND IGM),IMMUNOGLOBULINS (G AND M) TO SARS-COV2 IN PLASMA,Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study
NCT04347460,Recruiting,Observational,,Technische Universität München,Other,27-Mar-20,31-Aug-20,1-Jul-20,COHORT,20,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,PRESENCE OF SHLH AS DETERMINED BY EXPERT CHART REVIEW BY TWO INDEPENDENT REVIEWERS,"Establishing a Covid-19 Prospective Cohort to Document Cases of Secondary Hemophagocytic Lymphohistiocytosis (sHLH, Synonoums to Macrophage Activation Syndrome)"
NCT04347512,Withdrawn,Interventional,Phase 3,"University Hospital, Strasbourg, France",Other,2-Jun-20,2-Jun-20,2-Jun-20,TREATMENT,0,"SARS-COV2, COMMUNITY-ACQUIRED PNEUMONIA,COVID",,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE AND AZITHROMYCIN TREATMENT ARM.,"RATE OF PATIENTS REACHING A SIGNIFICANT HYPOXEMIA, IN EACH ARMS.",EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA
NCT04347538,"Active, not recruiting",Interventional,Not Applicable,Vanderbilt University Medical Center,Other,1-May-20,22-Jun-21,21-Jun-21,TREATMENT,90,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SALINE NASAL IRRIGATION,CHANGE IN SARS-COV-2 MUCOSAL IMMUNE RESPONSE IN THE NASOPHARYNX,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
NCT04347681,Recruiting,Interventional,Phase 2,King Fahad Specialist Hospital Dammam,Other,18-Apr-20,11-Apr-21,31-Dec-20,TREATMENT,575,CONVALESCENT PLASMA FOR COVID,SAUDI ARABIA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",CONVALESCENT PLASMA FROM RECOVERED COVID 19 DONOR,ICU LENGTH OF STAY,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19
NCT04347694,Recruiting,Observational,,Medical University of Vienna,Other,11-Apr-20,11-Apr-21,11-Apr-21,OTHER,400,SARS-COV2,AUSTRIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,STATUS OF IMMUNIZATION,COVID-19 Serology in Nephrology Health Care Workers
NCT04347798,Enrolling by invitation,Observational [Patient Registry],,University of Alberta,Other,20-Sep-21,21-Apr-21,21-Apr-21,CASE-CONTROL,500,COVID INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE/CHLOROQUINE,IMPACT OF ANTI-MALARIALS ON THE DEVELOPMENT AND SEVERITY OF COVID-19 IN THE ANTI-MALARIAL GROUP COMPARED TO THE NON-ANTI-MALARIAL GROUP,IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT
NCT04347824,Recruiting,Observational,,University Hospital Goettingen,Other,27-Apr-20,31-Dec-21,31-Dec-20,CASE-ONLY,100,COVID,GERMANY,ALL,"Child, Adult, Older Adult",,TIME TO DISEASE-AGGRAVATION,Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease
NCT04347850,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Feb-20,30-Dec-22,1-Dec-22,COHORT,500,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",BLOOD SAMPLE,NUMBER OF CONFIRMED COVID-19,"A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19) Infection, From Diagnosis to Long-term Follow-up"
NCT04347876,Recruiting,Observational,,Assiut University,Other,11-Apr-20,30-Jun-20,16-Jun-20,CASE-CONTROL,100,COVID,EGYPT,ALL,"12 Years to 80 Years   (Child, Adult, Older Adult)",TUBERCULIN TEST,PNEUMONIA SEVERITY INDEX,Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?
NCT04347889,Withdrawn,Interventional,Phase 2,Stony Brook University,Other,20-Apr-20,30-Dec-20,30-Dec-20,PREVENTION,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COVID-19 SEROCONVERSION RATE,Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT
NCT04347915,Recruiting,Interventional,Phase 2,Bukwang Pharmaceutical,Industry,6-May-20,31-Mar-21,30-Jan-21,TREATMENT,60,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",CLEVUDINE,THE RATE OF SUBJECTS TESTED AS NEGATIVE SARS-CORONAVIRUS-2 (SARS-COV-2),"A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19"
NCT04347928,Completed,Observational,,"University Hospital, Lille",Other,20-Apr-20,6-Nov-20,6-Nov-20,COHORT,15,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,INTRAPULMONARY SHUNT RATIO,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19
NCT04347941,Recruiting,Interventional,Not Applicable,University College Hospital Galway,Other,11-Jul-20,11-Sep-21,11-Jun-21,TREATMENT,200,"ARDS, HUMAN",IRELAND,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,THE EFFECT OF PRONE POSITIONING ON REQUIREMENT FOR INVASIVE MECHANICAL VENTILATION IN PATIENTS WITH COVID 19 INDUCED RESPIRATORY FAILURE.,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE
NCT04347954,Completed,Interventional,Phase 1/Phase 2,Stanford University,Other,15-Aug-20,13-Dec-20,13-Dec-20,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",POVIDONE-IODINE 2%,MEAN CHANGE IN VIRAL TITERS OF SARS-COV-2,Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers
NCT04347980,Recruiting,Interventional,Phase 3,Centre Chirurgical Marie Lannelongue,Other,20-Apr-21,20-Aug-21,20-Jun-21,TREATMENT,122,"RESPIRATORY DISTRESS SYNDROME, ADULT",FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DEXAMETHASONE AND HYDROXYCHLOROQUINE,DAY-28 MORTALITY,"Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial"
NCT04347993,Recruiting,Observational [Patient Registry],,Hackensack Meridian Health,Other,27-Mar-20,21-Apr-21,21-Apr-21,CASE-ONLY,5000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,NEED FOR HOSPITALIZATION,Real World Observational Database for COVID-19 Treatment and Outcomes
NCT04348071,Not yet recruiting,Interventional,Phase 2/Phase 3,"University of Colorado, Denver",Other,21-Jul-21,21-Oct-21,21-Aug-21,TREATMENT,80,COVID,,ALL,"18 Years to 89 Years   (Adult, Older Adult)",RUXOLITINIB,PHASE 2: CUMULATIVE INCIDENCE OF GRADE 3 AND 4 ADVERSE EVENTS (AES),Safety and Efficacy of Ruxolitinib for COVID-19
NCT04348214,Recruiting,Observational,,Ain Shams University,Other,22-Apr-20,1-Dec-20,1-Oct-20,COHORT,3000,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,RISK CATEGORIZATION OF HEALTHCARE WORKERS,Screening and Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals Using Real-time Geospatial Mapping for Emergency Healthcare Resource Mobilization and Management
NCT04348227,"Active, not recruiting",Observational [Patient Registry],,Hôpital Universitaire Fattouma Bourguiba,Other,1-Jan-19,4-Feb-21,1-Jan-20,COHORT,120,VENTILATOR ASSOCIATED PNEUMONIA,TUNISIA,ALL,"Child, Adult, Older Adult",ENHANCED HYGIENE MEASURES,MDR PATHOGENS IN ENDOTRACHEAL ASPIRATES,How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?
NCT04348240,Recruiting,Observational,,National Institute of Dental and Craniofacial Research (NIDCR),NIH,16-Apr-20,1-Jul-21,1-Jul-21,COHORT,90,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,TO DETERMINE SARS-COV-2 VIRAL LOAD AND INFECTIVITY INSALIVA THAT MAY CONTRIBUTE TO ASYMPTOMATIC TRANSMISSION,Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions
NCT04348305,"Active, not recruiting",Interventional,Phase 3,Scandinavian Critical Care Trials Group,Other,17-Apr-20,8-Jun-21,10-Sep-20,TREATMENT,1000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",HYDROCORTISONE,DAYS ALIVE WITHOUT LIFE SUPPORT AT DAY 28,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial
NCT04348370,Recruiting,Interventional,Phase 4,Texas A&M University,Other,20-Apr-20,21-Nov-21,21-May-21,PREVENTION,1800,CORONAVIRUS,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BCG VACCINE,INCIDENCE OF COVID 19 INFECTION,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses
NCT04348383,Recruiting,Interventional,Phase 2,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,Other,8-Apr-20,15-May-21,15-Apr-21,TREATMENT,150,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",DEFIBROTIDE 25 MG/KG 24 HOURS CONTINUOUS INFUSION FOR 15 DAYS,CLINICAL IMPROVEMENT.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome"
NCT04348396,Recruiting,Observational,,Istituto Nazionale di Ricovero e Cura per Anziani,Other,3-Apr-20,20-Dec-21,20-Dec-21,CASE-ONLY,300,COVID,ITALY,ALL,65 Years and older   (Older Adult),,DESCRIPTIVE-EPIDEMIOLOGICAL ANALYSIS OF HEALTH CONDITIONS,ReportAge-COVID Project: Clinical and Biological Predictors of COVID-19 Disease in Older Patients
NCT04348409,Recruiting,Interventional,Not Applicable,Azidus Brasil,Industry,25-May-20,31-Jul-20,31-Jul-20,TREATMENT,50,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE TABLETS,VIRAL LOAD,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition."
NCT04348422,Recruiting,Observational,,Assaf-Harofeh Medical Center,Other,1-May-20,31-Dec-21,1-Dec-21,COHORT,1000,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 RT-PCR,PROPORTION OF SYMPTOMATIC PATIENTS WITH IMMUNE RESPONSE (IGM/IGG/IGA),Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19
NCT04348435,Enrolling by invitation,Interventional,Phase 2,Hope Biosciences,Industry,14-May-20,30-Apr-21,15-Mar-21,PREVENTION,100,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",HB-ADMSCS,INCIDENCE OF HOSPITALIZATION FOR COVID-19,"A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19"
NCT04348448,Not yet recruiting,Observational,,AUSL Romagna Rimini,Other,20-Apr-21,20-Sep-21,20-Jul-21,COHORT,100,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CANAKINUMAB 150 MG/ML [ILARIS],INTENSIVE CARE TREATMENT,Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia
NCT04348461,Not yet recruiting,Interventional,Phase 2,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Other,6-Apr-20,30-Sep-20,15-Sep-20,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STROMAL CELLS,EFFICACY OF THE ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STEM CELLS DERIVED FROM ADIPOSE TISSUE ASSESSED BY SURVIVAL RATE),"Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19"
NCT04348474,Suspended,Interventional,Early Phase 1,Azidus Brasil,Industry,20-Apr-20,31-Jul-20,30-Jun-20,TREATMENT,200,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,CHANGE IN CLINICAL CONDITION,"Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus"
NCT04348500,"Active, not recruiting",Interventional,Phase 2,Cedars-Sinai Medical Center,Other,24-Apr-20,31-Mar-21,31-Dec-20,TREATMENT,17,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CLAZAKIZUMAB,EVALUATE THE SAFETY OF CLAZAKIZUMAB FOR THE TREATMENT OF PATIENTS WITH COVID-19 DISEASE AND SIGNS OF PULMONARY INVOLVEMENT,A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection
NCT04348513,Recruiting,Interventional,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Industry,29-May-20,31-May-21,2-May-21,TREATMENT,60,PULMONARY INFECTION,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",T3 SOLUTION FOR INJECTION,ASSESSMENT OF WEANING FROM CARDIORESPIRATORY SUPPORT,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)
NCT04348552,Recruiting,Observational,,Nantes University Hospital,Other,28-Apr-20,28-Jun-20,28-Jun-20,COHORT,1000,PATIENT SAFETY,FRANCE,ALL,"Child, Adult, Older Adult","PRIMARY CARE PROFESSIONALS REPORTS OF POTENTIAL PATIENT SAFETY INCIDENTS, NON-COVID-19 RELATED","DESCRIBE PATIENT SAFETY INCIDENTS (TYPES, SEVERITY, CONTRIBUTING AND CORRECTING FACTORS) - 1000 PSI REQUIRED",Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional Descriptive Study
NCT04348656,Recruiting,Interventional,Phase 3,Hamilton Health Sciences Corporation,Other,14-May-20,31-Dec-20,31-Oct-20,TREATMENT,1200,COVID,CANADA,ALL,"16 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,INTUBATION OR DEATH IN HOSPITAL,A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
NCT04348695,Recruiting,Interventional,Phase 2,Fundación de investigación HM,Other,12-Apr-20,13-May-20,13-May-20,TREATMENT,94,CORONAVIRUS INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB PLUS SIMVASTATIN,PERCENTAGE OF PATIENTS WHO DEVELOP SEVERE RESPIRATORY FAILURE.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.
NCT04348864,Recruiting,Interventional,Not Applicable,Neuroganics LLC,Industry,16-Apr-20,21-Apr-21,21-Apr-21,DIAGNOSTIC,200,COMMUNICABLE DISEASE,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)","COVID-19 ANTIGEN/ANTIBODY RAPID TESTING, MOBILE DEVICE IMAGE CAPTURE AND TELEMEDICINE SUPPORT",CLINICAL ACCURACY OF THE ANTIBODY AND ANTIGEN RAPID TESTS COMPARED TO LAMP/PCR-BASED TEST RESULT,Assessment of COVID-19 Diagnostic Self-testing Using Virtual Point-of-care
NCT04348877,Not yet recruiting,Interventional,Not Applicable,Ain Shams University,Other,20-Apr-20,20-Dec-21,20-Oct-21,TREATMENT,20,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ANTIBODY-RICH PLASMA FROM COVID-19 RECOVERED PATIENTS,VIRAL COVID-19 CLEARANCE,Plasma Rich Antibodies From Recovered Patients From COVID19
NCT04348929,Recruiting,Interventional,Not Applicable,"Central Hospital, Nancy, France",Other,16-Apr-20,1-Oct-21,16-Aug-21,SCREENING,927,POSTPARTUM DEPRESSION,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",SELF-ADMINISTERED QUESTIONNAIRES,"""LABOR AGENTRY SCALE QUESTIONNAIRE"" SCORE IN IMMEDIATE POST-PARTUM (DURATION OF HOSPITAL STAY)",Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care)
NCT04348942,"Active, not recruiting",Observational [Patient Registry],,ObvioHealth,Industry,29-May-20,1-May-21,1-May-21,COHORT,10000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,REGISTRY DATA,COVID-19 Study - A Primarily Prospective Observational Study of COVID-19 Clinical Characteristics and Acquired Immune Response Within the General Population
NCT04349098,Completed,Interventional,Phase 2,Karyopharm Therapeutics Inc,Industry,17-Apr-20,5-Oct-20,5-Oct-20,TREATMENT,202,CORONAVIRUS INFECTION,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",SELINEXOR,PERCENTAGE OF PARTICIPANTS WITH AT LEAST A 2 POINT IMPROVEMENT IN THE ORDINAL SCALE,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
NCT04349163,Completed,Observational,,"University Hospital, Angers",Other,10-May-20,25-Jun-20,15-Jun-20,COHORT,280,PSYCHOLOGICAL,FRANCE,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,COMPARE THE LEVEL OF RESILIENCE BETWEEN PHYSICIANS AND CAREGIVERS OF DIFFERENT SPECIALTIES AND IN DIFFERENT WORKPLACES ACCORDING TO THE COVID-19 EPIDEMIC.,Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period
NCT04349202,Recruiting,Observational,,William Beaumont Hospitals,Other,10-Apr-20,21-Jun-21,21-Jun-21,COHORT,56000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EUROIMMUN ASSAY,PREVALENCE COVID ANTIBODIES IN EMPLOYEES OF BEAUMONT HEALTH,Beaumont Health Large-scale Automated Serologic Testing for COVID-19
NCT04349228,Withdrawn,Interventional,Phase 3,Abderrahmane Mami Hospital,Other,28-Apr-20,15-Jul-20,15-Jul-20,PREVENTION,0,COVID,TUNISIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE (HCQ),SYMPTOMATIC COVID(+) INFECTION RATE,"Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study"
NCT04349241,Completed,Interventional,Phase 3,Ain Shams University,Other,18-Apr-20,20-Jun-20,1-Jun-20,TREATMENT,100,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FAVIPIRAVIR,VIRAL CLEARANCE,Efficacy and Safety of Favipiravir in Management of COVID-19
NCT04349371,Terminated,Interventional,Phase 2,Columbia University,Other,21-Apr-20,7-Jan-21,7-Jan-21,PREVENTION,8,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE,NUMBER OF SYMPTOMATIC ILLNESS IN AT RISK HEALTHCARE WORKERS,Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
NCT04349410,Completed,Interventional,Phase 2/Phase 3,The Camelot Foundation,Other,11-Apr-20,14-Sep-20,14-Sep-20,TREATMENT,1800,COVID POSITIVE,UNITED STATES,ALL,"Child, Adult, Older Adult","HYDROXYCHLOROQUINE, AZITHROMYCIN",IMPROVEMENT IN FMTVDM MEASUREMENT WITH NUCLEAR IMAGING.,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
NCT04349540,"Active, not recruiting",Observational,,Great Ormond Street Hospital for Children NHS Foundation Trust,Other,15-Apr-20,15-Jan-21,15-Oct-20,CASE-ONLY,40,COVID,UNITED KINGDOM,ALL,"3 Months and older   (Child, Adult, Older Adult)",NO INTERVENTION,COMPARISON OF INFLAMMATORY/IMMUNOLOGICAL BIOMARKERS <72 HOURS AFTER DEVELOPMENT OF OXYGEN REQUIREMENT,A Prospective Non Interventional Study to Evaluate the Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 Infection
NCT04349592,Completed,Interventional,Not Applicable,Hamad Medical Corporation,Industry,14-Apr-20,30-Aug-20,14-Aug-20,TREATMENT,456,COVID,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PROPORTION OF VIROLOGICALLY CURED (PCR-NEGATIVE STATUS) AS ASSESSED ON DAY SIX,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
NCT04349618,Recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,15-Apr-20,15-Apr-23,15-Apr-23,TREATMENT,200,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PROTECTIVE VENTILATION,A COMPOSITE SCORE BASED ON ALL-CAUSE MORTALITY AND THE NUMBER OF VENTILATOR FREE-DAYS (VFD),Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS
NCT04349631,"Active, not recruiting",Interventional,Phase 2,Hope Biosciences,Industry,22-Apr-20,1-May-21,24-Nov-20,PREVENTION,56,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",HB-ADMSCS,INCIDENCE OF HOSPITALIZATION FOR COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease"
NCT04349982,Recruiting,Observational [Patient Registry],,Medical University of Graz,Other,8-Apr-20,31-Jul-22,30-Jun-22,COHORT,50,"RISK FACTOR, CARDIOVASCULAR",AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)","BIOMARKER (TROPT, MYOGLOBIN, CK, CK-MB, LDH, D-DIMER, CRP, PCT)",ICU CV RISK AND BIOMARKER (E.G. TROPONIN),Prospective Observational ICU Trial in Critical Ill COVID-19 Patients (POINT-C) Cardiovascular Risk and the Effects on Myocardial Events in Critical Ill COVID-19 Patients
NCT04350073,Recruiting,Observational,,Duke University,Other,20-Apr-20,1-Dec-21,1-Oct-21,COHORT,120,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",Q-NRG METOBOLIC CART DEVICE,"METABOLIC AND NUTRITIONAL NEEDS OF COVID-19 PATIENTS: MEASURED BY CHANGES OF RESTING ENERGY EXPENDITURE(REE) OVER TIME, AS MEASURED BY THE INDIRECT CALORIMETRY Q-NRG DEVICE",Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)
NCT04350086,Withdrawn,Interventional,Phase 4,"University Hospital, Limoges",Other,20-Apr-20,20-Nov-20,20-Nov-20,TREATMENT,0,COVID INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TREATMENT WITH DEXMEDETOMIDINE,EFFICACY OF MILD TO MODERATE PALLIATIVE SEDATION INDUCED BY DEXMEDETOMIDINE.,Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
NCT04350099,Recruiting,Observational,,"University Hospital, Limoges",Other,15-Apr-20,15-Jun-21,15-Feb-21,COHORT,200,EMOTIONNAL DISTRESS; COVID,FRANCE,ALL,"Child, Adult, Older Adult",QUETIONNARY,ANXIETY,Emotional Burden of Healthcare Professionals and the Epidemic Related to Covid Infection 19 -
NCT04350281,Completed,Interventional,Phase 2,The University of Hong Kong,Other,9-Apr-20,7-Jul-20,1-Jul-20,TREATMENT,60,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON BETA-1B,TIME TO NEGATIVE NPS VIRAL LOAD,"An Open-label Randomized Controlled Trial on Interferon β-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection"
NCT04350320,Completed,Interventional,Phase 3,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,Other,30-Apr-20,30-Dec-20,20-Oct-20,TREATMENT,102,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE TABLETS,CHANGES IN THE PATIENTS' CLINICAL STATUS THROUGH THE 7 POINTS ORDINAL SCALE WHO R&D BLUEPRINT EXPERT GROUP,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria."
NCT04350450,Withdrawn,Interventional,Phase 2,Montefiore Medical Center,Other,20-Apr-21,20-Aug-21,20-Aug-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TIME TO RESOLUTION OF SYMPTOMS,"Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes"
NCT04350476,Withdrawn,Interventional,Not Applicable,Vivek Reddy,Other,17-Apr-20,1-May-20,1-May-20,SCREENING,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",VITALCONNECT VITAL SIGN PATCH,NUMBER OF DIFFERENT ARRHYTHMIAS,Remote Monitoring in Patients With Coronavirus Disease (COVID-19)
NCT04350580,Recruiting,Interventional,Phase 3,Centre Hospitalier St Anne,Other,11-Apr-20,21-Jun-21,21-Apr-21,TREATMENT,138,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HUMAN IMMUNOGLOBULIN,VENTILATOR-FREE DAYS,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections
NCT04350593,"Active, not recruiting",Interventional,Phase 3,Saint Luke's Health System,Other,22-Apr-20,21-Jun-21,21-Apr-21,TREATMENT,1250,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",DAPAGLIFLOZIN 10 MG,"PREVENTION OF COVID-19 COMPLICATIONS OR DEATH: DURING THE 30-DAY TREATMENT PERIOD, TIME TO FIRST OCCURRENCE OF NEW/WORSENED ORGAN DYSFUNCTION DURING INDEX HOSPITALIZATION OR DEATH FROM ANY CAUSE.","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19"
NCT04350671,Enrolling by invitation,Interventional,Phase 4,Shahid Beheshti University of Medical Sciences,Other,15-Apr-20,24-Apr-20,20-Apr-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"50 Years and older   (Adult, Older Adult)",INTERFERON BETA-1A,TIME TO CLINICAL IMPROVEMENT,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial"
NCT04350684,Enrolling by invitation,Interventional,Phase 4,Shahid Beheshti University of Medical Sciences,Other,15-Apr-20,24-Apr-20,22-Apr-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",UMIFENOVIR,TIME TO CLINICAL IMPROVEMENT,"Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial"
NCT04350710,Recruiting,Observational,,"University Hospital, Angers",Other,18-Mar-20,31-Dec-20,20-Apr-20,COHORT,50,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PEEP TRIAL,RECRUITMENT-TO INFLATION RATIO (R/I RATIO),Evaluation of Respiratory Mechanics and Lung Recruitment in Patients With SARS-CoV-2 Associated Acute Respiratory Distress Syndrome
NCT04350723,Recruiting,Interventional,Not Applicable,St. Joseph's Healthcare Hamilton,Other,10-Jun-20,30-Aug-21,30-Jul-21,TREATMENT,350,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",AWAKE PRONING,ENDOTRACHEAL INTUBATION,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial
NCT04350736,Completed,Interventional,Phase 1,Theravance Biopharma,Industry,23-Apr-20,24-Jun-20,24-Jun-20,TREATMENT,54,ACUTE LUNG INJURY (ALI) ASSOCIATED WITH COVID,UNITED KINGDOM,ALL,18 Years to 50 Years   (Adult),TD-0903,SAFETY AND TOLERABILITY OF SAD OF TD-0903: ADVERSE EVENTS,"A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19"
NCT04350931,Not yet recruiting,Interventional,Phase 3,Ain Shams University,Other,20-Apr-20,1-Dec-20,1-Oct-20,PREVENTION,900,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",INTRADERMAL INJECTION OF BCG VACCINE,INCIDENCE OF CONFIRMED COVID-19,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
NCT04351139,Completed,Observational,,Hospices Civils de Lyon,Other,6-May-20,30-Nov-20,30-Nov-20,CASE-CONTROL,205,GYNECOLOGIC CANCER,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",MODIFICATION OF THE PLANNED THERAPEUTIC MANAGEMENT,"PERCENTAGE OF PATIENTS WITH A CHANGE IN THE PLANNED THERAPEUTIC MANAGEMENT (SURGERY, CHEMOTHERAPY, RADIOTHERAPY, HORMONE THERAPY)",Impact of the COVID-19 Pandemic on Changes in Therapeutic Strategies in Gynecological Oncology
NCT04351152,Recruiting,Interventional,Phase 3,"Humanigen, Inc.",Industry,5-May-20,21-Mar-21,21-Mar-21,TREATMENT,516,CORONAVIRUS DISEASE 2019 (COVID) PNEUMONIA,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",LENZILUMAB,VENTILATOR-FREE SURVIVAL,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia"
NCT04351191,Recruiting,Interventional,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Other,15-Apr-20,30-Jun-20,30-May-20,TREATMENT,400,SARS-COV2,PAKISTAN,ALL,20 Years to 50 Years   (Adult),HYDROXYCHLOROQUINE SULFATE REGULAR DOSE,RT-PCR RESULT,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
NCT04351243,"Active, not recruiting",Interventional,Phase 2,Kinevant Sciences GmbH,Industry,12-Apr-20,21-Mar-21,1-Dec-20,TREATMENT,227,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GIMSILUMAB,INCIDENCE OF MORTALITY,"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)"
NCT04351295,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,20-Apr-20,1-Dec-20,1-Dec-20,TREATMENT,90,COVID,EGYPT,ALL,"Child, Adult, Older Adult",FAVIPIRAVIR,NUMBER OF PATIENTS WITH MORTALITY OR NEED FOR MECHANICAL VENTILATION,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment
NCT04351347,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,16-Jun-20,1-Dec-30,1-Dec-30,TREATMENT,300,COVID,EGYPT,ALL,"Child, Adult, Older Adult",IVERMECTIN,NUMBER OF PATIENTS WITH IMPROVEMENT OR DIED,Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment
NCT04351399,Completed,Observational,,"University Hospital, Lille",Other,27-Apr-20,4-May-20,4-May-20,FAMILY-BASED,318,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ASSESMENT,FREQUENCY OF RA PATIENTS WITH EMOTIONAL IMPACT (FEELING OF ISOLATION),Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak
NCT04351490,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Lille",Other,20-Apr-21,20-Jul-21,20-Jul-21,TREATMENT,3140,SARS-COV2,,ALL,"60 Years and older   (Adult, Older Adult)",ZINC GLUCONATE,SURVIVAL RATE IN ASYMPTOMATIC SUBJECTS AT INCLUSION,Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19
NCT04351503,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,9-Apr-20,22-Apr-21,22-Apr-21,OTHER,10000,SARS CORONAVIRUS (SARS-COV2) INFECTION,SWITZERLAND,ALL,"Child, Adult, Older Adult",STUDY A,"IDENTIFICATION OF FACTORS ASSOCIATED WITH (I) INFECTION (BINARY, YES/NO), (II) HOSPITALIZATION (BINARY, YES/NO), (III) REQUIREMENT FOR ICU TREATMENT (BINARY, YES/NO)",A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City
NCT04351516,Withdrawn,Interventional,Phase 2/Phase 3,University Hospital Tuebingen,Other,21-Apr-20,1-May-21,31-Dec-20,TREATMENT,0,SARS-COV2,GERMANY,ALL,65 Years and older   (Older Adult),HYDROXYCHLOROQUINE,● RATE OF HOSPITALIZATION OR DEATH AT DAY 7 AFTER STUDY INCLUSION,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients
NCT04351529,Recruiting,Observational [Patient Registry],,Arbeitsgemeinschaft medikamentoese Tumortherapie,Other,1-Apr-20,21-Dec-21,21-Dec-21,OTHER,1000,INFECTIOUS DISEASE,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",,DOCUMENTATION OF NATURAL COURSE AND THE THERAPEUTIC LANDSCAPE OF PATIENTS WITH COVID-19.,Austrian COVID-19 Registry (AGMT_COVID-19)
NCT04351542,Completed,Interventional,Not Applicable,Aarogyam UK,Other,6-Mar-20,12-Apr-20,6-Apr-20,SUPPORTIVE CARE,32,FLU LIKE ILLNESS,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),AYURVEDA,TIME TO ACHIEVE AFEBRILE,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial
NCT04351568,Recruiting,Observational,,Assiut University,Other,1-Apr-20,20-Aug-21,20-Jul-21,ECOLOGIC OR COMMUNITY,874,EVALUATING THE EFFECT OF SOCIAL MEDIA USAGE IN PROVIDING HEALTHCARE SERVICES DURING THE PERIOD OF 19 COVID PANDEMICS,EGYPT,ALL,18 Years to 60 Years   (Adult),QUESIONNAIR,TO EVALUATE THE EFFECT OF SOCIAL MEDIA USAGE IN MEDICAL PRACTICE DURING COVID 19 EPIDEMIC,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services; During the Period of 19 Covid Pandemics
NCT04351581,Recruiting,Interventional,Not Applicable,"University Hospital, Gentofte, Copenhagen",Other,18-May-20,20-Dec-21,20-Dec-21,TREATMENT,215,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",DISCONTINUATION OF ACEI/ARB,DAYS ALIVE AND OUT OF HOSPITAL WITHIN 14 DAYS AFTER RECRUITMENT,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19
NCT04351620,Recruiting,Interventional,Phase 1,University of Chicago,Other,20-Apr-21,20-Jun-21,20-Jun-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TOLERABILITY OF HIGH DOSE HCQ AS MEASURED BY HCQ DOSE MODIFICATION,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19
NCT04351633,Completed,Observational,,"University Hospital, Lille",Other,23-Apr-20,30-Apr-20,30-Apr-20,FAMILY-BASED,52,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ASSESMENT,PERCENTAGE OF PATIENT WITH FEELING OF DISABILITIES,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak
NCT04351646,Not yet recruiting,Observational,,"St George's, University of London",Other,15-Apr-20,15-Apr-22,15-Apr-22,COHORT,500,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,ANTIBODY TITRES TO SARS-COV-2,Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak (DARTS)
NCT04351659,Recruiting,Observational,,KK Women's and Children's Hospital,Other,14-Apr-20,20-Aug-21,20-Aug-21,COHORT,8,COVID,SINGAPORE,ALL,"21 Years to 65 Years   (Adult, Older Adult)",BLOOD DONATION FROM CONVALESCENT DONOR,SUCCESS RATE IN PRODUCTION OF SARS-COV-2 SPECIFIC T CELLS FROM CONVALESCENT DONOR,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
NCT04351711,Recruiting,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,9-Apr-20,22-Apr-21,22-Apr-21,CASE-CONTROL,130,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",IMMUNOLOGICAL PROFILING,MEMBRANE EXPRESSION OF HUMAN LEUKOCYTE ANTIGEN -DR ISOTYPE COMPARED TO NORMAL VALUES (BASED ON 150 HEALTHY VOLUNTEERS PREVIOUSLY SAMPLED),Immunological Profiling of Patients With COVID-19 in Respiratory Distress
NCT04351724,Recruiting,Interventional,Phase 2/Phase 3,Medical University of Vienna,Other,16-Apr-20,31-Mar-22,1-Dec-21,TREATMENT,500,COVID,AUSTRIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CHLOROQUINE OR HYDROXYCHLOROQUINE,SUSTAINED IMPROVEMENT (>48H) OF ONE POINT ON THE WHO SCALE,"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)"
NCT04351763,Recruiting,Interventional,Phase 2/Phase 3,Nicolaus Copernicus University,Other,27-Apr-20,10-Apr-21,2-Mar-21,TREATMENT,804,COVID,POLAND,ALL,"18 Years to 99 Years   (Adult, Older Adult)",AMIODARONE,CLINICAL IMPROVEMENT,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
NCT04351789,Recruiting,Interventional,Not Applicable,"Copenhagen University Hospital, Hvidovre",Other,1-May-20,23-Apr-21,23-Apr-21,PREVENTION,66,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",PSYCHOEDUCATIONAL INTERVENTION,ANXIETY 1 MONTH,Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial
NCT04351802,Recruiting,Observational,,University Hospital Plymouth NHS Trust,Other,11-May-20,20-Jan-21,20-Jan-21,COHORT,180,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND,DIAGNOSIS OF COVID-19 ON LUNG ULTRASOUND,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study
NCT04351854,Recruiting,Observational,,University of Cologne,Other,20-Apr-20,31-Aug-26,31-Dec-25,CASE-CONTROL,500,CORONAVIRUS INFECTION,GERMANY,ALL,"Child, Adult, Older Adult",RETROSPECTIVE DATA COLLECTION,IDENTIFICATION OF RISK FACTORS PRESENT AT THE EARLIEST STAGE OF HOSPITAL CARE (I.E. IN THE ED) THAT WARRANT HOSPITAL ADMISSION.,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
NCT04351906,Recruiting,Interventional,Not Applicable,University of Giessen,Other,3-May-20,1-Oct-21,1-Jun-21,TREATMENT,20,ARDS,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ECCO2R,DELTA CHANGE IN ARTERIAL PARTIAL PRESSURE OF CARBON DIOXIDE DURING ECCO2R TREATMENT,Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome
NCT04351919,Withdrawn,Interventional,Phase 4,Abderrahmane Mami Hospital,Other,5-May-20,15-Jul-20,15-Jul-20,TREATMENT,0,PATIENTS WITH COVID,TUNISIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,IMPROVMENT OR HEALING OF CLINICAL SIGNS,"Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+), inTunisia"
NCT04352348,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,31-Mar-20,31-Mar-22,31-May-21,BASIC SCIENCE,2000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES,IDENTIFICATION OF PROGNOSTIC FACTORS FOR PROGRESSION TO A SEVERE FORM OF COVID-19 INFECTION,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France)
NCT04352400,Not yet recruiting,Interventional,Phase 2/Phase 3,University Hospital Padova,Other,20-Apr-21,21-Dec-21,21-Dec-21,TREATMENT,256,COVID,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",NAFAMOSTAT MESILATE,TIME-TO-CLINICAL IMPROVEMENT,RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)
NCT04352465,Not yet recruiting,Interventional,Phase 1/Phase 2,Azidus Brasil,Industry,1-May-20,30-Nov-20,30-Jun-20,TREATMENT,42,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",METHOTREXATE,CHANGE IN CLINICAL CONDITIONS,Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study
NCT04352491,Completed,Observational,,"Institute of Liver and Biliary Sciences, India",Other,24-Apr-20,31-May-20,31-May-20,CASE-ONLY,347,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",NO INTERVENTION,ASSESSMENT OF THE FEAR LEVELS DURING THE COVID-19 DISEASE PANDEMIC AMONG PATIENTS WITH LIVER DISEASE (CURRENTLY UNDER TREATMENT FROM ILBS),An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease (FEELIV COVID)
NCT04352517,Completed,Observational,,University of Extremadura,Other,16-Mar-20,30-Sep-20,31-Aug-20,ECOLOGIC OR COMMUNITY,3500,SEDENTARY BEHAVIOR,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SURVEY,"IMPACT OF INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE-SCORE (HIGH, MODERATE, LOW LEVEL;HIGHER SCORES MEAN A BETTER OUTCOME) ON AVOIDANCE IMPACT OF COVID-19 THROUGH IES-R",Influence of Physical Activity on Psychological Responses During Coronavirus Disease (COVID-19) Pandemic: a Multi-center and Observational Study
NCT04352556,Recruiting,Observational,,Ospedale di Circolo - Fondazione Macchi,Other,7-Apr-20,30-Apr-21,30-Apr-21,COHORT,250,SARS-COV2 INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,TO EVALUATE MORTALITY.,SARS-CoV-2 Infection in Patients With Hematological Malignancies: the Italian Hematology Alliance
NCT04352582,Completed,Observational,,"University Hospital, Geneva",Other,14-Apr-20,30-Apr-20,30-Apr-20,OTHER,1194,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",SURVEY,HOW VACCINATION AND OTHER ATTITUDES ARE AFFECTED BY COVID,COVID-19 and Vaccination Attitudes
NCT04352608,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Sinovac Research and Development Co., Ltd.",Industry,16-Apr-20,13-Dec-20,10-Jul-20,PREVENTION,744,COVID,CHINA,ALL,18 Years to 59 Years   (Adult),TWO DOSES OF MEDIUM DOSAGE INACTIVATED SARS-COV-2 VACCINE AT THE EMERGENCY VACCINATION SCHEDULE,SAFETY INDEXES OF ADVERSE REACTIONS,"A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years"
NCT04352634,Recruiting,Observational,,University of Chile,Other,26-Apr-20,31-Dec-21,31-Dec-21,COHORT,2000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",EXPOSURE TO THE SARS-COV-2 AND ITS CONSEQUENCES,ANXIETY AND DEPRESSIVE SYMPTOMS,The Impact of the Covid-19 Pandemic on the Mental Health of Workers in Health Services: The Covid-19 HEalth caRe wOrkErS (HEROES) Study
NCT04352699,Completed,Observational,,Centre Hospitalier Universitaire de Nice,Other,15-Mar-20,1-May-20,17-Apr-20,COHORT,120,SURGERY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF UCI ADMISSION FOR SURGERY-RELATED COMPLICATION,Outcomes of naïve Patients Operated on for an Urological Cancer or Emergency During Periods of Social COVID-19 Containment: is it Reasonable to Limit Access to Surgical Care for All?
NCT04352751,Recruiting,Interventional,Not Applicable,Hilton Pharma,Industry,1-May-20,21-Apr-21,21-Apr-21,OTHER,2000,COVID,PAKISTAN,ALL,18 Years to 55 Years   (Adult),CONVALESCENT PLASMA,CHANGE IN COVID-19 SEVERITY STATUS,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020
NCT04352764,Recruiting,Observational [Patient Registry],,Texas Cardiac Arrhythmia Research Foundation,Other,27-Mar-20,31-Jan-21,31-Dec-20,CASE-CONTROL,5000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",CORONACIDETM COVID-19 IGM/IGG RAPID TEST AND PREMIER BIOTECH COVID-19 IGM/IGG RAPID TEST,PREVALENCE OF COVID-19 EXPOSURE,Use of the ANTIBODY BASED LATERAL FLOW IMMUNOASSAY TESTS FOR SARSCoV-2 THAT CAUSES CORONAVIRUS DISEASE 2019 (COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings
NCT04352803,Not yet recruiting,Interventional,Phase 1,Regeneris Medical,Other,20-Apr-21,26-Apr-21,24-Apr-21,TREATMENT,20,COVID PNEUMONIA,,ALL,"18 Years to 90 Years   (Adult, Older Adult)",AUTOLOGOUS ADIPOSE MSC'S,SAFETY - INCIDENCE OF UNEXPECTED ADVERSE EVENTS,IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)
NCT04352842,Completed,Observational,,RenJi Hospital,Other,21-Jan-20,8-Apr-20,8-Apr-20,COHORT,51,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",ECHOCARDIOGRAPHY,DEATH,Cardiac Structural and Functional Characteristics in COVID-19: A Dynamic Echocardiographic Study
NCT04352933,Recruiting,Interventional,Phase 3,Cambridge University Hospitals NHS Foundation Trust,Other,11-May-20,21-Apr-21,31-Oct-20,PREVENTION,1000,COVID,UNITED KINGDOM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE - DAILY DOSING,TIME TO POSITIVE COVID-19 DISEASE,ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)
NCT04352946,Not yet recruiting,Interventional,Phase 3,GeoSentinel Foundation,Other,24-Apr-20,24-Aug-20,24-Jun-20,PREVENTION,374,PROPHYLAXIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE PRE-EXPOSURE PROPHYLAXIS,CUMULATIVE INCIDENCE OF COVID-19 INFECTION,"Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial"
NCT04352959,Completed,Interventional,Not Applicable,Claude Bernard University,Other,27-Apr-20,11-Dec-20,11-Dec-20,PREVENTION,176,COVID,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",MOUTHRINSE WITH BÊTA-CYCLODEXTRIN AND CITROX,CHANGE FROM BASELINE AMOUNT OF SARS-COV-2 IN SALIVARY SAMPLES AT 7 DAYS,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study"
NCT04352985,Available,Expanded Access,,Spectral Diagnostics (US) Inc.,Industry,,,,,,SEPTIC SHOCK,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TORAYMYXIN PMX-20R (PMX CARTRIDGE),,Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
NCT04353011,Completed,Observational,,"University Hospital, Lille",Other,20-Apr-20,27-Apr-20,27-Apr-20,FAMILY-BASED,312,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ASSESMENT,HOSPITAL ANXIETY AND DEPRESSION SCALE QUESTIONNAIRE,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak
NCT04353037,Recruiting,Interventional,Phase 2,UnitedHealth Group,Industry,7-Apr-20,15-Jun-21,21-Apr-21,TREATMENT,850,CORONAVIRUS,UNITED STATES,ALL,"50 Years to 75 Years   (Adult, Older Adult)",GROUP A HCQ,SUB STUDY 1: PATIENTS,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19
NCT04353128,Recruiting,Interventional,Phase 2/Phase 3,Instituto de Investigación Hospital Universitario La Paz,Other,20-Apr-20,20-Dec-21,20-Oct-21,PREVENTION,450,COVID,SPAIN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MELATONIN 2MG,SARS-COV 2 INFECTION RATE,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.
NCT04353141,Recruiting,Observational,,KU Leuven,Other,28-Apr-20,31-Dec-20,31-May-20,COHORT,1850,COVID,BELGIUM,FEMALE,"Child, Adult, Older Adult",STANDARDIZED LUNG ULTRASOUND (LUS) EXAMINATION,DIAGNOSTIC PERFORMANCE OF LUS TO PREDICT POOR OUTCOME,A Prospective International Lung UltraSound Analysis (ILUSA) Study in Tertiary Maternity Wards During the SARS-CoV-2 Pandemic
NCT04353154,"Active, not recruiting",Observational,,Ottawa Heart Institute Research Corporation,Other,15-Apr-20,28-Feb-21,31-Jan-21,COHORT,66,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SPARTAN CUBE POINT-OF CARE COVID-19 TEST,SENSITIVITY,"Development and Evaluation of Applying a Point-of-Care COVID-19 Test Strategy to Triage Patients Presenting With Acute Coronary Syndromes, Respiratory or Hemodynamic Instability and Out of Hospital Cardiac Arrests"
NCT04353180,Not yet recruiting,Interventional,Phase 3,Kafrelsheikh University,Other,21-Feb-21,21-Mar-21,21-Feb-21,TREATMENT,100000,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DRUG ISOTRETINOIN (13 CIS RETINOIC ACID ) CAPSULES+STANDARD TREATMENT,LUNG INJURY SCORE,Isotretinoin in Treatment of COVID-19 (Randomized)
NCT04353206,Recruiting,Interventional,Early Phase 1,Noah Merin,Other,27-Jun-20,21-May-21,21-May-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MULTIPLE DOSES OF ANTI-SARS-COV-2 CONVALESCENT PLASMA,PROPORTION OF SUBJECTS WHO CONSENT TO THE STUDY AND RECEIVE AT LEAST ONE DOSE OF CONVALESCENT PLASMA.,A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19
NCT04353245,Not yet recruiting,Observational [Patient Registry],,University of Sao Paulo General Hospital,Other,1-Jun-20,30-Sep-21,30-Sep-21,CASE-CONTROL,130,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM,FIBROSIS,Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System: Effect of Hydroxychloroquine / Azithromycin Combined Therapy
NCT04353271,Terminated,Interventional,Phase 2/Phase 3,University of South Alabama,Other,17-Apr-20,8-Jul-20,8-Jul-20,TREATMENT,58,COVID,UNITED STATES,ALL,"19 Years to 85 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PERCENTAGE OF VIRUS FREE SUBJECTS,A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics
NCT04353284,Recruiting,Interventional,Phase 2,Yale University,Other,19-Jun-20,31-May-21,31-May-21,TREATMENT,114,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,CHANGE IN SARS-COV-2 VIRAL LOAD,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial"
NCT04353323,Not yet recruiting,Observational,,"University Hospital, Limoges",Other,25-May-20,25-Dec-20,25-Jun-20,COHORT,130,"INFECTION, COVID",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,SEROCONVERSION,Comparison of the Proportion of Covid19 Seroconversion of Caregivers Working or Not in the COVID Sector
NCT04353336,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,23-Mar-20,23-Dec-30,23-Sep-30,TREATMENT,200,COVID,EGYPT,ALL,"Child, Adult, Older Adult",CHLOROQUINE OR HYDROXYCHLOROQUINE,NUMBER OF PATIENTS WITH CURE OR DEATH,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
NCT04353401,Enrolling by invitation,Observational,,Vanda Pharmaceuticals,Industry,3-Aug-20,21-May-21,21-Apr-21,COHORT,5000,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,ASSOCIATIONS WITH SEVERITY AND OUTCOMES,Whole-Genome Sequencing Analysis of COVID-19 Positive Patients
NCT04353518,Recruiting,Interventional,Phase 3,Cadila Pharnmaceuticals,Industry,30-Jun-20,30-May-21,30-Mar-21,PREVENTION,4000,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",SUSPENSION OF HEAT KILLED (AUTOCLAVED) MYCOBACTERIUM W,NUMBER OF SUBJECT ACQUIRING COVID-19 INFECTION,"A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19."
NCT04353583,Recruiting,Observational [Patient Registry],,University of Giessen,Other,21-Apr-20,30-Jun-21,31-Mar-21,COHORT,400,ACUTE KIDNEY INJURY,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,GFR LOSS,Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19)
NCT04353596,Recruiting,Interventional,Phase 4,Medical University Innsbruck,Other,15-Apr-20,15-May-22,15-May-21,TREATMENT,208,SARS-COV2,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)","ACE INHIBITOR, ANGIOTENSIN RECEPTOR BLOCKER",COMBINATION OF MAXIMUM SEQUENTIAL ORGAN FAILURE ASSESSMENT (SOFA) SCORE AND DEATH,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial
NCT04353609,Recruiting,Observational,,"University Hospital, Lille",Other,18-Apr-20,20-Dec-21,20-Dec-21,COHORT,13770,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",,PROPORTION OF PATIENTS PRESENTING A SEVERE FORM OF COVID-19 REQUIRING AN INTENSIVE CARE UNIT ADMISSION OR LEADING TO DEATH,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study"
NCT04353674,Recruiting,Interventional,Not Applicable,Lawson Health Research Institute,Other,28-Apr-20,21-Jan-21,20-Dec-21,TREATMENT,40,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",CONTROL GROUP,EFFICACY OF A L-MOD AGAINST CONTROLS RECEIVING SUPPORTIVE CARE IN ICU.,Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients
NCT04354155,Recruiting,Interventional,Phase 2,Johns Hopkins All Children's Hospital,Other,2-Jun-20,15-Oct-22,22-Sep-21,PREVENTION,38,INFECTION VIRAL,UNITED STATES,ALL,"up to 18 Years   (Child, Adult)",ENOXAPARIN PREFILLED SYRINGE [LOVENOX],SAFETY OF IN-HOSPITAL THROMBOPROPHYLAXIS,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial
NCT04354259,Recruiting,Interventional,Phase 2,"University Health Network, Toronto",Other,13-May-20,30-Nov-20,1-Aug-20,TREATMENT,140,SARS-COV2,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PEGINTERFERON LAMBDA-1A,COHORT A (AMBULATORY) - PROPORTION SWAB NEGATIVE AT DAY 7 (PRIMARY EFFICACY ENDPOINT),"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19"
NCT04354272,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,13-Apr-20,20-Jun-20,20-Jun-20,COHORT,840,OROFACIAL PAIN,,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PAIN SCORE EVOLUTION MEASURED BY A 0-10 NUMERIC SCALE (NS) WHERE 0 IS NO PAIN AND 10 THE WORST PAIN IMAGINABLE,Evaluation of the Management of Dental Emergencies During COVID 19 Crisis
NCT04354389,Withdrawn,Interventional,Phase 2/Phase 3,"Ansun Biopharma, Inc.",Industry,25-Jul-20,30-Nov-20,30-Sep-20,TREATMENT,0,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",DAS181,PERCENT OF SUBJECTS RETURN TO ROOM AIR (RTRA),"DAS181 for COVID-19: A Phase II Multicenter, Randomized, Placebo-Controlled, Double-Blind Study"
NCT04354428,"Active, not recruiting",Interventional,Phase 2/Phase 3,University of Washington,Other,16-Apr-20,21-Jan-21,20-Dec-21,TREATMENT,300,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ASCORBIC ACID,LOWER RESPIRATORY TRACT INFECTION (LRTI) RATES,Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial
NCT04354441,Withdrawn,Interventional,Phase 2,Sir Mortimer B. Davis - Jewish General Hospital,Other,20-May-21,20-May-21,20-May-21,TREATMENT,0,COVID,,FEMALE,18 Years to 50 Years   (Adult),HYDROXYCHLOROQUINE SULFATE 200 MG,COVID-19-RELATED HOSPITAL ADMISSIONS,Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial
NCT04354519,Recruiting,Observational [Patient Registry],,Swansea University,Other,14-Mar-20,14-Jul-22,14-Jul-21,COHORT,3000,MULTIPLE SCLEROSIS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF COVID-19 INFECTIONS WITHIN AN MS COHORT IN THE UK,The UK MS Regsiter COVID-19 Substudy
NCT04354558,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,1-Jul-20,21-Aug-21,21-Jul-21,COHORT,200,EPIDEMIOLOGY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,VARIATION OF AGE BETWEEN CRITICALLY ILL PATIENTS WITH SARS COV2 ADMITTED IN ICU WITH NON CRITICALLY ILL PATIENTS WITH SARS COV2 ADMITTED IN ICU,Epidemiology and Outcomes of Critically Ill Patients With Covid 19: a French Single Centre Experience
NCT04354584,Recruiting,Observational,,Hvidovre University Hospital,Other,6-Apr-20,6-Apr-21,6-Apr-21,CASE-ONLY,20,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,WHITE BLOOD CELL COUNTS,"Early and Late Pulmonary and Systemic Inflammation in Critically Ill, Mechanically Ventilated Patients With Verified COVID-19"
NCT04354597,Not yet recruiting,Interventional,Not Applicable,King Hussein Cancer Center,Other,1-May-20,15-Oct-20,15-Aug-20,PREVENTION,200,COVID,JORDAN,ALL,"25 Years to 70 Years   (Adult, Older Adult)",HCQ & AZ,EFFECT OF HCQ AND AZ IN PREVENTING INFECTION WITH COVID-19 AMONG HEALTHCARE WORKERS WORKING WITH COVID-19 PATIENTS,"A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients"
NCT04354610,"Active, not recruiting",Interventional,Not Applicable,"Central Hospital, Nancy, France",Other,27-Apr-20,19-Mar-21,19-Dec-20,OTHER,57,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL SAMPLES SPECIFIC TO RESEARCH,WORSENING OF RENAL FUNCTION BY AT LEAST KDIGO GRADE 1 DURING HOSPITALIZATION FOR COVID-19 INFECTION,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection
NCT04354701,Recruiting,Observational [Patient Registry],,Vanderbilt-Ingram Cancer Center,Other,17-Mar-20,22-Dec-21,21-Dec-21,CASE-ONLY,10000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",WEB-BASED REDCAP SURVEY,WEB-BASED REDCAP SURVEY,The COVID-19 and Cancer Consortium (CCC19) Registry
NCT04354714,Withdrawn,Interventional,Phase 2,Washington University School of Medicine,Other,30-Jun-20,31-Dec-21,31-Jul-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB,OVERALL SURVIVAL,A Pilot Study of Ruxolitinib to Combat COVID-19
NCT04354753,Completed,Observational,,Aarogyam UK,Other,28-Mar-20,17-Apr-20,14-Apr-20,CASE-ONLY,80,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,PHYSICAL SYMPTOMS,AiM COVID for Covid 19 Tracking and Prediction
NCT04354766,Recruiting,Observational,,Hospices Civils de Lyon,Other,29-Apr-20,20-Jul-21,20-Jul-21,COHORT,10,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,PRODUCTION OF SEVERAL HUMAN MONOCLONAL ANTIBODIES CAPABLE OF NEUTRALIZING THE INFECTION OF A TARGET CELL BY SARS-COV-2.,Generation of Human Monoclonal Antibodies Neutralizing SARS-Cov-2 From B Cells of Convalescent Patients
NCT04354779,Completed,Observational,,AUVA,Other,11-May-20,28-Sep-20,23-Aug-20,COHORT,3301,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,AUSTRIA,ALL,"15 Years to 90 Years   (Child, Adult, Older Adult)",A SPECIFICALLY DESIGNED SELF-ADMINISTERED QUESTIONNAIRE,ANTIBODY STATUS IN HCW,Antikörperseroprävalenz Und Hintergrundinfektionsrate Von SARS-CoV-2 in Einem österreichischen Schlüsselkollektiv an Arbeitnehmer*Innen
NCT04354792,Completed,Observational,,Kasr El Aini Hospital,Other,1-May-20,10-Jun-20,10-Jun-20,COHORT,500,IMMUNOLOGIC ACTIVITY ALTERATION,EGYPT,ALL,25 Years to 60 Years   (Adult),SERUM SARS COV 2 IGG SCREENING IN HEALTH CARE WORKERS,NUMBER OF IGG SEROPOSITIVE HEALTH CARE WORKERS,Asymptomatic SARS- CoV2 Infection Among Healthcare Workers in Three University Hospitals: A Cross Sectional Study.
NCT04354805,Not yet recruiting,Interventional,Phase 2/Phase 3,Cairo University,Other,1-Aug-20,20-Nov-21,20-Oct-21,TREATMENT,100,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",CHLORPROMAZINE,CLINICAL IMPROVEMENT,Administration of Chlorpromazine as a Treatment for COVID-19
NCT04354818,Recruiting,Observational [Patient Registry],,Kirby Institute,Other,11-May-20,27-Apr-22,27-Apr-22,COHORT,1000,HIV-1-INFECTION,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",,"PERCENTAGE OF PATIENTS WHO REQUIRED HOSPITALISATION, DEVELOPED SEVERE ILLNESS (ICU ADMISSION) OR DIED",Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
NCT04354831,"Active, not recruiting",Interventional,Phase 2,Medical College of Wisconsin,Other,11-May-20,1-May-23,1-May-22,TREATMENT,131,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 CONVALESCENT PLASMA,OVERALL MORTALITY WITHIN 60 DAYS,"An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection"
NCT04354857,Recruiting,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,27-Mar-20,20-Nov-21,20-Jul-21,COHORT,454,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OLFACTORY AND GUSTATORY TESTS,SARS-COV-2 INFECTION STATUS,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
NCT04354870,Completed,Interventional,Phase 2,NYU Langone Health,Other,3-Apr-20,1-Oct-20,15-Sep-20,TREATMENT,130,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE (HCQ),FREQUENCY OF SEROCONVERSION TO SARS-COV-2,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2
NCT04355026,Recruiting,Interventional,Phase 4,General and Teaching Hospital Celje,Other,10-Apr-20,31-Jul-20,30-Jun-20,TREATMENT,90,COVID,SLOVENIA,ALL,"19 Years and older   (Adult, Older Adult)",BROMHEXINE ORAL TABLET AND/OR HYDROXYCHLOROQUINE TABLET,DURATION OF HOSPITALIZATION,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia
NCT04355052,Recruiting,Interventional,Phase 3,Sheba Medical Center,Other,11-Apr-20,11-Dec-20,11-Oct-20,TREATMENT,250,COVID - 19,ISRAEL,ALL,"18 Years to 120 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE IN COMBINATION WITH CAMOSTAT MESYLATE,CLINICAL STATE AS REFLECTED BY NEWS SCORING,"An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus"
NCT04355143,Recruiting,Interventional,Phase 2,"University of California, Los Angeles",Other,1-May-20,25-Apr-21,25-Apr-21,TREATMENT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE TABLETS,"COMPOSITE OF ALL-CAUSE MORTALITY, NEED FOR MECHANICAL VENTILATION, OR NEED FOR MECHANICAL CIRCULATORY SUPPORT (MCS)","Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)"
NCT04355234,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,4-May-20,31-Aug-21,31-Aug-21,SCREENING,2200,PREGNANCY,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",IDENTIFY SARS-COV-2 INFECTION BY SEROLOGY,SEROPREVALENCE OR NUMBER OF WOMEN WHO ARE POSITIVE FOR SARS-COV-2 IN PARTURIENT WOMAN,"Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns"
NCT04355247,Recruiting,Interventional,Phase 2,Auxilio Mutuo Cancer Center,Other,14-Apr-20,30-Apr-21,31-Jul-20,PREVENTION,20,COVID,PUERTO RICO,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE 80 MG/ML INJECTABLE SUSPENSION,CLINICAL COMPLETE RESPONSE CRITERIA,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
NCT04355338,Recruiting,Observational,,Butantan Institute,Other,25-Oct-20,30-May-22,30-May-21,COHORT,4100,COVID,BRAZIL,ALL,"Child, Adult, Older Adult",,INCIDENCE OF SARS-COV-2 INFECTION,Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil
NCT04355351,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,5-May-20,22-Oct-20,22-Oct-20,BASIC SCIENCE,400,"NEW CORONAVIRUS DISEASE (COVID), INFECTION WITH SARS-COV2",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,LEVEL OF IFN-GAMMA AFTER A NON-SPECIFIC STIMULATION OF T LYMPHOCYTES,Study of Immune Response During SARS-CoV-2 Infection
NCT04355364,Recruiting,Interventional,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,Other,21-Apr-20,21-Apr-21,21-Nov-20,TREATMENT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DORNASE ALFA INHALATION SOLUTION [PULMOZYME],EFFICACY OF INTRATRACHEAL ADMINISTRATION: OCCURRENCE OF AT LEAST ONE GRADE IMPROVEMENT,Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19
NCT04355429,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,5-May-20,20-Aug-21,20-Jul-21,TREATMENT,230,PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CAPTOPRIL 25MG,EFFICACY OF CAPTOPRIL NEBULIZATION ADDITION TO STANDARD OF CARE COMPARED TO STANDARD OF CARE.,Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study
NCT04355442,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-May-20,1-May-20,COHORT,300,MAXILLOFACIAL INJURIES,FRANCE,ALL,"Child, Adult, Older Adult",FACIAL FRACTURES REDUCTION OR OSTEOSYNTHESIS,EVOLUTION OF NUMBER OF MAXILLOFACIAL TRAUMA,Evolution of Maxillofacial Trauma Activity During COVID-19 Containment Measures: a French Multicentric Comparative Observational Study
NCT04355481,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,17-Apr-20,17-Dec-20,17-Oct-20,COHORT,150,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ESTIMATE THE PROPORTION OF PATIENTS HOSPITALIZED IN INTENSIVE CARE FOR A SARS-COV-2 VIRAL LUNG INFECTION AND CONTAMINATING THEIR ENVIRONMENT AT 1 METER.,Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit
NCT04355494,Available,Expanded Access,,Alexion Pharmaceuticals,Industry,,,,,,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ECULIZUMAB,,SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment
NCT04355507,Completed,Observational,,Assistance Publique - Hôpitaux de Paris,Other,1-Mar-20,16-Oct-20,16-Oct-20,COHORT,10735,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CHEST COMPUTED TOMOGRAPHY (CT),PREDICTIVE VALUES OF CT CRITERIA,Computed Tomography for Coronavirus Disease 19 Diagnosis
NCT04355533,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,29-Jul-20,22-Dec-21,22-Jul-21,DIAGNOSTIC,1000,COVID INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",SEROLOGY TEST,SEROCONVERSION AGAINST SARS-COV2 IN CHILDREN,Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents
NCT04355611,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-20,20-Apr-22,20-Apr-22,COHORT,2000,MULTIPLE SCLEROSIS,FRANCE,ALL,"Child, Adult, Older Adult",EVALUATION OF THE EPIDEMIOLOGICAL CHARACTERISTICS OF CORONAVIRUS INFECTION (SARS-COV-2),CLINICAL SEVERITY,Cohort Study Evaluating the Epidemiological Characteristics of Coronavirus Infection (SARS-CoV-2) in Patients With MS or NMO
NCT04355624,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,15-Apr-20,30-Jul-20,30-Apr-20,COHORT,80,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,KIDNEY INVOLVEMENT IN COVID-19 DISEASE,Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study
NCT04355637,Recruiting,Interventional,Phase 4,Sara Varea,Other,21-Apr-20,31-Aug-21,31-Aug-21,TREATMENT,300,CORONAVIRUS INFECTION,ARGENTINA,ALL,"18 Years to 79 Years   (Adult, Older Adult)",INHALED BUDESONIDE,PROPORTION OF PATIENTS IN BOTH ARMS FULFILLING THE CRITERIA FOR TREATMENT FAILURE,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia
NCT04355676,Withdrawn,Interventional,Phase 2,Karyopharm Therapeutics Inc,Industry,30-Apr-20,30-Aug-20,30-Aug-20,TREATMENT,0,CORONAVIRUS INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",SELINEXOR,PERCENTAGE OF PARTICIPANTS WITH AT LEAST A 2 POINT IMPROVEMENT IN THE ORDINAL SCALE,"A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19"
NCT04355702,Completed,Observational,,"University Hospital, Montpellier",Other,1-Mar-20,30-Dec-20,1-Dec-20,COHORT,130,SYSTEMIC LUPUS ERYTHEMATOSUS,FRANCE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,PREVALENCE AND SEVERITY OF COVID-19 INFECTION IN PATIENTS WITH SLE,Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus
NCT04355715,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-19,20-Oct-20,1-Oct-20,COHORT,200,COVID,FRANCE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,CONFIRMED DIAGNOSIS OF COVID-19 INFECTION,Evaluation of a COVID-19 Screening Strategy Combining Chest Low Dose CT and RT-PCR Test for Patients Admitted for Surgical or Interventional Procedures During the COVID 19 Outbreak
NCT04355728,Completed,Interventional,Phase 1/Phase 2,Camillo Ricordi,Other,25-Apr-20,31-Oct-20,31-Oct-20,TREATMENT,24,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UMBILICAL CORD MESENCHYMAL STEM CELLS + HEPARIN ALONG WITH BEST SUPPORTIVE CARE.,INCIDENCE OF PRE-SPECIFIED INFUSION ASSOCIATED ADVERSE EVENTS,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)
NCT04355741,Completed,Observational,,Universidade Nova de Lisboa,Other,20-Apr-20,16-Jul-20,1-Jul-20,CASE-ONLY,115,COVID,PORTUGAL,ALL,"18 Years and older   (Adult, Older Adult)",EXPOSURE,DIFFERENCES IN GUT MICROBIOTA COMPOSITION BETWEEN COVID-19 PATIENTS WITH DIFFERENT DEGREES OF DISEASE SEVERITY.,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease"
NCT04355767,Enrolling by invitation,Interventional,Phase 3,Stanford University,Other,11-Aug-20,22-Dec-21,22-Dec-21,TREATMENT,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,NUMBER OF PATIENTS WITH DISEASE PROGRESSION,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients
NCT04355793,Available,Expanded Access,,Incyte Corporation,Industry,,,,,,COVID,,ALL,"12 Years and older   (Child, Adult, Older Adult)",RUXOLITINIB,,An Open-Label Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
NCT04355871,Completed,Observational,,Fundacion SEIMC-GESIDA,Other,18-Mar-20,17-Apr-20,15-Apr-20,COHORT,4035,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,OVERALL MORTALITY,Characteristics and Predictors of Death Among Hospitalized Patients With COVID-19 in Spain
NCT04355884,Not yet recruiting,Observational,,The University of Hong Kong,Other,20-Apr-20,1-May-20,1-May-20,COHORT,100,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)","STANDARD 12-LEAD ECG, NT-PROBNP, ECHOCARDIOGRAPHY",NEW-ONSET CARDIAC ARRHYTHMIA,Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in COVID-19 Survivors
NCT04355897,Recruiting,Interventional,Early Phase 1,The Christ Hospital,Other,28-Apr-20,20-Aug-21,20-Jul-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CONVALESCENT COVID 19 PLASMA,REDUCE MORTALITY,Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease
NCT04355936,Completed,Interventional,Phase 4,Laboratorio Elea Phoenix S.A.,Industry,19-May-20,30-Nov-20,2-Nov-20,TREATMENT,400,COVID DRUG TREATMENT,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",TELMISARTAN ARM WILL RECEIVE 80 MG TELMISARTAN TWICE DAILY PLUS STANDARD CARE.,C REACTIVE PROTEIN,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial
NCT04355962,Recruiting,Interventional,Phase 3,University of Zurich,Other,23-Apr-20,31-Mar-22,31-Mar-22,TREATMENT,64,"ARDS, HUMAN",SWITZERLAND,ALL,"18 Years to 85 Years   (Adult, Older Adult)",SEVOFLURANE,COMPOSITE OUTCOME OF DEATH RATE (RATE OF PATIENTS THAT DID NOT SURVIVE) AND ORGAN FAILURE RATE (RATE OF PATIENTS SURVIVING WITH PERSISTENT ORGAN DYSFUNCTION) AT DAY 28,Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial
NCT04356144,Recruiting,Observational,,Medical University of Vienna,Other,15-Apr-20,1-Dec-20,1-Oct-20,COHORT,60,DISSEMINATED INTRAVASCULAR COAGULATION,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",THROMBIN GENERATION ASSAY (TGA),ETP (AUC) WITHOUT RHTHROMBOMODULIN (RHTM),Coagulation Assays in the Critically Ill Patient: a New Approach Using the Thrombomodulin-modified Thrombin Generation Assay (TGA-TM)
NCT04356365,Completed,Observational,,University of Oslo,Other,31-Mar-20,7-Apr-20,7-Apr-20,OTHER,10084,DEPRESSION,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",CROSS-SECTIONAL STUDY INVESTIGATING THE ASSOCIATION OF NPIS WITH MENTAL HEALTH,PATIENT HEALTH QUESTIONNAIRE 9,The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)
NCT04356378,Recruiting,Observational,,CHU de Reims,Other,2-Jun-20,2-Mar-22,2-Oct-21,COHORT,300,INFECTION WITH CORONAVIRUS SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA RECORD,PHYSICAL FUNCTIONAL LIMITATIONS,Long Term Physical Functional Performance in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation: a Multicentric Observational Study
NCT04356417,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-21,20-Jun-21,20-Jun-21,COHORT,6000000,"AMD, ACEI'S/ARB PREVENT/WORSEN RISK OF COVID INFECTION",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",#NAME?,IDENTIFICATION OF SERIOUS COVID-19 INFECTIONS,Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse: Cases of Synthetic Antimalarial Drugs and Anti-hypertensive Drugs
NCT04356443,Recruiting,Observational,,Massachusetts General Hospital,Other,15-Apr-20,31-Dec-20,31-Dec-20,COHORT,500,RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AIRGO RESPIRATORY MONITOR,"ENDOTRACHEAL INTUBATION DURING PRESENT HOSPITALIZATION, RECORDED THROUGH CHART REVIEW",Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection
NCT04356482,Recruiting,Interventional,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Other,20-May-20,20-Dec-21,20-Nov-21,TREATMENT,90,COVID,MEXICO,ALL,"16 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,CLINICAL IMPROVEMENT,DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19
NCT04356495,Recruiting,Interventional,Phase 2/Phase 3,"University Hospital, Bordeaux",Other,29-Jul-20,31-Aug-21,15-Aug-21,TREATMENT,820,CORONAVIRUS INFECTION,FRANCE,ALL,"50 Years and older   (Adult, Older Adult)",VITAMINS,PILOT PHASE: PROPORTION OF PARTICIPANTS WHO HAD A GRADE 3 OR 4 ADVERSE EVENT,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)
NCT04356508,Not yet recruiting,Interventional,Phase 2,Dr Gerry Gin Wai Kwok,Other,14-Apr-20,31-Aug-21,30-Jun-20,TREATMENT,15,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NIVOLUMAB,VIRAL CLEARANCE KINETICS,COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
NCT04356534,Completed,Interventional,Not Applicable,Royal College of Surgeons in Ireland - Medical University of Bahrain,Other,19-Apr-20,9-Jul-20,15-Jun-20,TREATMENT,40,SARS-COV2,BAHRAIN,ALL,"21 Years and older   (Adult, Older Adult)",PLASMA THERAPY USING CONVALESCENT PLASMA WITH ANTIBODY AGAINST SARS-COV-2,REQUIREMENT FOR INVASIVE VENTILATION,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial
NCT04356560,Enrolling by invitation,Observational,,"Rigshospitalet, Denmark",Other,23-Mar-20,31-Dec-20,30-Sep-20,COHORT,300,COVID,DENMARK,ALL,"Child, Adult, Older Adult","COVID-19 TEST, POLYMERASE CHAIN REACTION FOR SARS-COV-2",INCIDENCE OF HEALTHCARE WORKERS WITH SARS-COV-2,"SARS-CoV-2 Surveillance of Patients and Healthcare Workers at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark"
NCT04356586,Completed,Observational [Patient Registry],,Sciensano,Other,4-May-20,21-Aug-20,21-Aug-20,COHORT,287,COVID,BELGIUM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,PERCENTAGE OF SEROLOGICAL POSITIVE HEALTHCARE WORKERS,Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
NCT04356677,Not yet recruiting,Interventional,Phase 1,"Bausch Health Americas, Inc.",Industry,21-Feb-21,21-Apr-21,21-Apr-21,TREATMENT,50,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",50 MG/ML VIRAZOLE,CHANGE IN THE CLINICAL STATUS SEVERITY (CSS) RATING FROM THE FIRST DOSE DATE UP TO THE COMPLETION OF TREATMENT,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19"
NCT04356690,Recruiting,Interventional,Phase 2,Boston Medical Center,Other,8-May-20,22-Jun-21,21-Dec-21,SUPPORTIVE CARE,64,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ETOPOSIDE,CHANGE IN PULMONARY STATUS,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection"
NCT04356833,Recruiting,Interventional,Phase 2,"University College, London",Other,22-Apr-20,14-Jan-21,14-Jan-21,TREATMENT,24,COVID,UNITED KINGDOM,ALL,"16 Years to 70 Years   (Child, Adult, Older Adult)",NEBULISED RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR (RT-PA),TREATMENT EFFICACY - PERCENTAGE CHANGE IN PAO2/FIO2 RATIO,"A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)"
NCT04356885,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,1-Aug-20,30-Jul-20,COHORT,600,MENTAL DISORDER,FRANCE,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,TOTAL SCORE OF THE CARDIFF ANOMALOUS PERCEPTIONS SCALE (CAPS),Impact of Containment and Quarantine During COVID-19 Outbreack on Psychotic Symptoms in the General Population in France
NCT04356937,Completed,Interventional,Phase 3,Massachusetts General Hospital,Other,20-Apr-20,27-Aug-20,13-Jul-20,TREATMENT,243,SARS-COV2,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",TOCILIZUMAB,"THE PRIMARY ENDPOINT IS THE TIME FROM ADMINISTRATION OF THE INVESTIGATIONAL AGENT (OR PLACEBO) TO REQUIRING MECHANICAL VENTILATION AND INTUBATION, OR DEATH FOR SUBJECTS WHO DIE PRIOR TO INTUBATION",Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19
NCT04356950,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire de Nīmes,Other,28-Apr-20,22-Jul-21,22-Apr-21,OTHER,175,SEPSIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",THROMBIN GENERATION TEST ASSAY,28-DAY SURVIVAL RATE,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients: Thrombin Generation Potential in COVID-19 Infected Patients
NCT04357028,Suspended,Interventional,Phase 3,Kasr El Aini Hospital,Other,13-Jul-20,1-Jan-21,31-Dec-20,PREVENTION,200,COVID,EGYPT,ALL,18 Years to 50 Years   (Adult),MEASLES-MUMPS-RUBELLA VACCINE,COVID-19 DISEASE INCIDENCE,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)
NCT04357041,"Active, not recruiting",Observational,,"Clinical Nutrition Research Center, Illinois Institute of Technology",Industry,17-Apr-20,21-Dec-21,21-Apr-21,CASE-ONLY,500,"ALL, ADULT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,AUTOMATED SELF-ADMINISTERED 24-HOUR DIETARY RECALL (ASA24),"Effects of Stay-at-home Guidance on Dietary Intake, Physical Activity and Overall Well-being During COVID-19 Public Health Crisis"
NCT04357106,Recruiting,Interventional,Phase 2,Centro de Hematología y Medicina Interna,Other,13-Apr-20,20-Aug-21,20-Jul-21,TREATMENT,10,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,LUNG INJURY,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma
NCT04357275,Recruiting,Observational [Patient Registry],,University of Zurich,Other,13-Mar-20,22-Mar-21,21-Mar-21,COHORT,10000,CRITICAL ILLNESS,SWITZERLAND,ALL,"Child, Adult, Older Adult",ICU TREATMENT,ICU MORTALITY,The RIsk Stratification in COVID-19 Patients in the ICU Registry
NCT04357314,Completed,Observational,,French Cardiology Society,Other,1-Mar-20,31-May-20,31-May-20,COHORT,6332,MYOCARDIAL INFARCTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,THE PRIMARY ENDPOINT IS A COMPOSITE OF DEATH FROM ALL CAUSES AND MECHANICAL COMPLICATIONS OF ACUTE MYOCARDIAL INFARCTION (MI),Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study
NCT04357327,Completed,Interventional,Not Applicable,Università degli Studi dell'Insubria,Other,16-Apr-20,31-Jul-20,31-May-20,DIAGNOSTIC,122,COVID,ITALY,ALL,"Child, Adult, Older Adult",RAPID SALIVARY TEST,SENSIBILITY,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study
NCT04357340,Completed,Interventional,Not Applicable,Tehran University of Medical Sciences,Other,2-Apr-20,30-May-20,30-Apr-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 75 Years   (Adult, Older Adult)",PULMONARY PHYSIOTHERAPY TECHNIQUES,MIXED VENOUS O2 PRESSURE (PVO2),Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia
NCT04357366,Recruiting,Interventional,Phase 2,Hellenic Institute for the Study of Sepsis,Other,15-Apr-20,15-Apr-22,15-Apr-22,PREVENTION,1000,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,THE RATIO OF PATIENTS WHO WILL DEVELOP SERIOUS RESPIRATORY FAILURE (SRF),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial"
NCT04357418,Completed,Observational,,"Centre hospitalier de Ville-Evrard, France",Other,1-Apr-20,30-Jun-20,30-Jun-20,OTHER,187,ANXIETY STATE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",IT IS A SURVEY,STATE ANXIETY ASSESSED BY THE STATE-TRAIT ANXIETY INVENTORY (STAI),Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives (ICOS)
NCT04357431,Completed,Observational,,Assiut University,Other,22-Apr-20,30-May-20,26-May-20,OTHER,565,COVID,EGYPT,ALL,"Child, Adult, Older Adult",SELF-ADMINISTERED QUESTIONNAIRE,THE PERCENTAGE OF KNOWLEDGE REGARDING COVID-19 INFORMATION,"Knowledge, Attitude, Perceived Worry and Stigma About COVID-19 Among Egyptian Health Care Providers"
NCT04357444,Recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,23-Oct-20,23-Feb-21,2-Nov-20,TREATMENT,30,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",1: ILT101,THE PAO2/FIO2 RATIO AT D11,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
NCT04357457,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,3-Sep-20,20-Dec-21,20-Dec-21,TREATMENT,212,COVID,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ALMITRINE,RATE OF ENDOTRACHEAL INTUBATION,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium
NCT04357496,Not yet recruiting,Observational,,Centogene AG Rostock,Industry,20-Dec-20,30-Nov-21,30-Oct-21,COHORT,400,FEVER,,ALL,"60 Years and older   (Adult, Older Adult)",,IDENTIFICATION OF PROGNOSTIC PARAMETERS FOR SARS-COV-2 INFECTED PARTICIPANTS.,COVID-19 Epidemic Response Study: A National Observational Longitudinal Non-Interventional Protocol
NCT04357535,Completed,Observational,,Hakeam Abdulaziz Hakeam,Other,10-May-20,1-Aug-20,1-Jul-20,COHORT,314,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE-I) AND ANGIOTENSIN II RECEPTOR BLOCKERS (ARB),SEVERITY OF COVID-19 INFECTION,Prognosis of SARS-Cov 2 Positive Patients Receiving Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs)
NCT04357574,Enrolling by invitation,Observational,,Duke University,Other,14-Apr-20,21-Apr-21,21-Apr-21,OTHER,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELEHEALTH,RADIATION ONCOLOGY PROVIDERS PERCEPTION OF OF TELEHEALTH FOR ON TREATMENT PATIENTS IN LIEU OF IN PERSON ON TREATMENT VISITS DURING COVID-19,Assessing the Provider Implementation and Experience of TeleHealth During COVID-19 and Impact on Acute Encounters
NCT04357613,Not yet recruiting,Interventional,Phase 2,Versailles Hospital,Other,1-Sep-20,1-Dec-21,1-Dec-20,TREATMENT,99,SARS VIRUS,FRANCE,ALL,70 Years and older   (Older Adult),EXPERIMENTAL DRUG,TO EVALUATE THE BENEFIT OF EARLY IMATINIB THERAPY TO PREVENT SEVERE COVID-19 DISEASE IN HOSPITALIZED AGED PATIENTS.,A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.
NCT04357639,Recruiting,Observational [Patient Registry],,Centre Hospitalier Intercommunal Creteil,Other,28-May-20,31-Jul-21,31-Jan-21,COHORT,1040,HIV PATIENTS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,COMPARISON OF THE INCIDENCE OF COVID-19 INFECTION IN PLWHIV TREATED WITH LONG-TERM ANTIRETROVIRAL DRUGS INCLUDING A PROTEASE INHIBITOR AND THOSE WITHOUT A PROTEASE INHIBITOR,Prospective Description Study of the Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19
NCT04357730,Recruiting,Interventional,Phase 2,Denver Health and Hospital Authority,Other,14-May-20,21-Nov-21,21-Sep-21,TREATMENT,60,SEVERE ACUTE RESPIRATORY SYNDROME,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ALTEPLASE 50 MG [ACTIVASE],PAO2/FIO2 IMPROVEMENT FROM PRE-TO-POST INTERVENTION,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial
NCT04357769,Completed,Observational,,Federico II University,Other,10-Apr-20,25-Apr-20,20-Apr-20,CASE-CONTROL,400,PSYCHOLOGICAL DISTRESS,ITALY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",PSS (PERCEIVED STRESS SCALE),PERCEIVED STRESS SCALE (PSS) OUTCOME,A Study of Perceived Distress and Psychological Burden in Patients Suffering From Severe Mental Diseases During the COVID-19 Pandemic in Italy
NCT04357782,Completed,Interventional,Phase 1/Phase 2,Hunter Holmes Mcguire Veteran Affairs Medical Center,U.S. Fed,16-Apr-20,13-Oct-20,13-Oct-20,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",L-ASCORBIC ACID,INCIDENCE OF ADVERSE EVENTS,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial"
NCT04357808,Completed,Interventional,Phase 2,Maria del Rosario Garcia de Vicuña Pinedo,Other,13-Apr-20,4-Dec-20,30-Nov-20,TREATMENT,30,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB,MEAN CHANGE IN CLINICAL STATUS ASSESSMENT USING THE 7-POINT ORDINAL SCALE AT DAY 7 AFTER RANDOMISATION,Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection
NCT04357834,Recruiting,Observational,,"University Hospital Inselspital, Berne",Other,1-May-20,31-Dec-21,31-Dec-21,OTHER,100,COVID,SWITZERLAND,ALL,"18 Years to 120 Years   (Adult, Older Adult)",EQUIPMENT WITH SMARTWATCH THROUGHOUT HOSPITAL STAY ON THE GENERAL WARD,DIAGNOSTIC ACCURACY OF SMARTWATCH DATA IN PREDICTING ICU REQUIREMENT IN COVID-19 CONTRACTED INPATIENTS QUANTIFIED AS THE AREA UNDER THE RECEIVER OPERATOR CHARACTERISTICS CURVE (AUC ROC > 0.85).,Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories. The WAVE Study.
NCT04357847,Recruiting,Observational,,"University Hospital, Rouen",Other,9-Apr-20,31-Aug-21,31-Jul-21,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ASSOCIATION OF INTERCELLULAR ADHESION MOLECULE-1 PLASMA LEVEL WITH 28 DAYS MORTALITY,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection
NCT04357860,Not yet recruiting,Interventional,Phase 2,Maimónides Biomedical Research Institute of Córdoba,Other,27-Apr-20,27-Jul-20,27-Jul-20,TREATMENT,120,SARS-COV2,SPAIN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",SARILUMAB 200 MG/1.14 ML SUBCUTANEOUS SOLUTION [KEVZARA],VENTILATION REQUIREMENTS,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome
NCT04357886,Not yet recruiting,Observational,,Istanbul University-Cerrahpasa,Other,20-May-21,20-Jun-21,20-May-21,COHORT,1000,HEALTHY,TURKEY,ALL,"15 Years and older   (Child, Adult, Older Adult)",,COVID-19 AWARENESS SURVEY,New Coronavirus Awareness
NCT04357938,"Active, not recruiting",Observational,,Jena University Hospital,Other,15-Apr-20,30-Apr-21,20-Apr-21,COHORT,145,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",CT-IMAGING,SENSITIVITY AND SPECIFICITY OF CHEST CT IN DETECTING PNEUMONIA IN UNSPECIFIC SYMPTOMATIC PATIENTS WHO ARE TO BE ADMITTED TO HOSPITAL AND WHO ARE RT-PCR NEGATIVE FOR SARS-COV-2.,Risk Stratification With Chest Computed Tomography to Rule-out Suspected SARS-CoV-2 Infections of Unspecific Symptomatic Patients Before Hospital Admission
NCT04357977,Not yet recruiting,Observational,,"Kaligia Biosciences, LLC",Industry,20-Apr-21,20-Dec-21,20-Aug-21,ECOLOGIC OR COMMUNITY,300,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RBA-2,COVID +,A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device
NCT04357990,Recruiting,Interventional,Not Applicable,Kerecis Ltd.,Industry,4-Sep-20,21-Mar-21,21-Mar-21,TREATMENT,128,COVID,ICELAND,ALL,"18 Years and older   (Adult, Older Adult)",VIRUXAL ORAL AND NASAL SPRAY,NUMBER OF DAYS UNTIL COMPLETE RESOLUTION OF SYMPTOMS PER GROUP,"Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa"
NCT04358003,Recruiting,Interventional,Not Applicable,Marker Therapeutics AG,Industry,20-May-20,1-Dec-21,1-Aug-21,TREATMENT,2000,RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MARKER THERAPEUTICS D2000 CARTRIDGE (D2000) FOR USE WITH THE SPECTRA OPTIA® APHERESIS SYSTEM (OPTIA SPD PROTOCOL),ALL-CAUSE MORTALITY,Plasma Adsorption in Patients With Confirmed COVID-19 Infection
NCT04358029,Recruiting,Observational,,Vivek Reddy,Other,9-Apr-20,21-Dec-21,21-May-21,CASE-ONLY,10000,COVID CARDIAC,UNITED STATES,ALL,"Child, Adult, Older Adult",,FREQUENCY OF CARDIAC ARRHYTHMIAS,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)
NCT04358042,Recruiting,Observational [Patient Registry],,Nantes University Hospital,Other,24-Apr-20,1-Jan-23,1-Jan-22,COHORT,250,PSYCHIATRIC DISORDER,FRANCE,ALL,"15 Years and older   (Child, Adult, Older Adult)",BRIEF PSYCHIATRIC RATING SCALE,IMPACT OF THE COVID-19 PANDEMIC ON PSYCHIATRIC SYMPTOMATOLOGY,"PSYCHIatric Disorders and Covid-19 (PSYCHIC) : Observatory of the Psychiatric, Somatic and Pharmacological Impacts of the COVID-19 Pandemic on Patients Hospitalized for Psychiatric Disorders and Suspected to be Infected by COVID-19"
NCT04358068,Completed,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1-May-20,7-Jul-20,7-Jul-20,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE (HCQ),PROPORTION OF PARTICIPANTS WHO DIED FROM ANY CAUSE OR WERE HOSPITALIZED,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19"
NCT04358081,Completed,Interventional,Phase 3,Novartis Pharmaceuticals,Industry,1-May-20,27-Jul-20,27-Jul-20,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HCQ,PERCENTAGE OF PARTICIPANTS WHO ACHIEVE CLINICAL RESPONSE,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease"
NCT04358211,Available,Expanded Access,,"Nakhle Saba, MD",Other,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL: COVID-19 CONVALESCENT PLASMA,,Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19
NCT04358380,Enrolling by invitation,Observational,,"Austral University, Argentina",Other,15-Apr-20,31-Dec-20,31-Dec-20,COHORT,320,LIVER INJURY,ARGENTINA,ALL,"17 Years and older   (Child, Adult, Older Adult)",LIVER INJURY,LIVER INJURY IN PATIENTS WITH COVID-19,Liver Injury in Hospitalized Patients With COVID-19 in Latin America: Clinical Characteristics and Prognostic Factors
NCT04358406,Recruiting,Interventional,Phase 2,BioAegis Therapeutics Inc.,Industry,30-Jul-20,1-May-21,1-May-21,TREATMENT,60,SARS-COV2,ROMANIA,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN),"EFFICACY: PROPORTION OF SUBJECTS ALIVE NOT ON VASOPRESSORS, MECHANICAL VENTILATOR, AND DIALYSIS","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia"
NCT04358510,Completed,Observational,,Dascena,Industry,1-Apr-20,17-Apr-20,17-Apr-20,COHORT,114,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVIAGE,MORTALITY OUTCOME IN COVID-19 ICU PATIENTS,"Mortality Prediction Model for the Triage of COVID-19, Pneumonia and Mechanically Ventilated ICU Patients"
NCT04358536,Completed,Observational,,Dascena,Industry,1-Apr-20,17-Apr-20,17-Apr-20,COHORT,230,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVX,IDENTIFICATION OF COVID-19,Classification of COVID-19 Infection in Posteroanterior Chest X-rays With Common Deep Learning Architectures
NCT04358549,"Active, not recruiting",Interventional,Phase 2,"Fujifilm Pharmaceuticals U.S.A., Inc.",Industry,17-Apr-20,1-May-21,1-Nov-20,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FAVIPIRAVIR + STANDARD OF CARE,TIME TO VIRAL CLEARANCE,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19"
NCT04358588,No longer available,Expanded Access,,Bellerophon,Industry,,,,,,CORONAVIRUS INFECTION,,ALL,"18 Years to 95 Years   (Adult, Older Adult)",INO (INHALED NITRIC OXIDE) DELIVERED VIA THE INOPULSE DELIVERY SYSTEM,,"Expanded Access: Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19)"
NCT04358614,Completed,Interventional,Phase 2/Phase 3,Fabrizio Cantini,Other,16-Mar-20,7-Apr-20,5-Apr-20,TREATMENT,12,COVID,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BARICITINIB 4 MG ORAL TABLET,TO ASSESS THE SAFETY OF BARICITINIB COMBINED WITH ANTIVIRAL (LOPINAVIR-RITONAVIR) IN TERMS OF SERIOUS OR NON-SERIOUS ADVERSE EVENTS INCIDENCE RATE.,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact
NCT04358627,Not yet recruiting,Observational,,Hospital Clinic of Barcelona,Other,15-Apr-20,30-Jun-20,30-May-20,CASE-CONTROL,80,ACUTE RESPIRATORY DISTRESS SYNDROME,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",DEXMEDETOMIDINE INJECTABLE PRODUCT,MECHANICAL VENTILATION,Impact of Dexmedetomidine Infusion on the Time Course and Outcomes of Acute Respiratory Distress Syndrome (ARDS) in Patients Affected by the SARS-CoV-2 (COVID-19) Admitted to Critical Care Unit
NCT04358640,Completed,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,9-Apr-20,27-Apr-20,27-Apr-20,OTHER,1784,CRITICAL ILLNESS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ANXIETY,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey
NCT04358783,"Active, not recruiting",Interventional,Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,Other,27-Apr-20,30-May-21,1-May-21,TREATMENT,30,CORONAVIRUS INFECTION,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",PLASMA,EARLY ALL-CAUSE MORTALITY,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia"
NCT04358809,Recruiting,Interventional,Phase 3,Cadila Pharnmaceuticals,Industry,30-Jun-20,30-Apr-21,28-Feb-21,TREATMENT,480,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",SUSPENSION OF HEAT KILLED (AUTOCLAVED) MYCOBACTERIUM W,NUMBER OF PATIENTS WITH INCREASED DISEASE SEVERITY,"A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill."
NCT04358835,Withdrawn,Interventional,Not Applicable,Johns Hopkins University,Other,1-Sep-20,31-Dec-21,1-Sep-21,TREATMENT,0,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",KETOGENIC DIET,CHANGE IN THE PARTIAL PRESSURE OF CARBON DIOXIDE (PACO2),Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)
NCT04358926,Completed,Interventional,Not Applicable,Assaf-Harofeh Medical Center,Other,30-Apr-20,1-Nov-20,15-Oct-20,TREATMENT,30,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN THERAPY,SPO2,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
NCT04358939,Recruiting,Interventional,Not Applicable,"University Hospital, Tours",Other,27-Apr-20,24-Nov-21,10-Nov-21,TREATMENT,404,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PRONE DECUBITUS,THERAPEUTIC FAILURE WITHIN 14 DAYS OF RANDOMIZATION,Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome
NCT04358952,Recruiting,Observational,,"University Hospital, Toulouse",Other,4-Apr-20,4-Nov-20,4-Nov-20,OTHER,50,CARDIOMYOPATHIES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",GLOBAL LONGITUDINAL STRAIN,LEFT VENTRICULAR FUNCTION,Imaging Cardiac Phenotype of SARS-Cov-2 (Covid19) Infected Patients
NCT04359095,Recruiting,Interventional,Phase 2/Phase 3,Universidad Nacional de Colombia,Other,18-Aug-20,31-May-21,28-Feb-21,TREATMENT,1200,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",EMTRICITABINE/TENOFOVIR,MORTALITY,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial
NCT04359121,Recruiting,Observational,,Medical University of Graz,Other,15-Apr-20,15-Apr-24,15-Apr-23,COHORT,600,COVID,AUSTRIA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",QUESTIONNAIRES FOR SPECIFIC PHOBIA,DEVELOPMENT OF PHOBIAS,COVID-19 and the Developement of Phobic Fears of Disease
NCT04359212,Completed,Observational,,Quovadis Associazione,Other,1-May-20,31-Jul-20,30-Jun-20,COHORT,90,COVID DISEASE,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",THROMBOPROPHYLAXIS WITH LOW-MOLECULAR-WEIGHT HEPARIN OR FONDAPARINUX,THE CUMULATIVE PROPORTION OF ANY DISTAL OR PROXIMAL DEEP VENOUS THROMBOSIS OR OF SYMPTOMATIC PULMONARY EMBOLISM,Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19)
NCT04359225,Not yet recruiting,Interventional,Not Applicable,NHS Greater Glasgow and Clyde,Other,30-Jun-20,31-Dec-21,31-Dec-21,OTHER,80,TELEHEALTH,UNITED KINGDOM,ALL,"1 Year to 95 Years   (Child, Adult, Older Adult)",3D TELEMEDICINE,UNIVERSITY HOSPITALS OF NORTH NORTHWAY QUESTIONNAIRE,A Comparison of 3D and 2D Telemedicine: Communication During Covid 19
NCT04359251,Completed,Interventional,Not Applicable,"Southeast University, China",Other,5-Mar-20,25-Mar-20,25-Mar-20,TREATMENT,20,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",GAS EXCHANGES AT DIFFERENT PEEP,RESPIRATORY SYSTEM COMPLIANCE IMPROVEMENT,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study
NCT04359264,"Active, not recruiting",Interventional,Not Applicable,Unity Health Toronto,Other,20-Apr-20,30-Dec-20,29-May-20,PREVENTION,392,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",CASH TRANSFER,SYMPTOMS CONSISENT WITH COVID-19,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT)
NCT04359277,Terminated,Interventional,Phase 3,NYU Langone Health,Other,21-Apr-20,20-Sep-20,20-Sep-20,TREATMENT,77,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ENOXAPARIN HIGHER DOSE,"COMPOSITE INCIDENCE OF: ALL-CAUSE MORTALITY, CARDIAC ARREST, SYMPTOMATIC DEEP VENOUS THROMBOSIS, PULMONARY EMBOLISM, ARTERIAL THROMBOEMBOLISM, MYOCARDIAL INFARCTION, STROKE, OR SHOCK",A Randomized Trial of Anticoagulation Strategies in COVID-19
NCT04359290,"Active, not recruiting",Interventional,Phase 2,Philipps University Marburg Medical Center,Other,1-Jul-20,21-Jul-21,20-Dec-21,TREATMENT,15,"ARDS, HUMAN",GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB ADMINISTRATION,OVERALL SURVIVAL,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study"
NCT04359303,Not yet recruiting,Interventional,Phase 3,Javier Hidalgo Tallón,Other,20-Jul-21,20-Dec-21,20-Nov-21,TREATMENT,50,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",SYSTEMIC INDIRECT ENDOVENOUS OZONE THERAPY,COVID19 CLINICAL SCALE,Randomized Clinical Trial to Evaluate Efficacy and Safety of Systemic Indirect Endovenous Ozone Therapy (SIEVOT) as Adjuvant Treatment in COVID19 Non-intubated Patients
NCT04359316,Not yet recruiting,Interventional,Phase 4,Shahid Beheshti University of Medical Sciences,Other,20-Apr-20,5-May-20,3-May-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TIME TO CLINICAL IMPROVEMENT,"Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial"
NCT04359329,Recruiting,Interventional,Phase 2,Sharon Nachman,Other,20-Apr-20,15-Nov-20,15-Nov-20,TREATMENT,110,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ESTRADIOL PATCH,RATE OF HOSPITALIZATION,Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients
NCT04359407,Recruiting,Observational,,Walid HABRE,Other,27-Apr-20,31-Jan-21,31-Dec-20,CASE-ONLY,16,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,SWITZERLAND,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PRONE POSITIONING,TIDAL ELECTRICAL IMPEDANCE,The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome
NCT04359459,Not yet recruiting,Observational,,University Medical Center Groningen,Other,20-Jun-21,22-Jun-21,22-Jun-21,COHORT,150,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,NASAL EPITHELIAL TRANSCRIPTIONAL RESPONSE TO SARS-COV2,"Nasal CIliated EPithelial Genetic And Single Cell RNA prOfiLes of miLd, Severe and Very Severe COVID-Nineteen patIents (CIPOLLINI) Study"
NCT04359511,Not yet recruiting,Interventional,Phase 3,"University Hospital, Tours",Other,20-Jun-21,20-Dec-21,20-Dec-21,TREATMENT,210,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PREDNISONE,"CLINICAL IMPROVEMENT DEFINED BY THE IMPROVEMENT OF 2 POINTS ON A 7-CATEGORY ORDINAL SCALE, AT 14 DAYS.",Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France
NCT04359537,Recruiting,Interventional,Phase 2,Shaheed Zulfiqar Ali Bhutto Medical University,Other,1-May-20,25-Sep-20,25-Aug-20,PREVENTION,200,COVID,PAKISTAN,ALL,18 Years to 60 Years   (Adult),HYDROXYCHLOROQUINE SULFATE 200 MG,COVID-19-FREE SURVIVAL IN EXPERIMENTAL ARMS COMPARED TO PLACEBO,Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel
NCT04359602,Recruiting,Observational [Patient Registry],,"University of California, Los Angeles",Other,8-Apr-20,20-Apr-42,20-Apr-22,CASE-ONLY,10000,RECOVERED FROM COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SEROLOGICAL TESTING OF COVID PATIENTS,COVID-19 Recovered Volunteer Research Participant Pool Registry
NCT04359615,Not yet recruiting,Interventional,Phase 4,Shahid Beheshti University of Medical Sciences,Other,20-Apr-20,5-May-20,3-May-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,TIME TO CLINICAL IMPROVEMENT,"Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial"
NCT04359654,Recruiting,Interventional,Phase 2,"University College, London",Other,16-Jun-20,1-Nov-21,1-Aug-21,TREATMENT,50,COVID,UNITED KINGDOM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DORNASE ALFA INHALATION SOLUTION [PULMOZYME],MEASURING THE CHANGE IN INFLAMMATION,"A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19"
NCT04359667,Recruiting,Observational,,"University Hospital for Infectious Diseases, Croatia",Other,16-Jun-20,15-May-21,16-Apr-21,CASE-ONLY,30,COVID,CROATIA,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB 20 MG/ML INTRAVENOUS SOLUTION [ACTEMRA],SERUM INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR AS BIOMARKERS OF CLINICAL OUTCOMES IN PATIENTS WITH SEVERE CORONAVIRUS DISEASE (COVID-19) PNEUMONIA TREATED WITH TOCILIZUMAB,Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19)
NCT04359680,"Active, not recruiting",Interventional,Phase 3,Romark Laboratories L.C.,Industry,13-May-20,29-Mar-21,29-Mar-21,PREVENTION,1407,COVID,UNITED STATES,ALL,"18 Years to 120 Years   (Adult, Older Adult)",NITAZOXANIDE,THE PROPORTION OF SUBJECTS WITH SYMPTOMATIC LABORATORY-CONFIRMED COVID-19 IDENTIFIED AFTER START OF TREATMENT AND BEFORE THE END OF THE 6-WEEK TREATMENT PERIOD.,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection"
NCT04359693,Completed,Observational,,"University Hospital, Lille",Other,22-Apr-20,1-Jul-20,1-Jul-20,COHORT,1576,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CUMULATIVE INCIDENCE OF VENTILATOR-ASSOCIATED LOWER RESPIRATORY TRACT INFECTION,Impact of SARS-CoV-2 Infection on the Incidence of Ventilator-acquired Infections
NCT04359706,Recruiting,Observational,,"University Hospital, Lille",Other,8-May-20,20-Sep-21,20-Sep-21,COHORT,30,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COMPOSITION OF THE FECAL BACTERIAL AND FUNGAL MICROBIOTA,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2
NCT04359797,"Active, not recruiting",Interventional,Not Applicable,Vanderbilt University Medical Center,Other,27-Apr-20,21-Jun-21,17-Dec-20,SUPPORTIVE CARE,503,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRONE,MODIFIED WHO ORDINAL SCALE,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone
NCT04359810,Recruiting,Interventional,Phase 2,Max R. O'Donnell,Other,21-Apr-20,21-Apr-21,20-Dec-21,TREATMENT,219,SARS-COV2 INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA (ANTI-SARS-COV-2 PLASMA),DAY 28 SEVERITY OUTCOME,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19"
NCT04359836,Recruiting,Observational,,ProgenaBiome,Other,16-Apr-20,31-Jul-21,30-Apr-21,OTHER,250,GUT MICROBIOME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",THERE IS NO INTERVENTION IN THIS STUDY,CORRELATION OF MICROBIOME TO DISEASE VIA RELATIVE ABUNDANCE FOUND IN MICROBIOME SEQUENCING,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection
NCT04359849,Recruiting,Observational,,Portsmouth Hospitals NHS Trust,Other,20-May-21,22-Sep-21,22-May-21,COHORT,500,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"7 Years and older   (Child, Adult, Older Adult)",,TO PRODUCE WHOLE GENOME SEQUENCES FOR THE SARS-COV-2 VIRUS FROM VIRAL RNA SAMPLES,Sequencing and Tracking of Phylogeny in COVID-19 Study
NCT04359862,Recruiting,Interventional,Phase 4,Fundación para la Investigación del Hospital Clínico de Valencia,Other,16-Apr-20,30-Apr-21,31-Mar-21,TREATMENT,50,ACUTE RESPIRATORY DISTRESS SYNDROME,SPAIN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",SEVOFLURANE,PAO2/FIO2,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection
NCT04359875,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Tours",Other,20-Apr-21,20-Dec-21,20-Jun-21,HEALTH SERVICES RESEARCH,22000,CARDIOVASCULAR DISEASES,FRANCE,ALL,"18 Years to 110 Years   (Adult, Older Adult)",PHONE-CALL SCREENING AND MANAGEMENT BY A MEDICAL STUDENT/GENERAL PRACTITIONER TANDEM,HOSPITALIZATION(S) AT 1 MONTH,Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial
NCT04359901,Recruiting,Interventional,Phase 2,Westyn Branch-Elliman,U.S. Fed,10-Apr-20,23-Apr-21,22-Apr-21,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB,INTUBATION OR DEATH,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design
NCT04359914,Recruiting,Observational,,University of Rostock,Other,15-Apr-20,1-Apr-21,31-Dec-20,CASE-CONTROL,80,CRITICAL ILLNESS,GERMANY,ALL,"Child, Adult, Older Adult",,INCIDENCE OF DELIRIUM/NEUROCOGNITIVE IMPAIRMENT IN ADULT AND PEDIATRIC PATIENTS WITH COVID-19 COMPARED TO PATIENTS WITHOUT COVID-19,Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study
NCT04359927,Recruiting,Observational [Patient Registry],,Hospital Clinic of Barcelona,Other,20-Apr-20,31-Aug-25,31-Aug-21,CASE-CONTROL,10000,SARS-COV2,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,CARDIOVASCULAR MORTALITY,Long-term Effects of Coronavirus 2019 Disease on the Cardiovascular System in Patients Who Have Undergone a Diagnostic Nasopharyngeal Swab for SARS-CoV-2. CV COVID-19 Registry
NCT04359953,Recruiting,Interventional,Phase 3,"University Hospital, Strasbourg, France",Other,25-Apr-20,1-Jun-21,1-Jun-21,TREATMENT,1600,COVID INFECTION,FRANCE,ALL,"60 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TWO-WEEKS SURVIVAL RATE,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study"
NCT04359992,Not yet recruiting,Observational,,"University Hospital, Strasbourg, France",Other,17-Apr-20,1-May-21,17-Apr-21,COHORT,50,COVID INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",EXTRA BLOOD SAMPLE,PLATELET ACTIVATION INTENSITY WITH THE OCCURRENCE OF CLINICAL THROMBOTIC COMPLICATIONS,Study of Hemostasis in Case of Severe COVID-19
NCT04360096,Recruiting,Interventional,Phase 2/Phase 3,"NeuroRx, Inc.",Industry,15-Feb-21,1-Sep-21,15-Aug-21,TREATMENT,288,SARS-COV2,UNITED STATES,ALL,"12 Years to 85 Years   (Child, Adult, Older Adult)",RLF-100 (AVIPTADIL),PROGRESSION TO RESPIRATORY FAILURE,Inhaled Aviptadil for the Treatment of Moderate and Severe COVID-19
NCT04360122,Not yet recruiting,Interventional,Phase 3,Ain Shams University,Other,20-May-20,1-Dec-20,1-Nov-20,PREVENTION,100,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",LEVAMISOLE,DECREASE THE INCIDENCE OF COVID-19 INFECTION OR ITS SEVERITY,Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
NCT04360278,Recruiting,Observational,,National Institutes of Health Clinical Center (CC),NIH,21-Apr-20,14-Apr-30,14-Apr-30,COHORT,1500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,COLLECTION OF CONVALESCENT PLASMA,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19
NCT04360356,Not yet recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,20-May-21,20-Dec-21,20-Oct-21,TREATMENT,100,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",IVERMECTIN PLUS NITAZOXANIDE,NUMBER OF PATIENTS WITH COVID-19-NEGATIVE PCR,Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
NCT04360486,Available,Expanded Access,,U.S. Army Medical Research and Development Command,U.S. Fed,,,,,,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,AFGHANISTAN,ALL,"Child, Adult, Older Adult",ANTI-SARS-COV-2 CONVALESCENT PLASMA,,Expanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360538,Recruiting,Observational,,University of Chicago,Other,8-Apr-20,30-Dec-21,1-Jul-21,COHORT,500,CRITICAL ILLNESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUALITY OF LIFE,QUALITY OF LIFE SCORE,Long Term Outcomes of Patients With COVID-19
NCT04360551,Recruiting,Interventional,Phase 2,University of Hawaii,Other,1-Jul-20,30-Jun-21,30-Jun-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELMISARTAN 40MG,MAXIMUM CLINICAL SEVERITY OF DISEASE,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients"
NCT04360707,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,8-Apr-20,8-Apr-21,8-Apr-21,CASE-ONLY,300,SARS-COV2,FRANCE,ALL,"1 Year and older   (Child, Adult, Older Adult)",,CLINICAL PRESENTATION AND INCIDENCE OF COVID-19 INFECTION IN DIFFERENT COHORTS OF SOLID ORGAN TRANSPLANT PATIENTS,Clinical Presentation and Incidence of SARS-CoV-2 Infection in Different Cohorts of Solid Organ Transplant Patients and Follow-up in France
NCT04360733,Recruiting,Observational,,University of Bonn,Other,20-Apr-20,22-Sep-21,22-Apr-21,OTHER,200,SARS-COV2,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD DRAW,IMMUNE RESPONSE,Precision Immunology Approach to Better Understand the Divergent Host Responses Towards Infection With SARS-CoV-2
NCT04360759,Withdrawn,Interventional,Phase 3,University of Cape Town,Other,1-May-20,30-Jun-21,30-May-21,TREATMENT,0,COVID,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE OR HYDROXYCHLOROQUINE,EVENT-FREE SURVIVAL AT 28 DAYS POST-RANDOMIZATION BETWEEN EXPERIMENTAL GROUP AND STANDARD OF CARE GROUP,Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa
NCT04360811,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,17-Apr-20,22-Apr-21,21-Apr-21,OTHER,3600,PREGNANCY,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",COVID 19 DIAGNOSTIC TEST BY PCR,NUMBER OF POSITIVE COVID-19 WOMEN,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes"
NCT04360824,Recruiting,Interventional,Phase 4,University of Iowa,Other,6-May-20,16-Apr-21,16-Apr-21,TREATMENT,170,COVID ASSOCIATED COAGULOPATHY,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",INTERMEDIATE DOSE THROMBOPROPHYLAXIS,MORTALITY,COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19
NCT04360837,Recruiting,Interventional,Not Applicable,Szeged University,Other,6-May-20,1-Jun-21,1-Jun-21,DIAGNOSTIC,10,COVID,HUNGARY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ALVEOLAR RECRUITMENT,CHANGES IN LUNG COMPLIANCE,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT)
NCT04360850,Recruiting,Observational,,University of Washington,Other,24-Apr-20,25-Oct-21,25-Oct-21,ECOLOGIC OR COMMUNITY,10000,ONLINE THERAPY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SURVEY,RESPONSES TO THE SURVEY QUESTIONS,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic
NCT04360863,Recruiting,Observational,,The University of Hong Kong,Other,24-Apr-20,30-Dec-21,30-Dec-21,OTHER,150,SMOKING CESSATION,HONG KONG,ALL,"up to 25 Years   (Child, Adult)",TELEPHONE SURVEY,SMOKING BEHAVIORS,The Impact of Coronavirus Disease (COVID-19) Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong: A Survey Study
NCT04360876,Withdrawn,Interventional,Phase 2,"University of Colorado, Denver",Other,1-Sep-20,30-Jan-21,31-Dec-20,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE INJECTION,VENTILATOR FREE DAYS (VFD) AT DAY 28,Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial
NCT04360954,Completed,Observational,,Washington University School of Medicine,Other,23-Apr-20,8-Jul-20,8-Jul-20,CASE-ONLY,461,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC TEST,TEST SENSITIVITY,Evaluation of Commerical Antibody Tests for COVID-19
NCT04360980,Recruiting,Interventional,Phase 2,Shahid Beheshti University of Medical Sciences,Other,20-Mar-20,30-Nov-21,1-Sep-21,TREATMENT,80,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE TABLETS,CRPXN/R RATIO CHANGE,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial
NCT04361019,Recruiting,Observational,,Basque Country University,Other,16-Apr-20,20-Oct-20,20-Oct-20,COHORT,25000,PHYSICAL ACTIVITY,SPAIN,ALL,"Child, Adult, Older Adult",ON-LINE SURVEY,: INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE - SHORT FORM,Physical Activity in University Students Around COVID-19 Confinement: Determinants and Consequences on Health Status and Quality of Life
NCT04361032,Not yet recruiting,Interventional,Phase 3,Abderrahmane Mami Hospital,Other,4-Sep-20,4-Oct-20,4-Sep-20,TREATMENT,260,COVID,TUNISIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TOCILIZUMAB INJECTION,THE MORTALITY RATE,"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study"
NCT04361123,Enrolling by invitation,Observational,,"Michael Runyon, MD",Other,6-May-20,21-Dec-21,21-Dec-21,COHORT,450000,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DAILY SYNDROMIC SURVEILLANCE,SEROPREVALENCE OF SARS-COV-2 INFECTION IN THE GENERAL POPULATION OF NORTH CAROLINA,"A Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records"
NCT04361214,Recruiting,Interventional,Phase 1,University of Chicago,Other,5-May-20,21-Feb-21,21-Feb-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LEFLUNOMIDE,TOLERABILITY OF HIGH DOSE LEFLUNOMIDE AS MEASURED BY LEFLUNOMIDE DOSE MODIFICATIONS,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19
NCT04361253,Recruiting,Interventional,Phase 3,Brigham and Women's Hospital,Other,30-Apr-20,21-Dec-21,21-Jun-21,TREATMENT,220,COVID,UNITED STATES,ALL,"12 Months and older   (Child, Adult, Older Adult)",HIGH-TITER COVID-19 CONVALESCENT PLASMA (HT-CCP),MODIFIED WHO ORDINAL SCALE (MOS) SCORE,"A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity"
NCT04361318,Not yet recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,20-May-21,20-Dec-21,20-Oct-21,TREATMENT,100,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE PLUS NITAZOXANIDE,NUMBER OF PATIENTS WITH COVID-19-NEGATIVE PCR,Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope
NCT04361344,Terminated,Interventional,Not Applicable,Centre Hospitalier de PAU,Other,19-May-20,25-Oct-20,25-Oct-20,DIAGNOSTIC,2,COVID INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES,CHANGE OF NEURODEGENERATION MARKERS LEVEL,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid
NCT04361396,Recruiting,Interventional,Not Applicable,Centre Hospitalier René Dubos,Other,16-Jun-20,21-Jun-21,21-Jun-21,OTHER,60,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COLLECTION OF SAMPLES,ASSESSMENT OF THE PRESENCE OF THE SARS-COV-2 VIRUS AT T4,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients
NCT04361422,Not yet recruiting,Interventional,Phase 3,Tanta University,Other,1-Dec-20,21-Dec-21,21-Aug-21,TREATMENT,300,COVID,,ALL,18 Years to 40 Years   (Adult),ISOTRETINOIN ONLY PRODUCT IN ORAL DOSE FORM,CLINICAL CLEARANCE,Evaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19: Clinical Study
NCT04361435,Not yet recruiting,Interventional,Not Applicable,St. Justine's Hospital,Other,1-May-20,31-Dec-20,31-Jul-20,SUPPORTIVE CARE,50,COVID,,ALL,"Child, Adult, Older Adult",CHEST PHYSIOTHERAPY USING A NON-INVASIVE OSCILLATING DEVICE,SPO2/FIO2 RATIO,Comparison of Two Methods to Airway Clearance in Patients Admitted to Intensive Care Unit for COVID-19: A Pilot Corssover Randomized Controlled Trial
NCT04361448,Terminated,Interventional,Not Applicable,Jessa Hospital,Other,20-Apr-20,30-Jun-20,30-Jun-20,DIAGNOSTIC,30,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",SAMLING OF OROPHARYNX AND NASOPHARYNX,SENSITIVITY,Comparison of the Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR
NCT04361461,Withdrawn,Interventional,Phase 3,Apsen Farmaceutica S.A.,Industry,30-Apr-20,4-Nov-20,4-Nov-20,TREATMENT,0,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,INDIVIDUAL RESPONSE RATE,Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)
NCT04361474,"Active, not recruiting",Interventional,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,Other,18-May-20,25-May-21,24-Nov-20,TREATMENT,120,BUDESONIDE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BUDESONIDE NASAL,PATIENT WITH MORE THAN 2 POINTS ON THE ODORATEST,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
NCT04361500,Recruiting,Observational [Patient Registry],,Hannover Medical School,Other,15-Apr-20,1-Oct-21,1-Oct-20,CASE-ONLY,100,COVID,GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",SERAPH 100,SURVIVAL,Registry for the Evaluation of Safety and Effectiveness of the Seraph 100 Microbind Affinity Blood Filter in the Therapy of COVID-19 Patients (COSA)
NCT04361526,Recruiting,Interventional,Not Applicable,Manuel Castellà,Other,17-Apr-20,20-Jul-21,20-Jul-21,TREATMENT,40,CORONAVIRUS INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",CYTOKINE ADSORPTION,MECHANICAL VENTILATION-FREE DAYS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)
NCT04361552,Withdrawn,Interventional,Phase 3,Emory University,Other,7-Apr-20,2-Jun-20,2-Jun-20,TREATMENT,0,CEREBROVASCULAR ACCIDENT,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEST PRACTICE,7-DAY LENGTH OF INVASIVE MECHANICAL VENTILATION (MV),"Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial"
NCT04361565,Enrolling by invitation,Observational,,Centre Hospitalier Universitaire de Nice,Other,20-Mar-20,31-May-20,10-Apr-20,CASE-ONLY,50,COVID BY SARS-COV2 INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",,ANOSMIA,Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2
NCT04361591,Recruiting,Observational [Patient Registry],,Hospital Clinic of Barcelona,Other,1-Mar-20,21-Mar-21,1-Mar-21,COHORT,200,LIVER TRANSPLANT; COMPLICATIONS,SPAIN,ALL,"Child, Adult, Older Adult",OBSERVATIONAL ONLY,INCIDENCE OF COVID19 IN LT RECIPIENTS,COVID-19 in Liver Transplant Recipients in Spain: a Nationwide Prospective Study
NCT04361604,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-21,20-Oct-21,20-Oct-21,COHORT,270,ADULT PATIENTS LIVING WITH HIV (PLWHIV) WITH CONFIRMED INFECTION WITH SARS-COV2 SINCE 1ST JANUARY 2020,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL COLLECTION (PATIENTS CO INFECTED HIV SRAS-COV-2),"DESCRIBE THE COURSE OF COVID-19 DISEASE IN PATIENTS INFECTED WITH HIV,",Clinical Characterisation Protocol for COVID-19 in People Living With HIV
NCT04361643,Not yet recruiting,Interventional,Phase 4,Hospital Universitario Getafe,Other,27-Oct-20,31-Dec-21,31-Aug-21,TREATMENT,120,COVID,SPAIN,ALL,"60 Years and older   (Adult, Older Adult)","LENALIDOMIDE AS A 5 MG CAPSULE PO DAILY, DAYS 1, 3, AND 5.",CLINICAL IMPROVEMENT,Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease
NCT04361786,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Oct-20,30-Jun-20,CASE-ONLY,10,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,BIOLOGICAL ACQUIRED THROMBOPHILIA,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection: Search for Acquired Thrombophilia and Interferon-alpha Signature
NCT04361838,Recruiting,Interventional,Not Applicable,Kansas City Heart Rhythm Institute,Other,21-May-20,31-Aug-21,30-Jun-21,SUPPORTIVE CARE,1000,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 110 Years   (Adult, Older Adult)",PRAYER,IMPACT OF MULTI-DENOMINATIONAL PRAYER ON CLINICAL OUTCOMES OF CRITICALLY ILL COVID-19 PATIENTS IN THE INTENSIVE CARE UNIT ON MORTALITY.,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection
NCT04361877,Recruiting,Observational,,Klinikum der Universitaet Muenchen,Other,30-Mar-20,20-Apr-20,20-Apr-20,COHORT,1900,CARDIOVASCULAR PREVENTION BEHAVIOUR,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE OF PHYSICAL ACTIVITY,Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)
NCT04361903,Not yet recruiting,Observational,,Azienda USL Toscana Nord Ovest,Other,25-Apr-20,31-May-20,24-May-20,COHORT,13,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB ORAL TABLET,NUMBER OF PATIENTS WHO AVOID MECHANICAL ASSISTED VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH SARS-COV-2 COVID-19,COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study
NCT04361916,Terminated,Interventional,Not Applicable,Mario Negri Institute for Pharmacological Research,Other,21-Apr-20,30-Jun-20,30-Jun-20,HEALTH SERVICES RESEARCH,37,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HOME CARE MONITORING,SPO2 AT HOSPITAL ENTRY,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)
NCT04361942,Recruiting,Interventional,Phase 2,Red de Terapia Celular,Industry,1-May-20,31-Dec-20,30-Nov-20,TREATMENT,24,COVID PNEUMONIA,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,PROPORTION OF PATIENTS WHO HAVE ACHIEVED WITHDRAWAL OF INVASIVE MECHANICAL VENTILATION,"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)"
NCT04361981,Not yet recruiting,Observational [Patient Registry],,Sociedad Espanola de Angiologia y Cirugia Vascular,Other,20-Apr-21,31-Dec-20,31-Aug-20,COHORT,50,COVID,SPAIN,ALL,"Child, Adult, Older Adult",DEEP VENOUS DISEASE DIAGNOSTIC,DEEP VENOUS DISEASE INCIDENCE,National Cohort Study to Assess the Influence of COVID-19 Infection in Thromboembolic Venous Disease:
NCT04362059,Recruiting,Interventional,Not Applicable,University Hospital Southampton NHS Foundation Trust,Other,18-Jun-20,16-Nov-21,27-Jul-21,TREATMENT,24,RESPIRATORY INFECTIONS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COVSURF DRUG DELIVERY SYSTEM,OXYGENATION IMPROVEMENT,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19
NCT04362085,Recruiting,Interventional,Phase 3,Unity Health Toronto,Other,11-May-20,22-Apr-21,22-Mar-21,TREATMENT,462,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC ANTICOAGULATION,"COMPOSITE OUTCOME OF ICU ADMISSION (YES/NO), NON-INVASIVE POSITIVE PRESSURE VENTILATION (YES/NO), INVASIVE MECHANICAL VENTILATION (YES/NO), OR ALL-CAUSE DEATH (YES/NO) UP TO 28 DAYS.",Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)
NCT04362111,Recruiting,Interventional,Phase 3,University of Alabama at Birmingham,Other,29-Jul-20,21-Mar-21,21-Jan-21,TREATMENT,30,CYTOKINE STORM,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ANAKINRA,PERCENTAGE OF PATIENTS DISCHARGED FROM THE HOSPITAL ALIVE AND WITHOUT THE NEED FOR MECHANICAL VENTILATION.,Early Treatment of Cytokine Storm Syndrome in Covid-19
NCT04362124,Withdrawn,Interventional,Phase 3,Universidad de Antioquia,Other,20-Aug-21,21-Nov-21,21-Jun-21,SUPPORTIVE CARE,0,COVID,COLOMBIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",VACCINE BCG,PRIMARY OUTCOME,"Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medellín, Colombia, 2020"
NCT04362137,Completed,Interventional,Phase 3,Novartis Pharmaceuticals,Industry,2-May-20,17-Oct-20,17-Oct-20,TREATMENT,432,CYTOKINE STORM (COVID),ARGENTINA,ALL,"12 Years and older   (Child, Adult, Older Adult)",RUXOLITINIB,"PROPORTION OF PATIENTS WHO DIE, DEVELOP RESPIRATORY FAILURE [REQUIRE MECHANICAL VENTILATION] OR REQUIRE INTENSIVE CARE UNIT (ICU) CARE","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)"
NCT04362150,"Active, not recruiting",Observational,,"University of California, San Francisco",Other,21-Apr-20,21-Dec-24,31-Dec-22,COHORT,800,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,PARTICIPANT AGE,Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study
NCT04362176,Recruiting,Interventional,Phase 3,Vanderbilt University Medical Center,Other,24-Apr-20,21-Apr-21,21-Apr-21,TREATMENT,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PATHOGEN REDUCED SARS-COV-2 CONVALESCENT PLASMA,COVID-19 7-POINT ORDINAL CLINICAL PROGRESSION OUTCOMES SCALE,Passive Immunity Trial for Our Nation (PassItOn)
NCT04362189,"Active, not recruiting",Interventional,Phase 2,Hope Biosciences,Industry,30-Jun-20,31-Oct-21,31-Oct-21,TREATMENT,100,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",HB-ADMSC,INTERLEUKIN-6,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19"
NCT04362267,Recruiting,Observational,,"University Hospital, Lille",Other,15-Jun-20,20-Sep-21,20-Sep-21,COHORT,150,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SELF-ADMINISTERED QUESTIONNAIRE,THE INCIDENCE OF SARS- COV2 INFECTION HEATH CARE WORKER DIAGNOSED BY THE POSITIVITY OF SARS-COV2 RT-PCT AND SEROLOGICAL TESTING,Incidence of SARS-Cov2 Infection Among HCW in Lille University Hospital
NCT04362319,Completed,Observational,,University of Malaya,Other,15-May-20,31-May-20,31-May-20,COHORT,85,"BURNOUT, PROFESSIONAL",MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE FORMS,PREVALENCE OF BURNOUT AMONG ANAESTHESIOLOGY CLINICIANS DURING COVID-19,Burnout and Medical Errors in the Anaesthesiology Fraternity in an Exclusively Covid-19 Hospital: the Malaysian Experience
NCT04362332,Terminated,Interventional,Phase 4,UMC Utrecht,Other,14-Apr-20,8-Jun-20,8-Jun-20,TREATMENT,25,COVID,NETHERLANDS,ALL,"18 Years to 110 Years   (Adult, Older Adult)",CHLOROQUINE SULFATE,COMPOSITE ENDPOINT WITH DISEASE PROGRESSION DEFINED AS A NEWS2SCORE ≥ 7 WITHIN 14 DAYS OR RESULTING IN ADMISSION TO INTENSIVE/MEDIUM CARE UNIT OR RESULTING IN DEATH WITHIN 14 DAYS.,"An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19"
NCT04362345,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,9-Apr-20,9-Jan-21,9-Jan-21,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,IDENTIFICATION OF RISK FACTORS FOR SEVERITY (DEATH OR TRANSFER TO RESUSCITATION) OF COVID-19 INFECTION,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia in France
NCT04362358,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Strasbourg, France",Other,1-May-20,1-Oct-21,1-Oct-21,PREVENTION,120,"STRESS - PREVENTION OF SLEEP DISORDERS, PTSD AND DEPRESSION",,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ONLINE COGNITIVE BEHAVIORAL THERAPY (CBT),SIGNIFICANT SCORE REDUCTION AT THE PERCEIVED STRESS SCALE,Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial
NCT04362813,Completed,Interventional,Phase 3,Novartis Pharmaceuticals,Industry,30-Apr-20,22-Dec-20,16-Sep-20,TREATMENT,451,PNEUMONIA AND CYTOKINE RELEASE SYNDROME (COVID),FRANCE,ALL,"12 Years and older   (Child, Adult, Older Adult)",CANAKINUMAB,NUMBER OF PATIENTS WITH CLINICAL RESPONSE,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)"
NCT04362865,Recruiting,Observational,,National Cancer Institute (NCI),NIH,27-Apr-20,1-Dec-24,1-Dec-23,COHORT,210,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,CHARACTERIZE IMMUNE RESPONSE,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362930,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,27-Apr-20,24-Apr-22,24-Apr-22,COHORT,2000,NEUROLOGIC MANIFESTATIONS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CENTRAL OR PERIPHERAL NEUROLOGICAL SYMPTOMS OR PSYCHIATRIC SYMPTOMS OBSERVED IN PATIENTS WITH COVID-19,Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations
NCT04362943,Recruiting,Observational,,Complejo Hospitalario Universitario de Albacete,Other,20-Apr-20,31-Jul-20,15-May-20,OTHER,576,COVID,SPAIN,ALL,70 Years and older   (Older Adult),BARICITINIB OR ANAKINRA,MORTALITY,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults
NCT04362956,Completed,Observational,,Fundacion Infant,Other,10-Jul-20,1-Oct-20,1-Oct-20,CASE-CONTROL,114,COVID,ARGENTINA,FEMALE,"Child, Adult, Older Adult",,VERTICAL TRANSMISSION,Clinical and Immunologic Impact of SARS-CoV-2 in Hospitalized Pregnant Women and Neonates in Argentina
NCT04362969,Not yet recruiting,Observational,,"Hospital San Carlos, Madrid",Other,20-May-21,20-May-21,20-May-21,COHORT,300,COVID,ECUADOR,ALL,"18 Years and older   (Adult, Older Adult)",,CLINICAL CHARACTERISTICS OF PATIENTS WITH COVID-19,"Clinical Characteristics of Patients With SARS-CoV-2 (COVID-19) Infection in Guayaquil, Ecuador: COVID-EC Study"
NCT04362995,Recruiting,Observational,,St. Jude Children's Research Hospital,Other,23-Apr-20,25-Mar-21,22-Apr-21,COHORT,1517,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PROPORTION OF ASYMPTOMATIC SUBJECTS,SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
NCT04363008,Recruiting,Observational,,University of British Columbia,Other,30-Mar-20,30-Sep-21,30-Apr-20,COHORT,150,COVID,CANADA,ALL,"Child, Adult, Older Adult",SERUM INFLAMMATORY BIOMARKERS,INFLAMMATION,"COVID-19 Inflammatory Blood Biomarkers for Clinical Management, Prognosis and Evaluation of Interventions"
NCT04363034,Available,Expanded Access,,University of Arkansas,Other,,,,,,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,,Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program
NCT04363047,Enrolling by invitation,Observational,,University of Manchester,Other,1-Oct-20,1-May-21,1-May-21,COHORT,125,SARS VIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",40ML BLOOD SAMPLE,PREVALENCE AND ABUNDANCE OF CD4+ T LYMPHOCYTES,Immune Cells and the Coronavirus for Inflammatory Arthritis
NCT04363060,Not yet recruiting,Interventional,Phase 3,Nantes University Hospital,Other,30-Apr-20,30-Jul-20,30-Jul-20,TREATMENT,104,COVID PNEUMONIA,FRANCE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",AZITHROMYCIN WITH AMOXICILLIN/CLAVULANATE,RATE OF POSITIVE SARS-COV-2 RT-PCR,Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial
NCT04363099,Recruiting,Observational,,Maison de Sante Pluridisciplinaire de Creil,Other,1-Mar-20,31-Dec-20,30-Jun-20,COHORT,1000,COVID,FRANCE,ALL,"up to 99 Years   (Child, Adult, Older Adult)",OBSERVATIONAL,CLINICAL DESCRIPTION OF COVID 19 AMBULATORY CASES.,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.
NCT04363177,Not yet recruiting,Interventional,Not Applicable,Karolinska Institutet,Other,1-Nov-20,23-Jun-21,21-Jun-21,PREVENTION,200,PERINATAL DEPRESSION,CHINA,FEMALE,"18 Years and older   (Adult, Older Adult)",WEB-BASED PSYCHOSOCIAL PEER-TO-PEER SUPPORT,EDINBURGH POSTNATAL DEPRESSION SCALE (EPDS),Mental Health of Urban Mothers (MUM) Study: A Multi-center Randomized Controlled Trial
NCT04363203,Suspended,Interventional,Phase 3,Salomeh Keyhani MD,U.S. Fed,30-Apr-20,21-Aug-21,21-Mar-21,TREATMENT,300,SARS-COV2,UNITED STATES,ALL,"216 Months and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"DAYS TO RESOLUTION OF COUGH, FEVER AND SHORTNESS OF BREATH",VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)
NCT04363216,Not yet recruiting,Interventional,Phase 2,Thomas Jefferson University,Other,20-May-21,21-May-21,21-May-21,TREATMENT,66,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ASCORBIC ACID,CLINICAL IMPROVEMENT,Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment
NCT04363229,Not yet recruiting,Observational,,Assiut University,Other,20-Jul-21,21-Jun-21,21-May-21,OTHER,250,OCCUPATIONAL STRESS,,ALL,"22 Years and older   (Adult, Older Adult)",MASLACH BURNOUT INVENTORY QUESTIONNAIR,"THE MBI-HSS (MP) ADDRESSES THREE SCALES:EMOTIONAL EXHAUSTION ,DEPERSONALIZATION AND PERSONAL ACCOMPLISHMENT",Psychological Impact of COVID19 Among Doctors in Assiut University Hospitals
NCT04363268,Recruiting,Observational,,Medable Inc.,Other,20-Apr-20,1-Oct-31,20-Apr-30,COHORT,1000000,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,DEVELOPMENT OF POPULATION-BASED MODELS OF DISEASE RISK,"ACCESS (American COVID-19 Collaborative, Enabling Seamless Science) Master Digital Surveillance and Associated Clinical Trials Protocol for COVID-19"
NCT04363333,"Active, not recruiting",Observational,,Koç University,Other,27-Apr-20,31-Jul-21,31-May-21,COHORT,320,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",HOME SLEEP APNEA TESTING OR IN-HOSPITAL POLYSOMNOGRAPHY,THE RATE OF CLINICAL IMPROVEMENT,Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study
NCT04363346,"Active, not recruiting",Interventional,Phase 1,"Masonic Cancer Center, University of Minnesota",Other,14-May-20,22-Jan-21,22-Jan-21,TREATMENT,5,COVID,UNITED STATES,ALL,"18 Years to 76 Years   (Adult, Older Adult)",FT516,NUMBER OF PARTICIPANTS WITH DOSE LIMITING TOXICITY EVENTS,Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia
NCT04363372,Recruiting,Interventional,Phase 2,4D pharma plc,Industry,20-Jun-21,20-Sep-21,20-Aug-21,TREATMENT,90,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",MRX-4DP0004,CHANGE IN MEAN CLINICAL STATUS SCORE IN EACH TREATMENT ARM,"A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)"
NCT04363385,Recruiting,Interventional,Not Applicable,Centre Hospitalier Intercommunal Creteil,Other,31-May-20,31-May-21,31-May-21,PREVENTION,500,COVID,FRANCE,ALL,"Child, Adult, Older Adult",BIOLOGICAL TEST,PHENOTYPE/GENOTYPE CORRELATION RESEARCH MODULATING THE SEVERITY OF COVID-19 DISEASE,Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization
NCT04363437,Recruiting,Interventional,Phase 2,Maimonides Medical Center,Other,26-Apr-20,14-Jun-20,31-May-20,TREATMENT,70,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COLCHICINE,PERCENTAGE OF PATIENTS REQUIRING SUPPLEMENTAL OXYGEN BEYOND 8L NASAL CANNULA,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)
NCT04363450,Recruiting,Interventional,Phase 3,Louisiana State University Health Sciences Center in New Orleans,Other,27-Apr-20,1-Jun-21,31-Mar-21,PREVENTION,1700,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,INCIDENCE OF SYMPTOMATIC COVID-19 INFECTION IN HEALTHCARE WORKERS,Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
NCT04363463,Recruiting,Interventional,Not Applicable,Centre Hospitalier Régional d'Orléans,Other,28-Aug-20,28-Aug-22,28-Aug-22,SUPPORTIVE CARE,400,COVID,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",PRONE POSITION,"PERCENT AGE OF PATIENTS WHO WILL HAVE ENDOTRACHEAL INTUBATION OR NON-INVASIVE VENTILATION AT TWO PRESSURE LEVELS AND/OR DIE, IN EACH OF THE 2 RANDOMIZATION GROUPS.",Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress
NCT04363489,Not yet recruiting,Observational,,King's College London,Other,1-Aug-20,30-Sep-20,30-Aug-20,COHORT,60,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",WEARABLE MEDICAL DEVICE (EMPATICA E4),COVID-19 INFECTION,The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers)
NCT04363502,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,7-May-20,21-Jun-21,21-Jun-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CLAZAKIZUMAB,CHANGE IN C-REACTIVE PROTEIN (CRP) LEVEL,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04363528,Recruiting,Interventional,Not Applicable,Versailles Hospital,Other,24-Apr-20,30-Oct-20,30-Oct-20,SUPPORTIVE CARE,50,DEEP VEIN THROMBOSIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DOPPLER ECHO,INCIDENCE OF DEEP VEIN THROMBOSIS AT DOPPLER ECHO IN PATIENTS WITH SARS-COV-2 PNEUMOPATHY HOSPITALIZED IN ICU,Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU
NCT04363541,Recruiting,Interventional,Not Applicable,Instituto Nacional de Perinatologia,Other,27-Aug-20,22-Jun-21,22-Apr-21,TREATMENT,274,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",ELECTRIC PAD FOR HUMAN EXTERNAL PAIN THERAPY,PROGRESSION OF DISEASE (COMPOSITE OUTCOME),"A Multicenter, Open-label, Parallel-group, Randomized, Adaptive Trial to Evaluate Local Thermotherapy in Patients With Mild-to-moderate COVID-19, to Prevent Disease Progression"
NCT04363593,Completed,Interventional,Not Applicable,Centre Hospitalier de Cornouaille,Other,4-May-20,16-Nov-20,16-Nov-20,OTHER,2587,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TEST,SEROLOGICAL TEST EVALUATION,Serology COVID-19 From the Cornwall Hospital Union
NCT04363606,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Saint Etienne,Other,27-May-20,21-Dec-21,21-Apr-21,DIAGNOSTIC,82,CHRONIC FATIGUE SYNDROME,FRANCE,ALL,"35 Years to 80 Years   (Adult, Older Adult)",QUESTIONNAIRES,VOLUNTARY MAXIMUM FORCE REDUCTION,Chronic Fatigue Etiology and Recovery in Covid-19 Patients : the Role of Fatigability and Stay in Intensive Care
NCT04363632,Completed,Observational [Patient Registry],,Centre Leon Berard,Other,2-Apr-20,30-Jun-20,30-Jun-20,COHORT,1231,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",,MORTALITY OF CANCER PATIENTS UNDER ACTIVE ANTICANCER TREATMENT,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection
NCT04363671,Not yet recruiting,Observational,,Hôpital Cochin,Other,20-May-21,20-Dec-21,20-Jun-21,OTHER,30,REMOTE CONSULTATION,FRANCE,ALL,"11 Years and older   (Child, Adult, Older Adult)",,EXPLORATION OF THEMES EMERGING FROM ANALYSIS OF THE CONTENT OF THE INTERVIEW WITH THE ADOLESCENTS AND THERAPISTS,Qualitative Study of the Experience of Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine
NCT04363736,Completed,Interventional,Phase 2,Hoffmann-La Roche,Industry,5-May-20,12-Aug-20,12-Aug-20,TREATMENT,100,COVID PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIUZUMAB,SERUM CONCENTRATION OF INTERLEUKIN-6 (IL-6) FOLLOWING ADMINISTRATION OF 8 MG/KG IV TCZ,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia"
NCT04363749,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,27-Apr-20,27-Nov-21,27-Apr-21,BASIC SCIENCE,30,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","HYPOXIA : 14.3 AND 12.7% FIO2, HYPERCAPNIA 7% CO2, INSPIRATORY MECHANICAL CONSTRAINT",INTENSITY OF THE EMOTIONAL RESPONSE TO HYPOXIC EXPOSURE (14.3 ET 12.7% FIO2),Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?
NCT04363775,Completed,Interventional,Not Applicable,Lazarski University,Other,20-Jan-20,25-Feb-20,23-Feb-20,TREATMENT,35,TRACHEAL INTUBATION,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",THE STANDARD MACINTOSH LARYNGOSCOPE,TIME TO INTUBATION,Comparison of VieScope Versus Macintosh Laryngoscope for Emergency Intubation Under Level C Personal Protective Equipment Conditions
NCT04363788,Completed,Observational,,Lazarski University,Other,28-Feb-20,24-Apr-20,24-Apr-20,COHORT,300,CARDIAC ARREST,POLAND,ALL,"Child, Adult, Older Adult",DOUBLE GLOVES,NUMBER OF VISIBLE PUNCTURE,Should we Use Double Gloves During Procedures With Suspected/Confirmed COVID-19 Patient?
NCT04363814,Recruiting,Interventional,Phase 3,Inmunotek S.L.,Industry,10-Jun-20,31-Jul-21,1-Jul-21,TREATMENT,100,COVID,DOMINICAN REPUBLIC,ALL,"18 Years to 70 Years   (Adult, Older Adult)",BACTEK-R,CLINICAL RECOVERY,"A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19"
NCT04363827,"Active, not recruiting",Interventional,Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,Other,14-May-20,21-Sep-21,21-Jun-21,TREATMENT,2300,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,THE PROPORTION OF SUBJECTS OF GROUP 1 WHO BECOME SYMPTOMATIC AND/OR SWAB POSITIVE IN EACH ARM WITHIN 1 MONTH FROM RANDOMIZATION.,PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)
NCT04363840,Not yet recruiting,Interventional,Phase 2,Louisiana State University Health Sciences Center in New Orleans,Other,20-May-21,20-Dec-21,20-Dec-21,TREATMENT,1080,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ASPIRIN 81 MG,HOSPITALIZATION,"The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations"
NCT04363853,"Active, not recruiting",Interventional,Phase 2,Instituto Nacional de Cancerologia de Mexico,Other,1-Jun-20,1-Aug-21,1-Jun-21,TREATMENT,200,SARS-COV2,MEXICO,ALL,"18 Years to 90 Years   (Adult, Older Adult)",TOCILIZUMAB,HEMATIC BIOMETRY,Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab
NCT04363866,Withdrawn,Interventional,Phase 2,Oregon Health and Science University,Other,20-Aug-21,21-Sep-21,21-Mar-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CLINICAL STATUS AT DAY 5 ASSESSED BY A 6-POINT ORDINAL SCALE,A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)
NCT04364009,Terminated,Interventional,Phase 3,"University Hospital, Tours",Other,27-Apr-20,3-Nov-20,20-Oct-20,TREATMENT,71,COVID INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA PLUS OSOC,TREATMENT SUCCESS,"Efficacy and Safety of ANAkinra During Adult "" COVID-19 "" With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial"
NCT04364022,Recruiting,Interventional,Phase 3,Calmy Alexandra,Other,23-Apr-20,21-Mar-21,21-Mar-21,PREVENTION,300,PREVENTION OF COVID,SWITZERLAND,ALL,"16 Years and older   (Child, Adult, Older Adult)",LOPINAVIR/RITONAVIR,21-DAY INCIDENCE OF COVID-19 IN INDIVIDUALS EXPOSED TO SARS-COV- 2 WHO ARE ASYMPTOMATIC AT BASELINE (INTENT-TO-TREAT (ITT) ANALYSIS).,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial
NCT04364594,Completed,Interventional,Not Applicable,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,26-Mar-20,30-May-20,24-Apr-20,DIAGNOSTIC,50,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",CONJUNCTIVAL SWAB,CONJUNCTIVAL SWAB RESULTS BASED ON RT-PCR,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.
NCT04364698,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,7-May-20,20-Jun-21,20-Jun-21,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"CLINICAL, BIOLOGICAL AND RADIOLOGICAL CHARACTERISTICS",Observational Cohort of COVID-19 Patients at Raymond-Poincare
NCT04364711,Not yet recruiting,Observational,,UMC Utrecht,Other,1-May-20,30-Apr-22,30-Apr-22,COHORT,2000,COVID,,ALL,"Child, Adult, Older Adult",,PNEUMONIA SEVERITY INDEXES,Multi-centre EuRopean Study of MAjor Infectious Disease Syndromes (MERMAIDS) - Acute Respiratory Infections (MERMAIDS ARI) 2.0
NCT04364737,Recruiting,Interventional,Phase 2,NYU Langone Health,Other,17-Apr-20,30-Apr-23,31-Jan-23,TREATMENT,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,SCORE ON THE WHO 11-POINT ORDINAL SCALE FOR CLINICAL IMPROVEMENT AT 14 DAYS,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients
NCT04364763,Recruiting,Interventional,Phase 2,"Renibus Therapeutics, Inc.",Industry,5-Aug-20,31-Dec-21,30-Jun-21,TREATMENT,252,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RBT-9 (90 MG),EVALUATE THE EFFECT OF RBT-9 VERSUS PLACEBO ON CLINICAL STATUS OF COVID-19 PATIENTS AS MEASURED USING THE 8-POINT WORLD HEALTH ORGANIZATION (WHO) ORDINAL CLINICAL SCALE,"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)"
NCT04364802,Recruiting,Interventional,Phase 2,Alexandra Kejner,Other,29-Apr-20,21-May-21,21-May-21,PREVENTION,300,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",POVIDONE-IODINE NASAL SPRAY AND GARGLE,PERCENT OF HEALTHCARE WORKERS TESTING POSITIVE FOR COVID-19.,Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic
NCT04364815,Withdrawn,Interventional,Phase 3,University of the Philippines,Other,20-Dec-21,21-May-21,21-May-21,PREVENTION,0,COVID,PHILIPPINES,ALL,18 Years to 59 Years   (Adult),HYDROXYCHLOROQUINE PLUS STANDARD PREVENTIVE MEASURES,EFFICACY OF HCQ PROPHYLAXIS IN PREVENTING COVID-19 INFECTION,"Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial"
NCT04364828,Recruiting,Interventional,Not Applicable,University Hospital Tuebingen,Other,21-Oct-20,22-Aug-21,22-Apr-21,DIAGNOSTIC,1000,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",WHOLE GENOME ANALYSIS,VIRAL EVOLUTION,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression
NCT04364893,Recruiting,Interventional,Not Applicable,D'Or Institute for Research and Education,Other,9-Apr-20,1-Dec-20,1-Oct-20,TREATMENT,700,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",SUSPENSION OR MAINTENANCE OF ANGIOTENSIN RECEPTOR BLOCKERS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS,MEDIAN DAYS ALIVE AND OUT OF THE HOSPITAL,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial
NCT04364984,Recruiting,Observational [Patient Registry],,Medical Practice Prof D. Ivanov,Other,1-Apr-20,1-Aug-21,1-Apr-21,COHORT,10,HYPERTENSION,UKRAINE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",ANGIOTENSIN CONVERTING ENZYME INHIBITOR,BP (HYPERTENSIVE EFFICACY),"ARB, ACEi, DRi Usage in COVID-19"
NCT04365101,Recruiting,Interventional,Phase 1/Phase 2,Celularity Incorporated,Industry,13-May-20,30-Jun-21,30-Dec-20,TREATMENT,86,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CYNK-001,PHASE 1: FREQUENCY AND SEVERITY OF ADVERSE EVENTS (AE),A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
NCT04365127,Completed,Interventional,Phase 1,Sara Ghandehari,Other,27-Apr-20,20-Aug-20,20-Aug-20,TREATMENT,40,COVID,UNITED STATES,MALE,"18 Years and older   (Adult, Older Adult)",PROGESTERONE 100 MG,CHANGE IN CLINICAL STATUS OF SUBJECTS AT DAY 7 BASED ON THE FOLLOWING 7-POINT ORDINAL SCALE,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men"
NCT04365153,"Active, not recruiting",Interventional,Phase 2,The Cleveland Clinic,Other,24-Apr-20,30-Apr-21,28-Feb-21,TREATMENT,45,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CANAKINUMAB INJECTION 600MG,"TIME TO CLINICAL IMPROVEMENT UP TO DAY 14, DEFINED AS THE TIME IN DAYS FROM RANDOMIZATION TO EITHER AN IMPROVEMENT OF TWO POINTS ON A SEVEN-CATEGORY ORDINAL SCALE OR DISCHARGE FROM THE HOSPITAL, WHICHEVER OCCURS FIRST.",Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation
NCT04365166,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,21-Apr-20,21-Apr-22,21-Apr-22,CASE-ONLY,100,RESPIRATORY TRACT INFECTIONS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2
NCT04365231,Withdrawn,Interventional,Phase 3,"Hospital St. Joseph, Marseille, France",Other,1-Apr-20,1-Apr-21,1-Jun-20,TREATMENT,0,COVID,,FEMALE,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE AND AZITHROMYCIN TREATMENT,PERCENTAGE OF PATIENTS WITH A NEGATIVE RT-PCR TEST RESULT TO COVID-19,Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial
NCT04365257,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,13-May-20,30-Jun-21,30-Jun-21,TREATMENT,220,COVID,UNITED STATES,ALL,"45 Years to 85 Years   (Adult, Older Adult)",PRAZOSIN,DEATH,Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection
NCT04365309,Enrolling by invitation,Interventional,Phase 2/Phase 3,Xijing Hospital,Other,10-Feb-20,20-Jun-21,20-Apr-21,TREATMENT,128,NOVEL CORONAVIRUS PNEUMONIA,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ASPIRIN 100MG,CLINICAL RECOVERY TIME (TTCR),Protective Effect of Aspirin on COVID-19 Patients
NCT04365322,Recruiting,Observational [Patient Registry],,Centre Hospitalier Universitaire de Besancon,Other,20-Apr-20,20-Apr-25,1-Sep-20,COHORT,160,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ADDITIONAL BIOLOGICAL SAMPLES,SPECIFIC IMMUNE RESPONSES,Étude Des réponses Immunitaires Lymphocytaires spécifiques Chez Des Patients infectés Par le Virus SARS-CoV-2 : Caractéristiques Des Réponses Effectrices et Mémoires
NCT04365335,Completed,Observational,,Direction Centrale du Service de Santé des Armées,Other,25-Apr-20,12-Jun-20,12-Jun-20,COHORT,50,OCCUPATIONAL STRESS,FRANCE,ALL,18 Years to 60 Years   (Adult),ASSESSMENT OF WORK-RELATED STRESS,PROFESSIONAL BURNOUT,Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic
NCT04365348,Recruiting,Observational,,The University of Hong Kong,Other,27-Apr-20,30-Jun-21,31-Mar-21,COHORT,300,MENTAL HEALTH WELLNESS 1,HONG KONG,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,STRESS LEVEL,Exploring the Psychological Impact of the COVID-19 Outbreak on COVID-19 Survivors and Their Families
NCT04365361,Recruiting,Observational,,The University of Hong Kong,Other,26-Apr-20,31-Mar-21,30-Dec-20,ECOLOGIC OR COMMUNITY,300,MENTAL HEALTH WELLNESS 1,HONG KONG,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,STRESS LEVEL,Exploring the Psychological Impact of the COVID-19 on Higher Education Students
NCT04365439,Not yet recruiting,Interventional,Not Applicable,Enos Bernasconi,Other,27-Apr-20,30-Jun-20,30-May-20,TREATMENT,10,BLOOD PLASMA THERAPY,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BLOOD PLASMA,TITERS OF ANTI-SARS-COV-2 ANTIBODIES IN THE PLASMA DERIVED FROM CONVALESCENT DONORS,Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study
NCT04365517,Not yet recruiting,Interventional,Phase 3,University of Milan,Other,29-Dec-20,30-Dec-21,30-Mar-21,TREATMENT,170,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SITAGLIPTIN,TIME FOR CLINICAL IMPROVEMENT,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
NCT04365530,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,1-Apr-20,31-Dec-22,1-Apr-22,COHORT,2000,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,CLINICAL CONSEQUENCES OF A COVID-19 INFECTION IN THE CARE POPULATION,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City
NCT04365582,Suspended,Interventional,Phase 3,Groupe Hospitalier Paris Saint Joseph,Other,7-May-20,7-Feb-21,31-Dec-20,TREATMENT,640,COVID,FRANCE,ALL,"50 Years and older   (Adult, Older Adult)",AZITHROMYCIN,HOSPITAL ADMISSION,A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization
NCT04365595,Completed,Observational,,University of Zurich,Other,3-Jun-20,17-Feb-21,17-Feb-21,CASE-ONLY,58,SARS-COV2,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)","QUESTIONNAIRES, SPIROMETRY",HEALTH-RELATED QUALITY-OF-LIFE,Recovery in Patients With SARS-CoV-2 Associated Respiratory Failure
NCT04365608,Completed,Interventional,Not Applicable,Lazarski University,Other,20-Mar-20,10-Dec-20,30-Nov-20,TREATMENT,90,INTUBATION COMPLICATION,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",DIRECT LARYNGOSCOPY,INTUBATION SUCCESS RATE DURING AT THE FIRST LARYNGOSCOPY,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope
NCT04365634,Completed,Observational,,Tongji Hospital,Other,2-Feb-20,1-Apr-20,15-Mar-20,CASE-CONTROL,306,COVID,CHINA,ALL,"Child, Adult, Older Adult",,FIND THE PREDICTION FACTORS ASSOCIATED WITH HOSPITALIZED DEATH OF PATIENTS WITH COVID-19 BY UNIVARIATE AND MULTIVARIATE ANALYSIS,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients by Univariate and Multivariate Analysis.
NCT04365699,Completed,Interventional,Phase 2,NYU Langone Health,Other,8-Apr-20,31-Jan-21,31-Jan-21,TREATMENT,10,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AT-001,PROPORTION OF SUBJECTS WITH DECREASED LEFT VENTRICULAR EJECTION FRACTION ≥10% FROM BASELINE AT TIME OF HOSPITALIZATION,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection
NCT04365725,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,5-May-20,20-Jun-21,20-Jun-21,COHORT,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,CLINICAL COURSE ON DAY 15.,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections."
NCT04365738,Completed,Interventional,Not Applicable,Istanbul Bilgi University,Other,11-Mar-20,26-Apr-20,10-Apr-20,TREATMENT,270,COVID,TURKEY,ALL,28 Years to 45 Years   (Adult),REHABILITATION,DYSPNEA,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial
NCT04365764,Recruiting,Observational,,Groupe Hospitalier Pitie-Salpetriere,Other,14-Mar-20,31-Dec-20,31-Dec-20,CASE-CONTROL,400,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,COMPOSITE OF DEATH AND MECHANICAL VENTILATION,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
NCT04365816,Completed,Observational,,"University Hospital, Grenoble",Other,30-Apr-20,10-Jul-20,10-Jul-20,COHORT,403,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INTERVIEW,EVALUATION OF FOOD INTAKE AT 1 MONTH AFTER DISCHARGE FROM HOSPITAL FOR COVID,Evaluation of the Repercussions of the Coronavirus (Covid 19) Infection on Nutritional Health Status and Nutritional Care : an Observational French Cohort Study One Month After Their Discharge From Hospital
NCT04365881,Completed,Observational,,Modum Bad,Other,31-Mar-20,7-Apr-20,7-Apr-20,OTHER,10084,"LONELINESS, WORRY, RUMINATION, HEALTH ANXIETY, DEPRESSION, ANXIETY",NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",CROSS-SECTIONAL OBSERVATIONAL STUDY,UCLA LONELINESS SCALE-8 (ULS-8),Loneliness During the Non-pharmacological Epidemiological Interventions for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology
NCT04365959,"Active, not recruiting",Observational,,University of Milano Bicocca,Other,20-Mar-20,31-Dec-20,9-Apr-20,CASE-ONLY,56,SARS-COV2,ITALY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PRONE POSITION,NUMBER OF PATIENTS IN WHOM THE PRONE POSITION CAUSED AN INCREASE IN OXYGENATION,"Study of the Feasibility and Usefulness of the Prone Position in Patients With Respiratory Distress From Covid-19 Not Intubated, in Spontaneous Breath in Oxygen Therapy or Cpap"
NCT04365985,Recruiting,Interventional,Phase 2,William Beaumont Hospitals,Other,29-Apr-20,21-Aug-21,21-May-21,TREATMENT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NALTREXONE,PROGRESSION OF OXYGENATION NEEDS,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
NCT04366024,Recruiting,Observational,,Xinqiao Hospital of Chongqing,Other,17-Jan-20,31-Dec-21,30-Aug-20,CASE-ONLY,1000,COVID DISEASE,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",OTHER,THE CONSISTENCY OF PREDICTED SEVERE RATE AND OBSERVED SEVERE RATE OF COVID-19 PATIENTS,A Novel Nomogram to Predict Severity of COVID-19
NCT04366050,Recruiting,Interventional,Phase 2,"University of California, San Diego",Other,11-May-20,21-May-21,21-May-21,TREATMENT,560,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RAMIPRIL 2.5 MG ORAL CAPSULE,COMPOSITE OF MORTALITY OR NEED FOR ICU ADMISSION OR VENTILATOR USE,"A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19"
NCT04366063,Recruiting,Interventional,Phase 2/Phase 3,Royan Institute,Other,5-Apr-20,10-Dec-20,6-Jun-20,TREATMENT,60,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 65 Years   (Adult, Older Adult)",CELL THERAPY PROTOCOL 1,ADVERSE EVENTS ASSESSMENT,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial
NCT04366089,Recruiting,Interventional,Phase 2,"Roberto Poscia MD, PhD",Other,26-Mar-20,31-Dec-20,30-Oct-20,TREATMENT,152,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)","OXYGEN-OZONE THERAPY, PROBIOTIC SUPPLEMENTATION AND STANDARD OF CARE",DELTA IN THE NUMBER OF PATIENTS REQUIRING OROTRACHEAL INTUBATION DESPITE TREATMENT,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora
NCT04366115,Not yet recruiting,Interventional,Phase 1,AVM Biotechnology LLC,Industry,21-Jan-21,23-Jun-21,22-Jun-21,TREATMENT,16,ARDS,,ALL,"18 Years and older   (Adult, Older Adult)",AVM0703,DOSE-LIMITING TOXICITIES,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome"
NCT04366141,Completed,Interventional,Not Applicable,University of British Columbia,Other,1-May-20,1-Feb-21,1-Feb-21,PREVENTION,100,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 BARRIER BOX,TIME TO TRACHEAL INTUBATION (TTI),The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial
NCT04366154,"Active, not recruiting",Observational,,Centre Francois Baclesse,Other,15-Apr-20,21-May-21,15-Jul-20,COHORT,809,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,TO ASSESS THE IMPACT OF THE COVID-19 PANDEMIC ON THE MODIFICATIONS OF TREATMENTS ADMINISTERED IN HOSPITAL (DAY UNITS) TO PATIENTS WITH CANCER OR MALIGNANT HEMOPATHY,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers
NCT04366167,Recruiting,Observational,,Barts & The London NHS Trust,Other,18-Apr-20,31-Dec-21,19-Apr-21,COHORT,100,CARDIAC SURGERY,UNITED KINGDOM,ALL,"18 Years to 120 Years   (Adult, Older Adult)",CARDIAC SURGERY,CHANGE IN IMPACT OF EVENTS SCORES,An Observational Cohort Study to Explore Patient Outcome From Heart Surgery During the Covid-19 Pandemic (CardiacCovid)
NCT04366180,Recruiting,Interventional,Not Applicable,Biosearch S.A.,Industry,24-Apr-20,20-Oct-21,20-Jun-21,PREVENTION,314,COVID,SPAIN,ALL,"20 Years and older   (Adult, Older Adult)",PROBIOTIC,INCIDENCE OF SARS COV-2 INFECTION IN HEALTHCARE WORKERS,Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19
NCT04366206,Recruiting,Observational [Patient Registry],,Centre Hospitalier Intercommunal Robert Ballanger,Other,14-Mar-20,31-Jul-20,31-Jul-20,COHORT,143,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,COMPOSITE OF DEATH AND MECHANICAL VENTILATION,Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
NCT04366219,Not yet recruiting,Observational,,Centre Hospitalier le Mans,Other,20-Jun-21,28-Aug-22,28-Aug-20,OTHER,2000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,COMPARISON OF CLINICAL CHARACTERISTICS,"Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods."
NCT04366232,Terminated,Interventional,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Other,19-Aug-20,2-Oct-20,2-Oct-20,TREATMENT,2,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA ALONE (STAGES 2B/3),BIOLOGICAL CRITERIA,"Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib"
NCT04366245,Recruiting,Interventional,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,Other,23-Apr-20,21-Dec-21,21-Dec-21,TREATMENT,72,SARS-COV2,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYPERIMMUNE PLASMA,"SAFETY: INCIDENCE OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS GRADE 3 AND 4, RELATED TO THE PRODUCT UNDER INVESTIGATION OR THE ADMINISTRATION PROCEDURE, GRADUATED ACCORDING TO THE COMMON TOXICITY CRITERIA SCALE (CTCAE).","Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection"
NCT04366271,Recruiting,Interventional,Phase 2,"Hospital Infantil Universitario Niño Jesús, Madrid, Spain",Other,7-May-20,31-May-21,31-Jul-20,TREATMENT,106,COVID,SPAIN,ALL,"40 Years to 80 Years   (Adult, Older Adult)",MESENCHYMAL CELLS,MORTALITY DUE TO LUNG INVOLVEMENT DUE TO SARS-COV-2 VIRUS INFECTION AT 28 DAYS OF TREATMENT,Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19
NCT04366297,Completed,Interventional,Not Applicable,Lazarski University,Other,12-Jan-20,25-Feb-20,25-Feb-20,TREATMENT,41,CARDIAC ARREST,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",INTRAVENOUS ACCESS,SUCCESSFUL RATE OF FIRST INTRAVASCULAR ACCESS ATTEMPT,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial
NCT04366323,"Active, not recruiting",Interventional,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,Other,27-Apr-20,21-Oct-21,21-Oct-21,TREATMENT,26,SARS-COV2,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,SAFETY OF THE ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STEM CELLS DERIVED FROM ADIPOSE TISSUE ASSESSED BY ADVERSE EVENT RATE,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19"
NCT04366739,Not yet recruiting,Interventional,Phase 3,Centre Hospitalier St Anne,Other,29-Apr-20,30-Sep-20,30-Aug-20,TREATMENT,40,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CHLORPROMAZINE (CPZ),TIME TO RESPONSE (TTR),Repurposing of Chlorpromazine in Covid-19 Treatment
NCT04366752,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,22-Apr-20,22-Sep-20,22-Aug-20,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",VENOUS ULTRASOUND,VARIATION OF THROMBIN TIME (IN SECONDES) IN COVID-19 PATIENTS WITH PNEUMONIA ADMITTED IN ICU.,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy
NCT04366765,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,19-Mar-20,30-Jun-21,30-Jun-21,CASE-CONTROL,1500,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",,SHORT-TERM PROGNOSIS,Coronavirus Disease 19 Survival - The COVIVA Study
NCT04366778,Completed,Observational,,Hospices Civils de Lyon,Other,1-May-20,1-Jan-21,1-Jan-21,COHORT,341,THROMBOSIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TEM-TPA,COAGULABILITY,Evaluation of TEM-tPA (Thromboelastometry With tPA) to Detect Covid-19 Patients at High Risk of Thrombosis
NCT04366791,Suspended,Interventional,Phase 1/Phase 2,Emory University,Other,23-Apr-20,15-Apr-21,15-Apr-21,TREATMENT,10,PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOW DOSE RADIATION THERAPY,RATE OF EXTUBATION (FOR INTUBATED PATIENTS),The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19
NCT04366817,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-21,20-Jun-21,20-Apr-21,PREVENTION,120,POST PARTUM DEPRESSION,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",PSYCHOLOGICAL ASSESSMENT,PROPORTION OF PATIENTS WITH POSTPARTUM DEPRESSION DEFINED BY AN EPDS SCORE >12,Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic
NCT04366830,No longer available,Expanded Access,,Mesoblast International Sàrl,Industry,,,,,,MODERATE TO SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REMESTEMCEL-L,,"Intermediate-size Expanded Access of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome Due to COVID-19 Infection"
NCT04366856,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,26-Jun-20,21-Jan-21,20-Dec-21,TREATMENT,500,COVID,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",1: PRONE POSITIONING,"PROPORTION OF PATIENTS WHO MEET ONE OR BOTH FOLLOWING CRITERIA: NEED FOR INTUBATION (FOR MECHANICAL VENTILATION), OCCURRENCE OF DEATH DURING HOSPITAL STAY.",PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)
NCT04366882,Recruiting,Interventional,Not Applicable,Jessa Hospital,Other,14-Apr-20,20-Dec-21,20-Dec-21,HEALTH SERVICES RESEARCH,45,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",CT-SCAN WITH MINIMAL INVASIVE AUTOPSY,"DETERMINATION OF CAUSE OF DEATH AND CONTRIBUTING FACTORS BASED ON CLINICAL, RADIOLOGICAL, MICROBIOLOGICAL AND HISTOPATHOLOGICAL DATA OF THE DECEASED PATIENT","Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients"
NCT04366908,Recruiting,Interventional,Phase 2,Maimónides Biomedical Research Institute of Córdoba,Other,7-May-20,30-Jun-21,30-Jun-21,TREATMENT,1008,SARS-COV2,SPAIN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",BAT + CALCIFEDIOL,ADMISSION TO INTENSIVE CARE UNIT,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)
NCT04366921,Recruiting,Observational,,Maastricht University Medical Center,Other,10-Apr-20,21-Apr-21,21-Apr-21,COHORT,150,COVID,AUSTRIA,ALL,"Child, Adult, Older Adult",,AGE,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO
NCT04366934,Completed,Observational,,Institut Pasteur,Industry,4-May-20,29-Oct-20,29-Oct-20,CASE-CONTROL,26,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NASAL SWAB,MOLECULAR AND CELLULAR DEFECTS IN OLFACTORY EPITHELIUM,Study of the Pathogenesis of Olfactory Disorders in COVID-19
NCT04366947,Completed,Interventional,Not Applicable,Lazarski University,Other,14-Apr-20,30-Oct-20,20-Sep-20,TREATMENT,60,EMERGENCY MEDICINE,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",NIO® (INTRAOSSEOUS ACCESS),SUCCESS RATE OF FIRST INTRAVASCULAR ACCESS ATTEMPT,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting
NCT04366960,Recruiting,Interventional,Phase 3,Niguarda Hospital,Other,14-May-20,21-Nov-21,21-Aug-21,TREATMENT,2712,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,INCIDENCE OF VENOUS THROMBOEMBOLISM DETECTED BY IMAGING,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial
NCT04366986,Recruiting,Observational [Patient Registry],,Pregistry,Industry,23-Jun-20,30-Apr-24,30-Apr-24,COHORT,25000,COVID,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",TESTED FOR SARS-COV-2 (REGARDLESS OF THE RESULT),PREGNANCY OUTCOMES,International Registry of Coronavirus Exposure in Pregnancy (IRCEP)
NCT04367064,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,25-Apr-20,25-Dec-20,25-Nov-20,COHORT,1000,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,WE WILL COMPARE THE CLINICAL OUTCOME OF THE COVID 19 PATIENTS WITH THEIR AGE AND GENDER,To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)
NCT04367077,Recruiting,Interventional,Phase 2/Phase 3,"Athersys, Inc",Industry,28-Apr-20,22-Aug-21,21-Sep-21,TREATMENT,400,ARDS,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",MULTISTEM,VENTILATOR-FREE DAYS,A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)
NCT04367129,Recruiting,Observational,,University Hospital of Ferrara,Other,14-Apr-20,1-Apr-21,1-Apr-21,COHORT,1014,SARS-COV INFECTION,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",ECG,PHASE 1: ECG CHARACTERISTICS IN PATIENTS PRESENTING WITH SEVERE FORM OF SARS-COV-2 INFECTION,Electrocardiogram Analysis in COVID-19 Patients
NCT04367142,Not yet recruiting,Observational,,"University Hospital, Lille",Other,20-Sep-21,20-Dec-21,20-Nov-21,CASE-CONTROL,200,SARS-COV2,,ALL,"Child, Adult, Older Adult",COVID-19 RT-PCR,SENSITIVITY AND SPECIFICITY OF THE COR-DIAL BASED ON NASOPHARYNGEAL SWABS TAKEN ON ADMISSION OF THE PATIENT COMPARED TO THE FINAL DIAGNOSIS OF COVID-19 MADE BY THE MEDICAL TEAM,Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept
NCT04367168,Recruiting,Interventional,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,27-May-20,27-Apr-21,27-Apr-21,TREATMENT,174,COVID,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)",COLCHICINE,"NUMBER OF PATIENTS WITH IMPROVEMENT IN BODY TEMPERATURE, MYALGIA, ARTHRALGIA, TOTAL LYMPHOCYTE COUNT, D-DIMER, FIBRINOGEN AND FERRITIN LEVELS","Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection"
NCT04367207,Recruiting,Observational [Patient Registry],,University of Cape Town,Other,1-May-20,31-Dec-20,1-Dec-20,COHORT,2000,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY,"African Covid-19 Critical Care Outcomes Study: An African, Multi-centre Evaluation of Patient Care and Clinical Outcomes for Patients With COVID-19 Admitted to High-care or Intensive Care Units"
NCT04367337,"Active, not recruiting",Observational,,"University of Social Sciences and Humanities, Warsaw",Other,25-Mar-20,24-Mar-21,24-Mar-21,ECOLOGIC OR COMMUNITY,6079,HEALTH BEHAVIOR,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,HANDWASHING ADHERENCE,Health Behavior Change During COVID-19 Pandemic: the Focus on Handwashing
NCT04367350,Recruiting,Observational [Patient Registry],,University Hospital Tuebingen,Other,20-Mar-20,31-Mar-22,31-Mar-21,COHORT,500,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",LABORATORY BIOMARKERS,RATE OF ELEVATED CREATINE KINASE IN HYPERACUTE PHASE,Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
NCT04367363,Completed,Observational,,Jean Liu,Other,17-Mar-20,31-May-20,7-May-20,COHORT,151,CORONAVIRUS,SINGAPORE,ALL,"21 Years and older   (Adult, Older Adult)",SOCIAL MEDIA & NEWS CONSUMPTION,WHATSAPP USAGE,Tracking WhatsApp Behaviors During a Crisis: A Longitudinal Observation of Messaging Activities During the COVID-19 Pandemic
NCT04367402,Recruiting,Observational,,Azienda Ospedaliera San Paolo,Other,30-Mar-20,20-Sep-21,24-Apr-20,CASE-CONTROL,600,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",BIOMEDOMICS COVID-19 IGM-IGG RAPID TEST,RETROSPECTIVE STUDY ON INDIVIDUALS WITH OR WITHOUT SYMPTOMS TO VERIFY THE RELIABILITY OF A PROGNOSTIC/DIAGNOSTIC TEST BASED ON IGM/IGG ANALYSIS.,"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients"
NCT04367545,Completed,Interventional,Not Applicable,"University Hospital, Rouen",Other,16-Apr-20,17-May-20,17-May-20,DIAGNOSTIC,130,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA COLLECTION,NUMBER OF POSITIVE PATIENT USING SALIVA METHOD COMPARED TO NUMBER OF POSITIVE PATIENT USING STANDARD METHOD,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic
NCT04367636,Recruiting,Interventional,Not Applicable,University Ghent,Other,30-Apr-20,21-Sep-21,21-Sep-21,SUPPORTIVE CARE,100,RUMINATION,BELGIUM,ALL,"18 Years to 65 Years   (Adult, Older Adult)",BEHAVIORAL: OCAT-SHAM,"CHANGES IN DEPRESSION-, ANXIETY- AND PSYCHOSOMATIC STRESS SYMPTOMS",The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19: Validation of a New Online Treatment
NCT04367662,Completed,Interventional,Not Applicable,"University Hospital, Rouen",Other,9-Apr-20,14-May-20,14-May-20,OTHER,99,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,CLINICAL WORSENING (YES/NO) OF THE PATIENT DURING HOSPITALIZATION,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19
NCT04367714,Recruiting,Observational [Patient Registry],,Region MidtJylland Denmark,Other,15-Mar-20,1-Dec-21,1-Dec-21,COHORT,300,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,AANTIBODY RESPONSE,Antistof Respons Mod SARS-CoV-2 Hos Dialysepatienter i Forbindelse Med COVID-19
NCT04367740,Enrolling by invitation,Observational,,"University of North Carolina, Chapel Hill",Other,28-Apr-20,21-Apr-21,21-Apr-21,CASE-ONLY,10000,ASYMPTOMATIC CONDITION,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",TO ASSESS FOR DEVELOPMENT OF IGG ANTIBODIES AGAINST SARS-COV2,PERCENTAGE OF ASYMPTOMATIC PATIENTS WITH AN IGG RESPONSE FROM SARS-COV-2 INFECTION.,ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the SARS-CoV-2 Infection
NCT04367792,"Active, not recruiting",Observational,,A.O. Ospedale Papa Giovanni XXIII,Other,23-Apr-20,21-Mar-21,20-Oct-21,CASE-CONTROL,60,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,CARDIAC PATHOLOGICAL FINDINGS FROM SERIES OF 60 PATIENTS DYING FROM COVID-19 DISEASE,Pathology and Pathogenesis of Cardiac Injury in COVID-19 Infections in Humans
NCT04367805,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,27-Apr-20,20-Oct-21,20-Oct-21,CASE-ONLY,50,HEPATOCELLULAR CARCINOMA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NASOPHARYNGEAL COVID 19 RT-PCR,INCIDENCE OF COVID-19 INFECTION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN FRANCE,Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort
NCT04367831,Recruiting,Interventional,Phase 4,Columbia University,Other,2-May-20,21-Apr-21,20-Nov-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ENOXAPARIN PROPHYLACTIC DOSE,TOTAL NUMBER OF PATIENTS WITH CLINICALLY RELEVANT VENOUS OR ARTERIAL THROMBOTIC EVENTS IN ICU,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)
NCT04367857,Recruiting,Observational [Patient Registry],,Columbia University,Other,18-Apr-20,21-Oct-21,21-Oct-21,COHORT,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 SEROLOGY,PROPORTION SEROPOSITIVE,SARS-CoV-2 Seroprevalence Among Healthcare Workers: ARMOR Study Demonstration Project
NCT04367870,Recruiting,Observational,,UNICANCER,Other,23-May-20,21-May-21,20-Aug-21,COHORT,2500,ONCOLOGY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"TO EVALUATE THE ABILITY OF SARS-COV-2 IMMUNOASSAYS, FOLLOWING A POSITIVE RESULT, TO IDENTIFY PATIENTS WITH VERY LOW RISK OF RECURRENCE OF COVID-19 WITHIN 3 MONTHS.",COVID-19 Serodiagnosis in Oncology
NCT04367883,Recruiting,Observational,,Consorci Sanitari de Terrassa,Other,1-Mar-20,31-Aug-23,30-Sep-22,OTHER,2574,COVID,SPAIN,ALL,"Child, Adult, Older Adult",ACE INHIBITOR,HOSPITAL OUTPUT,Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection
NCT04367896,Completed,Observational,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,24-Mar-20,17-Apr-20,17-Apr-20,OTHER,1819,COVID OUTBREAK AND SOLID ORGAN TRANSPLANTATION,ITALY,ALL,"Child, Adult, Older Adult",SURVEY GROUP,MANAGEMENT OF SOLID ORGAN TRANSPLANT DURING COVID-19 PANDEMIC,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY
NCT04368000,Terminated,Interventional,Not Applicable,University of Utah,Other,29-Apr-20,6-Aug-20,6-Aug-20,TREATMENT,30,RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INTERMITTENT PRONE POSITIONING INSTRUCTIONS,CHANGE IN IMPUTED PARTIAL PRESSURE OF OXYGEN OVER FRACTION OF INSPIRED OXYGEN (PAO2/FIO2) FROM PERIPHERAL CAPILLARY OXYGEN SATURATION OVER FRACTION OF INSPIRED OXYGEN (SPO2/FIO2),Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization
NCT04368013,Not yet recruiting,Interventional,Not Applicable,Johan Normark,Other,28-Apr-20,14-Apr-26,14-Apr-26,SCREENING,400,COVID,SWEDEN,ALL,"15 Years to 100 Years   (Child, Adult, Older Adult)",EXTENDED SAMPLING AND PROCEDURES,MORTALITY,"Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial"
NCT04368026,Completed,Observational,,Jagiellonian University,Other,30-Mar-20,1-Dec-20,1-Dec-20,OTHER,70,"SURGICAL PROCEDURE, UNSPECIFIED",POLAND,ALL,"25 Years and older   (Adult, Older Adult)",NO INTERVENTION (SURVEY STUDY FOR MEDICAL DOCTORS).,DESCRIPTIVE DATA ON PERCEPTIONS OF CURRENT STATUS OF SURGICAL WARDS DURING THE PANDEMIC AND IMPACT OF THE PANDEMIC ON CONDUCTING SURGERY.,Surgical Care in Poland After COVID19 Outbreak - a National Survey Study
NCT04368065,Recruiting,Observational [Patient Registry],,Iqvia Pty Ltd,Industry,2-Apr-20,1-Jun-23,31-Dec-22,COHORT,100000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 SYMPTOM OCCURRENCE AND SEVERITY,Registry to Study Factors That May Impact COVID-19 Occurrence and Severity
NCT04368143,Recruiting,Observational [Patient Registry],,"Institute of Tropical Medicine, Belgium",Other,1-Apr-20,31-Dec-21,30-Dec-21,COHORT,100,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,PROVIDE PROOF-OF-CONCEPT THAT (LONGITUDINAL) B CELL REPERTOIRE MINING ALLOWS IDENTIFICATION OF EMERGING VIRUS SPECIFIC B CELL RECEPTOR VARIABLE REGIONS.,COVID-19 Immune Repertoire Sequencing
NCT04368156,"Active, not recruiting",Interventional,Not Applicable,Carlos Tornero,Other,20-Apr-20,23-Feb-21,23-Feb-21,TREATMENT,110,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",GAMMACORE® (VAGUS NERVE STIMULATION),INCIDENCE OF CHANGES IN SPECIFIC CLINICAL EVENTS IN PATIENTS WITH COVID-19.,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)"
NCT04368208,Completed,Observational,,Poitiers University Hospital,Other,29-Apr-20,27-Nov-20,21-Oct-20,COHORT,501,POSTNATAL DEPRESSION,FRANCE,FEMALE,18 Years to 50 Years   (Adult),ASSESSMENT OF POSTNATAL DEPRESSION USING THE THE EDINBURGH QUESTIONNAIRE BETWEEN 4 AND 6 WEEKS AFTER DELIVERY,REPORT POSTNATAL DEPRESSION BETWEEN 4 OF 6 WEEKS DURING THE COVID 19 PANDEMIA,Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression
NCT04368221,"Active, not recruiting",Observational,,Rennes University Hospital,Other,4-May-20,21-May-21,21-May-21,COHORT,576,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,OPPORTUNISTIC FUNGAL CO-INFECTIONS.,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
NCT04368234,Recruiting,Observational [Patient Registry],,Duke University,Other,18-Apr-20,30-Apr-25,30-Apr-25,COHORT,100000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,"DEVELOPMENT OF DATA REPOSITORY TO PROVIDE A SECURE, CENTRALIZED STORAGE LOCATION FOR COVID-19 RELATED SPECIMENS",Duke Shared Data and Specimen Repository Regarding COVID-19 Patients
NCT04368260,Recruiting,Interventional,Not Applicable,University of Virginia,Other,24-Apr-20,31-Jul-20,31-Jul-20,OTHER,40,COVID,UNITED STATES,ALL,"up to 99 Years   (Child, Adult, Older Adult)",CONTROL SWAB,NUMBER OF SUBJECTS FOR WHICH THE PROTOTYPE SWAB AND THE CONTROL SWAB PROVIDE THE SAME COVID-19 PCR RESULT,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
NCT04368299,Recruiting,Interventional,Not Applicable,Chinese University of Hong Kong,Other,1-May-20,31-Dec-21,31-Oct-21,HEALTH SERVICES RESEARCH,150,SLE,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",TELEMEDICINE,THE PERCENTAGE OF PATIENTS IN REMISSION OR LLDAS AT ONE YEAR.,"Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus (""TeleSLE"") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial"
NCT04368312,Not yet recruiting,Observational,,"University Hospital, Essen",Other,6-May-20,30-May-20,30-May-20,COHORT,100,PSYCHOLOGICAL DISTRESS,,ALL,"Child, Adult, Older Adult",NO INTERVENTION,PCL5 QUESTIONNAIRE,Psychological Impairment Due to Covid-19 in Hospital Staff
NCT04368338,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,28-Apr-20,28-Sep-21,28-Jan-21,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 RT-PCR,LUNG ULTRASOUND/BIOLOGICAL CORRELATION RESEARCH MODULATING THE SEVERITY OF COVID-19 DISEASE,Use of Lung Ultrasound in Patients Suspected of COVID-19 Infection in the Emergency Room
NCT04368351,"Active, not recruiting",Observational,,University of Roma La Sapienza,Other,1-Mar-20,31-Jul-20,30-Jun-20,CASE-CONTROL,70,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SIVOMIXX (200 BILLION),DELTA OF TIME OF DISAPPEARANCE OF ACUTE DIARRHEA,Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19
NCT04368377,Completed,Interventional,Phase 2,University of Milan,Other,6-Apr-20,23-Apr-20,23-Apr-20,TREATMENT,5,"PNEUMONIA, VIRAL",ITALY,ALL,"18 Years and older   (Adult, Older Adult)",TIROFIBAN INJECTION,P/F RATIO,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol
NCT04368390,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,3-Apr-20,21-Apr-21,21-Apr-21,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,NEURORADIOLOGICAL ANALYSIS OF PATIENTS BRAIN MRI,Imaging Analysis of COVID-19 + Patients With Abnormal Neurological Examination
NCT04368637,Recruiting,Observational,,Jordan Collaborating Cardiology Group,Other,3-May-20,30-Aug-20,30-Jul-20,COHORT,50,ACUTE MYOCARDIAL INFARCTION,JORDAN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,ACUTE CARDIOVASCULAR EVENT TRIGGERED BY COVID-19 STRESS,"Acute Cardiovascular Events Triggered by COVID-19-Related, Non-infectious Stress The Jordan COVID-9 caRdiovascular Events (JoCORE) Study"
NCT04368676,Recruiting,Interventional,Early Phase 1,Lawson Health Research Institute,Other,25-Jun-20,30-Jun-21,30-Jun-21,TREATMENT,60,JOB STRESS,CANADA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",SUDARSHAN KRIYA YOGA (SKY),RATE OF PARTICIPANT RECRUITMENT,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness (BREATH): an RCT for Frontline Hospital and Long-term Care Home Staff Managing the COVID-19 Pandemic
NCT04368728,"Active, not recruiting",Interventional,Phase 2/Phase 3,BioNTech SE,Industry,29-Apr-20,31-Jan-23,3-Aug-21,PREVENTION,43998,SARS-COV2 INFECTION,ARGENTINA,ALL,"12 Years and older   (Child, Adult, Older Adult)",BNT162B1,PERCENTAGE OF PARTICIPANTS IN PHASE 1 REPORTING LOCAL REACTIONS,"A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS"
NCT04368793,Recruiting,Observational,,China-Japan Friendship Hospital,Other,6-Apr-20,31-Dec-21,31-Dec-20,COHORT,200,COVID-2019 PNEUMONIA,CHINA,ALL,"20 Years to 85 Years   (Adult, Older Adult)",REMOTE PULMONARY REHABILITATION,SIX-MINUTE WALKING DISTANCE (6MWD),Intelligence-based Remote Pulmonary Rehabilitation and Efficacy Among Discharged COVID-19 Patients
NCT04368832,"Active, not recruiting",Observational,,"Central Hospital, Nancy, France",Other,25-Apr-20,30-Sep-21,31-Dec-20,OTHER,108,PREGNANCY RELATED,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",REMOTE CONSULTATION,SCORE OF PERCEIVED QUALITY OF PRENATAL CARE,ImPROving prenaTal carE During ConfinemenT: Impact of Confinement on the Quality of Prenatal Care Perceived in Low-risk Pregnancy
NCT04368845,Recruiting,Interventional,Not Applicable,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,Other,11-May-20,31-Mar-21,31-Mar-21,TREATMENT,100,COVID,GREECE,ALL,"20 Years to 65 Years   (Adult, Older Adult)",TELEREHABILITATION,PHYSICAL PERFORMANCE,"A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study"
NCT04368871,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,28-Apr-20,30-May-21,30-Jun-20,COHORT,200,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,RADIOGRAPHIC FINDINGS AND THEIR TEMPORAL CHANGES IN COVID-19 POSITIVE PATIENT: A PROSPECTIVE STUDY,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study
NCT04368884,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,22-Apr-20,30-Jul-21,30-Jun-21,COHORT,1000,COVID,INDIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,DEVELOPMENT OF ANTIBODIES,"A Prospective, Longitudinal, Observational Study to Assess the Seroconversion Status of Front Line Health Care Workers and Comparison With the Suspected or Confirmed Cases of COVID-19 Patients at Max Health Care (Project D)"
NCT04368897,Recruiting,Observational,,"Applied Biology, Inc.",Industry,1-May-20,1-Jun-21,1-Apr-21,CASE-CONTROL,200,SARS-COV2,SPAIN,MALE,"18 Years and older   (Adult, Older Adult)",CAG LENGTH <22,HOSPITAL-FREE DAYS TO DAY 28 [ TIME FRAME: 28 DAYS],In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
NCT04368923,"Active, not recruiting",Interventional,Not Applicable,Cairo University,Other,15-Mar-20,23-Jun-20,21-Jun-20,TREATMENT,60,COVID,EGYPT,ALL,21 Years to 40 Years   (Adult),OXYGEN THERAPY,ARTERIAL BLOOD GASES (ABG): PARTIAL PRESSURE OF OXYGEN AND CARBON DIOXIDE,Management of Covid-19 Patients During Home Isolation
NCT04368975,Recruiting,Observational [Patient Registry],,Hospital Clinic of Barcelona,Other,12-Mar-20,31-Dec-20,21-Apr-20,COHORT,500,ACUTE RESPIRATORY FAILURE WITH HYPOXIA,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,DISCONTINUATION FROM MECHANICAL VENTILATION,Main Features and Ventilatory Management of Patients With ARDS Caused by COVID-19
NCT04368988,"Active, not recruiting",Interventional,Phase 1/Phase 2,Novavax,Industry,25-May-20,18-Nov-21,1-Dec-20,PREVENTION,1419,COVID,AUSTRALIA,ALL,"18 Years to 84 Years   (Adult, Older Adult)",SARS-COV-2 RS - PHASE 1,PARTICIPANTS WITH SOLICITED ADVERSE EVENTS (AES) - PHASE 1,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects"
NCT04369066,Recruiting,Interventional,Not Applicable,Institut Curie,Other,28-Apr-20,28-Apr-22,28-Apr-21,HEALTH SERVICES RESEARCH,2800,VOLUNTEERS FROM THE INSTITUTE CURIE AND INSTITUTE PASTEUR STAFF WHO ARE NOT SHOWING ACTIVE SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES (COLLECTION OF 5 ML OF BLOOD IN A DRY TUBE),ANTIBODIES AGAINST THE SARS-COV-2 VIRUS IN SERUM AT INCLUSION,"COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur"
NCT04369274,Not yet recruiting,Interventional,Not Applicable,Massachusetts General Hospital,Other,21-Mar-21,21-Nov-21,21-Nov-21,TREATMENT,30,RESPIRATORY FAILURE,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MECHANICAL VENTILATION WITH THE AUTOMATED BVM COMPRESSOR,ARTERIAL OXYGENATION,A Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Ventilation for the Treatment of COVID-19 ARDS
NCT04369300,Recruiting,Observational [Patient Registry],,Max Healthcare Insititute Limited,Other,24-Apr-20,24-Feb-21,24-Nov-20,OTHER,1000,COVID,INDIA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",REGISTERY DATA COLLECTION,PREVALENCE (MAGNITUDE) OF ANXIETY OF GENERAL ADULT POPULATION DURING COVID-19,Prevalence Of Anxiety And Depression During COVID-19
NCT04369365,Recruiting,Interventional,Phase 2,Prof. Dr. Matthias Preusser,Other,27-Apr-20,27-Dec-20,27-Aug-20,PREVENTION,200,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",AZITHROMYCIN 500 MILLIGRAM (MG) ORAL TABLET,CUMULATIVE NUMBER OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) INFECTIONS,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic"
NCT04369378,Recruiting,Interventional,Not Applicable,Lake Erie College of Osteopathic Medicine,Other,19-Aug-20,30-Apr-21,28-Feb-21,TREATMENT,200,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MEDITATION APP USAGE,ANXIETY,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic
NCT04369456,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,22-Apr-20,22-Oct-20,22-Oct-20,OTHER,115,KIDNEY TRANSPLANT; COMPLICATIONS,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BLOOD SAMPLE,PREDICTIVE VALUE OF IL-6 CONTENTS OF WHOLE BLOOD SAMPLES AFTER EX VIVO STIMULATION,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
NCT04369469,"Active, not recruiting",Interventional,Phase 3,Alexion Pharmaceuticals,Industry,11-May-20,21-Jul-21,21-May-21,TREATMENT,270,COVID SEVERE PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RAVULIZUMAB,SURVIVAL (BASED ON ALL-CAUSE MORTALITY) AT DAY 29,"A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome"
NCT04369599,Suspended,Interventional,Not Applicable,Emory University,Other,11-Aug-20,21-Apr-21,21-Apr-21,TREATMENT,24,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",V/Q VEST,CHANGE IN ARTERIAL OXYGENATION LEVELS,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest
NCT04369690,Recruiting,Observational,,University of Ottawa,Other,3-Apr-20,3-Apr-21,3-Apr-21,COHORT,1000,COVID,CANADA,ALL,"12 Years and older   (Child, Adult, Older Adult)",,MENTAL HEALTH - STRESS,"How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic"
NCT04369742,Suspended,Interventional,Phase 2,NYU Langone Health,Other,15-Apr-20,21-Jun-21,21-Jun-21,TREATMENT,626,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE (HCQ),CUMULATIVE INCIDENCE OF SAES THROUGH DAY 30,"Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults"
NCT04369794,Recruiting,Interventional,Phase 4,"University of Campinas, Brazil",Other,10-Aug-20,23-Aug-21,21-Jun-21,TREATMENT,1000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",BCG,CLINICAL EVOLUTION OF COVID-19,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement"
NCT04369807,Recruiting,Observational,,Perspectum,Industry,21-Apr-20,31-May-23,31-May-23,COHORT,507,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",OUTPATIENT MRI,"CHARACTERISE PREVALENCE AND SEVERITY OF ORGAN VOLUME CHANGE AND DAMAGE (HEART, KIDNEYS AND LIVER)",Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
NCT04369820,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,31-Mar-20,20-Nov-21,20-Sep-21,OTHER,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DRAW BLOOD,SHOW AN OVEREXPRESSION OF C5A RECEPTOR IN PATIENTS WITH ARDS SECONDARY TO COVID-19 COMPARED TO CONTROL PATIENTS (PATIENTS WITH COVID-19 WITHOUT RESPIRATORY DISTRESS AND HEALTHY VOLUNTEERS).,C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19
NCT04369859,Recruiting,Observational,,Assistance Publique Hopitaux De Marseille,Other,23-Apr-20,22-Apr-21,22-Apr-21,COHORT,1300,PREGNANT WOMEN,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",EXAMINE THE IMPACT OF COVID-19 DURING PREGNANCY,COMPARE THE COMPLICATIONS RATES,Obstetric and Perinatal Outcomes of Women With COVID-19: A Prospective Cohort Study
NCT04369989,Enrolling by invitation,Observational,,OSF Healthcare System,Other,14-Apr-20,14-Apr-21,14-Apr-21,COHORT,1000,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,MORTALITY DURING THE COVID-19 TREATMENT HOSPITAL ENCOUNTER,Observational Study of COVID-19 Treatment Efficacy
NCT04370015,Not yet recruiting,Interventional,Not Applicable,"Services Institute of Medical Sciences, Pakistan",Other,15-May-20,15-Oct-20,30-Jun-20,PREVENTION,374,SARS-COV2,,ALL,18 Years to 60 Years   (Adult),HYDROXYCHLOROQUINE,PREVENTION OF SARS-COV-2 AS DETERMINED BY NEGATIVE RT-PCR AT THE END OF 12 WEEK STUDY PERIOD,Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial
NCT04370119,Recruiting,Observational,,University Medicine Greifswald,Other,27-Apr-20,25-May-21,21-May-21,COHORT,4000,SARS-COV2,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",NASAL SWAB,NUMBER OF PEOPLE WITH DETECTABLE ANTIBODIES TO SARS-COV-2,Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
NCT04370171,Completed,Observational,,"University Hospital, Strasbourg, France",Other,4-May-20,29-May-20,29-May-20,COHORT,610,DIABETES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CARE MODALITIES,COMPARISON OF METABOLIC CONTROL (HBA1C) BETWEEN DIABETIC PATIENTS FOLLOWED BY TELECONSULTATION AND PATIENTS WITH A CONVENTIONAL FOLLOW-UP DURING COVID-19 INFECTION.,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic: Prospective Observational Study
NCT04370197,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,3-Mar-20,30-Apr-20,30-Apr-20,CASE-ONLY,300,"STROKE, ACUTE",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,STUDY OF THE EFFECT OF PANDEMIC COVID-19 ON THE MANAGEMENT OF STROKE PATIENTS,Impact of th Covid-19 Epidemic on Acute Stroke Management
NCT04370210,Completed,Observational,,Centre Hospitalier René Dubos,Other,4-May-20,4-Jun-20,4-Jun-20,COHORT,247,SLEEP DISTURBANCE,FRANCE,ALL,7 Years to 12 Years   (Child),QUESTIONNAIRES,COMPARISON OF SLEEP QUALITY DURING COVID-19 CONTAINMENT BETWEEN CHILDREN USUALLY FOLLOWED IN CHILD PSYCHIATRY AND CHILDREN WITHOUT FOLLOW-UP,"Sleep Quality During COVID-19 Containment in Children 7 to 12 Years Old, Whether or Not Usually Followed in Child Psychiatry"
NCT04370223,Not yet recruiting,Interventional,Phase 3,Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta,Other,25-May-20,25-Dec-20,25-Oct-20,TREATMENT,208,COVID PNEUMONIA,SPAIN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",OZONE AUTO-HEMOTHERAPY,RATE OF PATIENTS ACHIEVING IMPROVEMENT IN CLINICAL CONDITION AT DAY 14 AFTER RECRUITMENT,A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia
NCT04370236,Recruiting,Interventional,Phase 2/Phase 3,"Inmune Bio, Inc.",Industry,21-Oct-20,21-Feb-21,21-Feb-21,TREATMENT,366,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INB03,PROPORTION OF PARTICIPANTS WITH DISEASE PROGRESSION FROM RANDOMIZATION TO 28 DAYS POST-RANDOMIZATION,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)"
NCT04370249,Completed,Observational,,Nantes University Hospital,Other,9-Apr-20,31-Aug-20,31-Aug-20,CASE-ONLY,313,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY ULTRASOUND,CONSTRUCTION OF A COMPOSITE CLINICAL-ECHO SCORE (VIRUSCORE) PREDICTIVE OF RISK OF WORSENING RESPIRATORY IMPAIRMENT IN COVID-19 ADULT PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19
NCT04370262,Completed,Interventional,Phase 3,Northwell Health,Other,7-Apr-20,7-Sep-20,7-Sep-20,TREATMENT,233,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SOC + INTRAVENOUS FAMOTIDINE,MORTALITY,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults"
NCT04370275,Recruiting,Observational,,Ospedale di Latisana,Other,23-Apr-20,31-May-20,23-May-20,COHORT,235,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,NEGATIVE PREDICTIVE VALUE OF LUNG ULTRASOUND IN THE DIAGNOSIS OF COVID-19,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia: a Multicenter Study in the Italian Outbreak
NCT04370288,Recruiting,Interventional,Phase 1,Mashhad University of Medical Sciences,Other,19-Apr-20,21-Sep-20,20-Sep-20,TREATMENT,20,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 90 Years   (Adult, Older Adult)","MCN (METHYLENE BLUE, VITAMIN C, N-ACETYL CYSTEINE)",PROPORTION OF PATIENTS REMAINING FREE OF NEED FOR MECHANICAL VENTILATION IN BOTH GROUPS,The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients
NCT04370678,Completed,Observational,,Region Zealand,Other,17-Apr-20,24-Apr-20,24-Apr-20,OTHER,79,ARTHROSCOPY,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",CHANGE IN PREFERENCE TO SURGERY UNDER COVID-19 PANDEMIC.,CHANGE IN PREFERENCE,Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures: COVID-19 Effect on Arthroscopic Patients in a University Hospital in Denmark
NCT04370782,Completed,Interventional,Phase 4,"St. Francis Hospital, New York",Other,28-Apr-20,30-Sep-20,30-Sep-20,TREATMENT,18,COVID,UNITED STATES,ALL,"30 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TIME TO RESOLUTION OF SYMPTOMS RELATIVE TO BASELINE (DAY 1 OF TRIAL),A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting
NCT04370808,Not yet recruiting,Observational,,University of Lisbon,Other,20-Jun-21,21-Mar-21,20-Oct-21,CASE-ONLY,500,COVID,PORTUGAL,ALL,"18 Years and older   (Adult, Older Adult)",EXPOSURE,DIFFERENCES IN VITAMIN D BLOOD LEVELS BETWEEN COVID-19 PATIENTS WITH DIFFERENT DEGREES OF DISEASE SEVERITY.,VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity
NCT04370821,Recruiting,Observational [Patient Registry],,Villanova University,Other,9-May-20,27-Apr-40,27-Apr-40,COHORT,20000,OCCUPATIONAL EXPOSURE TO SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SAMPLE SIZE OF ENROLLED CHAMPS STUDY PARTICIPANTS BY DEMOGRAPHIC CHARACTERISTICS DURING THE FIRST TWO YEARS OF THE STUDY,"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers"
NCT04370834,Terminated,Interventional,Phase 2,National Cancer Institute (NCI),NIH,28-May-20,14-Jan-21,14-Jan-21,OTHER,1,HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM,UNITED STATES,ALL,"2 Years and older   (Child, Adult, Older Adult)",TOCILIZUMAB,CLINICAL OUTCOME AS EVALUATED BY THE 7-CATEGORY CLINICAL STATUS ORDINAL SCALE,Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)
NCT04370886,Completed,Interventional,Not Applicable,Guangzhou Blood Center,Other,30-Apr-20,10-May-20,30-Apr-20,HEALTH SERVICES RESEARCH,456517,BLOOD DONATION,CHINA,ALL,18 Years to 60 Years   (Adult),BLOOD DONATION SMS,BLOOD DONATION RATE,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19
NCT04370938,Withdrawn,Interventional,Not Applicable,University of Pittsburgh,Other,29-Apr-20,29-Oct-20,29-Oct-20,OTHER,0,"PERCEIVED ORGANIZATIONAL SUPPORT, ANXIETY, BURNOUT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COPING STRATEGIES VIDEO,FEASIBILITY OF UNDERTAKING TASK,Exploring Provider Burnout During the COVID-19 Pandemic
NCT04371029,Recruiting,Interventional,Not Applicable,"University Hospital, Bordeaux",Other,28-Apr-20,28-Dec-20,28-Sep-20,OTHER,25,ARDS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PSG,PROPORTION OF PATIENTS WITH ALTERED SPLEEP,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS
NCT04371107,Not yet recruiting,Interventional,Phase 3,"Centre Hospitalier Universitaire, Amiens",Other,29-Apr-20,20-Jul-21,20-Jun-21,TREATMENT,64,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CONSULTATION,LENGTH OF SYMPTOM DURATION (IN DAYS) WITH AZITHROMYCIN TREATMENT,Proactive Care of Ambulatory COVID19 Patients: Open-labeled Randomized Trial
NCT04371250,"Active, not recruiting",Observational,,Erasme University Hospital,Other,30-Apr-20,30-Dec-20,31-May-20,COHORT,800,"RESILIENCE, PSYCHOLOGICAL",BELGIUM,ALL,18 Years to 25 Years   (Adult),SURVEY AND QUESTIONNAIRE,SELF-RATED MEASURE OF RESILIENCE,Mental Health Implications During and After the COVID-19 Pandemic Lock-down Measures in Youth (18 - 25 Years Old) in French-Speaking Belgium and Italy: Resilience and Loneliness Evaluation.
NCT04371289,"Active, not recruiting",Observational,,Istituto Auxologico Italiano,Other,8-Apr-20,10-Sep-21,10-Jul-20,COHORT,5500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,PREDICTIVE MODELING OF IN-HOSPITAL OUTCOME,Cardiovascular Risk and Effects of Cardiovascular Drug Therapy During nCoV-19 Infection
NCT04371302,Not yet recruiting,Observational,,University of Malaya,Other,1-May-20,30-Jun-20,30-Jun-20,COHORT,145,"BURNOUT, PROFESSIONAL",,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PREVALENCE OF BURNOUT AMONG ICU NURSES DURING COVID-19,Nursing Perspective on Burnout and Medical Errors in the Intensive Care Unit of an Exclusively Covid-19 Hospital: the Malaysian Experience
NCT04371315,Recruiting,Observational,,St. Jude Children's Research Hospital,Other,27-Apr-20,30-Jun-22,1-Jun-21,OTHER,400,CORONAVIRUS INFECTION,UNITED STATES,ALL,"up to 24 Years   (Child, Adult)",,CHARACTERISTICS AND OUTCOMES OF ACUTE RESPIRATORY INFECTIONS DUE TO COVID-19 IN CHILDREN.,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children"
NCT04371328,"Active, not recruiting",Observational [Patient Registry],,"University Hospital, Toulouse",Other,13-Mar-20,21-Mar-21,5-Jun-20,COHORT,1860,EMERGENCIES,FRANCE,ALL,"15 Years and older   (Child, Adult, Older Adult)",RECOP UNIT PATIENT,DESCRIBE THE CHARACTERISTICS OF PATIENTS ADMITTED TO RECOP UNITS ACCORDING TO THEIR VIROLOGICAL STATUS VIS-À-VIS COVID-19,"Emergency Management in a Dedicated Respiratory Unit of Patients With a Possible COVID-19 Infection (Unit ""COVID Possible"")"
NCT04371354,"Active, not recruiting",Observational,,Fundacion Miguel Servet,Other,27-Apr-20,27-Jul-21,14-Jun-21,OTHER,100,COVID DISEASE,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF NEW COVID INFECTION OF PATIENTS AND STAFF MEMBERS,Outcomes After Implementation of a Protective Protocol for Covid-19 in Large Spanish Endoscopy Units.
NCT04371367,"Active, not recruiting",Interventional,Phase 2,Assistance Publique Hopitaux De Marseille,Other,27-Apr-20,1-Mar-21,1-Mar-21,TREATMENT,208,COVID,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AVDORALIMAB,CLINICAL IMPROVEMENT USING WHO ORDINAL SCALE,"A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia"
NCT04371393,"Active, not recruiting",Interventional,Phase 3,Icahn School of Medicine at Mount Sinai,Other,30-Apr-20,22-Feb-21,21-Feb-21,TREATMENT,223,MESENCHYMAL STROMAL CELLS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REMESTEMCEL-L,NUMBER OF ALL-CAUSE MORTALITY,Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
NCT04371406,Withdrawn,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,20-Apr-21,20-Sep-21,20-Aug-21,TREATMENT,0,COVID,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE AND AZITHROMYCIN,RATE OF PATIENTS WITH OCCURRENCE OF AN UNFAVORABLE OUTCOME BETWEEN RANDOMIZATION AND DAY 14,Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients: Randomized Controlled Trial: MG-COVID
NCT04371419,Completed,Interventional,Not Applicable,"National Bureau of Economic Research, Inc.",Other,13-May-20,24-May-20,24-May-20,PREVENTION,15475,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MESSAGING,KNOWLEDGE BELIEFS AND PRACTICES RELATED TO COVID-19,COVID-19 Health Messaging to Underserved Communities
NCT04371432,Recruiting,Observational,,National Human Genome Research Institute (NHGRI),NIH,5-May-20,1-Jun-25,1-Jun-25,CASE-CONTROL,2500,COVID,UNITED STATES,ALL,"3 Years and older   (Child, Adult, Older Adult)",,MOLECULAR ETIOLOGY OF HOST SUSCEPTIBILITY TO SEVERE COVID-19,Genetics of COVID-19 Susceptibility and Manifestations
NCT04371471,Completed,Observational,,Groupe Hospitalier de la Rochelle Ré Aunis,Other,1-Mar-20,30-Apr-20,30-Apr-20,COHORT,50,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",STC-19 SCORE,STC-19 SCORE,Covid-19 Pandemic Triage Score in Patients With Known or Suspected SARS-CoV-2 Infection
NCT04371510,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,22-Apr-20,22-Feb-21,22-Oct-20,OTHER,115,COVID BY SARS-COV2 INFECTION,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BLOOD SAMPLE,PREDICTIVE VALUE OF IL-6 CONTENTS OF WHOLE BLOOD SAMPLES AFTER EX VIVO STIMULATION,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients
NCT04371523,Not yet recruiting,Interventional,Phase 3,St. Joseph's Healthcare Hamilton,Other,1-May-20,30-Aug-20,31-Jul-20,PREVENTION,1100,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",APO-HYDROXYCHLOROQUINE,POSITIVE FOR SARS-COV-2,Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE): A Parallel Randomized Controlled Trial
NCT04371562,Completed,Observational,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,1-Mar-20,15-Apr-20,31-Mar-20,COHORT,300,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,7-DAY DEATH,Predicting ICU Admission and Death for COVID-19 Patients in the Emergency Department. Comparison of Five Scoring Systems.
NCT04371601,"Active, not recruiting",Interventional,Early Phase 1,Fuzhou General Hospital,Other,1-Mar-20,31-Dec-22,31-Dec-21,TREATMENT,60,COVID PNEUMONIA,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",OSELTAMIVIR,"CHANGES OF OXYGENATION INDEX (PAO2/FIO2) ,BLOOD GAS TEST",Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
NCT04371640,Withdrawn,Interventional,Phase 1,Walter K. Kraft,Other,6-Jul-20,21-Aug-21,21-Jul-21,TREATMENT,0,SARS-COV2,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SIROLIMUS 1 MG/ML,CHANGE IN SARS-COV-2 VIRAL BURDEN FROM BASELINE TO DAY 7 OF TREATMENT,"A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)"
NCT04371679,Recruiting,Observational,,Hasselt University,Other,1-Apr-20,1-Dec-20,1-Oct-20,COHORT,40,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",NO INTERVENTIONS PLANNED,DEATH (ALL-CAUSE MORTALITY) OR DISCHARGE FROM ICU (LIMIT OF 4 MONTHS),Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients
NCT04371692,Not yet recruiting,Observational,,"University Hospital, Lille",Other,20-Apr-21,20-Sep-21,20-Sep-21,COHORT,100,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",SELF-ADMINISTERED QUESTIONNAIRE,THE PREVALENCE OF SARS- COV2 INFECTION HEALTH CARE WORKER WITH OR WITHOUT SYMPTOMS SUGGESTIVE OF A COVID-19 INFECTION,Prevalence of SARS-Cov2 Infection Among HCW in Lille University Hospital
NCT04371744,Completed,Observational [Patient Registry],,Assistance Publique Hopitaux De Marseille,Other,17-Apr-20,5-Jun-20,4-Jun-20,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CORRECTED QT (QTC) INTERVAL MEASUREMENT,"QT-Logs : a Clinical Study to Monitor Cardiac Safety, With Artificial Intelligence for QT Interval Analysis of ECG Data From Smartwatches, in Patients Receiving Hydroxychloroquine Treatment for COVID-19"
NCT04371822,Not yet recruiting,Interventional,Phase 1,Kafrelsheikh University,Other,20-Aug-21,20-Nov-21,20-Oct-21,TREATMENT,56,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SNPP PROTOPORPHYRIN PLUS SUNLIGHT EXPOSURE,LUNG INJURY SCORE,Efficacy of Based MRI Contrast Media Against Covid-19
NCT04371835,Recruiting,Observational,,Kirby Institute,Other,12-Aug-20,31-Dec-21,31-Dec-21,COHORT,1500,HIV-INFECTION/AIDS,NIGERIA,ALL,"18 Years and older   (Adult, Older Adult)",,CLINICAL FEATURES OF SYMPTOMATIC COVID-19 IN PEOPLE LIVING WITH HIV (PLWH),"COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, D²EFT, DolPHIN2 and NAMSAL"
NCT04371848,"Active, not recruiting",Observational,,Laval University,Other,16-Apr-20,7-May-20,7-May-20,COHORT,2465,EATING HABITS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE IN DIET QUALITY,Impact of the COVID-19 Pandemic on Diet Quality and Food Insecurity Among Adults From the Province of Québec in Canada: a NutriQuébec Sub-study
NCT04371926,Withdrawn,Interventional,Not Applicable,Texas Cardiac Arrhythmia Research Foundation,Other,20-Jun-21,21-Jul-21,21-Jun-21,PREVENTION,0,COVID,,ALL,"18 Months to 85 Years   (Child, Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE,TIME TO REACH NORMAL BODY TEMPERATURE,Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)
NCT04371952,Not yet recruiting,Interventional,Phase 3,Nantes University Hospital,Other,1-Jun-20,1-Dec-20,1-Dec-20,TREATMENT,330,COVID,FRANCE,ALL,"46 Years and older   (Adult, Older Adult)",DOXYCYCLINE,PERCENTAGE OF PATIENTS WITH CLINICAL RESPIRATORY AGGRAVATION,"Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study"
NCT04371965,Completed,Interventional,Phase 2,Poitiers University Hospital,Other,1-Sep-20,23-Oct-20,23-Oct-20,TREATMENT,24,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",POVIDONE-IODINE,CHANGE FROM BASELINE NASO-PHARYNGEAL VIRAL LOAD QUANTIFIED BY RT-PCR AT DAY7,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2"
NCT04371978,Recruiting,Interventional,Phase 3,Rabin Medical Center,Other,1-Oct-20,30-Sep-21,30-Jun-21,TREATMENT,100,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",LINAGLIPTIN 5 MG,TIME TO CLINICAL CHANGE,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
NCT04372004,Recruiting,Interventional,Phase 1,Texas Cardiac Arrhythmia Research Foundation,Other,8-May-20,21-Jun-21,21-May-21,DIAGNOSTIC,100,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",DIAGNOSTIC TESTS FOR COVID-19 INFECTION,DETECTION OF VIRAL INFECTION USING SEROLOGY AND VIRAL-RNA DETECTION KITS,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)
NCT04372017,"Active, not recruiting",Interventional,Phase 3,Sanford Health,Other,14-May-20,4-Jun-21,4-Jun-20,PREVENTION,1,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COHORT A: PERCENTAGE OF COVID-19 EXPOSED HEALTHCARE WORKERS TREATED WITH HYDROXYCHLOROQUINE WITH A POSITIVE COVID-19 TEST.,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection"
NCT04372030,Not yet recruiting,Interventional,Not Applicable,Université Catholique de Louvain,Other,1-May-20,31-Oct-21,30-Jun-20,HEALTH SERVICES RESEARCH,10000,HEALTH CARE UTILIZATION,,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE QUESTIONNAIRE,HEALTH CARE USE,"Utilisation de Soins Pendant la Crise Covid-19 : Recours, Report et Renoncement (US3R)"
NCT04372043,Not yet recruiting,Observational,,Saint-Joseph University,Other,30-Apr-20,30-Sep-20,30-Sep-20,COHORT,1200,SLEEP HYGIENE,LEBANON,ALL,"18 Years to 100 Years   (Adult, Older Adult)",QUESTIONNAIRE,SLEEP HYGIENE,Evaluation of the Sleep Hygiene in the Lebanese Population During the COVID-19 Confinement Period.
NCT04372056,Recruiting,Observational,,Oslo University Hospital,Other,6-May-20,6-May-21,6-May-21,COHORT,2200,COVID,NORWAY,ALL,"20 Years and older   (Adult, Older Adult)",VIEWS AND EXPERIENCES OF HEALTH CARE PROFESSIONALS WORKING IN INTENSIVE CARE UNITS DURING THE COVID-19 PANDEMIC,VIEWS AND EXPERIENCES OF HEALTH CARE PROFESSIONALS WORKING IN INTENSIVE CARE UNITS DURING THE COVID-19 PANDEMIC,A Norwegian Study on Views and Experiences of Health Care Professionals Working in Intensive Care Units During the COVID-19 Pandemic.
NCT04372082,Not yet recruiting,Interventional,Phase 3,"University Hospital, Lille",Other,20-May-21,23-May-21,23-May-21,TREATMENT,480,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OF CARE (SOC),DEATH,"Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial"
NCT04372186,"Active, not recruiting",Interventional,Phase 3,"Genentech, Inc.",Industry,14-May-20,1-Dec-21,18-Aug-20,TREATMENT,379,COVID PNEUMONIA,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,CUMULATIVE PROPORTION OF PARTICIPANTS REQUIRING MECHANICAL VENTILATION BY DAY 28,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia"
NCT04372199,Recruiting,Observational [Patient Registry],,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,29-Apr-20,27-May-20,27-May-20,COHORT,248,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,"TO IDENTIFY THE BEST PREDICTORS OF CRITICAL CORONAVIRUS PNEUMONIA AND TO REALIZE A SIMPLE SEVERITY SCORE ABLE TO EARLY CLASSIFY HIGH-RISK INDIVIDUALS ADMITTED TO INTERNAL MEDICINE DEPARTMENT FOR COVID-19 DISEASE, NEEDING AN INTENSIVE APPROACH",VALIDATION OF A SEVERITY SCORE TO IDENTIFY PATIENTS ADMITTED FOR COVID-19 PNEUMONIA AT HIGH RISK FOR AN INTENSIVE APPROACH
NCT04372368,No longer available,Expanded Access,,"University of Colorado, Denver",Other,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,,Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04372472,"Active, not recruiting",Observational,,"Cytovale, Inc.",Industry,7-Apr-20,29-May-20,29-May-20,COHORT,300,SEPSIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,TO DEMONSTRATE THE PERFORMANCE OF THE SEPTISCAN SYSTEM AS A DIAGNOSTIC MARKER OF LIFE-THREATENING ORGAN DYSFUNCTION CAUSED BY A DYSREGULATED HOST IMMUNE RESPONSE TO INFECTION.,SQuISH-COVID: A Pilot Study
NCT04372576,Recruiting,Observational,,Semmelweis University,Other,16-Apr-20,20-Aug-21,20-Aug-21,COHORT,30,VENTILATOR ASSOCIATED PNEUMONIA,HUNGARY,ALL,"18 Years and older   (Adult, Older Adult)",ASSESSMENT OF VENTILATOR-ASSOCIATED PNEUMONIA CRITERIA,28-DAY ALL-CAUSE MORTALITY,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients
NCT04372589,"Active, not recruiting",Interventional,Phase 2/Phase 3,University of Manitoba,Other,20-May-20,21-Jan-21,21-Jan-21,TREATMENT,1203,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HEPARIN,MORTALITY AND DAYS FREE OF ORGAN SUPPORT,"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)"
NCT04372602,Recruiting,Interventional,Phase 2,Washington University School of Medicine,Other,12-Oct-20,30-Apr-22,30-Nov-21,TREATMENT,28,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DUVELISIB,OVERALL SURVIVAL,A Pilot Study of Duvelisib to Combat COVID-19
NCT04372628,Recruiting,Interventional,Phase 2,Vanderbilt University Medical Center,Other,1-Jun-20,1-May-21,1-Apr-21,TREATMENT,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOPINAVIR/RITONAVIR 400 MG/100 MG,MODIFIED COVID ORDINAL OUTCOMES SCALE: STUDY DAY 15,Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19
NCT04372680,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,22-Apr-20,22-Sep-20,22-Sep-20,DIAGNOSTIC,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CTUS EXAMINATION,DELAY FROM THE START OF MECHANICAL VENTILATION WEANING PROCESS TO EXTUBATION,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial"
NCT04372693,Enrolling by invitation,Interventional,Not Applicable,Cairo University,Other,1-Sep-20,28-Feb-21,30-Jan-21,OTHER,180,DISTANCE LEARNING-ONLINE LEARNING,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",IMPLIMINTING ONLINE DISTANCE LEARNING,"STUDENTS' LEARNING PERCEPTION QUESTIONNAIRE (SLPQ),",Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement
NCT04372979,Recruiting,Interventional,Phase 3,Direction Centrale du Service de Santé des Armées,Other,14-Sep-20,21-Jun-21,21-May-21,TREATMENT,80,COVID,FRANCE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",TRANSFUSION OF SARS-COV-2 CONVALESCENT PLASMA.,SURVIVAL TIME WITHOUT NEEDS OF A VENTILATOR.,Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.
NCT04373005,"Active, not recruiting",Observational,,"University Health Network, Toronto",Other,11-May-20,30-Jun-21,30-Jun-21,COHORT,1000,COVID,CANADA,ALL,"Child, Adult, Older Adult",NASOPHARYNGEAL (NP) SWAB,RATE OF ASYMPTOMATIC COVID-19 INFECTION AMONG CANCER PATIENTS RECEIVING CANCER THERAPY,A Research Platform to Screen Patients in Oncology and Assess Impact - RESPONSE
NCT04373044,Recruiting,Interventional,Phase 2,University of Southern California,Other,1-May-20,1-May-22,1-May-21,TREATMENT,144,SYMPTOMATIC COVID INFECTION LABORATORY-CONFIRMED,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BARICITINIB,PROPORTION OF PATIENTS REQUIRING INVASIVE MECHANICAL VENTILATION OR DYING,A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
NCT04373096,Recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,7-Dec-20,31-Oct-21,31-Aug-21,PREVENTION,42,COVID,CANADA,ALL,"20 Years to 75 Years   (Adult, Older Adult)",CURRENT IPAC-UHN PPE,INCIDENCE OF CONTAMINATION OF ANY PART OF THE BASE CLOTHING OR EXPOSED SKIN OF THE UPPER BODY,Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures
NCT04373109,Completed,Observational,,Jeremia Held,Other,16-Apr-20,12-Oct-20,12-Oct-20,COHORT,36,STROKE,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION,REHABILITATION DATA,Stroke Rehabilitation Outcome During COVID-19 Lockdown
NCT04373135,"Active, not recruiting",Interventional,Not Applicable,"University of California, Los Angeles",Other,8-May-20,21-Mar-21,21-Feb-21,HEALTH SERVICES RESEARCH,2500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BRIEF EDUCATIONAL VIDEO,IMPROVEMENT IN KNOWLEDGE SURROUNDING SRA POLICY,A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.
NCT04373148,Recruiting,Observational,,Stanford University,Other,8-Apr-20,30-Apr-22,30-Apr-22,CASE-CONTROL,1000,CORONAVIRUS,UNITED STATES,ALL,"2 Years and older   (Child, Adult, Older Adult)",THERE IS NO INTERVENTION,TESTING IMMUNITY TO SARS-COV-2 OVER TIME,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19"
NCT04373161,Completed,Interventional,Not Applicable,Swedish Hospital,Other,20-Mar-20,22-Apr-20,22-Apr-20,DIAGNOSTIC,209,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HOME PULSE OXIMETRY MONITORING,HOSPITALIZATION IN COVID-19 PATIENTS WITH LOW HOME SPO2,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression
NCT04373200,Recruiting,Interventional,Not Applicable,Rennes University Hospital,Other,25-May-20,25-Nov-20,25-Nov-20,OTHER,75,SARS-COV2 CORONAVIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES COLLECTION,NUMBER OF INCREASED IMMUNE POPULATION,Human Ab Response & immunoMONItoring of COVID-19 Patients
NCT04373213,Not yet recruiting,Observational,,Erzincan University,Other,5-May-20,15-Jun-20,5-Jun-20,CASE-CONTROL,30,PLETH VARIABILITY INDEX,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",PLETH VARIABILITY INDEX,PLETH VARIABILITY INDEX,Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index
NCT04373291,"Active, not recruiting",Interventional,Phase 3,Bandim Health Project,Other,18-May-20,31-Dec-21,31-Jul-21,PREVENTION,1293,COVID,DENMARK,ALL,"18 Years to 100 Years   (Adult, Older Adult)",BCG-DENMARK,NUMBER OF DAYS OF UNPLANNED ABSENTEEISM FOR ANY REASON,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial
NCT04373382,"Active, not recruiting",Interventional,Not Applicable,"Mount Sinai Hospital, Canada",Other,27-Jul-20,22-Feb-21,22-Feb-21,PREVENTION,882,BURNOUT,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PEER RESILIENCE CHAMPION,CHANGE IN INSTANCES OF BURNOUT FOR HOSPITAL STAFF DUE TO THE PEER RESILIENCE CHAMPION INTERVENTION,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic
NCT04373460,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,3-Jun-20,31-Jan-23,21-Dec-22,TREATMENT,1344,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 CONVALESCENT PLASMA,CUMULATIVE INCIDENCE OF HOSPITALIZATION OR DEATH PRIOR TO HOSPITALIZATION,Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19
NCT04373486,Completed,Observational,,"University Hospital, Strasbourg, France",Other,3-Mar-20,1-May-20,30-Apr-20,CASE-ONLY,160,COVID WITH POSITIVE RT-PCR,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF POSITIVITY FOR ACUTE PULMONARY EMBOLISM,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels
NCT04373707,Recruiting,Interventional,Phase 4,"Central Hospital, Nancy, France",Other,13-May-20,21-Nov-21,21-Nov-21,PREVENTION,602,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,VENOUS THROMBOEMBOLISM,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE
NCT04373733,Recruiting,Interventional,Phase 3,Chelsea and Westminster NHS Foundation Trust,Other,1-May-20,31-Mar-21,31-Mar-21,TREATMENT,500,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,TIME TO IMPROVEMENT BY TWO POINTS ON A SEVEN-CATEGORY ORDINAL SCALE,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe
NCT04373759,Completed,Observational [Patient Registry],,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Other,2-May-20,30-Sep-20,30-Sep-20,COHORT,186,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CARDIOPULMONARY RESUSCITATION,INCIDENCE OF UNEXPECTED CARDIAC ARREST,Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs
NCT04373798,Recruiting,Observational,,Henning Bliddal,Other,4-May-20,30-Nov-20,30-Nov-20,COHORT,3000,CORONAVIRUS INFECTION,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",C-REACTIVE PROTEIN,HOSPITALISATION,Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study
NCT04373811,"Active, not recruiting",Observational,,Groupe Hospitalier Paris Saint Joseph,Other,16-Apr-20,13-Jul-21,13-Jul-21,COHORT,60,COVID,FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",LUNG ULTRASOUND,MEAN IN QUALITY OF LIFE SCORE AT ONE YEAR ON THE SHORT FORM HEALTH SURVEY (SF-36),Quality of Life and Functional Prognosis at One Year of Patients With COVID-19 Admitted in Post-ICU Setting
NCT04373824,Recruiting,Interventional,Not Applicable,Max Healthcare Insititute Limited,Other,25-Apr-20,25-Jul-20,25-Jul-20,TREATMENT,50,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",IVERMECTIN,EFFECT OF IVERMECTIN ON ERADICATION OF VIRUS.,To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study
NCT04373889,"Active, not recruiting",Observational,,Sciensano,Other,22-Apr-20,30-Apr-21,30-Apr-21,COHORT,850,SARS-COV2,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE OF PREVALENCE OF COVID-19 INFECTION AMONG BELGIAN ACTIVE HOSPITAL HEALTHCARE WORKERS (HCW),"SARS-COV-2 Prevalence, Seroprevalence and Seroconversion Among Healthcare Workers in Belgium During the 2020 COVID-19 Outbreak"
NCT04374019,Recruiting,Interventional,Phase 2,Susanne Arnold,Other,1-May-20,21-May-21,21-May-21,TREATMENT,240,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",IVERMECTIN,CLINICAL DETERIORATION,"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients"
NCT04374032,Completed,Interventional,Phase 2/Phase 3,Bosnalijek D.D,Industry,1-May-20,3-Nov-20,7-Oct-20,TREATMENT,120,COVID INFECTION,BOSNIA AND HERZEGOVINA,ALL,"18 Years and older   (Adult, Older Adult)",METENKEFALIN + TRIDECACTIDE,TIME TO ONSET OF CHANGE IN THE PATIENT'S CLINICAL CONDITION,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection"
NCT04374045,Completed,Observational [Patient Registry],,Centre Hospitalier Universitaire de Saint Etienne,Other,30-Apr-20,18-Jun-20,17-Jun-20,COHORT,50,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ECG-HOLTER,PERCENTAGE OF DYSAUTONOMIA PATIENTS FOUND WITHIN THE FIRST 24 HOURS OF HOSPITALIZATION (%),Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study
NCT04374058,"Active, not recruiting",Observational,,Dialisis Madariaga,Other,20-Mar-20,21-Mar-21,21-Mar-21,CASE-CONTROL,50,END STAGE RENAL DISEASE,ARGENTINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",LESS-FREQUENCY HEMODIALYSIS,MORTALITY,Reduced Frequency Hemodialysis in Prevalent Patients Due to the Coronavirus Disease
NCT04374071,Completed,Observational,,Henry Ford Health System,Other,12-Mar-20,30-Apr-20,27-Mar-20,COHORT,250,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,TRANSFER TO INTENSIVE CARE UNIT (ICU),Early Short Course Corticosteroids in Hospitalized Patients With COVID-19
NCT04374084,Recruiting,Interventional,Not Applicable,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Other,10-May-20,21-Dec-21,21-Dec-21,TREATMENT,60,COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MOXIBUSTION PLUS CUPPING,THE CHANGE OF THE AVERAGE VAS SCORE FROM BASELINE TO WEEK 4,Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial
NCT04374097,Completed,Observational,,University of Oslo,Other,31-Mar-20,7-Apr-20,7-Apr-20,OTHER,1778,POST TRAUMATIC STRESS DISORDER,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",,PTSD CHECKLIST FOR DSM-5 (PCL-5),Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak
NCT04374110,Recruiting,Observational [Patient Registry],,"Institute of Cardiology, Warsaw, Poland",Other,5-May-20,24-Aug-21,24-Jun-20,CASE-CONTROL,1000,COVID,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",CLINICAL DATA,ADVERSE EVENTS,Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19
NCT04374123,Completed,Observational,,Instituto Ecuatoriano de Enfermedades Digestivas,Other,20-Apr-20,15-Jun-20,20-May-20,COHORT,111,COVID,ECUADOR,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SEROLOGICAL SCREENING FOR IGG AND IGM ANTIBODIES AGAINST COVID-19,RATE OF COVID-19 NOSOCOMIAL INFECTION AMONG THE ENDOSCOPY STAFF AT THE END OF THE 30-DAYS STUDY.,COVID-19 Serologic Screening and a Strict Protocol in the Management of a Referral Gastrointestinal Endoscopy Unit: a Prospective Study
NCT04374149,"Active, not recruiting",Interventional,Phase 2,Prisma Health-Upstate,Other,30-Apr-20,1-Dec-20,25-Sep-20,TREATMENT,20,CYTOKINE RELEASE SYNDROME,UNITED STATES,ALL,"12 Years to 80 Years   (Child, Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE,OVERALL RESPONSE RATE,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)"
NCT04374279,Not yet recruiting,Interventional,Phase 2,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Other,21-Apr-21,22-Jan-21,22-Jan-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BICALUTAMIDE 150 MG ORAL TABLET,PERCENTAGE OF PARTICIPANTS WHO HAVE CLINICAL IMPROVEMENT AT DAY 7 AFTER RANDOMIZATION,A Phase II Trial to Promote Recovery From COVID-19 With Endocrine Therapy
NCT04374370,Available,Expanded Access,,AdventHealth,Other,,,,,,COVID,UNITED STATES,ALL,"6 Years to 99 Years   (Child, Adult, Older Adult)",SARSCOV2 CONVALESCENT PLASMA,,Severe Acute Respiratory Syndrome Coronavirus 2 of the Genus Betacoronavirus (SARSCoV2) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
NCT04374422,Completed,Observational,,Acibadem University,Other,10-Apr-20,12-Apr-20,12-Apr-20,COHORT,58,SEXUAL BEHAVIOR,TURKEY,FEMALE,"18 Years and older   (Adult, Older Adult)",FSFI SURVEY,FSFI (FEMALE SEXUAL FUNCTION INDEX)SCORE DIFFERENCE,Effect of SARS- COVID-19 Pandemic on Female Sexual Behavior
NCT04374461,Recruiting,Interventional,Phase 2,Memorial Sloan Kettering Cancer Center,Other,1-May-20,22-May-21,22-May-21,TREATMENT,84,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",N-ACETYLCYSTEINE,ARM A: NUMBER OF PATIENTS WHO ARE SUCCESSFULLY EXTUBATED AND/OR TRANSFERRED OUT OF CRITICAL CARE DUE TO CLINICAL IMPROVEMENT,Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection
NCT04374474,Withdrawn,Interventional,Phase 4,Lawson Health Research Institute,Other,10-Jan-21,10-Mar-22,10-Dec-21,TREATMENT,0,OLFACTORY DISORDER,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",OLFACTORY RETRAINING,CHANGE FROM BASELINE SNAP AND SNIFF THRESHOLD TEST AT 3 MONTHS,Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial
NCT04374487,"Active, not recruiting",Interventional,Phase 2,Max Healthcare Insititute Limited,Other,9-May-20,9-Aug-21,9-Aug-21,TREATMENT,100,COVID,INDIA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,THE PRIMARY OUTCOME IS A COMPOSITE MEASURE OF THE AVOIDANCE OF - 1. PROGRESSION TO SEVERE ARDS (P/F RATIO 100) AND 2. ALL-CAUSE MORTALITY AT 28 DAYS,"A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications"
NCT04374513,Completed,Observational,,Damanhour University,Other,2-Apr-20,1-Jul-20,1-Jun-20,OTHER,318,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,COMMUNITY PHARMACISTS FACING COVID-19,"SURVEY of RETAIL PHARMACISTS KNOWLEDGE, ROLE & BEHAVIOR DURING COVID-19 VIRUS OUTBREAK"
NCT04374526,Recruiting,Interventional,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,27-May-20,30-Jun-21,30-Apr-21,PREVENTION,182,CORONAVIRUS DISEASE 2019 )COVID),ITALY,ALL,65 Years and older   (Older Adult),COVID-19 CONVALESCENT PLASMA,RATE OF COVID-19 PROGRESSION,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.
NCT04374539,Recruiting,Interventional,Phase 2,Fundacion Clinic per a la Recerca Biomédica,Other,29-Apr-20,29-Aug-21,5-May-21,TREATMENT,116,CORONAVIRUS,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PLASMA EXCHANGE,IMPACT OF PLASMA EXCHANGE,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial
NCT04374552,Withdrawn,Interventional,Phase 2,"Rutgers, The State University of New Jersey",Other,5-May-20,21-Apr-21,20-Nov-21,TREATMENT,0,SARS-COV2 INFECTION,UNITED STATES,ALL,"20 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE &AZITHROMYCIN,THE PRIMARY OUTCOME IS THE RATE OF DECLINE IN VIRAL LOAD OVER THE 10 DAYS AFTER RANDOMIZATION,RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics
NCT04374565,"Active, not recruiting",Interventional,Phase 2,University of Virginia,Other,5-May-20,5-Apr-21,5-Apr-21,TREATMENT,29,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HIGH-TITER ANTI-SARS-COV-2 (COVID 19) CONVALESCENT PLASMA,TRANSFER TO ICU,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial
NCT04374591,"Active, not recruiting",Interventional,Not Applicable,Mansoura University,Other,1-Aug-20,1-Nov-20,1-Nov-20,TREATMENT,180,PNEUMONIA,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SODIUM BICARBONATE,TIME TO CLINICAL RECOVERY,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up
NCT04374617,Completed,Observational,,Hospital Universitari Vall d'Hebron Research Institute,Other,1-Apr-20,1-May-20,25-Apr-20,COHORT,230,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",DUPLEX ULTRASOUND AND COMPUTED TOMOGRAPHY ANGIOGRAPHY,VENOUS THROMBOEMBOLISMS,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
NCT04374643,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Dec-21,1-Dec-21,COHORT,500,DEPRESSION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SLEF QUESTIONNAIRES FULFILMENT,DEPRESSIVE SYMPTOMATOLOGY,Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population : PsyConfPop
NCT04374656,Recruiting,Observational,,Johns Hopkins University,Other,18-May-20,21-May-21,21-May-21,COHORT,50,CONJUNCTIVITIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PROPORTION OF CONJUNCTIVAL SAMPLES TESTED POSITIVE FOR SARS-COV-2,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting With Conjunctivitis to the Ophthalmology Clinics During the COVID-19 Pandemic
NCT04374695,Not yet recruiting,Observational,,Versailles Hospital,Other,1-May-20,1-Jul-20,1-Jun-20,CASE-CONTROL,700,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,PRIOR TREATMENT BY ACEI,"Association Between Hypertension, Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19"
NCT04374786,Enrolling by invitation,Interventional,Not Applicable,University of Arizona,Other,15-May-20,1-Oct-20,1-Sep-20,SUPPORTIVE CARE,328,PERCEIVED STRESS,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CALM MEDITATION APP,PERCEIVED STRESS SCALE,Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix
NCT04374838,Recruiting,Observational,,South Egypt Cancer Institute,Other,15-May-20,1-Sep-21,1-Aug-20,COHORT,20,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,PEDIATRIC CANCER CARE PATTERN DURING COVID 19 PANDEMIC,Effect of COVID-19 Pandemic on Pediatric Cancer Care
NCT04374903,Not yet recruiting,Interventional,Not Applicable,King Hussein Cancer Center,Other,1-May-20,1-Sep-20,1-Aug-20,TREATMENT,58,COVID PATIENTS,JORDAN,ALL,"18 Years and older   (Adult, Older Adult)",HCQ & AZ VS HCQ+SIR,TIME TO CLINICAL IMPROVEMENT (TTCI),"Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients: A Pilot, Multicenter Randomized Open-Label Trial"
NCT04374942,Enrolling by invitation,Interventional,Phase 3,Megan Landes,Other,30-Apr-20,30-Jan-22,27-Aug-20,PREVENTION,988,PRE-EXPOSURE PROPHYLAXIS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,MICROBIOLOGICALLY CONFIRMED COVID-19 (SARS-COV-2 INFECTION),"Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada"
NCT04375046,Not yet recruiting,Interventional,Phase 1,Kafrelsheikh University,Other,20-Sep-21,20-Oct-21,20-Sep-21,TREATMENT,24,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RECOMBINANT BACTERIAL ACE2 RECEPTORS -LIKE ENZYME OF B38-CAP (RBACE2),TIME COURSE OF BODY TEMPERATURE (FEVER),Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2
NCT04375098,Completed,Interventional,Phase 2,Pontificia Universidad Catolica de Chile,Other,4-May-20,17-Aug-20,17-Aug-20,TREATMENT,58,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,"PERCENTAGE MECHANICAL VENTILATION, HOSPITALIZATION LONGER THAN 14 DAYS OR DEATH DURING HOSPITALIZATION",Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial
NCT04375124,Recruiting,Interventional,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,Other,25-Apr-20,30-Sep-20,31-Aug-20,TREATMENT,20,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL/VACCINE: ANGIOTENSIN PEPTIDE (1-7) DERIVED PLASMA,MORTALITY,Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19
NCT04375137,Recruiting,Observational,,Shahid Beheshti University of Medical Sciences,Other,20-Apr-20,30-May-21,1-Apr-21,CASE-CONTROL,90,OXIDATIVE STRESS,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",OXIDATIVE STRESS ELISA KIT,MDA CONCENTRATION,Correlation Between Oxidative Stress Markers and COVID-19 Severity Index
NCT04375176,Recruiting,Observational,,Università degli Studi dell'Insubria,Other,27-Apr-20,31-Oct-20,30-Jun-20,CASE-ONLY,150,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",STUDY OF IMMUNE-MEDIATED MECHANISMS IN PATIENTS TESTED POSITIVE FOR SARS-COV-2,IMMUNE CELLS ACTIVITY,Study of Immune-mediated Mechanisms in Patients Tested Positive for SARS-CoV-2: Phenotypic and Functional Analysis of Monocytes and NK Cells in the Blood of Subjects Affected by Covid 19
NCT04375202,Recruiting,Interventional,Phase 2,University Of Perugia,Other,18-Apr-20,31-Oct-21,30-Jun-21,TREATMENT,308,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE 1 MG ORAL TABLET,RATE OF ENTERING THE CRITICAL STAGE,Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study
NCT04375397,Recruiting,Interventional,Phase 2,AbbVie,Industry,6-Jun-20,25-Aug-21,19-Mar-21,TREATMENT,46,CORONAVIRUS INDUCED DISEASE-2019 (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IBRUTINIB,PERCENTAGE OF PARTICIPANTS ALIVE AND WITHOUT RESPIRATORY FAILURE,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE)
NCT04375410,Enrolling by invitation,Observational,,Vendsyssel Hospital,Other,22-Apr-20,1-May-20,30-Apr-20,COHORT,7000,HAND ECZEMA,DENMARK,ALL,up to 13 Years   (Child),,DERMAL REACTION TO FREQUENT HAND WASH AND DISINFECTION IN CHILDREN,Re-opening of the Country and Dermal Consequences of Mandatory Intensified Handwash and Hand Disinfection Among a Danish Pediatric Population During the COVID19 Pandemic
NCT04375501,Completed,Observational,,Barts & The London NHS Trust,Other,1-Feb-20,15-Apr-20,15-Apr-20,COHORT,442,FEMORAL NECK FRACTURES,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)","SURGERY: DYNAMIC HIP SCREW, HEMIARTHROPLASTY, HIP REPLACEMENT, INTRAMEDULLARY NAIL",MORTALITY,The Effects of Coronavirus on Perioperative Morbidity and Mortality in a High-risk Population: A Multicentre Cohort Study
NCT04375644,Completed,Observational,,Hospices Civils de Lyon,Other,7-May-20,15-Jul-20,15-Jul-20,COHORT,1565,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES ON PSYCHOLOGICAL QUALITY OF LIFE,"STRESS STATE SCORE, DURING THE CONFINEMENT PERIOD",Impact of the COVID-19 Pandemic on the Quality of Psychological Life of Healthcare Professionals
NCT04375670,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,11-May-20,31-Dec-20,31-Dec-20,COHORT,1000,LIVER DISEASES,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,MORTALITY RATE RELATED TO COVID-19 IN PATIENTS WITH A CHRONIC LIVER DISEASE,COVID19-FOIE National Observatory. An Ambispective Cohort Study of All Consecutive Patients
NCT04375709,Recruiting,Observational,,Kantonsspital Winterthur KSW,Other,15-Mar-20,31-Aug-21,30-Jun-21,COHORT,60,COVID (NEW CORONAVIRUS) INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",PHYSICAL EXERCISE,HEALTH-RELATED QUALITY OF LIFE; EUROQOL (EQ-5D-5L),Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study
NCT04375735,Not yet recruiting,Interventional,Phase 1/Phase 2,Lawson Health Research Institute,Other,1-Jul-20,1-Jul-21,1-Jan-21,TREATMENT,20,"ARDS, HUMAN",,ALL,"18 Years and older   (Adult, Older Adult)",BOVINE LIPID EXTRACT SURFACTANT,ADVERSE EVENTS (PATIENT) - DECREASE IN OXYGENATION,Phase I/II Trial: Exogenous Surfactant Administration for Patients With COVID-19
NCT04375748,Recruiting,Observational,,"University Hospital, Toulouse",Other,15-Apr-20,15-Oct-21,15-Oct-21,COHORT,400,ACUTE MYOCARDITIS,FRANCE,ALL,"Child, Adult, Older Adult",PERFORMING ROUTINE CARE (CLINICAL AND PARACLINICAL TESTS),EVOLUTION OF THE PROPORTION OF POSITIVE SARS-COV-2 CASES.,"Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 Cases During the Covid-19 Pandemic, Case Characteristics and Prognoses"
NCT04375761,Completed,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1-May-20,24-Jan-21,24-Jan-21,FAMILY-BASED,5599,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"Child, Adult, Older Adult",COLLECTION OF BIOLOGICAL SAMPLES,CUMULATIVE INCIDENCE OF SARS-COV-2 RNA DETECTION IN NASAL SAMPLES AMONG INDEX PARTICIPANTS AND THEIR HOUSEHOLD CONTACTS OVER THE STUDY/SURVEILLANCE PERIOD,Human Epidemiology and Response to SARS-CoV-2 (DAIT-COVID-19-001)
NCT04375774,Recruiting,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,20-May-21,20-May-21,20-May-21,PREVENTION,10,COVID,BELGIUM,ALL,18 Years to 60 Years   (Adult),FFP2,EVALUATION OF AIRTIGHTNESS (FIT TEST),Verification of Alternative Do-it-yourself Equipment Respirators
NCT04376034,Recruiting,Interventional,Phase 3,West Virginia University,Other,16-Apr-20,30-Mar-21,30-Mar-21,TREATMENT,240,COVID,UNITED STATES,ALL,"31 Days and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA 1 UNIT,PLASMA DONOR,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma
NCT04376398,Completed,Observational [Patient Registry],,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,6-Apr-20,30-Aug-20,30-Jun-20,CASE-ONLY,200,COVID,BELGIUM,ALL,"up to 100 Years   (Child, Adult, Older Adult)",,GLOBAL EVALUATION OF THE IMPLICATION OF THE BELGIAN ANESTHESIOLOGISTS DURING COVID-19 PANDEMIC,Survey on Patients With Suspected or Confirmed COVID-19 Requiring Anesthesia Care for Their Intervention
NCT04376476,Recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,5-May-20,5-Jun-21,5-Jun-21,OTHER,450,"INFECTION, CORONAVIRUS",FRANCE,ALL,"up to 70 Years   (Child, Adult, Older Adult)",BLOOD SAMPLE,INITIAL BIOLOGICAL PROFILE OF CHILDREN AND ADULTS WITH COVID-19 INFECTION,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19)
NCT04376515,"Active, not recruiting",Interventional,Not Applicable,"University of California, Irvine",Other,20-Mar-20,1-Sep-21,1-Jun-21,SUPPORTIVE CARE,300,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HOPE INTERVENTION,ANXIETY,HOPE Intervention for COVID-19
NCT04376580,Enrolling by invitation,Observational,,Tiva Group,Other,30-Apr-20,30-Nov-20,31-Oct-20,ECOLOGIC OR COMMUNITY,100,COVID,ARGENTINA,ALL,"Child, Adult, Older Adult",,NUMBER OF PHYSICIAN USING LOS FLOW NASAL CANNULA DURING COVID 19 PANDEMIA,Incidence and Implications With the Use of Nasal Cannulas During COVID-19
NCT04376593,Enrolling by invitation,Interventional,Early Phase 1,"University of California, Davis",Other,1-May-20,22-May-21,21-May-21,DIAGNOSTIC,10,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",18F-ΑVΒ6-BP,ADMINISTRATION OF 18F-ΑVΒ6-BP,18F-αvβ6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection
NCT04376658,Recruiting,Observational,,Hospital Moinhos de Vento,Other,15-Jul-20,15-Jul-22,15-Apr-22,COHORT,1000,QUALITY OF LIFE,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19,ONE-YEAR UTILITY SCORE OF HEALTH-RELATED QUALITY OF LIFE,Assessment of Health-related Quality of Life and Long-term Outcomes After Hospitalization for COVID-19: A Multicenter Prospective Cohort Study
NCT04376684,"Active, not recruiting",Interventional,Phase 2,GlaxoSmithKline,Industry,28-May-20,13-Jan-21,13-Jan-21,TREATMENT,800,SEVERE ACUTE RESPIRATORY SYNDROME,ARGENTINA,ALL,"18 Years to 79 Years   (Adult, Older Adult)",OTILIMAB,PROPORTION OF PARTICIPANTS ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 28,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease"
NCT04376710,Completed,Observational,,"University of Colorado, Denver",Other,1-Jul-20,1-Oct-20,1-Oct-20,OTHER,180,COVID,UNITED STATES,ALL,"31 Days to 18 Years   (Child, Adult)",COMPLETION OF PRE-PANDEMIC SURVEY,EVALUATE SURGEON PERCEPTIONS TO TELEMEDICINE AND PERCEIVED BARRIERS TO IMPLEMENTATION,Surgical Telemedicine in the COVID-19 Pandemic Era
NCT04376775,"Active, not recruiting",Observational,,"University Hospital, Bordeaux",Other,11-May-20,11-Dec-20,11-Dec-20,COHORT,3602,TRANSPLANTATION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TRANSPLANT PATIENT,COMPLIANCE PRECAUTIONS WITH COVID-19,Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation
NCT04376788,Recruiting,Interventional,Phase 2,Ain Shams University,Other,20-May-20,1-Sep-20,1-Jul-20,TREATMENT,15,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EXCHANGE BLOOD TRANSFUSION FROM NORMAL DONOR,IMPROVEMENT OF CONDITION,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19
NCT04376814,Completed,Interventional,Not Applicable,Baqiyatallah Medical Sciences University,Other,29-Mar-20,25-May-20,5-Apr-20,TREATMENT,40,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",FAVIPIRAVIR,MORTALITY,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study"
NCT04376840,Recruiting,Interventional,Not Applicable,CHU de Reims,Other,28-May-20,28-Oct-22,28-Jan-22,DIAGNOSTIC,270,SEVERE SARS-COV2 PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE AND DATA RECORD,MEDIUM-TERM RESPIRATORY COMPLICATIONS,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia
NCT04376853,Recruiting,Observational,,University Hospital Heidelberg,Other,15-Apr-20,20-Jul-21,20-Jun-21,COHORT,50,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",APPLE WATCH SERIES 5,BIOMARKER,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch
NCT04376879,Recruiting,Observational,,"Central Hospital, Nancy, France",Other,16-May-20,22-May-21,22-May-21,COHORT,384,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA MONITORING FOR 48H WITHIN THE FIRST 24 HOURS OF ADMISSION FOR COVID-19,THE NUMBER OF INTUBATIONS IN COVID-19 PATIENTS INITIALLY HOSPITALISED IN WARDS,Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19)
NCT04376905,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Sep-20,1-Sep-20,COHORT,30,COVID,FRANCE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,CHANGES OF EXTRA VASCULAR LUNG WATER,Assessment of Extra Vascular Lung Water and Pulmonary Permeability by Transpulmonary Thermodilution in Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04376944,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Dec-20,1-Dec-20,CASE-CONTROL,300,CAREGIVERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,PROPORTION OF CAREGIVERS AND AGENTS WITH A POSITIVE SERODIAGNOSIS,Evaluating Effectiveness of Barrier Measures to Limit Nosocomial Transmission: Covid-19 Prevalence Survey Among Caregivers With Various Exposures
NCT04376996,Recruiting,Observational,,University of Ljubljana,Other,20-Apr-20,20-Dec-21,20-Oct-21,COHORT,3000,COVID,SLOVENIA,ALL,"Child, Adult, Older Adult",NO INTERVENTION PLANNED DUE TO THE OBSERVATIONAL STUDY DESIGN - ONLY A DIAGNOSTIC TESTING,PREVALENCE OF SARS-COV-2 RNA IN NASOPHARYNGEAL SAMPLES,Slovenian National COVID-19 Prevalence Study
NCT04377035,Recruiting,Observational,,"University Hospital, Gentofte, Copenhagen",Other,31-Mar-20,1-Mar-21,1-Mar-21,COHORT,1000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY DURING HOSPITALIZATION AND A CONFIRMED COVID-19 DIAGNOSIS,The ECHOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart and Lung by Ultrasound
NCT04377074,Completed,Observational,,University of Oslo,Other,31-Mar-20,7-Apr-20,7-Apr-20,OTHER,2880,PARENTAL STRESS,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",,MEASURE OF PARENTAL STRESS,Parenting in a Pandemic: Parental Stress During the COVID-19 and Its Association With Depression and Anxiety
NCT04377100,Recruiting,Interventional,Not Applicable,National Institute of Mental Health (NIMH),NIH,4-Mar-21,28-Feb-22,28-Feb-22,BASIC SCIENCE,5000,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COMPUTER TASK QUESTIONNAIRES,PATTERNS OF NEURAL CONNECTIVITY AS PREDICTORS,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses
NCT04377165,Terminated,Interventional,Not Applicable,The University of Queensland,Other,6-May-20,26-Aug-20,26-Aug-20,PREVENTION,34,COVID,,ALL,"18 Years to 90 Years   (Adult, Older Adult)",GAMIFICATION,TO COMPARE THE HOURS OF SICK LEAVE USED OVER THE COURSE OF THE 4-WEEK PERIOD POST RANDOMISATION FOR EACH GROUP,Innovative Tool to Limit Spread of SARS-CoV-2(COVID 19) in Residential Aged Care
NCT04377308,Recruiting,Interventional,Phase 4,University of Toledo Health Science Campus,Other,1-May-20,20-Oct-21,20-Apr-21,TREATMENT,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FLUOXETINE,HOSPITALIZATIONS,Fluoxetine to Reduce Intubation and Death After COVID19 Infection
NCT04377334,Not yet recruiting,Interventional,Phase 2,University Hospital Tuebingen,Other,20-Oct-21,21-Jul-21,21-Apr-21,TREATMENT,40,ARDS,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",MSC,LUNG INJURY SCORE,Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS
NCT04377412,Recruiting,Observational,,"Żelazna Medical Centre, LLC",Other,1-May-20,31-Oct-20,31-Aug-20,ECOLOGIC OR COMMUNITY,8500,ANXIETY,ALBANIA,FEMALE,"18 Years and older   (Adult, Older Adult)",PANDEMIC CONTROL MEASURES,ANXIETY,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic - a Web-based Cross-sectional Survey
NCT04377425,Withdrawn,Observational,,Aarhus University Hospital,Other,7-May-20,30-Jun-22,29-Nov-20,COHORT,0,NEUROLOGICAL DISEASES OR CONDITIONS,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 SWAP TEST PCR,PREVALENCE OF COVID-19 INFECTION IN CONSECUTIVE PATIENTS WITH NEUROLOGICAL SYMPTOMS,"COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms"
NCT04377464,Not yet recruiting,Observational,,Chinese University of Hong Kong,Other,5-May-20,30-Apr-22,30-Apr-21,COHORT,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","SF12, EQ-5D-5L AND WORK STATUS STANDARDIZED QUANTITATIVE ASSESSMENTS",SIX-MONTH SF-12V2(HK) SCORES,COVID-19 - Quality of Life After Infection
NCT04377477,Recruiting,Interventional,Not Applicable,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,Other,10-May-20,30-Aug-22,10-Aug-21,TREATMENT,30,COVID,ITALY,ALL,"50 Years and older   (Adult, Older Adult)",SINGLE FRACTION WHOLE LUNG RADIOTHERAPY,LENGHT OF HOSPITAL STAY (DAYS),Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19)
NCT04377490,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,4-May-20,20-Nov-21,20-Oct-21,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",VENOUS ULTRASOUND,VARIATION OF THROMBIN TIME (IN SECONDES) IN HOSPITALIZED COVID-19 PATIENTS,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy
NCT04377503,Not yet recruiting,Interventional,Phase 2,Hospital Sao Domingos,Other,20-May-21,20-Nov-21,20-Aug-21,TREATMENT,40,CYTOKINE RELEASE SYNDROME,,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB 180 MG/ML,PATIENT CLINICAL STATUS 15 DAYS AFTER RANDOMIZATION,Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial
NCT04377568,Recruiting,Interventional,Phase 2,The Hospital for Sick Children,Other,7-Oct-20,1-May-22,1-Dec-21,TREATMENT,100,HOSPITALIZED CHILDREN,CANADA,ALL,"up to 18 Years   (Child, Adult)",CONVALESCENT PLASMA (CP),CLINICAL RECOVERY,"A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children"
NCT04377581,Completed,Observational,,Milton S. Hershey Medical Center,Other,9-Apr-20,10-Jul-20,10-Jul-20,ECOLOGIC OR COMMUNITY,18251,PUBLIC HEALTH,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,KNOWLEDGE AND CONFIDENCE IN KNOWLEDGE OF COVID-19,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior"
NCT04377607,Recruiting,Observational,,Nevsehir Public Hospital,Other,1-Nov-20,30-Dec-20,20-Nov-20,OTHER,200,CORONAVIRUS INFECTION,TURKEY,ALL,"Child, Adult, Older Adult",FILE SCANNING,RELATIONSHIP BETWEEN SEVERITY OF DISEASE AND VALUES OF ERYTHROCYTE INDICES,An Important Index on Severity of Coronavirus Disease: Erythrocyte Haemoglobin Concentration
NCT04377620,Recruiting,Interventional,Phase 3,Incyte Corporation,Industry,24-May-20,30-Apr-21,30-Apr-21,TREATMENT,500,COVID,RUSSIAN FEDERATION,ALL,"12 Years and older   (Child, Adult, Older Adult)",PLACEBO,PROPORTION OF PARTICIPANTS WHO HAVE DIED DUE TO ANY CAUSE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)"
NCT04377646,Not yet recruiting,Interventional,Phase 3,Military Hospital of Tunis,Other,4-May-20,31-Jul-20,24-May-20,PREVENTION,660,SARS-COV2,TUNISIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,SARS COV2 INFECTION,A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)
NCT04377659,"Active, not recruiting",Interventional,Phase 2,Memorial Sloan Kettering Cancer Center,Other,1-May-20,1-May-22,1-May-22,TREATMENT,9,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,PROGRESSION OF RESPIRATORY FAILURE OR DEATH,A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
NCT04377672,Recruiting,Interventional,Phase 1,Johns Hopkins University,Other,28-May-20,28-May-22,28-May-21,TREATMENT,30,CORONAVIRUS INFECTION,UNITED STATES,ALL,"1 Month to 18 Years   (Child, Adult)",ANTI-SARS-COV-2 HUMAN CONVALESCENT PLASMA,SAFETY OF TREATMENT WITH HIGH-TITER ANTI-SARS-COV-2 PLASMA AS ASSESSED BY ADVERSE EVENTS,Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2
NCT04377685,Recruiting,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,1-Mar-20,30-Jun-21,30-Jun-21,COHORT,800,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CT-SCAN,DIAGNOSTIC OF COVID DISEASE COMPOSITE,"Prediction of Clinical Course in COVID19 Patients Using Unsupervised Classification Approaches of Clinical, Biological and the Multiparametric Signature of the Chest CT Scan Performed at Admission"
NCT04377711,Recruiting,Interventional,Phase 3,Covis Pharma S.à.r.l.,Industry,8-Jun-20,1-Dec-20,1-Sep-20,TREATMENT,400,COVID,UNITED STATES,ALL,"12 Years to 100 Years   (Child, Adult, Older Adult)",CICLESONIDE,PERCENTAGE OF PATIENTS HOSPITAL ADMISSION OR DEATH BY DAY 30,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection"
NCT04377724,"Active, not recruiting",Observational,,Goldhahn Jörg,Other,27-Apr-20,30-Jun-21,30-Jun-21,COHORT,3000,COVID,SWITZERLAND,ALL,18 Years to 64 Years   (Adult),,"SEROPREVALENCE AS WELL AS THE TITER OF SERUM ANTIBODIES (IGM, IGG AND IGA) TARGETING SARS-COV-2 ANTIGENS",Longitudinal Serological Study on the Spread and Course of COVID-19 Infections
NCT04377737,Withdrawn,Interventional,Not Applicable,Fondation Lenval,Other,15-May-20,20-Sep-21,20-Aug-21,DIAGNOSTIC,0,"INFECTION; VIRAL, CORONAVIRUS",FRANCE,ALL,3 Years to 10 Years   (Child),RT-PCR COVID-19,EVALUATION OF THE PREVALENCE OF POSITIVE REAL-TIME-POLYMERASE CHAIN REACTION (RT-PCR) IN SCHOOL CHILDREN DURING THE PANDEMIC PERIOD IN NICE,Incidence of Covid-19 in School Children During the Pandemic Period in Nice
NCT04377750,Recruiting,Interventional,Phase 4,Hadassah Medical Organization,Other,8-Apr-20,8-May-21,29-Apr-20,TREATMENT,500,COVID PNEUMONIA,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,SURVIVAL,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
NCT04377763,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,15-Jul-20,21-Mar-21,21-Mar-21,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,SENSIBILITY AND SPECIFICITY,Developement and Evaluation of Serological Assays for COVID-19
NCT04377776,Completed,Observational,,IRCCS San Raffaele,Other,4-May-20,18-May-20,18-May-20,COHORT,644,KIDNEY TRANSPLANT,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",PRACTICE DETAILS,GLOBAL PREVALENCE OF COVID-19 TX,Observational Study to Assess the Health Status of Transplanted Patients (Kidney or Pancreas or Pancreatic Islet Transplantation) at Transplant Medicine Unit (MITRA) During the COVID-19 Pandemic
NCT04377789,Completed,Interventional,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,Other,20-Mar-20,31-Aug-20,31-Jul-20,PREVENTION,447,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",QUERCETIN PROPHYLAXIS,PREVALENCE OF COVID-19 CALCULATED USING A QUESTIONNAIRE,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19
NCT04377802,Not yet recruiting,Interventional,Not Applicable,King Fahad Specialist Hospital Dammam,Other,17-May-20,30-Dec-20,16-Nov-20,PREVENTION,400,COVID,SAUDI ARABIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MOLECULAR TESTING FOR VIRUS RNA USING RT-PCR,HEALTH CARE PROVIDER SAFE RETURN TO WORK,"Safe Return to Regular Clinical Operation After COVID-19 Pandemic; (Oncology Center, Prospective Cohort)"
NCT04377815,Completed,Observational,,"University College, London",Other,23-Apr-20,24-Jun-20,14-May-20,COHORT,569,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",GENERAL PUBLIC COHORT,PERCENTAGE OF PEOPLE REPORTING CHANGES IN SMELL/TASTE,FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste
NCT04377997,Not yet recruiting,Interventional,Phase 2,Massachusetts General Hospital,Other,15-May-20,1-Jan-22,1-Jan-21,TREATMENT,300,CARDIOVASCULAR DISEASES,,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,"NUMBER OF PATIENTS WITH THE COMPOSITE EFFICACY ENDPOINT OF DEATH, CARDIAC ARREST, SYMPTOMATIC DEEP VENOUS THROMBOSIS, PULMONARY EMBOLISM, ARTERIAL THROMBOEMBOLISM, MYOCARDIAL INFARCTION, OR HEMODYNAMIC SHOCK.","A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer"
NCT04378244,Not yet recruiting,Interventional,Phase 1/Phase 2,Aveni Foundation,Other,12-Jan-21,12-Mar-22,12-Jan-22,TREATMENT,18,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DELTAREX-G,MAXIMUM TOLERATED DOSE,CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
NCT04378257,Not yet recruiting,Interventional,Phase 3,Sultan Qaboos University,Other,1-Jun-20,20-Oct-20,30-Sep-20,TREATMENT,70,DEPRESSIVE SYMPTOMS,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",THERAPIST GUIDED E-THERAPY,CHANGE IN DEPRESSIVE SYMPTOMS MEASURED BY PATIENT HEALTH QUESTIONNAIRE-9,Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic: An Open-Label 12 - Weeks Randomized Controlled Trail
NCT04378452,"Active, not recruiting",Observational [Patient Registry],,Fundació Institut Germans Trias i Pujol,Other,31-Mar-20,21-Jun-21,21-Jun-21,COHORT,56442,SARS-COV2,SPAIN,ALL,"16 Years and older   (Child, Adult, Older Adult)",COM-COVID ANONIMOUS SURVEY,"PSYCHOLOGICAL IMPACT OF THE OUTBREAK, TOTAL SCORE",Assessment of the Psycho-social Impact of COVID-19 Outbreak (COM-COVID)
NCT04378582,Completed,Observational,,University of Sao Paulo General Hospital,Other,7-May-20,5-Aug-20,28-Jul-20,CASE-ONLY,1589,SARS-COV2,BRAZIL,ALL,"14 Years to 100 Years   (Child, Adult, Older Adult)",RISK FACTORS,ICU SURVIVAL AT 28 DAYS,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
NCT04378595,Recruiting,Observational,,University of Texas at Austin,Other,10-Apr-20,30-Jul-21,30-Dec-20,COHORT,1000,FOOD INSECURITY,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DURING COVID-19 PANDEMIC,FOOD INSECURITY SCORE,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin Federally Qualified Health Centers
NCT04378686,Recruiting,Observational,,Universitaire Ziekenhuizen Leuven,Other,23-Apr-20,1-May-22,1-May-21,COHORT,500,SARS-COV2,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",DIALYSIS,ANTIBODIES AGAINST SARS-COV-2,A Comparative Study of Symptom-driven Surveillance vs. Cross-sectional Serological Screening of SARS-CoV-2 Infection of Patients With End-stage Kidney Disease Receiving Renal Replacement Therapy
NCT04378712,Completed,Interventional,Not Applicable,Guangzhou Institute of Respiratory Disease,Other,21-Jan-20,23-Mar-20,23-Mar-20,TREATMENT,90,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",HYDROGEN OXYGEN GENERATOR WITH NEBULIZER,THE PROPORTION OF PATIENTS WITH IMPROVED DISEASE SEVERITY AT DAY 2,"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial"
NCT04378738,Enrolling by invitation,Interventional,Not Applicable,Acibadem University,Other,1-May-20,8-May-20,7-May-20,HEALTH SERVICES RESEARCH,212,SOCIAL MEDIA,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,THE ROLE OF SOCIAL MEDIA,The Role of Social Media as an Information Source in Covid19 Pandemic
NCT04378777,Enrolling by invitation,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1-May-20,22-Mar-21,21-Mar-21,COHORT,2000,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL SAMPLE COLLECTION,MORTALITY RATE AMONG COVID-19 PATIENTS,A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19 (DAIT-COVID-19-002)
NCT04378803,Completed,Interventional,Not Applicable,University of Miami,Other,13-May-20,4-Aug-20,4-Aug-20,SUPPORTIVE CARE,53,WELL AGING,UNITED STATES,ALL,"60 Years to 95 Years   (Adult, Older Adult)",MINDFULNESS TRAINING (MT) CONNECT,CHANGE IN MINDFULNESS SKILLS AS MEASURED BY FIVE-FACET MINDFULNESS QUESTIONNAIRE (5FMQ),Mindfulness Training for Older Adults During the COVID-19 Pandemic
NCT04378829,Recruiting,Observational,,Konya Training and Research Hospital,Other,12-Sep-20,21-Oct-20,11-Oct-20,CASE-ONLY,40,COVID,TURKEY,ALL,"Child, Adult, Older Adult","PLATELET COUNT, PLATELET, MEAN PLATELET VOLUME AND PLATELET DISTRIBUTION WIDTH IN COVID-19",CHANGE IN PDW AND MPV PARAMETERS,"Does the Platelet Count, Mean Platelet Volume and Platelet Distribution Width Change in COVID-19 Pandemic, ?"
NCT04378842,Recruiting,Observational,,"University Hospital, Lille",Other,18-May-20,21-May-21,21-May-21,COHORT,690,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CUMULATIVE INCIDENCE OF ICU-ACQUIRED COLONIZATION RELATED MULTIDRUG RESISTANT BACTERIA,Impact of SARS-CoV-2 Infection on the Incidence of ICU Acquired Colonization Related to Multidrug-resistant Bacteria
NCT04378881,"Active, not recruiting",Observational,,Tabula Rasa HealthCare,Industry,1-Jun-20,30-Apr-21,30-Dec-20,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,CALCULATE THE MEDICATION RISK SCORE OF DE-IDENTIFIED PARTICIPANTS FROM MEDICARE/MEDICAID AND COMMERCIAL HEALTH INSURANCE PLANS USING THEIR CURRENT DRUG REGIMEN VIA OUR PROPRIETARY RISK STRATIFICATION PROCESS.,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations
NCT04378920,Recruiting,Interventional,Phase 1/Phase 2,Institut de cancérologie Strasbourg Europe,Other,14-Apr-20,30-Jun-21,30-Jun-21,TREATMENT,90,"COVID, SEPSIS OR OTHER CAUSES",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",LEAF-4L6715,PROPORTION OF PATIENTS SHOWING AN INCREASE OF AT LEAST 25% OF PAO2/FIO2 RATIO,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes"
NCT04379037,Recruiting,Interventional,Not Applicable,Nemechek Technologies,Industry,27-Jun-20,1-Nov-20,1-Sep-20,TREATMENT,50,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",TRANSCUTANEOUS AURICULAR VAGUS NERVE STIMULATION,SURVIVAL WITHOUT NEED OF MECHANICAL VENTILATION,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
NCT04379063,"Active, not recruiting",Observational,,Jon Bailey,Other,13-May-20,22-May-21,21-May-21,COHORT,342,"BURNOUT, PROFESSIONAL",CANADA,ALL,"Child, Adult, Older Adult",COVID-19 PANDEMIC,BURNOUT,COVID-19 Pandemic Short Interval National Survey Gauging Psychological Distress Among Physicians (COPING Survey): A Longitudinal Survey
NCT04379076,Recruiting,Interventional,Phase 2,Revimmune,Industry,14-May-20,30-Dec-21,30-Oct-21,TREATMENT,48,COVID,UNITED KINGDOM,ALL,"25 Years to 80 Years   (Adult, Older Adult)",INTERLEUKIN-7,"IMPROVEMENT OF THE ABSOLUTE LYMPHOCYTE COUNT (ALC) OF LYMPHOPENIC (ALC≤1000/MM3) COVID-19 INFECTED PARTICIPANTS OUT TO APPROXIMATELY 30 DAYS FOLLOWING INITIAL STUDY DRUG ADMINISTRATION OR HOSPITAL DISCHARGE (HD), WHICHEVE","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK"
NCT04379089,Recruiting,Observational,,University of Pittsburgh,Other,29-Apr-20,31-Dec-22,31-Dec-21,COHORT,500,COVID,UNITED STATES,ALL,up to 17 Years   (Child),OBSERVATIONAL STUDY ONLY,FREQUENCY OF NEUROLOGIC MANIFESTATIONS OF COVID 19 AMONG PEDIATRIC PATIENTS REQUIRING HOSPITAL ADMISSION FOR CONFIRMED OR PRESUMED COVID 19,Neurologic Manifestations of COVID 19 in Children
NCT04379154,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,14-Apr-20,21-Feb-21,21-Feb-21,OTHER,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",VOLATILE ORGANIC COMPOUNDS ANALYSIS,PROFILES OF VOLATILE ORGANIC COMPOUNDS (VOCS) IN EXHALED AIR BETWEEN 2 HEALTH CONDITIONS,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution
NCT04379232,Completed,Observational,,Hospices Civils de Lyon,Other,19-Mar-20,25-Apr-20,20-Apr-20,COHORT,112,DIGESTIVE CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SCREENING TEST FOR COVID ( RT PCR AND CT CHEST),SYMPTOMS OF COVID AFTER SURGERY,Surgical Activity During the Covid-19 Pandemic: Results for 112 Patients in a French Tertiary Care Center: A Retrospective Observational Cohort Study
NCT04379245,Completed,Observational,,Hospices Civils de Lyon,Other,30-Apr-20,4-May-20,30-Apr-20,COHORT,4200,HIV,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","DATA RESEARCH, DATABASE ANALYSIS",COVID ATTACK RATE,Study of the Attack Rate of COVID-19 Infection in Patients Infected With HIV and/or on Pre-exposure Prophylaxis (PrEP) and Possible Impact of Treatment With an HIV Protease Inhibitor
NCT04379258,Completed,Observational [Patient Registry],,Hospital Universitario Getafe,Other,8-Feb-21,8-Feb-21,8-Feb-21,COHORT,868,COVID,SPAIN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,ICU MORTALITY,"Epidemiological Analysis of the Mortality of Critically Ill Patients With the COVID-19 Admitted to the Intensive Care Unit: An Observational, Prospective and Multicenter Study"
NCT04379271,Recruiting,Interventional,Phase 2/Phase 3,Immunic AG,Industry,11-Jun-20,20-Oct-21,20-Sep-21,TREATMENT,230,COVID,BULGARIA,ALL,"18 Years and older   (Adult, Older Adult)",IMU-838,PROPORTION OF PATIENTS WITHOUT ANY NEED* FOR INV UNTIL END-OF-STUDY (EOS),"A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19"
NCT04379284,Recruiting,Observational,,Mayo Clinic,Other,8-May-20,31-Jul-21,30-Apr-21,CASE-ONLY,100,COVID,UNITED STATES,FEMALE,18 Years to 45 Years   (Adult),BIOSPECIMEN COLLECTION,DETERMINE THE PREVALENCE OF MATERNAL FETAL TRANSMISSION OF COVID19,Risks of COVID19 in the Pregnant Population
NCT04379297,"Active, not recruiting",Observational,,Luxembourg Institute of Health,Other,10-Apr-20,31-Dec-21,28-May-21,COHORT,1800,COVID,LUXEMBOURG,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE AND DYNAMICS OF THE SARS-COV 2 INFECTION IN LUXEMBURG,COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)
NCT04379310,Completed,Observational,,Nisantasi University,Other,1-May-20,8-May-20,5-May-20,COHORT,54,COVID,TURKEY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ACE INHIBITORS AND CALCIUM CHANNEL BLOCKERS,EXTEND OF LUNG INVOLVEMENT,Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia: A Single Center Experience in Turkey
NCT04379336,Recruiting,Interventional,Phase 3,TASK Applied Science,Other,4-May-20,28-Apr-21,28-Apr-21,PREVENTION,500,COVID,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",BACILLE CALMETTE-GUÉRIN (BCG),INCIDENCE OF HCWS HOSPITALIZED DUE TO COVID-19 PER ARM,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial"
NCT04379375,Terminated,Interventional,Not Applicable,Medical College of Wisconsin,Other,27-Jul-20,30-Sep-20,30-Sep-20,PREVENTION,45,HEALTH BEHAVIOR,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NUDGE,HAND WASHING BEHAVIOR,Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread
NCT04379440,Recruiting,Observational [Patient Registry],,Raffaele Antonelli Incalzi,Other,25-Apr-20,30-Nov-20,30-Sep-20,COHORT,1500,COVID,ITALY,ALL,"60 Years and older   (Adult, Older Adult)",,HEALTH STATUS (WHO CLASSIFICATION),"Geriatric Population COVID-19 Syndromic Characteristics and Clinical Outcomes: a Multi-setting, Multi-domain Observational Study (GEROCOVID Observational)"
NCT04379453,Recruiting,Interventional,Not Applicable,Hospital Israelita Albert Einstein,Other,27-Apr-20,27-Apr-20,27-Apr-20,TREATMENT,10,CORONARY ARTERY DISEASE,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ROBOT ASSISTED PERCUTANEOUS CARDIOVASCULAR INTERVENTION,SUCCESSFUL CARDIOVASCULAR INTERVENTION,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses
NCT04379466,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,5-May-20,21-Apr-21,11-Oct-20,COHORT,60,COVID,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,A LIST OF COVID-19 SPECIFIC TCR SEQUENCES,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19
NCT04379479,Not yet recruiting,Interventional,Phase 2,"National Polytechnic Institute, Mexico",Other,20-May-21,20-Dec-21,20-Aug-21,TREATMENT,562,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",DIALYZABLE LEUKOCYTE EXTRACT,"CHANGE IN THE SCORE OF THE ""CONTINGENCY SCALE TO ASSESS THE SEVERITY OF ACUTE RESPIRATORY DISEASE IN CASES SUSPECTED/CONFIRMED BY COVID-19""",Assessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T)
NCT04379492,Withdrawn,Interventional,Phase 2,Memorial Sloan Kettering Cancer Center,Other,5-May-20,25-Sep-20,25-Sep-20,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CLINICAL IMPROVEMENT ON THE ORDINAL SCALE FOR CLINICAL IMPROVEMENT (OSCI),"Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection"
NCT04379518,Recruiting,Interventional,Phase 1/Phase 2,Roswell Park Cancer Institute,Other,4-Sep-20,4-Sep-21,4-Sep-21,SUPPORTIVE CARE,44,MALIGNANT NEOPLASM,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT INTERFERON ALFA-2B,INCIDENCE OF ADVERSE EVENTS (AES),Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection
NCT04379531,Completed,Interventional,Not Applicable,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,Other,25-Apr-20,22-May-20,22-May-20,DIAGNOSTIC,230,PNEUMONIA,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",LOW-DOSE CHEST CT,EVALUATE THE CORRELATION BETWEEN STANDARD CT AND LOW-DOSE CT SCANS FOR THE DETECTION OF COMMUNITY-ACQUIRED PNEUMONIA.,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study
NCT04379544,"Active, not recruiting",Observational [Patient Registry],,University of Pennsylvania,Other,23-Apr-20,21-Dec-21,1-Sep-20,COHORT,125,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION ONLY,PATIENT REQUIRES INVASIVE MECHANICAL VENTILATION AND SUFFERS FROM ACUTE RESPIRATORY FAILURE.,Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19
NCT04379661,Completed,Interventional,Not Applicable,Columbia University,Other,7-May-20,31-Aug-20,7-Jul-20,SUPPORTIVE CARE,32,MS (MULTIPLE SCLEROSIS),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SUPPORT GROUP,RATE OF COMPLETION,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19
NCT04379986,Not yet recruiting,Interventional,Not Applicable,"Stéphane Cook, Prof",Other,1-May-20,1-Jun-20,31-May-20,DEVICE FEASIBILITY,30,BLOOD PRESSURE,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",SENSBIOSYS,FEASIBILITY OF NON-INVASIVE BP MONITORS: BLOOD PRESSURE,Remote Blood Pressure Monitoring With the Wearable SENBIOSYS Photoplethysmographic Device
NCT04380376,Recruiting,Interventional,Phase 2,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",Other,30-Apr-20,30-Oct-20,30-Oct-20,TREATMENT,60,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",MELPHALAN,THE CHANGES OF COVID ORDINAL OUTCOMES SCALE,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19"
NCT04380402,Not yet recruiting,Interventional,Phase 2,Mount Auburn Hospital,Other,20-May-20,8-May-22,31-Dec-21,TREATMENT,300,COVID,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ATORVASTATIN,"PROPORTION OF PATIENTS THAT PROGRESS TO SEVERE OR CRITICAL REQUIRING ICU ADMISSION AND/OR EMERGENCY SALVAGE THERAPY, OR DEATH",Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19
NCT04380519,Completed,Interventional,Phase 2/Phase 3,"R-Pharm International, LLC",Industry,23-Apr-20,24-Jul-20,10-Jul-20,TREATMENT,372,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 100 Years   (Adult, Older Adult)",RPH-104 80 MG,"PROPORTION OF PATIENTS, RESPONDED TO THE STUDY THERAPY, IN EACH OF THE TREATMENT GROUPS","An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)"
NCT04380532,"Active, not recruiting",Interventional,Phase 1/Phase 2,Immunitor LLC,Industry,15-May-20,15-Jun-21,15-May-21,TREATMENT,20,COVID,CANADA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",V-SARS,EFFECT ON CBC AS PER CTCAE V4.0,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill
NCT04380662,Not yet recruiting,Observational,,"University Hospital, Grenoble",Other,30-Jun-20,30-Dec-20,30-Sep-20,COHORT,800,COVID,FRANCE,ALL,"Child, Adult, Older Adult",RISK FACTORS,IDENTIFY THE FACTORS ASSOCIATED WITH THE WORSENING OF THE COVID19,RRisk Factors Worsening COVID19 (Coronavirus Infectious Disease 2019) for Outpatient With Home Monitoring (COVID-A-DOMEVA Study)
NCT04380688,Completed,Interventional,Phase 2,AstraZeneca,Industry,13-Jun-20,16-Nov-20,16-Nov-20,TREATMENT,62,COVID,UNITED STATES,ALL,"18 Years to 130 Years   (Adult, Older Adult)",ACALABRUTINIB,OCCURRENCE OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19"
NCT04380701,Recruiting,Interventional,Phase 1/Phase 2,BioNTech SE,Industry,23-Apr-20,23-Apr-21,23-Apr-21,TREATMENT,456,"INFECTIONS, RESPIRATORY",GERMANY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BNT162A1,"SOLICITED LOCAL REACTIONS AT THE INJECTION SITE (PAIN, TENDERNESS, ERYTHEMA/REDNESS, INDURATION/SWELLING) RECORDED UP TO 7 DAYS AFTER EACH IMMUNIZATION.","A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults"
NCT04380714,Completed,Observational,,"University Hospital, Montpellier",Other,1-May-20,1-Aug-20,30-May-20,ECOLOGIC OR COMMUNITY,700,PEOPLE INCARCERATED,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PERCENTAGE CHANGES IN THE CONSUMPTION OF PSYCHOACTIVE SUBSTANCES,Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.
NCT04380727,Completed,Observational [Patient Registry],,"Central Hospital, Nancy, France",Other,20-Mar-20,25-Apr-20,14-Apr-20,CASE-CONTROL,17,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGES FROM BASELINE PAO2 (MMHG),Almitrine and Severe COVID-19 Patients in ICU [Almitrine et Patients COVID-19 en Reanimation (French)]
NCT04380766,Completed,Observational [Patient Registry],,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Other,1-Jan-19,31-Jul-20,31-Jul-20,CASE-CONTROL,730,PANCREATIC CANCER,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",EVALUATION OF CHANGES IN THE DIAGNOSTIC-THERAPEUTIC PATHWAY FOR PATIENTS AFFECTED BY PANCREATIC CANCER,CHANGES IN PANCREATIC CANCER MANAGEMENT DURING THE COVID-19 PANDEMIC,Effects of Covid-19 Pandemic on Pancreatic Surgery in Italy. A Multicenter Observational Clinical Study
NCT04380779,Completed,Observational,,Manuel Monreal,Other,13-Apr-20,13-Oct-20,13-Oct-20,OTHER,2430,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,BLEEDING EVENTS AND COMPLICATIONS,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)
NCT04380792,Completed,Observational,,Manuel Monreal,Other,13-Apr-20,13-Oct-20,13-Oct-20,OTHER,2497,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,VTE EVENTS AND COMPLICATIONS,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital (SCREENING Study)
NCT04380818,Recruiting,Interventional,Not Applicable,Grupo de Investigación Clínica en Oncología Radioterapia,Other,5-Jun-20,1-Jul-21,4-May-21,SUPPORTIVE CARE,106,"PNEUMONIA, VIRAL",SPAIN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",LOW-DOSE RADIOTHERAPY,EFFICACY OF LOW-DOSE PULMONARY IRRADIATION ASSESSED BY CHANGE IN PAFI O2 BY 20%,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study
NCT04380870,Recruiting,Observational,,Center for Integrated Care,Other,11-Apr-20,11-Apr-25,11-Apr-21,ECOLOGIC OR COMMUNITY,500,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 114 Years   (Adult, Older Adult)",CHINESE HERBAL MEDICINE,PATIENT REPORTED MAIN COMPLAINT,"Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study"
NCT04380896,Recruiting,Observational,,Great Ormond Street Hospital for Children NHS Foundation Trust,Other,27-Apr-20,27-Jul-26,27-Jul-26,COHORT,1000,SARS-COV2 INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD TEST,CHANGE IN SERIAL MONTHLY LOG-TRANSFORMED ANTIBODY TITRE LEVELS AS MEASURED,COVID-19 Staff Testing of Antibody Responses Study (CO-STARS)
NCT04380909,Recruiting,Interventional,Not Applicable,University of Bern,Other,6-May-20,21-Apr-21,21-Apr-21,TREATMENT,80,PSYCHOLOGICAL DISTRESS,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",INTERNET-BASED SELF-HELP,"PATIENT HEALTH QUESTIONNAIRE (LÖWE ET AL., 2002)",Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19
NCT04380935,Recruiting,Interventional,Phase 2/Phase 3,Indonesia University,Other,18-May-20,31-Oct-20,31-Oct-20,TREATMENT,60,COVID,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,ALL-CAUSE MORTALITY,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia
NCT04380961,Recruiting,Interventional,Phase 2,"Janssen Pharmaceutica N.V., Belgium",Industry,24-Apr-20,28-Sep-21,28-Sep-21,TREATMENT,270,SEVERE OR CRITICAL CONFIRMED CORONAVIRUS DISEASE (COVID)-19,UNITED STATES,ALL,"18 Years to 84 Years   (Adult, Older Adult)",SIRUKUMAB,TIME TO IMPROVEMENT OF AT LEAST 2 CATEGORIES RELATIVE TO BASELINE ON THE 6-POINT ORDINAL CLINICAL RECOVERY SCALE,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease"
NCT04380987,Recruiting,Observational,,Luxembourg Institute of Health,Other,4-May-20,31-Dec-21,31-Jul-21,COHORT,200,COVID,LUXEMBOURG,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL SAMPLING,DESCRIPTION OF CLINICAL MANIFESTATIONS,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis
NCT04381000,Completed,Interventional,Not Applicable,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,Other,1-Apr-20,10-Jun-20,29-May-20,TREATMENT,170,CHRONIC PAIN,GREECE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",EXERCISE GROUP,ANXIETY AND DEPRESSION,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.
NCT04381013,Not yet recruiting,Interventional,Not Applicable,Stanford University,Other,21-Mar-21,21-Apr-21,21-Apr-21,DEVICE FEASIBILITY,4,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EMERGENCY VENTILATOR SPLITTER,COMPLETION OF 1-MINUTE TEST,Emergency Ventilator Splitting Between Two or More Patients Using a Single Ventilator to Address Critical Ventilator Shortages During a Pandemic
NCT04381052,Not yet recruiting,Interventional,Phase 2,Columbia University,Other,20-May-21,1-Aug-20,1-Aug-20,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLAZAKIZUMAB,CUMULATIVE INCIDENCE OF SERIOUS ADVERSE EVENTS ASSOCIATED WITH CLAZAKIZUMAB OR PLACEBO,A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NCT04381273,Recruiting,Observational,,Heidelberg University,Other,8-May-20,31-Jul-20,31-Jul-20,OTHER,1000,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,HOW DO PEOPLE ASSESS THEIR ORAL HEALTH-RELATED QUALITY OF LIFE IN TIMES OF THE COVID-19 PANDEMIC?,Oral Health and Psychosocial Factors During the Covid-19 Pandemic
NCT04381286,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Apr-19,31-Dec-21,1-Apr-21,COHORT,40,MECHANICAL VENTILATION,FRANCE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,DURATION OF MECHANICAL VENTILATION,Transpulmonary Driving Pressure in ARDS COVID19 Patients / TRANSPULMONARY-COVID19
NCT04381312,Recruiting,Observational,,"University Hospital, Grenoble",Other,9-Apr-20,9-Oct-21,9-Jul-21,COHORT,1000,RISK FACTORS FOR COVID OUTCOMES IN ELDERLY POPULATIONS,FRANCE,ALL,70 Years and older   (Older Adult),,MORTALITY,COVID-19 Chez la Personne âgée de Plus de 70 Ans : Impact Direct et Indirect à 3 Mois.
NCT04381338,Not yet recruiting,Interventional,Not Applicable,University of Padova,Other,10-May-20,30-Sep-20,30-Sep-20,TREATMENT,92,CORONA VIRUS DISEASE 19 (COVID),ITALY,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY AND MOTOR REHABILITATION,LENGTH OF ICU STAY,Pulmonary and Motor Rehabilitation for People With COVID-19 in Intensive Care Units to Reduce Length of Stay in Hospital
NCT04381351,Recruiting,Observational,,"Heinrich-Heine University, Duesseldorf",Other,16-Apr-20,31-Jul-21,1-Mar-21,COHORT,50,COVID,GERMANY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,PREDICITIVE VALUE OF NONCODING RNAS IN COVID-19 ASSOCIATED ORGAN DYSFUNCTION,The Role of Noncoding RNAs in COVID-19 and COVID-19 Associated Acute Kidney Injury (MiRCOVID)
NCT04381364,Recruiting,Interventional,Phase 2,"Ola Blennow, MD, PhD",Other,29-May-20,31-Dec-20,1-Dec-20,TREATMENT,446,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",CICLESONIDE INHALATION AEROSOL,DURATION OF RECEIVED SUPPLEMENTAL OXYGEN THERAPY,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
NCT04381377,"Active, not recruiting",Interventional,Phase 2/Phase 3,NPO Petrovax,Industry,29-Apr-20,21-Apr-21,21-Apr-21,TREATMENT,394,"INFECTIONS, CORONAVIRUS",RUSSIAN FEDERATION,ALL,"18 Years to 85 Years   (Adult, Older Adult)",AZOXIMER BROMIDE,CLINICAL STATUS OF THE PATIENT (ACCORDING TO 7-POINT ORDINAL SCALE),"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19)."
NCT04381819,Recruiting,Observational,,Oslo University Hospital,Other,2-Mar-20,31-Dec-23,28-Feb-22,COHORT,1000,SARS VIRUS,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 PCR,DEATH,"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of Inpatients During the COVID-19 Outbreak: A Prospective Cohort Study"
NCT04381845,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,10-Dec-20,10-Mar-21,10-Mar-21,DIAGNOSTIC,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVID19 IMMUNIZATION TESTING,NUMBER OF COVID-POSITIVE PATIENTS,Immunity and COVID Infections in the Psychiatric Population
NCT04381858,Completed,Interventional,Phase 3,Centenario Hospital Miguel Hidalgo,Other,6-May-20,26-Nov-20,26-Nov-20,TREATMENT,196,COVID PNEUMONIA,MEXICO,ALL,"16 Years to 90 Years   (Child, Adult, Older Adult)",PLASMA FROM COVID-19 CONVALESCENT PATIENT,MEAN HOSPITALIZATION TIME,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial
NCT04381871,Not yet recruiting,Interventional,Phase 2/Phase 3,Al-Neelain University,Other,1-Jun-20,1-Sep-20,1-Aug-20,TREATMENT,110,COVID,SUDAN,ALL,"5 Years to 90 Years   (Child, Adult, Older Adult)",ACACIA SENEGAL,MEAN CHANGE FROM BASELINE SCORE OF IMMUNE RESPONSE TO END OF THE TRIAL ( TIME FRAME: UP TO 4 WEEKS ),"Phase II ,III Randomized Double Blind Parallel Arms Clinical Trial of Potential Role of Gum Arabic ( Acacia Senegal) as Immunomodulatory Agent Among COVID 19 Patients in Sudan"
NCT04381884,Completed,Interventional,Phase 2,Laboratorio Elea Phoenix S.A.,Industry,18-May-20,29-Sep-20,29-Sep-20,TREATMENT,45,COVID DRUG TREATMENT,ARGENTINA,ALL,"18 Years to 69 Years   (Adult, Older Adult)",IVERMECTIN (IVER P®) ARM WILL RECEIVE IVM 600 ΜG / KG ONCE DAILY PLUS STANDARD CARE. CONTROL ARM WILL RECEIVE STANDARD CARE.,REDUCTION IN SARS-COV-2 VIRAL LOAD,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19"
NCT04381923,Not yet recruiting,Interventional,Not Applicable,University of Pennsylvania,Other,15-Feb-21,15-May-22,15-Feb-22,SUPPORTIVE CARE,200,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HELMET CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP),VENTILATOR-FREE DAYS (VFD),High Flow Nasal Oxygen Versus Continuous Positive Airway Pressure Helmet Evaluation: A Randomized Crossover Trial in COVID-19 Pneumonia
NCT04381936,Recruiting,Interventional,Phase 2/Phase 3,University of Oxford,Other,19-Mar-20,31-Dec-21,21-Dec-21,TREATMENT,40000,SEVERE ACUTE RESPIRATORY SYNDROME,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",LOPINAVIR-RITONAVIR,ALL-CAUSE MORTALITY,Randomised Evaluation of COVID-19 Therapy
NCT04381962,Recruiting,Interventional,Phase 3,University of Oxford,Other,29-May-20,13-Oct-20,13-Sep-20,TREATMENT,800,COVID,UNITED KINGDOM,ALL,"19 Years and older   (Adult, Older Adult)",AZITHROMYCIN CAPSULE,PROPORTION PROGRESSING TO RESPIRATORY FAILURE OR DEATH (ALL CLINICALLY-DIAGNOSED PARTICIPANTS),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2)
NCT04381988,Recruiting,Interventional,Phase 2,Memorial Sloan Kettering Cancer Center,Other,7-May-20,21-May-21,21-May-21,PREVENTION,132,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CUMULATIVE INCIDENCE OF SARS-COV-2 INFECTION,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)
NCT04382040,Recruiting,Interventional,Phase 2,MGC Pharmaceuticals d.o.o,Industry,8-May-20,21-Jan-21,20-Nov-21,TREATMENT,50,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",ARTEMIC,"TIME TO CLINICAL IMPROVEMENT, DEFINED AS A NATIONAL EARLY WARNING SCORE 2 (NEWS2) OF </= 2 MAINTAINED FOR 24 HOURS IN COMPARISON TO ROUTINE TREATMENT","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19"
NCT04382053,Completed,Interventional,Phase 2,Novartis Pharmaceuticals,Industry,27-May-20,24-Dec-20,24-Dec-20,TREATMENT,143,"COVID PNEUMONIA, IMPAIRED RESPIRATORY FUNCTION",ARGENTINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DFV890,APACHE II SEVERITY OF DISEASE SCORE ON DAY 15 OR ON THE DAY OF DISCHARGE (WHICHEVER IS EARLIER),"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function"
NCT04382066,Completed,Interventional,Phase 1,PharmaMar,Industry,12-May-20,23-Dec-20,23-Dec-20,TREATMENT,46,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PLITIDEPSIN 1.5 MG/DAY,FREQUENCY OF OCCURRENCE OF NEUTROPENIA ≥ GRADE 3,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization"
NCT04382092,Completed,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,23-Mar-20,24-Apr-20,24-Apr-20,DIAGNOSTIC,32,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",FILMARRAY PNEUMONIA,% OF COVID-19 CO-INFECTIONS,Co-infections in COVID-19 Critically Ill and Antibiotic Management
NCT04382131,Recruiting,Interventional,Not Applicable,University of Edinburgh,Other,23-Jun-20,31-Oct-20,31-Oct-20,TREATMENT,405,UPPER RESPIRATORY TRACT INFECTIONS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NACL SOLUTION,TIME TO RESOLUTION OF SYMPTOMS AS DEFINED BY THE SINGLE QUESTION 'HOW UNWELL DO YOU FEEL TODAY'.,Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19)
NCT04382196,"Active, not recruiting",Observational,,"University Hospital, Ghent",Other,17-Apr-20,31-Dec-22,31-Dec-22,COHORT,497,MENTAL HEALTH,BELGIUM,ALL,"Child, Adult, Older Adult",ONLINE SURVEY,DEPRESSIVE SYMPTOMS AT BASELINE,The Impact of the COVID-19 Pandemic on Mental Health and Quality of Life of Healthcare Workers in a University Hospital
NCT04382235,"Active, not recruiting",Observational,,University of Milano Bicocca,Other,26-Mar-20,30-Dec-20,30-Dec-20,COHORT,900,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",NON-INVASIVE VENTILATORY SUPPORT,THE NUMBER OF PATIENTS TREATED WITH NON-INVASIVE VENTILATION DEVICES.,Management Through Non-invasive Ventilatory Support of Patients Showing an Acute Respiratory Failure Related to COVID-19 in Non-intensive Wards
NCT04382391,Recruiting,Interventional,Not Applicable,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),Other,8-May-20,30-Dec-21,1-Mar-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GAMMACORE® SAPPHIRE (NON-INVASIVE VAGUS NERVE STIMULATOR),CHANGE IN INITIATION OF MECHANICAL VENTILATION IN PATIENTS WITH COVID-19 COMPARED TO THE CONTROL GROUP.,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)"
NCT04382417,Completed,Observational,,Region Västmanland,Other,26-Mar-20,12-Nov-20,12-Nov-20,COHORT,57,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL STUDY,DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH COVID-19 RECEIVING INTENSIVE CARE,Characteristics and Outcomes of Critically Ill Patients With Covid-19 in a Large Swedish County Hospital - a Prospective Observational Cohort Study
NCT04382469,Completed,Observational,,Alexandria University,Other,1-Feb-20,1-May-20,30-Apr-20,CASE-CROSSOVER,48,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,"RADIOLOGICAL PATTERN OF INITIAL PRESENTATION, DISEASE PROGRESS, HEALING AND RECOVERY",Egyptian Initial Experience About 2019 Novel Corona Virus Disease (COVID-19): Single-center Study Analysis of 48 Patients in Alexandria-Egypt Regarding Radiological Patterns and Co-morbid Lung Diseases
NCT04382495,Recruiting,Observational,,El Zaitoun Specialized Hospital,Other,15-Jun-20,1-Jun-21,1-Jun-21,OTHER,400,CANCER,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,PATIENTS' AND SURVIVORS' PERSPECTIVE OF THEIR CANCER CARE DURING COVID-19 PANDEMIC,The Impact of COVID-19 Pandemic on Cancer Care From Patients' and Survivors' Perspective
NCT04382508,Enrolling by invitation,Observational,,University Hospital Southampton NHS Foundation Trust,Other,22-Mar-20,21-Mar-21,21-Mar-21,COHORT,1500,IMMUNE SUPPRESSION,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,TO DESCRIBE COVID19 INFECTION IN CHILDREN/ADULTS WHO ARE VULNERABLE FOR INFECTION IN AN OUTPATIENTS SETTING,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.
NCT04382534,Recruiting,Observational,,Peking University Third Hospital,Other,10-Mar-20,31-Dec-20,30-Sep-20,COHORT,300,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RESPIRATORY REHABILITATION,SYMPTOMS AND SIGNS,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction
NCT04382547,Enrolling by invitation,Interventional,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Other,11-May-20,30-Jun-21,30-Jun-21,TREATMENT,40,COVID,BELARUS,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ALLOGENIC POOLED OLFACTORY MUCOSA-DERIVED MESENCHYMAL STEM CELLS,NUMBER OF CURED PATIENTS,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
NCT04382560,Completed,Interventional,Not Applicable,University of Parma,Other,2-May-20,31-May-20,31-May-20,OTHER,69,"BEHAVIOR, SOCIAL",ITALY,ALL,20 Years to 40 Years   (Adult),DEEP BREATHING TRAINING,DISPOSITIONAL QUESTIONNAIRE 1,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine
NCT04382586,"Active, not recruiting",Interventional,Phase 2,BeiGene,Industry,6-Jul-20,30-Apr-21,2-Feb-21,TREATMENT,93,COVID PULMONARY COMPLICATIONS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ZANUBRUTINIB,RESPIRATORY FAILURE-FREE SURVIVAL RATE AT DAY 28,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress"
NCT04382625,Withdrawn,Interventional,Phase 4,Kootenai Health,Other,20-Oct-21,1-Jun-22,1-Jan-22,TREATMENT,0,SARS-COV2 PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CHANGE FROM BASELINE OXYGENATION ON DAY 1 TO DAY 5,Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
NCT04382651,"Active, not recruiting",Interventional,Phase 2,Novartis Pharmaceuticals,Industry,7-Jun-20,14-Apr-21,6-Jan-21,TREATMENT,140,"COVID PNEUMONIA, IMPAIRED RESPIRATORY FUNCTION",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MAS825,APACHE II SEVERITY OF DISEASE SCORE ON DAY 15 OR ON DAY OF DISCHARGE (WHICHEVER IS EARLIER),"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function"
NCT04382729,Recruiting,Interventional,Not Applicable,"University of Turin, Italy",Other,17-Apr-20,20-Jul-21,20-Jul-21,SUPPORTIVE CARE,80,COVID PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",NEUROMUSCULAR ELECTRICAL STIMULATION,SHORT PHYSICAL PERFORMANCE BATTERY (SPPB) SCORE,Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial
NCT04382755,"Active, not recruiting",Interventional,Phase 2,"University Hospital, Ghent",Other,22-May-20,21-Apr-21,21-Feb-21,TREATMENT,81,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",ZILUCOPLAN®,MEAN CHANGE IN OXYGENATION,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure"
NCT04382768,Recruiting,Interventional,Not Applicable,Química Luar SRL,Industry,1-May-20,21-Jan-21,21-Jan-21,TREATMENT,40,CORONAVIRUS INFECTION,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",INHALED HYPERTONIC IBUPROFEN,"CHANGE IN THE SCALE OF ORDINARY COVID RESULTS AT 7, 14 AND 28 DAYS IN PATIENTS WITH ACUTE RESPIRATORY INFECTION, INDUCED BY SARS-COV-2, TREATED WITH INHALED IBUPROFEN.","Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19."
NCT04382781,Recruiting,Observational,,Spanish Network for Research in Infectious Diseases,Other,20-May-21,20-May-21,20-May-21,COHORT,500,COVID INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",NO-IMMUNOSUPPRESSIVE,INVASIVE VENTILATION OR DEATH,Effect of Immunosupressive Treatment in COVID-19 Patients Whit SAM-LIKE Profile: Retrospective Cohort Study (SAM-COVID Project)
NCT04382794,Completed,Observational,,University of Milan,Other,14-May-20,15-Jun-20,15-Jun-20,CASE-CONTROL,338,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",RETROSPECTIVE CASE-CONTROL ANALYSIS,CLINICAL PARAMETER OF ACUTE LUNG DISEASE,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients: Retrospective Study
NCT04382846,Recruiting,Interventional,Phase 3,Tanta University,Other,8-May-20,1-Dec-30,1-Dec-30,TREATMENT,160,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE,NUMBER OF PATIENTS WITH VIROLOGICAL CURE,Nitazoxanide in Treatment of COVID-19
NCT04382924,"Active, not recruiting",Interventional,Phase 2/Phase 3,Algernon Pharmaceuticals,Industry,5-Aug-20,22-Feb-21,22-Jan-21,TREATMENT,682,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",NP-120 (IFENPRODIL),PATIENT CLINICAL STATUS (ON THE WHO 7-POINT ORDINAL SCALE) AT DAY 15 IN IP VERSUS SOC CONTROL GROUP PATIENTS:,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
NCT04382950,Not yet recruiting,Interventional,Phase 1,Kafrelsheikh University,Other,20-Jul-21,20-Dec-21,20-Nov-21,TREATMENT,24,COVID,,ALL,18 Years to 60 Years   (Adult),RECOMBINANT BACTERIAL ACE2 RECEPTORS -LIKE ENZYME OF B38-CAP (RBACE2) PLUS AEROSOLIZED 13 CIS RETINOIC ACID,TIME COURSE OF BODY TEMPERATURE (FEVER),Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2
NCT04383002,Recruiting,Interventional,Phase 1,"University Health Network, Toronto",Other,2-Sep-20,20-Dec-21,20-Dec-21,TREATMENT,20,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE,COVID-19 PCR STATUS AT COMPLETION OF TREATMENT (DAY 7) FROM TRACHEAL ASPIRATE,Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19
NCT04383444,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,7-Jul-20,1-Aug-23,1-Aug-23,COHORT,1050,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,"RESULTS OF SARS-COV-2 RT- PCR TESTING, ANTIBODY ASSAY, AND CULTURE",Surveillance of Individuals Following SARS-CoV-2 Infection
NCT04383457,Completed,Observational [Patient Registry],,Vastra Gotaland Region,Other,15-Jun-20,8-Oct-20,8-Oct-20,COHORT,214,CORONAVIRUS INFECTION,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",RIA-DEVICE (REMOTE INVESTIGATION AND ASSESSMENT),AGREEMENT BETWEEN THE NEW CAMERA BASED METHOD AND REFERENCE STANDARD TO ESTIMATE BODY TEMPERATURE,Covid-19 Triage Using Camera-based AI
NCT04383470,Recruiting,Observational,,University of Padova,Other,26-Apr-20,22-Jun-21,21-Dec-21,ECOLOGIC OR COMMUNITY,100000,MENTAL HEALTH WELLNESS 1,GREECE,ALL,"6 Years and older   (Child, Adult, Older Adult)",,"MENTAL HEALTH SYMPTOMS, WELL-BEING CHANGE FROM LAST 2 WEEKS BEFORE THE PANDEMIC TO LAST 2 WEEKS DURING COVID-19 PANDEMIC",Collaborative Outcomes Study on Health and Functioning During Infection Times During COVID-19 Pandemic
NCT04383483,Recruiting,Observational,,Bursa Yüksek İhtisas Education and Research Hospital,Other,15-Jun-20,31-Aug-20,31-Jul-20,CASE-ONLY,100,CORONAVIRUS AS THE CAUSE OF DISEASES CLASSIFIED ELSEWHERE,TURKEY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COVICU,COVICU SCORE,CoV-ICU Score: Who Will Need Intensive Care in the Course of Corona Virus Disease?
NCT04383535,Completed,Interventional,Not Applicable,Hospital Italiano de Buenos Aires,Other,15-May-20,27-Sep-20,27-Sep-20,TREATMENT,333,SARS VIRUS,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT SARS COVID-19 PLASMA,CLINICAL STATUS DURING FOLLOW-UP AT 30TH DAY,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria"
NCT04383548,Not yet recruiting,Interventional,Not Applicable,Assiut University,Other,1-Jun-20,1-Jan-21,1-Dec-20,TREATMENT,100,COVID,,ALL,21 Years to 50 Years   (Adult),HYPER IMMUNOGLOBULINS CONTAINING ANTI-CORONA VS2 IMMUNOGLOBULIN,EFFICACY OF COVID19 HYPER IMMUNOGLOBULINS FOR PATIENTS,Randomized Prospective Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma in Prevention of Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients
NCT04383574,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Sinovac Research and Development Co., Ltd.",Industry,22-May-20,30-May-21,28-Aug-20,PREVENTION,422,COVID,CHINA,ALL,"60 Years and older   (Adult, Older Adult)","TWO DOSES OF LOW DOSAGE INACTIVATED SARS-COV-2 VACCINE AT THE SCHEDULE OF DAY 0,28",SAFETY INDEX-INCIDENCE OF ADVERSE REACTIONS,"A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged ≥60 Years"
NCT04383587,Completed,Interventional,Not Applicable,Mayo Clinic,Other,6-May-20,31-Jul-20,1-Jul-20,HEALTH SERVICES RESEARCH,300,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGIC TESTING,PREVALENCE OF COVID19 ANTIBODY POSITIVITY,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
NCT04383613,Recruiting,Interventional,Not Applicable,Unity Health Toronto,Other,15-May-20,1-Jun-21,1-Jun-21,OTHER,350,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,"COMPOSITE OUTCOME OF IN-HOSPITAL ALL-CAUSE MORTALITY, INVASIVE OR NON-INVASIVE MECHANICAL VENTILATION, OR NEED FOR FIO2 OF 60% OR MORE",Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE]
NCT04383626,Completed,Observational,,Cairo University,Other,2-Mar-20,5-May-20,5-Apr-20,OTHER,216,COVID,EGYPT,ALL,"20 Years and older   (Adult, Older Adult)",,FEAR AMONG DENTIST DURING COVID 19 EPIDEMIC,Fear and Practice Modification Among Dentists During COVID-19 Pandemic
NCT04383652,Recruiting,Observational,,Kirby Institute,Other,6-May-20,30-Jun-21,30-Jun-21,COHORT,200,COVID,AUSTRALIA,ALL,"Child, Adult, Older Adult",BIOLOGICAL SAMPLE AND CLINICAL DATA COLLECTION,CORONAVIRUS SEQUENCING,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales
NCT04383678,Recruiting,Observational,,Helsinki University Central Hospital,Other,1-Mar-20,31-Dec-20,31-Dec-20,COHORT,200,COVID,FINLAND,ALL,"Child, Adult, Older Adult",EXTRACORPOREAL MEMBRANE OXYGENATION,IN-HOSPITAL MORTALITY,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Multicenter European Study
NCT04383717,Not yet recruiting,Interventional,Phase 3,Cairo University,Other,5-May-20,30-Oct-20,30-Aug-20,TREATMENT,60,RESPIRATORY TRACT INFECTIONS,,ALL,"6 Years to 90 Years   (Child, Adult, Older Adult)",LEVAMISOLE AND ISOPRINOSINE,COVID 19 INDUCED FEVER IN BOTH GROUPS,The Efficacy of Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial
NCT04383730,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,26-Jun-20,31-May-21,30-Apr-21,COHORT,400,CRITICALLY ILLNESS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INTRAVENOUS SEDATION,"NUMBER OF DAYS OFF THE VENTILATOR (VFD28, FOR VENTILATOR-FREE DAYS), TAKING INTO ACCOUNT DEATH AS A COMPETING EVENT",Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
NCT04383886,Recruiting,Observational,,Hospices Civils de Lyon,Other,18-Apr-20,18-Aug-20,18-Aug-20,COHORT,200,EMERGENCY DEPARTMENT STAFF DURING THE COVID PANDEMIC,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",STRESS AND ANXIETY QUESTIONNAIRE,"CHANGE OF EMERGENCY DEPARTMENT STAFF'S LEVEL OF STRESS DURING THE COVID19 PANDEMIC, MEASURED USING THE CHAMOUX ET SIMARD VISUAL ANALOGIC SCALE",Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic
NCT04383899,Withdrawn,Observational,,"University Hospital, Bordeaux",Other,30-Sep-20,30-Nov-20,31-Oct-20,CASE-CONTROL,0,CORONAVIRUS INFECTION,,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,DESCRIBE MEDICATIONS USED PRIOR TO ADMISSION ASSOCIATED WITH WORSE INFECTION IN COVID-19 PATIENTS IN FRANCE.,Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019 (COVID-19) Infections: a Case-control Study
NCT04384029,"Active, not recruiting",Observational,,François MACH,Other,24-Mar-20,31-Mar-22,31-Mar-21,COHORT,7000,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 + PATIENTS,MOBIDITY DISCHARGE,"Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study"
NCT04384042,Recruiting,Observational,,Hospital Sultanah Bahiyah,Other,6-Jun-20,31-Mar-21,31-Mar-21,CASE-CONTROL,60,SARS-COV INFECTION,MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT-REPORTED ONLINE QUESTIONNAIRE ON OLFACTORY & TASTE DISTURBANCES,PRESENCE OR ABSENCE OF OLFACTORY AND TASTE DISTURBANCES IN STUDY PARTICIPANTS,Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Case-Control Study
NCT04384055,Enrolling by invitation,Observational,,Stanford University,Other,21-Mar-20,31-Dec-21,31-Dec-21,CASE-CONTROL,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND,"NUMBER OF PATIENTS EXPERIENCING DEATH, ICU ADMISSION, MECHANICAL VENTILATION, OR USE OF HIGH-FLOW NASAL CANNULA",Predicting Outcomes for Covid-19 Using Sonography
NCT04384250,Recruiting,Observational,,Mansoura University,Other,10-May-20,1-May-21,31-Aug-20,CASE-ONLY,50,GENETIC BASIS OF COVID INFECTION,EGYPT,ALL,"up to 50 Years   (Child, Adult)",WHOLE EXOME SEQUENCING,MUTATIONS LEADING TO INCREASE SUSCEPTIBILITY TO SARS-COV-2 INFECTION,Genetic Factors Influencing the Response to Infection With SARS-COV-2
NCT04384380,Completed,Interventional,Not Applicable,Taoyuan General Hospital,Other,1-Apr-20,31-May-20,31-May-20,TREATMENT,33,CORONAVIRUS INFECTION,TAIWAN,ALL,"20 Years to 79 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE 200 MG [PLAQUENIL],TIME TO NEGATIVELY RT-PCR,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment"
NCT04384406,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,9-May-20,1-May-20,COHORT,467,CHRONIC DISABLING,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PROPORTION OF PATIENTS NECESSITATING THE SCHEDULING OF A MEDICAL CONSULTATION,Assessment of the Consequences of the Abrupt Interruption of Physical and Rehabilitation Medicine Consultations During the Quarantine Period in France Between 2020 March 17th and May 11th
NCT04384419,Recruiting,Observational,,"University Hospital, Montpellier",Other,29-May-20,1-Jun-21,30-May-21,CASE-ONLY,1000,MENTAL DISORDER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PERCEPTION DISTORTIONS,"Real or Concieved Death Number Perception in Depression, Anxiety and in Schizotypal Personality Disorder Following Covid-19 Pandemic Lockdown"
NCT04384445,Recruiting,Interventional,Phase 1/Phase 2,Organicell Regenerative Medicine,Industry,8-Sep-20,31-Jul-21,30-Jun-21,TREATMENT,20,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ZOFIN,INCIDENCE OF ANY INFUSION ASSOCIATED ADVERSE EVENTS,"A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo"
NCT04384458,Recruiting,Interventional,Not Applicable,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,Other,20-Jul-20,21-Apr-21,10-Sep-20,PREVENTION,400,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PROPORTION OF PARTICIPANTS IN WHOM THERE WAS A POSITIVITY FOR SARS-COV-2.,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
NCT04384471,Completed,Observational,,McGill University,Other,29-Apr-20,1-Jul-20,1-Jul-20,CASE-ONLY,384,TYPE1DIABETES,CANADA,ALL,"1 Year and older   (Child, Adult, Older Adult)",ONLINE SURVEY,SELF-REPORTED ACUTE DIABETES COMPLICATION,Patient Living With Type 1 Diabetes' Experience During the COVID-19 Pandemic in Quebec
NCT04384497,Recruiting,Interventional,Phase 1/Phase 2,Joakim Dillner,Other,7-May-20,20-Dec-21,20-Jun-21,TREATMENT,50,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 CONVALESCENT PLASMA,NUMBER AND PROPORTION OF PATIENTS WITH PROGRESSION TO VENTILATION OR SUSTAINED REQUIREMENT OF SUPPLEMENTARY OXYGEN THERAPY,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
NCT04384549,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,20-May-20,20-Feb-21,20-Feb-21,PREVENTION,1120,INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BCG GROUP,INCIDENCE OF DOCUMENTED COVID-19 AMONG HEALTH CARE WORKERS EXPOSED TO SARS COV2 AND VACCINATED WITH BCG COMPARED TO PLACEBO.,Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers
NCT04384588,Recruiting,Interventional,Phase 2/Phase 3,Fundacion Arturo Lopez Perez,Other,7-Apr-20,6-Apr-21,6-Apr-21,TREATMENT,100,COVID INFECTION,CHILE,ALL,"15 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA FROM COVID-19 DONORS,IN-HOSPITAL MORTALITY SECONDARY TO COVID-19 AMONG PATIENTS TREATED WITH CONVALESCENT PLASMA,Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID)
NCT04384614,Withdrawn,Observational [Patient Registry],,Direction des Soins de Santé de Base,Other,15-May-20,15-Jul-20,15-Jul-20,OTHER,0,COVID,TUNISIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TEST PCR,DIFFERENCES RELATED TO EPIDEMIOLOGICAL DEMOGRAPHIC CHARACTERISTICS,Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study Multicentric Study
NCT04384705,Recruiting,Observational,,Centre Hospitalier Universitaire de la Réunion,Other,17-Jun-20,21-Jul-21,21-Jun-21,COHORT,500,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RESEARCH SPECIFIC BLOOD SAMPLE,CHANGE OF LIPID PROFILE DURING EXPOSURE TO SARS-COV-2,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital
NCT04384731,Recruiting,Interventional,Phase 2,Dr Christophe LENCLUD,Other,29-May-20,31-Jul-21,29-May-21,TREATMENT,20,COVID,FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",PORACTANT ALFA,EVOLUTION OF THE PAO2 / FIO2 RATIO BETWEEN THE MEASUREMENTS TAKEN BEFORE (T0) AND ONE HOUR AFTER THE END OF THE INVASIVE PROCEDURE (H1).,Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia
NCT04384887,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,25-Apr-20,26-Aug-20,25-Aug-20,CASE-CONTROL,100,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),COVID-19 POSITIVE PREGNANT WOMEN,EVALUATION OF DEPRESSION AND ANXIETY SCORE CHANGES OF COVID-19 POSITIVE PREGNANTS,"''(COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"""
NCT04384900,Recruiting,Interventional,Not Applicable,Nordsjaellands Hospital,Other,11-May-20,20-Dec-21,20-Nov-21,TREATMENT,150,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITION VENTILATION,DAYS ALIVE WITHOUT RESPIRATORY LIFE SUPPORT (INVASIVE MECHANICAL VENTILATION) AT DAY 28.,Accelerated Prone Position Ventilation of Patients With COVID-19
NCT04384926,Recruiting,Observational,,University of Birmingham,Other,30-Mar-20,31-Dec-20,31-Dec-20,COHORT,1000,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",ELECTIVE CANCER SURGERY,30-DAY POSTOPERATIVE COVID-19 INFECTION RATE,"Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis: an International, Multicentre, Observational Cohort Study (CovidSurg-Cancer)"
NCT04384965,Recruiting,Interventional,Not Applicable,Centre for Addiction and Mental Health,Other,12-May-20,1-Nov-22,1-May-22,TREATMENT,200,MAJOR DEPRESSIVE DISORDER,CANADA,ALL,"18 Years and older   (Adult, Older Adult)","MAGPRO X100 STIMULATOR, B70 FLUID-COOLED COIL",PROPORTION ACHIEVING REMISSION ON HAMILTON RATING SCALE FOR DEPRESION 24-IT (HRSD-24),A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic
NCT04385004,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,27-Apr-20,20-Jul-21,20-Jul-21,CASE-ONLY,320,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"ANALYSIS OF CLINICAL, BIOLOGICAL AND HISTOLOGICAL PULMONARY AND RENAL IMPAIRMENT RELATED TO SARS-COV-2","Characterization of the Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in the Intensive Care Unit"
NCT04385017,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,11-May-20,12-Jun-21,12-Jun-21,DIAGNOSTIC,40,COVID BY SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PATIENTS,LEVEL OF ACTIVATION OF INFLAMMASOMES IN MONOCYTES AND POLYMORPHONUCLEAR NEUTROPHILS DURING COVID-19,Role of Inflammasomes in COVID-19 Disease
NCT04385043,Recruiting,Interventional,Phase 2/Phase 3,University of Catanzaro,Other,1-May-20,15-May-21,15-Oct-20,TREATMENT,400,COVID,ITALY,ALL,18 Years to 60 Years   (Adult),PLASMA HYPERIMMUNE,DECREASE IN MORTALITY,Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection
NCT04385069,Recruiting,Observational,,"University College, London",Other,16-Apr-20,5-Jul-20,5-Jul-20,COHORT,500,COV-HI,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,TO COLLECT RETROSPECTIVE DEMOGRAPHIC INFORMATION ON 500 PEOPLE ADMITTED TO SELECTED HOSPITAL SITES ACROSS THE UK WITH A COVID-19 DIAGNOSIS CONFIRMED THROUGH POSITIVE LABORATORY PCR SWAB.,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study
NCT04385095,Recruiting,Interventional,Phase 2,Synairgen Research Ltd.,Industry,16-Mar-20,31-May-21,1-Feb-21,TREATMENT,820,SARS-COV2,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SNG001,ORDINAL SCALE FOR CLINICAL IMPROVEMENT,A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-β1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection
NCT04385108,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,4-Mar-20,31-Dec-21,31-Dec-21,BASIC SCIENCE,400,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD COLLECTION ON ADMISSION AND LONGITUDINALLY,IMMUNE SIGNATURE,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management
NCT04385121,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,16-Apr-20,21-Mar-21,16-Apr-20,COHORT,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNARY,EXISTENCE OF A POST-INTENSIVE CARE SYNDROME-FAMILY ((COMBINED SCORE OF THE HAD ( HOSPITAL ANXIETY AND DÉPRESSION SCALE) AND IES-R ( IMPACT OF EVENT SCALE-REVISED) QUESTIONNAIRES)),Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection
NCT04385147,Completed,Observational,,Al-Azhar University,Other,18-May-20,5-Jul-20,1-Jul-20,COHORT,670,"CHOLANGITIS, SECONDARY BILIARY",EGYPT,ALL,"Child, Adult, Older Adult",ENDOSCOPIC MANAGEMENT ACCORDING TO STANDARD OF CARE,"AGE, GENDER, NATIONALITY",The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study
NCT04385160,Recruiting,Observational,,Fondazione per la Ricerca Ospedale Maggiore,Other,13-May-20,31-Aug-22,15-Feb-22,COHORT,552,MYELOPROLIFERATIVE NEOPLASM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PULMONARY EMBOLISM (PE),Myeloproliferative Neoplasms (MPN) and COVID-19
NCT04385186,Not yet recruiting,Interventional,Phase 2,"National Blood Center Foundation, Hemolife",Other,20-Jun-20,30-Dec-20,30-Nov-20,TREATMENT,60,"INFECTIONS, CORONAVIRUS",COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",INACTIVATED CONVALESCENT PLASMA,MORTALITY REDUCTION IN COVID-19 PATIENTS TREATED WITH INACTIVATED CONVALESCENT PLASMA + SUPPORT TREATMENT,Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19
NCT04385199,Recruiting,Interventional,Phase 2,Henry Ford Health System,Other,4-May-20,1-Aug-20,1-Aug-20,TREATMENT,30,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,IMPROVEMENT IN RESPIRATORY DISEASE,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease
NCT04385212,Completed,Observational,,"University Hospital, Geneva",Other,13-Mar-20,14-Apr-20,14-Apr-20,COHORT,230,CORONAVIRUS INFECTION,SWITZERLAND,ALL,65 Years and older   (Older Adult),,TO EVALUATE THE RELATIVE CONTRIBUTIONS OF COMORBIDITIES ON INTRA-HOSPITALIZED DEATH,COVIDAge Study- Hospital Des Trois-Chêne
NCT04385238,Completed,Observational,,Pregistry,Industry,15-May-20,20-Jun-20,20-Jun-20,CASE-ONLY,6894,COVID,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",THIS IS AN ONLINE SURVEY WITH NO INTERVENTION.,NUMBER OF PARTICIPANTS WITH SYMPTOMS OF POST-TRAUMATIC STRESS DISORDER,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
NCT04385251,Recruiting,Observational,,University of Minnesota,Other,18-Jun-20,30-Jun-21,30-Jun-21,COHORT,10000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION,TIME TO HOSPITALIZATION,An International Observational Study of Outpatients With SARS-CoV-2 Infection
NCT04385264,Not yet recruiting,Interventional,Phase 2/Phase 3,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",Other,12-May-20,20-Oct-21,20-Aug-21,TREATMENT,800,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PROPORTION OF POOR OUTCOMES (IN INDEX CASES),"#StayHome: Efficacy of Early Hydroxychloroquine in Outpatients to Reduce Secondary Hospitalisation and Household Transmission of COVID-19 in Switzerland: A Double-blind, Randomised, Placebo-controlled Trial"
NCT04385576,Recruiting,Interventional,Not Applicable,University of Malaya,Other,15-May-20,30-Dec-20,15-Sep-20,BASIC SCIENCE,30,COVID,MALAYSIA,ALL,"Child, Adult, Older Adult",AEROSOL BOX,TIME TO SUCCESSFUL INTUBATION,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box"" : Clinical Evaluation of the ""Intubation Box"" for Ease of Intubation"
NCT04385771,Recruiting,Interventional,Not Applicable,Dr. Alexander Supady,Other,1-Sep-20,31-Oct-21,31-May-21,TREATMENT,80,CORONAVIRUS INFECTION,GERMANY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VV-ECMO + CYTOKINE ADSORPTION (CYTOSORB ADSORBER),IL-6 REDUCTION BY 75% OR MORE AFTER 72 HOURS AS COMPARED TO THE BASELINE MEASUREMENT,"Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation - Randomized, Controlled, Open-label Intervention, Multi-center Trial (CYCOV-II-study)"
NCT04385797,"Active, not recruiting",Observational [Patient Registry],,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,Other,4-May-20,31-Dec-20,31-Dec-20,COHORT,200,MILD COGNITIVE IMPAIRMENT,SPAIN,ALL,"55 Years and older   (Adult, Older Adult)",TELEPHONE INTERVIEW,"CHANGE ON COGNITIVE FUNCTION IN PEOPLE WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA PRIOR TO, DURING AND AFTER CONFINEMENT.",Cognitive Outcomes During COVID-19 confiNemeNt in Elderly and Their Caregivers Using Technologies for DEMentia
NCT04385810,Completed,Interventional,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,Other,27-Apr-20,29-Jul-20,29-Jul-20,PREVENTION,23,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OPHTHALMOLOGIC EXAM,DESCRIBE OPHTHALMOLOGIC DAMAGE TO THE CORNEA WITH DIRECT EXAM AT DAY 0,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19
NCT04385823,Completed,Observational,,Hôpital Louis Mourier,Other,1-Mar-20,4-May-20,4-May-20,COHORT,62,"RESPIRATORY SYNDROME, ACUTE, SEVERE",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS RECEIVING NASAL HIGH FLOW,CHANGES IN ROX INDEX,Use of High Flow Nasal Cannula Oxygen During Acute Hypoxemic Respiratory Failure Related to Covid-19 and Interest of the Respiratory-oxygenation Index (ROX Index): an Observational Study
NCT04385836,Recruiting,Interventional,Early Phase 1,"Ministry of Health, Saudi Arabia",Other,1-Jun-20,1-Sep-20,1-Sep-20,TREATMENT,150,CORONAVIRUS,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",ALPHA ONE ANTITRYPSIN INHALATION,CLINICAL IMPROVEMENT,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04385849,Not yet recruiting,Interventional,Phase 1,"ImmunityBio, Inc.",Industry,1-Jun-20,11-Jul-20,11-Jul-20,TREATMENT,30,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",N-803,PRELIMINARY SAFETY AND EFFICACY EVALUATION OF N-803 BY ADVERSE EVENT (AE) INCIDENCE,"Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19"
NCT04385901,Completed,Interventional,Not Applicable,University of Missouri-Columbia,Other,19-May-20,19-Sep-20,19-Sep-20,TREATMENT,26,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",THERAPY INTERVENTION,CHANGE IN 6 MINUTE WALK TEST,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth
NCT04385914,Not yet recruiting,Observational,,Atlantic Health System,Other,20-May-21,20-Dec-21,20-Sep-21,COHORT,200,CORONAVIRUS INFECTION,,FEMALE,18 Years to 50 Years   (Adult),COVID POSITIVE VIA TESTING,PREGNANCY OUTCOME,Demographics and Outcomes of Pregnant COVID 19 Positive Women in a Community Health System
NCT04385940,Not yet recruiting,Interventional,Phase 3,University of Alberta,Other,20-Jun-21,20-Dec-21,20-Aug-21,TREATMENT,64,COVID,,ALL,"17 Years and older   (Child, Adult, Older Adult)","DDROPS® PRODUCTS, 50,000 IU, ORAL",SYMPTOMS RECOVERY,Improving Vitamin D Status in the Management of COVID-19
NCT04386044,Not yet recruiting,Observational,,Tameside General Hospital,Other,1-Jun-20,1-Jun-21,31-Dec-20,OTHER,1000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 INFECTION,Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients
NCT04386070,Not yet recruiting,Interventional,Phase 3,University of Birmingham,Other,15-Nov-20,14-May-26,14-May-21,PREVENTION,6400,PULMONARY COMPLICATIONS IN SURGICAL PATIENTS,,ALL,"16 Years and older   (Child, Adult, Older Adult)",LOPINAVIR-RITONAVIR,PNEUMONIA FREE SURVIVAL; ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) FREE SURVIVAL; OR DEATH,Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
NCT04386083,Recruiting,Observational,,University of the Philippines,Other,10-Jun-20,21-Mar-21,20-Dec-21,COHORT,1342,CORONAVIRUS DISEASE 2019,PHILIPPINES,ALL,"19 Years and older   (Adult, Older Adult)",,MORTALITY (BINARY OUTCOME),COVID-19 Outcomes: A Retrospective Study of Neurological Manifestations and Associated Symptoms (The Philippine CORONA Study)
NCT04386109,Recruiting,Observational,,University of Oxford,Other,1-Apr-20,30-Sep-21,31-Mar-21,COHORT,500,NEONATAL COVID DISEASE,UNITED KINGDOM,ALL,up to 29 Days   (Child),NO INTERVENTION - EXPOSURE IS TO COVID-19,INCIDENCE OF NEONATAL COVID-19,Neonatal Complications of Coronavirus Disease (COVID-19)
NCT04386239,Recruiting,Interventional,Early Phase 1,ASST Fatebenefratelli Sacco,Other,21-Jan-21,21-Dec-21,21-Jan-21,TREATMENT,40,COVID,ITALY,ALL,"18 Years to 84 Years   (Adult, Older Adult)",SARILUMAB PREFILLED SYRINGE,PROPORTION OF PATIENTS WHO SHOW AN IMPROVEMENT OF THE RESPIRATORY FUNCTION,Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection
NCT04386252,Not yet recruiting,Interventional,Phase 1/Phase 2,"Aivita Biomedical, Inc.",Industry,21-Feb-21,22-Feb-21,21-Jul-21,PREVENTION,175,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",AV-COVID-19,CONFIRM SAFETY,"Adaptive Phase I-II Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies"
NCT04386265,Enrolling by invitation,Observational [Patient Registry],,"SerenaGroup, Inc.",Other,15-Apr-20,11-May-22,11-May-22,CASE-ONLY,100,COVID,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",,GATHER INFORMATION ON PATIENTS TREATED WITH HYPERBARIC OXYGEN THERAPY,The Compassionate Use of Hyperbaric Oxygen Therapy in the Treatment of COVID-19
NCT04386291,Recruiting,Interventional,Not Applicable,"Research Foundation for Mental Hygiene, Inc.",Other,25-May-20,30-Jan-22,19-May-21,TREATMENT,360,GENERALIZED ANXIETY,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ANXIETY REDUCTION TRAINING,GAD-7,Meditation and Yoga for Heightened Anxiety Related to COVID-19
NCT04386369,Completed,Observational,,"Central Hospital, Nancy, France",Other,15-Apr-20,1-Jun-20,1-Jun-20,COHORT,17,ARDS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AIRWAY PRESSURE RELEASE VENTILATION,PROPORTION OF PATIENTS IMPROVING PAO2/FIO2 RATIO AT 6 HOURS OF APRV,Evaluation of Airway Pressure Release Ventilation on Oxygenation in Acute Respiratory Distress Syndrome in Adult Patients With COVID-19 Pneumonia
NCT04386395,"Active, not recruiting",Observational,,"Central Hospital, Nancy, France",Other,30-Mar-20,30-May-20,1-May-20,COHORT,15,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGES IN MONOCYTES HLA-DR EXPRESSION,Whole Blood Immune Cells Characterization in Critically Ill COVID-19 Patients: A Prospective Study
NCT04386447,Withdrawn,Interventional,Phase 2,Azienda Ospedaliero-Universitaria di Parma,Other,1-Sep-20,31-Dec-20,31-Oct-20,TREATMENT,0,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OXYTOCIN,PROPORTION OF CASES WHO DURING 14 EXHIBIT ONE OF THE FOLLOWING CONDITIONS,"Phase II, Multicenter, Open-label, Rct With an Adaptive Design, to Assess Efficacy of Intravenous Administration of Oxytocin in Hospitalized Patients Affected by COVID-19"
NCT04386460,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,11-May-20,11-May-21,5-Jun-20,COHORT,100,NUTRITION POOR,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,BODY MASS INDEX,Covid-19 and Prevention of Malnutrition After Confinement by Dentists: Prospective Study Among 100 Adults Received in Dental Consultation at Nice University Hospital and Sent to Their Physician for Assessment and Nutritional Care
NCT04386512,Completed,Observational,,Versailles Hospital,Other,15-May-20,15-Jul-20,1-Jun-20,CASE-ONLY,89,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,Épidémiologie Clinique et caractéristiques Des Cas de Covid-19 Survenus Dans un Contexte de Lymphome Lors de la première Phase épidémique
NCT04386551,Completed,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,6-May-20,5-Aug-20,5-Aug-20,CASE-ONLY,501,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DETECTION OF SARS-COV-2 RNA IN THE SALIVA SAMPLE,Evaluation of the Performance of a Saliva Sample Versus a Nasopharyngeal Sample in the Diagnosis of COVID-19 by RT-PCR
NCT04386564,Completed,Observational,,I.M. Sechenov First Moscow State Medical University,Other,15-May-20,1-Sep-20,1-Aug-20,COHORT,340,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",MRNA IN URINE TEST,THE EFFECT OF COVID-19 SEVERITY ON THE SEVERITY OF RENAL FAILURE,Prospective Parallel-Group Study of the Relationship Between Kidney Injury Severity and Severity of COVID-19
NCT04386616,Completed,Interventional,Phase 2,"Genentech, Inc.",Industry,2-Jun-20,12-Feb-21,2-Jan-21,TREATMENT,410,COVID PNEUMONIA,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",MSTT1041A,"TIME TO RECOVERY, DEFINED AS THE TIME TO A SCORE OF 1 OR 2 ON THE 7-CATEGORY ORDINAL SCALE (WHICHEVER OCCURS FIRST)","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia"
NCT04386668,Terminated,Interventional,Not Applicable,"University College, London",Other,26-May-20,31-Aug-20,12-Jul-20,OTHER,80,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",LET IT OUT (LIO)-C,KESSLER PSYCHOLOGICAL DISTRESS SCALE (K10),Let It Out (LIO) and COVID19: a Randomised Controlled Trial of an Online Emotional Disclosure-based Intervention for Adults During the COVID19 Pandemic
NCT04386694,Completed,Interventional,Not Applicable,University of Nove de Julho,Other,18-May-20,17-Sep-20,17-Sep-20,TREATMENT,30,COVID,BRAZIL,ALL,"15 Years and older   (Child, Adult, Older Adult)",ACTIVE PBMT/SMF,TIME UNTIL DISCHARGE,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?
NCT04386720,Recruiting,Observational,,"University Hospital, Bordeaux",Other,25-May-20,25-May-21,25-May-21,CASE-ONLY,20,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COMPARISON OF THE PV CURVES,Measurement of Airway Opening Pressure (AOP) in Patients With Acute Respiratory Distress Syndrom With Pressure Volume Curve on the Ventilator and With Electrical Impedance Tomography (EIT) Derived Method in Comparison of the Curves in Patients With or Without Covid 19 Pneumoniae.
NCT04386759,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-May-21,20-Oct-21,20-Oct-21,COHORT,6000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COHORT,SARS-COV-2 INFECTION,COVID-19 Infection in Healthcare Workers: a Cohort Study
NCT04386850,Recruiting,Interventional,Phase 2/Phase 3,Tehran University of Medical Sciences,Other,14-Apr-20,15-Mar-21,15-Nov-20,PREVENTION,1500,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 75 Years   (Adult, Older Adult)",ORAL 25-HYDROXYVITAMIN D3,COVID-19 (SARA-COV-2) INFECTION,Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults
NCT04386876,Completed,Interventional,Phase 1,World Medicine ILAC SAN. ve TIC. A.S.,Industry,30-Apr-20,11-Jun-20,22-May-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,20 Years to 40 Years   (Adult),LOPINAVIR/RITONAVIR 200 MG/50 MG FILM TABLET,PRIMARY PK END POINTS,"Randomized, Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over Trial to Assess the BE of Orvical 200 mg/50 mg FT in Comparison With Kaletra 200 mg/50 mg FT in Healthy Male Subjects Under Fasting Conditions"
NCT04387214,Completed,Observational,,South Valley University,Other,13-Apr-20,10-Aug-20,10-Aug-20,OTHER,1426,COVID,EGYPT,ALL,18 Years to 60 Years   (Adult),SURVEY,MEASURE THE EFFECT OF COVID-19 PANDEMIC ON THE ACADEMIC PERFORMANCE OF VETERINARY MEDICAL STUDENTS,The Impact of COVID-19 Pandemic on the Academic Performance of Veterinary Medical Students and Researchers
NCT04387240,Not yet recruiting,Interventional,Phase 2,Princess Nourah Bint Abdulrahman University,Other,20-Dec-21,21-Apr-21,21-Apr-21,TREATMENT,22,COVID POSITIVE,SAUDI ARABIA,ALL,18 Years to 60 Years   (Adult),ARTEMISININ / ARTESUNATE,LENGTH OF STAY IN HOSPITAL,Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19
NCT04387253,Recruiting,Interventional,Not Applicable,Poitiers University Hospital,Other,23-May-20,23-Jul-21,23-Jul-21,DIAGNOSTIC,80,IDENTIFICATION OF THE MOTHER OR FETUS CONTAMINATION BY SARS COV-2,FRANCE,ALL,"Child, Adult, Older Adult",IDENTIFICATION BY PCR OF THE SARS-COV-2 VIRUS IN SAMPLES TAKEN FROM THE FETUS,ESTIMATE THE PREVALENCE OF SARS-COV-2 INFECTION IN WOMEN WITH LATE FETAL LOSS OF UNEXPLAINED CAUSE.,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID
NCT04387279,Recruiting,Observational,,Keimyung University Dongsan Medical Center,Other,24-Apr-20,30-Mar-21,30-Mar-21,COHORT,800,COVID,"KOREA, REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",INTERVIEW,PATIENT'S PERCEPTION OF COVID-19 AND MEDICAL USE PATTERNS,The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area
NCT04387292,Recruiting,Interventional,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,Other,7-Sep-20,21-May-21,21-May-21,OTHER,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OPHTHALMOLOGIC EXAM,DESCRIPTION OF THE OPHTHALMOLOGICAL PROBLEMS OBSERVED,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
NCT04387409,"Active, not recruiting",Interventional,Phase 3,Vakzine Projekt Management GmbH,Industry,25-May-20,1-May-21,1-May-21,PREVENTION,59,"INFECTION, RESPIRATORY TRACT",GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",VPM1002,NUMBER OF DAYS ABSENT FROM WORK DUE TO RESPIRATORY DISEASE (WITH OR WITHOUT DOCUMENTED SARS-COV-2 INFECTION),"A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System"
NCT04387643,Completed,Observational,,Aarogyam UK,Other,1-Mar-20,2-Apr-20,2-Apr-20,OTHER,52,COVID,INDIA,ALL,18 Years to 60 Years   (Adult),AYURVEDIC KADHA,PHYSICAL HEALTH,Protecting Health Care Workers During the COVID-19 Outbreak:Qualitative Study of AYUSH Initiative
NCT04387656,Recruiting,Observational,,National Cancer Institute (NCI),NIH,21-May-20,31-May-23,31-May-23,COHORT,2000,COVID INFECTION,CANADA,ALL,"Child, Adult, Older Adult",BIOSPECIMEN COLLECTION,PATIENT VARIABLES (FACTORS) ASSOCIATED WITH SEVERE ACUTE RESPIRATORY SYNDROME (SARS) CORONAVIRUS 2 (COVID-19) SEVERITY,NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCT04387708,Not yet recruiting,Observational,,Centre Psychothérapique de Nancy,Other,14-May-20,8-Jun-20,8-Jun-20,FAMILY-BASED,18,ANOREXIA NERVOSA,,ALL,"Child, Adult, Older Adult",,CONTENT ANALYSIS CONCERNING THE REORGANIZATION OF CARE FOR CHILDREN OR ADOLESCENT AND THIER PARENTS,Reorganization of Care in Patients Hospitalized in Child Psychiatry for Anorexia Nervosa at the Time of the Coronavirus-19 Epidemic in France: Qualitative Study Carried Out on Patients and Their Parents
NCT04387760,Recruiting,Interventional,Phase 2,Royal College of Surgeons in Ireland - Medical University of Bahrain,Other,11-Aug-20,14-May-21,14-Apr-21,TREATMENT,150,SARS-COV2,BAHRAIN,ALL,"21 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PRIMARY OUTCOME MEASURE WILL BE TIME TO VIRAL CLEARANCE,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial
NCT04387786,Completed,Observational,,Feinstein Institute for Medical Research,Other,31-Mar-20,4-Sep-20,24-Apr-20,CASE-ONLY,5,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",DORNASE ALFA,NUMBER OF PARTICIPANTS DISCHARGED FROM THE INTENSIVE CARE UNIT (ICU),Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series
NCT04387799,Completed,Observational,,Catholic University of the Sacred Heart,Other,13-May-20,17-Jun-20,12-Jun-20,CASE-CONTROL,520,"PNEUMONIA, VIRAL",ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",SEROLOGY FOR COVID-19,SEROLOGY,Major Determinants of COVID-19 Associated Pneumonia
NCT04387838,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,14-May-20,31-Jul-20,31-Jul-20,COHORT,900,SARS-COV2,FRANCE,ALL,18 Years to 62 Years   (Adult),ANTI-SARS-COV2 SEROLOGY,ANTI-SARS-COV2 SEROCONVERSION BETWEEN DAY 0 AND DAY 60.,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff
NCT04387890,Not yet recruiting,Observational,,Hospital Italiano de Buenos Aires,Other,1-Jun-20,31-Aug-20,31-Aug-20,COHORT,50,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGIC SARS-COV-2 SCREENING,PREVALENCE OF ANTI SARS-COV-2 ANTIBODIES (IGM AND IGG) IN HEALTH PERSONNEL,Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care
NCT04387929,Recruiting,Observational [Patient Registry],,Istituto Clinico Humanitas,Other,4-May-20,30-May-21,30-May-21,COHORT,6000,COVID,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",DETECTION OF ANTI-COVID-19 ANTIBODY LEVEL,SARS-COV-2 LEVELS OF IGG ANTIBODIES,Observational Cohort Study for the Detection of Anti-COVID-19 Antibody Levels in an Hospital Population
NCT04387955,Recruiting,Interventional,Not Applicable,Poitiers University Hospital,Other,30-Apr-20,21-Jun-21,21-May-21,DIAGNOSTIC,30,COVID,FRANCE,ALL,"12 Years and older   (Child, Adult, Older Adult)",BIOLOGICAL SAMPLE COLLECTION,STUDY OF THE LINK BETWEEN SARS-COV-2 INFECTION AND CHILBLAINS OBSERVED DURING COVID-19 EPIDEMICS.,Analysis of Chilblains Profile During COVID-19 Epidemic
NCT04387968,Recruiting,Observational,,Raphael Serreau,Other,24-Aug-20,24-Mar-21,24-Mar-21,ECOLOGIC OR COMMUNITY,5000,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years to 65 Years   (Adult, Older Adult)",COVID-19 PRESTO TEST,"STUDY THE PREVALENCE OF COVID-19 INFECTION, CORONAVIRUS (SARS CORONAVIRUS-2) IN TERRITORIAL AGENTS IN THE 3 STRUCTURES : CCTVL, LOIRE VALLEY REGION CENTRE, ORLEANS METROPOLITAN CITY","Epidemiological Study of the Covid-19 Presto Test Among Agents of the Local Authorities of CCTVL, Region Centre Val de Loire and Orleans Métropole. Correlation of IgM Level According to Contact With the Public"
NCT04388410,Recruiting,Interventional,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,25-Aug-20,31-Dec-20,30-Nov-20,TREATMENT,410,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,SEVERITY AND DEATH,Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.
NCT04388436,"Active, not recruiting",Observational [Patient Registry],,Mansoura University,Other,11-May-20,10-Oct-21,10-Jul-21,COHORT,100,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,MEASUREMENT OF PULMONARY FUNCTION CHANGES EITHER OBSTRUCTIVE OR RESTRICTIVE ALSO LUNG DIFFUSION AND IF THERE IS REMAINING INTERSTITIAL FIBROSIS,Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors
NCT04388514,Recruiting,Interventional,Not Applicable,Azienda Sanitaria-Universitaria Integrata di Udine,Other,8-Apr-20,8-Oct-20,8-Oct-20,TREATMENT,90,SARS-COV2 RESPIRATORY FAILURE,ITALY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",MEDICAL OZONE PROCEDURE,TIME OF RESPIRATORY IMPROVEMENT AND EARLIER WEANING FROM OXYGEN SUPPORT,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure
NCT04388527,"Active, not recruiting",Interventional,Phase 1,University of Pennsylvania,Other,30-Apr-20,30-Jun-21,30-Apr-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,PARTICIPANTS WITH SERIOUS ADVERSE EVENTS.,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2"
NCT04388579,Completed,Observational,,University of Lisbon,Other,20-Mar-20,27-Mar-20,27-Mar-20,COHORT,100,RESPIRATORY DISEASE,PORTUGAL,ALL,"18 Years to 88 Years   (Adult, Older Adult)",PULMONARY REHABILITATION,PATIENT'S SELF-EFFICACY,PRAISE@COVID-19: Screening Patients for a Strategic Shift to Pulmonary Telerehabilitation
NCT04388605,Recruiting,Observational [Patient Registry],,"University of California, San Francisco",Other,21-Apr-20,22-Sep-21,21-Sep-21,COHORT,11000,CORONAVIRUS INFECTION,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",,PREVALENCE OF SARS-COV-2 INFECTION THROUGHOUT PREGNANCY IN WOMEN,Assessing the Safety of Pregnancy In the CoRonavirus pandEmic: a Nationwide Prospective Study
NCT04388618,Recruiting,Observational,,Princess Nourah Bint Abdulrahman University,Other,15-Jun-20,31-Dec-20,31-Oct-20,CASE-CONTROL,250,ANOSMIA,SAUDI ARABIA,ALL,"12 Years to 65 Years   (Child, Adult, Older Adult)",NHANES SMELL AND TASTE TESTS,CORRELATION OF ANOSMIA AND AGEUSIA TO COVID19 POSITIVE PATIENTS,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia
NCT04388631,Recruiting,Observational [Patient Registry],,Tongji Hospital,Other,10-May-20,1-May-21,1-May-21,COHORT,200,CORONAVIRUS DISEASE 2019,CHINA,MALE,18 Years to 60 Years   (Adult),CORONAVIRUS DISEASE 2019,SPERM DENSITY,Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.
NCT04388644,Recruiting,Observational,,Taipei City Hospital,Other,20-Feb-20,30-May-20,20-May-20,CASE-ONLY,300,CORONAVIRUS INFECTION,TAIWAN,ALL,"20 Years to 65 Years   (Adult, Older Adult)",,THE NUMBER CONFIRMED COVID-19 CASES,"Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan."
NCT04388657,Recruiting,Observational,,Ramsay Générale de Santé,Other,1-May-20,1-Sep-20,1-Sep-20,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ECHO-DOPPLER,PERCENTAGE OF PATIENTS WITH ONE OR MORE DVTS.,Study of the Prevalence of Deep Vein Thrombosis in Patients Hospitalized in Intensive Care for Acute Respiratory Failure Linked to Pneumonia Documented With SARS-COV2
NCT04388670,Recruiting,Observational,,Policlinico Hospital,Other,22-Feb-20,31-Aug-20,22-Aug-20,COHORT,1500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,OVERALL NUMBER AND CHARACTERISTICS OF PATIENTS WITH COVID-19 IN ICU,Epidemiological and Clinical Characteristics of Patients With COVID-19 Admitted in Italian Intensive Care Units: a Multicentric Retrospective-prospective Cohort Study.
NCT04388683,"Active, not recruiting",Interventional,Phase 2,Tufts Medical Center,Other,12-May-20,31-Jul-21,30-Apr-21,TREATMENT,42,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",NITRIC OXIDE,"PREVENTION OF PROGRESSIVE SYSTEMIC DE-OXYGENATION, WITH ESCALATION TO HIGHER LEVELS OF OXYGEN AND VENTILATORY SUPPORT OR DEATH, ASSESSED USING A 7-POINT SEVERITY SCALE.",Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.
NCT04388709,Withdrawn,Interventional,Phase 2,Icahn School of Medicine at Mount Sinai,Other,20-Sep-21,5-Feb-21,5-Feb-21,TREATMENT,0,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",PEGINTERFERON LAMBDA-1A,NUMBER OF PARTICIPANTS WITH RESOLUTION OF HYPOXIA,A Randomized Phase 2 Trial of Peginterferon Lambda-1a (Lambda) for the Treatment of Hospitalized Patients Infected With SARS-CoV-2 With Non-critical Illness
NCT04388813,Recruiting,Observational,,Verily Life Sciences LLC,Industry,28-May-20,21-Mar-21,21-Feb-21,COHORT,1500,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PERFORMANCE (DISCRIMINATION / CALIBRATION) OF MODELS,Predictors of Severe COVID-19 Outcomes (PRESCO)
NCT04388826,"Active, not recruiting",Interventional,Phase 2,Veru Inc.,Industry,18-Jun-20,8-Feb-21,18-Dec-20,TREATMENT,40,"RESPIRATORY DISTRESS SYNDROME, ADULT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VERU-111,PROPORTION OF SUBJECTS THAT ARE ALIVE WITHOUT RESPIRATORY FAILURE AT DAY 29.,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)"
NCT04389294,Completed,Interventional,Not Applicable,"Hospital for Special Surgery, New York",Other,5-May-20,4-Sep-20,16-Jun-20,HEALTH SERVICES RESEARCH,143,COVID,UNITED STATES,ALL,"21 Years and older   (Adult, Older Adult)",SARS-COV2 SERUM ANTIBODY TESTING,CORRELATION BETWEEN SEROLOGY TESTING AND CLINICAL SUSPICION OF COVID-19,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020
NCT04389320,Completed,Observational,,Assiut University,Other,15-Mar-20,1-May-20,1-May-20,COHORT,60,RHEUMATOID ARTHRITIS,EGYPT,ALL,"20 Years to 70 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,IMMUNOGLOBULIN MESUREMENT,Antimalarial and Covid 19 in Rheumatoid Arthritis
NCT04389333,Completed,Interventional,Not Applicable,Changhai Hospital,Other,26-Mar-20,20-May-20,26-Apr-20,PREVENTION,40,GASTROINTESTINAL DISEASE,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",NON-CONTACT MAGNETICALLY-CONTROLLED CAPSULE ENDOSCOPY,MANEUVERABILITY SCORE,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial"
NCT04389359,Not yet recruiting,Interventional,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,Other,20-Sep-21,25-Aug-21,21-Aug-21,PREVENTION,1500,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE 200 MG,TIME TO CONFIRMED DIAGNOSIS OF COVID-19,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients
NCT04389372,Recruiting,Interventional,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Other,15-Mar-20,21-Dec-21,21-Mar-21,TREATMENT,50,MIGRAINE HEADACHE,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MINDFULNESS,EFFICACY OF MINDFULLNESS BY SMARTPHONE,Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency
NCT04389385,"Active, not recruiting",Interventional,Phase 1,TC Erciyes University,Other,1-May-20,31-May-21,30-Sep-20,SUPPORTIVE CARE,60,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",COVID-19 SPECIFIC T CELL DERIVED EXOSOMES (CSTC-EXO),ADVERSE REACTION (AE) AND SEVERE AE (SAE),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia
NCT04389411,Not yet recruiting,Interventional,Phase 3,McGill University,Other,1-Oct-20,21-Dec-21,21-Sep-21,TREATMENT,600,COVID,,ALL,"40 Years and older   (Adult, Older Adult)",MONTELUKAST 10MG,EMERGENCY ROOM VISITS AND HOSPITALIZATIONS,Repurposing Montelukast for the Attenuation and Prophylaxis of Severe COVID-19 Symptoms: The COvid-19 Symptom MOntelukast (COSMO) Trial
NCT04389450,Recruiting,Interventional,Phase 2,Pluristem Ltd.,Industry,1-Oct-20,22-Mar-21,21-May-21,TREATMENT,140,COVID,UNITED STATES,ALL,"40 Years to 80 Years   (Adult, Older Adult)",PLX-PAD,NUMBER OF VENTILATOR FREE DAYS,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19"
NCT04389463,Recruiting,Observational,,Nantes University Hospital,Other,11-May-20,30-Jun-22,11-May-22,COHORT,350,PATIENTS UNDERGOING CARDIAC OR THORACIC SURGERY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,HIGHEST VIS (VASOACTIVE-INOTROPIC SCORE) IN THE FIRST 12 HOURS POSTOPERATIVELY.,Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic ; International Cohort Study
NCT04389476,Not yet recruiting,Observational,,Kaohsiung Kai-Suan Psychiatric Hospital,Other,15-Jun-20,31-Jul-23,31-Jul-23,CASE-ONLY,2500,THE PSYCHOLOGICAL IMPACT OF COVID,,ALL,"20 Years and older   (Adult, Older Adult)",STANDARDIZED CRISIS MANAGEMENT AND COPING PROTOCOL PLAN TOWARD CORONAVIRUS DISEASE 2019 (COVID-19),PSYCHOLOGICAL IMPACTS BY CORONAVIRUS DISEASE 2019(COVID-19),The Impact and Coping Strategy of Taiwan Society and Medical and Nursing Institutes Toward the Biological Disaster-- Corona Virus Disease 2019 (COVID-19) as An Example
NCT04389489,Recruiting,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,14-May-20,30-Sep-20,25-Sep-20,ECOLOGIC OR COMMUNITY,140,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),,EVALUATION OF PREGNANT WOMEN DIAGNOSED WITH COVID-19 USING CAROL POSTPARTUM SEXUAL FUNCTION AND DYSPAREUNIA SCALE,Evaluation of Pregnant Women Diagnosed With COVID-19 Using Carol Postpartum Sexual Function and Dyspareunia Scale
NCT04389515,Recruiting,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,14-May-20,30-Sep-20,25-Sep-20,ECOLOGIC OR COMMUNITY,75,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),,"EVALUATION OF PREGNANT WOMEN DIAGNOSED WITH COVID-19 WITH ""POST-OPERATIVE RECOVERY INDEX"" AND ""PRENATAL CARE SATISFACTION AND PATIENT EXPECTATIONS SCALE""","Evaluation of Pregnant Women Diagnosed With COVID-19 With ""Post-operative Recovery Index"" and ""Prenatal Care Satisfaction and Patient Expectations Scale"""
NCT04389554,Completed,Observational [Patient Registry],,Kanuni Sultan Suleyman Training and Research Hospital,Other,14-May-20,29-May-20,28-May-20,CASE-CONTROL,300,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),BLOOD D-DIMER ASSAY,COMPARE D-DIMER VALUES OF COVID-19 PATIENTS AND HEALTHY PREGNANT WOMEN,Assessment of D-dimer Levels in Pregnant Women Diagnosed With COVID-19
NCT04389567,Completed,Observational,,Northwell Health,Other,12-May-20,25-May-20,25-May-20,CASE-ONLY,10,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FAMOTIDINE,SYMPTOMATIC IMPROVEMENT,Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series
NCT04389580,Not yet recruiting,Interventional,Phase 2,Kafrelsheikh University,Other,20-Jun-21,20-Sep-21,20-Aug-21,TREATMENT,160,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DRUG: ISOTRETINOIN PLUS TAMOXIFEN,LUNG INJURY SCORE,Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus
NCT04389645,Completed,Observational,,MeMed Diagnostics Ltd.,Industry,7-Apr-20,12-May-20,12-May-20,,52,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",IP-10 IN CDS PROTOCOL,IP-10 LEVELS,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients
NCT04389658,Completed,Observational,,Igenomix,Industry,7-May-20,25-Aug-20,10-Jun-20,OTHER,1526,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,PREVALENCE OF CONTAGIOUSNESS IN ASYMPTOMATIC INDIVIDUALS BY PCR,Retrospective Observational Study to Determine COVID-19 Contagious and Immunological Status in Asymptomatic Population of Highly Affected Areas
NCT04389671,Not yet recruiting,Interventional,Phase 1/Phase 2,Windtree Therapeutics,Industry,20-Oct-21,21-Apr-21,21-Mar-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",LUCINACTANT,OXYGENATION INDEX (OI) AREA UNDER THE CURVE (AUC)0-12,"A Multicenter, Single-Treatment Study to Assess the Safety and Preliminary Efficacy of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury"
NCT04389684,Recruiting,Observational,,Poitiers University Hospital,Other,27-May-20,27-Jul-21,27-Jul-21,COHORT,120,CHEMEOTHERAPY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PSYCHO-SOCIAL QUESTIONNAIRE,OVERALL SURVIVAL OF PATIENTS WITH METASTATIC COLORECTAL CANCER OR METASTATIC PANCREATIC CANCER,Clinical and Psycho-Social Impact on Patients With Digestive Tumors of Treatment and Care Modifications Linked to COVID-19 in France
NCT04389710,Recruiting,Interventional,Phase 2,Thomas Jefferson University,Other,15-Apr-20,14-Apr-21,14-Apr-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,NUMBER OF PATIENTS WHO RECEIVE COVID-19 CONVALESCENT PLASMA TRANSFUSIONS IN ACUTE CARE FACILITIES INFECTED WITH SARS-COV-2,Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04389801,Not yet recruiting,Interventional,Phase 4,Hesham Al-Inany,Other,1-Jun-20,31-Dec-20,30-Sep-20,TREATMENT,200,COVID,,ALL,"Child, Adult, Older Adult",DESFERAL 500 MG INJECTION,MORTALITY RATE,The Use of Desferal and Adjuvants for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection: A Randomized Controlled Trial
NCT04389840,Recruiting,Interventional,Phase 2/Phase 3,Chimerix,Industry,3-Jun-20,21-Jun-21,21-Feb-21,TREATMENT,525,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",DOCIPARSTAT SODIUM,PROPORTION OF PARTICIPANTS WHO ARE ALIVE AND FREE OF INVASIVE MECHANICAL VENTILATION,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
NCT04389944,Completed,Interventional,Not Applicable,"University Hospital, Basel, Switzerland",Other,31-Mar-20,30-Jun-20,30-Jun-20,TREATMENT,15,CORONAVIRUS DISEASE 2019 INFECTIOUS DISEASE (COVID INFECTION),SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA APPLICATION TO SARS-COV-2 INFECTED PATIENTS,SERIOUS ADVERSE EVENTS IN CONVALESCENT PLASMA TREATED PATIENTS,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19)
NCT04389996,"Active, not recruiting",Observational [Patient Registry],,Odense University Hospital,Other,14-May-20,1-May-23,21-Jul-20,COHORT,5000,CANCER,DENMARK,ALL,"18 Years to 125 Years   (Adult, Older Adult)",NO INTERVENTION,OVERALL QUALITY OF LIFE,COVID-19 Pandemic Impact on Patients With Cancer - a Danish Survey
NCT04390022,Completed,Interventional,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",Other,31-Jul-20,9-Oct-20,17-Sep-20,TREATMENT,24,COVID,SPAIN,ALL,18 Years to 59 Years   (Adult),IVERMECTIN,PROPORTION OF PATIENTS WITH A POSITIVE SARS-COV-2 PCR,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission
NCT04390061,Not yet recruiting,Interventional,Phase 2,Università Politecnica delle Marche,Other,20-Jun-21,20-Oct-21,20-Sep-21,TREATMENT,116,"PNEUMONITIS, INTERSTITIAL",,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TOFACITINIB,PREVENTION OF SEVERE RESPIRATORY FAILURE REQUIRING MECHANICAL VENTILATION,TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial
NCT04390074,Completed,Observational,,Uppsala University,Other,27-May-20,4-Jun-20,4-Jun-20,CASE-CONTROL,9905,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 AND INTENSIVE CARE,CHRONIC MEDICATIONS AS RISK FACTOR OF INTENSIVE CARE FOR COVID-19,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality
NCT04390126,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire Dijon,Other,20-Apr-20,7-Nov-21,7-May-21,COHORT,1200,CHRONIC CORONARY SYNDROME,FRANCE,ALL,"9 Months and older   (Child, Adult, Older Adult)",LIFE QUESTIONNAIRES,% ADHERENCE TO EACH PHARMACOLOGICAL CLASS,COVID-19 Related Lockdown Effects On Chronic Diseases
NCT04390139,Recruiting,Interventional,Phase 1/Phase 2,Banc de Sang i Teixits,Other,13-May-20,20-Dec-21,20-Oct-21,TREATMENT,30,COVID,SPAIN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",XCEL-UMC-BETA,ALL-CAUSE MORTALITY AT DAY 28,"A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19"
NCT04390152,Recruiting,Interventional,Phase 1/Phase 2,BioXcellerator,Industry,13-Jan-20,22-Apr-21,21-Dec-21,TREATMENT,40,ACUTE RESPIRATORY DISTRESS SYNDROME,COLOMBIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",WHARTON'S JELLY DERIVED MESENCHYMAL STEM CELLS.,INTERGROUP MORTALITY DIFFERENCE WITH TREATMENT,Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial
NCT04390165,Completed,Observational,,Hospital Sultanah Bahiyah,Other,6-Jun-20,30-Nov-20,30-Nov-20,CASE-ONLY,498,SARS-COV INFECTION,MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT-REPORTED ONLINE QUESTIONNAIRE ON OLFACTORY & TASTE DISTURBANCES,PRESENCE OR ABSENCE OF OLFACTORY AND TASTE DISTURBANCES IN COVID-19 PATIENTS,Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Cross-Sectional Study
NCT04390178,"Active, not recruiting",Interventional,Phase 1/Phase 2,Joakim Dillner,Other,10-Apr-20,20-Dec-21,20-Jun-21,TREATMENT,10,COVID,SWEDEN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SARS-COV-2 CONVALESCENT PLASMA,DISEASE PROGRESSION,Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease
NCT04390191,Recruiting,Interventional,Not Applicable,Icahn School of Medicine at Mount Sinai,Other,7-May-20,21-May-21,21-Apr-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONTINUOUS POSITIVE AIRWAY PRESSURE,EFFICACY ENDPOINT COMPOSITE SCORE,Early Continuous Positive Airway Pressure (CPAP) in COVID-19 Confirmed or Suspected Patients
NCT04390217,Not yet recruiting,Interventional,Phase 2,"Leading BioSciences, Inc",Industry,31-Oct-21,31-Mar-22,31-Dec-21,TREATMENT,120,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",LB1148,EFFECT OF LB1148 ON DISEASE PROGRESSION VIA MEASUREMENT OF THE PROPORTION OF PATIENTS WHO ARE ALIVE AND FREE OF RESPIRATORY FAILURE.,A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia
NCT04390269,Recruiting,Observational,,Mansoura University,Other,10-Sep-20,9-May-22,10-Oct-21,CASE-CONTROL,200,GENETIC PREDISPOSITION TO DISEASE,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,FOR THE PATIENTS,Various Molecular Markers With Predictive and Prognostic Significance in COVID-19 Outcome
NCT04390412,"Active, not recruiting",Interventional,Phase 1/Phase 2,Shahid Beheshti University of Medical Sciences,Other,4-May-20,20-Dec-21,30-Aug-20,SUPPORTIVE CARE,5,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"60 Years and older   (Adult, Older Adult)",LOW DOSE RADIOTHERAPY,CHANGE FROM BASELINE BLOOD OXYGENATION,Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial
NCT04390464,Recruiting,Interventional,Phase 4,Cambridge University Hospitals NHS Foundation Trust,Other,8-May-20,1-May-22,7-May-21,TREATMENT,1167,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",RAVULIZUMAB,"TIME TO INCIDENCE OF THE COMPOSITE ENDPOINT OF: DEATH, MECHANICAL VENTILATION, ECMO, CARDIOVASCULAR ORGAN SUPPORT, OR RENAL FAILURE",mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
NCT04390477,Recruiting,Interventional,Not Applicable,Bioithas SL,Industry,4-May-20,21-Sep-21,21-Jul-21,TREATMENT,40,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PROBIOTIC,CASES WITH DISCHARGE TO ICU.,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection
NCT04390503,Recruiting,Interventional,Phase 2,Columbia University,Other,20-May-21,21-Apr-21,21-Apr-21,TREATMENT,200,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA (ANTI-SARS-COV-2 PLASMA),RATE OF SEVERE DISEASE,"A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases"
NCT04390516,Completed,Interventional,Not Applicable,Dascena,Industry,24-Mar-20,30-May-20,4-May-20,DIAGNOSTIC,197,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVIAGE,MECHANICALLY VENTILATED PATIENT OUTCOME,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial
NCT04390555,Recruiting,Observational [Patient Registry],,University of Zurich,Other,30-Apr-20,21-Jul-21,20-Dec-21,COHORT,1500,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY.,COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry
NCT04390594,Recruiting,Interventional,Phase 3,Institut Pasteur de Dakar,Other,13-Aug-20,12-Aug-21,12-Feb-21,TREATMENT,186,COVID,SENEGAL,ALL,"18 Years and older   (Adult, Older Adult)",NAFAMOSTAT MESILATE,SARS-COV-2 VIRAL LOAD LEVEL,"Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal"
NCT04391101,Not yet recruiting,Interventional,Phase 3,Hospital San Vicente Fundación,Other,20-Jun-21,21-Dec-21,21-Jun-21,TREATMENT,231,SARS-COV2,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,INTRAHOSPITAL MORTALITY FROM ANY CAUSE,"Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial"
NCT04391127,Completed,Interventional,Phase 3,Centenario Hospital Miguel Hidalgo,Other,4-May-20,6-Nov-20,6-Nov-20,TREATMENT,108,COVID,MEXICO,ALL,"16 Years to 90 Years   (Child, Adult, Older Adult)",HYDROXYCHLOROQUINE,MEAN DAYS OF HOSPITAL STAY,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial
NCT04391140,Recruiting,Interventional,Not Applicable,Hospital Universitari Vall d'Hebron Research Institute,Other,13-May-20,21-Jun-21,20-Dec-21,SUPPORTIVE CARE,248,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITION,THERAPEUTIC FAILURE DEATH OR INTUBATION,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS
NCT04391166,"Active, not recruiting",Observational,,Vanderbilt University Medical Center,Other,20-May-20,1-May-22,1-May-22,COHORT,150,VISUAL IMPAIRMENT,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",NON INVASIVE VISUAL ACUITY TESTING,BEST CORRECTED VISUAL ACUITY (BCVA) PER EYE,Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic
NCT04391179,"Active, not recruiting",Interventional,Phase 2,University of Michigan,Other,31-May-20,21-Feb-21,21-Feb-21,TREATMENT,160,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIPYRIDAMOLE 100 MILLIGRAM(MG),CHANGE IN D-DIMER,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
NCT04391309,Not yet recruiting,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,21-Feb-21,22-Jan-21,21-Oct-21,TREATMENT,300,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-CD14,TIME TO CLINICAL RECOVERY,"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19"
NCT04391400,Not yet recruiting,Observational,,"Invivoscribe, Inc.",Industry,1-Jun-20,30-Jun-21,30-Jun-21,CASE-ONLY,500,SARS-COV2,,ALL,"Child, Adult, Older Adult",NASAL PHARYNGEAL (NP) SWAB SAMPLES,"IDENTIFICATION OF NUCLEIC ACID SEQUENCING, ANTIBODIES AND ANTIGENS TO BE USED IN DETECTION METHODS OR TREATMENTS AND/OR VACCINES","The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines"
NCT04391686,Recruiting,Observational [Patient Registry],,Centre Hospitalier Arras,Other,3-Jul-20,2-Nov-21,2-Nov-21,COHORT,90,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INDIRECT CALORIMETRY,THE RESTING ENERGY EXPENDITURE (IN KCAL / 24H) MEASURED BY INDIRECT CALORIMETRY DURING THE STAY IN INTENSIVE CARE.,Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context
NCT04391712,Completed,Interventional,Phase 2,Lowell General Hospital,Other,30-Apr-20,16-Jul-20,15-May-20,TREATMENT,10,COVID,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MLS LASER,PATIENT DISPOSITION POST TREATMENT,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease
NCT04391738,"Active, not recruiting",Observational,,"University Hospital, Lille",Other,1-Feb-20,30-Sep-20,15-May-20,COHORT,1200,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS ADMITTED TO INTENSIVE CARE UNIT WITH SARS-COV2,RELATIONSHIP BETWEEN BODY MASS INDEX (BMI) AND SARS-COV-2,Relationship Between Obesity and Severe Acute Respiratory Syndrome Coronavirus-2 in Patient With SARS-CoV-2 Admitted in Intensive Care : A Multicenter Retrospective Cohort Study
NCT04391816,Recruiting,Observational,,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,4-Mar-21,31-Dec-24,31-Dec-22,OTHER,700,ALCOHOL DRINKING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,AUDIT SCORE,COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study
NCT04391829,Recruiting,Interventional,Not Applicable,Universitair Ziekenhuis Brussel,Other,31-Aug-20,31-Aug-21,31-Aug-21,DIAGNOSTIC,20,COVID,BELGIUM,MALE,18 Years to 50 Years   (Adult),EJACULATED SEMEN SAMPLE,DETECTION OF SARS-COV-2 IN THE SEMEN,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males
NCT04391881,Recruiting,Observational,,Cairo University,Other,30-May-20,30-Aug-20,30-Aug-20,OTHER,500,ORAL HEALTH AND COVID,EGYPT,ALL,18 Years to 60 Years   (Adult),,ORAL MANIFESTATION,Oral Manifestation of COVID19
NCT04391920,Recruiting,Observational [Patient Registry],,"CytoSorbents, Inc",Industry,28-Aug-20,22-Oct-21,22-Aug-21,COHORT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CYTOSORB 300 ML DEVICE,ICU MORTALITY,"Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients"
NCT04391946,Recruiting,Observational [Patient Registry],,French Innovative Leukemia Organisation,Other,14-Mar-20,31-Dec-22,1-May-22,COHORT,50,"CHRONIC LYMPHOCYTIC LEUKEMIA, LYMPHOCYTIC LYMPHOMA OR WALDENSTROM DISEASE",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA REGISTRY,PROGNOSTIC FACTORS FOR HEALING OF COVID-19 INFECTION,National Prospective and Retrospective Follow-up of Patients With COVID-19 Infected Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenström Disease
NCT04392089,Recruiting,Observational,,Hvidovre University Hospital,Other,1-May-20,1-May-21,1-May-21,COHORT,20,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)","MASIMO, LIDCO",CHANGES IN CEREBRAL OXYGENATION (SCO2) DURING CARDIOVASCULAR AND PULMONARY OPTIMIZATION,Effects of Cardiovascular and Pulmonary Optimisation on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS
NCT04392115,Not yet recruiting,Interventional,Not Applicable,Ottawa Hospital Research Institute,Other,15-Jun-20,15-Sep-21,15-Dec-20,HEALTH SERVICES RESEARCH,372,COMORBIDITIES AND COEXISTING CONDITIONS,,ALL,65 Years and older   (Older Adult),THE PREPARE PROGRAM,PATIENT-REPORTED DISABILITY 90 DAYS AFTER ENROLLMENT,PRomoting Exercise During the Pandemic to Increase Activity and Reduce Effects of Social Isolation for COVID: The PREPARE for COVID Trial
NCT04392128,Withdrawn,Interventional,Phase 2,Institut de cancérologie Strasbourg Europe,Other,2-Sep-20,2-Sep-20,2-Sep-20,TREATMENT,0,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE 200 MG [PLAQUENIL],EVALUATION OF THE EFFICACY OF HYDROXYCHLOROQUINE AND AZITHROMYNCINE ON THE VIRAL LOAD DROP AT DAY 5.,"Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies"
NCT04392141,Recruiting,Interventional,Phase 1/Phase 2,Kermanshah University of Medical Sciences,Other,1-Apr-20,1-Nov-20,1-Nov-20,TREATMENT,200,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"10 Years and older   (Child, Adult, Older Adult)",STANDARD TREATMENT,MORTALITY RATE,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19
NCT04392219,Completed,Interventional,Phase 1,"Ridgeback Biotherapeutics, LP",Industry,10-Apr-20,11-Aug-20,11-Aug-20,TREATMENT,130,CORONAVIRUS,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),EIDD-2801,SAFETY AND TOLERABILITY OF SINGLE ASCENDING DOSE (SAD) OF EIDD-2801 (PART 1): ADVERSE EVENTS,"A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers"
NCT04392232,Recruiting,Interventional,Phase 2,TriHealth Inc.,Other,5-May-20,31-Dec-20,31-Dec-20,TREATMENT,100,CORONAVIRUS,UNITED STATES,ALL,"16 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,SURVIVAL RATE,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392245,Completed,Observational,,Societa Italiana di Chirurgia ColoRettale,Other,15-Apr-20,26-Apr-20,26-Apr-20,OTHER,1050,PROCTOLOGIC PRACTICE DURING COVID,ITALY,ALL,"Child, Adult, Older Adult",,PREDICTIVE POWER OF RESPONDENTS' AND HOSPITALS' DEMOGRAPHICS ON THE CHANGE OF STATUS OF PROCTOLOGIC SURGICAL AND OUTPATIENT ACTIVITIES,A Worldwide Survey on Proctologic Practice During Covid-19 Lockdown
NCT04392323,Recruiting,Interventional,Not Applicable,Northwell Health,Other,13-May-20,31-Jul-20,1-Jul-20,DIAGNOSTIC,500,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PCR AND SEROLOGY,COVID-19 TEST CONVERSION,Incidence of COVID-19 Test Conversion in Post-surgical Patients
NCT04392388,Recruiting,Observational,,"Institut National de la Santé Et de la Recherche Médicale, France",Other,1-May-20,31-Dec-20,31-Dec-20,COHORT,110000,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",NON APPLICABLE,CUMULATIVE INCIDENCE OF SARS-COV2 INFECTION IN THE GENERAL POPULATION.,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology"
NCT04392401,Recruiting,Observational,,Hospices Civils de Lyon,Other,11-May-20,21-Feb-21,21-Feb-21,COHORT,200,INTENSIVE CARE UNIT,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COLLECTION OF BLOOD SAMPLES IN ORDER TO CREATE A BIOCOLLECTION,KINETICS OVER TIME OF HLA-DR EXPRESSION ON THE SURFACE OF MONOCYTES,Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study
NCT04392414,Completed,Interventional,Phase 2,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",Other,1-May-20,23-Sep-20,10-Jul-20,TREATMENT,60,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 75 Years   (Adult, Older Adult)",COVID-19 CONVALESCENT HYPERIMMUNE PLASMA,"THE NUMBER AND PROPORTION OF PATIENTS WITH THE NORMAL BODY TEMPERATURE (≤37.2 C) AT THE DAY 1, 2, 3, 4, 5, 6, 7 AFTER THE START OF THERAPY","Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease"
NCT04392427,Not yet recruiting,Interventional,Phase 3,Mansoura University,Other,20-Oct-21,22-May-21,22-May-21,TREATMENT,100,COVID,EGYPT,ALL,"12 Years and older   (Child, Adult, Older Adult)","TREATMENT GROUP: WILL RECEIVE A COMBINATION OF NITAZOXANIDE, RIBAVIRIN AND IVERMECTIN FOR A DURATION OF SEVEN DAYS :",NEGATIVE TEST RESULT FOR COVID-19,"Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial"
NCT04392453,Recruiting,Interventional,Not Applicable,Fondazione Don Carlo Gnocchi Onlus,Other,26-Oct-20,21-Dec-21,21-Dec-21,TREATMENT,40,STROKE,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ROBOTIC THERAPY,SYSTEM USABILITY SCALE (SUS),Upper Limb Robotic Rehabilitation in Stroke Survivors Using a Portable Device During the COVID-19 Outbreak. A Feasibility Study
NCT04392531,Recruiting,Interventional,Phase 4,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Other,16-Apr-20,21-Mar-21,21-Mar-21,TREATMENT,120,COVID INFECTION,SPAIN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CYCLOSPORINE,SEVERITY CATEGORY,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection"
NCT04392713,Recruiting,Interventional,Not Applicable,"Combined Military Hospital, Pakistan",Other,15-Apr-20,20-Jul-21,20-Jul-21,TREATMENT,100,COVID,PAKISTAN,ALL,"15 Years to 65 Years   (Child, Adult, Older Adult)",IVERMECTIN 6 MG ORAL TABLET (2 TABLETS),NEGATIVE PCR,Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial
NCT04392778,Recruiting,Interventional,Phase 1/Phase 2,SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi,Other,1-Apr-20,20-Sep-21,20-Jul-21,TREATMENT,30,COVID,TURKEY,ALL,40 Years to 60 Years   (Adult),MSC TREATMENT,CLINICAL IMPROVEMENT,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study)
NCT04392973,Recruiting,Interventional,Not Applicable,King Abdullah International Medical Research Center,Other,21-May-20,21-Nov-21,21-Nov-21,TREATMENT,520,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR AND HYDROXYCHLOROQUINE,CLINICAL IMPROVEMENT,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19
NCT04393038,Recruiting,Interventional,Phase 2/Phase 3,Abivax S.A.,Industry,1-May-20,30-Apr-21,30-Dec-20,TREATMENT,1034,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",ABX464,"RATE OF PATIENTS WITH NO INVASIVE OR NON-INVASIVE MECHANICAL VENTILATION (IMV AND NIV, RESPECTIVELY), BUT EXCLUDING SIMPLE NASAL/MASK OXYGEN SUPPLEMENTATION, AND WHO ARE ALIVE","A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged ≥ 65 and Patients Aged ≥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2."
NCT04393051,Not yet recruiting,Interventional,Phase 2,"Azienda Ospedaliero, Universitaria Pisana",Other,20-May-20,30-Jul-20,30-Jun-20,TREATMENT,126,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",BARICITINIB ORAL TABLET,NEED OF INVASIVE MECHANICAL VENTILATION,"BARICIVID-19 STUDY: MultiCentre, Randomised, Phase IIa Clinical Trial Evaluating Efficacy and Tolerability of Baricitinib as add-on Treatment of In-patients With COVID-19 Compared to Standard Therapy"
NCT04393077,Completed,Interventional,Not Applicable,Istanbul Saglik Bilimleri University,Other,10-May-20,20-May-20,15-May-20,SUPPORTIVE CARE,80,STRESS,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EMOTIONAL FREEDOM TECHNIQUE,THE SUBJECTIVE UNITS OF DISTRESS SCALE,"Emotional Freedom Technique (EFT) Effect on Nurses' Stress, Anxiety and Burnout Levels During the COVID-19 Pandemic Process: A Randomized Controlled Study"
NCT04393142,Completed,Observational [Patient Registry],,Hospital Universitario Dr. Jose E. Gonzalez,Other,5-May-20,16-Feb-21,16-Feb-21,OTHER,96,CORONAVIRUS INFECTION,MEXICO,ALL,"1 Year and older   (Child, Adult, Older Adult)",,IDENTIFY ANTIBODIES,Observational Trial Evaluating the Serologic Status of Household Contacts of Patients Diagnosed With COVID-19
NCT04393155,Terminated,Observational,,University of Vermont,Other,16-Apr-20,25-Jan-21,20-Jan-21,COHORT,16,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19+ OBSERVATIONAL,SIX MINUTE WALK DISTANCE (6MWD),Understanding Immunology and Patient Outcomes of COVID-19: A 1-Year Longitudinal Follow-up Study of Hospitalized Patients
NCT04393233,Recruiting,Observational,,"University Hospital, Brest",Other,23-Apr-20,23-May-20,23-May-20,COHORT,300,RHEUMATOID ARTHRITIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,REDUCTION OR DISCONTINUATION OF THE DMARD THERAPY IN RELATION TO THE COVID-19 SANITARY CRISIS,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation
NCT04393246,Recruiting,Interventional,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,Other,3-Jul-20,15-Jun-21,15-Feb-21,TREATMENT,1407,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EDP1815,"TIME TO INCIDENCE OF THE COMPOSITE ENDPOINT OF: DEATH, MECHANICAL VENTILATION, ECMO, CARDIOVASCULAR ORGAN SUPPORT, OR RENAL FAILURE",mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)
NCT04393311,Not yet recruiting,Interventional,Phase 1/Phase 2,Stanford University,Other,21-Mar-21,21-Sep-21,21-Sep-21,TREATMENT,160,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ULINASTATIN,TIME TO RECOVERY,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients"
NCT04393324,Recruiting,Observational [Patient Registry],,"Hospital San Carlos, Madrid",Other,24-Apr-20,30-Jun-20,31-May-20,COHORT,2500,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,MORTALITY,The Critical Care Resources Adaptation to the SARS-CoV-2 Pandemic in Madrid
NCT04393402,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,20-Mar-20,31-Dec-20,31-Dec-20,COHORT,14,COVID,FRANCE,ALL,"18 Years to 95 Years   (Adult, Older Adult)",LUNG ULTRASOUND (LUS),LUS APPLICABILITY WITH COVID 19,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care
NCT04393415,Recruiting,Interventional,Not Applicable,Aljazeera Hospital,Other,25-May-20,1-Sep-20,25-Aug-20,SUPPORTIVE CARE,100,VIRUS,EGYPT,ALL,"20 Years to 70 Years   (Adult, Older Adult)",STEM CELLS,THE NUMBER OF PATIENTS WITH POSITIVE COVID 19 WHO WILL IMPROVE AFTER RECEIVING STEM CELLS,the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19
NCT04393428,Completed,Observational,,"University Hospital, Montpellier",Other,1-Mar-20,30-Jun-20,1-Jun-20,COHORT,100,COVID,FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",[TIMP-2]*[IGFBP-7],SENSIBILITY AND SPECIFICITY OF URINARY,Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19)
NCT04393558,Recruiting,Observational,,Shirley Ryan AbilityLab,Other,20-Apr-20,31-Dec-22,31-Dec-22,COHORT,100,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",ADAM SENSOR,BODY TEMPERATURE,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms
NCT04393636,Recruiting,Interventional,Not Applicable,Academisch Ziekenhuis Maastricht,Other,5-Jun-20,31-Dec-22,31-Dec-22,SUPPORTIVE CARE,394,CARDIOVASCULAR DISEASES,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",DIGITAL CARDIAC COUNSELING,MACES,Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)
NCT04393649,Recruiting,Observational [Patient Registry],,Jewish General Hospital,Other,20-Apr-20,19-Apr-21,19-Apr-21,COHORT,20000,COVID,CANADA,ALL,70 Years and older   (Older Adult),ESOGER,COVID-19 SYMPTOMS,First Level Socio-geriatric Evaluation in Period of Physical and Social Distancing in Frail Older Patients and Older Community Dwellers: ESOGER Databank
NCT04393727,Terminated,Interventional,Phase 2,"Azienda Ospedaliero, Universitaria Pisana",Other,1-May-20,30-Sep-20,30-Sep-20,TREATMENT,1,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,NEED OF INVASIVE MECHANICAL VENTILATION,Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial
NCT04393792,Recruiting,Interventional,Phase 1,Hampshire Hospitals NHS Foundation Trust,Other,20-May-21,20-Aug-21,20-Aug-21,TREATMENT,40,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",POVIDONE-IODINE,CHANGE IN VIRAL LOAD IN THE ORAL AND NASOPHARYNGEAL CAVITY,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?
NCT04393805,Recruiting,Observational,,Quovadis Associazione,Other,1-Jun-20,20-Dec-21,20-Dec-21,COHORT,877,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",LOW MOLECULAR WEIGHT HEPARIN,BLEEDING,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto
NCT04393818,Completed,Interventional,Phase 3,Fundació d'investigació Sanitària de les Illes Balears,Other,5-May-20,24-Aug-20,24-Aug-20,SUPPORTIVE CARE,560,MENTAL HEALTH DISORDER,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION APP,"DEPRESSION, ANXIETY AND STRESS",A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial
NCT04393948,Recruiting,Interventional,Not Applicable,Brigham and Women's Hospital,Other,20-Jun-21,20-Nov-21,20-Oct-21,TREATMENT,48,SARS-COV2,UNITED STATES,ALL,"40 Years and older   (Adult, Older Adult)",PHASE 1,PHASE 1: FEASIBILITY AND SAFETY OF TREATING HOSPITALIZED PATIENTS WITH SARS-COV-2 PNEUMONIA WITH SINGLE OR BILATERAL WHOLE LUNG IRRADIATION,Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia
NCT04393961,Recruiting,Interventional,Not Applicable,ProofPilot,Industry,5-Apr-20,29-Aug-20,29-Jul-20,DEVICE FEASIBILITY,600,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",PREMIER BIOTECH COVID-19 IGG/IGM RAPID TEST CASSETTE,DOES PARTICIPANT ACCURATELY READ RESULT,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study
NCT04393974,Recruiting,Observational,,Imperial College London,Other,24-Mar-20,24-Mar-22,24-Mar-22,CASE-ONLY,1000,CANCER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,DESCRIBE PRESENTING CHARACTERISTICS AND SEVERITY OR SARS-COV-2 INFECTION IN PATIENTS WITH CANCER,OnCovid: Natural History and Outcomes of Cancer Patients During the COVID19 Epidemic
NCT04394000,Completed,Observational [Patient Registry],,Jessa Hospital,Other,4-May-20,15-May-20,15-May-20,COHORT,72,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",THROMBOPROFYLAXIS PROTOCOL,2 WEEK MORTALITY,Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study
NCT04394013,Completed,Interventional,Not Applicable,Monash University Malaysia,Other,26-Aug-20,31-Dec-20,31-Dec-20,SUPPORTIVE CARE,70,MENTAL HEALTH ISSUE,MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",MINDFULNESS INTERVENTION,LONELINESS (UCLA-8 LONELINESS SCALE),A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period
NCT04394026,Recruiting,Observational,,Francesco De Cobelli,Other,16-Apr-20,31-Jul-21,30-Jun-21,COHORT,500,VIRAL PNEUMONIA,ITALY,ALL,"Child, Adult, Older Adult",,DESCRIBE QUALITATIVE AND QUANTITATIVE VARIABLES,COVID-19 Imaging Features
NCT04394039,Not yet recruiting,Interventional,Not Applicable,"National University, Singapore",Other,1-Jun-20,31-Dec-20,1-Aug-20,SUPPORTIVE CARE,34,STRESS,SINGAPORE,ALL,"21 Years to 75 Years   (Adult, Older Adult)",PUBLIC SPACE EXPOSURE,EEG POWER IN ALPHA BAND,Effects of COVID-19-Related Self-isolation on Psychological Response to Different Outdoor Environments in Singapore - Before & After Brain and Behavior Study
NCT04394078,Completed,Observational,,Okan University,Other,6-May-20,18-May-20,18-May-20,ECOLOGIC OR COMMUNITY,543,DEPRESSION,TURKEY,ALL,"15 Years to 65 Years   (Child, Adult, Older Adult)",ONLINE SURVEY,SOCIODEMOGRAPHIC INFORMATION FORM,Impact of COVID-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution
NCT04394104,Terminated,Observational,,"Rutgers, The State University of New Jersey",Other,27-May-20,31-May-20,31-May-20,OTHER,593,HEALTH BEHAVIOR,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,HEALTH BEHAVIOR CHANGE REGRESSION QUESTIONNAIRE,COVID-19 Health and Wellness Self-Assessment Survey
NCT04394117,Recruiting,Interventional,Phase 4,The George Institute,Other,19-Jun-20,30-Aug-21,30-Jun-21,TREATMENT,1500,SARS-COV2,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN RECEPTOR BLOCKERS,7-POINT NATIONAL INSTITUTE OF HEALTH CLINICAL HEALTH SCORE,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
NCT04394169,Recruiting,Interventional,Not Applicable,Hospital Clinic of Barcelona,Other,25-May-20,25-Mar-21,25-Sep-20,PREVENTION,102,POST ICU SYNDROME,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION PROGRAM,IMPACT OF INTERVENTION PROGRAM ON HEALTH-RELATED QUALITY OF LIFE (VAS),"Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial."
NCT04394182,Recruiting,Interventional,Not Applicable,Fundacion GenesisCare,Other,21-Apr-20,21-Apr-21,31-Dec-20,SUPPORTIVE CARE,15,"PNEUMONIA, VIRAL",SPAIN,ALL,"18 Years to 120 Years   (Adult, Older Adult)",ULTRA-LOW-DOSE RADIOTHERAPY,OXYGEN THERAPY STATUS AT DAY 2,Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers
NCT04394195,Recruiting,Observational,,CHU de Reims,Other,25-Mar-20,1-Sep-20,1-Jul-20,COHORT,200,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MEASUREMENT OF CIRCULATING SFLT1 CONCENTRATION,ASSOCIATION BETWEEN CONCENTRATION OF CIRCULATING SFLT1 AND USE OF VASOPRESSOR,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?
NCT04394208,Recruiting,Interventional,Phase 3,Cairo University,Other,16-Aug-20,28-Feb-21,30-Jan-21,TREATMENT,50,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SILYMARIN,TIME TO CLINICAL IMPROVEMENT,Trial of Silymarin in Adults With COVID-19 Pneumonia
NCT04394377,Recruiting,Interventional,Phase 4,Brazilian Clinical Research Institute,Other,21-Jun-20,21-Mar-21,21-Mar-21,TREATMENT,600,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",GROUP 1: RIVAROXABAN 20MG/D FOLLOWED BY ENOXAPARIN/UNFRACTIONATED HEPARIN WHEN NEEDED,"HIERARCHICAL COMPOSITE ENDPOINT COMPOSED OF MORTALITY, NUMBER OF DAYS ALIVE, NUMBER OF DAYS IN THE HOSPITAL AND NUMBER OF DAYS WITH OXYGEN THERAPY AT THE END OF 30 DAYS.",Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial
NCT04394390,Enrolling by invitation,Observational [Patient Registry],,Bursa City Hospital,Other,1-May-20,30-Jun-20,15-Jun-20,CASE-CONTROL,100,COVID,TURKEY,ALL,"Child, Adult, Older Adult",VITAMIN D,LABORATORY MEASURED VITAMIN D LEVELS,Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?
NCT04394403,Recruiting,Interventional,Not Applicable,Hebrew University of Jerusalem,Other,14-May-20,30-Jun-22,31-Dec-21,TREATMENT,120,STRESS,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",INTERNET-BASED GUIDED SELF-HELP BASED ON CBT PRINCIPLES,THE CORONAVIRUS HEALTH IMPACT SURVEY (CRISIS),Pilot Internet-based Self-Help Program for Managing Corona Stress vs. Waitlist Control
NCT04394416,Recruiting,Interventional,Phase 3,"University of Maryland, Baltimore",Other,2-Jun-20,1-Jun-23,1-Jun-22,TREATMENT,204,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IMATINIB,THE PROPORTION OF PATIENTS WITH A TWO-POINT CHANGE USING THE 8-CATEGORY ORDINAL SCALE,Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19
NCT04394429,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,24-Apr-20,24-Jun-21,24-Jun-21,CASE-ONLY,184,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ANALYSIS OF RISK FACTORS FOR INTUBATION TUBE OBSTRUCTION,Analysis of Events of Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation
NCT04394442,Recruiting,Interventional,Phase 2,Samah Lutfy,Other,21-Mar-20,20-Aug-21,20-Aug-21,TREATMENT,200,COVID,SAUDI ARABIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,TIME TO VIRAL CLEARANCE,Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial
NCT04394455,Enrolling by invitation,Interventional,Not Applicable,Universidad Nacional Autonoma de Honduras,Other,30-Jun-20,30-Dec-20,30-Nov-20,TREATMENT,236,ANXIETY,HONDURAS,ALL,"18 Years and older   (Adult, Older Adult)",BRIEF COGNITIVE BEHAVIORAL THERAPY,RATE REDUCTION IN DEPRESSIVE SYMPTOMS,Effect of Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry in Medical Staff During the COVID-19 Pandemic: A Multicentric Randomized Controlled Trial
NCT04394793,"Active, not recruiting",Interventional,Not Applicable,"All India Institute of Medical Sciences, New Delhi",Other,13-Jun-20,20-Sep-21,27-Aug-20,TREATMENT,10,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",LOW DOSE RADIATION THERAPY,SYMPTOMATIC IMPROVEMENT BY NATIONAL EARLY WARNING SCORE (NEWS),Low Dose Radiation Therapy for Covid-19 Pneumonia: A Pilot Study
NCT04394884,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,4-Mar-21,30-Apr-23,30-Apr-23,COHORT,120,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,TO CHARACTERIZE THE IMMUNOLOGIC MECHANISMS BY WHICH BTK INHIBITION MAY AMELIORATE HYPER- INFLAMMATORY RESPONSES IN PATIENTS WITH COVID-19.,Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19
NCT04395105,Recruiting,Interventional,Phase 3,Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno,Other,21-May-20,31-Jan-21,31-Dec-20,TREATMENT,284,"RESPIRATORY DISTRESS SYNDROME, ADULT",ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE (HIGH DOSE),VENTILATOR-FREE DAYS AT 28 DAYS,High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial
NCT04395144,Recruiting,Interventional,Not Applicable,Hôpital de Verdun,Other,15-May-20,31-Mar-21,30-Mar-21,TREATMENT,346,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",AWAKE PRONE POSITIONING,"RATE OF THERAPEUTIC FAILURE, DEFINED AS A COMBINED OUTCOME OF RATE OF INTUBATION OR DEATH",Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19
NCT04395170,Not yet recruiting,Interventional,Phase 2/Phase 3,"Lifefactors Zona Franca, SAS",Industry,20-Sep-21,21-Jun-21,20-Dec-21,TREATMENT,75,CORONAVIRUS DISEASE 2019 (COVID),COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,ADMISSION TO ICU AND/OR MECHANICAL VENTILATION,"A Randomized, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Use of Convalescent Plasma (PC) and Human Intravenous Anti COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19."
NCT04395300,Completed,Observational,,Assiut University,Other,30-Mar-20,16-May-20,30-Apr-20,ECOLOGIC OR COMMUNITY,143,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",WEB BASED SURVEY,MEASURE SLEEP QUALITY IN HEALTHCARE WORKER,Sleep Quality and Effect on General Health in Healthcare Personnel During COVID-19 Pandemic
NCT04395391,Completed,Observational,,Exact Sciences Corporation,Industry,18-May-20,16-Jun-20,21-May-20,COHORT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2,VALID SARS-COV-2 TEST,Usability Study of Home Collection and Mailing With SARS-CoV-2 Test Specimen Collection Materials (2020-06)
NCT04395430,Recruiting,Interventional,Not Applicable,KK Women's and Children's Hospital,Other,18-Sep-20,21-Oct-21,21-Jun-21,TREATMENT,40,PEDIATRIC OBESITY,SINGAPORE,ALL,4 Years to 7 Years   (Child),USUAL CARE,INTENSITY OF INTERVENTION,Adapting the US-based Clinic-community Model of Child Obesity Treatment Into an Online Intervention Model in Singapore During COVID-19
NCT04395456,Not yet recruiting,Interventional,Phase 2,Amyndas Pharmaceuticals S.A.,Industry,21-Sep-21,22-Dec-21,22-Sep-21,TREATMENT,144,ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO SARS-COV2 INFECTION (SEVERE COVID),,ALL,"18 Years and older   (Adult, Older Adult)",AMY-101,"THE PROPORTION OF PATIENTS WHO ARE ALIVE, WITHOUT EVIDENCE OF ARDS (I.E. PAO2/FIO2 >300 MM HG), WHO DO NOT REQUIRE ANY OXYGEN SUPPORT (IN ROOM AIR).","A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)"
NCT04395482,Recruiting,Observational,,University of Milano Bicocca,Other,7-May-20,15-Jun-21,15-Jun-21,COHORT,500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",LUNG CT SCAN ANALYSIS IN COVID-19 PATIENTS,A QUALITATIVE ANALYSIS OF PARENCHYMAL LUNG DAMAGE INDUCED BY COVID-19,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury by Machine Learning: a Multicenter Retrospective Cohort Study.
NCT04395508,Available,Expanded Access,,"Genentech, Inc.",Industry,,,,,,HER2-POSITIVE BREAST CANCER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PERTUZUMAB AND TRASTUZUMAB FIXED-DOSE COMBINATION FOR SUBCUTANEOUS ADMINISTRATION (PH FDC SC),,"An Expanded Access, Single-Arm, Multicenter Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic"
NCT04395599,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Lille",Other,20-May-21,20-Oct-21,20-Oct-21,PREVENTION,40,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)","CARTOGRAPHY OF AIR CONTAMINATION, ENVIRONMENT CONTAMINATION AND BIOLOGICAL FLUID BY SARS-COV2 DURING VISCERAL SURGERY IN COVID19 PATIENTS.",AIR CONTAMINATION,Assessment of Air Contamination Risk by Sars-Cov2 During Visceral Surgery in COVID19 Patients: Pilot Study.
NCT04395664,Completed,Observational,,Herlev and Gentofte Hospital,Other,16-Apr-20,1-Sep-20,1-Sep-20,COHORT,1000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",C3+ HOLTER MONITOR,IN-HOSPITAL MORTALITY DURING HOSPITALIZATION AND A CONFIRMED COVID-19 DIAGNOSIS,The ACOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart by Continuous ECG Monitoring
NCT04395716,Not yet recruiting,Interventional,Phase 1,ProgenaBiome,Other,20-Jul-21,21-Nov-21,21-Jun-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RESCURE™,THE RATE OF RECOVERY OF MILD OR MODERATE COVID-19 IN PATIENTS USING RESCURE™,A Phase I Study of ResCure™ to Treat COVID-19 Infection
NCT04395742,Not yet recruiting,Observational,,Poitiers University Hospital,Other,20-May-21,20-Dec-21,20-Dec-21,OTHER,93,CORONAVIRUS DISEASE 2019,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DATA COLLECTION,COMPARISON OF VITAL STATUS,"1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study"
NCT04395755,Completed,Observational,,Ospedale Policlinico San Martino,Other,1-Apr-20,15-May-20,15-May-20,COHORT,503,"INFERTILITY, FEMALE",ITALY,FEMALE,"18 Years and older   (Adult, Older Adult)",GENERALIZED ANXIETY DISORDER-7 (GAD-7),SEVERITY OF ANXIETY,Impact of COVID-19 Pandemic on the Psychological Status of Infertile Patients Who Had in Vitro Fertilization Treatment Interrupted or Postponed
NCT04395768,Recruiting,Interventional,Phase 2,"National Institute of Integrative Medicine, Australia",Other,9-Sep-20,31-Dec-21,30-Sep-21,TREATMENT,200,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN C,SYMPTOMS,"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study"
NCT04395781,Recruiting,Observational [Patient Registry],,KK Women's and Children's Hospital,Other,18-May-20,31-Dec-23,31-Dec-22,COHORT,2000,COVID,CHINA,ALL,"up to 21 Years   (Child, Adult)",,OVERALL SEVERITY OF ILLNESS,Pediatric Acute and Critical Care COVID-19 Registry of Asia
NCT04395794,Recruiting,Observational [Patient Registry],,Meshalkin Research Institute of Pathology of Circulation,Other,7-May-20,30-Nov-20,31-Aug-20,COHORT,900,SARS-COV2,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2-TEST,SARS-COV-2 POSITIVE TEST,SARS-CoV-2 Positive Carriers Among Asymptomatic meDIcal employeeS in hiGh-volUme cardIovaScular cEnter
NCT04395807,Recruiting,Interventional,Not Applicable,Lund University,Other,3-Jun-20,21-May-21,31-Dec-20,TREATMENT,120,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",HELMET CPAP,VENTILATOR-FREE DAYS (VFD),Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial
NCT04395833,Completed,Observational,,"University Hospital, Brest",Other,7-Apr-20,11-May-20,11-May-20,FAMILY-BASED,2500,IDENTIFY EMERGING HEALTH CHALLENGES FOR CHILDREN WITH MOTOR DISABILITIES AND THEIR PARENTS FACING THE COVID PANDEMIC,FRANCE,ALL,"up to 18 Years   (Child, Adult)",,EXPERIENCE DURING LOCKDOWN,Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic: Messages From Families Answering the ECHO French National Survey
NCT04395859,Recruiting,Observational,,Fondation Ophtalmologique Adolphe de Rothschild,Other,27-May-20,21-Dec-21,21-Dec-21,COHORT,1500,AGE RELATED MACULAR DEGENERATION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,CHANGE OF VISUAL ACUITY IN PATIENTS TREATED WITH REPEATED IVT ANTI-ANGIOGENS DURING THE COVID-19 EPIDEMIC,Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
NCT04395872,Not yet recruiting,Observational,,Daegu Catholic University Medical Center,Other,28-May-20,31-Dec-20,31-Dec-20,CASE-ONLY,54,COVID,,ALL,"Child, Adult, Older Adult",PSYCHIATRIC COUNSELING,CHANGE OF PHQ-9 (PATIENT HEALTH QUESTIONNAIRE-9),Psychiatric Consultation for COVID-19 Patients
NCT04395885,Completed,Observational,,Assiut University,Other,1-Jun-20,15-Sep-20,31-Aug-20,OTHER,306,SEXUAL DYSFUNCTION,EGYPT,ALL,18 Years to 40 Years   (Adult),ELECTRONIC QUESTIONNAIRE,THE PERCENTAGE OF STUDY PARTICIPANTS DIAGNOSED WITH SEXUAL DYSFUNCTION,Sexual Function Among Egyptian Healthcare Professionals During COVID 19 Pandemic
NCT04395911,Recruiting,Interventional,Not Applicable,SeaStar Medical,Industry,10-Sep-20,21-Dec-21,21-Jan-21,TREATMENT,30,AKI,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SCD,MORTALITY AT DAY 60,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection
NCT04395924,Recruiting,Observational,,Centre Hospitalier Régional d'Orléans,Other,5-May-20,21-May-21,21-May-21,COHORT,50,MATERNAL FETAL INFECTION TRANSMISSION,FRANCE,FEMALE,18 Years to 48 Years   (Adult),"DIAGNOSIS OF SARS-COV2 BY RT-PCR AND : IGG, IG M SEROLOGIES IN THE AMNIOTOC FLUID, THE BLOOD CORD AND THE PLACENTA",COVID-19 BY POSITIVE PCR IN CORD BLOOD AND / OR POSITIVE SEROLOGIES,Maternal-Foetal Transmission of COVID-19
NCT04395976,Not yet recruiting,Interventional,Not Applicable,British Ayurvedic Medical Council,Other,10-Jun-20,1-Oct-20,10-Sep-20,PREVENTION,120,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",AYURVEDA,CLINICAL CONFIRMATION OF COVID-19,Effect of Ayurveda as Prophylaxis for Suspected Covid-19 Patients: Randomised Controlled Trial
NCT04396067,Not yet recruiting,Interventional,Phase 2,Kafrelsheikh University,Other,20-Oct-21,20-Dec-21,20-Oct-21,TREATMENT,360,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",AEROSOLIZED 13 CIS RETINOIC ACID,LUNG INJURY SCORE,Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment
NCT04396106,Recruiting,Interventional,Phase 2,"Atea Pharmaceuticals, Inc.",Industry,26-May-20,21-May-21,21-Mar-21,TREATMENT,190,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",AT-527,PROPORTIONS (ACTIVE VS. PLACEBO) OF SUBJECTS WITH PROGRESSIVE RESPIRATORY INSUFFICIENCY.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19"
NCT04396197,Completed,Observational,,University Hospital Birmingham NHS Foundation Trust,Other,1-Mar-20,8-May-20,8-May-20,COHORT,92,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PHYSIOTHERAPY,MOBILITY LEVEL,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care Requiring Invasive Ventilation: An Observational Study
NCT04396210,Completed,Observational,,"University Hospital, Ghent",Other,14-May-20,18-Jun-20,18-Jun-20,OTHER,389,CORONAVIRUS,BELGIUM,ALL,18 Years to 47 Years   (Adult),QUESTIONNAIRE,PATIENTS PERSPECTIVES ON THE ABRUPTLY DISCONTINUATION OF THEIR FERTILITY TREATMENT BY USING A QUESTIONNAIRE,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic
NCT04396314,Not yet recruiting,Interventional,Not Applicable,Universitat de Lleida,Other,1-Feb-21,30-Sep-21,30-Jul-21,TREATMENT,54,POSTTRAUMATIC STRESS DISORDER,,ALL,"18 Years and older   (Adult, Older Adult)",BASIC BODY AWARENESS THERAPY,CHANGE IN DAVIDSON TRAUMA SCALE (DTS),"Effectiveness of Basic Body Awareness Therapy in Survivors of Covid-19, Health Workers and Women Suffering From Gender-based Violence Regarding Post-traumatic Stress Disorders: A Randomized Clinical Trial"
NCT04396353,Completed,Observational,,University of Sao Paulo General Hospital,Other,4-Jun-20,1-Oct-20,1-Oct-20,COHORT,1574,COVID,BRAZIL,ALL,"Child, Adult, Older Adult",ELECTRONIC QUESTIONNAIRE,NUMBER OF HOSPITALIZATIONS,"The Impact of EXercise TRAining, Physical Activity and Sedentary Lifestyle on Clinical Outcomes in Surviving Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2: Cross-sectional Study"
NCT04396600,Enrolling by invitation,Observational,,University of Minnesota,Other,8-Jun-20,25-May-22,25-May-22,COHORT,1200,STRESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MINNRAP PEER SUPPORT PROGRAM,CHANGE IN PROFESSIONAL QUALITY OF LIFE,The Professional Peer Resilience Initiative: Leveraging a Data-Driven Model to Maximize the Resilience of Healthcare Workers During the COVID-19 Pandemic
NCT04397172,Recruiting,Observational,,"University Hospital Inselspital, Berne",Other,9-Apr-20,21-Dec-21,21-Apr-21,COHORT,50,COVID,SWITZERLAND,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STUDY ARM,SHORT FORM (36) HEALTH SURVEY (SF-36),"Characterization of ARDS, Critical Illness Myopathy and Their Long-term Consequences in Patients With Covid-19 Disease: Effects of Inflammation, Mitochondrial Dysfunction and Plasma Concentrations of Various Sedative Drugs"
NCT04397237,"Active, not recruiting",Observational,,Pitié-Salpêtrière Hospital,Other,10-Jun-20,21-Jan-21,8-Dec-20,COHORT,3100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 SEROCONVERSION,"Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe"
NCT04397328,Not yet recruiting,Interventional,Phase 3,Lawson Health Research Institute,Other,19-May-20,30-Apr-21,30-Apr-21,PREVENTION,336,COVID,,ALL,"40 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,"INCIDENCE OF SYMPTOMATIC FEVER >37.8, DRY COUGH, OR SHORTNESS OF BREATH (RESIDENT/PATIENT REPORT OR NURSE OBSERVATION) RESPIRATORY INFECTION WITH CONFIRMED PCR+ RESULT FOR SARS-COV-2.",Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial
NCT04397380,Not yet recruiting,Observational,,NHS Greater Clyde and Glasgow,Other,20-May-20,1-Jul-20,3-Jun-20,COHORT,100,PYREXIA,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",THERMOGRAPHY,TEMPERATURE,COVID-19 Response - Thermography Based Fever Detection for Triaging of Patients - A Feasibility Study
NCT04397471,Not yet recruiting,Observational,,CCTU- Cancer Theme,Other,20-May-21,21-Dec-21,21-Dec-21,CASE-ONLY,10,HEALTHY VOLUNTEERS FOR BONE MARROW DONATION,UNITED KINGDOM,ALL,18 Years to 40 Years   (Adult),BONE MARROW HARVEST,DETERMINE FEASIBILITY OF RECRUITING HEALTHY VOLUNTEERS IN A CLINICALLY USEFUL TIMEFRAME.,A Study to Collect Bone Marrow for Process Development and Production of Bone Marrow Mesenchymal Stromal Cells to Treat Severe COVID19 Pneumonitis
NCT04397497,Not yet recruiting,Interventional,Phase 2,Ospedale San Raffaele,Other,22-May-20,22-Nov-20,22-Sep-20,TREATMENT,50,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",MAVRILIMUMAB,REDUCTION IN THE DEPENDENCY ON OXYGEN SUPPLEMENTATION,"A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial)"
NCT04397510,Enrolling by invitation,Interventional,Phase 4,Frederick Health,Other,1-Jun-20,31-Dec-21,31-Dec-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HEPARIN,MEAN DAILY PAO2 TO FIO2 RATIO,Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury
NCT04397523,Recruiting,Interventional,Not Applicable,Institute for Transfusion Medicine of RNM,Other,30-Apr-20,29-Apr-21,29-Apr-21,TREATMENT,200,CONVALESCENT PLASMA,NORTH MACEDONIA,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 CONVALESCENT PLASMA,DURATION OF OXYGENATION AND VENTILATION SUPPORT,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety
NCT04397562,Completed,Interventional,Phase 3,Biocad,Industry,29-Apr-20,3-Aug-20,3-Jul-20,TREATMENT,206,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",LEVILIMAB,PROPORTION OF PATIENTS WITH SUSTAINED CLINICAL RECOVERY,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19"
NCT04397575,"Active, not recruiting",Observational [Patient Registry],,Federation Francophone de Cancerologie Digestive,Other,3-Apr-20,21-Dec-21,1-Dec-21,COHORT,1509,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"NUMBER OF CASES OF SARS-COV-2 INFECTION AND MORTALITY RATE DIRECTLY RELATED TO THE INFECTION IN PATIENTS BEING FOLLOWED FOR DIGESTIVE, THORACIC, HEAD AND NECK, GYNECOLOGIC, CEREBRAL, UROLOGIC OR CUTANEOUS CANCER",Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
NCT04397588,Recruiting,Observational,,Rennes University Hospital,Other,21-Apr-20,21-Oct-20,21-Oct-20,COHORT,300,ARDS RELATED TO SEVERE ACUTE RESPIRATORY SYNDROME-CORONAVIRUS (SARS-COV) 2,FRANCE,ALL,"Child, Adult, Older Adult",,HOSPITAL MORTALITY,Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study
NCT04397614,Recruiting,Observational,,University of Oklahoma,Other,22-Jul-20,21-Dec-21,21-Dec-21,COHORT,500,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MHEALTH ASSESSMENTS,PERCENTAGE OF COMPLETION OF SMARTPHONE BASED SURVEYS,Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients
NCT04397666,Recruiting,Interventional,Not Applicable,Versailles Hospital,Other,15-May-20,15-Nov-20,15-Sep-20,OTHER,68,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CONJUNCTIVAL RT PCR,THE SARS-COV-2 POSITIVITY RATE IN PATIENTS WITH COVID-19 WITH OR WITHOUT SIGNS OF CONJUNCTIVITIS,RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19
NCT04397692,Recruiting,Interventional,Not Applicable,Beyond Air Inc.,Industry,13-Jun-20,30-Sep-20,30-Sep-20,DEVICE FEASIBILITY,20,CORONAVIRUS INFECTION,UNITED STATES,ALL,"22 Years to 65 Years   (Adult, Older Adult)",NITRIC OXIDE DELIVERED VIA LUNGFIT™ SYSTEM,TIME TO DETERIORATION,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)
NCT04397705,Recruiting,Interventional,Phase 1,The Christie NHS Foundation Trust,Other,12-Oct-20,21-Apr-21,21-Apr-21,OTHER,30,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT STATUS ENGINE,DEVICE TOLERABILITY (ATTRITION),Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.
NCT04397718,Recruiting,Interventional,Phase 2,VA Office of Research and Development,U.S. Fed,6-Jul-20,6-Jul-21,6-Jul-21,TREATMENT,198,COVID,UNITED STATES,MALE,"18 Years to 85 Years   (Adult, Older Adult)",DEGARELIX,"A COMPOSITE ENDPOINT OF MORTALITY, ONGOING NEED FOR HOSPITALIZATION, OR REQUIREMENT FOR MECHANICAL VENTILATION/EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) AT DAY 15 AFTER RANDOMIZATION.","Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix"
NCT04397757,"Active, not recruiting",Interventional,Phase 1,University of Pennsylvania,Other,13-May-20,30-Jun-21,30-Apr-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,PARTICIPANTS WITH SERIOUS ADVERSE EVENTS.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2."
NCT04397796,Recruiting,Interventional,Phase 1,"NantKwest, Inc.",Industry,3-Aug-20,21-Jun-21,21-Jun-21,TREATMENT,45,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BM-ALLO.MSC,INCIDENCE OF AES,"Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation"
NCT04397822,Recruiting,Observational,,"University Hospital, Toulouse",Other,16-Apr-20,22-Apr-21,21-Oct-21,COHORT,110,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES,ACTIVATION OF PLATELET NLRP3 INFLAMMASOME,Study of INFLAmmasome NLRP3 and PLAtelets Functions During Severe COVID-19 Infection
NCT04397835,Recruiting,Observational,,"University Hospital, Toulouse",Other,17-Apr-20,20-Apr-21,20-Apr-21,COHORT,800,COVID,FRANCE,ALL,"50 Years to 89 Years   (Adult, Older Adult)",,WORSENING OF CARDIOVASCULAR RISK (TREATMENTS),Psychological Impact of Quarantine During the COVID-19 Outbreak and Worsening of Cardiovascular Risk in the French General Population: a Prospective Cohort Study
NCT04397848,Completed,Observational,,"University Health Network, Toronto",Other,14-May-20,3-Jul-20,3-Jul-20,COHORT,3852,MENTAL HEALTH WELLNESS 1,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,IMPACT OF EVENT SCALE - REVISED (IES-R),Hearing and Supporting the Healthcare Workers: Mental Health Outcomes in Healthcare Workers During COVID-19
NCT04397900,Recruiting,Observational,,"TScan Therapeutics, Inc.",Industry,9-Apr-20,20-Jul-21,1-Jul-20,OTHER,80,IDENTIFY THE VIRAL EPITOPES OF MEMORY CD8 T CELLS FROM INDIVIDUALS THAT HAVE RECOVERED FROM SARS-COV2 INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",,IDENTIFY THE VIRAL EPITOPES OF MEMORY CD8+ T CELLS FROM INDIVIDUALS THAT HAVE RECOVERED FROM SARS-COV-2 INFECTION.,A Blood Collection Study From Volunteers Who Have Recovered From COVID-19 Infection to Identify Immunogenic Viral Epitopes in SARS-CoV-2
NCT04397939,Recruiting,Observational,,Icahn School of Medicine at Mount Sinai,Other,8-May-20,22-Mar-21,21-Mar-21,COHORT,5000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,NUMBER OF IN-HOSPITAL DEATH,Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19
NCT04398004,Completed,Interventional,Phase 2,Hellenic Institute for the Study of Sepsis,Other,6-May-20,30-Nov-20,30-Nov-20,PREVENTION,90,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",CLARITHROMYCIN,CLINICAL OUTCOME NEGATIVE FOR TWO PARAMETERS(HOSPITAL ADMISSION/DISEASE PROGRESSION),Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial
NCT04398043,Not yet recruiting,Observational,,Hospital de Clinicas José de San Martín,Other,15-May-20,30-Jul-20,30-Jun-20,COHORT,16,RT PCR,,ALL,"16 Years and older   (Child, Adult, Older Adult)",,ASSES SURFACE CONTAMINATION PERSONEL PROTECTIVE EQUIPMENT,Searching for SARS-CoV 2 in Personal Protective Equipment in Physicians in a University Hospital
NCT04398147,Not yet recruiting,Interventional,Phase 1/Phase 2,CanSino Biologics Inc.,Industry,1-Aug-20,30-Dec-21,20-Dec-21,PREVENTION,696,COVID,CANADA,ALL,"18 Years to 84 Years   (Adult, Older Adult)",RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),INCIDENCE OF THE SOLICITED AE IN ALL GROUPS,"A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults From 18 to <85 Years of Age in Canada"
NCT04398264,Recruiting,Observational [Patient Registry],,Inova Health System,Other,22-Jul-20,31-Mar-21,31-Mar-21,COHORT,100,CORONAVIRUS INFECTION,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",COVID-19 POSITIVE VIA TESTING,ASYMPTOMATIC COVID-19 POSITIVE PREGNANT WOMEN,Characteristics of COVID-19 Infection Among PREGnant Women
NCT04398277,Recruiting,Interventional,Not Applicable,Kent State University,Other,1-May-20,21-Apr-21,21-Apr-21,SUPPORTIVE CARE,1000,PSYCHOLOGICAL STRESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DAILY COPING TOOLKIT,PATIENT HEALTH QUESTIONNAIRE - 4,A Daily Coping Toolkit for Medical Personnel and First-Responders During the COVID-19 Pandemic
NCT04398290,Withdrawn,Interventional,Phase 2,Roger Alvarez,Other,1-Dec-20,15-Jul-21,1-Jun-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INHALED NITRIC OXIDE (INO),INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS,Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen
NCT04398303,Not yet recruiting,Interventional,Phase 1/Phase 2,Aspire Health Science,Other,20-May-21,20-Oct-21,20-Oct-21,TREATMENT,70,COVID PNEUMONIA,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ACT-20-MSC,MORTALITY AT DAY 30,"A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia"
NCT04399005,Completed,Interventional,Not Applicable,The First Affiliated Hospital of Zhejiang Chinese Medical University,Other,25-May-20,10-Jun-20,5-Jun-20,OTHER,240,DAILY ROOM DISINFECTION,CHINA,ALL,"Child, Adult, Older Adult",AFTER-EACH-CASE ROOM DISINFECTION,QUALIFIED RATE OF ROOM DISINFECTION,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.
NCT04399109,Recruiting,Interventional,Not Applicable,Dr Sze-Yuan Ooi,Other,20-May-20,19-May-21,19-May-21,SUPPORTIVE CARE,2000,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",TCC-COVID MHEALTH SOLUTION,RATE OF AVOIDABLE EMERGENCY DEPARTMENT PRESENTATIONS PER DIAGNOSED COVID-19 CASE,ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.
NCT04399252,Recruiting,Interventional,Not Applicable,Duke University,Other,24-Jun-20,25-May-22,25-May-22,BASIC SCIENCE,1000,MICROBIOME,UNITED STATES,ALL,"1 Year and older   (Child, Adult, Older Adult)",LACTOBACILTUS RHAMNOSUS GG,CHANGE IN SHANNON DIVERSITY,A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
NCT04399317,Recruiting,Interventional,Not Applicable,Hamad Medical Corporation,Industry,28-May-20,20-Aug-21,20-Jul-21,TREATMENT,20,ARDS ASSOCIATED WITH COVID,QATAR,ALL,"18 Years to 99 Years   (Adult, Older Adult)",FLOW CONTROLLED VENTILATION (EVONE-VENTILATOR),ARTERIAL OXYGEN PARTIAL PRESSURE (PAO2),Flow Controlled Ventilation in ARDS Associated With COVID-19
NCT04399356,Recruiting,Interventional,Phase 2,Tufts Medical Center,Other,1-Oct-20,12-Feb-21,1-Jan-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE,CHANGE IN RESPIRATORY VIRAL CLEARANCE (BY PCR),Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)
NCT04399603,Not yet recruiting,Observational,,Imperial College London,Other,18-May-20,17-Nov-21,17-Nov-21,OTHER,120,COVID,UNITED KINGDOM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",NO INTERVENTION-MECHANISTIC STUDY,VARIATION IN INFLAMMATORY MEDIATORS IN PATIENTS WITH MULTI-ORGAN FAILURE SUFFERING FROM COVID-19,Multi-organ Failure in SARS-CoV2: Identifying Mechanisms and Potential Therapeutic Targets
NCT04399681,Recruiting,Interventional,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,Other,10-May-20,10-Sep-20,10-Aug-20,DIAGNOSTIC,100,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",BEDSIDE LUNG ULTRASOUND,PRESENCE OF VIRAL PNEUMONIA CAUSED BY COVID 19,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department
NCT04399733,Not yet recruiting,Observational,,Future Genetics Limited,Other,1-Feb-21,1-Feb-24,1-Feb-23,COHORT,12800,"COVID, SARS-COV2 INFECTION",UNITED KINGDOM,ALL,"6 Years and older   (Child, Adult, Older Adult)",,"IDENTIFY COVID-19 SPECIFIC HOST-DEFENCE (""PROTECTIVE"") OR PREDISPOSING (""SUSCEPTIBILITY"") GENETIC BIOMARKERS",EMPOWER - BAME vs COVID: A Multi-site Clinical Cohort Research Study to Identify Genetic Associations and Candidate Therapeutic Targets to Reduce COVID-19 Morbidity & Mortality Rates in BAME Populations
NCT04399746,Recruiting,Interventional,Not Applicable,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Other,15-Mar-20,10-Jun-20,20-May-20,TREATMENT,30,COVID,MEXICO,ALL,"18 Years to 90 Years   (Adult, Older Adult)",IVERMECTIN,VIRAL CLEARANCE,A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol
NCT04399798,Not yet recruiting,Interventional,Phase 2,IRCCS Policlinico S. Matteo,Other,15-May-20,15-Nov-20,15-Sep-20,TREATMENT,13,CORONAVIRUS INFECTION,,ALL,"18 Years to 74 Years   (Adult, Older Adult)",BARICITINIB,RESPONSE TO TREATMENT: ABSENCE OF MODERATE TO SEVERE OXYGENATION IMPAIRMENT (BERLIN CRITERIA),"A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia"
NCT04399889,Recruiting,Interventional,Phase 1/Phase 2,"Joanne Kurtzberg, MD",Other,18-Jun-20,31-Jul-21,1-Apr-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HUMAN CORD TISSUE MESENCHYMAL STROMAL CELLS,SAFETY OF THE INVESTIGATIONAL PRODUCT,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
NCT04399967,Recruiting,Interventional,Not Applicable,The University of Hong Kong,Other,13-Jun-20,30-Jun-22,30-Jun-21,HEALTH SERVICES RESEARCH,842,SMOKING CESSATION,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",CHAT-BASED SUPPORT,BIOCHEMICAL VALIDATED QUIT RATE,"Building Capacity and Promoting Smoking Cessation in the Community Via ""Quit to Win"" Contest 2020: a Single-blind Randomized Controlled Trial on COVID-19 Related Brief Advice and Personalized Chat-based Intervention for Smoking Cessation"
NCT04399980,"Active, not recruiting",Interventional,Phase 2,The Cleveland Clinic,Other,20-May-20,31-May-21,31-May-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MAVRILIMUMAB,PROPORTION OF SUBJECTS ALIVE AND OFF OF OXYGEN AT DAY 14,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
NCT04400006,Completed,Observational,,Marmara University,Other,6-May-20,17-May-20,16-May-20,CASE-ONLY,71,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,THE SURVEY THAT WAS TAKEN BY TELEPHONE CALLS,The Effectiveness of Ozone Therapy in the Prevention of COVID-19 Infection
NCT04400019,Not yet recruiting,Interventional,Phase 2/Phase 3,University of Malaga,Other,20-Sep-21,1-Apr-21,15-Dec-20,PREVENTION,1930,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE ONLY PRODUCT IN ORAL DOSE FORM,NUMBER OF SECONDARY CASES OF SARS-COV2 INFECTION AMONG RESIDENTS AT SIX DAYS,"Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)"
NCT04400032,Recruiting,Interventional,Phase 1,Ottawa Hospital Research Institute,Other,15-May-20,21-Jun-21,21-Jan-21,TREATMENT,9,ACUTE RESPIRATORY DISTRESS SYNDROME,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AS ASSESSED BY CTCAE V4.0,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard Study
NCT04400058,"Active, not recruiting",Interventional,Phase 3,Octapharma,Industry,1-Jun-20,2-Feb-21,2-Feb-21,PREVENTION,208,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",OCTAGAM 10%,STABILIZATION OR IMPROVEMENT IN CLINICAL STATUS,Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
NCT04400279,Completed,Interventional,Not Applicable,University of British Columbia,Other,1-Jun-20,28-Nov-20,28-Nov-20,PREVENTION,334,DEPRESSIVE SYMPTOMATOLOGY,CANADA,ALL,18 Years to 64 Years   (Adult),YOGA GROUP,CHANGES IN DEPRESSIVE SYMPTOMOLOGY OVER THE COURSE OF THE EXERCISE INTERVENTION,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home
NCT04400305,Recruiting,Interventional,Not Applicable,University of Victoria,Other,20-May-20,31-Mar-21,31-Mar-21,OTHER,40,"PHYSICAL ACTIVITY, HEALTHY PROMOTION",CANADA,ALL,"18 Years and older   (Adult, Older Adult)",DIGITAL HEALTH ONLINE PLATFORM,RECRUITMENT RATE (MONTHLY),"""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention"""
NCT04400448,Not yet recruiting,Observational [Patient Registry],,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana,Other,1-Jun-20,31-Oct-20,31-Aug-20,ECOLOGIC OR COMMUNITY,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,ACCEPTANCE OF TELEMEDICINE,"Acceptance of Telemedicine in Outpatient Clinic Consultations During COVID-19 Pandemic. An International, Cross-sectional Study"
NCT04400461,"Active, not recruiting",Observational,,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,Other,15-May-20,31-Mar-21,30-Mar-21,COHORT,50,COVID,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DATA COLLECTION AND CLINICAL TESTING OF SUBJECTS,MEDICAL RESEARCH COUNCIL SUM SCORE (MRC- SS).,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation: an Observational Cohort Study
NCT04400682,Completed,Interventional,Phase 1,Novelfarma Ilaç San. ve Tic. Ltd. Sti.,Industry,28-May-20,18-Jun-20,5-Jun-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,20 Years to 40 Years   (Adult),FAVIRA 200 MG FILM TABLET,AUC0-TLAST,"Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions"
NCT04400799,Recruiting,Interventional,Phase 3,University of Zurich,Other,15-Jun-20,14-Apr-21,14-Mar-21,TREATMENT,1000,COVID,SWITZERLAND,ALL,"50 Years and older   (Adult, Older Adult)",ENOXAPARIN 40MG/0.4ML INJ SYRINGE 0.4ML,HOSPITALIZATIONS,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial
NCT04400812,Enrolling by invitation,Observational,,Zagazig University,Other,19-May-20,20-Oct-21,20-Sep-21,OTHER,5000,COVID,EGYPT,ALL,"16 Years to 70 Years   (Child, Adult, Older Adult)",QUESTIONNAIRE,KNOWLEDGE ABOUT COVID-19 BY QUESTIONNAIRE,Attitude and Perception of General Population in Sharkia Governerate Towards COVID-19 Pandemic
NCT04400838,Recruiting,Interventional,Phase 2/Phase 3,University of Oxford,Other,28-May-20,21-Sep-21,21-Sep-21,PREVENTION,12390,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",CHADOX1 NCOV-19 (ABS 260),ASSESS THE EFFICACY OF THE CANDIDATE CHADOX1 NCOV-19 AGAINST COVID-19 IN ADULTS AGED 18 YEARS AND OLDER.,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19"
NCT04400877,Completed,Observational,,"University Hospital, Linkoeping",Other,8-Jun-20,30-Sep-20,30-Jul-20,COHORT,7795,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC EXAMINATION FOR VENOUS THROMBOEMBOLISM,IS THERE AN INCREASED PREVALENCE OF VENOUS THROMBOEMBOLISM IN A REGIONAL HEALTHCARE SYSTEM IN SWEDEN DURING THE SARS-COV-2 PANDEMIC?,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic
NCT04400890,Recruiting,Interventional,Phase 2,"Marvin McCreary, MD",Other,12-Sep-20,21-Jan-21,20-Nov-21,TREATMENT,200,COVID,UNITED STATES,ALL,"45 Years and older   (Adult, Older Adult)",PLANT POLYPHENOL,HOSPITALIZATION RATES FOR COVID-19,Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of a Plant Polyphenol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)
NCT04400929,Recruiting,Interventional,Phase 2,Singapore General Hospital,Other,2-Jun-20,22-Jun-21,21-Jun-21,TREATMENT,30,COVID,SINGAPORE,ALL,"21 Years to 80 Years   (Adult, Older Adult)",SARGRAMOSTIM,MEASURING OXYGENATION,Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial
NCT04401033,Completed,Observational [Patient Registry],,Hospital del Río Hortega,Other,11-May-20,30-Jun-20,30-Jun-20,COHORT,450,SARS-COV2,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TELEPHONIC MEDICAL VISIT,SARS-COV-2 INFECTION IN PATIENTS,Prospective Observational Study Evaluating the Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopic Procedures (DECORE Study)
NCT04401046,Recruiting,Interventional,Not Applicable,Institut Paoli-Calmettes,Other,20-May-20,30-Oct-20,30-Oct-20,HEALTH SERVICES RESEARCH,4000,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY TO ASSESS POST TRAUMATIC STRESS AND ANXIETY AT INCLUSION AND 6 MONTHS LATER,SCORE OF THE IMPACT OF EVENT SCALE REVISITED SCALE,COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder
NCT04401072,Recruiting,Observational,,Damanhour University,Other,24-Apr-20,20-Oct-21,22-May-20,OTHER,500,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,ATTITUDE OF THE EGYPTIAN POPULATION DURING THE COVID 19 PANDEMIC IN RAMADAN,Survey Studying the Change in the Attitude and Behaviour of the Egyptian Population Toward COVID 19 Pandemic During the Holy Month Ramadan .
NCT04401085,Completed,Observational,,Institute of Health Information and Statistics of the Czech Republic,Other,23-Apr-20,1-May-20,1-May-20,COHORT,27000,COVID,CZECHIA,ALL,"8 Years to 89 Years   (Child, Adult, Older Adult)",SARS-COV-2 DIAGNOSTIC RAPID TEST,ESTIMATION OF THE ACTUAL PREVALENCE OF SARS-COV-2 POSITIVE PERSONS IN THE CZECH REPUBLIC.,Herd Immunity Study SARS-CoV-2-CZ-Preval
NCT04401098,Recruiting,Observational,,Damanhour University,Other,2-May-20,1-Apr-21,1-Oct-20,OTHER,700,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,AWARENESS OF EGYPTIAN POPULATION,"Survey Of Egyptian Population Change in Knowledge, Attitude and Behaviour Towards COVID 19 Outbreak"
NCT04401111,Recruiting,Observational,,Centre Hospitalier Universitaire de Nice,Other,16-Jun-20,15-Jun-21,15-Jun-21,COHORT,150,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,EVALUATION OF RECOVERY OF QUALITY OF LIFE IN FIRST YEAR AFTER ICU DISCHARGED IN PATIENTS HOSPITALISED FOR SEVERE PNEUMONIA AT SARS-COV2,Multiparametric Evaluation of One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia After Intensive Care Unit
NCT04401124,Not yet recruiting,Observational,,Beijing Friendship Hospital,Other,25-May-20,7-Jun-20,31-May-20,COHORT,500,GASTRIC CANCER,,ALL,"Child, Adult, Older Adult",NO INTERVENTION,TREATMENT OF FEVERS AT ARRIVAL,"A Descriptive Study on the Proper Management of Gastrointestinal Surgeries During the COVID-19 Pandemic, With an Emphasis on the Alteration of Surgical Protocol and Workflow"
NCT04401150,Recruiting,Interventional,Phase 3,Université de Sherbrooke,Other,14-Aug-20,22-Jan-21,21-Nov-21,TREATMENT,800,VITAMIN C,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN C,DEATH OR PERSISTENT ORGAN DYSFUNCTION,Lessening Organ Dysfunction With VITamin C - COVID
NCT04401163,Not yet recruiting,Observational [Patient Registry],,University of Aarhus,Other,20-May-21,22-Dec-21,21-Dec-21,COHORT,180,SARS-COV2,DENMARK,ALL,"18 Years to 85 Years   (Adult, Older Adult)",IMAGING OF THE LUNGS,IMAGING OF THE LUNGS,Long-term Pulmonary Outcomes After Infection With Sars-CoV-2
NCT04401202,Recruiting,Interventional,Phase 2,King Abdulaziz University,Other,21-May-20,31-Dec-20,31-Dec-20,TREATMENT,200,COVID,SAUDI ARABIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",NIGELLA SATIVA,PROPORTION OF PATIENTS WHO ARE CLINICALLY RECOVERED,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study"
NCT04401228,"Active, not recruiting",Observational,,Clinique Saint Pierre Ottignies,Other,1-Mar-20,1-Jan-21,1-May-20,COHORT,60,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)","PREDICT ADMISSION OF COVID-19 PATIENTS TO ICU AND DEATH WITH ROUTINE AND QUICKLY AVALAIBLE CLINICAL, BIOLOGICAL AND RADIOLOGICAL VARIABLES?",ADMISSION TO ICU,Development and Validation of Predictive Models for Intensive Care Admission and Death of COVID-19 Patients in a Secondary Care Hospital in Belgium.
NCT04401241,Completed,Observational,,Centre Hospitalier Princesse Grace,Other,1-Feb-20,15-May-20,1-May-20,OTHER,257,COVID,MONACO,ALL,"18 Years and older   (Adult, Older Adult)",,ROUTINE BIOMARKERS AND BLOOD CELL COUNT ARE DISCRIMINANT TO DIAGNOSE COVID-19,Accuracy of Routine Biomarkers and Blood Leucocytes Count to Assist Diagnosis of COVID-19-related Pneumonia in Adult Patients Visiting the Emergency Department
NCT04401254,Recruiting,Observational,,Australian and New Zealand Intensive Care Research Centre,Other,1-Jul-20,22-Apr-21,21-Dec-21,COHORT,300,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",,DISABILITY-FREE SURVIVAL,The COVID-Recovery Study
NCT04401293,Recruiting,Interventional,Phase 3,Northwell Health,Other,26-Apr-20,26-Apr-21,26-Apr-21,TREATMENT,308,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,"COMPOSITE OUTCOME OF ARTERIAL THROMBOEMBOLIC EVENTS, VENOUS THROMBOEMBOLIC EVENTS AND ALL-CAUSE MORTALITY AT DAY 30 ± 2 DAYS.",Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)
NCT04401371,Completed,Observational,,Cairo University,Other,1-May-20,10-May-20,10-May-20,OTHER,418,DISTANCE EDUCATION LEARNING ENVIRONMENT DURING COVID PANDEMIC,EGYPT,ALL,"Child, Adult, Older Adult",,ASSESSMENT OF DISTANCE EDUCATION LEARNING ENVIRONMENT EXPERIENCES AMONG DENTAL STUDENTS ENROLLED IN PEDIATRIC DENTISTRY ONLINE COURSE DURING COVID-19 CRISIS,Assessment of Dental Students Opinion About Distance Education Learning Environment During COVID-19 Pandemic (Cross-Sectional Study)
NCT04401410,Recruiting,Interventional,Phase 1,Baylor College of Medicine,Other,4-Nov-20,15-Aug-21,15-Aug-21,TREATMENT,58,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DOSE FINDING PHASE (MTD),DOSE ESCALATION PHASE: RATE OF DOSE LIMITING TOXICITIES BY CTCAE 5.0 [14 DAYS POST INFUSION],BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19
NCT04401423,Recruiting,Interventional,Phase 2,Columbia University,Other,20-Aug-21,21-Dec-21,21-Jun-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TXA127,CHANGE OF SERUM CREATININE,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19
NCT04401436,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,22-May-20,30-Jun-22,30-Jun-22,COHORT,350,CORONA VIRUS DISEASE 2019,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,"EVALUATION OF LYMPHOCYTE SUBSETS IN PATIENTS WITH COVID-19 AT VARIOUS STAGES OF DISEASE, INCLUDING RECOVERY.",COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
NCT04401449,Recruiting,Observational,,National Institutes of Health Clinical Center (CC),NIH,8-Jan-20,1-May-24,1-May-24,COHORT,180,ACUTE AND LONG TERM EFFECTS OF COVID:ON SYSTEMIC INFLAMMATION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,INFLAMMATORY RESPONSES OF CELLS IN LUNG AND CIRCULATION,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)
NCT04401475,Recruiting,Interventional,Phase 2,Edesa Biotech Inc.,Industry,25-Nov-20,21-Apr-21,21-Apr-21,TREATMENT,396,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SOC PLUS 15MG/KG EB05 IV,THE PROPORTION OF PATIENTS THAT ARE ALIVE WITHOUT ANY NEED FOR OXYGEN SUPPORT DEFINED AS A SCORE OF 3 OR LESS ON THE WHO COVID-19 NINE-POINT SCALE,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19"
NCT04401527,Withdrawn,Interventional,Phase 2,Hope Pharmaceuticals,Industry,22-Jul-20,15-Aug-20,15-Aug-20,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SODIUM NITRITE,SURVIVAL WITH UNASSISTED BREATHING,"Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study"
NCT04401540,Recruiting,Observational [Patient Registry],,Recep Tayyip Erdogan University Training and Research Hospital,Other,1-May-20,30-Dec-20,30-Oct-20,COHORT,90,COVID,TURKEY,ALL,up to 28 Days   (Child),,VERTICAL TRANSMISSION,Clinical and Epidemiological Characteristics of COVID-19 Infection on Babies of Prenatal COVID-19 Positive Women in Turkey
NCT04401579,Completed,Interventional,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,8-May-20,31-Jul-20,31-Jul-20,TREATMENT,1034,COVID,DENMARK,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PLACEBO,TIME TO RECOVERY,"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)"
NCT04401644,Not yet recruiting,Interventional,Not Applicable,Somerset NHS Foundation Trust,Other,20-Jun-21,21-Dec-21,21-Dec-21,DIAGNOSTIC,250,DIAGNOSES DISEASE,UNITED KINGDOM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",NOVEL LASER INFEROMETRY TEST FOR CORONA VIRUS,KAPPA VALUE,Laser Interferometry of Single Virus Particles Flowing Through Glass Microcapillaries to Detect Novel Coronavirus COVID-19
NCT04402060,Recruiting,Interventional,Phase 1/Phase 2,"Apellis Pharmaceuticals, Inc.",Industry,28-May-20,21-Jan-21,21-Jan-21,TREATMENT,66,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",APL-9,CUMULATIVE INCIDENCE OF TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS AND TREATMENT-EMERGENT ADVERSE EVENTS.,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19"
NCT04402203,Recruiting,Interventional,Phase 2/Phase 3,Bangladesh Medical Research Council (BMRC),Other,20-May-21,20-Jul-21,20-Jul-21,TREATMENT,50,COVID,BANGLADESH,ALL,"18 Years to 65 Years   (Adult, Older Adult)",FAVIPIRAVIR,NUMBER OF PARTICIPANTS NEGATIVE BY RT-PCR FOR THE VIRUS AT 4-10 DAYS AFTER INITIATION OF THERAPY.,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
NCT04402229,Completed,Observational,,Versailles Hospital,Other,12-May-20,31-Jul-20,31-Jul-20,OTHER,2000,NURSE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE OF PTSD-RELATED SYMPTOMS ASSESSED BY THE IES-R,Psychological Impact of the Covid-19 Pandemic on Student Nurses :Prevalence and Risk Factors of Acute Post-traumatic Stress Symptoms 1 Month After the Epidemic Peak
NCT04402814,Recruiting,Observational,,"Fadi Haddad, M.D.",Other,5-May-20,1-Dec-20,1-Oct-20,COHORT,90,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLUNGENE RAPID TEST CASSETTE,IGG/IGM ANTIBODIES,Evaluation and Correlation of SARS-Cov2 Virus IgG/IgM Rapid Test Cassette Clungene Test With the Standard Method of COVID19 Testing in Inpatients With or Without COVID19
NCT04402827,Recruiting,Observational,,Asociacion para el Estudio de las Enfermedades Infecciosas,Other,1-Aug-20,30-Jan-21,30-Dec-20,CASE-CONTROL,60,HEALTH CARE WORKER PATIENT TRANSMISSION,SPAIN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SUSCEPTIBILITY TO INFECTION,SUSCEPTIBILITY TO SARS COV-2 INFECTION ACCORDING TO ACE2 RECEPTOR,"Differences in Susceptibility to SARS CoV-2 Infection According to ACE2 and CD26 Receptors, Specific CD4/CD8 T Cell Response to Viral Peptides, and KIR Receptors Among Health Care Workers Highly Exposed to Patients With COVID-19 Diagnosis."
NCT04402840,Recruiting,Interventional,Not Applicable,West Virginia University,Other,24-Apr-20,21-Dec-21,21-Dec-21,TREATMENT,5,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STELLATE GANGLION BLOCK,ADVERSE EVENTS RELATED TO SGB,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
NCT04402853,Completed,Observational,,Università degli Studi dell'Insubria,Other,1-Feb-20,20-May-20,1-Mar-20,CASE-CROSSOVER,100,SARS-COV2,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",TEARS SWAB,VIRUS PRESENCE IN COVID 19 PATIENTS TEARS,SARS Cov-2 in Conjunctival Secretions in an Italian Lombardia Cohort of Patients
NCT04402866,Recruiting,Interventional,Phase 2,Theravance Biopharma,Industry,24-Jun-20,21-Apr-21,21-Apr-21,TREATMENT,222,ACUTE LUNG INJURY (ALI) ASSOCIATED WITH COVID,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TD-0903,PART 2: RESPIRATORY FAILURE-FREE DAYS (RFDS),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19"
NCT04402879,Recruiting,Interventional,Not Applicable,University of Calgary,Other,10-Nov-20,1-Jun-22,1-Dec-21,TREATMENT,596,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING (PP),HOSPITAL MORTALITY OR DISCHARGE TO HOSPICE,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic
NCT04402892,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,1-Jun-20,1-Mar-21,1-Mar-21,BASIC SCIENCE,60,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","35 ML BLOOD, 5 TUBES LITHIUM HEPARINATE AT EACH TIME (HOSPITALIZED PATIENTS )",IMMUNOLOGICAL MEMORY: RESOLUTION OF COVID-19 AFTER SARS-COV2 INFECTION.,SARS-CoV-2 Specific Memory B and T- CD4+ Cells
NCT04402905,Completed,Observational,,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,Other,15-Jun-20,15-Aug-20,15-Jul-20,COHORT,450,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-PSL COHORT,"Observational Study in Diagnosed Patients Covid-19, Supported on an Outpatient Basis."
NCT04402918,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Besancon,Other,17-May-20,31-Dec-20,19-May-20,DIAGNOSTIC,160,SARS-COV2,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL SAMPLES DAY OF DELIVERY,VROLOGICAL PROFILE OF NEWBORNS.,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy
NCT04402944,Recruiting,Interventional,Phase 2,Boston Children's Hospital,Other,5-Jul-20,31-Dec-21,31-May-21,TREATMENT,60,COVID,UNITED STATES,ALL,"3 Years and older   (Child, Adult, Older Adult)",PULMOZYME,VENTILATOR-FREE DAYS AT 28 DAYS,Pulmozyme to Improve COVID-19 ARDS Outcomes
NCT04402957,Recruiting,Interventional,Phase 2,Arch Biopartners Inc.,Industry,14-Oct-20,30-Jun-21,31-Mar-21,TREATMENT,60,COVID,CANADA,ALL,"45 Years to 80 Years   (Adult, Older Adult)",LSALT PEPTIDE,DEVELOPMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND OTHER ORGAN INJURIES,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)"
NCT04402970,Completed,Interventional,Phase 3,University of Missouri-Columbia,Other,19-Jun-20,31-Dec-20,31-Dec-20,TREATMENT,10,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DORNASE ALFA INHALATION SOLUTION,IMPROVEMENT IN PAO2/FIO2,Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2
NCT04402983,Completed,Interventional,Not Applicable,Istanbul Medipol University Hospital,Other,27-May-20,1-Dec-20,1-Dec-20,TREATMENT,34,COVID,TURKEY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PHYSIOTHERAPY,MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCORE,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients
NCT04403009,Recruiting,Observational,,The First Affiliated Hospital of Guangzhou Medical University,Other,1-Feb-20,20-Jun-20,6-Jun-20,COHORT,100,CORONAVIRUS DISEASE 2019,CHINA,ALL,"20 Years to 100 Years   (Adult, Older Adult)",NO INTERVENTION,LYMPHOCYTE CELL,The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19
NCT04403035,Recruiting,Observational,,Ascension South East Michigan,Other,10-May-20,9-May-21,1-Jul-20,COHORT,100,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",ID NOW VS. ACCULA,TEST CHARACTERISTICS,Comparison of the ID NOW and Accula Point-of-Care Assays for the Detection of Severe Acute Respiratory System CoV-2 (SARS-CoV-2)
NCT04403061,Completed,Observational,,Asociacion para el Estudio de las Enfermedades Infecciosas,Other,22-May-20,10-Jan-21,22-Dec-20,COHORT,106,"DISEASE, VIRAL",SPAIN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CYTOKINES MEASUREMENT,CHANGES IN CYTOKINES ASSOCIATED WITH SARS COV-2 INFECTION,Th1/Th2/Th17/TREG Response and TLRs Activation/KIR Receptors for Predicting the Evolution of the SARS Cov-2 Infected Patients
NCT04403100,Recruiting,Interventional,Phase 3,Cardresearch,Other,3-Jun-20,1-Feb-21,1-Feb-21,TREATMENT,1968,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE SULFATE TABLETS,PROPORTION OF PARTICIPANTS WHO WERE HOSPITALIZED FOR PROGRESSION OF COVID-19 DISEASE,"Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: ""The Hope Coalition"""
NCT04403243,Recruiting,Interventional,Phase 2,Lomonosov Moscow State University Medical Research and Educational Center,Other,8-May-20,23-Aug-20,22-Jul-20,TREATMENT,70,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,CHANGE FROM BASELINE IN CLINICAL ASSESSMENT SCORE COVID 19 (CAS COVID 19) FRAME: BASELINE,COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial
NCT04403269,Recruiting,Interventional,Phase 2,Versailles Hospital,Other,5-May-20,5-May-21,5-May-21,TREATMENT,35,SARS-COV2,FRANCE,ALL,75 Years and older   (Older Adult),IGIV,MORTALITY,"""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19"
NCT04403386,Recruiting,Observational,,National Institute of Environmental Health Sciences (NIEHS),NIH,1-Jun-20,31-May-22,31-May-22,COHORT,200,COVID,UNITED STATES,ALL,30 Years to 55 Years   (Adult),,LEVELS OF SENESCENT CD16+CD8+ T CELLS PRIOR TO COVID-19 DISEASE AND TIME TO COVID-19 DISEASE MORBIDITY (ANTIBODY POSITVITY).,"A Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19"
NCT04403438,Enrolling by invitation,Observational,,Istanbul University,Other,1-Apr-20,15-Jun-20,1-May-20,COHORT,45,BEHCET DISEASE,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)","IT WILL BE COMPARED PAIN, SLEEP, FATIGUE, PHYSICAL ACTIVITY LEVEL AND QUALITY OF LIFE AND QUESTIONING EXERCISE HABITS BEFORE AND AFTER THE COVID-19 OUTBREAK IN PATIENTS WITH BEHÇET AND FMF.",IPAQ-SF,"Pain, Sleep, Fatigue, Physical Activity Level, Quality of Life and Exercise Habits in Patients With Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic"
NCT04403477,Recruiting,Interventional,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Other,20-May-20,30-Oct-20,20-Jul-20,TREATMENT,20,COVID,BANGLADESH,ALL,"16 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,PROPORTION OF IN-HOSPITAL MORTALITY,"Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT"
NCT04403555,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,1-Jun-20,3-Dec-30,1-Dec-30,TREATMENT,160,COVID,EGYPT,ALL,"Child, Adult, Older Adult",IVERMECTIN,THE NUMBER OF PATIENTS WITH IMPROVEMENT OR MORTALITY,The Efficacy of Ivermectin in COVID-19 Treatment
NCT04403581,Not yet recruiting,Observational,,Ain Shams University,Other,20-May-21,20-Jun-21,20-Jun-21,COHORT,384,COVID,,ALL,23 Years to 55 Years   (Adult),QUESTIONNAIRE,"CROSS-SECTIONAL DESCRIPTIVE STUDY: EGYPTIAN DOCTORS STRESSES, KNOWLEDGE AND ATTITUDE DURING COVID-19 PANDEMIC","Cross-sectional Descriptive Study: Egyptian Doctors Stresses, Knowledge and Attitude During COVID-19 Pandemic"
NCT04403607,Recruiting,Observational,,NHS Greater Glasgow and Clyde,Other,22-May-20,21-Aug-21,30-Sep-20,COHORT,180,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,THE PRIMARY CARDIAC OUTCOME IS THE PROPORTION OF PATIENTS WITH A DIAGNOSIS OF MYOCARDIAL INFLAMMATION (MYOCARDITIS).,"Cardiovascular and Pulmonary Imaging in SARS-CoV-2: A Study of the Heart, Lungs and Wellbeing After COVID-19."
NCT04403646,Terminated,Interventional,Not Applicable,Hospital de Clinicas José de San Martín,Other,12-Jun-20,1-Nov-20,20-Oct-20,TREATMENT,124,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",ARBOX,TIME TO HOSPITAL DISCHARGE,Efficacy of Tannin Specific Natural Extract for Coronavirus Disease (COVID-19): Randomized Controlled Trial
NCT04403672,Recruiting,Observational [Patient Registry],,Bangladesh Medical Research Council (BMRC),Other,18-May-20,24-Jul-20,24-Jul-20,CASE-CONTROL,120,HIGH SENSITIVITY AND SPECIFICITY (WITH 95% CONFIDENCE INTERVAL) OF REALDETECT™ COVID RT-PCR KIT,BANGLADESH,ALL,"5 Years to 65 Years   (Child, Adult, Older Adult)",PERFORMANCE EVALUATION STUDY OF REALDETECT RT-PCR KIT FOR COVID-19 DETECTION,PERFORMANCE EVALUATION OF REALDETECT™ COVID-19 RT-PCR KIT,Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus
NCT04403685,Terminated,Interventional,Phase 3,Beneficência Portuguesa de São Paulo,Other,8-May-20,21-Jul-20,8-Jul-20,TREATMENT,129,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,EVALUATION OF CLINICAL STATUS,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS)
NCT04403828,Completed,Observational,,Fayoum University,Other,20-May-20,15-Jul-20,1-Jun-20,COHORT,323,COVID,EGYPT,ALL,"18 Years to 75 Years   (Adult, Older Adult)",SURVEY,PERSONAL PROTECTION MEASURES,Impact of COVID-19 on Personal Protection Among Dentist in Egypt: A Quick Online Survey
NCT04403880,Recruiting,Observational,,HIV Vaccine Trials Network,Other,13-May-20,21-Aug-21,21-Aug-21,COHORT,727,SARS-COV2,MALAWI,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLE COLLECTION,HUMORAL RESPONSES TO PEPTIDE ANTIGENS DERIVED FROM SARS-COV-2 STRUCTURAL PROTEINS AND REGIONS OF THE SPIKE PROTEIN NOT PRESENT IN VACCINES,Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals
NCT04403906,Not yet recruiting,Interventional,Not Applicable,Somerset NHS Foundation Trust,Other,20-Jun-21,21-Aug-21,21-Jun-21,DIAGNOSTIC,200,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PCL COV05 - COVID 19 AG RAPID FIA TEST (RAPID ANTIGEN TEST),TO COMPARE THE RESULT OF SARS-COV2 PCR TEST TO PCL RAPID ANTIGEN TEST,Evaluation of the PCL Rapid Point of Care Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2
NCT04403932,Completed,Observational,,"Hospital San Carlos, Madrid",Other,17-Apr-20,1-Aug-20,1-Jun-20,COHORT,300,CORONAVIRUS DISEASE 2019 (COVID),SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,SEVERE COVID-19,Cohort Study to Determine the Association Between Vitamin D Deficiency and Severity of the Disease in Patients With Coronarvirus Disease 2019 (COVID-19)
NCT04404062,"Active, not recruiting",Observational,,Richmond Pharmacology Limited,Industry,16-Mar-20,20-Aug-21,20-Aug-21,COHORT,500,COVID,UNITED KINGDOM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",COVID-19 RAPID TEST KIT (RAPG-COV-019),IDENTIFICATION OF ASYMPTOMATIC CARRIERS OF SARS-COV-2,Validation of a Membrane-based Immunoassay for the Detection of IgG and IgM Antibodies to SARS-CoV-2/COVID-19
NCT04404179,Completed,Observational,,"Services Institute of Medical Sciences, Pakistan",Other,27-Mar-20,2-May-20,2-May-20,CASE-ONLY,69,COVID,PAKISTAN,ALL,"Child, Adult, Older Adult",COVID-19 FACILITY,RECOVERY,Setting up a COVID-19 Care Facility at a Prison in Pakistan
NCT04404192,Not yet recruiting,Interventional,Phase 2,"VistaGen Therapeutics, Inc.",Industry,20-Nov-21,21-Sep-21,21-Jul-21,TREATMENT,30,ADJUSTMENT DISORDER WITH ANXIOUS MOOD,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PH94B,HAMILTON ANXIETY SCALE,A Phase 2a Open-label Study of the Efficacy and Safety of PRN PH94B Neuroactive Nasal Spray in the Treatment of Adjustment Disorder With Anxiety (AjDA) Associated With COVID-19
NCT04404218,Recruiting,Interventional,Phase 2,"University Health Network, Toronto",Other,4-Aug-20,21-May-21,21-Mar-21,TREATMENT,480,COVID,CANADA,ALL,"40 Years and older   (Adult, Older Adult)",AÇAÍ PALM BERRY EXTRACT - NATURAL PRODUCT,7-POINT ORDINAL SYMPTOM SCALE,Randomized Clinical Trial of Açaí Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19
NCT04404244,Recruiting,Observational,,Fatma Soliman Elsayed Ebeid,Other,1-Jan-20,1-Jun-21,1-Jan-21,CASE-ONLY,100,CORONAVIRUS COVID,EGYPT,ALL,"up to 18 Years   (Child, Adult)",,INCIDENCE OF COVID-19 AMONG CHILDREN WITH CANCER,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic
NCT04404270,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,26-May-20,21-Feb-21,21-Feb-21,COHORT,2500,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV2 SEROLOGY,PROPORTION ANTI-SARS-COV2 SEROPOSITIVE,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)
NCT04404361,Recruiting,Interventional,Phase 3,CTI BioPharma,Industry,22-May-20,31-Oct-21,31-Jul-21,TREATMENT,364,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PACRITINIB,PROPORTION OF PATIENTS WHO PROGRESS TO IMV AND/OR ECMO OR DEATH DURING THE 28 DAYS FOLLOWING RANDOMIZATION,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer"
NCT04404426,Recruiting,Interventional,Not Applicable,Rennes University Hospital,Other,2-Nov-20,15-Sep-21,15-Sep-21,TREATMENT,32,ARDS SECONDARY TO COVID PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",L-CITRULLINE,SOFA,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
NCT04404608,Not yet recruiting,Observational,,Dr Medhat Khafagy,Other,20-Jun-21,21-Dec-21,21-Jun-21,COHORT,90,LYMPHOPENIA,,ALL,"Child, Adult, Older Adult","COMPLETE BLOOD PICTURE, BONE MARROW ASPIRATION CYTOLOGY",DEATH OR RECOVERY,Study of the Etiology of Lymphopenia in Covid19 Viral Infection
NCT04405076,"Active, not recruiting",Interventional,Phase 2,"ModernaTX, Inc.",Industry,29-May-20,6-Oct-21,31-Mar-21,PREVENTION,600,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL: MRNA-1273,NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL AND SYSTEMIC ADVERSE REACTIONS (ARS),"A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older"
NCT04405102,Recruiting,Interventional,Phase 2,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,Other,16-Sep-20,1-Jan-24,1-Jan-23,TREATMENT,48,COVID,CANADA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",OZANIMOD,DAILY PATIENT PROGRESSION ASSESSED WITH THE WORLD HEALTH ORGANIZATION-ADAPTED 6-POINTS ORDINAL SCALE,A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial
NCT04405232,Recruiting,Observational,,Imperial College London,Other,25-May-20,25-Jun-21,25-Apr-21,COHORT,5000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NON-INTERVENTIONAL,"PREVALENCE AND CHARACTERISTICS OF COAGULATION ABNORMALITIES AND THEIR PREDICTIVE VALUE FOR RESPIRATORY FAILURE REQUIRING VENTILATION, MULTIORGAN FAILURE AND DEATH IN PATIENTS PRESENTING WITH COVID 19 INFECTION",Coagulopathy Associated With Coronavirus disease19 (CA-COVID19) A Multi-Centre Observational Study in UK
NCT04405271,Not yet recruiting,Interventional,Phase 3,Hospital Italiano de Buenos Aires,Other,31-Jul-20,15-Nov-20,15-Nov-20,PREVENTION,1378,HEALTHCARE WORKERS,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",EMTRICITABINE/TENOFOVIR ALAFENAMIDE 200 MG-25 MG ORAL TABLET,COVID-19 INCIDENT CASES,"Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)"
NCT04405310,Completed,Interventional,Phase 2,Grupo Mexicano para el Estudio de la Medicina Intensiva,Other,20-May-20,10-Dec-20,20-Nov-20,TREATMENT,42,SARS PNEUMONIA,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CONVALESCENT PLASMA OF PATIENTS WITH COVID-19,DEATH,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial"
NCT04405362,Not yet recruiting,Observational,,"University Hospital, Lille",Other,20-May-21,21-May-21,21-May-21,COHORT,753,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PATIENTS WITH POST-TRAUMATIC STRESS DISORDER (PTSD) DEFINED BY A TOTAL SCORE ON PCL-5 ≥ 31 AT THE TIME OF QUARANTINE,Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry
NCT04405466,Recruiting,Observational,,Miltenyi Biomedicine GmbH,Industry,22-Apr-20,31-Jan-21,28-Aug-20,COHORT,500,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,IMMUNE RESPONSES TO COMPONENTS OF SARS-COV-2,"A Prospective, Epidemiological, Cohort Study to Assess the Feasibility of Screening Healthy Asymptomatic Workers for the Presence of SARS-CoV-2 by Pharyngeal Swaps and Serology at Baseline, Day 21 and Day 40"
NCT04405492,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,25-May-20,25-Mar-21,25-Mar-21,DIAGNOSTIC,1210,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)","TAKING BLOOD SAMPLES (CAPILLARY AND VENOUS), SALIVA SAMPLING AND NASOPHARYNGEAL SAMPLING.",CLINICAL PERFORMANCE OF SEVERAL DIAGNOSTIC TESTS : TESTS BASED EITHER ON DETECTION OF THE VIRUS SARS-COV-2 OR DETECTION OF HUMAN ANTIBODIES GENERATED IN RESPONSE TO INFECTION,"Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19"
NCT04405544,Completed,Interventional,Not Applicable,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",Other,22-May-20,29-Oct-20,22-Jul-20,DIAGNOSTIC,51,ENCEPHALOPATHY,RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),CT-SCAN,THE PERCENTAGE OF PATIENTS WHO HAVE DEVELOPED ENCEPHALOPATHY,Determination of Acute Encephalopathy Predictors in Patients With COVID-19
NCT04405570,Completed,Interventional,Phase 2,"Ridgeback Biotherapeutics, LP",Industry,16-Jun-20,21-Feb-21,21-Feb-21,TREATMENT,204,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EIDD-2801,VIROLOGIC EFFICACY,"A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19"
NCT04405726,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,27-Mar-20,22-Mar-21,22-Mar-21,CASE-ONLY,500,SARS-COV2,FRANCE,ALL,"1 Year and older   (Child, Adult, Older Adult)",,CLINICAL PRESENTATION AND INCIDENCE OF COVID-19 INFECTION IN PATIENTS HOSPITALISED IN STRASBOURG HOSPITAL,"Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals"
NCT04405739,Recruiting,Interventional,Phase 2,"Ridgeback Biotherapeutics, LP",Industry,16-Jun-20,28-May-21,28-May-21,TREATMENT,80,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EIDD-2801,NUMBER OF PARTICIPANTS THAT ACHIEVE VIROLOGIC CLEARANCE AFTER ORAL ADMINISTRATION OF EIDD-2801,The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2
NCT04405843,Completed,Interventional,Phase 2/Phase 3,Centro de Estudios en Infectogía Pediatrica,Other,14-Jul-20,21-Dec-20,21-Dec-20,TREATMENT,476,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN ORAL PRODUCT,TIME TO EVENT,"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19"
NCT04405869,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,29-Apr-20,21-Apr-21,21-Apr-21,COHORT,300,PULMONARY THROMBOEMBOLISM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ANALYSIS OF INCIDENCE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH SARS-COV-2,Incidence of Thromboembolic Events and Prognosis of COVID-19 Patients Hospitalized in Intensive Care Units in France
NCT04405908,"Active, not recruiting",Interventional,Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,Industry,19-Jun-20,25-May-21,16-Oct-20,PREVENTION,150,COVID,AUSTRALIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",SCB-2019,INCIDENCE OF SOLICITED ADVERSE EVENTS (AES) AFTER VACCINATION,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers."
NCT04405921,Not yet recruiting,Interventional,Phase 3,Centre Hôpital Universitaire Farhat Hached,Other,20-Jul-21,21-Mar-21,20-Dec-21,TREATMENT,200,SARS-COV2 PNEUMONIA,TUNISIA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE 200 MG ORAL TABLET,"CLINICAL RECOVERY AT DAY-14, FROM THE START OF TREATMENT.","Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 Pneumonia: A Randomized,Open-label,Controlled Clinical Trial"
NCT04405934,Not yet recruiting,Interventional,Not Applicable,"University College, London",Other,20-Jul-21,21-Apr-21,20-Oct-21,HEALTH SERVICES RESEARCH,2000,COVID,,ALL,"Child, Adult, Older Adult",USE OF VIRUS (COVID-19) GENOME SEQUENCE REPORT TO INFORM INFECTION PREVENTION CONTROL PROCEDURES,INCIDENCE RATES OF IPC-DEFINED HOSPITAL-ONSET COVID-19 INFECTION (HOCIS),"A Phase III Prospective, Interventional, Cohort, Superiority Study to Evaluate the Benefit of Rapid COVID-19 Genomic Sequencing (the COVID-19 GENOMICS UK Project) on Infection Control in Preventing the Spread of the Virus in United Kingdom NHS Hospitals"
NCT04405973,Completed,Observational,,Dr. Alexander Supady,Other,19-May-20,30-Sep-20,30-Sep-20,COHORT,133,COVID,GERMANY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VV-ECMO,OVERALL SURVIVAL,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation - a Retrospective Multi-center Registry Study
NCT04405986,Recruiting,Interventional,Not Applicable,"University Hospital, Bordeaux",Other,19-May-20,19-Nov-21,19-Nov-21,HEALTH SERVICES RESEARCH,38,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AUDITORY EVOKED POTENTIALS (AEP),LATENCY OF ELECTROPHYSIOLOGICAL RESPONSE,Exploring Brain Damages After COVID-19 Infection
NCT04405999,Completed,Interventional,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Other,14-May-20,31-Aug-20,9-Aug-20,PREVENTION,50,INCREASED RISK OF SARS-COV2 INFECTION,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",BROMHEXINE HYDROCHLORIDE,POLYMERASE CHAIN REACTION (PCR),Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial
NCT04406038,"Active, not recruiting",Observational,,European University at St. Petersburg,Other,27-May-20,28-Oct-21,28-Oct-21,COHORT,1038,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",,"PREVALENCE OF THE SARS-COV-2 INFECTION IN SAINT PETERSBURG, RUSSIA","A Population-Based Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Saint Petersburg, Russia: Longitudinal Cohort Study"
NCT04406064,Withdrawn,Interventional,Phase 2,"Children's Hospital Medical Center, Cincinnati",Other,21-Jan-21,25-Jun-21,24-Jun-21,TREATMENT,0,VIRAL INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",VIRAL SPECIFIC T-CELLS (VSTS),SUCCESSFUL PRODUCTION OF VIRAL SPECIFIC T-CELLS,Viral Specific T-cells (VSTs) for Treatment of SARS-CoV-2/COVID-19
NCT04406090,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Jun-20,30-Jun-20,COHORT,50,ISCHEMIC STROKE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MECHANICAL TROMBECTOMY,INTRAHOSPITAL MORTALITY,Endovascular Thrombectomy in COVID-19 Infected Patients: Intrahospital and Peri-operative Outcomes
NCT04406181,Recruiting,Interventional,Not Applicable,Universitair Ziekenhuis Brussel,Other,18-May-20,1-Jan-21,31-Dec-20,SUPPORTIVE CARE,200,ANXIETY AND FEAR,BELGIUM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",HADS,ANXIETY/DEPRESSION BY MEANS OF HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS),Effect on the COVID-19 Pandemic-induced Reduction in Elective Surgery on Medical Events and Psychological Well-being of Patients Waiting for Cardiac Surgery
NCT04406194,Completed,Interventional,Phase 1,Atabay Kimya Sanayi Ticaret A.S.,Industry,14-May-20,19-Jun-20,22-May-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,20 Years to 40 Years   (Adult),FAVICOVIR 200 MG FILM TABLET,AUC0-TLAST OF FAVIPIRAVIR,"Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Favicovir 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions"
NCT04406233,Recruiting,Observational,,University of Sao Paulo,Other,23-May-20,23-May-22,23-May-22,COHORT,176,SARS-COV2,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",,TIME TO MEDICAL DISCHARGE,Muscle Mass and Strength as Predictors of Time to Medical Discharge and Mortality in Patients Hospitalized With COVID-19: A Prospective Observational Study
NCT04406246,Recruiting,Interventional,Phase 4,Materno-Perinatal Hospital of the State of Mexico,Other,21-May-20,31-Dec-20,31-Dec-20,TREATMENT,150,CORONAVIRUS INFECTION,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)",NITAZOXANIDE 500MG ORAL TABLET,HEALTH WORKERS THAT REQUIRE HOSPITALIZATION,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide
NCT04406324,Recruiting,Observational,,"University Hospital, Grenoble",Other,1-Jun-20,5-Mar-26,5-Mar-21,COHORT,400,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,DIFFUSION CAPACITY FOR CARBON MONOXIDE (CO) 3 MONTHS AFTER COVID DIAGNOSIS,"COVID-19: Prospective Follow-up of Pulmonary Function, Sleep Disorders, Quality of Life and Post-traumatic Stress"
NCT04406389,Recruiting,Interventional,Phase 4,Weill Medical College of Cornell University,Other,13-Oct-20,21-Dec-21,21-Jun-21,TREATMENT,186,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN SODIUM,30-DAY MORTALITY,InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)
NCT04406493,Recruiting,Interventional,Not Applicable,Hillel Yaffe Medical Center,Other,28-Apr-20,28-Apr-21,28-Apr-21,DIAGNOSTIC,50,ARDS,ISRAEL,ALL,"18 Years to 95 Years   (Adult, Older Adult)",LUNG IMPEDANCE TECHNIQUE,CORRELATION BETWEEN IMPUDENCE DETERIORATION TO CLINICAL CONDITIONS AND HOSPITALIZATION PERIOD,Monitoring of Lung Fluid Status of Hospitalized COVID-19 Patients by Lung Impedance Technique
NCT04406532,Not yet recruiting,Interventional,Not Applicable,Albert Einstein College of Medicine,Other,21-Feb-21,22-Mar-21,22-Jan-21,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PT-PAL,CHANGE IN PULMONARY FUNCTION (ST GEORGE'S RESPIRATORY QUESTIONNAIRE: SGRQ),Home Based Covid-19 Rehabilitation Program: Pilot Clinical Trial
NCT04406545,Recruiting,Observational,,"National Institute of Cardiology, Laranjeiras, Brazil",Other,15-May-20,20-Nov-21,15-Aug-20,COHORT,25,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",EVALUATION OF SKIN MICROVASCULAR FLOW AND REACTIVITY,"TO EVALUATE, THROUGH LASER DOPPLER, THE PRESENCE OF CHANGES IN SYSTEMIC MICROVASCULAR ENDOTHELIAL FUNCTION IN PATIENTS IN THE ACUTE PHASE OF COVID-19.",Investigation of Systemic Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of Coronavirus Disease-19.
NCT04406558,Recruiting,Observational,,Centre Hospitalier Intercommunal Creteil,Other,27-May-20,21-Apr-21,21-Mar-21,COHORT,400,PSYCHOLOGICAL ADAPTATION,FRANCE,ALL,"11 Years to 18 Years   (Child, Adult)",QUESTIONNAIRE,ANXIETY SCORE FROM THE GENERALIZED ANXIETY DISORDER 7 (GAD-7) QUESTIONNAIRE,Psychological Impact of the Health Measures Generated by the SarsCov-2 Pandemic in Adolescents (COVADO)
NCT04406571,Recruiting,Observational,,CHU de Reims,Other,1-Apr-20,22-Apr-21,21-Nov-21,COHORT,700,PANCREATIC ADENOCARCINOMA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA RECORD,PANCREATIC ADENOCARCINOMA TREATMENT,Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
NCT04406688,Recruiting,Observational,,University Hospital Muenster,Other,22-Jun-20,21-Mar-21,21-Feb-21,COHORT,300,ACUTE KIDNEY INJURY,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,OCCURENCE OF ACUTE KIDNEY INJURY (AKI),Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome
NCT04406844,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,9-May-20,30-Jun-21,30-Jun-21,COHORT,150,ONCOLOGY PATIENTS,INDIA,ALL,"12 Years to 98 Years   (Child, Adult, Older Adult)",,ONCOLOGY PATIENTS,An Observational Study to Identify the Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic and the Resulting Lockdown
NCT04407000,Completed,Interventional,Phase 1,World Medicine ILAC SAN. ve TIC. A.S.,Industry,23-Jun-20,8-Aug-20,20-Jul-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,20 Years to 40 Years   (Adult),TEST: FAVIPIRAVIR 200 MG (LOQULAR),PRIMARY PK END POINTS AUC0-TLAST,"Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Loqular 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions"
NCT04407117,Completed,Observational,,"Claus Anders Bertelsen, PhD, MD",Other,23-Mar-17,19-Apr-20,19-Apr-20,COHORT,6000000,APPENDICITIS,DENMARK,ALL,"Child, Adult, Older Adult",LOCK-DOWN AND SOCIAL DISTANCING,APPENDECTOMY,Change in the Incidence of Appendicitis in a Controlled Environment During the National Lockdown Throughout the COVID-19 Pandemic
NCT04407130,Completed,Interventional,Phase 2,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,16-Jun-20,20-Nov-20,30-Oct-20,TREATMENT,72,COVID PATIENTS,BANGLADESH,ALL,"40 Years to 65 Years   (Adult, Older Adult)",IVERMECTIN + DOXYCYCLINE + PLACEBO,VIROLOGICAL CLEARANCE,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial."
NCT04407143,Recruiting,Observational,,Fundación GECP,Other,15-Apr-20,30-Sep-21,30-Sep-21,COHORT,128,LUNG CANCER,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",IGG TEST,DESCRIPTION OF THE CHARACTERISTICS OF PATIENTS,Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
NCT04407156,Completed,Observational,,University Hospitals of Derby and Burton NHS Foundation Trust,Other,1-Jun-20,20-Jul-20,7-Jun-20,CASE-CONTROL,724,COVID,UNITED KINGDOM,ALL,"18 Years to 110 Years   (Adult, Older Adult)",ACUTE KIDNEY INJURY,INCIDENCE OF ACUTE KIDNEY INJURY IN COVID-19,Acute Kidney Injury In Corona Virus Infection Disease (COVID19) in United Kingdom
NCT04407169,Completed,Observational,,"Central Hospital, Nancy, France",Other,1-Jun-20,17-Nov-20,17-Nov-20,COHORT,617,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,"PERCENTAGE OF PATIENTS WHO REACHED, DURING THEIR HOSPITALIZATION, A VALUE GREATER THAN OR EQUAL TO 6 ON THE WHO COVID-19 INFECTION PROGRESSION SCALE",Evaluation of the Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease Hospitalized for Severe Forms
NCT04407182,Completed,Interventional,Phase 2,Catalysis SL,Industry,4-May-20,1-Oct-20,1-Aug-20,SUPPORTIVE CARE,60,COVID,ECUADOR,ALL,"18 Years to 70 Years   (Adult, Older Adult)",VIUSID AND ASBRIP,SYMPTOM RESOLUTION,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19
NCT04407195,"Active, not recruiting",Observational,,Northeastern University,Other,1-Jun-20,1-Jun-21,1-Jun-21,COHORT,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXPOSURE TO THE SARS-COV-2,EMOTIONAL IMPACT,Mental Health Outcomes Among US Healthcare Workers Exposed to COVID-19
NCT04407208,Completed,Interventional,Phase 1,Biofarma,Other,1-May-20,22-Jun-20,22-Jun-20,HEALTH SERVICES RESEARCH,10,CONVALESCENCE,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,PLAQUE REDUCTION NEUTRALIZATION TEST (PNRT),Convalescent Plasma Therapy in Patients With COVID-19
NCT04407221,Enrolling by invitation,Observational,,Vastra Gotaland Region,Other,16-Jun-20,1-May-24,1-May-24,COHORT,1100,TRANSPLANT RECIPIENTS,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",,SEROPREVALENCE OF SARS-COV-2 ANTIBODIES (POSITIVE ANTIBODY TEST),COVID-19 Research in Organ Transplant Recipients
NCT04407260,Completed,Observational,,Northwell Health,Other,6-Mar-20,1-May-20,1-May-20,COHORT,136,COVID -19,UNITED STATES,ALL,"Child, Adult, Older Adult",OXYGEN HOOD,OXYGEN SATURATION,"The Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study."
NCT04407273,"Active, not recruiting",Observational,,Institut Investigacio Sanitaria Pere Virgili,Other,14-May-20,30-Dec-20,20-Aug-20,CASE-ONLY,1200,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL,SARS-COV-2 SCALE OF SEVERITY (9 STEPS) IN COVID-19 INFECTED PATIENTS WITH STATIN THERAPY,STATIN THERAPY AND COVID-19 INFECTION (STACOV PROJECT)
NCT04407286,Completed,Interventional,Phase 1,Arizona State University,Other,19-May-20,30-Nov-20,30-Aug-20,TREATMENT,41,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN D3,VITAMIN D LEVELS,Vitamin D Testing and Treatment for Adults With COVID 19
NCT04407299,Completed,Observational,,Cairo University,Other,20-Apr-20,20-May-20,10-May-20,OTHER,360,COVID,EGYPT,ALL,"16 Years and older   (Child, Adult, Older Adult)",SELF-ADMINISTERED STRUCTURED QUESTIONNAIRE,SCORE OF FIVE-ITEM BRIEF SYMPTOM RATING SCALE (BSRS-5),"Impact of COVID-19 Pandemic on Attitude, Behaviour and Mental Health of Patients With Rheumatic Diseases"
NCT04407390,Recruiting,Interventional,Phase 2,University of Copenhagen,Other,1-Jun-20,1-May-22,1-May-21,TREATMENT,100,COVID,DENMARK,ALL,70 Years and older   (Older Adult),NICOTINAMIDE RIBOSIDE,HYPOXIC RESPIRATORY FAILURE,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19"
NCT04407429,Recruiting,Observational,,Medical University of Vienna,Other,27-May-20,27-Jun-21,27-Jun-21,COHORT,12000,SARS-COV2,AUSTRIA,ALL,"Child, Adult, Older Adult",LABORATORY ANALYSES,PREVALENCE OF ANTIBODY STATUS IN HEALTHCARE WORKERS AND IN PATIENTS ADMITTED FOR NON-COVID-19 RELATED SYMPTOMS OVER TIME,Vienna Versus SARS-CoV-2 Virus: A Prospective Large-scale Antibody Study of SARS-CoV-2 in Patients and Health Care Workers
NCT04407468,Completed,Observational,,Hospital General San Juan del Rio,Other,1-May-20,13-Jul-20,13-Jul-20,COHORT,827,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITION,TO ANALYZE THE RELATIONSHIP BETWEEN THE PRONE POSITION AND THE NEED FOR OROTRACHEAL INTUBATION.,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19 (APRONOX)
NCT04407494,Completed,Observational,,"University Hospital, Montpellier",Other,1-Mar-20,30-Apr-20,1-Apr-20,COHORT,809,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","REPORTING OF ANOSMIA, AGEUSIA AND OTHER CLINICAL SYMPTOMS",DIAGNOSTIC VALUES OF ANOSMIA AND AGEUSIA FOR COVID-19,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders in a Population Tested for COVID-19
NCT04407507,Not yet recruiting,Interventional,Phase 2,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,Other,20-Jun-21,20-Oct-21,20-Aug-21,TREATMENT,66,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,PARTICIPANTS WITH A DISEASE CONTROL STATUS DEFINED AS NO DISEASE PROGRESSION TO SEVERE.,"Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms"
NCT04407533,Recruiting,Observational,,McGill University,Other,25-May-20,31-Aug-22,31-Aug-22,ECOLOGIC OR COMMUNITY,1920,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",DIET TRACKING AND SURVEY,DIETARY INTAKE,Dietary Intake and Eating Habits During the COVID-19 Pandemic
NCT04407546,Recruiting,Observational,,Jonsson Comprehensive Cancer Center,Other,27-May-20,28-May-23,28-May-22,COHORT,300,IMMUNOSUPPRESSION,UNITED STATES,ALL,"Child, Adult, Older Adult",,TO DEFINE THE ROLE OF HOUSEHOLD CONTACT WITH CHILDREN OR SIBLINGS IN THE TRANSMISSION OF SARS-COV-2 TO IMMUNOCOMPROMISED PATIENTS.,Role of Children in the Transmission of SARS-CoV-2 in Households of Immunocompromised Persons
NCT04407559,Completed,Observational,,"University Hospital, Montpellier",Other,1-May-20,30-Sep-20,1-Sep-20,COHORT,216,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL ANALYSES TO BE LEAD ON A PRE-EXISTING BIOBANK,EVALUATE THE FALSE POSITIVE RESULTS RATE,Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients
NCT04407572,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,20-Apr-20,14-Jun-20,1-Jun-20,CASE-CONTROL,44,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),"SERUM ZINC, VITAMIN D VITAMIN B12 LEVELS .","SERUM ZINC, VITAMIN D VITAMIN B12 DEFICIENCY LEVELS",Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women
NCT04407585,Recruiting,Observational,,King's College London,Other,1-Jun-20,10-May-21,10-May-21,COHORT,1000000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 SWAB PCR TEST,SARS-COV-2 INFECTION,Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2
NCT04407598,"Active, not recruiting",Observational,,University of Leicester,Other,1-May-20,21-Jun-21,8-Jun-20,COHORT,160,COPD EXACERBATION,UNITED KINGDOM,ALL,"40 Years and older   (Adult, Older Adult)",,CHANGE IN COPD EXACERBATION RATE,Cross-Sectional Observation Telephone Survey Study to Understand the Changes in COPD Exacerbation Patterns and Potential Causes of These During the COVID-19 Pandemic
NCT04407663,Completed,Observational,,"University of Campania ""Luigi Vanvitelli""",Other,3-Mar-20,4-May-20,4-May-20,COHORT,138,BARIATRIC SURGERY CANDIDATE,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",TELEMEDICINE TO REMOTE OUTPATIENT VISIT IN BARIATRIC PATIENT,EVALUATION OF FEASIBILITY OF TELEMEDICINE IN OUTPATIENT VISIT IN BARIATRIC PATIENTS,"Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near. Brief Correspondence on a Single Center Experience. Cohort Study"
NCT04407689,Recruiting,Interventional,Phase 2,Revimmune,Industry,8-Jun-20,30-Dec-21,30-Jul-21,TREATMENT,48,COVID,FRANCE,ALL,"25 Years to 80 Years   (Adult, Older Adult)",INTERLEUKIN-7,"IMPROVEMENT OF THE ABSOLUTE LYMPHOCYTE COUNT (ALC) OF LYMPHOPENIC (ALC≤1000/MM3) COVID-19 INFECTED PARTICIPANTS OUT TO APPROXIMATELY 30 DAYS FOLLOWING INITIAL STUDY DRUG ADMINISTRATION OR HOSPITAL DISCHARGE (HD), WHICHEVER OCCURS FIRST","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium"
NCT04407923,Recruiting,Observational,,"University Hospital, Brest",Other,25-May-20,25-Nov-20,25-Nov-20,COHORT,150,JUVENILE IDIOPATHIC ARTHRITIS,FRANCE,ALL,up to 17 Years   (Child),,REDUCTION OR DISCONTINUATION OF THE DMARD THERAPY IN RELATION TO THE COVID-19 SANITARY CRISIS,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context
NCT04408001,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,4-Jun-20,4-Jun-21,4-Jun-21,COHORT,800,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CLINICAL INTERVIEW,INDUCED SARS-COV2 IMMUNITY,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff
NCT04408014,Not yet recruiting,Observational,,Butantan Institute,Other,1-Jun-20,30-Jul-20,15-Jul-20,OTHER,18901,COVID,,ALL,"6 Months to 100 Years   (Child, Adult, Older Adult)",SEROLOGICAL TEST,PREVALENCE OF ANTIBODIES AGAINST SARS-COV-2 THROUGH SEROLOGICAL TESTING,Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo
NCT04408027,Recruiting,Interventional,Not Applicable,The Hospital for Sick Children,Other,1-Jun-20,1-Jun-21,1-Jun-21,TREATMENT,20,ANXIETY DISORDER OF CHILDHOOD OR ADOLESCENCE,CANADA,ALL,12 Years to 17 Years   (Child),VIRTUAL-CARE COGNITIVE BEHAVIOURAL THERAPY,PARTICIPATION BARRIERS,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions
NCT04408040,Recruiting,Interventional,Phase 2,"Northside Hospital, Inc.",Other,14-Jul-20,31-Jul-24,31-Jul-24,TREATMENT,700,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,ARMS 1 & 2: NUMBER OF CRITICAL AND SEVERE COVID-19 INFECTED PATIENTS WHO ARE TRANSFUSED WITH CONVALESCENT PLASMA RESULT IN LOWER DEATH RATES THAN THE REPORTED FATALITY RATE,"Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak"
NCT04408066,Recruiting,Interventional,Not Applicable,LumiraDx UK Limited,Industry,30-Apr-20,30-Apr-22,30-Apr-22,DIAGNOSTIC,2000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLE COLLECTION/PERFORMANCE EVALUATION (A),PERFORMANCE OF THE LUMIRADX ASSAY VERSUS REFERENCE METHODS WITH REGARDS TO CLINICAL SENSITIVITY AND SPECIFICITY FOR THE DETECTION OF THE SARS-COV-2 IGG/IGM AND VIRAL ANTIGEN IN PATIENT SAMPLES.,Specimen Collection for Development and Performance Evaluation of the LumiraDx Platform Point of Care Tests for Sars-Cov-2 IgG/IgM & Antigen to be Used as an Aid in Diagnosis of COVID-19
NCT04408131,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,28-May-20,27-Jan-21,27-Jan-21,DIAGNOSTIC,2000,HOMELESS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,THE COVID MORTALITY RATE,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study
NCT04408157,Recruiting,Interventional,Not Applicable,King's College London,Other,20-May-20,22-Dec-21,22-Aug-21,TREATMENT,548,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SELF-MANAGEMENT BOOKLET (SWITCH: STAY WELL DURING COVID-19),"WARWICK-EDINBURGH MENTAL WELLBEING SCALE (WEMWBS): TENNANT ET AL., 2007",A Research Study to Evaluate the Efficacy of a Self-management Booklet (Stay Well During COVID-19; SWitCh) to Promote Wellbeing During the COVID-19 Pandemic
NCT04408170,Recruiting,Observational,,Manchester University NHS Foundation Trust,Other,19-Jun-20,30-Jun-21,30-Jun-21,COHORT,1000,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",POINT-OF-CARE TEST FOR SARS-COV-2,IF THE PARTICIPANT HAS AN ACTIVE SARS-COV-2 INFECTION DURING ADMISSION,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)
NCT04408183,Recruiting,Interventional,Phase 2,"GeneOne Life Science, Inc.",Industry,1-Jun-20,21-Mar-21,21-Feb-21,PREVENTION,225,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GLS-1200,EVALUATE THE NUMBER OF GLS-1200 TOPICAL NASAL SPRAY ADVERSE EVENTS AS ASSESSED BY CTCAE V5.0,"Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection in Healthcare Personnel"
NCT04408196,Completed,Observational,,Fondazione Don Carlo Gnocchi Onlus,Other,26-May-20,22-Feb-21,15-Feb-21,COHORT,121,REHABILITATION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,SHORT FORM-36 HEALTH SURVEY (SF36),Effects of Social Distancing on the Quality of Life and on the Emotional-affective Sphere of Caregivers and Patients Hospitalized in Residential Rehabilitation Departments: an Observational Study.
NCT04408209,Recruiting,Interventional,Not Applicable,National and Kapodistrian University of Athens,Other,23-Apr-20,15-Sep-21,30-Aug-21,TREATMENT,60,COVID INFECTION,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,SURVIVAL,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial
NCT04408222,"Active, not recruiting",Observational,,Columbia University,Other,16-Apr-20,21-May-21,21-Apr-21,COHORT,29,OXYGEN DEFICIENCY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AWAKE PRONING,CHANGE IN SPO2,Awake Proning in Patients With COVID-19-Induced Acute Hypoxemic Respiratory Failure
NCT04408235,Not yet recruiting,Interventional,Phase 3,Azienda Ospedaliero-Universitaria di Modena,Other,20-Jun-21,21-Jun-21,21-Jun-21,TREATMENT,300,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ENOXAPARIN,"CLINICAL WORSENING, DEFINED AS THE OCCURRENCE OF AT LEAST ONE OF THE FOLLOWING EVENTS, WHICHEVER COMES FIRST:",Randomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical Ventilation
NCT04408248,Recruiting,Observational,,Guy's and St Thomas' NHS Foundation Trust,Other,20-Aug-20,30-Jun-21,31-May-21,COHORT,30,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,ANY STAGE OF ACUTE KIDNEY INJURY,AKI Biomarkers for Prediction of Acute Kidney Injury in Critically Ill Patients With COVID-19 and Respiratory Disease
NCT04408287,Recruiting,Interventional,Not Applicable,Lawson Health Research Institute,Other,15-Sep-20,31-Oct-21,28-Feb-21,TREATMENT,50,SPINAL CORD INJURIES,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",WEBEX PHYSICAL ACTIVITY PROGRAM,TREATMENT SATISFACTION,Improving Activity Engagement Among Persons With SCI During COVID-19
NCT04408326,Recruiting,Observational,,Guy's and St Thomas' NHS Foundation Trust,Other,1-Jun-20,1-May-21,1-May-21,CASE-CONTROL,50,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN II,PROPORTIONS OF PATIENTS WITH MEAN ARTERIAL PRESSURE ≥ 65 MMHG OR AN INCREASE OF MEAN ARTERIAL PRESSURE ≥10 MMHG AT 3 HOURS,Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome
NCT04408339,Recruiting,Observational [Patient Registry],,Universitätsklinikum Hamburg-Eppendorf,Other,15-Apr-20,14-Apr-22,14-Apr-21,COHORT,500,CANCER,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,RATE OF HOSPITALIZATION,COVID-19 Disease in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care in the Hamburg Metropolitan Area Including Prospective Biobanking
NCT04408365,Recruiting,Observational,,Guy's and St Thomas' NHS Foundation Trust,Other,5-Aug-20,31-May-21,31-May-21,COHORT,82,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE OF PLASMA BIO-ADRENOMEDULLIN,"Endothelial Function, Inflammation, and Organ Dysfunction in Critically Ill Patients With COVID-19"
NCT04408378,Recruiting,Observational,,Gaziosmanpasa Taksim Research and Education Hospital,Other,5-Jun-20,20-Aug-20,20-Jul-20,CASE-CONTROL,156,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",OBSERVATION OF COVID 19 PNEUMONIA,ESTIMATION OF INFLAMMATORY CHANGES IN COVID 19 PNEUMONIA BY USING MVP/PLT RATIO,Retrospective Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients
NCT04408391,Withdrawn,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,20-May-20,6-Jul-20,6-Jul-20,CASE-ONLY,0,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BRAIN MRI SCAN,BRAIN REGIONAL HOMOGENEITY BETWEEN COVID-19 PATIENTS WITH AND WITHOUT ANOSMIA,Descriptive Pilot Study of Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
NCT04408456,Completed,Interventional,Phase 3,Postgraduate Institute of Medical Education and Research,Other,1-Mar-20,31-Jul-20,31-Jul-20,PREVENTION,325,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",HCQ,INCIDENCE CONFIRMED CASE OF COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial
NCT04409184,Withdrawn,Observational,,Medical College of Wisconsin,Other,14-Aug-20,14-Aug-20,14-Aug-20,COHORT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,CHARACTERIZATION OF SPECIFIC T CELL RESPONSES IN PERIPHERAL BLOOD ISOLATED FROM PATIENTS THAT HAVE BEEN EXPOSED TO SARS-COV-2.,Evaluation of Whole Blood Samples From Coronavirus Disease 2019 (COVID-19) Convalescent Patients to Study Immune Response and Severity of Disease Predictors
NCT04409197,Completed,Observational,,"University Hospital, Grenoble",Other,8-May-20,11-Jul-20,8-Jun-20,COHORT,4789,COMORBIDITIES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"ANALYSE THE VARIATION IN WEIGHT LOSS KINETICS BEFORE, DURING AND AFTER CONFINEMENT IN PATIENTS ENROLLED IN A WEIGHT REDUCTION PROGRAMME (RNPC) IN FRANCE","Evaluation of Changes in Weight, Sleep, and Other Psycho-behavioural Parameters During Covid-19 Confinement in Subjects Monitored by the RNPC Network"
NCT04409249,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,15-Mar-20,28-May-20,25-May-20,OTHER,155,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),"IMAGING, BLOOD TESTS",THE FACTORS AFFECTING PROGNOSIS IN PREGNANT WOMEN DIAGNOSED WITH COVID-19,Prognostic Factors in Pregnant Women With COVID-19
NCT04409262,"Active, not recruiting",Interventional,Phase 3,Hoffmann-La Roche,Industry,16-Jun-20,5-Mar-21,1-Feb-21,TREATMENT,650,COVID PNEUMONIA,BRAZIL,ALL,"12 Years and older   (Child, Adult, Older Adult)",REMDESIVIR,"TIME FROM ADMINISTRATION OF TOCILIZUMAB/PLACEBO TO HOSPITAL DISCHARGE OR ""READY FOR DISCHARGE,"" DEFINED AS A SCORE OF 1 ON A 7-POINT ORDINAL SCALE","A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia"
NCT04409275,Recruiting,Observational,,Fundación para la Investigación del Hospital Clínico de Valencia,Other,21-May-20,31-Jul-21,31-Dec-20,CASE-ONLY,500,PULMONARY FIBROSIS,SPAIN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,"PULMONARY FIBROTIC CHANGES, SHORT AND MEDIUM TERM",STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
NCT04409327,Terminated,Interventional,Phase 2,Restorbio Inc.,Industry,11-Jul-20,24-Jan-21,27-Dec-20,PREVENTION,36,COVID,UNITED STATES,ALL,65 Years and older   (Older Adult),RTB101,THE PERCENTAGE OF SUBJECTS WHO DEVELOP LABORATORY-CONFIRMED COVID-19: - WITH PROTOCOL-DEFINED PROGRESSIVE SYMPTOMS OR - ARE HOSPITALIZED OR - DIE,Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults ≥65 Years in a Nursing Home in Which ≥1 Person(s) Have Lab Confirmed COVID19
NCT04409483,Withdrawn,Interventional,Phase 3,Epicentre,Other,1-Jun-20,31-Dec-20,31-Dec-20,TREATMENT,0,COVID,,ALL,"12 Years and older   (Child, Adult, Older Adult)",LOPINAVIR-RITONAVIR DRUG COMBINATION,HOSPITALIZATION OR DEATH,Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
NCT04409496,"Active, not recruiting",Interventional,Not Applicable,The University of Hong Kong,Other,2-Jun-20,30-Jun-21,31-Mar-21,TREATMENT,108,SMOKING CESSATION,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",CHAT-BASED INSTANT MESSAGING SUPPORT,BIOCHEMICALLY-VALIDATED TOBACCO ABSTINENCE,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial
NCT04409509,Completed,Interventional,Phase 2,CSL Behring,Industry,1-Jul-20,12-Jan-21,12-Jan-21,TREATMENT,124,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","GARADACIMAB, FACTOR XIIA ANTAGONIST MONOCLONAL ANTIBODY",THE INCIDENCE OF TRACHEAL INTUBATION OR DEATH PRIOR TO TRACHEAL INTUBATION,"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)"
NCT04409522,Recruiting,Interventional,Not Applicable,Mohammad Sadegh Bagheri Baghdasht,Other,12-May-20,25-Sep-20,5-Jun-20,TREATMENT,55,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",MELATONIN,MELATONIN,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients
NCT04409535,"Active, not recruiting",Observational,,University of New Mexico,Other,7-May-20,31-Mar-21,25-Feb-21,ECOLOGIC OR COMMUNITY,500,ACTIVITIES,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",WHOQOL-BREF SURVEY,WORLD HEALTH ORGANIZATION QUALITY OF LIFE-BRIEF SCALE,Effects of the COVID-19 Health Emergency on the Biopsychosocial Health of Rural Residents of New Mexico Using Mixed Methods Research
NCT04409574,Not yet recruiting,Observational,,Assiut University,Other,20-Jun-21,21-Jun-21,21-Mar-21,CASE-ONLY,31,"INFECTION, CORONAVIRUS",,ALL,18 Years to 50 Years   (Adult),,"THE TIME OF COVID 19 VIRAL CLEARANCE IN MEDICAL HEALTHCARE WORKERS AND ITS RELATION TO CLINICAL PRESENTATION, SEVERITY AMONG AND RESOLUTION OF SYMPTOMS.",COVID19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals
NCT04409743,Recruiting,Interventional,Not Applicable,Stanford University,Other,7-Jun-20,21-Nov-21,21-May-21,PREVENTION,50,SLEEP DISTURBANCE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REMOTE COGNITIVE BEHAVIORAL THERAPY FOR INSOMNIA,CHANGE IN INSOMNIA CLINICAL DIAGNOSIS OVER TIME,"Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms"
NCT04409821,Recruiting,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,29-May-20,22-Feb-21,22-Feb-21,SUPPORTIVE CARE,50,POSTTRAUMATIC STRESS DISORDER,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",TELE-DELIVERED PSYCHOLOGICAL INTERVENTION,RECRUITMENT RATE,COVID-19 Caregiver Emotional Support
NCT04409834,Recruiting,Interventional,Phase 4,The TIMI Study Group,Other,5-Aug-20,21-May-21,21-May-21,PREVENTION,750,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UNFRACTIONATED HEPARIN IV,PRIMARY ENDPOINT: VENOUS OR ARTERIAL THROMBOTIC EVENTS,"A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients"
NCT04409847,Recruiting,Observational,,NHS Greater Glasgow and Clyde,Other,1-Jun-20,31-May-21,30-Apr-21,COHORT,70,COVID,UNITED KINGDOM,ALL,30 Years to 60 Years   (Adult),ABPM,ABPM SYSTOLIC BLOOD PRESSURE,COVID-19 Blood Pressure Endothelium Interaction Study
NCT04409873,Not yet recruiting,Interventional,Phase 2,"University of California, San Francisco",Other,7-Dec-20,30-Nov-21,30-Jun-21,SUPPORTIVE CARE,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ORAL-B MOUTH SORE MOUTHWASH,CHANGE IN SARS-COV-2 VIRAL LOAD,Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19)
NCT04409886,Not yet recruiting,Interventional,Not Applicable,Maimonides Medical Center,Other,1-Jun-20,30-Mar-21,31-Dec-20,TREATMENT,30,"COVID, CORONAVIRUS",,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC CHAMBER,OXYGENATION INDEX,The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial
NCT04409899,"Active, not recruiting",Observational,,Fundacio Puigvert,Other,20-Mar-20,31-Dec-20,30-Jun-20,COHORT,300,COVID,SPAIN,ALL,"Child, Adult, Older Adult",BLOOD TESTS,RATE OF SARS-COV-2/COVID-19 IN A SELECTED COHORT OF UROLOGICAL PATIENTS UNDERGOING SURGERY,The Utility of Enhanced Pre- and Post-surgical Protocols to Prevent the Spread of COVID-19 in a Large Urological Department (UroCovid Study)
NCT04409925,Recruiting,Interventional,Phase 1,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,25-Dec-20,21-Aug-21,21-Apr-21,TREATMENT,25,COVID INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",RHDNASE I,SAFETY OF INHALED RHDNASE1 IN NON-VENTILATED COVID-19 PATIENTS BY REPORTING OF ADVERSE EVENTS,Phase I Pilot Study Investigating the Safety and Feasibility of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected Patients
NCT04409951,Not yet recruiting,Observational,,Damanhour University,Other,20-Nov-21,21-Sep-21,21-Mar-21,CASE-CROSSOVER,100,"EVENT, LIFE CHANGE",EGYPT,ALL,"16 Years to 40 Years   (Child, Adult)",,IMPACT OF COVID-19 ON PHARMACY EDUCATION STUDY IN EGYPT,Impact of Covid-19 on Pharmacist Student Education in Egypt
NCT04410016,Recruiting,Interventional,Not Applicable,University of Nottingham,Other,25-May-20,30-Nov-20,31-Jul-20,OTHER,45,MENTAL HEALTH WELLNESS 1,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",STAFF WELLBEING CENTRES,WARWICK-EDINBURGH MENTAL WELLBEING SCALE,Evaluation of a Workplace Intervention to Implement Supported COVID-19 Wellbeing Centres in a Healthcare Workplace During and After the Coronavirus Pandemic: The COVID-WELL Study
NCT04410107,Recruiting,Observational,,Federal University of Rio Grande do Sul,Other,15-May-20,2-Aug-22,31-Dec-20,COHORT,134,COVID,BRAZIL,ALL,"Child, Adult, Older Adult",LUNG FUNCTION TESTS,FORCED EXPIRATORY VOLUME IN THE FIRST SECOND/FORCED VITAL CAPACITY,"Short and Long Term Assessment of Lung Function, Exercise Capacity and Health-Related Quality of Life in Survivors of Severe COVID-19"
NCT04410159,Completed,Interventional,Phase 2,Universiti Sains Islam Malaysia,Other,22-Jun-20,6-Jul-20,29-Jun-20,TREATMENT,20,COVID,MALAYSIA,ALL,"18 Years and older   (Adult, Older Adult)",POVIDONE-IODINE,NUMBER OF PARTICIPANTS WITH EARLY VIRAL CLEARANCE,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients"
NCT04410263,Recruiting,Observational,,University of Zurich,Other,9-Apr-20,31-Dec-23,30-Dec-23,COHORT,300,CORONAVIRUS INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)","SAMPLING (EDTA BLOOD, PHARYNGEAL AND NOSE SWABS, BRONCHOALVEOLAR LAVAGE ,URINE)",CHANGE OF PRO-INFLAMMATORY RESPONSE OVER THE ICU STAY AS A CAUSATIVE FOR PRIMARY ENDOTHELIAL DYSFUNCTION,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches
NCT04410328,Recruiting,Interventional,Phase 3,"Rutgers, The State University of New Jersey",Other,21-Oct-20,15-Dec-21,15-Mar-21,TREATMENT,132,COVID,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",DIPYRIDAMOLE ER 200MG/ ASPIRIN 25MG ORALLY/ENTERALLY AND STANDARD OF CARE,COVID (CORONAVIRUS DISEASE-19) ORDINAL SCALE,A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection
NCT04410354,Terminated,Interventional,Phase 2,"ViralClear Pharmaceuticals, Inc.",Industry,16-Jun-20,1-Dec-20,1-Dec-20,TREATMENT,44,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MERIMEPODIB,"NUMBER OF SUBJECTS NOT HOSPITALIZED OR, IF HOSPITALIZED, FREE OF RESPIRATORY FAILURE","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)"
NCT04410432,Recruiting,Observational,,Centre Hospitalier Universitaire Dijon,Other,29-Sep-20,21-Aug-21,21-Aug-21,COHORT,63,"SARS COV2, IMMUNE RESPONSE",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE COLLECTION,PERCENTAGE OF CIRCULATING TH1 LYMPHOCYTES,Immune Response and Risk of Serious Infection to SARS-Cov2
NCT04410458,Enrolling by invitation,Interventional,Not Applicable,Guangzhou Blood Center,Other,31-May-20,12-Jun-20,31-May-20,HEALTH SERVICES RESEARCH,506517,BLOOD DONATION,CHINA,ALL,18 Years to 60 Years   (Adult),BLOOD DONATION SMS,BLOOD DONATION RATE,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19（Repeat Trial）
NCT04410471,Recruiting,Observational [Patient Registry],,Magdalena Salcedo,Other,29-May-20,30-Jun-21,29-May-20,CASE-CONTROL,300,LIVER TRANSPLANT INFECTION,SPAIN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CLIA OF IGG AND IGM AGAINST SARS-COV-2,INCIDENCE OF IGG AGAINST SARS-COV-2,Development and Persistence of Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients in Comparison With Immunocompetent Patients
NCT04410484,"Active, not recruiting",Observational,,Hull University Teaching Hospitals NHS Trust,Other,22-May-20,20-Aug-21,20-Aug-21,CASE-CONTROL,1500,INFLAMMATORY BOWEL DISEASES,UNITED KINGDOM,ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",,FLARE OF IBD NEEDING CHANGE IN THERAPY OR SURGERY,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
NCT04410510,Recruiting,Interventional,Phase 2/Phase 3,Hospital Universitario San Ignacio,Other,30-Sep-20,21-Jun-21,20-Dec-21,SUPPORTIVE CARE,100,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",P2ET (CAESALPINIA SPINOSA EXTRACT),EVALUATE THE EFFICACY OF P2ET IN REDUCING THE LENGTH OF HOSPITAL STAY OF PATIENTS WITH CLINICAL SUSPICION OR CONFIRMED CASE OF COVID-19,"Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia."
NCT04410536,Recruiting,Interventional,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Other,15-Jun-20,22-Jul-21,21-Dec-21,TREATMENT,25,"MIGRAINE, HEMICRANIA",ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SYMPTOMATIC DRUGS,DROP OUT RATES,Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up
NCT04410549,Recruiting,Interventional,Not Applicable,IRCCS San Raffaele,Other,1-Jun-20,31-Dec-21,31-Dec-21,DIAGNOSTIC,10,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",OPTICAL COHERENCE TOMOGRAPHY (OCT),OPTICAL COHERENCE TOMOGRAPHY PULMONARY MICROTHROMBOSIS ASSESSMENT IN COVID-19 PNEUMONIA PATIENTS,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study
NCT04410562,Recruiting,Interventional,Phase 3,Barcelona Institute for Global Health,Other,13-May-20,1-Aug-21,13-May-21,TREATMENT,714,PREGNANCY RELATED,SPAIN,FEMALE,"Child, Adult, Older Adult",HYDROXYCHLOROQUINE,NUMBER OF PCR CONFIRMED CASES AMONG PREGNANT WOMEN,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
NCT04410692,Completed,Interventional,Not Applicable,"National University, Singapore",Other,15-May-20,17-May-20,16-May-20,OTHER,560,"HEALTH KNOWLEDGE, ATTITUDES, PRACTICE",SINGAPORE,ALL,"18 Years and older   (Adult, Older Adult)",PREDICTION MARKET,PREDICTIONS OF COVID-19 CASES AND DEATHS,Can the Prediction Market Improve Predictions of COVID-19?
NCT04410718,Recruiting,Observational,,Steno Diabetes Center Copenhagen,Other,20-Apr-20,30-Nov-20,30-Oct-20,COHORT,100,DIABETES MELLITUS,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",GLYCAEMIC LEVELS,PLASMA GLUCOSE LEVELS AND LEFT VENTRICULAR EJECTION FRACTION,Glycaemia and Cardiac Function in Patients With COVID-19
NCT04410835,Recruiting,Observational,,Medical University of Graz,Other,28-Apr-20,28-Apr-21,31-Dec-20,COHORT,1000,CORONAVIRUS INFECTION,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SURVEY,"GLOBAL SYMPTOM LOAD (ANXIETY, SOMATISATION, DEPRESSION, GLOBAL SYMPTOM INDEX)",Psychological Impact and Effect of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders - an Online Survey
NCT04410939,Completed,Observational,,Istanbul Medipol University Hospital,Other,10-Apr-20,21-May-20,20-May-20,CASE-CROSSOVER,179,COVID,TURKEY,FEMALE,"Child, Adult, Older Adult",REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION,RATE OF POSITIVE COVID-19 CASES IN ASYMPTOMATIC PREGNANT WOMEN,COVID-19 PCR Test Results in Asymptomatic Pregnants Admitted for Birth and Other Interventions in Our Clinic
NCT04411147,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,17-Jun-20,31-Dec-27,31-Dec-27,COHORT,900,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,MEDICAL SEQUELAE IN COVID- 19 SURVIVORS,A Longitudinal Study of COVID-19 Sequelae and Immunity
NCT04411433,"Active, not recruiting",Interventional,Phase 3,"Ministry of Health, Turkey",Other,8-May-20,1-Jun-21,31-Dec-20,TREATMENT,1008,SARS-COV2,TURKEY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",FAVIPIRAVIR (3200 MG + 1200 MG),TIME TO RECOVERY (DISCHARGE),"An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19"
NCT04411446,Recruiting,Interventional,Phase 4,Vitamin D Study Group,Other,11-Aug-20,28-Dec-20,15-Dec-20,TREATMENT,1264,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN D,RESPIRATORY SOFA.,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients
NCT04411459,Completed,Observational,,Azienda Usl di Bologna,Other,1-Feb-20,16-Oct-20,30-Jun-20,COHORT,470,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INVASIVE MECHANICAL VENTILATION,DURATION OF MECHANICAL VENTILATION AND 28 DAYS VENTILATOR FREE DAYS,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome
NCT04411511,Recruiting,Observational,,Maastricht University Medical Center,Other,6-May-20,6-May-21,6-Nov-20,COHORT,4000,COVID,NETHERLANDS,ALL,4 Years to 17 Years   (Child),EXPOSURE TO THE DUTCH MEASURES DUE TO THE COVID-19 PANDEMIC.,CHANGE IN WEIGHT CHILD,"The Influence of the Covid-19 Pandemia on the Health Behaviour of Primary School Children (and Their Parents) - COVID-19, Obesity and Lifestyle in Children"
NCT04411563,Recruiting,Observational [Patient Registry],,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,Other,21-May-20,20-Dec-21,20-Sep-21,COHORT,105,PROGNOSIS,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TAKING BIOLOGICAL SAMPLES,DETERMINATION OF THE RELATIONSHIP BETWEEN THE SEVERITY OF DISEASE AND EPIGENETIC FACTORS IN COVID 19,The Effect of miRNA and Epigenetic Modifications on Prognosis in Covid-19 Infection
NCT04411576,Recruiting,Observational,,Karolinska University Hospital,Other,23-Apr-20,31-Dec-20,1-Jul-20,COHORT,40000,SARS-COV2,SWEDEN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",THROAT SWAB SAMPLE FOR MEASURING CURRENT INFECTION WITH SARS-COV-2,SARS-COV-2 INFECTION,"Studies on Current and Past SARS-CoV-2 Infection (and COVID-19) in Healthcare in Stockholm, Sweden"
NCT04411602,Recruiting,Interventional,Phase 1,Ascension South East Michigan,Other,7-Apr-20,31-Dec-20,31-Dec-20,TREATMENT,90,SEVERE ACUTE RESPIRATORY SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 PLASMA,TRANSFUSION OF PATIENTS IN THE ICU WITH CONVALESCENT PLASMA FOR COVID-19-INDUCED RESPIRATORY FAILURE.,Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19
NCT04411628,Completed,Interventional,Phase 1,Eli Lilly and Company,Industry,28-May-20,26-Aug-20,26-Aug-20,BASIC SCIENCE,24,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",LY3819253,NUMBER OF PARTICIPANTS WITH ONE OR MORE SERIOUS ADVERSE EVENT(S) (SAES) CONSIDERED BY THE INVESTIGATOR TO BE RELATED TO STUDY DRUG ADMINISTRATION,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19"
NCT04411667,"Active, not recruiting",Interventional,Phase 4,"George Sakoulas, MD",Other,28-Apr-20,30-Nov-20,1-Nov-20,TREATMENT,34,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OCTAGAM,MECHANICAL VENTILATION,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection
NCT04411680,Recruiting,Interventional,Phase 2,"Partner Therapeutics, Inc.",Industry,18-Aug-20,21-Mar-21,21-Jan-21,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARGRAMOSTIM,CHANGE IN OXYGENATION PARAMETER OF P(A-A)O2 GRADIENT BY DAY 6,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia
NCT04411784,"Active, not recruiting",Observational,,Hull University Teaching Hospitals NHS Trust,Other,20-May-20,20-Jul-21,20-Jul-21,CASE-CONTROL,200,INFLAMMATORY BOWEL DISEASES,UNITED KINGDOM,ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",,PRIMARY OUTCOME MEASURE: THE NEED FOR IN-HOSPITAL COLECTOMY OR RESCUE THERAPY,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study"
NCT04412018,Recruiting,Interventional,Phase 2,Canadian Medical and Surgical Knowledge Translation Research Group,Other,4-Jun-20,20-Dec-21,20-Dec-21,TREATMENT,100,COVID,CANADA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ICOSAPENT ETHYL,CHANGE IN HS-CRP LEVELS FROM THE RANDOMIZATION VISIT (DAY 1) TO THE DAY 14 VISIT,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19)
NCT04412031,Completed,Observational,,Hospices Civils de Lyon,Other,11-Nov-19,15-May-20,14-May-20,COHORT,802,TO PREDICT AN UNFAVORABLE EVOLUTION OF COVID AT THE HOSPITAL ADMISSION OF PATIENTS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NON APPLICABLE,"NEED OF MECHANICAL VENTILATION, TRANSFER TO AN INTENSIVE CARE UNIT OR DEATH WITHIN 21 DAYS OF ADMISSION.",Bayesian Network to Predict Transfer in Intensive Care Units or Death in Newly Covid-19 Hospitalized Patient
NCT04412057,Recruiting,Interventional,Phase 2,"Aevi Genomic Medicine, LLC, a Cerecor company",Industry,9-Jun-20,20-Nov-21,20-Oct-21,TREATMENT,82,COVID PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CERC-002,PROPORTION OF PATIENT ALIVE AND FREE OF RESPIRATORY FAILURE,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury"
NCT04412226,Completed,Observational,,Derince Training and Research Hospital,Other,10-Jun-20,30-Jun-20,30-Jun-20,OTHER,13,"INTUBATION, INTRATRACHEAL",TURKEY,ALL,"Child, Adult, Older Adult",AEROSOL BOX,FIRST PASS SUCCESS,"Effect of Using Barrier Devices for Intubation in COVID-19 Patients: Randomized, Prospective, Manikin Study"
NCT04412239,Recruiting,Interventional,Not Applicable,Health Science Center of Xi'an Jiaotong University,Other,20-Apr-20,20-Dec-20,20-Dec-20,OTHER,200,TB - TUBERCULOSIS,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT-CENTRED ADVICE ON TELEPHONE CONSULTATION IN TB PATIENTS:,"EFFICIENCY OF THE TELEPHONE CONSULTATION,",To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic
NCT04412252,Withdrawn,Interventional,Phase 2,Pfizer,Industry,6-Jul-20,18-Oct-20,16-Sep-20,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",TOFACITINIB,CLINICAL STATUS USING ORDINAL SCALE,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVING STANDARD OF CARE THERAPY"
NCT04412265,Recruiting,Observational,,University of Milano Bicocca,Other,16-Apr-20,1-Mar-21,1-Mar-21,CASE-ONLY,300,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",RELATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH COVID-19.,DEVELOPMENT OF A TOOL TO MEASURE FRAILTY,Relationship Between Frailty and Clinical Outcomes in Elderly Patients With COVID-19
NCT04412278,Completed,Observational,,Okan University,Other,1-Jun-20,8-Jun-20,8-Jun-20,ECOLOGIC OR COMMUNITY,392,COVID,TURKEY,ALL,"15 Years to 65 Years   (Child, Adult, Older Adult)",ONLINE SURVEY,EXERCISE BENEFITS AND BARRIERS SCALE,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers: Cross Sectional Study on Turkish Society and Interpretation With Physical Activity Level
NCT04412291,Recruiting,Interventional,Phase 2,Karolinska University Hospital,Other,11-Jun-20,21-Jun-21,21-Mar-21,TREATMENT,120,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA PREFILLED SYRINGE,TIME TO RECOVERY,"A Multi-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study"
NCT04412304,Completed,Observational,,Karolinska Institutet,Other,6-Mar-20,28-May-20,30-Apr-20,COHORT,166,COVID,SWEDEN,ALL,"Child, Adult, Older Adult",DOSE OF TINZAPARIN OR DALTEPARIN,28-DAYS ICU MORTALITY,"Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden"
NCT04412317,Recruiting,Observational [Patient Registry],,Centre Hospitalier Intercommunal Creteil,Other,3-Jun-20,31-May-21,30-May-21,COHORT,600,COVID,FRANCE,ALL,up to 14 Years   (Child),,PERCENTAGE OF CHILDREN SCREENED WITH A POSITIVE PCR RESULT OR A POSITIVE RAPID ANTIGENIC DIAGNOSTIC (RAD) TEST,"National Observatory of the Care of Young Sick Children in Community or Not, Indications and Cost-effectiveness of PCR-Sars-CoV-2 - VIGIL Study"
NCT04412330,Recruiting,Interventional,Not Applicable,University of Kentucky,Other,1-May-20,1-May-21,1-May-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ICU RECOVERY + PHYSICAL THERAPY,ADVERSE EVENTS (SAFETY),Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study
NCT04412343,Completed,Interventional,Not Applicable,University of British Columbia,Other,23-May-20,5-Oct-20,5-Oct-20,PREVENTION,241,WELL-BEING (PSYCHOLOGICAL FLOURISHING),CANADA,ALL,65 Years and older   (Older Adult),VIRTUAL GROUP INTERVENTION,WELL-BEING (PSYCHOLOGICAL FLOURISHING),The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial
NCT04412356,Recruiting,Interventional,Not Applicable,"Sahlgrenska University Hospital, Sweden",Other,4-Jun-20,1-Feb-21,1-Dec-20,TREATMENT,180,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",TRACHEOTOMY,MECHANICAL VENTILATION,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial"
NCT04412369,Not yet recruiting,Observational,,University of Cambridge,Other,20-Jun-21,21-Jun-21,21-Jun-21,CASE-ONLY,20,COVID,UNITED KINGDOM,ALL,"18 Years to 99 Years   (Adult, Older Adult)",NON-INVASIVE CARDIAC IMAGING,"NUMBER OF PARTICIPANTS WITH A DIAGNOSIS OF COVID-19 RELATED MYOCARDITIS, TYPE 1 OR 2 MYOCARDIAL INFARCTION AND/OR OTHER MECHANISM OF CARDIAC INJURY CONFIRMED BY MULTI-MODALITY IMAGING.",Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury
NCT04412382,Recruiting,Observational [Patient Registry],,Azienda Ospedaliera Universitaria Integrata Verona,Other,1-Jun-20,31-Dec-21,31-Dec-20,CASE-CONTROL,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",NETOSIS MARKERS,NETOSIS AND MORTALITY,Covid-19: Possible Role of Neutrophil Extracellular Traps
NCT04412395,Not yet recruiting,Interventional,Phase 2,"National Research Centre, Egypt",Other,1-Jun-20,30-Sep-20,31-Aug-20,TREATMENT,516,CORONAVIRUS INFECTION,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LACTOFERRIN (APOLACTOFERRIN),SURVIVAL RATE.,Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory Therapy in Patients Diagnosed With COVID-19 Disease
NCT04412460,Recruiting,Observational,,University Hospital Tuebingen,Other,20-Mar-20,31-Dec-21,31-Dec-21,COHORT,500,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,ICU MORTALITY,Echocardiography in Patients With Covid-19 Undergoing Intensive Care Therapy
NCT04412473,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,30-Apr-20,21-Jun-21,21-Jun-21,CASE-ONLY,1000,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ANALYSIS OF RESPIRATORY DISTRESS AND ANTITHROMBOLYTIC THERAPY IN PATIENTS WITH COVID19,COVID-19 Respiratory Distress and Antithrombotic Drugs inSubject's Habits
NCT04412486,Recruiting,Interventional,Early Phase 1,"Gailen D. Marshall Jr., MD PhD",Other,1-Jun-20,31-May-22,31-May-22,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID CONVALESCENT PLASMA,CHANGE IN PAO2/FIO2 AFTER CCP TRANSFUSION.,An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19
NCT04412538,Recruiting,Interventional,Phase 1/Phase 2,Chinese Academy of Medical Sciences,Other,15-May-20,21-Sep-21,20-Sep-21,PREVENTION,942,COVID,CHINA,ALL,18 Years to 59 Years   (Adult),LOW DOSAGE INACTIVATED SARS-COV-2 VACCINE ON A 0- AND 28-DAY SCHEDULE,ADVERSE REACTIONS/EVENTS RATE,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years"
NCT04412551,Recruiting,Observational [Patient Registry],,"Dalarna County Council, Sweden",Other,20-May-20,31-Dec-20,31-Dec-20,COHORT,50,CORONAVIRUS INFECTION,SWEDEN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,IDENTIFICATION OF REQUIREMENT OF MECHANICAL VENTILATION,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19
NCT04412655,"Active, not recruiting",Observational,,"Università degli Studi del Piemonte Orientale ""Amedeo Avogadro""",Other,5-May-20,2-Jun-20,30-May-20,COHORT,6609,ST ELEVATED MYOCARDIAL INFARCTION UNDERGOING MECHANICAL REPERFUSION,ITALY,ALL,"Child, Adult, Older Adult",PERCUTANEOUS CORONARY REVASCULARIZATION FOR STEMI,NUMBER OF PATIENTS UNDERGOING PRIMARY ANGIOPLASTY,International Study on Acute Coronary Syndromes - ST-segment Elevation Myocardial Infarction COVID 19
NCT04412668,Completed,Interventional,Phase 2,"aTyr Pharma, Inc.",Industry,12-Jun-20,21-Dec-20,21-Dec-20,TREATMENT,32,SARS-COV2 (COVID) SEVERE PNEUMONIA,PUERTO RICO,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ATYR1923 1 MG/KG,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19)
NCT04412746,Recruiting,Observational,,"Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen",Other,1-Apr-20,30-Jun-20,30-Jun-20,COHORT,100,CORONAVIRUS INFECTION,ALGERIA,ALL,"16 Years and older   (Child, Adult, Older Adult)",MANAGEMENT OF COVID-19,PREVALENCE OF DIABETES AMONG ALL HOSPITALIZED COVID-19,Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms
NCT04412772,Recruiting,Interventional,Phase 3,Queen's Medical Centre,Other,12-Jun-20,31-Dec-21,31-Dec-21,TREATMENT,300,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",TOCILIZUMAB,CLINICAL STATUS (ON A 7-POINT ORDINAL SCALE) AT DAY 28,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19"
NCT04412785,Recruiting,Interventional,Phase 1,University of Pennsylvania,Other,30-Jun-20,21-Dec-21,21-Apr-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CYCLOSPORINE,"SAFETY-OXYGEN, ICU TRANSFER AND VENTILATION",Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
NCT04413006,Recruiting,Interventional,Not Applicable,University of Manitoba,Other,25-May-20,31-Mar-21,31-Dec-20,TREATMENT,28,CHRONIC PAIN,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SELF-COMPASSION FOR CHRONIC PAIN VIRTUAL GROUP TREATMENT PROGRAM,CHANGE OVER TIME IN SCORES ON THE SELF-COMPASSION SCALE (SCS),A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery
NCT04413045,Completed,Observational,,Assiut University,Other,20-May-20,28-Jul-20,28-Jul-20,OTHER,61,COVID,EGYPT,ALL,"Child, Adult, Older Adult",PREVALENCE OF COVID-19,PATIENT PROGNOSIS SCORE,Prevalence and Clinical Characteristics of Novel COVID-19 Cases at One Quarantine Hospital; a National Analysis
NCT04413058,Completed,Observational,,Haydarpasa Numune Training and Research Hospital,Other,10-Apr-20,10-Sep-20,10-Sep-20,CASE-CROSSOVER,260,MENSTRUAL IRREGULARITY,TURKEY,FEMALE,18 Years to 47 Years   (Adult),,RATE OF IRREGULAR MENSTRUAL CYCLE,Menstrual Cycle Characteristics of Healthcare Professionals at Covid 19 Pandemic Hospital
NCT04413071,Completed,Observational,,AORTICA Group,Other,25-May-20,12-Jun-20,12-Jun-20,COHORT,142,SARS-COV2,SPAIN,ALL,"18 Years to 71 Years   (Adult, Older Adult)",PASSED INFECTION OF SARS-COV-2,MYOCARDITIS,Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study
NCT04413435,Completed,Observational,,Nevsehir Public Hospital,Other,30-Oct-20,25-Dec-20,15-Dec-20,OTHER,105,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",FILE SCANNING,POLYMERASE CHAIN REACTION (PCR) TEST,Clinical Characteristics of Critically Ill Patients With 2019 Novel Coronavirus (COVID-19): Do We Need a New Triage System?
NCT04413747,Not yet recruiting,Interventional,Not Applicable,Health Ricerca e Sviluppo S.R.L.,Industry,15-Aug-20,30-Sep-21,1-Jun-21,SUPPORTIVE CARE,1000,CORONAVIRUS INFECTION,ITALY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",MORNING YOGA-BASED BREATHING SUPPORT,MORTALITY,Yoga- Based Breathing for Vagus Nerve Stimulation as Home-care Adjuvant Treatment Against Burden COVID-19
NCT04413838,Not yet recruiting,Interventional,Phase 2,Hospices Civils de Lyon,Other,15-Jun-20,15-Sep-21,15-Jun-21,TREATMENT,120,"OBESITY, COVID INFECTION",FRANCE,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NIVOLUMAB,PATIENT'S CLINICAL STATE,"Study of the Efficiency and Security of NIVOLUMAB Therapy, Used in Immuno-stimulation, in Hospitalized Obese Individuals at Risk to Evolve Towards Severe Forms of COVID-19 Infection. Multicentric, Paralleled, Randomized, Controlled Trial"
NCT04413864,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,24-Apr-20,28-Feb-21,28-Feb-21,OTHER,50,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INFLAMMATORY CYTOKINES AND CHEMOKINES PROFILES OF PATIENTS WITH DEXMEDETOMIDINE ADMINISTRATION,CHANGE OF INFLAMMATORY CYTOKINES CONCENTRATION (MMOL / L) IN COVID19 + PATIENTS FROM BASELINE AT 6 MONTHS,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19
NCT04413877,Not yet recruiting,Observational [Patient Registry],,University of Liege,Other,20-Oct-21,21-Nov-21,21-Oct-21,COHORT,600,FRAILTY SYNDROME,,ALL,65 Years and older   (Older Adult),,INCIDENCE OF FRAILTY,Implementation of the Integrated Care of Older People App and ICOPE Monitor in Primary Care (ICOPE)
NCT04413955,Recruiting,Observational [Patient Registry],,"Children's Hospital Medical Center, Cincinnati",Other,1-Jun-20,31-Dec-21,31-Dec-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SERAPH®-100 MICROBIND® AFFINITY BLOOD FILTER,"RATE OF KNOWN, EXPECTED, OR UNANTICIPATED ADVERSE DEVICE EFFECTS",Seraph®-100 Microbind® Affinity Blood Filter for the Treatment of COVID-19 Under Emergency Use Authorization: Data Registry
NCT04413968,Completed,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,2-Jun-20,2-Oct-20,2-Jul-20,DIAGNOSTIC,600,CORONAVIRUS,FRANCE,ALL,"1 Month and older   (Child, Adult, Older Adult)",RAPID DETECTION TEST,ASSESS THE SEROLOGICAL STATUS/RATE OF PAST INFECTIONS IN THE CHILDREN OF PRIORITY STAFF IN THE NURSERY DURING THE CONTAINMENT PERIOD,"Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study"
NCT04414059,Not yet recruiting,Observational,,Elsan,Other,21-Mar-21,21-Aug-21,21-Jun-21,CASE-ONLY,155,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COMPLICATIONS ONSET,Complications Risk Factors in Patients Hospitalized for COVID-19 Infection: Role of Proteins Electrophoresis
NCT04414098,Not yet recruiting,Interventional,Phase 2,Marcelo Iastrebner,Other,1-Jun-20,15-Sep-20,15-Aug-20,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",INC424 / RUXOLITINIB,EVALUATE THE EFFICACY OF RUXOLITINIB IN THE TREATMENT OF COVID-19 SEVERE ACUTE RESPIRATORY SYNDROME,Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2
NCT04414124,"Active, not recruiting",Interventional,Not Applicable,Kaleido Biosciences,Industry,2-Aug-20,21-Feb-21,21-Feb-21,OTHER,350,MILD-TO-MODERATE COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",KB109 + SELF SUPPORTIVE CARE (SSC),NUMBER OF PATIENTS EXPERIENCING STUDY-PRODUCT RELATED TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19"
NCT04414241,Not yet recruiting,Interventional,Phase 3,Universidad Peruana Cayetano Heredia,Other,20-Jun-21,20-Oct-21,20-Sep-21,PREVENTION,320,SARS-COV2,PERU,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,EFFICACY: PROPORTION OF PARTICIPANTS WITH POSITIVE MOLECULAR OR SEROLOGIC TESTING FOR SARS-COV-2,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial"
NCT04414267,Recruiting,Interventional,Phase 4,Hellenic Institute for the Study of Sepsis,Other,26-May-20,25-May-21,25-May-21,PREVENTION,900,COVID,GREECE,ALL,"50 Years and older   (Adult, Older Adult)",BCG VACCINE,"POSITIVE FOR THE RESPIRATORY QUESTIONNAIRE CONSISTED OF QUESTIONS CONCERNING THE APPEARANCE OF SYMPTOMS POSSIBLY, PROBABLY AND/OR DEFINITIVELY RELATED TO COVID-19 ON VISIT 3.",A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial
NCT04414293,Recruiting,Interventional,Not Applicable,Hospital Provincial de Castellon,Other,1-Oct-20,31-Dec-21,31-Jul-21,TREATMENT,41,COVID,SPAIN,ALL,65 Years and older   (Older Adult),LUNG LOW DOSE RADIATION,BLOOD OXYGEN SATURATION LEVEL,Phase II Study of Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
NCT04414319,Recruiting,Observational,,University Hospital Center of Martinique,Other,15-Apr-20,15-Apr-23,15-Apr-21,OTHER,350,SARS-COV2,FRANCE,ALL,70 Years and older   (Older Adult),,LOSS OF AUTONOMY,Impact of SARS-CoV-2 Infection in a Population Aged 70 Years or Older on Loss of Autonomy
NCT04414371,Recruiting,Interventional,Not Applicable,"Rutgers, The State University of New Jersey",Other,20-May-20,31-Dec-20,31-Dec-20,SUPPORTIVE CARE,200,STRESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",YOGA,STRESS,Tools for Wellbeing COVID-19 National Study of Undergraduate Students
NCT04414410,Enrolling by invitation,Observational,,Hospital Ambroise Paré Paris,Other,12-May-20,30-Sep-20,30-Sep-20,COHORT,1500,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,INCIDENCE OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia
NCT04414618,"Active, not recruiting",Interventional,Phase 2,RedHill Biopharma Limited,Industry,2-Jul-20,21-Jun-21,26-Nov-20,TREATMENT,42,CORONAVIRUS INFECTION,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",OPAGANIB,MEASUREMENT OF THE OXYGEN REQUIREMENT,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia"
NCT04414631,Recruiting,Interventional,Phase 2,"University Hospital, Basel, Switzerland",Other,6-Aug-20,21-Jul-21,21-Jun-21,TREATMENT,120,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years to 85 Years   (Adult, Older Adult)",CONESTAT ALFA,DISEASE SEVERITY,"Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19)."
NCT04414657,Recruiting,Observational,,Regina Grossmann,Other,9-Apr-20,30-Apr-22,30-Apr-22,COHORT,500,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING FOR BIOBANK,BLOOD SAMPLING FOR BIOBANK,Development of a SARS-CoV-2 Research Biobank
NCT04414826,Recruiting,Interventional,Not Applicable,University of Texas at Austin,Other,25-May-20,21-May-21,21-May-21,TREATMENT,120,LONELINESS,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MINDFULNESS ALONE (MO) INTERVENTION,REVISED UNIVERSITY OF CALIFORNIA LOS ANGELES LONELINESS SCALE - 8 (ULS-8),Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness
NCT04414904,Withdrawn,Observational,,Imperial College London,Other,10-Jun-20,10-Jun-20,10-Jun-20,CASE-CONTROL,0,"INFERTILITY, MALE",UNITED KINGDOM,MALE,18 Years to 50 Years   (Adult),EXPOSURE: COVID-19 INFECTION,SEMEN PARAMETERS,Determining the Reproductive Health of Men Post-COVID-19 Infection
NCT04415060,Recruiting,Interventional,Phase 3,Sunnybrook Health Sciences Centre,Other,15-Jun-20,15-Jun-23,15-Jun-23,TREATMENT,752,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",ISOFLURANE INHALANT PRODUCT,HOSPITAL MORTALITY,"SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study"
NCT04415073,Suspended,Interventional,Phase 2,Syndax Pharmaceuticals,Industry,30-May-20,15-Nov-20,15-Nov-20,TREATMENT,186,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SNDX-6352,PROPORTION OF SUBJECTS ALIVE AND FREE OF RESPIRATORY FAILURE,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Axatilimab for the Treatment of Hospitalized Patients With Respiratory Signs and Symptoms Secondary to Novel Coronavirus Disease (COVID-19)"
NCT04415086,Recruiting,Interventional,Phase 2,University of Sao Paulo General Hospital,Other,1-Jun-20,22-May-22,20-Apr-22,TREATMENT,120,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,TIME ELAPSED UNTIL CLINICAL IMPROVEMENT OR HOSPITAL DISCHARGE,"Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion: a Multicenter, Open-labeled, Randomized and Controlled Study"
NCT04415151,Recruiting,Interventional,Phase 2,Yale University,Other,29-Jul-20,31-Mar-21,31-Mar-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",TOFACITINIB 10 MG,DISEASE SEVERITY,Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)
NCT04415359,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,20-May-20,21-Jul-21,21-Jul-21,CASE-ONLY,700,COVID,FRANCE,FEMALE,18 Years to 43 Years   (Adult),,STUDY OF THE EVOLUTION OF PREGNANCIES IN THE FIRST TRIMESTER FOLLOWING MAR MANAGEMENT DURING A COVD-19 PANDEMIC PERIOD,Evaluation of the Evolution of Pregnancies in the First Trimester Following a Medically Assisted Procreation (MAR) Management During a COVD-19 Pandemic Period
NCT04415879,Completed,Interventional,Not Applicable,The Cleveland Clinic,Other,1-Jun-20,1-Aug-20,1-Aug-20,HEALTH SERVICES RESEARCH,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",N-95 RESPIRATOR,EXERCISE CAPACITY,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.
NCT04416009,Recruiting,Observational [Patient Registry],,Gaziosmanpasa Taksim Research and Education Hospital,Other,5-Jul-20,20-Feb-21,20-Dec-20,COHORT,52,EXTRACELLULAR FLUID ALTERATION,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",NİCAS,ECW,the Determination of Extracellular Water (ECW) Which is Detected by Bioimpedence Method on Severe and Mild Covid 19 Pneumonia Clinical Course
NCT04416048,Recruiting,Interventional,Phase 3,"Charite University, Berlin, Germany",Other,30-Nov-20,30-May-21,30-Apr-21,PREVENTION,400,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",RIVAROXABAN,"COMPOSITE ENDPOINT OF VENOUS THROMBOEMBOLISM (DVT AND/OR FATAL OR NON-FATAL PE), ARTERIAL THROMBOEMBOLISM, NEW MYOCARDIAL INFARCTION, NON-HEMORRHAGIC STROKE, ALL-CAUSE MORTALITY OR PROGRESSION TO INTUBATION AND INVASIVE VENTILATION",Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)
NCT04416061,"Active, not recruiting",Observational,,Hong Kong Sanatorium & Hospital,Industry,25-May-20,31-Aug-20,31-Jul-20,COHORT,2500,COVID,HONG KONG,ALL,"Child, Adult, Older Adult",COVID 19 DIAGNOSTIC TEST,PROPORTION OF ASYMPTOMATIC SUBJECTS,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed
NCT04416100,Recruiting,Observational,,Medical University Innsbruck,Other,29-Apr-20,28-Apr-22,28-Apr-22,COHORT,130,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY FUNCTION TESTS,PATTERN OF PULMONARY ABNORMALITIES IN SARS-COV2 INFECTED PATIENTS AFTER 1 MONTH,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection
NCT04416113,Not yet recruiting,Interventional,Not Applicable,Cairo University,Other,20-Aug-21,21-Feb-21,20-Dec-21,TREATMENT,60,PHOTODYNAMIC THERAPY& LOW LEVEL LASER IN MANAGEMENT OF COVID,,ALL,"Child, Adult, Older Adult",PHOTOBIOMODULATION AND PHOTODYNAMIC THERAPY,PARTICIPANTS ACHIEVING EITHER A MAJOR CLINICAL RESPONSE OR PARTIAL CLINICAL RESPONSE (PCR) DEFINED BY WHO,Photobiomodulation and Photodynamic Therapy for the Treatment of COVID-19 A Randomized Controlled Clinical Trials
NCT04416139,Recruiting,Interventional,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,1-May-20,1-May-21,30-Apr-21,TREATMENT,10,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",INFUSION IV OF MESENCHYMAL STEM CELLS,FUNCTIONAL RESPIRATORY CHANGES: PAO2 / FIO2 RATIO,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study
NCT04416256,Recruiting,Observational,,Paris Translational Research Center for Organ Transplantation,Other,1-Feb-20,22-Feb-21,22-Feb-21,COHORT,230000,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,ORGAN TRANSPLANTATION ACTIVITY DURING COVID-19 PANDEMIC,Consequences of the COVID-19 Pandemic on Worldwide Organ Procurement and Transplantation
NCT04416308,Recruiting,Interventional,Not Applicable,Rennes University Hospital,Other,29-May-20,10-Oct-20,10-Jul-20,DIAGNOSTIC,13000,CORONAVIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NG TEST,RATE OF PRESENCE OF ANTI-SARS-COV-2 ANTIBODIES (IG G _ IG M) AMONG EMPLOYEES WORKING IN A GHT HAUTE BRETAGNE HEALTH ESTABLISHMENT.,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne
NCT04416334,Recruiting,Interventional,Phase 3,Instituto de Investigación Marqués de Valdecilla,Other,19-Aug-20,31-Dec-21,25-Aug-21,PREVENTION,954,SARS-COV2 INFECTION (COVID),SPAIN,ALL,"60 Years and older   (Adult, Older Adult)",COLCHICINE PLUS SYMPTOMATIC TREATMENT (PARACETAMOL),NUMBER OF PARTICIPANTS WHO DIE DUE TO COVID-19 INFECTION,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19)
NCT04416347,Recruiting,Observational,,St George's University Hospitals NHS Foundation Trust,Other,15-Jun-20,30-Apr-22,30-Apr-22,COHORT,800,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV2 INFECTION,SARS-COV-2 HOSPITAL MORTALITY,"COVID-19, Clinical Predictors and Evolution of Disease in Hospitalised and Intensive Care Patients at St George's Hospital"
NCT04416360,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,5-May-20,21-Jan-21,20-Jul-21,OTHER,40,AUTISM SPECTRUM DISORDER,FRANCE,ALL,6 Years to 17 Years   (Child),INTERVIEW BY PSYCHOLOGISTS,INTERVIEW OF THE PARENTS : CONTEXTUAL DATA,Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak
NCT04416373,Recruiting,Observational,,Universidade Nova de Lisboa,Other,22-Mar-20,23-Dec-21,23-Dec-21,COHORT,300,CORONAVIRUS INFECTION,PORTUGAL,FEMALE,"16 Years to 55 Years   (Child, Adult)",RT PCR SARS-COV-2,SARS-COV-2 NEONATAL INFECTION,COVID-19 and Pregnancy Outcomes: a Portuguese Collaboration Study
NCT04416399,Terminated,Interventional,Phase 2,University of Oxford,Other,16-Jul-20,12-Jan-21,12-Jan-21,TREATMENT,146,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BUDESONIDE DRY POWDER INHALER,EMERGENCY DEPARTMENT ATTENDANCE OF HOSPITALISATION RELATED TO COVID-19,Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation
NCT04416438,Recruiting,Observational,,French Innovative Leukemia Organisation,Other,18-May-20,31-Dec-20,31-Dec-20,COHORT,50,MYELOPROLIFERATIVE NEOPLASM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF SERIOUS CORONAVIRUS INFECTION IN DIFFERENT MNP PATIENT SUBGROUPS,Observational Study of the Impact of the COronaVirus Disease 2019 (COVID-19) Epidemic on Patients With Myeloproliferative Neoplasias
NCT04416464,Not yet recruiting,Observational,,Universidade do Porto,Other,15-Jun-20,1-Oct-22,31-Jul-22,COHORT,230,QUALITY OF LIFE,PORTUGAL,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PNEUMONIA,HEALTH-RELATED QUALITY OF LIFE.,"Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study"
NCT04416893,Not yet recruiting,Observational,,Centre Hospitalier Intercommunal Creteil,Other,7-Jun-20,15-Nov-20,15-Sep-20,COHORT,630,COVID,,ALL,up to 15 Years   (Child),RT-PCR SARS-COV2,PROPORTION OF ASYMPTOMATIC CHILDREN OR CHILDREN WITH MILD RESPIRATORY SYMPTOMS,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care-Part 2 After the Lifting of the Lockdown"
NCT04416919,Recruiting,Interventional,Not Applicable,University of Oklahoma,Other,15-Jul-20,25-May-21,25-May-21,PREVENTION,20,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ASSEMBLED MASK,SUCCESS PERCENTAGE,A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study
NCT04417153,Recruiting,Observational,,"National University, Singapore",Other,20-Sep-19,30-Jun-22,30-Jun-22,COHORT,1000,"STRESS, PSYCHOLOGICAL",SINGAPORE,ALL,"21 Years and older   (Adult, Older Adult)",MINDFULNESS BASED INTERVENTION,CHANGE IN SUBJECTIVE MEASURES OF SLEEP QUALITY: PITTSBURGH SLEEP QUALITY INDEX TOTAL SCORE,Who Benefits More? Optimising Mindfulness Based Interventions for Improved Psychological Outcomes
NCT04417257,Recruiting,Interventional,Phase 2,Laurent Pharmaceuticals Inc.,Industry,29-Jun-20,30-May-21,30-Apr-21,TREATMENT,240,COVID DISEASE,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",LAU-7B,PROPORTION OF PATIENTS ALIVE AND FREE OF RESPIRATORY FAILURE (ORDINAL SCALE SCORES 1-4),"RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease"
NCT04417270,Recruiting,Interventional,Not Applicable,Northwell Health,Other,12-Jun-20,31-Dec-20,30-Nov-20,OTHER,50,DIABETES MELLITUS,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",FREESTYLE LIBRE 14 DAY CGM SYSTEM,COMPARISON OF VALUES BETWEEN TWO DEVICES,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge
NCT04417335,"Active, not recruiting",Interventional,Phase 4,Radboud University,Other,16-Apr-20,21-May-21,21-May-21,PREVENTION,2014,COVID,NETHERLANDS,ALL,"60 Years and older   (Adult, Older Adult)",BCG VACCINE,SARS-COV-2 RELATED HOSPITAL ADMISSION,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-Guérin Vaccination, a Randomized Controlled Trial"
NCT04417374,Completed,Observational,,"University Hospital, Montpellier",Other,1-May-20,30-Jun-20,30-May-20,COHORT,94,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DESCRIPTION OF GROUPS CARACTERISTICS,NUMBER OF HOSPITALIZED PATIENTS,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in Pandemic and Confinement Context"
NCT04417673,Not yet recruiting,Observational,,National Human Genome Research Institute (NHGRI),NIH,4-Mar-21,31-Dec-24,31-Dec-24,COHORT,1000,ISOLATION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,STRESS,A Longitudinal Survey Study on Living With Sickle Cell Disease in the COVID-19 Pandemic
NCT04418128,Not yet recruiting,Interventional,Phase 2/Phase 3,Gyeongsang National University Hospital,Other,10-Jun-20,30-Apr-21,30-Mar-21,TREATMENT,84,CORONAVIRUS INFECTION,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",NAFAMOSTAT MESYLATE,PROPORTION OF PATIENTS WITH CLINICAL IMPROVEMENT,Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial
NCT04418193,Withdrawn,Observational,,Centre Hospitalier Princesse Grace,Other,6-Apr-20,4-Feb-21,4-Feb-21,COHORT,0,CORONAVIRUS,MONACO,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,"NUMBER OF DEATH FROM ANY CAUSE, OR THE NEED FOR INTUBATION AND MECHANICAL VENTILATION DURING THE 14 DAYS FOLLOWING INCLUSION AND START OF TREATMENT.","Therapeutic Management in Patients With COVID-19 Infection at Risk of Secondary Aggravation: Patient Preference Trial Comparing Routine Care, Treatment With Hydroxychloroquine or Treatment With Hydroxychloroquine Plus Azithromycin"
NCT04418206,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,1-Jun-20,1-Jun-21,1-Dec-20,PREVENTION,300,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS COVID 19,IGA SPECIFIC CELLS OF SARS,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
NCT04418245,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire de Nīmes,Other,1-Mar-20,20-Jul-21,20-Jun-21,CASE-ONLY,1000,COVID,FRANCE,ALL,"Child, Adult, Older Adult",IMAGING BY THORACIC SCANNER,VITAL STATUS,Identification of Thoracic CT Scan Biomarkers by Deep Learning for Evaluating the Prognosis of Patients With COVID-19 Disease
NCT04418284,Recruiting,Observational,,South Valley University,Other,5-Jun-20,5-Nov-20,5-Nov-20,OTHER,400,COVID,EGYPT,ALL,"17 Years to 35 Years   (Child, Adult)",SURVEY,MEASURE THE STUDENTS' INTEREST IN STUDYING ANATOMY ON-LINE.,Evaluation of the Online Learning of Veterinary Anatomy During COVID-19 Pandemic
NCT04418375,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,8-Jun-20,22-Mar-21,21-Feb-21,COHORT,4000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"IDENTIFICATION OF MARKERS ASSOCIATED WITH ASYMPTOMATIC COVID + STATUS (RESULTS OF THE SEROLOGICAL TEST) VERSUS SYMPTOMATIC COVID + STATUS THROUGH A QUESTIONNAIRE (MEDICAL HISTORY, WORK ENVIRONMENT, LIFESTYLE) AND A BIOLOGICAL COLLECTION",Identification of Markers Associated With the Risk of COVID-19 Infection and Symptomatic COVID+ Versus Asymptomatic COVID+ Status Through the Establishment of a Biological Collection During Serological Screening in APHP Professionals
NCT04418505,Recruiting,Interventional,Not Applicable,Vielight Inc.,Industry,2-Sep-20,1-Mar-21,1-Mar-21,TREATMENT,280,COVID,CANADA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",VIELIGHT RX PLUS,TIME TO RECOVERY,A Randomized Study Evaluating the Efficacy of the Vielight RX Plus in the Treatment of COVID-19 Respiratory Symptoms
NCT04418518,Recruiting,Interventional,Phase 3,Weill Medical College of Cornell University,Other,24-Jun-20,21-Dec-21,21-Jun-21,TREATMENT,1200,COVID,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,INTUBATION OR DEATH IN HOSPITAL,CONCOR-1: A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness
NCT04418531,Not yet recruiting,Interventional,Not Applicable,Piero Luigi Ruggenenti,Other,20-Jun-21,20-Sep-21,20-Sep-21,TREATMENT,10,"PNEUMONIA, VIRAL",ITALY,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-CORONAVIRUS ANTIBODIES (IMMUNOGLOBULINS) OBTAINED WITH DFPP FORM CONVALESCENT PATIENTS,TIME TO WEANING OF OXYGEN SUPPORT,A Pilot Study to Explore the Efficacy and Safety of Rescue Therapy With Antibodies From Convalescent Patients Obtained With Double-filtration Plasmapheresis (DFPP) and Infused in Patients With Coronavirus Disease 2019 (COVID-19) and Need of Oxygen Support Without Mechanical Ventilation
NCT04418544,Recruiting,Observational,,Soniphi LLC,Industry,1-Jun-20,20-Dec-21,20-Dec-21,COHORT,400,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DEVICE USED TO RECORD VOICE FOR SCREENING,SENSITIVITY AND SPECIFICITY,Testing of Soniphi Vocal Feature Analysis Algorithm for COVID-19
NCT04418557,Recruiting,Observational [Patient Registry],,University Hospitals Cleveland Medical Center,Other,28-Apr-20,31-Jul-21,31-Jul-21,CASE-CONTROL,200,COVID,UNITED STATES,FEMALE,18 Years to 50 Years   (Adult),RT-PCR AND ANTIBODY TESTING,PRESENCE OF COVID-19 VIRUS,COVID-19 and Obstetric Transmission
NCT04418609,Recruiting,Observational,,Emanuela Keller,Other,1-May-20,30-May-22,30-Apr-22,COHORT,30,NEUROLOGIC COMPLICATION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",FURTHER PROCESSING OF HEALTH DATA,PREVALENCE OF NEUROLOGICAL COMPLICATIONS,Neuro-COVID-19: Neurological Complications of COVID-19
NCT04418947,Completed,Interventional,Not Applicable,University of Pennsylvania,Other,15-Jun-20,17-Jul-20,17-Jul-20,OTHER,11120,COMMUNICATION RESEARCH,UNITED STATES,ALL,"Child, Adult, Older Adult",COMMUNICATION TYPE,PERCENT WITH VISIT OR PROCEDURE WITH PROVIDER,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial
NCT04419025,Recruiting,Interventional,Phase 2,Cambridge Health Alliance,Other,23-Sep-20,30-Jun-21,31-Mar-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",N-ACETYLCYSTEINE,DECREASE IN RESPIRATORY RATE,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease
NCT04419545,Recruiting,Observational,,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Other,24-Mar-20,31-Mar-21,31-Dec-20,CASE-CONTROL,2500,RADIOLOGY,ITALY,ALL,"Child, Adult, Older Adult",NEURAL NETWORK DIAGNOSIS ALGORITHM,SENSIBILITY AND SPECIFICITY OF NEURAL NETWORK DIAGNOSIS,Covid Radiographic Images Data-set for A.I
NCT04419571,Completed,Observational,,"Barking, Havering and Redbridge University Hospitals NHS Trust",Other,23-Mar-20,16-Jun-20,16-Jun-20,COHORT,94,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EMERGENCY LAPAROTOMY,30-DAY MORTALITY,Emergency Laparotomies and Outcomes During the COVID-19 Pandemic - a Retrospective Cohort Study
NCT04419610,Recruiting,Interventional,Early Phase 1,Imperial College London,Other,9-Oct-20,21-Jun-21,1-Apr-21,HEALTH SERVICES RESEARCH,60,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",TRV027,COAGULOPATHY ASSOCIATED WITH COVID-19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19
NCT04419623,Recruiting,Interventional,Phase 1/Phase 2,"Telios Pharma, Inc.",Industry,9-Jul-20,21-Jul-21,21-Jul-21,TREATMENT,146,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PART 1 - TL-895,PART 1 - RECOMMENDED DOSE OF TL-895,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer"
NCT04419870,Recruiting,Observational,,National Human Genome Research Institute (NHGRI),NIH,4-Mar-21,1-May-25,1-May-25,CASE-CONTROL,200,MITOCHONDRIAL DISEASE,UNITED STATES,ALL,"2 Months and older   (Child, Adult, Older Adult)",,"WE WILL PERFORM WHOLE BLOOD TRANSCRIPTOMIC ANALYSIS, HUMORAL RESPONSE PROFILING AND SOLUBLE MEDIATOR PROFILING.","Acute Infection in Mitochondrial Disease: An Observational Prospective Natural History Study of Metabolism, Infection and Immunity During the COVID19 Pandemic"
NCT04420182,Recruiting,Interventional,Not Applicable,Lawson Health Research Institute,Other,17-Aug-20,31-Dec-21,30-Jun-21,TREATMENT,2000,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VIRTUAL CARE AT HOME,14 DAY PATIENT SATISFACTION QUESTIONNAIRE,COVID-19 Virtual Care at Home
NCT04420247,Completed,Interventional,Phase 3,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,Other,16-Apr-20,3-Sep-20,20-Aug-20,TREATMENT,142,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE,WORLD HEALTH ORGANIZATION (WHO) 9-LEVELS ORDINAL SCALE (FROM 0-8),Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
NCT04420260,Not yet recruiting,Interventional,Not Applicable,Unidad de Investigación Genética Molecular,Other,20-Jul-21,20-Sep-21,20-Sep-21,PREVENTION,300,COVID,,ALL,18 Years to 60 Years   (Adult),GROUP A: OROPHARYGEAL SPRAY AND IMMUNOSTIMULANT,SEROCONVERSION OF IGM FOR COVID-19.,"Scheme of Primary Prevention of Infection by COVID-19, in Health Providers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia"
NCT04420273,"Active, not recruiting",Interventional,Not Applicable,Northwestern University,Other,2-Jul-20,30-Dec-21,30-Mar-21,PREVENTION,1000,MELANOMA,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",SSE EDUCATIONAL INTERVENTION,CHANGE IN SSE PERFORMANCE,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter
NCT04420286,Recruiting,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,6-May-20,5-Jun-21,5-Jun-21,OTHER,9000,CORONAVIRUS INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",,ORIGIN OF THE ICU BEDS CREATED DURING THE COVID-19 OUTBREAK IN FRANCE.,Study of the Increase in ICU Beds Capacity and Caregivers During COVID-19 Pandemic in France : the FRENCH ICU Study
NCT04420299,Recruiting,Interventional,Phase 2,Fundación de investigación HM,Other,4-Jun-20,31-Mar-21,31-Mar-21,TREATMENT,120,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BEMIPARIN,PROPORTION OF PATIENTS THAT WORSEN,"A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19"
NCT04420312,Completed,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,1-Mar-20,20-Apr-20,20-Apr-20,CASE-CONTROL,1024,PULMONARY EMBOLISM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,IMPACT OF PE ON COVID-19 PATIENTS,Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome
NCT04420338,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,5-Jun-20,15-Dec-20,15-Dec-20,DIAGNOSTIC,800,CHRONIC HEMODIALYSIS PATIENTS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,THE PREVALENCE OF SARS-COV2 SEROCONVERSION IN CHRONIC HEMODIALYSIS PATIENTS,"SeroCOVIDial Study: Assessment of SARS-COV2 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study"
NCT04420364,Not yet recruiting,Interventional,Phase 2/Phase 3,Brigham and Women's Hospital,Other,1-Mar-21,31-Dec-21,30-Sep-21,TREATMENT,50,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",MAINTENANCE OR REDUCTION OF IMMUNOSUPPRESSION,CHANGE IN IL-6 CONCENTRATION FROM BASELINE TO DAY 7,Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
NCT04420390,Recruiting,Interventional,Not Applicable,"Hospital San Carlos, Madrid",Other,1-May-20,8-Sep-20,31-Jul-20,TREATMENT,41,COVID,SPAIN,ALL,"60 Years and older   (Adult, Older Adult)",RADIOTHERAPY,RADIOLOGICAL RESPONSE,Low Dose Radiotherapy as Antinflammatory Treatment for COVID-19 Pneumonitis
NCT04420416,Recruiting,Observational,,Instituto Mexicano del Seguro Social,Other,1-Apr-20,30-Jul-20,30-Jul-20,COHORT,720,"DEPRESSION, ANXIETY",MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,ACADEMIC SELF-CONCEPT SCALE SCORE,"dePression, Anxiety, aNd acaDemic pErforMance In Covid-19: PANDEMIC Study."
NCT04420468,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Jun-21,20-Dec-21,20-Dec-21,COHORT,20,COVID,FRANCE,ALL,up to 17 Years   (Child),,ACUTE MYOCARDITIS,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children
NCT04420637,Enrolling by invitation,Observational,,Medical University of Graz,Other,15-Jun-20,21-Dec-21,20-Dec-21,COHORT,1000,COVID,AUSTRIA,ALL,"Child, Adult, Older Adult",,LIVER DISEASE,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases
NCT04420676,Recruiting,Interventional,Not Applicable,Medical University of Graz,Other,24-Sep-20,22-Dec-21,21-Dec-21,TREATMENT,120,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",OMNIBIOTIC AAD,STOOL CALPROTECTIN,"Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection: A Randomized, Double-blind, Placebo Controlled, Telemedicine Study (SynCov Study)"
NCT04420741,Recruiting,Interventional,Phase 2,Pär Johansson,Other,15-Jun-20,31-May-21,31-May-21,TREATMENT,80,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",ILOPROST,MECHANICAL VENTILATION FREE DAYS,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy
NCT04420806,Completed,Interventional,Not Applicable,University of Erlangen-Nürnberg Medical School,Other,14-Mar-20,30-Oct-20,30-Jul-20,TREATMENT,21,EXERCISE,GERMANY,FEMALE,48 Years to 60 Years   (Adult),HIT-EXERCISE,BODY COMPOSITION,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women
NCT04420988,Available,Expanded Access,,"Rutgers, The State University of New Jersey",Other,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,,Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
NCT04421027,Recruiting,Interventional,Phase 3,Eli Lilly and Company,Industry,12-Jun-20,20-Jun-21,19-May-21,TREATMENT,1400,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",BARICITINIB,PERCENTAGE OF PARTICIPANTS WHO DIE OR REQUIRE NON-INVASIVE VENTILATION/HIGH-FLOW OXYGEN OR INVASIVE MECHANICAL VENTILATION (INCLUDING EXTRACORPOREAL MEMBRANE OXYGENATION [ECMO]),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection"
NCT04421391,Recruiting,Interventional,Not Applicable,Therapeutic Solutions International,Industry,8-Jun-20,8-Nov-20,1-Nov-20,TREATMENT,500,COVID,UNITED STATES,ALL,"18 Years to 120 Years   (Adult, Older Adult)",QUADRAMUNE(TM),PREVENTION OF COVID-19,Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations
NCT04421404,"Active, not recruiting",Interventional,Phase 2,"Priscilla Hsue, MD",Other,9-Jun-20,30-Apr-21,30-Apr-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA (CCP),MECHANICAL VENTILATION OR DEATH ENDPOINT,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients
NCT04421508,"Active, not recruiting",Interventional,Phase 3,Bellerophon Pulse Technologies,Industry,12-Jul-20,21-Jun-21,28-Dec-20,TREATMENT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INOPULSE,THE PROPORTION OF SUBJECTS WHO DIED OR HAD RESPIRATORY FAILURE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)"
NCT04421534,Not yet recruiting,Interventional,Phase 2/Phase 3,Cairo University,Other,20-Jun-21,20-Nov-21,20-Sep-21,TREATMENT,150,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",LACTOFERRIN,TIME TO CLINICAL IMPROVEMENT,Efficacy and Safety of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19
NCT04421612,Recruiting,Interventional,Not Applicable,Haukeland University Hospital,Other,2-Apr-20,31-Dec-21,1-Mar-21,SUPPORTIVE CARE,400,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",CO-MESTRING (CO-COPING),THE PATIENT HEALTH QUESTIONNAIRE,COVID-19 - No Health Without Mental Health
NCT04421625,Recruiting,Interventional,Not Applicable,Institut Cancerologie de l'Ouest,Other,15-Jun-20,15-Jun-22,15-Jun-22,SCREENING,12000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC TEST FOR SARS-COV2 FOR PATIENTS AND HEALTH STAFF,ESTABLISHMENT OF A CLINICAL BASIS FOR TO DESCRIBE THE NUMBER AND SEVERITY OF COVID-19 INFECTIONS IN CANCER CENTRES STAFF AND PATIENTS.,"Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic: Constitution of a Biological Collection Linked to a Prospective, Multicenter Cohort Study"
NCT04421664,Terminated,Interventional,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,25-Mar-20,17-Aug-20,17-Aug-20,TREATMENT,70,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,ORDINAL SCALE OF COVID19 DISEASE SEVERITY AT 14 DAYS,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
NCT04422275,Not yet recruiting,Interventional,Phase 2,Washington University School of Medicine,Other,1-Jun-21,31-Dec-23,1-Jun-23,TREATMENT,200,ANOSMIA,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BUDESONIDE,UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST (UPSIT),Coronavirus Smell Therapy for Anosmia Recovery
NCT04422340,Recruiting,Observational,,Hospices Civils de Lyon,Other,1-Apr-20,15-Aug-20,15-Aug-20,COHORT,185,"COVID DISEASE, SEVERE FORM",FRANCE,ALL,"60 Years and older   (Adult, Older Adult)",GROUP1,EVALUATION OF THE IMPACT OF AGE ON MORTALITY AT 30 DAYS AFTER ADMISSION TO INTENSIVE CARE,A Multicentric Survey on Patients Over 60 Admitted to Intensive Care for Severe Forms of COVID Infection: Search for Prognostic Criteria Associated With Survival
NCT04422353,Recruiting,Interventional,Not Applicable,Federal University of Rio Grande do Sul,Other,1-May-20,30-Dec-24,30-Dec-20,TREATMENT,60,PARKINSON DISEASE,BRAZIL,ALL,"50 Years to 80 Years   (Adult, Older Adult)",VIDEO DANCE CLASSES,QUALITY OF LIFE (QOL),The Impact of Video Dance Class and Unsupervised Physical Activity on Parkinson's People During the Covid-19 Pandemic: Interventional
NCT04422379,Not yet recruiting,Observational,,Max Healthcare Insititute Limited,Other,7-Jun-20,30-Aug-20,30-Jul-20,COHORT,314,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,COVID-19 POSITIVE CASE,COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study
NCT04422418,Recruiting,Observational,,Khalifa University for Science and Technology,Other,1-Jul-20,31-Dec-20,14-Dec-20,COHORT,200,CARDIOVASCULAR RISK FACTOR,UNITED ARAB EMIRATES,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE FROM BASELINE BURNOUT AT 2-3 MONTHS AND 6 MONTHS,Multi-Center Prospective Cohort Study: Impact of Burnout on Cardiovascular and Immune Biomarkers Among Frontline Healthcare Professionals During Covid-19 Pandemic in Abu Dhabi Emirate
NCT04422444,Recruiting,Observational [Patient Registry],,Corporacion Parc Tauli,Other,1-Jun-20,1-Jun-22,1-May-21,COHORT,100,COVID,SPAIN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",QUESTIONNAIRES,CHANGE FROM BASELINE SHORT FORM 12 HEALTH SURVEY (SF12) AT 12 MONTH,Characterization and Management of Post Intensive Care Syndrome in COVID19 Patients.
NCT04422470,Recruiting,Observational [Patient Registry],,"National Research Center for Hematology, Russia",Other,22-Jun-20,22-Jul-21,22-Jan-21,COHORT,200,CORONAVIRUS INFECTION AND HEMATOLOGIC DISEASES,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",NON-INTERVENTIONAL STUDY,30-DAY ALL-CAUSE MORTALITY,Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19)
NCT04422509,Recruiting,Interventional,Phase 1/Phase 2,Radboud University,Other,3-Oct-20,3-Aug-21,3-Aug-21,TREATMENT,80,COVID,NETHERLANDS,ALL,"16 Years and older   (Child, Adult, Older Adult)",LANADELUMAB,OXYGEN,Lanadelumab for Treatment of COVID-19 Disease
NCT04422522,"Active, not recruiting",Observational,,Al-Azhar University,Other,15-Mar-20,30-Jun-20,15-May-20,CASE-ONLY,45,"FIBROMYALGIA, PRIMARY",EGYPT,ALL,"19 Years and older   (Adult, Older Adult)",,NUMBER OF FM PATIENTS,Prevalence of Fibromyalgia in the Rheumatology Outpatient Clinics in the UAE During the COVID-19 Pandemic: a Cross-sectional Study
NCT04422535,Recruiting,Observational,,Matilde Zaballos,Other,29-May-20,1-Dec-20,1-Sep-20,COHORT,80,CORONAVIRUS INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,ASSESSING THE QT AND QTC INTERVAL IN PATIENTS ADMITTED TO INTENSIVE CARE UNITS FOR COVID-19 INFECTION,Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients
NCT04422561,Completed,Interventional,Phase 2/Phase 3,Zagazig University,Other,31-May-20,27-Jul-20,14-Jul-20,PREVENTION,340,COVID,EGYPT,ALL,"16 Years to 70 Years   (Child, Adult, Older Adult)",IVERMECTIN TABLETS,"DEVELOPMENT OF SYMPTOMS ( FEVER ,COUGH, SORE THROAT, MYALGIA,DIARRHEA, SHORTNESS OF BREATH)",Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19
NCT04422574,Completed,Observational,,"University Hospital, Montpellier",Other,1-May-20,30-May-20,1-May-20,ECOLOGIC OR COMMUNITY,97,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,COVID 19 SEROLOGY,COVID 19 Serology in Pulmonologists : Pneumo Sero Cov
NCT04422587,Completed,Observational [Patient Registry],,"University Hospital, Toulouse",Other,13-Mar-20,7-Jun-20,5-Jun-20,COHORT,1860,EMERGENCIES,FRANCE,ALL,"15 Years and older   (Child, Adult, Older Adult)",RECOP UNIT PATIENT,DEVELOP A PREDICTIVE MODEL OF THE RISK OF BEING COVID-19 FOR PATIENTS ADMITTED TO THE EMERGENCY ROOM FOR DYSPNEA,Evaluation of the COVID-19 Infection Response in Patients Admitted to the Emergency Department for Dyspnea
NCT04422613,"Active, not recruiting",Interventional,Not Applicable,"University Hospital, Toulouse",Other,28-May-20,22-May-21,21-May-21,DIAGNOSTIC,73,"PNEUMONIA, VIRAL",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY ANOMALIES 4 MONTHS AFTER DOCUMENTED COVID-19 PNEUMONIA,ALTERATION OF THE DLCO,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
NCT04422626,Not yet recruiting,Observational,,University of Pecs,Other,1-Jul-20,1-Dec-22,1-Jul-22,COHORT,42,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE IN THE PARTIAL PRESSURE OF OXYGEN/FRACTION OF INSPIRED OXYGEN (PAO2/FIO2) RATIO AFTER CYTOSORB THERAPY,Data Collection on the Application of Cytokine Adsorption Therapy on Patients With Acute Respiratory Failure Caused by COVID-19
NCT04422678,Not yet recruiting,Interventional,Phase 3,Alexandria University,Other,20-Jun-21,20-Oct-21,20-Sep-21,TREATMENT,30,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",IMATINIB MESYLATE,PRIMARY ENDPOINT: DISEASE PROGRESSION,Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia: A Pilot Study
NCT04422691,Recruiting,Observational,,St. Olavs Hospital,Other,1-Jul-20,25-Dec-21,20-Dec-21,COHORT,200,COVID,NORWAY,ALL,"17 Years and older   (Child, Adult, Older Adult)",LUNG ULTRASOUND,MORTALITY,Bruk av Ultralyd i Evaluering av Pasienter Med Mistenkt COVID-19 Infeksjon i Norge
NCT04422769,"Active, not recruiting",Observational,,Washington University School of Medicine,Other,22-May-20,31-Mar-21,31-Mar-21,COHORT,250,SPINAL CORD INJURIES,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NIH TOOLBOX INSTRUMENTAL SUPPORT SURVEY - CHANGE IN INSTRUMENTAL SUPPORT,Tracking Needs of Persons With a Spinal Cord Injury (SCI) During the COVID-19 Pandemic
NCT04422873,Recruiting,Observational,,University of Portsmouth,Other,3-Jun-20,1-Jan-21,1-Jan-21,COHORT,40,END STAGE RENAL DISEASE,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,"QUALITATIVE ASSESSMENT OF THE EFFECT OF COVID-19 RESTRICTIONS ON PATIENTS' WELL-BEING, QUALITY OF LIFE AND PHYSICAL ACTIVITY AND SEDENTARY BEHAVIOURS","The Impact of Coronavirus (COVID-19) Restrictions on Wellbeing, Quality of Life and Physical Activity in People With End-stage Renal Disease, Currently Dialysing In-centre Versus at Home in the UK and Their Experience of Telemedicine"
NCT04422977,Not yet recruiting,Interventional,Not Applicable,Centre Hospitalier Saint Joseph Saint Luc de Lyon,Other,8-Jun-20,30-Jun-20,30-Jun-20,DIAGNOSTIC,900,SARS-COV2,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",SARS-COV-2 SEROLOGY,MEASUREMENT OF OVERALL SEROPREVALENCE OF SARS-COV-2 IN AN HOSPITAL STAFF,Serological Study of the Exposure of Personnel to Sars-cov-2 in an Urban Hospital Two Months After Managing an Influx of COVID Patients 19
NCT04423003,Completed,Observational [Patient Registry],,University Hospital Tuebingen,Other,1-Mar-20,15-May-20,15-May-20,COHORT,10,"CHANGE; ENDOSCOPY, COVID",GERMANY,ALL,"Child, Adult, Older Adult",ENDOSCOPIC INTERVENTION,DEATH IN TIME OF OBSERVATION,"Impact of the COVID-19 Pandemic on an Interdisciplinary Endoscopy Unit in a German ""Hotspot"" Area: a Single Center Experience"
NCT04423042,Not yet recruiting,Interventional,Phase 3,University of Calgary,Other,30-Jul-20,21-Jun-21,21-Jun-21,TREATMENT,30,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,ALL-CAUSE MORTALITY,A Nested Interventional Cohort Study to Assess the Efficacy and Safety of Adjunctive Humanized Monoclonal Interleukin-6 Receptor Blocker Tocilizumab (TCZ) Therapy to Standard of Care for the Reduction of Hyperinflammation Related Mortality in SARS-Cov2 Positive Patients
NCT04423289,Completed,Interventional,Not Applicable,Hospital Universitari Vall d'Hebron Research Institute,Other,31-Mar-20,18-May-20,4-May-20,SUPPORTIVE CARE,150,FACE-TO-FACE RECONSULTATION TO EMERGENCY ROOM,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",FARMALARM,RE-CONSULTATION,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial
NCT04423315,Completed,Observational,,Nisantasi University,Other,8-Jun-20,20-Jul-20,15-Jul-20,COHORT,70,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,LENGTH OF HOSPITAL STAY,Thrombosis Risk Assessment May Predict Clinical Presentation and Length of Hospital Stay in Covid-19 Pneumonia
NCT04423640,Recruiting,Observational,,"Coordinación de Investigación en Salud, Mexico",Other,15-Apr-20,15-Aug-20,15-Jun-20,COHORT,200,SARS-COV2,MEXICO,ALL,"16 Years and older   (Child, Adult, Older Adult)",ACTIVE COVID-19 DISEASE,SERUM LEVELS OF CYTOKINES AND CHEMOKINES,The Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With Coronavirus Disease 2019 (COVID-19)
NCT04423692,Recruiting,Observational,,Aljazeera Hospital,Other,1-Jun-20,20-Aug-20,15-Aug-20,OTHER,30,VIRAL INFECTION,EGYPT,FEMALE,18 Years to 42 Years   (Adult),LABS,THE NUMBER OF PREGNANT WOMEN WHO HAVE KNOWLEDGE ABOUT COVID-19,Knowledge About Covid-19 Infection in Pregnant Women
NCT04423770,"Active, not recruiting",Observational,,American Dental Association,Other,8-Jun-20,8-Jun-21,8-Jun-21,ECOLOGIC OR COMMUNITY,4000,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,COVID-19 PROBABLE OR CONFIRMED CASE,COVID-19 Related Health and Infection Control Practices Among Dentists
NCT04423861,Not yet recruiting,Interventional,Phase 3,Azidus Brasil,Industry,20-Dec-21,21-May-21,21-Apr-21,TREATMENT,380,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE,NEED OF MECHANICAL VENTILATION,"A Phase III, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition"
NCT04423978,Completed,Observational,,Azienda Unità Sanitaria Locale Reggio Emilia,Other,4-May-20,15-Jun-20,15-Jun-20,ECOLOGIC OR COMMUNITY,1826,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,THE RATIO OF INDIVIDUALS LIVING IN THE PROVINCE OF REGGIO EMILIA WHO COMPLETED THE SURVEY,Implications of Covid-19 on the Lifestyle Changes and Supports Used (ICOLS): a Survey in the Province of Reggio Emilia
NCT04423991,Completed,Interventional,Not Applicable,Dascena,Industry,10-Mar-20,4-Jun-20,4-Jun-20,DIAGNOSTIC,290,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",COVIAGE,MORTALITY OUTCOME,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial
NCT04424004,"Active, not recruiting",Observational,,Duke University,Other,9-Jun-20,30-Jun-21,30-Jun-21,ECOLOGIC OR COMMUNITY,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PCR AND SEROLOGY TESTING,ESTIMATE THE PREVALENCE OF COVID-19 INFECTION BASED ON RESPONSES TO QUESTIONNAIRE ITEMS ON SYMPTOMS AND PRACTICES USING A BIWEEKLY ELECTRONIC SURVEY.,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study
NCT04424017,Recruiting,Observational,,Egyptian Center for Research and Regenerative Medicine,Other,7-Jun-20,30-Sep-20,30-Sep-20,OTHER,726,COVID,EGYPT,ALL,18 Years to 60 Years   (Adult),SPECIFIC ANTI-SARS-COV-2 ANTIBODIES,DESCRIBE THE SEROLOGICAL STATUS OF INDIVIDUALS IN THE STUDY BY PRESENCE OF SPECIFIC ANTI-SARS-COV-2 ANTIBODIES,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
NCT04424056,Not yet recruiting,Interventional,Phase 3,Assistance Publique Hopitaux De Marseille,Other,1-Sep-20,1-Nov-22,30-Sep-22,TREATMENT,216,COVID,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ANAKINRA +/- RUXOLITINIB (STAGES 2B/3),VENTILATION FREE DAYS AT D28,"An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease"
NCT04424082,Recruiting,Interventional,Not Applicable,Karolinska Institutet,Other,9-Jun-20,7-Nov-20,7-Nov-20,SUPPORTIVE CARE,40,CORONAVIRUS,SWEDEN,ALL,"Child, Adult, Older Adult",REMOVAL OF DEAD SPACE FILTER,CHANGE IN CARBON DIOXIDE ELIMINATION (VCO2) I.E. ML CO2 ELIMINATED/MINUTE,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients
NCT04424134,Recruiting,Interventional,Phase 3,Lomonosov Moscow State University Medical Research and Educational Center,Other,16-May-20,23-Aug-20,18-Jul-20,TREATMENT,80,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",BROMHEXINE AND SPIRONOLACTONE,CHANGE FROM BASELINE IN CLINICAL ASSESSMENT SCORE COVID 19 (CAS COVID 19),Open Label Randomized Clinical Trial BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization
NCT04424212,"Active, not recruiting",Interventional,Not Applicable,Linkoeping University,Other,10-Jun-20,21-Aug-21,21-Jun-21,TREATMENT,120,DEPRESSION AND QUALITY OF LIFE RELATED TO THE CORONAVIRUS PANDEMIC,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION GROUP CORONACOPE,BECKS DEPRESSION INVENTORY-II,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic
NCT04424355,Recruiting,Observational,,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,Other,19-May-20,20-Dec-21,19-Jul-21,COHORT,115,CORONAVIRUS INFECTION,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",CHEST MRI,NUMBER OF ZONES OF PULMONARY PARENCHYMA CORRESPONDING TO VIRAL PNEUMONIA DETECTED BY CHEST MRI IN COMPARISON WITH CT SCAN,Possibilities of Chest Magnetic Resonance Imaging (MRI) in Diagnostics of COVID-19. The Use of MRI to Assess Lung Damage in Patients With Coronavirus Infection
NCT04424446,Recruiting,Observational,,National Institutes of Health Clinical Center (CC),NIH,13-Jul-20,1-Jun-21,1-Jun-21,CASE-ONLY,5000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SALIVA SARS-COV-2 RT-PCR TEST RESULTS,Evaluation of Saliva as Source of Detection for SARS-CoV-2
NCT04424771,Completed,Observational,,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,Other,1-Mar-20,1-Jul-20,30-Jun-20,COHORT,800,COVID,ITALY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MASLACH BURNOUT INVENTORY (MBI),NUMBER OF PATIENTS WITH DIAGNOSIS OF PTSD.,PTSD in Health Workers During COVID-19 Pandemia
NCT04424797,Recruiting,Interventional,Not Applicable,Poudre Valley Health System,Other,13-Jul-20,20-Dec-21,20-Dec-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,INCIDENCE OF INTUBATION,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol
NCT04424836,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,15-May-20,5-Jun-20,4-Jun-20,CASE-CONTROL,43,CORONAVIRUS INFECTION,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",HIGH FLOW NASAL CANNULA DEVICE,SHORT TERM MORTALITY,the Effect of HFNC Treatment on Mortality and Length of ICU Stay in Patient With COVID-19 Pneumonia
NCT04424849,Recruiting,Observational,,Tepecik Training and Research Hospital,Other,15-Mar-20,15-Jul-20,15-Jun-20,COHORT,40,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",CT-SCAN,INVASIVE RESPIRATORY SUPPORT IN PATIENTS WITH COVID-19,Initial Thoracic CT Findings and Mechanical Ventilation Requirement in Patients Admitted to Intensive Care Unit With COVID-19
NCT04424901,Recruiting,Interventional,Phase 2,UConn Health,Other,3-May-20,30-May-21,1-May-21,TREATMENT,100,COVID PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIPYRIDAMOLE,COAGULATION SYSTEM,"A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients"
NCT04424940,Not yet recruiting,Observational [Patient Registry],,University of Kinshasa,Other,1-Sep-20,1-Sep-21,1-Jun-21,COHORT,800,COVID,"CONGO, THE DEMOCRATIC REPUBLIC OF THE",ALL,"15 Years to 75 Years   (Child, Adult, Older Adult)",,NUMBER OF PARTICIPANTS WITH TREATMENT-TOMEKA® USAGE AS ASSESSED BY EDUCATION,TOMEKA® Project Was Sponsored by the University of Kinshasa: it's an Observational Study by Its Reviewed Documentation
NCT04424992,Recruiting,Observational,,University of Milano Bicocca,Other,28-Feb-20,21-Dec-21,21-Dec-21,COHORT,1433,SARS-COV2,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL COHORT STUDY ON THE NATURAL HISTORY OF HOSPITALIZED SARS-COV-2 PATIENTS.,COVID19 INFECTION CLINICAL EVOLUTION,Observational Cohort Study on the Natural History of Hospitalized SARS-COV-2 Patients: the STORM Trial
NCT04425005,Completed,Interventional,Not Applicable,University of Sao Paulo,Other,10-May-20,7-Dec-20,7-Dec-20,TREATMENT,55,BARIATRIC SURGERY,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HOME-BASED EXERCISE,CHANGE FROM BASELINE ON WAIST CIRCUMFERENCE AT 3 MONTHS OF FOLLOW-UP.,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial
NCT04425031,Recruiting,Interventional,Phase 4,Aalborg University Hospital,Other,25-Aug-20,1-Mar-24,1-Dec-22,PREVENTION,780,HYPOXEMIC RESPIRATORY FAILURE,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",OXYGEN,DAYS ALIVE WITHOUT ORGAN SUPPORT,Handling Oxygenation Targets in COVID-19 Patients With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target
NCT04425044,Completed,Observational,,Aarogyam UK,Other,12-Apr-20,28-May-20,18-May-20,COHORT,1000,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",OTHER,FEVER,Efficacy of AiM Covid Self Monitoring in Detecting Infection of COVID-19
NCT04425213,Completed,Observational,,"Central Hospital, Nancy, France",Other,12-May-20,26-May-20,25-May-20,COHORT,250,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ICU MORTALITY,"Obesity as a Risk Factor for Mortality of Critically Ill Patients With Coronavirus Disease 2019 (COVID-19): a Cohort Study of the First Wave in Nancy, France"
NCT04425252,Completed,Interventional,Phase 1/Phase 2,"Clear Creek Bio, Inc.",Industry,1-Aug-20,29-Dec-20,29-Dec-20,TREATMENT,23,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BREQUINAR,SAFETY/TOLERABILITY MEASURED BY RATES OF POST RANDOMIZATION ADVERSE EVENTS AND HEMATOLOGY/CHEMISTRY SAFETY LABS.,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)
NCT04425317,Recruiting,Interventional,Not Applicable,CRG UZ Brussel,Other,24-Jun-20,15-Jun-21,15-Jun-21,DIAGNOSTIC,20,INFERTILITY,BELGIUM,FEMALE,"up to 45 Years   (Child, Adult)",BLOOD SAMPLE,"PRESENCE OR ABSENCE OF SARS-COV-2 IN FOLLICULAR FLUID, CUMULUS CELLS, IMMATURE OOCYTES AND ENDOMETRIUM",Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment
NCT04425382,Recruiting,Observational,,Hamad Medical Corporation,Industry,1-Mar-20,20-Sep-21,20-Jul-21,OTHER,200,CORONAVIRUS,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",DARUNAVIR/COBICISTAT,TIME TO CLINICAL IMPROVEMENT AND/OR VIROLOGICAL CLEARANCE (COMPOSITE ENDPOINT),Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar
NCT04425460,Not yet recruiting,Interventional,Phase 3,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,20-Jun-21,20-Sep-21,20-Aug-21,TREATMENT,256,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",FAVIPIRAVIR,TIME FROM RANDOMIZATION TO CLINICAL RECOVERY,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type"
NCT04425499,Not yet recruiting,Interventional,Not Applicable,Université de Montréal,Other,20-Jun-21,20-Jun-21,20-Jun-21,OTHER,60,ADVANCED SUTURING SKILLS,,ALL,"18 Years and older   (Adult, Older Adult)",LEARNING RUNNING SUBCUTICULAR SUTURES ON THE GAMIFIED EDUCATIONAL NETWORK,RETENTION OF THE CORRECT TECHNIQUE FOR RUNNING SUBCUTICULAR SUTURES,A Gamified Network for Surgical Education During COVID-19: A Randomized Controlled Trial
NCT04425538,Completed,Interventional,Phase 2,Tufts Medical Center,Other,1-Jun-20,22-Jan-21,22-Jan-21,TREATMENT,17,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INFLIXIMAB,TIME TO IMPROVEMENT IN OXYGENATION,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
NCT04425616,Recruiting,Interventional,Not Applicable,University Hospital Southampton NHS Foundation Trust,Other,4-Jun-20,30-Nov-22,30-Nov-21,TREATMENT,1100,CANCER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EXERCISE,PHYSICAL FUNCTION,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions to Maintain and Improve Mental and Physical Health in People With Cancer Who Are Following Social Distancing Guidance: A COVID-19 Targeted Trial
NCT04425629,Recruiting,Interventional,Phase 2/Phase 3,Regeneron Pharmaceuticals,Industry,16-Jun-20,28-Aug-21,10-Apr-21,TREATMENT,6420,COVID,CHILE,ALL,"Child, Adult, Older Adult",REGN10933+REGN10987 COMBINATION THERAPY,PROPORTION OF PATIENTS WITH TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS (SAES),"A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19"
NCT04425707,Recruiting,Interventional,Not Applicable,"Ministry of Health and Population, Egypt",Other,9-Jun-20,1-Sep-20,1-Jul-20,TREATMENT,100,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,TO EVALUATE THE ROLE OF IVERMECTIN AS A LINE OF TREATMENT FOR COVID 19,The Use of Ivermectin In the Treatment of COVID 19 Patients
NCT04425720,Recruiting,Interventional,Not Applicable,Montefiore Medical Center,Other,1-Sep-20,1-Jun-21,1-Jun-21,SUPPORTIVE CARE,300,COVID,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",LIFESIGNALS BIOSENSOR 1AX*,MONITORED VERSUS NON-MONITORED IN-PATIENT ADMISSION,Use of Remote Patient Monitoring (RPM) Platform for COVID-19 Patient
NCT04425733,Withdrawn,Interventional,Phase 1,Merck Sharp & Dohme Corp.,Industry,7-Jul-20,10-Nov-20,10-Nov-20,TREATMENT,0,CORONAVIRUS DISEASE 2019 (COVID),,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MK-5475,NUMBER OF PARTICIPANTS WHO EXPERIENCE AN ADVERSE EVENT (AE),"A Study to Assess the Safety, Tolerability, and Pharmacodynamics of Multiple Dose MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia"
NCT04425759,Recruiting,Observational [Patient Registry],,Hospital de Mataró,Other,8-Jun-20,30-Jun-21,30-Jun-21,COHORT,2400,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,"ANTIBODIES TO SARS-COV2: IGA, IGM, IGG","Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses and Assymptomatic Carriers Among a Cohort of 2,300 Healthcare Workers at the Consorci Sanitari Del Maresme (CSdM)"
NCT04425772,Not yet recruiting,Interventional,Not Applicable,"HeNan Sincere Biotech Co., Ltd",Industry,12-Jun-20,12-Aug-20,12-Aug-20,TREATMENT,342,COVID,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",FNC+STANDARD OF CARE,CHANGE (REDUCTION) IN VIRAL LOAD FROM BASELINE,"A Randomized,Double Blinded, Double Dummy, Parallel Controlled Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）"
NCT04425837,Not yet recruiting,Interventional,Phase 2/Phase 3,Fundación Santa Fe de Bogota,Other,20-Jul-21,21-Feb-21,21-Feb-21,TREATMENT,236,SARS-COV2,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 CONVALESCENT PLASMA TREATMENT,MORTALITY,"Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19: A Randomized, Controlled Study CRI-CP (Coronavirus Investigation - Convalescent Plasma)"
NCT04425850,Completed,Observational,,Eurnekian Public Hospital,Other,1-Jun-20,10-Aug-20,10-Aug-20,COHORT,229,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",IOTA CARRAGEENAN NASAL SPRAY AND IVERMECTIN ORAL DROPS (USED AS BUCCAL DROPS),NUMBER OF INFECTED SUBJECTS,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel
NCT04425863,Completed,Observational,,Eurnekian Public Hospital,Other,1-May-20,30-Aug-20,30-Aug-20,COHORT,167,SEVERE ACUTE RESPIRATORY SYNDROME,ARGENTINA,ALL,"5 Years and older   (Child, Adult, Older Adult)","IVERMECTIN 5 MG/ML ORAL SOLUTION, ASPIRIN 250 MG TABLETS",PATIENTS WHO IMPROVED THEIR CONDITION OR DID NOT WORSEN IT,"Evaluation of Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of covid19"
NCT04425889,Completed,Observational,,Hospital Universitario Dr. Jose E. Gonzalez,Other,5-May-20,1-Jun-20,30-May-20,COHORT,156,COVID,MEXICO,ALL,"18 Years to 99 Years   (Adult, Older Adult)","COVID-19 IGG/IGM RAPID TEST CASSETTE TEST (HEALGEN SCIENTIFIC, HOUSTON, TEXAS, USA)",PRESENCE OF ANTIBODY,Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers in a COVID-19 Unit
NCT04425915,Recruiting,Interventional,Phase 3,"Institute of Liver and Biliary Sciences, India",Other,14-Jun-20,30-May-21,30-May-21,TREATMENT,400,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,"EFFICACY OF CONVALESCENT PLASMA IN SEVERE COVID 19 PATIENTS IN TIME TO CLINICAL IMPROVEMENT (CLINICAL IMPROVEMENT: REDUCTION OF TWO POINTS IN ORDINAL SCALE OR LIVE DISCHARGE FROM THE INTENSIVE CARE UNIT, WHICHEVER IS EARLIER)",Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial
NCT04426006,"Active, not recruiting",Interventional,Not Applicable,Institut Bergonié,Other,1-Jun-20,21-Dec-21,21-Jun-21,PREVENTION,550,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PRO-SERO-COV,SEROLOGICAL IMMUNE STATUS TO AN INFECTION BY THE SARS-COV-2 VIRUS,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic - PRO-SERO-COV
NCT04426071,Recruiting,Observational,,Lawson Health Research Institute,Other,1-Jun-20,21-Dec-21,21-Dec-21,COHORT,142,BRAIN INJURIES,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE IN FEAR OF COVID-19,COVID-19 and Disability: The Impact of a Societal Lockdown on Those With Spinal Cord and Brain Injuries
NCT04426084,"Active, not recruiting",Observational [Patient Registry],,Karolinska Institutet,Other,1-Mar-20,31-Dec-22,11-May-20,CASE-CONTROL,22784,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",HYPERTENSION,SEVERE COVID-19,"Cardiovascular Disease, Cardiovascular Risk Factors, Treatments and Severe COVID-19 Outcomes. A Nationwide Registry-based Case-Control Study"
NCT04426201,Recruiting,Interventional,Phase 2,Revimmune,Industry,20-Dec-20,31-Dec-21,30-Apr-21,TREATMENT,48,COVID,UNITED STATES,ALL,"25 Years to 80 Years   (Adult, Older Adult)",CYT107,"IMPROVEMENT OF THE ABSOLUTE LYMPHOCYTE COUNT (ALC) OF LYMPHOPENIC (ALC≤1000/MM3) COVID-19 INFECTED PARTICIPANTS OUT TO APPROXIMATELY 30 DAYS FOLLOWING INITIAL STUDY DRUG ADMINISTRATION OR HOSPITAL DISCHARGE (HD), WHICHEVER OCCURS FIRST","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort"
NCT04426253,"Active, not recruiting",Observational,,Szeged University,Other,5-Jun-20,31-Jul-21,31-Dec-20,CASE-ONLY,1000,COVID,HUNGARY,ALL,"18 Years and older   (Adult, Older Adult)",,IDENTIFICATION OF GENETIC FACTORS DETERMINING THE COURSE OF THE DISEASE IN CASE OF COVID-19,"Identification of Genetic Factors Determining Disease Course and Preparation of Pharmacogenetic Applications in the New Type of Coronavirus Infection, COVID-19"
NCT04426266,Completed,Observational,,Szeged University,Other,1-May-20,28-Sep-20,28-Sep-20,COHORT,441,QUESTIONNAIRE DESIGNS,HUNGARY,ALL,"18 Years and older   (Adult, Older Adult)",,SOCIODEMOPRAPHIC FACTORS,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population
NCT04426279,Recruiting,Observational,,"University Hospital, Lille",Other,18-Aug-20,21-Feb-21,21-Feb-21,COHORT,1500,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ASSESMENT,ANALYSIS OF COVID-19-RELATED MORBIDITY AND MORTALITY IN PATIENTS WITH IRC UNDER IS.,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
NCT04426292,Recruiting,Interventional,Not Applicable,Universitair Ziekenhuis Brussel,Other,12-May-20,12-May-21,23-Oct-20,HEALTH SERVICES RESEARCH,3500,SARS-COV2,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TESTING,SEROPREVALENCE,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
NCT04426305,Enrolling by invitation,Interventional,Not Applicable,University Ghent,Other,21-May-20,30-Oct-20,20-Jun-20,SUPPORTIVE CARE,140,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",COMMUNITY HEALTH WORKER SUPPORT,CHANGE IN PATIENT-REPORTED EMOTIONAL SUPPORT (BASED ON THE PROMIS® EMOTIONAL SUPPORT INSTRUMENT),Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing
NCT04426318,Completed,Interventional,Not Applicable,"University of Wisconsin, Madison",Other,14-Jun-20,12-Jan-21,12-Jan-21,TREATMENT,733,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HEALTHY MINDS PROGRAM FOUNDATIONS TRAINING,CHANGE FROM BASELINE ON AN AGGREGATE MEASURE OF PSYCHOLOGICAL DISTRESS THAT AVERAGES THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS) ANXIETY AND DEPRESSIVE MEASURES AND THE NIH PERCEIVED STRESS SCALE,COVID-19 and the Healthy Minds Program for Educators
NCT04426344,Withdrawn,Interventional,Not Applicable,Washington University School of Medicine,Other,20-Oct-21,20-Dec-21,20-Dec-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ENSOETM DEVICE,VIRAL LOAD MEASURED IN TRACHEAL ASPIRATE 72 HOURS AFTER INITIATION OF CORE WARMING,"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study"
NCT04426695,Recruiting,Interventional,Phase 1/Phase 2,Regeneron Pharmaceuticals,Industry,11-Jun-20,16-Apr-21,16-Apr-21,TREATMENT,6900,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",REGN10933+REGN10987 COMBINATION THERAPY,INCIDENCE OF DEATH OR REQUIRED MECHANICAL VENTILATION,"A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19"
NCT04427098,Recruiting,Interventional,Phase 2,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,Other,22-May-20,30-Oct-20,30-Oct-20,TREATMENT,300,COVID,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",ENOXAPARIN 40 MG/0.4 ML INJECTABLE SOLUTION,TO INVESTIGATE THE EFFICACY OF ENOXAPARIN IN IMPROVING THE CLINICAL OUTCOME OF HOSPITALIZED PATIENTS WITH MODERATE-SEVERE COVID-19.,"Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19"
NCT04427137,Recruiting,Interventional,Not Applicable,Centre for Addiction and Mental Health,Other,9-Jun-20,22-Dec-21,22-Jun-21,TREATMENT,50,BIPOLAR DEPRESSION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)","MAGPRO X100 STIMULATOR, B70 FLUID-COOLED COIL",PROPORTION ACHIEVING REMISSION ON HAMILTON RATING SCALE FOR DEPRESION 24-IT (HRSD-24),A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol as a Substitute for Patients With Bipolar Depression Needing Electroconvulsive Therapy During the COVID-19 Pandemic
NCT04427176,Completed,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,29-Apr-20,28-May-20,28-May-20,OTHER,15,NURSE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ARFC MASK,"EVALUATE THE FEASIBILITY OF THE USE OF AN ARFC MASK BY NURSING STAFF, IN TERMS OF TOLERANCE",Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).
NCT04427254,Not yet recruiting,Interventional,Not Applicable,Fondation Ophtalmologique Adolphe de Rothschild,Other,21-Jan-21,23-Jan-21,23-Jan-21,OTHER,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","CEREBROSPINAL FLUID SAMPLING, MENINGEAL AND BRAIN PARENCHYMA BIOPSIES",PERCENTAGE OF PATIENTS WITH COVID-19 POSITIVE SAMPLES/BIOPSIES,Study of the Sars-Cov2 Neuroinvasiveness - COVID19
NCT04427267,Completed,Observational,,"Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""",Other,3-Jun-20,27-Jun-20,27-Jun-20,CASE-CONTROL,6,THERMAL CONDITION OF HEALTH WORKERS WHO USE PERSONAL PROTECTIVE EQUIPMENT FROM BIOLOGICAL HAZARDS DURING THEIR WORK WITH COVID PATIENTS,RUSSIAN FEDERATION,ALL,18 Years to 45 Years   (Adult),PERSONAL PROTECTIVE EQUIPMENT FROM BIOLOGICAL HAZARD,SKIN THERMOMETRY,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment for Biological Factors During Their Work With COVID-19 Patients
NCT04427280,Recruiting,Observational,,Royal Marsden NHS Foundation Trust,Other,26-May-20,21-Apr-21,20-Oct-21,COHORT,60,INFECTIOUS DISEASE,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,"PROPORTION OF PATIENTS, AT EACH SAMPLE TIMEPOINT, WITH A POSITIVE DETECTION OF IGM AND IGG SPECIFIC ANTIBODIES TO SARS-COV-2.",Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
NCT04427332,Completed,Observational,,University of Milano Bicocca,Other,11-Jun-20,16-Oct-20,16-Oct-20,COHORT,376,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INVESTIGATION OF SMELL AND TASTE DISORDERS,IDENTIFICATION OF DEMOGRAPHIC AND CLINICAL FACTORS IN COVID19 PATIENTS.,Smell and Taste Disorders in COVID-19 Patients: Prospective Observational Study
NCT04427345,Recruiting,Observational,,University of Milano Bicocca,Other,30-Apr-20,30-Apr-21,30-Apr-21,COHORT,1000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",PREDICTIVE FACTORS FOR CLINICAL RESPONSE IN PATIENTS WITH COVID-19.,IDENTIFY RISK FACTORS FOR INTRA-HOSPITAL MORTALITY.,Predictive Clinical Response Factors in COVID-19 Patients
NCT04427358,Completed,Observational,,"University Hospital, Strasbourg, France",Other,7-May-20,7-Sep-20,7-Aug-20,CASE-ONLY,100,COVID,FRANCE,ALL,70 Years and older   (Older Adult),,1. ANALYSIS OF THE RATE OF RT-PCR SARS-COV-2 POSITIVE AT 1 MONTH OF COVID INFECTION,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population
NCT04427501,Recruiting,Interventional,Phase 2/Phase 3,Eli Lilly and Company,Industry,17-Nov-19,31-May-21,20-Sep-20,TREATMENT,3300,COVID,PUERTO RICO,ALL,"12 Years and older   (Child, Adult, Older Adult)",LY3819253,PERCENTAGE OF PARTICIPANTS WHO EXPERIENCE COVID-RELATED HOSPITALIZATION OR DEATH FROM ANY CAUSE,"A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness"
NCT04427566,Recruiting,Interventional,Phase 2,Ohio State University Comprehensive Cancer Center,Other,23-Jul-20,31-Dec-21,31-Dec-21,TREATMENT,24,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RADIATION THERAPY,MORTALITY RATE OF SUBJECTS TREATED WITH WHOLE LUNG LOW-DOSE RADIATION,Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise
NCT04427631,Not yet recruiting,Interventional,Not Applicable,Cambridgeshire Community Services NHS Trust,Other,22-Jun-20,1-Jun-21,1-Jan-21,TREATMENT,20,HEARING IMPAIRED CHILDREN,UNITED KINGDOM,ALL,3 Years to 11 Years   (Child),BONE CONDUCTION HEADPHONES,"ACCEPTABILITY OF MANAGEMENT STRATEGY, QUESTIONNAIRE",Exploring Interventions for Children With Chronic Otitis Media With Effusion ('Glue Ear') When Services Are Reduced During Covid-19
NCT04427735,Recruiting,Observational,,Beijing Friendship Hospital,Other,24-Jan-19,24-Jul-21,24-Jul-21,CASE-CROSSOVER,200,STEMI,CHINA,ALL,"Child, Adult, Older Adult",,MACE (MAJOR ADVERSE CARDIOVASCULAR EVENTS),Effect of Covid-19 Epidemic on Primary PCI and Prognosis in Patients With Acute STEMI
NCT04427813,Not yet recruiting,Observational,,Aljazeera Hospital,Other,11-Jun-20,12-Jul-20,5-Jul-20,OTHER,400,SEXUAL BEHAVIOR,EGYPT,ALL,18 Years to 60 Years   (Adult),QUESTIONAIRE TO HUSBAND AND WIFE,THE NUMBER OF PARTNERS THAT HAVE UNUSUAL BEHAVIOUR,Sexual and Marital Health and Problems During the Covid -19 in the Last Months
NCT04427865,Not yet recruiting,Interventional,Phase 2/Phase 3,Cairo University,Other,20-Jul-21,20-Nov-21,20-Sep-21,PREVENTION,200,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",PROPHYLACTIC LACTOFERRIN DAILY,INCIDENCE OF SARS-COV-2,Efficacy of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19
NCT04427878,Not yet recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,1-Jul-20,9-Jul-21,9-Jul-20,OTHER,5,COVID PATIENTS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOPSIES OF SUBCUTANEOUS ADIPOSE TISSUE,THE PRESENCE OF SARS-COV2 IN ADIPOSE TISSUE OF COVID19 PATIENTS,Is Adipose Tissue a Reservoir for SARS-Cov2 Spread?
NCT04428008,Recruiting,Interventional,Phase 2,Inova Health System,Other,12-Jan-21,22-Jan-21,21-Apr-21,PREVENTION,240,COVID,UNITED STATES,ALL,"60 Years and older   (Adult, Older Adult)",THYMALFASIN,REDUCTION IN DOCUMENTED INFECTION WITH COVID-19 REDUCTION IN INFECTION WITH COVID-19,A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Renal Dialysis Patients
NCT04428021,Recruiting,Interventional,Phase 2,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Other,15-Jun-20,15-Dec-21,15-Jun-21,TREATMENT,180,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD THERAPY PROTOCOL (STP),30-DAYS SURVIVAL,"Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial"
NCT04428073,Not yet recruiting,Interventional,Phase 1,GeneCure Biotechnologies,Industry,20-Jul-21,21-Dec-21,21-Jul-21,TREATMENT,32,COVID,,ALL,18 Years to 60 Years   (Adult),COVAX-19™,TO EVALUATE THE SAFETY OF A THERAPEUTIC COVID-19 VACCINE IN PARTICIPANTS BY MEASURING THE SEVERITY OF LOCAL AND SYSTEMIC ADVERSE EVENTS AND LABORATORY ABNORMALITIES.,A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected Patients
NCT04428099,Recruiting,Interventional,Not Applicable,University of the Balearic Islands,Other,13-Jan-20,12-Jul-22,12-Jan-22,TREATMENT,186,"DEPRESSIVE DISORDER, TREATMENT-RESISTANT",SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",LIFESTYLE CHANGE PROMOTION PROGRAM,DEPRESSION SEVERITY,Effectiveness of a Healthy Lifestyle Promotion Program as Adjunctive Teletherapy for Treatment-resistant Major Depression During Covid 19 Pandemic: A Randomized Clinical Trial Protocol
NCT04428268,Withdrawn,Interventional,Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,Other,10-Mar-20,16-Feb-21,10-Jun-20,TREATMENT,0,COVID PNEUMONIA,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE PHOSPHATE TABLETS,OVERALL MORTALITY,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia"
NCT04428801,Not yet recruiting,Interventional,Phase 2,Celltex Therapeutics Corporation,Industry,10-Jan-21,10-Jan-24,10-Jan-22,TREATMENT,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",AUTOLOGOUS ADIPOSE-DERIVED STEM CELLS,TOLERABILITY AND ACUTE SAFETY OF ADMSC INFUSION BY ASSESSMENT OF THE TOTAL NUMBER OF AES/SAES RELATED AND NON-RELATED WITH THE MEDICATION,Clinical Study for the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus 2019 (COVID-19)
NCT04429334,Not yet recruiting,Interventional,Phase 2,Inotrem,Industry,20-Aug-21,21-Mar-21,21-Mar-21,TREATMENT,60,COVID,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",NANGIBOTIDE,ADVERSE EVENTS,"Exploratory Study of the Safety, Tolerability and Efficacy of Nangibotide in Mechanically Ventilated Patients With COVID-19 and Features of Systemic Inflammation A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features"
NCT04429477,Completed,Observational [Patient Registry],,University of Sao Paulo,Other,1-May-20,31-Jul-20,15-Jul-20,COHORT,50,INTRACRANIAL HYPERTENSION,BRAZIL,ALL,"1 Year and older   (Child, Adult, Older Adult)",CEREBRAL COMPLIANCE AND HEMODYNAMICS MONITORING,DETECTION OF CEREBRAL COMPLIANCE IMPAIRMENT BY THE B4C SENSOR,Assessment of Cerebral Compliance and Hemodynamics in Severe COVID-19
NCT04429529,"Active, not recruiting",Interventional,Phase 1,Tychan Pte Ltd.,Industry,9-Jun-20,21-Feb-21,20-Nov-21,TREATMENT,32,CORONAVIRUS DISEASE-2019 (COVID),SINGAPORE,ALL,21 Years to 50 Years   (Adult),TY027,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AS ASSESSED BY CTCAE V4.0,"Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers"
NCT04429555,Recruiting,Interventional,Phase 2,MediciNova,Industry,11-Jan-21,1-Dec-21,30-Jun-21,TREATMENT,40,"PNEUMONIA, VIRAL",UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",IBUDILAST,PROPORTION OF SUBJECTS FREE FROM RESPIRATORY FAILURE,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome"
NCT04429594,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,28-Jul-20,31-Dec-25,15-Jul-25,BASIC SCIENCE,1000,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,POSITIVE SEROLOGIES,Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement
NCT04429620,Recruiting,Observational,,Szeged University,Other,30-May-20,31-Dec-20,31-Dec-20,CASE-CONTROL,100,SARS-COV2,HUNGARY,ALL,"18 Years and older   (Adult, Older Adult)",IMMUNFLUORESCENCE,SENSITIVITY OF THE METHOD BY SARS-COV2 ELISA COMPARED,Prospective Assay for SARS-CoV-2 Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
NCT04429711,Recruiting,Interventional,Not Applicable,Sheba Medical Center,Other,12-May-20,31-Oct-20,30-Sep-20,TREATMENT,100,COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",IVERMECTIN ORAL PRODUCT,VIRAL CLEARANCE AT DAY 6,"Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial"
NCT04429724,"Active, not recruiting",Interventional,Not Applicable,Tourcoing Hospital,Other,6-Jul-20,21-Dec-21,21-Apr-21,PREVENTION,2129,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC TEST COVID-19,NUMBER OF CONTAMINATED PERSONNEL,Health Professional Exposure Assessment to Covid-19
NCT04429763,Not yet recruiting,Interventional,Phase 2,Trustem,Industry,20-Jul-21,20-Nov-21,20-Sep-21,TREATMENT,30,COVID,,ALL,"18 Years to 79 Years   (Adult, Older Adult)",UMBILICAL CORD DERIVED MESENCHYMAL STEM CELLS,CLINICAL DETERIORATION OR DEATH,Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19
NCT04429815,Not yet recruiting,Observational,,"Central Hospital, Nancy, France",Other,1-Jul-20,1-Apr-21,1-Mar-21,COHORT,489,SMOKING BEHAVIORS,,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TEST FOR COVID-19.,PERCENTAGE OF PATIENTS WITH A POSITIVE SEROLOGICAL TEST FOR COVID-19.,Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19
NCT04429828,Not yet recruiting,Interventional,Not Applicable,University of Nottingham,Other,13-Jun-20,30-Dec-20,30-Sep-20,SUPPORTIVE CARE,45,PSYCHOLOGICAL WELLBEING,,ALL,"Child, Adult, Older Adult",COVID-19 E-PACKAGE: PSYCHOLOGICAL WELLBEING FOR HEALTHCARE WORKERS,QUALITATIVE INTERVIEWS WITH HEALTHCARE STUDENTS,PoWerS Study: Psychological Wellbeing for Healthcare Students: Evaluation of a COVID-19 Digital Learning Package
NCT04429854,"Active, not recruiting",Interventional,Phase 2,Universitaire Ziekenhuizen Leuven,Other,2-May-20,2-Nov-21,1-Mar-21,TREATMENT,483,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,PATIENTS REQUIRING MECHANICAL VENTILATION OR DEATH,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA"
NCT04429867,"Active, not recruiting",Interventional,Phase 4,WellStar Health System,Other,7-May-20,7-Dec-20,7-Dec-20,TREATMENT,700,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,IMPACT OF HYDROXYCHLOROQUINE IN HOSPITALIZED PATIENTS WITH COVID-19 AND RISK FACTORS FOR SEVERE/CRITICAL DISEASE.,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease
NCT04430049,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,22-Jun-20,22-Jan-23,22-Oct-21,CASE-CONTROL,480,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID ICU CONTAINMENT MEASURES,ANXIETY,"Impact of the Restrictive Visiting Policy During the Covid-19 Pandemic on Anxiety, Depression and Post-traumatic Stress Disorder for Relatives of ICU Patients"
NCT04430062,Completed,Observational,,Azienda Socio Sanitaria Territoriale di Lodi,Other,1-May-20,30-May-20,20-May-20,CASE-ONLY,14,GENERAL SURGERY,ITALY,ALL,"Child, Adult, Older Adult",SURGICAL PROCEDURES PERFORMED UNDER GENERAL ANESTHESIA,MORTALITY,Short-term Outcome of Covid-19 Surgical Patients: Case-series of a High-risk Area Community Hospital
NCT04430322,Recruiting,Observational,,Centre Hospitalier Régional Metz-Thionville,Other,1-Mar-20,30-Jun-21,31-Dec-20,OTHER,330,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,ICU ADMISSION,Coronavirus Disease 2019 (Covid-19) at the Regional Hospital Center Metz-Thionville: a Descriptive Study
NCT04430374,Recruiting,Observational [Patient Registry],,Hamad Medical Corporation,Industry,2-Jun-20,31-Dec-20,31-Dec-20,COHORT,100,CARDIOVASCULAR DISEASES,QATAR,ALL,"Child, Adult, Older Adult",NO INTERVERNTION,THE IMPACT OF COVID-19 ON CARDIOVASCULAR PATIENT,Qatar Cardiovascular COVID-19 Registry
NCT04430608,Recruiting,Interventional,Not Applicable,Nordsjaellands Hospital,Other,25-May-20,25-May-21,25-Apr-21,OTHER,72,DIABETES,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",DEXCOM G6,TIME IN RANGE (TIR) FOR BLOOD GLUCOSE,Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring
NCT04431180,Enrolling by invitation,Interventional,Not Applicable,Guangzhou Blood Center,Other,13-Jun-20,30-Jun-20,13-Jun-20,HEALTH SERVICES RESEARCH,403535,BLOOD DONATION,CHINA,ALL,18 Years to 60 Years   (Adult),BLOOD DONATION SMS,BLOOD DONATION RATE,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19#Second Repeat Trial#
NCT04431284,Completed,Observational,,Hospices Civils de Lyon,Other,16-Jun-20,16-Dec-20,16-Dec-20,OTHER,37,FEEDING AND EATING DISORDERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,COMPARISON OF THE BMI (KG/M²) EVOLUTION BETWEEN THE TWO GROUPS,Impact of COVID-19 Lockdown on Severely Obese Patients With or Without Binge Eating Behaviors
NCT04431297,Not yet recruiting,Interventional,Not Applicable,Icahn School of Medicine at Mount Sinai,Other,1-Apr-21,22-Jun-21,30-Jun-21,SUPPORTIVE CARE,30,CHRONIC STRESS,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MINDFULNESS ROUNDS,CHANGE IN PERCEIVED STRESS SCALE,The Impact of Virtual Mindfulness Education Sessions on Staff Perceived Stress During COVID-19
NCT04431310,Recruiting,Observational,,Nordsjaellands Hospital,Other,27-Mar-20,1-Aug-25,1-Aug-25,COHORT,300,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",SERIAL SEROCONVERSION MEASUREMENTS IN HOSPITAL EMPLOYEES DURING THE COVID-19 PANDEMIC,SEROLOGY TESTING FOR SPECIFIC COVID-19,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic
NCT04431414,Recruiting,Observational,,COVID-19 Prevention Network,Other,20-Jul-20,21-Sep-21,21-Sep-21,COHORT,800,SARS-COV2,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLE COLLECTION,RESPONSE RATE OF SARS-COV-2-SPECIFIC B CELLS IN PERIPHERAL BLOOD SAMPLES,A Prospective Study of Acute Immune Responses to SARSCoV-2 Infection
NCT04431453,Recruiting,Interventional,Phase 2/Phase 3,Gilead Sciences,Industry,21-Jul-20,21-Feb-21,21-Feb-21,TREATMENT,52,COVID,ITALY,ALL,"up to 18 Years   (Child, Adult)",REMDESIVIR,PROPORTION OF PARTICIPANTS EXPERIENCING ANY TREATMENT-EMERGENT ADVERSE EVENTS,"A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19"
NCT04431466,Recruiting,Interventional,Phase 2,Universidade Federal de Sao Carlos,Other,1-Jul-20,1-Jul-21,1-Dec-20,TREATMENT,64,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,TIME TO UNDETECTABLE SARS-COV-2 VIRAL LOAD IN THE NASOPHARYNGEAL SWAB.,Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)
NCT04431856,Completed,Interventional,Not Applicable,University of Miami,Other,15-May-20,17-Nov-20,17-Nov-20,PREVENTION,80,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UNIFIED PROTOCOL FOR COVID-19 PARENTING STRESS (UP-COVID),MEASURE OF ANXIETY AS ASSESSED BY THE OASIS,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment
NCT04431869,Recruiting,Observational [Patient Registry],,"University of Colorado, Denver",Other,18-Aug-20,22-Jul-21,22-Jul-21,COHORT,200,PREGNANCY RELATED,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,RATES OF INTESTINAL ATRESIAS AND LIMB ABNORMALITIES,In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers
NCT04431908,Recruiting,Observational,,Yale University,Other,15-Jun-20,1-Oct-20,1-Sep-20,COHORT,250,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OLFACTORY DEVICE,"SENSITIVITY, SPECIFICITY AND ACCURACY",Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
NCT04432038,Recruiting,Observational,,Gdansk University of Physical Education and Sport,Other,19-Jun-20,30-Jun-21,19-Jun-21,COHORT,50000,ADULT,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",,LEVELS OF PHYSICAL ACTIVITY,Healthy Lifestyle or Pro-health Obsession During the Pandemic - a Multinational Study
NCT04432051,Recruiting,Interventional,Not Applicable,Gaziosmanpasa Taksim Research and Education Hospital,Other,26-May-20,10-Aug-20,8-Aug-20,OTHER,100,ULTRASONOGRAPHY,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MECHANICAL VENTILATOR SETTINGS AND POSITION,CHANGE IN PO2 VALUES,The Significance of Lung Ultrasonography in the Follow-up and Treatment of COVID-19 Patients With Respiratory Failure
NCT04432103,Not yet recruiting,Interventional,Phase 3,Centro Medico ABC,Other,19-Jun-20,30-Sep-20,30-Jul-20,TREATMENT,36,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ANTI SARS-COV 2 CONVALESCENT PLASMA IN SEVERE COVID-19 PATIENTS,INCIDENCE OF CRITICAL PNEUMONIA,Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
NCT04432272,"Active, not recruiting",Interventional,Phase 2,William Beaumont Hospitals,Other,16-Jul-20,21-Aug-21,21-Jun-21,TREATMENT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,AVOIDANCE OF INTUBATION AT 28 DAYS (GROUP A),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
NCT04432298,Recruiting,Interventional,Phase 2,FibroGen,Industry,20-Jun-20,21-Jan-21,20-Dec-21,TREATMENT,130,COVID,UNITED STATES,ALL,"40 Years to 85 Years   (Adult, Older Adult)",PAMREVLUMAB,PROPORTION OF SUBJECTS WHO NEVER RECEIVED MECHANICAL VENTILATION AND/OR ECMO AND ALIVE,"Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease"
NCT04432324,"Active, not recruiting",Interventional,Phase 2,"Instituto Grifols, S.A.",Industry,2-Jun-20,21-Mar-21,21-Feb-21,TREATMENT,100,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",INTRAVENOUS IMMUNE GLOBULIN,PERCENTAGE OF PARTICIPANTS DYING OR REQUIRING ICU ADMISSION,"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19"
NCT04432350,Not yet recruiting,Observational,,Tabula Rasa HealthCare,Industry,15-Jun-20,31-May-21,31-Dec-20,COHORT,50000,COVID,,ALL,"Child, Adult, Older Adult",,THE RATE OF MORTALITY IN PATIENTS WITH A CONFIRMED (POSITIVE TEST RESULT) COVID-19 INFECTION OBSERVED BY PRESCRIBEWELLNESS PHARMACIES WILL BE DETERMINED.,Assessment of Mortality Rates in SARS-CoV-2 Infected Populations Treated With Repurposed Medications
NCT04432766,Not yet recruiting,Interventional,Phase 1/Phase 2,Bio-Thera Solutions,Industry,20-Oct-20,18-Aug-21,20-Jan-21,TREATMENT,174,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BAT2020,INCIDENCE OF ADVERSE EVENTS (AES),"A Phase 1/2, Multi-Center, Randomized Study to Assess Safety, Pharmacokinetics, Immunogenicity, and Efficacy of BAT2020 in Hospitalized Patients Infected With SARS-CoV-2 (COVID-19)"
NCT04432779,Recruiting,Observational,,Centre Hospitalier Universitaire Saint Pierre,Other,25-May-20,24-Jun-21,24-Jun-21,COHORT,3000,PREGNANCY,BELGIUM,ALL,"Child, Adult, Older Adult",NO INTERVENTION,OUTCOME OF PREGNANCY,Impact of SARS-CoV-2 Infection During Pregnancy on Newborns and Young Children
NCT04432805,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,15-Jun-20,15-Jun-21,15-Jun-21,DIAGNOSTIC,160,PREGNANT WOMEN SUSPECTED OF COVID,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",PERFORMING OF LUNG ULTRASOUND,DESCRIPTION OF THE LESIONS,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19
NCT04432870,Enrolling by invitation,Observational,,Massachusetts General Hospital,Other,9-Jun-20,30-Jun-21,30-May-21,OTHER,200,COLON CANCER,UNITED STATES,ALL,"45 Years to 75 Years   (Adult, Older Adult)",,INTEREST IN COLON CANCER SCREENING,Patients' Preferences About Rescheduling Colonoscopies Delayed Due to COVID-19: Cross Sectional Study
NCT04432922,Completed,Observational,,Centre Hospitalier Intercommunal Creteil,Other,1-Nov-20,15-Nov-20,15-Nov-20,OTHER,15,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITALIZED PATIENTS FOR COVID-19 INFECTION,"TO HIGHLIGHT THE PERCEPTIONS, REPRESENTATIONS AND EXPERIENCES OF SEPTIC ISOLATION OF PATIENTS HOSPITALIZED FOR COVID-19 INFECTION","Perceptions, Representations and Experiences of Septic Isolation of Hospitalized"
NCT04432948,Recruiting,Observational,,General and Maternity Hospital of Athens Elena Venizelou,Other,15-May-20,20-Dec-21,20-Aug-21,OTHER,200,COVID,GREECE,FEMALE,"18 Years and older   (Adult, Older Adult)",PHQ-9 DEPRESSION SCALE,ASSOCIATION BETWEEN COVID-19 PANDEMIC AND MATERNAL PSYCHOLOGICAL DISTRESS,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.
NCT04432961,Not yet recruiting,Observational,,Cambridge University Hospitals NHS Foundation Trust,Other,20-Jul-21,21-Jul-21,20-Sep-21,CASE-ONLY,200,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,RESEARCH DATABASE OF EHR RECORDS FROM COVID-19 PATIENTS PROCESSED USING NLP TOOLS FOR NAMED ENTITY RECOGNITION AND LINKING ADAPTED TO CUH EMR DATA TO IDENTIFY VARIABLES OF INTEREST,A Database and Analytics Study of Free Text Clinical Notes and Structured Data to Investigate Phenotype Associations With Outcomes in Patients With COVID-19
NCT04432987,Recruiting,Interventional,Phase 2,Acibadem University,Other,25-May-20,25-Sep-20,25-Aug-20,TREATMENT,60,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",PULMOZYME,RESPONSE,Determination of Dornase Alpha Effectiveness in COVID-19 Treatment
NCT04433000,Recruiting,Observational,,University of Siena,Other,15-Mar-20,10-Jun-20,10-Jun-20,CASE-ONLY,34,COVID PNEUMONIA,ITALY,ALL,"Child, Adult, Older Adult",BUTTERFLY,BLAND-ALTMAN ESTIMATE OF BIAS AND LIMITS OF AGREEMENT (LOA) OF PATIENT MEAN SCORES OBTAINED WITH THE TWO INSTRUMENTS,Comparison Between a Pocket Sized and a High End Ultrasound Scanner in the Evaluation of Lung Involvement in Patients With Covid-19 Pneumonia
NCT04433013,Not yet recruiting,Interventional,Phase 3,Nanyang Technological University,Other,20-Jul-21,21-Feb-21,20-Dec-21,TREATMENT,300,COVID,,ALL,"21 Years and older   (Adult, Older Adult)",LIANHUA QINGWEN,PROPORTION OF PARTICIPANTS WHO TEST NEGATIVE FOR COVID-19,A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
NCT04433026,Not yet recruiting,Observational,,Assiut University,Other,20-Aug-21,1-Sep-21,1-Jul-21,CASE-ONLY,90,COVID,,ALL,"Child, Adult, Older Adult","N TERMINAL PRO B TYPE NATRIURETIC PEPTIDE (NTPROBNP), D-DIMER, AND SERUM TROPININ - I","MEASUREMENT OF N-TERMINAL PRO-B TYPE NATRIURETIC PEPTIDE, TROPONIN-I AND D-DIMER IN COVID-19 PATIENTS","B-natriuretic Peptide (BNP), Serum Troponin-I, and D-dimer as Risk Factors for In-hospital Death in Patients With COVID-19"
NCT04433039,Completed,Observational,,Alexandria University,Other,22-May-20,14-Jun-20,12-Jun-20,CASE-CROSSOVER,130,COVID,EGYPT,ALL,"4 Years to 80 Years   (Child, Adult, Older Adult)",,COVID19 VERSUS H1N1; RADIOLOGICAL COMPARATIVE STUDY,COVID-19 Versus H1N1 Viral Pneumonia: A Retrospective Comparative Study for Spectrum of HRCT Findings Among 130 Patients
NCT04433078,Recruiting,Interventional,Phase 2,Temple University,Other,22-Jun-20,21-Jul-21,21-Jan-21,TREATMENT,20,CYTOKINE STORM,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DOXYCYCLINE,"TIME FREE OF EITHER HOSPITALIZATION, HYPOXEMIA, ICU ADMISSION OR DEATH",RepurpoSing Old Drugs TO SuppRess a Modern Threat: The STORM Trial
NCT04433260,Recruiting,Observational,,Queen Mary University of London,Other,25-Jul-20,21-Sep-21,21-May-21,COHORT,1050,MENTAL HEALTH,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)","QUESTIONNAIRE INCLUDING VALIDATED TOOLS SUCH AS PATIENT HEALTH QUESTIONNAIRE (PHQ-9), THE 7-ITEM GENERALISED ANXIETY DISORDER (GAD- 7), THE 7-ITEM INSOMNIA SEVERITY INDEX",PRESENCE OF ANXIETY AT BASELINE,"Immediate and Mid-term Implications of the Covid-19 Pandemic on the Physical, Behavioural and Mental Health of Healthcare Workers: A Cohort Study of Doctor, Nurses and Other Health Care Workers"
NCT04433286,Not yet recruiting,Observational,,Mansoura University,Other,15-Jun-20,31-Aug-20,31-Jul-20,OTHER,1000,PHYSICAL STRESS,EGYPT,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,CHANGE IN BURNOUT BEFORE COVID-19 AND DURING COVID-19,COVID-19 - Implications on Surgeons' Burnout and Career Satisfaction
NCT04433312,Not yet recruiting,Observational [Patient Registry],,Mansoura University,Other,1-Jul-20,1-Dec-20,30-Oct-20,OTHER,10000,"SATISFACTION, PATIENT",EGYPT,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,QUALITY OF LIFE OF THE PATIENTS,Impact of Cancellation of Non-urgent Surgical Cases on Patients During the COVID-19 Pandemic
NCT04433325,Not yet recruiting,Observational,,Rennes University Hospital,Other,20-Jun-21,20-Sep-21,20-Jul-21,CASE-CONTROL,150,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF DEATH,COVID-19 Critically Ill Patients' Evolution After Medical Transport by Train From Paris Intensive Care Units to West of France Intensive Care Units
NCT04433364,Recruiting,Observational [Patient Registry],,"Sahlgrenska University Hospital, Sweden",Other,2-Jun-20,2-Jun-41,2-Jun-21,COHORT,1200,SARS-COV2,SWEDEN,FEMALE,"18 Years and older   (Adult, Older Adult)","BIOLOGICAL SAMPLES, QUESTIONNAIRES AND INTERVIEWS",BIOBANK WITH LINKAGE TO REGISTERS,COPE - COVID-19 in Pregnancy and Early Childhood - a Study Protocol for a Prospective Multicentre Cohort Study
NCT04433546,Terminated,Interventional,Phase 2,PhaseBio Pharmaceuticals Inc.,Industry,15-Jul-20,2-Dec-20,2-Dec-20,TREATMENT,54,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",PEMZIVIPTADIL (PB1046),TIME TO CLINICAL RECOVERY FROM INITIATION OF PEMZIVIPTADIL (PB1046),"A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)"
NCT04433754,Completed,Observational,,Uşak University,Other,1-Mar-20,12-Jun-20,11-Jun-20,CASE-CONTROL,500,PANCREATITIS,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",BIOCHEMICAL ANALYSIS,TO COMPARE PRESENCE OF FEVER IN PATIENTS WITH AND WITHOUT PANCREATIC INJURY,Pancreatic Injury in Patients With COVID-19 Disease
NCT04433871,Recruiting,Observational [Patient Registry],,"University Hospital, Caen",Other,27-Apr-20,27-Apr-23,27-Apr-22,COHORT,300,COVID,FRANCE,ALL,"1 Month to 30 Years   (Child, Adult)","NO INTERVENTION, OBSERVATIONAL",ONCOLOGIC DATA,National SFCE Cohort of SARS-CoV-2 Infections (COVID-19) in Pediatric Oncology and Hematology
NCT04433910,"Active, not recruiting",Interventional,Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,Other,30-Aug-20,22-Feb-21,21-Jan-21,TREATMENT,106,COVID,GERMANY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CONVALESSCENT PLASMA,COMPOSITE ENDPOINT OF SURVIVAL AND NO LONGER FULFILLING CRITERIA OF SEVERE COVID-19.,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19"
NCT04433949,Recruiting,Interventional,Phase 3,Emory University,Other,12-Jun-20,30-May-22,30-May-22,TREATMENT,52,PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEST PRACTICE,TIME TO CLINICAL RECOVERY,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19): A Randomized Phase III of Best Supportive Care +/- Whole Lung Low-Dose Radiation Therapy in Hospitalized Patients
NCT04433988,Not yet recruiting,Interventional,Phase 1/Phase 2,Sadat City University,Other,13-Jun-21,30-Dec-21,30-Dec-21,TREATMENT,200,COVID,EGYPT,ALL,18 Years to 60 Years   (Adult),PENTOXIFYLLINE,PRIMARY OUTCOME,Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
NCT04434014,Recruiting,Observational,,October University for Modern Sciences and Arts,Other,8-Jun-20,28-Jun-20,18-Jun-20,ECOLOGIC OR COMMUNITY,300,"DIET, HEALTHY",EGYPT,ALL,20 Years to 60 Years   (Adult),PROPER DIET,REGENERATION OF TASTE,Proper Nutrition and Its Relationship to Oral Diseases in the Era of Corona
NCT04434118,Enrolling by invitation,Observational,,Sadat City University,Other,20-Mar-20,30-Dec-21,30-Dec-21,CASE-CONTROL,600,RHEUMATOID ARTHRITIS,EGYPT,ALL,18 Years to 60 Years   (Adult),TRADITIONAL ANTIRHEUMATIC DRUGS,THE RISK OF COVID-19 INFECTION AMONG RA PATIENTS,"Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study"
NCT04434131,Recruiting,Interventional,Phase 2,University of New Mexico,Other,28-Apr-20,28-Apr-25,28-Apr-21,PREVENTION,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,CORRELATION BETWEEN THE NAB DOSE TITER IN THE CONVALESCENT PLASMA AND CHANGE OR LACK OF CHANGE WHEN COMPARING PRE-TREATMENT AND DAY ONE NAB TITERS TO INPATIENTS WITH DOCUMENTED COIVD-19 INFECTION,"Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19"
NCT04434144,Completed,Observational [Patient Registry],,"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar",Other,2-May-20,5-Jun-20,5-Jun-20,CASE-ONLY,116,IVERMECTIN,BANGLADESH,ALL,"16 Years to 80 Years   (Child, Adult, Older Adult)",IVERMECTIN + DOXYCYCLINE,"NUMBER OF PARTICIPANTS WITH ""TREATMENT SUCCESS"" DETERMINE BY A NEGATIVE RT PCR FOR COVID19.",A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
NCT04434157,Completed,Observational,,Hospital Regional de Alta especialidad de Ixtapaluca,Other,28-Mar-20,5-May-20,5-May-20,COHORT,221,COVID,MEXICO,ALL,"Child, Adult, Older Adult",,CLINICAL COMPLICATIONS AND MORTALITY,Association of the Neutrophil/Lymphocyte Ratio and Lymphocyte /Platelet Ratio With Clinical Complications and Mortality in COVID-19 Patients
NCT04434248,"Active, not recruiting",Interventional,Phase 2/Phase 3,Chromis LLC,Industry,23-Apr-20,20-Jul-21,20-Jul-21,TREATMENT,330,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,"RATE OF VIRAL ELIMINATION BY DAY 10 [PILOT STAGE, DOSE SELECTION]","An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19"
NCT04434261,"Active, not recruiting",Observational,,Instituto Brasileiro de Controle do Cancer,Other,11-May-20,31-Dec-20,31-Dec-20,COHORT,1500,SARS-COV2,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",PT-PCR TEST FOR SARS-COV-2,"INCIDENCE OF PATIENTS WITH A POSITIVE TEST FOR SARS-COV-2, DETECTED IN THE PREOPERATIVE SCREENING PROGRAM",Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2
NCT04434417,Recruiting,Observational,,European Institute of Oncology,Other,15-Apr-20,31-Dec-21,31-Jul-21,COHORT,1000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",2019-NCOV IGG/IGM RAPID TEST CASSETTE,EVALUATION OF THE RATE OF SARS-COV-2 POSITIVE CANCER PATIENTS AND HEALTH PROFESSIONALS IN A COMPREHENSIVE CANCER CENTER OR IN A CANCER SETTING.,"Clinical Validation of a Simple and Fast Immunochromatographic Assay for Qualitative Determination of Specific ImmunoGLObulin IgG/IgM Antibodies to 2019- nCoV in Whole bLood, Serum or Plasma Specimen"
NCT04435015,Not yet recruiting,Interventional,Phase 1/Phase 2,Yale University,Other,1-Feb-21,30-Jul-21,30-Jul-21,TREATMENT,200,COAGULOPATHY,,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESYLATE,PERCENT CHANGE IN PLASMA D-DIMER,The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
NCT04435028,Completed,Observational,,Horus University,Other,14-Jan-19,13-Aug-19,13-Aug-19,OTHER,111,BREAST CANCER,EGYPT,FEMALE,30 Years to 60 Years   (Adult),KETOTIFEN 1 MG,PROPHYLAXIS EFFECT OF KETOTIFEN ON PATIENT'S HEARTS DURING THE TREATMENT OF ANTHRACYCLINES,Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19
NCT04435041,"Active, not recruiting",Observational [Patient Registry],,University of Oxford,Other,1-Jun-20,30-Nov-21,31-May-21,OTHER,1,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",,RECAP EARLY WARNING SCORE,"Remote-by-Default Care in the COVID-19 Pandemic: Addressing the Micro-, Meso-, and Macro-level Challenges of a Radical New Service Model"
NCT04435080,Completed,Observational,,Koç University,Other,15-Mar-20,11-Jun-20,11-Jun-20,COHORT,35,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,HAND GRIP STRENGTH,Physical Rehabilitation in Intensive Care Unit in Acute Respiratory Distress Syndrome Patients With COVID-19
NCT04435106,Completed,Observational,,Shaare Zedek Medical Center,Other,3-Apr-20,15-May-20,1-May-20,CASE-CONTROL,23,CORONAVIRUS INFECTION,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",OPAGANIB,MEASURE THE TIME TO WEANING FROM HIGH-FLOW NASAL CANNULA,Compassionate Use of Opaganib in Patients With Severe COVID-19
NCT04435119,Completed,Observational,,"University Hospital, Angers",Other,15-Mar-20,15-May-20,15-May-20,COHORT,96,CORONAVIRUS,FRANCE,ALL,70 Years and older   (Older Adult),,"NUMBER OF DEATHS OF ANY CAUSE IN NURSING-HOME RESIDENTS WITH SARS-COV-2 INFECTION, DEPENDING ON THE USE OF BOLUS VITAMIN D3 SUPPLEMENTATION DURING OR JUST BEFORE COVID-19",COvid-19 et VITamine d en EHPAD
NCT04435184,Completed,Interventional,Phase 2,Johns Hopkins University,Other,9-Jul-20,4-Jan-21,28-Nov-20,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CRIZANLIZUMAB,SOLUBLE P-SELECTIN LEVEL,Crizanlizumab for Treating COVID-19 Vasculopathy
NCT04435223,Completed,Observational,,Centre Hospitalier Universitaire Dijon,Other,7-Apr-20,7-May-20,7-May-20,COHORT,62,COVID SEVERE PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL ASSAYS IN PARTICULAR ON THE LIPID METABOLISM,CHOLESTEROL CONCENTRATION,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen
NCT04435275,Recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,2-Jan-21,1-May-21,31-Mar-21,OTHER,50,COVID,CANADA,ALL,"18 Years to 80 Years   (Adult, Older Adult)","VIRTUAL ASSISTANT FIRST, THEN HUMAN COACH",PERFORMANCE OF HEALTHCARE WORKERS,Development of an Automated and Scalable Virtual Assistant to Aid in PPE Adherence and Clinical Protocols for Healthcare Worker Safety
NCT04435314,Not yet recruiting,Interventional,Phase 2,Azidus Brasil,Industry,20-Jun-21,20-Aug-21,20-Aug-21,PREVENTION,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE,THE PROPORTION OF SUBJECTS WITH LABORATORY-CONFIRMED COVID-19 IDENTIFIED AFTER START OF TREATMENT AND BEFORE THE END OF THE STUDY,"Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities"
NCT04435327,Recruiting,Observational,,University of Milano Bicocca,Other,17-Aug-20,21-Apr-21,21-Apr-21,COHORT,300,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,"REDUCTION OF DIFFUSION OF LUNG CO (DLCO, SINGLE BREATH TECHNIQUE)",SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia
NCT04435353,Recruiting,Interventional,Not Applicable,Astana Medical University,Other,22-Mar-20,1-Feb-21,31-Dec-20,TREATMENT,200,RESPIRATORY DISTRESS SYNDROME,KAZAKHSTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",VIBROLUNG,RECOVERY RESPIRATORY FAIL,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19
NCT04435379,"Active, not recruiting",Interventional,Phase 3,Vakzine Projekt Management GmbH,Industry,18-Jun-20,30-Sep-21,30-Sep-21,PREVENTION,2038,"INFECTION, RESPIRATORY TRACT",GERMANY,ALL,"60 Years and older   (Adult, Older Adult)",VPM1002,NUMBER OF DAYS WITH SEVERE RESPIRATORY DISEASE AT HOSPITAL AND/OR AT HOME,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System"
NCT04435457,Recruiting,Observational [Patient Registry],,University of Texas Southwestern Medical Center,Other,1-Sep-20,30-Jun-21,30-Jun-21,COHORT,70,SARS-COV2,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,PREVALENCE OF MYOCARDITIS,Uncovering the Cardiac Phenotype of Individuals With SARS-COV-2 and Cardiac Injury
NCT04435522,Completed,Interventional,Phase 1,Rhode Island Hospital,Other,1-Oct-20,31-Dec-20,31-Dec-20,TREATMENT,9,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",MARAVIROC,RATE OF COMPLETION,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2
NCT04435587,Recruiting,Interventional,Phase 4,Mahidol University,Other,13-Jul-20,21-Nov-21,21-Jun-21,TREATMENT,80,ASYMPTOMATIC INFECTIONS,THAILAND,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN PILL,ADVERSE EVENT RATES,Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection
NCT04435717,Recruiting,Interventional,Phase 2,Hospital Universitario Ramon y Cajal,Other,4-May-20,4-Aug-20,4-Aug-20,TREATMENT,78,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB 20 MG/ML INTRAVENOUS SOLUTION [ACTEMRA]_#1,CHANGE IN IL-12 VALUES IN THE 3 STUDY GROUPS FROM THE START OF TREATMENT (D0) AND ON DAYS D + 1 AND D + 3.,"Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19"
NCT04435795,Recruiting,Interventional,Phase 2/Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,14-Sep-20,25-Mar-21,25-Feb-21,TREATMENT,454,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",NORMAL SALINE INTRANASAL,"PROPORTION OF PARTICIPANTS WITH NO SYMPTOMS OF COUGH, FEVER OR DYSPNEA",Ciclesonide Clinical Trial for COVID-19 Treatment
NCT04435808,Terminated,Interventional,Phase 1/Phase 2,University of New Mexico,Other,14-Apr-20,15-Jul-20,15-Jul-20,PREVENTION,1,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,SARS-COV-2 INFECTION,Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2
NCT04436276,"Active, not recruiting",Interventional,Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,Industry,15-Jul-20,2-Feb-24,3-Dec-21,OTHER,1085,HEALTHY,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",AD26.COV2.S,"COHORTS 1, 2, AND 3: NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL ADVERSE EVENTS (AES) FOR 7 DAYS AFTER FIRST VACCINATION","A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older"
NCT04436458,Not yet recruiting,Interventional,Phase 2,"First Wave Bio, Inc.",Industry,21-Jun-21,21-Dec-21,21-Aug-21,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE ORAL TABLET,"THE PRIMARY ENDPOINT IS THE RATE OF FAECAL SARS-COV-2 VIRUS CLEARANCE (RECTAL SWAB OR STOOL SAMPLE) ASSESSED BY RT-PCR IN THE NICLOSAMIDE GROUP, COMPARED TO THE PLACEBO GROUP","Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms"
NCT04436471,Completed,Interventional,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,17-Jun-20,10-Aug-20,3-Aug-20,PREVENTION,38,PREVENTIVE IMMUNIZATION COVID,RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),GAM-COVID-VAC,CHANGING OFANTIBODY LEVELS AGAINST THE SARS-COV-2 GLYCOPROTEIN S IN 42 DAYS,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers"
NCT04436484,Recruiting,Observational,,University Hospital Plymouth NHS Trust,Other,29-Apr-20,19-Feb-21,19-Feb-21,COHORT,200,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PERIPHERAL BLOOD SAMPLING,MORTALITY,Immune Dysfunction in COVID-19: Investigation of Mechanisms and Identification of Immune Biomarkers of Clinical Outcome
NCT04437121,Completed,Observational,,University of Thessaly,Other,30-Apr-20,24-May-20,24-May-20,CASE-CROSSOVER,397,EATING BEHAVIOR,GREECE,ALL,"24 Months to 18 Years   (Child, Adult)",ONLINE SURVEY ABOUT DIETARY AND LIFESTYLE HABITS,CHANGE IN WEIGHT (CHILD),Dietary and Lifestyle Habits of Children and Adolescents and Their Parents During the Pandemic of COVID-19 in Greece: The COV-EAT Study
NCT04437342,Completed,Observational,,General and Maternity Hospital of Athens Elena Venizelou,Other,30-Jun-20,27-Oct-20,30-Aug-20,OTHER,330,POSTPARTUM DEPRESSION,GREECE,FEMALE,"18 Years and older   (Adult, Older Adult)",PHQ-9 (PATIENT HEALTH QUESTIONNAIRE) DEPRESSION SCALE,CORRELATION BETWEEN THE COVID-19 PANDEMIC AND POSTPARTUM DEPRESSION WITH EPDS SCALE (EDINBURGH POSTNATAL DEPRESSION SCALE),Postpartum Depression in the Covid-19 Pandemic and the Impact of Anaesthesia
NCT04437693,Not yet recruiting,Interventional,Phase 2/Phase 3,Hamad Medical Corporation,Industry,31-Aug-20,31-Dec-21,30-Aug-21,PREVENTION,500,COVID,,ALL,18 Years to 60 Years   (Adult),HYDROXYCHLOROQUINE,PREVENTION OF SARS-COV-2 INFECTION,Post Exposure Prophylaxis (PEP) in Healthcare Workers Exposed to COVID-19 Patients: A Double-blind Randomized Clinical Trial
NCT04437706,Enrolling by invitation,Observational,,Duke University,Other,11-Dec-20,30-Jun-22,30-Jun-22,ECOLOGIC OR COMMUNITY,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PARTICIPANTS WITH ACTIVE INFECTION,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
NCT04437719,Recruiting,Interventional,Not Applicable,Groupe Hospitalier Paris Saint Joseph,Other,29-Jun-20,31-Dec-21,29-Dec-21,OTHER,100,ONCOLOGY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OBVIO-19 APP,COVID-19 INFECTION'S SYMPTOMS,"Longitudinal Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group, Paris, France for a Period of 6 Months During the COVID-19 Pandemic in 2020"
NCT04437823,Recruiting,Interventional,Phase 2,Jinnah Hospital,Other,1-Jun-20,30-Jun-21,31-May-21,TREATMENT,20,CORONAVIRUS INFECTION,PAKISTAN,ALL,"30 Years to 70 Years   (Adult, Older Adult)",INTRAVENOUS INFUSIONS OF STEM CELLS,SAFETY AND EFFICACY ASSESSMENT OF INFUSION ASSOCIATED ADVERSE EVENTS,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients
NCT04437875,Completed,Interventional,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,17-Jun-20,10-Aug-20,3-Aug-20,PREVENTION,38,PREVENTIVE IMMUNIZATION COVID,RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),GAM-COVID-VAC LYO,THE CHANGING OF ANTIBODY LEVELS AGAINST THE SARS-COV-2 GLYCOPROTEIN S AT 42 DAYS,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers"
NCT04437901,Not yet recruiting,Observational [Patient Registry],,Hospital Clinic of Barcelona,Other,20-Jun-21,21-Dec-21,20-Dec-21,COHORT,10000,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",,ARRHYTHMIA,COVIDAR - International Registry on Arrhythmias in COVID-19
NCT04437940,Completed,Observational,,Acibadem University,Other,15-Jun-20,30-Nov-20,10-Jul-20,COHORT,38,COVID,TURKEY,FEMALE,"18 Years to 70 Years   (Adult, Older Adult)",VAGINAL FLUID COVID-19 PCR TEST,VAGINAL FLUID COVID-19 PCR TEST RESULT,Evaluation of Vaginal Fluid for Covid-19 Positivity
NCT04438057,Recruiting,Interventional,Phase 2,Metro Infectious Disease Consultants,Other,12-Aug-20,12-Aug-21,12-Aug-20,TREATMENT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CCP,TIME TO RESOLUTION OF SYMPTOMS,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
NCT04438070,Recruiting,Interventional,Not Applicable,St. Joseph's Healthcare Hamilton,Other,10-Apr-20,20-Jun-21,20-Jun-21,SCREENING,400,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 SWAB,COVID-19 DETECTION RATE,COVID Screening Strategies in Homeless Shelters
NCT04438239,Completed,Observational,,Azienda Unità Sanitaria Locale Reggio Emilia,Other,22-Jun-20,31-Dec-20,31-Dec-20,OTHER,150,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)","NONE, THIS STUDY IS OBSERVATIONAL","NUMBER OF PARTICIPANTS WITH CONSIDERABLE DYSPNEA: MEDICAL RESEARCH COUNCIL (MRC, 0-4, LOWER SCORE BETTER OUTCOME)",Rehabilitation Needs After COVID-19 Hospital Treatment (REACT): an Observational Study
NCT04438629,Recruiting,Observational,,Azienda Ospedaliera Universitaria Integrata Verona,Other,26-Mar-20,26-Nov-20,10-Jun-20,COHORT,80,ALLERGY AND IMMUNOLOGY,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",COVID-19 TREATMENT,COVID-19 ASSOCIATED IMMUNE DISORDER,Evaluation of Immune Response in COVID-19 Patients
NCT04438694,Recruiting,Interventional,Phase 1/Phase 2,Cairo University,Other,1-Jun-20,31-Dec-21,31-May-21,TREATMENT,67,COVID,EGYPT,ALL,"21 Years to 70 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,DURATION OF HOSPITALIZATION/RECOVERY STATUS,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection
NCT04438837,Not yet recruiting,Interventional,Not Applicable,Rambam Health Care Campus,Other,20-Jul-21,22-Jun-21,22-Jun-21,PREVENTION,582,CORONAVIRUS DISEASE 2019 (COVID),ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,CLINICAL COVID-19,Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial
NCT04438850,Recruiting,Interventional,Phase 2,IRCCS Sacro Cuore Don Calabria di Negrar,Other,31-Jul-20,21-May-21,21-Feb-21,TREATMENT,102,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,SADR,"Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19"
NCT04438863,Recruiting,Observational,,Sheba Medical Center,Other,8-Aug-20,1-Sep-21,1-Sep-21,COHORT,90,COVID,ISRAEL,ALL,"18 Years to 85 Years   (Adult, Older Adult)",HOME SPIROMETRY,HOSPITALIZATION,A Descriptive Pilot Study of Daily Home Spirometry for Early Detection of Pulmonary Complications in High Risk Patients With COVID19
NCT04438941,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,25-Mar-20,20-Jun-20,20-Jun-20,CASE-ONLY,100,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ANALYSIS OF THE EFFECT OF PRONE POSITION IN PATIENTS WITH COVID-19 IN INTENSIVE CARE,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic
NCT04438954,Completed,Observational,,Ankara Yildirim Beyazıt University,Other,5-May-20,18-Jun-20,5-Jun-20,CASE-ONLY,30,MULTIPLE SCLEROSIS,TURKEY,ALL,21 Years to 58 Years   (Adult),,FATIGUE,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels of Multiple Sclerosis Patients in the COVID-19 Pandemic"
NCT04438967,Recruiting,Observational,,Miro Health,Other,16-Jun-20,31-Dec-21,31-Dec-21,COHORT,10000,BRAIN HEALTH,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,TEST THE HYPOTHESIS THAT COVID-19 INFECTION WILL LEAD TO INCREASED RISK OF NEUROLOGICAL IMPAIRMENT,Brain Health in the Time of COVID-19
NCT04438980,Recruiting,Interventional,Phase 3,Fundacion Miguel Servet,Other,15-May-20,21-Feb-21,20-Dec-21,TREATMENT,72,COVID PNEUMONIA,SPAIN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",METHYLPREDNISOLONE,PROPORTION OF PATIENTS DEVELOPING TREATMENT FAILURE,Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial
NCT04438993,Recruiting,Observational,,NHS Lanarkshire,Other,29-May-20,20-Nov-21,20-Oct-21,COHORT,100,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,CARDIAC ABNORMALITIES IN COVID-19 DISEASE IN-PATIENTS,"An Observational Study of Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) to Determine the Degree of Myocardial Injury Using Biomarkers and Echocardiography, and the Impact of This on Cardiovascular Outcomes"
NCT04439006,Recruiting,Interventional,Phase 2,Jennifer Woyach,Other,22-Jul-20,31-Dec-22,31-Dec-21,TREATMENT,72,APLASTIC ANEMIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEST PRACTICE,PROPORTION OF PATIENTS WITH DIMINISHED RESPIRATORY FAILURE AND DEATH,Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
NCT04439045,Recruiting,Interventional,Phase 3,"University Health Network, Toronto",Other,24-Jun-20,1-Jul-21,1-Apr-21,PREVENTION,3626,SARS-COV2 INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VPM1002,COVID-19 INFECTION,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity"
NCT04439071,Recruiting,Interventional,Phase 2/Phase 3,PTC Therapeutics,Industry,9-Jul-20,31-Jul-21,31-Jul-21,TREATMENT,380,PNEUMONIA,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",PTC299,TIME FROM RANDOMIZATION TO RESPIRATORY IMPROVEMENT,Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)
NCT04439084,Enrolling by invitation,Observational,,Stanford University,Other,6-Mar-20,21-Jun-21,21-Jun-21,COHORT,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE CHART REVIEW,ALL-CAUSE MORTALITY,COVID-19 in Patients With Chronic Liver Diseases
NCT04439825,Not yet recruiting,Interventional,Phase 1,DeNova Research,Other,15-Jul-20,15-Oct-20,15-Sep-20,TREATMENT,45,MOOD,UNITED STATES,ALL,"10 Years to 75 Years   (Child, Adult, Older Adult)",BOTULINUM NEUROTOXIN,SELF- PERCEPTION OF MOOD BEFORE TREATMENT AND AFTER ACHIEVING AN OPTIMAL COSMETIC RESULT AS DETERMINED BY THE PI.,Randomized Controlled Single Blind Cross Over Trial Evaluating the Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction in a Post Covid Period.
NCT04440007,Recruiting,Interventional,Phase 2,"Sorrento Therapeutics, Inc.",Industry,9-Oct-20,21-May-21,21-Mar-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ABIVERTINIB,PROPORTION OF SUBJECTS ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 28,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19"
NCT04440098,Completed,Observational,,University of Miami,Other,22-Apr-20,11-May-20,11-May-20,CASE-ONLY,1008,LONELINESS,UNITED STATES,ALL,18 Years to 35 Years   (Adult),,LONELINESS AS EVALUATED BY THE UCLA LONELINESS SCALE,Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology
NCT04441047,Not yet recruiting,Interventional,Phase 1/Phase 2,"Immunovative Therapies, Ltd.",Industry,6-Mar-21,31-Dec-22,7-Mar-22,PREVENTION,40,VIRUS DISEASES,UNITED STATES,ALL,65 Years and older   (Older Adult),ALLOSTIM,FREQUENCY OF VACCINE EVENTS,Safety and Efficacy of ALLOSTIM® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly Adults
NCT04441372,Recruiting,Observational [Patient Registry],,"Medecins Sans Frontieres, Spain",Other,1-Oct-20,1-May-21,1-May-21,COHORT,600,SARS-COV2,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",,CLINICAL AND BIOCHEMICAL PROGNOSTIC MARKERS,Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
NCT04441385,Recruiting,Interventional,Phase 2,Hospital Universitario Infanta Leonor,Other,26-Jun-20,20-Dec-20,30-Nov-20,TREATMENT,200,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MARAVIROC 300 MG,PROPORTION OF PATIENTS DEVELOPING SEVERE ARDS.,"Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19)."
NCT04441398,Not yet recruiting,Interventional,Phase 2/Phase 3,Azidus Brasil,Industry,20-Jul-21,20-Sep-21,20-Sep-21,TREATMENT,300,COVID,,ALL,"50 Years and older   (Adult, Older Adult)",NITAZOXANIDE,CHANGE IN SIGNS AND SYMPTOMS SCALE,"Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJ"
NCT04441424,Completed,Interventional,Not Applicable,Alkarkh Health Directorate-Baghdad,Other,3-Apr-20,1-Jun-20,1-Jun-20,TREATMENT,49,IMMUNOTHERAPY,IRAQ,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,DEATH VERSUS SURVIVAL OF TREATED PATIENTS,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq"
NCT04441476,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire Dijon,Other,21-Apr-20,21-Nov-21,21-Jul-21,COHORT,3000,PSYCHOLOGICAL STRAIN,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,PS-ICU SCALE SCORE,Ethical and Psychological Support for Health Care Professions in Intensive Care Units in the COVID19 Pandemic Context: Adequacy With Needs and Psychological Impact Crisis and Post-crisis
NCT04441489,Completed,Observational,,Centre Hospitalier Princesse Grace,Other,27-Mar-20,27-May-20,3-May-20,CASE-ONLY,13,COVID,MONACO,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,PRIMARY ENDPOINT,Assessment of Lung Inflammation With FDG PET/CT in COVID-19
NCT04441502,Recruiting,Observational,,IRCCS Policlinico S. Donato,Other,30-Mar-20,31-Dec-21,30-Sep-21,COHORT,240,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,CIRCULATING MARKERS FOR COVID-19 SIGNATURE,Identification of Predictors for the Evolution of COVID-19 Related Interstitial Pneumonia by Transcriptomic and Seroproteomic Techniques
NCT04441632,Completed,Interventional,Not Applicable,Cedars-Sinai Medical Center,Other,15-Jun-20,30-Jul-20,26-Jul-20,TREATMENT,24,BURNOUT,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",POSITIVE FEEDBACK,"TEAMWORK CLIMATE, AS MEASURED BY SELECTED ITEMS FROM THE VALIDATED SAFETY ATTITUDE QUESTIONNAIRE (SAQ)","The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)"
NCT04441684,Recruiting,Interventional,Not Applicable,"University Hospital, Strasbourg, France",Other,17-Apr-20,21-Aug-21,7-May-20,SCREENING,1800,SARS-COV2 SEROLOGICAL STATUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE FOR SEROLOGICAL TEST,"PRESENCE OF SPECIFIC SARS-COV2 ANTIBODIES IN THE SERUM IN THE 3 GROUPS OF SUBJECTS STUDIED, AT THE INCLUSION VISIT (D0).","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France"
NCT04441710,Recruiting,Observational [Patient Registry],,Hospices Civils de Lyon,Other,27-Oct-20,24-Apr-21,22-Apr-21,COHORT,2500,COVID,FRANCE,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,ESTABLISHMENT OF A RELIABLE PREDICTION MODEL FOR THE EFFECTIVENESS OF VIRUS CONTROL,Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
NCT04441814,Enrolling by invitation,Observational,,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Other,23-Jul-19,21-Jul-21,21-Jul-21,COHORT,960,COVID,ITALY,ALL,"50 Years to 75 Years   (Adult, Older Adult)",,TEMPORAL VARIATIONS IN THE FREQUENCY AND MORPHOLOGY OF SSNS ACCORDING TO THE COVID-19 EPIDEMIC,Frequency and OUtcome of Sub-solid Pulmonary Nodules in Asymptomatic Subjects Tested by Chest CT Screening Versus COVID-19 Patients (FOUND) - Ancillary Study to Smile Protocol NCT03654105
NCT04441918,Recruiting,Interventional,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",Other,5-Jun-20,11-Dec-20,11-Dec-20,TREATMENT,40,COVID; AND HIGH INFECTION RISK OF SARS-COV2,CHINA,ALL,"15 Years to 45 Years   (Child, Adult)",JS016 (ANTI-SARS-COV-2 MONOCLONAL ANTIBODY),CORRELATION OF ADVERSE EVENTS WITH THE INVESTIGATIONAL PRODUCT,"A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose"
NCT04441996,"Active, not recruiting",Interventional,Phase 4,Emory University,Other,17-Jul-20,21-Feb-21,21-Feb-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE (TPE),CHANGE IN PLASMA VISCOSITY,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
NCT04442048,Recruiting,Interventional,Phase 3,Canadian Cancer Trials Group,Other,25-Jun-20,31-Mar-22,31-Dec-21,TREATMENT,1500,CANCER,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",IMM-101,"THE RATE OF ""FLU-LIKE ILLNESS"" WHICH INCLUDES:","COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure"
NCT04442087,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,19-Jun-20,21-Sep-21,21-Sep-21,BASIC SCIENCE,400,SARS-COV2,FRANCE,ALL,"Child, Adult, Older Adult",SEROLOGY SARS-COV2,SEROPREVALENCE OF ANTIBODIES ANTI- SARS COV2 IN CHILDREN OF HOSPITAL WORKERS,Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-Hôpitaux Paris
NCT04442152,Enrolling by invitation,Interventional,Not Applicable,"Promundo, United States",Other,20-Jun-21,20-Aug-21,20-Aug-21,PREVENTION,1000,GENDER RELATIONS,RWANDA,ALL,26 Years to 40 Years   (Adult),MENCARE+/BANDEBEREHO FATHERS'/COUPLES' GROUP EDUCATION,GENDER DIVISION OF CAREGIVING/DOMESTIC TASKS,Phone Survey for Understanding the Impact of COVID-19 on Caregiving and Family Dynamics on Bandebereho Study Participants
NCT04442165,Recruiting,Observational,,"Institute of Tropical Medicine, Belgium",Other,15-Dec-20,14-Jul-21,14-Jul-21,COHORT,15393,COVID,MOZAMBIQUE,ALL,"Child, Adult, Older Adult",,COVID-19 DISEASE INCIDENCE RATE (SYMPTOMATIC INFECTIONS PER MONTH),Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique Using Population-based (Sero)Surveillance
NCT04442178,Recruiting,Interventional,Phase 2,Revimmune,Industry,15-Sep-20,31-Dec-21,30-Oct-21,TREATMENT,48,COVID,UNITED STATES,ALL,"25 Years to 80 Years   (Adult, Older Adult)",CYT107,"IMPROVEMENT OF THE ABSOLUTE LYMPHOCYTE COUNT (ALC) OF LYMPHOPENIC (ALC≤1000/MM3) COVID-19 INFECTED PARTICIPANTS OUT TO APPROXIMATELY 30 DAYS FOLLOWING INITIAL STUDY DRUG ADMINISTRATION OR HOSPITAL DISCHARGE (HD), WHICHEVER OCCURS FIRST","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort"
NCT04442191,Recruiting,Interventional,Phase 2,University of Illinois at Chicago,Other,5-May-20,5-May-21,5-May-21,TREATMENT,50,COVID,UNITED STATES,ALL,"40 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,OXYGEN SUPPLEMENTATION,"Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study"
NCT04442204,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,4000,DEPRESSION,,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE STUDY ACROSS TWO TIME-POINTS EXAMINING THE IMPACT OF VIRAL MITIGATION PROTOCOLS ON MENTAL HEALTH,PATIENT HEALTH QUESTIONNAIRE 9,Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic
NCT04442217,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,4000,ADHERENCE TO WHO-ADVISED HYGIENE-RELATED BEHAVIOR,,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE STUDY WITH TWO MEASUREMENT POINTS INVESTIGATING THE IMPACT OF VIRAL MITIGATION PROTOCOLS ON MENTAL HEALTH,ADHERENCE TO WHO-ADVISED HYGIENE-RELATED,Factors Associated With Adherence to Hygiene-related Behaviors and Viral Mitigation Protocols During the COVID-19 Pandemic
NCT04442230,Recruiting,Interventional,Phase 2,"Altimmune, Inc.",Industry,10-Oct-20,21-Feb-21,21-Feb-21,TREATMENT,96,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NASOVAX,PROPORTION OF PATIENTS WITH CLINICAL WORSENING,"Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)"
NCT04442243,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,889,POST TRAUMATIC STRESS DISORDER,,ALL,"18 Years and older   (Adult, Older Adult)",,PTSD CHECKLIST FOR DSM-5 (PCL-5),PTSD Symptoms Among Health Workers and Public Service Providers After the COVID-19 Outbreak: A 3 Month Follow up
NCT04442282,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,5041,ANXIETY,,ALL,"18 Years and older   (Adult, Older Adult)",,PATIENT HEALTH QUESTIONNAIRE 9 (PHQ-9),"Difficulties in Emotion-regulation and Interpersonal Problems, and Their Association With Anxiety and Depression During and After the COVID-19 Pandemic"
NCT04442308,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,1440,PARENTING,,ALL,"18 Years and older   (Adult, Older Adult)",,PARENTAL STRESS,Parental Stress After the Covid-19 Pandemic: Predictors and Outcome
NCT04442360,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,4000,DEPRESSION,,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE STUDY WITH TWO MEASUREMENT POINTS INVESTIGATING THE IMPACT OF VIRAL MITIGATION PROTOCOLS ON MENTAL HEALTH,PATIENT HEALTH QUESTIONNAIRE 9,The Impact of Information Sources on Mental Health During the COVID-19 Pandemic
NCT04442386,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,1500,PARENTAL BURNOUT,,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE STUDY WITH TWO MEASUREMENT POINTS INVESTIGATING THE IMPACT OF VIRAL MITIGATION PROTOCOLS ON PARENTAL BURNOUT,THE PARENTAL BURNOUT INVENTORY (PBI),Parental Burnout During the COVID-19 Pandemic: Risk Factors and Predictors
NCT04442789,Recruiting,Observational,,University of Giessen,Other,20-May-20,31-Dec-23,31-Dec-21,COHORT,30,LUNG DISEASES,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,SEQUELAE AFTER COVID-19,Long-term Sequelae of Severe Sars-CoV-2 Infections
NCT04442958,Completed,Interventional,Not Applicable,Bagcilar Training and Research Hospital,Other,15-May-20,17-Jun-20,15-Jun-20,TREATMENT,60,ACUTE RESPIRATORY DISTRESS SYNDROME,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CONVALESCENT IMMUNE PLASMA,PLASMA FERRITIN LEVEL,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome
NCT04443075,Recruiting,Observational,,First Affiliated Hospital Xi'an Jiaotong University,Other,24-Jun-20,30-Aug-20,3-Aug-20,COHORT,180,"STRESS DISORDERS, POST-TRAUMATIC",CHINA,ALL,18 Years to 50 Years   (Adult),FAECAL SAMPLE COLLECTOR,GUT MICROBIOME COMPOSITION OF EXPOSED GROUP,Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress of Fighting Against 2019-nCoV
NCT04443140,Completed,Observational [Patient Registry],,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,Other,15-Mar-20,10-Jul-20,1-Jul-20,COHORT,131,COVID,TURKEY,FEMALE,18 Years to 40 Years   (Adult),"PCR, LUNG ULTRASOUND",PCR POSITIVITY,Evaluation of COVID-19 Incidence in Patients With Preeclampsia During Pandemic
NCT04443179,Recruiting,Observational,,King's College London,Other,5-Apr-13,23-Dec-21,23-Dec-21,CASE-CONTROL,790,AUTISM SPECTRUM DISORDER,UNITED KINGDOM,ALL,"16 Years to 75 Years   (Child, Adult, Older Adult)",,NEURODEVELOPMENTAL OUTCOMES,Brain Imaging and Infant Development
NCT04443257,Enrolling by invitation,Observational,,"University Hospital, Montpellier",Other,8-Jul-20,25-Jul-21,25-Jul-21,COHORT,200,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ASSESSMENT OF THE SEQUELAE AFTER HOSPITALIZATION FOR SARS-COV-2,DEVELOPMENT OR WORSENING OF A VENTILATORY DISORDER AND/OR CHRONIC RESPIRATORY FAILURE ASSESSED BY SPIROMETRY,REassessement After Hospitalization for Sars-COV-2 Infection : Standardized Assessment of Sequelae and Comorbidities 3 to 6 Months After Hospitalization
NCT04443270,Not yet recruiting,Interventional,Phase 1,"CMN ""20 de Noviembre""",Other,27-Jul-20,31-Jan-21,31-Oct-20,PREVENTION,200,COVID,MEXICO,ALL,18 Years to 59 Years   (Adult),CHLOROQUINE PHOSPHATE,NEGATIVE POLYMERASE CHAIN REACTION ASSAY AT DAY 0,Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients
NCT04443361,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,5000,INSOMNIA,,ALL,"18 Years and older   (Adult, Older Adult)",,BERGEN INSOMNIA SCALE (BIS),Insomnia After the COVID-19 Pandemic
NCT04443673,Recruiting,Interventional,Not Applicable,Instituto Nacional de Enfermedades Respiratorias,Other,20-Aug-20,30-Jun-21,28-Feb-21,TREATMENT,82,COVID,MEXICO,ALL,"Child, Adult, Older Adult",GLYCINE,MORTALITY,Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation
NCT04443699,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,4000,MENTAL WELL-BEING,,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE STUDY WITH TWO MEASUREMENT POINTS INVESTIGATING THE IMPACT OF VIRAL MITIGATION PROTOCOLS ON MENTAL HEALTH,THE SHORT WARWICK-EDINBURGH MENTAL WELL-BEING SCALE (SWEMWBS),Predictors of Mental Well-being During the COVID-19 Pandemic
NCT04443712,Recruiting,Observational,,Samia Girgis,Other,29-May-20,1-Dec-21,1-Jun-21,COHORT,1900,CORONAVIRUS DISEASE 2019 (COVID),EGYPT,ALL,"Child, Adult, Older Adult",,THE INCIDENCE OF THE NEW COVID19 AMONG HOSPITALIZED PATIENTS,Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)
NCT04443725,Not yet recruiting,Interventional,Phase 2/Phase 3,Cairo University,Other,20-Jul-21,20-Dec-21,20-Oct-21,TREATMENT,100,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)","HYDROXYCHLOROQUINE , SOFOSBUVIR, DACLATASVIR",VIROLOGICAL CURE,Efficacy and Safety of Anti-hepatitis C Drugs in the Treatment of COVID-19
NCT04443764,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,287,MIGRANTS,,ALL,"18 Years and older   (Adult, Older Adult)",,PATIENT HEALTH QUESTIONNAIRE 9,Status and Predictors of Mental Health Symptoms Among Migrants and Refugees During the COVID-19 Pandemic
NCT04443803,Not yet recruiting,Observational,,Randy Loftus,Other,1-Jul-20,31-Aug-20,31-Aug-20,CASE-ONLY,9,COVID,,ALL,"18 Years to 120 Years   (Adult, Older Adult)",,PERIOPERATIVE TRANSMISSION OF SARS-COV-2,Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program
NCT04443868,Not yet recruiting,Interventional,Phase 2,Sanotize Research and Development corp.,Industry,21-Jan-21,21-Jul-21,21-Apr-21,TREATMENT,50,SARS-COV INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE-RELEASING DRUG,TO MEASURE THE EFFICACY OF NONI COMPARED TO SALINE PLACEBO CONTROL TO SHORTEN THE DURATION OF COVID-19 VIRAL INFECTIVITY,"Double-Blinded, Placebo-Controlled Parallel, Phase II Clinical Efficacy Study Evaluating NORS To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Mild COVID-19"
NCT04443881,Recruiting,Interventional,Phase 2/Phase 3,Fundacion Miguel Servet,Other,8-May-20,21-Mar-21,20-Dec-21,TREATMENT,180,COVID PNEMONIA,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ANAKINRA 149 MG/ML PREFILLED SYRINGE [KINERET],"TREATMENT SUCCESS, DEFINED AS NUMBER OF PATIENTS NOT REQUIRING MECHANICAL VENTILATION TO ASSESS THE EFFECT OF ANAKINRA IN ADDITION TO STANDARD TREATMENT ON THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH SEVERE COVID-19 AND CSS PNEUMONIA.","Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection"
NCT04444115,Not yet recruiting,Observational,,Modum Bad,Other,22-Jun-20,13-Jul-20,13-Jul-20,ECOLOGIC OR COMMUNITY,10084,LONELINESS DURING COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,UCLA LONELINESS SCALE-8 (ULS-8),Loneliness During the COVID-19 Pandemic: Change and Predictors of Change From Strict to Lifted Social Distancing Protocols
NCT04444271,Recruiting,Interventional,Phase 2,Dr. Zaineb Akram,Other,1-May-20,30-Sep-20,30-Aug-20,TREATMENT,20,COVID,PAKISTAN,ALL,"10 Years and older   (Child, Adult, Older Adult)",MESENCHYMAL STEM CELLS,OVERALL SURVIVAL,"Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)"
NCT04444297,Not yet recruiting,Interventional,Not Applicable,NHS Greater Glasgow and Clyde,Other,31-Jul-20,31-Jan-21,31-Jan-21,OTHER,40,TELEMEDICINE,UNITED KINGDOM,ALL,"16 Years to 75 Years   (Child, Adult, Older Adult)",3D TELEMEDICINE,PRESENCE QUESTIONNAIRE,3D Telemedicine During COVID-19: Non-clinical Validation
NCT04444310,"Active, not recruiting",Observational [Patient Registry],,Assiut University,Other,15-Jun-20,30-Sep-20,18-Jun-20,COHORT,100,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,MEASURE LEVEL OF ABS IN ASYMPTOMATIC CLOSE CONTACTS OF COVID 19 PATIENTS.,Antibody Responses in Asymptomatic Close Contacts of COVID-19 Patients and Their Implications
NCT04444323,Not yet recruiting,Interventional,Not Applicable,NHS Greater Glasgow and Clyde,Other,1-Sep-20,1-Jan-21,1-Jan-21,OTHER,50,TELEMEDICINE,UNITED KINGDOM,ALL,"1 Year to 95 Years   (Child, Adult, Older Adult)",3D TELEMEDICINE,PRESENCE QUESTIONNAIRE,3D Telemedicine During COVID-19: Cohort Study
NCT04444336,Not yet recruiting,Observational,,University of Oslo,Other,22-Jun-20,13-Jul-20,13-Jul-20,OTHER,4000,DEPRESSION,,ALL,"18 Years and older   (Adult, Older Adult)",CROSS-SECTIONAL STUDY EXAMINING THE IMPACT OF INFORMATION SOURCES TO OBTAIN INFORMATION ABOUT COVID-19 ON DEPRESSION AND ANXIETY SYMPTOMS,THE PATIENT HEALTH QUESTIONNAIRE 9,Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study
NCT04444401,Recruiting,Observational,,European Institute of Oncology,Other,15-Jun-20,15-Dec-21,15-Jun-21,CASE-ONLY,50,NEUROENDOCRINE TUMORS,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,CORRELATION BETWEEN CLINICAL PARAMETERS AND SARS-COV-2 INFECTION,InterNaTional rEgistry oN Sars-cov-2posItiVe nEuroendocrine Neoplasm Patients (INTENSIVE)
NCT04444531,Completed,Observational,,Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta,Other,20-Mar-20,26-May-20,19-May-20,COHORT,18,COVID PNEUMONIA,SPAIN,ALL,"Child, Adult, Older Adult",,TIME TO CLINICAL IMPROVEMENT,Ozone Therapy for Patients With COVID-19 Pneumonia: Preliminary Report of a Prospective Case-control Study
NCT04444557,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,17-Apr-20,1-May-20,1-May-20,COHORT,97,DEPRESSION,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",BECK DEPRESSION INVENTORY (BDI),SCORE OF BECK DEPRESSION INVENTORY,Effect of COvid-19 on Mental Health in Syrian and Turkish Maintenance HemoDialysis Patients: COST-HD Study
NCT04444596,Recruiting,Interventional,Not Applicable,Medical University Innsbruck,Other,17-Jun-20,31-Mar-21,31-Mar-21,DIAGNOSTIC,100,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",CONJUNCTIVAL SWAB AND NASOPHARYNGEAL SWAB,SARS-COV2 POSITIVE CONJUNCTIVAL SWABS,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19
NCT04444609,Recruiting,Observational,,Imperial College London,Other,18-Jun-20,22-Jun-21,21-Jun-21,COHORT,230,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)","BLOOD TESTS SPUTUM, NASAL LAVAGE AND BRUSHING",ANTI-VIRAL CYTOKINE LEVELS IN BLOOD SAMPLES IN CHRONIC RESPIRATORY DISEASE ASSOCIATED WITH SUSCEPTIBILITY TO SEVERE COVID-19 INFECTION,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort
NCT04444661,"Active, not recruiting",Observational,,University of Erlangen-Nürnberg Medical School,Other,10-Jun-20,31-Dec-20,11-Nov-20,COHORT,21,OSTEOPOROSIS,GERMANY,MALE,74 Years to 95 Years   (Older Adult),,SMI,Effects of COVID-19 Induced Deconditioning After Long-term High Intensity Resistance Exercise in Older Men With Osteosarcopenia A Randomized Controlled Trial
NCT04444674,"Active, not recruiting",Interventional,Phase 1/Phase 2,University of Oxford,Other,24-Jun-20,21-Dec-21,20-Dec-21,PREVENTION,2130,CORONAVIRUS,SOUTH AFRICA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",CHADOX1 NCOV-19,ASSESS THE INCIDENCE OF ADVERSE EVENTS (INTERVENTION-RELATED AND INTERVENTION-UNRELATED) IN HIV-NEGATIVE ADULTS AGED 18-65 YEAR RECEIVING CANDIDATE CHADOX1 NCOV-19 VACCINE OR PLACEBO (SAFETY),"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV"
NCT04444687,Not yet recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,20-Aug-21,21-Feb-21,20-Dec-21,CASE-CONTROL,20,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TEST FOR SARS-COV-2,SARS-COV-2 RNA DETECTION,Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?
NCT04444700,Recruiting,Interventional,Phase 3,University of Sao Paulo General Hospital,Other,4-Jul-20,31-Dec-20,30-Nov-20,TREATMENT,462,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC ANTICOAGULATION,COMPOSITE MAIN OUTCOME,Utilização da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com síndrome respiratória Aguda Grave Por COVID-19
NCT04444713,Not yet recruiting,Observational,,Modum Bad,Other,22-Jun-20,13-Jul-20,13-Jul-20,ECOLOGIC OR COMMUNITY,10084,DEPRESSIVE SYMPTOMS,,ALL,"18 Years and older   (Adult, Older Adult)",,PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9),Centrality in the Cross-sectional Network of Depressive Symptom and Metacognitive Variables During COVID-19: Do Central Variables Predict Overall Symptom Reduction From Periods of Strict to Lifted Social Distancing Protocols?
NCT04444986,Completed,Interventional,Phase 1,Kocak Farma,Industry,5-Jun-20,13-Jun-20,11-Jun-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,18 Years to 40 Years   (Adult),FAVIR 200 MG FT,AUC0-TLAST OF FAVIPIRAVIR,"Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Favir 200 Mg Ft In Comparison With Avigan 200 Mg Ft In Healthy Male Subjects Under Fasting Conditions"
NCT04445207,Available,Expanded Access,,Jonathan Gerber,Other,,,,,,COVID,UNITED STATES,ALL,"12 Years and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,,Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04445220,Recruiting,Interventional,Phase 1/Phase 2,"Sentien Biotechnologies, Inc.",Industry,19-Nov-20,21-Jul-21,21-Feb-21,TREATMENT,22,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SBI-101,SAFETY AND TOLERABILITY AS MEASURED BY INCIDENCE OF IP-RELATED SERIOUS ADVERSE EVENTS,"A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy"
NCT04445233,"Active, not recruiting",Observational,,"University of North Carolina, Chapel Hill",Other,29-Apr-20,21-Jun-21,21-Jun-21,COHORT,315,COVID,UNITED STATES,ALL,"1 Year and older   (Child, Adult, Older Adult)",,NUMBER OF HOUSEHOLDS WITH NEW SARS-COV-2 INFECTION BY DAY 28,The COVID-19 Household Transmission Study (CO-HOST) - Epidemiology of SARS-CoV-2 Transmission Within the Household
NCT04445246,Recruiting,Interventional,Phase 2,Hamad Medical Corporation,Industry,23-May-20,31-May-21,31-May-21,TREATMENT,40,COVID,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",INHALED ILOPROST,CHANGE IN OXYGENATION PARAMETERS,Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure
NCT04445259,Recruiting,Observational,,Guy's and St Thomas' NHS Foundation Trust,Other,20-Jun-20,31-May-21,31-May-21,COHORT,300,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF ANY STAGE OF ACUTE KIDNEY INJURY,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury
NCT04445272,Completed,Interventional,Phase 2,Fundacion SEIMC-GESIDA,Other,22-May-20,23-Dec-20,23-Dec-20,TREATMENT,495,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,TO CALULATE THE TIME OF INTUBATION,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study"
NCT04445285,Recruiting,Interventional,Phase 2,Jon Simmons,Other,28-Apr-20,28-Feb-21,30-Nov-20,TREATMENT,44,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PULMOZYME/ RECOMBINANT HUMAN DEOXYRIBONUCLEASE (RH-DNASE),MORTALITY AT 28 DAYS,Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
NCT04445311,Recruiting,Interventional,Phase 2/Phase 3,Zagazig University,Other,31-May-20,15-Aug-20,30-Jul-20,TREATMENT,100,COVID,EGYPT,ALL,"18 Years to 70 Years   (Adult, Older Adult)",IVERMECTIN,TIME TO BE SYMPTOMS FREE,Use of Ivermectin as a Therapeutic Option for Patients With COVID-19
NCT04445324,"Active, not recruiting",Interventional,Not Applicable,Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal,Other,25-Aug-20,20-Dec-21,25-Aug-20,SUPPORTIVE CARE,30,PSYCHOTIC DISORDERS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",TRANSITIONAL ONLINE PEER SUPPORT GROUP (N=20),ASSESSMENT OF PATIENTS' CURRENT STATUS : RECOVERY (PERSONAL RECOVERY),Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19 : A Feasibility Study of a Trial
NCT04445337,Not yet recruiting,Interventional,Not Applicable,University of Nebraska,Other,20-Jul-21,21-Jul-21,21-Jul-21,TREATMENT,10,COVID,,ALL,"19 Years to 85 Years   (Adult, Older Adult)",STELLATE GANGLION BLOCK,EVALUATE THE SAFETY OF A NEW MODIFIED STELLATE GANGLIA BLOCK (SGB) IN ARDS,Stellate Ganglion Blockade in COVID-19 Positive Patients
NCT04445376,Completed,Interventional,Not Applicable,Government College University Faisalabad,Other,3-Jul-20,3-Oct-20,10-Sep-20,TREATMENT,20,COVID,PAKISTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PHYSICAL EXERCISES,6 MINUTE WALK TEST,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.
NCT04445389,Recruiting,Interventional,Phase 1/Phase 2,"Genexine, Inc.",Industry,17-Jun-20,17-Jun-22,17-Mar-21,PREVENTION,210,SARS-COV2,"KOREA, REPUBLIC OF",ALL,18 Years to 50 Years   (Adult),GX-19,INCIDENCE OF SOLICITED ADVERSE EVENTS,"A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects"
NCT04445402,Recruiting,Observational [Patient Registry],,Columbia University,Other,30-Apr-20,1-May-22,1-May-21,OTHER,1500,PEDIATRIC CANCER,UNITED STATES,ALL,"up to 21 Years   (Child, Adult)",,NUMBER OF TRISTATE AREA PEDIATRIC HOT PATIENTS TESTED FOR COVID-19 THAT COMPLETED 1 YEAR FOLLOW-UP,Retrospective and Prospective Database of COVID-19 Prevalence and Clinical Course in Pediatric and Young Adult Hematology/ Oncology/Stem Cell Therapy Patients in the New York Tri-State Area.
NCT04445415,Not yet recruiting,Observational,,Assiut University,Other,1-Jul-20,1-Sep-21,1-Jun-21,CASE-ONLY,250,COVID,,ALL,"Child, Adult, Older Adult",COVID-19 ANTIBODIES TESTING,DIAGNOSTIC VALUE OF COVID-19 ANTIBODIES TESTING,Diagnostic Value of New- Covid 19 Antibodies Testing Among Laboratory Healthcare Workers
NCT04445428,Enrolling by invitation,Interventional,Phase 4,Bandim Health Project,Other,15-Jul-20,21-Dec-21,21-Sep-21,PREVENTION,3400,"POLIOVIRUS VACCINE, ORAL",GUINEA-BISSAU,ALL,"50 Years and older   (Adult, Older Adult)",ORAL POLIO VACCINE + INFORMATION,MORTALITY OR INFECTIOUS DISEASE CAUSING CONSULTATION OR ADMISSION (COMPOSITE OUTCOME),Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau
NCT04445441,Completed,Observational,,Centre Muraz,Other,24-Apr-20,30-Nov-20,3-Sep-20,COHORT,153,CORONAVIRUS INFECTION,BURKINA FASO,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,CLEARANCE OF VIRAL LOAD,An Observational Study to Assess the Effectiveness of the Standard of Care (Hydroxychloroquine+Azythromicin or Chloroquine+Azythromicin) Recommended by the Ministry of Health for the Treatment of the Coronavirus Infection in Burkina Faso
NCT04445454,Recruiting,Interventional,Phase 1/Phase 2,University of Liege,Other,12-Jun-20,30-Sep-22,30-Sep-22,TREATMENT,20,CORONAVIRUS INFECTION,BELGIUM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,TO EVALUATE THE SAFETY OF INTRAVENOUS INFUSION OF MSC IN PATIENTS WITH SEVERE TO CRITICAL COVID-19 PNEUMONIA,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection
NCT04445467,Recruiting,Interventional,Phase 2,Bayside Health,Other,1-Aug-20,20-Nov-21,20-Nov-21,TREATMENT,190,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,TIME TO VIROLOGICAL CURE,An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection
NCT04445493,Not yet recruiting,Observational,,"MindRhythm, Inc.",Industry,1-Oct-20,21-Jun-21,20-Dec-21,COHORT,250,"STROKE, ACUTE",,ALL,"18 Years and older   (Adult, Older Adult)",MINDRHYTHM HARMONY,PREVALENCE OF COVID-19 INFECTION IN SUSPECTED STROKE POPULATION,EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic
NCT04445506,Completed,Observational,,The Miriam Hospital,Other,1-Apr-20,31-May-20,31-May-20,CASE-CONTROL,50,CORTICOSTEROIDS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,EFFECT ON TRANSFERS TO ICU AND ESCALATION OF CARE NEEDING MECHANICAL VENTILATION,"The Effect of the Short-term Use of Systemic Corticosteroids in COVID-19 Patients in Regard to Hospital Length of Stay, Morbidly and/or Mortality."
NCT04445597,Recruiting,Interventional,Not Applicable,Universitaire Ziekenhuizen Leuven,Other,7-May-20,31-Dec-22,31-Dec-22,BASIC SCIENCE,90,SARS-COV2,BELGIUM,ALL,"Child, Adult, Older Adult",SAMPLING OF TISSUE,PREVALENCE OF SARS-COV-2 IN THE SAMPLED TISSUE,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19
NCT04445610,Not yet recruiting,Observational,,Ain Shams University,Other,1-Jul-20,1-Nov-20,1-Sep-20,CASE-ONLY,60,CORONAVIRUS (COVID),EGYPT,ALL,"Child, Adult, Older Adult",,VIRAL CLEARANCE,Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?
NCT04445623,Not yet recruiting,Interventional,Phase 3,Azienda Ospedaliera Universitaria Integrata Verona,Other,20-Jul-21,21-Jan-21,20-Oct-21,TREATMENT,128,COVID,ITALY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PRASUGREL HYDROCHLORIDE 10 MG ORAL TABLET,P/F RATIO AT DAY 7,Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients
NCT04445870,Recruiting,Observational,,CHU de Reims,Other,1-May-20,20-Dec-21,20-Dec-21,OTHER,100,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA RECORD,DATA RECORD,Oncology Care Pathway's Modifications Impact During COVID-19 Pandemic : the ONCOCARE-COV Study
NCT04445935,Recruiting,Interventional,Phase 4,Hamad Medical Corporation,Industry,28-Jun-20,28-Mar-21,28-Sep-20,SUPPORTIVE CARE,100,ANTICOAGULATION IN COVID ARDS,QATAR,ALL,"18 Years to 99 Years   (Adult, Older Adult)",BIVALIRUDIN INJECTION,P/F RATIO,Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial
NCT04445961,Completed,Observational,,I.M. Sechenov First Moscow State Medical University,Other,1-May-20,14-Aug-20,14-Aug-20,CASE-ONLY,117,SARS PNEUMONIA,RUSSIAN FEDERATION,ALL,"18 Years to 90 Years   (Adult, Older Adult)",RESPIRATORY MECHANICS MEASUREMENT,OPTIMUM POSITIVE END-EXPIRATORY PRESSURE (PEEP) LEVEL,Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure: Multicentral Observational Study
NCT04446065,Not yet recruiting,Interventional,Phase 2/Phase 3,MELISA Institute Genomics & Proteomics Research SpA,Industry,30-Sep-20,30-Oct-21,30-Sep-21,PREVENTION,524,COVID,,ALL,"25 Years and older   (Adult, Older Adult)",PREVIFENON®,EVENT OF CLINICAL ACUTE RESPIRATORY DISEASE WITH A DIAGNOSIS OF COVID-19 CONFIRMED WITH RTPCR,"A Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Protect Health Workers Against COVID-19 by Using Previfenon® as Chemoprophylaxis During a SARS-CoV-2 Outbreak. The HERD Study"
NCT04446104,Completed,Interventional,Phase 3,"National University Hospital, Singapore",Other,13-May-20,31-Aug-20,31-Aug-20,PREVENTION,4257,COVID,SINGAPORE,MALE,21 Years to 60 Years   (Adult),HYDROXYCHLOROQUINE SULFATE TABLETS,"LABORATORY-CONFIRMED COVID-19 IN TREATMENT ARMS (HYDROXYCHLOROQUINE, IVERMECTIN, ZINC AND POVIDONE IODINE)",A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial)
NCT04446169,"Active, not recruiting",Observational,,University of Florence,Other,27-Jun-20,2-Mar-21,1-Sep-20,COHORT,43,SARS-COV2,ITALY,MALE,"18 Years to 80 Years   (Adult, Older Adult)",SARS-COV 2 RNA PCR URINE,SARS-COV 2 PRESENCE IN SEMEN,"COVID-19 (SARS-CoV-2) in Urine and Semen: Qualitative and Quantitative Analyses and Evaluation of STD, Sexual Function, Fertility and Urinary Function"
NCT04446286,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,18-Jun-20,18-Aug-20,18-Aug-20,CASE-ONLY,50,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE DESCRIPTION OF EFFECT OF THE ECMO-VV OR ECMO-VA IN THE MANAGEMENT OF SEVERE ARDS REFRACTORY IN PATIENTS OF THE STRASBOURG AND LOUVAIN CENTRES WITH COVID-19,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
NCT04446338,Recruiting,Observational,,University Hospital Tuebingen,Other,13-May-20,20-Aug-21,30-Jun-20,COHORT,300,"HISTORY OF COVID, SEROPREVALENCE",GERMANY,ALL,"Child, Adult, Older Adult",ANTIBODY TEST,SEROPREVALENCE,Immune Status: Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Sample of the Eye Department (University Eye Hospital and Research Institute Tübingen)
NCT04446377,Recruiting,Interventional,Phase 2,"AI Therapeutics, Inc.",Industry,15-Jul-20,30-Apr-21,31-Mar-21,TREATMENT,142,COVID DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",APILIMOD DIMESYLATE CAPSULE,VIRAL LOAD CHANGE,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19"
NCT04446429,Completed,Interventional,Not Applicable,"Applied Biology, Inc.",Industry,15-Sep-20,21-Jan-21,24-Dec-20,TREATMENT,262,COVID,BRAZIL,MALE,"18 Years and older   (Adult, Older Adult)",PROXALUTAMIDE,COVID-19 HOSPITALIZATION,Anti-Androgen Treatment for COVID-19
NCT04447131,Recruiting,Observational,,University of Sao Paulo,Other,29-Apr-20,30-Jul-21,30-Jun-21,CASE-CONTROL,200,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",VENIPUNCTURE IN PERIPHERAL VEIN,PLATELET AGGREGATION ANALYZED BY MULTIPLATE-ADP,Effect of SARS-CoV-2 Infection on Platelet Aggregation and Other Coagulation Parameters
NCT04447144,Recruiting,Observational,,Cairo University,Other,1-Jun-20,1-Sep-20,1-Aug-20,COHORT,200,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,WESTERN VERSUS MEDITERRANEAN DIET IN COVID-19 OUTCOME,"Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience"
NCT04447209,Recruiting,Observational,,University of Malaya,Other,6-Jun-20,31-May-21,31-Dec-20,COHORT,300,DIETARY DIVERSITY,MALAYSIA,ALL,6 Months to 6 Years   (Child),"DIETARY COUNSELLING ON FOOD GROUPS ACCORDING TO IYC FEEDING PRACTICES, WHO",MINIMAL DIETARY DIVERSITY (MDD) OF MORE THAN 5 FOOD GROUPS IN 24 HOURS,Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study
NCT04447222,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,12-May-20,21-Jul-21,21-Jul-21,COHORT,1242,COVID INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",QUALITY-OF-LIFE ASSESSMENT,CORONAVIRUS DISEASE-2019 (COVID19)-SPECIFIC PSYCHOLOGICAL DISTRESS,COVID-19: Well-Being and HRQOL in Cancer Patients Who Participated in Prior Behavioral Clinical Trials
NCT04447235,Recruiting,Interventional,Phase 2,Instituto do Cancer do Estado de São Paulo,Other,23-Jul-20,21-Feb-21,20-Dec-21,TREATMENT,176,CANCER,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,INCIDENCE OF SEVERE COMPLICATIONS DUE COVID-19 INFECTION,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19"
NCT04447404,Recruiting,Interventional,Phase 2,Durect,Industry,21-Sep-20,21-Oct-21,21-Sep-21,TREATMENT,80,SARS-COV2,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DUR-928,COMPOSITE ENDPOINT OF ALIVE AND FREE OF ORGAN FAILURE,"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of DUR-928 in Subjects Infected With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury"
NCT04447469,Recruiting,Interventional,Phase 2/Phase 3,"Kiniksa Pharmaceuticals, Ltd.",Industry,27-Jul-20,21-Apr-21,21-Feb-21,TREATMENT,573,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",MAVRILIMUMAB,COHORT 1: PROPORTION OF PARTICIPANTS ALIVE AND WITHOUT RESPIRATORY FAILURE AT DAY 15,"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation"
NCT04447495,Not yet recruiting,Observational,,Medical College of Wisconsin,Other,1-Jul-20,31-Dec-20,31-Dec-20,CASE-CONTROL,500,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",IAMP TEST,VALIDATE IAMP TESTING KIT,Self-sampling for the Study of COVID-19
NCT04447534,Recruiting,Interventional,Phase 3,Tanta University,Other,23-Jun-20,1-Oct-30,1-Oct-30,TREATMENT,200,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE,NUMBER OF PATIENTS WITH IMPROVEMENT OR MORTALITY,Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?
NCT04447638,Completed,Observational,,Çanakkale Onsekiz Mart University,Other,20-Mar-20,1-Jun-20,1-Jun-20,CASE-ONLY,24,TRACHEOSTOMY,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",TRACHEOSTOMY WITH AEROSOL BOX IN COVID-19 POSITIVE PATIENTS,COMPLICATIONS OBSERVED IN THE CASES IN WHICH WE APPLIED PERCUTANEOUS TRACHEOSTOMY WITH AEROSOL BOX,Percutaneous Tracheostomy With Aerosol Box in COVID-19 Positive Patients in Intensive Care Unit: a Clinical Trial
NCT04447781,Recruiting,Interventional,Phase 1/Phase 2,International Vaccine Institute,Other,15-Jul-20,22-Feb-22,22-Feb-22,PREVENTION,160,CORONAVIRUS INFECTION,"KOREA, REPUBLIC OF",ALL,19 Years to 64 Years   (Adult),INO-4800,PRIMARY OUTCOME MEASURES,"A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers"
NCT04447833,Recruiting,Interventional,Phase 1,Uppsala University,Other,17-Jun-20,30-Jun-25,30-Dec-20,TREATMENT,9,"ARDS, HUMAN",SWEDEN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MESENCHYMAL STROMAL STEM CELLS - KI-MSC-PL-205,THE INCIDENCE OF PRE-SPECIFIED TREATMENT RELATED ADVERSE EVENTS OF INTEREST (TRAEIS).,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy
NCT04448054,Recruiting,Observational,,Fondation Ophtalmologique Adolphe de Rothschild,Other,20-May-20,20-Nov-21,20-Nov-21,CASE-ONLY,100,"ESTIMATE, WITH THE CONTRIBUTION OF OPTIMIZED MRI, THE PREVALENCE OF NEUROLOGICAL AND NEUROVASCULAR MANIFESTATIONS ON IMAGING IN THE EVENT OF SARS-COV2",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MRI,"PERCENTAGE OF PATIENTS INCLUDED WITH AT LEAST ONE SIGN OF NEUROMENINGEAL, NEUROSENSORY OR NEUROVASCULAR INVOLVEMENT ON MRI IMAGING WITH THE SPECIFIC SEQUENCES USED.","Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas"
NCT04448119,Recruiting,Interventional,Phase 2,Appili Therapeutics Inc.,Industry,16-Oct-20,21-Mar-21,21-Mar-21,PREVENTION,760,COVID,CANADA,ALL,65 Years and older   (Older Adult),FAVIPIRAVIR,CONTROL OF OUTBREAK,Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)
NCT04448145,Recruiting,Observational,,Columbia University,Other,26-Mar-20,1-Mar-21,1-Mar-21,COHORT,250,COVID,UNITED STATES,ALL,"7 Years and older   (Child, Adult, Older Adult)",,DURATION OF SARS-COV-2 VIRAL PERSISTENCE IN NASO/OROPHARYNGEAL SAMPLES,"Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases"
NCT04448405,Completed,Observational,,"University Hospital, Montpellier",Other,18-Jun-20,30-Oct-20,1-Oct-20,COHORT,100,DEVIANT SEXUAL FANTASIES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE FOR EVALUATION OF CONFINEMENT ON DEVIANT SEXUAL FANTASIES,IMPACT OF CONFINEMENT ON DEVIANT FANTASIES,Descriptive Study on the Impact of Covid-19 Lockdown on Deviant Sexual Fantasies
NCT04448418,"Active, not recruiting",Observational,,Unita Complessa di Ostetricia e Ginecologia,Other,20-May-20,20-Nov-20,20-Jun-20,COHORT,300,TRANSGENDER PERSONS,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",WEB BASED SURVEY,ASSESSMENT OF THE SPECIFIC HEALTH NEED OF THE TRANSPOPULATION DURING THE COVID-19 PANDEMIC IN ITALY,Observational Evaluation of the Impact of COVID-19 Outbreak on Transgender Subject's Health and on the Organization of Trans-population Health Care Services
NCT04448704,Completed,Observational,,Yale-NUS College,Other,22-Jun-20,11-Oct-20,11-Oct-20,COHORT,1011,MENTAL HEALTH ISSUE,SINGAPORE,ALL,"21 Years and older   (Adult, Older Adult)",,DASS-21 SCORES,Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak
NCT04448717,Recruiting,Observational,,University of Zurich,Other,16-Jun-20,21-Mar-21,21-Mar-21,COHORT,8000,SARS-COV2,SWITZERLAND,ALL,"5 Years and older   (Child, Adult, Older Adult)",COVID-19 ANTIBODY TESTING,"SEROPREVALENCE OF SARS-COV-2 IGG, IGM AND/OR IGA ANTIBODIES",Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in a Public School Population - a Population-based Observational Study to Inform Policy Making
NCT04448743,Not yet recruiting,Observational,,"University Hospital, Strasbourg, France",Other,20-Jun-21,21-Nov-21,21-Nov-21,COHORT,175,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,WESTERN BLOT MEASUREMENT OF ACE2 RECEPTOR EXPRESSION IN PORCINE CELLS,Role of Circulating Microparticles in Covid-19 Infection
NCT04448756,Recruiting,Interventional,Phase 2,"EMD Serono Research & Development Institute, Inc.",Industry,29-Jul-20,6-Jun-21,6-Jun-21,TREATMENT,150,CORONAVIRUS DISEASE 2019,BRAZIL,ALL,"18 Years to 75 Years   (Adult, Older Adult)",M5049,PERCENTAGE OF PARTICIPANTS ALIVE AND NOT REQUIRING SUPPLEMENTAL OXYGENATION,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia"
NCT04448769,Completed,Interventional,Not Applicable,"Central Hospital, Nancy, France",Other,26-Jun-20,24-Jul-20,24-Jul-20,SCREENING,2006,CORONAVIRUS INFECTION,FRANCE,ALL,"5 Years and older   (Child, Adult, Older Adult)",ANTI-SARS-COV-2 IGT SEROPOSITIVITY,ANTI-SARS-COV-2 IGT (IGM/IGA/IGG) SEROPOSITIVITY,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area
NCT04448782,Completed,Observational,,Corporacion Parc Tauli,Other,9-Mar-20,30-Jun-20,30-Jun-20,COHORT,32,MECHANICAL VENTILATION COMPLICATION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",ASYNCHRONIES DETECTION,INCIDENCE AND PATTERN OF PRESENTATION OF REVERSE TRIGGERING IN COVID-19 PATIENTS UNDER INVASIVE MECHANICAL VENTILATION,Characterization of Reverse Triggering and Other Asynchronies in COVID-19 Patients Under Invasive Mechanical Ventilation
NCT04449042,Recruiting,Observational [Patient Registry],,Boston Children's Hospital,Other,1-Apr-20,25-Dec-21,25-Dec-21,COHORT,15000,AIRWAY MANAGEMENT,UNITED STATES,ALL,"up to 18 Years   (Child, Adult)",AIRWAY MANAGEMENT DURING SEDATION OR GENERAL ANESTHESIA,AIRWAY COMPLICATIONS,"Pediatric Airway Management Complications During the COVID-19 Pandemic. An International, Multicenter, Observational Registry: The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry"
NCT04449081,Completed,Observational,,Melaka Manipal Medical College,Other,25-Apr-20,20-Jun-20,10-Jun-20,COHORT,215,ACUTE RESPIRATORY DISTRESS SYNDROME,MALAYSIA,ALL,18 Years to 30 Years   (Adult),"KNOWLEDGE, ATTITUDE, PRACTICE, AWARENESS, PREFERENCE","KNOWLEDGE, ATTITUDE, PRACTICE OF DENTAL STUDENTS TOWARDS COVID-19","Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study"
NCT04449094,Completed,Observational,,Centre Hospitalier Universitaire de Nice,Other,28-Feb-20,4-Apr-20,30-Mar-20,ECOLOGIC OR COMMUNITY,200,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,ATTACK RATE,Socio-demographic Factors and Emergence of the COVID 19 Epidemic in the City of Nice in 2020
NCT04449276,"Active, not recruiting",Interventional,Phase 1,CureVac AG,Industry,18-Jun-20,21-Dec-21,21-Dec-21,PREVENTION,280,SEVERE ACUTE RESPIRATORY SYNDROME,BELGIUM,ALL,18 Years to 60 Years   (Adult),CVNCOV VACCINE,NUMBER OF PARTICIPANTS WITH GRADE 3 ADVERSE REACTIONS OR ANY SERIOUS ADVERSE EVENT (SAE) CONSIDERED RELATED TO TRIAL VACCINE WITHIN AT LEAST 24 HOURS AFTER THE FIRST VACCINATION,"COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults"
NCT04449380,Recruiting,Interventional,Phase 2,Emanuele Bosi,Other,2-Nov-20,21-Jun-21,21-Apr-21,TREATMENT,126,COVID VIRUS INFECTION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON-SS-1A,TIME TO NEGATIVE CONVERSION OF SARS-COV-2 NASOPHARYNGEAL SWAB,"Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-β-1a (IFNβ-1a) in COVID-19 Patients"
NCT04449588,Recruiting,Interventional,Phase 2/Phase 3,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",Industry,23-Jul-20,7-Aug-22,7-Aug-21,TREATMENT,368,COVID PNEUMONIA,BANGLADESH,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BDB-001 INJECTION,TIME TO RECOVERY OF PERIPHERAL CAPILLARY OXYGEN SATURATION (SPO2) FROM BASELINE,"A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III"
NCT04449627,Not yet recruiting,Observational,,Royal Free Hospital NHS Foundation Trust,Other,31-Aug-20,31-Jan-21,31-Oct-20,COHORT,125,ANXIETY DISORDERS,,ALL,"18 Years and older   (Adult, Older Adult)",FEELING GOOD DIGITAL APP,ANXIETY AS MEASURED BY GENERALISED ANXIETY DISORDER SCORE (GAD-7) SCALE,Psychological Impact of Admission With Covid-19 During the SARS-CoV-2 Pandemic: Naturalistic Cohort Study With a Digital Intervention
NCT04449718,Completed,Interventional,Not Applicable,University of Sao Paulo,Other,1-Jun-20,7-Oct-20,7-Oct-20,TREATMENT,240,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN D,LENGTH OF HOSPITALIZATION,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial"
NCT04449731,Recruiting,Observational,,Universidad de Granada,Other,20-Mar-20,30-Jun-21,30-Aug-20,ECOLOGIC OR COMMUNITY,30000,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,ADHERENCE TO THE MEDITERRANEAN DIET BEFORE AND DURING THE COVID-19 CONFINEMENT,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population
NCT04449783,Recruiting,Observational,,Liverpool University Hospitals NHS Foundation Trust,Other,25-Jun-20,25-Sep-20,25-Aug-20,COHORT,150,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PRE-OPERATIVE SCREENING,DIAGNOSIS OF COVID BEFORE SURGERY,A Cohort Study to Assess the Effectiveness of Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery Patients in the COVID-19 Pandemic
NCT04449965,Not yet recruiting,Interventional,Early Phase 1,"St. Paul's Hospital, Canada",Other,1-Jul-20,1-Dec-20,1-Nov-20,TREATMENT,81,COVID,,ALL,"19 Years and older   (Adult, Older Adult)",POVIDONE-IODINE,CHANGE IN SARS-COV-2 POSITIVITY IN THE SALIVA,The Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19)
NCT04449978,Recruiting,Observational,,The Hospital for Sick Children,Other,9-Apr-20,31-Dec-22,30-Jun-22,COHORT,1082,CORONAVIRUS,CANADA,ALL,up to 10 Years   (Child),,CUMULATIVE INCIDENCE OF COVID-19,TARGet Kids! COVID-19 Study of Children and Families
NCT04450004,"Active, not recruiting",Interventional,Phase 1,Medicago,Industry,10-Jul-20,31-Dec-21,20-Sep-21,PREVENTION,180,SARS-COV2,CANADA,ALL,18 Years to 55 Years   (Adult),INTRAMUSCULAR VACCINE,IMMEDIATE ADVERSE EVENT (AES),"A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age"
NCT04450017,Recruiting,Observational,,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",Other,6-Apr-20,20-Aug-21,20-Jul-21,CASE-ONLY,150,SARS-COV2,RUSSIAN FEDERATION,ALL,"18 Years to 90 Years   (Adult, Older Adult)","THE DEMOGRAPHIC, CLINICAL, LABORATORY, AND INSTRUMENTAL DATA",MECHANICAL VENTILATION DURATION,Clinical Features of Severe Patients With COVID-19
NCT04450277,Completed,Observational [Patient Registry],,Khoo Teck Puat Hospital,Other,1-Apr-20,31-May-20,31-May-20,COHORT,15,COVID,SINGAPORE,ALL,"18 Years and older   (Adult, Older Adult)",EMERGENCY SURGERY,SURGICAL MORBIDITY IN PATIENTS WITH COVID-19 INFECTION AND GENERAL SURGICAL CONDITIONS,Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic Based on Case Series
NCT04451174,Recruiting,Interventional,Phase 3,University of Chile,Other,23-Jun-20,30-Dec-20,30-Nov-20,TREATMENT,184,COVID,CHILE,ALL,"18 Years to 90 Years   (Adult, Older Adult)",PREDNISONE,"COMPOSITE PRIMARY END-POINT: ADMISSION TO ICU, NEED FOR INVASIVE MECHANICAL VENTILATION OR ALL-CAUSE DEATH BY DAY 28",Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia (PREDCOVID)
NCT04451239,Not yet recruiting,Interventional,Not Applicable,Ameera Gamal Abdelhameed,Other,30-Jun-20,20-Jul-21,20-Jul-21,TREATMENT,12,KERATONJUNCTIVITIS,KUWAIT,ALL,"Child, Adult, Older Adult",TOPICAL STEROIDS AND CYCLOSPORIN-A,SYMPTOM IMPROVEMENT,Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study
NCT04451291,Not yet recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,24-Aug-20,24-Feb-21,24-Feb-21,TREATMENT,20,COVID,CANADA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",DECIDUAL STROMAL CELLS (DSC),NUMBER OF VENTILATOR FREE DAYS FOLLOWING INFUSION OF DECIDUAL STROMAL CELLS,DSC-COVID-19: An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19
NCT04451317,Recruiting,Observational,,"University Hospital, Toulouse",Other,12-Jun-20,21-Aug-21,21-Aug-21,CASE-CONTROL,600,PHYSICAL ACTIVITY,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","QUESTIONNAIRE, PHONE CALL",PHYSICAL ACTIVITY MEASURE,"Changes in Physical and Sports Activity, Anxiety and Sleep Patterns Following the Containment Period Imposed by the COVID-19 Pandemic in Patients With Chronic Medical Conditions and in Healthy Athletes."
NCT04451577,Recruiting,Observational,,Istituto Clinico Humanitas,Other,1-Jun-20,1-Jun-23,1-Jun-21,CASE-CONTROL,5000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,CLINICAL RESPONSE TO COVID-19,"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection: a Retrospective-prospective Cohort Study"
NCT04451694,Recruiting,Observational,,"Central Hospital, Nancy, France",Other,1-Apr-20,30-Nov-20,30-Jul-20,COHORT,800,COVID,FRANCE,ALL,"16 Years and older   (Child, Adult, Older Adult)",NUTRITIONAL INTERVENTION,NUTRITIONAL EVALUATION,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19
NCT04451889,Recruiting,Interventional,Not Applicable,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",Other,1-Aug-20,1-Sep-21,1-Jul-21,DIAGNOSTIC,15,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MINIPROBE ALVEOFLEX,NUMBER OF COVID-19 PARTICIPANTS WITH NOTABLE DIFFERENCES IN THE PCLE IMAGES IN COMPARISON WITH THE PCLE IMAGES OF NON-COVID-19 PARTICIPANTS,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients
NCT04451902,Not yet recruiting,Observational [Patient Registry],,Imagine Institute,Other,30-Jun-20,30-Jun-21,30-Dec-20,COHORT,80,RARE DISEASES,,ALL,"Child, Adult, Older Adult",,ANALYSIS OF THE IMPACT OF COVID-19 INFECTION ON RARE SKIN DISEASES: COMPLICATIONS,COVID-19 and Rare Skin Diseases. European Observational Study (Data Research) During an Epidemic
NCT04451993,Completed,Observational,,Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital,Other,25-Jun-20,30-Sep-20,1-Sep-20,CASE-CONTROL,63,OBSTRUCTIVE SLEEP APNEA-HYPOPNEA SYNDROME,TURKEY,ALL,"19 Years to 70 Years   (Adult, Older Adult)",,PHYSICAL ACTIVITY,"Are the Sleep Quality and Physical Activity Levels of Osas Patients Differently From Healthy People During the COVID-19 Pandemic:a Prospective, Descriptive Study"
NCT04452097,Not yet recruiting,Interventional,Phase 1/Phase 2,Baylx Inc.,Industry,1-Mar-21,31-Dec-21,31-Dec-21,TREATMENT,39,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS + BEST SUPPORTIVE CARE,INCIDENCE OF INFUSION-RELATED ADVERSE EVENTS,A Phase 1/2a Study of the Safety and Efficacy of BX-U001 for the Treatment of Severe COVID-19 Pneumonia With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS).
NCT04452318,Recruiting,Interventional,Phase 3,Regeneron Pharmaceuticals,Industry,13-Jul-20,15-Aug-21,15-Jun-21,TREATMENT,2450,HEALTHY PARTICIPANTS,"MOLDOVA, REPUBLIC OF",ALL,"Child, Adult, Older Adult",REGN10933 + REGN10987,PROPORTION OF PARTICIPANTS WHO HAVE A RT-QPCR CONFIRMED SARS-COV-2 INFECTION (EITHER SYMPTOMATIC OR ASYMPTOMATIC) DURING THE EAP,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2"
NCT04452422,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,23-Jun-20,23-Sep-20,23-Sep-20,CASE-ONLY,30,DEEP VENOUS THROMBOSIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF CUMULATED DEEP VENOUS THROMBOSIS AMONG THE HOSPITALIZATION,High Prevalence of Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology
NCT04452435,Completed,Interventional,Phase 2,Vicore Pharma AB,Industry,21-Jul-20,13-Oct-20,13-Oct-20,TREATMENT,106,COVID,INDIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",C21,CHANGE FROM BASELINE IN C-REACTIVE PROTEIN (CRP) AFTER TREATMENT WITH C21 200 MG DAILY DOSE (100 MG B.I.D.),"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation"
NCT04452474,Not yet recruiting,Interventional,Phase 2/Phase 3,R-Pharm,Industry,30-Jun-20,29-Jan-21,16-Nov-20,TREATMENT,376,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",OLOKIZUMAB 64 MG,"PERCENTAGE OF SUBJECTS ACHIEVING A CHANGE IN THEIR CLINICAL STATUS DEFINED AS IMPROVEMENT FOR AT LEAST 2 CATEGORIES OF THE 5-POINTS CLINICAL STATUS SCALE RELATIVE TO BASELINE OR IN THE ""NOT HOSPITALIZED"" CATEGORY","A Multicenter, Randomized, Double-blind, Adaptive, Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe SARS-CoV-2 Infection (COVID-19)"
NCT04452487,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,1-Jun-20,21-Jun-21,21-Jun-21,CASE-CONTROL,2500,PATIENT HOSPITALIZED IN DISEASE INFECTIOUS UNIT,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DECISIONS OF LIMITATIONS AND STOP PROCESSING,DECISIONS OF LIMITATIONS AND THERAPEUTIC STOPS,Study of the Consequences of Infection on Compliance of Modalities of Decisions of Limitations and Stops of Treatments
NCT04452565,Recruiting,Interventional,Phase 2/Phase 3,"NeuroActiva, Inc.",Industry,15-Oct-20,15-Feb-21,31-Dec-20,PREVENTION,525,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",DRUG: NA-831,1. TIME (HOURS) TO RECOVERY,"Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection"
NCT04452604,Not yet recruiting,Observational,,French Innovative Leukemia Organisation,Other,1-Aug-20,1-Dec-23,1-Aug-23,COHORT,30,ACUTE MYELOBLASTIC LEUKEMIA,,ALL,"18 Years and older   (Adult, Older Adult)",,CLINICAL PROGNOSTIC FACTORS FOR INFECTION WITH COVID-19,National Retrospective Monitoring of Patients With Acute Leukemia Infected by COronaVirus Disease 2019 (COVID-19)
NCT04452617,Completed,Observational,,Institut Mutualiste Montsouris,Other,19-Mar-20,1-Jul-20,8-Apr-20,COHORT,40,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,OCCURRENCE OF SEVERE CARDIAC ARRHYTHMIA: TORSADE DE POINTES AND CARDIAC ARREST OR SUDDEN DEATH,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
NCT04452630,Recruiting,Observational,,Assistance Publique Hopitaux De Marseille,Other,23-Jun-20,30-Nov-21,23-Jul-20,COHORT,200,CARDIOVASCULAR CONSEQUENCES AFTER AN EPISODE OF COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INFECTIOUS DISEASE AND CARDIOLOGY CLINICAL CONSULTATIONS,"PRESENCE OF AT LEAST ONE CLINICAL, BIOLOGICAL AND/OR IMAGING CARDIOVASCULAR ANOMALY WITHIN 1 MONTH OF RECOVERING",The CardioPostCovid Study: Cardiovascular Consequences After COVID-19
NCT04452643,Withdrawn,Interventional,Phase 3,Inmunotek S.L.,Industry,20-Oct-21,21-Dec-21,21-Dec-21,PREVENTION,0,COVID,MEXICO,ALL,"18 Years to 65 Years   (Adult, Older Adult)",BACMUNE (MV130),INCIDENCE OF SUBJECTS WITH COVID-19,"Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel"
NCT04452669,Recruiting,Interventional,Phase 2,Aerogen Pharma Limited,Industry,15-Sep-20,1-Sep-21,1-May-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VENTAPROST (INHALED EPOPROSTENOL DELIVERED VIA A DEDICATED DELIVERY SYSTEM),REDUCTION IN RESPIRATORY FAILURE,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation"
NCT04452682,Completed,Observational,,Mansoura University,Other,25-May-20,21-Jun-20,21-Jun-20,CASE-ONLY,998,COVID,EGYPT,ALL,"Child, Adult, Older Adult",COVID 19 IMPACT,THE ICU ADMISSION WITH ASSOCIATED PNEUMONIA,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice
NCT04452695,Completed,Observational,,Brigham and Women's Hospital,Other,10-Mar-20,10-Aug-20,3-Aug-20,COHORT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DOCTOR SPOT,ACCEPTANCE OF ROBOTIC TELEHEALTH SYSTEM,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19
NCT04452708,Recruiting,Observational,,Chinese University of Hong Kong,Other,11-Jun-20,10-Jun-21,10-Jun-21,COHORT,15,RESPIRATORY FAILURE,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",HFNC,DETECTION OF VIRAL RNA FROM ONE OR MORE PARTICIPANTS' AIR SAMPLES,The Safety of High Flow Nasal Cannula and Noninvasive Ventilation for Treatment of Patients With COVID-19 Complicated by Respiratory Failure
NCT04452773,Recruiting,Interventional,Not Applicable,Reig Jofre Group,Industry,14-Jul-20,21-Dec-21,20-Sep-21,PREVENTION,315,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MANREMYC,DOCUMENTED CUMULATIVE INCIDENCE OF SARS-COV-2 INFECTION,"Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the Manremyc® Food Supplement to Prevent SARS-CoV-2 Infection"
NCT04452799,Not yet recruiting,Interventional,Early Phase 1,Tanta University,Other,1-Jul-20,30-Oct-20,1-Oct-20,TREATMENT,100,CORONAVIRUS INFECTION,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HESPERIDIN AND DIOSMIN MIXTURE,PCR TEST,Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt
NCT04452812,Not yet recruiting,Interventional,Phase 1/Phase 2,Universidad Autonoma de Coahuila,Other,6-Jul-20,1-Apr-21,1-Mar-21,TREATMENT,15,COVID PNEUMONIA,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,ALL-CAUSE MORTALITY,"Pilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19"
NCT04452942,Not yet recruiting,Observational,,EicOsis Human Health Inc.,Industry,20-Jul-21,21-Apr-21,20-Sep-21,COHORT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGES ON EICOSANOID LIPID MEDIATORS,Dynamic Changes in Cytokine and Eicosanoid Mediators Among Hospitalized Patients With Coronavirus Infectious Disease 2019 (COVID-19)
NCT04453280,Completed,Observational,,Institute of Health Information and Statistics of the Czech Republic,Other,18-May-20,3-Jun-20,3-Jun-20,COHORT,695,COVID,CZECHIA,ALL,"8 Years and older   (Child, Adult, Older Adult)",QUANTITATIVE ANALYSIS OF ANTI-SARS-COV-2-ANTIBODIES,DETERMINATION OF THE CONCENTRATION OF ANTI-SARS-COV-2 ANTIBODIES IN RELATION TO THE CATEGORIES OF CURED PATIENTS.,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity)
NCT04453371,Not yet recruiting,Interventional,Phase 3,Negovsky Reanimatology Research Institute,Other,15-Oct-20,15-Feb-21,15-Jan-21,TREATMENT,50,ACUTE RESPIRATORY DISTRESS SYNDROME,,ALL,"18 Years and older   (Adult, Older Adult)",TISSUE PLASMINOGEN ACTIVATOR,P/F (PAO2/FIO2) CHANGE DURING THE FIRST 72HRS AFTER THE END OF THE PROCEDURE IN ADULT PATIENTS WITH SEVERE ATYPICAL ARDS CAUSED BY SARS-2-COV.,Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): A Multicentral Randomized Trial (AtTAC-trial)
NCT04453384,Recruiting,Interventional,Phase 2,Nantes University Hospital,Other,1-Sep-20,21-Dec-21,20-Dec-21,TREATMENT,414,SARS VIRUS,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",XAV-19,PHASE 2A: XAV-19 ANTIBODY TITERS,"A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia"
NCT04453475,Recruiting,Interventional,Not Applicable,Jacobs University Bremen gGmbH,Other,1-Jul-20,31-Dec-21,31-Jul-21,HEALTH SERVICES RESEARCH,1230,PSYCHOSOMATIC DISORDER,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",TRAINING SESSION ADRESSING INFORMATION AND HEALTH LITERACY,"INTEREST IN DIGITAL INTERVENTIONS (ATTITUDES, BEHAVIORAL INTENTIONS, BEHAVIORAL EXPERIENCES)",Therapies to Achieve Treatment Goals While Being Exposed to Hygiene and Distance Rules: Feasibility and Benefits of Digital Services During the COVID19 Pandemic (Anhand-COVID19)
NCT04453488,Not yet recruiting,Interventional,Phase 3,Fundació Institut Germans Trias i Pujol,Other,30-Jul-20,20-Dec-21,20-Dec-21,PREVENTION,315,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",RUTI® VACCINE,DOCUMENTED CUMULATIVE INCIDENCE OF SARS-COV-2 INFECTION,"Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI® Vaccine to Prevent SARS-CoV-2 Infection"
NCT04453501,Completed,Observational,,Centre d'Investigation Clinique et Technologique 805,Other,2-Mar-20,25-Apr-20,25-Apr-20,COHORT,132,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",FAVORABLE OUTCOME,FAVORABLE OUTCOME,Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study
NCT04453514,Recruiting,Interventional,Not Applicable,National University of Natural Medicine,Other,21-Jul-20,20-Oct-21,20-Oct-21,SUPPORTIVE CARE,200,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TRAUMA-INFORMED YOGA VIDEO RECORDING,NUMBER OF PARTICIPANTS ENROLLED OVER 3 MONTHS,Cultivating Calm During COVID-19: A Feasibility Study of Video-based Trauma-informed Yoga
NCT04453527,Recruiting,Observational,,Portsmouth Hospitals NHS Trust,Other,28-May-20,21-Sep-21,21-May-21,COHORT,100,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,COMPLEMENT ACTIVATION,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Coronavirus Disease 2019
NCT04453540,Not yet recruiting,Observational,,"Central Hospital, Nancy, France",Other,1-Jul-20,30-Aug-20,30-Aug-20,CASE-ONLY,150,INFECTIOUS DISEASE,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",FILMARRAY PCR ON RESPIRATORY SAMPLES,THERAPEUTIC DECISION,Impact of the Syndromic PCR System FilmArray on Management of ICU Patients With Severe Pulmonary Disease in the Context of the Covid-19 Pandemic.
NCT04453553,Not yet recruiting,Interventional,Not Applicable,Queen Mary University of London,Other,2-Jul-20,28-Sep-20,28-Aug-20,DIAGNOSTIC,50,COVID,UNITED KINGDOM,ALL,"18 Years to 130 Years   (Adult, Older Adult)",Q16 TESTING,COV-2 INFECTION AFTER 21 DAYS,COVID-19 in Vitro Diagnostic Near-patient Testing in Care Environments Using a Cluster Randomised Open-label Trial Design in an East London Care Home Population
NCT04453566,Recruiting,Observational,,Uskudar University,Other,27-May-20,20-Dec-21,24-Aug-20,OTHER,120,COVID,TURKEY,ALL,18 Years to 35 Years   (Adult),ONLINE SURVEY,SOCIODEMOGRAPHIC INFORMATION AND TRAINING CHARACTERISTICS,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes."
NCT04453579,Completed,Observational [Patient Registry],,University of Rome Tor Vergata,Other,9-Mar-20,30-May-20,4-May-20,CASE-ONLY,116,OBESE,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TELEPHONIC INTERVIEW DURING THE ITALIAN LOCKDOWN.,PSYCHOLOGICAL CONDITIONS,Was it Right to Stop Bariatric Surgery During COVID-19 Lockdown?
NCT04453657,Enrolling by invitation,Interventional,Not Applicable,Johns Hopkins University,Other,4-Feb-21,21-Sep-21,21-Sep-21,SUPPORTIVE CARE,270,"STRESS, PSYCHOLOGICAL",UNITED STATES,ALL,"3 Years to 99 Years   (Child, Adult, Older Adult)",FAMILYCHILDCARE (PROVISIONAL NAME OF APP),CHANGE IN PERCEIVED LEVEL OF STRESS AS ASSESSED BY THE PERCEIVED STRESS SCALE,"Adapting and Delivering a Tele-Wellness Supported Digital Toolkit to Baltimore City's Approved Family Child Care Home Providers Caring for Children of Essential Workers: Promoting Health, Early Literacy, and Quality Parent Engagement Amid COVID-19: A Pilot Study"
NCT04453670,Completed,Observational,,University of Versailles,Other,10-Mar-20,15-May-20,11-May-20,CASE-ONLY,7,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AUTOPSY,DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME RELATED TO CORONAVIRUS-2 IN BRAIN TISSUES,A Prospective Observational Autopsy Study of Neuropathology in Adults Intensive Care Unit Patients With COVID 19
NCT04453748,Enrolling by invitation,Observational [Patient Registry],,Silesian Centre for Heart Diseases,Other,8-Jun-20,30-Nov-21,31-Oct-21,COHORT,200,COVID,POLAND,ALL,"18 Years to 120 Years   (Adult, Older Adult)",COMPLEX DIAGNOSTIC PANEL,PREVALENCE OF COVID-19 COMPLICATIONS,"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications"
NCT04453774,Not yet recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,16-Oct-20,23-Apr-21,21-Feb-21,HEALTH SERVICES RESEARCH,1000,CORONAVIRUS,CANADA,ALL,"Child, Adult, Older Adult",COVIDFREE@HOME,NUMBER OF PARTICIPANTS WITH AN UNPLANNED HOSPITAL ADMISSIONS,Covidfree@Home: At Home Monitoring Using Mobile Devices for Patients With Covid19
NCT04453839,Available,Expanded Access,,"NeuroRx, Inc.",Industry,,,,,,CRITICAL COVID WITH RESPIRATORY FAILURE,UNITED STATES,ALL,"12 Years to 100 Years   (Child, Adult, Older Adult)",RLF-100 (AVIPTADIL),,RLF-100 (Aviptadil) Intermediate Population Expanded Access Protocol
NCT04453852,Recruiting,Interventional,Phase 1,Vaxine Pty Ltd,Industry,30-Jun-20,1-Jul-21,1-Jul-21,PREVENTION,40,CORONAVIRUS INFECTION,AUSTRALIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",COVID19 VACCINE,INCIDENCE OF ADVERSE EVENTS,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects"
NCT04453891,Not yet recruiting,Observational,,Nguyen Thu Ngan Trinh,Industry,15-Jul-21,15-Dec-21,15-Dec-21,COHORT,16,COVID,,ALL,"55 Years and older   (Adult, Older Adult)",MONITORING PHYSIOLOGICAL DATA WITH THE HEXOSKIN SMART SHIRT,QUALITATIVE ASSESSMENT OF THE FEASIBILITY OF THE HEXOSKIN PLATFORM AND VIRTUAL RECRUITMENT PROCESS VIA THREE SUBJECTIVE FEEDBACK QUESTIONNAIRES PROVIDED TO ALL PATIENTS ENROLLED IN THE STUDY.,"Evaluating the Feasibility of Monitoring Symptomatic COVID-19 Patients, and Predicting Disease Progression Using a Validated Digital Health Program"
NCT04453969,Recruiting,Observational,,Deborah O'Connor,Other,24-May-20,21-Jan-21,21-Jan-21,COHORT,50,SARS-COV2,CANADA,ALL,"Child, Adult, Older Adult",COVID-19,PRESENCE OF SARS-COV-2 IN BREASTMILK,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a
NCT04453982,Recruiting,Observational,,Deborah O'Connor,Other,21-Jun-20,21-Feb-21,21-Feb-21,COHORT,500,SARS-COV2,CANADA,ALL,"Child, Adult, Older Adult",HUMAN MILK DONORS,PREVALENCE OF SARS-COV-2 IN BREASTMILK,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b
NCT04454307,Not yet recruiting,Interventional,Phase 1/Phase 2,Tanta University,Other,20-Jul-21,20-Oct-21,20-Aug-21,TREATMENT,100,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TRAMADOL,NUMBER OF COVID-19 PCR NEGATIVE CASES,Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients: A Randomized Double Blind Controlled Clinical Trial
NCT04454333,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,3-Jun-20,20-Jun-20,18-Jun-20,COHORT,466,INFECTION,TURKEY,ALL,"18 Years to 95 Years   (Adult, Older Adult)",,NUMERIC RATING SCALE FOR PAIN,COVID-19 in Pain Perspective
NCT04454372,Not yet recruiting,Observational,,Hospital Sao Domingos,Other,15-Jul-20,30-Nov-20,20-Sep-20,COHORT,187,COVID,,ALL,"1 Year and older   (Child, Adult, Older Adult)",DEMOGRAPHIC AND CLINICAL DATA OBTAINED FROM HOSPITAL'S ELECTRONIC MEDICAL RECORD.,OUTCOME 30 DAYS AFTER ICU ADMISSION,Clinical Characteristics and Outcomes of 187 Critically Ill Patients With COVID-19
NCT04454398,Withdrawn,Interventional,Phase 1,"Sorrento Therapeutics, Inc.",Industry,20-Sep-21,21-Jan-21,21-Jan-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVI-GUARD,INCIDENCE OF ADVERSE EVENTS (SAFETY),"A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19"
NCT04454606,Completed,Interventional,Not Applicable,Bangkok Metropolitan Administration Medical College and Vajira Hospital,Other,1-May-20,31-May-20,15-May-20,PREVENTION,43,COVID,THAILAND,ALL,18 Years to 60 Years   (Adult),FIT TEST,FIT TEST,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19
NCT04455243,Not yet recruiting,Interventional,Phase 3,Dr. Tariq Alhawassi,Other,1-Aug-20,30-Aug-21,30-Aug-21,TREATMENT,1180,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",N-ACETYL CYSTEINE,TIME TO RECOVERY,Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19
NCT04455308,Completed,Interventional,Not Applicable,Rennes University Hospital,Other,21-Jul-20,19-Oct-20,19-Oct-20,OTHER,269,CHILBLAINS,FRANCE,ALL,"Child, Adult, Older Adult",BIOLOGICAL SAMPLE COLLECTION,"LEVEL OF VIRAL EXPOSURE IN ""CASE FAMILY"" COMPARED TO ""COMPARATOR FAMILY""","Chilblains, COVID-19 and Lockdown: Epidemiologic Study"
NCT04455347,Recruiting,Observational [Patient Registry],,Imagine Institute,Other,15-Jun-20,22-Jun-21,22-Jun-21,COHORT,80,COVID INFECTION,FRANCE,ALL,"up to 20 Years   (Child, Adult)",,IMAGING DATA AT BASELINE,Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked
NCT04455360,Recruiting,Interventional,Not Applicable,University Hospital Southampton NHS Foundation Trust,Other,1-Oct-20,21-Sep-21,21-Mar-21,SUPPORTIVE CARE,26,POST TRAUMATIC STRESS DISORDER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EYE MOVEMENT DESENSITISATION AND REPROCESSING RECENT TRAUMATIC EVENT PROTOCOL,"FEASIBILITY OF RECRUITMENT, INTERVENTION ADHERENCE, INCIDENCE OF TREATMENT RELATED ADVERSE EVENTS AND TRIAL COMPLETION TO FINAL ASSESSMENT TIMEPOINTS",EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial
NCT04455451,Recruiting,Observational,,University Hospital Tuebingen,Other,6-Aug-20,23-Jun-21,22-Dec-21,COHORT,2000,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,Intensive Care Therapy of Covid-19 Disease in Germany an Multi-center Observational Study
NCT04455815,Recruiting,Interventional,Phase 2/Phase 3,Cancer Research UK,Other,25-Sep-20,31-Aug-21,31-Aug-21,TREATMENT,389,COVID INFECTION,UNITED KINGDOM,ALL,"50 Years and older   (Adult, Older Adult)",CAMOSTAT,NUMBER OF PARTICIPANTS WHO REQUIRE HOSPITAL ADMISSION AND REQUIRE SUPPLEMENTAL OXYGEN.,"A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion"
NCT04455958,Not yet recruiting,Interventional,Phase 2,OHSU Knight Cancer Institute,Other,1-Nov-20,1-Nov-21,1-Nov-21,TREATMENT,75,HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LOPINAVIR/RITONAVIR,SEVERITY OF SYMPTOMS,"A Double-Blind, Randomized, Placebo-Controlled Phase II Study of Lopinavir/Ritonavir Versus Placebo in COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year"
NCT04456010,Completed,Observational,,"University Hospital, Montpellier",Other,1-Jun-20,30-Jul-20,30-Jul-20,OTHER,600,COVID,FRANCE,ALL,18 Years to 60 Years   (Adult),QUESTIONNAIRE,PERSONAL EXPERIENCE OF THE COVID19 PANDEMIC AND THE DISCONTINUATION OF THEIR FERTILITY TREATMENT PANDEMIC AND THE DISCONTINUATION,Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART)
NCT04456036,Recruiting,Observational [Patient Registry],,Università Politecnica delle Marche,Other,1-Jul-20,30-Jun-21,31-Dec-20,COHORT,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,"CHANGE FROM PRE-COVID-19 CONDITION IN ADL INDEPENDENCE ON THE MOD. RANKIN SCALE SCORE AT THE ENROLMENT (T0) ASSESSMENT, AT 3, 6 AND 12 MONTHS","Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care: Study of Functional Evolution, Predictors of Activities and Participation Recovery After Severe Covid-19 and Rehabilitation Role"
NCT04456049,Not yet recruiting,Interventional,Phase 2,Ricardo Pereira Mestre,Other,20-Jul-21,21-Dec-21,21-Dec-21,TREATMENT,90,COVID INFECTION,SWITZERLAND,MALE,"50 Years and older   (Adult, Older Adult)",ENZALUTAMIDE,EFFICACY OF ENZALUTAMIDE,COVID_ENZA Trial: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
NCT04456062,Recruiting,Interventional,Not Applicable,Sunnybrook Health Sciences Centre,Other,4-Aug-20,21-Mar-21,21-Mar-21,HEALTH SERVICES RESEARCH,150,PSYCHIATRIC HOSPITALIZATION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",CARING CONTACTS,HOPKINS SYMPTOM CHECKLIST-25 (HSCL-25),Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic
NCT04456075,Recruiting,Observational,,Heidelberg University,Other,1-Apr-20,22-Apr-21,22-Apr-21,COHORT,100,SARS-COV2,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,TLCO,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19
NCT04456088,Withdrawn,Interventional,Phase 2,Beyond Air Inc.,Industry,15-Jul-20,15-Dec-20,15-Nov-20,TREATMENT,0,COVID,,ALL,"22 Years to 75 Years   (Adult, Older Adult)",150 PPM NITRIC OXIDE DELIVERED THROUGH LUNGFIT DELIVERY SYSTEM,TIME TO DETERIORATION,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2
NCT04456101,Recruiting,Observational,,"Wuhan Union Hospital, China",Other,19-Jun-20,1-Jun-22,1-Dec-20,COHORT,240,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,PULMONARY FUNCTION,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"
NCT04456153,Completed,Interventional,Phase 2,University of Texas Southwestern Medical Center,Other,22-Jul-20,31-Jan-21,31-Jan-21,TREATMENT,61,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXPERIMENTAL GROUP,PRIMARY ANALYSIS,Atovaquone for Treatment of COVID-19
NCT04456361,"Active, not recruiting",Interventional,Early Phase 1,Instituto de Medicina Regenerativa,Industry,16-Apr-20,15-Dec-20,15-Oct-20,TREATMENT,9,"ARDS, HUMAN",MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STEM CELLS DERIVED FROM WHARTON JELLY OF UMBILICAL CORDS,OXYGEN SATURATION,A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19
NCT04456413,Recruiting,Interventional,Phase 2,Hackensack Meridian Health,Other,6-Nov-20,21-Nov-21,21-Nov-21,TREATMENT,306,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,HOSPITALIZATION RATE,Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection
NCT04456426,Not yet recruiting,Observational,,Hospital Departamental de Villavicencio,Other,20-Jul-21,20-Aug-21,20-Aug-21,ECOLOGIC OR COMMUNITY,250,COVID,,ALL,"up to 120 Years   (Child, Adult, Older Adult)",,MORTALITY,"Evaluation of the Characteristics of Patients and Healthcare Workers With Suspected or Confirmed of COVID-19 in Villavicencio and Meta State, Colombia"
NCT04456439,Available,Expanded Access,,Mesoblast International Sàrl,Industry,,,,,,MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID),,ALL,2 Months to 17 Years   (Child),REMESTEMCEL-L,,"Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)"
NCT04456452,Completed,Interventional,Phase 1,Ampio Pharmaceuticals. Inc.,Industry,27-Jul-20,30-Nov-20,8-Sep-20,TREATMENT,10,COVID,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",AMPION,INCIDENCE AND SEVERITY OF ADVERSE EVENTS,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampion™ in Adult COVID-19 Patients Requiring Oxygen Supplementation
NCT04456556,Completed,Observational,,Minia University,Other,27-Apr-20,30-Jun-20,20-Jun-20,CASE-ONLY,5,ENDOPHTHALMITIS AND ORBITAL CELLULITIS,EGYPT,ALL,"Child, Adult, Older Adult",,COMBINED ENDOPHTHALMITIS AND ORBITAL CELLULITIS IN PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19),Combined Endophthalmitis and Orbital Cellulitis in Patients With Novel Coronavirus Disease (COVID-19)
NCT04456595,"Active, not recruiting",Interventional,Phase 3,Butantan Institute,Other,21-Jul-20,22-Feb-21,17-Dec-20,PREVENTION,12688,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ADSORBED COVID-19 (INACTIVATED) VACCINE,INCIDENCE OF COVID-19 CASES AFTER TWO-DOSES IMMUNIZATION SCHEDULE,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac"
NCT04456933,Recruiting,Observational,,Corporacion Parc Tauli,Other,29-Jun-20,28-Feb-22,31-Dec-21,COHORT,148,COLON CANCER,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",EXTRACORPOREAL LEFT HEMICOLECTOMY ANASTOMOSIS,PERCENTAGE OF ANASTOMOTIC LEAK (AL),RESECTION AND INTRACORPOREAL ANASTOMOSIS IN LAPAROSCOPIC LEFT COLECTOMY AS AN ADAPTATION TO THE PANDEMIC CAUSED BY SARS-CoV-2 (COVID19). A COMPARATIVE COHORT STUDY
NCT04457349,Recruiting,Interventional,Not Applicable,Alexandria University,Other,25-Jul-20,20-Jan-21,29-Dec-20,TREATMENT,10,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE (TPE),MORTALITY,Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?
NCT04457388,Completed,Interventional,Not Applicable,Aarogyam UK,Other,25-Mar-20,15-Jun-20,15-Jun-20,SUPPORTIVE CARE,18,CHRONIC PAIN,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),TELE-YOGA THERAPY,PAIN INTENSITY,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial
NCT04457505,Recruiting,Observational [Patient Registry],,"Consorcio Centro de Investigación Biomédica en Red, M.P.",Other,8-May-20,31-May-21,31-May-21,COHORT,5000,ACUTE RESPIRATORY DISTRESS SYNDROME,SPAIN,ALL,"Child, Adult, Older Adult",,ONE YEAR MORTALITY,"Risk Factors, Personalized Prognoses and 1-year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19"
NCT04457570,Recruiting,Observational,,Hospices Civils de Lyon,Other,15-Jun-20,15-Feb-21,15-Dec-20,CASE-CONTROL,600,"COVID, CANCER",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MORTALITY,MORTALITY FOR SARS-COV-2 INFECTION,ONCOVID-AURA: Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer
NCT04457609,Recruiting,Interventional,Phase 1,Indonesia University,Other,20-Jul-21,20-Sep-21,20-Aug-21,TREATMENT,40,COVID,INDONESIA,ALL,"18 Years to 95 Years   (Adult, Older Adult)",OSELTAMIVIR,CLINICAL IMPROVEMENT: PRESENCE OF DYSPNEA,Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients
NCT04457726,Recruiting,Interventional,Phase 1/Phase 2,KK Women's and Children's Hospital,Other,1-Jul-20,22-Dec-21,21-Mar-21,TREATMENT,18,COVID,SINGAPORE,ALL,"1 Year to 90 Years   (Child, Adult, Older Adult)",SARS-COV-2 SPECIFIC T CELLS,DOSE-LIMITING TOXICITIES,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19
NCT04457817,Enrolling by invitation,Interventional,Not Applicable,"University of Colorado, Denver",Other,1-Dec-20,21-Jul-21,21-Jul-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CRI MANAGEMENT,VOLUME OF IV FLUID INFUSED,CRI and Continuous Assessment of Hemodynamic Compensation to Guide Fluid and Pressor Management in Severely Ill Patients With COVID-19
NCT04458246,Recruiting,Interventional,Not Applicable,University of Sao Paulo,Other,20-Jul-21,21-Jun-21,20-Dec-21,TREATMENT,140,CHRONIC DISEASE,BRAZIL,ALL,"10 Years to 19 Years   (Child, Adult)",EXERCISE TRAINING GROUP,SAFETY AND EFFICACY OF A HOME-BASED EXERCISE TRAINING PROGRAM,"Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial"
NCT04458298,Recruiting,Interventional,Phase 2,"Orpheris, Inc.",Industry,1-Jul-20,31-Jan-21,31-Jan-21,TREATMENT,24,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OP-101,NUMBER OF PARTICIPANTS WITH TREATMENT EMERGENT ADVERSE EVENTS GRADED AS ASSESSED BY CTCAE VERSION 4.0,"A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19"
NCT04458337,Recruiting,Observational,,Centre hospitalier de l'Université de Montréal (CHUM),Other,13-Mar-20,13-Apr-21,13-Mar-21,COHORT,120,COVID,CANADA,ALL,"Child, Adult, Older Adult",,SURVIVAL UP TO 30 DAYS AFTER SURGERY,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study
NCT04458363,Completed,Interventional,Early Phase 1,Emory University,Other,4-Jul-20,1-Sep-20,1-Sep-20,TREATMENT,3,COVID,UNITED STATES,ALL,"up to 22 Years   (Child, Adult)",CONVALESCENT PLASMA (CP),"NUMBER OF GRADE 3-5 ADVERSE EVENTS THAT ARE POSSIBLE, PROBABLY OR DEFINITELY RELATED TO THE CONVALESCENT PLASMA (CP) INFUSION",Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study
NCT04458519,Recruiting,Interventional,Not Applicable,Centre hospitalier de l'Université de Montréal (CHUM),Other,16-Jul-20,30-Apr-21,30-Apr-21,TREATMENT,40,COVID INFECTION,CANADA,ALL,18 Years to 59 Years   (Adult),PROBIORINSE,CHANGE IN SEVERITY OF COVID-19 INFECTION,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection
NCT04458948,"Active, not recruiting",Interventional,Phase 2,University of New Mexico,Other,24-Mar-20,24-Mar-25,24-Mar-21,TREATMENT,10000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,DURATION OF VIRAL SHEDDING,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection
NCT04459247,"Active, not recruiting",Interventional,Not Applicable,Postgraduate Institute of Medical Education and Research,Other,15-Jun-20,10-Sep-20,30-Aug-20,TREATMENT,30,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",VIT D,VIRUS NEGATIVITY,"Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study"
NCT04459286,Recruiting,Interventional,Phase 2,Obafemi Awolowo University,Other,9-Oct-20,30-Apr-21,31-Mar-21,TREATMENT,98,COVID,NIGERIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",NITAZOXANIDE AND ATAZANAVIR/RITONAVIR,TIME TO CLINICAL IMPROVEMENT,"A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study"
NCT04459312,Recruiting,Observational,,"Heinrich-Heine University, Duesseldorf",Other,1-Jun-20,30-Sep-20,10-Jul-20,COHORT,600,ANTIBODY COVID,GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ANTIBODY TEST (SARS-COV2),PRESENCE OF ANTIBODIES AGAINST SARS-COV2,National Covid-Surveillance Physicians
NCT04459325,Completed,Interventional,Phase 3,AO GENERIUM,Industry,1-Jun-20,20-Jul-20,20-Jul-20,TREATMENT,100,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",TIGERASE® AND BEST AVAILABLE CARE,THE PROPORTION OF PATIENTS WITH MECHANICAL VENTILATION,A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
NCT04459351,Recruiting,Observational,,Chelsea and Westminster NHS Foundation Trust,Other,19-Jun-20,23-Jun-21,23-May-21,COHORT,500,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,IDENTIFICATION OF BASELINE CHARACTERISTICS WHICH CORRELATE WITH DISEASE SEVERITY,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs
NCT04459364,Completed,Observational [Patient Registry],,Attgeno AB,Industry,1-Jun-20,15-Jul-20,7-Jul-20,COHORT,67,"HYPERTENSION, PULMONARY",SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE,"The Prevalence of Pulmonary Hypertension, With or Without Right Ventricular Loading, in Patients With COVID-19 Who Are Being Treated With a Respirator in the Intensive Care Unit."
NCT04459390,Recruiting,Observational,,Assiut University,Other,20-Jul-20,20-Nov-20,20-Oct-20,CASE-CONTROL,100,COVID,EGYPT,ALL,"Child, Adult, Older Adult",REALTIME PCR,RATE OF RECOVERY/ ICU ADMISSION/ NEED FOR MECHANICAL VENTILATION,Impact of Comorbidities on COVID19 Outcome
NCT04459403,Completed,Observational,,Cairo University,Other,8-Jun-20,30-Dec-20,30-Dec-20,CASE-ONLY,400,CORONAVIRUS INFECTION,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,"PSYCHIATRIC WELL-BEING, LEVEL OF ANXIETY, SYMPTOMS OF DEPRESSION AND COPING STRATEGIES QUESTIONNAIRE",Psychiatric Disturbances in Patients Infected With COVID-19: A Cross Sectional Study
NCT04459455,Completed,Interventional,Not Applicable,Stony Brook University,Other,19-Aug-20,15-Oct-20,15-Oct-20,TREATMENT,500,ANXIETY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONTAIN COVID ANXIETY SSI,CHANGE IN ANXIETY CONTROL QUESTIONNAIRE (ACQ) FROM BASELINE TO IMMEDIATELY POST-INTERVENTION,"Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic"
NCT04459520,Completed,Interventional,Not Applicable,"University of California, Los Angeles",Other,23-Jul-20,29-Jul-20,28-Jul-20,SCREENING,1400,COVID,UNITED STATES,ALL,"18 Years to 110 Years   (Adult, Older Adult)",POSITIVE COVID TEST RESULT - HYPOTHETICAL SCENARIO,BEHAVIORAL INTENTIONS,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance
NCT04459533,Completed,Observational,,Hospices Civils de Lyon,Other,1-Jun-20,1-Jun-20,1-Jun-20,CASE-CONTROL,250,NEUROMUSCULAR BLOCKADE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TOF PROTOCOL,NMB AGENTS CONSUMPTION,The Use of Neuromuscular Blockade Monitor as a Strategy for Neuromuscular Blockade Agents Saving in ICU COVID-19 Patients
NCT04459637,Not yet recruiting,Observational [Patient Registry],,Peking University First Hospital,Other,1-Jul-20,10-Mar-21,10-Mar-21,COHORT,200,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,DETERIORATION OF THE CONDITION,Surveillance of COVID-19 Using Smart Wearable Devices: a Prospective Study
NCT04459676,Recruiting,Interventional,Phase 2,Angion Biomedica Corp,Industry,31-Jul-20,20-Oct-21,20-Oct-21,TREATMENT,100,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OF CARE (SOC) + ANG-3777,"PROPORTION OF PATIENTS ALIVE, WITHOUT THE NEED FOR MECHANICAL VENTILATION AND FREE OF THE NEED FOR RRT (ON AN ONGOING BASIS) AT DAY 28","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia"
NCT04459689,Recruiting,Observational [Patient Registry],,Imagine Institute,Other,15-Mar-20,31-Mar-22,31-Mar-22,CASE-ONLY,200,PRIMARY IMMUNE DEFICIENCY,FRANCE,ALL,"Child, Adult, Older Adult",,SURVIVAL OF PATIENTS WITH PID AFFECTED BY COVID-19,Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey
NCT04459702,Not yet recruiting,Interventional,Phase 2,ProgenaBiome,Other,20-Jul-21,21-Dec-21,21-Jul-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,EFFICACY OF TREATMENT BY REDUCED SYMPTOMS NEWS (NATIONAL EARLY WARNING SYSTEM) SCORES,"A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection"
NCT04459819,Completed,Observational,,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Other,1-Mar-20,30-Sep-20,30-Sep-20,CASE-ONLY,84,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RESPIRATORY PHYSIOTHERAPY,NUMBER OF PHYSIOTHERAPY TREATMENTS,"Monocentric, Observational, Retrospective Study on Respiratory Physiotherapy in Severe COVID-19 Patients: the FTR-COVID Study."
NCT04459962,Completed,Interventional,Not Applicable,Ancon Technologies Ltd,Industry,29-Jun-20,7-Jan-21,7-Jan-21,DIAGNOSTIC,330,COVID INFECTION,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",BREATH TEST & CHEEK SWAB,TO INVESTIGATE/ EXAMINE THE EFFECTIVENESS OF NANOTECHNOLOGY BIOMARKER TAGGING (NBT) IN DETECTING COVID-19 INFECTION USING BREATH SAMPLES OF PATIENTS WITH COVID-19 SYMPTOMS,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis
NCT04459975,Recruiting,Observational,,Hospices Civils de Lyon,Other,1-Apr-20,20-Nov-21,20-Oct-21,COHORT,200,ON OCCURRENCE OF ACURATE KIDNEY INJURY DURING INTENSIVE CARE UNIT,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NON INTERVENTIONAL STUDY,"PRIMARY ENDPOINT IS THE INCIDENCE, THE SEVERITY AND THE MORTALITY ASSOCIATED WITH AKI DURING COVID-19 SEVERE INFECTION",Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units
NCT04460014,Recruiting,Interventional,Not Applicable,Karolinska Institutet,Other,30-Sep-20,1-Aug-21,1-Mar-21,PREVENTION,164,INTRUSIVE MEMORIES OF TRAUMATIC EVENT(S),SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",SIMPLE COGNITIVE TASK INTERVENTION,NUMBER OF INTRUSIVE MEMORIES OF TRAUMATIC EVENT(S),"Reducing Intrusive Memories After Trauma Via a Simple Cognitive Intervention During COVID-19 in Hospital Staff: ""EKUT-P"" (Enkel Kognitiv Uppgift Efter Trauma Under COVID-19 - sjukvårdspersonal) - A Randomized Controlled Trial (RCT)"
NCT04460027,Completed,Interventional,Phase 1,Athena Robinson,Industry,22-Jun-20,30-Nov-20,30-Nov-20,TREATMENT,180,SUBSTANCE USE DISORDERS,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",WOEBOT SUBSTANCE USE DISORDER,CHANGE OF NUMBER OF DAYS DRINKING,Woebot for Substance Use Disorders During COVID-19
NCT04460105,Withdrawn,Interventional,Phase 1,Shire,Industry,31-Oct-20,27-Jan-21,27-Jan-21,TREATMENT,0,COVID PNEUMONIA,,ALL,"18 Years and older   (Adult, Older Adult)",LANADELUMAB,NUMBER OF PARTICIPANTS WITH TREATMENT EMERGENT ADVERSE EVENTS (TEAES),"A Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 Pneumonia"
NCT04460170,Recruiting,Observational [Patient Registry],,University Medical Center Groningen,Other,1-Jul-20,1-Feb-22,1-Feb-22,COHORT,100,QUALITY OF LIFE,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,GENERAL HEALTH,COVID-19 Follow up Intensive Care Studies
NCT04460183,Recruiting,Interventional,Phase 2/Phase 3,Thirty Respiratory Limited,Industry,29-Jul-20,23-Apr-21,27-Jan-21,TREATMENT,300,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)","RESP301, A NITRIC OXIDE GENERATING SOLUTION",PROPORTION OF PARTICIPANTS WHO PROGRESS BY AT LEAST ONE LEVEL HIGHER ON THE MODIFIED WHO ORDINAL SCALE BY DAY 14,"An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)"
NCT04460196,Completed,Observational [Patient Registry],,"University Hospital, Angers",Other,8-Jul-20,18-Sep-20,18-Sep-20,COHORT,900,EMERGENCY MEDICINE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,RATE OF PATIENTS WHO GAVE UP CONSULTING IN THE EMERGENCY DEPARTMENT,Healthcare Renunciation During the Confinement Period in Connection With the COVID-19 Epidemic in Adult Emergency Departments
NCT04460274,Completed,Observational,,Turkish Ministry of Health Izmir Teaching Hospital,Other,31-Dec-19,20-Jun-20,15-Jun-20,COHORT,7882471,COVID,TURKEY,ALL,"Child, Adult, Older Adult",MODEL BUILDING,NUMBER OF CONFIRMED CASES OF COVID-19,Time Series Model For Forecasting the Number of Covid-19 Cases Worldwide - A Prospective Cohort Study
NCT04460443,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,1-Aug-20,31-Aug-21,1-Aug-21,TREATMENT,60,COVID,EGYPT,ALL,"Child, Adult, Older Adult",SOFOSBUVIR,NUMBER OF PATIENTS WITH RESPONSE TO TREATMENT,Sofosbuvir Based Regimens in Treatment of COVID 19 Patients
NCT04460469,Recruiting,Observational,,Cairo University,Other,1-Jul-20,20-Sep-21,20-Sep-21,OTHER,1500,ANXIETY,EGYPT,ALL,"Child, Adult, Older Adult",,CORRELATE BETWEEN THE LEVEL OF ANXIETY AND THE PRACTICE OF ORAL HYGIENE DURING COVID-19 PANDEMIC IN DENTAL STUDENTS OF CAIRO UNIVERSITY,Self-assessment of Anxiety Level and Oral Hygiene Practice in Dental Students of Cairo University During Covid-19 Pandemic
NCT04460534,Recruiting,Interventional,Not Applicable,GCS Ramsay Santé pour l'Enseignement et la Recherche,Other,7-May-20,31-Aug-21,31-Jul-21,DIAGNOSTIC,100,COVID,FRANCE,MALE,"18 Years to 65 Years   (Adult, Older Adult)",DIAGNOSTIC,TESTING FOR THE PRESENCE OF COVID-19 (SARS-COV-2 VIRUS) IN THE SEMEN,Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab)
NCT04460547,Not yet recruiting,Observational,,Qassim University,Other,25-Jul-20,20-Sep-20,15-Aug-20,COHORT,200,COVID,,ALL,"1 Year and older   (Child, Adult, Older Adult)",CONVALESCENT PLASMA TRANSFUSION,GEOGRAPHICAL DISTRIBUTION OF THE INTERVENTIONAL STUDIES AFTER 11TH OF MARCH 2020.,Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study
NCT04460599,Recruiting,Observational,,Centre d'Investigation Clinique et Technologique 805,Other,8-Mar-20,30-Sep-20,30-Jul-20,COHORT,30,ENCEPHALITIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION,PRIMARY,Description of neurolOgical Involvement Observed During SARS COV2 Infection
NCT04460638,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,23-Jul-20,22-Jul-21,22-Jul-21,COHORT,600,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA COLLECTION,DEVELOPMENT OF A TEST BASED ON THE MALDI-TOF PROFILING METHOD TO DETECT INDIVIDUALS INFECTED WITH SARS-COV2 FROM SALIVA SAMPLE.,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
NCT04460651,Recruiting,Interventional,Phase 3,Estudios Clínicos Latino América,Other,14-Aug-20,21-Jan-21,21-Jan-21,TREATMENT,2000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",ICOSAPENT ETHYL (IPE),PERCENTAGE OF SARS-COV-2 POSITIVE SUBJECTS,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial
NCT04460664,Enrolling by invitation,Observational,,HemoSonics LLC,Industry,14-Aug-20,15-Feb-21,31-Jan-21,COHORT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUANTRA SYSTEM,QUANTRA CLOT TIME RESULTS,Exploratory Assessment of the Coagulation Changes Associated With Severe Inflammation in COVID-19 Patients
NCT04460677,Recruiting,Interventional,Not Applicable,"Rutgers, The State University of New Jersey",Other,12-Aug-20,31-Mar-21,31-Mar-21,PREVENTION,80,PSYCHOLOGICAL DISTRESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EMOTIONAL SUPPORT PLAN,DECREASED DISTRESS ON PATIENT HEALTH QUESTIONNAIRE (PHQ-9),ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease)
NCT04460690,Enrolling by invitation,Interventional,Not Applicable,"University of Wisconsin, Madison",Other,13-Jul-20,21-Jul-21,21-Jul-21,DIAGNOSTIC,10000,COVID,UNITED STATES,ALL,"5 Years and older   (Child, Adult, Older Adult)",RAPID ONSITE COVID-19 DETECTION,NUMBER OF SAMPLES TESTED CONSISTENTLY AND ACCURATELY PER PROTOCOL,"Rapid, Onsite COVID-19 Detection"
NCT04460703,Completed,Interventional,Not Applicable,Yale University,Other,3-Jul-20,8-Jul-20,8-Jul-20,OTHER,4000,VACCINATION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONTROL MESSAGE,INTENTION TO GET COVID-19 VACCINE,"Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1"
NCT04461340,Recruiting,Interventional,Phase 2,Alexandria University,Other,15-Aug-20,30-Nov-20,30-Oct-20,TREATMENT,40,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SIROLIMUS,TIME TO CLINICAL RECOVERY,Efficacy and Safety of Sirolimus for Treating COVID-19 Infection
NCT04461353,Completed,Interventional,Phase 1,"Pulmoquine Therapeutics, Inc",Industry,25-Jun-20,17-Aug-20,17-Aug-20,TREATMENT,12,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AEROLIZED HYDROXYCHLOROQUINE SULFATE,INCIDENCES OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES) AS ASSESSED BY TGSHAAV (SEPTEMBER 2007) OR CTCAE VERSION 5.0,"A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers"
NCT04461379,"Active, not recruiting",Interventional,Phase 3,Hospital Universitario Dr. Jose E. Gonzalez,Other,21-Jul-20,1-Jan-21,1-Jan-21,PREVENTION,908,BCG,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",BCG VACCINE,DEMONSTRATE COVID- 19 DISEASE INCIDENCE AMONG HEALTH CARE WORKERS:,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial"
NCT04461925,Recruiting,Interventional,Phase 1/Phase 2,Institute of Cell Therapy,Industry,2-May-20,21-Dec-21,2-May-21,TREATMENT,30,COVID PNEUMONIA,UKRAINE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PLACENTA-DERIVED MMSCS; CRYOPRESERVED PLACENTA-DERIVED MULTIPOTENT MESENCHYMAL STROMAL CELLS,"CHANGES OF OXYGENATION INDEX PAO2/FIO2, MOST CONVENIENTLY THE P/F RATIO.",Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord
NCT04462120,"Active, not recruiting",Observational,,Assiut University,Other,16-Jun-20,30-Jul-20,18-Jun-20,COHORT,100,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,MEASURE LEVEL OF POLYMORPHISMS OF INTERLEUKIN (IL)-12 RECEPTOR B1 (IL-12RB1) AND TNF- Α ALPHA ON COVID-19 RELATED SEVERE ACUTE RESPIRATORY SYNDROME (SARS-COV-2).,Association Between IL-12RB and TNF-alpha Gene Polymorphism With Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study
NCT04462367,Recruiting,Observational,,Instituto Materno Infantil Prof. Fernando Figueira,Other,1-Jul-20,20-Dec-22,30-Jun-22,COHORT,180,COVID,BRAZIL,FEMALE,"Child, Adult, Older Adult",,NEAR MISS MATERNAL:,Clinical and Laboratory Predictors of COVID-19 Progression and Maternal and Perinatal Outcomes in Infected Pregnant and Postpartum Women in Six Reference Centers in the Northeast of Brazil
NCT04462393,Completed,Observational,,Linkoeping University,Other,6-Mar-20,6-May-20,6-May-20,COHORT,1563,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",ADMISSION TO ICU FOR COVID-19,30-DAY MORTALITY,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19 During the First 60 Days of the 2020 Pandemic
NCT04462627,Recruiting,Interventional,Not Applicable,Hanane EL KENZ,Other,14-Apr-20,21-Dec-21,21-Dec-21,PREVENTION,500,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD GROUP DETERMINATION,ANTI-A ANTIBODY CONCENTRATION,Reduction of COVID 19 Transmission to Health Care Professionals
NCT04462757,Suspended,Interventional,Phase 2,University of Manchester,Other,28-May-20,31-Dec-20,31-Aug-20,HEALTH SERVICES RESEARCH,5,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA 100MG/0.67ML INJ SYRINGE,PLASMA IL-1RA LEVELS,Subcutaneous and Intravenous IL-1Ra (Anakinra) in COVID-19 Infection - Feasibility & Pharmacokinetics/Pharmacodynamics Study
NCT04462783,Not yet recruiting,Interventional,Not Applicable,University of Michigan,Other,21-Mar-21,21-Sep-21,21-Aug-21,OTHER,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SYMPTOMS ENTERED INTO THE COVIDX APPLICATION,CHANGE IN THE PERCENT OF PARTICIPANTS USING THE COVIDX WEB APPLICATION (APP) ON 50% OR GREATER OF DAYS,Feasibility of Self-monitoring and Patient Decision Support for Suspected COVID-19 Patients After Emergency Department Discharge
NCT04462848,Not yet recruiting,Interventional,Phase 1,"University of California, Los Angeles",Other,20-Aug-21,24-Dec-21,24-Sep-21,TREATMENT,30,CORONAVIRUS INFECTION,UNITED STATES,ALL,1 Month to 17 Years   (Child),ANTI-SARS-COV-2 HUMAN CONVALESCENT PLASMA,CUMULATIVE INCIDENCE OF GRADE 3 AND GRADE 4 ADVERSE EVENTS,Phase I Study of the Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2
NCT04463004,"Active, not recruiting",Interventional,Phase 2,Virginia Commonwealth University,Other,2-Sep-20,21-Aug-21,21-Aug-21,TREATMENT,2,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MAVRILIMUMAB,PROPORTION OF SUBJECTS ALIVE AND OFF OF OXYGEN AT DAY 14,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
NCT04463264,Recruiting,Interventional,Phase 2/Phase 3,Laboratorios Roemmers S.A.I.C.F.,Industry,26-Jun-20,26-Dec-20,15-Nov-20,TREATMENT,135,COVID,ARGENTINA,ALL,18 Years to 59 Years   (Adult),NITAZOXANIDE,ERADICATION OF SARS COV-2 FROM PATIENTS' RESPIRATORY TRACT SECRETIONS BY TREATMENT DAY 7TH.,"Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study"
NCT04463420,Recruiting,Interventional,Not Applicable,Baqiyatallah Medical Sciences University,Other,15-Aug-20,15-Dec-20,15-Nov-20,TREATMENT,224,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 75 Years   (Adult, Older Adult)",PHR160 SPRAY,DYSPNEA,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study
NCT04463433,Recruiting,Interventional,Not Applicable,Beijing Normal University,Other,1-Feb-20,31-Jan-22,31-Dec-21,PREVENTION,300,PARENT-CHILD RELATIONSHIP AND COUPLE RELATIONSHIP UNDER COVID IN CHINA,CHINA,ALL,30 Years to 60 Years   (Adult),COGNITIVE AND BEHAVIORAL INTERVENTION.,PARENT-CHILD CONFLICT,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China
NCT04463472,"Active, not recruiting",Interventional,Phase 1/Phase 2,"AnGes, Inc.",Industry,29-Jun-20,31-Jul-21,28-Sep-20,PREVENTION,30,COVID,JAPAN,ALL,"20 Years to 65 Years   (Adult, Older Adult)",AG0301-COVID19,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY],"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults"
NCT04463602,"Active, not recruiting",Interventional,Phase 2,Cadila Healthcare Limited,Industry,25-Jul-20,28-Feb-21,25-Jan-21,TREATMENT,24,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",DESIDUSTAT,CHANGE IN CLINICAL STATUS OF SUBJECT ON A 7-POINT ORDINAL SCALE,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients"
NCT04463628,Recruiting,Observational,,Centre Hospitalier Intercommunal Creteil,Other,15-May-20,30-Jun-21,30-Nov-20,COHORT,1200,CYSTIC FIBROSIS IN CHILDREN,FRANCE,ALL,"14 Years and older   (Child, Adult, Older Adult)",QUESTIONNAIRE,"CANCELLATION OR POSTPONEMENT OF CONSULTATIONS BY THE HEALTH PROFESSIONAL OR PATIENT,","Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic"
NCT04463706,Recruiting,Observational,,Hospital Galdakao-Usansolo,Other,1-Jun-20,31-Dec-21,30-Jun-21,COHORT,20000,COVID,SPAIN,ALL,"Child, Adult, Older Adult",PREDICTORS ADVERSE EVOLUTION,CLINICAL DETERIORATION,Clinical Characterization of CoVid19 Infection: Prognostic Stratification and Complications
NCT04463758,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,11-May-20,22-Oct-21,22-Feb-21,COHORT,3060,COVID INFECTION,FRANCE,FEMALE,"Child, Adult, Older Adult",AN AUTO-QUESTIONNAIRE COMPRISING THREE PSYCHOMETRIC SCALES,JOINT EVALUATION OF MORBI-MORTALITY FOR MOTHER AND CHILD UP TO 12 WEEKS POSTPARTUM,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns
NCT04463823,Not yet recruiting,Observational,,Oslo University Hospital,Other,6-Jul-20,31-May-25,31-May-22,CASE-ONLY,500,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",,OBSERVATION,Covid-19 Convalescent Plasma Used for Treatment of Patients in Norway - a Monitoring Study
NCT04463849,Recruiting,Interventional,Not Applicable,University of Milan,Other,30-Jun-20,30-Jun-21,30-Jun-21,DIAGNOSTIC,90,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STIMULATION TEST WITH ARGININE INFUSION IN ORDER TO VERIFY THE POSSIBLE EXISTENCE OF DAMAGE TO THE BETA CELL FUNCTION INDUCED BY COVID-19 INFECTION,SERUM Β - CELLULAR FUNCTION INDEX INSULIN LEVELS,Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients
NCT04463862,Recruiting,Observational [Patient Registry],,"University Hospital, Strasbourg, France",Other,4-Jun-20,4-Sep-20,4-Sep-20,COHORT,250,COVID CONFIRMED CASES,BELGIUM,ALL,"50 Years and older   (Adult, Older Adult)",,COVID-19 RELATED-MORTALITY,Air Pollution and COVID-19 Mortality in Geriatric Patients: a Multicenter Study
NCT04464395,Recruiting,Interventional,Phase 1,"Corvus Pharmaceuticals, Inc.",Industry,1-Jul-20,31-Aug-21,31-Mar-21,TREATMENT,70,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CPI-006,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS TO DETERMINE SINGLE DOSE OF CPI-006 THAT IS SAFE IN PATIENTS WITH COVID-19,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody
NCT04464408,Recruiting,Interventional,Phase 2/Phase 3,King Abdullah International Medical Research Center,Other,23-Jul-20,21-Dec-21,21-Dec-21,TREATMENT,576,COVID,SAUDI ARABIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",FAVIPIRAVIR,PCR NEGATIVE,A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19
NCT04464460,Withdrawn,Interventional,Phase 1,Takeda,Industry,25-Sep-20,30-Oct-20,30-Oct-20,TREATMENT,0,CORONAVIRUS DISEASE,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",TAK-671,NUMBER OF PARTICIPANTS REPORTING ONE OR MORE TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),"A Randomized, Double-blind, Placebo-Controlled Multicenter Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 2 Different Intravenous Doses of TAK-671 for the Treatment of Coronavirus Disease 2019 in Adults"
NCT04464486,Enrolling by invitation,Interventional,Not Applicable,University of Utah,Other,21-Apr-20,31-May-21,31-Mar-21,SUPPORTIVE CARE,300,ONCOLOGY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SCH INTERVENTION,HEALTH CARE UTILIZATION COMPARISON,Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home During the Pandemic
NCT04465058,Recruiting,Observational,,Assiut University,Other,8-Jul-20,10-Aug-20,8-Aug-20,OTHER,50,COVID,EGYPT,ALL,"Child, Adult, Older Adult",COVID19,CLINICAL CHARACTERISTICS,Clinical Characteristics and Outcome in Critically Ill COVID 19 Patients
NCT04465474,Recruiting,Observational [Patient Registry],,Chinese University of Hong Kong,Other,1-May-20,31-Dec-22,30-Apr-22,OTHER,3000,COVID,CHINA,FEMALE,"18 Years and older   (Adult, Older Adult)",NON INTERVENTION,SEROCONVERSION DURING PREGNANCY - DSS1,"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)"
NCT04465513,Not yet recruiting,Interventional,Not Applicable,Hofseth Biocare ASA,Industry,31-Aug-20,31-Aug-21,31-Aug-21,TREATMENT,100,ASTHMA; EOSINOPHILIC,CANADA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BEST STANDARD OF CARE + CARDIO,OXYGENATION REQUIREMENTS DURING HOSPITAL STAY (OXYGEN SATURATION RATES),"Randomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and/or Steroid-resistant Asthma Population With COVID-19 Infection"
NCT04465552,Recruiting,Observational,,Kansas City Heart Rhythm Research Foundation,Other,10-Jul-20,21-Oct-21,21-Jun-21,CASE-CONTROL,750,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS RECEIVED STANDARD OF CARE TREATMENT DURING HOSPITALIZATION,"TO BETTER CHARACTERIZE ARRHYTHMIC MANIFESTATIONS, EMPLOYED TREATMENT STRATEGIES AND LONG- TERM OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS IN THE US THROUGH A MULTICENTER RETROSPECTIVE CHART REVIEW.",Arrhythmic Manifestations and Management Strategies in Hospitalized COVID-19 Patients: Proposal for a Multicenter Registry
NCT04465604,Recruiting,Interventional,Not Applicable,King Faisal Specialist Hospital & Research Center,Other,1-Jul-20,21-May-21,1-Nov-20,TREATMENT,50,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",WEARING SURGICAL FACE MASK SPRAYED WITH HYPERTONIC SALINE,IMPROVEMENT OF RESPIRATORY SYMPTOMS,HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19
NCT04465656,Recruiting,Observational,,"Hospital St. Joseph, Marseille, France",Other,7-Jul-20,30-Apr-21,31-Oct-20,COHORT,250,PULMONARY EMBOLISM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY TEST FOR COVID-19,% OF PATIENTS FOR EACH GROUP PRESENTING THE OCCURRENCE OF PE COMPLICATIONS DEFINED BY THE OCCURRENCE OF AT LEAST ONE OF THE FOLLOWING EVENTS UP TO 6 MONTHS AFTER PE DIAGNOSIS.,Registry of the Evolution of Diagnosed and/or Hospitalized Patients for Pulmonary Embolism During the Covid-19 Pandemic: Retrospective and Prospective Multicentric Study.
NCT04465695,Recruiting,Interventional,Phase 2,The University of Hong Kong,Other,14-Jul-20,30-Sep-21,30-Jun-21,TREATMENT,81,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON BETA-1B,CLINICAL ALLEVIATION OF SYMPTOMS,"An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection"
NCT04465981,Recruiting,Observational,,INanoBio Inc.,Industry,20-Jul-21,21-Jun-21,20-Dec-21,COHORT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLING,DETECTION TEST OF COVID-19,"A Longitudinal, Non-randomized Study to Evaluate the Utility of the INanoBio's Protein Arrays in Detecting Unique Antibodies in COVID-19 Patients"
NCT04466098,Recruiting,Interventional,Phase 2,"Masonic Cancer Center, University of Minnesota",Other,30-Jul-20,1-Dec-21,1-Dec-21,TREATMENT,30,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,INCIDENCE OF GRADE 3-5 INFUSIONAL TOXICITIES AND PREDEFINED HEMODYNAMIC OR RESPIRATORY ADVERSE EVENTS RELATED TO THE INFUSION OF MSC,"Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)"
NCT04466241,Recruiting,Interventional,Phase 2/Phase 3,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),Other,27-Nov-20,26-Mar-21,26-Mar-21,TREATMENT,294,COVID,CÔTE D'IVOIRE,ALL,"18 Years and older   (Adult, Older Adult)",LOPINAVIR/RITONAVIR 200 MG-50 MG ORAL TABLET,PROPORTION OF PATIENTS WITH UNDETECTABLE NASOPHARYNGEAL SWAB SARS-COV-2 PCR AND C-REACTIVE PROTEIN (CRP) < 27 MG/L AT DAY 11,Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV): a Phase IIb Randomized Clinical Trial
NCT04466280,Recruiting,Interventional,Not Applicable,Baqiyatallah Medical Sciences University,Other,15-Jul-20,15-Dec-20,15-Nov-20,PREVENTION,180,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,PCR TEST,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran"
NCT04466306,Enrolling by invitation,Observational [Patient Registry],,Children's Healthcare of Atlanta,Other,15-Apr-20,1-Jul-21,8-Jul-20,COHORT,250,ACUTE KIDNEY INJURY,CANADA,ALL,"up to 25 Years   (Child, Adult)",,ACUTE KIDNEY INJURY (AKI),SARS-CoV2 Pediatric Acute Kidney Injury Registry and Collaborative
NCT04466371,Not yet recruiting,Observational,,Misr International University,Other,15-Oct-20,1-Nov-21,1-Jan-21,CASE-ONLY,9209,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,SATISFACTION WITH ONLINE LEARNING,Perceptions of Undergraduate Students and Teaching Staff on Online Teaching and Learning in the Wake of COVID-19 Pandemic in an Egyptian Private University: A Cross-Sectional Study
NCT04466462,Completed,Observational,,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Other,26-May-20,30-Jun-20,30-Jun-20,CASE-CROSSOVER,1000,SARS-COV2 INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PARTICIPANTS WITH PAST SARS-COV-2 INFECTION,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel
NCT04466540,Recruiting,Interventional,Phase 4,Hospital Alemão Oswaldo Cruz,Other,12-May-20,30-Mar-21,28-Jan-21,TREATMENT,1300,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,HOSPITALIZATION,"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19"
NCT04466605,Completed,Interventional,Not Applicable,Aarogyam UK,Other,30-Mar-20,6-Jul-20,30-Jun-20,SUPPORTIVE CARE,64,CHRONIC MUSCULOSKELETAL PAIN,INDIA,ALL,18 Years to 60 Years   (Adult),TELE-YOGA THERAPY,SEVERITY OF PAIN,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial
NCT04466644,Completed,Observational,,Igenomix,Industry,8-Jun-20,25-Aug-20,24-Aug-20,OTHER,340,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ELISA,PREVALENCE OF CONTAGIOUSNESS IN ASYMPTOMATIC INDIVIDUALS BY PCR WITH NASOPHARYNGEAL SWABS,"A Multicenter, Prevalence Study to Evaluate the Infectious and Immunological Status of COVID-19 in Asymptomatic Subjects Attending ART Centres After the Pandemic Lockdown in the USA"
NCT04466657,Not yet recruiting,Interventional,Not Applicable,Obafemi Awolowo University,Other,1-Nov-20,30-Apr-21,28-Feb-21,SUPPORTIVE CARE,90,COVID,NIGERIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ANTIOXIDATION THERAPY,TIME TO CLINICAL IMPROVEMENT,A Study to Evaluate Antioxidant Therapy for Moderate to Severe COVID-19 With or Without Comorbidities
NCT04466670,Recruiting,Interventional,Phase 3,University of Sao Paulo General Hospital,Other,8-Jul-20,30-Apr-21,30-Dec-20,TREATMENT,310,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",UNFRACTIONATED HEPARIN,HOSPITAL DISCHARGE - ALIVE / DEATH,Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial
NCT04466683,Recruiting,Interventional,Phase 2,Ohio State University Comprehensive Cancer Center,Other,28-Aug-20,31-Dec-22,31-Dec-21,TREATMENT,100,COVID,UNITED STATES,ALL,"50 Years and older   (Adult, Older Adult)",LOW DOSE RADIATION 35 CGY,STEP 1 DOSE SELECTION,Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for Patients With SARS-COV-2 Pneumonia
NCT04466800,Recruiting,Interventional,Not Applicable,Rennes University Hospital,Other,30-Jul-20,30-Nov-21,2-Apr-21,SUPPORTIVE CARE,160,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION GROUP_REHABILITATION PROGRAM,IMPACT OF A MULTIDISCIPLINARY AND PERSONALIZED REHABILITATION PROGRAM ON COVID PATIENTS'S QUALITY OF LIFE,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients
NCT04466839,Completed,Observational,,"University Hospital, Toulouse",Other,2-Jul-20,18-Dec-20,18-Dec-20,CASE-ONLY,411,PARKINSON DISEASE,FRANCE,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE AND INTERVIEW,IMPACT OF CONTAINMENT RELATED TO THE COVID-19 PANDEMIC.,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients
NCT04466982,Recruiting,Observational,,Cambridge University Hospitals NHS Foundation Trust,Other,2-Jul-20,22-Jan-21,21-Aug-21,COHORT,90,OLFACTORY DISORDER,UNITED KINGDOM,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,UPSIT SCORES,"Objective Assessment of Olfactory Dysfunction and Impact on Quality of Life in SARS CoV-2 (COVID-19)Infection Using the UPSIT, eQOD and SNOT-22 Questionnaires: A Prospective Observational Cohort Study"
NCT04467008,Completed,Observational,,CMC Ambroise Paré,Other,15-Jul-20,15-Aug-20,15-Aug-20,COHORT,113,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,POSITIVITY OF THE RAPID DIAGNOSTIC TEST,Evaluation of Covid-19 Rapid Diagnostic Tests on Blood Drop
NCT04467047,Not yet recruiting,Interventional,Phase 1,Hospital de Clinicas de Porto Alegre,Other,25-Jul-20,30-Dec-20,30-Oct-20,TREATMENT,10,COVID,,ALL,"Child, Adult, Older Adult",MESENCHYMAL STROMAL CELLS INFUSION,OVERALL SURVIVAL,Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19
NCT04467086,Recruiting,Interventional,Phase 3,Ottawa Hospital Research Institute,Other,11-Dec-20,21-May-21,21-Apr-21,TREATMENT,108,MECHANICAL VENTILATION,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",PROPRANOLOL HYDROCHLORIDE,PRIMARY SEDATIVE DOSE CHANGE,Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation: An Open-label Randomized Controlled Trial (PROACTIVE)
NCT04467112,Recruiting,Observational,,Owlstone Ltd,Industry,30-Jul-20,20-Dec-21,20-Oct-21,COHORT,100,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",BREATH BIOPSY FACE MASKS WITH REMOVABLE FILTERS AND FITTED PVA STRIP,DETECTION OF NCOVID-19 USING A FACE MASK,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols
NCT04467151,Withdrawn,Interventional,Phase 2,Kashif Khan,Other,20-Oct-21,21-Dec-21,21-Oct-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 PLASMA,DISEASE PROGRESSION MEASURED BY WHO SCALE,"A Randomized, Double-blind, Placebo-controlled Trial of Anti-SARS-CoV-2 Plasma in Hospitalized Non-ICU Patients With COVID-19"
NCT04467840,Recruiting,Interventional,Phase 2/Phase 3,RedHill Biopharma Limited,Industry,21-Aug-20,21-Jun-21,21-May-21,TREATMENT,464,COVID,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",OPAGANIB,SUPPLEMENTAL OXYGEN REQUIREMENT,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia"
NCT04467918,"Active, not recruiting",Interventional,Phase 2/Phase 3,University of Sao Paulo,Other,6-Jul-20,16-Dec-20,16-Nov-20,TREATMENT,100,SARS-COV2,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CANNABIDIOL,PREVENTION OF SEVERE/CRITICAL STAGE OF COVID19,"Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial"
NCT04467931,"Active, not recruiting",Observational,,University of Utah,Other,19-Jan-20,31-Dec-20,21-Oct-20,COHORT,10000,HYPERTENSION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ACEI/ARB,ALL-CAUSE-HOSPITALIZATION OR ALL-CAUSE MORTALITY,Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans
NCT04468009,Recruiting,Interventional,Phase 2,Hospital de Infecciosas Francisco Javier Muniz,Other,25-Jun-20,21-Feb-21,19-Jan-21,TREATMENT,36,SARS-ASSOCIATED CORONAVIRUS,ARGENTINA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,MORTALITY AT ICU AT 30 DAYS,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
NCT04468035,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,1-Jun-20,31-Dec-21,31-Dec-21,COHORT,30,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,MEDIUM-TERM EVOLUTION BETWEEN 3 AND 6 MONTHS,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS (Acute Respiratory Distress Syndrome) on SARS-CoV2 Viral Pneumonia Requiring Mechanical Ventilation
NCT04468087,Not yet recruiting,Interventional,Phase 2/Phase 3,Hospital do Coracao,Other,1-Dec-20,30-Apr-21,28-Feb-21,TREATMENT,1005,COVID,BRAZIL,ALL,"18 Years to 90 Years   (Adult, Older Adult)",ATAZANAVIR,PHASE II FIRST STEP: CHANGE IN THE SLOPE OF SARS-COV 2 VIRAL LOAD,"Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX: REVOLUTIOn"
NCT04468139,Recruiting,Interventional,Phase 4,"Ministry of Health, Saudi Arabia",Other,20-Jun-20,30-Jul-20,20-Jul-20,TREATMENT,60,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",QUERCETIN,DAYS OF STAY AT HOSPITAL AFTER TREATMENT AND DISCHARGE,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19"
NCT04468217,Recruiting,Observational,,Neurognos,Industry,2-Jun-20,25-Sep-20,15-Sep-20,CASE-CONTROL,150,COVID,CHILE,ALL,"18 Years to 75 Years   (Adult, Older Adult)","OBTAINMENT OF NASOPHARYNGEAL, OROPHARYNGEAL, BUCCAL, NASAL AND SALIVA SAMPLES",EVALUATION OF AN ALTERNATIVE METHOD OF OBTAINING VIRAL RNA FOR THE DETECTION OF SARS-COV-2 VIRUS IN NASOPHARYNGEAL SAMPLES.,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR
NCT04468256,Recruiting,Observational,,Imperial College London,Other,26-Jul-20,22-Jul-21,22-Jul-21,CASE-CONTROL,1000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 EXPERIENCE SURVEYS,"QUALITATIVE MEASURES OF EXPOSURE, PERCEPTION OF RISK, BEHAVIOUR, AND EXPERIENCE DURING THE COVID-19 PANDEMIC.",The Heart Hive COVID-19 Study: A Longitudinal Observational Study of the Impact and Clinical Outcomes of the COVID-19 Pandemic on Individuals With Heart Muscle Disease
NCT04468308,Recruiting,Observational,,Medical University Innsbruck,Other,8-Sep-20,21-Mar-21,21-Mar-21,COHORT,116,SENILE CATARACT,AUSTRIA,ALL,"50 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,IMPROVEMENT VISION-RELATED QUALITY OF LIFE,Assessment of Vision-related Quality of Life (VRQOL) in Cataract Patients During the COVID-19 Pandemic
NCT04468386,"Active, not recruiting",Observational,,Biomerica,Industry,7-Jul-20,30-Mar-21,30-Mar-21,CASE-ONLY,40,FOCUS IN ON COLLECTING PAIRED SPECIMENS FOR MATRIX EQUIVALENCY,UNITED STATES,ALL,"21 Years and older   (Adult, Older Adult)",,MATRIX EQUIVALENCY,Specimen Collection Study Protocol; Internal Biomerica Normal Specimen Collection and Banking for Use in COVID-19 Serological Product Development
NCT04468412,"Active, not recruiting",Observational,,Radboud University,Other,14-Jul-20,30-Sep-21,30-Sep-21,COHORT,203,COVID,NETHERLANDS,ALL,"16 Years and older   (Child, Adult, Older Adult)",CAROTID ARTERY REACTIVITY TESTING,ENDOTHELIAL DYSFUNCTION,Influence of COVID-19 on Vascular Endothelial Function
NCT04468581,Completed,Observational,,Yale-NUS College,Other,3-Apr-20,17-Jul-20,17-Jul-20,COHORT,505,CORONAVIRUS,SINGAPORE,ALL,"21 Years and older   (Adult, Older Adult)",USE OF MOBILE APPLICATION,DEMOGRAPHIC INFORMATION,Characteristics of TraceTogether Users
NCT04468646,Recruiting,Interventional,Phase 3,Prof. Dr. Fridoon Jawad Ahmad,Other,15-Jun-20,30-Aug-20,15-Jul-20,TREATMENT,100,"NEUROKININ 1 RECEPTOR, SUBSTANCE P, RESPIRATORY ILLNESS, INFLAMMATION, COVID, CORONAVIRUS",PAKISTAN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",NK-1R ANTAGONIST,TIME TO IMPROVEMENT ON A 7-POINT ORDINAL SCALE AS COMPARED TO BASELINE,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients
NCT04468789,Not yet recruiting,Observational,,Boston University,Other,21-Apr-21,22-Dec-21,22-Oct-21,COHORT,150945,HIV,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",SIX-MONTH ARV DISPENSING,UPTAKE OF 6MMD,Evaluation of the National Department of Health's Six-month Antiretroviral Treatment Dispensing Demonstration Pilot in Primary Health Care Clinics in the Context of the COVID-19 Pandemic and Response in South Africa
NCT04468802,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,1-Feb-20,1-Jul-20,30-Jun-20,CASE-ONLY,32,COVID,TURKEY,ALL,"Child, Adult, Older Adult",CASE FATALITY RATE,CASE FATALITY RATE,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by SARS CoV-2 in OECD Countries?
NCT04468893,Recruiting,Interventional,Not Applicable,Universidad Internacional de Valencia,Other,20-May-20,15-Jan-21,31-Dec-20,TREATMENT,128,ANXIETY,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ONLINE INTERVENTION MENTAL HEALTH COVID-19,DECREASE IN THE SCORE OF ANXIETY SYMPTOMS,"Effectiveness of a Self-applied Positive Psychology Online Intervention Program ""Mental Health COVID-19"" in Mexican Population: A Randomized Controlled Trial."
NCT04468958,Recruiting,Interventional,Phase 1,"SAb Biotherapeutics, Inc.",Industry,5-Aug-20,20-Dec-21,20-Sep-21,TREATMENT,28,COVID,UNITED STATES,ALL,18 Years to 60 Years   (Adult),SAB-185,NUMBER OF PARTICIPANTS HAVING ADVERSE EVENTS,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects"
NCT04468971,Recruiting,Interventional,Phase 1,"Cellenkos, Inc.",Industry,29-Sep-20,30-Sep-21,30-Sep-21,TREATMENT,45,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CK0802,REGIMEN RELATED ≥ GRADE 3 TOXICITY WITHIN 48 HOURS OF FIRST INFUSION,"Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)"
NCT04469114,"Active, not recruiting",Interventional,Phase 2,Hospital Israelita Albert Einstein,Other,16-Sep-20,1-Mar-21,1-Mar-21,TREATMENT,260,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TOFACITINIB 10 MG,DEATH OR RESPIRATORY FAILURE UNTIL DAY 28,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia"
NCT04469153,Recruiting,Observational,,Hospices Civils de Lyon,Other,29-Jun-20,31-Dec-20,1-Sep-20,COHORT,57,THE PROGNOSTIC VALUE OF FERRITIN,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION / EVALUATION OF THE FERRITIN AND GLYCOSYLATED FERRITIN BY STANDARD APPROVED SEROLOGICAL TESTS,ASSESSMENT OF THE PROGNOSTIC VALUE OF FERRITIN IN SARS-COV2 POSITIV PATIENTS,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19
NCT04469179,Recruiting,Interventional,Phase 1,"SAb Biotherapeutics, Inc.",Industry,20-Aug-20,20-Dec-21,20-Sep-21,TREATMENT,21,COVID,UNITED STATES,ALL,18 Years to 60 Years   (Adult),SAB-185,NUMBER OF PARTICIPANTS HAVING ADVERSE EVENTS,"A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19"
NCT04469491,Suspended,Interventional,Phase 2,"Centre Hospitalier Universitaire, Amiens",Other,20-Sep-20,21-Apr-21,21-Apr-21,TREATMENT,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",INHALED TYPE I INTERFERON,OXYGEN REQUIREMENT SCORE AT DAY 0,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study
NCT04469621,Completed,Interventional,Phase 1,Sanofi,Industry,17-Jul-20,23-Oct-20,23-Oct-20,TREATMENT,68,CORONAVIRUS INFECTION,ARGENTINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SAR443122,RELATIVE CHANGE FROM BASELINE IN CRP LEVEL,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19"
NCT04469634,"Active, not recruiting",Interventional,Not Applicable,"Institute of Tropical Medicine, Belgium",Other,31-Jul-20,21-Jul-21,21-Jul-21,BASIC SCIENCE,150,SARS-COV2,BELGIUM,ALL,"18 Years to 99 Years   (Adult, Older Adult)","ASSESSING ANTIBODY RESPONSES, NEUTRALIZING CAPACITY AND MEMORY B-CELL FUNCTION",ANTIBODY LEVELS OVER TIME,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?
NCT04469647,Enrolling by invitation,Observational,,Johns Hopkins Aramco Healthcare,Other,19-Jul-20,15-Jun-21,15-Jan-21,COHORT,1200,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY TEST,SEROCONVERSION STATUS,COVID 19 Antibody Seroprevalence Amongst Healthcare Workers in Johns Hopkins Aramco Healthcare
NCT04469660,Recruiting,Observational,,Max Healthcare Insititute Limited,Other,18-May-20,30-Sep-20,30-Aug-20,COHORT,1300,PSYCHOLOGICAL STRESS,INDIA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,THERAPEUTIC SESSIONS EMPHASIZING ON STRESS,Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare
NCT04470258,Recruiting,Interventional,Not Applicable,Escola de Saúde Pública do Ceará,Other,2-Aug-20,20-Dec-21,29-Sep-20,DEVICE FEASIBILITY,10,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ELMO PROJECT AT COVID-19: STUDY IN HUMANS,USABILITY TESTS OF THE ELMO SYSTEM USING EURISTIC USABILITY PRINCIPLES,Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability
NCT04470297,Not yet recruiting,Interventional,Phase 2,Associação Fundo de Incentivo à Pesquisa,Other,20-Sep-21,21-Mar-21,20-Nov-21,TREATMENT,100,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RAMELTEON 8MG,TIME TO RESOLUTION OF SYMPTOMS [NATIONAL EARLY WARNING SCORE 2 (NEWS2) OF 0],Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
NCT04470323,Recruiting,Observational,,Assiut University,Other,22-Jul-20,20-Nov-21,20-Oct-21,CASE-CONTROL,100,T CELL DEFICIENCY,EGYPT,ALL,"Child, Adult, Older Adult",FLOW CYTOMETRY,CD4+ (T-HELPER CELLS) IN COVID 19 PATIENTS AND HEALTHY VOLUNTEERS.,Functional Exhaustion of T Cells in COVID19 Patients
NCT04470414,Not yet recruiting,Observational,,Assiut University,Other,1-Aug-20,1-Sep-21,1-Jul-21,COHORT,100,COVID,EGYPT,ALL,"20 Years and older   (Adult, Older Adult)",IGG ANTIBODIES IMMUNOASSAY,LEVELS OF IGG IN THE SERUM OF RECOVERED COVID-19 PATIENTS,COVID-19 IgG Antibodies in the Serum of Recovered Patients: a Longitudinal Study
NCT04470427,"Active, not recruiting",Interventional,Phase 3,"ModernaTX, Inc.",Industry,27-Jul-20,27-Oct-22,27-Oct-22,PREVENTION,30420,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MRNA-1273,EFFICACY: NUMBER OF PARTICIPANTS WITH A FIRST OCCURRENCE OF COVID-19 STARTING 14 DAYS AFTER SECOND DOSE OF MRNA-1273,"A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older"
NCT04470531,Recruiting,Interventional,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Other,12-Jul-20,30-Jan-21,12-Oct-20,TREATMENT,94,COVID,BANGLADESH,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ORAL CO-TRIMOXAZOLE,LENGTH OF STAY IN HOSPITAL (IN DAYS),Role of Co-trimoxazole in Severe COVID-19 Patients
NCT04470544,Recruiting,Interventional,Phase 2,Alan Bryce,Other,28-Jul-20,15-Sep-22,15-Sep-22,TREATMENT,264,SEVERE ACUTE RESPIRATORY SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,CHANGE IN THE PROPORTION OF PATIENTS ALIVE AND FREE FROM RESPIRATORY FAILURE,"RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor"
NCT04470557,Not yet recruiting,Observational,,Assiut University,Other,15-Jul-20,1-Dec-20,1-Oct-20,OTHER,100,COVID,,ALL,"Child, Adult, Older Adult","D-DIMER,CBC.ESR,CRP,",ESTIMATION OF SEVERITY OF PATIENTS WITH COVID-19 IN RELATION TO LABORATORY FINDINGS.,The Relationship Between Lab Finding and COVID-19 Severity: Multicenter Study
NCT04470583,Recruiting,Observational,,Chelsea and Westminster NHS Foundation Trust,Other,9-Oct-20,2-Dec-21,21-Nov-21,COHORT,116,COVID,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),,PROPORTIONS OF LEUKOCYTE SUBSETS AND THROMBOCYTES IN PREGNANT/POSTNATAL AND NON-PREGNANT COVID-19 POSITIVE WOMEN.,Evaluation of Clinical Parameters Following COVID-19 Infection in Pregnancy (COpregVID)
NCT04470609,Enrolling by invitation,Interventional,Phase 1/Phase 2,Chinese Academy of Medical Sciences,Other,10-Jul-20,21-Nov-21,20-Nov-21,PREVENTION,471,COVID,CHINA,ALL,"60 Years and older   (Adult, Older Adult)",LOW DOSAGE INACTIVATED SARS-COV-2 VACCINE ON A 0- AND 28-DAY SCHEDULE,ADVERSE REACTIONS/EVENTS RATE,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ⩾60 Years"
NCT04470622,Recruiting,Interventional,Phase 2,Heron Therapeutics,Industry,20-Jul-20,21-Jul-21,21-Jun-21,TREATMENT,100,COVID,PUERTO RICO,ALL,"18 Years and older   (Adult, Older Adult)",APREPITANT INJECTABLE EMULSION,PROPORTION OF SUBJECTS ALIVE AND DISCHARGED FROM THE HOSPITAL.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19"
NCT04470648,Recruiting,Observational,,"Institut National de la Santé Et de la Recherche Médicale, France",Other,22-Jul-20,21-Aug-21,21-Aug-21,OTHER,183,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD TEST FOR SARS-COV2 SEROLOGY,SARS-COV-2 SEROPREVALENCE IN 3 CENTERS FOR HOMELESS AND PEOPLE IN SOCIAL DISTRESS,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
NCT04470739,Recruiting,Interventional,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,Other,30-May-20,30-Oct-20,30-Sep-20,DIAGNOSTIC,20,COVID,TURKEY,ALL,up to 7 Hours   (Child),CHEST X-RAY,CARDIOTHYMIC INDEX,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?
NCT04470869,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,12-Jun-20,12-Oct-21,12-Apr-21,PREVENTION,130,POST TRAUMATIC STRESS DISORDER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PHONE CALL,INCIDENCE OF PTSD OBSERVED 6 MONTHS AFTER PATIENT'S DISCHARGE FROM THE INTENSIVE CARE UNIT,Impact of the Psychiatric Intervention OLAF on the Post Traumatic Disorder in the Relatives of Patients Hospitalized in Intensive Care Unit During the SARS-Cov-2 Pandemic Confinement in France.
NCT04470999,Recruiting,Interventional,Not Applicable,"Serhat Gumrukcu, MD PhD",Other,15-Apr-20,31-Dec-20,30-Sep-20,BASIC SCIENCE,25,COVID,UNITED STATES,ALL,18 Years to 60 Years   (Adult),LEUKAPHERESIS,CELLULAR IMMUNE SYSTEM PROFILING,Cellular Immune Profile Changes in Individuals With Active or Past COVID-19 Infection
NCT04471051,Recruiting,Observational,,"University of Colorado, Denver",Other,30-Apr-20,21-Apr-21,21-Apr-21,COHORT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,INPATIENT MORTALITY,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients
NCT04471519,"Active, not recruiting",Interventional,Phase 1/Phase 2,Bharat Biotech International Limited,Industry,13-Jul-20,30-Jun-21,30-Jun-21,PREVENTION,755,COVID,INDIA,ALL,"12 Years to 65 Years   (Child, Adult, Older Adult)",BBV152A - PHASE I,PHASE 1: OCCURRENCE OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers"
NCT04471636,Recruiting,Interventional,Not Applicable,Ludwig-Maximilians - University of Munich,Other,18-Sep-20,21-Mar-21,21-Feb-21,TREATMENT,600,COVID,GERMANY,ALL,40 Years to 59 Years   (Adult),WITHINGS SCANWATCH,RATE OF PARTICIPANTS WITH A COMBINATION OF HOSPITALIZATION AND UNPLANNED USE OF HOSPITAL EMERGENCY DEPARTMENT OR EMERGENCY MEDICAL SERVICE,Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients
NCT04471649,Recruiting,Observational,,Tanta University,Other,15-Jun-20,20-Nov-21,20-Oct-21,CASE-CONTROL,80,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PATIENTS IN NEED FOR HOSPITALIZATION,Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study
NCT04471701,Recruiting,Observational,,"Institute of Biomedical Technologies-National Research Council, Italy",Other,13-Apr-20,31-Aug-20,31-Jul-20,COHORT,200000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",ENVIRONMENTAL EXPOSURE AND CLINICAL FEATURES,NUMBER OF PARTICIPANTS (%) WITH COVID-19-LIKE SYMPTOMS,Italian Web-based EPICOVID19 Cross-sectional Survey
NCT04471766,Enrolling by invitation,Interventional,Not Applicable,Bandim Health Project,Other,20-Jul-20,21-Aug-21,21-Jun-21,PREVENTION,40000,COVID,GUINEA-BISSAU,ALL,"10 Years and older   (Child, Adult, Older Adult)",CERTIFIED CLOTH FACE MASK PLUS PREVENTIVE INFORMATION,REPORTED COVID-LIKE ILLNESS,Evaluation of Locally Produced Cloth Face Mask on COVID-19 and Respiratory Illnesses Prevention at the Community Level - a Cluster-randomized Trial
NCT04471831,Not yet recruiting,Interventional,Not Applicable,"University of Lagos, Nigeria",Other,13-Jul-20,31-Dec-21,21-Jun-21,TREATMENT,30,CORONAVIRUS INFECTION,,ALL,"18 Years to 120 Years   (Adult, Older Adult)",REHABILITATION EXERCISE PROTOCOL,CYCLE THRESHOLD (CT) VALUES AS RECORDED FROM THE SERIES OF THE QRT-PCR,"Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study"
NCT04472013,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,12-Aug-20,22-Dec-21,22-Dec-21,COHORT,40,COVID DISEASE,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION FROM LUMBAR PUNCTURE,MRI IMAGING DATA,"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19"
NCT04472052,Completed,Observational,,University Hospital Tuebingen,Other,16-Mar-20,31-May-20,31-May-20,COHORT,143,PERFORATED APPENDICITIS,GERMANY,ALL,"16 Years and older   (Child, Adult, Older Adult)",APPENDECTOMY,RATE OF PERFORATED APPENDICITIS,Incidence of Perforated Appendicitis in Times of Corona Crisis
NCT04472078,Completed,Observational [Patient Registry],,Hospital Italiano de Buenos Aires,Other,10-Jun-20,11-Dec-20,26-Jun-20,COHORT,873,SARS-COV2,ARGENTINA,ALL,"14 Years and older   (Child, Adult, Older Adult)",SEROLOGICAL ASSAY OR IGG FOR SARS-COV-2,TO ESTABLISH THE SEROPREVALENCE OF SARS-COV-2,"Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) in a Vulnerable Neighbourhood, Buenos Aries Argentina"
NCT04472494,Recruiting,Interventional,Phase 2,Bristol-Myers Squibb,Industry,24-Aug-20,14-Jan-21,13-Jan-21,TREATMENT,129,COVID,PUERTO RICO,ALL,"18 Years and older   (Adult, Older Adult)",ABATACEPT,PROPORTION OF PARTICIPANTS WITH COMPOSITE END POINT OF MECHANICAL VENTILATION OR DEATH PRIOR TO OR ON DAY 28,"Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise"
NCT04472559,Not yet recruiting,Interventional,Not Applicable,"University of California, Los Angeles",Other,25-Dec-20,25-Feb-21,25-Jan-21,TREATMENT,200,QUALITY OF LIFE,,ALL,"18 Years and older   (Adult, Older Adult)",SELF-ACUPRESSURE,HEALTH RELATED QUALITY OF LIFE,Randomized Controlled Trial of Acupressure for Health-Related Quality of Life and Perception of Stress Among Health Care Providers During the COVID-19 Pandemic
NCT04472572,Available,Expanded Access,,Hackensack Meridian Health,Other,,,,,,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,,Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
NCT04472585,Recruiting,Interventional,Phase 1/Phase 2,Sohaib Ashraf,Other,14-Nov-20,30-Oct-21,15-Aug-21,TREATMENT,180,CORONAVIRUS INFECTION,PAKISTAN,ALL,18 Years to 60 Years   (Adult),IVERMECTIN INJECTABLE SOLUTION,QRT-PCR,Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients
NCT04472611,Not yet recruiting,Interventional,Phase 3,Yale University,Other,1-Aug-20,1-Aug-22,1-Aug-21,TREATMENT,466,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OF CARE (SOC) AND COLCHICINE+ROSUVASTATIN,COVID 19 SEVERITY,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
NCT04472728,Recruiting,Interventional,Phase 2/Phase 3,Biophytis,Industry,16-Jun-20,21-Sep-21,21-Jul-21,TREATMENT,310,COVID,BELGIUM,ALL,"45 Years and older   (Adult, Older Adult)",BIO101,END-OF-PART 1 INTERIM ANALYSIS: PROPORTION OF SUBJECTS WITH ALL CAUSE MORTALITY OR WITH RESPIRATORY FAILURE.,"Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients"
NCT04472793,Recruiting,Observational,,"Children's Hospital Medical Center, Cincinnati",Other,11-May-20,23-Dec-21,22-Dec-21,CASE-CONTROL,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2,THE 6-MONTH CUMULATIVE INCIDENCE OF ACQUIRED COVID INFECTION IN THE STUDY COHORT.,Repeated Employee Testing for Understanding Our Recovery to Normal
NCT04473053,Recruiting,Interventional,Phase 2/Phase 3,University of Edinburgh,Other,3-Jul-20,3-Dec-21,3-Jul-21,TREATMENT,60,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",NAFAMOSTAT MESILATE,THE SAFETY OF THE CANDIDATE THERAPIES IN COVID-19 PATIENTS BY MEASURING PHYSIOLOGICAL CHANGES IN THE CIRCULATORY AND RESPIRATORY SYSTEM.,Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19
NCT04473105,Recruiting,Observational,,Nottingham University Hospitals NHS Trust,Other,1-May-20,31-Jan-21,31-Dec-20,OTHER,500,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,VENTILATION,Optimising Resource Allocation Via Prediction of Outcomes for Suspected and Proven Covid-19
NCT04473118,Recruiting,Observational,,Hamad Medical Corporation,Industry,11-Jul-20,21-Jun-21,20-Sep-21,COHORT,25000,COVID,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY,"TO REFLECT THE EFFECT OF COVID-19 ON THE BURNOUT, ANXIETY, DEPRESSION AND STRESS LEVELS OF HEALTHCARE PROFESSIONALS DURING THE COVID-19 CRISIS","Burnout, Anxiety, Depression, Stress (BADS) and Post-Trauma Stress Disorder (PTSD) in Healthcare Workers Exposed to COVID-19 Patients"
NCT04473131,Recruiting,Observational,,Hamad Medical Corporation,Industry,27-Apr-20,22-Jun-21,22-Jun-21,COHORT,300,COVID,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,TO CREATE AN IMMUNE PROFILE FOR EACH COVID19-POSITIVE PATIENT DURING THEIR ICU STAY,Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study
NCT04473157,Completed,Observational,,Ain Shams University,Other,1-Jul-20,30-Dec-20,30-Nov-20,CASE-ONLY,58,ANOSMIA,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,RECOVERY FROM ANOSMIA,Detection of SARS-CoV-2 in Patients Presenting With Anosmia During COVID-19 Pandemic Era in Egypt
NCT04473170,Completed,Interventional,Phase 1/Phase 2,Abu Dhabi Stem Cells Center,Other,4-Apr-20,14-Jul-20,20-May-20,TREATMENT,146,CORONAVIRUS DISEASE 2019 (COVID),UNITED ARAB EMIRATES,ALL,"18 Years and older   (Adult, Older Adult)",AUTOLOGOUS NON-HEMATOPOIETIC PERIPHERAL BLOOD STEM CELLS (NHPBSC),ADVERSE REACTIONS INCIDENCE.,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)"
NCT04473183,Recruiting,Observational,,University of Minnesota,Other,21-Jul-20,22-Jan-21,22-Jan-21,COHORT,3000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SPECIMEN COLLECTION,PREVALENCE OF SYMPTOMATIC INFECTION,Epidemiologic Assessment of SARS-CoV-2 Prevalence in Minnesota
NCT04473248,Completed,Interventional,Not Applicable,Spartan Bioscience Inc.,Industry,28-Jun-20,30-Aug-20,30-Aug-20,DIAGNOSTIC,27,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SPARTAN COVID-19 SYSTEM,ASSES THE % AGREEMENT BETWEEN PREDICATE RESULTS AND SPARTAN COVID-19 RESULTS.,Evaluation of Clinical Sample Collection Project: Spartan COVID-19
NCT04473261,Recruiting,Interventional,Phase 1/Phase 2,Sohaib Ashraf,Other,14-Jul-20,15-Aug-21,15-Jul-21,TREATMENT,200,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",IODINE COMPLEX,QRT-PCR,Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients
NCT04473274,Completed,Interventional,Phase 4,Samaritan Health Services,Other,21-May-20,1-Dec-20,1-Nov-20,TREATMENT,10,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PIOGLITAZONE,ADVERSE EVENTS OUTCOMES WITHOUT ATTRIBUTION,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study"
NCT04473300,Recruiting,Observational,,Osaka University,Other,11-May-20,31-Aug-20,31-Aug-20,COHORT,20,CRITICAL ILLNESS,JAPAN,ALL,"18 Years and older   (Adult, Older Adult)",,THE DISTRIBUTION OF VENTILATION,Assessment of Lung Recruitablity of Acute Respiratory Distress Syndrome With SARS-CoV-2 Pneumonia by Electrical Impedance Tomography: a Prospective Observational Study
NCT04473352,Not yet recruiting,Observational [Patient Registry],,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,Other,20-Sep-21,21-Nov-21,21-Sep-21,OTHER,80,COVID,,MALE,"18 Years and older   (Adult, Older Adult)",,ACCURACY OF COVID19 DETECTION,Diagnostic Accuracy of COVID-19 Detection Tests in Different Body Fluids of Infected Men and Concordance With Viral Cultures
NCT04473365,Recruiting,Observational,,Mekelle University,Other,20-Jul-20,30-Jun-21,30-Jun-21,COHORT,186,SARS-COV2,ETHIOPIA,ALL,"Child, Adult, Older Adult",,PROPORTION OF PATIENTS IDENTIFIED AS COVID-19 BY AND MONITORING VIRUS CLEARANCE WITH COVID-19 USING ALGORITHM OF RDTS.,Rapid Diagnostic Profiling of SARS-CoV-2 in the Context of Persistent Immune Activation in Sub-Saharan Africa (Profile-Cov)
NCT04473547,Recruiting,Observational,,Mansoura University,Other,15-Jul-20,20-Dec-21,30-Aug-20,COHORT,215,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,ADHERENCE LEVEL TO CORONAVIRUS DISEASE 19 PREVENTIVE MEASURES AMONG NURSING STUDENTS DURING WRITTEN EXAMS.,Adherence of Nursing Students to Preventive Measures Towards Coronavirus Disease 19 During Written Exams
NCT04473599,Recruiting,Interventional,Not Applicable,"University of California, Berkeley",Other,17-Apr-20,1-Apr-21,1-Apr-21,PREVENTION,200,DEPRESSIVE SYMPTOMS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UNIFORM RANDOM MESSAGE DELIVERY,DEPRESSION SCORES,Stay Well at Home: A Text-messaging Study to Improve Mood and Help Cope With Social Distancing
NCT04473690,Recruiting,Interventional,Phase 1/Phase 2,"Kentucky BioProcessing, Inc.",Industry,30-Dec-20,23-Mar-22,6-May-21,PREVENTION,180,COVID,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",LOW DOSE OF KBP-COVID-19,SOLICITED ADMINISTRATION SITE REACTIONS,"A First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 SARS-CoV-2 Vaccine With Adjuvant in Healthy Seronegative Adults Aged 18-49 and 50-70"
NCT04473898,Completed,Interventional,Not Applicable,KTO Karatay University,Other,19-Jun-20,17-Feb-21,19-Oct-20,SUPPORTIVE CARE,35,COVID,TURKEY,ALL,"25 Years to 70 Years   (Adult, Older Adult)",AEROBIC EXERCISE TRAINING,DYSPNOEA,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training
NCT04474067,Recruiting,Observational,,Hadassah Medical Organization,Other,28-Jun-20,21-Mar-21,21-Mar-21,CASE-CONTROL,300,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,CLINICAL OUTCOMES OF PATIENTS WITH COVID-19 USING THE NATIONAL EARLY WARNING SCORE 2 (NEWS2) SYSTEM,A Multi-Center Study Evaluating Clinical Course in Patients With COVID-19 and Its Relationship to Cytokine Storm
NCT04474080,Not yet recruiting,Interventional,Not Applicable,St. Joseph's Healthcare Hamilton,Other,15-Jan-21,21-Jul-21,21-Jul-21,PREVENTION,1080,BURNOUT,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VIRTUAL PEER SUPPORT PLATFORM,ASSESS AND MEASURE OVERALL BURNOUT,The Role of Virtual Peer Support Platforms for Reducing Stress and Burnout Among Frontline Healthcare Workers During COVID-19: A Randomized Controlled Trial
NCT04474236,Recruiting,Observational,,"University Hospital, Toulouse",Other,27-May-20,27-Mar-21,27-Feb-21,COHORT,148,COVID,FRANCE,ALL,"17 Years and older   (Child, Adult, Older Adult)",THORACIC LUNG ULTRASOUND,"AREA UNDER THE CURVE (AUC) OF A PREDICTIVE MODEL BUILT ON LUS AND CLINICAL (Q-SOFA, SPIO2/FIO2) DATA",Use of Lung Ultrasound for COVID-19 Patient's Initial Triage Assessment and Early Monitoring: a Pilot Study
NCT04474249,Recruiting,Observational,,Uppsala University,Other,25-Jun-20,22-Dec-21,22-Dec-21,COHORT,300,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,Uppföljning av Patienter Som intensivvårdats för COVID-19
NCT04474288,Recruiting,Observational,,Bassett Healthcare,Other,16-Jul-20,21-Jul-21,21-Jul-21,CASE-CONTROL,400,COVID IMMUNOLOGY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 ANTIBODY TESTING,SARS-COV-2 IGG,SARS-CoV-2 Specific Immune Responses in Hospitalized Persons Under Investigation (PUIs) With Negative Nasopharyngeal PCR Swabs - The COVID-19 PUI Reality Check (CPRC) Study
NCT04474301,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,11-Jun-20,1-Jul-21,1-Jul-21,CASE-ONLY,1152,COVID INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",SURVEY ADMINISTRATION,EXPERIENCES DURING THE COVID-19 PANDEMIC,Well-Being and Quality of Life in Melanoma Patients During COVID-19 Pandemic
NCT04474340,Recruiting,Interventional,Phase 1,"Ministry of Health, Kuwait",Other,21-May-20,30-Dec-20,30-Sep-20,TREATMENT,300,"MODERATE COVID PNEUMONIA, SEVERE COVID PNEUMONIA",KUWAIT,ALL,"15 Years to 85 Years   (Child, Adult, Older Adult)",COVID-19 CONVALSCENT PLASMA,TIME TO CLINICAL IMPROVEMENT,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients: Multicenter Interventional Study
NCT04474444,Recruiting,Observational,,University of Lincoln,Other,23-Mar-19,23-Mar-21,23-Mar-21,CASE-ONLY,55000,"ALCOHOL USE, UNSPECIFIED",UNITED KINGDOM,ALL,"Child, Adult, Older Adult",ATTENDANCE BY AMBULANCE CREW,ATTENDANCES FOR ALCOHOL AND DRUG USE,Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP): Exploring Attendance at Incidents Involving Substance and/or Alcohol Use During COVID-19 Pandemic
NCT04474457,"Active, not recruiting",Observational,,"Ministry of Health, Turkey",Other,11-Jun-20,1-Jun-21,31-Dec-20,COHORT,1000,COVID,TURKEY,ALL,"15 Years and older   (Child, Adult, Older Adult)",FAVIPIRAVIR,TIME TO RECOVERY (DISCHARGE),An ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving Favipiravir
NCT04474483,Recruiting,Interventional,Phase 2,State University of New York at Buffalo,Other,6-Nov-20,31-Mar-21,31-Mar-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MELATONIN,CUMULATIVE INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection
NCT04474496,Enrolling by invitation,Observational,,University of Arkansas,Other,27-Jul-20,15-Dec-20,15-Dec-20,OTHER,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ASSESSING IMPACT OF COVID19,EFFECTS OF COVID-19 ON SOCIAL DETERMINANTS OF HEALTH,Impact of COVID-19 on Marshallese Communities in the U.S.
NCT04475068,Recruiting,Observational,,Hospital Nacional Edgardo Rebagliati Martins,Other,17-Jul-20,20-Oct-21,20-Sep-21,COHORT,12,SARS-COV2,PERU,ALL,"18 Years and older   (Adult, Older Adult)",LATERAL POSITION (LEFT AND RIGHT LATERAL DECUBITUS),EFFECTS OF A POSTURAL RECRUITMENT MANEUVER IN LUNG AERATION,Feasibility and Physiological Effects of a Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection
NCT04475081,Not yet recruiting,Interventional,Phase 3,Louisiana State University Health Sciences Center in New Orleans,Other,17-Aug-20,1-Dec-21,31-Oct-21,PREVENTION,60,SEPSIS SYNDROME,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MMR VACCINE,INDUCTION OF MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS),Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation
NCT04475107,Recruiting,Interventional,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,Industry,9-Jul-20,21-Sep-21,21-Apr-21,TREATMENT,76,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",PYRONARIDINE-ARTESUNATE,PROPORTION (%) OF PATIENTS WITH VIROLOGICAL CLEARANCE OF SARS-COV-2 AT DAY 7 POST-DOSE*,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients"
NCT04475120,Completed,Interventional,Phase 2/Phase 3,University of Rome Tor Vergata,Other,15-Apr-20,2-Jul-20,2-Jul-20,TREATMENT,60,COVID,ITALY,ALL,"20 Years and older   (Adult, Older Adult)",LIPOSOMAL LACTOFERRIN,RATE OF VIRAL CLEARANCE TIME TO VIRAL CLEARANCE,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
NCT04475185,Recruiting,Interventional,Not Applicable,Nantes University Hospital,Other,20-Jul-20,20-Dec-21,20-Dec-21,SUPPORTIVE CARE,117,ACUTE RESPIRATORY DISTRESS SYNDROME,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MAKAIR,NUMBER OF DYSFUNCTIONS,"Interventional, Open, Non-comparative, Multicenter Study to Assess the Safety and Effectiveness of the Use of the MakAir Artificial Ventilator in the Expected Situation of a Shortage of Technical Devices for Invasive Mechanical Ventilation, Linked to the Coronavirus COVID-19"
NCT04475211,Recruiting,Observational,,"University Hospital, Lille",Other,10-Aug-20,22-Aug-21,22-Aug-21,COHORT,1000,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"NUMBER OF PATIENTS ""CONFIRMED CASES"" OF SARS-COV-2 INFECTION WHO DIED AT D28 OF INCLUSION",Predictors of Mortality at Day 28 of Patients Treated at Lille University Hospital for COVID-19
NCT04475302,Recruiting,Interventional,Phase 3,"Tuberculosis Research Centre, India",Other,1-Jul-20,21-May-21,21-Jan-21,PREVENTION,2175,COVID,INDIA,ALL,"60 Years to 80 Years   (Adult, Older Adult)",BCG VACCINE (FREEZE-DRIED),MORTALITY DUE TO COVID-19 DISEASE,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India
NCT04475471,Recruiting,Observational,,Public Health Foundation of India,Other,11-Jun-20,30-Dec-21,30-Jun-21,COHORT,5200,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",,ASSESSMENT OF THE PATIENTS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE),WHF COVID-19 and Cardiovascular Disease Survey
NCT04475484,Recruiting,Observational,,Hospices Civils de Lyon,Other,10-Jun-20,31-Dec-20,31-Dec-20,ECOLOGIC OR COMMUNITY,30000,INVESTIGATING PSYCHOLOGICAL IMPACT,FRANCE,ALL,"6 Years to 18 Years   (Child, Adult)",ONLINE QUESTIONNAIRE,PROPORTION OF CHILDREN PRESENTING SIGNS OF PSYCHOLOGICAL SUFFERING DURING CONFINEMENT.,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children
NCT04475562,Completed,Interventional,Not Applicable,Maastricht University Medical Center,Other,6-Apr-20,1-Jul-20,6-May-20,DIAGNOSTIC,219,SARS-COV INFECTION,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",AEONOSE,COVID 19 POSITIVE VS NEGATIVE,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study
NCT04475575,Completed,Interventional,Not Applicable,Maastricht University Medical Center,Other,6-Apr-20,1-Jul-20,30-Jun-20,DIAGNOSTIC,222,SARS-COV INFECTION,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",AEONOSE,COVID-19 ANTIBODIES VS COVID-19 NEGATIVE,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study
NCT04475588,Completed,Interventional,Phase 2,Biocon Limited,Industry,1-May-20,8-Jul-20,8-Jul-20,TREATMENT,30,ACUTE RESPIRATORY DISTRESS SYNDROME,INDIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ITOLIZUMAB IV INFUSION,ONE-MONTH MORTALITY RATE BETWEEN THE TWO ARMS,"A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications"
NCT04475601,Recruiting,Interventional,Phase 2,Andreas Josefsson,Other,15-Jul-20,8-May-22,8-Jul-21,TREATMENT,500,COVID,SWEDEN,ALL,"50 Years and older   (Adult, Older Adult)",ENZALUTAMIDE PILL,TIME TO WORSENING OF DISEASE,"A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)"
NCT04475913,Completed,Interventional,Not Applicable,October University for Modern Sciences and Arts,Other,11-Jul-18,20-Aug-20,11-Jul-20,TREATMENT,56,EDENTULOUS MOUTH,EGYPT,ALL,"50 Years to 65 Years   (Adult, Older Adult)",DIG AXIAL,IMPLANT LOSS,"In a Post -Covid-19 World, What is the Clinical Influence of Digital vs Analog Impression in Cases of All-on-4 - Prosthesis ?"
NCT04475991,Not yet recruiting,Interventional,Phase 2,Hospital General de México Dr. Eduardo Liceaga,Other,21-Feb-21,21-Jun-21,21-Apr-21,TREATMENT,100,COVID,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MARAVIROC + CURRENTLY USED THERAPY,PATIENTS FREE OF MECHANICAL VENTILATION OR DEATH,"Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19"""
NCT04476589,Recruiting,Observational,,Massachusetts General Hospital,Other,1-Jul-20,30-Mar-23,30-Jun-22,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FUNCTIONAL MRI,DISABILITY RATING SCALE SCORE,Prognostication of Recovery in Early Disorders of Consciousness After COVID-19
NCT04476602,Recruiting,Observational,,Northwell Health,Other,27-Apr-20,31-Dec-20,31-Dec-20,COHORT,500,COVID (SARS-COV2),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,HOSPITAL ADMISSION,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol
NCT04476667,Recruiting,Interventional,Not Applicable,Queen's University,Other,15-Jun-20,21-May-21,21-May-21,TREATMENT,80,MENTAL HEALTH ISSUE,CANADA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",E-PSYCHOTHERAPY,CHANGE IN STRESS,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19"
NCT04476680,Not yet recruiting,Interventional,Not Applicable,Royal Centre for Defence Medicine,Other,1-Sep-20,28-Apr-21,28-Apr-21,PREVENTION,4400,SARS-COV INFECTION,UNITED KINGDOM,ALL,18 Years to 30 Years   (Adult),VITAMIN D 1000 IU,SEROCONVERSION,Reducing Asymptomatic Infection With Vitamin D in Coronavirus Disease
NCT04476706,No longer available,Expanded Access,,Novartis Pharmaceuticals,Industry,,,,,,CYTOKINE RELEASE SYNDROME IN COVID-INDUCED PNEUMONIA,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CANAKINUMAB,,Managed Access Program (MAP) to Provide Access to Canakinumab Treatment of Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
NCT04476719,"Active, not recruiting",Interventional,Phase 1,Atabay Kimya Sanayi Ticaret A.S.,Industry,9-Jul-20,20-Aug-20,22-Jul-20,OTHER,18,BIOEQUIVALENCE,TURKEY,MALE,20 Years to 40 Years   (Adult),ATAFENOVIR 200 MG KAPSUL,PRIMARY PK ENDPOINT,"Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Atafenovir 200 Mg Kapsul In Comparison With Arbidol 100 Mg Kapsul In Healthy Male Subjects Under Fasting Conditions"
NCT04476745,Enrolling by invitation,Interventional,Not Applicable,Applied Science Private University,Other,5-Oct-20,20-Feb-21,15-Dec-20,PREVENTION,100,CYTOKINE STORM,JORDAN,ALL,"30 Years to 66 Years   (Adult, Older Adult)",VITAMIN D3,IL-1 BETA,"The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency"
NCT04476823,Completed,Observational,,Centre Hospitalier Universitaire de Nice,Other,15-Mar-20,31-May-20,31-May-20,ECOLOGIC OR COMMUNITY,71,CLINICAL PRACTICE DURING THE COVID CRISIS,FRANCE,ALL,"Child, Adult, Older Adult",ACTIVITY,ACTIVITY,Practice in Clinical and Molecular Thoracic European Pathology Laboratories During the COVID-19 Pandemic.
NCT04476888,Completed,Interventional,Not Applicable,Aga Khan University,Other,26-Apr-20,10-Oct-20,15-Sep-20,TREATMENT,110,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA (CP),DECREASE LENGTH OF STAY,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan
NCT04476914,Recruiting,Observational,,"University of Colorado, Denver",Other,29-Jun-20,31-Dec-21,31-Dec-21,COHORT,250,RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SYMPTOMS OF POST-TRAUMATIC STRESS DISORDER (PTSD),Psychological Distress Symptoms in Family Members of Patients With COVID-19 Respiratory Failure in Intensive Care Units
NCT04476927,Not yet recruiting,Interventional,Not Applicable,Nanose Medical Ltd.,Industry,1-Aug-20,30-Jun-21,30-May-21,OTHER,300,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",DIANOSE,COLLECTING AND ANALYZING OF DIANOSE SENSORS SIGNALS FROM POTENTIAL VOC MARKERS IN THE BREATH SAMPLES OF ALL SUBJECTS TO BUILD AND VALIDATE A PREDICTIVE ALGORITHMIC MODEL FOR DIAGNOSING COVID 19.,Collecting and Evaluating Data of Potential Volatile Biomarkers in the Exhaled Air of Subjects With and Without COVID-19 by DiaNose
NCT04476940,Not yet recruiting,Interventional,Not Applicable,Meharry Medical College,Other,20-Sep-21,22-Jun-21,21-Oct-21,PREVENTION,200,COVID,UNITED STATES,FEMALE,18 Years to 45 Years   (Adult),COVID-19 BREASTFEEDING SUPPORT,COVID-19 BREASTFEEDING GUIDANCE ADHERENCE AT BIRTH.,An Intervention to Promote COVID-19 Breastfeeding Guideline Adherence Among African American Mothers
NCT04476953,Enrolling by invitation,Interventional,Phase 2,Mayo Clinic,Other,3-Aug-20,21-Jul-21,21-Jul-21,TREATMENT,70,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,SERIOUS ADVERSE EVENTS,COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults
NCT04476979,Recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,16-Jul-20,31-Dec-21,31-Mar-21,TREATMENT,120,CORONAVIRUS INFECTION,FRENCH GUIANA,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,SURVIVAL WITHOUT NEEDS OF VENTILATOR UTILIZATION AT DAY 14,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
NCT04476992,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Federal State Budgetary Scientific Institution, Research Institute of Cardiology",Other,24-Jul-20,17-Sep-21,17-Jul-21,TREATMENT,20,HYPOXEMIA,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",NITRIC OXIDE-SESSIONS,CHANGE IN METHEMOGLOBIN LEVEL AT 48 HOURS,A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients
NCT04477083,"Active, not recruiting",Interventional,Not Applicable,Mansoura University,Other,15-Jul-20,15-Aug-20,15-Aug-20,TREATMENT,40,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",INHALABLE HYDROXYCHLOROQUINE (HCQ),TIME TO CLINICAL RECOVERY DEFINED AS 3 DAYS AFEBRILE WITH IMPROVED COUGH AND OTHER CLINICAL SIGNS,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19"
NCT04477213,Not yet recruiting,Observational,,NMC Specialty Hospital,Other,15-Jan-21,15-Feb-21,15-Feb-21,COHORT,600,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,RATE OF COVID-19 IN HEALTHCARE WORKERS (HCWS),Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers- A Multicentric Retrospective Study
NCT04477473,Recruiting,Observational,,"University Hospital, Geneva",Other,30-Jun-20,31-Aug-20,30-Jul-20,OTHER,100,COVID PANDEMIC,SWITZERLAND,ALL,"18 Years to 100 Years   (Adult, Older Adult)",QUESTIONNAIRE-BASED OBSERVATIONAL STUDY,QUESTIONNAIRE,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group: Patients Under Long Term Noninvasive Ventilation for Chronic Hypercapnic Respiratory Failure in Geneva. An Observational Monocentric Study
NCT04477642,Withdrawn,Interventional,Phase 1/Phase 2,Beth Israel Deaconess Medical Center,Other,20-Aug-21,20-Dec-21,20-Oct-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ABATACEPT,MECHANICAL VENTILATION-FREE SURVIVAL,Abatacept for Patients With COVID-19 and Respiratory Distress
NCT04477655,Recruiting,Interventional,Not Applicable,Hospital Civil de Guadalajara,Other,3-May-20,30-Dec-20,30-Nov-20,TREATMENT,200,COVID,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AWAKE PRONE POSITIONING,INTUBATION RATE,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial
NCT04477668,Recruiting,Interventional,Not Applicable,King Abdullah International Medical Research Center,Other,8-Feb-21,22-Jan-21,21-Dec-21,TREATMENT,320,COVID,SAUDI ARABIA,ALL,"14 Years and older   (Child, Adult, Older Adult)",HELMET NON-INVASIVE VENTILATION,28-DAY ALL-CAUSE MORTALITY,Helmet Non-Invasive Ventilation for COVID-19 Patients
NCT04477889,Recruiting,Observational,,Methodist Health System,Other,20-Jun-20,26-Dec-21,25-Dec-21,OTHER,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TREATMENT FOR COVID-19,PATIENT CHARACTERISTICS,Methodist Health System COVID-19 Patient Registry
NCT04477902,Recruiting,Observational,,Altura,Industry,1-Jul-20,1-Jul-22,1-Jul-22,ECOLOGIC OR COMMUNITY,50000,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",NONE - OBSERVATIONAL,LONGITUDINAL SURVEY,"A Longitudinal, Long-Term, Observational Study of COVID-19 Experience and Health Effects"
NCT04477954,Terminated,Interventional,Phase 2,Asociación Argentina de Medicina Hiperbárica e Investigación,Other,6-Jul-20,30-Dec-20,6-Nov-20,TREATMENT,40,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN,TIME TO NORMALIZE THE OXYGEN REQUIREMENT (OXYGEN DEPENDENCE),Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia
NCT04477993,Recruiting,Interventional,Phase 2/Phase 3,Vanderson Geraldo Rocha,Other,17-Jul-20,31-Dec-21,17-Feb-21,TREATMENT,200,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,BRAZIL,ALL,"18 Years to 95 Years   (Adult, Older Adult)",JANUS KINASE INHIBITOR (RUXOLITINIB),A COMPOSITE OUTCOME OF DEATH OR ICU ADMISSION OR MECHANICAL VENTILATION AT DAY 14.,"Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection"
NCT04478019,Recruiting,Interventional,Early Phase 1,"University of Wisconsin, Madison",Other,7-Jul-20,30-Apr-21,30-Apr-21,PREVENTION,94,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",10% POVIDONE-IODINE NASAL DECOLONIZATION SWAB PLUS 0.12% CHG ORAL RINSE,NUMBER OF PARTICIPANTS WITH COVID-19 DIAGNOSIS,Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study
NCT04478071,Recruiting,Interventional,Phase 2,"The University of Texas Health Science Center, Houston",Other,22-Aug-20,1-Aug-22,1-Aug-22,TREATMENT,300,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VADADUSTAT,"NUMBER OF PARTICIPANTS WHO ARE CLASSIFIED 8 (DEAD), 7 (HOSPITALIZED, ON INVASIVE MECHANICAL VENTILATION OR ECMO), OR 6 (HOSPITALIZED, ON NON-INVASIVE VENTILATION OR HIGH FLOW OXYGEN DEVICES) ON THE NIAID ORDINAL SCALE",Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
NCT04478539,Recruiting,Interventional,Not Applicable,Zan Mitrev Clinic,Other,1-Jun-20,1-Jul-21,1-Jun-21,TREATMENT,35,COVID,NORTH MACEDONIA,ALL,"18 Years and older   (Adult, Older Adult)",EXTRACORPOREAL BLOOD PURIFICATION USING THE OXIRIS® (AN69ST) HEMOFILTER,"CHANGES IN CYTOKINE LEVELS OF INTERLEUKIN (IL) 6, IL-8 AND TUMOR NECROSIS FACTOR-Α (PG/ML)",Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients
NCT04479124,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,10-Mar-20,14-Jul-20,30-Jun-20,COHORT,2000,TRAUMA,TURKEY,ALL,"up to 50 Years   (Child, Adult)",COVID-19 PCR,TRAUMA ADMISSIONS,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul
NCT04479137,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,10-Mar-20,14-Jul-20,30-Jun-20,COHORT,5000,COVID,TURKEY,ALL,18 Years to 50 Years   (Adult),PCR FOR COVID-19,MORTALITY BASED ON COVID-19,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul
NCT04479150,Completed,Observational [Patient Registry],,Hospital Universitari de Bellvitge,Other,1-Mar-20,31-Aug-20,31-Aug-20,COHORT,5307,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,30-DAY MORTALITY,Postoperative Complications and Mortality of Patients Submited to Emergency Digestive Surgery During the COVID-19 Pandemic (COVIDCIR Study): a Multicenter Cohorts' Study Protocol
NCT04479163,Completed,Interventional,Not Applicable,Fundacion Infant,Other,4-Jun-20,25-Oct-20,25-Oct-20,PREVENTION,165,COVID,ARGENTINA,ALL,65 Years and older   (Older Adult),CONVALESCENT PLASMA,DEVELOPMENT OF SEVERE RESPIRATORY DISEASE DEFINED AS A RESPIRATORY RATE (RR)>30 AND/OR AN O2 SAT<93%,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.
NCT04479202,Completed,Interventional,Phase 4,Chinese Medical Association,Other,8-Feb-20,23-Apr-20,18-Apr-20,TREATMENT,76,BERBERINE,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BERBERINE,CHANGES IN DIARRHEA FREQUENCY AND BRISTOL STOOL SCALE,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19
NCT04479280,Completed,Observational,,Assiut University,Other,20-Jul-20,16-Aug-20,16-Aug-20,CASE-CONTROL,70,COAGULATION DISORDER,EGYPT,ALL,"Child, Adult, Older Adult","SONCLOT COAGULATION AND PLATELET FUNCTION ANALYZER SCP1, SIENCO, USA",CLOT RATE FORMATION,Evaluation of the Role of Sonoclot Signature in Assessment of Coagulopathy in Critically Ill COVID 19 Patients
NCT04479293,Recruiting,Observational,,Assiut University,Other,1-Jul-20,30-Nov-20,30-Oct-20,COHORT,400,COVID,EGYPT,ALL,"Child, Adult, Older Adult",POST COVID-19 FUNCTIONAL SATUS SCALE,NUMBER OF FUNCTIONAL LIMITATIONS POST COVID-19,Assessment of Functional Recovery From COVID-19 Using the Proposed Post- COVID-19 Functional Status Score
NCT04479319,Recruiting,Observational,,Ankara University,Other,31-Dec-20,21-Oct-21,21-Jun-21,CASE-ONLY,10000,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",THORAX CT,DIAGNOSING COVID-19,Developing Hybrid Decision Support System Algorithm for COVID-19 Diagnosis Between RT-PCR Graphics and Thorax CT Images Using Deep Learning
NCT04479332,Not yet recruiting,Interventional,Not Applicable,National Taiwan University Hospital,Other,1-Aug-20,31-Jul-22,31-Jul-22,TREATMENT,334,CORONAVIRUS INFECTION,,ALL,"20 Years and older   (Adult, Older Adult)",TRACHEAL INTUBATION AND CARDIOPULMONARY RESUSCITATION,THE SUCCESS RATE OF TRACHEAL INTUBATION BETWEEN RESUSCITATION AREA AND NEGATIVE PRESSURE ISOLATION ROOMS,The Change of Critical Patient Managements and Subsequent Influences Under Epidemic of Coronavirus Disease 19 (COVID-19)
NCT04479345,Not yet recruiting,Observational,,Assiut University,Other,20-Jul-21,20-Sep-21,20-Sep-21,COHORT,100,"KNOWLEDGE, ATTITUDES, PRACTICE",,ALL,"25 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,THE KNOWLEDGE AND ATTITUDE TOWARD PPE DURING ENDOSCOPY,"Knowledge, Attitude and Practice of Gastrointestinal Endoscopists Toward PPE in COVID-19 Era"
NCT04479358,Recruiting,Interventional,Phase 2,University of Chicago,Other,10-Sep-20,1-Mar-21,1-Dec-20,TREATMENT,332,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,TIME TO RECOVERY,"COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation"
NCT04479488,Recruiting,Observational [Patient Registry],,Hospital Israelita Albert Einstein,Other,27-Jul-20,21-Feb-21,21-Jan-21,COHORT,2000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL ADMISSION,ALL-CAUSE MORTALITY,"Brazilian COVID-19 Registry for Clinical Presentation of Individuals With COVID-19: a National, Multicentre, Prospective Observational Study (SARS-Brazil)"
NCT04479540,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,26-May-20,31-Aug-21,26-May-21,DIAGNOSTIC,120,"PNEUMONIA, VIRAL",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOGRAPHY SCANNER,RATE OF PATIENTS WITH PULMONARY EMBOLISM,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With SARS Coronavirus (COV-2) Lung Disease
NCT04479631,"Active, not recruiting",Interventional,Phase 1,Brii Biosciences Limited,Industry,12-Jul-20,21-Mar-21,21-Mar-21,TREATMENT,16,COVID,CHINA,ALL,18 Years to 49 Years   (Adult),BRII-196,INCIDENCE OF ADVERSE EVENTS (AES) BY CTCAE V5.0,"A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-196 Administered Intravenously to Healthy Adult Volunteers"
NCT04479644,"Active, not recruiting",Interventional,Phase 1,Brii Biosciences Limited,Industry,13-Jul-20,21-Mar-21,21-Mar-21,TREATMENT,17,COVID,CHINA,ALL,18 Years to 49 Years   (Adult),BRII-198,INCIDENCE OF ADVERSE EVENTS (AES) BY CTCAE V5.0,"A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-198 Administered Intravenously to Healthy Adult Volunteers"
NCT04479982,Recruiting,Observational,,Assiut University,Other,24-Sep-20,31-Dec-20,31-Dec-20,OTHER,70,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,MICROBIAL INFECTIONS AND ANTIMICROBIAL RESISTANCE (AMR) PATTERNS ASSOCIATED WITH HOSPITALIZED PATIENTS WITH 2019 NOVEL CORONAVIRUS DISEASE (COVID 19),Microbial Infections and Antimicrobial Resistance (AMR) Patterns Associated With Hospitalized Patients With 2019 Novel Coronavirus Disease (COVID 19)
NCT04480034,Recruiting,Observational,,University of Roma La Sapienza,Other,15-Jul-20,30-May-21,31-Jan-21,COHORT,1600,BARIATRIC SURGERY CANDIDATE,ITALY,ALL,18 Years to 60 Years   (Adult),BARIATRIC PROCEDURES,POSTOPERATIVE COVID-19 INFECTION,"Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study."
NCT04480060,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,10-Mar-20,14-Jul-20,30-Jun-20,COHORT,100000,COVID,TURKEY,ALL,18 Years to 50 Years   (Adult),COVID-19 DIAGNOSTIC PCR,MORTALITY OF THE COVID-19 PATIENTS,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic: Retrospective Cohort Study
NCT04480112,Enrolling by invitation,Interventional,Not Applicable,Boston University,Other,2-Jun-20,21-May-21,21-May-21,OTHER,150,MEMORY DISORDERS,UNITED STATES,ALL,"Child, Adult, Older Adult",TECHNOLOGY BASED SOCIAL INTERACTIONS,CHANGE IN MEMORY PERFORMANCE,Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment
NCT04480138,Recruiting,Interventional,Phase 2,Cadila Healthcare Limited,Industry,11-Aug-20,30-May-21,15-Apr-21,TREATMENT,40,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",PEGYLATED INTERFERON-Α2B,CHANGE IN CLINICAL STATUS OF SUBJECT ON A 7-POINT ORDINAL SCALE,"A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - α2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)"
NCT04480333,Recruiting,Interventional,Phase 1,"NeuroActiva, Inc.",Industry,15-Sep-20,31-Mar-21,31-Dec-20,TREATMENT,45,COVID,UNITED STATES,ALL,21 Years to 50 Years   (Adult),DRUG: NA-831 - 0.10 MG/KG,PROPORTION OF PARTICIPANTS EXPERIENCING ANY TREATMENT-EMERGENT ADVERSE EVENTS,"A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers"
NCT04480398,Completed,Observational,,Aarogyam UK,Other,12-May-20,3-Jul-20,15-Jun-20,COHORT,91,COVID,INDIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",GUDUCHI GHAN VATI,VIROLOGIC CLEARANCE,A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
NCT04480411,Not yet recruiting,Interventional,Not Applicable,Stanford University,Other,21-Mar-21,22-Feb-21,22-Feb-21,OTHER,50,DIAGNOSES DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DOCTORGRAM PATIENT KIT,PATIENT PROVIDER EXPERIENCE SURVEY SCORE,Use of Technology and Telemedicine to Improve Quality of Care in COVID 19 Patients
NCT04480424,Recruiting,Interventional,Phase 2,Grifols Therapeutics LLC,Industry,17-Sep-20,21-May-21,21-Apr-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GAMUNEX-C,ALL-CAUSE MORTALITY RATE THROUGH DAY 29,"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit"
NCT04480515,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,11-Mar-20,30-Jun-20,15-Jun-20,COHORT,5000,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",IN-HOSPITAL MORTALITY RATE,IN-HOSPITAL MORTALITY,Does COVID-19 Pandemic Reduce In-hospital Mortality?
NCT04480580,Completed,Observational,,University of Cagliari,Other,30-Mar-20,30-Jun-20,30-Apr-20,COHORT,100,COVID,ITALY,ALL,"Child, Adult, Older Adult",SARS-COV-2 AB,SEROPREVALENCE OF SARS-COV-2,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery
NCT04480593,Completed,Interventional,Phase 2/Phase 3,D'Or Institute for Research and Education,Other,2-Jun-20,30-Aug-20,30-Aug-20,TREATMENT,120,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",BRAZILIAN GREEN PROPOLIS EXTRACT (EPP-AF),COMPOSITE CLINICAL OUTCOME WITH OXYGEN THERAPY DEPENDENCY TIME OR HOSPITALIZATION TIME,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study."
NCT04480606,Not yet recruiting,Interventional,Not Applicable,Istinye University,Other,1-Aug-20,20-Nov-20,20-Nov-20,PREVENTION,88,EXERCISE PROGRAM,,ALL,65 Years to 80 Years   (Older Adult),HOME EXERCISE PROGRAM,PHYSICAL ACTIVITY SCALE FOR THE ELDERLY,"Effects of Home Exercise Program Applied to the Socially Isolated Elderly Due to COVID-19 on Physical Activity Level, Functional Capacity and Quality of Life"
NCT04480632,Not yet recruiting,Interventional,Phase 2,Fundación Cardiovascular de Colombia,Other,1-Aug-20,22-Aug-21,21-Aug-21,TREATMENT,44,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,IN-HOSPITAL MORTALITY,Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19
NCT04480957,Recruiting,Interventional,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",Industry,4-Aug-20,21-Jan-21,20-Dec-21,TREATMENT,92,SARS-COV2,SINGAPORE,ALL,"21 Years to 80 Years   (Adult, Older Adult)",ARCT-021 DOSE 1,"INCIDENCE, SEVERITY AND DOSE-RELATIONSHIP OF AES","A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects"
NCT04481360,Not yet recruiting,Observational,,Assiut University,Other,20-Aug-21,21-Sep-21,21-Aug-21,COHORT,100,CORONAVIRUS,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CT OF THE CHEST,CLINICAL EVALUATION,Evaluation of Clinical Characteristics and Outcome of COVID19 Pneumonia in Assiut
NCT04481477,Not yet recruiting,Observational,,Corporacion Parc Tauli,Other,20-Sep-21,31-Dec-20,20-Dec-21,CASE-ONLY,450,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)","NURSING CARE TO REDUCE ANXIETY, FEAR AND LONELINESS",THE ADEQUACY OF NURSING CARE TO THE NEEDS OF THE PATIENT,Impact on Patients of Nurses' Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19
NCT04481516,Recruiting,Observational,,Doncaster And Bassetlaw Hospitals NHS Foundation Trust,Other,1-Jul-20,1-Feb-21,31-Dec-20,COHORT,30,STRESS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",YOGA,ALLEVIATED STRESS 1 - SHORT TERM,Effect of Breathing-based Meditation (Sudarshan Kriya Yoga) in NHS Health Care Workers With Possible COVID-19 Related Stress and Anxiety Disorder
NCT04481529,"Active, not recruiting",Observational,,"University Hospital, Limoges",Other,29-Jul-20,15-Jan-21,15-Dec-20,CASE-ONLY,1576,INFECTION VIRAL,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HEALTH QUESTIONNAIRE,NUMBER OF SUBJECTS WITH A COVID-19 SEROCONVERSION,Study of the COVID-19 Serological Status of Hospital Staff Working or Not in the COVID-19 Sector in 3 French Regions Facing the COVID-19 Epidemic With Varying Degrees of Intensity
NCT04481620,Recruiting,Observational,,"University Hospital, Bordeaux",Other,31-Aug-20,31-Jan-21,30-Dec-20,COHORT,1315,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,OCCURRENCE OF SIGNIFICANT CLINICAL DEGRADATION,"Evelopment and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT"
NCT04481633,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,9-Sep-20,21-Sep-21,21-Sep-21,OTHER,800,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID 19 SEROLOGY,RATE OF PATIENTS WITH POSITIVE ANTI-COVID19 SEROLOGY,Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease
NCT04481646,Recruiting,Observational [Patient Registry],,University of Leicester,Other,12-Jun-20,25-Jun-21,22-Jun-21,COHORT,630,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",FACE MASK SAMPLING,COMPARISON WITH NASO-PHARYNGEAL SWAB,The Efficacy and Feasibility of Face Mask Sampling for Hospitalised Adult Patients and Healthcare Workers With Suspected COVID-19
NCT04481685,Recruiting,Interventional,Phase 2,University of Kansas Medical Center,Other,20-Jul-20,22-Jul-21,21-Jul-21,TREATMENT,36,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ATI-450,RESPIRATORY FAILURE-FREE SURVIVAL IN PARTICIPANTS WITH MODERATE-SEVERE COVID-19 WHO ARE TREATED WITH ATI-450,"A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19"
NCT04482023,Not yet recruiting,Observational,,Corporacion Parc Tauli,Other,20-Sep-21,31-Dec-20,20-Nov-21,CASE-ONLY,150,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)","TRAINING VIDEO ON ANXIETY, FEAR AND LONELINESS IN THE COVID-19 ENVIRONMENT.",RATE OF CARE ACTIONS IDENTIFIED BY NURSES,Emotional Support and Stress Management Activities Offered by Nurses to Patients Diagnosed With COVID-19 During Hospital Admission
NCT04482205,Completed,Observational,,Aga Khan University,Other,16-Mar-20,31-May-20,31-May-20,OTHER,840,ECONOMIC BURDEN,PAKISTAN,ALL,"Child, Adult, Older Adult",,THE EFFECT OF COVID -19 ON THE TOTAL COSTS OF INPATIENT CARE,Covid -19 Pandemic: Economic Burden on Patients Operated for Traumatic Close Fractures in Musculoskeletal Service Line of a Tertiary Care Hospital
NCT04482361,Completed,Observational [Patient Registry],,Ministerio de Salud de Ciudad Autónoma de Buenos Aires,Other,6-Aug-20,22-Dec-20,22-Dec-20,ECOLOGIC OR COMMUNITY,5900,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",PRESENCE OF SPECIFIC ANTI-SARS-COV-2 ANTIBODIES,PREVALENCE OF IGG FOR COVID-19,SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES
NCT04482387,Recruiting,Interventional,Not Applicable,Cambridge University Hospitals NHS Foundation Trust,Other,24-Jul-20,1-Jul-21,1-Jul-21,DIAGNOSTIC,250,VISUAL IMPAIRMENT,UNITED KINGDOM,ALL,"5 Years to 85 Years   (Child, Adult, Older Adult)",DIGIVIS VISUAL ACUITY APP,COMPARISON OF VISUAL ACUITY MEASUREMENT USING DIGIVIS TESTING AND STANDARD VISUAL ACUITY TESTING,DigiVis: Validation of Self-testing Visual Acuity Web-based App to Aid Ophthalmic Telephone Consultations During Covid19 Lockdown and Subsequent Social Distancing Crisis
NCT04482595,Recruiting,Interventional,Phase 2,Humanetics Corporation,Industry,11-Nov-20,22-May-21,21-Aug-21,TREATMENT,66,PULMONARY FIBROSIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIO 300 ORAL SUSPENSION,CHANGE IN DLCO,A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
NCT04482621,Recruiting,Interventional,Phase 2,Johns Hopkins University,Other,14-Sep-20,21-Jul-21,21-May-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DECITABINE,CHANGE IN CLINICAL STATE AS ASSESSED BY A 6-POINT ORDINAL SCALE,Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial
NCT04482634,Recruiting,Interventional,Not Applicable,Koç University,Other,1-Sep-20,22-Aug-21,22-Aug-21,TREATMENT,122,PULMONARY REHABILITATION,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",REMOTE CONTROLLED EXERCISE,6-MINUTE WALK TEST,Is Tele-rehabilitation Superior to Home Exercise Program in the Pulmonary Rehabilitation of the Patients With COVID-19 With Post-intensive Care Syndrome? A Randomized Controlled Trial
NCT04482647,Recruiting,Interventional,Phase 1,M.D. Anderson Cancer Center,Other,17-Jun-20,1-Jul-21,1-Jul-21,SUPPORTIVE CARE,50,COVID INFECTION,UNITED STATES,ALL,"up to 70 Years   (Child, Adult, Older Adult)",MEDIA INTERVENTION,STUDY RECRUITMENT,Breathing Techniques and Meditation for Health Care Workers During COVID-19
NCT04482673,Recruiting,Interventional,Phase 4,Medical University of South Carolina,Other,31-Jul-20,31-Dec-21,31-Dec-21,PREVENTION,140,COVID,UNITED STATES,ALL,"50 Years and older   (Adult, Older Adult)",DAILY VITAMIN D3,CHANGE IN TOTAL CIRCULATING 25(OH)D CONCENTRATION,The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina
NCT04482686,Recruiting,Interventional,Phase 2,ProgenaBiome,Other,9-Dec-20,21-Jul-21,21-May-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",IVERMECTIN,TIME TO NON-INFECTIVITY BY RT-PCR,A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection
NCT04482699,Recruiting,Interventional,Phase 1/Phase 2,Rapa Therapeutics LLC,Industry,30-Dec-20,1-Jun-22,30-Dec-21,TREATMENT,88,SEVERE COVID DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RAPA-501-ALLO OFF-THE-SHELF THERAPY OF COVID-19,DOSE-LIMITING TOXICITY (DLT),"Phase I/Phase II Trial of Off-the-Shelf Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease"
NCT04482712,Not yet recruiting,Interventional,Phase 1/Phase 2,The University of Texas Health Science Center at San Antonio,Other,21-Apr-21,23-Jan-21,22-Jan-21,TREATMENT,20,ACUTE LUNG INJURY/ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS),UNITED STATES,ALL,"60 Years and older   (Adult, Older Adult)",RAPAMYCIN,SURVIVAL RATE,Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)
NCT04483271,Enrolling by invitation,Interventional,Not Applicable,Applied Science Private University,Other,2-Oct-20,10-Feb-21,15-Dec-20,PREVENTION,100,CYTOKINE STORM,JORDAN,ALL,"30 Years to 66 Years   (Adult, Older Adult)",300 MG OF OMEGA3-FA,IL-1 BETA,The Effect of Omega-3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People
NCT04483375,Completed,Interventional,Phase 1,Sinocelltech Ltd.,Industry,24-Jul-20,25-Dec-20,25-Dec-20,TREATMENT,33,CORONAVIRUS DISEASE 2019(COVID),CHINA,ALL,"18 Years and older   (Adult, Older Adult)",SCTA01,DOSE-LIMITING TOXICITY(DLT),"A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects"
NCT04483622,Recruiting,Observational,,Sohag University,Other,12-Jun-20,15-Feb-21,13-Jan-21,CASE-ONLY,30,COVID,EGYPT,ALL,"16 Years to 90 Years   (Child, Adult, Older Adult)",,RISING TITRE OF IGG ANTIBODIES,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients
NCT04483635,Recruiting,Interventional,Phase 3,St. Justine's Hospital,Other,8-Feb-21,31-Dec-21,30-Sep-21,PREVENTION,2414,COVID,CANADA,ALL,"18 Years to 69 Years   (Adult, Older Adult)",PLACEBO,CHANGE IN INCIDENCE OF LABORATORY-CONFIRMED COVID-19 INFECTION,PROTECT RCT (PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams
NCT04483752,Recruiting,Interventional,Not Applicable,Centre Chirurgical Marie Lannelongue,Other,8-Jun-20,8-Nov-21,8-Feb-21,DIAGNOSTIC,100,COV2 SARS PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CHEST CT SCAN,DESCRIPTION OF THE DIFFERENT TYPES OF LESIONS,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images
NCT04483830,Completed,Interventional,Phase 2/Phase 3,Clinedem,Other,5-Jun-20,7-Sep-20,6-Aug-20,TREATMENT,243,COVID,MEXICO,ALL,"40 Years to 80 Years   (Adult, Older Adult)",SULODEXIDE,HOSPITAL CARE,Sulodexide in the Treatment of Early Stages of COVID-19
NCT04483908,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,10-Apr-20,30-May-22,30-May-22,COHORT,550,COVID INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD DRAW,QUALITATIVE METHOD VALIDATION (YES/ NO),COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses (SERO-BL-COVID-19)
NCT04483960,Recruiting,Interventional,Phase 3,University of Melbourne,Other,28-Jul-20,31-Dec-22,31-Dec-21,TREATMENT,2400,SARS-COV2 INFECTION (COVID),AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",NAFAMOSTAT MESILATE,DEATH FROM ANY CAUSE OR REQUIREMENT OF NEW INTENSIVE RESPIRATORY SUPPORT (INVASIVE OR NON-INVASIVE VENTILATION) OR VASOPRESSOR/INOTROPIC SUPPORT.,"A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)"
NCT04483973,Not yet recruiting,Interventional,Phase 2,"Sound Pharmaceuticals, Incorporated",Industry,20-Dec-21,21-Apr-21,21-Apr-21,TREATMENT,60,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",EBSELEN,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients"
NCT04484025,Not yet recruiting,Interventional,Phase 2,"Sound Pharmaceuticals, Incorporated",Industry,20-Dec-21,21-Apr-21,21-Apr-21,TREATMENT,60,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",EBSELEN,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients"
NCT04484207,Recruiting,Interventional,Not Applicable,"Research Foundation for Mental Hygiene, Inc.",Other,6-Jul-20,26-Oct-20,20-Oct-20,HEALTH SERVICES RESEARCH,200,BRIEF VIDEO-BASED INTERVENTION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",A SHORT VIDEO INTERVENTION,HELP SEEKING BEHAVIOR,Addressing COVID-19 Mental Health Problems Among US Veterans
NCT04484493,Completed,Interventional,Phase 3,Benha University,Other,8-Aug-20,3-Nov-20,25-Oct-20,TREATMENT,100,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",MOMETASONE FUROATE NASAL SPRAY,IMPROVEMENT OF OLFACTION,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients
NCT04484545,"Active, not recruiting",Observational,,Glasgow Royal Infirmary,Other,1-Apr-20,1-Jun-21,1-Jun-21,COHORT,250,COVID,UNITED KINGDOM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",PROGNOSTIC SCORE,MORTALITY,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection
NCT04484597,Recruiting,Observational,,Port Said University,Other,15-Mar-20,15-Sep-20,15-Aug-20,CASE-CONTROL,100,POSITIVE COVID BY PCR,EGYPT,ALL,"Child, Adult, Older Adult",RT PCR,CORRELATION OF COVID-19 ANTIBODY TO PCR,Predictors of COVID-19 Infection and Disease Progression
NCT04485130,Not yet recruiting,Interventional,Phase 2,"University of California, San Francisco",Other,1-Feb-21,1-Feb-22,30-Aug-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DISULFIRAM,"IMMUNOLOGIC IMPACT OF 5 DAYS OF DISULFIRAM, AS MEASURED BY THE FOLD-CHANGE IN PLASMA LEVELS OF PRO-INFLAMMATORY CYTOKINES (E.G, INTERLEUKIN 6, INTERLEUKIN 1-BETA, ETC.).","DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19"
NCT04485169,Completed,Interventional,Not Applicable,UNICEF,Other,1-Apr-20,31-Jul-20,31-Jul-20,TREATMENT,280,COVID,PAKISTAN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE,SURVIVAL,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study
NCT04485338,Recruiting,Observational,,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,1-Aug-20,1-Mar-21,31-Dec-20,COHORT,200,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,THE PROGNOSTIC CAPACITY OF THE RADIOGRAPHIC ASSESSMENT OF LUNG EDEMA (RALE) SCORE OF THE FIRST CXR UNDER INVASIVE VENTILATION IN PATIENTS WITH SEVERE COVID-19.,Radiographic Assessment of Lung Edema in Invasively Ventilated COVID-19 Patients (RALE-COVID) - Protocol for an International Multicenter Retrospective Study
NCT04485351,Recruiting,Observational,,"Central Hospital, Nancy, France",Other,20-Jul-21,20-Sep-21,20-Aug-21,COHORT,700,DIABETES MELLITUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,COMPARE GLYCATED HEMOGLOBIN LEVELS OF PATIENTS WITH DIABETES FROM THE UNIVERSITY HOSPITAL OF NANCY BETWEEN THE PERIOD PRECEDING AND FOLLOWING THE LOCKDOWN RELATED TO THE COVID-19 PANDEMIC.,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes: a Monocentric Cross-sectional Study
NCT04485364,"Active, not recruiting",Observational,,Groupe Hospitalier Paris Saint Joseph,Other,14-Apr-20,31-Oct-20,14-Apr-20,OTHER,100,CORONAVIRUS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,INFLAMMATORY RESPONSE IN THE EVOLUTION OF RESPIRATORY DISEASES,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia: BioCovid Study
NCT04485429,Recruiting,Interventional,Phase 3,D'Or Institute for Research and Education,Other,20-Jul-20,31-Dec-20,31-Dec-20,TREATMENT,268,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,RATE OF INVASIVE MECHANICAL VENTILATION,"Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia: A Randomized, Controlled, 2x2 Factorial Study"
NCT04485741,Recruiting,Observational,,"Strados Labs, Inc.",Industry,23-Sep-20,31-Aug-21,1-Jun-21,COHORT,30,COPD,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RESP,CLINICAL UTILITY AS ASSESSED BY THE PI,Clinical Utility of Strados System in Periodically Recording Auscultation to Provide Replay Capability and Telemedicine Monitoring of Inpatients After Initial Clinical Assessment.
NCT04486001,Recruiting,Interventional,Phase 1,"Sorrento Therapeutics, Inc.",Industry,15-Dec-20,15-Jan-22,15-Jan-22,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PSC-04,FREQUENCY OF ALL ADVERSE EVENTS,COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells
NCT04486144,Enrolling by invitation,Interventional,Not Applicable,HealthQuilt,Other,20-May-20,1-Sep-20,1-Sep-20,TREATMENT,100,COVID POSITIVE PATIENT,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PROPRIETARY EXTRACT OF NERIUM OLEANDER,COVID19 SYMPTOMS,Impact of a Proprietary Extract of Nerium Oleander on Symptoms and Mortality :A Feasibility Study
NCT04486313,"Active, not recruiting",Interventional,Phase 3,Romark Laboratories L.C.,Industry,13-Aug-20,8-Feb-21,8-Feb-21,TREATMENT,1092,COVID,UNITED STATES,ALL,"12 Years to 120 Years   (Child, Adult, Older Adult)",NITAZOXANIDE,REDUCING THE TIME TO SUSTAINED RESPONSE,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19"
NCT04486404,Enrolling by invitation,Observational,,Universidad Miguel Hernandez de Elche,Other,1-Apr-20,30-Nov-20,30-Jun-20,COHORT,2500,ACUTE STRESS DISORDER,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SURVEY,PREVALENCE OF ACUTE STRESS,"Personal Protective Equipmente Needs, Perceptions and Acute Stress Among Healthcare Workers Caring for COVID-19 Patients in South America"
NCT04486417,Recruiting,Observational,,University of Roma La Sapienza,Other,1-Jun-20,31-Jul-20,22-Jul-20,OTHER,20,OBESITY,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,REJECTION RATE (%),Feasibility of a Telematics Pre-operative Assessment in a Bariatric Center of Excellence During Covid-19 Phase 2: a Prospective Observational Study
NCT04486482,Recruiting,Interventional,Not Applicable,Kaleido Biosciences,Industry,12-Jan-21,21-Mar-21,21-Mar-21,OTHER,50,MILD-TO-MODERATE COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",KB109 + SELF SUPPORTIVE CARE (SSC),NUMBER OF PATIENTS EXPERIENCING STUDY-PRODUCT RELATED TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting"
NCT04486508,Recruiting,Interventional,Phase 3,Rajaie Cardiovascular Medical and Research Center,Other,30-Jul-20,7-May-21,7-Apr-21,TREATMENT,600,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",INTERMEDIATE DOSE ENOXAPARIN/ UNFRACTIONATED HEPARIN,"A COMPOSITE OF ACUTE VTE, ARTERIAL THROMBOSIS, TREATMENT WITH ECMO, OR ALL-CAUSE MORTALITY",Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19
NCT04486521,Recruiting,Observational,,King Faisal Specialist Hospital & Research Center,Other,22-Jul-20,22-Jul-21,22-Jul-21,OTHER,11000,CRITICAL ILLNESS,SAUDI ARABIA,ALL,"14 Years and older   (Child, Adult, Older Adult)",INTERLEUKIN 6 (IL6) ANTAGONIST,VENTILATOR-FREE DAYS,Clinical Outcome of Anti-IL6 vs Anti-IL6 Corticosteroid Combination in Patients With SARS-CoV-2 Cytokine Release Syndrome
NCT04486729,Recruiting,Observational,,Sanatorio Anchorena San Martin,Other,1-Jul-20,20-Oct-20,10-Oct-20,CASE-CROSSOVER,15,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",HIGH PEEP WITH END INSPIRATORY PAUSE,DRIVING TRANSPULMONARY PRESSURE (CMH2O),Respiratory System Mechanics and Gas Exchange Characteristics Applying Different Ventilatory Strategies in Patients With SARS-CoV-2
NCT04487119,Completed,Observational,,Benha University,Other,12-Aug-20,23-Aug-20,20-Aug-20,COHORT,29,COVID,EGYPT,ALL,"up to 18 Years   (Child, Adult)",,HEMATOLOGICAL FINDINGS,Pediatric COVID-19 Infection; Do Clinical Features and Hematological Parameters Predict the Need for ICU Admission?
NCT04487171,Recruiting,Interventional,Not Applicable,"Centre Hospitalier Universitaire, Amiens",Other,21-Jul-20,21-Aug-21,21-Jul-21,OTHER,248,POSTPARTUM DEPRESSION,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,VARIATION OF PREVALENCE OF CLINICALLY-SIGNIFICANT POST-PARTUM DEPRESSIVE SYMPTOMS,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic
NCT04487197,Completed,Observational,,Antonio Secchi,Other,15-Jul-20,15-Jan-21,15-Jan-21,COHORT,282,KIDNEY TRANSPLANT,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE FOR SEROEPIDEMIOLOGICAL INVESTIGATION,SERUM-PREVALENCE OF COVID-19 TX,"SARS-CoV2 (COVID-19) Seroepidemiological Investigation in Transplanted Population Subjects of Kidney, Kidney-pancreas, Isolated Pancreas, Langerhans Islets"
NCT04487210,"Active, not recruiting",Interventional,Phase 1,Medigen Vaccine Biologics Corp.,Industry,7-Oct-20,30-Jun-21,30-Jan-21,PREVENTION,45,COVID,TAIWAN,ALL,20 Years to 50 Years   (Adult),MVC-COV1901,SAFETY OF MVC-COV1901,"A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901"
NCT04487444,Recruiting,Interventional,Phase 2,Rhode Island Hospital,Other,10-Sep-20,21-Jun-21,21-Mar-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",THYMALFASIN,TIME TO RECOVERY (FREE OF RESPIRATORY FAILURE),A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia
NCT04487574,Completed,Interventional,Phase 3,RSV Therapeutics LLC,Industry,25-Jul-20,29-Oct-20,29-Oct-20,TREATMENT,118,SARS-COV2 INFECTION,RUSSIAN FEDERATION,ALL,"18 Years to 75 Years   (Adult, Older Adult)",XC221,PATIENT RATE WITH A TRANSITION TO CATEGORY 3 OR LOWER ACCORDING TO THE WHO SCALE BY DAY 14 AFTER THE BEGINNING OF DRUG ADMINISTRATION.,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19"
NCT04487639,Recruiting,Interventional,Not Applicable,"University Hospital, Clermont-Ferrand",Other,10-Jul-20,21-Jul-21,21-Jul-21,DIAGNOSTIC,250,SPERM PRESERVATION IN ONCOLOGICAL PATIENTS,FRANCE,MALE,18 Years to 60 Years   (Adult),"SARS-COV-2 RESEARCH IN NASOPHARYNGEAL SWAB, SPERM AND SEROLOGICS",DETECTION OF SARS-COV-2 IN SPERM DURING FERTILITY PRESERVATION PROCEDURES BY RT-QPCR,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients During the COVID-19 Pandemic ?
NCT04487665,Not yet recruiting,Observational,,Cairo University,Other,15-Sep-20,15-Dec-20,15-Nov-20,ECOLOGIC OR COMMUNITY,50,COVID,,ALL,18 Years to 40 Years   (Adult),,ORAL ULCER,Oral Manifestations of COVID-19: a Multicentre Observational Study
NCT04487691,Recruiting,Interventional,Not Applicable,"Regenexx, LLC",Industry,8-Dec-20,30-Dec-21,1-Jun-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",NEBULIZED PLATELET LYSATE,SPIROMETRY-FVC AND FEV1/FVC TESTS,Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome
NCT04487769,Recruiting,Observational,,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,1-Jun-20,21-Oct-21,21-Aug-21,COHORT,30,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,LIBERATION FROM INVASIVE VENTILATION,Early Lung Ultrasound Score Predicts Duration of Ventilation and ICU Mortality in COVID-19 Invasively Ventilated Patients
NCT04487873,Recruiting,Observational,,Hacettepe University,Other,23-Jul-20,31-Dec-20,18-Dec-20,CASE-CONTROL,28,COVID,TURKEY,ALL,18 Years to 60 Years   (Adult),,COVID-19 PHOBIA,COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
NCT04487886,Recruiting,Interventional,Phase 2,Emory University,Other,18-Nov-20,22-Feb-21,22-Feb-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DUVELISIB,NUMBER OF PARTICIPANTS REQUIRING MECHANICAL VENTILATION OR DYING,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection
NCT04487951,Recruiting,Observational,,Cairo University,Other,1-Jul-20,1-Jan-21,1-Nov-20,CASE-CONTROL,100,COVID PNEUMONIA,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)","PRO BNP , VITAMIN D",NT-PRO-BNP AND VITAMIN D,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
NCT04487964,Recruiting,Interventional,Not Applicable,Egyptian Biomedical Research Network,Other,1-Jan-20,21-Jan-21,1-Dec-20,PREVENTION,70,COVID,EGYPT,ALL,"12 Years to 65 Years   (Child, Adult, Older Adult)",LICORICE EXTRACT,INCREASED NUMBER OF PEOPLE RECOVERING FROM COVID-19,Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine
NCT04487977,Recruiting,Observational,,Spanish Society of Anesthesia and Critical Care (SEDAR),Other,22-Apr-20,30-Sep-20,30-Sep-20,OTHER,5000,AIRWAY MANAGEMENT,SPAIN,ALL,"Child, Adult, Older Adult",SURVEY,PREFERRED DEVICE,International Survey on Airway Management in COVID-19 Patients (ISAM-COVID)
NCT04487990,Recruiting,Interventional,Not Applicable,University of Sao Paulo General Hospital,Other,29-Jun-20,21-Jul-21,20-Dec-21,TREATMENT,90,ACUTE KIDNEY INJURY,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",UNFRACTIONATED HEPARIN,CLOTTED DIALYZERS,CoV-Hep Study: Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19
NCT04488081,Recruiting,Interventional,Phase 2,QuantumLeap Healthcare Collaborative,Other,31-Jul-20,1-Nov-22,24-Jul-22,TREATMENT,1500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,IDENTIFY AGENTS THAT WILL RESULT IN SUBSTANTIAL IMPROVEMENTS TO THE CLINICAL CONDITION OF PARTICIPANTS WITH COVID-19,I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
NCT04488471,Recruiting,Observational,,Sheffield Teaching Hospitals NHS Foundation Trust,Other,30-Jun-20,30-Jun-22,30-Jun-22,COHORT,232,INFLAMMATORY BOWEL DISEASES,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",,WHAT IMPACT HAS THE ISOLATION OF PATIENTS DURING SOCIAL ISOLATION HAD IN TERMS OF PSYCHOLOGICAL MORBIDITY?,Impact of Isolation in Patients With IBD During the 2020 COVID-19 Crisis: a Mixed Methods Study
NCT04488484,"Active, not recruiting",Interventional,Not Applicable,Groupe Hospitalier Paris Saint Joseph,Other,1-Jul-20,31-Dec-21,31-Dec-21,DIAGNOSTIC,450,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY TEST FOLLOW-UP,IMMUNE RESPONSE DESCRIPTION,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group
NCT04488510,"Active, not recruiting",Observational,,Groupe Hospitalier Paris Saint Joseph,Other,6-May-20,30-Nov-20,6-May-20,OTHER,150,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RESEARCH OF THE BACTERIA RESPONSIBLE FOR NOSOCOMIAL PNEUMONIA,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia: COVAP Study
NCT04488549,Completed,Observational,,Treviso Regional Hospital,Other,20-May-20,10-Jun-20,10-Jun-20,OTHER,1051,COLO-RECTAL CANCER,ITALY,ALL,"Child, Adult, Older Adult",SURVEY,PREDICTIVE POWER OF RESPONDENTS' AND HOSPITALS' DEMOGRAPHICS ON DELAYING COLORECTAL CANCER CARE ACROSS 6 GEOGRAPHICAL REGIONS,DElayed COloRectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)
NCT04488562,Recruiting,Observational [Patient Registry],,Erasmus Medical Center,Other,8-May-20,31-Dec-21,1-Dec-21,COHORT,150,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,VAS,Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands
NCT04488575,Recruiting,Interventional,Phase 2,"Evelo Biosciences, Inc.",Industry,26-Aug-20,6-Jul-21,6-Jul-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EDP1815,CHANGE FROM BASELINE TO THE LOWEST S/F OXYGEN RATIO,A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection
NCT04488588,Completed,Observational,,Assiut University,Other,15-Mar-20,1-Jul-20,1-May-20,COHORT,1064,COVID,EGYPT,ALL,36 Years to 63 Years   (Adult),KAPLAN MEIER ANALYSIS,NUMBER OF CO-MORBIDITIES IN HOSPITALIZED PATIENTS WITH COVID-19,Survival and 30-days Hospital Outcome in Hospitalized COVID-19 Patients in Upper Egypt: Multi-center Study
NCT04488796,Recruiting,Interventional,Not Applicable,"Western University, Canada",Other,7-Sep-20,20-Dec-21,20-Dec-21,PREVENTION,145,HEALTH BEHAVIOUR CHANGE,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",ASSIGNED STRATEGIES: OPT-IN,CHANGE IN SEDENTARY BEHAVIOUR BREAK FREQUENCY,"STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers, a Pilot Randomized Controlled Trial"
NCT04489446,Recruiting,Interventional,Phase 1/Phase 2,Universidad Nacional Andres Bello,Other,19-Aug-20,21-Mar-21,20-Dec-21,TREATMENT,40,COVID,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",SILDENAFIL,ARTERIAL OXYGENATION,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial
NCT04489628,Not yet recruiting,Interventional,Phase 1/Phase 2,University Hospitals Cleveland Medical Center,Other,1-Aug-20,1-Aug-21,1-Aug-21,TREATMENT,110,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN D3 OR PLACEBO,PATIENTS REQUIRING ADMISSION TO THE HOSPITAL OR EXPERIENCING DEATH,Tele-health Enabled Clinical Trial for COVID-19: Vitamin D as an Immunomodulator to Prevent Complications and Reduce Resource Utilization in Outpatients
NCT04490174,Recruiting,Observational,,National Institute of Environmental Health Sciences (NIEHS),NIH,8-Jan-20,1-Jun-22,1-Jun-22,COHORT,2500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,ANTI-SARS-COV-2 ANTIBODIES,Serological Surveillance for COVID-19 in Central North Carolina
NCT04490200,Not yet recruiting,Interventional,Not Applicable,University of Brasilia,Other,30-Nov-20,31-Jul-21,31-Jan-21,PREVENTION,1000,COVID,,ALL,20 Years to 59 Years   (Adult),VESTA RESPIRATOR,INCIDENCE OF LABORATORY-CONFIRMED COVID-19,Effectiveness of a Novel Respirator With Chitosan Nanoparticles to Reduce the Incidence of SARS-CoV-2 Infection in Healthcare Professionals: Randomized Controlled Trial (VESTA Trial)
NCT04490239,"Active, not recruiting",Interventional,Early Phase 1,Joshua Sharp,Other,9-Oct-20,20-Nov-21,20-Nov-21,PREVENTION,6,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",INTRANASAL HEPARIN SODIUM (PORCINE),"ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT), ACUTE PHASE",Intranasal Heparin Tolerability Study
NCT04490278,Recruiting,Interventional,Not Applicable,Washington University School of Medicine,Other,29-Sep-20,30-Jul-21,30-Jul-21,SUPPORTIVE CARE,80,POST ICU SYNDROME,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",MEDICAL RECORD REVIEW - INPATIENT TREATMENT,ACCEPTANCE WITH VIRTUAL COV-PICS VISITS - AIM,"COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Clinic: Modern, Convenient and Practical Recovery Care"
NCT04490473,Recruiting,Interventional,Not Applicable,DILEK SAYIK,Other,24-Jul-20,24-Apr-21,24-Mar-21,OTHER,300,ANXIETY,TURKEY,ALL,18 Years to 60 Years   (Adult),SURVEY WORK,ANXIETY IN SARS-COV-2,Turkish Validity And Reliability of the SARS-CoV-2 Anxiety Scale
NCT04490486,Not yet recruiting,Interventional,Phase 1,Joshua M Hare,Other,1-Sep-21,1-Jun-24,1-Jun-24,TREATMENT,21,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UCMSCS,PERCENT OF PARTICIPANTS WITH TREATMENT RELATED SERIOUS ADVERSE EVENTS (SAE),"Phase I, Randomized, Double Blinded, Placebo Control Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 With Moderate to Severe Symptoms"
NCT04490772,Not yet recruiting,Observational,,Assiut University,Other,20-Jul-21,20-Sep-21,20-Sep-21,COHORT,200,INFECTIOUS,,ALL,"Child, Adult, Older Adult",LABORATORY TESTS,CLINICAL DATA QUESTIONNAIRE,Characteristics and Outcomes of Gastrointestinal Manifestations of COVID-19
NCT04490811,Recruiting,Observational,,Hôpital Necker-Enfants Malades,Other,9-Apr-20,31-Dec-21,31-Dec-21,COHORT,800,COVID,FRANCE,ALL,"up to 18 Years   (Child, Adult)",NO INTERVENTION. OBSERVATIONAL COHORT STUDY,SEROLOGICAL TEST,Seroprevalence and Immunoprotection Against SARS-CoV2 in Children Hospitalized in Paris
NCT04490824,Recruiting,Interventional,Not Applicable,Institute of Progressive Medicine,Other,1-Oct-20,30-Apr-21,30-Mar-21,TREATMENT,100,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",KELEA EXCELLERATED WATER,INHALATION OF KELEA EXCELLERATED WATER IN COVID-19 INFECTED INDIVIDUALS,Can Inhalation of KELEA Excellerated Water Reduce the Time Required for Covid-19 Infected Individuals to Become Symptom-Free and to Test Negative Using Either the PCR or Antigen Assay
NCT04490837,"Active, not recruiting",Observational [Patient Registry],,Corporacion Parc Tauli,Other,22-Jun-20,30-Sep-20,31-Jul-20,CASE-CONTROL,3500,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",ELISA AND RAPID TEST TO DETECT ANTIBODIES AGAINST COVID-19,IGG ANTI-COVID-19,Rapid Diagnostic Test for COVID-19 Based on Antibody Detection
NCT04490850,Recruiting,Interventional,Not Applicable,Institut Pasteur,Industry,15-Jul-20,15-Jul-21,15-Jul-21,PREVENTION,1500,CORONAVIRUS INFECTION,FRENCH GUIANA,ALL,"Child, Adult, Older Adult",BLOOD SAMPLE,MEASURE OF THE COVID-19 IMMUNITY OF THE POPULATION,COVID-19 Seroprevalence Study in French Guiana
NCT04491071,Not yet recruiting,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,20-Sep-21,20-Dec-21,20-Dec-21,COHORT,405,STRESS DISORDER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",GENERALIZED ANXIETY DISORDER-7 (GAD 7),RESULTS OF THE GENERALIZED ANXIETY DISORDER (GAD-7),Stress Induced by the COVID-19 Pandemic and Nonconfinement: Study of Anxiety Factors and Potential Effects on Immunity.
NCT04491201,Recruiting,Observational,,Lei Li,Other,27-Jul-20,27-Sep-20,27-Sep-20,COHORT,6000,COVID PANDEMICS,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",CUSTOMIZED QUESTIONNAIRE,THE CHANGES OF WORKLOAD OF PHYSICIANS DURING COVID-19 PANDEMICS COMPARED WITH 2019 YEAR,National Survey of the Impact of COVID-19 Pandemics on Chinese Physicians of Obstetrics and Gynecology
NCT04491214,Completed,Observational,,"University Hospital, Strasbourg, France",Other,24-Jul-20,21-Jan-21,21-Jan-21,COHORT,112,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUALITY OF LIVE ASSESSMENT,ASSESS QUALITY OF LIFE AFTER SEVERE COVID INFECTION,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19)
NCT04491227,Enrolling by invitation,Observational,,"University of California, San Diego",Other,5-May-20,31-Mar-23,30-Apr-22,COHORT,2000,COVID,BOLIVIA,ALL,"18 Years and older   (Adult, Older Adult)",,AKI INCIDENCE,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
NCT04491240,Completed,Interventional,Phase 1/Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",Other,20-Jul-20,20-Oct-20,1-Oct-20,OTHER,30,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EXO 1 INHALATION,NUMBER OF PARTICIPANTS WITH NON-SERIOUS AND SERIOUS ADVERSE EVENTS DURING TRIAL,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia
NCT04491292,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,18-May-20,30-Apr-21,30-Apr-21,COHORT,20000,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ADMINISTRATION,CHANGE IN PSYCHOSOCIAL OUTCOMES,Psychosocial Impact of COVID-19 Pandemic on MD Anderson Workforce
NCT04491318,Recruiting,Observational,,Investigación en Hemofilia y Fisioterapia,Other,1-Jul-20,29-Jul-20,25-Jul-20,COHORT,27,HEMOPHILIA ARTHROPATHY,SPAIN,MALE,"18 Years to 65 Years   (Adult, Older Adult)",OBSERVATIONAL,CHANGE FROM BASELINE FREQUENCY OF HEMARTHROSIS AFTER CONFINEMENT PERIOD,Effects of COVID-19 Quarantine on the Musculoskeletal Status of Adult Hemophilia Patients. An Observational Study
NCT04491994,Completed,Interventional,Phase 3,UNICEF,Other,10-Apr-20,31-May-20,31-May-20,TREATMENT,540,COVID,PAKISTAN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HCQ,NUMBER OF PARTICIPANTS WITH PROGRESSION,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial
NCT04492189,Completed,Observational,,"University Hospital, Montpellier",Other,1-Apr-20,30-Jun-20,30-May-20,OTHER,40,EATING DISORDERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,VARIATION IN EATING DISORDERS,Impact of Containment Measures in People With Eating Disorders: a Descriptive Study
NCT04492202,Not yet recruiting,Observational,,Istinye University,Other,1-Aug-20,10-Dec-20,20-Nov-20,OTHER,200,COVID,,ALL,"22 Years to 75 Years   (Adult, Older Adult)",SURVEY,"QUESTIONNAIRE FOR THE EVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTISE LEVELS OF HEALTHCARE PROFESSIONALS FOR COVID-19","Comparison of the Knowledge, Attitudes, and Practices Towards COVID-19 Between Different Healthcare Professionals"
NCT04492228,Recruiting,Interventional,Not Applicable,Ospedale Policlinico San Martino,Other,1-Sep-20,30-May-21,31-Dec-20,TREATMENT,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",KETOGENIC DIET,MORTALITY RATE IN THE KETOGENIC GROUP DIET VS STANDARD ONE,Randomized Open Controlled Clinical Trial to Evaluate the Effectiveness of a Eucaloric Ketogenic Nutrition in Comparison With a Standard Nutrition in Covid-19 Disease in Reducing Cytokine Storm Syndrome and ARDS
NCT04492254,Not yet recruiting,Interventional,Phase 3,Thrombosis Research Institute,Other,20-Jul-21,21-Jul-21,21-Jan-21,TREATMENT,1370,COVID,,ALL,"55 Years and older   (Adult, Older Adult)",ENOXAPARIN,HOSPITAL ADMISSION,"Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive Patients"
NCT04492267,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,7-Jul-20,7-Jan-21,7-Jan-21,CASE-ONLY,700,INFLAMMATORY BOWEL DISEASE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE ANALYSIS OF SEVERITY AND SPECIFIC NEEDS IN CASE OF SARS-COV-2 INFECTION IN IBD PATIENTS,"SARS-CoV-2 Infection in Patients From Two Tertiary Inflammatory Bowel Disease (IBD) Centres: Frequency of Suspected and Confirmed Infections, Severity and Outcome Management"
NCT04492358,Recruiting,Interventional,Phase 2/Phase 3,Maria Joyera Rodríguez,Other,22-Oct-20,21-Oct-21,21-Oct-21,TREATMENT,144,COVID,SPAIN,ALL,65 Years and older   (Older Adult),COLCHICINE,NUMBER OF PATIENTS THAT A SHORT CYCLE OF STEROIDS ADMINISTERED TOGETHER WITH COLCHICINE REDUCES MORTALITY FROM COVID-19,"Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center"
NCT04492371,Recruiting,Observational,,European Myeloma Network,Other,1-Jul-20,21-Jul-21,21-Jul-21,COHORT,500,MULTIPLE MYELOMA,AUSTRIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,NATURE OF COVID19,COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS: AN EUROPEAN OBSERVATIONAL STUDY
NCT04492384,Completed,Observational,,Eurasian Association of Therapists,Other,11-Jun-20,14-Jan-21,14-Jan-21,COHORT,3500,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",NON-INTERVENTIONAL,RATE OF NON-INFECTIOUS DISEASES,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients
NCT04492410,"Active, not recruiting",Interventional,Not Applicable,Centre Antoine Lacassagne,Other,21-Jul-20,21-May-21,21-May-21,SCREENING,500,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RAPID SEROLOGICAL TEST,TO EVALUATE THE PREVALENCE OF COVID-19,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)
NCT04492449,Not yet recruiting,Observational,,University of Sao Paulo,Other,21-Jan-21,22-Dec-21,21-Apr-21,OTHER,260,EXPOSURE DURING PREGNANCY,,FEMALE,"16 Years to 40 Years   (Child, Adult)",CONGENITAL MALFORMATION,PERIODONTAL STATUS,"Evaluation of Systemic and Oral Conditions of Pregnant Women and Their Babies, With Exposure to Coronavirus SARS-CoV-2"
NCT04492475,Completed,Interventional,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,5-Aug-20,21-Dec-20,21-Dec-20,TREATMENT,969,COVID,JAPAN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",INTERFERON BETA-1A,"TIME TO RECOVERY FOR PATIENTS WITH BASELINE ORDINAL SCORE 4, 5, AND 6","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)"
NCT04492501,Completed,Interventional,Not Applicable,UNICEF,Other,1-Apr-20,20-Jul-20,20-Jul-20,TREATMENT,600,COVID,PAKISTAN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE,SURVIVAL,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19"
NCT04492514,Recruiting,Interventional,Phase 2,Kristin Hudock,Other,20-May-20,31-May-21,31-May-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MAVRILIMUMAB,PRIMARY OUTCOME MEASURE:,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
NCT04492527,Recruiting,Interventional,Not Applicable,University of British Columbia,Other,28-Jul-20,31-Jul-21,30-Jun-21,PREVENTION,75,CHRONIC DISEASE,CANADA,ALL,65 Years and older   (Older Adult),TELEHEALTH COACHING SESSIONS,CHANGE FROM BASELINE: HEALTH DIRECTED BEHAVIOUR AT 2 MONTHS,A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH)
NCT04492865,Not yet recruiting,Observational,,Assiut University,Other,30-Jul-20,30-Oct-20,30-Aug-20,COHORT,150,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",MSCT,ACCURACY OF NON CONTRAST MSCT CHEST IN COVID-19,MSCT Chest in Suspected COVID-19 Patients in Correlation With Symptomology and Laboratory Findings
NCT04492891,Recruiting,Interventional,Phase 2,"Bryan Burt, MD",Other,23-Nov-20,23-Nov-25,23-Nov-25,TREATMENT,75,SARS (DISEASE),UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CYCLOSPORINE,WHO COVID-19 CLINICAL SEVERITY SCALE,Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of COVID-19(+) Non-ICU Hospital Inpatients
NCT04492904,Recruiting,Observational,,"Clinical Nutrition Research Centre, Singapore",Other,23-Jul-20,31-Mar-21,31-Mar-21,CASE-CONTROL,5000,COVID,SINGAPORE,ALL,"21 Years to 70 Years   (Adult, Older Adult)",HOME-USE TEST AND FOLLOW-UP QUESTIONNAIRE,TASTE AND SMELL ACUITY,Singapore COVID-19 Chemosensory Tracking (SCCT) Study
NCT04492943,Completed,Observational,,Massachusetts General Hospital,Other,20-Apr-20,30-Jun-20,30-Jun-20,COHORT,35,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SURVIVAL OUTCOME,To Observe Whether Isoflurane Can Treat COVID-19 Patients
NCT04493242,Not yet recruiting,Interventional,Phase 2,"Direct Biologics, LLC",Industry,1-Sep-20,31-Dec-20,30-Nov-20,TREATMENT,60,COVID,,ALL,"18 Years to 85 Years   (Adult, Older Adult)",DB-001,ALL-CAUSE MORTALITY,Extracellular Vesicle Infusion Treatment for Severe COVID-19
NCT04493268,Completed,Observational,,Hospital Nacional Profesor Alejandro Posadas,Other,7-Mar-20,21-Jul-20,20-Jul-20,COHORT,250,HYPONATREMIA,ARGENTINA,ALL,"1 Month to 100 Years   (Child, Adult, Older Adult)",,MORTALITY,HYPONATREMIA AND INFLAMMATION AND CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS
NCT04493294,Not yet recruiting,Interventional,Phase 1/Phase 2,International Geriatric Radiotherapy Group,Other,20-Nov-21,21-Dec-21,21-Dec-21,TREATMENT,500,COVID PNEUMONITIS,,ALL,65 Years and older   (Older Adult),LOW DOSE WHOLE LUNG RADIOTHERAPY FOR OLDER PATIENTS WITH COVID-19 PNEUMONITIS,MORTALITY RATE,Low Dose Whole Lung Radiotherapy for Older Patients With Coronavirus 19 Disease (COVID-19) Pneumonitis: Practical Protocol by the International Geriatric Radiotherapy Group
NCT04493307,Recruiting,Observational,,LifeBridge Health,Other,30-Jun-20,21-Jun-21,21-Feb-21,OTHER,100,COVID,UNITED STATES,ALL,"3 Years and older   (Child, Adult, Older Adult)",PHLEBOTOMY,FREQUENCY OF HYPERCOAGULABILITY AS MEASURED BY THROMBOELASTOGRAPHY MEASURED BY TEG AND PLATELET AGGREGATION.,"The Evaluation of Hemostasis by Thromboelastography, Platelet Function Testing, and Biomarker Analysis in Hospitalized COVID-19 Patients"
NCT04493359,Recruiting,Interventional,Phase 2/Phase 3,University of Sao Paulo,Other,25-Jul-20,14-Feb-22,14-Feb-22,TREATMENT,240,COVID,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RENIN-ANGIOTENSIN SYSTEM INHIBITORS,NEED FOR ICU OR MORTALITY,Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial
NCT04494204,Completed,Interventional,Phase 2/Phase 3,PUNEET MITTAL,Other,7-Aug-20,20-Dec-20,1-Dec-20,TREATMENT,100,TREATMENT OF COVID VIRUS INFECTION,INDIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",IMMUNOFREE TABLETS AND REGINMUNE CAPSULE,TIME (DAYS) TO CLINICAL IMPROVEMENT FROM STUDY ENROLLMENT,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients."
NCT04494386,Recruiting,Interventional,Phase 1/Phase 2,"Restem, LLC.",Industry,23-Jul-20,30-Nov-21,30-Oct-20,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UMBILICAL CORD LINING STEM CELLS (ULSC),INCIDENCE OF DOSE LIMITING TOXICITY (DLT),Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19
NCT04494399,Recruiting,Interventional,Phase 2,The University of Hong Kong,Other,29-Jul-20,1-Aug-22,1-Jul-22,TREATMENT,96,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON BETA-1B,CLINICAL SYMPTOMS ALLEVIATION,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection"
NCT04494646,Completed,Interventional,Phase 2,NYU Langone Health,Other,8-Sep-20,8-Jan-21,8-Jan-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BARDOXOLONE METHYL,INCIDENCE OF SERIOUS ADVERSE EVENTS,"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)"
NCT04494724,Recruiting,Interventional,Phase 2,The Methodist Hospital System,Other,13-Jul-20,31-Jul-21,31-Dec-20,TREATMENT,60,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLAZAKIZUMAB,PRIMARY ENDPOINT,A Phase 2 Trial to Evaluate the Safety and Tolerability of Clazakizumab® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection
NCT04494776,Recruiting,Observational,,Helio Tedesco Silva Junior,Other,21-May-20,2-Apr-22,3-Nov-21,COHORT,500,SARS-COV2 INFECTION,BRAZIL,ALL,"Child, Adult, Older Adult",,DEATH,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Infection (COVID-19) in Kidney Transplant Recipients: a Brazilian Multicenter Study
NCT04494867,Recruiting,Interventional,Not Applicable,Sharp HealthCare,Other,19-Aug-20,20-Dec-21,20-Dec-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CORE WARMING,PAO2/FIO2 RATIO,"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study"
NCT04494893,Recruiting,Observational,,Adaptive Biotechnologies,Industry,24-Apr-20,31-Jan-21,31-Dec-20,COHORT,1000,COVID,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",,COMPARISON OF DISEASE-SPECIFIC TCR SIGNATURES IN PATIENTS AND CONTROLS,ImmuneRACE - Immune Response Action to COVID-19 Events
NCT04494984,Completed,Interventional,Phase 2/Phase 3,Inmunova S.A.,Other,27-Jul-20,30-Dec-20,23-Nov-20,TREATMENT,242,COVID,ARGENTINA,ALL,"18 Years to 79 Years   (Adult, Older Adult)",INM005,CLINICAL CHANGES IN COVID-19 SYMPTOMS,"A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease."
NCT04495101,Recruiting,Interventional,Phase 2,"Instituto Grifols, S.A.",Industry,29-Jul-20,21-May-21,21-Apr-21,TREATMENT,100,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PROLASTIN,PERCENTAGE OF SUBJECTS DYING OR REQUIRING ICU ADMISSION,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19"
NCT04495543,Recruiting,Interventional,Not Applicable,Unity Health Toronto,Other,1-Dec-20,21-Aug-21,21-Aug-21,PREVENTION,75,SUICIDAL IDEATION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",BRIEF SKILLS FOR SAFER LIVING,CHANGE IN SUICIDAL IDEATION USING BECK SCALE FOR SUICIDE IDEATION,"Mitigating Suicide Risk During the COVID-19 Pandemic Via Telehealth Using an Intensive Single Session of ""Brief Skills for Safer Living"""
NCT04495764,Completed,Observational,,Davita Clinical Research,Industry,20-Jul-20,12-Feb-21,12-Feb-21,COHORT,2504,SARS-COV2 INFECTION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,ANTI-SARS-COV-2 ANTIBODIES,Registry of Sustained Immunity to COVID-19 Among ESKD Patients
NCT04495803,Not yet recruiting,Interventional,Not Applicable,St. Joseph's Healthcare Hamilton,Other,10-Aug-20,1-Aug-22,1-Aug-22,TREATMENT,120,PERINATAL ANXIETY,,FEMALE,18 Years to 45 Years   (Adult),COGNITIVE BEHAVIOURAL GROUP THERAPY FOR PERINATAL ANXIETY,STATE-TRAIT INVENTORY OF COGNITIVE AND SOMATIC ANXIETY (STICSA),Augmented Cognitive Behavioural Group Therapy for Perinatal Anxiety During a Global Pandemic (COVID-19)
NCT04495816,Recruiting,Interventional,Phase 2,Icahn School of Medicine at Mount Sinai,Other,15-Jul-20,21-Aug-21,21-Aug-21,TREATMENT,126,ANOSMIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OMEGA-3 FATTY ACID SUPPLEMENT,BRIEF SMELL IDENTIFICATION TEST (BSIT),COVID-19 Anosmia Study
NCT04495842,Recruiting,Interventional,Not Applicable,Franklin School of Integrative Health Sciences,Other,1-Oct-20,30-Jun-21,31-Mar-21,SUPPORTIVE CARE,65,STRESS,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ESSENTIAL OIL BLEND,CHANGE FROM BASELINE IN STATE ANXIETY ON THE STATE PORTION OF THE STATE TRAIT ANXIETY SCALE (STAI-S) AT 15 MINUTES,The Effect of Aromatherapy on COVID-19-induced Anxiety
NCT04495907,Recruiting,Observational,,Davita Clinical Research,Industry,6-Aug-20,21-Jun-21,21-Mar-21,COHORT,1000,SARS-COV2 INFECTION (ASYMPTOMATIC),UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,SARS-COV-2 IGG,COVID-19 Progression in End-Stage Kidney Disease
NCT04495933,Recruiting,Interventional,Phase 1,The University of Queensland,Other,13-Jul-20,21-Sep-21,20-Oct-21,PREVENTION,216,SARS-COV2,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",MF59 ADJUVANTED SARS-COV-2 SCLAMP VACCINE 5MCG,FREQUENCY OF SOLICITED LOCAL REACTOGENICITY ADVERSE EVENTS (AES),"A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over"
NCT04496076,Enrolling by invitation,Observational,,University of Pittsburgh,Other,2-Apr-20,31-Mar-21,31-Dec-20,COHORT,300,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY,Severe Neurologic Injury Outcomes During COVID-19 Crisis
NCT04496128,Enrolling by invitation,Observational,,University of Pittsburgh,Other,13-Apr-20,31-Mar-21,31-Dec-20,COHORT,300,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE OF NEUROLOGICAL MANIFESTATIONS,Neurological Complications of COVID-19
NCT04496141,"Active, not recruiting",Observational,,Hong Kong Sanatorium & Hospital,Industry,27-Jul-20,30-Nov-20,30-Nov-20,COHORT,70,COVID,HONG KONG,ALL,"Child, Adult, Older Adult",SARS-COV-2 ANTIBODY IMMUNOASSAYS,THE ACCURACY OF THE DIFFERENT COMMERCIAL SARS-COV-2 ANTIBODY IMMUNOASSAYS,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19
NCT04496245,Recruiting,Interventional,Phase 3,The University of Queensland,Other,24-Aug-20,30-Jun-21,30-Jun-21,PREVENTION,1000,RESPIRATORY VIRAL INFECTION,AUSTRALIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",BRONCHO-VAXOM®,ACUTE RESPIRATORY INFECTION NECESSITATING WORKFORCE REMOVAL,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
NCT04496869,Not yet recruiting,Observational,,Hospices Civils de Lyon,Other,20-Jul-21,20-Dec-21,20-Sep-21,COHORT,600,INFERTILITY TREATMENT,FRANCE,FEMALE,18 Years to 43 Years   (Adult),ONLINE QUESTIONNAIRE,PSYCHOLOGICAL IMPACT ASSESSED BY SCORES OF PSS10 SCALES.,"Psychological Impact of COVID19 Among Women Undergoing Infertility Treatment, a French Cohort"
NCT04497194,Recruiting,Observational [Patient Registry],,Azienda Ospedaliera Universitaria Integrata Verona,Other,1-Mar-20,30-Sep-20,30-Aug-20,COHORT,500,CORONAVIRUS DISEASE 2019,ITALY,ALL,"Child, Adult, Older Adult",NOT APPLICABLE (OBSERVATIONAL STUDY),EPIDEMIOLOGICAL PREDICTORS OF POOR OUTCOMES IN COVID-19 PATIENTS ADMITTED TO UNIVERSITY HOSPITAL OF VERONA,"Registry of Biological Samples, Clinical Information and Epidemiological Data of COVID-19 Patients Admitted at the University Hospital of Verona (AOUI Verona)"
NCT04497246,Recruiting,Observational,,Murielle Surquin,Other,29-May-20,20-Dec-21,20-Dec-21,COHORT,5000,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,IMPACT EVENT SCALE-REVISED (IES-R),"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)"
NCT04497272,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,7-Aug-20,7-Oct-21,7-Aug-21,DIAGNOSTIC,150,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PATIENTS,IDENTIFYING THE METABOLOMIC SIGNATURE,Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)
NCT04497298,Recruiting,Interventional,Phase 1,Institut Pasteur,Industry,10-Aug-20,21-Oct-21,20-Nov-21,PREVENTION,90,COVID,BELGIUM,ALL,18 Years to 55 Years   (Adult),TWO COVID-19 VACCINE CANDIDATE (TMV-083) ADMINISTRATIONS - LOW DOSE,TO ASSESS THE SAFETY AND TOLERABILITY OF THE COVID-19 VACCINE FOLLOWING ONE OR TWO CONSECUTIVE INTRAMUSCULAR INJECTIONS IN HEALTHY VOLUNTEERS,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase"
NCT04497311,Recruiting,Observational,,Universidad de Guanajuato,Other,15-Jun-20,30-Apr-22,30-Apr-21,COHORT,100,SARS-COV2,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)",THORAXIC COMPUTED TOMOGRAPHY,RADIOLOGICAL FINDINGS,Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients
NCT04497324,Not yet recruiting,Interventional,Phase 2,Universidad Peruana Cayetano Heredia,Other,20-Aug-20,31-Dec-20,30-Nov-20,TREATMENT,100,COVID,PERU,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,TRANSFUSION-RELATED SERIOUS ADVERSE EVENTS,PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19
NCT04497389,Recruiting,Interventional,Phase 1/Phase 2,University of Utah,Other,28-Oct-20,15-Sep-21,15-Sep-21,TREATMENT,60,SARS COV-2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HUMAN AMNIOTIC FLUID,C-REACTIVE PROTEIN,A Phase I/II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients
NCT04497402,Recruiting,Observational [Patient Registry],,University of Roma La Sapienza,Other,1-Sep-20,1-Jun-22,1-Sep-21,COHORT,88,COVID,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,SEX DIFFERENCES IN PLATELET AND IMMUNE FUNCTION AND COVID19 SEVERITY,Sex-Informed Data in the COVID-19 Pandemic.
NCT04497415,Recruiting,Interventional,Not Applicable,"Research Foundation for Mental Hygiene, Inc.",Other,21-Oct-20,30-Jan-21,30-Nov-20,HEALTH SERVICES RESEARCH,1200,BRIEF VIDEO-BASED INTERVENTION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VIDEO-BASED INTERVENTION,HELP-SEEKING BEHAVIOR,The COVID-19 and Healthcare Workers: An Active Intervention
NCT04497441,Recruiting,Observational,,Qassim University,Other,10-Jun-20,15-Aug-20,10-Aug-20,OTHER,385,COVID,SAUDI ARABIA,ALL,"19 Years and older   (Adult, Older Adult)",ELECTRONIC SURVEY QUESTIONNAIRE,NETIZENS' PERCEPTION OF THE SOURCES OF COVID-19 INFORMATION,Perceptions of Netizens Regarding COVID-19 Information & Information Sources: A Cross Sectional Study
NCT04497454,Recruiting,Interventional,Not Applicable,University of Sao Paulo General Hospital,Other,8-May-20,1-Dec-21,1-Jul-21,TREATMENT,128,RESPIRATORY DISTRESS SYNDROME,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",EIT-GROUP,AVERAGE DAILY MODIFIED LUNG INJURY SCORE UNTIL DAY 28,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) - COVEN Study
NCT04497467,Recruiting,Observational,,National Taiwan University Hospital,Other,1-Aug-20,31-Dec-20,31-Dec-20,COHORT,1200000,PATIENT PREFERENCE,TAIWAN,ALL,"Child, Adult, Older Adult",,THE NUMBER OF THE OUT-PATIENT VISITS,An Analysis of Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic
NCT04497519,Completed,Interventional,Phase 1,University Medical Center Groningen,Other,15-Sep-20,1-Nov-20,15-Oct-20,TREATMENT,12,COVID,NETHERLANDS,ALL,"18 Years to 65 Years   (Adult, Older Adult)",INHALED HYDROXYCHLOROQUINE,LOCAL TOLERABILITY,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers; a Pilot Study
NCT04497610,Not yet recruiting,Observational [Patient Registry],,Instituto Costarricense de Investigaciones Clínicas ICIC,Other,4-Aug-20,15-Aug-20,15-Aug-20,COHORT,1000,COVID,COSTA RICA,ALL,"7 Years and older   (Child, Adult, Older Adult)",BREATH SAMPLE,PRESENCE OF DISEASE,SARS-CoV-2 (COVID-19) Detection Using the Breath Analizer TeraSystem
NCT04497623,Completed,Interventional,Not Applicable,Fundación Neumologica Colombiana,Other,28-Jul-20,20-Sep-20,13-Aug-20,DEVICE FEASIBILITY,5,COVID,COLOMBIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",INVASIVE MECHANICAL VENTILATION USING THE UNISABANA-HERONS VENTILATOR DURING 24 HOURS,IMPROVEMENT OR MAINTENANCE OF THE OXYGENATION LEVEL MEASURED BY PAO2,"Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1"
NCT04497636,Recruiting,Observational,,Pontificia Universidad Catolica de Chile,Other,3-Jul-20,31-Jan-21,31-Jan-21,COHORT,1092,ANXIETY,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",,DEPRESSIVE SYMPTOMS,"Mental Health Impact of the COVID-19 Pandemic Among Immigrants in Santiago, Chile (STRING-COVID)"
NCT04497649,Recruiting,Interventional,Phase 2/Phase 3,Tanta University,Other,1-Jul-20,10-Apr-21,1-Apr-21,TREATMENT,100,COVID,EGYPT,ALL,"Child, Adult, Older Adult",SOFOSBUVIR,NUMBER OF PATIENTS WITH IMPROVEMENT OR MORTALITY,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.
NCT04497779,Recruiting,Observational,,City of Hope Medical Center,Other,13-Jul-20,21-Aug-22,21-Aug-21,COHORT,800,ASYMPTOMATIC COVID INFECTION LABORATORY-CONFIRMED,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOSPECIMEN COLLECTION,CONVALESCENT PLASMA (CCP) UNITS INFUSED IN CORONAVIRUS DISEASE-2019 (COVID-19) PATIENTS,Evaluation of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
NCT04497818,Completed,Observational,,Qassim University,Other,16-Jun-20,25-Jul-20,16-Jul-20,OTHER,385,COVID,SAUDI ARABIA,ALL,"20 Years and older   (Adult, Older Adult)",CROSS SECTIONAL STUDY USING SCIENTIFICALLY VALIDATED PSYCHOMETRIC SCALES,FEAR OF COVID-19 INFECTION,Correlation of Fear of COVID-19 Infection and Dental Treatment Anxiety Among Netizens: A Cross-sectional Study.
NCT04497922,Recruiting,Interventional,Not Applicable,Brigham and Women's Hospital,Other,25-Jan-21,15-May-21,30-Apr-21,OTHER,100,"SATISFACTION, PATIENT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",E-INK SCREEN,EMERGENCY DEPARTMENT SATISFACTION: LIKERT SCALE,Improving Patient Satisfaction Through Information Display Using Virtual White Boards
NCT04497948,Terminated,Interventional,Phase 1,Acerta Pharma BV,Industry,21-Sep-20,18-Nov-20,18-Nov-20,TREATMENT,8,COVID,BRAZIL,ALL,"18 Years to 100 Years   (Adult, Older Adult)",ACALABRUTINIB,ACALABRUTINIB AND ACP-5862 PLASMA PK PARAMETER: AUC12H,"An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19"
NCT04497987,Recruiting,Interventional,Phase 3,Eli Lilly and Company,Industry,2-Aug-20,29-Jun-21,8-Mar-21,PREVENTION,5000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LY3819253,PERCENTAGE OF PARTICIPANTS WITH COVID-19 WITHIN 21 DAYS OF DETECTION,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study"
NCT04498065,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire Dijon,Other,1-Mar-20,21-Jul-21,1-Jul-20,COHORT,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL DATA,CHARACTERIZE THE MYOCARDIAL DAMAGE ASSOCIATED WITH COV-2 SARS INFECTION,MYocardial DOmmages Related to COVID-19
NCT04498091,"Active, not recruiting",Observational,,Centre Hospitalier Universitaire Dijon,Other,15-Mar-20,21-Jul-21,1-Jul-20,COHORT,35,ACUTE MYOCARDIAL INFARCTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL DATA,CHARACTERIZING TYPE 2 MYOCARDIAL INFARCTION ASSOCIATED WITH COV-2 SARS INFECTION,EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19
NCT04498247,"Active, not recruiting",Interventional,Phase 1/Phase 2,Merck Sharp & Dohme Corp.,Industry,27-Aug-20,26-Apr-22,26-Apr-22,PREVENTION,260,CORONAVIRUS DISEASE (COVID),AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",V591,PERCENTAGE OF PARTICIPANTS WITH AT LEAST 1 SOLICITED INJECTION SITE ADVERSE EVENT,"A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants"
NCT04498273,Recruiting,Interventional,Phase 3,Frank C Sciurba,Other,7-Sep-20,21-Sep-21,21-Sep-21,PREVENTION,7000,COVID,UNITED STATES,ALL,"40 Years to 80 Years   (Adult, Older Adult)",APIXABAN 2.5 MG,HOSPITALIZATION FOR CARDIOVASCULAR/PULMONARY EVENTS,COVID-19 Outpatient Thrombosis Prevention Trial: A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis
NCT04498286,Recruiting,Observational,,Zoé van Kempen,Other,6-Aug-20,1-Dec-21,1-Nov-21,COHORT,800,MULTIPLE SCLEROSIS,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",TESTING OF SARS-COV-2 ANTIBODIES,THE CORRELATION OF COVID-19 DISEASE COURSE WITH MS IMMUNOMODULATORY TREATMENT,COVID-19 and SARS-CoV-2 Antibodies in Multiple Sclerosis Patients: a Large Study in the Amsterdam MS Cohort
NCT04498299,Recruiting,Observational,,Miguel Ayala León,Other,1-Sep-20,30-Nov-20,1-Oct-20,COHORT,30,"ECHOCARDIOGRAPHY, STRESS",MEXICO,ALL,18 Years to 45 Years   (Adult),ECHOCARDIOGRAM 2D,• LA VOLUME INDEX,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
NCT04498325,Not yet recruiting,Interventional,Phase 1,Washington University School of Medicine,Other,28-Feb-21,30-Nov-21,30-Nov-21,TREATMENT,42,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NT-I7,SAFE AND TOLERABLE DOSE OF NT-I7 (PHASE I ONLY),"A Phase I and Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2"
NCT04498377,Recruiting,Interventional,Phase 2,Generon (Shanghai) Corporation Ltd.,Industry,26-Jan-21,31-Dec-21,30-Sep-21,TREATMENT,38,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",F-652,NIAID 8-POINT ORDINAL SCALE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19"
NCT04498416,Recruiting,Observational,,Fondation Lenval,Other,27-Apr-20,21-Jul-21,21-Jul-21,COHORT,70,MENTAL HEALTH DISORDER,FRANCE,ALL,up to 17 Years   (Child),QUANTITATIVE AND QUALITATIVE ASSESSMENTS OF MENTAL HEALTH,DIAGNOSIS OF POSSIBLE PSYCHOLOGICAL AND PSYCHIATRIC DIFFICULTIES AT BASELINE,"Methodology of "" CoCo 20 "": a Longitudinal Follow-up Study of the Paediatric Population and Their Families During and After the Coronavirus Pandemic and the Confinement"
NCT04498442,Completed,Interventional,Not Applicable,Beth Israel Deaconess Medical Center,Other,22-May-20,22-Oct-20,22-Oct-20,OTHER,8519,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SIMHA KRIYA,CHANGE IN PERCEIVED STRESS LEVELS,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls"
NCT04498507,Completed,Observational,,University of Liege,Other,16-Apr-20,30-Oct-20,30-Oct-20,COHORT,39,CRITICAL ILLNESS,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",HADS QUESTIONNAIRE,OCCURENCE OF ANXIETY AND DEPRESSION,Psychosocial Outcomes in Families of Patients Admitted in ICU for COVID-19 During the Pandemic in Belgium
NCT04498546,Recruiting,Observational [Patient Registry],,KTO Karatay University,Other,20-Jul-20,30-Sep-21,30-Mar-21,OTHER,60,EXERCISE TEST,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,RESTING HEART RATE,The Effects of Mask Usage on Exercise Capacity and Related Parameters During the COVİD-19 Pandemic
NCT04498936,Completed,Interventional,Phase 4,Assiut University,Other,15-Jul-20,30-Oct-20,30-Oct-20,TREATMENT,240,COVID,EGYPT,ALL,"12 Years to 65 Years   (Child, Adult, Older Adult)",SOFOSBUVIR AND LEDIPASVIR,CHANGE OF PCR FROM POSITIVE TO NEGATIVE,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial"
NCT04499300,Recruiting,Observational,,Murielle Surquin,Other,9-Jun-20,20-Dec-21,20-Dec-21,COHORT,50,COVID,BELGIUM,ALL,90 Years and older   (Older Adult),DATA COLLECTION FROM MEDICAL FILES,DEMOGRAPHIC DATA,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age
NCT04499313,Recruiting,Interventional,Phase 3,Chattogram General Hospital,Other,2-Aug-20,30-Nov-20,15-Nov-20,TREATMENT,60,COVID,BANGLADESH,ALL,"20 Years to 80 Years   (Adult, Older Adult)",DEXAMETHASONE,MORTALITY RATE (IN HOSPITAL),The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19
NCT04499378,Not yet recruiting,Observational,,Universidad de Guanajuato,Other,15-Aug-20,30-Apr-22,30-Apr-21,COHORT,200,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LUNG CT,ORAL INTUBATION,Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients at IMSS Guanajuato
NCT04499391,Recruiting,Interventional,Not Applicable,Milton S. Hershey Medical Center,Other,4-Dec-20,22-Jul-21,22-Jul-21,PREVENTION,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PROJECT ECHO,INFECTION RATE,"COVID-19 Project ECHO for Nursing Homes: A Patient-centered, Randomized-controlled Trial to Implement Infection Control and Quality of Life Best Practice"
NCT04499677,Recruiting,Interventional,Phase 2,"University College, London",Other,24-Sep-20,1-Mar-21,11-Dec-20,TREATMENT,240,COVID,UNITED KINGDOM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",FAVIPIRAVIR,UPPER RESPIRATORY TRACT VIRAL LOAD AT DAY 5,"Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19"
NCT04500067,Completed,Interventional,Phase 3,Biopharma Plasma LLC,Industry,7-May-20,15-Sep-20,15-Sep-20,TREATMENT,76,COVID,UKRAINE,ALL,"18 Years and older   (Adult, Older Adult)",IVIG,PERIOD DURATION (IN DAYS) TO CLINICAL IMPROVEMENT,"An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2"
NCT04500132,Recruiting,Interventional,Phase 2,Enzychem Lifesciences Corporation,Industry,28-May-20,22-May-21,21-Aug-21,TREATMENT,60,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",EC-18,RATE OF TRANSITION TO ARDS,"Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia"
NCT04500366,Recruiting,Interventional,Not Applicable,McMaster University,Other,26-Aug-20,21-May-21,21-Apr-21,PREVENTION,70,FRAILTY,CANADA,ALL,65 Years and older   (Older Adult),SOCIALIZATION,CHANGE IN PHYSICAL FUNCTION,GERAS Frailty Rehabilitation at Home: Virtual Bundled Care for Seniors Who Are Frail to Build Strength and Resilience During COVID-19
NCT04500418,Recruiting,Interventional,Phase 2,"Charite University, Berlin, Germany",Other,25-Aug-20,30-Sep-21,30-Sep-21,TREATMENT,183,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",CENICRIVIROC (CVC),SUBJECT´S RESPONDER STATUS (SCORE ON THE 7-POINT ORDINAL SCALE ON DAY 15),Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
NCT04500600,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,11-Jun-20,1-Jul-21,1-Jul-21,CASE-ONLY,50000,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUALITY-OF-LIFE ASSESSMENT,EXPERIENCES DURING THE CORONAVIRUS DISEASE 2019 (COVID-19) PANDEMIC,Well-Being and Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic
NCT04500626,Not yet recruiting,Interventional,Phase 2/Phase 3,Ottawa Hospital Research Institute,Other,21-Apr-21,22-Aug-21,22-Aug-21,TREATMENT,234,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",OXYGEN,7-LEVEL COVID ORDINAL OUTCOME SCALE,Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients
NCT04500639,Recruiting,Observational,,University of Alberta,Other,23-Jul-20,31-Mar-23,31-Dec-20,CASE-CONTROL,14000,SARS-COV2 INFECTION,CANADA,ALL,"Child, Adult, Older Adult",,IBUPROFEN EXPOSURE FOR SYMPTOM MANAGEMENT,Do Common Medications Alter the Course of COVID-19?
NCT04500652,Recruiting,Observational,,Dokuz Eylul University,Other,27-Jun-20,1-Oct-20,30-Aug-20,OTHER,310,ANXIETY,TURKEY,ALL,"24 Years to 80 Years   (Adult, Older Adult)",,"DEPRESSION, ANXIETY AND STRESS SCALES 21 SCORE",Evaluation of Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians During the Covid-19 Pandemic
NCT04501172,Completed,Observational,,Democritus University of Thrace,Other,25-Jun-20,14-Aug-20,24-Jul-20,OTHER,1214,COVID,GREECE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",QUESTIONNAIRE COMPLETION,DEMOGRAPHIC CHARACTERISTICS,Impact of Spectacles on Compliance to Mask-wearing Directives in Greece
NCT04501432,Completed,Observational,,Ludwig Boltzmann Institute for Digital Health and Prevention,Other,14-Jul-20,24-Oct-20,24-Oct-20,COHORT,27,CARDIAC REHABILITATION,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,WORK LOAD (W),Cardiac Rehabilitation and Ongoing Physical Activity During the Coronavirus Disease (COVID-19) Pandemic: An Exploratory Mixed-Methods Study
NCT04501445,Recruiting,Interventional,Not Applicable,Rush University Medical Center,Other,14-Sep-20,15-Sep-21,1-Aug-21,SUPPORTIVE CARE,100,FAMILY MEMBERS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",WRITTEN SUMMARY OF ROUNDS,SYMPTOMS OF POST-TRAUMATIC STRESS DISORDER (PTSD) INITIAL,Relieving the Burden of Psychological Symptoms Among Families of Critically Ill Patients With COVID-19
NCT04501458,"Active, not recruiting",Interventional,Not Applicable,Surgical Systems Research Group,Other,10-Aug-20,10-Jun-21,10-Jun-21,PREVENTION,200000,COVID,KENYA,ALL,"18 Years to 100 Years   (Adult, Older Adult)","TRAINING OF YOUTH, COMMUNITY HEALTH ASSISTANTS AND COMMUNITY HEALTH WORKERS.",MORTALITY,"Western Kenya Integrated COVID-19 Response Leveraging the Community Health Strategy, Youth, and Technology to Flatten the COVID-19 Curve and Improve COVID-19 Case Detection, Isolation and Management in Western Kenya"
NCT04501783,"Active, not recruiting",Interventional,Phase 3,R-Pharm,Industry,20-May-20,20-Aug-21,29-Jul-20,TREATMENT,168,COVID,RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),FAVIPIRAVIR,TIME TO CLINICAL IMPROVEMENT,Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19)
NCT04501796,Recruiting,Interventional,Phase 1,NeoImmuneTech,Industry,20-Aug-21,21-Dec-21,21-Oct-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",DOUBLE-BLIND NT-I7,EVALUATE THE SAFETY OF A SINGLE DOSE OF NT-I7 IN A DOSE ESCALATION FASHION,"A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19"
NCT04501822,Recruiting,Observational,,Tomsk National Research Medical Center of the Russian Academy of Sciences,Other,19-Jul-20,31-Dec-21,19-Jul-21,COHORT,380,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)","EVALUATION OF CLINICAL, INSTRUMENTAL AND LABORATORY DIAGNOSTICS TESTS",ECHOCARDIOGRAPHIC ASSESSMENT OF CARDIAC FUNCTION,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia
NCT04501952,Recruiting,Interventional,Phase 3,Gilead Sciences,Industry,18-Sep-20,21-Apr-21,21-Apr-21,TREATMENT,1264,COVID,DENMARK,ALL,"12 Years and older   (Child, Adult, Older Adult)",RDV,COMPOSITE ENDPOINT OF CORONAVIRUS DISEASE 2019 (COVID-19) RELATED HOSPITALIZATION (DEFINED AS AT LEAST 24 HOURS OF ACUTE CARE) OR ALL-CAUSE DEATH BY DAY 28.,"A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting"
NCT04501965,Enrolling by invitation,Interventional,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,Other,1-Jun-20,30-Sep-20,30-Aug-20,TREATMENT,231,COVID,GUINEA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE/AZITHROMYCINE,VIROLOGIC CLEARANCE OF THROAT SWABS OR LOWER RESPIRATORY TRACT SECRETIONS,"Evaluation de l'efficacité et de la tolérance de Quinquina et d'un phytomédicament "" ACAR "" en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptômes"
NCT04501978,Recruiting,Interventional,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,4-Aug-20,22-Jul-21,22-Jul-21,TREATMENT,10000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",LY3819253,TIME FROM RANDOMIZATION TO SUSTAINED RECOVERY,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19"
NCT04501991,Completed,Observational,,University of Pisa,Other,11-Mar-20,30-Jun-20,4-May-20,COHORT,114,TYPE 2 DIABETES,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ANTIDIABETIC TREATMENT,GLUCOSE,Determining the Impact of COVID-19 Lockdown on Metabolic Control in Individuals With Type 2 Diabetes
NCT04502056,"Active, not recruiting",Interventional,Not Applicable,"National Bureau of Economic Research, Inc.",Other,31-Jul-20,21-Sep-21,21-Sep-20,PREVENTION,20000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ACKNOWLEDGEMENT RACIAL INJUSTICE AMA,THE NUMBER OF PARTICIPANTS WITH KNOWLEDGE OF COVID RELATED SYMPTOMS AND TRANSMISSION AS ASSESSED BY A QUESTIONNAIRE WE'VE DEVELOPED SPECIFICALLY RELEVANT TO THE INTERVENTION VIDEOS WE ARE USING FOR THE PROJECT.,Covid-19 Messaging to Underserved Communities - 2nd Experiment
NCT04502069,Withdrawn,Interventional,Phase 1/Phase 2,RedHill Biopharma Limited,Industry,20-Aug-21,21-Jun-21,21-Feb-21,TREATMENT,0,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",OPAGANIB,TIME TO BREATHING ROOM AIR,Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen But Not Mechanical Ventilation
NCT04502108,Recruiting,Observational,,Slavko Rogan,Other,1-Apr-20,31-Dec-22,31-Dec-22,COHORT,1000,EXERCISE,SWITZERLAND,ALL,"18 Years to 65 Years   (Adult, Older Adult)",COVID19,PHYSICAL ACTIVITY 2020,Online Survey About Physical Activity and Nutrition During and After Coronavirus Pandemic
NCT04502342,Enrolling by invitation,Interventional,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,Other,1-Jun-20,30-Sep-20,30-Aug-20,TREATMENT,30,COVID,GUINEA,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCLOROQUINE AND AZYTHROMYCINE,VIROLOGICAL CLEARANCE OF THROAT SWABS OR LOWER RESPIRATORY TRACT SECRETIONS,Évaluationefficacité et tolérance d'Une médication à Base de Cosphérunate et d'un phytomédicament Antiviral Par Voie Orale en Comparaison Avec un Traitement à Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications
NCT04502368,Recruiting,Observational,,Erasme University Hospital,Other,1-Sep-20,30-Apr-21,30-Mar-21,CASE-ONLY,15,FIBEROPTIC BRONCHOSCOPY (FOB),BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",FIBEROPTIC BRONCHOSCOPY (FOB),REGIONAL COMPLIANCE VARIATION,Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients: Impact on Respiratory Mechanics and Gas Exchange
NCT04502433,Recruiting,Interventional,Phase 2,Chiesi Farmaceutici S.p.A.,Industry,6-Jan-21,31-Jul-21,31-Jul-21,TREATMENT,85,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED KINGDOM,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CUROSURF® (PORACTANT ALFA),NUMBER OF VENTILATOR-FREE DAYS,"Multicenter, Open-label, Randomised Trial to Assess the Efficacy and Tolerability of Poractant Alfa(Porcine Surfactant, Curosurf®) in Hospitalized Patients With SARS-COV-19 Acute Respiratory Distress Syndrome (ARDS)"
NCT04502472,Recruiting,Interventional,Phase 2/Phase 3,Inova Health Care Services,Other,6-Jun-20,31-Dec-21,31-Dec-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA TRANSFUSION,CHANGE IS CLINICAL STATUS,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2)
NCT04502667,Recruiting,Interventional,Phase 3,"Coordinación de Investigación en Salud, Mexico",Other,15-Jul-20,21-Apr-21,21-Feb-21,TREATMENT,40,COVID,MEXICO,ALL,1 Month to 17 Years   (Child),CHOLECALCIFEROL,"INTERLEUKINS (IL-2,6,7,10) (PG/ML)",Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial
NCT04503057,Recruiting,Observational [Patient Registry],,Lund University Hospital,Other,1-May-20,1-May-24,1-May-23,CASE-CONTROL,300,COVID,SWEDEN,ALL,"16 Years to 90 Years   (Child, Adult, Older Adult)",,COVID-19 RT-PCR DETECTION IN EBP,Exhaled Breath Particles as a Clinical Indicator for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrom (ARDS) in COVID-19 Positive and Negative Patients
NCT04503434,Completed,Observational [Patient Registry],,Hospital Clinic of Barcelona,Other,15-May-20,6-Jun-20,31-May-20,COHORT,517,PATIENT PREFERENCE,SPAIN,ALL,"Child, Adult, Older Adult",,THE PICKER PATIENT EXPERIENCE QUESTIONNAIRE,Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support
NCT04503447,Completed,Observational,,"Institute of Tropical Medicine, Belgium",Other,1-Aug-20,9-Sep-20,9-Sep-20,OTHER,330,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",,SARS-COV-2 SEROPREVALENCE ITM STAFF,Severe Acute Respiratory Syndrome Coronavirus (CoV) 2 (SARS-CoV-2) Seroprevalence Study in Institute of Tropical Medicine (ITM) Staff
NCT04503525,Recruiting,Observational,,Lille Catholic University,Other,25-May-20,30-Jun-21,25-May-21,OTHER,50,SARS-COV,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NUTRITIONAL ASSESSMENT,NUTRITIONAL STATUS OF COVID INFECTED PATIENTS,Nutritional Assessment of French Hospitalized Patients Infected With COVID-19
NCT04504032,"Active, not recruiting",Interventional,Phase 2,Bill & Melinda Gates Medical Research Institute,Other,2-Sep-20,21-Apr-21,21-Apr-21,TREATMENT,600,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",RIVAROXABAN,NUMBER OF PARTICIPANTS WITH GRADE 3 OR GRADE 4 ADVERSE EVENTS (AES),"A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19"
NCT04504240,Recruiting,Interventional,Phase 3,Chattogram General Hospital,Other,1-Aug-20,30-Oct-20,30-Oct-20,TREATMENT,200,COVID,BANGLADESH,ALL,"16 Years to 80 Years   (Child, Adult, Older Adult)",FAMOTIDINE 20 MG,SYMPTOMATIC IMPROVEMENT,Role of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 Patients
NCT04504734,Enrolling by invitation,Interventional,Phase 3,"Revive Therapeutics, Ltd.",Industry,27-Nov-20,1-Jun-21,1-May-21,TREATMENT,1000,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BUCILLAMINE,EFFICACY: FREQUENCY OF HOSPITALIZATION OR DEATH,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19"
NCT04504877,"Active, not recruiting",Interventional,Phase 2/Phase 3,University of Sao Paulo,Other,16-Jun-20,16-Dec-20,16-Nov-20,PREVENTION,120,COVID,BRAZIL,ALL,24 Years to 60 Years   (Adult),CANNABIDIOL,AMBI-HSS: ABBREVIATED MASLACH BURNOUT INVENTORY - HUMAN SERVICES SURVEY,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial
NCT04505098,Recruiting,Interventional,Phase 4,Kaiser Permanente,Other,7-Aug-20,28-Feb-23,7-Aug-21,PREVENTION,16500,COVID,UNITED STATES,ALL,"50 Years and older   (Adult, Older Adult)",ICOSAPENT ETHYL,PERCENTAGE OF PATIENTS WITH MODERATE OR SEVERE CONFIRMED VIRAL URIS,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)
NCT04505592,Recruiting,Interventional,Phase 2,Hooman Poor,Other,25-Sep-20,21-Dec-21,21-Jun-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",TENECTEPLASE,NUMBER OF PARTICIPANTS FREE OF RESPIRATORY FAILURE,Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19
NCT04505605,"Active, not recruiting",Observational,,Groupe Hospitalier Paris Saint Joseph,Other,14-May-20,30-Nov-20,30-Nov-20,OTHER,200,COMMUNITY-ACQUIRED PNEUMONIA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLES,EVALUATION OF THE DOSAGE OF BIOMARKERS,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia: the LPSARS2 Study
NCT04505631,Recruiting,Observational,,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,Other,10-Jun-20,21-Jun-21,21-Jun-21,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PRESENCE OF RESPIRATORY SEQUELAE,Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study
NCT04505709,Enrolling by invitation,Observational [Patient Registry],,Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,Other,1-Aug-20,1-Aug-21,1-Aug-21,COHORT,1000,COVID,SPAIN,ALL,"18 Months and older   (Child, Adult, Older Adult)",,IDENTIFICATION OF HOST GENETIC MARKERS ASSOCIATED WITH THE EVOLUTION OF COVID-19,"STOP-Coronavirus: Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19"
NCT04505722,"Active, not recruiting",Interventional,Phase 3,Janssen Vaccines & Prevention B.V.,Industry,7-Sep-20,2-Jan-23,22-Jan-21,PREVENTION,44325,PARTICIPANTS WITH OR WITHOUT STABLE CO-MORBIDITIES ASSOCIATED WITH PROGRESSION TO SEVERE COVID AT DIFFERENT STAGES OF THE PROTOCOL,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",AD26.COV2.S,NUMBER OF PARTICIPANTS WITH FIRST OCCURRENCE OF MOLECULARLY CONFIRMED MODERATE TO SEVERE/CRITICAL CORONAVIRUS DISEASE (COVID-19) WITH SERONEGATIVE STATUS,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older"
NCT04505761,Recruiting,Interventional,Not Applicable,Radboud University,Other,1-Aug-20,1-Jan-21,1-Jan-21,TREATMENT,40,CORONAVIRUS,NETHERLANDS,ALL,"16 Years and older   (Child, Adult, Older Adult)",VIRTUAL REALITY,SEMI-STRUCTURED INTERVIEW WITH 15 PATIENTS ON THEIR EXPERIENCES OF VR FOR REHABILITATION FROM COVID-19.,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study"
NCT04505774,Recruiting,Interventional,Phase 4,Matthew Neal MD,Other,4-Sep-20,21-Dec-21,21-Mar-21,TREATMENT,2000,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",THERAPUTIC HEPARIN,21 DAY ORGAN SUPPORT (RESPIRATORY OR VASOPRESSOR) FREE DAYS,"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19"
NCT04506229,Recruiting,Observational,,Texas Cardiac Arrhythmia Research Foundation,Other,20-Aug-20,21-Sep-21,21-Aug-21,CASE-ONLY,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",WHOLE EXOME SEQUENCING,GENETIC VARIANTS WITH VS WITHOUT COVID-19,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function
NCT04506268,"Active, not recruiting",Interventional,Not Applicable,University of Pennsylvania,Other,9-Sep-20,21-Jan-21,13-Oct-20,SCREENING,1200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OPT-OUT RECRUITMENT EMAIL,PROPORTION ENROLLED,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure
NCT04506515,Completed,Observational,,Hospital General Universitario de Valencia,Other,9-Apr-20,30-Apr-20,19-Apr-20,ECOLOGIC OR COMMUNITY,3000,COVID,SPAIN,ALL,"18 Years to 70 Years   (Adult, Older Adult)",PSYCHOLOGICAL STRESS AND ADAPTATION AT WORK SCORE (PSAS),PSAS (PSYCHOLOGICAL STRESS AND ADAPTATION AT WORK SCORE) DURING THE CRISIS,Psychological Impact of COVID-19 Pandemic in Healthcare Workers in Spain: A Cross-sectional Study. PSIMCOV Group
NCT04506528,Recruiting,Observational [Patient Registry],,"University of Wisconsin, Madison",Other,10-Aug-20,23-Dec-21,23-Jan-21,COHORT,170000,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,MORTALITY DUE TO COVID-19,Investigating the Association Between Smoking Status and COVID-19 Outcomes: Collecting Data From Health Systems Affiliated With the National Cancer Institute's Cancer Center Cessation Initiative (C3I)
NCT04506632,Recruiting,Observational,,Sheffield Teaching Hospitals NHS Foundation Trust,Other,2-Jun-20,26-Apr-22,2-Apr-21,ECOLOGIC OR COMMUNITY,100,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",,CHANGES IN DEPRESSION,COST-NHS: COvid Burden in STaff Working in the NHS: A Study to Assess the Mental Health Burden of the COVID-19 Pandemic on NHS Healthcare Staff
NCT04507230,Recruiting,Observational,,Assiut University,Other,7-Aug-20,31-Oct-20,31-Oct-20,COHORT,150,COAGULOPATHY,EGYPT,ALL,"Child, Adult, Older Adult",,COAGULATION SCREEN,Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt
NCT04507256,"Active, not recruiting",Interventional,Phase 1,AstraZeneca,Industry,18-Aug-20,25-Oct-21,25-Oct-21,TREATMENT,60,COVID,UNITED KINGDOM,ALL,18 Years to 55 Years   (Adult),AZD7442,NUMBER OF PARTICIPANTS WITH ADVERSE EVENTS (AES) AND SERIOUS AES,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults"
NCT04507282,Completed,Observational,,Bursa Postgraduate Hospital,Other,15-May-20,15-Jul-20,1-Jul-20,COHORT,80,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",LMWH,SUBPROPHYLACTIC ANTICOGULATION LEVEL,Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
NCT04507867,Not yet recruiting,Interventional,Not Applicable,Anahuac University,Other,20-Aug-21,20-Dec-21,20-Oct-21,SUPPORTIVE CARE,240,COVID,,ALL,"30 Years to 75 Years   (Adult, Older Adult)",NUTRITIONAL SUPPORT SYSTEM (NSS),OXYGEN SATURATION,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
NCT04507893,Recruiting,Observational,,University of Palermo,Other,15-Mar-20,1-Dec-22,30-Sep-20,CASE-ONLY,80,COVID,ITALY,ALL,"18 Years to 95 Years   (Adult, Older Adult)","CLINICAL, LABORATORY AND IMAGING CHARACTERISTICS OF PNEUMONIA","EVALUATION OF THE CLINICAL CHARACTERISTICS OF PATIENTS WITH CLINICAL PRESENTATION SUGGESTIVE OF COVID-19 INFECTION, CLASSIFIED ACCORDING TO THE RESULTS OF PCR ASSAY AS ""COVID-19 PATIENTS"" AND ""COVID-19 NEGATIVE CONTROLS"".","Clinical, Laboratory and Imaging Comparison Between COVID-19 Pneumonia Confirmed by PCR Detection on Nasopharyngeal Swab and Negative Swab Pneumonia"
NCT04508023,Recruiting,Interventional,Phase 3,"Janssen Research & Development, LLC",Industry,13-Aug-20,16-Apr-21,3-Mar-21,TREATMENT,4000,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RIVAROXABAN,"TIME TO FIRST OCCURRENCE OF A COMPOSITE ENDPOINT OF SYMPTOMATIC VTE, MI, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, NON-CNS SYSTEMIC EMBOLIZATION, ALL-CAUSE HOSPITALIZATION AND ALL-CAUSE MORTALITY","A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection"
NCT04508075,Recruiting,Interventional,Phase 3,PT Bio Farma,Industry,10-Aug-20,21-Sep-21,21-Jan-21,PREVENTION,1620,SARS-COV2 INFECTION,INDONESIA,ALL,18 Years to 59 Years   (Adult),SARS-COV-2 VACCINE (INACTIVATED),INCIDENCE OF LABORATORY-CONFIRMED COVID-19 AFTER THE SECOND DOSE,"A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia"
NCT04508439,Recruiting,Interventional,Not Applicable,Hospital Regional de Alta especialidad de Ixtapaluca,Other,20-Jun-20,30-Dec-20,30-Aug-20,TREATMENT,130,COVID,MEXICO,ALL,"18 Years to 90 Years   (Adult, Older Adult)",ENOXAPARIN,LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) AND VENTILATORY SUPPORT TIME,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
NCT04508556,Not yet recruiting,Observational,,Owlstone Ltd,Industry,20-Sep-21,21-Apr-21,20-Dec-21,COHORT,500,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",BREATH BIOPSY FACE MASKS WITH REMOVABLE FILTERS AND FITTED PVA STRIP,POSITIVE CONTROL FOR TECHNICAL VALIDATION,Performance Assessment of SARS-CoV-2 Detection Through Analysis of Exhaled Breath Aerosols
NCT04508712,Recruiting,Observational [Patient Registry],,RenJi Hospital,Other,10-Aug-20,31-Aug-21,31-Aug-21,CASE-ONLY,900,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",,PHYSICAL FUNCTIONS,Long-term Outcomes in Patients With COVID-19
NCT04508777,Enrolling by invitation,Observational,,University of Pennsylvania,Other,9-Sep-20,21-Mar-21,8-Dec-20,COHORT,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA-BASED TESTING,TEST COMPLIANCE,COVID SAFE: COVID-19 Screening Assessment for Exposure
NCT04508868,Terminated,Interventional,Not Applicable,Uppsala University,Other,31-Aug-20,23-Dec-20,23-Dec-20,TREATMENT,41,DEPRESSION,SWEDEN,ALL,65 Years and older   (Older Adult),BRIEF BEHAVIORAL ACTIVATION WITH MENTAL IMAGERY,"CHANGE FROM BASELINE IN DEPRESSIVE SYMPTOMS USING THE MONTGOMERY-ASBERG DEPRESSION RATING SCALE, MADRS-S",Behavioral Activation and Mental Imagery Delivered Via Telephone for the Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19: A Randomized Clinical Trial
NCT04508920,Recruiting,Observational [Patient Registry],,"Centro en Insuficiencia Cardiaca, Mexico",Other,15-May-19,15-Jul-21,15-Jun-21,COHORT,76,CARDIOVASCULAR DISEASES,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)","SYMPTOMATOLOGY, TREATMENT. DAILY ACTIVITIES AND ANXIETY FOR CARDIOVASCULAR PATIENTS SURVEY (STRATA)",NYHA CLASS DETERIORATION,"A Survey to Assess Effects of the Covid-19 Pandemic on Symptomatology, Treatment and Medical Care for Cardiovascular Patients"
NCT04508933,Not yet recruiting,Observational,,Istanbul University-Cerrahpasa,Other,1-Sep-20,31-Dec-20,30-Sep-20,CASE-CONTROL,10,"RESPIRATORY DISTRESS SYNDROME, ADULT",TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",EXTRAVASCULAR LUNG WATER INDEX,EXTRAVASCULAR LUNG WATER INDEX,"Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and ""Typical""ARDS Patients"
NCT04508959,Recruiting,Observational [Patient Registry],,McMaster University,Other,15-Apr-20,21-Jul-21,21-Jul-21,COHORT,1500,CORONAVIRUS INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,SERIOUS COVID-19 INFECTION,A Rapid Research Platform to Inform Prevention & Improve the Clinical Management of COVID-19 Illness for Priority Older Adult Groups: The McMaster Multi-regional Hospital Coronavirus Registry
NCT04508972,Recruiting,Observational,,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,1-Jul-20,1-Nov-20,1-Oct-20,COHORT,200,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",ALEXA AMAZON,CORRELATION BETWEEN DATA CAPTURED USING AMAZON ALEXA COMPARED TO MANUAL (HUMAN) COLLECTED DATA.,Voice-based Identification of Clinical Features Requiring Emergent Action in Patients With Suspected COVID-19 Infection (VOICE-COVID) Study
NCT04508985,Not yet recruiting,Interventional,Not Applicable,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,1-Sep-20,1-Sep-21,1-Jan-21,TREATMENT,40,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TEMPORARILY HOLDING THE RAAS INHIBITOR [INTERVENTION],GLOBAL RANK SCORE,Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial
NCT04509713,Recruiting,Observational,,ARCTEC,Industry,2-Jul-20,31-Oct-20,30-Sep-20,COHORT,16250,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",COLLECTION OF ODOUR SAMPLES,SENSITIVITY AND SPECIFICITY PRECISION OF DOGS TO DETECT PEOPLE WITH COVID-19 BY THEIR ODOUR.,Using Medical-detection Dogs to Identify People With SARS-CoV-: Phase I: Proof-of-concept Studies
NCT04509752,Recruiting,Observational,,Hacettepe University,Other,8-Oct-20,28-Feb-21,15-Feb-21,COHORT,50,DYSPHAGIA,TURKEY,ALL,25 Years to 60 Years   (Adult),SURVEY,ONLINE SURVEY,Experiences in Dysphagia Management During COVID-19 Pandemic
NCT04509947,"Active, not recruiting",Interventional,Phase 1,Janssen Pharmaceutical K.K.,Industry,11-Aug-20,8-Dec-21,8-Jan-21,PREVENTION,250,HEALTHY,JAPAN,ALL,"20 Years and older   (Adult, Older Adult)",AD26.COV2.S,NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL ADVERSE EVENTS (AES) FOR 7 DAYS AFTER FIRST VACCINATION,"A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults"
NCT04509973,Recruiting,Interventional,Phase 3,Scandinavian Critical Care Trials Group,Other,27-Aug-20,17-Feb-22,17-Sep-21,TREATMENT,1000,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,DAYS ALIVE WITHOUT LIFE SUPPORT AT DAY 28,Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia
NCT04509986,Not yet recruiting,Observational,,University of Birmingham,Other,1-Oct-20,1-Dec-20,31-Oct-20,COHORT,1000,SURGERY,,ALL,"Child, Adult, Older Adult",,POST-OPERATIVE MORTALITY,GlobalSurg-CovidSurg Week: Determining the Optimal Timing for Surgery Following SARS-CoV-2 Infection
NCT04509999,Recruiting,Interventional,Phase 3,University of Florida,Other,26-Oct-20,22-Sep-21,22-Sep-21,TREATMENT,100,COVID,UNITED STATES,MALE,"18 Years to 99 Years   (Adult, Older Adult)",BICALUTAMIDE 150 MG ORAL TABLET,PROPORTION X 100 = PERCENT OF PATIENTS WITH IMPROVED COVID-19 SYMPTOMS,Randomized Trial of Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection
NCT04510012,Recruiting,Observational,,"University Hospital Inselspital, Berne",Other,5-Mar-20,5-Mar-21,5-Mar-21,COHORT,150,SARS-COV INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)","ANALYSIS OF CYTOKINE RESPONSE, INNATE AND ADAPTIVE IMMUNE RESPONSE, COMPLEMENT ACTIVATION, AND SERUM NEUROFILAMENTS AS A MARKER OF NEUROLOGICAL DAMAGE.",CYTOKINE RESPONSE TO SARS-COV-2,Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals
NCT04510025,Recruiting,Observational,,University of Oxford,Other,13-May-20,1-May-23,1-May-23,COHORT,616,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",MAGNETIC RESONANCE IMAGING,"PREVALENCE OF DAMAGE (QUANTITATIVE MEASURES OF INJURY) ON LUNG, HEART, LIVER, KIDNEYS AND BRAIN MRI.","Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health"
NCT04510038,Recruiting,Interventional,Phase 2/Phase 3,Miami Cardiac and Vascular Institute,Other,1-Jan-20,1-Jan-22,1-Sep-21,TREATMENT,75,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COLCHICINE,ALL CAUSE MORTALITY,Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)
NCT04510194,Recruiting,Interventional,Phase 2/Phase 3,University of Minnesota,Other,1-Jan-21,21-Aug-21,21-Jun-21,TREATMENT,750,COVID,UNITED STATES,ALL,"30 Years to 85 Years   (Adult, Older Adult)",METFORMIN,DECREASED OXYGENATION,COVIDOUT: Outpatient Treatment of COVID-19 With Metformin (Former Title: MET-COVID)
NCT04510207,Recruiting,Interventional,Phase 3,China National Biotec Group Company Limited,Industry,16-Jul-20,16-Sep-21,16-Mar-21,PREVENTION,45000,COVID,BAHRAIN,ALL,"18 Years and older   (Adult, Older Adult)",INACTIVATED SARS-COV-2 VACCINE (VERO CELL),THE INCIDENCE OF COVID-19 CASES AFTER TWO-DOSES OF VACCINATION,"Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above"
NCT04510233,Not yet recruiting,Interventional,Phase 2,Tanta University,Other,20-Sep-21,20-Dec-21,20-Oct-21,TREATMENT,60,COVID,,ALL,18 Years to 60 Years   (Adult),IVERMECTIN NASAL,PCR OF SARS-COV2 RNA,Ivermectin Inhalation Forms in the Management of COVID-19 Egyptian Patients
NCT04510402,Not yet recruiting,Interventional,Phase 1/Phase 2,Brigham and Women's Hospital,Other,20-Aug-21,21-Apr-21,21-Feb-21,PREVENTION,50,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",POVIDINE IODINE NASAL SWABS,"NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AS ASSESSED BY SELF REPORTING, METABOLIC AND ENDOCRINE METRICS",Phase I/II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects
NCT04510441,Recruiting,Observational,,Imperial College London,Other,26-May-20,1-May-22,1-May-22,COHORT,2000,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NIL INTERVENTION,ACCURACY OF MACHINE LEARNING TO BE ABLE TO PREDICT OUTCOME OF CORONAVIRUS (COVID-19) INFECTION,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms and Imaging
NCT04510454,Recruiting,Interventional,Not Applicable,Centre Leon Berard,Other,2-Nov-20,21-May-21,21-May-21,DIAGNOSTIC,200,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NASOPHARYNGEAL AND THROAT/OROPHARYNGEAL SWABS ANALYSES BY RT-PCR AND DDPCR,TO DETERMINE THE DDPCR ABILITY TO DETECT THE SARS-COV-2 IN NASOPHARYNGEAL SAMPLES OF SYMPTOMATIC PATIENTS WITH SUSPECTED COVID-19 INFECTION,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19
NCT04510467,Not yet recruiting,Observational,,"University Hospital, Lille",Other,21-Jan-21,21-Aug-21,21-Aug-21,CASE-CONTROL,1313,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,FREQUENCY OF PTSD DEPENDING ON WHETHER OR NOT AUTOIMMUNE PATIENTS HAVE EXPERIENCED COVID,Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort
NCT04510493,Recruiting,Interventional,Phase 3,"University Hospital, Basel, Switzerland",Other,23-Oct-20,23-Sep-21,23-Sep-21,TREATMENT,116,CORONAVIRUS INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",CANAKINUMAB,UNMATCHED WIN RATIO AFTER TREATMENT WITH CANAKINUMAB COMPARED TO PLACEBO (COMPOSITE ENDPOINT),Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial
NCT04510519,Not yet recruiting,Observational,,"Kintsugi Mindful Wellness, Inc.",Industry,1-Sep-20,30-Jun-21,30-Jun-21,COHORT,50,MAJOR DEPRESSIVE DISORDER,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,PATIENT HEALTH QUESTIONNAIRE (PHQ-9),Scaling Mental Healthcare in COVID-19 With Voice Biomarkers: An Observational Study
NCT04510623,Recruiting,Observational,,University of British Columbia,Other,17-Mar-20,30-Jun-22,30-Jun-21,COHORT,500,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",ARBS AND/OR ACE INHIBITORS,COVID-19 WHO ORDINAL SCALE,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?
NCT04510662,Recruiting,Interventional,Phase 2,Abraham Edgar Gracia-Ramos,Other,20-Aug-21,21-Apr-21,21-Mar-21,TREATMENT,60,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",TELMISARTAN,DEATH,Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19
NCT04511429,Recruiting,Observational [Patient Registry],,D'Or Institute for Research and Education,Other,30-Jun-20,21-Apr-21,20-Oct-21,COHORT,200,"INFECTIONS, CORONAVIRUS",BRAZIL,ALL,"1 Month to 18 Years   (Child, Adult)",,"SEROLOGY (IGM, IGG) FOR COVID-19.",COVID-19 in Immunosuppressed Children
NCT04511650,Recruiting,Interventional,Phase 2,Aerpio Therapeutics,Industry,21-Oct-20,21-Feb-21,21-Feb-21,TREATMENT,180,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RAZUPROTAFIB SUBCUTANEOUS SOLUTION,PROPORTION OF SUBJECTS ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 7,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)"
NCT04511780,Not yet recruiting,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,21-Jan-21,22-Sep-21,22-Sep-21,COHORT,5000,CRITICAL ILLNESS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE FILLING,POST-TRAUMATIC STRESS DISORDER,"Psychological Impact of COVID-19 Outbreak on Caregivers Involved in Intensive Care Unit Patient Management: Impact on the Occurrence of Post-traumatic Stress Disorder, Anxiety, Depression and Burn Out Syndrome"
NCT04511819,Recruiting,Interventional,Phase 3,Fulcrum Therapeutics,Industry,28-Aug-20,21-Jun-21,21-Jun-21,TREATMENT,410,COVID,BRAZIL,ALL,"50 Years and older   (Adult, Older Adult)",LOSMAPIMOD ORAL TABLET,DAY 28 MORTALITY,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)"
NCT04511923,Recruiting,Interventional,Phase 1/Phase 2,University College Hospital Galway,Other,23-Dec-20,22-Jan-21,21-Dec-21,TREATMENT,40,COVID,IRELAND,ALL,"18 Years and older   (Adult, Older Adult)",NEBULISED HEPARIN,D-DIMER PROFILE,Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland
NCT04511949,Completed,Interventional,Not Applicable,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,Other,12-Jul-20,30-Nov-20,30-Sep-20,OTHER,500,CORONAVIRUS INFECTION,FRANCE,ALL,"3 Years and older   (Child, Adult, Older Adult)","COVID-19 IGG / IGM RAPID TEST (WHOLE BLOOD, SERUM, PLASMA)",MEASURE OF THE PROPORTION OF CONTACT PERSONS WHO HAVE DEVELOPED ANTI-SARS-COV-2 ANTIBODIES (SECONDARY TRANSMISSION RATE) WITHIN THE SAME HOUSEHOLD OF A SUBJECT WHO HAD A COVID-19 DISEASE ASSESSED BY A RAPID DIAGNOSTIC-ORIENTED TEST,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease
NCT04511962,Not yet recruiting,Observational,,Hull University Teaching Hospitals NHS Trust,Other,12-Aug-20,20-Jan-22,25-Nov-21,ECOLOGIC OR COMMUNITY,40,PULMONARY DISEASE,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",TELE-PULMONARY REHABILITATION,RECRUITMENT - CONTACT TO CONSENT RATIO,"A Feasibility, Randomised Controlled Trial of Tele-rehabilitation Following COVID-19"
NCT04512027,Completed,Interventional,Not Applicable,Composite Interceptive Med Science,Industry,15-Sep-20,16-Oct-20,19-Sep-20,TREATMENT,10,COVID,INDIA,ALL,18 Years to 45 Years   (Adult),PROLECTIN-M; A (1-6)-ALPHA-D-MANNOPYRANOSE CLASS,SARSCOV2 VIRAL COPY NUMBER,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial"
NCT04512079,Recruiting,Interventional,Phase 4,Valentin Fuster,Other,8-Sep-20,22-Mar-21,21-Dec-21,TREATMENT,3600,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,TIME TO FIRST EVENT,FREEDOM COVID Anticoagulation Strategy Randomized Trial
NCT04512118,Completed,Observational,,"Central Hospital, Nancy, France",Other,15-Mar-20,30-Jul-20,30-Jun-20,CASE-ONLY,22,PRESENCE OF COVID COMPATIBLE CT ABNORMALITIES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PET-CT OF 18F-FDG,VISUAL ANALYSIS OF PULMONARY LOBES,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients
NCT04512300,Completed,Observational,,Cairo University,Other,15-Jun-20,25-Jun-20,25-Jun-20,OTHER,267,DENTAL TREATMENT DURING COVID -19,EGYPT,ALL,"Child, Adult, Older Adult",,ASSESSMENT OF PARENTAL ATTITUDE TOWARD CHILDREN DENTAL VISIT DURING CORONAVIRUS CRISIS,Parental Attitude Toward Children Dental Treatment and Care During COVID-19 Pandemic (Cross -Sectional Study)
NCT04513158,Recruiting,Interventional,Phase 2,"Joseph M. Flynn, D.O., MPH",Other,14-Aug-20,31-Dec-21,1-Aug-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CONVALESCENT PLASMA,DETERMINE THE THERAPEUTIC EFFICACY (RESPONSE RATE) OF CONVALESCENT PLASMA INFUSION IN PATIENTS AT HIGH RISK FOR MORTALITY WHEN INFECTED BY SARS-COV-2 (COVID-19).,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
NCT04513184,Recruiting,Interventional,Phase 2,Edda Sciutto Conde,Other,14-Jul-20,31-Jul-21,30-Mar-21,TREATMENT,60,COVID,MEXICO,ALL,"18 Years to 75 Years   (Adult, Older Adult)",IV DEXAMETHASONE,TIME OF CLINICAL IMPROVEMENT,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19
NCT04513210,Enrolling by invitation,Observational,,Jagiellonian University,Other,10-Oct-20,28-Feb-22,30-Oct-21,CASE-CONTROL,300,COVID,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",,RELATION OF CHANGES IN ULTRASOUND AND PROGRESSION TO RESPIRATORY FAILURE,"Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity, Length of Hospitalization and Long-term Complications and of Covid-19 Infection"
NCT04513314,Not yet recruiting,Interventional,Phase 4,University of Miami,Other,1-Nov-21,1-Nov-22,1-Nov-22,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VALPROATE,CHANGE FROM BASELINE RASS SCORE OF +3 OR GREATER,"A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium"
NCT04513470,"Active, not recruiting",Interventional,Phase 1,Hadassah Medical Organization,Other,1-Aug-20,21-Feb-21,21-Jan-21,PREVENTION,5,COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ALLOCETRA-OTS,ASSESSMENT OF SAFETY BY DETERMINING THE NUMBER OF PARTICIPANTS WITH ANY ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE),"A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction"
NCT04513496,Not yet recruiting,Observational,,Fundacion Ibis,Other,1-Sep-20,1-Jul-22,1-Mar-22,COHORT,4000,TELEMEDICINE,,ALL,"18 Years and older   (Adult, Older Adult)",,TELEMEDICINE REACH. RE-AIM FRAMEWORK,"Delivery of HIV Care Through Telemedicine in Public Hospitals in Buenos Aires, Argentina During COVID-19 Pandemic: Implementation Research"
NCT04513561,Not yet recruiting,Observational,,"University Hospital, Lille",Other,20-Dec-21,21-Mar-21,21-Mar-21,COHORT,4500,INFLAMMATORY DISEASE,,ALL,"18 Years and older   (Adult, Older Adult)",,"THE ANSWER WILL BE CONSIDERED POSITIVE IF THE PATIENT ANSWERS ""TOTALLY AGREE"", OR ""AGREE"", OR ""SLIGHTLY AGREE"", OR ""NEITHER AGREE NOR DISAGREE"".","Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology)."
NCT04513847,Completed,Observational,,Dermatrials Research,Other,13-Aug-20,6-Oct-20,13-Sep-20,CASE-CONTROL,661,PSORIASIS,CANADA,ALL,"Child, Adult, Older Adult",,"PERCENTAGE OF PATIENTS NOT UNDERSTANDING THE INTERACTION OF VACCINES AND THEIR BIOLOGIC, ASSESSED WITH VOLUNTARY SURVEY.",PsoVac: A Psoriatic Patient-based Survey on the Understanding of the Use of Vaccines While on Biologics During the Covid-19 Pandemic
NCT04513964,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,1-Nov-20,30-Jun-21,31-Dec-20,CASE-CONTROL,60,HEART FAILURE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,IMPACT OF COVID-19 ON EXERCISE CAPACITY GAIN AFTER CARDIOVASCULAR REHABILITATION,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation
NCT04513990,Recruiting,Interventional,Not Applicable,M.D. Anderson Cancer Center,Other,9-Apr-20,30-Apr-21,30-Apr-21,DIAGNOSTIC,1500,COVID INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",BIOSPECIMEN COLLECTION,SENSITIVITY OF DIAGNOSTIC TEST,Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2
NCT04514003,Recruiting,Observational,,Sykehuset Telemark,Other,1-Jul-20,31-Dec-35,31-Dec-23,CASE-CONTROL,5000,COVID,NORWAY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,SARS-COV-2 IGG ANTIBODY LEVEL,The Corona and COVID-19 Study in Telemark and Agder - COVITA
NCT04514016,"Active, not recruiting",Observational,,University of Miami,Other,12-Aug-20,31-Mar-21,31-Mar-21,COHORT,64,SARS-COV INFECTION,UNITED STATES,ALL,"3 Years to 25 Years   (Child, Adult)",,NUMBER OF PARTICIPANTS WHO TESTED POSITIVE WITH SARS COV-2 INFECTION,"Cross Sectional Survey Of Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (COV-2) Infection And Seroprevalence In A Cohort Of HIV-Infected Children, Youth, And Adolescents"
NCT04514302,Not yet recruiting,Interventional,Phase 1/Phase 2,Hospital San Jose Tec de Monterrey,Other,20-Oct-20,20-Jun-21,20-Feb-21,TREATMENT,51,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,PROPORTION OF PATIENTS WITH IMPROVEMENT IN CLINICAL STATUS,Pilot Study to Evaluate Safety and Efficacy of Anti-SARS-CoV-2 Equine Immunoglobulin F(ab')2 Fragments (INOSARS) in Hospitalized Patients With COVID-19
NCT04514627,Recruiting,Interventional,Not Applicable,Olive View-UCLA Education & Research Institute,Other,13-Jul-20,31-Jul-21,31-Jul-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AURICULAR PERCUTANEOUS NEUROSTIMULATION,"HYPOXEMIA VIA OXYGEN LEVEL, OR SATURATION (SPO2) IN PERCENT",Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19
NCT04514705,Recruiting,Interventional,Not Applicable,Universidade Metodista de Piracicaba,Other,11-Aug-20,31-Dec-21,31-Dec-21,TREATMENT,20,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",EXERCISE,CHARACTERISTICS OF LUNG,Clinical Respiratory Investigation in Post Covid-19 Patients
NCT04514874,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,1-Sep-20,20-Dec-21,20-Dec-21,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PREVALENCE OF COVID-19 INFECTION AMONG FRENCH MILITARY PROFESSIONAL AIRCREW,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
NCT04514900,"Active, not recruiting",Interventional,Not Applicable,University of South Carolina,Other,23-Sep-20,15-Sep-21,15-Sep-21,TREATMENT,120,OBESITY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VIDEO CHAT +PERSONALIZED FEEDBACK,WEIGHT LOSS,Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic
NCT04515108,Completed,Observational,,Ankara City Hospital Bilkent,Other,10-Mar-20,10-Aug-20,5-Aug-20,COHORT,108,"PREGNANCY, INFECTIONS IN",TURKEY,FEMALE,18 Years to 42 Years   (Adult),CLINICAL ASSESSMENT,"COMPLETE BLOOD COUNT PARAMETERS (INCLUDING THE NUMBER OF LYMPHOCYTES, LEUKOCYTES, MONOCYTES, PLATELETS AND RED BLOOD CELLS).",Comparison of Hematological Parameters and Perinatal Outcomes in COVID-19 Pregnancies and Healthy Pregnancy Cohort
NCT04515147,"Active, not recruiting",Interventional,Phase 2,CureVac AG,Industry,28-Sep-20,9-Nov-21,9-Nov-21,PREVENTION,674,CORONAVIRUS,PANAMA,ALL,"18 Years and older   (Adult, Older Adult)",CVNCOV 6 ΜG,NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL ADVERSE EVENTS,"COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age"
NCT04515199,Recruiting,Observational [Patient Registry],,Cairo University,Other,1-Jul-20,21-Mar-21,21-Jan-21,COHORT,400,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,PERCENT OF ADHERENCE TO ISOLATION MEASURES,Effectiveness of Telemedicine Use in Home Management of Adult Egyptian Mild COVID-19 Cases
NCT04515225,Not yet recruiting,Observational,,"University Hospital, Strasbourg, France",Other,15-Sep-20,15-Sep-20,15-Sep-20,COHORT,500,HIV INFECTIONS,,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,SEROPREVALENCE OF SARS-COV-2,Seroprevalence of SARS-CoV-2 Antibodies Among Adult Patients Living With HIV
NCT04516486,"Active, not recruiting",Observational,,Assistance Publique - Hôpitaux de Paris,Other,9-Mar-20,31-Dec-20,24-May-20,COHORT,180,"RESPIRATORY DISTRESS SYNDROME, ADULT",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RETROSPECTIVE METAGENOMICS ON CLINICAL SAMPLES COLLECTED DURING HOSPITALIZATION,IDENTIFY TWO ENDOTYPES (HYPER-INFLAMMATORY AND CO-INFECTIONS) AND QUANTIFY THEIR PROGNOSTIC VALUE IN TERMS OF SHORT-TERM MORTALITY (DAY 28) IN PATIENTS TREATED FOR ARDS INFECTED WITH SARS-COV2.,Characterization and Prognostic Impact of Inflammatory Responses by Host Transcriptomics and Co-infection by Metagenomics in Patients With ARDS COVID-19 in Intensive Care
NCT04516512,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,1-Sep-20,1-Jan-21,1-Jan-21,SCREENING,2500,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BLOOD DRAW,DETERMINATION OF THE IMMUNOLOGICAL PARAMETERS (IMMUNOGLOBINS G) OF THE SARS-COV-2 INFECTION,SARS-CoV-2 Seroprevalence Among Adults People Living in Jail
NCT04516564,Recruiting,Interventional,Phase 1,Akesobio Australia Pty Ltd,Industry,20-Sep-21,21-Apr-21,21-Mar-21,OTHER,32,CORONAVIRUS DISEASE 2019 (COVID),NEW ZEALAND,ALL,18 Years to 55 Years   (Adult),AK119,INCIDENCE OF TREATMENT-EMERGENT AES,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects"
NCT04516668,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Nov-21,20-Nov-21,20-Nov-21,COHORT,250,POST PARTUM DEPRESSION,,ALL,"18 Years and older   (Adult, Older Adult)",,EVALUATION OF HOSPITAL ANXIETY AND DEPRESSION SCALE (HAD),Survey About Anxious and Depressive Symptoms During COVID-19 in Women Who Have Medical History of Post-partum Depression: Interest of Tele-consultation
NCT04516746,"Active, not recruiting",Interventional,Phase 3,AstraZeneca,Industry,28-Aug-20,14-Feb-23,16-Mar-21,TREATMENT,32459,COVID,ARGENTINA,ALL,"18 Years to 130 Years   (Adult, Older Adult)",AZD1222,THE EFFICACY OF 2 IM DOSES OF AZD1222 COMPARED TO SALINE PLACEBO FOR THE PREVENTION OF COVID-19,"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
NCT04516759,Recruiting,Interventional,Phase 2,St George Street Capital,Other,12-Aug-20,21-Mar-21,21-Mar-21,TREATMENT,150,COVID,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",AZD1656,CLINICAL IMPROVEMENT BY DAY 14,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19"
NCT04516811,Recruiting,Interventional,Phase 3,South African National Blood Service,Other,21-Sep-20,31-Jul-22,30-Dec-21,TREATMENT,600,COVID,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA (CCP) PLUS STANDARD OF CARE (SOC),CLINICAL IMPROVEMENT,"A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19"
NCT04516824,Completed,Observational,,Ghurki Trust and Teaching Hospital,Other,19-Mar-20,15-Aug-20,13-Jul-20,OTHER,2160,ORTHOPAEDIC DISORDERS,PAKISTAN,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ORTHOPAEDIC SURGICAL PROCEDURES,CLINICAL AND FUNCTIONAL CHARACTERISTICS,Experience of Workforce From Orthopaedic and Spine Center Ghurki Trust Hospital Pakistan During COVID-19
NCT04516837,Recruiting,Interventional,Phase 2,Peking University People's Hospital,Other,31-Aug-20,22-Aug-21,21-Aug-21,TREATMENT,120,IMMUNE THROMBOCYTOPENIA,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ELTROMBOPAG,COMPLETE RESPONSE,The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic
NCT04516850,Not yet recruiting,Observational,,Ricardo Pereira Mestre,Other,1-Sep-20,31-Aug-21,31-Aug-21,OTHER,500,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",EXPRESSION OF RECEPTORS AND ACTIVATING PROTEASES,EXPRESSION OF RECEPTORS AND ACTIVATING PROTEASES,An Exploratory Analysis of the Expression of Receptors and Activating Proteases Mediating SARS-CoV-2 Entry and the Association Between HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients
NCT04516915,Recruiting,Interventional,Phase 2,University Hospitals Coventry and Warwickshire NHS Trust,Other,15-Jun-20,21-Jul-21,21-May-21,TREATMENT,120,COVID,UNITED KINGDOM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",IMU-838,TO EVALUATE WHETHER TIME-TO-IMPROVEMENT IS SIGNIFICANTLY BETTER IN IMU-838 PLUS OSELTAMIVIR (IONIC INTERVENTION) VS. OSELTAMIVIR ALONE IN ADULT SUBJECTS WITH COVID-19,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19"
NCT04516928,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,21-Sep-20,2-Nov-20,2-Nov-20,COHORT,950,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ANTI-SARS-COV2 SEROLOGY,PROPORTION OF ANTI-SARS-COV2 SEROPOSITIVE PARTICIPANTS,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
NCT04516941,Not yet recruiting,Interventional,Phase 3,"University Hospital Inselspital, Berne",Other,1-Oct-20,31-Dec-21,1-Oct-21,TREATMENT,420,SARS-COV INFECTION,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",EDOXABAN TABLETS,EDOXABAN VS. NO ACTIVE TREATMENT,Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting
NCT04516954,Enrolling by invitation,Interventional,Early Phase 1,Vinmec Research Institute of Stem Cell and Gene Technology,Other,1-Aug-20,30-Dec-20,30-Nov-20,TREATMENT,10,COVID,VIETNAM,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CONVALESCENT COVID 19 PLASMA,EVALUATE THE SAFETY,Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness
NCT04517006,Not yet recruiting,Interventional,Not Applicable,University of Toronto,Other,21-Jan-21,21-Mar-21,21-Mar-21,SUPPORTIVE CARE,1542,HAPPINESS,,ALL,"18 Years and older   (Adult, Older Adult)",SELF-FOCUSED ACTS,CHANGE IN HAPPINESS FROM BASELINE USING THE SUBJECTIVE HAPPINESS SCALE,Prosocial Behavior Can Safeguard Mental Health and Foster Emotional Well-being During the COVID-19 Pandemic: A Randomized Clinical Trial
NCT04517097,Completed,Observational,,Centre Georges Francois Leclerc,Other,12-May-20,30-Jun-20,30-Jun-20,COHORT,1680,CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,SEROPREVALENCE OF SARS-COV-2,Study of the Specific Seroprevalence of SARS-CoV-2 in a Sample of Patients and Salaried Staff From a French Anti-cancer Center at the End of the Containment Period of the SARS-CoV-2 Pandemic
NCT04517123,Recruiting,Interventional,Not Applicable,Johns Hopkins University,Other,1-Sep-20,31-Dec-21,31-Dec-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,OCCURRENCE OF AN ESCALATION IN RESPIRATORY RELATED CARE (YES VS NO),"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study"
NCT04517136,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,14-Sep-20,14-Feb-21,14-Feb-21,COHORT,60,COVID,FRANCE,ALL,18 Years to 60 Years   (Adult),ASSESSMENT OF WORK-RELATED STRESS,PROFESSIONAL BURNOUT,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
NCT04517162,Recruiting,Interventional,Phase 1/Phase 2,Janette Furuzawa Carballeda,Other,19-Aug-20,19-Jun-21,19-Feb-21,TREATMENT,90,COVID,MEXICO,ALL,"18 Years to 80 Years   (Adult, Older Adult)",COLLAGEN-POLYVINYLPYRROLIDONE,CLINICAL PRIMARY OUTCOME MEASURE,Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial
NCT04517188,Not yet recruiting,Interventional,Phase 4,Halodine LLC,Industry,1-Apr-21,1-Jul-21,1-Jul-21,PREVENTION,40,SARS-COV2 INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",POVIDONE-IODINE SOLUTION 1.25% W/W [0.125% AVAILABLE IODINE] USP,NASOPHARYNGEAL SARS-COV-2 VIRAL LOAD,A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19
NCT04517396,Enrolling by invitation,Interventional,Phase 2,University of Pennsylvania,Other,18-Aug-20,31-Aug-21,31-Aug-21,TREATMENT,700,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FENOFIBRATE/FENOFIBRIC ACID,HIERARCHICAL COMPOSITE ENDPOINT,FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019
NCT04517422,Completed,Interventional,Not Applicable,"AB Biotics, SA",Industry,19-Aug-20,2-Feb-21,2-Feb-21,OTHER,300,SARS-COV INFECTION,MEXICO,ALL,18 Years to 60 Years   (Adult),PROBIOTICS,SEVERITY PROGRESSION OF COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial
NCT04517630,Recruiting,Observational [Patient Registry],,Instituto Nacional de Enfermedades Respiratorias,Other,1-Jun-20,30-Sep-22,30-Sep-21,COHORT,90,CORONAVIRUS INFECTION,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)","URINARY NGAL, TIMP-2, IGFBP7, IL-6, VIRAL LOAD AND METABOLOMIC",URINARY LEVELS OF RENAL BIOMARKERS,Acute Kidney Injury In Subjects With Severe Acute Respiratory Syndrome Due to SARS-CoV2 Infection
NCT04517682,Enrolling by invitation,Observational,,Ambry Genetics,Industry,21-May-20,30-Dec-20,15-Dec-20,COHORT,300,RNA VIRUS INFECTIONS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RT-PCR,DETECTION OF COVID-19 SARS-COV-2 IN SALIVA SAMPLES VERSUS NASOPHARYNGEAL SAMPLES,SARS -CoV-2 Detection in Saliva Samples: A Test Validation Protocol
NCT04517695,Recruiting,Observational,,NYU Langone Health,Other,1-Aug-20,1-Feb-21,1-Feb-21,COHORT,30,COVID,UNITED STATES,ALL,"18 Years to 95 Years   (Adult, Older Adult)",BVA-100,TOTAL BLOOD VOLUME (ABSOLUTE AND RELATIVE TO IDEAL BODY WEIGHT),"Blood Volume, Components and Capillary Leak in SARS-CoV-2 Infections"
NCT04518410,Recruiting,Interventional,Phase 2/Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,19-Aug-20,21-Dec-21,21-Dec-21,TREATMENT,2000,CORONAVIRUS,PUERTO RICO,ALL,"18 Years and older   (Adult, Older Adult)",LY3819253,DURATION OF COVID-19 SYMPTOMS (PHASE 2),Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)
NCT04518514,Recruiting,Interventional,Not Applicable,RWTH Aachen University,Other,20-Apr-20,30-Nov-20,31-Oct-20,OTHER,100,PATIENTS UNDERGOING ELECTIVE SURGERY WITH ANESTHESIA,GERMANY,ALL,"Child, Adult, Older Adult",TAPE-SOFTWARE,FEASIBILITY (AS DEFINED BELOW) OF TELEMEDICAL RISK ASSESSMENT AND PREOPERATIVE EVALUATION IN ANESTHESIOLOGY AS ASSESSED BY A QUESTIONNAIRE.,Telemedical Risk Assessment and Preoperative Evaluation for Anesthesia During the COVID-19 Pandemic
NCT04518735,Completed,Observational,,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Other,1-Apr-20,30-Jun-20,30-Jun-20,CASE-CONTROL,1707,COVID,SPAIN,ALL,"Child, Adult, Older Adult",ANTITHROMBOTIC THERAPY (ANTICOAGULANT AND/OR ANTIPLATELET) BEFORE ADMISSION FOR COVID19,MORTALITY,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients
NCT04518969,Recruiting,Interventional,Not Applicable,Dr David DE BELS,Other,3-May-20,1-Dec-20,1-Dec-20,TREATMENT,24,COVID,BELGIUM,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CYTOSORB,COMPARING % OF CHANGE IN CYTOKINE'S CLEARANCES OF PRO ET ANTI -INFLAMMATORY TYPES,"Comparing the Cytokine Clearances of Pro-, and Anti-inflammatory Mediators, Chemokines and Complement in the COVID-19 Patients Treated With CytoSorb as Compared to the Same Patient Population Who do Not Receive Blood Purification Treatment"
NCT04519034,Not yet recruiting,Observational,,Guy's and St Thomas' NHS Foundation Trust,Other,1-Sep-20,31-Dec-20,30-Sep-20,OTHER,27000,COVID,UNITED KINGDOM,ALL,"1 Year to 100 Years   (Child, Adult, Older Adult)",NO INTERVENTION,"COLLECTING VITAMIN D RESULTS IN PATIENTS FROM THE SOUTH-EAST LONDON AREA TOGETHER WITH AGE, SEX, ETHNICITY AND BMI AND OTHER RELEVANT LABORATORY RESULTS.",Retrospective Pilot Study of Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection
NCT04519125,Not yet recruiting,Interventional,Phase 2/Phase 3,Hospital Universitario San Ignacio,Other,30-Aug-20,1-Apr-21,31-Dec-20,PREVENTION,950,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",TENOFOVIR/ EMTRICITABINE ( 300 MG / 200 MG DAILY DURING 60 DAYS) + PERSONAL PROTECTIVE EQUIPMENT (PPE),SARS-COV-2 INFECTION,Effectiveness of the Use of Personal Protective Equipment in Addition to Tenofovir/Emtricitabine for the Prevention of the Transmission of SARS-COV-2 to Health Care Personnel. Randomized Clinical Trial
NCT04519216,Recruiting,Interventional,Not Applicable,"University of California, Davis",Other,31-Jul-20,30-Sep-21,30-Jun-21,OTHER,39,BREASTFEEDING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELESIMULATION,CHANGE IN PRACTICE PATTERNS,"Breastfeeding Education in the Time of COVID-19. Hybrid Telesimulation With Standardized Patients for Pediatric and Family Medicine Trainees, a Randomized Trial"
NCT04519255,"Active, not recruiting",Observational,,"Fifth Affiliated Hospital, Sun Yat-Sen University",Other,1-Jul-20,31-Jul-23,31-Dec-22,CASE-CONTROL,60,PET/CT,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,NUMBER OF CLINICALLY CURED PATIENTS WITH SEVERE COVID-19,"Single-center, Open, Prospective, Randomized Pilot Study for Quantitative Analysis of Whole Body Inflammatory Lesions in Recovered COVID-19 Patients by 18F-FDG-PET/CT"
NCT04519307,"Active, not recruiting",Observational,,Dr. Behcet Uz Children's Hospital,Other,1-Mar-20,31-Aug-20,1-Aug-20,CASE-CONTROL,72,VIRAL INFECTION,TURKEY,ALL,up to 1 Month   (Child),,GENERAL CHARACTERISTICS OF THE INFANTS WITH RESPIRATORY INFECTION AT THE NICU ADMISSION,Evaluation of Newborns Presenting With Suspected COVID 19: A Single Center Experience
NCT04519320,Recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Besancon,Other,18-May-20,18-Aug-25,18-Aug-21,DIAGNOSTIC,140,SARS-COV2,FRANCE,ALL,"18 Years to 79 Years   (Adult, Older Adult)",PULMONARY FUNCTION TESTING,"PROPORTION OF PATIENTS WITH AN ALTERATION OF THE CAPILLARY ALVEOLUS BARRIER AT 12 MONTHS OF FOLLOW-UP, CHARACTERIZED BY A DECREASED OF THE DIFFUSING CAPACITY FOR CARBON MONOXIDE (DLCO) BELOW THE LOWER LIMIT OF NORMAL",Medium and Long Term Follow-up of SARS-COV-2 Infected Patients Treated at Besançon and Dijon Hospitals: Research and Characterization of Pulmonary Sequelae
NCT04519372,"Active, not recruiting",Observational,,"University Hospital, Basel, Switzerland",Other,1-Apr-20,31-Mar-21,14-Jun-20,OTHER,4099,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",TESTING FOR SARS-COV-2,PROPORTION OF SARS-COV-2 -INFECTED PATIENTS,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting (Covid-Screen Quality Control Study)
NCT04519385,Completed,Interventional,Not Applicable,South Valley University,Other,1-Mar-20,5-Aug-20,1-Jul-20,TREATMENT,69,"PNEUMONIA, VIRAL",EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,PROPORTION OF PARTICIPANTS WITH OVERALL SURVIVAL AT 14 DAYS,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases
NCT04519398,Recruiting,Observational,,Grigore T. Popa University of Medicine and Pharmacy,Other,18-Aug-20,18-Aug-21,17-Feb-21,ECOLOGIC OR COMMUNITY,60,COVID,ROMANIA,ALL,"18 Years and older   (Adult, Older Adult)",COMPLETE THROMBOPHILIC PROFILE TESTING BY MULTIPLEX PCR,NUMBER OF PATIENTS WITH THROMBOPHILIC PROFILE ALTERATIONS,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events
NCT04519411,Recruiting,Interventional,Not Applicable,Mayo Clinic,Other,21-May-20,31-Jan-22,31-Dec-21,OTHER,10,COVID,UNITED STATES,ALL,up to 17 Years   (Child),TRANSPULMONARY PRESSURE MEASUREMENTS,TRANSPULMONARY PRESSURE,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
NCT04519424,Withdrawn,Interventional,Phase 2,CSL Behring,Industry,20-Sep-21,21-May-21,21-Apr-21,TREATMENT,0,CORONAVIRUS DISEASE 2019 (COVID),,ALL,"18 Years and older   (Adult, Older Adult)",CSL324,PROPORTION OF SUBJECTS PROGRESSING TO ENDOTRACHEAL INTUBATION OR DEATH PRIOR TO ENDOTRACHEAL INTUBATION,"A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL324 in Coronavirus Disease 2019 (COVID-19)"
NCT04519437,"Active, not recruiting",Interventional,Phase 1,Regeneron Pharmaceuticals,Industry,26-Jul-20,25-Oct-21,25-Oct-21,TREATMENT,974,HEALTHY,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",REGN10933+REGN10987,INCIDENCE OF ADVERSE EVENT OF SPECIAL INTERESTS (AESIS) THAT OCCUR WITHIN 4 DAYS OF STUDY DRUG ADMINISTRATION,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers"
NCT04519502,Recruiting,Observational,,The George Washington University Biostatistics Center,Other,23-Jun-20,31-Dec-21,31-Mar-21,COHORT,26400,COVID,UNITED STATES,FEMALE,"Child, Adult, Older Adult",,MATERNAL MORTALITY AND MORBIDITY COMPOSITE,Maternal Morbidity and Mortality During the COVID-19 Pandemic
NCT04520191,Not yet recruiting,Observational,,University of New Mexico,Other,1-Sep-20,30-Sep-21,1-Aug-21,COHORT,529,COVID REALTED DISRUPTION IN PATIENT WITH DIABETES AND CKD,,ALL,"21 Years to 80 Years   (Adult, Older Adult)",,DISRUPTION IN HEALTH CARE,Home-based Kidney Care in Native Americans of New Mexico (HBKC) -COVID-19 Related Disruption in Health and Health Care
NCT04520620,Withdrawn,Interventional,Phase 4,Centre Hospitalier Universitaire de Saint Etienne,Other,2-May-20,10-Jul-20,10-Jul-20,TREATMENT,0,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",LOVENOX 40 MG IN 0.4 ML PREFILLED SYRINGE,MEASURE OF ANTI-XA ACTIVITY,Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.
NCT04520880,Not yet recruiting,Observational,,Dammam University,Other,20-Aug-21,21-Feb-21,20-Dec-21,OTHER,158,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2 INFECTION),SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",TESTING PROCEDURE FOR BINDING ANTIBODIES,CHANGES IN THE LEVELS OF S SPECIFIC ANTIBODIES IN SEVERELY ILL PATIENTS COMPARED TO MILD CASES.,Antibodies Responses to SARS-CoV 2 Infection (COVID-19) in Hospitalized Patients. A Prospective Observational Study
NCT04521010,Completed,Observational,,Poznan University of Medical Sciences,Other,1-Jan-20,30-Apr-20,30-Apr-20,OTHER,700,COVID PANDEMIC,POLAND,ALL,"Child, Adult, Older Adult",COVID-19 PANDEMIC,NUMBER OF DAYS AN INDIVIDUAL PERSON WAS ABSENT,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in Poznań
NCT04521036,Not yet recruiting,Interventional,Phase 1/Phase 2,Vinmec Research Institute of Stem Cell and Gene Technology,Other,1-Dec-20,30-Oct-21,30-Jun-21,TREATMENT,44,COVID,VIETNAM,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CONVALESCENT PLASMA AS THERAPY FOR COVID-19 PATIENTS,CHANGE IN MORTALITY,Assessment of the Safety and Efficacy of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness
NCT04521088,Recruiting,Observational [Patient Registry],,Wissenschaftliches Institut Bethanien e.V,Other,2-Jul-20,31-Dec-20,31-Dec-20,COHORT,1000,COVID,GERMANY,ALL,"Child, Adult, Older Adult",,POSSIBLE RISK FACTORS,Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic
NCT04521296,Not yet recruiting,Interventional,Phase 2,Daewoong Pharmaceutical Co. LTD.,Industry,20-Aug-21,20-Dec-21,20-Dec-21,TREATMENT,90,MILD TO MODERATE COVID,,ALL,"19 Years and older   (Adult, Older Adult)",DWJ1248,TIME TO SARS-COV-2 ERADICATION,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19"
NCT04521309,Completed,Interventional,Phase 1/Phase 2,Dow University of Health Sciences,Other,19-Jun-20,8-Feb-21,26-Jan-21,TREATMENT,50,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 ANTIBODY BASED IVIG THERAPY,28 DAYS MORTALITY,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients
NCT04521322,Recruiting,Interventional,Phase 4,Ariel Dogliotti,Other,24-Jul-20,30-Nov-20,30-Oct-20,PREVENTION,400,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",IOTA-CARRAGEENAN,DIAGNOSE OF COVID19 DISEASE,"Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)"
NCT04521400,Not yet recruiting,Interventional,Phase 2,Shahid Beheshti University of Medical Sciences,Other,20-Aug-20,11-Sep-20,4-Sep-20,TREATMENT,100,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",HIGH DOSE INTERFERON-BETA 1A,TIME TO CLINICAL IMPROVEMENT,"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19"
NCT04522037,Recruiting,Observational,,Hospices Civils de Lyon,Other,1-Jun-20,21-Feb-21,20-Sep-21,COHORT,200,PATIENTS HOSPITALIZED IN THE HOSPICES CIVILS OF LYON,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION / COMPARE THE DIFFERENCE IN RESPIRATORY RATE BETWEEN H0 AND H12 OF THE INITIATION OF MORPHINE BETWEEN THE CONTROL AND INTERVENTIONAL GROUPS,TITLE : REDUCTION OF RESPIRATORY RATE BETWEEN HOUR 0 AND HOUR 12 AT INITIATION OF MORPHINE TREATMENT,Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon
NCT04522076,"Active, not recruiting",Observational,,National Research Center for Preventive Medicine,Other,6-Apr-20,1-May-22,1-May-22,COHORT,1124,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",,OVERALL SURVIVAL,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia
NCT04522089,Recruiting,Interventional,Phase 1,Adimmune Corporation,Industry,24-Aug-20,20-Mar-21,20-Nov-20,PREVENTION,70,COVID,TAIWAN,ALL,20 Years to 60 Years   (Adult),ADIMRSC-2F,THE SOLICITED ADVERSE EVENTS (SOAES),"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers"
NCT04522128,Recruiting,Interventional,Not Applicable,University of Manchester,Other,22-May-20,31-Dec-22,31-Mar-22,OTHER,969,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BEHAVIOUR CHANGE TECHNIQUE INTERVENTION TO IMPROVE QUALITY OF LIFE,CHANGE IN WORLD HEALTH ORGANISATION QUALITY OF LIFE COMBINATION,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?
NCT04522310,Recruiting,Observational,,Centre Hospitalier de Lens,Other,20-May-20,7-Oct-20,7-Oct-20,CASE-ONLY,183,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MR-PRO-ADM,ASSOCIATION OR CORRELATION BETWEEN MR-PROADM AT DAY 1 AND DAY 3 AND THE ONSET OF VISCERAL FAILURES EXTRA RESPIRATORY IN REANIMATION.,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis
NCT04522466,Terminated,Interventional,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Other,3-Apr-20,28-May-20,28-May-20,TREATMENT,7,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE (HCQ),PHARMACOKINETICS OF HYDROXYCHLOROQUINE (HCQ),Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients
NCT04522492,"Active, not recruiting",Interventional,Not Applicable,Hospital de Clinicas de Porto Alegre,Other,11-Aug-20,21-Jun-21,21-Mar-21,TREATMENT,18,SKIN PICKING,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",INTERNET-BASED COGNITIVE BEHAVIORAL THERAPY,CHANGE IN GLOBAL CLINICAL IMPRESSION SCALE,Impact of COVID-19 Pandemia on the Mental Health of Patients With Skin Picking Disorder and Their Treatment With Remote Cognitive Behavioral Therapy: Controlled Clinical Trial
NCT04522817,Withdrawn,Interventional,Phase 1,"Caladrius Biosciences, Inc.",Industry,5-Oct-20,21-May-21,21-May-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLBS119,ADVERSE EVENTS,CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage
NCT04522830,Recruiting,Interventional,Phase 2,"Beech Tree Labs, Inc.",Industry,30-Jul-20,1-Jul-21,30-Jun-21,TREATMENT,40,SARS-COV2 INFECTION,UNITED STATES,ALL,"40 Years and older   (Adult, Older Adult)",BTL-TML-COVID,MEAN DURATION AND SEVERITY OF DISEASE,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection"
NCT04522986,Not yet recruiting,Interventional,Phase 1,"Rohto Pharmaceutical Co., Ltd.",Industry,20-Sep-21,21-Dec-21,21-Dec-21,TREATMENT,6,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,JAPAN,ALL,"20 Years and older   (Adult, Older Adult)",MESENCHYMAL STEM CELL,SAFETY: ADVERSE EVENT,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
NCT04523012,Recruiting,Observational,,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,Other,1-Jul-20,30-Jun-22,30-Jun-21,COHORT,2200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROPREVALENCE OF SARS-COV-2 INFECTION IN PATIENTS WITH HIV INFECTION,MEASURE OF SEROPREVALENCE OF COVID-19 INFECTION ASSESSED BY THE LEVEL OF ANTI-COVID-19 IGG ANTIBODIES IN THE POPULATION OF PEOPLE LIVING WITH HIV MONITORED AT THE PITIÉ-SALPÊTRIÈRE HOSPITAL,Seroprevalence of SARS-CoV-2 Infection in Patients With HIV Infection
NCT04523051,Recruiting,Observational,,Centre Hospitalier Régional Metz-Thionville,Other,1-Apr-20,1-May-21,1-Apr-21,COHORT,40,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,FUNCTIONAL INDEPENDENCE MEASURE (FIM) AT THE ADMISSION,Rehabilitation After Admission in Intensive Care Unit for COVID-19: an Observational Study
NCT04523090,Recruiting,Interventional,Phase 2/Phase 3,University of Cape Town,Other,27-Aug-20,21-Aug-21,21-Apr-21,TREATMENT,960,COVID,SOUTH AFRICA,ALL,"18 Years to 120 Years   (Adult, Older Adult)",NITAZOXANIDE,TIME SPECIFIC DISEASE SEVERITY,"The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting"
NCT04523181,Recruiting,Interventional,Phase 2,Golden Biotechnology Corporation,Industry,8-Oct-20,31-May-21,30-Apr-21,TREATMENT,174,COVID,ARGENTINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ANTROQUINONOL,RECOVER RATIO,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19"
NCT04523246,Recruiting,Interventional,Early Phase 1,Barbara Carlson,Other,1-Sep-20,1-Sep-21,1-Jul-21,BASIC SCIENCE,250,HERPES ZOSTER,UNITED STATES,ALL,65 Years to 100 Years   (Older Adult),"SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED)",EVIDENCED OF ACTIVE AND TRAINED INNATE IMMUNITY,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study"
NCT04523571,"Active, not recruiting",Interventional,Phase 1,BioNTech RNA Pharmaceuticals GmbH,Industry,28-Jul-20,21-Aug-21,30-Sep-20,PREVENTION,144,SARS-COV2,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BNT162B1,"OCCURRENCE OF SOLICITED LOCAL REACTIONS IN THE SUBJECTS (E.G., VACCINATION SITES: PAIN/TENDERNESS, ERYTHEMA/REDNESS, INDURATION/SWELLING) DURING THE 14-DAYS AFTER EACH DOSE OF BNT162B1 OR PLACEBO.","Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study"
NCT04523610,Recruiting,Interventional,Not Applicable,Lady Davis Institute,Other,2-Oct-20,22-Oct-21,21-Oct-21,HEALTH SERVICES RESEARCH,258,"DEPRESSION, ANXIETY",CANADA,ALL,"18 Years and older   (Adult, Older Adult)",TELEHEALTH PHONE CALLS,PERCEIVED STRESS SCALE (PSS),Telehealth Intervention Program for Older Adults (TIP-OA) Struggling With Mental Health/Cognitive Issues
NCT04523831,Completed,Interventional,Phase 3,Dhaka Medical College,Other,1-Jun-20,10-Sep-20,22-Aug-20,TREATMENT,400,COVID,BANGLADESH,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN AND DOXYCYCLINE,NUMBER OF PATIENTS WITH EARLY CLINICAL IMPROVEMENT,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care
NCT04524052,Not yet recruiting,Interventional,Phase 1,Daewoong Pharmaceutical Co. LTD.,Industry,20-Aug-21,20-Dec-21,20-Dec-21,TREATMENT,32,HEALTHY,,ALL,18 Years to 45 Years   (Adult),DWRX2003,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,"Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Pharmacokinetics (PK) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in Healthy Volunteers"
NCT04524156,Not yet recruiting,Interventional,Not Applicable,Erasme University Hospital,Other,4-Oct-20,4-May-23,4-Sep-21,BASIC SCIENCE,100,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",PHYSIOLOGY,TRANSCUTANEOUS PO2 AND PCO2 AS PREDICTIVE FACTORS FOR RESPIRATORY DETERIORATION,COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
NCT04524234,Completed,Observational,,"Sahlgrenska University Hospital, Sweden",Other,20-Apr-20,30-Sep-20,31-Aug-20,COHORT,132,COVID,SWEDEN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ECHOCARDIOGRAPHY,MORTALITY,Cardiac Dysfunction in Critically Ill Patients With COVID-19
NCT04524507,Recruiting,Interventional,Phase 2,"University of North Carolina, Chapel Hill",Other,27-Aug-20,21-May-21,21-May-21,TREATMENT,56,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",HIGH-TITER CONVALESCENT COVID-19 PLASMA (CCP1),CUMULATIVE INCIDENCE OF SERIOUS ADVERSE EVENTS (SAES) AT STUDY DAY 14,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19"
NCT04524520,Recruiting,Observational,,Western Sussex Hospitals NHS Trust,Other,5-May-20,8-May-22,8-May-21,COHORT,30,EXPLORING RISK ASSESSMENT AND RECOVERY FROM COVID INFECTION IN HOSPITALISED PATIENTS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,PHYSICAL,"COVID19-OR (SARS-CoV-2):Observation, Risk & Recovery. An Observational Study Exploring Risk Assessment and Recovery From COVID-19 (SARS-CoV-2) Infection in Hospitalised Patients"
NCT04524598,Recruiting,Interventional,Not Applicable,"Limbix Health, Inc.",Industry,20-Jul-20,31-Dec-20,31-Dec-20,TREATMENT,410,DEPRESSION,UNITED STATES,ALL,"13 Years to 21 Years   (Child, Adult)",LIMBIX SPARK,CHANGE IN DEPRESSIVE SYMPTOMS,Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
NCT04524663,Recruiting,Interventional,Phase 2,Stanford University,Other,19-Dec-20,21-Jun-21,21-Jun-21,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CAMOSTAT MESILATE,TIME UNTIL CESSATION OF SHEDDING OF SARS-COV-2 VIRUS,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19"
NCT04524715,Not yet recruiting,Interventional,Not Applicable,Ward Photonics LLC,Industry,31-Mar-21,31-Mar-22,31-Mar-22,TREATMENT,64,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NON-INVASIVE RED LLLT TREATMENT TO CHEST OF PATIENT.,INFLAMMATION OF THE LUNGS - O2,Low-Level Laser Therapy Treatment of Lung Inflammation in COVID-19 Patients
NCT04524754,Recruiting,Observational,,Ain Shams University,Other,11-Jul-20,30-Nov-20,11-Sep-20,CASE-ONLY,218,ANOSMIA,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,OLFACTION,Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19
NCT04524962,Recruiting,Interventional,Phase 1/Phase 2,Cartesian Therapeutics,Industry,15-Sep-20,25-Sep-22,25-Sep-21,TREATMENT,30,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DESCARTES 30,TO ASSESS THE SAFETY OF DESCARTES-30 IN PATIENTS WITH MODERATE-TO-SEVERE ARDS.,Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome
NCT04525079,Recruiting,Interventional,Phase 1,Celltrion,Industry,18-Jul-20,30-Nov-20,31-Aug-20,SCREENING,32,SARS-COV2 INFECTION,"KOREA, REPUBLIC OF",ALL,19 Years to 55 Years   (Adult),CT-P59,PRIMARY SAFETY OUTCOME,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects"
NCT04525287,Recruiting,Observational,,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Other,20-Feb-20,20-Aug-20,20-Aug-20,CASE-CROSSOVER,1000,CORONAVIRUS INFECTION,CHINA,ALL,"Child, Adult, Older Adult",,CHEST CT AND CLINICAL FEATURES,Prediction Models for Diagnosis and Prognosis of Severe COVID-19
NCT04525378,Recruiting,Interventional,Phase 1,D'Or Institute for Research and Education,Other,1-Jul-20,31-Oct-20,30-Sep-20,TREATMENT,20,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STROMAL CELL-BASED THERAPY,INTRAHOSPITAL MORTALITY,Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome: a Pilot Clinical Study
NCT04525404,Recruiting,Observational,,University of Alberta,Other,12-Nov-20,1-Sep-21,1-Sep-21,COHORT,228,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)","MRI (HEART, BRAIN, LUNGS, LIVER)",NATIVE MYOCARDIAL T1 RELAXATION TIME,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients
NCT04525417,Completed,Interventional,Not Applicable,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,Other,25-Apr-20,25-Oct-20,25-Sep-20,DIAGNOSTIC,75,COVID IMMUNE STATUS OF HEALTHCARE WORKERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",AAZ COVID-19 RAPID TEST,TO ASSESS THE PREDICTIVE VALUE OF COVID-19 RAPID TEST,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2
NCT04525443,Completed,Observational,,"Hospital San Carlos, Madrid",Other,3-Jun-20,11-Feb-21,11-Nov-20,CASE-CONTROL,110,COVID,SPAIN,ALL,"Child, Adult, Older Adult",,REACTIVE HYPEREMIA INDEX (RHI),Assessment of Endothelial Vasodilator Function in COVID-19 Patients
NCT04525716,Recruiting,Observational,,Karolinska Institutet,Other,1-Mar-20,31-Dec-20,31-Aug-20,COHORT,2000,COVID,SWEDEN,ALL,"Child, Adult, Older Adult",COVID-19 INFECTION STATUS,DEATH,"How Does Covid-19 Affect Patient Outcome Following Surgery? A Hospital Based Cohort in Stockholm, Sweden"
NCT04525742,Completed,Interventional,Not Applicable,Gaziosmanpasa Taksim Research and Education Hospital,Other,5-Jul-20,15-Sep-20,30-Aug-20,SCREENING,309,COVID,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",DIFFICULTIES LIVED BY DISABLED CHILDREN'S PARENTS IN THE PERIOD OF COVID-19 PANDEMIC,A QUESTIONNAIRE THAT WE CREATED WILL BE USED TO DETERMINE THE DIFFICULTIES EXPERIENCED BY DISABLED CHILDREN'S PARENTS DURING COVID 19 PANDEMIC RELATED TO THEIR MEDICAL FOLLOW-UP,COVID-19 Pandemic From the Perspective of Parents of Disabled Children
NCT04525820,Recruiting,Interventional,Not Applicable,Prof. Dr. Jörg Leuppi,Other,15-Dec-20,30-Jun-21,31-May-21,TREATMENT,80,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",SINGLE HIGH DOSE VITAMIN D,LENGTH OF HOSPITALIZATION,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study"
NCT04525911,Recruiting,Observational,,Hôpital Européen Marseille,Other,26-Aug-20,22-Oct-21,21-Mar-21,COHORT,258,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC TEST: SEROLOGY TEST FOR COVID-19,EVALUATION OF POST-TRAUMATIC STRESS SYMPTOMS (POST TRAUMATIC STRESS DISORDER (PTSD) SCALE) AT M3 FOR PATIENTS AND CAREGIVERS,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital
NCT04526054,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,3-Sep-20,3-Sep-21,3-Sep-21,DIAGNOSTIC,30,OLFACTION DISORDERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ENT EXAM,TO COMPARE THE QUALITATIVE AND QUANTITATIVE MORPHOLOGICAL ABNORMALITIES OF THE OLFACTORY BULB DETECTED BY MRI ON INITIAL EXAMINATION IN COVID-19 ANOSMIC VERSUS COVID-19 NORMOSMIC PATIENTS.,Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients
NCT04526145,Not yet recruiting,Interventional,Not Applicable,Ohio State University,Other,31-Jan-21,30-Jan-22,14-Sep-21,HEALTH SERVICES RESEARCH,30,"STRESS, PSYCHOLOGICAL",,FEMALE,"45 Years to 65 Years   (Adult, Older Adult)",STRESS AND EMOTION MANAGEMENT,"DETERMINE THE FEASIBILITY OF A SYNCHRONOUS WEB-BASED HEALTH EDUCATION PROGRAM, OF OUR PROJECT.",Operating Under Resilience (OUR) Project: Stress and Emotion Management for Black/African American Women With Hypertension In a Covid--19 Social Distancing Society
NCT04526405,Completed,Observational,,University of Milano Bicocca,Other,14-Jul-20,3-Nov-20,3-Nov-20,COHORT,63,THALASSEMIA MAJOR,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 S1/S2 IGG,POSITIVE SUBJECTS,Study on the Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases Subject to Chronic Transfusion Support.
NCT04526717,Not yet recruiting,Interventional,Phase 1,Joseah Bio,Industry,21-Dec-21,22-Dec-21,22-Dec-21,TREATMENT,15,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",MPT0B640,MTD,"Phase 1, Open Label, Single Arm Study to Evaluate the Safety, Tolerability and Efficacy of MPT0B640 in Patients With COVID-19 Infection"
NCT04526769,Not yet recruiting,Observational,,University of Minnesota,Other,20-Sep-21,21-Apr-21,21-Apr-21,CASE-ONLY,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TEAR COLLECTION,COVID-19 VIRUS DETECTION IN TEARS,Detecting SARS-CoV-2 Virus in Tears From Patients With COVID-19
NCT04526821,Not yet recruiting,Interventional,Phase 2,Universidad Peruana Cayetano Heredia,Other,1-Sep-20,1-Nov-21,30-Jun-21,PREVENTION,336,SARS-COV2,PERU,ALL,18 Years to 59 Years   (Adult),BOVINE LACTOFERRIN,NUMBER OF COVID-19 INFECTIONS DURING THE 12 WEEKS OF INTERVENTION,"Bovine Lactoferrin for the Prevention of COVID-19 Infection in Physicians and Nurses in Hospitals in Lima, Peru: a Double Blinded Randomized Clinical Trial (LF-COVID)"
NCT04526912,Recruiting,Interventional,Phase 1,Viela Bio,Industry,28-Aug-20,21-Jul-21,21-Apr-21,TREATMENT,48,ACUTE LUNG INJURY,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VIB7734,"THE PROPORTION OF PATIENTS WHO ACHIEVE TREATMENT SUCCESS THROUGH DAY 28, DEFINED AS AVOIDANCE OF DEATH AND CRITICAL ILLNESS",A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection
NCT04526977,Recruiting,Observational,,Asociacion para el Estudio de las Enfermedades Infecciosas,Other,10-Jan-21,30-Sep-21,30-Jun-21,CASE-CONTROL,90,COVID,SPAIN,ALL,"18 Years to 85 Years   (Adult, Older Adult)",IMMUNE RESPONSE STUDY,CHANGES IN IMMUNE CELLULAR RESPONSE,"Differences in Susceptibility and Cytokine Profile, Specific CD4/CD8 T Cell Response, Toll Like Receptors (TLRs) and Killer Immunoglobulin-like Receptors (KIRs) Among HIV-1-infected Individuals With Previous or Current COVID-19"
NCT04526990,Recruiting,Interventional,Phase 3,CanSino Biologics Inc.,Industry,15-Sep-20,30-Jan-22,30-Dec-21,PREVENTION,40000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),INCIDENCE OF COVID-19 CASES,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older"
NCT04527081,"Active, not recruiting",Interventional,Phase 1/Phase 2,"AnGes, Inc.",Industry,31-Aug-20,30-Sep-21,9-Nov-20,PREVENTION,30,COVID,JAPAN,ALL,"20 Years to 65 Years   (Adult, Older Adult)",AG0302-COVID19,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY],"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults"
NCT04527133,"Active, not recruiting",Interventional,Not Applicable,Aviron LLC,Industry,11-Jun-20,31-Aug-20,11-Aug-20,TREATMENT,30,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",APROTININ,TIME TO ELIMINATION OF SARS-COV-2 VIRUS,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19
NCT04527198,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Sep-21,21-Jun-21,21-Jun-21,OTHER,40,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BRAINSTEM RESPONSES ASSESSMENT SEDATION SCORE (BRASS),BRAINSTEM DYSFUNCTION PREVALENCE,Brainstem Dysfunction in Ventilated and Deeply Sedated COVID-19 Critically Ill Patients: a Prospective Observational Study
NCT04527211,Not yet recruiting,Interventional,Phase 3,Javeriana University,Other,7-Sep-20,16-Dec-20,30-Nov-20,PREVENTION,550,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,CLINICAL DEVELOPMENT OF COVID-19 DISEASE DURING THE INTERVENTION PERIOD,"Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel at All Levels of Care, During the 2020 Pandemic: A Randomized Clinical Controled Trial"
NCT04527224,Not yet recruiting,Interventional,Phase 1/Phase 2,Nature Cell Co. Ltd.,Industry,1-Dec-20,1-Apr-22,1-Oct-21,TREATMENT,10,COVID,,ALL,"19 Years to 80 Years   (Adult, Older Adult)",ASTROSTEM-V,TREATMENT RELATED ADVERSE EVENTS,A Phase I/Ⅱa Trial to Explore the Safety and Efficacy of Allogenic Adipose Tissue-derived Mesenchymal Stem Cell (AstroStem-V) Therapy in Patients With COVID-19 Pneumonia
NCT04527315,Recruiting,Observational [Patient Registry],,NYU Langone Health,Other,17-Jul-20,23-Aug-21,23-Aug-21,CASE-CONTROL,350,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,LEVEL OF INFLAMMATORY MARKERS,Assessment of ICU and Non-ICU Survivors: A Creation of a COVID Survivorship Database
NCT04527354,"Active, not recruiting",Interventional,Phase 2,PHARMENTERPRISES LLC,Industry,8-Sep-20,20-Nov-21,20-Nov-21,TREATMENT,60,SARS-COV2 INFECTION,RUSSIAN FEDERATION,ALL,"18 Years to 75 Years   (Adult, Older Adult)",TREAMID,RATE OF CLINICALLY SIGNIFICANT CHANGE IN FVC AND/OR DLCO AT WEEK 4 RELATIVE TO THE BASELINE VALUE,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia"
NCT04527432,Recruiting,Interventional,Not Applicable,The Royal Wolverhampton Hospitals NHS Trust,Other,16-Dec-20,31-Mar-22,31-Mar-22,HEALTH SERVICES RESEARCH,3000,CORONAVIRUS INFECTION,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",SURVEY,THE NUMBER OF EMPLOYEES TESTED WHO HAVE EVIDENCE OF SARS-COV-2 ANTIBODIES,"A Pilot Assessment of the COVID-19 Antibody Status and Associated Factors, in Individuals Employed by a Large Acute NHS Trust During the Coronavirus Pandemic"
NCT04527458,Completed,Observational,,University of Edinburgh,Other,24-Feb-20,2-Aug-20,2-Aug-20,COHORT,70000,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",PATIENT CHARACTERISTICS,CASE FATALITY,Case Fatalities in Hospitalised COVID-19 Patients in the UK: An ISARIC Study
NCT04527471,"Active, not recruiting",Interventional,Phase 2,Verona Pharma Inc,Industry,4-Sep-20,21-Mar-21,21-Feb-21,TREATMENT,45,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ENSIFENTRINE DOSE 1,PROPORTION OF PATIENTS WITH RECOVERY,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19"
NCT04527497,Recruiting,Observational,,Wissenschaftliches Institut Bethanien e.V,Other,1-Aug-20,31-Aug-21,30-May-21,COHORT,50,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,CONVALESCENCE/DEATH,Clinical Course and Treatment of COVID-19 Inpatients in Hospital
NCT04527562,Completed,Interventional,Not Applicable,Dhaka Medical College,Other,14-Jul-20,10-Dec-20,15-Nov-20,TREATMENT,299,COVID,BANGLADESH,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,"TIME TO DEVELOP CLINICAL DETERIORATION, DEFINED AS THE TIME FROM RANDOMIZATION TO A DETERIORATION OF TWO POINTS (FROM THE STATUS AT RANDOMIZATION) ON A SEVEN-CATEGORY ORDINAL SCALE.","Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy"
NCT04527575,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",Other,27-Jul-20,21-May-21,21-May-21,PREVENTION,100,COVID,RUSSIAN FEDERATION,ALL,18 Years to 60 Years   (Adult),EPIVACCORONA (EPIVACCORONA VACCINE BASED ON PEPTIDE ANTIGENS FOR THE PREVENTION OF COVID-19),THE PROPORTION OF VACCINATED VOLUNTEERS WITH NO LABORATORY CONFIRMED SYMPTOMS CAUSED BY SARS-COV-2 WITHIN 9 MONTHS POST VACCINATION,"Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)"
NCT04527601,Completed,Observational,,"Rigshospitalet, Denmark",Other,21-Aug-20,13-Sep-20,13-Sep-20,COHORT,885,EXTREME PREMATURITY,DENMARK,ALL,22 Weeks to 28 Weeks   (Child),,NUMBER OF ELGAN ADMISSIONS DURING PEAK THREE MONTHS OF COVID-19 COMPARED TO CORRESPONDING MONTHS IN 2019,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments
NCT04527614,Enrolling by invitation,Interventional,Not Applicable,Sciensano,Other,24-Sep-20,30-May-21,30-May-21,DIAGNOSTIC,2000,"INFLUENZA, HUMAN",BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",QRT-PCR AND SEROLOGY,TIME TO OCCURRENCE OF ILI AND ARI BOTH IN PARTICIPANTS PREVIOUSLY EXPOSED TO SARS-COV-2 AND CONTROLS,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Multicentre Academic Prospective Cohort Study in Nursing Home During the Winter Season 2020-2021
NCT04528329,Recruiting,Interventional,Phase 4,ClinAmygate,Other,30-Aug-20,15-Apr-21,1-Apr-21,TREATMENT,300,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",EARLY-DEXAMETHASONE,TIME TO RECOVERY,Time to Recover of Anosmia and / or Ageusia and Early Corticosteroid Use
NCT04528368,Recruiting,Interventional,Phase 2,D'Or Institute for Research and Education,Other,11-Dec-20,30-May-21,30-Apr-21,TREATMENT,60,COVID,BRAZIL,ALL,"Child, Adult, Older Adult",CONVALESCENT PLASMA,AREA UNDER THE CURVE OF SARS-COV-2 VIRAL LOAD OBTAINED FROM NASOPHARYNGEAL AND /OR OROPHARYNGEAL SWABS.,Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support
NCT04528641,Recruiting,Interventional,Phase 1,ReiThera Srl,Industry,10-Aug-20,31-Jul-21,31-Jul-21,PREVENTION,90,COVID,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",GRAD-COV2,"ASSESS THE SAFETY, TOLERABILITY AND REACTOGENICITY OF GRAD-COV2: OCCURRENCE OF SOLICITED LOCAL AE SIGNS AND SYMPTOMS","A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects"
NCT04528667,Recruiting,Interventional,Phase 2,"Sorrento Therapeutics, Inc.",Industry,6-Jan-21,21-May-21,21-May-21,TREATMENT,400,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",STI-5656,PROPORTION OF SUBJECTS DISCHARGED FROM HOSPITAL,"A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19"
NCT04528771,Not yet recruiting,Interventional,Phase 1,Robert Schilz,Other,31-Oct-20,30-Apr-21,31-Mar-21,TREATMENT,21,SARS-COV2 INFECTION,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",SNO,LENGTH OF HOSPITAL STAY,Phase 1b Safety Trial for S-Nitrosylation Therapy to Treat COVID-19 Induced Respiratory Distress
NCT04528888,Not yet recruiting,Interventional,Phase 3,Massimo Girardis,Other,1-Sep-20,30-Jul-21,30-Jun-21,TREATMENT,210,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ENOXAPARIN,ALL-CAUSE MORTALITY AT DAY 28,"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design"
NCT04528901,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,4-Sep-20,22-Dec-21,22-Dec-21,COHORT,1080,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"DETERMINE AND COMPARE THE SEROPREVALENCE FOR SARS-COV2 AMONG PATIENTS WITH RESPIRATORY PATHOLOGIES MONITORED IN PNEUMOLOGY AT THE STRASBOURG UNIVERSITY HOSPITAL, IN THE CLUSTER ZONE OF THE GRAND EST.",Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)
NCT04528927,Withdrawn,Interventional,Phase 3,Abderrahmane Mami Hospital,Other,15-May-20,15-Jul-20,15-Jul-20,TREATMENT,0,COVID,TUNISIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HCQ,EVALUATE THE RATE OF PATIENTS CURED AT THE END OF THE STUDY.,"Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia Multicentric Randomized Comparative Study"
NCT04529408,Recruiting,Observational,,Imperial College London,Other,26-Aug-20,26-Aug-20,26-Aug-20,COHORT,60,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EARSATS PULSE OXIMETER PROBE,IN-EAR VS FINGER SPO2,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up
NCT04529421,Not yet recruiting,Observational,,Oslo Metropolitan University,Other,20-Sep-21,20-Dec-21,20-Dec-21,COHORT,70000,INFECTION,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE INSTRUCTION,COVID-19 INCIDENCE,Relationship Between In-person Instruction and COVID-19 Incidence Among University Students: A Prospective Cohort Study
NCT04529447,Completed,Observational,,Jaseng Hospital of Korean Medicine,Other,10-Jun-20,10-Aug-20,10-Aug-20,OTHER,485,COVID,"KOREA, REPUBLIC OF",ALL,"Child, Adult, Older Adult",SURVEY,SATISFACTORY SERVICE REGARDING HOSPITAL RESPONSE TO COVID-19,Hospital Operational Response Strategy and Experience During the COVID-19 Pandemic in a Spine-specialty Korean Medicine Training Hospital
NCT04529460,Not yet recruiting,Observational,,Royal Free Hospital NHS Foundation Trust,Other,1-Sep-20,30-Apr-21,29-Jan-21,COHORT,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 ANTIBODY POINT OF CARE TEST KIT,SENSITIVITY AND SPECIFICITY OF THE COVID-19 ANTIBODY TESTING KIT,Post Market Clinical Study of a Point of Care COVID-19 IgG-IgM Rapid Test in Healthy Volunteers
NCT04529499,"Active, not recruiting",Interventional,Phase 3,Dr. Reddy's Laboratories Limited,Industry,20-Aug-20,31-Mar-21,31-Mar-21,TREATMENT,780,COVID,KUWAIT,ALL,"21 Years to 80 Years   (Adult, Older Adult)",AVIGAN,PRIMARY EFFICACY ENDPOINT: TIME TO RESOLUTION OF HYPOXIA (STAGE I),"A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients"
NCT04529525,Recruiting,Interventional,Phase 2/Phase 3,Instituto de Cardiología de Corrientes,Other,19-Aug-20,15-Mar-21,28-Feb-21,TREATMENT,500,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,PERCENTAGE OF HOSPITALIZATION OF MEDICAL CAUSE IN PATIENTS WITH COVID-19 IN EACH ARM,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled"
NCT04530136,Recruiting,Interventional,Phase 2,Pharming Technologies B.V.,Industry,30-Nov-20,30-Nov-21,15-Aug-21,TREATMENT,120,CONFIRMED CORONAVIRUS DISEASE,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",RUCONEST,DISEASE SEVERITY ON THE 7-POINT WHO ORDINAL SCALE,"Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)"
NCT04530357,Completed,Interventional,Phase 1/Phase 2,Research Institute for Biological Safety Problems,Other,19-Sep-20,30-Nov-20,25-Nov-20,PREVENTION,244,COVID,KAZAKHSTAN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",QAZCOVID-IN® - COVID-19 INACTIVATED VACCINE,FREQUENCY OF ADVERSE EVENTS UP TO SEVEN DAYS AFTER IMMUNIZATION,"Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-IN®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder"
NCT04530370,Recruiting,Interventional,Early Phase 1,South Valley University,Other,29-May-20,1-Sep-20,20-Sep-21,TREATMENT,30,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",RECOVERED COVID 19 PATIENTS PLASMA,SATISFACTORY OUTCOME,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients
NCT04530396,"Active, not recruiting",Interventional,Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,7-Sep-20,1-May-21,1-May-21,PREVENTION,33758,COVID PREVENTION,RUSSIAN FEDERATION,ALL,"18 Years to 111 Years   (Adult, Older Adult)",GAM-COVID-VAC,PERCENTAGE OF TRIAL SUBJECTS WITH CORONAVIRUS DISEASE 2019 (COVID-19) DEVELOPED WITHIN 6 MONTHS AFTER THE FIRST DOSE,"Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-СoV-2 Infection Prophylactic Treatment"
NCT04530409,Recruiting,Interventional,Phase 4,ClinAmygate,Other,26-Aug-20,1-May-21,1-Apr-21,TREATMENT,450,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",EARLY-DEXAMETHASONE,PERCENTAGE OF CASES THAT WILL NEED HOSPITALIZATION,Timing of Corticosteroids in COVID-19
NCT04530422,Completed,Interventional,Phase 3,Almaza Military Fever Hospital,Other,15-Apr-20,23-Jul-20,8-Jul-20,TREATMENT,250,COVID,EGYPT,ALL,"18 Years to 75 Years   (Adult, Older Adult)",SOFOSBUVIR PLUS LEDIPASVIR,THERAPEUTIC SUCCESS (CURED),Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment
NCT04530435,Recruiting,Interventional,Not Applicable,Bispebjerg Hospital,Other,6-Oct-20,30-Apr-21,30-Apr-21,PREVENTION,400,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",PEP FLUTE,SELF-REPORTED CAT-SCORE (COPD ASSESSMENT TEST),PEP Flute-selfcare to Prevent Respiratory Deterioration and Hospitalization Among COVID-19 Patients: a Randomized Trial
NCT04530448,Recruiting,Interventional,Phase 4,West Virginia University,Other,5-Oct-20,21-Mar-21,21-Jan-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SODIUM BICARBONATE,PH,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
NCT04530461,Recruiting,Observational,,faida agili,Other,1-Jun-20,31-Jan-21,30-Nov-20,COHORT,200,SARS-COV INFECTION,TUNISIA,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TEST,SEROLOGICAL PROFILE,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT04530474,Not yet recruiting,Interventional,Phase 3,Temple University,Other,1-Oct-20,31-Dec-21,30-Jun-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN PILL,CLINICAL IMPROVEMENT,Outpatient Use of Ivermectin in COVID-19
NCT04530500,Enrolling by invitation,Observational,,"University of California, Irvine",Other,13-Aug-20,24-Jun-23,24-Jun-23,COHORT,200,COVID,UNITED STATES,MALE,"18 Years to 90 Years   (Adult, Older Adult)",COVID-19 ANDROGEN SENSITIVITY TEST (COVAST),NUMBER OF PATIENTS DECEASED,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
NCT04530539,Recruiting,Interventional,Not Applicable,Lancaster General Hospital,Other,5-Oct-20,1-Dec-21,1-Sep-21,SUPPORTIVE CARE,150,COVID,UNITED STATES,ALL,"50 Years and older   (Adult, Older Adult)",VITAMIN C,SYMPTOM SEVERITY,The Effect of Melatonin and Vitamin C on COVID-19
NCT04530578,Recruiting,Interventional,Phase 4,"Clinica San Camilo, Argentina",Other,1-Jun-20,1-Jun-21,30-Oct-20,TREATMENT,200,COVID,ARGENTINA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",HEPARIN SODIUM,PERCENTAGE OF PATIENTS REQUIREMENT MECHANICAL VENTILATION,Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)
NCT04530604,Recruiting,Interventional,Phase 1,Gregory Yanik,Other,1-Oct-20,1-Oct-21,1-Oct-21,TREATMENT,12,COVID,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DEFIBROTIDE,NUMBER OF MAJOR HEMORRHAGIC COMPLICATIONS WITHIN 14 DAYS OF INITIATION OF TREATMENT,Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)
NCT04530617,Recruiting,Interventional,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,5-Oct-20,30-Apr-21,30-Apr-21,TREATMENT,360,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,RATE OF HOSPITALIZATIONS AND OXYGEN USE,"Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients"
NCT04530656,"Active, not recruiting",Interventional,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,Other,28-Aug-20,28-Aug-21,28-Oct-20,PREVENTION,168,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)","TWO DOSES OF MIDDLE-DOSE RECOMBINANT SARS-COV-2 VACCINE (SF9 CELL) AT THE SCHEDULE OF DAY 0, 28",OCCURRENCE OF ADVERSE REACTIONS (AR) WITHIN 7 DAYS AFTER EACH DOSE OF THE RECOMBINANT SARS-COV-2 VACCINE (SF9 CELL) OR PLACEBO.,"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study"
NCT04530682,Not yet recruiting,Observational,,"University Hospital, Montpellier",Other,1-Feb-21,24-Jul-21,20-Jul-23,COHORT,5000,RHEUMATOID ARTHRITIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,SEROPREVALENCE OF COVID-19 IN PATIENTS WITH INFLAMMATORY RHEUMATISMS,Seroprevalence and Clinical Expression of SARS-CoV-2 Infection in Patients With Chronic Inflammatory Rheumatisms and Impact of Immuno-suppressive Drugs on the Persistence of Anti-SARS-CoV2 Antibodies During Two Years of Follow-up
NCT04531111,Recruiting,Observational,,Ain Shams University,Other,7-Jul-20,20-Aug-21,20-Aug-21,CASE-ONLY,150,TYPE 1 DIABETES,EGYPT,ALL,"2 Years to 18 Years   (Child, Adult)",,IMPACT OF COVID-19 PANDEMIC AND LOCKDOWN ON GLYCEMIC CONTROL AMONG A SAMPLE OF EGYPTIAN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt: A Pilot Study
NCT04531202,Recruiting,Observational [Patient Registry],,D'Or Institute for Research and Education,Other,2-Mar-20,30-Sep-21,30-Sep-20,COHORT,2000,CORONAVIRUS INFECTION (COVID),BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",,CLINICAL CHARACTERIZATION OF CORONAVIRUS DISEASE-2019 (COVID-19),Clinical Characterization Protocol for Severe Emerging Infections: Coronavirus
NCT04531254,"Active, not recruiting",Observational,,The Hospital for Sick Children,Other,10-Aug-20,20-Dec-21,20-Oct-21,COHORT,240,COVID,CANADA,ALL,"4 Years to 18 Years   (Child, Adult)",PERSONAL BEHAVIOURS,TOTAL NUMBER OF HAND-TO-FACE CONTACTS PER PARTICIPANT,Understanding the Impact of Public Health Measures Planned for School Reopening During COVID-19 Using Simulation Exercises
NCT04531319,Completed,Observational,,Istanbul Training and Research Hospital,Other,15-Aug-20,1-Oct-20,1-Oct-20,CASE-CONTROL,50,COVID,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FLOW CYTOMETRIC ANALYSIS,T CELL SUBTYPE RATIOS,Evaluation of Immune Cell Subgroups in Covid 19 Patients
NCT04531345,Completed,Observational,,Istanbul Training and Research Hospital,Other,1-Oct-20,15-Nov-20,1-Nov-20,CASE-CONTROL,60,COVID,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FLOW CYTOMETRIC ANALYSIS,CYTOKINE LEVELS OF PATIENTS,The Cytokine Status of Covid-19 Patients
NCT04531501,Recruiting,Observational,,Chronomics Limited,Industry,29-Jun-20,29-Sep-20,29-Sep-20,COHORT,400,COVID,UNITED KINGDOM,ALL,"18 Years to 117 Years   (Adult, Older Adult)",SALIVA AND NPS TEST,TEST RESULT,COVID-19 Saliva Test Research Study - Evaluation of High Throughput COVID-19 Testing Via Saliva Based Sampling and Alternative RNA Extraction Methods.
NCT04531618,Recruiting,Interventional,Not Applicable,Columbia University,Other,13-Aug-20,21-Dec-21,21-Dec-21,PREVENTION,280,CHILD DEVELOPMENT,UNITED STATES,ALL,up to 72 Hours   (Child),FAMILY NURTURE INTERVENTION (FNI),CHANGE IN WELCH EMOTIONAL CONNECTION SCORE,Promoting Mother-Infant Emotional Connection During the COVID-19 Pandemic: an Randomized Controlled Trial (RCT) of Virtual Family Nurture Intervention
NCT04531735,"Active, not recruiting",Observational,,Dr. Behcet Uz Children's Hospital,Other,1-Mar-20,31-Aug-20,1-Aug-20,CASE-CONTROL,28,RSV INFECTION,TURKEY,ALL,up to 1 Month   (Child),,OXYGEN STATUS AND EVALUATION OF NEONATAL INTENSIVE CARE STAY,Is Respiratory Syncytial Virus Infection More Dangerous Than Covid 19 in the Neonatal Period?
NCT04531748,Not yet recruiting,Interventional,Phase 2,"Reena Mehra, MD",Other,21-Mar-21,21-Sep-21,21-Sep-21,TREATMENT,390,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TOREMIFENE,PEAK INCREASE IN COVID-19 SIGN AND SYMPTOM SCORE,Selective Estrogen Modulation and Melatonin in Early COVID-19
NCT04531774,Recruiting,Interventional,Not Applicable,Naser Morina,Other,28-Aug-20,1-Jun-21,1-Jun-21,PREVENTION,160,STRESS,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",RECHARGE,CHANGE FROM BASELINE IN PSYCHOLOGICAL DISTRESS KESSLER PSYCHOLOGICAL DISTRESS SCALE (K10) AT WEEK 5 AND WEEK 13,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19
NCT04532294,Recruiting,Interventional,Phase 1,BeiGene,Industry,8-Sep-20,15-Jun-21,19-Feb-21,BASIC SCIENCE,30,COVID,AUSTRALIA,ALL,18 Years to 60 Years   (Adult),BGB DXP593,NUMBER OF PARTICIPANTS EXPERIENCING TREATMENT EMERGENT ADVERSE EVENTS (TEAES),"A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects"
NCT04532372,Recruiting,Interventional,Phase 1/Phase 2,City of Hope Medical Center,Other,7-Jan-21,18-Sep-22,18-Sep-22,TREATMENT,30,HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEST PRACTICE,"INCIDENCE OF TOXICITY, GRADED ACCORDING TO THE NCI CTCAE VERSION 5",A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
NCT04532411,Completed,Observational,,Massachusetts General Hospital,Other,1-Mar-20,30-Sep-20,30-Sep-20,OTHER,28948,SARS-COV INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",PERSONAL PROTECTIVE TESTING BOOTH,CHANGE IN TESTING THROUGHPUT AFTER HEXAPOD IMPLEMENTATION,Evaluation of SARS-CoV-2 Sample Acquisition Efficiency and PPE Usage With and Without the Hexapod Personal Protective Booth
NCT04532554,Withdrawn,Interventional,Phase 4,ClinAmygate,Other,26-Oct-20,20-Dec-20,10-Dec-20,TREATMENT,0,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",GROWTH HORMONE,NEED FOR HOSPITALIZATION,The Impact of Growth Hormone in Obese Cases With Covid-19
NCT04532632,Completed,Observational [Patient Registry],,Pinar Ay Sayin,Other,1-Sep-20,9-Oct-20,1-Oct-20,OTHER,40,SMELL DISORDER,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,TASTE AND SMELL IMPAIRMENT,Taste and Smell Impairment in Critically Ill COVID-19 Patients
NCT04532931,Recruiting,Interventional,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,Industry,3-Sep-20,21-Oct-21,21-Jun-21,TREATMENT,250,COVID,SOUTH AFRICA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",STANDARD OF CARE (PARACETAMOL),INCIDENCE OF SARS-COV-2 CLEARANCE,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19"
NCT04533048,Completed,Interventional,Phase 1,"Mabwell (Shanghai) Bioscience Co., Ltd.",Industry,7-Aug-20,2-Dec-20,16-Nov-20,TREATMENT,42,COVID,CHINA,ALL,18 Years to 45 Years   (Adult),MW33 INJECTION,ADVERSE EVENT,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy Subjects"
NCT04533347,Recruiting,Interventional,Phase 2,60 Degrees Pharmaceuticals LLC,Industry,19-Feb-21,22-Jun-21,8-Jun-21,TREATMENT,275,COVID DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TAFENOQUINE ORAL TABLET,PROPORTION OF PATIENTS WITH CLINICAL RECOVERY OF COVID-19 SYMPTOMS ON DAY 14,A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease
NCT04533360,Enrolling by invitation,Observational [Patient Registry],,Kingman Regional Medical Center,Other,28-Sep-20,1-May-21,9-Oct-20,ECOLOGIC OR COMMUNITY,3000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VITROS ANTI-SARS-COV-2 IGG TEST,SEROPREVELENCE OF SARS-COV-2 ANTIBODIES AMONG ADULTS IN KINGMAN AZ,Seroprevalence of SARS CoV2 Antibodies Among Adults in Kingman AZ
NCT04533399,Recruiting,Interventional,Phase 2,Novavax,Industry,17-Aug-20,21-Nov-21,21-Nov-21,PREVENTION,4400,SARS-COV2 INFECTION,SOUTH AFRICA,ALL,"18 Years to 84 Years   (Adult, Older Adult)",SARS-COV-2 RS/MATRIX-M1 ADJUVANT,"COHORT 1: HIV- PARTICIPANTS WITH SYMPTOMATIC MILD, MODERATE, OR SEVERE COVID-19","A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV"
NCT04534400,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,1-Sep-20,15-Jan-21,15-Jan-21,COHORT,1000,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",THORACIC CT-SCAN,CORRELATION BETWEEN ALTERED PULMONARY VOLUME AND ORDINAL SEVERITY SCALE,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
NCT04534478,Not yet recruiting,Interventional,Phase 4,Hospital Universitari Vall d'Hebron Research Institute,Other,7-Sep-20,15-Dec-21,2-May-21,TREATMENT,120,COVID PNEUMONIA,,ALL,"18 Years and older   (Adult, Older Adult)",PREDNISONE,CHANGE IN PULMONARY DIFFUSION.,"Randomized, Open, Parallel, Single-center, Non-inferiority Clinical Trial, With an Active Control Group, Comparing Two Oral Prednisone Regimens With the Aim of Optimizing the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Infection"
NCT04534569,Completed,Observational,,NMC Specialty Hospital,Other,4-Sep-20,6-Oct-20,3-Oct-20,OTHER,40,COVID,UNITED ARAB EMIRATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",EXPERTS CONSENSUS,CONSENSUS USING PARTICIPATING EXPERTS OPINIONS.,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF) Using Modified Delphi Methodology
NCT04534595,Recruiting,Observational,,Unity Health Toronto,Other,30-Apr-19,21-Mar-21,21-Mar-21,CASE-ONLY,1500,COVID EXPERIENCE,CANADA,ALL,4 Years to 13 Years   (Child),COVID-19,DIRECT EXPERIENCE WITH COVID-19 VIRUS,Data Collection on the Model Schools Pediatric Health Initiative at 5 School Based Health Clinic (SBHC) Sites: COVID-19 Questionnaire
NCT04534608,"Active, not recruiting",Observational,,Universitätsklinikum Hamburg-Eppendorf,Other,11-May-20,31-Mar-21,30-Jun-20,FAMILY-BASED,6000,SARS-COV2,GERMANY,ALL,"up to 18 Years   (Child, Adult)",,ACUTE INFECTION BY SARS-COV-2,Prevalence of Infection and Seroconversion and the Clinical Course of the Novel Coronavirus SARS-CoV-2 Infection in Children Between 0 to 18 Years of Age in Hamburg and Surroundings
NCT04534621,Not yet recruiting,Observational,,Trate - Tratamentos Especializados,Other,26-Aug-20,18-Sep-20,6-Sep-20,OTHER,948,COVID,,ALL,"Child, Adult, Older Adult",ELECTRONIC SURVEY,"WHAT MEASURES HAVE BEEN IMPLEMENTED TO AVOID SARS-COV2 TRANSMISSION WHEN TAKING CARE OF PATIENTS, DURING THE COVID-19 PANDEMIC.",How Brazilian Chiropractors Are Being Affected and What Strategies They Have Developed for Facing the COVID-19 Pandemic
NCT04534673,Recruiting,Interventional,Phase 2,Soroka University Medical Center,Other,5-Aug-20,31-Dec-21,31-Dec-21,TREATMENT,40,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",LAMBDA 180 MCG S.C,VIRAL SHEDDING IN DAYS SINCE INITIAL DIAGNOSIS,Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial
NCT04534712,Not yet recruiting,Observational,,Postgraduate Institute of Medical Education and Research,Other,1-Sep-20,1-Feb-21,1-Dec-20,COHORT,100,COVID,INDIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LYMPHOCYTE MONOCYTE RATIO,PROGRESSION,Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19
NCT04534725,Recruiting,Interventional,Phase 3,"Peter MacCallum Cancer Centre, Australia",Other,17-Dec-20,21-Dec-21,21-Dec-21,TREATMENT,2282,CANCER,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON ALFA,INCIDENCE OF COVID-19 IN CANCER PATIENTS USING INTERFERON-ALPHA AS PROPHYLAXIS WITHOUT KNOWN POSITIVE CONTACT WITH COVID-19 (COVID-19 CONFIRMED BY QPCR FROM RESPIRATORY SWAB),COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.
NCT04534790,Completed,Interventional,Not Applicable,Instituto Mexicano del Seguro Social,Other,24-Jul-20,8-Jan-21,12-Dec-20,TREATMENT,30,COVID PNEUMONIA,MEXICO,ALL,"18 Years to 100 Years   (Adult, Older Adult)",LOW DOSE RADIOTHERAPY,CLINICAL IMPROVEMENT,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia"
NCT04534803,Not yet recruiting,Interventional,Phase 3,Harvard Medical School,Other,1-Sep-21,30-Nov-22,30-Oct-22,PREVENTION,2100,COVID,,ALL,70 Years and older   (Older Adult),BCG VACCINE,TO ASSESS THE EFFICACY OF BCG VACCINATION COMPARED TO PLACEBO IN REDUCING SEVERE COVID-19 DISEASE AMONG ELDERLY RESIDENTS OF SKILLED NURSING FACILITIES.,Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial
NCT04535063,Recruiting,Interventional,Phase 3,Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno,Other,18-Apr-20,25-Feb-21,30-Dec-20,TREATMENT,200,COVID PNEUMONIA,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",COVID19 CONVALESCENT PLASMA INFUSION,28 DAYS SURVIVAL,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
NCT04535128,Recruiting,Observational [Patient Registry],,Brigham and Women's Hospital,Other,24-Mar-20,30-Mar-21,31-Dec-20,COHORT,10000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,FREQUENCY OF ARTERIAL OR VENOUS THROMBOEMBOLISM OVER 30 DAYS,"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications (CORONA-VTE NETWORK)"
NCT04535154,"Active, not recruiting",Observational,,"University Hospital, Akershus",Other,31-Mar-20,1-Jun-22,1-Jun-21,COHORT,264,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTIONS,FORCED VITAL CAPACITY,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19
NCT04535167,Recruiting,Interventional,Phase 1,Pfizer,Industry,9-Sep-20,5-Jul-21,5-Jul-21,TREATMENT,72,VIRAL DISEASE,UNITED STATES,ALL,"18 Years to 79 Years   (Adult, Older Adult)",PF-07304814,FREQUENCY OF TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),"A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND EXTENDED (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19"
NCT04535297,Completed,Observational,,University of Haifa,Other,10-May-20,30-Jun-20,30-May-20,CASE-ONLY,198,PARKINSON DISEASE,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",EXPOSURE,PATIENT ACTIVATION MEASURE (PAM®),Consequences of the COVID-19 Lockdown on Health and Well-being of Patients With Parkinson Disease and Post-stroke
NCT04535674,Recruiting,Interventional,Phase 2,Apogenix AG,Industry,9-Oct-20,21-May-21,21-Feb-21,TREATMENT,400,COVID INDUCED PNEUMONIA,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",ASUNERCEPT,TIME TO SUSTAINED IMPROVEMENT OF ONE CATEGORY (I.E. TWO CONSECUTIVE DAYS) FROM RANDOMISATION,"A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease"
NCT04535700,Recruiting,Interventional,Phase 4,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,Other,18-Sep-20,10-Apr-21,10-Mar-21,TREATMENT,76,TYPE 2 DIABETES,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PIOGLITAZONE 30 MG,"PATIENTS TREATED WITH PIOGLITAZONE, TOGETHER WITH CONVENTIONAL TREATMENT FOR COVID-19 INFECTION, WHO DURING THEIR ADMISSION EVOLVE TOWARDS THE NEED TO RECEIVE SUPPORT WITH MECHANICAL VENTILATION, ENTER THE ICU AND / OR DIE.","Non-blinded, Randomized and Controlled Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19"
NCT04535778,Recruiting,Interventional,Not Applicable,King's College London,Other,16-Nov-20,1-Jun-21,1-Jun-21,TREATMENT,200,TREATMENT OF ILLNESS-RELATED DISTRESS IN PHYSICAL LTCS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",COMPASS,CHANGE IN PATIENT HEALTH QUESTIONNAIRE ANXIETY AND DEPRESSION SCALE (PHQ-ADS),Pilot RCT for COMPASS: an Online CBT Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic.
NCT04535791,Recruiting,Interventional,Phase 3,"Coordinación de Investigación en Salud, Mexico",Other,15-Jul-20,21-Jul-21,21-May-21,TREATMENT,400,COVID,MEXICO,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CHOLECALCIFEROL,NUMBER OF PARTICIPANTS WITH COVID-19,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial
NCT04535856,Completed,Interventional,Phase 1,Ina-Respond,Other,14-Nov-20,14-Jan-21,14-Jan-21,TREATMENT,9,COVID,INDONESIA,ALL,"19 Years and older   (Adult, Older Adult)",ALLOGENEIC MESENCHYMAL STEM CELL,INCIDENCE OF TEAE* IN TREATMENT GROUP,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled"
NCT04535869,Recruiting,Interventional,Phase 3,Mansoura University,Other,28-Dec-20,3-Sep-21,1-Apr-21,TREATMENT,50,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SOFOSBUVIR 400 MG PLUS DACLATASVIR 200MG,RATE OF VIROLOGICAL CURE BY RT -PCR FOR COVID -19USING THE TRIPLE THERAPY AS COMPARED TO STANDARD TREATMENT,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)
NCT04536051,Recruiting,Interventional,Phase 3,University of Oxford,Other,2-Jun-20,21-Sep-21,21-Sep-21,PREVENTION,10300,CORONAVIRUS,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CHADOX1 NCOV-19 SINGLE DOSE + PARACETAMOL,EVALUATE THE EFFICACY OF CHADOX1 NCOV-19 VACCINE AGAINST COVID-19 DISEASE CONFIRMED WITH PCR,"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine"
NCT04536090,Not yet recruiting,Interventional,Phase 2,Institut de Recherches Cliniques de Montreal,Other,20-Nov-21,21-May-21,21-Apr-21,TREATMENT,150,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ISOQUERCETIN (IQC-950AN),DISEASE PROGRESSION,An Open-Label Randomized Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of 2019 Novel Coronavirus Disease (COVID-19)
NCT04536285,Completed,Observational,,Ain Shams University,Other,1-May-20,31-Aug-20,31-Aug-20,CASE-ONLY,36,TYPE 1 DIABETES,EGYPT,ALL,"1 Year to 18 Years   (Child, Adult)",,CLINICAL CHARACTERISTIC OF PEDIATRIC AND ADOLESCENT PATIENTS WITH TYPE 1 DIABETES HOSPITALIZED WITH COVID -19.,Clinical Characteristics and Outcome of Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic: Data From a Single Center Surveillance Study in Egypt
NCT04536298,Recruiting,Interventional,Phase 3,Brigham and Women's Hospital,Other,28-Dec-20,30-Apr-21,30-Apr-21,TREATMENT,2700,COVID,UNITED STATES,ALL,"30 Years and older   (Adult, Older Adult)",VITAMIN D,HOSPITALIZATION OR DEATH IN INDEX CASES,"A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members"
NCT04536350,Not yet recruiting,Interventional,Phase 1,Prof. Dr. Jörg Leuppi,Other,21-Jan-21,22-Mar-21,21-Dec-21,TREATMENT,80,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",AVIPTADIL 67ΜG,TIME TO CLINICAL IMPROVEMENT,"Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS: a Randomized, Placebo Controlled, Multicenter Trial"
NCT04536363,Not yet recruiting,Interventional,Phase 2,Alonso Vera Torres,Other,1-Oct-20,1-Mar-21,1-Dec-20,TREATMENT,284,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","ANALOGS, PROSTAGLANDIN E1",MORTALITY,Effectiveness and Safety of the Administration of Intravenous Prostaglandin E1 Analog in the Reduction of Mortality and Complications of Patients With COVID-19
NCT04536376,Recruiting,Interventional,Not Applicable,Mayo Clinic,Other,15-Jan-21,31-Dec-21,2-Aug-21,SUPPORTIVE CARE,10,RESILIENCE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RESILIENCE PROGRAM,CHANGES IN BIOMETRIC TRENDS,First Responder Resiliency Program for Health Care Professionals During a Pandemic
NCT04536441,Completed,Interventional,Not Applicable,Universiti Tunku Abdul Rahman,Other,1-Apr-20,30-Jun-20,30-May-20,PREVENTION,161,MENTAL HEALTH WELLNESS,MALAYSIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ULTRA BRIEF ONLINE MINDFULNESS-BASED INTERVENTION,CHANGES OF SUBJECTIVE UNIT OF DISTRESS,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial
NCT04536935,Enrolling by invitation,Interventional,Not Applicable,University of Washington,Other,21-Jan-21,21-Feb-21,21-Feb-21,TREATMENT,2000,DEPRESSION,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",MOBILE MENTAL HEALTH APP - 1,PATIENT HEALTH QUESTIONNAIRE (PHQ-9),"Acceptability, Usability and Effectiveness of Mental Health Apps for Suicide Prevention in Essential Workers and the Unemployed During SARS-CoV-2"
NCT04537117,Completed,Observational,,Fayoum University,Other,20-Apr-20,5-May-20,5-May-20,OTHER,202,COVID,EGYPT,ALL,"Child, Adult, Older Adult",QUESTIONAIRE,RESPONSES,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19"
NCT04537130,Not yet recruiting,Interventional,Phase 1,Instituto Oncológico Dr Rosell,Other,1-Dec-20,22-Jun-21,21-Jun-21,TREATMENT,40,PULMONARY FIBROSIS,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",IN01 VACCINE,SAFETY (FREQUENCY/SEVERITY OF AES),Phase Ib Controlled Exploratory Trial for Treatment of Fibrosing Interstitial Lung Disease Patients Secondary to SARS-CoV-2 Infection With IN01 Vaccine (COVINVAC)
NCT04537208,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Sanofi Pasteur, a Sanofi Company",Industry,3-Sep-20,21-Nov-21,21-Nov-21,PREVENTION,440,COVID (HEALTHY VOLUNTEERS),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 VACCINE FORMULATION 1 WITH ADJUVANT 1,NEUTRALIZING ANTIBODY TITER AT DAY 1,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older
NCT04537299,Not yet recruiting,Interventional,Phase 2,Mayo Clinic,Other,21-Feb-21,23-Dec-21,23-Dec-21,TREATMENT,150,COVID,UNITED STATES,ALL,65 Years and older   (Older Adult),FISETIN,CHANGE IN COVID-19 SEVERITY,COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes
NCT04537338,Not yet recruiting,Observational,,Agencia Costarricense de Investigaciones Biomedicas,Other,14-Sep-20,14-Sep-22,14-Sep-22,CASE-CONTROL,2000,COVID,,ALL,"6 Months to 100 Years   (Child, Adult, Older Adult)",1. CHARACTERIZE THE IMMUNE RESPONSE AFTER INFECTION WITH SARS-COV-2,COVID-19 SEROCONVERSION,Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica
NCT04537351,Recruiting,Interventional,Phase 1/Phase 2,Cynata Therapeutics Limited,Industry,24-Aug-20,31-Mar-21,31-Mar-21,TREATMENT,24,COVID,AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",CYP-001,TREND IN TRAJECTORY OF PAO2/FIO2 RATIO (P/F RATIO) BETWEEN GROUPS,"A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19"
NCT04537559,Enrolling by invitation,Observational,,"University Hospital, Geneva",Other,1-Mar-20,31-Oct-20,31-Jul-20,COHORT,40000,COVID,SWITZERLAND,ALL,"16 Years and older   (Child, Adult, Older Adult)",,INTRA-HOSPITAL MORTALITY,Impact of the COVID-19 Pandemic on the Morbidity and Mortality of Non-COVID-19 Patients Hospitalized Around the Epidemic Peak in the Geneva Area (Switzerland) (No COVID Impact)
NCT04537572,Not yet recruiting,Interventional,Not Applicable,Salveo Diagnostics,Industry,20-Sep-21,22-Sep-21,22-Sep-21,DIAGNOSTIC,300,COVID,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",COMPARISON OF SAMPLE COLLECTION METHODS,"LABORATORY DETERMINATION OF PRESENCE OF ANTI-SARS-COV2 ANTIBODIES (IGM, IGA, AND IGG)",A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing
NCT04537585,Not yet recruiting,Interventional,Not Applicable,"Guyguy K Tshima, MD",Other,20-Nov-21,22-Dec-21,22-Nov-21,PREVENTION,2000,COVID,"CONGO, THE DEMOCRATIC REPUBLIC OF THE",ALL,"15 Years to 65 Years   (Child, Adult, Older Adult)",TOMEKA®,NUMBER OF PARTICIPANTS WITH TREATMENT-TOMEKA® USAGE,"A Multi-center, Investigator-blinded, Randomized Clinical Trial, 18-months, Parallel-group to Compare the Efficacy of Tomeka® Foods Versus Vernonia Amygdalina in the Prevention and Maintenance of Remission of COVID-19 in DRC"
NCT04537650,Enrolling by invitation,Observational,,"University Health Network, Toronto",Other,1-Jan-21,31-Dec-21,31-Aug-21,COHORT,75,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VIDEOFLUOROSCOPIC SWALLOWING STUDY (VFSS),SWALLOWING SAFETY,The Pathophysiology of Swallowing Impairment in People Recovering From COVID-19
NCT04537663,Recruiting,Interventional,Phase 4,UMC Utrecht,Other,25-Aug-20,21-Apr-21,20-Nov-21,PREVENTION,5200,RESPIRATORY TRACT INFECTIONS,NETHERLANDS,ALL,"60 Years and older   (Adult, Older Adult)",BACILLE CALMETTE-GUÉRIN (BCG),"THE TRIAL HAS AN ADAPTIVE PRIMARY ENDPOINT. BASED ON PREDEFINED OBJECTIVE AND QUANTITATIVE CRITERIA THE PRIMARY ENDPOINT WILL BE EITHER A CLINICALLY RELEVANT RESPIRATORY TRACT INFECTION, OR COVID-19.",Bacillus Calmette-Guérin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial
NCT04537806,Recruiting,Interventional,Phase 3,Sage Therapeutics,Industry,18-Dec-20,21-Oct-21,21-Oct-21,TREATMENT,100,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BREXANOLONE,PERCENTAGE OF PARTICIPANTS WHO ARE ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 28,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
NCT04537858,"Active, not recruiting",Interventional,Not Applicable,University of Sao Paulo,Other,18-Jun-20,1-Dec-20,20-Aug-20,TREATMENT,50,COVID,BRAZIL,ALL,"20 Years to 80 Years   (Adult, Older Adult)",VIRTUAL REALITY THERAPY FIRST,HEART RATE VARIABILITY,Analysis of the Influence of Rehabilitation With Virtual Reality on the Heart Rate Variability of Individuals Under Treatment of COVID-19 in a Hospital Unit.
NCT04537949,"Active, not recruiting",Interventional,Phase 1/Phase 2,BioNTech SE,Industry,9-Sep-20,22-Feb-21,21-Mar-21,PREVENTION,96,COVID,GERMANY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BNT162B3,"SOLICITED LOCAL REACTIONS AT THE INJECTION SITE (PAIN/TENDERNESS, ERYTHEMA/REDNESS, INDURATION/SWELLING) RECORDED UP TO 7 DAYS AFTER EACH IMMUNIZATION.","A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults"
NCT04537962,Enrolling by invitation,Interventional,Not Applicable,Hospital Israelita Albert Einstein,Other,11-Jun-20,30-Aug-21,30-Sep-20,SUPPORTIVE CARE,70,CORONAVIRUS INFECTION,BRAZIL,ALL,"18 Years to 90 Years   (Adult, Older Adult)",COLGATE PERIOGARD MOUTHWASH,"VIRAL LOAD OF SARS-COV-2 IN THE ORAL MUCOSA, OROPHARYNX AND SALIVA OF HOSPITALIZED PATIENTS ALREADY CONSIDERED POSITIVE FOR THE VIRUS","Avaliação do Covid-19 na Cavidade Oral, Orofaringe e Saliva após desinfecção Com soluções Antimicrobianas Orais: Estudo Piloto."
NCT04537975,Withdrawn,Interventional,Not Applicable,SeaStar Medical,Industry,15-Sep-20,15-Jan-21,15-Nov-20,TREATMENT,0,CONTINUOUS RENAL REPLACEMENT THERAPY,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",C2RX,PULMONARY OXYGENATION FUNCTION,A Randomized Clinical Trial of CLR2.0 Hemofiltration Treatment (C2Rx) in Severe or Critically Ill Adults With COVID-19 Infection
NCT04538456,Recruiting,Observational,,The Christie NHS Foundation Trust,Other,15-Oct-20,21-Apr-21,21-Apr-21,COHORT,800,LUNG CANCER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE AND OPTIONAL INTERVIEW,PHYSICAL AND SOCIAL IMPACT,"Understanding the Physical, Social and Psychological Impact of COVID-19 on Frail and Shielded Lung Cancer Patients"
NCT04538469,Not yet recruiting,Observational,,University of Glasgow,Other,20-Sep-21,21-Dec-21,21-Dec-21,COHORT,1000,CARDIOVASCULAR DISEASES,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COVID VISITATION RESTRICTIONS,DURATION OF DELIRIUM,"Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff"
NCT04538586,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,1-May-20,1-Dec-25,1-Dec-20,COHORT,1000,COVID SCREENING,FRANCE,ALL,"16 Years and older   (Child, Adult, Older Adult)",,STRESS MEASURES,"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures"
NCT04539262,Recruiting,Interventional,Phase 1/Phase 2,Gilead Sciences,Industry,14-Sep-20,21-Apr-21,21-Mar-21,TREATMENT,152,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR (RDV),TIME-WEIGHTED AVERAGE CHANGE FROM BASELINE IN SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) VIRAL LOAD THROUGH DAY 7,"A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation"
NCT04539275,Recruiting,Interventional,Phase 3,VA Office of Research and Development,U.S. Fed,16-Nov-20,18-Jul-22,20-Jun-22,TREATMENT,702,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,PROPORTION OF PARTICIPANTS DEVELOPING ACUTE HYPOXEMIC RESPIRATORY FAILURE OR ALL-CAUSE DEATH,VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1)
NCT04539626,Not yet recruiting,Interventional,Not Applicable,"CMN ""20 de Noviembre""",Other,1-Oct-20,30-Mar-21,31-Dec-20,TREATMENT,60,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ESTROGEN THERAPY,CLINICAL IMPROVE TO ESTROGEN THERAPY IN NON-SEVERE COVID-19 PATIENTS CLINICAL IMPROVE TO ESTROGEN THERAPY IN NON-SEVERE COVID-19 PATIENTS,Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital
NCT04539795,Recruiting,Interventional,Phase 1/Phase 2,University of Alabama at Birmingham,Other,1-Nov-20,30-Sep-21,30-Sep-21,TREATMENT,15,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ALVELESTAT,NUMBERS AND % OF SUBJECTS WHO EXPERIENCE AT LEAST 1 TREATMENT-EMERGENT ADVERSE EVENT,"A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)"
NCT04539821,Recruiting,Interventional,Not Applicable,VA Office of Research and Development,U.S. Fed,1-Oct-20,30-Jun-21,31-Mar-21,HEALTH SERVICES RESEARCH,60,CHRONIC PAIN,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",VCPM,THE PERCENT OF PATIENTS WHO AGREE TO BUPRENORPHINE TRANSFER,Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond)
NCT04539834,"Active, not recruiting",Observational,,Zagazig University,Other,1-May-20,1-Oct-20,1-Aug-20,CASE-ONLY,52,ELECTROLYTE IMBALANCE,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ELECTROLYTES,ELECTROLYTES DISTURBANCES IN PATIENTS WITH COVID-19,Electrolyte State in Patients With COVID-19
NCT04539873,Not yet recruiting,Interventional,Phase 3,Fundación Universitaria de Ciencias de la Salud,Other,15-Mar-21,15-Sep-21,15-Jul-21,TREATMENT,128,CORONAVIRUS INFECTION,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE 0.5 MG,NUMBER OF PARTICIPANTS WHO DIE OR REQUIRE TRANSFER TO INTESIVE CARE UNIT,Impact of Colchicine in Hospitalized Colombian Patients With COVID-19
NCT04540029,Recruiting,Observational,,"IRCCS National Neurological Institute ""C. Mondino"" Foundation",Other,6-May-20,31-May-23,31-Oct-22,CASE-CONTROL,600,PRENATAL STRESS,ITALY,ALL,up to 12 Months   (Child),MATERNAL STRESS,INFANT NEGATIVE EMOTIONALITY,Measuring Outcomes of Maternal COVID-19-related Prenatal Exposure
NCT04540120,Recruiting,Interventional,Phase 2,Olatec Therapeutics LLC,Industry,25-Sep-20,21-Jul-21,21-Jun-21,TREATMENT,80,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",DAPANSUTRILE CAPSULES,PROPORTION OF SUBJECTS WITH CLINICAL DETERIORATION,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome"
NCT04540185,Enrolling by invitation,Interventional,Phase 3,"NeuroActiva, Inc.",Industry,1-Nov-20,31-Dec-22,1-Nov-22,PREVENTION,3600,COVID,NEW ZEALAND,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL: ORAL POLIO VACCINE,NUMBER OF PARTICIPANTS WITH A FIRST OCCURRENCE OF COVID-19 STARTING 14 DAYS AFTER SECOND DOSE OF OPV WITH OR WITHOUT NA-831,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19"
NCT04540393,Suspended,Interventional,Phase 3,AstraZeneca,Industry,2-Sep-20,11-May-21,11-May-21,PREVENTION,100,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 130 Years   (Adult, Older Adult)",AZD1222,INCIDENCE OF SAES FOLLOWING THE FIRST VACCINATION AND THROUGHOUT THE STUDY DURATION (DAY 180) [SAFETY AND TOLERABILITY].,"A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
NCT04540406,Recruiting,Interventional,Phase 2,Notitia Biotechnologies Company,Industry,8-Feb-21,1-Jun-21,1-May-21,TREATMENT,100,SUSPECTED OR CONFIRMED COVID,UNITED STATES,ALL,"18 Years to 69 Years   (Adult, Older Adult)",NBT-NM108,GUT MICROBIOTA COMPOSITION,Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes Mellitus
NCT04540419,"Active, not recruiting",Interventional,Phase 3,NPO Petrovax,Industry,11-Sep-20,31-Jul-21,30-May-21,PREVENTION,500,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 85 Years   (Adult, Older Adult)",RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),SUPERIORITY OF THE VACCINE AD5-NCOV TO PLACEBO BY THE LEVEL OF SEROCONVERSION,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers"
NCT04540484,Recruiting,Observational,,Advocate Health Care,Other,26-Aug-20,24-Sep-21,24-Sep-21,COHORT,900,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,IDENTIFYING POSITIVE COVID-19 IGG FORMATION,The Prevalence of SARS-CoV-2 IgG Antibody Formation in Physicians at Advocate Lutheran General Hospital and Their Household Members
NCT04540926,Not yet recruiting,Interventional,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,Other,20-Sep-21,30-Sep-20,20-Sep-21,TREATMENT,200,COVID PNEUMONIA,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",CYCLOSPORIN A,NUMBER OF DAYS TO CLINICAL IMPROVEMENT UNTIL HOSPITAL DISCHARGE OR DEATH.,"Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic"
NCT04540939,Recruiting,Interventional,Not Applicable,University of Michigan,Other,19-Oct-20,21-Dec-21,21-Dec-21,TREATMENT,60,TRAUMA,UNITED STATES,ALL,"18 Years to 72 Years   (Adult, Older Adult)",MINDFULNESS-BASED COGNITIVE THERAPY,PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS-ADULT SHORT FORM LEVEL 2) ANXIETY SURVEY,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy
NCT04541472,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,1-May-20,1-Dec-20,1-Dec-20,COHORT,1000,DENTAL SURGEON,FRANCE,ALL,"16 Years and older   (Child, Adult, Older Adult)",,STRESS MEASURES,Influence of the COVId-19 Pandemic on the STRESS of Dental Surgeons
NCT04541485,Not yet recruiting,Interventional,Phase 1,Daewoong Pharmaceutical Co. LTD.,Industry,6-Oct-20,29-Jan-21,20-Oct-20,TREATMENT,40,COVID PATIENTS,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",DWRX2003,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,"Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients"
NCT04541680,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,29-Oct-20,21-Dec-21,21-Mar-21,TREATMENT,250,SARS-COV2 INDUCED PULMONARY FIBROSIS,FRANCE,ALL,"18 Years to 89 Years   (Adult, Older Adult)",NINTEDANIB 150 MG [OFEV],THE PRIMARY OBJECTIVE IS TO ASSESS WHETHER NINTEDANIB SLOWS THE PROGRESSION OF LUNG FIBROSIS IN COVID-19 SURVIVORS AS ASSESSED BY THE DECLINE IN THE FORCED VITAL CAPACITY (FVC) OVER 12 MONTHS COMPARED TO PLACEBO.,"""Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"""
NCT04541979,Recruiting,Interventional,Phase 2,Region Skane,Other,4-Jun-20,1-Jun-21,1-May-21,TREATMENT,100,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",AEROSOLIZED DNASE,"TIME TO CESSATION OF OXYGEN THERAPY DNASE I TO THAT OF PLACEBO (NACL, 0.9%) ON TIME TO CESSATION OF OXYGEN THERAPY HOSPITALIZED PATIENTS WITH COVID-19 AND RESPIRATORY DYSFUNCTION.","Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study"
NCT04542031,Not yet recruiting,Interventional,Not Applicable,The Royal Wolverhampton Hospitals NHS Trust,Other,20-Oct-21,21-Oct-21,21-Oct-21,OTHER,7911,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PREVALENCE OF COVID 19,COVID-19 Prevalence in a Single Large UK Rheumatology Centre and the Impact on Quality of Life From Stringent Social Distancing
NCT04542044,Completed,Observational,,"University Hospital, Geneva",Other,2-Apr-20,30-Jun-20,5-May-20,COHORT,40,COVID,SWITZERLAND,ALL,"18 Years to 99 Years   (Adult, Older Adult)",MANAGEMENT STRATEGY OF OUTPATIENT WITH MILD TO MODERATE SARS-COV-2 PNEUMONIA,SECONDARY HOSPITALIZATION(S) OR DEATH COVID-19 RELATED,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia (PneumoCoV-Ambu)
NCT04542083,Not yet recruiting,Observational,,"University Hospital, Montpellier",Other,20-Jan-21,30-Jun-21,1-Jun-21,OTHER,4000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DAILY NUMBER OF ADMISSIONS FOR ACUTE CARDIO- AND NEURIVASCULAR CONDITIONS IN FRANCE.,Impact of COVID-19 on Unplanned Admissions for Acute Cardiovascular and Neurovascular Conditions in France
NCT04542122,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Caen",Other,3-Sep-20,2-Aug-21,30-Apr-21,OTHER,500,MORALS,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CHOICES AND JUDGEMENTS,OXFORD UTILITARIANISM SCALE,Moral Judgements and Choices of Caregivers in the Time of COVID-19 Pandemic: a Randomized Experimental Study
NCT04542200,Enrolling by invitation,Observational,,Northwell Health,Other,1-Jan-21,31-Dec-22,31-Dec-22,COHORT,70812,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTIBODY TESTING,COVID-19 ANTIBODIES,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment
NCT04542213,Recruiting,Interventional,Phase 3,Hospital Regional de Alta Especialidad del Bajio,Other,1-Aug-20,30-Sep-20,30-Sep-20,TREATMENT,28,HYPERGLYCEMIA,MEXICO,ALL,"18 Years to 75 Years   (Adult, Older Adult)",LINAGLIPTIN TABLET,GLUCOSE LEVELS,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
NCT04542226,Completed,Observational,,NPO Petrovax,Industry,31-Mar-20,30-Oct-20,15-Jul-20,COHORT,81,"INFECTIONS, CORONAVIRUS",BELARUS,ALL,"18 Years and older   (Adult, Older Adult)",POLYOXIDONIUM,CLINICAL STATUS OF THE PATIENT (ACCORDING TO 7-POINT ORDINAL SCALE),Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19
NCT04542330,Recruiting,Interventional,Phase 3,Bandim Health Project,Other,15-Sep-20,22-Mar-21,22-Jan-21,PREVENTION,1900,COVID,DENMARK,ALL,65 Years to 110 Years   (Older Adult),BCG-DENMARK,ACUTE INFECTION,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.
NCT04542343,Recruiting,Interventional,Not Applicable,Charles Drew University of Medicine and Science,Other,1-Nov-20,30-Sep-21,30-Sep-21,SUPPORTIVE CARE,265,CORONAVIRUS,UNITED STATES,ALL,65 Years and older   (Older Adult),"CHANGE IN KNOWLEDGE, MOTIVATION, SKILLS, RESOURCES",PERCENTAGE OF PARTICIPANTS ACHIEVING IMPROVEMENT OF HEALTH CONDITIONS USING THE SEVERITY OF MEDICAL CHRONIC CONDITIONS SURVEYS,"Multilevel, Multidisciplinary, Faith-Based Participatory Interventions to Reduce COVID-19 Related-Risks Among Underserved African Americans"
NCT04542395,Not yet recruiting,Interventional,Not Applicable,Charles Drew University of Medicine and Science,Other,1-Jun-21,30-Nov-22,30-Nov-22,SUPPORTIVE CARE,310,CORONAVIRUS,,ALL,"18 Years and older   (Adult, Older Adult)",INCREASING WILLINGNESS AND UPTAKE OF COVID-19 TESTING AND VACCINATION,"PREVALENCE OF COVID-19 TESTING, PNEUMOCOCCAL AND INFLUENZA VACCINATIONS USING TEST HISTORY SELF-REPORT",Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents
NCT04542408,Recruiting,Interventional,Phase 3,Universitätsklinikum Hamburg-Eppendorf,Other,12-Nov-20,30-Sep-21,31-May-21,TREATMENT,172,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ANTICOAGULATION AGENTS (EDOXABAN AND/OR HIGH DOSE LMWH),COMBINED ENDPOINT: ALL-CAUSE MORTALITY AND/ OR VENOUS THROMBOEM-BOLISM AND/ OR ARTERIAL THROMBOEMBOLISM,Hamburg Edoxaban for Anticoagulation in COVID-19 Study
NCT04542421,Recruiting,Interventional,Not Applicable,"University of Colorado, Denver",Other,1-Jul-20,1-Dec-21,1-Jul-21,HEALTH SERVICES RESEARCH,90,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",LUNG ULTRASOUND USE IN PATIENTS HOSPITALIZED WITH COVID,ADOPTION OF LUNG ULTRASOUND BY HOSPITALISTS CARING FOR PATIENTS WITH COVID,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19
NCT04542434,Not yet recruiting,Interventional,Phase 2,"First Wave Bio, Inc.",Industry,21-Jun-21,21-Dec-21,21-Oct-21,TREATMENT,148,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE ORAL TABLET,MORTALITY,"A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19"
NCT04542447,Recruiting,Interventional,Phase 1,Natureceuticals Sdn Bhd,Industry,1-Sep-20,30-Sep-20,30-Sep-20,TREATMENT,10,COVID,INDIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",NUVASTATIC,TO EVALUATE SAFETY AND EFFICACY NUVASTATIC™ (C5OSEW5050ESA),An Open Label Proof of Concept Study to Assess Aspects of Safety and Efficacy of Nuvastatic™ (C5OSEW5050ESA) as an Immunomodulator Adjuvant Therapy to the Standard Care of Treatment in Covid 19 Patients.
NCT04542512,Recruiting,Observational [Patient Registry],,Poissy-Saint Germain Hospital,Other,1-Oct-20,21-Sep-21,31-May-21,CASE-ONLY,800,"CHOLECYSTITIS, ACUTE",FRANCE,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,CORRELATION BETWEEN COVID-19 PNEUMONIA AND NECROTIC CHOLECYSTITIS,Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic: the ChoCO-WSES Prospective Multicenter Observational Study.
NCT04542694,Completed,Interventional,Phase 3,"Promomed, LLC",Other,21-May-20,20-Aug-20,10-Aug-20,TREATMENT,200,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FAVIPIRAVIR,RATE OF CLINICAL STATUS IMPROVEMENT,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19"
NCT04542850,Recruiting,Interventional,Not Applicable,Royal College of Surgeons in Ireland - Medical University of Bahrain,Other,15-Nov-20,15-Sep-21,15-Jun-21,TREATMENT,40,SARS-COV2,BAHRAIN,ALL,"21 Years to 70 Years   (Adult, Older Adult)",5-ALA-PHOSPHATE + SFC (5-ALA + SFC),THE INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS (SAFETY AND TOLERABILITY) OF 5-ALA-PHOSPATE + SFC IN PATIENTS WITH ACUTE MODERATE OR SEVERE RESPIRATORY ILLNESS SECONDARY TO INFECTION WITH SARS-COV-2 VIRUS (COVID-19).,"An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)"
NCT04542876,Completed,Interventional,Not Applicable,Aarogyam UK,Other,1-May-20,18-Aug-20,31-Jul-20,TREATMENT,46,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",GUDUCHI GHAN VATI,VIROLOGIC CLEARANCE,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study
NCT04542915,"Active, not recruiting",Observational,,American Dental Association,Other,29-Sep-20,21-Oct-21,21-Oct-21,ECOLOGIC OR COMMUNITY,4776,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,COVID-19 PROBABLE OR CONFIRMED CASE,COVID-19-Related Health and Practices Among Dental Hygienists
NCT04542941,Completed,Interventional,Not Applicable,Makerere University,Other,16-Jun-20,31-Dec-20,31-Dec-20,TREATMENT,136,COVID,UGANDA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COVID CONVALESCENT PLASMA,TIME TO VIRAL CLEARANCE (RT-PCR NEGATIVITY),Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial
NCT04542954,Completed,Observational [Patient Registry],,Hamid Al-Essa Organ Transplant Center,Other,1-Mar-20,31-Aug-20,31-Aug-20,COHORT,104,COVID,KUWAIT,ALL,"Child, Adult, Older Adult",OPTIMIZED MANAGEMENT OF COVID-19 POSITIVE KIDNEY TRANSPLANT RECIPIENTS: SINGLE CENTER EXPERIENCE FROM THE MIDDLE EAST,PATIENT OUTCOME,Renal Dysfunction Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19) Patients: Kuwait Experience
NCT04542967,Recruiting,Interventional,Phase 2,Hospital Central Militar,Other,23-Jun-20,30-Sep-20,2-Sep-20,TREATMENT,150,SEVERE COVID DISEASE,MEXICO,ALL,"18 Years to 90 Years   (Adult, Older Adult)",BIOLOGICAL,DISEASE PROGRESSION,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease
NCT04542980,Not yet recruiting,Observational,,Namida Lab,Industry,15-Sep-20,31-Dec-20,31-Dec-20,CASE-CONTROL,200,SARS-COV2 INFECTION,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",SARS-COV2 AUTOANTIBODY DETECTION,QUALITATIVE ASSESSMENT OF IGM AND/OR IGG BY INDIRECT ELISA ASSAY.,"Qualitative Evaluation of Tear Fluid and Blood for IgM and IgG Produced in Response to SARS-CoV2, the Virus Responsible for COVID-19."
NCT04542993,Recruiting,Interventional,Phase 2,Swedish Medical Center,Other,8-Sep-20,22-Jun-21,21-Sep-21,SUPPORTIVE CARE,60,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ZINC PICOLINATE,REDUCTION IN SARS-COV-2 VIRAL LOAD,"Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)"
NCT04543006,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Grenoble",Other,8-Sep-20,31-Dec-21,30-Sep-21,PREVENTION,170,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY,ANTI-SARS-COV-2 NEUTRALIZING ANTIBODY TITERS,Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
NCT04543760,Recruiting,Interventional,Not Applicable,"Hospital St. Joseph, Marseille, France",Other,1-Oct-20,21-May-21,21-Mar-21,OTHER,18,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITION,[PAO2 / FIO2] RATIO,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.
NCT04544033,Recruiting,Observational,,Tanta University,Other,15-Sep-20,21-Jan-21,20-Dec-21,CASE-ONLY,120,COVID,EGYPT,ALL,"Child, Adult, Older Adult",INTERLEUKEN 6 LEVEL MEASURMENT,INTERLEUKEN- 6 GENE (174G/C) SINGLE NUCLEOTIDE POLYMORPHISM,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients
NCT04544072,Recruiting,Observational,,Universitair Ziekenhuis Brussel,Other,1-May-20,1-Mar-21,1-Dec-20,COHORT,400,SARS-COV INFECTION,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,"TOTAL ANTIMICROBIAL CONSUMPTION FOR SUSPICION OF SECONDARY BACTERIAL RESPIRATORY INFECTIONS IN HOSPITALIZED PATIENTS IN COVID WARDS WITH A CLINICAL OR PCR-BASED COVID DIAGNOSIS, EXPRESSED AS 'DAILY DEFINED DOSES/HOSPITALIZATION'.",A Prospective Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards of a Tertiary University Hospital During the COVID-19 Pandemic
NCT04544150,Completed,Observational,,Assiut University,Other,1-Jun-20,1-Sep-20,1-Sep-20,CASE-ONLY,220,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,FREQUENCY OF GIT SYMPTOMS AMONG PATIENTS WITH COVID-19 INFECTION,Gastrointestinal Manifestations in COVID-19: Symptoms and Signs and Its Impact on the Outcome
NCT04544176,Completed,Observational,,Nottingham University Hospitals NHS Trust,Other,1-Jan-20,1-Jan-21,30-Jun-20,COHORT,48000,COVID,UNITED KINGDOM,ALL,"16 Years to 100 Years   (Child, Adult, Older Adult)",OBSERVATIONAL,A MICROBIOLOGICAL DIAGNOSIS OF COVID INFECTION.,Determining the Risk of Developing Symptomatic SARS-COV2-19 Infection After Attending Hospital for Radiological Examinations: a Controlled Cohort Study
NCT04544605,Recruiting,Observational,,Hong Kong Baptist University,Other,7-Sep-20,31-Dec-21,30-Sep-21,CASE-ONLY,150,POST COVID,CHINA,ALL,"Child, Adult, Older Adult",INDIVIDUALIZED-CHINESE HERBAL MEDICINE,CHANGE IN CM DIAGNOSTIC PATTERN & CLINICAL CHARACTERISTICS USING CM SYNDROME DIFFERENTIATION ASSESSMENT,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients: An Observational Study
NCT04544878,Recruiting,Observational [Patient Registry],,Bicetre Hospital,Other,26-Mar-20,1-Jun-21,1-Jun-21,COHORT,100,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,NUMBER OF PATIENT WITH SECONDARY INFECTION,Clinical and Biological Characteristics of Critically Ill Patients With COVID-19 Admitted to Pediatric Intensive Care Unit
NCT04544891,Not yet recruiting,Observational [Patient Registry],,"Central Hospital, Nancy, France",Other,1-Oct-20,1-Apr-23,1-Oct-22,COHORT,1000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,PROGNOSTIC VALUE OF THE TREM-1 PATHWAY ACTIVATION ON CLINICAL WORSENING,Prognostic Significance of the TREM-1 Pathway Activation in COVID-19
NCT04545008,Not yet recruiting,Interventional,Phase 1,Prisma Health-Upstate,Other,20-Sep-21,21-Aug-21,21-Mar-21,TREATMENT,42,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",FAMOTIDINE,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AS ASSESSED BY CTCAE V5.0,A Phase I Clinical Trial of the Combination of Famotidine (FAM) and Oral N-Acetyl Cysteine (NAC) Open Label for Outpatient Treatment of Subjects With Newly Diagnosed SARS-CoV-2 Infection
NCT04545047,"Active, not recruiting",Observational,,VA Office of Research and Development,U.S. Fed,1-May-20,30-Jun-22,31-Dec-21,OTHER,10000,CORONAVIRUS DISEASE 2019 (COVID),UNITED STATES,ALL,"21 Years to 80 Years   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,ALL-CAUSE MORTALITY,CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
NCT04545060,Recruiting,Interventional,Phase 2/Phase 3,"Vir Biotechnology, Inc.",Industry,27-Aug-20,21-Jul-21,21-Jan-21,TREATMENT,1360,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",VIR-7831,PROPORTION OF PARTICIPANTS WHO HAVE PROGRESSION OF COVID-19 THROUGH DAY 29,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients"
NCT04545242,Not yet recruiting,Interventional,Phase 4,Dr. Negrin University Hospital,Other,8-Feb-21,30-Dec-23,30-Sep-23,TREATMENT,980,ACUTE HYPOXEMIC RESPIRATORY FAILURE,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,60-DAY MORTALITY,Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)
NCT04545541,Recruiting,Interventional,Phase 2/Phase 3,Australian National University,Other,1-Nov-20,22-Jun-21,22-Apr-21,TREATMENT,300,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NEBULISED UNFRACTIONATED HEPARIN (UFH),ALIVE AND VENTILATOR FREE SCORE,Can Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT): Protocol for an Investigator-initiated International Meta-trial of Randomised Studies
NCT04545749,Recruiting,Interventional,Phase 1,"United Biomedical Inc., Asia",Industry,25-Sep-20,31-Aug-21,18-Jan-21,PREVENTION,60,COVID,TAIWAN,ALL,20 Years to 55 Years   (Adult),UB-612,SAFETY OF UB-612 VACCINE,"A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers"
NCT04546191,Completed,Observational [Patient Registry],,Landspitali University Hospital,Other,1-Jul-20,1-Sep-20,1-Sep-20,COHORT,1580,COVID,ICELAND,ALL,"18 Years and older   (Adult, Older Adult)",,SYMPTOMS,Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland
NCT04546581,"Active, not recruiting",Interventional,Phase 3,University of Minnesota,Other,8-Oct-20,21-Jul-21,21-Jul-21,TREATMENT,593,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",HYPERIMMUNE IMMUNOGLOBULIN TO SARS-COV-2 (HIVIG),ORDINAL OUTCOME SCALE - DAY 7,"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19"
NCT04546737,Recruiting,Interventional,Not Applicable,"Centre Hospitalier Universitaire, Amiens",Other,8-Sep-20,22-May-21,21-Jul-21,OTHER,20,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MAGNETIC RESONANCE SPECTROSCOPY (MRS).,VARIATION FROM BASELINE OF MRI RADIOLOGICAL SEMIOLOGY IN COVID-19 PATIENTS,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients"
NCT04546776,Enrolling by invitation,Observational,,Quadram Institute Bioscience,Other,8-Sep-20,22-Jun-21,22-Jun-21,COHORT,200,SARS-COV INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,"PREVALENCE AND PERSISTENCE OF THE SARS-COV-2 VIRUS IN THE FAECES, AND CHANGE IN ASSOCIATED HEALTH STATUS",Prevalence and Persistence of SARS-CoV-2 in Stool of COVID-19 Positive Subjects
NCT04546841,Recruiting,Interventional,Phase 1,University Hospital Tuebingen,Other,27-Nov-20,20-Dec-21,30-Sep-21,PREVENTION,36,COVID VACCINE,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",MULTIPEPTIDE COCKTAIL,SAFETY- EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) STATUS,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults
NCT04547114,Recruiting,Observational,,Klinikum Bayreuth GmbH,Industry,14-Sep-20,30-Apr-21,31-Dec-20,CASE-CONTROL,200,SARS-COV2 INFECTION,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",MULTICAPILLARY COLUMN COUPLED ION MOBILITY SPECTROMETRY,CORRECT CLASSIFICATION OF SARS-COV-2 INFECTED AND NOT INFECTED SUBJECTS,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects
NCT04547127,"Active, not recruiting",Interventional,Phase 2,"Instituto Grifols, S.A.",Industry,29-Apr-20,21-Mar-21,21-Feb-21,TREATMENT,200,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT ANTI-SARS-COV-2 MBT PLASMA,ALL-CAUSE MORTALITY RATE,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)"
NCT04547140,Recruiting,Interventional,Phase 2,Grifols Therapeutics LLC,Industry,29-Jan-21,21-Sep-21,21-Apr-21,TREATMENT,100,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",LIQUID ALPHA1-PROTEINASE INHIBITOR (HUMAN),PERCENTAGE OF PARTICIPANTS DYING OR REQUIRING ICU ADMISSION,"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19"
NCT04547218,Completed,Observational,,University of Malaya,Other,22-Jun-20,31-Dec-20,31-Dec-20,CASE-ONLY,150,AGE PROBLEM,MALAYSIA,ALL,65 Years and older   (Older Adult),,INCIDENCE OF ELECTIVE SURGERIES HAS POSTPONED DURING COVID-19 PANDEMIC IN GERIATRIC POPULATION,Study on Incidence of Elective Surgery Postponed During COVID-19 Pandemic in Geriatric Population
NCT04547257,Not yet recruiting,Interventional,Not Applicable,ExThera Medical Europe BV,Industry,1-Feb-21,15-Oct-21,15-Aug-21,TREATMENT,42,COVID,NETHERLANDS,ALL,"18 Years to 90 Years   (Adult, Older Adult)",SERAPH 100,CHANGE IN ORGAN FAILURE,Safety and Performance Evaluation of Seraph 100 Filter in the Treatment of Patients With COVID-19
NCT04547283,Recruiting,Interventional,Not Applicable,Atrium Health,Other,14-Jun-20,30-Sep-20,20-Sep-20,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",USUAL CARE,AVERAGE S/F RATIO,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial
NCT04547634,Enrolling by invitation,Interventional,Not Applicable,University of Malaga,Other,1-Jul-20,20-Dec-21,20-Nov-21,TREATMENT,30,CANCER METASTATIC,SPAIN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",THERAPEUTIC EXERCISE AND EDUCATION,SUITABILITY OF EXERCISE INTENSITY,Effect of a Telerehabilitation-exercise Intervention in Oncology Patients in the Covid-19 Pandemic
NCT04547660,Completed,Interventional,Phase 3,Hospital de Clinicas de Porto Alegre,Other,16-Jul-20,7-Jan-21,7-Jan-21,TREATMENT,160,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,CLINICAL IMPROVEMENT,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial"
NCT04548492,Not yet recruiting,Observational,,Ain Shams University,Other,14-Sep-20,21-Jan-21,20-Dec-21,CASE-CROSSOVER,175,THE USE OF MODERN TECHNOLOGY APPLICATIONS IN HOME ISOLATION,,ALL,"35 Years and older   (Adult, Older Adult)",SURVEY,RATE OF REASSURANCE DELIVERED FROM DOCTORS TO PATIENTS THROUGH WHATSAPP,The Validity of Modern Mobile Applications in Management of COVID-19 Home Isolation Patients: a Randomized Survey for Health Care Professionals
NCT04548505,Not yet recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,20-Oct-21,23-Mar-21,23-Mar-21,COHORT,100,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,MAGNITUDE OF THE DECREASE IN AEROBIC PERFORMANCE ON RETURN TO WORK,Recovery of Exertion Ability Following COVID-19 Infection in Military Staff
NCT04548531,Enrolling by invitation,Interventional,Not Applicable,Massachusetts General Hospital,Other,10-Sep-20,30-May-21,30-Apr-21,HEALTH SERVICES RESEARCH,800,COLON CANCER,UNITED STATES,ALL,"45 Years to 75 Years   (Adult, Older Adult)",SHARED DECISION MAKING,SHARED DECISION MAKING (SDM) PROCESS SCALE SCORE,Engaging Patients in Colon Cancer Screening Decisions During COVID-19
NCT04548544,Completed,Interventional,Not Applicable,"University of California, San Francisco",Other,18-Oct-19,20-May-20,20-May-20,BASIC SCIENCE,21,HEALTHY,UNITED STATES,ALL,"14 Years to 18 Years   (Child, Adult)","TRAINING FOR AWARENESS, RESILIENCE, AND ACTION (TARA)",CHANGE IN EMOTIONAL PROBLEMS,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic
NCT04548557,Not yet recruiting,Interventional,Phase 3,University of Health Sciences Lahore,Other,15-Sep-20,15-Nov-20,15-Oct-20,TREATMENT,60,COVID,PAKISTAN,ALL,"18 Years to 90 Years   (Adult, Older Adult)",INTRAVENOUS IMMUNOGLOBULIN THERAPY,IN HOSPITAL DAYS,Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial
NCT04548895,Recruiting,Observational,,"Health Stream Analytics, LLC",Industry,30-Dec-20,26-Oct-21,30-Jun-21,ECOLOGIC OR COMMUNITY,30,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",OBSERVATIONAL MEASUREMENT OF BIOMETRIC DATA. NO CHANGE TO HEALTH CARE PROVIDED.,PROPORTION OF QUALITY SIGNALS OBTAINED OUT OF ALL MONITORING TIME FOR EACH DEVICE,Non-invasive Biometric Monitoring for the Prevention of COVID-19 Transmission and Deaths in Nursing Homes
NCT04548908,Recruiting,Observational,,Centre Hospitalier Sud Essonne,Other,3-Aug-20,30-Jun-21,30-Apr-21,COHORT,1300,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","SERELOGY TESTING, RT PCR",GENERAL PREVALENCE OF COVID-19,Prevalence Of COVID-19 Among Health-workers in a French General Hospital
NCT04548934,Completed,Interventional,Not Applicable,Institute of Mountain Emergency Medicine,Other,13-Sep-20,31-Jan-21,31-Oct-20,TREATMENT,34,CARDIOPULMONARY RESUSCITATION,ITALY,ALL,18 Years to 60 Years   (Adult),PERSONAL PROTECTIVE EQUIPMENT (PPE),DEPTH OF CHEST COMPRESSION,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic
NCT04549337,Recruiting,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,25-Sep-20,1-May-21,1-May-21,PREVENTION,10,COVID,DENMARK,ALL,"40 Years and older   (Adult, Older Adult)",EXERCISE TRAINING,10-POINT LIKERT SCALE,Investigator-blinded Randomized Controlled Trial Examining the Safety and Feasibility of Different Exercise Training Programs in Patients Who Have Survived COVID-19
NCT04549350,Completed,Observational,,Zagazig University,Other,19-May-20,5-Sep-20,18-Aug-20,OTHER,217,SLEEP QUALITY,EGYPT,ALL,25 Years to 60 Years   (Adult),PSQI,PRESENCE OF POOR SLEEP QUALITY OR NOT,Sleep Quality Among Health Care Workers During COVID-19 Pandemic: Kuwait Experience
NCT04549376,Recruiting,Interventional,Phase 2,"Pi Research Consultancy Center, Bangladesh",Other,1-Jul-20,30-Oct-20,20-Oct-20,PREVENTION,200,COVID,BANGLADESH,ALL,"15 Years to 90 Years   (Child, Adult, Older Adult)",POVIDONE-IODINE 0.4% NI,PROPORTION OF COVID-19 POSITIVE CASES FOLLOWING INTERVENTION,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial
NCT04549636,Recruiting,Observational,,McMaster University,Other,18-Sep-20,21-Dec-21,21-Dec-21,COHORT,92,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",V/Q SPECT-CT,SHORT-TERM DIFFERENCE IN VENTILATION DEFECT PERCENT ASSESSED BY VENTILATION SPECT-CT - HEALTHY,Prospective Longitudinal Study to Characterize and Understand the Clinical Relevance of SARS-CoV2 Related Ventilation and Perfusion Injury Evaluated by V/Q SPECT-CT in an Asthmatic and Healthy Population
NCT04549831,Recruiting,Observational,,University of Siena,Other,8-Apr-20,8-Apr-26,8-Apr-21,CASE-CONTROL,2000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",MASSIVE PARALLEL SEQUENCING OF HOST GENOME,TO IDENTIFY THE GENETIC DETERMINANTS OF COVID-19 SEVERITY,Identification of the Genetic Bases Determining COVID-19 Clinical Variability in the Italian Population
NCT04549922,"Active, not recruiting",Interventional,Phase 2,Hospital do Coracao,Other,22-Oct-20,21-Dec-21,21-Feb-21,TREATMENT,111,COVID,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ISIS 721744,DAYS ALIVE WITHOUT RESPIRATORY SUPPORT (ANY SUPPLEMENTAL OXYGEN) AFTER 15 DAYS (DAFOR15),Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial
NCT04550312,Recruiting,Observational,,The First Affiliated Hospital with Nanjing Medical University,Other,20-Sep-21,20-Oct-21,20-Oct-21,OTHER,80000,LIFESTYLE ALTERATION,CHINA,ALL,"Child, Adult, Older Adult",,NUMERIC VALUES OF ALL-CAUSE DEATH AND THE DEATH RATES OF NON-COVID DISEASES,The Impact of Lifestyle Alteration by Strict Prevention Measures on Non-COVID Deaths in the Region With Low COVID-19 Transmission Rate
NCT04550325,Completed,Interventional,Phase 1/Phase 2,"Kamada, Ltd.",Industry,5-Aug-20,26-Nov-20,26-Nov-20,TREATMENT,12,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",KAMADA ANTI-SARS-COV-2,"ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, AND DEATHS","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia"
NCT04550338,Not yet recruiting,Interventional,Phase 3,University of Alabama at Birmingham,Other,1-Aug-21,31-Mar-23,31-Dec-22,PREVENTION,100,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",TRANEXAMIC ACID,CONVERSION FROM NEGATIVE TO POSITIVE COVID-19 TEST,Antiviral Effects of Tranexamic Acid (TXA) as a Preventative Treatment Following COVID-19 Exposure
NCT04550351,"Active, not recruiting",Interventional,Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",Industry,19-Aug-20,31-Dec-21,18-Dec-20,PREVENTION,50,CORONAVIRUS,CHINA,ALL,"60 Years and older   (Adult, Older Adult)",BIOLOGICAL/VACCINE: RECOMBINANT NEW CORONAVIRUS VACCINE (CHO CELL) LOW-DOSE GROUP,THE NUMBER OF ADVERSE EVENTS AFTER INTRAMUSCULAR INJECTION,"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above"
NCT04550390,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,15-Sep-20,15-Oct-20,15-Oct-20,COHORT,2400,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA COLLECTION,QUALITATIVE RESULT OF MOLECULAR TESTS FOR THE SARS-COV-2 VIRUS.,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19.
NCT04550403,Recruiting,Observational,,Azienda Ospedaliero-Universitaria di Parma,Other,30-Jul-20,31-Dec-21,30-May-21,COHORT,700,DIABETES MELLITUS,ITALY,ALL,"Child, Adult, Older Adult",,PREVALENCE OF INTENSIVE CARE UNIT ADMISSION AND/OR IN-HOSPITAL MORTALITY AMONG COVID-19 INPATIENTS,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes
NCT04551274,Not yet recruiting,Interventional,Not Applicable,Simon Fraser University,Other,1-Oct-20,30-Nov-20,30-Nov-20,SUPPORTIVE CARE,20,MOOD,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",MUSIC THERAPY,CHANGE IN PERCEIVED STRESS SCORE - NIH EMOTION TOOLBOX,Investigating the Use of Virtual Music Therapy in Frontline Healthcare Workers During COVID-19
NCT04551339,Enrolling by invitation,Interventional,Not Applicable,Mayo Clinic,Other,28-Sep-20,14-Sep-21,14-Jun-21,OTHER,4500,HEALTHY,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",PRESERVISION AREDS FORMULATION SOFT GELS OR TABLETS,COVID-19 ILLNESS REQUIRING HOSPITALIZATION,Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study
NCT04551378,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,13-Jul-20,31-Dec-21,31-Dec-21,COHORT,600,COVID INFECTION,UNITED STATES,ALL,18 Years to 39 Years   (Adult),QUALITY-OF-LIFE ASSESSMENT,CORONAVIRUS DISEASE 2019 (COVID-19) SPECIFIC PSYCHOLOGICAL STRESS,Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors
NCT04551547,Recruiting,Interventional,Phase 1/Phase 2,"Sinovac Research and Development Co., Ltd.",Industry,31-Oct-20,21-Sep-21,21-Feb-21,PREVENTION,552,COVID,CHINA,ALL,3 Years to 17 Years   (Child),"TWO DOSES OF LOW DOSAGE INACTIVATED SARS-COV-2 VACCINE AT THE SCHEDULE OF DAY 0,28",SAFETY INDEX-INCIDENCE OF ADVERSE REACTIONS,"A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years"
NCT04551690,Completed,Observational,,"Hospital San Juan de Dios, Santiago",Other,15-Apr-20,15-Jul-20,15-Jul-20,CASE-CONTROL,720,PREGNANCY,CHILE,FEMALE,18 Years to 45 Years   (Adult),,PREVALENCE OF SARS-COV-2 IN PREGNANT PATIENTS ON LABOR,"Analysis of Prevalence, Pregnancy Outcomes and Sociodemographic Conditions in Women at Labour With and Without Coronavirus 19 Disease COVID-19 in a Public Hospital in Chile"
NCT04551755,Not yet recruiting,Interventional,Phase 2,Bangladesh Medical Research Council (BMRC),Other,20-Sep-21,20-Dec-21,20-Nov-21,TREATMENT,188,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN AND DOXYCYCLINE,TIME TO OUTCOME MEASURE OF FEVER (<100.40F)AND COUGH,The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases: a Randomized Double Blind Placebo Controlled Trial
NCT04551768,Recruiting,Interventional,Phase 1,"Bausch Health Americas, Inc.",Industry,10-Feb-21,21-Jul-21,21-Jul-21,TREATMENT,50,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",50 MG/ML VIRAZOLE,CHANGE IN THE CLINICAL STATUS SEVERITY (CSS) RATING FROM THE FIRST DOSE DATE UP TO THE COMPLETION OF TREATMENT,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19"
NCT04551781,Completed,Interventional,Not Applicable,South Valley University,Other,1-Apr-20,30-Jul-20,30-Jul-20,TREATMENT,450,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",20 MG PREDNISONE FOR 14 DAYS,IMPROVED,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis
NCT04551898,Not yet recruiting,Interventional,Phase 2,BeiGene,Industry,30-Oct-20,28-Feb-21,31-Dec-20,TREATMENT,180,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",BGB-DXP593,CHANGE FROM BASELINE TO DAY 8 IN SARS-COV-2 VIRAL SHEDDING AS MEASURED BY REVERSE TRANSCRIPTION-QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR) IN NASOPHARYNGEAL SWAB SAMPLES,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19"
NCT04551911,Recruiting,Interventional,Phase 2,"OPKO Health, Inc.",Industry,26-Oct-20,21-Apr-21,21-Feb-21,TREATMENT,160,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RAYALDEE 30MCG EXTENDED-RELEASE (ER) CAPSULE,SEVERITY AND DURATION OF DISEASE AS EVIDENCED BY COVID-19 SYMPTOMS USING THE FLU-PRO© QUESTIONNAIRE.,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)"
NCT04552340,Recruiting,Observational,,Istituto Clinico Humanitas,Other,16-Mar-20,23-Jul-21,23-Mar-21,COHORT,1500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",PATIENT WITH SAR-COV-2 INFECTION,MORTALITY PREDICTORS IN PATIENTS WITH RESPIRATORY FAILURE WHO REQUIRE OXYGEN THERAPY IN THE INTENSIVE CARE UNIT OR VENTILATORY SUPPORT.,"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV: A Retrospective-Prospective Cohort Study."
NCT04552366,"Active, not recruiting",Interventional,Phase 1,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Other,29-Sep-20,30-Jun-21,31-Dec-20,PREVENTION,149,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",AD5-NCOV,INCIDENCE OF THE AE IN ALL GROUPS,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older
NCT04552379,Recruiting,Interventional,Phase 3,Pontificia Universidad Catolica de Chile,Other,1-Dec-20,21-Dec-21,21-Apr-21,TREATMENT,1240,SARS-COV INFECTION,CHILE,ALL,"18 Years to 79 Years   (Adult, Older Adult)",PEGINTERFERON BETA-1A,"THE PROPORTION OF INDEX CASES SHEDDING SARS-COV-2, AT DAY 11, IN THE ACTIVE ARM COMPARED TO THE STANDARD OF CARE ARM.",A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19)
NCT04552392,Not yet recruiting,Observational,,Dr. Ram Manohar Lohia Hospital,Other,20-Sep-20,20-Oct-20,20-Oct-20,CASE-ONLY,100,QUARANTINE,INDIA,ALL,18 Years to 60 Years   (Adult),NO INTERVENTION,DEPRESSION,Psychological Impact of Institutional Quarantine - A Cross-Sectional Observational Study
NCT04552483,Completed,Interventional,Phase 2,Universidade Federal do Rio de Janeiro,Other,8-Jun-20,5-Sep-20,20-Aug-20,TREATMENT,392,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE,DAYS WITH FEVER,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19
NCT04552951,Recruiting,Interventional,Phase 4,Fundación para la Investigación Biosanitaria del Principado de Asturias,Other,4-Apr-20,30-Dec-20,14-Sep-20,TREATMENT,80,COVID,SPAIN,ALL,"Child, Adult, Older Adult",CHOLECALCIFEROL,MORTALITY,Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias
NCT04553055,Completed,Observational [Patient Registry],,Beni-Suef University,Other,20-Jul-20,15-Sep-20,15-Sep-20,ECOLOGIC OR COMMUNITY,413,COVID,EGYPT,ALL,"20 Years and older   (Adult, Older Adult)",ONLINE QUESTIONNAIRES,ANTIBIOTIC MISUSE,Assessment of Community Pharmacies Related Antibiotic Misuse and Application of Infection Control Measures During COVID-19 Pandemic
NCT04553575,Recruiting,Observational [Patient Registry],,CHU de Reims,Other,25-Sep-20,22-Sep-21,22-Sep-21,COHORT,499,CORONAVIRUS INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",SEROLOGY,HEALTH STATUS IN THE 2 YEARS AFTER COVID-19 DIAGNOSIS,Follow-up CoViD-19 Patients Hospitalized in Reims University Hospital Between the 01/03/2020 and 30/04/2020
NCT04553705,Recruiting,Interventional,Phase 2/Phase 3,Beni-Suef University,Other,20-Sep-20,4-Dec-20,4-Nov-20,TREATMENT,200,COVID,SAUDI ARABIA,ALL,25 Years to 40 Years   (Adult),OMEGA 3/NIGELLA SATIVA OIL,CLINICAL IMPROVEMENT,Impact of Different Treatment Modalities on Immunity Against COVID-19
NCT04554251,Enrolling by invitation,Observational,,Assiut University,Other,1-Sep-20,30-Dec-20,1-Dec-20,COHORT,100,COVID,EGYPT,ALL,"Child, Adult, Older Adult",SURVEY,GLOBAL IMPACT OF COVID-19 ON BASELINE PATIENTS NUMBER,"Global Impact of COVID-19 on Pulmonology Special Units (Bronchoscopy, Thoracoscopy, Ultrasonography and Sleep Lab)"
NCT04554264,Recruiting,Interventional,Not Applicable,"Centre Hospitalier Universitaire, Amiens",Other,1-Sep-20,22-Sep-21,21-Sep-21,SUPPORTIVE CARE,160,COMPLICATED GRIEF,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PROPORTION OF COMPLICATED GRIEF 4 MONTH AFTER DEATH IN RELATIVE FROM PATIENTS WHO DIED IN ICU AFTER COVID-19 INFECTION EVALUATE WITH ICG SCORE.,Complicated Grief in ICU in the Aftermath of COVID-19
NCT04554433,Not yet recruiting,Interventional,Phase 3,Mansoura University,Other,1-Dec-20,1-Jun-22,1-Oct-21,TREATMENT,80,COVID,,ALL,20 Years to 60 Years   (Adult),ETHANOL WITH ASPRIN,DISINFECTION OF COVID-19 IN HUMAN RESPIRATORY TRACT .,Disinfection of SARS-COV-2 ( COVID-19 ) in Human Respiratory Tract by Controlled Ethanol Vapor Inhalation Combined With Oral Asprin .
NCT04554979,Completed,Observational,,Cairo University,Other,1-Jun-20,15-Jul-20,15-Jul-20,COHORT,199,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE PILL,COVID-19 DISEASE SPECTRUM AND DURATION,Corona Virus (COVID-19) Disease Duration and Gastrointestinal Tract (GIT) Manifestations; Can be New Disease Severity Classification. A Pilot Egyptian Single National Center Experience
NCT04554992,"Active, not recruiting",Interventional,Phase 1,The Methodist Hospital System,Other,20-Mar-20,22-Jun-21,22-Jun-21,TREATMENT,350,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID 19 CONVALESCENT PLASMA,CUMULATIVE INCIDENCE OF SERIOUS ADVERSE EVENTS RELATED TO THE TREATMENT INTERVENTION.,Convalescent Plasma for the Treatment of Coronavirus Disease 2019
NCT04555005,Completed,Interventional,Not Applicable,Instituto de Investigación Hospital Universitario La Paz,Other,10-Mar-20,26-Apr-20,26-Apr-20,SUPPORTIVE CARE,1000,MINDFULNESS,SPAIN,ALL,"Child, Adult, Older Adult",MINDFULNESS BASED INTERVENTION,PERCEIVED HELPFULNESS TO REDUCE CURRENT STRESS,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain"
NCT04555096,Recruiting,Interventional,Phase 2,"Galera Therapeutics, Inc.",Industry,9-Sep-20,21-Dec-21,21-Nov-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GC4419,28 DAY ALL-CAUSE MORTALITY,"A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)"
NCT04555109,Recruiting,Observational,,The Hospital for Sick Children,Other,30-Jun-20,31-Mar-22,30-Jun-21,COHORT,1000,COVID,CANADA,ALL,"17 Years to 65 Years   (Child, Adult, Older Adult)",,SEROPREVALENCE AND DURATION OF PROTECTIVE IMMUNITY,Convalescent Plasma for COVID-19 Research (CONCOR) Donor Study
NCT04555122,Not yet recruiting,Interventional,Not Applicable,"University of California, Irvine",Other,29-Sep-20,28-Jul-22,28-May-22,OTHER,52500,SOCIAL DISTANCE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SOCIAL DISTANCING ADVERTISEMENTS,MOBILITY,COVID-19 Ad Intervention for Social Distancing
NCT04555148,Recruiting,Interventional,Phase 2,Green Cross Corporation,Industry,20-Sep-20,21-Aug-21,30-Dec-20,TREATMENT,60,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",GC5131,ORDINAL SCALE OUTCOME,"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19"
NCT04555187,"Active, not recruiting",Observational,,Oregon Health and Science University,Other,8-Jun-20,21-Dec-21,21-Dec-21,COHORT,60000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER AND RATE OF PERSONS WITH CARDIOVASCULAR COMPOSITE OUTCOME,Cardiovascular Risk Stratification in Covid-19
NCT04555213,Recruiting,Interventional,Phase 1,Noxopharm Limited,Industry,30-Sep-20,21-Jun-21,21-Mar-21,TREATMENT,40,COVID,"MOLDOVA, REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",NOX66,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)
NCT04555954,Completed,Observational,,Pamukkale University,Other,11-Apr-20,20-Aug-20,31-Jul-20,OTHER,205,"HEALTH, SUBJECTIVE",TURKEY,ALL,"Child, Adult, Older Adult",SURVEYS AND QUESTIONNAIRES,PHYSICAL ACTIVITY LEVEL,"Determining the Physical Activity Level of Healthy Adults During Novel Coronavirus (COVID-19) (SARS-CoV-2 Infection) Pandemic: a Descriptive, Cross-sectional Study"
NCT04556149,Completed,Observational,,"Level 42 AI, Inc.",Industry,1-Oct-20,2-Dec-20,2-Dec-20,CASE-CONTROL,34,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",IMPULSE™ UNA E-STETHOSCOPE,DIAGNOSTIC PERFORMANCE CHARACTERISTICS,SARS-CoV-2/COVID-19 Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulse™ Una
NCT04556318,Recruiting,Observational,,B. Braun Melsungen AG,Industry,23-Sep-20,21-Mar-21,21-Mar-21,COHORT,392,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ION MOBILITY SPECTROMETRY (IMS),SARS-COV-2 RELATED VOLATILE ORGANIC COMPOUNDS (VOC),Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2
NCT04556513,Recruiting,Observational,,Centre Hospitalier Universitaire Dijon,Other,18-Sep-20,22-Nov-21,21-Dec-21,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PARACLINICAL EXAMINATION,RESPIRATORY SEQUELAE 6 MONTHS AFTER RESUSCITATION.,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
NCT04556565,Recruiting,Observational,,Jordi Alonso,Other,8-May-20,21-May-21,21-May-21,COHORT,16000,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,POST-TRAUMATIC STRESS DISORDER,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain
NCT04556604,Completed,Observational,,Medway Primary Care Trust,Other,10-Apr-20,14-Aug-20,14-Aug-20,ECOLOGIC OR COMMUNITY,45,CONSENT,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",EDUCATIONAL MEETINGS AND VISUAL PROMPTS,COMPLIANCE TO CONSENTING PRACTICE,Consent for Surgery During the COVID-19 Pandemic
NCT04556630,Not yet recruiting,Observational,,"University Hospital, Lille",Other,20-Oct-21,20-Dec-21,20-Dec-21,COHORT,360,ASSISTED REPRODUCTION,,ALL,"18 Years and older   (Adult, Older Adult)",,LEVEL OF ANXIETY AND/OR DEPRESSION OF MPA PATIENTS (MALE AND FEMALE COUPLES) BY HOSPITAL ANXIETY AND DEPRESSION SCALE (HAD) SCORE.,Evaluation of the Experience of Lock Down Related to the Covid-19 Epidemic and Its Impact on the Project of Parenthood of the Couples Followed in Assisted Reproduction
NCT04556864,Not yet recruiting,Observational,,Juan Victor Lorente,Other,1-Oct-20,1-Apr-21,30-Dec-20,COHORT,67,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,TOTAL AMOUNT OF HYPOTENSION,Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to SARS-CoV-2 Infection
NCT04557046,Recruiting,Interventional,Not Applicable,LumiraDx UK Limited,Industry,26-Jun-20,31-Dec-21,30-Nov-21,DIAGNOSTIC,400,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",NASAL SWAB,PERFORMANCE EVALUATION,A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag Test at Point of Care Testing Sites
NCT04557241,Completed,Interventional,Not Applicable,Indiana University,Other,14-Jan-20,31-Jan-21,14-Jan-21,PREVENTION,1017,COVID BEHAVIORAL PROPHYLAXIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BRIEF INFORMATIONAL INFOGRAPHIC,CHANGE IN TRUST IN SCIENCE,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis
NCT04557358,Enrolling by invitation,Observational,,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",Other,1-Oct-20,31-Dec-22,31-Dec-22,COHORT,346,RHEUMATOID ARTHRITIS,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 SURVEY,CHANGE IN THE PATTERN OF THE USUAL MEDICAL CARE AMONG THE RHEUMATIC DISEASE PATIENTS,Impact in the Medical Care Among the Rheumatic Diseases Patients in a Tertiary Hospital in México During the COVID-19 Pandemic
NCT04557605,Completed,Interventional,Not Applicable,University of Saskatchewan,Other,14-Sep-20,15-Oct-20,15-Oct-20,TREATMENT,14,HYPOXEMIA,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PROGRESSIVE CYCLING EXERCISE TEST TO EXHAUSTION,TIME TO EXHAUSTION DURING EXERCISE,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise
NCT04558021,Recruiting,Interventional,Phase 3,Imuneks Farma ilac San. Tic. A.S.,Industry,8-Oct-20,14-Feb-21,30-Jan-21,TREATMENT,200,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE SUSPENSION,PHYSICIAN'S JUDGMENT ON CLINICAL RECOVERY FROM THE TIME OF ADMISSION,"A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)"
NCT04558125,"Active, not recruiting",Interventional,Phase 4,Cedars-Sinai Medical Center,Other,8-Sep-20,30-Jun-22,31-Dec-21,TREATMENT,45,PULMONARY EMBOLISM,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",TNKASE,PERCENT IMPROVEMENT IN SHOCK INDEX (DEFINED AS HEART RATE DIVIDED BY SYSTOLIC BLOOD PRESSURE) 6 HOURS AFTER THE TNK/PLACEBO BOLUS.,"Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial"
NCT04558203,Recruiting,Observational [Patient Registry],,ClinAmygate,Other,22-Sep-20,30-May-21,25-May-21,COHORT,450,COVID,EGYPT,ALL,"Child, Adult, Older Adult",,INCIDENCE OF AUTOIMMUNE CONDITIONS,"The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice"
NCT04558307,Enrolling by invitation,Observational,,Mayo Clinic,Other,3-Jun-20,1-Dec-21,1-Jun-21,ECOLOGIC OR COMMUNITY,1000,CORONAVIRUS DISEASE (COVID),UNITED STATES,ALL,"Child, Adult, Older Adult",PILOT A RAPID SARS-COV-2 TESTING STRATEGY,INTERVENTION FEASIBILITY MEASURES - FQHC STAFF,Enhancing Rapid Health Response in National Crises: Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations Through Community-Academic Partnerships
NCT04558320,Recruiting,Observational,,University of Rochester,Other,2-Jul-20,1-Apr-21,1-Apr-21,COHORT,100,CORONAVIRUS INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",,MEAN CHANGE IN SARS-COV-2 VIRAL LOAD IN BREAST MILK,COVID-19 and Lactating Mothers
NCT04558372,Completed,Interventional,Not Applicable,Gadjah Mada University,Other,1-Apr-20,12-Dec-20,12-Dec-20,DIAGNOSTIC,1999,COVID,INDONESIA,ALL,"4 Years and older   (Child, Adult, Older Adult)",EXHALED BREATH SAMPLING,DIAGNOSTIC ACCURACY OF ELECTRONIC NOSE SIGNAL IN COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia
NCT04558385,"Active, not recruiting",Observational,,Lahore General Hospital,Other,1-Jul-20,15-Feb-21,15-Feb-21,CASE-ONLY,275,COVID,PAKISTAN,ALL,"Child, Adult, Older Adult",IGG SARS COV2,IGG SARS COV2,Seroconversion in COVID-19 Recovered Population: an Observational Study
NCT04558411,Recruiting,Interventional,Not Applicable,"Rutgers, The State University of New Jersey",Other,12-Sep-20,15-Dec-20,15-Dec-20,PREVENTION,150,EMOTIONAL REGULATION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIALECTICAL BEHAVIORAL THERAPY (DBT) SKILLS,DISTRESS,"Pilot Study of a Brief, Scaleable Intervention for COVID-19 Mental Health Sequelae in College Students"
NCT04558424,Not yet recruiting,Interventional,Not Applicable,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",Other,1-Oct-20,1-Sep-21,1-Sep-21,SUPPORTIVE CARE,50,COVID,BANGLADESH,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ZINC GLUCONATE AND ASCORBIC ACID,SYMPTOMS REDUCTION TIME FRAME,"Randomized, Double -Blind, Placebo Controlled, Trial to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU"
NCT04558437,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,12-Jun-20,31-Dec-20,31-Dec-20,COHORT,20000,POST TRAUMATIC STRESS DISORDER (PTSD),FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,"PREVALENCE OF PTSD AMONG APHP STAFF DURING THE COVID-19 EPIDEMIC AND AT A DISTANCE (INCLUSION, 3 MONTHS OR 6 MONTHS).",Prevalence and Development of Post-traumatic Stress Disorder and Anxiety and Depressive Symptoms Among AP-HP Staff During the Covid-19 Epidemic
NCT04558450,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Sep-21,1-Jun-32,22-Jun-21,DIAGNOSTIC,360,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CAROTID-FEMORAL PULSE-WAVE VELOCITY,PWV,Covid-19 Effects on ARTErial StIffness and Vascular AgiNg
NCT04558463,Recruiting,Interventional,Phase 3,Indonesia University,Other,16-Apr-20,30-Oct-20,30-Sep-20,TREATMENT,100,COVID,INDONESIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",FAVIPIRAVIR,CLINICAL RADIOLOGIC CHANGES,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial
NCT04558476,Recruiting,Interventional,Phase 2,University of Liege,Other,1-Sep-20,1-Sep-22,1-Sep-22,TREATMENT,500,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,VITAL STATUS,A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial
NCT04558645,Completed,Observational,,Gazi University,Other,18-Sep-20,26-Dec-20,18-Dec-20,CASE-CONTROL,118,TYPE 1 DIABETES MELLITUS,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ONLINE SURVEY,PHYSICAL ACTIVITY LEVEL,"Evaluation of Quality of Life, Physical Activity and Depression in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic"
NCT04558749,Recruiting,Observational,,Assiut University,Other,1-Oct-20,21-Jun-21,21-Apr-21,OTHER,150,COVID,EGYPT,FEMALE,"Child, Adult, Older Adult",STATE-TRAIT ANXIETY INVENTORY SCALE,THE MEAN SCORES ANXIETY AND DEPRESSION AMONG PREGNANT WOMEN DURING COVID-19 PANDEMIC,Assessment of Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic
NCT04558996,Recruiting,Observational [Patient Registry],,Puerta de Hierro University Hospital,Other,1-Mar-20,31-Mar-21,31-Dec-20,COHORT,3000,COVID,SPAIN,FEMALE,"18 Years and older   (Adult, Older Adult)",,MATERNAL COMPLICATIONS,REGISTRO EPIDEMIOLOGICO DE COVID 19 EN GESTANTES
NCT04559009,Recruiting,Observational [Patient Registry],,Atrium Health,Other,15-Oct-20,30-Apr-24,31-Dec-23,CASE-CONTROL,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 INCIDENCE AND PREVALENCE IN THE ALS POPULATION,COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
NCT04559035,Enrolling by invitation,Interventional,Not Applicable,Augusta University,Other,24-Sep-20,31-Dec-20,31-Dec-20,TREATMENT,200,COVID,UNITED STATES,ALL,"55 Years and older   (Adult, Older Adult)",NASAL LAVAGE,FREQUENCY,Nasal Irrigation to Reduce COVID-19 Morbidity
NCT04559074,Recruiting,Interventional,Phase 4,Queen Mary University of London,Other,23-Oct-20,31-Jul-21,30-Apr-21,TREATMENT,1000,HYPERTENSION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",AMLODIPINE,REDUCTIONS IN BLOOD PRESSURE IN PARTICIPANTS WITH PRIMARY HYPERTENSION AND INADEQUATE BP CONTROL BY UP-TITRATION OF AMLODIPINE IN 1-2 MG INCREMENTS.,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic
NCT04559100,Enrolling by invitation,Observational,,Fundacion Clinica Valle del Lili,Other,15-Nov-20,1-Oct-21,1-Oct-21,OTHER,112,COVID,COLOMBIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CHEST RADIOGRAPHY,LUNG FUNCTION,"Clinical, Radiological, Lung Function, and Quality of Life Characterization of Patients With Severe/Critical Infection by SARS-COV-2 (COVID-19) Virus, After 6 and 12 Months of Hospital Discharge"
NCT04559113,Recruiting,Interventional,Not Applicable,Lahore General Hospital,Other,1-May-20,30-Dec-20,30-Dec-20,TREATMENT,200,SARS-COV INFECTION,PAKISTAN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",METHYLPREDNISOLONE INJECTABLE PRODUCT,CLINICAL RESPONSE AFTER ADMINISTRATION,Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial
NCT04559542,Recruiting,Observational,,Norwegian School of Sport Sciences,Other,10-Sep-20,31-Dec-20,30-Nov-20,COHORT,200,BODY WEIGHT CHANGES,NORWAY,FEMALE,"16 Years to 40 Years   (Child, Adult)",,LOW ENERGY AVAILABILITY FOR FEMALES QUESTIONNAIRE (LEAF-Q),"Management of Body Weight Regulation, Symptoms of Low Energy Availability, Body Acceptance, Eating Disorders, and Sexual Harassment Among Female Martial Art Athletes, and Impact of COVID-19 on Training and Sport Participation"
NCT04560205,Recruiting,Interventional,Phase 1,Lahore General Hospital,Other,1-May-20,30-Dec-20,30-Dec-20,TREATMENT,50,SARS-COV INFECTION,PAKISTAN,ALL,"15 Years to 80 Years   (Child, Adult, Older Adult)",TOCILIZUMAB,CLINICAL RESPONSE AFTER ADMINISTRATION,Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19
NCT04560231,Recruiting,Interventional,Early Phase 1,Lahore General Hospital,Other,1-Jun-20,30-Nov-20,30-Nov-20,TREATMENT,30,SARS-COV INFECTION,PAKISTAN,ALL,"15 Years to 80 Years   (Child, Adult, Older Adult)",REMDESIVIR,CLINICAL RESPONSE AFTER ADMINISTRATION,Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study
NCT04560257,Recruiting,Interventional,Not Applicable,Lahore General Hospital,Other,1-May-20,30-Dec-20,30-Dec-20,TREATMENT,30,SARS-COV INFECTION,PAKISTAN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HIGH FLOW NASAL CANNULA HFNC,CLINICAL RESPONSE OF HFNC,Prone Positioning and High Flow Nasal Canula (HFNC) Therapy: A Game Changer in COVID-19 Outcome
NCT04560413,Completed,Observational,,Fatih Sultan Mehmet Training and Research Hospital,Other,1-Jun-20,10-Aug-20,25-Jul-20,OTHER,77,SARS-COV2,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,HOSPITAL ANXIETY AND DEPRESSION SCALE,"Depression, Anxiety and SARS-CoV-2 Phobia in Post-stroke Patients During SARS-CoV-2 Pandemic"
NCT04560530,Completed,Observational,,Tanta University,Other,1-Mar-20,1-Sep-20,30-Jul-20,COHORT,76,COVID,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",NON-ENHANCED CT SCAN OF THE CHEST,PNEUMONIA SEVERITY.,The Use of Preoperative CT Chest Scan in the Pre-anesthetic Assessment of COVID-19
NCT04560608,Recruiting,Observational [Patient Registry],,"University Hospital, Angers",Other,15-Mar-20,31-Jan-21,31-Jan-21,COHORT,255,COVID,FRANCE,ALL,70 Years and older   (Older Adult),,MEDICAL HISTORY AND CO-MORBIDITIES,"Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19"
NCT04560855,Recruiting,Observational,,Withings,Industry,14-Sep-20,14-Sep-21,14-Jun-21,COHORT,400,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CONNECTED DEVICES MEASUREMENTS,SENSITIVITY AND SPECIFICITY OF THE PATIENT'S AGGRAVATION WITH A LOGISTIC REGRESSION MODEL,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home
NCT04560881,"Active, not recruiting",Interventional,Phase 3,Laboratorio Elea Phoenix S.A.,Industry,16-Sep-20,1-Dec-21,1-Dec-21,PREVENTION,3000,COVID VIRUS INFECTION,ARGENTINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",INACTIVATED SARS-COV-2 VACCINE (VERO CELL),INCIDENCE OF COVID-19 CASES AFTER TWO-DOSES OF VACCINATION,"Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years"
NCT04561024,"Active, not recruiting",Observational,,"Ensemble Group Holdings, LLC",Industry,1-Mar-20,31-Dec-20,30-Oct-20,COHORT,4000,COVID,HONG KONG,ALL,"18 Years to 120 Years   (Adult, Older Adult)",AI MODEL,DIAGNOSTIC PERFORMANCE OF AI MODEL,Evaluation of a Chest X-Ray AI Neural Network (RadGen SARS-CoV2 Detection System) for the Detection of RT-PCR Confirmed SARS-Cov2 Covid-19 Pneumonia
NCT04561063,Recruiting,Interventional,Phase 2,"University of Witwatersrand, South Africa",Other,8-Dec-20,21-Jul-21,21-Jul-21,PREVENTION,1950,COVID,SOUTH AFRICA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",NITAZOXANIDE,NUMBER OF SARS-COV-2 INFECTIONS,"A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers at High Risk of Exposure to SARS-CoV-2"
NCT04561076,Not yet recruiting,Interventional,Phase 1,Hengenix Biotech Inc,Industry,9-Dec-20,18-Sep-21,6-Sep-21,OTHER,24,COVID,,ALL,18 Years to 60 Years   (Adult),HLX70,"NUMBER OF PARTICIPANTS WITH ADVERSE EVENTS, SERIOUS ADVERSE EVENT AND INFUSION-RELATED REACTIONS AS ASSESSED BY CTCAE V5.0","A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers"
NCT04561089,Enrolling by invitation,Observational,,"Illumina, Inc.",Industry,13-Feb-20,30-Apr-21,28-Feb-21,CASE-ONLY,2000,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVIDSEQ TEST,POSITIVE PERCENT AGREEMENT (PPA) AND NEGATIVE PERCENT AGREEMENT (NPA) BETWEEN THE COVIDSEQ TEST AND A COMPARATOR EUA TEST FOR THE DETECTION OF SARS-COV-2 RNA,Evaluation of the COVIDSeq Test in Saliva Specimens From Illumina Personnel
NCT04561102,Enrolling by invitation,Observational,,"Illumina, Inc.",Industry,11-Sep-20,30-Apr-21,28-Feb-21,CASE-ONLY,2500,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIAGNOSTIC TEST FOR DETECTION OF SARS-COV-2,POSITIVE PERCENT AGREEMENT (PPA) AND NEGATIVE PERCENT AGREEMENT (NPA) BETWEEN THE COVIDSEQ TEST AND A COMPARATOR EUA TEST FOR THE DETECTION OF SARS-COV-2 RNA,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From an Asymptomatic Population
NCT04561141,Not yet recruiting,Observational,,Assiut University,Other,1-Dec-20,1-Jan-22,1-Dec-21,OTHER,85,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,IDENTIFY POST COVID SYMPTOMS,Post Covid Syndrome: Clinical Pattern and Functional Assessment
NCT04561154,Recruiting,Interventional,Not Applicable,Centre Hospitalier le Mans,Other,11-Jun-20,11-Jun-22,11-Jun-21,OTHER,134,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,IDENTIFY FUNCTIONNAL AND PSYCHOSOCIAL COMPLAINTS,Identifying Functional and Psycho-social Complaints After Hospitalization for Severe SARS-CoV-2 Infection (COVID19)- REPERCOV
NCT04561180,Not yet recruiting,Interventional,Phase 2,"Evergreen Therapeutics, Inc.",Industry,21-Jun-21,21-Dec-21,21-Oct-21,TREATMENT,96,PNEUMONIA AS ONE OF THE LUNG COMPLICATIONS CAUSED BY SARS-COV2 INFECTION,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EG-HPCP-03A,THE PROPORTION OF PATIENTS ALIVE AND WITHOUT RESPIRATORY FAILURE,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia"
NCT04561193,Recruiting,Observational,,Methodist Health System,Other,30-May-20,21-May-21,20-Dec-21,COHORT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL,PREVALENCE OF SUBSEQUENT AND CO-INFECTIONS,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19)
NCT04561219,Completed,Interventional,Phase 2,Universidade Federal do Rio de Janeiro,Other,19-Apr-20,2-Oct-20,2-Oct-20,TREATMENT,500,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",NITAZOXANIDE,OROTRACHEAL INTUBATION RATE,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial"
NCT04562246,Recruiting,Observational,,Henry Ford Health System,Other,14-Aug-20,21-Aug-21,21-Aug-21,COHORT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGIC ASSAYS FOR ANTIBODIES TO SARS-COV-2,PREVALENCE OF ANTIBODIES TO SARS-COV-2,Laboratory Validation of SARS-CoV-2 IgG and IgM Serologic Assays on an Automated Immunoassay System
NCT04562285,Recruiting,Observational,,Henry Ford Health System,Other,23-Jun-20,21-Jun-21,21-Jun-21,COHORT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGIC IMMUNOASSAYS TO SARS-COV-2 ANTIBODIES,DETECTION OF ANTIBODIES TO SARS-COV-2 IN HUMAN SERUM AND PLASMA,Initial and Sustained Immunity to SARS-CoV-2 Measured by Serologic Assays on an Automated Immunoassay System
NCT04563065,Recruiting,Interventional,Not Applicable,Universidad Politecnica de Madrid,Other,1-Aug-20,31-Dec-23,30-Nov-20,PREVENTION,280,PREGNANCY COMPLICATIONS,SPAIN,FEMALE,18 Years to 50 Years   (Adult),EXERCISE PROGRAM,MATERNAL WEIGHT GAIN,"Active Pregnancy, Prevention Against the Effects of COVID-19"
NCT04563156,Enrolling by invitation,Observational,,University of Sao Paulo General Hospital,Other,23-Jun-20,31-Dec-21,30-Jun-21,COHORT,100,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",LUNG FUNCTION TEST,QUALITY OF LIFE ASSESSMENT OF A SURVIVOR OF SEVERE COVID-19 INFECTION 6 MONTHS AFTER HOSPITAL DISCHARGE;,Follow-up and Rehabilitation of Survivors of Severe Covid-19 Infection
NCT04563208,Recruiting,Interventional,Phase 2,"University of Witwatersrand, South Africa",Other,9-Dec-20,21-Mar-21,21-Feb-21,TREATMENT,40,COVID,SOUTH AFRICA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PLACEBO,RATE OF DECLINE IN VIRAL LOAD,"A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)"
NCT04563247,Completed,Observational,,Lahore General Hospital,Other,1-Jul-20,8-Feb-21,8-Feb-21,COHORT,970,COVID,PAKISTAN,ALL,20 Years to 60 Years   (Adult),IGG SARS COV 2 ANTIBODIES,SARS COV 2 IGG ANTIBODIES,Seroprevalence of SARS-CoV 2 Among Asymptomatic Frontline Healthcare Workers During COVID 19: A Cross Sectional Study
NCT04563442,Not yet recruiting,Observational [Patient Registry],,Assiut University,Other,15-Oct-20,25-Feb-23,15-Oct-22,CASE-CROSSOVER,200,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COMPLICATION,IDENTIFYING DIFFERENT CO-MORBIDITIES AND COMPLICATIONS OF COVID-19 INFECTION.,Comorbidities And Complications Associated With Covid-19 Infection
NCT04563650,Recruiting,Interventional,Not Applicable,"Centre Hospitalier Universitaire, Amiens",Other,18-Sep-20,21-Nov-21,21-May-21,SCREENING,330,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,TITERS OF COVID-19 NEUTRALISING ANTIBODIES,Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence
NCT04563676,Recruiting,Interventional,Not Applicable,"Centre Hospitalier Universitaire, Amiens",Other,22-Sep-20,21-Mar-21,21-Mar-21,SCREENING,400,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD TEST,8-HOUR CORTISOL LEVEL IN PATIENTS WITH COVID19 PNEUMONIA,Physiopathology and Sequelae of COVID-19 Infection
NCT04563689,Completed,Interventional,Not Applicable,Dentaid SL,Industry,18-Jun-20,23-Oct-20,22-Oct-20,OTHER,23,COVID,COLOMBIA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CHX0.12+CPC0.05 ORAL RINSE (PERIOAIDACTIVE CONTROL),EXPLORATORY CHANGE IN VIRAL LOAD,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado médico en Casa en Cali - 2020.
NCT04563702,"Active, not recruiting",Interventional,Phase 1,Vaxart,Industry,21-Sep-20,21-Oct-21,10-Dec-20,PREVENTION,35,COVID,UNITED STATES,ALL,18 Years to 54 Years   (Adult),VXA-COV2-1,FREQUENCY OF SOLICITED SYMPTOMS OF REACTOGENICITY,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers"
NCT04564040,Completed,Interventional,Phase 1,AstraZeneca,Industry,12-Oct-20,11-Dec-20,11-Dec-20,TREATMENT,20,MANTLE CELL LYMPHOMA,GERMANY,ALL,18 Years to 55 Years   (Adult),ACALABRUTINIB TREATMENT A,PART 1 AND 2: AREA UNDER PLASMA CONCENTRATION-TIME CURVE FROM TIME ZERO TO INFINITY (AUCINF),"A 2-Part, Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Tablet Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect"
NCT04564274,Recruiting,Observational,,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,4-Mar-21,1-Sep-21,1-Sep-21,OTHER,5000,CHRONIC HEALTH CONDITIONS,UNITED STATES,ALL,"1 Month and older   (Child, Adult, Older Adult)",,"TO QUANTIFY THE FREQUENCY AND SEVERITY OF COVID INFECTION IN PATIENTS WITH RARE AND COMMON DISEASES, LOOKING FOR CONDITIONS THAT INCREASE RISK OF SEVERE OUTCOMES.",Natural History Study: COV2Base-a Rare Disease by COVID Study
NCT04564287,Enrolling by invitation,Observational,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,28-Oct-20,1-Dec-22,1-Dec-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,MRI BRAIN ABNORMALITIES,An Observational Study of Neurologic Function After COVID-19 Infection
NCT04564716,"Active, not recruiting",Interventional,Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,28-Sep-20,10-Apr-21,28-Mar-21,PREVENTION,100,COVID,BELARUS,ALL,18 Years to 60 Years   (Adult),GAM-COVID-VAC,PERCENTAGE OF TRIAL SUBJECTS WITH CORONAVIRUS DISEASE 2019 (COVID-19) DEVELOPED WITHIN 6 MONTHS AFTER THE FIRST DOSE,"Сlinical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-СoV-2 Infection Prophylactic Treatment in Republic of Belarus"
NCT04565067,Recruiting,Observational,,National Institute on Aging (NIA),NIH,4-Mar-21,1-Sep-22,31-Dec-21,COHORT,120,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,DETERMINE CD8 T CELLS THAT ARE RESPONSIVE TO SARS-COV-2.,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans a Clinical Observation Trial
NCT04565080,Recruiting,Observational,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,4-Mar-21,31-Dec-21,31-Dec-21,ECOLOGIC OR COMMUNITY,150,PARKINSON'S DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE IN NEUROLOGICAL SYMPTOMS DOMAIN OF THE SURVEY BETWEEN PRE AND POST COVID 19 IN FMD AND PD PATIENTS.,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD)
NCT04565106,Completed,Observational,,Hvidovre University Hospital,Other,15-Apr-20,31-May-20,31-May-20,COHORT,16,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",CLOSED-LOOP CONTROL OF OXYGEN SUPPLEMENTATION BY O2MATIC,TIME IN SPO2 TARGET,Automatic Oxygen Titration With O2matic® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure
NCT04565197,"Active, not recruiting",Interventional,Early Phase 1,Lahore General Hospital,Other,1-May-20,30-Dec-20,30-Dec-20,TREATMENT,20,SARS-COV INFECTION,PAKISTAN,ALL,"15 Years to 80 Years   (Child, Adult, Older Adult)",CONVALESCENT PLASMA,CLINICAL OUTCOME AFTER PLASMA THERAPY,Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients: An Interventional Study
NCT04565249,Recruiting,Interventional,Phase 2,"Pliant Therapeutics, Inc.",Industry,22-Oct-20,31-Oct-21,31-Aug-21,TREATMENT,36,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PLN-74809,"NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS AND LABORATORY ABNORMALITIES, ASSESSED BY CTCAE V5.0","A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)"
NCT04565379,Recruiting,Interventional,Phase 2,Shaperon,Industry,25-Sep-20,30-Nov-20,30-Nov-20,TREATMENT,60,COVID PNEUMONIA,ROMANIA,ALL,"18 Years to 79 Years   (Adult, Older Adult)",NUSEPIN® 0.1 MG,DIFFERENCE IN TIME TO CLINICAL IMPROVEMENT (TTCI) BETWEEN THE 2 TREATMENTS AND THE PLACEBO GROUP (IN DAYS),"A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients"
NCT04565392,Not yet recruiting,Interventional,Phase 4,drpykessupplements.com,Industry,1-May-21,31-Jan-22,1-Nov-21,TREATMENT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FAMOTIDINE 20 MILLIGRAM TABLET,CLINICAL COURSE BINARY OUTCOME,Proof-of-concept Randomized Placebo-controlled Trial of Famotidine for Outpatients With COVID-19
NCT04565509,Recruiting,Interventional,Not Applicable,Washington University School of Medicine,Other,20-Nov-20,21-Sep-22,30-Jun-22,HEALTH SERVICES RESEARCH,2500,COVID,UNITED STATES,ALL,"5 Years to 90 Years   (Child, Adult, Older Adult)",GENERAL COMMUNICATION MESSAGE,ADOPTION OF WEEKLY TESTING BY EACH PARTICIPANT,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic
NCT04565522,Not yet recruiting,Observational,,"Simeone Andrulli, MD",Other,21-Sep-20,31-Oct-21,30-Sep-21,COHORT,5000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",PROSPECTIVE OBSERVATION,INCIDENT RISK OF COVID-19 INFECTION,Transmission of COVID-19 Among Patients and Health Personnel in Dialysis Centers: a Cohort Prospective Study (DIAL-COVID-19)
NCT04565665,Recruiting,Interventional,Phase 1,M.D. Anderson Cancer Center,Other,29-Jul-20,30-Apr-21,30-Apr-21,TREATMENT,70,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEST PRACTICE,INCIDENCE OF COMPOSITE SERIOUS ADVERSE EVENTS (PILOT),Emergency Use Pilot Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
NCT04565782,Recruiting,Observational,,Assiut University,Other,15-Sep-20,31-Dec-20,1-Nov-20,COHORT,150,SARS-COV INFECTION,EGYPT,ALL,"Child, Adult, Older Adult",,THE OCCURRENCE OF CORONA VIRUS INFECTION (CONFIRMED OR SUSPECTED) AMONG LIVER TRANSPLANT RECIPIENTS,Corona Virus Infection Among Liver Transplant Recipients: A Multicenter Study
NCT04566276,Not yet recruiting,Interventional,Phase 1,Chulalongkorn University,Other,21-Jan-21,21-Jun-21,21-Mar-21,OTHER,96,COVID VACCINE,THAILAND,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CHULACOV19 MRNA VACCINE,FREQUENCY OF ADVERSE EVENTS,"A Phase 1/2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 mRNA Vaccine in Healthy Adults"
NCT04566770,Recruiting,Interventional,Phase 2,CanSino Biologics Inc.,Industry,24-Sep-20,20-Oct-22,21-Aug-21,PREVENTION,481,COVID,CHINA,ALL,"6 Years and older   (Child, Adult, Older Adult)",RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR),SAFETY INDEXES OF ADVERSE REACTIONS,"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV"
NCT04566965,Recruiting,Observational,,"Children's Hospital Medical Center, Cincinnati",Other,18-Aug-20,31-Dec-23,31-Dec-22,CASE-CONTROL,230,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2,THE 12-MONTH CUMULATIVE INCIDENCE OF ACQUIRED COVID INFECTION IN THE STUDY COHORT.,Serology to Covid for Recording Exposures and Evaluating Needs (SCREEN)
NCT04567173,Recruiting,Interventional,Phase 2/Phase 3,University of the Philippines,Other,21-Sep-20,30-Jun-21,30-Jun-21,TREATMENT,136,COVID,PHILIPPINES,ALL,"19 Years and older   (Adult, Older Adult)",ANTI-SARS-COV-2 CONVALESCENT PLASMA,INCIDENCE OF SERIOUS ADVERSE EVENTS,"A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial"
NCT04567576,Not yet recruiting,Observational,,Fundación Santa Fe de Bogota,Other,20-Oct-21,31-Oct-21,21-May-21,COHORT,150,RHEUMATIC DISEASES,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS),CLINICAL BEHAVIOR OF THE DISEASE // COVID-19,Predictive Factors for COVID-19 in Rheumatology Study Based on Information Collected in The COVID-19 Global Rheumatology Alliance
NCT04567810,Completed,Interventional,Phase 1,Stanford University,Other,18-Sep-20,14-Dec-20,14-Dec-20,PREVENTION,48,COVID,AUSTRALIA,ALL,18 Years to 45 Years   (Adult),ANTI-SARS-COV-2 IGY,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED ADVERSE EVENTS,"A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)"
NCT04567836,Recruiting,Observational,,University of Milano Bicocca,Other,1-Jun-20,1-Dec-20,1-Dec-20,COHORT,3000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INVESTIGATION OF THE PREVALENCE OF TEST POSITIVITY,PREVALENCE OF TEST POSITIVITY,Screening of Health-care Workers in an University Hospital: an Observational Prospective Study on the Screening of Hospital Workers for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04567927,Completed,Observational,,Chiesa Alessandro Felice,Other,3-Mar-20,28-May-20,28-May-20,COHORT,80,SARS VIRUS,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",ULTRASONOGRAPHY,PERIOD PREVALENCE OF DEEP VEIN THROMBOSIS (DVT),Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With SARS-CoV-2 Infection
NCT04567953,"Active, not recruiting",Interventional,Not Applicable,Paradigm Laboratories LLC,Industry,28-Jul-20,27-Jun-21,30-Jan-21,SCREENING,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA COLLECTION,THE CLINICAL EVALUATION OF SALIVA AS SPECIMEN FOR COVID-19 MOLECULAR TEST,COVID-19 Tests With Saliva Specimens
NCT04567979,"Active, not recruiting",Observational,,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,11-Jun-20,30-Oct-20,30-Sep-20,COHORT,149,COVID,MEXICO,ALL,"Child, Adult, Older Adult",,SARS-COV-2 INFECTION RATE IN PATIENTS WITH SOLID TUMORS.,Prospective Determination of COVID-19 Infection Rate in Patients With Solid Tumors and Healthcare Workers of the Chemotherapy and Radiotherapy Unit at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador.
NCT04568005,Completed,Observational [Patient Registry],,Fatih Sultan Mehmet Training and Research Hospital,Other,1-Jun-20,1-Aug-20,1-Aug-20,OTHER,60,LYMPHEDEMA,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,CORONAVIRUS PHOBIA SCALE,"Evaluation of Lymphedema Patients Treatment Processes, Health Status, Coronavirus Phobia, Quality of Life, Anxiety and Depression During Covid-19 Pandemic"
NCT04568018,Recruiting,Observational,,Biosurf LLC.,Industry,3-Jul-20,21-Dec-21,31-Dec-20,COHORT,120,ARDS DUE TO COVID,RUSSIAN FEDERATION,ALL,"18 Years to 75 Years   (Adult, Older Adult)",SURFACTANT,MEAN DURATION OF OXYGEN THERAPY (DAYS) IN THE TREATMENT GROUP AND IN THE CONTROL GROUP.,"Open-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19)"
NCT04568031,"Active, not recruiting",Interventional,Phase 1/Phase 2,AstraZeneca,Industry,23-Aug-20,10-Nov-21,10-Nov-21,PREVENTION,256,COVID,JAPAN,ALL,"18 Years and older   (Adult, Older Adult)",AZD1222,PROPORTION OF PARTICIPANTS WHO HAVE A POST TREATMENT SERORESPONSE TO THE SPIKE ANTIGENS OF AZD1222,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19"
NCT04568044,Recruiting,Observational,,Imperial College London,Other,16-Sep-20,3-Jul-23,31-Dec-22,COHORT,96,COVID,UNITED KINGDOM,ALL,18 Years to 60 Years   (Adult),BLOOD SAMPLE,"PHENOTYPING ANTIBODY SECRETING CELLS (ASCS) AND MEMORY B CELLS DURING COVID-19 INFECTION, AND POST RECOVERY.",Evaluation of Cell-mediated and Humoral Immunity Following COVID-19 in Pregnancy
NCT04568096,Not yet recruiting,Interventional,Phase 2,Kafrelsheikh University,Other,20-Nov-21,20-Dec-21,20-Dec-21,TREATMENT,160,THE LUNG COMPLICATION OF COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AEROSOLIZED ALL-TRANS RETINOIC ACID PLUS ORAL TAMOXIFEN,LUNG INJURY SCORE,Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19
NCT04568122,Recruiting,Interventional,Not Applicable,Stanford University,Other,20-Nov-20,21-Aug-21,21-Apr-21,DIAGNOSTIC,3015,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA TEST KIT,AN INDICATOR FOR DISCREPANCY IN INTERPRETATION OF FINDINGS BY PARTICIPANT VERSUS BY TECHNICIAN VIA PHOTO (INTERRATER RELIABILITY),"Rapid Turnaround, Home-based Saliva Testing for COVID-19"
NCT04568135,Not yet recruiting,Observational,,Siyan Clinical Corporation,Other,31-Oct-20,31-Dec-21,31-Dec-21,OTHER,1000,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SURVEY,SURVEY: EPIDEMIC-PANDEMIC IMPACTS INVENTORY (EPII),A Survey Study to Assess the Impact of the COVID-19 Pandemic on Participants With Pre-Existing Mental Health Diagnosis
NCT04568148,Recruiting,Observational,,University of Kansas Medical Center,Other,15-Apr-20,31-Dec-21,31-Dec-21,OTHER,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,BIOSPECIMEN COLLECTION,COVID-19 Biorepository
NCT04568356,Completed,Interventional,Not Applicable,"E25Bio, Inc.",Industry,24-Apr-20,24-Sep-20,12-Jun-20,DIAGNOSTIC,200,SARS COV-2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DIRECT ANTIGEN TESTS FOR COVID-19,PERCENT POSITIVE AGREEMENT AND NEGATIVE PERCENT AGREEMENT,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART"""
NCT04568421,Recruiting,Observational [Patient Registry],,Sociedad Argentina de Reumatologia,Other,18-Aug-20,31-Dec-21,31-Dec-21,COHORT,3000,RHEUMATIC DISEASES,ARGENTINA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",IMMUNOSUPPRESSIVE AGENTS,MORTALITY,Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection
NCT04568499,Not yet recruiting,Observational,,Johns Hopkins Bloomberg School of Public Health,Other,20-Oct-21,21-Mar-21,21-Mar-21,COHORT,1000,COVID,,ALL,"5 Years and older   (Child, Adult, Older Adult)",,HOSPITALIZATION,"Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings: a Prospective Cohort Study in South Sudan and DRC"
NCT04568525,Completed,Interventional,Not Applicable,Kyrgyz State Medical Academy,Other,1-Jul-20,1-Aug-20,25-Jul-20,DIAGNOSTIC,195,COVID,KYRGYZSTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PASSIVE MICROWAVE RADIOMETRY,DETERMINE SENSITIVITY AND SPECIFICITY OF MWR DIAGNOSTICS OF PNEUMONIA IN PATIENTS WITH COVID-19. (DIAGNOSED BY PCR AND CT),Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19
NCT04568551,Recruiting,Observational,,Martin-Luther-Universität Halle-Wittenberg,Other,1-Oct-20,31-Jul-21,31-Mar-21,COHORT,300,ANXIETY STATE,GERMANY,FEMALE,"18 Years and older   (Adult, Older Adult)",,ANXIETY FOR ANOMALIES DURING COVID-19-PANDEMIC AND BEFORE (PERCENTAGE DIFFERENCE IN AGREEMENT TO THE ITEMS OF THE QUESTIONNAIRE),"COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor - CAASPtrial"
NCT04568564,Recruiting,Interventional,Not Applicable,Istanbul Medipol University Hospital,Other,1-Oct-20,1-May-21,1-May-21,SUPPORTIVE CARE,40,LUNG CANCER,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)","BREATHING EXERCISE, INTENSIVE SPIROMETRY USE, SUPPORTED COUGH, PROGRESSIVE MOBILISATION AND AMBULATION",MAJOR COMPLICATION RATE,Telerehabilitation of Reduced Physiotherapy Service in SARS-CoV-2 Pandemic Process in Lung Surgery Patients
NCT04568655,Completed,Observational,,The First Affiliated Hospital of Guangzhou Medical University,Other,1-Feb-20,1-Jul-20,1-Jul-20,COHORT,23,NONINVAVIE VENTILATION TO PATIENTS WITH COVID,CHINA,ALL,"20 Years to 80 Years   (Adult, Older Adult)",NONINVASIVE VENTILATION,SUCCESS RATE,The Noninvasive Ventilation to COVID-19 Patients With Respiratory Failure
NCT04568707,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,23-Oct-20,15-Oct-22,15-Oct-22,BASIC SCIENCE,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,DOSAGE OF SERIC MARKERS (ANTI-SARS-COV2 IGG) OR GENETIC MARKERS (GENETIC VARIANTS) OBSERVED DURING COVID 19 INFECTION IN PATIENTS,Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19
NCT04568811,"Active, not recruiting",Interventional,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,Other,26-Sep-20,27-Sep-21,25-Oct-20,PREVENTION,89,ADENOVIRUS TYPE-5 VECTORED COVID VACCINE,CHINA,ALL,"Child, Adult, Older Adult",ADENOVIRUS TYPE-5 VECTORED COVID-19 VACCINE,OCCURRENCE OF ADVERSE REACTIONS WITHIN 14 DAYS AFTER BOOSTER VACCINATION,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years"
NCT04568850,Recruiting,Observational,,Lahore General Hospital,Other,1-Jul-20,28-Feb-21,28-Feb-21,CASE-ONLY,50,COVID,PAKISTAN,ALL,"Child, Adult, Older Adult",PLASMA IGG LEVELS,SERUM IGG FOR SARS COV 2 WILL BE MONITORED,Waxing and Waning of Serum SARS CoV 2 IgG Level: A Prospective Study
NCT04568863,Recruiting,Interventional,Phase 2,Pharmamel S.L.,Industry,20-Jun-20,30-Nov-20,30-Oct-20,TREATMENT,18,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MELATONIN INTRAVENOUS,MORTALITY,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)"
NCT04568876,Recruiting,Interventional,Phase 4,Epitech Group SpA,Industry,23-Oct-20,21-Nov-21,21-Nov-21,SUPPORTIVE CARE,40,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)","MICRONIZED AND ULTRA-MICRONIZED PALMITOYLETHANOLAMIDE (MPEA AND UMPEA, 300MG + 600MG) ORAL SUSPENSION",NUMBER OF RESPONDER PARTICIPANTS AFTER 7 DAYS OF TREATMENT,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study"
NCT04568889,"Active, not recruiting",Interventional,Not Applicable,Harvard University,Other,28-Sep-20,30-Jun-21,26-Oct-20,HEALTH SERVICES RESEARCH,1000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",A $10 SURVEY INCENTIVE,EFFECT OF MONETARY INCENTIVES IN INCREASING UNIT RESPONSE 1,Minnesota COVID-19 Testing Project
NCT04569019,Recruiting,Observational,,Medical University of Warsaw,Other,1-Sep-20,1-Jul-22,1-Aug-21,CASE-CROSSOVER,1000,VACCNATION IN HCW,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",VACCIANTION STATUS IN HEALTH CARE WORKERS,ASSESMENT OF VACCINATION INDEKS IN THE HSOPITAL BY USING QUESTIONARE,Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of the University Clinical Center of the Medical University of Warsaw
NCT04569188,Completed,Interventional,Phase 2,Azienda Socio Sanitaria Territoriale di Mantova,Other,15-May-20,3-Sep-20,15-Aug-20,TREATMENT,21,COVID,ITALY,ALL,65 Years and older   (Older Adult),CONVALESCENT PLASMA,DEATH,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19
NCT04569227,Not yet recruiting,Interventional,Phase 2,Enzychem Lifesciences Corporation,Industry,16-Nov-20,21-Nov-21,21-Sep-21,TREATMENT,60,COVID PNEUMONIA,,ALL,"18 Years and older   (Adult, Older Adult)",EC-18,PROPORTION OF PATIENTS ALIVE AND FREE OF RESPIRATORY FAILURE THROUGH AT DAY 28,"Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS"
NCT04569266,Recruiting,Interventional,Not Applicable,Groupe Hospitalier Paris Saint Joseph,Other,7-Aug-20,7-May-22,7-Nov-21,TREATMENT,200,DYSPNEA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SPECIFIC EXERCISE REHABILITATION TREATMENT,EVALUATE THE EFFECT OF EXERCISE REHABILITATION ON POST-ICU DYSPNEA,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU
NCT04569292,Recruiting,Observational,,Ospedale Andrea Tortora di Pagani,Other,1-Jan-20,21-Aug-21,21-Apr-21,CASE-ONLY,150,COVID,ITALY,ALL,"Child, Adult, Older Adult",NO INTERVENTION ON PATIENTS,DESCRIBE CANCER PATIENTS WITH COVID-19 AND THEIR CLINICAL COURSE,Clinical Course of Cancer Patients Who Contracted COVID 19 Infection: An Observational Study
NCT04569344,Enrolling by invitation,Observational,,"University of California, San Francisco",Other,1-Jan-20,21-Jun-22,31-Mar-21,COHORT,40000,VENOUS THROMBOEMBOLISM,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LABORATORY TEST POSITIVE FOR SARS-COV-2 VIRUS,ACUTE VENOUS THROMBOEMBOLISM (VTE),COVID-19 and Venous Thromboembolism Risk
NCT04569383,Recruiting,Interventional,Phase 1,Universitätsklinikum Hamburg-Eppendorf,Other,5-Oct-20,21-May-21,21-May-21,PREVENTION,30,COVID,GERMANY,ALL,18 Years to 55 Years   (Adult),MVA-SARS-2-S VACCINATIONS (DAYS 0 & 28),PERCENTAGE OF PARTICIPANTS EXPERIENCING SOLICITED LOCAL OR SYSTEMIC REACTOGENICITY AS DEFINED BY THE STUDY PROTOCOL,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S"
NCT04569786,"Active, not recruiting",Interventional,Phase 1,Merck Sharp & Dohme Corp.,Industry,29-Oct-20,15-Feb-21,15-Feb-21,PREVENTION,252,CORONAVIRUS DISEASE (COVID),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",V590,PERCENTAGE OF PARTICIPANTS WITH AT LEAST 1 SOLICITED INJECTION SITE ADVERSE EVENT,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults"
NCT04569825,Recruiting,Interventional,Early Phase 1,University Of Anbar,Other,1-Aug-20,15-Oct-20,30-Sep-20,TREATMENT,250,CLINICAL TRIAL,IRAQ,ALL,"18 Years and older   (Adult, Older Adult)",OPHTAMESONE,RECOVERY RATE OF ANOSMIA AND SHORTEN RECOVERY TIME,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease
NCT04569851,Enrolling by invitation,Observational,,Medsavana,Other,1-Jan-20,30-Oct-21,1-Oct-21,OTHER,100000,COVID INFECTION,SPAIN,ALL,"Child, Adult, Older Adult",,FACTORS THAT PREDICT DISEASE PROGNOSIS AND OUTCOMES IN COVID-19 PATIENTS - HOSPITALIZATION,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 Using Big Data and Artificial Intelligence Techniques (BigCoviData)
NCT04569877,Recruiting,Interventional,Phase 2,University of Giessen,Other,24-Sep-20,25-Dec-22,25-Dec-22,TREATMENT,238,SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PNEUMONIA,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",MOLGRAMOSTIM NEBULISER SOLUTION,MECHANICAL VENTILATION,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID)
NCT04570189,Recruiting,Observational,,AusculSciences Canada Inc.,Industry,1-Oct-20,21-Jan-21,21-Jan-21,COHORT,40,COVID,CANADA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",AUSCUL-X,FEASIBILITY AND USE OF AUSCUL-X FOR LISTENING TO HEART AND LUNG SOUNDS WILL BE ASSESSED BY ICU CLINICIANS TO DETERMINE AUSCUL-X IS AT LEAST EQUIVALENT TO A DIGITAL STETHOSCOPE USING A LIKERT SCALE FOR COMPARISON.,"Evaluating Auscul-X, a Touch Free Digital Stethoscope, for Physical Distancing to Protect Patients and Health Care Professionals From COVID-19 (The Auscul-X Study)"
NCT04570202,Recruiting,Interventional,Not Applicable,"University Hospital, Tours",Other,20-Nov-20,20-Aug-22,20-Aug-21,TREATMENT,900,DEPRESSION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",EMDR,EFFICACY ON SYMPTOMS OF POST-TRAUMATIC STRESS DISORDER,"Symptoms of Depression, Stress and Burnout, and Long-term Psychological Impact in Health Care Professionals Exposed to the Novel Coronavirus Disease 2019 Outbreak (HARD-COVID-19 - Health cAre woRkers exposeD to covID-19)"
NCT04570254,"Active, not recruiting",Interventional,Not Applicable,Unidad Temporal COVID-19 en Centro Citibanamex,Other,19-Aug-20,15-Nov-20,15-Oct-20,TREATMENT,11,"PNEUMONIA, VIRAL",MEXICO,ALL,"Child, Adult, Older Adult",VITAMIN C,DEATH FROM ANY CAUSE,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia
NCT04570384,Recruiting,Interventional,Phase 2,"Asklepion Pharmaceuticals, LLC",Industry,15-Oct-20,28-Dec-21,28-May-21,TREATMENT,60,ACUTE HYPOXEMIC RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",L-CITRULLINE,PRIMARY BIOCHEMICAL OBJECTIVE TO MEASURE LEVELS OF CITRULLINE AND ARGININE IN THE BLOOD,"Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness"
NCT04570397,Recruiting,Interventional,Phase 3,Brigham and Women's Hospital,Other,18-Dec-20,21-Nov-21,21-May-21,TREATMENT,32,COVID,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",RAVULIZUMAB,ASSESS THE EFFICACY OF RAVULIZUMAB TO AMELIORATE SARS-COV-2 (COVID-19)-INDUCED ACUTE KIDNEY INJURY MANIFESTING AS THROMBOTIC MICROANGIOPATHY.,C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy
NCT04570449,Withdrawn,Interventional,Early Phase 1,Milton S. Hershey Medical Center,Other,20-Nov-21,21-Dec-21,21-Nov-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FLUOXETINE,RATE OF HOSPITALIZATION,Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
NCT04570462,Recruiting,Interventional,Not Applicable,Northwell Health,Other,18-May-20,31-Dec-20,31-Dec-20,TREATMENT,20,COVID ARDS,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",HYPOTHERMIA VIA COOLING MACHINE- ARCTIC SUN 5000,CHANGES IN METABOLIC REQUIREMENT DURING AND AFTER HYPOTHERMIA,Application of Mild Hypothermia for COVID-19 Acute Respiratory Distress
NCT04570488,Recruiting,Interventional,Not Applicable,NYU Langone Health,Other,15-May-20,15-May-21,30-Dec-20,HEALTH SERVICES RESEARCH,1200,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",EPIC RISK SCORE DISPLAY,REDUCTION IN DAYS FROM FIRST LOW-RISK SCORE TO DISCHARGE,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients
NCT04570501,Not yet recruiting,Interventional,Phase 1/Phase 2,Stanford University,Other,21-Mar-21,21-Aug-21,21-Aug-21,TREATMENT,160,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN-(1-7),TIME TO RECOVERY,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients"
NCT04570982,Recruiting,Observational,,"Dr. Pradip Gyanwali,MD",Other,30-Jul-20,30-Dec-20,30-Oct-20,CASE-CROSSOVER,200,COVID,NEPAL,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,AVAILABILITY OF CONVALESCENT PLASMA,Compassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Prospective Observational Study (Amended Protocol)
NCT04572360,Not yet recruiting,Interventional,Not Applicable,Hong Kong Baptist University,Other,1-Oct-20,30-Jun-23,31-Dec-22,TREATMENT,172,CORONAVIRUS DISEASE (COVID),HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",CARDIORESPIRATORY EXERCISE,SIX-MINUTE WALK TEST (6MWT) IN CARDIORESPIRATORY FITNESS TEST,Would Cardiorespiratory Exercise and Chinese Herbal Medicine Facilitate Rehabilitation From Pulmonary Fibrosis Among Post-discharge Patients With COVID-19? Clinical Efficacy and Mechanisms
NCT04572399,Completed,Interventional,Not Applicable,Cedars-Sinai Medical Center,Other,30-Oct-20,28-Dec-20,28-Dec-20,TREATMENT,5,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",UV LIGHT TREATMENT,CHANGE IN VIRAL LOAD,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study
NCT04572412,Recruiting,Interventional,Not Applicable,Lancashire Teaching Hospitals NHS Foundation Trust,Other,25-Nov-20,21-Apr-21,21-Apr-21,HEALTH SERVICES RESEARCH,13,COVID,UNITED KINGDOM,ALL,"50 Years and older   (Adult, Older Adult)",LOW DOSE RADIOTHERAPY,FEASIBILITY OF RECRUITMENT,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia (a Phase I Feasibility Trial)
NCT04572438,Recruiting,Observational,,"University College, London",Other,1-Aug-20,1-Aug-21,1-Apr-21,COHORT,2500,TRACHEOSTOMY COMPLICATION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",TRACHEOSTOMY,TIME TO WEAN,COVIDTrach; a UK National Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy
NCT04573062,Recruiting,Observational,,National Institute of Neurological Disorders and Stroke (NINDS),NIH,4-Mar-21,31-Dec-24,31-Dec-24,CASE-ONLY,1200,POST-CORONAVIRUS DISEASE 19,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,SCREENING PHASE,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
NCT04573153,Recruiting,Interventional,Phase 2/Phase 3,ScandiBio Therapeutics AB,Industry,21-Sep-20,31-Mar-21,31-Jan-21,TREATMENT,400,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE + METABOLIC COFACTOR SUPPLEMENTATION,THE EVALUATION OF CLINICAL EFFICACY OF THE COMBINATION OF METABOLIC COFACTOR SUPPLEMENTATION AND HYDROXYCHLOROQUINE,"A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients"
NCT04573270,Completed,Interventional,Phase 1,Thomas Advanced Medical LLC,Industry,24-Apr-20,1-Sep-20,20-Aug-20,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRIMEPRO,SURVIVAL RATES,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients
NCT04573322,Recruiting,Interventional,Phase 1/Phase 2,Diffusion Pharmaceuticals Inc,Industry,10-Sep-20,14-Dec-21,14-Nov-21,TREATMENT,224,SARS-COV2 (COVID),ROMANIA,ALL,"18 Years and older   (Adult, Older Adult)",TRANS SODIUM CROCETINATE,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS (SAFETY AND TOLERABILITY),"Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects"
NCT04573335,Completed,Observational,,"Services Institute of Medical Sciences, Pakistan",Other,1-Jun-20,30-Jul-20,15-Jul-20,COHORT,1282,DIABETES,PAKISTAN,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,ALL-CAUSE MORTALITY,Health-related Outcomes and Behaviour Changes in a Cohort of Diabetic Population During COVID-19 Pandemic: Results of a Telephonic Survey
NCT04573348,Recruiting,Observational,,Savicell Diagnostics Ltd,Other,14-Oct-20,10-Oct-21,10-May-21,OTHER,400,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",SAVICELL'S IMMUNOBIOPSY™,POSITIVE AND NEGATIVE DIAGNOSIS (SCORED 0/1 DICHOTOMOUSLY) IN ACCORDANCE WITH TEST RESULTS (MA/ELISA/PCR),"Prospective, One Center, Four Groups, Open, Comparative, Controlled Study to Explore T Cells Response to SARS COV 2 Peptides by Metabolic Activity Method in Convalesce and Healthy Individuals Versus Antibody Response"
NCT04573361,Completed,Interventional,Not Applicable,Real Centro Universitario Maria Cristina,Other,2-May-20,27-May-20,27-May-20,TREATMENT,723,MUSCULOSKELETAL PAIN,SPAIN,ALL,"14 Years and older   (Child, Adult, Older Adult)",CHIROPRACTIC CARE (ONE VISIT),PAIN INTENSITY,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial
NCT04573634,Recruiting,Observational,,Jill M Kolesar,Other,15-May-20,31-Dec-23,31-Dec-23,COHORT,960,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE OF COVID-19,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition (START) - Assessment of COVID19 Penetrance in HCW and Non HCW in Kentucky
NCT04573764,Not yet recruiting,Interventional,Not Applicable,Steno Diabetes Center Copenhagen,Other,1-Oct-20,1-Jan-22,1-Oct-21,TREATMENT,12,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","D-BETA-HYDROXYBUTYRATE-(R)-1,3 BUTANEDIOL MONOESTER",LEFT VENTRICULAR EJECTION FRACTION,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19
NCT04573855,Not yet recruiting,Interventional,Phase 1/Phase 2,D'Or Institute for Research and Education,Other,1-Dec-20,31-Mar-21,28-Feb-21,TREATMENT,41,COVID,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",ANTI-SARS-COV-2 IMMUNOGLOBULIN,RATE OF ADVERSE EVENTS RELATED TO THE INFUSION OF ANTI-SARS-COV-2 IMMUNOGLOBULIN THROUGH CTCAE V4.0.,TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19: A PHASE I / II STUDY
NCT04573868,Recruiting,Observational [Patient Registry],,Hospitales Universitarios Virgen del Rocío,Other,1-Mar-20,30-Sep-20,30-Jun-20,CASE-ONLY,1000,MORTALITY,SPAIN,ALL,"14 Years and older   (Child, Adult, Older Adult)",,MORTALITY,"National Study ""AEC COVID-19"" on Patients Undergoing Surgical Intervention During the SARS-CoV-2 Pandemic."
NCT04574050,Not yet recruiting,Interventional,Not Applicable,King's College Hospital NHS Trust,Other,3-Dec-20,30-Jun-22,4-Apr-22,TREATMENT,40,CANCER,,ALL,"18 Years and older   (Adult, Older Adult)",SELF-BREATHE,FEASIBILITY: THE NUMBER OF PATIENTS RECRUITED INTO THIS STUDY OVER A 12-MONTH PERIOD,"A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial"
NCT04574219,Recruiting,Interventional,Not Applicable,"Children's Hospital Medical Center, Cincinnati",Other,3-Nov-20,22-Dec-21,22-Oct-21,SUPPORTIVE CARE,184,ANXIETY,CANADA,ALL,4 Years to 12 Years   (Child),USE OF FACETIME WITH CHILD AND PARENTS DURING INDUCTION,VIRTUAL PRESENCE CAUSE DELAYS IN OPERATING ROOM,Feasibility and Acceptability of Virtual Parental Presence on Induction of Anesthesia - Modernizing Solutions for Pediatric Anesthesia in Response to COVID-19
NCT04574765,Recruiting,Observational,,"University Health Network, Toronto",Other,16-Apr-20,16-Apr-21,16-Apr-21,COHORT,100000,HEALTHCARE WORKER,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",NASOPHARYNGEAL SWAB,PERCENTAGE OF HEALTHCARE WORKERS WHO ARE ASYMPTOMATIC AND COVID-19 POSITIVE,"A Research Platform to Screen and Protect Individuals That Work Within a Food Production, Healthcare, Research or Clinical Organization - RESPECT"
NCT04574869,Not yet recruiting,Interventional,Phase 1,"ReAlta Life Sciences, Inc.",Industry,20-Oct-21,21-Jul-21,21-Mar-21,TREATMENT,42,ACUTE LUNG INJURY,UNITED STATES,ALL,"18 Years to 69 Years   (Adult, Older Adult)",RLS-0071,"FREQUENCY AND SEVERITY OF ADVERSE EVENTS, INCLUDING SERIOUS ADVERSE EVENTS, BY TREATMENT GROUP AND DOSE LEVEL, INCLUDING THE FREQUENCY OF PREMATURE DISCONTINUATION OF STUDY INTERVENTION DUE TO ADVERSE EVENTS.","A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, PK, & PD of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure"
NCT04575038,Recruiting,Interventional,Phase 2,"Clear Creek Bio, Inc.",Industry,19-Nov-20,28-Feb-21,28-Feb-21,TREATMENT,100,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BREQUINAR,SARS-COV-2 VIRAL LOAD,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2"
NCT04575064,"Active, not recruiting",Interventional,Phase 2/Phase 3,Professor Dr. Bernd Mühlbauer,Other,29-Jun-20,22-Nov-21,22-Mar-21,TREATMENT,400,SARS-COV2 INFECTION,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OF CARE (SOC),IMPROVEMENT OF CLINICAL STATUS ON THE ORDINAL 7-POINT SEVERITY-SCALE AT DAY 15.,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
NCT04575168,Recruiting,Observational,,Spartan Bioscience Inc.,Industry,30-Oct-20,20-Nov-21,20-Nov-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SPARTAN COVID-19 TEST,PERCENT AGREEMENT BETWEEN SOC TEST AND SPARTAN COVID-19 TEST,Assess the Performance of Spartan COVID-19 V2 System in a Clinical Setting in Comparison to a Laboratory (Standard of Care (SOC)) PCR Method
NCT04575532,Enrolling by invitation,Observational,,"physIQ, Inc.",Industry,5-Oct-20,22-Jan-21,15-Jan-21,COHORT,400,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","USE OF THE PINPOINTIQ SOLUTION (PHYSIQ, INC.)",DEVELOPMENT OF COVID DECOMPENSATION INDEX,Personalized Analytics and Wearable Biosensor Platform for Early Detection of COVID-19 Decompensation
NCT04575545,Not yet recruiting,Observational,,Hôpital Européen Marseille,Other,20-Oct-21,22-Apr-21,21-Mar-21,COHORT,600,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY TEST FOR COVID-19,% OF PATIENTS WITH POSITIVE SEROLOGICAL TESTS FOR COVID-19,Prevalence of COVID-19 Infection in a Cohort of Patient Infected by the HIV and Patients Taking PrEP Pre-exposure Prophylaxis
NCT04575558,Withdrawn,Interventional,Phase 2,Latin American Cooperative Oncology Group,Other,30-Jun-20,30-Oct-20,1-Sep-20,TREATMENT,0,SARS-COV2,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE AND AZITHROMYCIN,CLINICAL DETERIORATION RATE,"A Randomized, Multi-institutional, Phase 2 Study of Hydroxichloroquine Plus Azithromycin for High Risk SARS-CoV-2 Positive Patients (COVID-19)"
NCT04575571,Recruiting,Observational,,Laval University,Other,29-Apr-20,29-Apr-25,29-Apr-25,COHORT,5000,PSYCHOSOCIAL IMPACTS OF THE COVID PANDEMIC,CANADA,ALL,"14 Years and older   (Child, Adult, Older Adult)","NO INTERVENTION, THIS IS AN OBSERVATIONAL STUDY THAT USES VALIDATED QUESTIONNAIRES AND QUALITATIVE INTERVIEWS..","DEPRESSION, ANXIETY AND STRESS SCALE-21 (DASS-21)",The MAVIPAN Protocol: For a Structured Response to the Psychosocial Consequences of the Restrictive Measures Imposed by the Global Health COVID-19 Pandemic
NCT04575584,Recruiting,Interventional,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,Industry,19-Oct-20,30-Dec-21,27-Jun-21,TREATMENT,1300,CORONAVIRUS DISEASE (COVID),BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",MOLNUPIRAVIR,TIME-TO-SUSTAINED RECOVERY,"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19"
NCT04575597,Recruiting,Interventional,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,Industry,19-Oct-20,26-Dec-21,23-Jun-21,TREATMENT,1450,CORONAVIRUS DISEASE (COVID),BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",MOLNUPIRAVIR,PERCENTAGE OF PARTICIPANTS WHO ARE HOSPITALIZED AND/OR DIE,"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19."
NCT04575610,Recruiting,Interventional,Phase 2,Yale University,Other,30-Nov-20,31-Mar-21,31-Mar-21,TREATMENT,68,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PF-06650833,ALL-CAUSE MORTALITY AT DAY 29,Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC)
NCT04576299,"Active, not recruiting",Observational,,Universidad Miguel Hernandez de Elche,Other,1-Sep-20,15-Dec-20,30-Oct-20,ECOLOGIC OR COMMUNITY,800,PATIENT SAFETY,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",GROUP 1,PATIENT SAFETY PERCEPTION.,Health Care Workers' Perception of Patient Safety During the COVID-19 Pandemic: Opportunities and Challenges
NCT04576312,"Active, not recruiting",Interventional,Phase 1,UNION therapeutics,Industry,29-Jun-20,30-Apr-21,31-Dec-20,OTHER,64,COVID,DENMARK,ALL,"18 Years to 65 Years   (Adult, Older Adult)",UNI911 INHALATION,ASSESS SAFETY OF UNI911 INHALATION IN HEALTHY VOLUNTEERS: AE FREQUENCY,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19"
NCT04576351,Recruiting,Observational,,Oslo University Hospital,Other,1-Sep-20,31-Dec-23,31-Dec-23,COHORT,150,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION,RATE OF PERIPHERAL AND CENTRAL NERVOUS AFFECTION,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19
NCT04576728,Recruiting,Interventional,Phase 2,Biotest,Industry,6-Oct-20,21-May-21,21-May-21,TREATMENT,164,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TRIMODULIN,CLINICAL DETORIATION RATE,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19"
NCT04577105,Completed,Observational,,Instituto Nacional de Cardiologia Ignacio Chavez,Other,1-Apr-20,1-Oct-20,31-Aug-20,COHORT,233,COVID,MEXICO,ALL,"Child, Adult, Older Adult",SIMPLE CHEST TOMOGRAPHY,ASSESSMENT OF THE LEVEL OF SUSPICION OF SARS-COV2 INFECTION,"Risk Factors, Prognosis and Findings by Computed Tomography in Patients Infected by COVID-19 and Its Association With Severity."
NCT04577235,Completed,Interventional,Not Applicable,Gaziosmanpasa Taksim Research and Education Hospital,Other,5-Jun-20,5-Sep-20,5-Aug-20,DIAGNOSTIC,29,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",SEVERITY OF LUNG INVOLVEMENT WITH COVID-19.,THE EVALUATION OF THE CORRELATION BETWEEN THE BASELINE LUS SCORE AND MORTALITY RATE OF PATIENTS WITH SEVERE COVID-19 PNEUMONIA WHO WERE FOLLOWED UP IN THE INTENSIVE CARE UNIT,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.
NCT04577378,Not yet recruiting,Interventional,Phase 2,Kafrelsheikh University,Other,20-Oct-20,20-Nov-20,20-Nov-20,TREATMENT,45,COVID,EGYPT,ALL,"15 Years to 80 Years   (Child, Adult, Older Adult)",DRUG: ISOTRETINOIN(AEROSOLIZED 13 CIS RETINOIC ACID) PLUS AEROSOLIZED ITRACONAZOLE,LUNG INJURY SCORE,Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach
NCT04577534,Recruiting,Interventional,Phase 3,Jarmo Oksi,Other,14-Aug-20,31-Dec-21,31-Dec-21,TREATMENT,90,COVID,FINLAND,ALL,"18 Years and older   (Adult, Older Adult)",IV TOCILLIZUMAB (TCZ),CLINICAL STATUS AT DAY 28,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease
NCT04578132,Recruiting,Observational,,Spanish Oncology Genito-Urinary Group,Other,24-Nov-20,21-Oct-21,21-Jun-21,ECOLOGIC OR COMMUNITY,250,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,BASELINE CHARACTERISTICS,Observational Retrospective-prospective Study in Patients With Genitourinary Tumors Presenting COVID-19 Infection (SOGUG-COVID-19)
NCT04578158,Recruiting,Interventional,Phase 2/Phase 3,Liaquat University of Medical & Health Sciences,Other,29-Sep-20,28-Jun-21,28-Apr-21,TREATMENT,200,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD COVID-19 CARE,PERCENTAGE OF SUBJECTS WITH COVID-19 DISEASE PROGRESSION,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19."
NCT04578197,Recruiting,Observational,,Karolinska University Hospital,Other,18-Aug-20,22-Nov-21,22-Jun-21,COHORT,100,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",,THE ASSOCIATION BETWEEN CHANGES IN BLOOD BIOMARKERS FOR INFLAMMATION AND THE PRESENCE OF NEURORADIOLOGICALLY VERIFIED BRAIN INJURY AND NEUROCOGNITIVE DISORDER,"NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients"
NCT04578210,Recruiting,Interventional,Phase 1/Phase 2,Instituto de Investigación Hospital Universitario La Paz,Other,4-Sep-20,21-Mar-21,21-Jan-21,TREATMENT,58,CORONAVIRUS INFECTION,SPAIN,ALL,"up to 80 Years   (Child, Adult, Older Adult)",T MEMORY CELLS AND NK CELLS,"OCCURRENCE OF DLTS IN ALL PATIENTS DURING THE STUDY TREATMENT, UNTIL 21 DAYS AFTER CELL INFUSION AND THE MTD",A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia
NCT04578236,Not yet recruiting,Interventional,Phase 2,Kafrelsheikh University,Other,20-Nov-21,21-Jan-21,20-Dec-21,TREATMENT,360,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AEROSOLIZED 13 CIS RETINOIC ACID PLUS INHALATION ADMINISTRATION BY NEBULIZATION CAPTOPRIL 25MG,LUNG INJURY SCORE,"Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)"
NCT04578509,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,19-Oct-20,21-Jun-21,21-Apr-21,COHORT,2750,SARS-COV2 INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",NASOPHARYNGEAL SWAB,POSITIVITY OF RT-PCR ON NASOPHARYNGEAL SWAB FOR THE SARS-COV-2 VIRUS,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva (COVID-19)
NCT04579289,Completed,Observational,,Rennes University Hospital,Other,15-Jun-20,1-Sep-20,1-Sep-20,ECOLOGIC OR COMMUNITY,230,COVID,FRANCE,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,CASE OF COVID 19,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions_COVID-19
NCT04579393,Recruiting,Interventional,Phase 2,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,27-Jan-20,31-Jan-22,31-Jan-22,TREATMENT,80,CORONAVIRUS DISEASE 2019,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,CUMULATIVE INCIDENCE OF SAES,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19
NCT04579458,Withdrawn,Observational,,Vanderbilt University Medical Center,Other,28-Dec-20,22-Jan-21,22-Jan-21,CASE-ONLY,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COLLECTION OF TEARS AND SALIVA.,CO-RELATION OF COVID-19 ACTIVITY,Assessment of COVID (Coronavirus Disease)-19 in Tearfilm
NCT04579471,Recruiting,Observational,,Universitaire Ziekenhuizen Leuven,Other,1-Jul-20,31-Dec-21,31-Dec-21,COHORT,2000,COVID,BELGIUM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",SARS-COV-2 IGG,PREVALENCE AND RISK-FACTORS FOR SARS-COV-2 INFECTION,Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study
NCT04579549,Enrolling by invitation,Interventional,Not Applicable,"University of Wisconsin, Madison",Other,29-Sep-20,21-Sep-21,21-Sep-21,DIAGNOSTIC,10000,COVID,UNITED STATES,ALL,"5 Years and older   (Child, Adult, Older Adult)",SALIVA ASSAY,NUMBER OF PARTICIPANT PHONE SURVEY RESPONSES,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay
NCT04579562,Not yet recruiting,Observational,,University Hospitals of Derby and Burton NHS Foundation Trust,Other,1-Nov-20,31-Oct-21,31-Mar-21,CASE-CONTROL,5000,ACUTE KIDNEY INJURY,,ALL,"18 Years to 110 Years   (Adult, Older Adult)",NO INTERVENTION,ALL-CAUSE MORTALITY,Regional Epidemiology of COVID-19 and Acute Kidney Injury in England
NCT04579588,Enrolling by invitation,Observational,,Stanford University,Other,29-Oct-20,1-Dec-22,1-Dec-22,CASE-CONTROL,100,CORONAVIRUS INFECTION,UNITED STATES,ALL,18 Years to 64 Years   (Adult),FLU SHOT,TESTING IMMUNITY TO THE FLU VACCINE OVER TIME,Understanding Immunity to the Flu Vaccine in COVID-19 Patients
NCT04579627,Completed,Observational,,Royal Cornwall Hospitals Trust,Other,14-May-20,8-Jun-20,8-Jun-20,COHORT,358,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",QUESTIONNAIRE,CHANGE IN FACIAL HAIR BETWEEN JANUARY 2020 AND DURING APRIL 2020.,How Has the Increased Use of FFP3 Style Respirators During the COVID-19 Pandemic Affected Hospital Doctor's Facial Hair? Implications for Staff Safety and Welfare.
NCT04579640,"Active, not recruiting",Interventional,Phase 3,Queen Mary University of London,Other,27-Oct-20,30-Jun-21,30-Jun-21,PREVENTION,6200,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",VITAMIN D,PROPORTION OF PARTICIPANTS EXPERIENCING AT LEAST ONE DOCTOR-DIAGNOSED OR LABORATORY-CONFIRMED ACUTE RESPIRATORY INFECTION OF ANY CAUSE.,Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population
NCT04581018,Recruiting,Interventional,Not Applicable,Siew Chien NG,Other,13-Aug-20,30-Apr-22,30-Oct-21,SUPPORTIVE CARE,50,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",HEALTH SUPPLEMENTS,COMBINED SYMPTOM SCORE,An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection
NCT04581031,Recruiting,Interventional,Not Applicable,The Christie NHS Foundation Trust,Other,11-Jul-20,1-Feb-21,1-Feb-21,OTHER,60,COVID,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",CONTINUOUS VITAL SIGN MONITORING - ISANSYS PATIENT STATUS ENGINE,"DEVELOPMENT OF AN AI MODEL TO PREDICT CLINICALLY RELEVANT OUTCOMES FOR WARD-BASED PATIENTS WITH COVID-19 MONITORED FOR UP TO 20 DAYS. METRICS TO BE EMPLOYED DEPEND ON THE ALGORITHM USED BUT INCLUDE, LOG-LOSS, PRECISION AND/OR RECALL AND CONFUSION MATRIX.",COntinuous Signs Monitoring In Covid-19 Patients
NCT04581044,Completed,Observational,,Cairo University,Other,17-Sep-20,23-Oct-20,23-Oct-20,CASE-CROSSOVER,197,PSORIASIS,EGYPT,ALL,"25 Years and older   (Adult, Older Adult)",,QUESTIONNAIRE TO ASSESS 1) PRESCRIPTION PATTERN FOR PSORIASIS PATIENTS DURING COVID-19 2) MANAGEMENT PATTERN FOR PSORIASIS PATIENTS DURING COVID-19,Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study
NCT04581070,Terminated,Observational,,Cancer Trials Ireland,Other,29-Apr-20,9-Oct-20,9-Oct-20,COHORT,4,CANCER,IRELAND,ALL,"18 Years and older   (Adult, Older Adult)",,A QUALITATIVE DESCRIPTION,"COVID-IYON Study. Prospective, Multisite, Descriptive, Observational Clinical/Epidemiological Study Examining Data Pertaining to Clinical Outcomes and Organizational Responses to the 2020 SARS-Coronavirus-2 (SARS-CoV-2) Pandemic"
NCT04581083,Completed,Observational,,Hunter College of City University of New York,Other,8-Oct-20,30-Oct-20,10-Oct-20,OTHER,30,COVID,BOLIVIA,ALL,21 Years to 64 Years   (Adult),RT-PCR,VALIDATION,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic, Tarija-Bolivia"
NCT04581096,Recruiting,Observational [Patient Registry],,Hospital General Universitario de Valencia,Other,2-Oct-20,15-Jun-21,15-Feb-21,COHORT,3000,COVID,SPAIN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",NO INTERVENTION,SPATIOTEMPORAL SPREAD,Evaluation of the Response of COVID-19 Spread With a Spatiotemporal Analysis in a Tertiary Hospital
NCT04581135,Recruiting,Observational [Patient Registry],,"University Hospital Inselspital, Berne",Other,1-May-20,1-Jun-23,30-Apr-23,COHORT,500,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19,PULMONARY FOLLOW-UP SEQUELAE IN PATIENTS AFTER COVID-19,Prospective Observational Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT04581148,Not yet recruiting,Observational,,University of Erlangen-Nürnberg Medical School,Other,5-Oct-20,22-May-21,22-May-21,COHORT,2000,SARS-COV2,,ALL,"up to 18 Years   (Child, Adult)",BLOOD TEST FOR IGG ANTIBODIES AGAINST SARS-COV-2,"PREVALENCE OF IGG ANTIBODIES AGAINST SARS-COV-2 AT TIMEPOINT ""MONTH 6""",Determination of SARS-CoV2 Antibody Prevalence in Pediatric Patients
NCT04581161,Recruiting,Interventional,Not Applicable,Hill-Rom,Industry,28-Aug-20,20-Oct-21,20-Oct-21,TREATMENT,10,ACUTE RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LIFE2000® VENTILATOR,LIFE2000® COMPARED TO HFNC (AIRVO),A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients
NCT04581187,Not yet recruiting,Observational [Patient Registry],,Gruppo Italiano Malattie EMatologiche dell'Adulto,Other,20-Oct-21,24-Oct-21,22-Oct-21,COHORT,400,HEMATOLOGIC MALIGNANCIES,,ALL,"18 Years and older   (Adult, Older Adult)",QUALITY OF LIFE ASSESSMENT,HRQOL IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES,An onLine-pLatform to Improve Patient-centered Care During the COVID-19 pAndemic: a GIMEMA surveillaNce Program in hematologiC malignanciEs
NCT04581200,Recruiting,Interventional,Not Applicable,Duke University,Other,25-Jan-21,30-Sep-21,31-Jul-21,SUPPORTIVE CARE,300,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LIFT,CHANGE IN PATIENT HEALTH QUESTIONNAIRE-9 ITEM SCALE (PHQ-9),"Addressing Psychological Distress Symptoms Among Serious Illness Survivors of a Viral Pandemic With a Completely Self-directed, Symptom-responsive Mobile Mindfulness Intervention: a Randomized Controlled Trial"
NCT04581291,Completed,Interventional,Not Applicable,Istanbul Gelisim University,Other,1-Jan-20,1-Oct-20,1-Jun-20,PREVENTION,30,COVID,TURKEY,ALL,24 Years to 45 Years   (Adult),MODERATE INTENSITY AEROBIC EXERCISES,IMMUNE SYSTEM MARKERS,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial
NCT04581577,Recruiting,Observational,,Royal Brompton & Harefield NHS Foundation Trust,Other,11-Sep-20,17-Dec-20,17-Dec-20,COHORT,75,NEUROMUSCULAR DISEASES,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",SEMI-STRUCTURED TELEPHONE QUESTIONNAIRE,QUALITATIVE EVALUATION OF THE PERCEIVED CLINICAL AND PSYCHOSOCIAL IMPACT OF THE COVID-19 PANDEMIC IN PATIENTS WITH NEUROMUSCULAR AND NEUROLOGICAL DISORDERS,Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
NCT04581746,Recruiting,Interventional,Not Applicable,Tourcoing Hospital,Other,25-Nov-20,21-Dec-21,21-Dec-21,PREVENTION,1800,VIRUS-HIV,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,PREVALENCE OF SARS COV2 INFECTION IN PVVIH IN HAUTS DE FRANCE,Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
NCT04581811,Recruiting,Interventional,Not Applicable,University of Alabama at Birmingham,Other,10-Nov-20,21-Jun-21,21-May-21,TREATMENT,52,ARDS,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PROLONGED PRONED POSITIONING,DURATION IN PRONE POSITION,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study
NCT04581863,"Active, not recruiting",Interventional,Not Applicable,University of Pennsylvania,Other,30-Nov-20,31-Oct-21,5-Feb-21,SUPPORTIVE CARE,850,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PULSE OXIMETER,DIFFERENCE IN DAYS ALIVE AND OUT OF HOSPITAL,Randomized Trial of Adding Pulse Oximetry to an Automated Text-messaging Program for Remotely Monitoring Patients at Home With COVID-19
NCT04581889,Recruiting,Observational,,University Hospital Tuebingen,Other,2-Jul-20,21-Dec-21,21-Jul-21,COHORT,2380,SEVERE ACUTE RESPIRATORY SYNDROME,GERMANY,ALL,"1 Year to 18 Years   (Child, Adult)",DIAGNOSTIC TEST,"INCIDENCE OF SARS-COV-2 INFECTION IN INFANTS, CHILDREN AND ADOLESCENTS","Prospective, Seroepidemiological, Non-invasive Cohort Study in Tübingen Children Age-stratified by Nursery and School Attendance"
NCT04581915,Recruiting,Interventional,Phase 2/Phase 3,Fatima Mayat,Other,8-Sep-20,31-Dec-21,31-Dec-21,TREATMENT,420,COVID,SOUTH AFRICA,ALL,"18 Years and older   (Adult, Older Adult)",TRIAZAVIRIN (RIAMILOVIR),TO COMPARE THE SLOPE OF CYCLE THRESHOLD(CT) VALUES OF NASOPHARYNGEAL SWABS IN PEOPLE RECEIVING TRIAZAVIRIN VERSUS PLACEBO,"A Pragmatic, Individually Randomised, Double-blind, Placebo-controlled Trial of Triazavirin (TZV) for the Treatment of Mild-moderate SARS-CoV-2 Infection A Phase II and III Clinical Trial"
NCT04581928,Recruiting,Observational,,ClinAmygate,Other,10-Oct-20,15-Apr-21,10-Apr-21,COHORT,300,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,TIME TO RECOVERY,Patients Reactions Towards Their Diagnosis as Having COVID-19: A Cohort Study
NCT04581954,Recruiting,Interventional,Phase 1/Phase 2,Imperial College London,Other,2-Oct-20,31-Jul-21,30-Jun-21,TREATMENT,456,CORONAVIRUS,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",RUXOLITINIB,ALL-CAUSE MORTALITY,Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia
NCT04582201,Recruiting,Interventional,Phase 1,"AgenTus Therapeutics, Inc.",Industry,21-Sep-20,15-Oct-21,24-Apr-21,TREATMENT,55,"RESPIRATORY DISTRESS SYNDROME, ADULT",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AGENT-797,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
NCT04582214,Recruiting,Interventional,Not Applicable,Hill-Rom,Industry,28-Sep-20,1-Jan-21,1-Jan-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",METANEB® SYSTEM,TIME ON MECHANICAL VENTILATION,A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized With COVID-19
NCT04582266,Not yet recruiting,Observational,,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Other,15-Oct-20,15-Jan-22,15-Jan-22,COHORT,40,COVID,PUERTO RICO,FEMALE,"Child, Adult, Older Adult",REMDESIVIR,PK OUTCOME: AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE (AUC) OF RDV,Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
NCT04582318,Recruiting,Interventional,Phase 1/Phase 2,"NGM Biopharmaceuticals, Inc",Industry,8-Nov-20,21-Sep-21,21-Jun-21,TREATMENT,48,SARS-COV2 INFECTION,AUSTRALIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NGM621,TREATMENT EMERGENT ADVERSE EVENTS - PART 1,"A Randomized, Double Blind, Placebo Controlled, Combined Phase 1/2 Single Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of NGM621 in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Subjects With Confirmed SARS-CoV-2 Infection"
NCT04582331,Recruiting,Observational,,Sonde Health,Industry,10-Sep-20,30-Apr-21,30-Apr-21,COHORT,300,COVID,INDIA,ALL,"12 Years and older   (Child, Adult, Older Adult)",SMARTPHONE-BASED VOICE AND SELF-REPORTED SYMPTOM COLLECTION,VOCAL BIOMARKER PERFORMANCE IN COVID-19 POSITIVE VS. HEALTHY CONTROLS,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis
NCT04582344,Recruiting,Interventional,Phase 3,Health Institutes of Turkey,Other,14-Sep-20,15-Apr-21,15-Feb-21,PREVENTION,13000,COVID,TURKEY,ALL,18 Years to 59 Years   (Adult),CORONAVAC,PROTECTION INDEXES OF TWO VACCINE DOSES FOR SYMPTOMATIC COVID-19,"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated"
NCT04582903,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,4-Mar-21,31-Aug-25,31-Aug-25,COHORT,500,COVID INFECTION,UNITED STATES,ALL,"up to 99 Years   (Child, Adult, Older Adult)",,CHARACTERIZATION OF THE DYNAMIC CHANGES OF INNATE AND ADAPTIVE IMMUNE RESPONSES DURING SARS COV 2 INFECTION AND CONVALESCENCE.,Send-in Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
NCT04583189,Completed,Interventional,Not Applicable,Centre Hospitalier Intercommunal Creteil,Other,1-Oct-20,25-Nov-20,25-Nov-20,DIAGNOSTIC,500,COVID,FRANCE,ALL,"up to 18 Years   (Child, Adult)",PERFORMANCE OF THE TEST ANTIGENIC AND TEST RT-PCR,"COMPARISON OF THE PERFORMANCE OF THE BIOSYNEX COVID-19 AG BSS RAPID ANTIGENIC TEST AGAINST THE RT-PCR COVID-19 REFERENCE TEST WITH THE ALLPLEXTM 2019-NCOV KIT (SEEGENE, SOUTH KOREA) IN CHILDREN WITH SYMPTOMS CONSISTENT WITH COVID19 INFECTION",Evaluation Des Performances du Test Rapide antigénique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pédiatriques
NCT04583228,Not yet recruiting,Interventional,Phase 1,Hengenix Biotech Inc,Industry,30-Nov-20,31-May-21,10-Apr-21,OTHER,40,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HLX71,"NUMBER OF PARTICIPANTS WITH ADVERSE EVENTS, SERIOUS ADVERSE EVENT AND INFUSION-RELATED REACTIONS AS ASSESSED BY CTCAE V5.0","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects"
NCT04583293,Recruiting,Observational,,University Hospitals of Derby and Burton NHS Foundation Trust,Other,8-Dec-20,22-Oct-21,22-Oct-21,COHORT,220,ACUTE KIDNEY INJURY,UNITED KINGDOM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",NO INTERVENTION,INCIDENCE OF KIDNEY DISEASE PROGRESSION AT 12 MONTHS.,Long-term Outcomes After Acute Kidney Injury in Coronavirus Disease (COVID-19)
NCT04583306,Recruiting,Observational [Patient Registry],,Fondazione Don Carlo Gnocchi Onlus,Other,1-Jun-20,1-Jun-21,15-Dec-20,CASE-CONTROL,120,COVID,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)","RAMAN ANALYSIS OF SALIVA, CHARACTERIZATION OF THE RAMAN DATABASE AND BUILDING OF THE CLASSIFICATION MODEL",IDENTIFICATION AND CHARACTERIZATION OF A NEW COVID-19 SALIVARY SIGNATURE THROUGH RAMAN SPECTROSCOPY,Characterization of the COVID-19 Raman Signature of Saliva as a Potential Tool for the Fast Discrimination of SARS-CoV-2 Infection and Severity
NCT04583319,Recruiting,Observational,,Firalis SA,Industry,20-Oct-21,21-Mar-21,20-Nov-21,CASE-CONTROL,160,SARS-COV,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",EASYCOV POC,POSITIVE PERCENT AGREEMENT (PPA),"A Prospective, Non-interventional Study for Validation of a Rapid, Non-invasive IVD as a Point-of-care Test for Diagnosis of SARS-COV-2 Infection"
NCT04583345,Recruiting,Observational,,Ebru Calik Kutukcu,Other,1-Jun-20,1-May-21,1-Mar-21,CASE-CONTROL,32,HYPERTENSION,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",QUESTIONNAIRES,PHYSICAL ACTIVITY,Comparison of Physical Activity Levels and Disease Attitudes of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic
NCT04583410,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,22-Oct-20,22-Jun-21,21-Dec-21,TREATMENT,1633,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NICOTINE PATCH,SARS-COV2 SEROCONVERSION BETWEEN W0 AND W19 AFTER RANDOMIZATION,Efficacy of Nicotine in Preventing COVID-19 Infection
NCT04583449,Recruiting,Interventional,Not Applicable,University of East London,Other,19-Aug-20,1-Dec-20,1-Dec-20,PREVENTION,250,VIRAL INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",MENTAL IMAGERY,FACE COVERING WEARING CONSISTENCY,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic
NCT04583566,Recruiting,Observational [Patient Registry],,Tanta University,Other,4-Oct-20,3-Oct-22,3-Oct-21,CASE-CONTROL,40,CORONAVIRUS INFECTION,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",COVID-19 DIAGNOSTIC AND ASSESSMENT TESTS,DIFFERENTIAL GENE EXPRESSION PROFILE.,"Studies on the Differential Expression of Cytokines, Transcriptome and miRNA in the Context of COVID-19 Infection in Egyptian Community"
NCT04583592,Recruiting,Interventional,Phase 2,Sagent Pharmaceuticals Inc.,Industry,9-Nov-20,21-Feb-21,21-Feb-21,TREATMENT,300,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,DISEASE PROGRESSION AT DAY 28,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients"
NCT04583761,"Active, not recruiting",Observational,,Assistance Publique - Hôpitaux de Paris,Other,12-Oct-20,21-Mar-21,21-Feb-21,COHORT,700,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,QUESTIONNAIRE TO ASSESS STRENGTH OF CORRELATION BETWEEN CURRENT SMOKING AND SARS-COV-2 RT-PCR POSITIVITY,Tobacco and Nicotine Consumption and the Risk of Acquisition of COVID-19: A Case Control Study Among Healthcare Workers
NCT04583865,"Active, not recruiting",Observational,,"University Hospital, Toulouse",Other,7-Oct-20,14-Mar-22,14-Sep-21,COHORT,400,ANESTHESIA,FRANCE,ALL,"1 Month to 18 Years   (Child, Adult)",TELECONSULTATION,ASSESS THE FEASIBILITY OF TELECONSULTATION (TLC) IN PEDIATRIC ANESTHESIA IN FRANCE IN THE CONTEXT OF THE COVID 19 PANDEMIC.,Assessment of the Feasibility and Quality of the Consultation by TeleConsultation in Pediatric Anesthesia in the Context of the Covid 19 Pandemic
NCT04583956,Recruiting,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,14-Oct-20,31-Dec-21,31-Dec-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",PLACEBO,CLINICAL EFFICACY IN ADULTS HOSPITALIZED WITH COVID-19 ACCORDING TO CLINICAL STATUS ON AN 8-POINT ORDINAL SCALE.,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
NCT04583969,Recruiting,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,19-Oct-20,31-Dec-21,31-Dec-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",LENZILUMAB,CLINICAL EFFICACY IN ADULTS HOSPITALIZED WITH COVID-19 ACCORDING TO CLINICAL STATUS ON AN 8-POINT ORDINAL SCALE.,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
NCT04583982,Completed,Observational,,Adaptive Biotechnologies,Industry,9-Oct-20,4-Dec-20,4-Dec-20,COHORT,180,CORONAVIRUS DISEASE (COVID),UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",T-DETECT™ SARS-COV-2 ASSAY,DEMONSTRATE CLINICAL AGREEMENT OF T-DETECT™ SARS-COV-2 ASSAY,ImmuneSense™ COVID-19 Study
NCT04583995,Recruiting,Interventional,Phase 3,Novavax,Industry,28-Sep-20,14-Jan-22,21-Jan-21,PREVENTION,15000,SARS-COV2 INFECTION,UNITED KINGDOM,ALL,"18 Years to 84 Years   (Adult, Older Adult)",SARS-COV-2 RS/MATRIX M1-ADJUVANT,"PARTICIPANTS WITH SYMPTOMATIC MILD, MODERATE, OR SEVERE CORONAVIRUS DISEASE 2019 (COVID-19)","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom"
NCT04584411,Not yet recruiting,Observational,,Assiut University,Other,1-Nov-20,1-Jan-24,1-Nov-21,COHORT,50,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CARDIAC MAGNETIC RESONANCE IMAGING,EVALUATION OF THE INCIDENCE OF ARRHYTHMIA AND CONDUCTION BLOCK IN COVID-19 PATIENTS USING HOLTER,Patterns of Arrhythmias and Conduction Block in COVID-19 Patients and Its Relation to Myocardial Injury Detected by Cardiac Magnetic Resonance
NCT04584424,Not yet recruiting,Observational,,Ethiopian Public Health Institute,Other,30-Oct-20,14-Nov-21,14-Sep-21,COHORT,6390,EPIDEMIOLOGY,ETHIOPIA,ALL,"Child, Adult, Older Adult",THE STUDY DOES NOT REQUIRED,NUMBER OF PATIENTS SURVIVAL OR DEATH,Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia: Multi-Site Cohort Study
NCT04584437,Not yet recruiting,Interventional,Not Applicable,GAAD Medical Research Institute Inc.,Other,31-Jan-21,10-Jul-21,10-May-21,TREATMENT,400,COVID,CANADA,ALL,"Child, Adult, Older Adult",INFRARED ENERGY AND DIETARY SUPPLEMENT,TREATMENT AND PREVENTION OF COVID-19 PANDEMIC.,The Treatment and Prevention of Covid-19 Pandemic Using Infrared and /or Vitamin C.
NCT04584450,Completed,Observational,,Hacettepe University,Other,2-Sep-20,31-Dec-20,31-Dec-20,OTHER,100,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,POST-COVID-19 FUNCTIONAL STATUS SCALE (TURKISH VERSION),Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale
NCT04584541,Recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,11-Jun-20,23-Dec-21,23-Jul-21,BASIC SCIENCE,150,SPONDYLOARTHRITIS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD TESTS,DETECTION OF SARS-COV-2 RNA IN FECES AND NASOPHARYNGEAL SWABS,Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments
NCT04584567,Recruiting,Interventional,Phase 3,Hedi Gharsallah,Other,20-Nov-20,1-Mar-21,1-Feb-21,PREVENTION,1100,COVID,TUNISIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",DOXYCYCLIN,DECREASING THE NUMBER OF CASES INFECTED WITH COVID 19,Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers
NCT04584580,Recruiting,Interventional,Phase 4,Ain Shams University,Other,1-Aug-20,31-Dec-20,31-Oct-20,SUPPORTIVE CARE,50,CORONAVIRUS DISEASE (COVID)19,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",LOW-MOLECULAR-WEIGHT HEPARIN,MORTALITY,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia
NCT04584593,Recruiting,Interventional,Not Applicable,"University Hospital, Toulouse",Other,2-Oct-20,22-Feb-21,22-Feb-21,OTHER,50,COVID,FRANCE,MALE,18 Years to 50 Years   (Adult),SAMPLE,SARS-COV-2 GENOMIC RNA IN PATIENT SPERM,Pilot Study to Detect SARS-CoV-2 Virus in Sperm : a COVID-19 Study.
NCT04584606,Recruiting,Observational,,Ain Shams University,Other,27-Jun-20,30-Dec-20,31-Oct-20,CASE-ONLY,100,CORONAVIRUS DISEASE (COVID),EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",LAB WORKUP (ON ADMISSION AND REGULARLY DURING FOLLOW UP).,RECOVERY,Ain Shams University Experience: Clinical Characteristics and Outcome Determinants of Hospitalized Covid-19 Patients at Ain Shams University Obour Hospital
NCT04584658,Recruiting,Observational,,Cambridge University Hospitals NHS Foundation Trust,Other,15-Sep-20,21-Dec-21,21-Oct-21,COHORT,36,DYSPHAGIA,UNITED KINGDOM,ALL,"18 Years to 85 Years   (Adult, Older Adult)",FIBREOPTIC ENDOSCOPIC EVALUATION OF SWALLOWING (FEES),PRIMARY ENDPOINT IS SEVERITY OF DYSPHONIA AND DYSPHAGIA AT THE TIME OF INITIAL ASSESSMENT T = DAY 0 (FOR ITU PATIENTS: DAY 0 = 24 HOURS AFTER EXTUBATION OR DECANNULATION).,Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19): A Prospective Observational Cohort Study.
NCT04584671,Not yet recruiting,Observational,,"Western University, Canada",Other,1-Dec-20,1-Dec-24,1-Dec-22,COHORT,200,COVID,CANADA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",HYPERPOLARIZED XENON-129 MRI OF THE LUNGS,DETERMINE LONG-TERM RESPIRATORY IMPAIRMENT IN COVID-19 SURVIVORS WHO DID AND DID NOT REQUIRE HOSPITALIZATION AT ONE YEAR AS MEASURED BY VDP.,Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI and CT For Rapid Evaluations and NExt-wave Healthcare Planning
NCT04584684,Recruiting,Interventional,Phase 2,"University of North Carolina, Chapel Hill",Other,18-Dec-20,23-Sep-21,22-Sep-21,TREATMENT,480,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",1.5-2% W/V HYDROGEN PEROXIDE,CHANGE IN QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) FROM BASELINE TO 15 MINUTES,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus
NCT04584697,Withdrawn,Interventional,Phase 1/Phase 2,"Sorrento Therapeutics, Inc.",Industry,20-Dec-21,21-Apr-21,21-Apr-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVI-AMG,"INCIDENCE OF ADVERSE EVENTS BY TYPE, FREQUENCY, SEVERITY, AND CAUSALITY (SAFETY)","A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Outpatients With COVID-19 Who Are Asymptomatic or Have Mild Symptoms"
NCT04584710,"Active, not recruiting",Interventional,Phase 2,Restorbio Inc.,Industry,13-Oct-20,21-Feb-21,21-Feb-21,PREVENTION,60,COVID,UNITED STATES,ALL,65 Years and older   (Older Adult),RTB101,TO DETERMINE THE LENGTH OF TIME FROM DATE OF RECEIPT OF A POSITIVE SARS-COV2 TEST RESULT TO DATE OF FIRST DOSE OF STUDY DRUG IN ASYMPTOMATIC ADULTS AGE ≥ 65 YEARS,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years"
NCT04585945,Recruiting,Observational,,Prisma Health-Upstate,Other,4-Aug-20,30-Sep-21,31-Mar-21,CASE-CONTROL,100,COVID,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",POSITIVE FOR SARS-COV-2 INFECTION,"INFLAMMATORY BIOMARKERS IN UMBILICAL CORD BLOOD BETWEEN WOMEN WITH COVID-19 DISEASE IN THE FIRST, SECOND AND THIRD TRIMESTER OF PREGNANCY AND DETERMINE IF DIFFERENCES ARE MEDIATED BY SEVERITY OF THE ILLNESS.",Pregnancy Outcomes During the Pandemic: Using Placental Pathology and Gene Expression to Understand Fetal Risk
NCT04586114,"Active, not recruiting",Observational,,"Central Hospital, Nancy, France",Other,1-Mar-20,31-Dec-20,31-May-20,COHORT,200,ACUTE RESPIRATORY DISTRESS SYNDROME SECONDARY TO COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CORTICOSTEROIDS AND DERIVATIVES,MORTALITY IN ICU,Effect of Early Corticosteroid Therapy on Mortality in Patient With Acute Respiratory Distress Syndrome Secondary to Covid-19
NCT04586140,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,9-Nov-20,30-Apr-22,30-Apr-21,COHORT,30,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,INTEREST OF GAREC,Operation of the Groupe Hospitalier Paris Saint-Joseph Clinical Ethical Reflection Assistance Group During the COVID-19
NCT04586153,Not yet recruiting,Interventional,Phase 2/Phase 3,Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd,Industry,30-Dec-20,30-Sep-21,28-Apr-21,TREATMENT,456,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",MEPLAZUMAB FOR INJECTION,TIME TO SUSTAINED CLINICAL IMPROVEMENT,"A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults"
NCT04586413,Recruiting,Observational,,Medialis Ltd.,Industry,7-Oct-20,25-Oct-21,22-Oct-21,COHORT,100,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION - QUALITY OF LIFE MEASURE,DESIGN OF PAC19QOL MEASURE (PHASE ONE),Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg)
NCT04587219,"Active, not recruiting",Interventional,Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,22-Oct-20,30-Apr-21,30-Mar-21,PREVENTION,110,CORONAVIRUS INFECTION,RUSSIAN FEDERATION,ALL,"60 Years to 111 Years   (Adult, Older Adult)",GAM-COVID-VAC,CHANGING OF ANTIBODY LEVELS AGAINST THE SARS-COV-2 GLYCOPROTEIN S IN 42 DAYS,"An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years"
NCT04587245,Recruiting,Observational,,"ND Sciences, LLC",Industry,1-Oct-20,15-Oct-21,15-Oct-21,COHORT,100,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",ONLINE QUESTIONNAIRE AND INTERVIEWS,"CHANGE IN MONTHLY INCOME OF HEALTHCARE PROVIDERS FROM BASELINE TO 6, 9 AND 12 MONTHS AFTER THE BEGINNING OF THE COVID-RELATED EVENTS",The Provider Insurance Revenue Study
NCT04587258,Recruiting,Observational,,Rhode Island Hospital,Other,28-Aug-20,1-Sep-22,1-Sep-22,ECOLOGIC OR COMMUNITY,100,BREAST CANCER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INFORMATIONAL VIDEOS AND SOCIAL MEDIA CAMPAIGNS ENCOURAGING CANCER SCREENING.,INCREASE SCREENING RATES FOR BREAST AND COLORECTAL CANCER,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island: A Community Based Quality Improvement Project of the Lifespan Cancer Institute
NCT04587323,Recruiting,Observational,,University of Alabama at Birmingham,Other,22-May-20,20-May-23,20-Mar-23,COHORT,100,COVID DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,LABORATORY ASSAYS,COVID-19 RELATED SUBMISSION: VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
NCT04587375,Completed,Observational,,"University Hospital, Montpellier",Other,1-Mar-20,30-May-20,1-May-20,COHORT,50,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PLASMA ALDOSTERONE LEVELS,Diagnosis of Endocrine Dysfunctions in Covid-19 : Explorations of the Plasma Renin and Aldosterone Levels in Patients With Covid-19 Infection.
NCT04587414,"Active, not recruiting",Interventional,Not Applicable,UKK Institute,Other,6-Mar-19,31-Oct-20,31-Oct-20,SUPPORTIVE CARE,122,TYPE2 DIABETES,FINLAND,ALL,"20 Years to 69 Years   (Adult, Older Adult)",EHEALTH +COUNSELLING CONTACTS,CHANGE IN TOTAL MEAN DAILY STEP COUNT,Personalized eHealth Intervention in Patients With Type 2 Diabetes to Promote Daily Physical Activity Utilizing 24h Self-monitoring - Implementation Frustrated by COVID-19 Epidemic
NCT04587921,Recruiting,Interventional,Not Applicable,University of Sao Paulo General Hospital,Other,22-Jun-20,22-Jun-21,22-Jan-21,SUPPORTIVE CARE,90,OXIMETRY,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",DIGITAL OXIMETER MONITORING,FEASIBILITY OF THE SYSTEM: DETERMINATION OF THE NUMBER OF VALID VERSUS NOT VALID OR MISSED MEASUREMENTS,Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19
NCT04588363,Recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,19-Nov-20,22-Nov-21,21-Nov-21,COHORT,250,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2),UNITED STATES,ALL,"up to 20 Years   (Child, Adult)",SARS-COV-2 AND/OR MIS-C EXPOSURE,"PROPORTION OF PARTICIPANTS WITH EITHER COVID-19-RELATED DEATH, REHOSPITALIZATION, MAJOR COMPLICATIONS AFTER SARS-COV-2 ILLNESS AND/OR MIS-C AT 6 MONTHS POST ILLNESS PRESENTATION",An Observational Cohort Study to Determine Late Outcomes and Immunological Responses After Infection With SARS-CoV-2 in Children With and Without Multisystem Inflammatory Syndrome (MIS-C)
NCT04588415,Enrolling by invitation,Interventional,Not Applicable,Ottawa Hospital Research Institute,Other,3-Jan-21,1-Jan-22,1-Dec-21,SUPPORTIVE CARE,200,BEREAVEMENT,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",BEREAVEMENT VIRTUAL SUPPORT GROUP,THE INVENTORY FOR COMPLICATED GRIEF-REVISED (ICG-R) SCORE AT 6 MONTHS POST-DEATH,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic
NCT04588441,Not yet recruiting,Interventional,Phase 2,University of Florida,Other,21-Mar-21,22-Dec-21,22-Dec-21,TREATMENT,30,ACUTE RESPIRATORY DISTRESS,,ALL,"18 Years to 105 Years   (Adult, Older Adult)",ADENOSINE,IMPROVED COVID-19 SYMPTOMS,Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 (The ARCTIC Trial)
NCT04588480,"Active, not recruiting",Interventional,Phase 1/Phase 2,BioNTech SE,Industry,21-Oct-20,30-Nov-21,30-Nov-21,PREVENTION,160,SARS-COV2 INFECTION,JAPAN,ALL,"20 Years to 85 Years   (Adult, Older Adult)",BNT162B2,PERCENTAGE OF PARTICIPANTS REPORTING LOCAL REACTIONS,"A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS"
NCT04588792,Recruiting,Interventional,Phase 2/Phase 3,Queen's University,Other,1-Feb-21,1-Oct-21,1-Oct-21,TREATMENT,640,COVID,CANADA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",NEBULIZED FUROSEMIDE,IMPROVEMENT IN PULMONARY GAS EXCHANGE,Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study
NCT04588909,"Active, not recruiting",Observational,,Sheri Kashmir Institute of Medical Sciences,Other,23-Mar-20,22-Oct-20,22-Sep-20,COHORT,100,COLO-RECTAL CANCER,INDIA,ALL,"Child, Adult, Older Adult",COLORECTAL RESECTIONS,EARLY POST OPERATIVE MORTALITY,Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy
NCT04589104,Completed,Interventional,Not Applicable,Duke University,Other,26-May-20,17-Aug-20,17-Aug-20,SUPPORTIVE CARE,63,DISTRESS DUE TO COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXPRESSIVE WRITING,RESILIENCE,Expressive Writing for COVID-19 Resilience
NCT04589117,Completed,Interventional,Not Applicable,Duke University,Other,27-May-20,2-Aug-20,2-Aug-20,SUPPORTIVE CARE,11,PARENTS DURING COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXPRESSIVE WRITING,RESILIENCE,Expressive Writing for COVID-19 Resilience for Parents
NCT04589923,Recruiting,Observational,,Xim Limited,Industry,14-Sep-20,22-Jan-21,22-Jan-21,COHORT,200,HYPERTENSION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",LIFELIGHT® DATA COLLECT BLOOD PRESSURE GROUP,PRIMARY OBJECTIVE,The Measurement of VItal SIgns by Lifelight® Data Collect Software in comparisON to the Standard of Care in Acutely Unwell Patients - The VISION-Acute Study
NCT04589936,Recruiting,Interventional,Not Applicable,Cambridge University Hospitals NHS Foundation Trust,Other,3-Sep-20,30-Jun-21,30-Jun-21,TREATMENT,56,PNEUMONIA,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITIONING,PERIPHERAL OXYGEN SATURATION,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care (PRONE-COVID Study)
NCT04589949,Recruiting,Interventional,Phase 3,Erasmus Medical Center,Other,12-Oct-20,1-Nov-23,1-Nov-22,TREATMENT,690,COVID,NETHERLANDS,ALL,"50 Years and older   (Adult, Older Adult)",CONVP,HIGHEST DISEASE STATUS,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
NCT04590053,Recruiting,Interventional,Phase 2,Hadassah Medical Organization,Other,20-Oct-20,21-Mar-21,21-Feb-21,PREVENTION,24,COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ALLOCETRA-OTS,ASSESSMENT OF SAFETY BY DETERMINING THE NUMBER OF PARTICIPANTS WITH ANY ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE),"A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction"
NCT04590170,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,30-Oct-20,30-Apr-23,30-Oct-22,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",POST-INTENSIVE CARE UNIT SYNDROME,CHANGE ON COGNITIVE IMPAIRMENT: VIGILANCE (RASS),French Cohort of covid19 Patients With Post-intensive Care Syndrome : Rehabilitation From Intensive Care Unit to Home Return
NCT04590209,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Oct-21,20-Dec-21,20-Dec-21,BASIC SCIENCE,25,ADULT PATIENTS WITH LESIONS ON FINGERS OR TOES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,DETECTION OF SARS-COV-2 BY REAL-TIME PCR AND SEROLOGICAL TEST,Clinical and Mechanistic Study of Patients With a Recent Acrosyndrome
NCT04590222,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Nov-21,21-Nov-21,21-Nov-21,CASE-CONTROL,80,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLE,LEVELS OF LYMPHOCYTES T DR + CD38 + AND OF MONOCYTES CD14 DIM + CD16 +.,Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
NCT04590261,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,1-Nov-20,1-Nov-23,1-Nov-22,SCREENING,120,COVID; SARS-COV2,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",BLOOD SAMPLING,MYELOID CELL SUB-POPULATION PHENOTYPE,Myeloid Cells in Patients With Covid-19 Pneumonia
NCT04590274,Not yet recruiting,Interventional,Phase 1,International Brain Research Foundation,Other,20-Nov-21,21-Dec-21,21-Dec-21,PREVENTION,5000,COVID,,ALL,"Child, Adult, Older Adult",HYDROXYCHLOROQUINE,PERCENTAGE OF INDIVIDUALS WHO DEVELOP COVID-19 SYMPTOMS,Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04590352,Completed,Observational,,Radboud University,Other,26-Mar-20,13-May-20,13-May-20,COHORT,187,SARS-COV2 INFECTION,NETHERLANDS,ALL,"Child, Adult, Older Adult",NASOPHARYNGEAL AND THROAT SWAB,MUCOSAL ANTIBODIES,Mucosal Immunity in Patients Diagnosed With SARS-CoV-2 Infection and Their Household Contacts
NCT04590365,Not yet recruiting,Interventional,Not Applicable,Swansea University,Other,30-Jan-21,1-Dec-21,1-Nov-21,PREVENTION,480,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",CARRAGEENAN NASAL AND THROAT SPRAY,RATE OF COVID-19 INFECTION IN HEALTHCARE PROFESSIONALS,Efficacy of Iota-carrageenan Nasal Spray Prophylaxis for Healthcare Professionals Treating Patients During the COVID-19 Pandemic - A Double Blind Randomised Placebo-controlled Trial
NCT04590378,Recruiting,Observational,,Uşak University,Other,1-Mar-20,1-Dec-20,1-Nov-20,COHORT,600,COVID,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",INTENSIVE CARE UNIT ADMISSION RATIO,PULMONARY EMBOLISM,Evaluation of the Patients With COVID-19 in Terms of Pulmonary Embolism
NCT04590430,"Active, not recruiting",Interventional,Phase 1,HiFiBiO Therapeutics,Industry,20-Oct-20,21-Jul-21,21-Feb-21,TREATMENT,24,HEALTHY,UNITED STATES,ALL,18 Years to 60 Years   (Adult),HFB30132A,NUMBER OF PARTICIPANTS WITH TREATMENT EMERGENT SERIOUS ADVERSE EVENTS (TESAES),"A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose First-in-Human Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered HFB30132A, a Monoclonal Antibody Directed Against SARS-CoV-2, in Healthy Adult Subjects"
NCT04590469,Not yet recruiting,Interventional,Not Applicable,University of Exeter,Other,20-Nov-20,1-Jan-22,1-Sep-21,TREATMENT,2880,DEMENTIA,,ALL,"60 Years and older   (Adult, Older Adult)",COVID WHELD,DEMENTIA QUALITY OF LIFE - DEMQOL PROXY,Evidence-Based Supported Digital Intervention for Improving Wellbeing and Health of People Living in Care Homes and Care Home Staff (WHELD) During COVID-19: An RCT to Evaluate COVID-19 Adapted E-WHELD: Benefits and Cost-Effectiveness
NCT04590547,Not yet recruiting,Interventional,Phase 2,"GeneOne Life Science, Inc.",Industry,21-Feb-21,21-Nov-21,21-Oct-21,TREATMENT,132,PNEUMONITIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GLS-1027,INCIDENCE OF SERIOUS ADVERSE EVENTS RELATIVE TO TREATMENT GROUP,"Safety, Tolerability and Efficacy of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection"
NCT04590586,Recruiting,Interventional,Phase 3,Amgen,Industry,24-Nov-20,28-Jan-22,28-Jan-22,TREATMENT,1400,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OF CARE,TIME TO CONFIRMED CLINICAL RECOVERY,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
NCT04590794,"Active, not recruiting",Observational,,University of Thessaly,Other,11-Oct-20,28-Feb-21,31-Jan-21,COHORT,500,COVID,GREECE,ALL,"18 Years to 120 Years   (Adult, Older Adult)",SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR,RESPIRATORY COMPLICATIONS,A Prospective Observational Study on Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Adult Patients With Covid-19
NCT04591015,Recruiting,Interventional,Phase 3,Scripps Whittier Diabetes Institute,Other,1-Feb-21,31-Aug-21,31-Jul-21,PREVENTION,172,"DIABETES MELLITUS, TYPE 2",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL: DD-CA,READMISSION RATE (30-DAYS),Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19
NCT04591158,Recruiting,Interventional,Not Applicable,Bridge to Health Medical and Dental USA,Other,15-Sep-20,21-Sep-21,21-Sep-21,DIAGNOSTIC,100,COVID,CANADA,ALL,"18 Years to 120 Years   (Adult, Older Adult)",BUTTERFLY IQ,IF PATIENTS CAN PERFORM LUNG ULTRASOUND.,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19
NCT04591184,Not yet recruiting,Interventional,Phase 1,Entos Pharmaceuticals Inc.,Industry,21-Mar-21,22-Aug-21,21-Aug-21,PREVENTION,72,SARS-COV2,,ALL,"18 Years to 84 Years   (Adult, Older Adult)",COVIGENIX VAX-001 PLACEBO,SAFETY OF A 2-DOSE REGIMEN OF VAX-001 WHEN DOSES ARE GIVEN 14 DAYS APART,"Phase I/II Trial to Evaluate Safety, Tolerability, Immunogenicity of a Prophylactic Plasmid DNA Vaccine for SARS CoV-2 [Covigenix VAX-001] in Healthy Adults From 18 to <85 Years of Age"
NCT04591210,Recruiting,Interventional,Phase 3,Ottawa Heart Institute Research Corporation,Other,27-Jan-21,22-Aug-21,21-Dec-21,TREATMENT,1155,COVID,CANADA,ALL,65 Years and older   (Older Adult),ANGIOTENSIN CONVERTING ENZYME INHIBITOR,DEATH,"Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial"
NCT04591600,Completed,Interventional,Phase 1/Phase 2,Alkarkh Health Directorate-Baghdad,Other,1-Jul-20,14-Oct-20,30-Sep-20,TREATMENT,140,COVID,IRAQ,ALL,"16 Years to 86 Years   (Child, Adult, Older Adult)",IVERMECTIN AND DOXYCYLINE,MORTALITY RATE,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq"
NCT04591613,Recruiting,Interventional,Not Applicable,Tourcoing Hospital,Other,31-Dec-20,22-Aug-21,22-Aug-21,OTHER,1000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,CLINICAL DESCRIPTION OF ASTHENIA,Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort
NCT04591704,Recruiting,Observational,,Uşak University,Other,20-Mar-20,1-Nov-20,15-Oct-20,CASE-CONTROL,2000,COVID,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)","HOSPITALISATION, NECESSITY OF ICU, MORTALITY RATE, LUNG INVOLVEMENT",DURATION OF HOSPITALISATION,The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19
NCT04591717,Recruiting,Interventional,Phase 1,"ImmunityBio, Inc.",Industry,19-Oct-20,19-Nov-21,19-Nov-21,TREATMENT,60,COVID,UNITED STATES,ALL,18 Years to 55 Years   (Adult),HAD5-S-FUSION+N-ETSD VACCINE,INCIDENCE OF MAAES AND SAES,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers"
NCT04591873,Not yet recruiting,Observational,,National Taiwan University Hospital,Other,10-Oct-20,30-Oct-21,10-Oct-21,CASE-CONTROL,100,CRITICAL ILLNESS,TAIWAN,ALL,"20 Years to 99 Years   (Adult, Older Adult)",TELEMEDICINE,TIME TO COMPLETE INTUBATION,Application of Telemedicine to Optimize Teamwork and Infection Control of Critical Patients in Isolation Rooms in the Emergency Department During Novel Coronavirus Disease 2019 Outbreak
NCT04592055,Recruiting,Observational,,Uşak University,Other,20-Mar-20,1-Nov-20,15-Oct-20,CASE-ONLY,500,DIABETES MELLITUS,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,A1C,The Effect of COVID-19 on the Glycemic Control in Patients With Diabetes Mellitus
NCT04592354,Recruiting,Interventional,Not Applicable,Terra Biological LLC,Industry,15-Oct-20,15-Jun-21,15-Apr-21,TREATMENT,40,TREATMENT OF FATIGUE AFTER RESOLUTION OF COVID INFECTION,UNITED STATES,FEMALE,"18 Years to 65 Years   (Adult, Older Adult)",OXALOACETATE MEDICAL FOOD/DIETARY SUPPLEMENT,FATIGUE,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors
NCT04592510,Not yet recruiting,Observational,,Cairo University,Other,21-Feb-21,22-Jan-21,21-Oct-21,ECOLOGIC OR COMMUNITY,345,SARS-COV2,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,ATTITUDE OF PEDIATRIC DENTISTS TOWARD TREATING PATIENTS IN TIME OF COVID-19.,Impact of COVID-19 on Pediatric Dental Practice During First and Second Wave : A Cross -Sectional Study Among a Group of Pediatric Dentists
NCT04592549,Recruiting,Interventional,Phase 1,Ology Bioservices,Industry,4-Dec-20,30-Sep-21,30-Sep-21,TREATMENT,40,SARS-COV2,UNITED STATES,ALL,18 Years to 55 Years   (Adult),ADM03820,THE NUMBER OF PARTICIPANTS WITH SERIOUS ADVERSE EVENTS FOLLOWING ADMINISTRATION OF ADM03820 TO THE FINAL VISIT,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults"
NCT04592705,Recruiting,Interventional,Phase 1,Larkin Community Hospital,Other,11-Sep-20,30-Aug-21,30-Aug-21,DEVICE FEASIBILITY,10,COVID,UNITED STATES,ALL,"18 Years to 69 Years   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE,TIME TO CLINICAL STATUS DOWNGRADE OR DISCHARGE.,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients
NCT04592835,Not yet recruiting,Interventional,Phase 1,Daewoong Pharmaceutical Co. LTD.,Industry,19-Oct-20,30-Jun-21,13-Dec-20,TREATMENT,24,COVID PATIENTS,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",DWRX2003,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,"A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers"
NCT04593069,Recruiting,Interventional,Not Applicable,Ziekenhuis Oost-Limburg,Other,7-Oct-20,28-Feb-21,28-Feb-21,OTHER,60,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",NEUROCOGNITIVE ASSESSMENT,NEUROCOGNITIVE IMPAIRMENT MEASURED BY RBANS,"Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study"
NCT04593433,Not yet recruiting,Interventional,Not Applicable,Jewish General Hospital,Other,4-Mar-21,4-Sep-21,4-Jul-21,OTHER,40,SOCIAL ISOLATION,CANADA,ALL,65 Years and older   (Older Adult),MUSEUM VIRTUAL GUIDED TOURS,WELL-BEING,"A 3-month Cycle of Virtual Weekly Montreal Museum of Fine Arts Tours to Promote Social Inclusion, Well-being, Quality of Life and Health in Older Community Members : a Pilot Study"
NCT04593641,"Active, not recruiting",Interventional,Phase 1,Celltrion,Industry,4-Sep-20,23-Dec-20,22-Oct-20,TREATMENT,18,SARS-COV2 INFECTION,"KOREA, REPUBLIC OF",ALL,18 Years to 60 Years   (Adult),CT-P59,TO EVALUATE THE PRELIMINARY SAFETY AND TOLERABILITY OF CT-P59 UP TO DAY 14 OF THE LAST ENROLLED SUBJECT,"A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection"
NCT04593654,Completed,Observational,,Karolinska Institutet,Other,1-Mar-20,15-Oct-20,15-Aug-20,COHORT,257,COVID,SWEDEN,ALL,"Child, Adult, Older Adult",DOSE OF TINZAPARIN OR DALTEPARIN,28-DAY MORTALITY,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients - More Patients Included and 90-day Follow up
NCT04593940,Recruiting,Interventional,Phase 3,Daniel Benjamin,Other,15-Oct-20,21-Sep-21,21-Aug-21,TREATMENT,2160,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INFLIXIMAB,NUMBER OF PATIENTS THAT RECOVERED FROM COVID-19,Randomized Master Protocol for Immune Modulators for Treating COVID-19
NCT04594278,Not yet recruiting,Interventional,Not Applicable,"University Health Network, Toronto",Other,1-Nov-20,1-Jul-21,1-Apr-21,HEALTH SERVICES RESEARCH,100,STRESS,,ALL,"18 Years and older   (Adult, Older Adult)",MINDFULNESS BASED INTERVENTION,PERCEIVED STRESS,Remote Delivery of a Mindfulness-based Intervention to Decrease Anxiety Levels and Burnout Among Health-care Professionals During the Covid-19 Pandemic
NCT04594291,Recruiting,Observational,,University Hospitals of Derby and Burton NHS Foundation Trust,Other,7-Oct-20,23-Sep-21,23-Sep-21,COHORT,60,ACUTE KIDNEY INJURY,UNITED KINGDOM,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MRI SCANS,MRI ASSESSMENT OF GLOBAL ORGAN STRUCTURE AT 12 MONTHS.,Long-term Outcomes After Acute Kidney Injury in Coronavirus Disease (COVID-19) as Determined by Multiparametric Magnetic Resonance Imaging (MRI)
NCT04594330,Recruiting,Interventional,Phase 2,Gadjah Mada University,Other,1-Jun-20,31-Dec-20,31-Dec-20,TREATMENT,60,CORONAVIRUS INFECTION,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",VIRGIN COCONUT OIL (VCO),ORDINAL SCALE FOR MEASURING CLINICAL IMPROVEMENT BY THE WORLD HEALTH ORGANIZATION (WHO),Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients
NCT04594343,Recruiting,Interventional,Phase 2,ETICA,Other,20-Nov-20,21-Apr-21,21-Mar-21,TREATMENT,200,COVID,BRAZIL,ALL,"50 Years and older   (Adult, Older Adult)",DISULFIRAM,CHANGE FROM BASELINE TO DAY 7 FOR CYTOKINE IL-18,"A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19"
NCT04594356,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,19-Nov-20,30-Jun-21,31-Jan-21,COHORT,126,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,EVALUATION OF THE NETOSIS PROCESS,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist"
NCT04594395,Not yet recruiting,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,4-Mar-21,31-Dec-23,31-Dec-23,COHORT,2700,HEALTHY VOLUNTEERS,CAMBODIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,PRESENCE OR ABSENCE OF SARSCOV-2 IMMUNOGLOBULIN IN PARTICIPANT SERA BY ELISA OPTICAL DENSITY CHANGE.,Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in Healthy Volunteers
NCT04594460,Not yet recruiting,Interventional,Not Applicable,Guangzhou Institute of Respiratory Disease,Other,31-Oct-20,31-Dec-21,31-Oct-21,TREATMENT,198,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)","HYDROGEN-OXYGEN GENERATOR WITH NEBULIZER, AMS-H-03",(VO2MAX),A Clinical Trial to Evaluate the Efficacy and Safety of Hydrogen-oxygen Mixed Gas Inhalation in Convalescent Severe/Critically Ill Patients With Novel Coronavirus Pneumonia (COVID-19)
NCT04594525,Not yet recruiting,Interventional,Not Applicable,Hamad Medical Corporation,Industry,21-Jun-21,22-Jun-21,21-Sep-21,PREVENTION,58,PERINATAL DEPRESSION,,FEMALE,18 Years to 49 Years   (Adult),LOW-INTENSITY PSYCHOSOCIAL INTERVENTIONS THROUGH TELEMENTAL HEALTH,BASELINE (T0) PERINATAL DEPRESSION THROUGH THE 10-POINTS EDINBURGH POSTNATAL DEPRESSION (SCALE (EPDS-10),Low-intensity Psychosocial Interventions in Pregnant Women in Response to COVID-19: Maternal Mental Health Matters An Interventional Study
NCT04594668,Recruiting,Interventional,Phase 2,University of Aarhus,Other,24-Apr-20,31-Dec-21,24-Apr-21,TREATMENT,46,"ARDS, HUMAN",DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",SENICAPOC,PAO2/FIO2 RATIO,"Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency - A Randomized, Open-Label, Phase II Trial"
NCT04595084,Not yet recruiting,Interventional,Not Applicable,Cambridge Health Alliance,Other,15-Feb-21,1-Nov-22,1-Nov-21,TREATMENT,240,DEPRESSION,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",MINDFULNESS BASED COGNITIVE THERAPY FOR RESILIENCE DURING COVID-19 PLUS CHAMINDWELL,DEPRESSION SEVERITY (CAT-DI),Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use
NCT04595097,Not yet recruiting,Interventional,Not Applicable,Escola Superior de Ciencias da Saude,Other,1-Feb-21,30-Sep-21,20-Aug-21,TREATMENT,120,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",INSPIRATORY MUSCLE TRAIING,HEALTH- RELATED QUALITY OF LIFE,Adjunctive Inspiratory Muscle Training for Patients With COVID-19
NCT04595110,Recruiting,Observational,,ANNA FALANGA,Other,25-Mar-20,10-May-21,25-Apr-21,COHORT,400,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL STUDY,INCIDENCE OF MORTALITY AMONG ENROLLED COVID-19 PATIENTS,Extensive Investigation of the Hemostatic Profile in a Prospective Cohort of Patients Affected by COVID-19
NCT04595123,Recruiting,Observational,,University of Minho,Other,15-Jun-20,15-Jun-21,1-Nov-20,COHORT,3900,POST TRAUMATIC STRESS DISORDER,ALBANIA,FEMALE,"18 Years and older   (Adult, Older Adult)",,DEPRESSIVE SYMPTOMS,Impact of COVID-19 Pandemic in Perinatal Mental Health
NCT04595136,Not yet recruiting,Interventional,Phase 1/Phase 2,United Medical Specialties,Other,2-Nov-20,29-Jan-21,15-Dec-20,TREATMENT,60,SARS-COV2 INFECTION,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",DRUG COVID19-0001-USR,CHANGE ON VIRAL LOAD RESULTS FROM BASELINE AFTER USING COVID19-0001-USR VIA NEBULIZATION,A Two-arm Randomized Double-blind Study With COVID19-0001-USR Administered Via Nebulization to Patients With Mild and/or Moderate Severe Acute Respiratory Syndrome (SARS-COV-2) Infection to Decrease Viral Load
NCT04595175,Recruiting,Observational [Patient Registry],,"Brian Tiffany, MD",Other,10-Jun-20,30-Dec-21,30-Jun-21,COHORT,2000,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,BASELINE IGG ASSAY INFORMATION,Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)
NCT04595240,Completed,Observational,,Assiut University,Other,1-May-20,15-Oct-20,15-Oct-20,OTHER,100,COVID,EGYPT,MALE,20 Years to 45 Years   (Adult),SEMEN ANALYSIS,CHANGES OF SEMEN VOLUME IN (ML)BY COVID-19 FROM NORMAL VALUES.,Semen Analysis Changes in Covid-19 Positive Patients
NCT04595695,Completed,Interventional,Not Applicable,"University of North Carolina, Chapel Hill",Other,3-Sep-20,14-Dec-20,12-Nov-20,HEALTH SERVICES RESEARCH,200,COMMUNICATION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TRANSPARENT MASK,PATIENT MASK PREFERENCE QUANTITATIVE,The Effect of Clear Masks in Improving Patient Relationships
NCT04595773,Recruiting,Interventional,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),NIH,22-Jan-21,31-Dec-23,31-Dec-23,TREATMENT,90,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AEROBIC EXERCISE TRAINING,6 MINUTE WALK TEST DISTANCE,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE): A Randomized Controlled Trial"
NCT04595903,Not yet recruiting,Interventional,Not Applicable,Aethlon Medical Inc.,Industry,21-Jan-21,21-Aug-21,21-Aug-21,TREATMENT,40,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HEMOPURIFIER,INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS,Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device
NCT04596085,Recruiting,Interventional,Not Applicable,"The Herb, Inc",Industry,16-Sep-20,30-Jan-21,30-Nov-20,SUPPORTIVE CARE,124,COVID,INDIA,ALL,"50 Years to 90 Years   (Adult, Older Adult)",INVESTIGATIONAL PRODUCT - VIRACIDE,NEWS SCORE,"A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)"
NCT04596098,Recruiting,Observational,,"University Hospital, Grenoble",Other,30-Apr-20,30-Sep-21,30-Jun-21,COHORT,100,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,"ISOLATION OF RECOMBINANT MONOCLONAL NEUTRALIZING ANTIBODIES DIRECTED AGAINST SARS-COV-2, ISOLATED FROM COVID19 HOSPITALIZED PATIENTS BLOOD PROBES.",Immune Responses to COVID-19 (SARS-CoV-2 Related Infection); Isolation of Human Neutralizing Monoclonal Antibodies for Therapeutics and Vaccine Design Approaches: a Prospective Monocentric Trial With Collaborative Sample Collection.
NCT04596579,Enrolling by invitation,Observational,,H. Lee Moffitt Cancer Center and Research Institute,Other,9-Oct-20,9-Oct-22,9-Oct-21,ECOLOGIC OR COMMUNITY,1200,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 ANTIBODY ANALYSIS,PERCENTAGE OF PARTICIPANTS WHO TEST POSITIVE FOR SARS-COV-2 ANTIBODIES AT FIRST VISIT,SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida
NCT04596657,Recruiting,Interventional,Not Applicable,The Cooper Health System,Other,27-Oct-20,21-Nov-21,21-Oct-21,PREVENTION,2099,RESPIRATORY TRACT INFECTIONS,UNITED STATES,ALL,"52 Years and older   (Adult, Older Adult)",VITAMIN D SUPPLEMENTATION,RESPIRATORY TRACT INFECTION,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections in Hospital Workers: a Pragmatic Study
NCT04596839,Recruiting,Interventional,Not Applicable,Dr. Md. Alimur Reza,Industry,4-Sep-20,30-Apr-21,28-Feb-21,TREATMENT,60,COVID,BANGLADESH,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,DURATION OF HOSPITAL STAY (DAYS),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial"
NCT04596943,Recruiting,Observational,,Radboud University,Other,15-Oct-20,30-Jan-21,31-Dec-20,COHORT,10,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",[68GA]GA-DOTA-(RGD)2 PET/CT,UPTAKE OF [68GA]GA-DOTA-(RGD)2 IN THE LUNG PARENCHYMA,[68Ga]Ga-DOTA-(RGD)2 PET/CT Imaging of Activated Endothelium in Lung Parenchyma of COVID-19 Patients
NCT04597034,Recruiting,Interventional,Not Applicable,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,Other,2-Oct-20,30-Mar-22,30-Dec-21,TREATMENT,35,COVID,MEXICO,ALL,"18 Years to 75 Years   (Adult, Older Adult)",AN69-OXIRIS,PRIMARY OUTCOME:,"A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study."
NCT04597047,Recruiting,Interventional,Not Applicable,LumiraDx UK Limited,Industry,20-Aug-20,31-Dec-22,31-Oct-22,DIAGNOSTIC,200,COVID,UNITED STATES,ALL,"2 Years and older   (Child, Adult, Older Adult)",CAPILLARY COLLECTION & TESTING,PERFORMANCE EVALUATION,"A Multicenter Covid-19 Study Conducted to Evaluate the Agreement Between Fingerstick Whole Blood, Venous Whole Blood, Plasma & Serum as Determined on the LumiraDx POC SARS-CoV-2 Ab Test & to Evaluate the Ease of Use at Point of Care Sites"
NCT04597216,Recruiting,Interventional,Not Applicable,"University Hospital, Grenoble",Other,15-Oct-20,31-Dec-21,31-Dec-20,DIAGNOSTIC,200,COVID,FRANCE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",SAMPLE OF BLOOD AND SALIVA,FEASIBILITY OF PROTEOMIC PROFILE,Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix
NCT04597242,Available,Expanded Access,,ContraFect,Industry,,,,,,MRSA BLOODSTREAM INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXEBACASE,,Expanded Access Study of a Single Dose of Exebacase in Addition to Antistaphylococcal Antibiotics for the Treatment of Persistent Methicillin-Resistant Staphylococcus Aureus (MRSA) Bloodstream Infections (Including Right Sided Endocarditis) in Patients Who Are Hospitalized With Coronavirus Disease 2019 (COVID-19)
NCT04597736,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Clermont-Ferrand",Other,20-Nov-21,22-Feb-21,21-Nov-21,DIAGNOSTIC,100,COVID,FRANCE,ALL,"Child, Adult, Older Adult","BIOLOGICAL COLLECTION WITH NASOPHARYNGEAL SAMPLES, SALIVA, BLOOD, STOOL AND URINE",VIROLOGICAL PROFILE,Biological Collection for the Study of the Relationship Between the Biological Profiles Observed and the Clinical Evolutions Within the Same Cluster of Transmission of the Coronavirus SARS-CoV-2
NCT04597775,Not yet recruiting,Interventional,Phase 2/Phase 3,"Regional Center for Disease Control and Prevention, Jordan",Other,27-Oct-20,31-Jan-21,15-Jan-21,PREVENTION,93,SARS-COV INFECTION,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",HYDROXYCHLOROQUINE,INCIDENCE RATE OF COVID-19 ON DAY 14 ACCORDING TO POSITIVE RESULTS OF RT-PCR RATE AT DAY 14,"A Prospective, Randomized, Adaptive Phase II/III Clinical Trial, Controlled, Open-label, 3-arms, Parallel, Multi-centred, Chemoprevention of COVID-19: Hydroxychloroquine Post Exposure Prophylaxis For COVID-19"
NCT04597853,Not yet recruiting,Observational,,University of Zurich,Other,20-Oct-20,31-Dec-21,31-Oct-21,COHORT,25,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ASSESSMENT OF LUNG MECHANICS AND HEART-LUNG INTERACTIONS,TIME DEPENDENT COMPLIANCE CHANGE,"Assessment of Lung Mechanics in SARS-CoV-2/ COVID-19 Acute Respiratory Distress Syndrome: A Holistic, Longitudinal Analysis of the Lung-heart-ventilator Interaction"
NCT04598256,Completed,Observational [Patient Registry],,Tepecik Training and Research Hospital,Other,1-Jun-20,31-Aug-20,31-Aug-20,OTHER,77,COVID,TURKEY,ALL,"1 Year to 18 Years   (Child, Adult)",ENDOSCOPIC PROCEDURE,THE NUMBER OF PARTICIPIANTS WHO WAS INFECTED WITH COVID-19. NORMALIZATION PROCESS OF COVID-19 PANDEMIC,Evaluation of Children Who Were Underwent Endoscopic Procedures in the Normalization Process of Covid-19 Pandemic
NCT04598334,Not yet recruiting,Observational,,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,15-Feb-21,21-Jun-21,21-Apr-21,COHORT,75,"CYTOKINE STORM, COVID",BANGLADESH,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,COVID-19 POSITIVE PARTICIPANTS HAVING HIGH CYTOKINES,"Investigating the Inflammatory Cytokines and Cytokine Storm Among Bangladeshi Patients With COVID-19: a Prospective, Observational Study"
NCT04598347,Recruiting,Observational [Patient Registry],,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Other,8-Aug-20,23-Jan-22,8-Jan-22,CASE-ONLY,225,COVID,SPAIN,FEMALE,"18 Years to 90 Years   (Adult, Older Adult)",,PERINATAL SARS-COV-2 INFECTION,Valuation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19
NCT04598581,"Active, not recruiting",Interventional,Not Applicable,"University Hospital, Basel, Switzerland",Other,2-Nov-20,21-Nov-21,21-Oct-21,TREATMENT,22,SEVERE-ACUTE-RESPIRATORY-SYNDROME-CORONAVIRUS-2 (SARS-COV2),SWITZERLAND,ALL,"40 Years and older   (Adult, Older Adult)",LOW DOSE RADIATION THERAPY (LD-RT),VENTILATOR FREE DAYS (VFD),Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2)
NCT04598594,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,6-Nov-20,21-Nov-21,21-Sep-21,TREATMENT,220,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","PATCH, NICOTINE",MORTALITY,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients
NCT04598620,Recruiting,Observational,,Inger Lise Gade,Other,19-Sep-20,1-Oct-21,1-Oct-21,CASE-ONLY,50,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,PREDICTION OF ADMISSION TO ICU IN HOSPITALIZED COVID-19 PATIENTS,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
NCT04599959,Completed,Interventional,Not Applicable,Boehringer Ingelheim,Industry,26-Oct-20,20-Jan-21,20-Jan-21,DIAGNOSTIC,144,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLING OF SARS-COV-2 RNA FROM NASOPHARYNGEAL SWAB SPECIMEN OR SALIVA COLLECTED VIA SALIVETTE CORTISOL,SARS-COV-2-RNA DETECTABILITY IN SWAB AND SALIVETTE SAMPLES,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With Salivette® Cortisol, to Diagnose SARS-CoV-2 Virus Infection"
NCT04599998,Enrolling by invitation,Observational,,Koc University Hospital,Other,15-Oct-20,1-Mar-21,15-Feb-21,COHORT,37,COVID,TURKEY,ALL,"18 Years to 80 Years   (Adult, Older Adult)","SPIROMETRY, THORACIC CT, CPET, 6 MINUTE WALKING TEST, SF-36 QUESTIONNAIRE",FORCED VITAL CAPACITY (FVC),"Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia Related to Lung Functions, Radiology and Exercise Capacity"
NCT04600141,Recruiting,Interventional,Phase 3,University of Sao Paulo,Other,10-Nov-20,31-Dec-21,20-Oct-21,TREATMENT,308,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TOCILIZUMAB,PROPORTION OF PATIENTS WITH CLINICAL IMPROVEMENT,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial
NCT04600440,Recruiting,Interventional,Not Applicable,Skane University Hospital,Other,25-Apr-20,28-Feb-22,31-Dec-21,TREATMENT,100,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,NUMBER OF DAYS IN NEED OF OXYGEN,Convalescent Plasma in the Treatment of Covid-19
NCT04600713,Not yet recruiting,Interventional,Not Applicable,Vastra Gotaland Region,Other,21-Jan-21,25-Oct-21,25-Aug-21,TREATMENT,180,ATRIAL FIBRILLATION PAROXYSMAL,,ALL,"40 Years to 85 Years   (Adult, Older Adult)",PT-X AND IMT,HEALTH-RELATED QUALITY OF LIFE,Physiotherapist Led Exercise Within Cardiac Rehabilitation and Inspiratory Muscle Training and Patients With Paroxysmal Atrial Fibrillation - a Randomized Controlled Trial
NCT04600895,Recruiting,Interventional,Phase 3,Appili Therapeutics Inc.,Industry,30-Nov-20,21-Oct-21,21-Aug-21,TREATMENT,826,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,TIME TO SUSTAINED CLINICAL RECOVERY,Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)
NCT04600999,Recruiting,Interventional,Phase 3,University of Pecs,Other,7-Oct-20,21-Jun-21,21-Jun-21,TREATMENT,150,SARS-COV2 INFECTION,HUNGARY,ALL,"18 Years to 74 Years   (Adult, Older Adult)",FAVIPIRAVIR,TIME TO IMPROVEMENT IN BODY TEMPERATURE,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -
NCT04601012,Completed,Observational,,Federico II University,Other,20-Sep-20,22-Oct-20,20-Oct-20,CASE-CONTROL,40,COVID,ITALY,ALL,18 Years to 60 Years   (Adult),OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY,"THE MEASUREMENTS OF RETINAL FEATURES IN PATIENTS WITH PREVIOUS DIAGNOSIS OF COVID19, USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.",Optical Coherence Tomography Angiography in Patients Affected by SARS-CoV-2 Infection: a Pilot Study
NCT04601077,Recruiting,Interventional,Phase 1/Phase 2,Nitric Oxide Innovations LLC,Industry,1-Nov-20,31-Jul-21,1-Jun-21,TREATMENT,100,COVID,UNITED STATES,ALL,"50 Years to 85 Years   (Adult, Older Adult)","NITRIC OXIDE LOZENGES, 30 MG",LOW BLOOD PRESSURE,Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American Origin
NCT04601090,Recruiting,Observational [Patient Registry],,Oslo University Hospital,Other,16-Sep-20,22-Sep-21,22-Sep-21,COHORT,250,COVID,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",ICU TREATMENT,ICU SURVIVAL RATE,Survival Rates and Long-term Outcomes for Patients With COVID-19 Admitted to Norwegian ICUs
NCT04601415,Not yet recruiting,Observational,,Imperial College London,Other,1-Feb-21,1-Oct-22,1-Oct-22,COHORT,1500,HEART FAILURE,,ALL,"18 Years and older   (Adult, Older Adult)",ECG FROM HANDHELD DEVICE,AREA UNDER RECEIVER OPERATING CURVE,"Diagnosis of Heart Failure in the Post-COVID-19 Clinic, Primary Care and Hospital Setting Using a Digital Stethoscope With Artificial Intelligence (AI) Electrocardiogram (ECG)"
NCT04602000,Recruiting,Interventional,Phase 2/Phase 3,Celltrion,Industry,25-Sep-20,21-Sep-21,20-Dec-21,TREATMENT,1020,SARS-COV2 INFECTION,"KOREA, REPUBLIC OF",ALL,"18 Years and older   (Adult, Older Adult)",CT-P59/PLACEBO,TO EVALUATE THE THERAPEUTIC EFFICACY CT-P59 FOR PART 1 (PHASE II),"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection"
NCT04602260,Recruiting,Observational,,McMaster University,Other,9-Jun-20,21-Sep-21,21-Sep-21,COHORT,211,COVID,CANADA,ALL,"40 Years and older   (Adult, Older Adult)",,CHANGE IN ACTIVITY MEASURE FOR POST ACUTE CARE (AM-PAC) BASIC MOBILITY INPATIENT VERSION,Functional Recovery of Older Hospitalised Patients With COVID-19: a Prospective and Retrospective Cohort Study Extension to the Coronavirus Registry (COREG)
NCT04602286,Recruiting,Interventional,Not Applicable,The University of Queensland,Other,28-Oct-20,21-Mar-21,21-Mar-21,TREATMENT,292,"PAIN, INTRACTABLE",AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",MEDITATION (1 X 20-MINUTE GUIDED AUDIO TRAINING),PAIN INTENSITY,"An Online Randomized Controlled Trial Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Pain Experience in Adults With Recurrent and Chronic Pain"
NCT04602312,Recruiting,Interventional,Not Applicable,The University of Queensland,Other,28-Oct-20,21-Mar-21,21-Mar-21,TREATMENT,624,CATASTROPHIZING CORONAVIRUS (COVID),AUSTRALIA,ALL,"18 Years and older   (Adult, Older Adult)",MEDITATION (1 X 20-MINUTE GUIDED AUDIO TRAINING),CORONAVIRUS-RELATED CATASTROPHIZING,"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults"
NCT04602351,Not yet recruiting,Observational,,NMC Specialty Hospital,Other,15-Jan-21,15-Feb-21,15-Feb-21,CASE-ONLY,200,COVID,UNITED ARAB EMIRATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",COMMUNICATION,CHANGES IN THE PATTERN OF FAMILY MEMBERS VISITING PROCESS,"Communication in ICU During COVID-19: Multinational, Multicentric Cross-sectional Survey (ComICU)"
NCT04602442,Enrolling by invitation,Interventional,Phase 2,Olga Tyumina,Other,1-Oct-20,30-Dec-21,1-Aug-21,OTHER,90,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EXO 1 INHALATION,NUMBER OF PARTICIPANTS WITH NON-SERIOUS AND SERIOUS ADVERSE EVENTS DURING TRIAL,The Extended Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Two-Sided Pneumonia
NCT04602481,Recruiting,Observational,,University of Bern,Other,31-May-20,31-May-25,31-May-22,COHORT,1000,PRIMARY CILIARY DYSKINESIA,SWITZERLAND,ALL,"Child, Adult, Older Adult",,SARS-COV-2,COVID-19 in People With Primary Ciliary Dyskinesia
NCT04602507,Recruiting,Interventional,Phase 2,CES University,Other,7-Dec-20,21-Mar-21,21-Mar-21,TREATMENT,100,COVID,COLOMBIA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",IVERMECTIN,ADMISSION TO THE INTENSIVE CARE UNIT.,Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial
NCT04602637,"Active, not recruiting",Observational,,Kine Kinesiologia Deportiva y Funcional,Other,15-Dec-19,15-Jan-21,15-Dec-20,CASE-ONLY,3,MONITOR TRAINING LOAD,ARGENTINA,MALE,"Child, Adult, Older Adult",TRAINING LOAD,TRAINING LOAD,Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study
NCT04602832,Enrolling by invitation,Interventional,Not Applicable,University of British Columbia,Other,14-Oct-20,20-Dec-21,20-Dec-21,OTHER,350,WELL-BEING,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",ENDURING HAPPINESS AND CONTINUED SELF-ENHANCEMENT (ENHANCE) FOR COVID-19,BECK DEPRESSION INVENTORY - II (BDI-II),A Randomized Controlled Trial of an Online Well-Being Intervention (The ENHANCE Program) for Improving Individuals Health and Well-Being During the COVID-19 Pandemic
NCT04602871,Recruiting,Interventional,Not Applicable,Scentech Medical Technologies Ltd,Industry,3-Jul-20,30-Jan-21,30-Jan-21,DIAGNOSTIC,108,COVID,ISRAEL,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BREATH BIOPSY,CORRELATION BETWEEN VOLATILE ORGANIC COMPOUNDS PATTERN IN-BREATH BIOPSY AND COVID-19 DETECTION.,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study
NCT04602884,Suspended,Interventional,Not Applicable,Scentech Medical Technologies Ltd,Industry,22-Sep-20,30-Dec-20,30-Dec-20,DIAGNOSTIC,50,COVID,ISRAEL,ALL,18 Years to 55 Years   (Adult),BREATH BIOPSY SAMPLING USING THE RECIVA BREATH SAMPLER,CORRELATION BETWEEN VOLATILE ORGANIC COMPOUNDS PATTERN AND COVID-19 DETECTION STATUS.,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis: First Cross-Sectional Study
NCT04602949,Not yet recruiting,Interventional,Not Applicable,Scentech Medical Technologies Ltd,Industry,12-Nov-20,28-Feb-21,28-Feb-21,DIAGNOSTIC,4000,COVID,ISRAEL,ALL,"18 Years to 75 Years   (Adult, Older Adult)",BREATH BIOPSY ANALYSIS,PRESENCE OF VOLATILE ORGANIC COMPOUNDS INDICATING CARRIERS OF COVID-19.,Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Validation Study
NCT04603079,Not yet recruiting,Interventional,Not Applicable,"Forman Christian College, Pakistan",Other,1-Apr-21,1-Sep-21,1-Aug-21,HEALTH SERVICES RESEARCH,200,NURSE'S ROLE,,FEMALE,"Child, Adult, Older Adult",INTERVENTION FOR COVID-19 PREVENTIVE PROTOCOLS,CORE COMPETENCIES IN NURSES FOR INFECTION CONTROL AND PREVENTION (MIN AND SIL 2014),A Randomized Control Trial to Change Nurse Leadership in Maintaining Minimum Service Delivery Standards for Hospital Infection Control in the Era of COVID-19
NCT04603105,Not yet recruiting,Observational,,The Clatterbridge Cancer Centre NHS Foundation Trust,Other,28-Feb-21,31-Oct-22,31-Oct-21,COHORT,9000,CANCER,,ALL,"Child, Adult, Older Adult",,TO DETERMINE THE COVID-19 FATALITY RATE OVERALL IN THE CANCER POPULATION USING THE MOST UP TO DATE DATASET FROM THE FIRST WAVE.,Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) - a Prospective Companion Study for Patients With Cancer and COVID-19
NCT04603651,No longer available,Expanded Access,,Eli Lilly and Company,Industry,,,,,,COVID,,ALL,"12 Years and older   (Child, Adult, Older Adult)",BAMLANIVIMAB,,Expanded Access Information for Physicians for Bamlanivimab (LY3819253) Emergency Investigational New Drug [EIND]
NCT04603664,Recruiting,Observational,,Ain Shams University,Other,30-Oct-20,21-Mar-21,21-Feb-21,CASE-ONLY,88,"BIOCHEMICAL MARKERS ,NGAL,CYSTATIN C, ACUTE KIDNEYINJURY, COVID",EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SERUM NGAL AND CYSTATIN C,MEASURE BOTH CYSTATIN C AND NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN EVERY OTHER DAY FOR 3 TIMES (NGAL) AS RECENT BIOMARKERS IN PREDICTION OF AKI IN PATIENTS WITH COVID-19.,Role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in Prediction of Acute Kidney Injury in Patients With Covid-19 Infection
NCT04603677,Enrolling by invitation,Observational,,Colorado State University,Other,8-Jul-20,30-Jul-22,30-Jul-22,COHORT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,EVALUATION OF PARAMETERS FOR MARKERS OF SARS-COV-2 INFECTION AND PREDICTORS FOR SEVERE DISEASE,Northern Colorado Coronavirus Biobank: A Biorepository for Acute and Convalescent Patient Samples From Coloradoans Infected With SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2)
NCT04603690,Withdrawn,Interventional,Phase 3,Liaquat University of Medical & Health Sciences,Other,15-Dec-20,14-Jun-21,14-May-21,TREATMENT,0,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE,IMPROVEMENT IN THE CLINICAL STATUS,"A Randomized, Open-labeled, and Controlled Trial to Study the Benefits of Colchicine in Patients With COVID-19"
NCT04603729,Completed,Interventional,Phase 3,Fatima Memorial Hospital,Other,30-May-20,1-Jul-20,30-Jun-20,TREATMENT,100,COVID DISEASE,PAKISTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",DEXAMETHASONE 2 MG/ML,TEMPERATURE (F),Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease
NCT04603742,Not yet recruiting,Interventional,Phase 2,Weill Medical College of Cornell University,Other,20-Nov-21,22-Feb-21,21-Dec-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",ANAKINRA,NUMBER OF SUBJECTS ALIVE WITHOUT HAVING REQUIRED MECHANICAL VENTILATION,"Anakinra in Adults With Severe COVID-19 and Features of Cytokine Storm Syndrome: A Randomized, Double-blind, Placebo-controlled Trial"
NCT04603755,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,26-Oct-20,22-Apr-21,22-Apr-21,COHORT,15,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ELECTRICAL IMPEDANCE TOMOGRAPHY,COEFFICIENT OF CORRELATION BETWEEN THE PERCENTAGE OF DERECRUITMENT OF DEPENDENT AREAS (MEASURED WITH ELECTRICAL IMPEDANCE TOMOGRAPHY) AND THE RESPONSE TO PRONE POSITION,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome
NCT04603781,Recruiting,Interventional,Phase 2/Phase 3,University of Texas at Austin,Other,4-Dec-20,31-Dec-21,31-Dec-21,TREATMENT,160,ANXIETY DEPRESSION,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CBD ISOLATE,PROMIS EMOTIONAL DISTRESS INDEX,Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Placebo-Controlled Clinical Trial
NCT04603794,Recruiting,Interventional,Phase 4,Ohio State University,Other,1-Oct-20,20-Nov-21,20-Nov-21,PREVENTION,60,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",0.5% POVIDONE IODINE,REAL TIME REVERSE TRANSCRIPTASE QUANTITATIVE PCR,"Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients"
NCT04603924,Recruiting,Interventional,Phase 2/Phase 3,NeuroBo Pharmaceuticals Inc.,Industry,7-Oct-20,22-Jun-21,21-Jun-21,TREATMENT,436,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE,SAFETY AND TOLERABILITY OF ANA001 AS MEASURED BY THE INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS (TEAE'S) (PART 1 AND PART 2),A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients
NCT04603963,Terminated,Interventional,Not Applicable,Elaine Cristina Pereira <elaine.cpereira@einstein.br>,Other,1-Jun-20,23-Oct-20,10-Oct-20,TREATMENT,55,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",POWER BREATHE,IMPACT ON FUNCTIONALITY,Efects of Inspiratory Muscle Training in Patients With COVID-19 After Acute Phase. Prospective Study
NCT04604080,Completed,Observational,,Islamia University of Bahawalpur,Other,1-Nov-20,18-Nov-20,18-Nov-20,OTHER,390,"DEPRESSION, ANXIETY",PAKISTAN,ALL,"Child, Adult, Older Adult",SERVICE OF QUESTIONNAIRE,PREVALENCE ESTIMATION OF DEPRESSION IN ADULTS,Post-COVID-19 Epidemic Depression Assessment in Adults in South Punjab Pakistan
NCT04604119,Completed,Observational [Patient Registry],,Sisli Hamidiye Etfal Training and Research Hospital,Other,1-May-20,1-Jun-20,30-May-20,OTHER,104,SARS-COV2,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,ANXIETY,Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic
NCT04604145,Recruiting,Interventional,Not Applicable,David Grant U.S. Air Force Medical Center,U.S. Fed,3-Feb-21,21-Jun-21,21-Jun-21,DIAGNOSTIC,65,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 TESTING ON THE EPPENDORF THERMAL CYCLER PCR SYSTEM USING SELF-COLLECTED SALIVA AS THE SPECIMEN,PERCENT POSITIVE AGREEMENT BETWEEN SELF-COLLECTED SALIVA SAMPLES AND HEALTHCARE-WORKER COLLECTED NASOPHARYNGEAL SAMPLES,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR
NCT04604184,Recruiting,Interventional,Phase 2,Boehringer Ingelheim,Industry,3-Nov-20,26-May-21,20-Mar-21,TREATMENT,130,COVID,BRAZIL,ALL,"50 Years and older   (Adult, Older Adult)",BI 764198,PATIENTS ALIVE AND FREE OF MECHANICAL VENTILATION,BI 764198 Efficacy and Safety in Prevention/Progression of ARDS and ARDS-related Complications Secondary to COVID-19 (ACTION ON COVID-19)
NCT04604223,Not yet recruiting,Interventional,Phase 4,Dasman Diabetes Institute,Other,15-Nov-20,29-Jun-21,29-Jun-21,TREATMENT,1506,COVID,,ALL,"21 Years and older   (Adult, Older Adult)",PIOGLITAZONE 45 MG,HSCRP LEVEL,Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19
NCT04604249,"Active, not recruiting",Observational,,Centre d'Expertise sur l'Altitude EXALT,Other,26-Oct-20,31-Dec-21,30-Nov-21,ECOLOGIC OR COMMUNITY,200,COVID,PERU,ALL,"18 Years and older   (Adult, Older Adult)","SARS-COV-2 RAPID DIAGNOSTIC TEST (COVID-PRESTO® IGM/IGG, AAZ, BOULOGNE-BILLANCOURT, FRANCE)",1. PREVALENCE OF SEROCONVERSION FOR SARS-COV-2.,"Prevalence of COVID-19 and Risk Factors Associated With Seroconversion in La Rinconada, the Highest City of the World - 5,100 m"
NCT04604327,Recruiting,Interventional,Phase 3,"Clinica Universidad de Navarra, Universidad de Navarra",Other,26-Oct-20,31-Jul-21,31-May-21,PREVENTION,164,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BEMIPARIN SODIUM,CLINICAL DETERIORATION,"Ensayo clínico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilácticas o terapéuticas de Bemiparina en Pacientes Con COVID-19"
NCT04604678,Not yet recruiting,Interventional,Phase 2,AgelessRx,Industry,21-Feb-21,21-Oct-21,21-Aug-21,TREATMENT,80,COVID,UNITED STATES,ALL,"30 Years to 70 Years   (Adult, Older Adult)",METFORMIN,REDUCTION OF COVID-19 SYMPTOMS AFTER 1 WEEK OF TREATMENT WITH METFORMIN AND LDN,Pilot Study Into the Use of Metformin and Low Dose Naltrexone (LDN) for Patients With Coronavirus Disease 2019 (COVID-19) - Assessment of Short and Long Term Effects
NCT04604704,Recruiting,Interventional,Phase 2,AgelessRx,Industry,28-Jan-21,21-Oct-21,21-Aug-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",NALTREXONE,REDUCTION OF FATIGUE IN POST-COVID-19 SYNDROME BY TREATMENT WITH LDN AND NAD+,Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19)
NCT04604743,Not yet recruiting,Interventional,Not Applicable,University of Alabama at Birmingham,Other,1-May-21,30-Jun-23,30-Jun-23,PREVENTION,4,VACCINE REFUSAL,UNITED STATES,ALL,15 Years to 17 Years   (Child),"INTERVENTION, TBN",HPV VACCINATION,Exploratory Sequential Mixed Methods Cluster Randomized Controlled Implementation Science Trial to Develop a Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for African American Older Adolescents in Rural Alabama
NCT04604769,Completed,Observational,,University of Liege,Other,26-Jun-19,1-Sep-20,1-Sep-20,COHORT,60,CORONAVIRUS,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,STRESS AT WORK,Perceived Stress and Needs Among Medical Staff in ICU During COVID-19 Crisis
NCT04604977,Recruiting,Interventional,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Other,15-Sep-20,21-Dec-21,21-Oct-21,OTHER,25,HEADACHES CHRONIC,ITALY,ALL,"12 Years to 18 Years   (Child, Adult)",MINDFULNESS,REDUCTION OF HEADACHE DAYS,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Chronic Migraine and High Frequency Migraine Without Aura After the Covid-19 Emergency
NCT04605172,Enrolling by invitation,Observational,,"Central Hospital, Nancy, France",Other,2-Nov-20,21-May-21,21-Apr-21,CASE-CONTROL,1000,PREMATURE BIRTH,FRANCE,ALL,up to 28 Days   (Child),HOSPITALIZATION FOR PREMATURE BIRTH,EVALUATE THE IMPACT OF CONFINEMENT ON THE RATE OF SPONTANEOUS PREMATURITY AT THE REGIONAL UNIVERSITY MATERNITY HOSPITAL OF NANCY (MRUN),The Impact of the SARS CoV-2 Lockdown Policy on Spontaneous Premature Birth at the Regional University Maternity Hospital of Nancy
NCT04605588,Recruiting,Interventional,Phase 2,"Rutgers, The State University of New Jersey",Other,2-Dec-20,21-Apr-21,21-Apr-21,TREATMENT,70,SARS-COV INFECTION,UNITED STATES,ALL,"21 Years and older   (Adult, Older Adult)",NITAZOXANIDE,RATE OF DECLINE IN VIRAL LOAD OVER THE 10 DAYS AFTER RANDOMIZATION,"A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo"
NCT04605692,Completed,Observational,,Akdeniz University,Other,9-Mar-20,20-May-20,20-May-20,COHORT,706,BURNOUT,TURKEY,ALL,"Child, Adult, Older Adult",,706 OF PARTICIPANTS' BURNOUT (MBI) AND STRESS LEVELS DURING THE COVID 19 PANDEMIC PROCESS ASSESSED WITH SURVEY.,Attitudes and Predictive Factors of Psychological Distress and Occupational Burnout Among Dentists During COVID-19 Pandemic in Turkey
NCT04605757,Recruiting,Observational,,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,Other,30-Jul-20,30-Jul-21,30-Apr-21,COHORT,100,SARS-COV2 PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)","CLINICAL, FUNCTIONAL AND RADIOLOGICAL LUNG INVOLVEMENT EVOLUTION",LONG TERM EVOLUTION OF CLINICAL INVOLVEMENT DUE TO SARS-COV-2 PNEUMONIA / SYMPTOMS,Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Long-term Impact and Predictors of Possible Lasting Damage: Follow the Covid Study
NCT04605887,Recruiting,Interventional,Phase 2,Rambam Health Care Campus,Other,18-Jan-21,24-Apr-21,23-Nov-21,TREATMENT,120,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",ANGIOTENSIN 1-7,NEED FOR MECHANICAL VENTILATION,Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2(SARS-CoV-2)
NCT04605926,Withdrawn,Interventional,Phase 3,Equillium,Industry,20-Nov-21,21-Jun-21,21-Apr-21,TREATMENT,0,CORONAVIRUS,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",EQ001,PROPORTION OF SUBJECTS WHO HAVE RECOVERED AT DAY 28.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Itolizumab in Subjects Hospitalized With COVID-19"
NCT04605952,Completed,Observational,,Tata Main Hospital,Other,1-Jul-20,30-Aug-20,30-Aug-20,COHORT,201,COVID,INDIA,ALL,18 Years to 60 Years   (Adult),REPEAT SARS-COV-2 IGG ANTIBODIES AT 45-65 DAYS,PERCENTAGE OF CASES RETAINING SARS-COV-2 IGG ANTIBODIES AT 45-65 DAYS,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive
NCT04605965,Recruiting,Observational [Patient Registry],,Tulane University,Other,9-Jun-20,22-Jun-21,22-Jun-21,CASE-ONLY,100,COVID,UNITED STATES,ALL,"18 Years to 120 Years   (Adult, Older Adult)",,INCIDENCE OF MAJOR CARDIOVASCULAR EVENTS,Wearable Health Data to Investigate Long-term Cardiovascular and Behavioral Health Outcomes in COVID-19 Patients After Discharge: The WEAICOR Study
NCT04606069,Not yet recruiting,Interventional,Phase 1/Phase 2,"University of Maryland, Baltimore",Other,1-Nov-20,31-Jan-22,30-Nov-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REGADENOSON,PROPORTION OF PATIENTS ALIVE AND FREE OF RESPIRATORY FAILURE THROUGH THE 30-DAY TRIAL.,Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients
NCT04606407,Recruiting,Interventional,Not Applicable,Beyond Air Inc.,Industry,25-Nov-20,7-Sep-21,7-Sep-21,TREATMENT,90,VIRAL PNEUMONIA,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LUNGFIT™,INCIDENCE OF SERIOUS ADVERSE EVENTS,"Prospective, Open-label, Randomized, Multi-Center Study for Safety and Efficacy Evaluation of Inhaled Nitric Oxide (NO) Given Intermittently to Adults With Viral Pneumonia"
NCT04606498,Recruiting,Observational,,Henry M. Jackson Foundation for the Advancement of Military Medicine,Other,18-Dec-20,1-Feb-22,31-Dec-21,COHORT,200,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL,TIME SPENT ON MEDICATIONS USED TO INCREASE BLOOD PRESSURE,Blood Purification With Seraph® 100 Microbind® Affinity Blood Filter for the Treatment of Severe COVID-19: An Observational Study (PURIFY-OBS-1)
NCT04606563,Recruiting,Interventional,Phase 3,University of British Columbia,Other,9-Oct-20,30-Jun-21,30-Jun-21,TREATMENT,1372,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",LOSARTAN,MORTALITY,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?
NCT04606732,Recruiting,Observational [Patient Registry],,University of Bologna,Other,20-Sep-20,31-Dec-21,31-Dec-21,COHORT,2000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,"Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia"
NCT04606784,Recruiting,Interventional,Phase 1,Ampio Pharmaceuticals. Inc.,Industry,28-Oct-20,31-Mar-21,31-Jan-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",AMPION,INCIDENCE AND SEVERITY OF ADVERSE EVENTS,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Ampion In Adults With Respiratory Distress Secondary to COVID-19 Infection
NCT04607915,Not yet recruiting,Interventional,Not Applicable,Centre for Addiction and Mental Health,Other,5-Feb-21,31-Mar-21,31-Mar-21,SUPPORTIVE CARE,30,TYPE 2 DIABETES,,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION FOR TECC MODEL,FEASIBILITY - RECRUITMENT NUMBERS,Technology-enabled Collaborative Care for Diabetes (TECC-Diabetes) Management During COVID: A Feasibility Study
NCT04607928,Recruiting,Interventional,Phase 2,Institut d'Investigació Biomèdica de Bellvitge,Other,1-Aug-20,1-Aug-21,1-Aug-21,PREVENTION,148,FIBROTIC PULMONARY SEQUELAE POST-COVID INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",PIRFENIDONE,TO INVESTIGATE THE EFFECT OF PIRFENIDONE ON FIBROTIC SIGNS INDUCED BY COVID19 INFECTION,Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis
NCT04607941,Recruiting,Observational,,Institut Pasteur,Industry,27-Oct-20,30-Jun-21,4-Jun-21,CASE-CONTROL,57720,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,"ODDS-RATIOS OF SARS-COV-2 INFECTION ON SOCIO-DEMOGRAPHIC FACTORS, BEHAVIORS AND PRACTICES AND VISITED PLACES REPORTED BY THE PARTICIPANTS IN THE ONLINE QUESTIONNAIRE","Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2"
NCT04608097,Recruiting,Interventional,Not Applicable,Uppsala University,Other,28-Oct-20,15-Jan-21,15-Jan-21,BASIC SCIENCE,66,HEALTHY PARTICIPANTS,SWEDEN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SIMPLE COGNITIVE TASK INTERVENTION,NUMBER OF INTRUSIVE MEMORIES RELATED TO THE TRAUMA FILM,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities
NCT04608201,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,9-Dec-20,21-Dec-21,21-Dec-21,TREATMENT,220,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NICOTINE 7 MG/ 24H TRANSDERMAL PATCH - 24 HOUR,THE UNFAVORABLE OUTCOME ON DAY 14,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients
NCT04608214,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,1-Nov-20,4-Aug-21,6-May-21,TREATMENT,100,SARS-COV2,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ALISPORIVIR,CHANGE IN SARS-COV-2 VIRAL LOAD IN NASOPHARYNGEAL SWABS,"Evaluation of the Efficacy, Safety and Tolerability of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19). A Randomised, Open-label, Proof of Concept, Phase 2 Study"
NCT04608266,Recruiting,Interventional,Phase 3,Assistance Publique - Hôpitaux de Paris,Other,3-Dec-20,22-Mar-21,22-Jan-21,TREATMENT,596,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CAMOSTAT MESYLATE,HOSPITALIZATION FOR COVID-19 DETERIORATION OR DEATH WITHOUT HOSPITALIZATION,A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)
NCT04608305,Recruiting,Interventional,Phase 1/Phase 2,Israel Institute for Biological Research (IIBR),Other,28-Oct-20,1-Jun-22,1-May-21,PREVENTION,1040,COVID,ISRAEL,ALL,"18 Years to 85 Years   (Adult, Older Adult)","IIBR-100, LOW DOSE (PRIME)","PHASE I AND II - THE NUMBER, GRADE AND PERCENTAGE OF STUDY PARTICIPANTS WHO EXPERIENCE ANY STUDY INJECTION-ASSOCIATED AES OR SAES.","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults"
NCT04608383,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,1-Nov-20,1-Jan-22,1-Jan-22,CASE-ONLY,20,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ADDITIONAL AND MINIMAL COLLECTION OF PRODUCTS OF THE HUMAN BODY CARRIED OUT DURING A SAMPLE FOR STANDARD OF CARE,THE MAIN OBJECTIVE OF THE STUDY IS TO DEMONSTRATE THE PRESENCE OF SARS-COV-2 IN THE EXSUFFLATED GAS AT THE END OF LAPAROSCOPY.,Laparoscopy and COVID-19 Contamination
NCT04609085,Enrolling by invitation,Observational,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,4-Mar-21,30-Apr-23,30-Apr-23,CASE-ONLY,5000,SARS-COV2 VIRUS,UNITED STATES,ALL,"up to 89 Years   (Child, Adult, Older Adult)",,TO ESTIMATE THE PROPORTION OF PEOPLE WITH RARE DISEASES WHO HAVE DETECTABLE ANTIBODIES TO SARS-COV2 IN THE NCATS RDCRN RARE DISEASES SURVEY OVER TIME.,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population
NCT04609332,Recruiting,Observational [Patient Registry],,University of Chile,Other,10-Nov-20,21-Nov-21,21-Aug-21,COHORT,40,COVID,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",ENDOTHELIAL DAMAGE AND ANGIOGENIC BIOMARKERS,CHANGE FROM BASELINE SYNDECAN-1 CONCENTRATION AT 10TH DAY,Association of Endothelial Damage and Angiogenesis Biomarkers With Morbidity and Mortality in SARS-CoV-2 Infection
NCT04609371,Enrolling by invitation,Interventional,Not Applicable,"St. Mary's Research Center, Canada",Other,21-Oct-20,1-May-21,1-Mar-21,SUPPORTIVE CARE,176,MENTAL HEALTH WELLNESS 1,CANADA,ALL,65 Years and older   (Older Adult),SELF-CARE TOOLS,CONSENT RATE,Assisting Family Physicians With Gaps in Mental Health Care Generated by the COVID-19 Pandemic: A Randomized Controlled Trial
NCT04609423,Recruiting,Interventional,Phase 4,Oslo University Hospital,Other,10-Nov-20,23-May-21,21-May-21,PREVENTION,80000,COVID,NORWAY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",COD LIVER OIL,NUMBER OF PARTICIPANTS DIAGNOSED WITH SERIOUS COVID-19,"A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults"
NCT04609462,Completed,Interventional,Not Applicable,Fundacion Clinica Valle del Lili,Other,11-Aug-20,10-Feb-21,13-Jan-21,TREATMENT,199,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",CONVENTIONAL OXYGEN THERAPY,INTUBATION RATE,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.
NCT04609488,Not yet recruiting,Observational,,Zealand University Hospital,Other,1-Nov-20,1-Oct-22,30-Sep-22,CASE-ONLY,30,TO ASSESS SURFACTANT LEVELS IN LUNG FLUID,,ALL,"19 Years and older   (Adult, Older Adult)",SURFACTANT ASSESSMENT,SURFACTANT,An Exploratory Study to Assess Surfactant Levels in COVID-19 Patients Who Will be on Ventilatory Support Due to Severe Respiratory Failure
NCT04609501,"Active, not recruiting",Observational [Patient Registry],,Hillel Yaffe Medical Center,Other,1-Jun-20,30-Jun-24,30-Jun-23,COHORT,440,DELIVERY; TRAUMA,ISRAEL,FEMALE,18 Years to 50 Years   (Adult),,THE RELATIONS BETWEEN FEAR OF COVID-19 AND POSTNATAL DEPRESSION SYMPTOMS.,"Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship in the Shadow of a Socioeconomic Crisis"
NCT04609722,Recruiting,Interventional,Not Applicable,Adiyaman University Research Hospital,Other,1-Jul-20,15-Feb-21,1-Feb-21,SUPPORTIVE CARE,60,ANXIETY,TURKEY,ALL,18 Years to 45 Years   (Adult),SOLUTION-FOCUSED SUPPORT PROGRAM,STATE-TRAIT ANXIETY INVENTORY (STAI),Effect of Solution-Focused Support Program on Anxiety Levels of Parents With Children Aged 3-6 Years During the COVID-19 Pandemic
NCT04609774,Completed,Observational,,Hospital Italiano de Buenos Aires,Other,8-Oct-20,1-Dec-20,20-Nov-20,CASE-CROSSOVER,8,CORONAVIRUS DISEASE (COVID),ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 DETECTION,AIRBORNE TRANSMISSION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus: a Dilemma
NCT04609839,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,27-Oct-20,27-Apr-23,27-Apr-23,CASE-ONLY,200,PATIENT ADMITTED TO INTENSIVE CARE UNIT FOR COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",FOLLOW-UP OF PATIENTS WITH COVID-19,"THE PRESENCE OF RESPIRATORY, RENAL, CARDIAC, MOTOR, NEUROLOGICAL, AND PSYCHOLOGICAL SEQUELAE WILL BE ASSESSED BY SPECIALIST DOCTORS DURING THE 12 MONTHS FOLLOWING THE PATIENT'S DISCHARGE FROM INTENSIVE CARE.",TeleRea'nCo : FOLLOW-UP OF PATIENTS WITH COVID-19.
NCT04609865,Recruiting,Interventional,Phase 3,"University Hospital, Strasbourg, France",Other,4-Nov-20,4-Feb-24,31-Dec-21,TREATMENT,100,ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS),FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",LIDOCAINE 2%,ALVEOLAR-CAPILLARY GAS EXCHANGE AFTER TWO DAYS OF TREATMENT,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
NCT04609969,Completed,Interventional,Not Applicable,Centre Hospitalier Régional d'Orléans,Other,13-Oct-20,17-Oct-20,17-Oct-20,DIAGNOSTIC,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RT-QPCR TEST,EVALUATION OF COVID VIRO® DIAGNOSTIC SPECIFICITY,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i
NCT04610138,Not yet recruiting,Interventional,Phase 2,Clene Nanomedicine,Industry,21-Feb-21,21-Aug-21,21-Jul-21,TREATMENT,276,COVID,,ALL,"40 Years to 90 Years   (Adult, Older Adult)",CNM-ZNAG,"THE PROPORTION OF PARTICIPANTS WHO REQUIRE COVID-19 RELATED HOSPITALIZATION, ARE HOSPITALIZED FOR COVID-19 RELATED MEDICAL SUPPORT, OR ARE DECEASED WITHIN 28-DAYS FOLLOWING RANDOMIZATION.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ZnAg Liquid Solution to Treat COVID-19 in Acutely Symptomatic Non-Hospitalized Participants"
NCT04610489,Not yet recruiting,Interventional,Not Applicable,Carilion Clinic,Other,1-Nov-20,31-Jan-21,31-Jan-21,DIAGNOSTIC,800,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",QUIDEL SOFIA SARS ANTIGEN FIA,SENSITIVITY,Diagnostic Performance of an Antigen Test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
NCT04610502,"Active, not recruiting",Interventional,Phase 2,Caja Costarricense de Seguro Social,Other,6-Sep-20,6-Dec-20,6-Oct-20,TREATMENT,26,COVID,COSTA RICA,ALL,"18 Years and older   (Adult, Older Adult)",ADMINISTRATION OF EQUINE IMMUNOGLOBULIN ANTI SARS-COV-2,"TO EVALUATE THE EFFICACY AND SAFETY OF TWO FORMULATIONS OF EQUINE ANTI-SARS-COV-2 IMMUNOGLOBULINS (""S"" AND ""M"").","Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19"
NCT04610515,Recruiting,Observational [Patient Registry],,Rush University Medical Center,Other,15-Dec-20,14-Nov-22,14-Nov-22,COHORT,4800,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENT MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS),Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)
NCT04610541,"Active, not recruiting",Interventional,Phase 3,University of Pecs,Other,12-Oct-20,30-Nov-21,30-Oct-21,TREATMENT,2000,SARS-COV2 INFECTION,HUNGARY,ALL,"12 Years to 100 Years   (Child, Adult, Older Adult)",REMDESIVIR-HU,TO ASSESS THE SAFETY AND TOLERABILITY OF REM USE IN HUNGARY IN THE CONDITIONALLY APPROVED INDICATION (EMA),Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients
NCT04610554,Completed,Observational,,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",Other,14-May-20,12-Oct-20,12-Oct-20,COHORT,74,COVID PNEUMONIA,ITALY,ALL,"Child, Adult, Older Adult",,LUNG DIFFUSING CAPACITY FOR NITRIC OXIDE (DLNO),Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19
NCT04610567,Recruiting,Interventional,Phase 1/Phase 2,University of Sao Paulo General Hospital,Other,27-Oct-20,15-Jul-21,15-Mar-21,TREATMENT,100,CORONAVIRUS,BRAZIL,ALL,"18 Years to 85 Years   (Adult, Older Adult)",METHOTREXATE-LDE PHASE 1,DURATION OF HOSPITAL STAY,Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.
NCT04610801,Recruiting,Interventional,Phase 3,Larkin Community Hospital,Other,8-Aug-20,8-Aug-21,8-Aug-21,TREATMENT,200,COVID,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",NASAL SPRAY,CHANGE FROM BASELINE REACTIVE TO NON-REACTIVE ON COVID 19 RT PCR IN 7 DAYS,A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection
NCT04611230,Recruiting,Observational,,AbbVie,Industry,5-Nov-20,24-Sep-21,24-Sep-21,COHORT,1250,SEVERE ACUTE RESPIRATORY SYNDROME - CORONAVIRUS 2 (SARS-COV2),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PERCENTAGE OF PARTICIPANTS WITH EVIDENCE OF PRIOR SARS-COV-2 INFECTION,"EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois: CONTACT"
NCT04611243,Recruiting,Observational,,Chinese University of Hong Kong,Other,22-May-20,21-May-22,21-May-22,COHORT,80,LUNG FUNCTION,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",KALETRA AND BETA INTERFERON,SPIROMETRY,"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19"
NCT04611256,Recruiting,Interventional,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,Other,1-Aug-20,30-Dec-20,30-Nov-20,TREATMENT,20,COVID,MEXICO,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MSC,CHANGE FORM BASELINE IN ARTERIAL OXYGEN SATURATION,Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition
NCT04611269,Completed,Observational [Patient Registry],,Argentinian Intensive Care Society,Other,20-Mar-20,31-Oct-20,31-Oct-20,COHORT,950,RESPIRATORY FAILURE,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",,ICU MORTALITY,"Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina: a Prospective, Multicenter Cohort Study"
NCT04611399,Recruiting,Interventional,Not Applicable,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,Other,3-Feb-21,1-Nov-21,1-Nov-21,PREVENTION,90,STRESS RELATED DISORDER,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",VR FOR PSYCHOEDUCATION AND RELAXATION,CHANGE IN SCORE AT THE STATE-TRAIT ANXIETY INVENTORY -Y2,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support
NCT04611425,Not yet recruiting,Interventional,Phase 2,Nantes University Hospital,Other,1-Nov-20,1-May-21,1-May-21,SUPPORTIVE CARE,30,ACUTE RESPIRATORY FAILURE,FRANCE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",REMIMAZOLAM,"COMPOSITE ENDPOINT INCLUDING A COMBINATION OF CARDIO-VASCULAR AND SEDATION EVENTS, FROM BASELINE (BEFORE INFUSION) TO 8 HOURS, AFTER THE BEGINNING OF REMIMAZOLAM INFUSION","REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study"
NCT04611802,"Active, not recruiting",Interventional,Phase 3,Novavax,Industry,27-Dec-20,30-Dec-22,31-Mar-21,PREVENTION,30000,SARS-COV INFECTION,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 RS/MATRIX-M1 ADJUVANT (INITIAL VACCINATION PERIOD),"PARTICIPANTS WITH SYMPTOMATIC MILD, MODERATE, OR SEVERE CORONAVIRUS DISEASE 2019 (COVID-19)","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years"
NCT04611841,Enrolling by invitation,Observational,,Federal Research and Clinical Center of Physical-Chemical Medicine,Other,21-Jul-20,22-Dec-21,22-Dec-21,COHORT,250,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,DETERMINATION OF ANTIBODY BINDING OF PATIENTS DIAGNOSED WITH COVID-19 TO PROTEINS OF THE SARS-COV-2 VIRUS,Medical-biological Research of the Pathogenesis of Disease Caused by SARS-CoV-2
NCT04612972,Recruiting,Interventional,Phase 3,Universidad Peruana Cayetano Heredia,Other,10-Sep-20,1-Sep-21,31-Dec-20,PREVENTION,6000,COVID,PERU,ALL,18 Years to 60 Years   (Adult),INACTIVATED SARS COV 2 VACCINE (VERO CELL). WUHAN,PRIMARY ENDPOINT,"Ensayo Clínico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la Población Sana de 18 años o más, en Perú"
NCT04613050,Recruiting,Interventional,Not Applicable,Cairo University,Other,2-Jul-20,20-Feb-22,24-Dec-21,TREATMENT,80,COVID INFECTION,EGYPT,ALL,35 Years to 45 Years   (Adult),RESPIRATORY TRAINING,COMPLETE BLOOD PICTURE,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients
NCT04613245,Recruiting,Observational [Patient Registry],,Cairo University,Other,1-May-20,1-Mar-21,30-Jan-21,CASE-ONLY,400,ASTHMA CHRONIC,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",,ASTHMA CONTROL QUESTIONNAIRE (ACQ),Health-Related Quality of Life of Patients With Asthma and Its Associated Factors During the Pandemic of COVID-19
NCT04613271,Suspended,Interventional,Phase 3,Ina-Respond,Other,15-Oct-20,30-Jun-21,30-Jun-21,TREATMENT,210,INFECTIOUS DISEASE,INDONESIA,ALL,18 Years to 59 Years   (Adult),FAVIPIRAVIR,CLINICAL IMPROVEMENT MEASURED BY NO SIGN & SYMPTOM FOR 3 DAYS AND RTPCR NEGATIVE,"Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia"
NCT04613297,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,19-Oct-20,21-Oct-21,21-Oct-21,OTHER,120,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BASELINE AND DURING HOSPITALIZATION BLOOD SAMPLES,"COMPARISON OF THE PERCENTAGE OF T CELLS EXPRESSING THE HLA-G RECEPTOR ILT2 (CD3+CD4+ILT2+ T CELLS, AND CD3+CD8+ILT2+ T CELLS) BETWEEN THE 3 GROUPS OF PATIENTS.",HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment
NCT04613310,Recruiting,Interventional,Not Applicable,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",Other,25-Sep-20,31-Dec-20,31-Dec-20,DIAGNOSTIC,1250,COVID,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",RAPID DIAGNOSTIC TEST VS PCR,PROPORTION OF SARS-COV-2 POSITIVE PATIENTS FOR THE TWO DIFFERENT SAMPLING TYPES (SALIVA VS NASOPHARYNGEAL) AND TWO METHODS (RDT VS PCR) .,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2: a Comparative Clinical Trial
NCT04613739,Recruiting,Interventional,Not Applicable,Harvard Pilgrim Health Care,Other,8-Dec-20,31-Jan-23,1-Sep-21,HEALTH SERVICES RESEARCH,430,ASTHMA,UNITED STATES,ALL,"4 Years to 64 Years   (Child, Adult)",INSURANCE NAVIGATION,INSURANCE COVERAGE,Comparing Patient-Centered Outcomes for Adults and Children With Asthma in High-Deductible Health Plans With and Without Preventive Drug Lists: COVID Enhancement
NCT04613817,Recruiting,Observational [Patient Registry],,Sciensano,Other,3-Dec-20,31-Aug-21,30-Jun-21,COHORT,1640,SARS-COV2,BELGIUM,ALL,8 Years to 14 Years   (Child),,CHANGE OF PREVALENCE OF ANTIBODIES AGAINST SARS-COV-2 AMONG BELGIAN CHILDREN AGED 8-9 YEARS,Prevalence and Incidence of Antibodies Against SARS-CoV-2 in Children Measured for One Year in Belgium: a Sero-epidemiological Prospective Cohort Study
NCT04613986,Not yet recruiting,Interventional,Not Applicable,University of Zurich,Other,20-Dec-21,21-Dec-21,21-Aug-21,TREATMENT,20,SEVERE COVID,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",THERAPEUTIC PLASMAEXCHNAGE,RELATIVE ADAMTS13 DEFICIENCY,"Randomized, Prospective, Open-label, Controlled Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat the Systemic Inflammatory Response Against SARS-CoV2 and the Associated Coagulopathy"
NCT04614012,Recruiting,Interventional,Not Applicable,ANNA FALANGA,Other,2-Jul-20,2-Jul-22,2-Jul-22,TREATMENT,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",TREATED WITH HYPERIMMUNE PLASMA,DEATH,The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection
NCT04614025,Recruiting,Interventional,Phase 2,Pluristem Ltd.,Industry,20-Nov-21,22-Mar-21,21-May-21,TREATMENT,40,COVID,GERMANY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",PLX-PAD,NUMBER OF VENTILATOR-FREE DAYS,"A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19"
NCT04614844,Recruiting,Interventional,Not Applicable,Yale University,Other,6-Jan-21,15-Nov-22,15-Sep-22,OTHER,84,PHYSICIAN STRESS LEVELS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SIMULATION INTERVENTION,CHANGE IN END-OF-SHIFT HEART RATE VARIABILITY,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS) Randomized Control Trial
NCT04614883,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,21-Oct-20,21-Oct-21,21-Oct-21,OTHER,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",VOLATILE ORGANIC COMPOUNDS ANALYSIS,VALIDATE THE INTEREST OF VOCS ANALYZED BY ELECTRONIC NOSES AND / OR MASS SPECTROMETRY FOR THE DIAGNOSIS OF A COVID-19 INFECTION,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening
NCT04614948,Recruiting,Interventional,Phase 3,Janssen Vaccines & Prevention B.V.,Industry,16-Nov-20,11-May-23,10-May-22,PREVENTION,30000,PARTICIPANTS WITH OR WITHOUT STABLE CO-MORBIDITIES ASSOCIATED WITH PROGRESSION TO SEVERE COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",AD26.COV2.S,NUMBER OF PARTICIPANTS WITH FIRST OCCURRENCE OF MOLECULARLY CONFIRMED MODERATE TO SEVERE/CRITICAL COVID-19 AND WHO WERE SERONEGATIVE AT BASELINE,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older"
NCT04615000,Recruiting,Observational [Patient Registry],,"University Hospital, Ghent",Other,29-Oct-20,1-Nov-21,1-Nov-21,COHORT,1000,COVID,BELGIUM,ALL,"up to 18 Years   (Child, Adult)",SARS-COV-2 SEROLOGICAL ASSESSMENT (IGG),SEROCONVERSION RATE OF CHILDREN WITH CHRONIC CONDITIONS FOLLOWED IN A TERTIARY CENTRE,SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort
NCT04615026,Recruiting,Observational [Patient Registry],,University Hospital Augsburg,Other,4-Nov-20,30-Jun-21,30-Jun-21,CASE-ONLY,400,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",DUPLEX SONOGRAPHY,PREVALENCE OF THROMBOSIS,Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity
NCT04615052,Recruiting,Interventional,Not Applicable,University of Sao Paulo,Other,26-Sep-20,21-Dec-21,31-Oct-21,TREATMENT,60,COVID,BRAZIL,ALL,"40 Years to 75 Years   (Adult, Older Adult)",EXERCISE TRAINING,CHANGE FROM BASELINE ON QUALITY OF LIFE ASSESSED BY THE SF-36 HEALTH SURVEY QUESTIONNAIRE AT 12 WEEKS.,Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial
NCT04615195,Recruiting,Observational,,"University Hospital, Toulouse",Other,10-Jun-20,30-Nov-20,2-Jul-20,COHORT,1000,POST TRAUMATIC STRESS DISORDER,FRANCE,ALL,8 Years to 15 Years   (Child),CRIES 13 QUESTIONNAIRE,SIGNS OF POST TRAUMATIC STRESS DISORDER,Effect of COVID19-related COntainment in ChildreN
NCT04615208,Recruiting,Observational,,University of Manitoba,Other,19-Dec-20,30-Dec-21,30-Oct-21,COHORT,200,COVID,CANADA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SUSPECTED OF COVID-19 INFECTION,BEING POSITIVE OR NEGATIVE ON COVID-19 SWAB FLUID TEST,A Touchless Tool to Screen for COVID-19 for Reopening Industries
NCT04615390,Recruiting,Observational,,University Hospital of Ferrara,Other,30-Mar-20,3-Jun-21,3-Jun-21,COHORT,200,COVID_REHABILITATION,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",EARLY REHABILITATION,BORG SCALE,Recovery Profiles in Patients With COVID 19 Outcomes Undergoing Rehabilitation
NCT04615416,Recruiting,Interventional,Not Applicable,"Teachers College, Columbia University",Other,1-May-20,23-Jan-21,21-Jan-21,TREATMENT,100,"DISTRESS, EMOTIONAL",UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EMOTION REGULATION TRAINING VIA TELEHEALTH,"CHANGES IN ANXIETY, DEPRESSION, AND DISTRESS",Open Trial of Emotion Regulation Training Via Telehealth for Distressed Adults During the COVID-19 Pandemic
NCT04615429,"Active, not recruiting",Interventional,Phase 2,Cristina Avendaño Solá,Other,15-Sep-20,22-Jan-21,4-Jan-21,TREATMENT,20,ACUTE RESPIRATORY DISTRESS SYNDROME,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MESENCHYMAL STROMAL CELLS,CHANGE IN THE PAO2/FIO2* RATIO FROM BASELINE TO DAY 7 OF TREATMENT ADMINISTRATION,"Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19"
NCT04615676,Completed,Observational [Patient Registry],,"University Hospital, Toulouse",Other,27-Apr-20,17-Jul-20,17-Jul-20,COHORT,4734,SARS-COV2,FRANCE,ALL,"15 Years and older   (Child, Adult, Older Adult)",FOLLOW-UP PHONE CALL,HOSPITALIZATION,Prospective Evaluation of the Predictive Criteria of Severity Related to Patient Calling Emergency Centre for Low or High Respiratory Infection With or Without Fever and Suspected to be COVID-19.
NCT04615728,Completed,Observational,,Cambridge University Hospitals NHS Foundation Trust,Other,1-Nov-19,6-Oct-20,5-Jul-20,COHORT,207,ACUTE APPENDICITIS,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",LAPAROSCOPIC OR OPEN APPENDICECTOMY,MORTALITY,"APPENDICITIS DURING THE COVID-19 PANDEMIC: TO OPERATE OR NOT TO OPERATE, THAT IS THE QUESTION: COHORT STUDY FROM A TERTIARY CENTRE"
NCT04615741,Recruiting,Interventional,Not Applicable,University of Lethbridge,Other,1-Nov-20,30-Apr-21,28-Feb-21,TREATMENT,200,MENTAL HEALTH WELLNESS 1,CANADA,FEMALE,"18 Years to 75 Years   (Adult, Older Adult)",TRAUMA INFORMED YOGA,CHANGES IN TOBACCO USE,Improving Health and Wellness During COVID-19
NCT04615871,Not yet recruiting,Interventional,Phase 2,Vladimír Džavík,Other,30-Nov-20,31-Mar-22,31-Dec-21,TREATMENT,400,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",SEMAGLUTIDE,COMPOSITE OF DEATH OR MECHANICAL VENTILATION,Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Randomized Controlled Trial
NCT04615936,Recruiting,Interventional,Not Applicable,Sunnybrook Health Sciences Centre,Other,10-Jul-20,31-May-21,31-May-21,TREATMENT,100,COVID,CANADA,ALL,"Child, Adult, Older Adult",METHYLENE-BLUE PHOTODISINFECTION,RT-QPCR,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract
NCT04615949,Not yet recruiting,Interventional,Phase 2/Phase 3,Cardiol Therapeutics Inc.,Industry,20-Dec-21,21-Sep-21,21-Sep-21,PREVENTION,422,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","CANNABIDIOL, PHARMACEUTICALLY PRODUCED WITH < 5 PPM THC",ALL-CAUSE MORTALITY,"Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial"
NCT04615975,Recruiting,Interventional,Not Applicable,University of Padova,Other,1-Nov-20,30-Aug-21,30-Jul-21,TREATMENT,28,COVID,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",KETOGENIC DIET WITH PHYTOEXTRACTS,INFLAMMATION PANEL: INTERLEUKINE 6 (IL-6),Pilot Study: Ketogenic Diet as Protective Factor During SARS-CoV-2 Infection
NCT04616001,Not yet recruiting,Interventional,Phase 4,Sharp HealthCare,Other,1-Nov-20,30-Jun-21,30-Jun-21,TREATMENT,10,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IVIG,HOSPITAL LENGTH OF STAY,Pilot Study of the Use of IVIG in Patients With Severe COVID-19 Infections Requiring Mechanical Ventilation and to Assess Their Biological Responses to IVIG Therapy
NCT04616846,Recruiting,Interventional,Not Applicable,Centre Antoine Lacassagne,Other,4-Aug-20,15-Sep-21,15-Sep-21,SCREENING,120,NEOPLASMS MALIGNANT,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PERIPHERAL VENOUS ULTRASOUND,RATE OF VENOUS THROMBOEMBOLISM,Thromboembolic Risk Screening in Patients With Cancer and COVID-19
NCT04616950,Recruiting,Observational,,Groupe Hospitalier Paris Saint Joseph,Other,1-Dec-20,31-Dec-21,30-Jun-21,COHORT,800,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,HOSPITAL COURSE OF PATIENTS WITH CANCER OF THE DIGESTIVE SYSTEM,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System: Description of Typical Pathways and Simulation Model
NCT04616976,Completed,Observational,,"Southeast University, China",Other,1-Jan-20,1-Nov-20,29-Feb-20,CASE-CONTROL,78,COVID CONVALESCENT PLASMA TREATMENT,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,28-DAY MORTALITY,Efficiency of Convalescent Plasma Therapy in Management of Critically Ill Patients With COVID-19: a Matched Case-control Study
NCT04616989,Not yet recruiting,Interventional,Not Applicable,Makerere University,Other,1-Jan-21,30-Jul-21,30-Jun-21,HEALTH SERVICES RESEARCH,840,COMMUNITY MENTAL HEALTH,,ALL,"18 Years and older   (Adult, Older Adult)",PSYCHO-EDUCATION,CHANGE IN MENTAL HEALTH LITERACY,Integration of Mental Health Care in Communities Affected by the COVID-19 Pandemic in Central Uganda
NCT04617119,Not yet recruiting,Interventional,Not Applicable,DR. JASSIM ALGHAITH,Other,1-Nov-20,6-Apr-21,6-Feb-21,PREVENTION,38,COVID,KUWAIT,ALL,21 Years to 60 Years   (Adult),THRESHOLD IMT DEVICE,CHANGES IN RESPIRATORY MUSCLE PERFORMANCE,The Effects of Multi-modality Physiotherapy in Delaying or Preventing COVID-19 Patient From Admitting to ICU: A Pilot Study
NCT04617262,Not yet recruiting,Interventional,Not Applicable,The New School,Other,20-Nov-21,21-Sep-21,21-Aug-21,TREATMENT,100,DEPRESSION,,ALL,"18 Years and older   (Adult, Older Adult)",REMOTE PROBLEM MANAGEMENT PLUS,"PSYCHOLOGICAL OUTCOMES PROFILE; UNABBREVIATED SCALE TITLE ""PSYCHOLOGICAL OUTCOMES PROFILE""",Pilot Feasibility Study of Remote Problem Management Plus to Improve Well-being and Functioning of Adults Affected by COVID-
NCT04617483,Recruiting,Interventional,Phase 3,"Sinovac Research and Development Co., Ltd.",Industry,31-Oct-20,31-May-21,28-Nov-20,PREVENTION,1040,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)","TWO DOSES OF COMMERCIAL SCALE INACTIVATED SARS-COV-2 VACCINE AT THE SCHEDULE OF DAY 0,14",IMMUNOGENICITY INDEX-GEOMETRIC MEAN TITER(GMT) OF NEUTRALIZING ANTIBODY,"A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults"
NCT04617535,Available,Expanded Access,,Regeneron Pharmaceuticals,Industry,,,,,,COVID,,,"Child, Adult, Older Adult",REGN10933+REGN10987 COMBINATION THERAPY,,Compassionate Use of REGN-COV2 for the Treatment of COVID-19
NCT04618042,Recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,13-Nov-20,21-Jul-21,21-Jul-21,TREATMENT,50,ARDS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",FX06,CHANGE IN EXTRAVASCULAR LUNG WATER INDEX (EVLWI),FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia
NCT04618341,Completed,Observational,,Revival Active,Other,30-Mar-20,28-Jul-20,30-Jun-20,OTHER,32,ANXIETY,UNITED KINGDOM,ALL,11 Years to 17 Years   (Child),,ANXIETY,A Clinical Study of Online Active Play Program With Adolescents During COVID-19 Lockdown
NCT04618796,Not yet recruiting,Observational,,Assiut University,Other,1-Apr-21,1-May-22,1-Apr-22,CASE-CROSSOVER,100,VACCINE REFUSAL,,ALL,1 Year to 2 Years   (Child),VACCINE,MEASURE THE VACCINATION COVERAGE RATE AMONG THE STUDIED CHILDREN AFTER THE COVID-19 PANDEMIC,Effect of COVID-19 Pandemic on Vaccination Compliance Among Children Attending Assiut University Children Hospital
NCT04618835,Recruiting,Observational,,Betsi Cadwaladr University Health Board,Other,11-Jan-21,3-Nov-21,3-Nov-21,COHORT,1000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",40-STEPS-TEST,CHANGE IN DECISION TO DISCHARGE,Exertional Desaturation as a Marker of Risk - Validation Study for the 40-steps-test; A Multi-centre Prospective Observational Cohort Study
NCT04618861,Completed,Observational,,Kafkas University,Other,13-Oct-20,2-Nov-20,2-Nov-20,CASE-CONTROL,127,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,MEASSURING THE SERUM SURFACTANT PROTEIN D LEVELS IN PATIENT WHO HAVE COVID-19 INFECTION OR PNEUMONIA.,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study
NCT04619290,Recruiting,Interventional,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,Other,12-Oct-20,30-Dec-20,30-Nov-20,TREATMENT,46,SARS COV 2,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",SUBLINGUAL METHYLENE BLUE,CHANGE FORM BASELINE IN ARTERIAL OXYGEN SATURATION,Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic
NCT04619368,Recruiting,Observational [Patient Registry],,"University Hospital, Toulouse",Other,27-Jul-20,22-Jul-21,22-Jul-21,COHORT,100,HUMAN ARDS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",FOLLOW UP CALLS,INCIDENCE OF POST-TRAUMATIC STRESS DISORDER (PTSD) WITH THE POST-TRAUMATIC CHECKLIST-5 (PCL-5) 12 MONTHS AFTER INTENSIVE-CARE,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-CoV-2 (COVID-19)
NCT04619407,Recruiting,Observational,,University Medicine Greifswald,Other,4-Nov-20,21-Mar-21,21-Mar-21,COHORT,300,SARS-COV2,GERMANY,ALL,"3 Years to 67 Years   (Child, Adult, Older Adult)",NASOPHARYNGEAL SWAB,SHARE OF PARTICIPANTS WITH SARS-COV-2 DETECTABLE IN PCR,"Screening for SARS-CoV-2-Infections in Teachers, Childcare Educators, Pupils and Preschoolers in the State of Mecklenburg-Vorpommern"
NCT04619576,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,1-Jun-20,21-Dec-25,21-Dec-25,COHORT,1000,OCCUPATIONAL HEALTH,FRANCE,ALL,"10 Years and older   (Child, Adult, Older Adult)",OCCUPATIONAL HEALTH WORKERS,STRESS MEASURES,Influence of the COVId-19 Pandemic on STRESS of Occupational Health Workers
NCT04619628,Recruiting,Interventional,Phase 1,"Codagenix, Inc",Industry,11-Dec-20,22-May-21,21-Jun-21,PREVENTION,48,COVID,UNITED KINGDOM,ALL,18 Years to 30 Years   (Adult),COVI-VAC,REACTOGENICITY,"First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19"
NCT04619680,Recruiting,Interventional,Phase 4,Icahn School of Medicine at Mount Sinai,Other,18-Nov-20,21-Jul-21,21-Jul-21,TREATMENT,120,PULMONARY FIBROSIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NINTEDANIB,CHANGE IN FORCED VITAL CAPACITY (FVC),Early Nintedanib Deployment in COVID-19 Interstitial Fibrosis
NCT04619693,Recruiting,Observational,,"University Hospital, Montpellier",Other,18-Nov-20,18-Sep-21,18-Sep-21,COHORT,100,"PNEUMONIA, VIRAL",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,TREATMENT FAILURE (YES/NO),Determination of Biomarkers for the Prediction of Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
NCT04619706,Recruiting,Interventional,Phase 2,"FSD Pharma, Inc.",Industry,14-Dec-20,5-Dec-21,14-Aug-21,TREATMENT,350,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FSD201,PERCENTAGE OF PARTICIPANTS WITH DISEASE PROGRESSION AT DAY 28,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19"
NCT04619719,Not yet recruiting,Interventional,Not Applicable,NYU Langone Health,Other,15-Feb-21,15-Feb-22,15-Jun-21,TREATMENT,600,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN THERAPY (HBOT),INCIDENCE OF 60-DAY PATIENT MORTALITY,"Multi-Center, Randomized Control Trial to Study the Effectiveness of Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Respiratory Distress"
NCT04620798,"Active, not recruiting",Interventional,Not Applicable,Indiana University,Other,14-Sep-20,20-Dec-21,20-Dec-21,SCREENING,1700,SARS-COV2,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",IMMEDIATE VS. DELAYED PROVISION OF ANTIBODY TEST RESULTS,FREQUENCY OF HANDWASHING,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
NCT04621058,Recruiting,Interventional,Phase 3,Bioaraba Health Research Institute,Other,9-Nov-20,30-Nov-21,30-Nov-21,TREATMENT,108,SAR,SPAIN,ALL,"Child, Adult, Older Adult",VITAMIN D,MORTALITY,Efficacy of Treatment With Vitamin D in Patients Diagnosed With COVID-19 Who Presenting Vitamin D Deficiency and Pneumonia.
NCT04621071,Recruiting,Interventional,Not Applicable,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Other,5-Jan-21,21-Apr-21,21-Mar-21,TREATMENT,84,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",PROBIOTICS (2 STRAINS 10X10^9 UFC),DURATION OF SYMPTOMS OF THE COVID-19,"Evaluation of the Efficacy of Probiotics to Reduce the Duration and Symptoms of COVID-19 (PROVID-19 Study): a Randomized, Double-blind, Controlled Trial"
NCT04621084,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,1-Apr-20,31-Dec-25,31-Dec-25,COHORT,1000,NUTRITION,FRANCE,ALL,"10 Years and older   (Child, Adult, Older Adult)",EATING HABITS,STRESS MEASURES,Influence of the COVId-19 Pandemic on STRESS and Eating Habits
NCT04621123,Recruiting,Interventional,Phase 2,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Other,30-Oct-20,21-Oct-21,21-Feb-21,TREATMENT,474,SARS-COV2 INFECTION,SPAIN,ALL,"50 Years and older   (Adult, Older Adult)",CONVALESCENT ANTI-SARS-COV-2 MBT PLASMA,HOSPITALIZATION RATE (SAFETY AND EFFICACY),Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert)
NCT04621149,Recruiting,Interventional,Phase 2,"Profact, Inc.",Other,15-Nov-20,31-Mar-21,31-Mar-21,TREATMENT,120,COVID,UNITED STATES,ALL,"20 Years to 70 Years   (Adult, Older Adult)",CHLORINE DIOXIDE,REDUCTION IN PARTICIPANT SYMPTOMS OF COVID-19,"A Phase 2 Screening Study of Candidate Non-prescription Treatments for COVID-19: A Patient-driven, Randomized, Factorial Study Evaluating Patient-reported Outcomes (PROFACT-01)"
NCT04621214,Completed,Observational,,University of Lahore,Other,21-Mar-20,28-Apr-20,28-Apr-20,CASE-ONLY,60,AUDIO-VISUAL TRIAGE SYSTEM,PAKISTAN,ALL,20 Years to 38 Years   (Adult),AUDIO-VISUAL TRIAGE SYSTEM (AVT),POLYMERASE CHAIN REACTION (PCR) TO DETECT SARS-COV-2 VIRUS,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy
NCT04621461,Completed,Interventional,Phase 4,"St. Francis Hospital, New York",Other,20-Dec-20,8-Feb-21,8-Feb-21,TREATMENT,3,CORONAVIRUS INFECTION,UNITED STATES,ALL,"30 Years and older   (Adult, Older Adult)",ZINC SULFATE 220 MG,NUMBER OF PARTICIPANTS HOSPITALIZED AND/OR REQUIRING REPEAT EMERGENCY ROOM VISITS,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting"
NCT04621552,Completed,Observational,,"University Hospital, Montpellier",Other,1-Jan-15,30-Oct-20,30-Jun-20,CASE-CONTROL,186,ANEURYSM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",WEB EMBOLIZATION,MEDIAN DURATION OF THE INTERVENTION,Comparison of Woven EndoBridge Device Sizing With Conventional Measurements and Virtual Simulation Using the Sim&Size Software: A Multi-Center Experience
NCT04621903,Completed,Interventional,Not Applicable,Aarogyam UK,Other,8-Oct-20,3-Nov-20,27-Oct-20,SUPPORTIVE CARE,26,COVID,UNITED KINGDOM,ALL,"20 Years to 70 Years   (Adult, Older Adult)",SHANSHAMANI VATI PLUS,TIME TO COVID-19 SYMPTOMS RELIEF,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research
NCT04622332,Not yet recruiting,Interventional,Phase 1,"Sironax USA, Inc.",Industry,15-Dec-20,15-Dec-21,15-Dec-21,TREATMENT,60,CORONAVIRUS INFECTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SIR1-365,PROPORTION OF PATIENTS WITH ANY TEAES DURING THE TREATMENT PERIOD,"A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19"
NCT04622748,Recruiting,Observational,,"National Institute on Drug Dependence, China",Other,10-Jul-20,10-Dec-20,10-Dec-20,CASE-CONTROL,160,COGNITION,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TRIER SOCIAL STRESS TEST,WORKING MEMORY,An Investigation of Neurocognitive Functions and the Influencing Factors in Recovered Patients With COVID-19
NCT04622826,Recruiting,Interventional,Phase 2,Azienda USL Toscana Nord Ovest,Other,15-May-20,31-Dec-20,31-Dec-20,PREVENTION,50,COVID PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",IMMUNE PLASMA,ITU ADMISSION,"Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva"
NCT04622865,Recruiting,Interventional,Phase 2,AB Science,Industry,1-Jun-20,21-Jun-21,21-Jun-21,TREATMENT,200,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",MASITINIB,CLINICAL STATUS OF PATIENTS AT DAY-15 USING A 7-POINT ORDINAL SCALE,"Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19"
NCT04622891,Completed,Interventional,Not Applicable,South Valley University,Other,1-Apr-20,30-Jul-20,30-Jul-20,TREATMENT,300,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",CLARITHROMYCIN 500MG,TIME TO FEVER CONTROL,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial"
NCT04623021,Completed,Interventional,Phase 2,Chong Kun Dang Pharmaceutical,Industry,25-Sep-20,12-Dec-20,12-Dec-20,TREATMENT,104,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",NAFAMOSTAT MESILATE,TIME TO CLINICAL IMPROVEMENT,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia"
NCT04623047,Recruiting,Observational,,Duke University,Other,2-Apr-20,1-Feb-22,1-Feb-22,OTHER,100000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,ACCURACY OF PREDICTIVE MODEL USING SMART WATCH DATA TO PREDICT COVID-19 SYMPTOMS AS MEASURED BY SELF-REPORTS OF SYMPTOM QUESTIONNAIRE.,Using Smart Watches to Detect and Monitor COVID-19
NCT04623138,Not yet recruiting,Observational,,Evidation Health,Industry,20-Nov-21,21-May-21,21-May-21,COHORT,950,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,"DEVELOPMENT OF DATABASE CONTAINING PHYSIOLOGICAL, BEHAVIORAL DATA IN COMBINATION WITH SARS-COV-2 INFECTION","A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and SARS-CoV-2 Infection"
NCT04623177,"Active, not recruiting",Observational,,Instituto de Investigacion Sanitaria La Fe,Other,1-Mar-20,20-Nov-21,30-Sep-20,COHORT,950,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,ICU MORTALITY,"Effectiveness of Thromboprophylaxis With Low Molecular Weight Heparin in Critically Ill Patients With COVID-19. A Prospective, Cohort, Multicenter Study."
NCT04623255,Recruiting,Interventional,Phase 2,"University College, London",Other,16-Oct-20,1-Nov-21,15-Oct-21,TREATMENT,20,COVID,UNITED KINGDOM,ALL,"18 Years to 70 Years   (Adult, Older Adult)",OCTAPLAS,CHANGE IN INFLAMMATORY MARKER-CRP,A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection (COVIPLEX)
NCT04623346,"Active, not recruiting",Observational,,Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization,Other,11-Mar-20,1-Dec-20,1-Nov-20,COHORT,262,ANKLE FRACTURES,TURKEY,ALL,85 Years and older   (Older Adult),OBSERVATION FOR STUDY GROUP,COMPARISON OF THE TWO GROUPS IN TERMS OF BONY UNION,Orthopaedic Conservative Treatment in the Time of Covid-19 Pandemic
NCT04623385,Not yet recruiting,Interventional,Phase 4,Kafrelsheikh University,Other,20-Nov-21,21-Dec-21,20-Dec-21,TREATMENT,1000,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",AEROSOLIZED 13 CIS RETINOIC ACID PLUS INHALATION INHALED TESTOSTERONE,LUNG INJURY SCORE,Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?
NCT04623619,Not yet recruiting,Interventional,Not Applicable,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Other,15-Dec-20,31-Jul-21,29-Apr-21,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ACETYL L-CARNITINE,IN-HOSPITAL MORTALITY,Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia
NCT04623671,Recruiting,Interventional,Phase 2,Capricor Inc.,Industry,15-Nov-20,30-Jun-21,30-Apr-21,TREATMENT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CAP-1002,SAFETY OF CAP-1002,"A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)"
NCT04623697,Recruiting,Observational [Patient Registry],,Hospital of South West Jutland,Other,1-Nov-20,30-Oct-23,30-Oct-23,CASE-CONTROL,600,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",,STIMULATED INSULIN SECRETION,Covid-19 and Type 1 Diabetes - a Multicenter Study
NCT04624048,Not yet recruiting,Observational,,University of Salamanca,Other,4-Dec-20,4-Apr-21,4-Jan-21,ECOLOGIC OR COMMUNITY,30000,INFECTION VIRAL,,ALL,"17 Years to 85 Years   (Child, Adult, Older Adult)",COVID-19 SURVEY,IMPACT OF COVID-19,"""Influence of Physical Exercise on the Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, COVID-19"""
NCT04624503,Recruiting,Observational,,"Humanitas Hospital, Italy",Other,1-Oct-20,1-Oct-21,1-Jun-21,COHORT,500,COVID,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,CARDIOVASCULAR MORTALITY,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19 (Rilevanza Clinica e Prognostica Del Coinvolgimento Cardiovascolare Nei Pazienti Affetti da COVID-19)
NCT04624997,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,8-Jun-20,20-Dec-21,20-Dec-21,COHORT,1000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BIOLOGICAL SAMPLE,MEASURE D-DIMERS (NG/ML) TO STUDY COAGULOPATHY TO CHARACTERIZE COVID-19,Evaluation de la COagulopathie et de la Dysfonction enDOthéliale Comme Facteur prédictif de la gravité de l'Infection Par SARS-CoV-2 / COVID-19
NCT04625036,Recruiting,Observational [Patient Registry],,Istituti Clinici Scientifici Maugeri SpA,Other,30-May-20,21-Jun-21,21-Apr-21,CASE-ONLY,30,COVID PNEUMONIA,ITALY,ALL,"30 Years to 80 Years   (Adult, Older Adult)",SINGLE PASSIVE LEG MOVEMENT,LEG BLOOD FLOW,Pilot Study on Peripheral Vascular Function in Covid-19 Patient
NCT04625075,Recruiting,Observational,,University of Edinburgh,Other,10-Jun-20,10-Jun-22,10-Jun-21,CASE-CONTROL,40,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",CARDIAC MRI,MRI WITH GADOLINIUM,Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (MEMORY- COVID)
NCT04625114,Recruiting,Interventional,Phase 2,"University Hospital, Ghent",Other,4-Nov-20,1-Jan-23,1-Oct-22,TREATMENT,150,COVID,BELGIUM,ALL,"18 Years to 100 Years   (Adult, Older Adult)",CAMOSTAT,EFFICACY IN TERMS OF VIRAL LOAD OR SURROGATE,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden
NCT04625218,Not yet recruiting,Observational,,"University Hospital, Toulouse",Other,21-Jan-21,21-May-21,21-May-21,OTHER,40,COVID PNEUMONIA,,ALL,"18 Years and older   (Adult, Older Adult)",,RESIDUAL PLASMA CONCENTRATION,Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) in the Critically Ill Patient: Pharmacokinetic Study. (CHLORO-VID)
NCT04625257,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,24-Oct-20,21-Mar-21,21-Mar-21,COHORT,3000,CORONAVIRUS INFECTIOUS DISEASE 2019 (COVID),SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",SALIVA BASED ASSAY: CRUDE RNA EXTRACTION,QUALITATIVE METHOD VALIDATION OF THE CRUDE EXTRACTION IN COMBINATION WITH THE LAMP OR THE NGS (COUNT VALUES FOR DETECTION),"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)"
NCT04625296,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,17-Sep-20,21-Jan-21,21-Jan-21,COHORT,75,HEALTHCARE WORKER FACING COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEMI-DIRECTIVE INTERVIEW,DIVERSITY OF THEMES EXTRACTED ABOUT CARE SITUATIONS MANAGEMENT OF THE COVID-19 EPIDEMIC.,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 Epidemic
NCT04625725,Recruiting,Interventional,Phase 3,AstraZeneca,Industry,21-Nov-20,2-Feb-22,2-Aug-21,PREVENTION,5000,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",AZD7442,THE INCIDENCE OF THE FIRST CASE OF SARS COV-2 RT PCR POSITIVE SYMPTOMATIC ILLNESS,"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19."
NCT04625738,Not yet recruiting,Interventional,Phase 2,"Central Hospital, Nancy, France",Other,6-Nov-20,6-Aug-22,16-May-22,TREATMENT,30,COVID ARDS,,ALL,"18 Years and older   (Adult, Older Adult)",EX VIVO EXPANDED WHARTON'S JELLY MESENCHYMAL STEM CELLS,PAO2 / FIO2 RATIO,Efficacy of Infusions of Mesenchymal Stem Cells From Wharton Jelly in the Moderate to Severe SARS-Cov-2 Related Acute Respiratory Distress Syndrome (COVID-19): A Phase IIa Double-blind Randomized Controlled Trial
NCT04625972,Recruiting,Interventional,Phase 3,AstraZeneca,Industry,2-Dec-20,21-Jan-22,21-Jan-22,PREVENTION,1125,COVID,UNITED KINGDOM,ALL,"18 Years to 120 Years   (Adult, Older Adult)",AZD7442,THE INCIDENCE OF THE FIRST CASE OF SARS COV-2 RT PCR POSITIVE SYMPTOMATIC ILLNESS,"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19"
NCT04625985,Recruiting,Interventional,Phase 2,Laboratorios Silanes S.A. de C.V.,Industry,14-Jul-20,31-Mar-21,31-Dec-20,TREATMENT,20,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",METFORMIN GLYCINATE,VIRAL LOAD,"Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb"
NCT04626050,Not yet recruiting,Interventional,Not Applicable,Weill Medical College of Cornell University,Other,21-Jan-21,22-Jan-21,22-Jan-21,TREATMENT,120,POST-TRAUMATIC STRESS DISORDER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",MEDICAL MUSIC,FEASIBILITY INDICATOR: RECRUITMENT (PHASE I),"A Brief Phased Two-Step Intervention for Treating General Psychological Distress, PTSD and Co-Morbidities in Healthcare Workers Consequent to the COVID-19 Pandemic"
NCT04626076,Recruiting,Observational [Patient Registry],,Certara,Industry,13-Aug-20,31-Oct-21,30-Jun-21,OTHER,10000,SARS-COV INFECTION,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",COMPARATIVE OBSERVATIONAL COHORT STUDY,"OCCURRENCE OF SARS-COV-2 INFECTION AMONG HCWS CARING FOR COVID-19 PATIENTS, IN TERMS OF TIME, GEOGRAPHY, HEALTHCARE SETTING, TYPE OF HCW.",International Registry of Healthcare Workers Exposed to COVID-19 Patients
NCT04626089,Not yet recruiting,Interventional,Phase 2,Laboratorios Silanes S.A. de C.V.,Industry,30-Nov-20,31-Mar-21,30-Dec-20,TREATMENT,20,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",METFORMIN GLYCINATE,VIRAL LOAD,"Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb."
NCT04627194,"Active, not recruiting",Observational,,Semey State Medical University,Other,20-Feb-20,1-Dec-20,30-Apr-20,COHORT,1000,COVID,KAZAKHSTAN,ALL,"Child, Adult, Older Adult",,CLINICAL AND DEMOGRAPHIC PREDICTORS OF DISEASE SEVERITY AMONG HOSPITALIZED COVID-19 PATIENTS.,"Epidemiological and Clinical Characteristics of COVID-19 Patients in Kazakhstan in Early 2020: a Retrospective, Observational Cohort Study"
NCT04627233,Not yet recruiting,Interventional,Phase 1,Shahid Beheshti University of Medical Sciences,Other,20-Dec-20,1-Apr-21,1-Mar-21,TREATMENT,20,COVID,"IRAN, ISLAMIC REPUBLIC OF",ALL,"18 Years to 70 Years   (Adult, Older Adult)",HUMAN EZRIN PEPTIDE 1 (HEP1),TIME TO CLINICAL IMPROVEMENT OF DISEASE SYMPTOMS,The Clinical Trial of Application of Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection
NCT04627467,"Active, not recruiting",Interventional,Phase 2,Fundacion Clinica Valle del Lili,Other,28-Mar-20,14-Feb-21,9-Jul-20,PREVENTION,3217,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",CHLOROQUINE,COVID-19 INFECTION,Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19)
NCT04627519,Recruiting,Interventional,Not Applicable,Universitas Padjadjaran,Other,9-Dec-20,15-Mar-21,31-Jan-21,SUPPORTIVE CARE,85,COVID,INDONESIA,ALL,18 Years to 50 Years   (Adult),RHEA HEALTH TONE®,LENGTH OF STAY,"A Multicenter, Randomized, Open-label, Controlled Trial to Assess Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia"
NCT04627584,Recruiting,Interventional,Phase 2,"Mabwell (Shanghai) Bioscience Co., Ltd.",Industry,29-Dec-20,21-Sep-21,21-May-21,TREATMENT,150,COVID,CHINA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MW33 INJECTION,SARS-COV-2 VIRAL LOAD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19"
NCT04627623,Recruiting,Observational,,Medical University of Silesia,Other,22-Jun-20,22-Apr-21,22-Mar-21,CASE-CROSSOVER,6000,COVID,POLAND,ALL,"Child, Adult, Older Adult",IGM AND IGG ANTIBODIES ASSAY,ESTIMATION OF PREVALENCE OF SPECIFIC ANTI-SARS-COV-2 IGM AND IGG ANTIBODIES IN GENERAL POPULATION.,Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020
NCT04627675,Recruiting,Interventional,Phase 1,Providence Health & Services,Other,30-Dec-20,22-May-21,21-May-21,PREVENTION,36,SARS-COV2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CORVAX,TOXICITY,"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response"
NCT04628000,Recruiting,Observational,,Parkview Medical Center,Other,27-Oct-20,14-Apr-22,14-Oct-21,COHORT,50,VITAMIN D DEFICIENCY,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VITAMIN D,LOS DURATION IN DAYS,Baseline Vitamin D Deficiency and COVID-19 Disease Severity/Need for Escalation of Care
NCT04628039,Not yet recruiting,Interventional,Not Applicable,VA Office of Research and Development,U.S. Fed,1-Mar-21,31-Oct-24,1-Aug-24,HEALTH SERVICES RESEARCH,506,COVID,UNITED STATES,ALL,"18 Years to 89 Years   (Adult, Older Adult)",REHABILITATION-FOCUSED PROGRAM,EUROQOL 5 DIMENSION 5 LEVEL (EQ-5D-5L) VISUAL ANALOG SCORE,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs (LAUREL Study)"
NCT04628104,Not yet recruiting,Observational [Patient Registry],,Assiut University,Other,1-Jan-21,23-Oct-21,22-Oct-21,COHORT,60,MYOCARDIAL INFARCTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CARDIAC MAGNETIC RESONANCE,COMPARISON BETWEEN COVID-19 AND COVID-19 PRESENTED WITH MYOCARDIAL INFARCTION,CMR Findings in COVID-19 Patients Presenting With Myocardial Infarction
NCT04628143,Not yet recruiting,Interventional,Phase 2,Chong Kun Dang Pharmaceutical,Industry,20-Nov-20,30-Jun-21,30-May-21,TREATMENT,100,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NAFAMOSTAT MESILATE,TIME TO CLINICAL IMPROVEMENT,"Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19"
NCT04628195,Completed,Observational,,Pontificia Universidad Catolica de Chile,Other,1-Apr-20,1-Aug-20,30-Jun-20,COHORT,100,COVID,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",,PERCENTAGE OF PATIENTS WITH LEFT VENTRICLE DYSFUNCTION (HYPOKINETIC),Cardiac Performance in Mechanically Ventilated Patients With Severe Pneumonia by SARS-CoV-2: Echo-COVID Study
NCT04628208,Recruiting,Observational,,Spartan Bioscience Inc.,Industry,17-Nov-20,21-Jan-21,21-Jan-21,CASE-ONLY,60,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SPARTAN COVID-19 V2 SYSTEM,PERCENT AGREEMENT BETWEEN SOC TEST AND SPARTAN COVID-19 TEST,Assess the Performance of Spartan COVID-19 V2 System in a Clinical Setting in Comparison to a Laboratory (Standard of Care (SOC)) PCR Method (Canada Alternate)
NCT04628637,Completed,Observational,,Kafkas University,Other,16-Apr-20,10-Oct-20,1-Oct-20,CASE-CONTROL,144,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",SERUM PROTEIN LEVEL ANALYSIS,DETERMINATION OF THE CHANGE OF THE SERUM GRP-78 PROTEIN LEVELS IN PATIENTS WHO HAVE COVID-19 INFECTION COMPARED TO CONTROL GROUP,High GRP78 Levels in Covid-19 Infection: A Case-Control Study
NCT04629001,"Active, not recruiting",Observational [Patient Registry],,Assiut University,Other,1-Sep-20,1-Dec-21,1-Sep-21,COHORT,1000,PREGNANCY WITHOUT COMPLICATIONS EXCEPT GETTING COVID INFECTION,EGYPT,FEMALE,18 Years to 40 Years   (Adult),"COVID-19 PCR , IGM",FETAL MORBIDITY,Effect of Covid-19 on Outcomes of Pregnancy
NCT04629105,Recruiting,Interventional,Phase 1,Longeveron LLC,Industry,24-Jul-20,25-Jul-21,21-Aug-21,TREATMENT,70,"ARDS, HUMAN",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LONGEVERON MESENCHYMAL STEM CELLS (LMSCS),INCIDENCE OF TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS,"A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Longeveron Mesenchymal Stem Cells (LMSCs)"
NCT04629157,Recruiting,Interventional,Not Applicable,Alder Hey Children's NHS Foundation Trust,Other,5-Nov-20,19-Nov-20,19-Nov-20,DIAGNOSTIC,400,THIS IS A PILOT STUDY WHICH AIMS TO ASSESS THE VALIDITY AND APPLICABILITY OF LATERAL FLOW ASSAYS (LFAS) WHICH CAN BE USED AS A POINT OF CARE TEST FOR COVID,UNITED KINGDOM,ALL,up to 17 Years   (Child),INNOVA LATERAL FLOW DEVICE,ACCEPTABILITY OF TEST,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19
NCT04629183,Recruiting,Observational,,Azienda Ospedaliera Città della Salute e della Scienza di Torino,Other,1-Nov-20,31-Jul-21,30-Apr-21,COHORT,400,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INTEGRATED CLINICAL EVALUATION,COMPOSITE OUTCOME,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department
NCT04629222,Completed,Observational,,Pierre Yves MARIE,Other,11-Mar-20,23-Jul-20,20-Jul-20,CASE-CONTROL,10,VENTILATION LUNG SCINTIGRAPHY DURING COVID INFECTION,FRANCE,ALL,"Child, Adult, Older Adult",,TRACHEOBRONCHITIS SIGNS MAY BE OBSERVED ON VENTILATION LUNG SCINTIGRAPHY DURING COVID-19 INFECTION.,Tracheobronchitis May Constitute the Main Sign of Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients
NCT04629638,Completed,Observational,,Kanuni Sultan Suleyman Training and Research Hospital,Other,1-Aug-20,20-Nov-20,15-Nov-20,CASE-CONTROL,500,COVID,TURKEY,FEMALE,18 Years to 45 Years   (Adult),"MATERNAL ATTACHMENT, EDINBURGH DEPRESSION SCORING AND POSTPARTUM ANXIETY SCALE SCORES",MATERNAL ATTACHMENT IN SARS- COV2 POSITIVE AND NEGATIVE PREGNANT WOMEN,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women
NCT04629703,Not yet recruiting,Interventional,Phase 3,Rigel Pharmaceuticals,Industry,20-Dec-21,21-Oct-21,21-Aug-21,TREATMENT,308,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",FOSTAMATINIB,PROGRESSION TO SEVERE/CRITICAL DISEASE WITHIN 29 DAYS OF FIRST DOSE OF STUDY TREATMENT,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects"
NCT04629755,Completed,Interventional,Not Applicable,University of Washington,Other,4-Apr-20,3-Aug-20,3-Aug-20,PREVENTION,1765,DEPRESSION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INTERVENTION,CHANGE IN DEPRESSED MOOD,A Smartphone Intervention for Relational and Mental Well Being
NCT04629989,Recruiting,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,13-Nov-20,15-Feb-21,15-Feb-21,SUPPORTIVE CARE,27,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD OXYGEN DELIVERY SYSTEM,CHANGES IN PAO2,The Effects of Two Systems Above Low-flow Nasal Cannula on Arterial Oxygen Tension in Patients With COVID-19 : Surgical Face Mask Versus Double-trunk Mask
NCT04630015,Recruiting,Observational,,"University of California, San Francisco",Other,31-Aug-20,31-Dec-23,1-Aug-23,COHORT,250,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SURVEY ADMINISTRATION,CHANGES IN THE PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM (PROMIS) ANXIETY SHORT FORM OVER TIME,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth
NCT04630054,Recruiting,Interventional,Not Applicable,Yale University,Other,15-Nov-20,15-Feb-21,15-Feb-21,PREVENTION,450000,COVID,BANGLADESH,ALL,"18 Years and older   (Adult, Older Adult)",FACE MASK,SYMPTOMATIC SARS-COV2 INFECTION,Can Face Masks Reduce Transmission of SARS-CoV-2 in Bangladesh? A Cluster Randomized Controlled Trial
NCT04631172,Completed,Observational [Patient Registry],,Selcuk University,Other,1-May-20,15-Oct-20,30-Sep-20,OTHER,150,SARS-COV2,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)","CORONAVIRUS ANXIETY SCALE , COVID-19 PHOBIA SCALE",CORONAVIRUS ANXIETY SCALE (CAS),Evaluation of Covid-19 Anxiety and Phobia Levels of the Parents of Pediatric Patients
NCT04631367,Not yet recruiting,Interventional,Not Applicable,University of Toronto,Other,1-Feb-21,20-Sep-21,20-May-21,PREVENTION,404,"KNOWLEDGE, ATTITUDES, PRACTICE",,ALL,"16 Years to 24 Years   (Child, Adult)",KUKAA SALAMA: MHEALTH INTERVENTION,CHANGES IN COVID-19 PREVENTION PRACTICES,"Kukaa Salama (Staying Safe): A Pre-Post Trial of a mHealth Social Group for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Kampala, Uganda"
NCT04631380,Recruiting,Interventional,Not Applicable,Hospital do Coracao,Other,1-Aug-20,21-Jan-21,21-Jan-21,OTHER,200,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",PRAYER,DEATH OR RECOVERY,"A Double Blind, Controlled, Randomized, Prospective Study That Will Evaluate the Impact of Remote Intercession Prayer on the Clinical Evolution of Patients Diagnosed With COVID -19 in HCOR."
NCT04631497,Recruiting,Observational,,Jagiellonian University,Other,1-Jul-20,31-Dec-21,31-Dec-21,COHORT,100,DEPRESSION,POLAND,ALL,"18 Years to 70 Years   (Adult, Older Adult)",TEST,DEPRESSION,"Assessment of Stress, Depression and Anxiety in Healthcare Caring for Patients With COVID-19"
NCT04631536,Not yet recruiting,Interventional,Phase 3,Lebanese American University Medical Center,Other,10-Jan-21,1-May-21,31-Jan-21,TREATMENT,80,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ATORVASTATIN + L-ARGININE + FOLIC ACID + NICORANDIL + NEBIVOLOL,CLINICAL IMPROVEMENT,Managing Endothelial Dysfunction in Moderate COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital
NCT04631666,Not yet recruiting,Interventional,Phase 1/Phase 2,University of Cologne,Other,23-Nov-20,30-Jun-21,30-Jun-21,TREATMENT,69,SARS-COV INFECTION,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HUMAN MONOCLONAL ANTIBODY DZIF-10C (GROUP 1A-2D),INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY],A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
NCT04631705,Not yet recruiting,Interventional,Phase 1/Phase 2,University of Cologne,Other,23-Nov-20,30-Jun-21,30-Jun-21,TREATMENT,69,SARS-COV INFECTION,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HUMAN MONOCLONAL ANTIBODY DZIF-10C (GROUP 1A-2D),INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY],A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
NCT04631861,Completed,Observational,,Wonju Severance Christian Hospital,Other,1-Jan-14,31-Jul-20,31-Jul-20,CASE-CONTROL,132069,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,SARS-COV-2 POSITIVITY RATE (%),Physical Activity and the Risk of COVID-19 Infection and Mortality
NCT04632043,Not yet recruiting,Interventional,Not Applicable,Evangelismos Hospital,Other,18-Nov-20,1-May-21,1-Apr-21,TREATMENT,80,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",ENDOTRACHEAL INTUBATION,TIME FROM ONSET OF SEVERE ACUTE HYPOXEMIC RESPIRATORY FAILURE TO INTUBATION,Effect of Early versUs Delayed intubatiOn on Clinical Outcomes of Patients With COVID-19 (EUDOCO): a Feasibility Randomized Controlled Trial
NCT04632082,Enrolling by invitation,Interventional,Not Applicable,Hospital de Clinicas de Porto Alegre,Other,5-Nov-20,20-Jul-21,13-Jul-21,PREVENTION,2200,MENTAL HEALTH WELLNESS 1,BRAZIL,ALL,"Child, Adult, Older Adult",TELEPSYCHOEDUCATION WITH PERSONALIZED VIDEOS,INCIDENT CASES IN 6 MONTHS,A Pragmatic Superiority Randomized Controlled Trial Comparing Telepsychoeducation Plus Personalized Videos vs. Telepsychoeducation Without Personalized Videos for the Prevention of Future Emotional Distress in Professionals From Essential Services With Low to Moderate Levels of Emotional Distress in Brazil in the Context of COVID-19
NCT04632173,Not yet recruiting,Observational,,Hellenic Cooperative Oncology Group,Other,1-Dec-20,30-Jun-21,31-Jan-21,COHORT,750,HEAD AND NECK CANCER,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",NON INTERVENTIONAL STUDY,DEMOGRAPHIC FEATURES,HERODOTUS: Head and Neck cancERs International cOviD-19 collabOraTion
NCT04632355,Not yet recruiting,Observational,,Fondazione Don Carlo Gnocchi Onlus,Other,1-Dec-20,31-Jul-21,31-Jul-21,COHORT,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",INTERVIEW,SELF-REPORTED VERSION OF THE LEEDS ASSESSMENT OF NEUROPATHIC SYMPTOMS AND SIGNS,After the First and Second Wave in Italy: What Effects of Musculoskeletal Pain Did the Covid-19 in Patients Who Have Hospital Care?
NCT04632368,Recruiting,Interventional,Not Applicable,Duke University,Other,20-Nov-20,21-Apr-21,21-Apr-21,SUPPORTIVE CARE,80,"BURNOUT, PROFESSIONAL",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TRANSCENDENTAL MEDITATION,CHANGE IN SELF REPORTED STRESS SYMPTOMS,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic
NCT04632381,Not yet recruiting,Interventional,Phase 1,Effector Therapeutics,Industry,16-Nov-20,1-Jul-21,5-Apr-21,TREATMENT,36,CORONAVIRUS INFECTION,,ALL,18 Years to 64 Years   (Adult),ZOTATIFIN,SAFETY AS ASSESSED BY THE INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)"
NCT04632537,Recruiting,Interventional,Phase 3,Henry M. Jackson Foundation for the Advancement of Military Medicine,Other,7-Dec-20,23-Apr-21,22-Nov-21,PREVENTION,550,COVID,UNITED STATES,ALL,18 Years to 64 Years   (Adult),TICE® BCG (FOR INTRAVESICAL USE) BCG LIVE STRAIN OF THE BCG (MERCK) VACCINE,INCIDENCE OF SYMPTOMATIC RT-PCR-CONFIRMED SARS-COV-2 INFECTION,Novel Use of an Existing Vaccine (BCG) Alliance: The NUEVA Trial
NCT04632602,Recruiting,Interventional,Not Applicable,Assistance Publique Hopitaux De Marseille,Other,4-Apr-20,31-Jan-21,31-Dec-20,OTHER,20,RESPIRATORY FAILURE,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PHYSIOLOGICAL EFFECTS OF AWAKE PRONE POSITION IN COVID 19 PATIENTS,"GLOBAL INHOMOGENEITY INDEX VARIATIONS (EXPRESSED IN PERCENTAGE) BETWEEN BASELINE, SUPINE AND PRONE POSITION PERIODS.",Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure: a Randomized Cross Over Electrical Impedance Tomography Study
NCT04632615,Recruiting,Observational,,Istituto Ortopedico Galeazzi,Other,22-May-20,28-Feb-21,28-Feb-21,COHORT,230,SLEEP,ITALY,ALL,18 Years to 40 Years   (Adult),,CHANGE IN SUBJECTIVE SLEEP QUALITY,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak
NCT04632706,Recruiting,Interventional,Early Phase 1,MedinCell S.A,Industry,22-Sep-20,21-May-21,21-Feb-21,OTHER,24,COVID,UNITED KINGDOM,MALE,18 Years to 45 Years   (Adult),IVERMECTIN,PHARMACOKINETIC CONCENTRATIONS - (MAXIMUM PLASMA CONCENTRATION [CMAX]),"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers"
NCT04632719,Recruiting,Interventional,Not Applicable,University of Sao Paulo,Other,8-Nov-20,29-Dec-23,29-Dec-20,TREATMENT,200,COGNITIVE IMPAIRMENT,BRAZIL,ALL,"8 Years to 88 Years   (Child, Adult, Older Adult)",THE USE OF THE MENTALPLUS® DIGITAL GAME FOR ASSESSMENT AND REHABILITATION OF COGNITIVE FUNCTION AFTER REMISSION OF THE SYMPTOMS OF COVID-19,ASSESSMENT OF COGNITIVE FUNCTIONS AFTER COVID-19,MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19
NCT04632732,Recruiting,Observational [Patient Registry],,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,Other,26-Oct-20,1-Dec-21,7-Oct-21,COHORT,140,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 TEST,"BLOOD APELINS-13/12, -17/16, -36",Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
NCT04633772,Recruiting,Interventional,Phase 1/Phase 2,Erasme University Hospital,Other,5-Aug-20,28-Feb-21,1-Feb-21,TREATMENT,130,"INFECTION, CORONAVIRUS",BRAZIL,ALL,"17 Years to 81 Years   (Child, Adult, Older Adult)",ANGIOTENSIN-(1-7),SUPPLEMENTAL OXYGEN-FREE DAYS (SOFDS),Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2
NCT04633915,Recruiting,Observational,,"Saint Petersburg State University, Russia",Other,26-Nov-20,21-Aug-21,21-Aug-21,COHORT,40,DIALYSIS,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",,ANTI-SARS-COV-2 IGG LEVEL,A Comparison of Antibody Response Against SARS-CoV-2 in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
NCT04633941,Completed,Observational,,Singapore General Hospital,Other,1-Jun-20,30-Jul-20,30-Jul-20,COHORT,272,"DIABETES MELLITUS, TYPE 2",SINGAPORE,ALL,"18 Years to 65 Years   (Adult, Older Adult)",STANDARD CARE,WEIGHT,Comparing the Impact of Social Distancing and Lockdown on Bariatric Patients Versus Non-Surgical Obese Patients During COVID-19 Pandemic - Cross Sectional Study
NCT04633980,Not yet recruiting,Interventional,Phase 1,"University Hospital, Grenoble",Other,1-Dec-20,30-Sep-21,30-Aug-21,TREATMENT,10,COVID,,ALL,"18 Years and older   (Adult, Older Adult)","MIXTURE 3,6% H2 IN N2 (96.4%)",ADVERSE EVENTS,Hydrogen Inhalation Therapy in Patients With Moderate Covid-19: Phase-1 Clinical Trial
NCT04634214,Not yet recruiting,Observational,,India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals,Other,16-Nov-20,16-May-21,16-Feb-21,CASE-CONTROL,1050,COVID,INDIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,SEVERITY OF COVID 19 AMONG PEOPLE WITH AND WITHOUT DIABETES,Study on Characteristics and Prognosis of Diabetes and Non Diabetes Patients With COVID 19 Among Southern Indian Population
NCT04634318,Recruiting,Interventional,Not Applicable,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Other,10-Dec-20,22-Dec-21,21-Dec-21,OTHER,118,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RESPIRATORY REHABILITATION PROGRAM (RR).,DISTANCE WALKED IN THE 6-MIN WALK TEST (6 MWT).,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae. Assessment and Therapeutic Indication of Tele-rehabilitation Versus Conventional Rehabilitation
NCT04634370,Not yet recruiting,Interventional,Phase 1,Hospital de Clinicas de Porto Alegre,Other,2-Jan-21,30-Mar-21,30-Mar-21,TREATMENT,24,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",NATURAL KILLER CELLS INFUSION,OVERALL SURVIVAL,Fase I Clinical Trial on Natural Killer Cells for COVID-19
NCT04634409,Recruiting,Interventional,Phase 2,Eli Lilly and Company,Industry,29-Jan-20,29-Jun-21,8-Mar-21,TREATMENT,700,COVID,PUERTO RICO,ALL,18 Years to 64 Years   (Adult),LY3819253,PERCENTAGE OF PARTICIPANTS WITH SARS-COV-2 VIRAL LOAD GREATER THAN 5.27,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)"
NCT04634422,Recruiting,Interventional,Not Applicable,Wladimir Szpirt,Other,16-Nov-20,30-Jun-22,30-Jun-21,TREATMENT,220,RESPIRATORY FAILURE,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",PLASMA EXCHANGE AND CONVALESCENT PLASMA,ALIVE AT DAY 90TH,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure - the COVID PLEX+CCP Trial
NCT04634799,Recruiting,Interventional,Phase 1/Phase 2,Northwestern University,Other,8-Jan-21,30-Jun-22,30-Nov-21,TREATMENT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TM5614,CLINICAL IMPROVEMENT,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19)
NCT04634903,"Active, not recruiting",Interventional,Not Applicable,Stony Brook University,Other,19-Nov-20,31-Jul-21,1-May-21,TREATMENT,2409,DEPRESSION,UNITED STATES,ALL,13 Years to 16 Years   (Child),SUPPORTIVE THERAPY SSI,CHANGE IN ADOLESCENT DEPRESSIVE SYMPTOM SEVERITY,Comparing Two Online Single-Session Interventions for Adolescent Depression: Outcomes of a Randomized Trial
NCT04635241,Recruiting,Interventional,Phase 2/Phase 3,Australian National University,Other,1-Jun-20,1-Jun-21,1-Apr-21,TREATMENT,712,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",UNFRACTIONATED HEPARIN,INTUBATION RATE,INHALEd Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 Meta-trial
NCT04635592,Not yet recruiting,Observational,,University Medical Centre Ljubljana,Other,20-Nov-21,31-Jan-21,31-Dec-20,COHORT,300,SARS-COV INFECTION,SLOVENIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",SARS-COV2 NASAL SWAB,POSITIVE NASAL SWAB AND SEROLOGICAL TEST,Serological Diagnostics of COVID-19 and Risk Factors for Infection Among Different Groups of Health Care Workers at Surgical Division at Tertiary Hospital
NCT04635605,Recruiting,Interventional,Phase 2,Fondazione Epatocentro Ticino,Other,5-Nov-20,31-Dec-22,31-Dec-21,TREATMENT,64,SARS-COV2,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",METHYLENE BLUE,TO COMPARE THE VIRAL LOAD KINETICS IN THE ENROLLED PATIENTS WITH A SARS-COV-2 POSITIVE NASOPHARYNGEAL SWAB DEMONSTRATING A REDUCTION OF THE AREA UNDER THE CURVE DAY 0- DAY 21 OF AT LEAST 25%,"Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV2- Affected Patients: a Phase 2, Randomized, Placebo- Controlled, Single Blind Clinical Trial"
NCT04635618,Enrolling by invitation,Interventional,Not Applicable,Hospital de Clinicas de Porto Alegre,Other,5-Nov-20,20-Jul-21,13-Jul-21,TREATMENT,999,MENTAL DISORDER,BRAZIL,ALL,"Child, Adult, Older Adult",COGNITIVE BEHAVIORAL BRIEF-TELEPSYCHOTHERAPY,SYMPTOM REDUCTION AT 1-MONTH,"A Pragmatic Superiority Randomized Controlled Trial Comparing Brief Cognitive Behavioral Telepsychotherapy, Brief Interpersonal Telepsychotherapy and Telepsychoeducation for the Reduction of Emotional Distress During COVID-19 Outbreak in Professionals and Students From Essential Services With a High Level of Emotional Distress in Brazil in the Context of COVID-19"
NCT04635787,Enrolling by invitation,Observational,,Northwestern University,Other,5-Nov-20,30-Oct-22,30-Sep-22,COHORT,300,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANNE ONE,1.EFFICACY OF WEARABLE DEVICE TO DETECT RESPIRATORY INFECTION PARAMETERS: COUGH COUNT,ICU-Grade Wearable Sensors With Novel Respiratory Biomarkers to Diagnose and Detect Pre- and Very Early Symptomatic COVID-19 Infection Using Predictive Machine Learning Algorithms
NCT04635813,Completed,Observational,,University of Cagliari,Other,10-Mar-20,12-Nov-20,30-Sep-20,CASE-CONTROL,3800,THYROID DISEASE,ITALY,ALL,"Child, Adult, Older Adult",THYROIDECTOMY,QUANTIFY THE OVERALL REDUCTION OF SURGICAL ACTIVITY FOR THYROID DISEASE,The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study
NCT04635943,Recruiting,Interventional,Phase 2,Universidad Peruana Cayetano Heredia,Other,28-Aug-20,28-Jan-21,28-Dec-20,TREATMENT,68,COVID,PERU,ALL,"18 Years to 90 Years   (Adult, Older Adult)",IVERMECTIN,PROPORTION OF PATIENTS WITH A POSITIVE SARS-COV-2 PCR.,Randomized Phase IIA Clinical Trial to Compare the Efficacy of Ivermectin Versus Placebo to Obtain Negative PCR Results in Patients With Early Phase COVID-19
NCT04636021,Recruiting,Observational [Patient Registry],,Pinnacle Health Cardiovascular Institute,Other,1-Aug-20,30-Jun-22,31-Dec-21,OTHER,1000,CORONAVIRUS INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",COVID-19 TESTING,NUMBER OF SUBJECTS WHO CONTRACT COVID-19 WHILE HOSPITALIZED FOR ELECTIVE OUTPATIENT PROCEDURES,Restoring Non-Emergent Cardiovascular Care in the Peri-COVID 19 Era
NCT04636034,Recruiting,Interventional,Phase 3,University Hospital Bispebjerg and Frederiksberg,Other,12-Jan-21,21-Nov-21,21-Aug-21,TREATMENT,60,HEADACHE,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",SPHENOPALATINE GANGLION BLOCK WITH LOCAL ANESTHETIC,"HYPERACTIVITY IN THE SPHENOPALATINE GANGLION ASSESSED BY PAIN INTENSITY (0-100MM ON A VISUAL ANALOGUE SCALE, VAS) OF THE POSTDURAL HEADACHE IN STANDING POSITION IN THE GROUP ROPIVACINE-LIDOCAINE AND ""SHAM"".","The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial"
NCT04636086,Recruiting,Interventional,Phase 4,University of Liege,Other,12-Nov-20,28-Feb-21,31-Jan-21,TREATMENT,100,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",CHOLECALCIFEROL,VITAMIN D SERUM CONCENTRATION,"Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study"
NCT04636203,Not yet recruiting,Observational,,Neuromed IRCCS,Other,15-Dec-20,15-Jun-22,15-Sep-21,COHORT,3500,SARS-COV2 INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",,SARS-COV-2 INFECTION,Burden of SARS-CoV-2 Infection in Populations With High or Low Risk of Infection
NCT04636294,Completed,Observational,,Jessa Hospital,Other,1-Aug-20,15-Feb-21,15-Feb-21,CASE-CONTROL,30000,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",SARS-COV-2 PCR,RATIO OF POSITIVITY CONVERSION AFTER RECEIVING A COVID-19 BORDERLINE PCR RESULT.,Follow-up of Patients With a Borderline COVID-19 PCR Test Result
NCT04636320,Recruiting,Interventional,Not Applicable,"University Hospital, Bordeaux",Other,13-Jun-20,13-Apr-21,13-Jan-21,DIAGNOSTIC,240,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CONTRAST-ENHANCED CMR,PREVALENCE OF MYOCARDIAL SCARS,Prevalence of Silent Myocardial Scars on Cardiac Magnetic Resonance Following COVID-19 Infection
NCT04636333,Recruiting,Interventional,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,Other,30-Oct-20,7-Jan-22,7-Apr-21,PREVENTION,216,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)","TWO DOSES OF MIDDLE-DOSE RECOMBINANT SARS-COV-2 VACCINE (CHO CELL) AT THE SCHEDULE OF DAY 0, 14",THE PROPORTION OF ADVERSE REACTIONS (AR) UP TO DAY 28 AFTER PRIME AND BOOST VACCINATION OF THE RECOMBINANT SARS-COV-2 VACCINE (CHO CELL) OR PLACEBO.,Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study
NCT04636554,Available,Expanded Access,,"Adaptive Phage Therapeutics, Inc.",Industry,,,,,,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PHAGE THERAPY,,"Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii, P. Aeruginosa or S. Aureus"
NCT04636671,Not yet recruiting,Interventional,Phase 3,University of Trieste,Other,25-Nov-20,30-Apr-21,31-Mar-21,TREATMENT,680,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",METHYLPREDNISOLONE,SURVIVAL,Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial)
NCT04636697,Recruiting,Interventional,Phase 2/Phase 3,Medicago,Industry,19-Nov-20,30-Apr-22,31-Dec-21,PREVENTION,30918,SARS-COV2 INFECTION,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",INTRAMUSCULAR INJECTION,PHASE 2 PORTION: IMMEDIATE ADVERSE EVENT (AES),"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older"
NCT04637295,Recruiting,Observational,,University of Nebraska,Other,27-Jan-21,30-Jun-21,30-Jun-21,COHORT,1000,NEOPLASMS MALIGNANT,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)",,PHYSICAL ACTIVITY,"Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19"
NCT04637828,Recruiting,Interventional,Phase 2,Genoscience Pharma,Industry,18-Nov-20,30-Oct-21,30-Jul-21,TREATMENT,178,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",GNS561,"NUMBER AND PROPORTION OF PARTICIPANTS, PER RANDOMIZED GROUP, WITH A LOSS OF ONE OR TWO GRADES OF NATIONAL EARLY WARNING SCORE (NEWS2) SCORE AT DAY-7 COMPARED TO BASELINE","Cure COVID: A Prospective, Controlled, Randomized Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection"
NCT04637867,Recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,23-Nov-20,1-Nov-21,1-Nov-21,OTHER,200,INFECTION VIRAL,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","COLLECTION OF BLOOD, SALIVARY AND NASOPHARYNGEAL SAMPLES.",SEROPREVALENCE OF SARS-COV-2 ANTIBODIES IN LABORATORY CONFIRMED SARS-COV-2 PATIENTS,Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study
NCT04637893,Not yet recruiting,Observational,,Istituto Clinico Humanitas,Other,16-Dec-20,31-Mar-21,31-Mar-21,COHORT,1000,COLORECTAL CANCER,,ALL,"Child, Adult, Older Adult",COLONOSCOPY,COLORECTAL CANCER PREVENTION,The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study
NCT04637906,Recruiting,Interventional,Not Applicable,"University of Campania ""Luigi Vanvitelli""",Other,18-Nov-20,18-Sep-21,18-Feb-21,PREVENTION,290,COVID,ITALY,ALL,"19 Years and older   (Adult, Older Adult)",BIOARGININA®,REDUCTION OF P / F NORMALIZATION TIMES,"Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Randomized, Parallel Group, Double-blind Placebo-controlled Clinical Trial"
NCT04638634,Recruiting,Interventional,Phase 1,CSL Behring,Industry,2-Feb-21,21-May-21,21-May-21,OTHER,24,CORONAVIRUS DISEASE 2019 (COVID),AUSTRALIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",CSL760,TOTAL IMMUNOGLOBULIN (IGG) CONCENTRATION OF CSL760,"A Single Center, Phase 1, Single-Ascending Dose, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects"
NCT04638673,Recruiting,Interventional,Phase 2,Medical University of South Carolina,Other,19-Nov-20,21-Jun-21,21-Jun-21,TREATMENT,30,CORONAVIRUS,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",SOTERIX TAVNS MODEL 0125-LTE STIMULATOR - ACTIVE-ACTIVE GROUP,CHANGE IN SCORE OF PATIENT HEALTH QUESTIONNAIRE-9,Testing a Wearable Telemedicine-controllable taVNS Device for NeuroCovid Recovery and Rehab
NCT04638842,Recruiting,Interventional,Not Applicable,Universidad Internacional de Valencia,Other,24-Dec-20,1-Jun-21,1-Jun-21,TREATMENT,42,GRIEF,MEXICO,ALL,18 Years to 60 Years   (Adult),ONLINE INTERVENTION GRIEF COVID-19,DECREASE IN THE SCORES OF THE CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION (CES-D) SCALE,"Effectiveness of a Self-applied Multi-component Psychological Online Intervention Based on UX, for the Prevention of Complicated Grief Disorder in the Mexican Population During the COVID-19 Outbreak: A Randomized Clinical Trial"
NCT04639349,Recruiting,Interventional,Not Applicable,Cairo University,Other,19-Nov-20,1-Mar-21,1-Mar-21,TREATMENT,40,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,EGYPT,MALE,"50 Years to 70 Years   (Adult, Older Adult)",EXERCISE GROUP,CORTISOL,Effect of Home Exercise Activity on Cortisol and Depression in COPD Patients During the Pandemic COVID-19
NCT04639375,Recruiting,Interventional,Phase 4,E-MO Biology Inc,Industry,15-Nov-20,18-Apr-21,18-Apr-21,PREVENTION,300,SARS-COV2,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VACCINATED WITH POLIO VACCINE (IPV),PERCENTAGE OF SUBJECTS WITH ANTIBODIES TO SARS-COV-2 RDRP FOLLOWING IPV VACCINATION,A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2)
NCT04639427,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Nov-21,21-Feb-21,21-Feb-21,CASE-ONLY,4,ORAL-LINGUO-FACIAL PRAXIES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,ORAL-LINGUO-FACIAL MOTRICITY TEST,Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases
NCT04639440,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,23-Nov-20,23-Nov-21,22-Nov-21,CASE-CONTROL,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ADIPOSE TISSUE,COMPARISON OF THE EXPRESSION OF ACE2 AND TMPRSS2 IN THE SUBCUTANEOUS AND VISCERAL ADIPOSE TISSUE OF OBESE PATIENTS. DETERMINATION OF CELLS EXPRESSING ACE2 AND TMPRSS2 IN WHOLE HUMAN ADIPOSE TISSUE.,Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives
NCT04639466,Recruiting,Interventional,Phase 1,City of Hope Medical Center,Other,11-Dec-20,10-Nov-22,10-Nov-22,TREATMENT,129,COVID,UNITED STATES,ALL,18 Years to 55 Years   (Adult),PLACEBO ADMINISTRATION,INCIDENCE OF ADVERSE EVENTS,"Phase 1 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections to Healthy Adult Volunteers"
NCT04640038,Recruiting,Interventional,Phase 3,Children's Hospital of Philadelphia,Other,18-Dec-20,22-Dec-21,22-Dec-21,DIAGNOSTIC,30,COVID,UNITED STATES,ALL,up to 17 Years   (Child),SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES,"ESTIMATE THE PROPORTION OF PATIENTS WITH NORMAL PERFUSION VERSUS AREA(S) OF HYPOPERFUSION IN HEART, KIDNEYS AND/OR BRAIN",Contrast Enhanced Ultrasound (CEUS) Detection of Microvascular Perfusion Impairment in COVID-19 Pediatric Patients
NCT04640168,Recruiting,Interventional,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NIH,24-Nov-20,30-Jun-21,30-Apr-21,TREATMENT,1500,COVID,JAPAN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",BARICITINIB,"THE PROPORTION OF SUBJECTS NOT MEETING CRITERIA FOR ONE OF THE FOLLOWING TWO ORDINAL SCALE CATEGORIES AT ANY TIME: 8) DEATH; 7) HOSPITALIZED, ON INVASIVE MECHANICAL VENTILATION OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)"
NCT04640181,Not yet recruiting,Interventional,Phase 2,St. David's HealthCare,Other,1-Dec-20,31-Jul-21,30-Jun-21,TREATMENT,150,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",ENOXAPARIN,DEATH OR 30-DAY ALL CAUSE MORTALITY,"A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)"
NCT04640194,Recruiting,Interventional,Phase 2/Phase 3,Boehringer Ingelheim,Industry,16-Dec-20,1-Sep-22,29-May-22,TREATMENT,270,ACUTE RESPIRATORY DISTRESS SYNDROME,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",ALTEPLASE,TIME TO CLINICAL IMPROVEMENT OR HOSPITAL DISCHARGE,"The TRISTARDS Trial - ThRombolysIS Therapy for ARDS A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care (SOC) Compared With SOC Alone, in Patients With Acute Respiratory Distress Syndrome (ARDS) Triggered by COVID-19"
NCT04640233,Recruiting,Interventional,Phase 2/Phase 3,Dr. Reddy's Laboratories Limited,Industry,30-Nov-20,21-Sep-21,21-Aug-21,PREVENTION,1600,COVID PREVENTION,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",GAM-COVID-VAC,ADVERSE EVENTS,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects"
NCT04640402,Recruiting,Interventional,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,Other,17-Nov-20,18-Nov-21,18-Feb-21,PREVENTION,960,COVID,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",LOW-DOSE RECOMBINANT COVID-19 VACCINE (SF9 CELLS) (18-59 YEARS) & TWO DOSE REGIMEN,GEOMETRIC MEAN (GMT) OF SPECIFIC ANTIBODY,"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above"
NCT04640428,Recruiting,Observational,,King's College Hospital NHS Trust,Other,10-Jul-20,31-Oct-21,31-Oct-21,COHORT,2000,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,ACCURACY OF THE COMPUTED TOMOGRAPHY ANGIOGRAPHY BIOMARKER RELATIVE TO THE COVID-19 RT-PCR TEST,COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study
NCT04640610,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Dec-21,21-Sep-21,21-Jun-21,COHORT,40,ADENOIDECTOMY,FRANCE,ALL,"Child, Adult, Older Adult",STORAGE OF OPERATING WASTE,EXPRESSION OF ACE 2 RECEPTOR AND TMPRSS2 SERINE PROTEASE,"Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults"
NCT04641182,Completed,Observational [Patient Registry],,Pontificia Universidad Catolica de Chile,Other,6-Jul-20,16-Sep-20,16-Aug-20,COHORT,66,COVID,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",PRONE POSITION,THERAPEUTIC FAILURE,Observational Study of Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure
NCT04641195,Not yet recruiting,Interventional,Phase 3,Harvard School of Public Health,Other,1-Mar-21,31-Mar-22,30-Nov-21,TREATMENT,700,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN D3 (CHOLECALCIFEROL),TIME TO RECOVERY,A Randomized Trial to Determine the Effect of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India
NCT04641481,"Active, not recruiting",Interventional,Phase 3,Bharat Biotech International Limited,Industry,25-Nov-20,1-Dec-22,30-Mar-21,PREVENTION,25800,COVID,INDIA,ALL,"18 Years to 99 Years   (Adult, Older Adult)",BBV152,FIRST OCCURRENCE OF VIROLOGICALLY CONFIRMED (RT-PCR POSITIVE) SYMPTOMATIC CASES OF COVID-19.,"An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adults≥18 Yrs of Age"
NCT04641806,Not yet recruiting,Observational,,Versailles Hospital,Other,15-Dec-20,16-Sep-21,16-Apr-21,CASE-CONTROL,120,B-CELL LYMPHOMA,,ALL,"18 Years and older   (Adult, Older Adult)",,IMMUNOLOGICAL RESPONSE TO SARS COV2,Clinical and Immunological Evolution of Covid-19 Occurring in a Context of Non-Hodgkin Lymphoma
NCT04641858,Recruiting,Interventional,Phase 4,University of Southern Denmark,Other,3-Dec-20,22-Mar-21,22-Feb-21,PREVENTION,1050,COVID,CAPE VERDE,ALL,"18 Years and older   (Adult, Older Adult)",BCG-DENMARK,DAYS OF UNPLANNED ABSENTEEISM DUE TO ILLNESS,BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT)
NCT04641988,Completed,Observational,,"University Hospital, Montpellier",Other,1-Feb-20,30-Jun-20,1-Mar-20,COHORT,111,COVID,FRANCE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,HS-CTNT,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19) : COROBIOCHIC
NCT04642014,Not yet recruiting,Interventional,Not Applicable,Wroclaw Medical University,Other,1-Dec-20,1-May-22,21-Feb-22,TREATMENT,500,COVID CONVALESCENT PLASMA TREATMENT,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA TREATMENT,"DEATH, FOR ANY REASON","A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness"
NCT04642040,Recruiting,Interventional,Not Applicable,Sisli Hamidiye Etfal Training and Research Hospital,Other,30-Jun-20,21-Jan-21,21-Jan-21,TREATMENT,100,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY REHABILITATION,CHANGE IN DYSPNEA LEVEL AS MEASURED BY MODIFIED MEDICAL RESEARCH COUNCIL (MMRC) DYSPNEA SCALE,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia
NCT04642196,Completed,Observational,,"University Hospital, Linkoeping",Other,2-May-20,10-Oct-20,10-Oct-20,COHORT,155,COVID,SWEDEN,ALL,"Child, Adult, Older Adult",,FRAILTY,COVID-19 in Home Healthcare and Mortality
NCT04642326,"Active, not recruiting",Interventional,Not Applicable,RD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.,Industry,26-Jun-20,4-May-21,1-Jul-20,TREATMENT,50,COVID,TURKEY,ALL,"40 Years to 75 Years   (Adult, Older Adult)",TEST GROUP: EXPERIMENTAL - UVC THERAPY APPLIED,PCR SAMPLING,"Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis"
NCT04642339,Not yet recruiting,Interventional,Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,20-Nov-21,21-Dec-21,21-Oct-21,PREVENTION,2000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",GAM-COVID-VAC,SEROCONVERSION RATE,"Randomized, Double-blind, Placebo Controlled, Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection"
NCT04642638,"Active, not recruiting",Interventional,Phase 2/Phase 3,Inovio Pharmaceuticals,Industry,30-Nov-20,22-Sep-21,22-Sep-21,PREVENTION,401,CORONAVIRUS INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",INO-4800,PHASE 2: CHANGE FROM BASELINE IN ANTIGEN-SPECIFIC CELLULAR IMMUNE RESPONSE MEASURED BY INTERFERON-GAMMA (IFN-Γ) ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY,"Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure"
NCT04642703,Recruiting,Observational,,University of Chile,Other,3-Mar-20,30-Nov-21,30-Nov-20,COHORT,100,MECHANICAL VENTILATION,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",,90-DAYS MORTALITY RATE,Mortality in Patients With Severe SARS-CoV-2 Pneumonia Who Underwent Tracheostomy Due to Prolonged Mechanical Ventilation
NCT04642950,Recruiting,Interventional,Phase 2/Phase 3,Nobelpharma,Industry,17-Dec-20,31-Oct-21,31-Oct-21,TREATMENT,60,COVID,JAPAN,ALL,"20 Years to 80 Years   (Adult, Older Adult)",SARGRAMOSTIM,2-RANK IMPROVEMENT ON A 7-POINT ORDINAL SCALE,A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)
NCT04643054,Not yet recruiting,Interventional,Not Applicable,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Other,1-Dec-20,30-Mar-21,28-Feb-21,TREATMENT,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",OVOTRANSFERRIN,IN-HOSPITAL MORTALITY,Efficacy and Safety of Ovotransferrin in COVID-19 Patients With Mild-to-Moderate Disease
NCT04643444,Enrolling by invitation,Observational,,University of Bern,Other,9-Feb-21,22-Jun-21,22-Jan-21,COHORT,1000,SARS-COV2 INFECTION,SWITZERLAND,ALL,"18 Years to 65 Years   (Adult, Older Adult)",BLOOD SAMPLING,SEROPREVALENCE,"Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland"
NCT04643522,Completed,Observational,,Ankara City Hospital Bilkent,Other,7-Jan-20,10-Oct-20,5-Oct-20,COHORT,21,"SPERM COUNT, LOW",TURKEY,MALE,18 Years to 40 Years   (Adult),CLINICAL ASSESSMENT,"SEMEN ANALYSES PARAMETERS INCLUDING SPERM MOTILITY (TOTAL, PROGRESSIVE, NON-PROGRESSIVE AND IMMOTILE",Does COVID-19 Worsen the Semen Parameters? Early Results of a Tertiary Health Center
NCT04643548,Recruiting,Observational,,"University Hospital, Clermont-Ferrand",Other,13-Oct-20,13-Aug-21,13-Jun-21,COHORT,20,SARS-COV2 INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DOSAGE OF BIOMARKERS TYPICALLY EXPLORED IN INTENSIVE CARE UNIT DELIRIUM,Neurological Abnormalities in SARS-CoV-2 ICU Patients. A Prospective Study. NeuroCOVID Study
NCT04643561,"Active, not recruiting",Interventional,Phase 1/Phase 2,Hadassah Medical Organization,Other,1-Nov-20,31-Dec-20,31-Dec-20,OTHER,5,COVID,ISRAEL,MALE,"18 Years and older   (Adult, Older Adult)",TRAVELAN OTC,INCREASE LEVELS OF IFNΓ,A Feasibility Trial Using Trevalan in Healthy Volunteers for Increasing an in Vitro Immune Response to COVID-19 Proteins
NCT04643678,Recruiting,Interventional,Phase 2/Phase 3,Hamad Medical Corporation,Industry,30-Oct-20,30-Oct-21,30-Apr-21,TREATMENT,80,COVID,QATAR,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,TREATMENT SUCCESS AT DAY 14,Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial
NCT04643691,Recruiting,Interventional,Phase 2,Assistance Publique Hopitaux De Marseille,Other,11-Sep-20,30-Oct-22,30-Sep-22,TREATMENT,90,COVID,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LOSARTAN 50 MG AND SPIRONOLACTONE 25 MG PILLULES ORAL USE,SOFA SCORE,Benefit of Treatment With Losartan and Spironolactone on the Regulation of the Renin-angiotensin System in the Prognosis of Patients Infected With COVID-19 and Suffering From Acute Respiratory Distress Syndrome
NCT04643860,Not yet recruiting,Observational,,Neuromed IRCCS,Other,20-Dec-21,21-May-21,21-Feb-21,COHORT,1000,SARS-COV2 INFECTION COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",DIFFERENTIAL LEUCOCYTE COUNT (CLDC) DEVICE AND ALGORITHM,VALIDATION,"A New Point-of-care Test Based on Differential Leucocyte Count, Suitable for a Mass Screening Program to Detect SARS-CoV-2: A Diagnostic Accuracy Study"
NCT04643964,Recruiting,Interventional,Not Applicable,Ohio State University,Other,20-Nov-21,20-Nov-21,20-Nov-21,TREATMENT,501,DEPRESSIVE SYMPTOMS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ENTRÉE: COGNITIVE SKILLS,CHANGE IN THE QUICK INVENTORY OF DEPRESSIVE SYMPTOMS-SELF REPORT (QIDS-SR),Building Mental Health Resilience in the COVID-19 Pandemic.
NCT04644120,Recruiting,Interventional,Phase 1,AbbVie,Industry,10-Dec-20,3-Aug-21,2-Aug-21,TREATMENT,24,CORONAVIRUS DISEASE-2019 (COVID),ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",ABBV-47D11,NUMBER OF PARTICIPANTS WITH STUDY-DRUG RELATED GRADE 3 OR HIGHER ADVERSE EVENTS (AES),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 in Adults Hospitalized With COVID-19"
NCT04644146,Recruiting,Observational,,Hospices Civils de Lyon,Other,1-Dec-20,1-Dec-21,1-Jun-21,CASE-CONTROL,40,COVID,FRANCE,ALL,"18 Years to 70 Years   (Adult, Older Adult)",GENETIC,PRIMARY CRITERIA OF DATA EVALUATION,Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection) in Patients Without Comorbidities
NCT04644159,Recruiting,Observational,,Institut Pasteur,Industry,13-Nov-20,1-Nov-23,30-Jun-22,COHORT,2000,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),FRANCE,ALL,"5 Years and older   (Child, Adult, Older Adult)",HUMAN BIOLOGICAL SAMPLES,PRESENCE OF SPECIFIC ANTI-SARS-COV-2 ANTIBODIES IN THE DIFFERENT STUDY GROUPS.,Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation in Early 2020
NCT04644172,Recruiting,Interventional,Phase 1/Phase 2,University of Alabama at Birmingham,Other,1-Nov-20,24-Nov-21,23-Nov-21,TREATMENT,40,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SPEED OF PROCESSING TRAINING,CANADIAN OCCUPATION PERFORMANCE MEASURE (COPM),Improving Thinking in Everyday Life: Pilot Study C
NCT04644185,Not yet recruiting,Interventional,Phase 2/Phase 3,Sinocelltech Ltd.,Industry,10-Feb-21,10-Oct-21,10-May-21,TREATMENT,795,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",SCTA01,THE CLINICAL EFFICACY OF SCTA01 (PHASE II AND III),"A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19"
NCT04644198,Recruiting,Interventional,Phase 2,The University of The West Indies,Other,1-Apr-21,1-Dec-21,1-Dec-21,TREATMENT,30,"COVID, CONVALESCENT PLASMA TREATMENT",JAMAICA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",CONVALESCENT PLASMA INFUSION,MORTALITY,Pilot Study of Convalescent COVID-19 Plasma Transfusion in Severe COVID-19 Patients at a Type A Teaching Hospital in Jamaica
NCT04644276,Not yet recruiting,Interventional,Not Applicable,Philips Clinical & Medical Affairs Global,Industry,18-Jan-21,15-Feb-21,15-Feb-21,OTHER,30,RESPIRATORY FAILURE,UNITED STATES,ALL,"18 Years to 85 Years   (Adult, Older Adult)",MASK WITH MASK ADHESIVE/ARM 1,MEDICAL ADHESIVE-RELATED SKIN INJURY (MARSI) AND EASE OF USE,Feasibility Study of a Mask Adhesive in Patients Treated With NIV in an Institutional Setting
NCT04644302,Recruiting,Observational,,University Hospital Hradec Kralove,Other,1-Feb-20,21-Dec-21,21-Jul-21,COHORT,25,VIRAL PNEUMONIA,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",MICROCIRCULATION RECORDING,CHANGE IN PROPORTION OF PERFUSED VESSELS (PPV) PARAMETER,"Circulatory and Endothelial Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis - Prospective, Observational Pilot Study"
NCT04644328,Not yet recruiting,Interventional,Not Applicable,"National Bureau of Economic Research, Inc.",Other,14-Nov-20,26-Nov-21,26-Nov-20,PREVENTION,20000000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FACEBOOK ADS ON THE IMPORTANCE OF STAYING SAFE DURING THE THANKSGIVING HOLIDAY,COVID CASE RATE,The Doctors for Coronavirus Prevention Project Thanksgiving Messaging Campaign
NCT04644341,Recruiting,Observational,,University of Manitoba,Other,15-Jan-21,1-Nov-21,31-Aug-21,CASE-ONLY,20,COVID,CANADA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CARDIOVASCULAR AND RESPIRATORY SYSTEMS MONITORING,BLOOD PRESSURE,Post Discharge Tele-monitoring of COVID-19 Survivors for Long-Term Impacts and Point-of-Care
NCT04644705,Recruiting,Interventional,Phase 1,Charité Research Organisation GmbH,Other,2-Nov-20,31-May-21,31-May-21,TREATMENT,28,HEALTHY VOLUNTEERS,GERMANY,ALL,18 Years to 45 Years   (Adult),NICLOSAMIDE,TREATMENT EMERGENT NUMBER OF ADVERSE EVENTS,A 3-part Study to Investigate the Safety and Pharmacokinetics of a Novel Niclosamide Solution as a Treatment Option for COVID-19 in Combination With Camostat
NCT04645368,Recruiting,Observational,,NPO Petrovax,Industry,1-Jul-20,21-Jul-21,21-Apr-21,COHORT,160,"FIBROSES, PULMONARY",RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",BOVHYALURONIDASE AZOXYMER,THE SEVERITY OF LUNG TISSUE LESIONS WITH FIBROSIS AND INTERSTITIAL CHANGES ON DAY 75,"Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19."
NCT04645407,Completed,Interventional,Phase 4,ShuGuang Hospital,Other,1-Feb-20,15-Apr-20,15-Apr-20,TREATMENT,66,NOVEL CORONAVIRUS PNEUMONIA,CHINA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",FUZHENG HUAYU TABLET,THE PERCENTAGE OF PATIENTS SHOWING IMPROVEMENT IN CHEST CT,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study
NCT04645433,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,15-Mar-20,15-May-20,15-May-20,COHORT,100,MORTALITY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY FOR ICU,Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit: Single Center Experience
NCT04645498,Not yet recruiting,Observational,,"University Hospital, Lille",Other,21-Jan-21,23-Jan-21,23-Jan-21,COHORT,77,COVID,,ALL,"Child, Adult, Older Adult",,FREQUENCY OF MHM IMBALANCE TRIGGERED BY COVID-19,Prospective Study on the Impact of COVID-19 on the Equilibrium of Hereditary Metabolic Disease (MHM) in Patients With or Who Have Contracted COVID-19
NCT04645563,Completed,Observational,,Kafkas University,Other,11-Mar-20,31-May-20,30-May-20,CASE-CONTROL,144,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",SENDING THORAX CT VIDEO IMAGES VIA SMARTPHONE APPLICATIONS,ANALYZING THE EFFECT OF CONSULTATION VIA WHATSAPP TO LENGHT OF STAY THE PATIENTS IN EMERGENCY MEDICINE DEPARTMENT.,Using Whatsapp for the Consultation of Covid-19 Suspected Patients in Pandemic Polyclinics; A Retrospective Case Control Study
NCT04646031,Available,Expanded Access,,"Tasly Pharmaceuticals, Inc.",Industry,,,,,,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",T89 CAPSULE,,"Expanded Access Use of T89 in An Intermediate-size Patients Population for the Treatment of Severe ""Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)"" Infection Disease Patients (COVID-19)"
NCT04646044,Recruiting,Interventional,Phase 1,Nektar Therapeutics,Industry,13-Nov-20,27-Mar-21,28-Jan-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BEMPEGALDESLEUKIN,AUC OF BEMPEG/STANDARD OF CARE (SOC) (PK).,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19"
NCT04646109,Completed,Interventional,Phase 3,Afyonkarahisar Health Sciences University,Other,11-May-20,2-Sep-20,2-Sep-20,TREATMENT,66,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,GENDER DISTRIBUTION OF THE PATIENTS,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management
NCT04646239,Recruiting,Observational,,Washington University School of Medicine,Other,17-Dec-20,21-Apr-21,21-Feb-21,COHORT,80,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HETEROLOGOUS STIMULI,CYTOKINE (OR CHEMOKINE) PRODUCTION IN RESPONSE TO HETEROLOGOUS STIMULI,"Determining Biomarkers of Trained Immunity in a Randomized Controlled Trial of the Measles, Mumps, and Rubella Vaccine - a Sub-study of the CROWN CORONATION Trial"
NCT04646421,Recruiting,Observational,,Lund University,Other,30-Nov-20,30-Nov-21,31-Oct-21,CASE-CONTROL,3626,PROBLEM GAMBLING,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",MOTIVATIONAL TELEPHONE INTERVENTION,CHANGE IN GAMBLING FREQUENCY.,"Responsible Gambling Telephone Intervention to High-risk Gamblers by a State-owned Gambling Operator in Sweden. Effectiveness, User Satisfaction and Acceptability of the Motivational Telephone Intervention of AB Svenska Spel."
NCT04646525,Recruiting,Observational,,Selcuk University,Other,1-Oct-20,1-Feb-21,1-Feb-21,CASE-ONLY,300,COVID,TURKEY,ALL,1 Year to 16 Years   (Child),PHYSICAL EXAMINATION,THE PRIMARY OUTCOME OF OUR STUDY WAS THE EVALUATION OF PEDIATRIC PATIENTS DIAGNOSED WITH COVID-19 AND WHO HAD COVID-19 INFECTION IN TERMS OF ADENOID AND TONSILLAR TISSUE HYPERTROPHY AND THE PRESENCE OF CHRONIC OR RECURRENT INFECTION.,The Relationship Between Mild Covid-19 Infection in Pediatric Patients and Protection of Secondary Lymphoid Organs
NCT04646551,Not yet recruiting,Observational,,Assiut University,Other,20-Dec-21,22-Jan-21,21-Dec-21,OTHER,165,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,ASSESSMENT OF THE PATTERN AND RISK FACTORS OF COVID-19 BETWEEN INFECTED HEALTHCARE WORKERS,Assessment of the Pattern and Risk Factors of Covid-19 Between Infected Healthcare Workers at Assiut University Hospitals
NCT04646590,Recruiting,Interventional,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",Industry,16-Dec-20,22-Apr-21,22-Apr-21,PREVENTION,29000,PREVENTION OF COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",RECOMBINANT NEW CORONAVIRUS VACCINE (CHO CELL) GROUP,THE ENDPOINT OF EFFICACY STUDY,"A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19"
NCT04646603,Recruiting,Interventional,Phase 1/Phase 2,MedRegen LLC,Industry,28-Jan-21,5-Jun-21,1-Apr-21,TREATMENT,18,COVID,UNITED STATES,ALL,18 Years to 45 Years   (Adult),MRG-001,PHASE I,"A Combined Phase I Double-Blind Randomized Placebo Controlled Study in Healthy Subjects /Phase IIa, Randomized, Double-blind, Placebo Controlled, Multi-center Study in Subjects Infected With SARS CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001"
NCT04646616,Not yet recruiting,Interventional,Not Applicable,Drexel University,Other,6-Jan-21,31-Oct-21,31-Oct-21,PREVENTION,800,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COMMUNITY POPULAR OPINION LEADER (POL) BASED INTERVENTION,RISK OF EXPOSURE TO COVID-19,CRISOL: Building Community Resilience and Integrating Efforts to Understand and Address Syndemic Health Conditions Afflicting Young LatinoImmigrants
NCT04646642,Not yet recruiting,Observational,,David Grant U.S. Air Force Medical Center,U.S. Fed,20-Dec-21,21-May-21,21-Feb-21,COHORT,160,COPING SKILLS,,ALL,"Child, Adult, Older Adult",,PATIENT HEALTH QUESTIONNAIRE-2 (PHQ-2),"Psychological Health, Coping Strategies and Preferences of David Grant USAF Medical Center COVID-19 Deployers: A Critical Needs Assessment"
NCT04646655,Recruiting,Interventional,Phase 3,ASST Fatebenefratelli Sacco,Other,27-Jul-20,31-Jul-21,31-May-21,TREATMENT,300,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ENOXAPARIN,MORTALITY RATE,Enoxaparin at Prophylactic or Therapeutic Doses With Monitoring of Outcomes in Subjects Infected With COVID-19: a Pilot Study on 300 Cases Enrolled at ASST-FBF-Sacco
NCT04647305,Not yet recruiting,Interventional,Not Applicable,"University of Los Andes, Columbia",Other,20-Dec-21,21-Mar-21,21-Mar-21,PREVENTION,233,SARS-COV2 INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",CLOSED FACE SHIELD WITH SURGICAL FACE MASK USE,COVID-19 INCIDENCE,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission: A Randomized Controlled Trial
NCT04647604,Recruiting,Interventional,Phase 2,Karolinska University Hospital,Other,23-Jun-20,30-Apr-21,30-Apr-21,TREATMENT,40,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",OMEGAVEN®,CHANGES IN INFLAMMATORY BIOMARKERS,"Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A Single-blind, Randomized, Placebo-controlled Feasibility Study"
NCT04647656,Not yet recruiting,Interventional,Not Applicable,Assaf-Harofeh Medical Center,Other,1-Jan-21,1-Jan-23,1-Jan-22,TREATMENT,70,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",HYPERBARIC OXYGEN,COGNITIVE HEALTH ASSESSMENT (NEUROTRAX),"Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome: a Prospective, Randomized, Double Blind Study."
NCT04647669,Not yet recruiting,Interventional,Phase 3,The University of The West Indies,Other,1-Feb-21,31-Dec-21,30-Nov-21,TREATMENT,100,COVID,JAMAICA,ALL,"18 Years to 100 Years   (Adult, Older Adult)",REMDESIVIR,ALL CAUSE MORTALITY,"WHO Public Health Emergency ""Solidarity"" Clinical Trial for COVID-19 Treatments"
NCT04647682,Recruiting,Observational,,"University Hospital, Toulouse",Other,1-Nov-20,31-Dec-21,30-Jun-21,CASE-ONLY,30,COVID INFECTION,FRANCE,ALL,75 Years and older   (Older Adult),PHYSICAL ACTIVITY PROGRAM,CHANGE OF ADHERENCE OF THE INTERVENTION,Feasibility and Effect of Implementing Physical Activity Program Implementation During Covid-19 in Hospitalized Positive Covid-19 Older Adults
NCT04647695,Recruiting,Interventional,Phase 2,The University of Hong Kong,Other,20-Nov-20,30-Sep-21,31-Jul-21,TREATMENT,100,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",INTERFERON BETA-1B,CLINICAL IMPROVEMENT,An Open-label Randomized Controlled Trial on Interferon β-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection
NCT04647734,Not yet recruiting,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,1-Jan-21,31-Dec-21,31-Dec-21,HEALTH SERVICES RESEARCH,40,"COVID, SARS-COV2",DENMARK,ALL,"40 Years and older   (Adult, Older Adult)",HIGH INTENSITY INTERVAL TRAINING,CHANGE IN LEFT VENTRICULAR MASS,The Protective Potential of Exercise Training on the Cardiopulmonary Morbidity After COVID-19
NCT04647747,Recruiting,Interventional,Not Applicable,Ostfold Hospital Trust,Other,30-Nov-20,31-Dec-21,30-Mar-21,PREVENTION,40,COVID,NORWAY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SELF MEASUREMENT WITH PULSE OXIMETER,NUMBER OF PATIENTS WHO MANAGE TO PERFORM DAILY MEASUREMENTS OF SPO2,Silent Hypoxia and Awake Proning in COVID-19 Patients: Home Monitoring and Self-Reporting
NCT04647994,Recruiting,Observational,,University of Sao Paulo General Hospital,Other,21-Sep-20,13-Jun-22,1-Jul-21,COHORT,500,PREGNANT WOMEN,BRAZIL,FEMALE,"17 Years to 50 Years   (Child, Adult)",SARS-COV-2 SEROLOGY,DIAGNOSTIC TEST: SARS-COV-2 SEROLOGY,Exploratory Study in COVID-19 During Pregnancy
NCT04648410,Recruiting,Observational,,Brno University Hospital,Other,16-Feb-21,1-Dec-21,30-Mar-21,OTHER,2000,SEVERE COVID,CZECHIA,ALL,"up to 100 Years   (Child, Adult, Older Adult)",QUESTIONNAIRE,SYSTEMIC CORTICOSTEROIDS AMONG PATIENTS WITH COVID-19 ARDS PRACTICE - QUESTIONNAIRE (ELECTRONIC SURVEY),Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study)
NCT04648709,Not yet recruiting,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,1-Feb-21,1-Dec-22,1-Jun-21,COHORT,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ELISPOT,T CELL IMMUNE RESPONSE,Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19
NCT04648800,Recruiting,Interventional,Phase 3,Hanna Czajka,Other,7-Jul-20,21-Apr-21,20-Dec-21,PREVENTION,1000,COVID,POLAND,ALL,"25 Years and older   (Adult, Older Adult)",BCG-10 VACCINE,"DEATH AND LIFE- OR HEALTH-THREATENING CONDITION (CARDIAC ARREST WITH EFFECTIVE RESUSCITATION, SHOCK, SEVERE RESPIRATORY FAILURE, SEVERE RENAL FAILURE, STROKE/TRANSIENT CEREBRAL ISCHAEMIA)","A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland"
NCT04649021,"Active, not recruiting",Interventional,Phase 2,BioNTech SE,Industry,4-Dec-20,21-Dec-21,21-Dec-21,PREVENTION,950,SARS-COV2,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",BNT162B2,SARS-COV-2 SERUM NEUTRALIZING TITERS - SEROCONVERSION RATES (SCR),"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study"
NCT04649086,Recruiting,Interventional,Not Applicable,"University Hospital, Clermont-Ferrand",Other,5-Jun-20,5-Dec-21,5-Oct-21,TREATMENT,120,COVID,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",REHABILITATION BY ECCENTRIC EXERCISES,FUNCTIONAL WALKING CAPACITY,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection: Research Protocol for Randomized Controlled Trial (CovExc)
NCT04649151,Recruiting,Interventional,Phase 2/Phase 3,"ModernaTX, Inc.",Industry,9-Dec-20,30-Jun-22,30-Jun-22,PREVENTION,3000,SARS-COV2,UNITED STATES,ALL,12 Years to 17 Years   (Child),MRNA-1273,NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL AND SYSTEMIC ADVERSE REACTIONS (ARS),"A Phase 2/3, Randomized, Observer-Blind, Placebo Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS CoV 2 Vaccine in Healthy Adolescents 12 to <18 Years of Age"
NCT04649320,Recruiting,Observational,,Medical University Innsbruck,Other,23-Nov-20,31-Dec-20,31-Dec-20,COHORT,300,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,INFLUENCE OF THE COVID-19 PANDEMIC ON CANCER PATIENT'S DAILY LIFE,Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)
NCT04649333,Completed,Observational,,Medical University Innsbruck,Other,15-Jun-20,31-Aug-20,31-Aug-20,COHORT,1336,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",,"THE TYPE, EXTENT AND INTENSITY OF PHYSICAL ACTIVITY",COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures
NCT04649424,Not yet recruiting,Interventional,Not Applicable,Orthopaedic Innovation Centre,Other,20-Dec-21,28-Feb-21,31-Dec-20,OTHER,72,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",CANSWAB,AMOUNT OF SARS-COV2 VIRUS (COVID-19) COLLECTED,Comparative Evaluation of Nasopharyngeal Swabs for Sampling and Detection of SARS-CoV2
NCT04649515,Recruiting,Interventional,Phase 3,Tychan Pte Ltd.,Industry,4-Dec-20,30-Dec-21,31-Aug-21,TREATMENT,1305,CORONAVIRUS DISEASE-2019 (COVID),SINGAPORE,ALL,"21 Years to 100 Years   (Adult, Older Adult)",TY027,"TO EVALUATE THE EFFICACY OF A SINGLE DOSE INTRAVENOUS (IV) INFUSION OF TY027 IN REDUCING DISEASE PROGRESSION, DEFINED AS PROGRESSION TO SCORE 4 AND BELOW ON COVID SCALE","Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19"
NCT04649658,Completed,Observational,,University of Modena and Reggio Emilia,Other,1-Mar-20,30-Nov-20,1-Jun-20,COHORT,93,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PRONE POSITION,ENDOTRACHEAL INTUBATION,Awake Prone Position in Critical and Severe COVID-19 Patients Undergoing Noninvasive Respiratory Support: a Retrospective Multicenter Cohort Study
NCT04649736,Recruiting,Interventional,Not Applicable,Universidad Peruana Cayetano Heredia,Other,26-Oct-20,30-Mar-21,30-Mar-21,TREATMENT,108,COVID,PERU,ALL,"50 Years and older   (Adult, Older Adult)",RESPIRATORY AND PSYCHOLOGICAL REHABILITATION,SIX MINUTE WALK DISTANCE,Prevalence of Altered Pulmonary Function Post-infection by COVID-19 and Impact of Participation in a Pilot Program of Comprehensive Rehabilitation in the Short and Medium-term
NCT04649775,Not yet recruiting,Interventional,Not Applicable,Duke University,Other,30-Jan-21,21-Jun-21,21-May-21,TREATMENT,50,CORONAVIRUS INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",AIRFLO2,IMPROVE HYPOXIA AS MEASURED BY CHANGE BETWEEN BASELINE P:F RATIO AND REPEAT P:F RATIO,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19
NCT04649827,Recruiting,Observational,,Escola de Saúde Pública do Ceará,Other,2-Apr-20,30-Dec-21,30-Jun-20,CASE-ONLY,3000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CLINICAL OBSERVATION,ICU OUTCOME,"SARS-CoV-2 Epidemiology Study at e Referenced Hospital in Fortaleza, Brazil: ResCOVID Study"
NCT04649840,Enrolling by invitation,Observational,,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,Other,1-Oct-20,31-Dec-21,31-Dec-21,OTHER,60,COVID,BELARUS,ALL,"18 Years and older   (Adult, Older Adult)",HUMORAL AND CELLULAR IMMUNITY,THE DYNAMICS OF HUMORAL AND CELLULAR IMMUNITY,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients
NCT04649879,Not yet recruiting,Interventional,Phase 2/Phase 3,Joakim Dillner,Other,3-Dec-20,1-Feb-22,1-Feb-22,TREATMENT,920,COVID,SWEDEN,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 CONVALESCENT PLASMA,COVID-19 RELATED MORTALITY WITHIN 28 DAYS,Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial
NCT04649918,"Active, not recruiting",Observational,,Schön Klinik Berchtesgadener Land,Other,25-Nov-20,30-Apr-21,16-Jan-21,COHORT,50,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY REHABILITATION,CHANGE IN 6-MINUTE WALK DISTANCE,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19 - an Observational Trial
NCT04649931,Recruiting,Observational,,B. Braun Melsungen AG,Industry,14-Dec-20,21-May-21,21-May-21,COHORT,400,SARS (SEVERE ACUTE RESPIRATORY SYNDROME),GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ION MOBILITY SPECTROMETRY (IMS),SARS-COV-2 RELATED VOLATILE ORGANIC COMPOUNDS (VOC),Study to Evaluate Whether Differences in Exhaled Breath Can be Identified Using Ion Mobility Spectrometry (IMS) in Subjects Tested Positive for SARS-CoV-2 Infection and Subjects Tested Negative
NCT04649944,Not yet recruiting,Observational,,University of Milan,Other,5-Feb-21,31-Dec-21,1-Nov-21,OTHER,40,COVID,ITALY,ALL,"4 Years to 99 Years   (Child, Adult, Older Adult)",SEROLOGICAL TEST AND PHONE INTERVIEW,DETECTION OF IGG AND IGM ANTIBODIES FOR SARS-COV-2 IN CHILDREN AGED BETWEEN 4 AND 16 Y.O. COHABITING WITH AT LEAST A SUBJECT WITH A PREVIOUS DIAGNOSIS OF COVID-19.,Assessment of the Serological Profile of Children and Adolescents Between 4 and 16 Years of Age Cohabiting With at Least One Family Member Who Tested Positive to COVID-19: an Observational Study
NCT04649957,Not yet recruiting,Observational,,University of Derby,Other,4-Jan-21,17-Dec-21,17-Dec-21,COHORT,100,"INFECTIONS, RESPIRATORY",UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,POST-COVID-19 FUNCTIONAL STATUS (PCFS) SCALE,Profiling the Determinants of Recovery to Establish Novel Rehabilitation Guidelines to Improve Clinically Relevant and Patient-reported Outcomes in the Post-COVID-19 Period
NCT04649996,Completed,Observational,,University of Milano Bicocca,Other,1-Sep-20,30-Nov-20,31-Oct-20,COHORT,532,ACUTE APPENDICITIS,ITALY,ALL,"Child, Adult, Older Adult",APPENDECTOMY,COMPLICATED APPENDICITIS,Variation of Incidence and Clinical Presentation of Acute Appendicitis During a Pandemic.
NCT04650035,Completed,Observational,,Yarmouk University,Other,1-Nov-20,10-Nov-20,4-Nov-20,OTHER,60,COVID,JORDAN,ALL,"Child, Adult, Older Adult",,NUMBER OF SURGICAL OPERATIONS PERFORMED WHETHER ELECTIVE OR EMERGENCY,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak : A Survey
NCT04650087,Recruiting,Interventional,Phase 3,"Thomas Ortel, M.D., Ph.D.",Other,21-Apr-21,21-Sep-21,21-Aug-21,PREVENTION,5320,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",APIXABAN 2.5 MG,"COMPOSITE OUTCOME OF SYMPTOMATIC DEEP VEIN THROMBOSIS, PULMONARY EMBOLISM, OTHER VENOUS THROMBOEMBOLISM, ISCHEMIC STROKE, MYOCARDIAL INFARCTION, OTHER ARTERIAL THROMBOEMBOLISM, AND ALL-CAUSE MORTALITY AS MEASURED BY HOSPITAL RECORDS.","COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge"
NCT04650178,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,26-May-20,1-Jul-21,1-Jul-21,COHORT,274,COVID INFECTION,UNITED STATES,ALL,"Child, Adult, Older Adult",QUALITY-OF-LIFE ASSESSMENT,HEALTH-RELATED QUALITY OF LIFE AND CORONAVIRUS DISEASE 2019 (COVID-19)-SPECIFIC DOMAINS OF INTEREST,COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials
NCT04650191,Recruiting,Observational [Patient Registry],,Milton S. Hershey Medical Center,Other,1-Mar-20,21-Dec-21,21-Jun-21,CASE-CONTROL,300,CORONAVIRUS INFECTION,UNITED STATES,ALL,"up to 90 Years   (Child, Adult, Older Adult)",IDENTIFICATION OF GENETIC VARIANTS,CORRELATION OF SURFACTANT PROTEIN GENETIC VARIANTS WITH SEVERITY OF COVID-19 INFECTION,Surfactant Protein Genetic Variants in COVID-19 Infection
NCT04651374,Not yet recruiting,Interventional,Not Applicable,Lawson Health Research Institute,Other,20-Dec-21,21-Apr-21,21-Mar-21,TREATMENT,40,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",GEKO T3,FEASIBILITY OF RECRUITMENT,COVID-19 And Geko Evaluation: The CAGE Study
NCT04651387,Not yet recruiting,Interventional,Not Applicable,Neuromed IRCCS,Other,21-Jan-21,21-Aug-21,21-Jun-21,SUPPORTIVE CARE,74,SARS-COV INFECTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",OZONIZED OIL (HOO,VIRAL LOAD OF SARS-COV-2,Efficacy and Safety of Ozonised Oil (HOO) as Adjuvant Nutrition Supplement in COVID-19 Patients With Mild-to-Moderate Disease - HOO-COVID Project
NCT04651400,Recruiting,Observational,,Octapharma,Industry,19-Oct-20,21-Jun-21,21-Jun-21,COHORT,300,COVID,AUSTRIA,ALL,"Child, Adult, Older Adult",ANTITHROMBIN III,ANTITHROMBIN LEVELS,"Multinational, Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection"
NCT04651413,Recruiting,Observational,,University Hospitals of North Midlands NHS Trust,Other,24-Nov-20,31-Mar-21,31-Mar-21,OTHER,800,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",PCR VALUE,DETERMINE IF THERE IS AN INVERSE CORRELATION WITH RISK OF POOR OUTCOME INCLUDING ADMISSION TO INTENSIVE CARE; MECHANICAL VENTILATION AND 28-DAY MORTALITY.,Can Quantitative (Real-time) Polymerase Chain Reaction (PCR) Cycle Threshold (Ct) Values be Used to Predict Poor Outcomes for Patients Infected With SARS-CoV-2? A Local Exploratory Sub-study at The University Hospitals of North Midlands NHS Trust in Collaboration With the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 Trial
NCT04651790,Recruiting,Interventional,Phase 3,Pontificia Universidad Catolica de Chile,Other,27-Nov-20,22-Mar-21,22-Jan-21,PREVENTION,2300,COVID,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 INACTIVATED VACCINE,"FREQUENCY OF SOLICITED AND UNSOLICITED ADVERSE EVENTS THAT OCCUR DURING THE PERIOD OF ONE WEEK AFTER EACH DOSE OF THE VACCINE IN TWO VACCINATION SCHEDULES: 0,14 AND 0,28 DAYS STRATIFIED BY AGE GROUP (18-59 YEARS, AND 60 OR MORE YEARS).","Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults."
NCT04651959,"Active, not recruiting",Interventional,Phase 1,Pharma Plant,Industry,13-Nov-20,20-Dec-20,18-Nov-20,OTHER,30,BIOEQUIVALENCE,TURKEY,MALE,18 Years to 55 Years   (Adult),AVICOD 200 MG FILM TABLET,FAVIPIRAVIR AUC0-TLAST,"Open-label, Randomised, Single Oral Dose, Two-period, Cross-over Trial to Assess to Bioequivalence of Favira 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions"
NCT04652102,Recruiting,Interventional,Phase 2/Phase 3,CureVac AG,Industry,14-Dec-20,4-Mar-23,5-Mar-21,PREVENTION,36500,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",CVNCOV,NUMBER OF PARTICIPANTS WHO EXPERIENCE A FIRST EPISODE OF VIROLOGICALLY-CONFIRMED {REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) POSITIVE} CASE OF COVID-19 OF ANY SEVERITY,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older"
NCT04652115,Not yet recruiting,Interventional,Phase 2,Brigham and Women's Hospital,Other,1-Jan-21,1-Nov-23,1-Nov-22,TREATMENT,42,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",DEFIBROTIDE,THE RATE OF ADVERSE EVENT OF SPECIAL INTEREST (BLEEDING AND HYPOTENSION),A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19
NCT04652505,Recruiting,Observational,,M.D. Anderson Cancer Center,Other,13-Jul-20,31-Mar-21,31-Mar-21,COHORT,700,COVID INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE ADMINISTRATION,PATIENT-REPORTED SEVERITY OF DEPRESSION,Coping With COVID: The Effect of the COVID-19 Public Health Crisis on Mental Well-Being in Cancer Patients Seen at the Psychiatric Oncology Clinic
NCT04652518,Recruiting,Interventional,Phase 2,PureTech,Industry,11-Dec-20,21-Dec-21,21-Aug-21,TREATMENT,168,COVID,ROMANIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",LYT-100,CHANGE IN DISTANCE WALKED ON THE SIX-MINUTE WALK TEST (6MWT),"A Phase 2 Randomized, Double-blind, Placebo-controlled Safety and Efficacy Trial of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease"
NCT04652596,Enrolling by invitation,Interventional,Not Applicable,Boston Medical Center,Other,8-Feb-21,22-Oct-21,22-Jun-21,PREVENTION,250,FOOD INSECURITY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRODUCE PRESCRIPTION PROGRAM,CHANGE IN FOOD SECURITY,Comparative Effectiveness of Two Interventions to Reduce Food Insecurity During the COVID-19 Pandemic
NCT04652648,Completed,Interventional,Phase 4,Bryn Mawr Hospital,Other,27-May-20,15-Nov-20,31-Oct-20,PREVENTION,54,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYDROXYCHLOROQUINE,COVID-19 SYMPTOM DEVELOPMENT WITH POSITIVE PCR TEST,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts
NCT04652674,Recruiting,Interventional,Not Applicable,Cedars-Sinai Medical Center,Other,28-Sep-20,30-Jun-21,30-Jun-21,HEALTH SERVICES RESEARCH,70,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",TELEMEDICINE VISIT,PATIENT SATISFACTION,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial
NCT04652765,Recruiting,Interventional,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Other,3-Feb-21,23-Jan-21,23-Jan-21,TREATMENT,60,COVID,UNITED STATES,ALL,"60 Years and older   (Adult, Older Adult)",CAMOSTAT MESILATE,NUMBER OF PARTICIPANTS REQUIRING HOSPITALIZATION,COMBO Trial: Camostat With Bicalutamide for COVID-19
NCT04653727,Recruiting,Observational,,"Charite University, Berlin, Germany",Other,6-Jan-21,21-Dec-21,21-May-21,OTHER,3000,COVID,GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",CROSS-SECTIONAL SURVEY,SARS-COV-2 INFECTION,Effects of Interventions and Lifestyle Modifications in Integrative Medicine and the Course of Infectious Respiratory Diseases Including COVID-19
NCT04653831,Recruiting,Interventional,Not Applicable,Soroka University Medical Center,Other,8-Nov-20,21-Dec-21,21-Nov-21,TREATMENT,100,COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",PIRFENIDONE,VENTILATION FREE DAYS TO DAY 28 (VFD28),Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial
NCT04653844,"Active, not recruiting",Observational,,"University Hospital, Montpellier",Other,1-Feb-20,30-Mar-21,20-Feb-21,OTHER,7000000,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,SARS-COV-2 REINFECTION RATE,SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database
NCT04653857,"Active, not recruiting",Observational,,"University Hospital, Montpellier",Other,1-Apr-20,1-Jan-21,30-Apr-20,CASE-ONLY,250,COVID,FRANCE,ALL,"10 Years to 50 Years   (Child, Adult)",,PREVALENCE OF CARDIAC ABNORMALITY,Evaluation of Cardiological Tests Before Returning to Sport in Athletes After COVID-19 Infection (CADE Study)
NCT04654325,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,20-Dec-21,21-Dec-21,21-Dec-21,OTHER,1280,SARS-COV2,,ALL,"18 Years and older   (Adult, Older Adult)",CONJUNCTIVAL SWAB,PRESENCE OF SARS-COV-2 GENOME IN TEARS,Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients
NCT04654416,Completed,Observational,,Clínica Medellín - Grupo Quirónsalud,Other,20-Mar-20,20-Aug-20,7-Aug-20,CASE-CROSSOVER,301,COVID,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",CORTICOSTEROID WITH OR WITHOUT COLCHICINE,OUTCOME,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia
NCT04654442,Recruiting,Observational,,"University Hospital, Grenoble",Other,4-Feb-21,15-May-21,21-May-21,CASE-CONTROL,60,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TESTNPASS,FEASIBILITY OF TESTNPASS IVDMD FOR COVID19 DIAGNOSIS ON SALIVA SAMPLES.,Evaluation of the Feasibility and Analytic Performance of TestNPass (In Vitro Diagnosis Medical Device) for CoViD-19 Diagnosis on Saliva Sample. : a Pilot Study
NCT04654481,Recruiting,Interventional,Not Applicable,Icahn School of Medicine at Mount Sinai,Other,20-Dec-21,21-Nov-21,21-Feb-21,SUPPORTIVE CARE,30,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HCFWO,CHANGE IN FORCED EXPIRATORY VOLUME IN ONE SECOND (FEV1),Feasibility of Using a Home-Based High Frequency Chest Wall Oscillation Device (AffloVest) in At-Risk Respiratory Patients to Decrease Acute Respiratory Care Burden During the COVID-19 Pandemic
NCT04655521,Recruiting,Observational,,Universität des Saarlandes,Other,2-Dec-20,21-Nov-21,21-Aug-21,CASE-CONTROL,300,COVID,GERMANY,ALL,"3 Months and older   (Child, Adult, Older Adult)",,DIFFERENTIAL EXPRESSION OF BIOMARKERS BETWEEN COVID-19 AND CONTROLS,The Dynamics of the Immune Response to Infection by SARS Coronavirus 2
NCT04655586,Recruiting,Interventional,Phase 2/Phase 3,"ARCA Biopharma, Inc.",Industry,10-Dec-20,31-May-21,30-Apr-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years to 90 Years   (Adult, Older Adult)",RNAPC2,CHANGE IN D-DIMER LEVEL FROM BASELINE TO DAY 8 (PHASE 2B),"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)"
NCT04655612,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Dec-20,30-Jul-21,1-Jul-21,COHORT,5000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,PROPORTION OF PATIENTS WITH INFLAMMATORY CHRONIC RHEUMATIC DISEASES WITH POSITIVE SARS-COV-2 SERODIAGNOSIS,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases
NCT04655625,"Active, not recruiting",Interventional,Phase 2/Phase 3,"AnGes, Inc.",Industry,23-Nov-20,31-Mar-22,27-May-21,PREVENTION,500,COVID,JAPAN,ALL,"18 Years and older   (Adult, Older Adult)",GROUP A (AG0302-COVID19),INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,"A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults"
NCT04655638,Recruiting,Interventional,Not Applicable,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,Other,10-Feb-21,1-Mar-22,10-Jan-22,TREATMENT,364,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HIGH FLOW NASAL THERAPY,PROPORTION OF PATIENTS NEEDING ESCALATION OF TREATMENT DURING HOSPITAL STAY,High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial)
NCT04655716,Not yet recruiting,Interventional,Phase 3,Guy's and St Thomas' NHS Foundation Trust,Other,1-Feb-21,30-Mar-22,31-Jan-22,TREATMENT,80,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SODIUM BICARBONATE 150MEQ/L/D5W INJ,PROPORTION OF PATIENTS TREATED WHO ACHIEVE >50% OF URINE MEASUREMENTS ABOVE PH 7.0 OVER THE DURATION OF INTERVENTION,Urine Alkalinisation to Prevent Acute Kidney Injury in COVID-19
NCT04656444,Not yet recruiting,Observational [Patient Registry],,Fondation Lenval,Other,21-Apr-21,21-Jun-21,21-Jun-21,COHORT,250,COVID,FRANCE,ALL,up to 17 Years   (Child),,PARENTAL COMPLIANCE,Parental Compliance After Telephone Triage Advice During and After Confinement During the COVID-19 Epidemic in France
NCT04656613,Not yet recruiting,Interventional,Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,20-Dec-21,21-Dec-21,21-Aug-21,PREVENTION,1000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",GAM-COVID-VAC,SARS-COV-2 GLYCOPROTEIN-SPECIFIC ANTIBODIES TITER,"A Phase III, Randomized, Double -Blind, Placebo-controlled Trial to Evaluate Immunogenicity and Safety of the Gam-COVID-Vac Combined Vector Vaccine in Prophylactic Treatment for SARS-СoV-2 Infection in the United Arab Emirates"
NCT04656626,Completed,Interventional,Not Applicable,Imam Abdulrahman Bin Faisal University,Other,7-Jul-20,5-Sep-20,21-Jul-20,OTHER,146,"STRESS, PSYCHOLOGICAL",SAUDI ARABIA,ALL,"22 Years and older   (Adult, Older Adult)",BRIEF MINDFULNESS BASED INTERVENTION,REDUCTION OF ANXIETY SYMPTOM SEVERITY,"Brief Mindfulness Based Intervention for Front-Line Medical Staff in the COVID19 Pandemic to Improve Psychological Wellbeing, a Randomized Controlled Multicenter Trial"
NCT04656691,Enrolling by invitation,Interventional,Phase 4,Daniel Griffin,Industry,4-Jan-21,21-May-21,21-May-21,TREATMENT,7500,COVID,UNITED STATES,ALL,65 Years and older   (Older Adult),BAMLANIVIMAB,EFFICACY - DETERMINING HOSPITALIZATION RATES,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
NCT04657263,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Nov-20,30-May-21,1-May-21,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",VACCINE COVERAGE ASSESSMENT,NUMBER OF PERSONS AT RISK OF INFECTION UP TO DATE WITH THEIR MANDATORY AND RECOMMENDED VACCINATIONS DURING COVID19 PANDEMIC,Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection
NCT04657406,Available,Expanded Access,,Organicell Regenerative Medicine,Industry,,,,,,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ZOFINTM,,Expanded Access to ZofinTM (OrganicellTM Flow) for the Treatment of Patients With Mild to Moderate COVID-19 Due to SARS-Cov-2 for Outpatient and Inpatient Population
NCT04657419,Not yet recruiting,Observational,,"University Hospital, Bordeaux",Other,5-Dec-20,30-Jun-21,31-May-21,COHORT,720,COVID,,ALL,18 Years to 45 Years   (Adult),SURVEY,FATIGUE SEVERITY SCALE,Fatigue and Sleep in Patients With COVID-19
NCT04657445,Recruiting,Observational,,"University Hospital, Ioannina",Other,17-Nov-20,21-Jun-21,21-May-21,COHORT,100,OLFACTORY AND TASTE DYSFUNCTION IN SARS-COV2 INFECTION,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",VISUAL ANALOGUE SCALE,OFLACTORY AND TASTE DYSFUNCTION IN SARS-COV2 INFECTION,"EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY"
NCT04657458,Available,Expanded Access,,"Direct Biologics, LLC",Industry,,,,,,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",BONE MARROW MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES INFUSION TREATMENT,,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment: Expanded Access Protocol for Patients With COVID-19 Associated ARDS Who Do Not Qualify for Phase II Randomized Control Trial
NCT04657471,Recruiting,Interventional,Not Applicable,"University Hospital, Angers",Other,8-Dec-20,8-Jun-21,8-Jun-21,TREATMENT,1300,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",REVISED HOME-COV SCORE,THE SAFETY OF THE REVISED HOME-COV SCORE STRATEGY FOR HOME TREATMENT,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.
NCT04657484,Recruiting,Interventional,Not Applicable,Postgraduate Institute of Medical Education and Research,Other,8-Dec-20,7-Dec-21,7-Dec-21,TREATMENT,100,POST COVID DIFFUSE LUNG DISEASE,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",MEDIUM DOSE PREDNISOLONE,PROPORTION OF SUBJECTS WITH A COMPLETE RADIOLOGIC RESPONSE,Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia
NCT04657497,Recruiting,Interventional,Phase 3,Ono Pharmaceutical Co. Ltd,Industry,9-Nov-20,31-May-21,31-May-21,TREATMENT,110,SARS-COV2 INFECTION (COVID),JAPAN,ALL,"18 Years and older   (Adult, Older Adult)",FOY-305,TIME TO SARS-COV-2 NEGATIVE TEST,"A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)"
NCT04657510,Recruiting,Observational,,Istituto Ortopedico Galeazzi,Other,14-Nov-20,31-Dec-20,1-Dec-20,COHORT,140,COVID,ITALY,ALL,"45 Years and older   (Adult, Older Adult)",COVID-19,SURVIVAL AT DISCHARGE DAY (COMPARISON BETWEEN THE TWO GROUPS),Femoral frACturEs and COVID-19. Retrospective Comparative Cohort Study on the Early Prognosis of Patients Affected by Proximal Femur Fractures and COVID-19.
NCT04657809,"Active, not recruiting",Interventional,Phase 2,Soad Ali,Other,1-Oct-20,20-Feb-21,18-Feb-21,TREATMENT,40,ANOSMIA,EGYPT,ALL,"18 Years to 70 Years   (Adult, Older Adult)",INSULIN FILM,SMELL SENSATION IMPROVEMENT,"""Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation."""
NCT04658121,Enrolling by invitation,Observational,,COVID-19 Prevention Network,Other,4-Feb-21,30-May-21,30-May-21,ECOLOGIC OR COMMUNITY,3920,COVID,PUERTO RICO,ALL,"2 Months and older   (Child, Adult, Older Adult)",,TO ESTIMATE THE PREVALENCE OF SARS-COV-2 IGG SEROPOSITIVITY AMONG INDIVIDUALS IN COMMUNITIES SURROUNDING SELECTED NIAID CLINICAL RESEARCH SITES,SARS-CoV-2 Prevalence Study
NCT04658433,Recruiting,Interventional,Not Applicable,Applied Science Private University,Other,5-Dec-20,30-Mar-21,15-Feb-21,PREVENTION,100,CARDIOVASCULAR RISK FACTOR,JORDAN,ALL,"35 Years to 65 Years   (Adult, Older Adult)",300 MG OF OMEGA3-FA,SERUM ACE LEVELS,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the COVID-19 Uninfected Jordanian People
NCT04658979,Recruiting,Interventional,Not Applicable,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,Other,20-Dec-21,22-Jan-21,21-Mar-21,TREATMENT,30,CHRONIC PULMONARY DISEASE,CANADA,ALL,"20 Years to 80 Years   (Adult, Older Adult)",PULMONARY TELE-REHABILITATION,FEASABILITY - PATIENTS´ SATISFACTION WITH THE PROGRAM BETWEEN BASELINE AND THE UP TO 12 WEEKS FOLLOW-UP,Evaluation of the Feasibility and Safety of a Pulmonary Tele-rehabilitation Program in the Times of COVID-19
NCT04659109,Not yet recruiting,Interventional,Phase 2,Acticor Biotech,Industry,20-Dec-21,21-Jul-21,21-Apr-21,TREATMENT,60,SARS-COV INFECTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",GLENZOCIMAB,PROGRESSION FROM MODERATE TO SEVERE RESPIRATORY DISTRESS ASSESSED AT DAY 4,"A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome"
NCT04659122,Not yet recruiting,Interventional,Phase 1,"Airway Therapeutics, Inc.",Industry,21-Jan-21,21-Jul-21,21-Jun-21,TREATMENT,9,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",AT-100,DETERMINING THE HIGHEST-TOLERATED & SAFETY-TESTED AT-100 DOSE,"Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection"
NCT04659135,Recruiting,Observational [Patient Registry],,American Society of Clinical Oncology,Other,19-Apr-20,22-Dec-21,22-Dec-21,CASE-ONLY,2000,NEOPLASMS,UNITED STATES,ALL,"Child, Adult, Older Adult",,CHANGES TO CANCER TREATMENTS,ASCO Survey on Coronavirus Disease 2019 (COVID-19) in Oncology (ASCO) Registry
NCT04659187,Recruiting,Observational,,Asklepios proresearch,Industry,26-Mar-20,1-Jul-21,30-May-21,COHORT,4000,COVID,GERMANY,ALL,"Child, Adult, Older Adult",,COMPOSITE OF DEATH AND/OR NEED FOR MECHANICAL VENTILATION AND/OR ADMISSION TO ICU,"""CORONA Germany"" - Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany"
NCT04659200,Completed,Observational,,Bezmialem Vakif University,Other,1-Sep-20,7-Dec-20,5-Dec-20,CASE-ONLY,20,COVID INFECTION,TURKEY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VENOUS BLOOD WAS COLLECTED FOR BIOCHEMISTRY TESTING.,COMPARISON OF THYROID STIMULATING HORMONE (TSH) BETWEEN GROUPS,"Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer"
NCT04659239,Enrolling by invitation,Interventional,Phase 3,Chinese Academy of Medical Sciences,Other,28-Jan-21,22-Jul-21,21-Sep-21,PREVENTION,34020,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",INACTIVATED SARS-COV-2 VACCINE (VERO CELL),THE INCIDENCE OF COVID-19 CASES AFTER TWO-DOSES OF VACCINATION,"A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above"
NCT04659252,Not yet recruiting,Observational,,"Institute of Cancer Research, United Kingdom",Other,15-Jan-21,1-Oct-21,1-Apr-21,COHORT,70,MULTIPLE MYELOMA,,ALL,"21 Years and older   (Adult, Older Adult)",N/A - SAMPLES COLLECTED ALONG ROUTINE CARE SAMPLES ONLY,VALIDATED FLC,Circulating Tumour Protein Quantification From Capillary Blood for Patient Selfsampling and Safe Remote Monitoring of Multiple Myeloma During COVID-19
NCT04659304,Not yet recruiting,Interventional,Phase 1,Enlivex Therapeutics Ltd.,Industry,21-Mar-21,22-Mar-21,21-Dec-21,TREATMENT,50,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ALLOCETRA-OTS,SAFETY - ADVERSE EVENTS,"A Multi-Center Study, Placebo-Controlled, Evaluating Safety, Tolerability and Efficacy of Different Doses and Regimens of Allocetra-OTS in Patients With COVID-19"
NCT04659356,Recruiting,Observational,,Nantes University Hospital,Other,1-Sep-20,1-Mar-21,1-Dec-20,COHORT,600,CORONAVIRUS INFECTIOUS DISEASE (COVID),FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS ADMITTED IN INTENSIVE CARE UNITS,INCIDENCE OF NOSOCOMIAL COVID-19,"Evaluation of a SARS-CoV-2 Infectious Risk Management Protocol on the Transmission of Nosocomial COVID in Intensive Care Unit"""
NCT04659460,Not yet recruiting,Interventional,Not Applicable,Unity Health Toronto,Other,15-Dec-20,1-Sep-21,31-Mar-21,TREATMENT,30,COVID,,ALL,"16 Years and older   (Child, Adult, Older Adult)",REMOTE ISCHEMIC CONDITIONING,INTERLEUKIN 1-BETA (IL-1B) (PG/ML),Remote Ischemic Conditioning as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
NCT04659473,Not yet recruiting,Observational,,University of Salamanca,Other,9-Dec-20,20-Dec-20,20-Dec-20,ECOLOGIC OR COMMUNITY,1000,COVID,SPAIN,ALL,"Child, Adult, Older Adult",ONLINE SURVEY,WHAT'S YOUR WORK OR STUDY SYSTEM NOWADAYS?,"COVID-19, the Third Wave Update People Coping With the COVID-19. A Cross-sectional Online Spanish Survey"
NCT04659486,Enrolling by invitation,Interventional,Not Applicable,University of Sao Paulo,Other,24-Sep-20,30-Apr-21,30-Apr-21,TREATMENT,100,COVID,BRAZIL,ALL,"7 Years to 18 Years   (Child, Adult)",HOME-BASED EXERCISE TRAINING,QUALITY OF LIFE ASSESSED BY THE PEDIATRIC QUALITY OF LIFE INVENTORY (PEDS-QOL),Prospective Studies in School-aged Children and Adolescents With COVID-19 Treated at HCFMUSP
NCT04659707,Recruiting,Interventional,Phase 1,University of Kansas Medical Center,Other,22-Feb-21,31-Dec-21,31-Dec-21,DIAGNOSTIC,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HYPERPOLARIZED XE129,VENTILATION DEFECT PERCENTAGE,Evaluating Lung Structure and Function in Survivors of COVID-19 Using Hyperpolarized 129Xe MRI
NCT04659746,Recruiting,Interventional,Not Applicable,Universidad Autónoma de Encarnación,Other,9-Dec-20,9-Dec-21,28-Feb-21,SUPPORTIVE CARE,96,QUALITY OF LIFE,PARAGUAY,ALL,"18 Years and older   (Adult, Older Adult)",MEJORACARE,CHANGE ON HEALTH-RELATED QUALITY OF LIFE,mHealth Technology to Optimize Mental Health in Chronic Patients During the COVID-19 Outbreak in Paraguay
NCT04659759,Recruiting,Observational,,Thomas Jefferson University,Other,17-Nov-20,30-Jun-22,31-Dec-21,COHORT,300,COVID,UNITED STATES,FEMALE,"Child, Adult, Older Adult",COVID-19 EXPOSURE,MATERNAL COVID-19 SEROLOGY (IGG AND IGM),COVID-19 in Pregnancy: Utilizing Immunology Through Epidemiology to Improve Perinatal/Neonatal Outcomes
NCT04659772,Enrolling by invitation,Interventional,Phase 2,Ayan Sen,Other,20-Dec-21,20-Dec-21,20-Dec-21,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CLAZAKIZUMAB,ADVERSE EVENTS,A Randomized Placebo-Controlled Safety And Dose-Finding Study For The Use Of The Il-6 Inhibitor Clazakizumab in Patients With Life-Threatening COVID-19 Infection
NCT04659876,Completed,Observational,,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,Other,22-Mar-20,8-Dec-20,1-Sep-20,COHORT,445,COVID AND MORTALITY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",CLINICAL FEATURES AND LABORATORY VALUES,MORTALITY,Clinical Characteristics and Laboratory Values Affecting Mortality in Critical COVID 19 Patients Followed in the Intensive Care Unit
NCT04659889,Recruiting,Observational,,HCA International Limited,Other,20-Dec-21,21-Jun-21,21-Jun-21,CASE-CONTROL,100,LONG COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING (VENESECTION),OBSERVATION OF FREQUENCY OF ABNORMAL HAEMATOLOGICAL PARAMETERS AND ASSOCIATION WITH LONG-COVID CLINICAL PHENOTYPES VERSUS CONTROLS.,Analysis of the Relationship Between Clinical and Haematological Phenotypes in Long COVID
NCT04659928,Not yet recruiting,Interventional,Phase 4,"The University of Texas Health Science Center, Houston",Other,1-Dec-20,1-Dec-22,1-Dec-22,PREVENTION,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HIGH VOLUME EVACUATION (HVE),NUMBER OF BACTERIAL COLONY FORMING UNITS (CFUS) .,Evaluation of Aerosol in a Dental Clinic
NCT04659941,Recruiting,Interventional,Phase 2,Universidade Federal do Rio de Janeiro,Other,1-Oct-20,1-Oct-22,1-Oct-21,PREVENTION,1000,COVID VACCINE,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",BCG VACCINE,COMPARE THE CUMULATIVE INCIDENCE OF SARS-COV-2 INFECTION,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers
NCT04660422,Recruiting,Observational,,Dana-Farber Cancer Institute,Other,15-Dec-20,14-May-21,14-May-21,COHORT,13150,ADVANCED CARE PLANNING,UNITED STATES,ALL,65 Years and older   (Older Adult),VITALTALK COMMUNICATION SKILLS TRAINING,RATE FOR ADVANCED CARE PLANNING (ACP) DOCUMENTATION,Advance Care Planning: Communicating With Outpatients for Vital Informed Decisions
NCT04661189,Recruiting,Interventional,Not Applicable,Montreal Heart Institute,Other,18-May-20,1-Dec-22,1-May-22,PREVENTION,118,CARDIOVASCULAR DISEASES,CANADA,ALL,"50 Years to 100 Years   (Adult, Older Adult)",PHYSICAL EXERCISE TRAINING,CHANGE IN GENERAL COGNITIVE FUNCTIONING,The Cognitive and spOrt Virtual EPIC Training Study: Investigating the Effects of Home-based Exercise and Cognitive Training in Cardiovascular Diseases
NCT04661410,Recruiting,Interventional,Not Applicable,Drexel University,Other,1-Dec-20,30-Mar-22,1-Dec-21,TREATMENT,60,BULIMIA NERVOSA,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",REWARD RE-TRAINING,BINGE EATING FREQUENCY ASSESSED BY THE EATING DISORDER EXAMINATION,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic
NCT04661423,Not yet recruiting,Interventional,Not Applicable,IHU Strasbourg,Other,21-Jan-21,22-Jun-21,22-Jun-21,OTHER,60,POST ICU REHABILITATION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",REMOTE AUTOMATED MONITORING SYSTEM,"DETERMINATION OF THE QUALITY OF MEASUREMENTS OF CLINICAL SIGNS PROVIDED BY MULTISENSE® STRIP IN COMPARISON TO MEASUREMENTS MADE WITH CONVENTIONAL MEDICAL DEVICES IN THE HOSPITAL SETTING, IN TERMS OF ACCURACY.",Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era
NCT04661462,Recruiting,Observational,,Medical University Innsbruck,Other,30-Sep-20,31-Dec-21,30-Sep-21,OTHER,1000,COVID,AUSTRIA,ALL,"16 Years and older   (Child, Adult, Older Adult)",ONLINE SURVEY,POPULATION BASED DATA ON SPECTRUM AND RECOVERY FROM COVID-19 SYMPTOMS,Health After COVID-19 in the European Region Tyrol - South Tyrol
NCT04661527,Recruiting,Interventional,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",Other,22-Apr-20,30-Dec-20,30-Dec-20,TREATMENT,60,COVID DRUG TREATMENT,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",SARILUMAB,CHANGE IN A SEVERITY RATING ON A 7-POINT ORDINAL SCALE,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
NCT04661540,Not yet recruiting,Interventional,Phase 2,"CalciMedica, Inc.",Industry,21-Feb-21,21-May-21,21-May-21,TREATMENT,36,PNEUMONIA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CM4620-IE (INJECTABLE EMULSION),DECREASE IN INTERFERON-GAMMA PRODUCING T-CELLS IN BRONCOALVEOLAR LAVAGE (BAL) FLUID,A Single-Blind Dose-Ranging Pharmacodynamic Study of Auxora for the Treatment of Patients With Critical COVID-19 Pneumonia
NCT04661631,Recruiting,Observational [Patient Registry],,Fundacion Clinica Valle del Lili,Other,8-May-20,30-Nov-21,31-Jul-21,OTHER,451,ULTRASONOGRAPHY,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND,THE BEST CUT-OFF POINT FOR LUNG ULTRASOUND TO DISCRIMINATE SUSPECTED CASES OF ACTIVE SARS-COV-2 INFECTION,Lung Ultrasound in COVID-19 Infection Screening for Patients With Indication of Emergency Surgery
NCT04661657,Recruiting,Observational [Patient Registry],,Columbia University,Other,28-Dec-20,30-Sep-22,31-Dec-21,COHORT,70,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TRANSTHORACIC ECHOCARDIOGRAM (TTE),PERCENTAGE OF MYOCARDIUM DEMONSTRATING LATE GADOLINIUM ENHANCEMENT,COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae (COLUMBIA CARDS) Registry
NCT04661813,Not yet recruiting,Interventional,Not Applicable,Case Western Reserve University,Other,21-Feb-21,22-Aug-21,22-Aug-21,HEALTH SERVICES RESEARCH,75,HIV-1-INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",EXTRA-CVD VIRTUAL CARE,PROPORTION OF ELIGIBLE PARTICIPANTS WHO AGREE TO PARTICIPATE,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
NCT04661839,Recruiting,Interventional,Phase 1,Emergent BioSolutions,Industry,24-Dec-20,21-Sep-21,21-Sep-21,TREATMENT,56,SARS-COV2,UNITED STATES,ALL,18 Years to 60 Years   (Adult),COVID-HIGIV,NUMBER OF SUBJECTS WITH ADVERSE EVENTS (AES) POST-DOSING,"A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) Administered as a Single Dose or a Repeat Dose Regimen to Healthy Adults"
NCT04661930,Recruiting,Interventional,Phase 3,Hebrew University of Jerusalem,Other,13-Dec-20,1-Dec-21,1-Apr-21,TREATMENT,50,CORONA VIRUS DISEASE (COVID),ISRAEL,ALL,"18 Years to 85 Years   (Adult, Older Adult)",TRICOR® 145MG TABLETS,DIFFERENCE IN PLASMA MARKERS AT 14 DAYS,Controlled Trial of Fenofibrate for Patients With COVID-19 Requiring Hospitalization
NCT04662021,Enrolling by invitation,Interventional,Not Applicable,Cairo University,Other,10-Dec-20,25-Feb-21,10-Feb-21,TREATMENT,40,ANXIETY DEPRESSION DISORDER,EGYPT,FEMALE,18 Years to 25 Years   (Adult),AEROBIC EXERCISES,DASS 21,"The Effect of Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety, Depression and Stress-related to Covid 19 Pandemics Among University Students: a Comparative Study"
NCT04662060,Not yet recruiting,Interventional,Phase 2,Stanford University,Other,21-Mar-21,22-Mar-21,22-Mar-21,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ACEBILUSTAT,FOR VIRAL DOMAIN:TIME UNTIL CESSATION OF SHEDDING OF SARS-COV-2 VIRUS,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19"
NCT04662073,Not yet recruiting,Interventional,Phase 2,Stanford University,Other,21-Mar-21,22-Mar-21,22-Mar-21,TREATMENT,120,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CAMOSTAT,FOR VIRAL DOMAIN:TIME UNTIL CESSATION OF SHEDDING OF SARS-COV-2 VIRUS,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19"
NCT04662086,Not yet recruiting,Interventional,Phase 2,Stanford University,Other,21-Mar-21,22-Mar-21,22-Mar-21,TREATMENT,240,COVID,UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ACEBILUSTAT,FOR VIRAL DOMAIN:TIME UNTIL CESSATION OF SHEDDING OF SARS-COV-2 VIRUS,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19"
NCT04662437,Completed,Observational,,Bezmialem Vakif University,Other,10-Sep-20,9-Dec-20,1-Dec-20,CASE-CONTROL,150,COVID INFECTION,TURKEY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",VENOUS BLOOD WAS COLLECTED FOR BIOCHEMISTRY TESTING,COMPARISON OF PARATHYROID HORMONE BETWEEN GROUPS,"The Status of Parathyroid Hormone Secretion and Its Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer in Hospitalized Covid-19 Patients"
NCT04662671,Completed,Interventional,Phase 1/Phase 2,EmitBio Inc.,Industry,18-Nov-20,30-Jan-21,9-Dec-20,TREATMENT,31,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",RD-X19,PRIMARY SAFETY MEASURE,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19"
NCT04662684,Recruiting,Interventional,Phase 3,Science Valley Research Institute,Other,16-Oct-20,30-Jun-21,30-Apr-21,PREVENTION,320,COVID,BRAZIL,ALL,"18 Years to 90 Years   (Adult, Older Adult)",RIVAROXABAN 10 MG,VENOUS THROMBOEMBOLISM AND VTE RELATED-DEATH,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
NCT04663555,Recruiting,Interventional,Phase 4,Brno University Hospital,Other,2-Feb-21,31-Mar-23,31-Mar-22,TREATMENT,300,COVID,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,NUMBER OF VENTILATOR-FREE DAYS (VFDS) AT 28 DAYS AFTER RANDOMIZATION,"Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial)"
NCT04663594,Recruiting,Interventional,Not Applicable,University of Oxford,Other,4-Dec-20,21-Mar-21,21-Mar-21,OTHER,400,DEPRESSION,UNITED KINGDOM,ALL,"16 Years to 24 Years   (Child, Adult)",WOFB,PANAS,An Online Cultural Experience to Support Mental Health in People Aged 16-24 During COVID-19: the O-ACEPOP (Online Active Community Engagement Proof of Principle) Study
NCT04663659,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,15-Mar-20,15-May-20,15-May-20,CASE-CONTROL,150,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,MORTALITY,The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized in the COVID Intensive Care Unit in the COVID-19 Pandemic
NCT04663737,Recruiting,Interventional,Phase 2,"Chris Recknor, MD",Industry,3-Dec-20,26-Mar-21,26-Feb-21,TREATMENT,20,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SILMITASERTIB,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY]) WITHIN THE CX-4945 TREATMENT GROUP ASSESSED BY CTCAE V5.0,"A Phase II, Randomized and Controlled Investigator Initiated Trial Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Outpatient Adult Subjects With Moderate Coronavirus Disease 2019 (COVID-19)"
NCT04663776,Recruiting,Observational,,Boston Children's Hospital,Other,4-Nov-20,8-Dec-21,8-Dec-21,COHORT,100000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF INFLUENZA-LIKE ILLNESS (ILI) AND COVID-LIKE ILLNESS (CLI) IN A STUDY PARTICIPANT.,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform
NCT04663906,Not yet recruiting,Observational,,University of Aberdeen,Other,15-Jan-21,31-May-21,31-May-21,OTHER,300,ISOTRETINOIN ADVERSE REACTION,,ALL,"16 Years to 40 Years   (Child, Adult)",,PRIMARY OUTCOME,"Does Oral Isotretinoin Increase the Risk of Developing Infection With and Complications From Covid-19, Compared to an Age-matched Background Population"
NCT04663945,Recruiting,Interventional,Not Applicable,"University of Colorado, Denver",Other,11-Dec-20,1-Aug-21,1-Jun-21,TREATMENT,45,COVID,UNITED STATES,ALL,"35 Years to 100 Years   (Adult, Older Adult)",BIOBEHAVIORAL TELE-REHABILITATION SESSIONS,30 SECOND CHAIR STAND TEST,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID Survivors
NCT04664010,"Active, not recruiting",Interventional,Not Applicable,Xi'an International Medical Center Hospital,Other,6-Feb-20,31-Jan-21,14-Jan-21,TREATMENT,60,COVID,CHINA,ALL,"18 Years to 70 Years   (Adult, Older Adult)","ALPHA-INTERFERON ALPHA, ABIDOL, RIBAVIRIN, BUZHONG YIQI PLUS AND MINUS FORMULA, HUHUANG DETOXICITY PASTE, BAIMU QINGRE JIEDU PASTE, FUMIGATION/INHALATION OF VITAMIN C",RECOVERY TIME,Efficacy and Safety of High-dose Vitamin C Combined With Traditional Chinese Medicine in the Treatment of Moderate and Severe Coronavirus Pneumonia (COVID-19)
NCT04664023,Recruiting,Observational,,Poitiers University Hospital,Other,9-Dec-20,30-Jul-22,30-Jul-22,COHORT,120,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)","BLOOD COLLECTION AT DAY 8, DAY 16, DAY 24, MONTH 6 AND MONTH 12 AFTER FIRST SYMPTOMS FROM SARS-COV-2 INFECTION",NEUTRALIZING ANTIBODIES,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 and Its Resolution"
NCT04664049,Recruiting,Observational,,"National Research Institute of Chinese Medicine, Ministry of Health and Welfare",Other,23-Dec-20,31-Dec-22,31-Dec-22,CASE-ONLY,51000,SARS-COV2,TAIWAN,ALL,"Child, Adult, Older Adult",NRICM101,NEGATIVE OF COVID-19 TEST,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection
NCT04664075,Not yet recruiting,Observational,,Imperial College London,Other,21-Jan-21,30-Jun-21,30-Apr-21,CASE-ONLY,100,INFLUENZA,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",RESPIRATORY INFECTIONS,DESCRIBE THE AETIOLOGY OF INFLUENZA-LIKE ILLNESS IN HOSPITALISED ADULTS,Predicting Severity and Disease Progression in Influenza-like Illness
NCT04664101,Not yet recruiting,Interventional,Not Applicable,Duke University,Other,1-Apr-21,1-May-23,1-May-23,TREATMENT,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","REMOTELY MONITORED, MHEALTH (REMM) SUPPORTED HIGH INTENSITY INTERVAL TRAINING (HIIT)",PERCENTAGE OF EXERCISE SESSION COMPLETED DAILY AS MEASURED BY SMART DEVICE MONITORING.,"REmotely Monitored, Mobile Health Supported High Intensity Interval Training to Improve Functional Recovery of Survivors of Critical Illness (REMM-HIIT-ICU-COVID)"
NCT04664296,Recruiting,Observational,,Hospices Civils de Lyon,Other,21-Dec-20,21-Mar-21,21-Mar-21,CASE-ONLY,75,INFECTION VIRAL,FRANCE,ALL,"Child, Adult, Older Adult",REVIEW OF MEDICAL PATIENT FILE,"PERCENTAGE OF POSSIBLE CONTAMINANTS, ADULTS, ADOLESCENTS AND CHILDREN WITH COVID-19",Epidemiology of CoV-2 SARS Infections: Dynamics of Community Contamination in Children and Adults
NCT04664309,Not yet recruiting,Observational,,Stanford University,Other,21-Mar-21,23-Jan-21,23-Jan-21,CASE-ONLY,1000,COVID,UNITED STATES,ALL,18 Years to 64 Years   (Adult),NO INTERVENTION,PERCENTAGE OF PARTICIPANTS WITH IMMUNITY TO COVID-19 VACCINES OVER TIME,Understanding Immunity to the COVID-19 Vaccines
NCT04665115,Not yet recruiting,Interventional,Phase 2,Academic and Community Cancer Research United,Other,30-Jun-21,1-May-25,1-May-22,TREATMENT,134,ASYMPTOMATIC COVID INFECTION LABORATORY-CONFIRMED,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IBRUTINIB,PROPORTION OF PATIENTS WHO REQUIRE HOSPITALIZATION FOR THEIR COVID-19 DISEASE OR DIE (COHORT 1),A Prospective Study of Patients With B-Cell Hematologic Malignancies on Ibrutinib Therapy Who Are Infected With Coronavirus Disease 2019 (COVID-19)
NCT04665193,Recruiting,Interventional,Not Applicable,University of British Columbia,Other,23-Nov-20,30-Apr-21,30-Apr-21,SCREENING,900,ASYMPTOMATIC CONDITION,CANADA,ALL,"19 Years to 80 Years   (Adult, Older Adult)",RAPID ANTIGEN TEST,COVID-19 STATUS,An Approach to Screening for SARS-CoV-2 at YVR: UBC-PHC-WestJet-YVR COVID-19 Screening Study
NCT04665245,Enrolling by invitation,Observational,,University of Iowa,Other,15-Dec-20,21-Apr-21,21-Apr-21,COHORT,500,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,BODY TEMPERATURE,Contact Network Transmission Modeling of Healthcare Associated Infections: Symptom-Based Markers for COVID-19 Transmission
NCT04665258,Recruiting,Observational,,University of Miami,Other,14-Dec-20,14-Jun-21,14-Jun-21,CASE-ONLY,60,"INFERTILITY, MALE",UNITED STATES,MALE,18 Years to 50 Years   (Adult),,SPERM CONCENTRATION,Corona Virus Disease 19 (COVID-19) Vaccine and Impact on Fertility Study
NCT04665752,Recruiting,Observational,,National Eye Institute (NEI),NIH,2-Feb-21,30-Jun-23,30-Jun-23,COHORT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,PERCENTAGE OF PARTICIPANTS,"Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors, a Natural History, Observational Study"
NCT04665778,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,4-Dec-20,21-Mar-21,21-Mar-21,CASE-ONLY,1516,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL BEDROOM BOOKING,VARIATION OF THE LENGTH OF STAY BETWEEN HIGH PROBABILITY OF HOSPITALIZATION GROUP AND NOT HIGH RISK OF HOSPITALIZATION GROUP.,Prediction of the Patient Pathway in Emergency Room in an Exceptional Sanitary Situation
NCT04665960,Not yet recruiting,Observational,,NMC Specialty Hospital,Other,1-Mar-21,31-Mar-21,20-Mar-21,COHORT,40,COVID,UNITED ARAB EMIRATES,ALL,"25 Years to 70 Years   (Adult, Older Adult)",,CONSENSUS USING PARTICIPATING EXPERTS OPINIONS.,Expert Statements on Infection Control in Intensive Care Unit for Severe Acute Respiratory Syndrome Coronavirus 2
NCT04666012,Recruiting,Interventional,Phase 1/Phase 2,"Cellid Co., Ltd.",Industry,29-Dec-20,22-Apr-21,21-Mar-21,PREVENTION,150,COVID,"KOREA, REPUBLIC OF",ALL,19 Years to 64 Years   (Adult),ADCLD-COV19,INCIDENCE OF SOLICITED ADVERSE EVENTS(AES),"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Randomized, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers"
NCT04666025,Recruiting,Observational,,City of Hope Medical Center,Other,23-Sep-20,23-Sep-22,23-Sep-22,COHORT,36,"ACCELERATED PHASE CML, BCR-ABL1 POSITIVE",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOSPECIMEN COLLECTION,SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS 2 (COV-2) SPIKE PROTEIN (S)-SPECIFIC IGG CONCENTRATION AND T CELL LEVELS,Observational Study of SARS-CoV-2 Donor-Recipient Immunity Transfer
NCT04666064,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,10-Dec-20,21-Jul-21,21-Jun-21,CASE-ONLY,100,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",COVID19 RT-PCR,CONCORDANCE BETWEEN COVID19 RT-PCR RESULTS AND LUNG ULTRASOUND RESULTS,Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room
NCT04666116,Recruiting,Interventional,Not Applicable,Hospital de Sagunto,Other,1-Apr-20,21-Feb-21,20-Dec-21,TREATMENT,96,COVID,SPAIN,ALL,"18 Years to 99 Years   (Adult, Older Adult)",DIETARY SUPPLEMENTATION IN PATIENTS WITH COVID DISEASE ADMITTED TO HOSPITAL,VIRAL LOAD DURING THE PERIOD OF ADMISSION TO THE NASOPHARYNGEAL SMEAR.,Changes in Viral Load in Patients With COVID-19 Disease After Dietary Supplementation With Probiotics: A Randomized Clinical Trial
NCT04666207,Recruiting,Observational,,"Rigshospitalet, Denmark",Other,25-May-20,30-Jun-21,31-Jan-21,COHORT,20,COVID,DENMARK,ALL,up to 17 Years   (Child),PCR,SALVIA SAMPLES HAVE EQUAL OR HIGHER SENSIBILITY THAN NASAL SWAPS IN CHILDREN FOR DETECTION OF SARS-COV-2,"A Cohort Study of Non-hospitalized SARS-CoV-2 Positive Children in Denmark: Viral Shedding, Symptoms and Exposure"
NCT04666233,Not yet recruiting,Interventional,Not Applicable,University Hospital Padova,Other,21-Jan-21,21-Mar-21,21-Mar-21,TREATMENT,48,NEONATES NEEDING RESUSCITATION AT BIRTH,,ALL,"Child, Adult, Older Adult",NEONATAL RESUSCITATION WITH PPE FOR THE PREVENTION OF SARS-COV-2 INFECTION,INITIATION OF POSITIVE PRESSURE VENTILATION,Does Personal Protective Equipment for the Prevention of SARS-Cov-2 Infection Impact the Timing of Ventilation in Neonates Needing Resuscitation at Birth? A Crossover Randomized Controlled Trial
NCT04666246,Recruiting,Observational,,University of Modena and Reggio Emilia,Other,1-Mar-20,1-Feb-22,1-Feb-21,COHORT,40,ACUTE RESPIRATORY FAILURE,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,INSPIRATORY EFFORT QUANTIFICATION,Inspiratory Effort Assessment in Patients With COVID-19 Pneumonia Undergoing Non Invasive Respiratory Support
NCT04666285,Not yet recruiting,Observational,,University of Southampton,Other,20-Dec-21,20-Dec-21,20-Dec-21,COHORT,1000,MENTAL HEALTH WELLNESS 1,UNITED KINGDOM,ALL,"12 Years to 57 Years   (Child, Adult)",EXPERIENCE OF PANDEMIC,MENTAL HEALTH IN WOMEN,A Survey of Southampton Women's Survey Women's and Offspring's Health and Wellbeing During the COVID-19 Pandemic and Lockdown.
NCT04666311,Not yet recruiting,Observational,,Klaus Reither,Other,20-Dec-21,22-May-21,21-Nov-21,COHORT,1400,PULMONARY TUBERCULOSIS,LESOTHO,ALL,"18 Years and older   (Adult, Older Adult)",ACCURACY OF CAD4TB AND AFINION CRP ASSAY FOR PULMONARY TB,DETERMINE CAD4TB CUT-OFF VALUE,"Prospective, Multicentre Evaluation of the Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for the Diagnosis of Pulmonary Tuberculosis in Presumptive Adult TB Patients (TB TRIAGE+ Accuracy)"
NCT04666441,Recruiting,Interventional,Phase 2,Regeneron Pharmaceuticals,Industry,15-Dec-20,24-Apr-21,1-Mar-21,TREATMENT,1400,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",REGN10933+REGN10987 COMBINATION THERAPY,"TIME-WEIGHTED AVERAGE DAILY CHANGE FROM BASELINE IN VIRAL LOAD (LOG10 COPIES/ML), AS MEASURED BY REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION (RT-QPCR) IN NASOPHARYNGEAL (NP) SWAB SAMPLES",A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection
NCT04666493,Recruiting,Interventional,Not Applicable,Evdokia Anagnostou,Other,4-Dec-20,30-Nov-21,30-Nov-21,TREATMENT,100,AUTISM SPECTRUM DISORDER,CANADA,ALL,8 Years to 13 Years   (Child),"COGNITIVE BEHAVIOR THERAPY (CBT), SPECIFICALLY USING THE FACING YOUR FEARS (FYF) CURRICULUM","SCREEN FOR CHILD ANXIETY RELATED EMOTIONAL DISORDERS (SCARED), PARENT VERSION",Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19: A Research Project to Provide and Evaluate Virtual Mental Health Care
NCT04666558,Recruiting,Interventional,Not Applicable,University of Alberta,Other,30-Nov-20,17-Dec-21,17-Dec-21,SUPPORTIVE CARE,216,CANCER,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",EXERCISE & NUTRITION,LOWER EXTREMITY FUNCTIONAL SCALE (LEFS),Heal-Me PiONEeR (Personalized Online Nutrition and Exercise Routines) - Reconnecting Vulnerable Outpatients With Multidisciplinary Care - a Randomized Controlled Trial Assessing 3 Levels of Online Programming in the Time of COVID
NCT04666597,Recruiting,Observational,,"Universidad El Bosque, Bogotá",Other,15-Nov-20,2-Mar-22,2-Mar-22,CASE-ONLY,420,DENTAL CARIES IN CHILDREN,ARGENTINA,ALL,3 Years to 8 Years   (Child),MODIFIED CARIESCARE INTERNATIONAL MANAGEMENT,OUTCOME AT THE TOOTH SURFACE AND AT THE INDIVIDUAL LEVEL,CariesCare International Adapted for the Pandemic in Children: Caries OUT Multicentre Single-group Interventional Study
NCT04666753,Completed,Observational,,Fagron Iberica S.A.U.,Industry,2-Jul-20,29-Sep-20,29-Sep-20,COHORT,40,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",IMMUNOFORMULATION,CLINICAL SYMPTOMS DURATION,Retrospective Observational Study to Describe the Evolution of SARS-CoV-2 Disease and the Profile of Patients Treated or Not With Imuno TF® and a Combination of Nutraceuticals and Who Have Tested Positive for COVID-19
NCT04666779,Not yet recruiting,Observational [Patient Registry],,Real Centro Universitario Maria Cristina,Other,14-Dec-20,28-Feb-21,31-Jan-21,COHORT,500,ACCESS TO CHIROPRACTIC CARE SERVICES,SPAIN,ALL,"16 Years and older   (Child, Adult, Older Adult)",CHIROPRACTIC CARE,PAIN INTENSITY,Access to Chiropractic Care During the COVID-19 Pandemic: a Prospective Comparative Cohort Trial
NCT04667247,Recruiting,Interventional,Phase 1/Phase 2,Gordon Saxe,Other,3-Dec-20,1-Aug-21,1-Apr-21,TREATMENT,66,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FOTV,ADVERSE EVENTS,"Multicenter Double Blind, Placebo Controlled RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19"
NCT04667286,Not yet recruiting,Interventional,Not Applicable,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,Other,30-Dec-20,1-Jul-21,1-Jun-21,TREATMENT,100,COVID INFECTION,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",PRONE POSITION (PP),NUMBER OF DAY FREE OF VENTILATORY SUPPORT,"Pronation in Spontaneously Breathing Patients With Acute Respiratory Failure Deu to Covid-19: Multicenter, Randomised Study"
NCT04667442,Recruiting,Observational,,Nanomix,Industry,1-Dec-20,21-Mar-21,21-Mar-21,OTHER,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NANOMIX ELAB® COVID-19 RAPID ANTIGEN PANEL (NON-INTERVENTIONAL),DEMONSTRATE CLINICAL AGREEMENT BETWEEN AN EUA RT-PCR METHODOLOGY AND THE NANOMIX ELAB® COVID-19 RAPID ANTIGEN PANEL,An Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects
NCT04667780,Recruiting,Interventional,Phase 3,Ayub Teaching Hospital,Other,10-Dec-20,9-Jul-21,9-May-21,TREATMENT,102,COVID,PAKISTAN,ALL,"18 Years to 65 Years   (Adult, Older Adult)",COLCHICINE,CHANGES IN THE PATIENTS' CLINICAL STATUS THROUGH THE 7 POINTS ORDINAL SCALE WHO R&D BLUEPRINT EXPERT GROUP,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
NCT04667923,Recruiting,Observational,,I.M. Sechenov First Moscow State Medical University,Other,1-Oct-20,21-Jun-21,21-Mar-21,CASE-ONLY,50,COVID,RUSSIAN FEDERATION,ALL,"18 Years to 80 Years   (Adult, Older Adult)",RESPIRATORY MONITORING,INTUBATION RATE,Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome to Prevent Tracheal Intubation: the COVID-NIV Study
NCT04667936,Recruiting,Observational,,Goethe University,Other,1-Mar-20,1-Jan-21,15-Dec-20,COHORT,100,PRONE POSITION,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",TREATMENT GROUP,POSITION THERAPY,Evaluation of Impaired Sedation in Patients With Moderate to Severe COVID-19 ARDS
NCT04667962,Recruiting,Observational,,Direction Centrale du Service de Santé des Armées,Other,23-Dec-20,21-Sep-21,21-Sep-21,COHORT,302,"BURNOUT, CAREGIVER",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE QUESTIONNAIRE,BURN-OUT ASSESSMENT TOOL (BAT) SCORE AT ENROLLMENT.,Impact of the Change in Hospital Service of Caregivers During COVID-19 Health Crisis on Operational Strain
NCT04668170,Recruiting,Observational,,"University Hospital, Toulouse",Other,5-May-20,31-Dec-21,31-Dec-21,COHORT,340,COVID,FRANCE,ALL,"18 Years to 110 Years   (Adult, Older Adult)",BLOOD COLLECTION ON ADMISSION AND LONGITUDINALLY,IMMUNE SIGNATURE ON ADMISSION : PHENOTYPIC PROFILE OF BLOOD T-CELLS,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management
NCT04668196,Recruiting,Observational,,Hospital Universitari Vall d'Hebron Research Institute,Other,22-May-20,21-Jan-21,21-Jan-21,COHORT,300,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",HIGH-FLOW NASAL CANNULA TREATMENT,TREATMENT FAILURE,Noninvasive Respiratory Support Outside the Intensive Care Unit in COVID-19 Pneumonia: a Multicentric Study (CATCOVID-AIR)
NCT04668209,Recruiting,Interventional,Phase 2,University of Arizona,Other,1-Jan-21,31-Mar-21,31-Mar-21,TREATMENT,40,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SILMITASERTIB,INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS [SAFETY AND TOLERABILITY],"Phase II, Randomized, Investigator Initiated Trial to Evaluate Safety and to Explore Clinical Benefit of Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)"
NCT04668222,Not yet recruiting,Interventional,Phase 1/Phase 2,The University of Hong Kong,Other,15-Dec-20,30-Nov-22,30-Nov-22,PREVENTION,480,COVID,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",YU-PING-FENG FORMULA,"POTENTIAL COVID-19 SUSCEPTIBLE BODY CONSTITUTIONS WILL BE MEASURED BY THE SCALE OF ""SELF-TEST FOR CLASSIFICATION AND JUDGMENT OF BODY CONSTITUTION BY TRADITIONAL CHINESE MEDICINE (TCM) THEORY""","Based on the Theory of ""Body Constitution of Chinese Medicine"" and ""Combination of Prescription and Syndrome"" to Improve COVID-19 Susceptible Body Constitution of Residents in Hong Kong"
NCT04668235,Not yet recruiting,Interventional,Phase 3,HRH Holdngs Limited,Other,20-Dec-21,21-Jun-21,21-Jun-21,TREATMENT,342,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",AZVUDINE,NEGATIVE CONVERSION RATE,"Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial"
NCT04668313,Recruiting,Observational [Patient Registry],,NHS Greater Glasgow and Clyde,Other,29-Sep-20,29-Sep-21,30-Dec-20,COHORT,150,RESPIRATORY FAILURE,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",,MACHINE-LEARNING MODEL DEVELOPMENT,COVID-19 Advanced Respiratory Physiology (CARP) Study
NCT04668339,Recruiting,Interventional,Phase 2,"Arcturus Therapeutics, Inc.",Industry,7-Jan-21,30-Apr-22,30-Apr-22,PREVENTION,600,COVID,SINGAPORE,ALL,"18 Years and older   (Adult, Older Adult)",ARCT-021 SINGLE DOSE PRIMING,PERCENTAGES OF PARTICIPANTS REPORTING SOLICITED LOCAL ADVERSE EVENTS,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants"
NCT04668404,Recruiting,Observational [Patient Registry],,Postgraduate Institute of Medical Education and Research,Other,24-Aug-20,1-Feb-21,1-Jan-21,CASE-ONLY,50,COVID,INDIA,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SONOCLOT,CORRELATION OF OF CONVENTIONAL COAGULATION TESTS WITH POINT OF CARE COAGULATION TEST USING SONOCLOT IN COVID-19 PATIENTS.,Study of Coagulation Profile and Role of Heparin-like Effect in Patients With COVID-19
NCT04668469,Completed,Interventional,Not Applicable,Benha University,Other,8-Jun-20,30-Oct-20,15-Sep-20,TREATMENT,600,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",IVERMECTIN,NUMBER OF PARTICIPANTS WITH IMPROVEMENT OF CLINICAL CONDITION (SYMPTOMS AND SIGNS),Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic
NCT04668625,Completed,Interventional,Not Applicable,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",Other,30-Nov-20,8-Jan-21,20-Dec-20,PREVENTION,1000,COVID (SARS-COV2),SPAIN,ALL,18 Years to 59 Years   (Adult),PARTICIPATE IN A MASSIVE MUSICAL EVENT,INCIDENCE RATE OF PEOPLE INFECTED WITH SARS-COV-2 8 DAYS AFTER RANDOMIZATION,Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study
NCT04668911,Recruiting,Observational,,Eastman Dental Insitute and Hospital,Other,13-Dec-20,12-Dec-21,12-Dec-21,COHORT,150,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SWAB,ORAL MICROBIAL SIGNATURE,"Oral Health, Microbial Burden and COVID-19"
NCT04668937,Completed,Observational,,"Central Hospital, Nancy, France",Other,18-Mar-20,30-Jun-20,18-Mar-20,COHORT,11000,NUMBER OF PATIENTS DURING THE STUDYING PERIOD,FRANCE,ALL,up to 17 Years   (Child),,NUMBER OF PATIENT WHO CAME TO NANCY'S PEDIATRIC EMERGENCIES DURING THE STUDY PERIOD,Conséquences of the COVID-19 Lockdown Measures on the CHRU Nancy
NCT04668950,Recruiting,Interventional,Phase 3,Washington University School of Medicine,Other,22-Dec-20,21-Sep-21,21-Jul-21,TREATMENT,1100,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",FLUVOXAMINE,CLINICAL DETERIORATION,"Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial"
NCT04669015,Not yet recruiting,Interventional,Phase 3,Genova Inc.,Industry,21-Jan-21,21-Aug-21,21-Aug-21,TREATMENT,914,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NOVAFERON,RATE OF CLINICAL DETERIORATION,"NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients With Moderate to Severe COVID-19"
NCT04669054,"Active, not recruiting",Observational,,"University Hospital, Montpellier",Other,1-Dec-20,30-Jul-21,30-May-21,COHORT,102,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DEPRESSIVE SYMPTOMATOLOGY (PHQ-9),Hospital Interns Psychological State During the COVID-19 Pandemic
NCT04669509,Completed,Observational,,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,Other,1-Apr-20,14-Dec-20,1-Oct-20,COHORT,532,COVID; LIVER INJURY; MORTALITY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",LIVER FUNCTION TESTS,7 AND 28 DAY MORTALITY,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit
NCT04669912,Completed,Observational,,Centre Hospitalier Sud Francilien,Other,15-Jan-21,22-Jan-21,22-Jan-21,COHORT,77,TYPE 1 DIABETES,FRANCE,ALL,"13 Years to 25 Years   (Child, Adult)",GLUCOSE CONTROL AND SENSOR USAGE,CHANGES IN PERCENTAGE OF TIME SPENT IN RANGE 70-180 MG/DL AFTER LOCKDOWN COMPARED TO BEFORE LOCKDOWN,Observational Study of Glycemic Control and Self-management of Young People (Aged 13 to 25 Years ) With Type 1 Diabetes During COVID-19 Lockdown.
NCT04669925,"Active, not recruiting",Observational,,Mario Negri Institute for Pharmacological Research,Other,1-Sep-20,21-Jul-21,21-Jan-21,COHORT,10000,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,DAILY CALLS TO THE EMERGENCY SYSTEM,Tsunami Project - Description and Prediction of COVID-19 Impact on the Lombardy Region's Emergency System
NCT04669938,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,4-Dec-20,31-Mar-22,31-Mar-22,CASE-ONLY,200,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OROPHARYNGEAL AND INTESTINAL MICROBIOTA,IDENTIFY RISK FACTORS ASSOCIATED WITH SEVERE FORMS OF COVID-19,Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease in Hospitalized Patients
NCT04669990,Recruiting,Observational,,Nepal Health Research Council,Other,19-Nov-20,19-Nov-21,31-Oct-21,CASE-ONLY,2000,COVID,NEPAL,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,DEMOGRAPHICS OF RECIPIENTS,Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study
NCT04670003,Not yet recruiting,Observational [Patient Registry],,Weprom,Other,21-Jan-21,21-Mar-21,21-Mar-21,COHORT,20000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",USERS,DESCRIPTION OF THE METHODS OF CONTAMINATION OF PATIENTS,Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application: an Observational Study
NCT04670094,"Active, not recruiting",Observational,,University of Milano Bicocca,Other,30-Dec-20,21-Dec-21,21-Dec-21,COHORT,2500,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY,Comorbidities and Risk Score for Severity and Outcome in Patients With Infection by SARS-CoV-2.
NCT04670328,Completed,Observational,,FMH College of Medicine and Dentistry,Other,1-May-20,31-Jul-20,31-Jul-20,CASE-ONLY,101,COVID,PAKISTAN,ALL,"17 Years to 75 Years   (Child, Adult, Older Adult)",NOT REQUIRED,"COMPLETE BLOOD COUNT- HEMOGLOBIN. WHITE BLOOD COUNT, PLATELET COUNT, NEUTROPHIL TO LYMPHOCYTE RATIO",Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity
NCT04671017,"Active, not recruiting",Interventional,Phase 1/Phase 2,Valneva Austria GmbH,Industry,16-Dec-20,21-Aug-21,15-Feb-21,PREVENTION,153,SARS-COV2 VIRUS INFECTION,UNITED KINGDOM,ALL,18 Years to 55 Years   (Adult),VLA2001,FREQUENCY AND SEVERITY OF SOLICITED AES (LOCAL AND SYSTEMIC REACTIONS) WITHIN 7 DAYS AFTER ANY VACCINATION,"A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted Sars-Cov-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects"
NCT04672291,Not yet recruiting,Interventional,Phase 1,"Oncovir, Inc.",Industry,1-Apr-21,16-Jan-24,31-Dec-23,PREVENTION,43,COVID - 19,CANADA,ALL,18 Years to 40 Years   (Adult),POLY-ICLC (HILTONOL®),"SAFETY AND TOLERABILITY, DOSE LIMITING TOXICITY","A Phase I-Ib, Double-blinded, Randomized Repeated Dose Multicenter, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults"
NCT04672343,Recruiting,Observational,,Centre Hospitalier Universitaire Dijon,Other,19-Oct-20,22-Jan-21,21-Apr-21,COHORT,300,SARS-COV2,FRANCE,ALL,70 Years and older   (Older Adult),DATA COLLECTION,DEATH,IPrognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2
NCT04672395,Not yet recruiting,Interventional,Phase 2/Phase 3,Clover Biopharmaceuticals AUS Pty Ltd,Industry,21-Mar-21,22-Jul-21,22-Jul-21,PREVENTION,22000,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",CPG 1018/ALUM-ADJUVANTED SCB-2019 VACCINE,NUMBER OF PARTICIPANTS WITH A FIRST OCCURRENCE OF COVID-19 OF ANY SEVERITY STARTING 14 DAYS AFTER SECOND DOSE OF SCB-2019,"A Double-Blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and Older"
NCT04672564,Not yet recruiting,Interventional,Phase 3,"Shenyang Tonglian Group CO., Ltd",Industry,14-Jan-21,30-Jun-21,30-Jun-21,TREATMENT,300,CORONAVIRUS DISEASE 2019,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",CARRIMYCIN,PERCENTAGE OF PATIENTS ALIVE WITHOUT NEED FOR SUPPLEMENTAL OXYGEN AND ONGOING IN PATIENT-MEDICAL CARE (SOC TREATMENT FOR COVID-19) AT DAY 28,"A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients"
NCT04672590,Not yet recruiting,Observational,,University of Liverpool,Other,21-Jan-21,21-Dec-21,21-Dec-21,CASE-CONTROL,681,DISEASES OF THE NERVOUS SYSTEM,,ALL,"18 Years and older   (Adult, Older Adult)",PRIMARY EXPOSURE IS HYPOXIA (NO INTERVENTION),ACUTE NEW-ONSET NEUROLOGICAL DISEASE,"COVID-19 Neurological Disease: A Prospective Study in Brazil, India and Malawi"
NCT04673149,Recruiting,Interventional,Phase 1/Phase 2,"GeneOne Life Science, Inc.",Industry,23-Dec-20,31-Dec-22,31-Jul-22,PREVENTION,345,SARS-COV2,"KOREA, REPUBLIC OF",ALL,"19 Years to 65 Years   (Adult, Older Adult)",GLS-5310,INCIDENCE OF ADVERSE EVENTS,"Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults"
NCT04673162,Not yet recruiting,Interventional,Phase 3,Azienda Unità Sanitaria Locale Reggio Emilia,Other,20-Dec-21,21-Jun-21,21-Apr-21,TREATMENT,260,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)","METHYLPREDNISOLONE, PLACEBO",LENGTH OF HOSPITALIZATION,"A Randomized, Multicentre, Double-blind Study to Evaluate the Efficacy of High-dose Administration of Methylprednisolone in Addition to Standard Treatment, in SARS-CoV2 (COVID-19) Pneumonia Patients"
NCT04673214,Recruiting,Interventional,Phase 3,Gilberto Cruz Arteaga,Other,16-Dec-20,12-Feb-21,2-Feb-21,TREATMENT,62,COVID,MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",AZITHROMYCIN / IVERMECTIN / RIBAROXABAN / PARACETAMOL,ESTIMATE CLINICAL SYMPTOMS BY DAYS OF FOLLOW-UP IN PATIENTS WITH COVID-19 UNDER TREATMENT WITH AZITHROMYCIN/IVERMECTIN/RIBAROXABAN/PARACETAMOL VS. AZITHROMYCIN/RIBAROXABAN/PARACETAMOL FOLLOWED BY VIDEO CALL FOR 14 DAYS FROM U.M.F 13 AND U.M.F 20,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20
NCT04673279,Recruiting,Observational [Patient Registry],,Hospital Italiano de Buenos Aires,Other,2-Dec-20,1-Jul-21,10-Apr-21,COHORT,189,CORONAVIRUS DISEASE 2019,ARGENTINA,ALL,"14 Years to 90 Years   (Child, Adult, Older Adult)",SEROLOGY,TO ESTIMATE THE PROPORTION OF PEOPLE WITH POSITIVE IGG ANTIBODIES FOR COVID-19 WHO HAVE POSITIVE IGG ANTIBODIES AFTER 5 MONTH OF THE FIRST MEASUREMENT,"Long-term Persistence of Immunoglobulin G Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Vulnerable Neighbourhood in Buenos Aires, Argentina"
NCT04673292,Enrolling by invitation,Interventional,Not Applicable,Johns Hopkins University,Other,8-Feb-21,21-Aug-21,21-Aug-21,SCREENING,3000,CORONAVIRUS INFECTION,UNITED STATES,ALL,"5 Years and older   (Child, Adult, Older Adult)",FIXED SITE STANDARD OF CARE TESTING,TIME TO RECEIPT OF SARS COV-2 TESTING RESULTS,Community Collaboration to Combat COVID-19
NCT04673318,Not yet recruiting,Interventional,Not Applicable,"University of Massachusetts, Amherst",Other,21-Jan-21,23-Dec-21,23-Dec-21,BASIC SCIENCE,87,COVID,,ALL,"55 Years to 85 Years   (Adult, Older Adult)",HEAT THERAPY,GAIT SPEED,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy
NCT04673331,Recruiting,Observational,,Hacettepe University,Other,4-Nov-20,4-Nov-21,4-Nov-21,CASE-CONTROL,24,CYSTIC FIBROSIS,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",EXERCISE CAPACITY,PHYSICAL ACTIVITY LEVEL-INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE,"Comparison of Physical Activity, Exercise Capacity, Quality of Life, Cognitive Function and Coronavirus Phobia Levels of Adult Cystic Fibrosis Patients With Healthy Individuals With Telerehabilitation in the COVID-19 Pandemic"
NCT04674189,Recruiting,Interventional,Phase 3,CureVac AG,Industry,23-Dec-20,30-Apr-22,30-Jun-21,PREVENTION,2520,CORONAVIRUS,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",CVNCOV VACCINE,NUMBER OF PARTICIPANTS WITH MEDICALLY-ATTENDED ADVERSE EVENTS,"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)"
NCT04674410,"Active, not recruiting",Observational,,National Institutes of Health Clinical Center (CC),NIH,1-Mar-20,28-Feb-21,31-Jan-21,COHORT,100000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ANTIBIOTIC,IN-HOSPITAL MORTALITY OR DISCHARGE TO HOSPICE,Utility of Empiric Antibiotics on Admission for Non-intubated Patients With Novel Coronavirus Diseases 2019 (COVID-19): A Retrospective Cohort Study of Electronic Health Records
NCT04674553,Completed,Observational,,"Services Institute of Medical Sciences, Pakistan",Other,10-Nov-20,10-Dec-20,10-Dec-20,OTHER,100,OBESITY,PAKISTAN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,IN-HOSPITAL MORTALITY,Effect of Obesity Among COVID-19 Patients in Critical Care Settings
NCT04674566,Not yet recruiting,Interventional,Phase 1/Phase 2,Corat Therapeutics Gmbh,Industry,31-Jan-21,30-Apr-21,30-Apr-21,TREATMENT,45,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COR-101,PROPORTION OF PATIENTS WITH TREATMENT-EMERGENT ADVERSE EVENTS (TEAES),"Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, First-in-human, Phase Ib/II Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of COR-101 in Hospitalized Patients"
NCT04674644,Completed,Interventional,Not Applicable,Suleyman Demirel University,Other,16-Oct-20,23-Oct-20,23-Oct-20,OTHER,850,COVID PANDEMIC,TURKEY,ALL,"23 Years and older   (Adult, Older Adult)",THE PSYCHOSOCIAL EFFECTS OF COVID-19 PANDEMIC ON DENTAL PROFESSIONALS,THE PSYCHOSOCIAL EFFECTS OF COVID-19 PANDEMIC ON DENTAL PROFESSIONALS USING THE TURKISH VERSION OF THE FEAR OF COVID-19 SCALE,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department
NCT04675086,Withdrawn,Interventional,Phase 3,"Blessing Corporate Services, Inc",Other,21-Jan-21,21-Dec-21,21-Sep-21,TREATMENT,0,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ALPHA1-PROTEINASE INHIBITOR,DURATION OF NEW NON-INVASIVE VENTILATION OR HIGH FLOW OXYGEN USE (MEASURED BY DAYS),"A Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP, an Alpha-1 Antitrypsin Infusion Therapy With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection"
NCT04675281,Recruiting,Observational,,Nantes University Hospital,Other,24-Apr-20,24-Apr-21,24-Apr-21,COHORT,100,SARS-COV2,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",2 POST-MORTEM TRANSCUTANEOUS LUNG BIOPSIES (1 ANTERIOR ; 1 POSTERIOR) USING ANATOMICAL LANDMARKS,ANALYSIS OF THE PATHOLOGICAL FINDINGS OF A LARGE COHORT OF PATIENTS WHO DIED FROM COVID-19 IN THE ICU,Pathological Findings in Critically-ill Patients Who Died From SARS-CoV-2 Related Acute Respiratory Distress Syndrome
NCT04676867,Recruiting,Interventional,Phase 2,DalCor Pharmaceuticals,Industry,11-Jan-21,21-Mar-21,21-Feb-21,TREATMENT,208,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",DALCETRAPIB,TO EVALUATE THE TIME TO SUSTAINED CLINICAL RESOLUTION OF SYMPTOMS OF COVID-19,"A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19"
NCT04676971,Recruiting,Interventional,Phase 2,"ImmuneMed, Inc.",Industry,11-Dec-20,18-Oct-21,7-Jul-21,TREATMENT,105,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HZVSF-V13,CLINICAL FAILURE AT DAY 28,"Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study"
NCT04677270,Completed,Interventional,Not Applicable,Karolinska Institutet,Other,31-Aug-20,30-Nov-20,30-Nov-20,OTHER,397,PROBLEM SOLVING,SWEDEN,ALL,"16 Years and older   (Child, Adult, Older Adult)",DIGITAL PROBLEM SOLVING TOOL,SYSTEM USABILITY SCALE,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic
NCT04677283,Recruiting,Observational,,Gérond'if,Other,5-Apr-20,21-Mar-21,20-Dec-21,COHORT,2020,SYMPTOMS RELATED TO COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"TO DEFINE POSITIVE CASES OF CORONAVIRUS BY ""POLYMERASE CHAIN REACTION"" RESULTS AND SYMPTOMATOLOGIES","Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France."
NCT04677478,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,20-Dec-21,22-Jan-21,22-Jan-21,COHORT,20,TUBERCULOSIS,,ALL,"18 Years and older   (Adult, Older Adult)",IMPACT OF RESPIRATORY ISOLATION ON QUALITY OF LIFE,QUALITY OF LIFE USING SEMI-STRUCTURED INTERVIEW.,Impact of the Respiratory Isolation on the Quality of Life in Patients Hospitalized for Tuberculosis or COVID-19
NCT04677660,"Active, not recruiting",Interventional,Phase 1/Phase 2,Takeda,Industry,21-Jan-21,3-Mar-22,3-Mar-22,PREVENTION,200,PREVENTION OF INFECTIOUS DISEASE CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2),JAPAN,ALL,"20 Years and older   (Adult, Older Adult)",TAK-919,PERCENTAGE OF PARTICIPANTS WITH REPORTED SOLICITED LOCAL ADVERSE EVENTS (AES) FOR 7 DAYS FOLLOWING EACH VACCINATION,"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-919 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)"
NCT04677842,"Active, not recruiting",Observational [Patient Registry],,PENTA Foundation,Other,1-Jan-13,1-Jan-25,11-Nov-20,COHORT,10000,HIV INFECTIONS,,ALL,up to 17 Years   (Child),ART THERAPY,CD4 COUNT IN ADULTHOOD OF YOUNG PEOPLE WITH HIV ASSESSED USING ROUTINE CLINICAL DATA,European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC): Paediatric Protocol
NCT04678024,Enrolling by invitation,Observational,,Istituto Ortopedico Galeazzi,Other,18-Nov-20,21-Nov-21,21-Aug-21,COHORT,410,COVID,ITALY,ALL,"Child, Adult, Older Adult",,SENSITIVITY,Multicentric Sensitivity Assessment of Antibody Diagnostic Tests Developed for Diagnosis of SARS-CoV2 Infection
NCT04678193,Enrolling by invitation,Observational [Patient Registry],,"Aventyn, Inc.",Industry,24-Dec-20,30-Jun-22,30-Jun-21,COHORT,27000,COVID,INDIA,ALL,"18 Years and older   (Adult, Older Adult)",COROMEC REGISTRY WITH ECL-19,PREDICTORS OF POST COVID-19 COMPLICATIONS AND PREDICTORS OF HOSPITALIZATION,COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy
NCT04678687,"Active, not recruiting",Interventional,Not Applicable,Dokuz Eylul University,Other,1-Jan-21,1-Jan-22,1-Jun-21,DIAGNOSTIC,10,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)","LIVER, LUNG, HEART AND KIDNEY BIOPSY",THE LEVEL OF HISTOPATHOLOGICAL CHANGES,Evaluation of Postmortem Biopsy Specimens of COVID-19 Cases
NCT04678700,Recruiting,Interventional,Not Applicable,European University of Madrid,Other,1-Mar-21,1-Aug-21,1-Jun-21,TREATMENT,40,COVID- CORONAVIRUS- SARS-COV2,SPAIN,ALL,"18 Years to 70 Years   (Adult, Older Adult)",CHEST PHYSIOTHERAPY POST-COVID19,EUROQOL-5D EUROPEAN QUALITY OF LIFE-5 DIMENSIONS,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance
NCT04678739,Recruiting,Interventional,Phase 3,M Abdur Rahim Medical College and Hospital,Other,15-Aug-20,28-Feb-21,30-Jan-21,TREATMENT,150,COVID,BANGLADESH,ALL,"16 Years to 80 Years   (Child, Adult, Older Adult)",REMDESIVIR,TIME TO CLINICAL IMPROVEMENT (TTCI),Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04678778,Recruiting,Interventional,Not Applicable,University of Southern California,Other,19-Mar-19,17-Feb-21,17-Feb-21,OTHER,11,HEALTHY AGING,UNITED STATES,ALL,"50 Years to 85 Years   (Adult, Older Adult)",PHYSICAL AND COGNITIVE ACTIVITY,MAGNETIC RESONANCE IMAGE (MRI) BRAIN SCAN OF HIPPOCAMPAL VOLUME (CUBIC MM),Targeted Physical and Cognitive Activity in a VR Environment - COVID-19 Protocol
NCT04678830,Not yet recruiting,Interventional,Phase 2,"CytoDyn, Inc.",Industry,21-Jan-21,23-Jul-21,23-Jun-21,TREATMENT,102,CORONAVIRUS DISEASE 2019,,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBOS,CHANGE FROM BASELINE IN FATIGUE SEVERITY SCORE AT DAY 28,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]"
NCT04678843,Not yet recruiting,Interventional,Early Phase 1,Jennifer Couturier,Other,21-Jan-21,21-Dec-21,21-Oct-21,TREATMENT,36,ANOREXIA NERVOSA,,ALL,"10 Years to 18 Years   (Child, Adult)",VIRTUAL FAMILY-BASED TREATMENT,KEY COMPONENTS OF FBT,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond
NCT04679168,Recruiting,Observational [Patient Registry],,Seoul National University Hospital,Other,1-Jun-20,31-Dec-21,31-Dec-21,COHORT,310,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",,IDENTIFICATION OF ENVIRONMENTAL HAZARD EXPOSURE LEVELS AND INFLUENCING FACTORS,Change of Environmental Chemical Exposures and Prevalence of Chronic Kidney Disease After Epidemiological Spread of SARS-CoV-2 (COVID-19)
NCT04679272,Completed,Observational,,"University Hospital, Montpellier",Other,1-Dec-20,1-Feb-21,30-Jan-21,COHORT,2000,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,HOSPITALIZATION RATES FOR COVID-19,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA
NCT04679350,Not yet recruiting,Interventional,Phase 2,"ImmuneMed, Inc.",Industry,21-Mar-21,21-Jul-21,21-Jun-21,TREATMENT,48,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",HZVSF-V13,CHANGES FROM BASELINE IN THE CLINICAL IMPROVEMENT SCORE ON AN 8-POINT SCALE AT DAY 21,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients"
NCT04679415,Recruiting,Interventional,Phase 2,"ImmuneMed, Inc.",Industry,17-Dec-20,21-May-21,21-Apr-21,TREATMENT,63,COVID,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",HZVSF-V13,CLINICAL FAILURE RATE AT DAY 28,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients"
NCT04679428,Recruiting,Observational,,The University Clinic of Pulmonary and Allergic Diseases Golnik,Other,7-May-20,7-May-23,7-May-22,CASE-ONLY,230,COVID,SLOVENIA,ALL,"18 Years and older   (Adult, Older Adult)",,IMMUNOLOGICAL CHANGES DURING AND AFTER COVID-19 INFECTION,Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus
NCT04679493,Not yet recruiting,Interventional,Phase 1,NP Therapeutics,Other,20-Dec-21,21-Feb-21,21-Feb-21,TREATMENT,16,COVID,RUSSIAN FEDERATION,MALE,18 Years to 45 Years   (Adult),XC7 100 MG SINGLE,NUMBER OF ADVERSE EVENTS (AES) PER TREATMENT ARM,"Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers"
NCT04679584,Recruiting,Observational,,University Hospital Schleswig-Holstein,Other,16-Nov-20,31-Dec-30,31-Dec-21,COHORT,2000,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATION OF DIFFERENT COURSES OF SARS-COV-2 INFECTION IN DIFFERENT PHASES (ACUTE VS. POST-ACUTE) AND SETTINGS,LONGTERM MORBIDITIES AND SEQUELS OF SARS-COV-2 INFECTIONS IN THE GENERAL POPULATION,COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP)
NCT04679909,Recruiting,Interventional,Phase 1,"Altimmune, Inc.",Industry,21-Feb-21,22-Feb-21,22-Feb-21,PREVENTION,180,HEALTHY VOLUNTEERS,UNITED STATES,ALL,18 Years to 55 Years   (Adult),ADCOVID,REACTOGENICITY,"A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses"
NCT04680819,Not yet recruiting,Observational [Patient Registry],,Ataturk University,Other,25-Dec-20,25-Jan-21,25-Jan-21,COHORT,50,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ANATOLIAN PROPOLIS,COVID-19 POSITIVE,Evaluation of the Effect of Anatolian Propolis on Covid-19 in Healthcare Professionals
NCT04680858,Enrolling by invitation,Interventional,Not Applicable,University of Ulm,Other,1-Jul-20,15-Feb-21,31-Jan-21,HEALTH SERVICES RESEARCH,500,ENDOSCOPY,GERMANY,ALL,"18 Years to 68 Years   (Adult, Older Adult)",DECT,COMMUNICATION ASSOCIATED ADVERSE EVENTS,Impact of Digital Enhanced Telecommunication for Team Communication in Endoscopic Procedures During COVID-19 Pandemic
NCT04680949,Recruiting,Interventional,Phase 3,Hellenic Institute for the Study of Sepsis,Other,23-Dec-20,20-Dec-21,20-Sep-21,TREATMENT,600,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",ANAKINRA,COMPARISON OF THE DISTRIBUTION OF FREQUENCIES OF EACH SCORE OF A 5-SCALE PATIENT STATE EVALUATED FROM THE 11-POINT WHO CLINICAL PROGRESSION ORDINAL SCALE (CPS) BETWEEN THE TWO ARMS OF TREATMENT,"suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial"
NCT04681001,Recruiting,Interventional,Not Applicable,Marinomed Biotech AG,Industry,20-Dec-20,30-Jun-21,30-May-21,PREVENTION,300,RESPIRATORY VIRAL INFECTION,AUSTRIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NASAL SPRAY,PRESENCE OF COVID-19 SYMPTOMS INCLUDING SYMPTOMS OF RESPIRATORY VIRAL INFECTION DOCUMENTED IN A DIARY,Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients
NCT04681040,Recruiting,Observational,,"National Center for Global Health and Medicine, Japan",Other,19-Dec-20,31-Aug-22,31-Mar-22,COHORT,1000,COVID,BRAZIL,ALL,"20 Years and older   (Adult, Older Adult)",,RISK STRATIFICATION OF COVID-19 PARTICIPANTS USING URINE BIOMARKERS,Monitoring of COVID-19 Using Urine POC Kit
NCT04681053,Recruiting,Interventional,Phase 3,Mansoura University,Other,25-Feb-21,31-Dec-21,30-Apr-21,TREATMENT,80,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",IVERMECTIN POWDER,RATE OF VIROLOGICAL CURE BY RT -PCR FOR COVID -19 USING IVERMECTIN WHEN COMPARED TO STANDARD TREATMENT,Efficacy and Safety of Inhaled Ivermectin in the Treatment of SARS-COV-2 (COVID-19)
NCT04681079,Not yet recruiting,Observational,,Theravance Biopharma,Industry,21-Jan-21,21-Feb-21,21-Feb-21,OTHER,10,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ALBUTEROL SULFATE (MDI),VIRAL LOAD,"A 2-Period, Crossover Study to Assess the Impact of Nebulizer With Filtered Mouthpiece vs MDI With Spacer on Viral Load in Rooms of Subjects With Mild to Moderate COVID-19"
NCT04681092,Not yet recruiting,Interventional,Phase 1/Phase 2,University Medical Center Groningen,Other,18-Jan-21,30-Jun-21,30-Apr-21,PREVENTION,130,COVID,NETHERLANDS,ALL,18 Years to 55 Years   (Adult),AKS-452,SAFETY / TOLERABILITY,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study
NCT04681157,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,3-Apr-20,3-Apr-21,3-Apr-21,CASE-ONLY,300,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE ANALYSIS OF DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SUSPECTED OR ALREADY CONFIRMED SARS-COV2 INFECTION WITH ANOSMIA AND / OR AGEUSIA,Retrospective Study on Anosmias and Ageusias Linked to Infection by SARS-Cov 2
NCT04681261,Completed,Observational,,Hacettepe University,Other,4-May-20,4-Jun-20,4-Jun-20,COHORT,699,COVID,TURKEY,ALL,"19 Years to 65 Years   (Adult, Older Adult)",THIS STUDY IS NOT AN INTERVENTION STUDY,OCCUPATIONAL BALANCE QUESTIONNAIRE,"Evaluation of Occupational Balance, Fear and Agoraphobia in Adults"
NCT04681365,Not yet recruiting,Observational,,Manchester University NHS Foundation Trust,Other,1-Feb-21,2-Jun-21,1-May-21,COHORT,66,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",STAFF WILL WEAR AND EVALUATE BUBBLE-PAPR (NON-CE MARKED PAPR),THE PRIMARY ENDPOINT IS THAT PARTICIPATING STAFF RATE BUBBLE PAPR TO BE MORE COMFORTABLE THAN CURRENT PPE.,A Phase I Study of an 'In-house' Developed Prototype Powered Air Purifying Respirator (PAPR) for Use as Personal Protective Equipment (PPE) for Healthcare Workers (Bubble PAPR)
NCT04681430,Recruiting,Interventional,Phase 2,"Heinrich-Heine University, Duesseldorf",Other,8-Jan-21,21-Nov-21,21-May-21,TREATMENT,1094,CORONAVIRUS INFECTION,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,WHO ORDINAL COVID-19 SCALE UP TO DAY 28,Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals
NCT04681755,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,19-May-20,19-May-21,19-May-21,CASE-ONLY,55,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE ANALYSIS OF THE NEUROLOGICAL DISORDER AFTER SEVERE SARS-COV-2 INFECTION,Rehabilitation Required Due to Functional Neurological Impairment and Respiratory Disorders After Severe SARS-CoV-2 Infection in ICU Units
NCT04681859,Not yet recruiting,Interventional,Not Applicable,Bangladesh University of Engineering and Technology,Other,30-Dec-20,1-May-21,1-Apr-21,TREATMENT,40,COVID,BANGLADESH,ALL,18 Years to 60 Years   (Adult),HIGH FLOW NASAL OXYGEN (HFNO) TREATMENT,NUMBER OF VENTILATOR-FREE DAYS,Safety and Efficacy Evaluation of a Low-cost CPAP Device for Hypoxemic COVID-19 Patients: A Pilot Study
NCT04681950,Recruiting,Observational,,Biocerna LLC,Industry,24-Nov-20,31-Dec-20,30-Dec-20,CASE-ONLY,500,SUBJECTS POSSIBLY EXPOSED TO COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,MATCHING RESULTS FROM DIFFERENT COLLECTION TYPES,Assessment of Unsupervised Self-Collected Saliva Sample Compared to Clinician CollectedSaliva Sample and Clinician Collected Anterior Nares Sample in a COVID-19 and Influenza A/Influenza B Screening Program
NCT04682041,Recruiting,Interventional,Not Applicable,"Entera Health, Inc",Industry,22-Dec-20,30-Jun-21,30-Jun-21,TREATMENT,420,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BOVINE PLASMA-DERIVED IMMUNOGLOBULIN CONCENTRATE,CHANGE IN PLASMA IL-6 LEVELS,"Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention Containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People With COVID-19"
NCT04682093,Enrolling by invitation,Observational,,European Society for Emergency Medicine (EUSEM) Research Network,Other,9-Mar-20,28-Feb-21,31-Jan-21,COHORT,8000,COVID,CROATIA,ALL,"18 Years to 130 Years   (Adult, Older Adult)",,HOSPITALIZATION,Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED (EUROCOV Study)
NCT04682132,"Active, not recruiting",Observational,,Polk County Fire Rescue,Other,26-May-20,21-Jan-21,31-Dec-20,COHORT,686,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","COVID-19 ANTIGEN AND ANTIBODY TESTS, AND INFLUENZA RAPID TEST",PREVALENCE OF COVID-19 AMONGST COUNTY EMERGENCY PERSONNEL,County-wide Emergency Personnel Assessment of COVID-19 and Influenza Status
NCT04682197,Not yet recruiting,Interventional,Not Applicable,Wake Forest University Health Sciences,Other,21-Apr-21,22-Apr-21,22-Apr-21,SUPPORTIVE CARE,100,HEALTH PERSONNEL,,ALL,"18 Years and older   (Adult, Older Adult)",CERESET RESEARCH,CHANGE IN IMPACT OF EVENT SCALE-REVISED (IES-R),Cereset Research To Reduce Stress And Anxiety In Healthcare Workers In The Time Of COVID-19
NCT04682548,Recruiting,Observational,,NYU Langone Health,Other,5-Jan-21,21-Dec-21,21-Dec-21,COHORT,1000,MULTIPLE SCLEROSIS,UNITED STATES,ALL,18 Years to 60 Years   (Adult),,SEROPOSITIVIE RATE AGAINST SARS-COV-2,"Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls"
NCT04682561,Not yet recruiting,Interventional,Not Applicable,Unity Health Toronto,Other,21-Jan-21,22-Feb-21,22-Jan-21,TREATMENT,40,STRESS,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SUPPORTIVE TRAUMA EXPOSURE PREPARATION PROGRAM,CHANGES FROM BASELINE TO POST-INTERVENTION (8 WEEKS) IN HEALTHCARE WORKER BURNOUT USING PROFESSIONAL QUALITY OF LIFE: COMPASSION SATISFACTION AND FATIGUE VERSION 5 (PROQOL) BURNOUT SUBSCALE,The STEP Program: Building Trauma Resilience Among Nurses and Personal Support Workers at Providence Healthcare During and Beyond the COVID-19 Pandemic
NCT04682574,Recruiting,Interventional,Not Applicable,University of Lahore,Other,2-Nov-20,10-Jan-21,30-Dec-20,TREATMENT,15,CORONAVIRUS INFECTION,PAKISTAN,ALL,"Child, Adult, Older Adult",VITAMIN C,PARTIAL PRESSURE OF OXYGEN IN ARTERIAL BLOOD TO FRACTION OF INSPIRED OXYGEN (P/F RATIO),Efficacy of Mega Dose Vitamin C in Critically Ill COVID-19 Patients
NCT04682873,Recruiting,Interventional,Phase 3,"Joint Stock Company ""Farmak""",Industry,15-May-20,1-Jul-21,1-Jun-21,TREATMENT,700,COVID DISEASE,UKRAINE,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ENISAMIUM IODIDE,EFFICACY - TIME FROM DAY 1 (RANDOMIZATION AND TREATMENT START) TO CLINICAL CHANGE,"A Multi-centre, Double-blind, Randomised, Placebo-controlled, Trial to Assess the Efficacy and Safety of Amizon® Max, Manufactured by Farmak JSC, in Combination With Basic Treatment, in Subjects With Moderate Covid-19"
NCT04682912,Recruiting,Observational,,Mersin Training and Research Hospital,Other,30-Jan-21,21-Feb-21,21-Feb-21,COHORT,2000,COVID INFECTION,TURKEY,ALL,"1 Month to 18 Years   (Child, Adult)",,PATIENT MEDICAL FILES,ABO-Rh Blood Types and COVID-19 Infection in Children: Is There a Link?
NCT04683224,Not yet recruiting,Interventional,Phase 2/Phase 3,COVAXX,Industry,1-Feb-21,22-Mar-23,22-Mar-23,PREVENTION,7320,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",UB-612,"THE INCIDENCE OF LOCAL REACTIONS, SOLICITED SYSTEMIC EVENTS, AES, MAAES, SAES AND AESIS","A Phase 2/3 Randomized, Multicenter, Double-Blind, Placebo Controlled, Dose-Response Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 Vaccine in Adults"
NCT04683328,Not yet recruiting,Interventional,Phase 2/Phase 3,Sinocelltech Ltd.,Industry,25-Feb-21,25-Nov-21,25-May-21,TREATMENT,560,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SCTA01,ALL-CAUSE MORTALITY RATE AT D29,"An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)"
NCT04683484,Recruiting,Interventional,Phase 1/Phase 2,Nanogen Pharmaceutical Biotechnology Joint Stock Company,Industry,10-Dec-20,10-Aug-21,10-Jun-21,PREVENTION,620,COVID,VIETNAM,ALL,"12 Years to 75 Years   (Child, Adult, Older Adult)",NANOCOVAX,SOLICITED ADVERSE EVENTS,"Clinical Trials of Phase 1, 2 of Nanocovax Manufactured by Nanogen"
NCT04683744,Recruiting,Observational,,Indiana University,Other,21-Jan-21,23-Jul-21,23-Jul-21,OTHER,100,COLORECTAL CANCER SCREENING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SEMI-STRUCTURED INTERVIEWS-PATIENTS,"IDENTIFY FACILITATORS AND BARRIERS TO IMPLEMENTING DECISION AIDS, PROVIDER NOTIFICATIONS, AND PERSONAL RISK CALCULATION USING AN ELECTRONIC HEALTH RECORD TO PROMOTE COLORECTAL CANCER SCREENING.",Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
NCT04684433,Recruiting,Observational,,Brugmann University Hospital,Other,14-Apr-20,31-Dec-20,31-Dec-20,COHORT,707,COVID,BELGIUM,ALL,"Child, Adult, Older Adult",DATA EXTRACTION FROM MEDICAL FILES,SURGERY CODE,Surgery in the Time of COVID-19 Pandemic
NCT04684446,Not yet recruiting,Interventional,Phase 1/Phase 2,AstraZeneca,Industry,16-Mar-21,16-Nov-21,16-Nov-21,PREVENTION,100,COVID,,ALL,"18 Years to 130 Years   (Adult, Older Adult)",AZD1222,INCIDENCE OF LOCAL AND SYSTEMIC SOLICITED AES FOR 7 DAYS POST EACH DOSE INCIDENCE OF UNSOLICITED AES FOR 28 DAYS POST EACH DOSE INCIDENCE OF SAES AND AESIS TO 28 DAYS POST SECOND DOSE,"A Phase I/II Open-label Randomized Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, Given in Combination With rAd26-S, Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for the Prevention of COVID 19"
NCT04684550,Not yet recruiting,Interventional,Phase 2/Phase 3,Hospital Universitario San Ignacio,Other,15-Feb-21,15-Aug-21,15-Jun-21,PREVENTION,556,SARS-COV INFECTION,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",STABILIZED HYPOCHLOROUS ACID,PREVENTION OF INFECTION BY COVID19,Randomized Controlled Clinical Study (RCT) Phase 3 of the Safety and Efficacy of Hypochlorous Acid in the Prophylaxis of Healthcare Personnel at High Risk of Infection by SARS-CoV2 (COVID19) Versus Placebo
NCT04684602,Recruiting,Interventional,Phase 1/Phase 2,Thomas Advanced Medical LLC,Industry,9-Jul-20,9-Dec-30,9-Jul-30,TREATMENT,5000,AUTOIMMUNE DISEASES,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PRIMEPRO™/ PRIMEMSK™,ASSESSMENT OF QUALITY OF LIFE (QOL) VIA 36-ITEM SHORT FORM SURVEY (SF-36) CHANGE FROM BASELINE AT 6 AND 12 MONTHS.,"Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions"
NCT04684615,Enrolling by invitation,Observational,,National Institute of Mental Health (NIMH),NIH,4-Mar-21,31-Jul-22,31-Jul-22,COHORT,1000,DEPRESSION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,"TO DESCRIBE THE RELATIONSHIP BETWEEN STRESSORS RELATED TO COVID-19, SELF-RATED MEASURES OF MENTAL HEALTH SYMPTOMS, AND DISTRESS AMONG A RANGE OF PARTICIPANTS INCLUDING VARIOUS PATIENT POPULATIONS AND HEALTHY VOLUNTEERS.",Mental Health Impact of the COVID-19 Pandemic on Amish and Mennonite Participants in AMBiGen
NCT04684836,Not yet recruiting,Observational,,Weill Medical College of Cornell University,Other,21-Feb-21,23-Dec-21,22-Apr-21,COHORT,216000,ASTHMA,UNITED STATES,ALL,"19 Years and older   (Adult, Older Adult)","EXPOSURE TO TELEMEDICINE, AFTER THE ONSET OF THE PANDEMIC",NUMBER OF AVOIDABLE EMERGENCY DEPARTMENT (ED) ADMISSIONS,Evaluating the Comparative Effectiveness of Telemedicine in Primary Care: Learning From the COVID-19 Pandemic
NCT04685213,Recruiting,Interventional,Phase 1,Baylor College of Medicine,Other,18-Aug-20,18-Aug-21,18-Aug-21,SUPPORTIVE CARE,20,COVID,UNITED STATES,ALL,"18 Years to 100 Years   (Adult, Older Adult)",ELECTRICAL STIMULATION,CHANGE IN MUSCLE FUNCTION,Electrical Stimulation Therapy for Preventing Hospital-acquired Weakness in Critically Ill COVID-19 Patients - A Proof of Concept Randomized Controlled Trial
NCT04685447,Recruiting,Interventional,Not Applicable,Universita degli Studi di Genova,Other,16-Mar-20,1-Mar-21,20-Apr-20,OTHER,30,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",EXPANDED HEMODIALYSIS FOR COVID19 MAINTENANCE HEMODIALYSIS PATIENTS,"LONGITUDINAL CHANGES OF INTERLEUKIN-6 (IL-6), INTERLEUKIN-8 (IL-8), INTERLEUKIN-10 (IL-10), AND INTERFERON-GAMMA (IFN-Γ) PLASMA LEVELS DURING COVID19 IN HEMODIALYSIS PATIENTS",Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients Affected by COVID-19: Effects of 2 Different Dialysis Strategies
NCT04685512,Recruiting,Interventional,Phase 2/Phase 3,"University Hospital, Caen",Other,18-Nov-20,1-Apr-21,1-Apr-21,TREATMENT,180,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",TENOFOVIR DISOPROXIL AND EMTRICITABINE,PHASE 2B: REDUCTION OF SARS-COV2 VIRAL LOAD ASSESSED BY CT PCR AT DAY-4 ADJUSTED ON CT PCR SARS-COV2 VIRAL LOAD AT BASELINE (ANCOVA),Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial
NCT04685603,Recruiting,Interventional,Phase 1,Indonesia-MoH,Other,7-Dec-20,31-Jan-22,31-Jan-21,PREVENTION,27,COVID,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",AV-COVID-19,FREQUENCY OF SOLICITED LOCAL AND SYSTEMIC REACTOGENICITY ADVERSE EVENTS (AES),"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies"
NCT04685629,Recruiting,Observational,,"University Hospital, Antwerp",Other,7-May-20,22-Dec-21,22-May-22,COHORT,50,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",25 POST ICU-PATIENTS,HEALTH RELATED QUALITY OF LIFE (GENERAL WELL-BEING) QUESTIONNAIRE,Long-term Follow-up of Covid-19 Patients in Their Home Environment After Hospitalization in a Covid Department or Intensive Care Unit
NCT04685655,Recruiting,Interventional,Not Applicable,Heidelberg University,Other,7-Jan-20,31-Dec-22,31-Dec-21,TREATMENT,228,THERAPEUTIC PLASMA EXCHANGE,GERMANY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE,SURVIVAL,RescuE pLAsma eXchange in Severe COVID-19 (RELAX Severe COVID-19)
NCT04685681,Not yet recruiting,Interventional,Not Applicable,State University of New York at Buffalo,Other,1-Jan-21,31-Mar-21,31-Mar-21,PREVENTION,50,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HIKING CHALLENGE,FREQUENCY OF LOWER-RISK ACTIVITIES,Examining Adults' Activity Choices During COVID-19: The UB GO Study
NCT04686409,Not yet recruiting,Observational,,University of Ulm,Other,11-Jan-21,31-Aug-22,31-Jan-22,CASE-ONLY,500,ADVERSE EVENTS IN COVID VACCINATION,GERMANY,ALL,"18 Years to 95 Years   (Adult, Older Adult)",COVID-19 VACCINES,NUMBER OF PARTICIPANTS WITH TREATMENT-RELATED SIDE EFFECTS,App-based Symptom Tracking After Corona Vaccination (CoCoV)
NCT04686539,Not yet recruiting,Interventional,Phase 1,Sheba Medical Center,Other,20-Dec-20,22-Jan-21,21-Nov-21,TREATMENT,50,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",CBD,CLINICAL DETERIORATION,Synthetic CBD Oil Droplets as a Therapy for Mild to Moderate SARS-CoV-2 Infection. Assesment of Efficacy and Safety.
NCT04686565,Recruiting,Observational,,Diskapi Yildirim Beyazit Education and Research Hospital,Other,15-Feb-20,28-Feb-21,28-Feb-21,CASE-ONLY,100,CEREBRAL PALSY,TURKEY,ALL,"3 Years to 18 Years   (Child, Adult)",,THE STATUS OF THE CHILD TO BENEFIT FROM HEALTH-EDUCATION SERVICES,Evaluation The Effect of The Covid-19 Pandemic on Children With CerebralPalsy and The Caregivers' Quality of Life
NCT04686578,Recruiting,Observational,,Diskapi Yildirim Beyazit Education and Research Hospital,Other,1-Dec-20,28-Feb-21,15-Feb-21,CASE-CONTROL,100,FIBROMYALGIA,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,LEVEL OF COVID-19 ANXIETY,"Investigation the Effect of Covid-19 Fear, Anxiety on Daily Life, Sleep Quality, and Anxiety-depression of the Patients With Fibromyalgia"
NCT04686708,Completed,Observational,,Gulhane Training and Research Hospital,Other,11-Mar-19,11-Sep-20,11-Sep-20,COHORT,750,EMERGENCIES,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",EMERGENCY GENERAL SURGICAL ADMISSIONS,INCIDENCE OF GENERAL SURGICAL EMERGENCIES,Impact of the COVID-19 Pandemic on Emergency General Surgery Outcomes: a Single-center Cohort Study
NCT04686721,Recruiting,Observational [Patient Registry],,Istituto Clinico Humanitas,Other,20-Dec-20,21-Oct-21,21-Sep-21,CASE-CONTROL,200,TRACHEAL STENOSIS,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",CHEST CT SCAN + BASELINE SPIROMETRY,INCIDENCE OF TRACHEAL STENOSIS FOLLOWING EITHER PROLONGED INTUBATION OR TRACHEOSTOMY IN COVID-19 PATIENTS,"A Retrospective and Prospective Observational, Multicentric, Case-control Clinical Study for the Evaluation of Tracheal Stenosis Among Patients With COVID-19 and Prolonged Intubation or Tracheostomy."
NCT04686734,Not yet recruiting,Observational,,"University Hospital, Akershus",Other,6-Jan-21,21-Oct-21,21-Apr-21,COHORT,500,COVID,,ALL,"12 Years to 25 Years   (Child, Adult)",NO ACTIVE INTERVENTION (OBSERVATIONAL ONLY),FATIGUE,Long-term Effects of COVID-19 in Adolescents
NCT04686747,Enrolling by invitation,Observational,,S.M. Misericordia Hospital,Other,21-Jan-21,30-Jun-21,1-Mar-21,COHORT,2000,PANCREATIC CANCER,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,"RATE OF ADVANCED ESOPHAGEAL, GASTRIC, PANCREATIC AND COLORECTAL CANCER IN 2020 COMPARED TO 2019.",COVID - 19 and Advanced Gastro-intestinal Cancer Treatment
NCT04686760,Recruiting,Interventional,Not Applicable,University of Lahore,Other,15-Nov-20,15-Jan-21,15-Jan-21,TREATMENT,30,CORONAVIRUS INFECTION,PAKISTAN,ALL,"Child, Adult, Older Adult",NITROGLYCERIN,RATIO OF PARTIAL PRESSURE OF OXYGEN IN ARTERIAL BLOOD TO FRACTION OF INHALED OXYGEN,Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients
NCT04686773,Not yet recruiting,Interventional,Phase 2,R-Pharm,Industry,10-Feb-21,20-Sep-21,9-Apr-21,PREVENTION,100,COVID,AZERBAIJAN,ALL,"18 Years to 100 Years   (Adult, Older Adult)",AZD1222,INCIDENCE OF SERIOUS ADVERSE EVENTS (SAES) POST FIRST DOSE UNTIL THE STUDY END,"A Phase II Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, Given in Combination With rAd26-S, Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for the Prevention of COVID 19"
NCT04687488,Completed,Interventional,Not Applicable,Universitaire Ziekenhuizen Leuven,Other,23-Jul-20,9-Nov-20,9-Nov-20,OTHER,15,AEROSOL GENERATION AND DROPLET DISPERSION AND DEPOSITION DURING NASO-GASTRIC INTUBATION FOR GASTROINTESTINAL MOTILITY INVESTIGATIONS,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",FLUORESCEIN,"NUMBER OF DROPLETS SPREAD ON THE INVESTIGATOR AND THEIR LOCATION ON GOWN OR GOGGLES, BY THE END OF THE PROCEDURE OF NASO-GASTRIC INTUBATION FOR GASTROINTESTINAL MOTILITY INVESTIGATIONS.",COVID-19: The Study of Aerosol Generation and Droplet Dispersion and Deposition During Naso-gastric Intubation for Gastrointestinal Motility Investigations
NCT04688372,"Active, not recruiting",Observational,,National Institutes of Health Clinical Center (CC),NIH,1-Oct-20,15-Feb-21,15-Feb-21,COHORT,100000,VOLUME OUTCOME RELATIONSHIP AMONG COVID INPATIENTS IN US HOSPITALS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SURGE INDEX,IN-HOSPITAL MORTALITY OR DISCHARGE TO HOSPICE,Association Between Hospital Case Burden and Mortality Risk Among Patients Hospitalized With COVID-19: A Retrospective Cohort Study of U.S. Hospitals
NCT04688502,Not yet recruiting,Interventional,Not Applicable,University of Saskatchewan,Other,11-Jan-21,15-Mar-21,28-Feb-21,PREVENTION,24,DYSPNEA,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HIGH INTENSITY INTERVAL TRAINING,CHANGE FROM BASELINE IN BOX JUMPS,The Effects of Wearing a Face Mask During COVID-19 on Performance and Intensity Markers During CrossFit Exercise
NCT04688840,Completed,Observational,,Tanta University,Other,1-Jan-20,1-Dec-20,1-Sep-20,OTHER,167,TELEMEDICINE,EGYPT,ALL,"Child, Adult, Older Adult",HIP ARTHROPALSTY,WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX (WOMAC),Smartphone Application: A Possible Solution for Follow up of Patients With Hip Arthroplasty During COVID-19 Pandemic
NCT04689399,Completed,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,26-Dec-20,31-Dec-20,31-Dec-20,DIAGNOSTIC,4697,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)","STANDARD Q COVID-19 AG - TEST, PRODUCED BY SD BIOSENSOR INC.",SENSITIVITY AND SPECIFICITY OF THE RAPID ANTIGEN TEST OF COVID-19,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test
NCT04689464,Recruiting,Observational,,Alhasan Mujtaba Al-Mudhaffer,Other,1-Dec-20,1-May-21,28-Feb-21,CASE-ONLY,500,COVID,IRAQ,ALL,"15 Years and older   (Child, Adult, Older Adult)",,DEPRESSION,COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19
NCT04689477,Recruiting,Observational [Patient Registry],,Corporacion Parc Tauli,Other,25-May-20,21-Dec-21,21-Dec-21,COHORT,612,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",VASCULAR OCCLUSION TEST,28-DAY MORTALITY,Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients
NCT04689490,Recruiting,Observational,,Hospital Clínico Universitario de Valladolid,Other,1-Aug-20,31-Dec-20,31-Dec-20,COHORT,50,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",CARDIOPULMONARY EXERCISE TEST,AEROBIC CAPACITY,Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients
NCT04689542,Recruiting,Interventional,Not Applicable,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Other,1-Jan-21,1-Aug-21,1-Aug-21,SUPPORTIVE CARE,30,COVID,BELGIUM,ALL,"18 Years to 65 Years   (Adult, Older Adult)",SIT-TO-STAND TEST,CHANGES IN DYSPNEA LEVEL,Effects of Surgical Face Mask on Submaximal Exercise Test in Patients With COVID-19
NCT04689672,Recruiting,Observational,,IRCCS San Raffaele,Other,16-Dec-20,10-May-21,10-May-21,COHORT,600,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND,PATIENTS' SHORT-TERM OUTCOME,Predictivity of hEmoGasAnalysis Associated to Bedside Lung UltraSound in Determining COVID-19 Severity in the Emergency Departement
NCT04689711,Enrolling by invitation,Observational,,Tufts Medical Center,Other,7-Dec-20,31-Aug-21,31-Aug-21,COHORT,16,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGES IN MODEL DISCRIMINATION (MODEL 1: NEED FOR MV IN PATIENTS HOSPITALIZED WITH COVID-19),Generalizable Prognostic Models for Patient-Centered Decisions in COVID-19
NCT04689724,Recruiting,Observational,,"University Health Network, Toronto",Other,10-Aug-20,22-May-21,21-Feb-21,COHORT,250,COVID_AIRWAYS MANAGEMENT,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,SERIOUS ADVERSE EVENTS AT INTUBATION,Determining Airway Management Related Outcomes in COVID19 Patients and in Health Care Providers
NCT04690114,Recruiting,Observational [Patient Registry],,Shaare Zedek Medical Center,Other,1-Oct-20,31-Jul-21,31-May-21,ECOLOGIC OR COMMUNITY,2000,SARS-COV2 INFECTION,ISRAEL,ALL,"up to 18 Years   (Child, Adult)",,SARS-COV-2 SEROPOSITIVITY,"Incidence, Prevalence. Risk Factors and Epidemiology of SARS-CoV-2 Seropositivity in the Pediatric Population"
NCT04690387,"Active, not recruiting",Interventional,Phase 1,"Aivita Biomedical, Inc.",Industry,7-Dec-20,22-Jan-21,13-Jan-21,PREVENTION,27,COVID,INDONESIA,ALL,"18 Years and older   (Adult, Older Adult)",AV-COVID-19,INCIDENCE AND SEVERITY OF ADVERSE EVENTS (SAFETY),"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies"
NCT04690400,Not yet recruiting,Interventional,Not Applicable,Federal University of Pelotas,Other,18-Jan-21,30-Apr-21,30-Apr-21,TREATMENT,28,FIBROMYALGIA,,FEMALE,30 Years to 60 Years   (Adult),EXPERIMENTAL: ACTIVE CARE GROUP,CHANGES IN THE WIDESPREAD PAIN INDEX,"Adaptations From a Telehealth Stretching Exercise Program on Painful Conditions, Depression, Sleep and Functionality of Women With Fibromyalgia During the Covid-19 Pandemic: a Randomized Clinical Trial"
NCT04690413,Enrolling by invitation,Interventional,Not Applicable,"NOWDiagnostics, Inc.",Industry,1-Sep-20,31-Dec-20,31-Dec-20,DIAGNOSTIC,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NOWDX COVID-19 TEST,PERCENTAGE OF CLINICAL AGREEMENT BETWEEN NOWDX COVID-19 TEST AND EMERGENCY USE AUTHORIZED OR FDA CLEARED COMPARATOR.,NOWDx Test for the Detection of Antibodies to COVID-19
NCT04690816,Recruiting,Observational,,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),NIH,11-Feb-21,31-Dec-24,31-Dec-24,CASE-CONTROL,350,SYSTEMIC AUTOIMMUNE DISEASES,UNITED STATES,ALL,"15 Years and older   (Child, Adult, Older Adult)",,"PRIMARY OBJECTIVE: CHARACTERIZE HOW COVID-19 MODULATES SYSTEMIC INFLAMMATION, AUTOIMMUNITY FEATURES, ORGAN DAMAGE AND VASCULOPATHY IN ADULT AND PEDIATRIC PATIENTS WITH A PREVIOUS DIAGNOSIS OF SYSTEMIC AUTOIMMUNITY. ASSESS HOW SUBJECTS WITH SYSTE...",The Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases; An Observational Prospective Study
NCT04690920,Completed,Interventional,Not Applicable,University of Lahore,Other,23-Jul-20,10-Dec-20,10-Dec-20,SUPPORTIVE CARE,200,CORONA VIRUS DISEASE 2019 (COVID),PAKISTAN,ALL,"Child, Adult, Older Adult",TOCILIZUMAB,RATIO OF PARTIAL PRESSURE OF OXYGEN IN ARTERIAL BLOOD TO FRACTION OF INHALED OXYGEN,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach
NCT04691180,Recruiting,Interventional,Phase 1,Brii Biosciences Limited,Industry,5-Jan-21,21-Aug-21,21-Aug-21,TREATMENT,24,COVID,CHINA,ALL,18 Years to 49 Years   (Adult),BRII-196 AND BRII-198,INCIDENCE OF ADVERSE EVENTS (AES) BY CTCAE V5.0,"A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibodies, Brii-196 and BRII-198, Administered Intravenously to Healthy Adult Volunteers"
NCT04691609,Recruiting,Observational,,Assiut University,Other,1-Mar-20,23-Sep-21,23-Mar-21,COHORT,2500,ACS-COVID-ASSIUT,EGYPT,ALL,"Child, Adult, Older Adult",,"MAIN NUMBER, DISTRIBUTION AND OUCOME OF ALL ACS PATIENTS COMING TO ASSIUT HEART HOSPITAL",Assiut University Registry for ACS Patients During COVID-19 Pandemic
NCT04691895,"Active, not recruiting",Observational [Patient Registry],,University of Bologna,Other,1-May-20,31-Dec-21,30-Sep-20,CASE-CONTROL,2000,COVID DISEASE,ITALY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",SARS-COV2 INFECTION,PREVALENCE OF GASTROINTESTINAL SYMPTOMS IN PATIENTS ADMITTED TO HOSPITAL FOR COVID19 DISEASE AS ASSESSED BY GSRS QUESTIONNAIRE,Gastrointestinal Symptoms of SARS-CoV-2 Infection: a Prospective Multicentre Study
NCT04691908,"Active, not recruiting",Interventional,Phase 3,Research Institute for Biological Safety Problems,Other,25-Dec-20,30-Jul-21,31-Mar-21,PREVENTION,3000,COVID,KAZAKHSTAN,ALL,"18 Years and older   (Adult, Older Adult)",QAZCOVID-IN®-VACCINE AGAINST COVID-19,TERMS OF SEROCONVERSION (THE PROPORTION OF PERSONS WITH A FOURFOLD OR HIGHER CHANGE IN ANTIBODY TITERS TO SARS-COV-2),"Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-in®-Vaccine Against COVID-19 in Healthy Adult Volunteers"
NCT04691921,Completed,Observational,,NMC Specialty Hospital,Other,4-Jan-21,31-Jan-21,18-Jan-21,COHORT,1055,COVID,INDIA,ALL,"20 Years to 70 Years   (Adult, Older Adult)",CURRENT CLINICAL PRACTICES OF PARTICIPATING PHYSICIANS,CHOICE AND INDICATION OF PHARMACOLOGICAL AGENTS FOR MANAGEMENT OF SEVERE COVID-19,Nation-wide Cross-sectional Survey on Current Pharmacological Practices in Severe COVID-19
NCT04691934,Completed,Observational,,Turkiye Yuksek Ihtisas Education and Research Hospital,Other,11-Mar-20,25-Dec-20,25-Dec-20,COHORT,61,COVID,TURKEY,FEMALE,"18 Years and older   (Adult, Older Adult)",ANESTHESIA MANAGEMENT,OBSTETRIC ANESTHESIA PRACTICES,Our Anesthesia Experiences in COVID-19 Positive Patients Undergoing Cesarean Section: A Retrospective Single-center Cohort Study
NCT04691947,Recruiting,Interventional,Phase 1,Health Institutes of Turkey,Other,5-Nov-20,15-Mar-22,1-Mar-21,PREVENTION,44,COVID VACCINE,TURKEY,ALL,18 Years to 55 Years   (Adult),ERUCOV-VAC,TO ASSESS THE SAFETY AND TOLERABILITY OF THE COVID-19 VACCINE,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design."
NCT04692129,Recruiting,Observational,,Corporacion Parc Tauli,Other,29-May-20,31-Dec-21,31-Dec-21,COHORT,100,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGE IN TISSUE OXYGENATION (STO2),"Short-term Effects of Prone Positioning on Tissue Oxygen Saturation, Measured by Near-infrared Spectroscopy, in COVID-19 Patients With Acute Respiratory Distress Syndrome"
NCT04692779,Recruiting,Observational,,Rush University Medical Center,Other,31-Jan-21,30-Oct-21,30-Oct-21,COHORT,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LUNG ULTRASOUND (LUS),OXYGENATION AND LUNG ULTRASOUND SCORE (LUS),"A Prospective Clinical Study to Explore the Mechanism of Patients' Response to Prone Positioning in ARDS Patients, Including COVID-19"
NCT04693026,Recruiting,Interventional,Phase 3,M Abdur Rahim Medical College and Hospital,Other,10-Sep-20,5-Mar-21,15-Feb-21,TREATMENT,150,COVID,BANGLADESH,ALL,"Child, Adult, Older Adult",REMDESIVIR,TIME TO CLINICAL IMPROVEMENT (TTCI),Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDS
NCT04693052,Enrolling by invitation,Observational,,Northwestern University,Other,10-Dec-20,30-Jun-21,1-Feb-21,OTHER,600,PSYCHIATRIC DISORDER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTIONS,PATIENT CHOOSING TELEHEALTH AS AN OPTION FOR FUTURE CARE,Attitudes Towards Receiving Mental Health Care Using Telehealth During the COVID-19 Pandemic
NCT04693689,Not yet recruiting,Interventional,Not Applicable,"National University, Singapore",Other,15-Jan-21,30-Jan-21,30-Jan-21,HEALTH SERVICES RESEARCH,32400,TRUST,,ALL,"18 Years and older   (Adult, Older Adult)",RNA VACCINE,WILLINGNESS TO RECEIVE COVID-19 VACCINE,"Novelty, Conformity and Trust in Vaccines"
NCT04693975,Recruiting,Observational [Patient Registry],,Universidade Estadual de Londrina,Other,16-Oct-20,22-Oct-21,22-Oct-21,OTHER,94,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,BRAZIL,ALL,"Child, Adult, Older Adult",,PHYSICAL ACTIVITY IN DAILY LIFE,Impact of Social Distancing During the COVID-19 Pandemic on Non-infected People With Chronic Respiratory Diseases
NCT04694014,Enrolling by invitation,Observational,,African Wood Inc,Other,15-Oct-20,30-Jun-21,30-May-21,COHORT,20,EMOTIONAL INTELLIGENCE,KENYA,ALL,"25 Years to 67 Years   (Adult, Older Adult)",EI OPEN ENDED PRE-SURVEY AND SEMI STRUCTURED INTERVIEW,EMOTIONAL INTELLIGENCE COMPETENCES FRONTLINE HEALTHCARE PROFESSIONAL NEED IN THEIR LEADERS,Emotional Intelligence Skills Leaders and Managers Need to Engage Frontline Healthcare Professionals During Covid-19 Pandemic
NCT04694482,Recruiting,Observational,,University of Milano Bicocca,Other,12-Nov-20,31-Jan-21,31-Jan-21,CASE-CONTROL,200,PSYCHOSIS;SCHIZOPHRENIC,ITALY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",PSYCHOMETRIC SCALE ADMINISTRATION,BRIEF PSYCHIATRIC RATING SCALE (BPRS),The Psychopathological Impact of the SARS-CoV-2 Epidemic on Subjects Suffering From Mental Disorders: Data From ASST Monza
NCT04694573,Recruiting,Observational [Patient Registry],,Heidelberg University,Other,28-Dec-20,28-Dec-22,28-Dec-21,CASE-CONTROL,600,COVID,GERMANY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,CHANGE IN DNDSA DEVELOPMENT (PRE-TX COVID-19 SERUM STUDY),Collaborative Transplant Study (CTS) Pre- and Post-Transplantation Covid-19 Serum Studies: Antibody Development Following a SARS-CoV-2 Infection
NCT04694612,Recruiting,Interventional,Phase 3,Nepal Health Research Council,Other,1-Jan-21,31-May-21,31-Mar-21,TREATMENT,676,COVID,NEPAL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",FAVIPIRAVIR,CLINICAL IMPROVEMENTS IN MILD CASES,"Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical Trial"
NCT04694638,Recruiting,Interventional,Not Applicable,Mayo Clinic,Other,21-May-20,21-May-21,21-May-21,SUPPORTIVE CARE,24,PRONE POSITIONING,UNITED STATES,ALL,"18 Years to 110 Years   (Adult, Older Adult)",BODY POSITION CHANGE,RATE OF INTUBATION,"The Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in Acute Hypoxemic and/or Hypercapnic Respiratory Failure Secondary to COVID-19 Infection: A Feasibility, Safety Phase One, Open Label Study"
NCT04694651,Recruiting,Observational [Patient Registry],,Assiut University,Other,15-Dec-20,15-Feb-21,30-Jan-21,COHORT,400,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",,MEASURE FREQUENCY OF ACCEPTANCE OF VACCINATION,A National Survey of Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt
NCT04694664,Completed,Observational,,Pregistry,Industry,1-Oct-20,1-Dec-20,1-Dec-20,COHORT,18000,PREGNANCY RELATED,UNITED STATES,FEMALE,"18 Years to 65 Years   (Adult, Older Adult)",THIS IS AN ONLINE SURVEY WITH NO INTERVENTION.,PERCENTAGE OF ACCEPTANCE OF A COVID-19 VACCINE,Vaccine Confidence Among Pregnant Women and Mothers During the COVID-19 Pandemic
NCT04694703,Recruiting,Observational,,Izmir Bakircay University,Other,6-Jan-21,21-Mar-21,21-Feb-21,COHORT,20,COVID,TURKEY,ALL,"35 Years to 65 Years   (Adult, Older Adult)",COVID-19 GROUP,CHANGE OF THE LEVELS OF TRACE ELEMENT AT BASELINE AND DISCHARGE,"Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Patients Diagnosed With COVID-19 Before and After COVID-19 Treatment"
NCT04694716,Recruiting,Observational,,Izmir Bakircay University,Other,6-Jan-21,21-Mar-21,21-Feb-21,COHORT,40,COVID,TURKEY,ALL,"35 Years to 65 Years   (Adult, Older Adult)",NO INTERVENTION,LEVELS OF SERUM TRACE ELEMENTS PARAMETERS,Determination of Serum Trace Element and Physical Activity Levels in COVID-19 Patients
NCT04694742,Recruiting,Observational,,ASST Fatebenefratelli Sacco,Other,1-Sep-20,15-Apr-21,31-Mar-21,COHORT,100,ARDS,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",DATA COLLECTING,VENTILATORY RATIO CORRELATION,Ventilatory Efficiency in Critically Ill COVID-19 Patients
NCT04694768,Recruiting,Observational,,Assiut University,Other,1-Jul-20,31-Jan-21,1-Jan-21,COHORT,100,POST COVID SYNDROME,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",REHABILITATION,OPTIMIZING HEALTH AND FUNCTIONING OUTCOMES,The Effect of Implementing a Nursing Program Intervention on Improvement of Health Quality of Post Covid-19 Patients
NCT04695158,Recruiting,Observational,,Izmir Bakircay University,Other,6-Jan-21,21-Mar-21,21-Feb-21,COHORT,60,COVID,TURKEY,ALL,"35 Years to 65 Years   (Adult, Older Adult)",COVID-19 GROUP (GROUP I),CHANGE OF THE LEVELS OF HEMOGLOBIN A1C AND LIPID PROFILES AT BASELINE AND DISCHARGE FOR GROUP I AND GROUP II,"Determination of Hemoglobin A1c, Lipid Profiles, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Patients With Type II Diabetes and/or COVID-19"
NCT04695197,Recruiting,Interventional,Phase 3,Liverpool School of Tropical Medicine,Other,8-Jan-21,31-Jul-23,1-Nov-22,TREATMENT,142,COVID,BURKINA FASO,ALL,"6 Months to 100 Years   (Child, Adult, Older Adult)",ARTEMETHER-LUMEFANTRINE (AL),INCIDENCE OF SARS-COV-2 CLEARANCE,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso
NCT04695301,Recruiting,Interventional,Not Applicable,Hospital Israelita Albert Einstein,Other,1-Jul-20,21-Aug-21,1-Jul-21,OTHER,50,COVID,BRAZIL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",REHABILITATION PROTOCOL THROUGH A DIGITAL PLATFORM,CHARACTERIZE THE CLINICAL FUNCTION PROFILE OF PATIENTS AFFECTED BY COVID-19,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation
NCT04695379,Recruiting,Observational,,"University Hospital, Bordeaux",Other,26-May-20,26-Nov-22,26-Nov-22,COHORT,150,MYASTHENIA GRAVIS,FRANCE,ALL,"1 Year to 99 Years   (Child, Adult, Older Adult)",,SEVERITY OF MYASTHENIA GRAVIS EVALUATED BY THE MYASTHENIA GRAVIS OF AMERICA (MGFA) SCORE,Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection: Consequences on the Severity of Myasthenic Syndrome and Reciprocal Impact of the Two Pathologies on Their Respective Treatments
NCT04695457,Completed,Observational,,Centre Hospitalier Annecy Genevois,Other,15-Jul-20,16-Nov-20,16-Nov-20,COHORT,74,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF COVID-19 OUTBREAK IN FRENCH ALPS' NURSING HOMES,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps
NCT04695652,Recruiting,Interventional,Phase 2,Medigen Vaccine Biologics Corp.,Industry,30-Dec-20,22-Jun-21,21-Jun-21,PREVENTION,3700,COVID VACCINE,TAIWAN,ALL,"20 Years and older   (Adult, Older Adult)",MVC-COV1901(S PROTEIN WITH ADJUVANT),INCIDENCE OF ADVERSE EVENT WITHIN 28 DAYS POST THE SECOND STUDY INTERVENTION (SAFETY OF MVC-COV1901),"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901"
NCT04695678,"Active, not recruiting",Observational,,Wissenschaftliches Institut Bethanien e.V,Other,1-Jul-20,30-Jun-21,31-Jan-21,COHORT,4000,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 NASAL/PHARYNGEAL SWAB,PREVALENCE OF LATENT COVID-19 INFECTIONS AT ONE POINT IN TIME AMONG RESIDENTS AND STAFF OF ALL OLD PEOPLE'S AND NURSING HOMES IN SOLINGEN.,Epidemiological Multicohort Study of Latent COVID-19 Infections in Residents and Staff of Nursing Homes in the City of Solingen
NCT04695704,Not yet recruiting,Interventional,Phase 3,Jordi Gol i Gurina Foundation,Other,1-Apr-21,31-Dec-22,31-Mar-22,TREATMENT,284,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MONTELUKAST,COP ASSESSMENT TEST SCALE (CAT),"Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID: E-SPERANZA COVID PROJECT"
NCT04695743,Recruiting,Interventional,Not Applicable,"University College, London",Other,1-Sep-20,1-Sep-22,1-Jun-22,TREATMENT,50,DEMENTIA,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",ONLINE COGNITIVE STIMULATION THERAPY,ADAS-COG (ADAPTED FOR VIRTUAL USE) - CHANGE IS BEING ASSESSED,Virtual CST - A Collaborative Proof of Concept Study With FaceCog HK in Response to the Covid-19 Pandemic
NCT04695756,Recruiting,Observational,,Hospital Italiano de Buenos Aires,Other,15-Dec-20,15-Jul-21,15-Jun-21,ECOLOGIC OR COMMUNITY,1000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 PANDEMIC,TO COMPARE THE NUMBER OF PATIENTS REGISTERED ON THE LIVER TRANSPLANT WAITING LIST DURING THE EPIDEMIOLOGICAL WEEKS OF COVID-19 PANDEMIC IN ARGENTINA AND THE SAME WEEKS OF 2019 ACCORDING TO NATIONAL DATA REGISTRY OF PROCUREMENT AND TRANSPLANTATION,Impact of Coronavirus Disease 2019 (COVID-19) Epidemic in Patients Requiring Liver Transplantation
NCT04695821,Not yet recruiting,Interventional,Not Applicable,Senti Tech Ltd,Industry,21-Jan-21,21-Mar-21,21-Feb-21,DEVICE FEASIBILITY,10,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SENTI V1.0 DEVICE,PATIENT-RATED DEVICE ACCEPTABILITY,"A Small-scale Study to Capture Acoustic Pathophysiological Parameters, in the Community, Through a Wearable Device, and to Evaluate the Technical and Practical Feasibility of Utilising This Data as Part of a Medical Device System for the Monitoring and Evaluation of Covid-19 at Home"
NCT04696562,Not yet recruiting,Interventional,Not Applicable,Ankara University,Other,1-Jan-21,31-Mar-21,31-Mar-21,SUPPORTIVE CARE,44,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",DEEP BREATHING EXERCISE WITH TRIFLO,OXYGEN SATURATION (%),"The Effect of Deep Breathing Exercise Applied With Triflo on Dyspnea, Anxiety and Quality of Life in Patients Treated for COVID-19: Randomized Controlled StudyPatients Treated for COVID-19: A Randomized Controlled Study"
NCT04696601,Not yet recruiting,Interventional,Not Applicable,Centre Hospitalier Universitaire de Nice,Other,10-Jan-21,10-Feb-22,10-Feb-21,SCREENING,2000,OLFACTION DISORDERS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",OLFACTORY TEST,OLFACTORY TEST,Rapid Screening for Olfactory Disorders in Covid-19 Infection
NCT04696679,Completed,Observational,,Assistance Publique Hopitaux De Marseille,Other,19-Jun-20,31-Dec-20,30-Nov-20,OTHER,170,VERY PRETERM CHILDREN WITH DYSEXECUTIVE DISORDERS,FRANCE,ALL,7 Years to 9 Years   (Child),PATIENT QUALITY OF LIFE ASSESSMENT,ASSESSMENT OF THE QUALITY OF LIFE USING THE QUESTIONNAIRE KIDSCREEN 10 INDEX,Quality of Life of Very Preterm Children With Dysexecutive Disorders at Elementary School Age During the Confinement-deconfinement Period of Covid-19 Pandemic
NCT04696913,Not yet recruiting,Observational,,University of Aberdeen,Other,1-Jan-21,22-Nov-21,22-Nov-21,CASE-CONTROL,347,COVID,,ALL,"16 Years and older   (Child, Adult, Older Adult)",EXPOSURE: POSITIVE COVID-19 INFECTION,NUMBER OF PULMONARY EMBOLISM CASES RELATED TO COVID-19.,Does COVID-19 Infection Increase the Risk of Pulmonary Embolism? A Retrospective Case-control Study
NCT04697030,Completed,Observational,,Sialkott College of Physical Therapy,Other,15-Sep-20,22-Dec-20,15-Oct-20,OTHER,443,"BURNOUT, PSYCHOLOGICAL",PAKISTAN,ALL,"13 Years to 19 Years   (Child, Adult)",,BURNOUT RATING SCALE,Behavioral Outcomes Among Adolescent Population During Covid-19 Pandemic Lockdown in Pakistan: A Lower Middle Income Country Experience
NCT04697654,"Active, not recruiting",Interventional,Phase 1,Taiwan Liposome Company,Industry,14-Oct-20,30-Apr-21,30-Apr-21,TREATMENT,30,COVID,AUSTRALIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TLC19,INCIDENCE OF AES,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers"
NCT04697927,Recruiting,Observational,,Memorial Sloan Kettering Cancer Center,Other,30-Dec-20,22-Dec-21,22-Dec-21,COHORT,10000,COVID INFECTIONS IN CANCER PATIENTS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,DEVELOP A COMPREHENSIVE REGISTRY DATABASE,Ascertainment of Epidemiologic Risk Information to Assess Susceptibility to and Severity of SARS-CoV-2 Infection
NCT04698044,Completed,Observational,,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",Other,8-May-20,25-Jun-20,25-Jun-20,COHORT,1107,ANXIETY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL ANXIETY DEPRESSION SCALE,HADS,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period: A Population-based Comparative Study
NCT04698083,Completed,Observational,,Ankara Education and Research Hospital,Other,22-Jul-20,5-Nov-20,15-Oct-20,CASE-ONLY,160,COVID,TURKEY,ALL,"Child, Adult, Older Adult","ELECTROCARDIOGRAPHY ,TOMOGRAPHIC IMAGING","DIFFERENCES IN THE ELECTROCARDIOGRAPHIC QRS AXIS SHIFT(°),",Retrospective Evaluation of Electrocardiographic Findings of Right Ventricular Overload in Covid 19 Patients With Respiratory Distress
NCT04698382,"Active, not recruiting",Observational,,National Institutes of Health Clinical Center (CC),NIH,1-Aug-20,1-May-21,1-Apr-21,COHORT,5000,SEPSIS,UNITED STATES,ALL,"Child, Adult, Older Adult",,PREVALENCE OF HOSPITAL AND ICU ADMISSION,"Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis"
NCT04698798,Recruiting,Interventional,Not Applicable,Hasselt University,Other,2-Jan-21,21-May-21,21-May-21,BASIC SCIENCE,16,CACHEXIA,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",MUSCLE BIOPSY,SKELETAL MUSCLE BIOPSY,Skeletal Muscle Wasting in SARS-CoV-2 Infected ICU (Intensive Care Unit) Patients
NCT04698837,Not yet recruiting,Observational,,"University Hospital Inselspital, Berne",Other,21-Jan-21,21-Jun-21,21-Jun-21,OTHER,30,SARS-COV2,SWITZERLAND,ALL,"18 Years to 110 Years   (Adult, Older Adult)",,"TOTAL AMOUNT OF DUMMY-INHALED VIRUS COPIES PER 30 MINUTES SAMPLING PER SIZE FRACTION (>10 ΜM, <10 ΜM)",AeroCOVID 1: Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2 Using Patient Proximity Environmental Sampling With a Highly Efficient Bioaerosol and Droplet Collection Dummy
NCT04698993,Not yet recruiting,Interventional,Not Applicable,Drägerwerk AG & Co. KGaA,Industry,21-Jan-21,21-Mar-21,21-Mar-21,DIAGNOSTIC,1650,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",DRÄGER ANTIGEN TEST SARS-COV-2,SENSITIVITY,Dräger Antigen Test SARS-CoV-2 Clinical Performance Study
NCT04699058,Recruiting,Observational,,"Institute of Tropical Medicine, Belgium",Other,17-Jul-20,31-Jan-21,31-Dec-20,ECOLOGIC OR COMMUNITY,1650,SARS-COV INFECTION,"CONGO, THE DEMOCRATIC REPUBLIC OF THE",ALL,"Child, Adult, Older Adult",COVID-ANTIBODY TEST,COVID ANTIBODY PREVALENCE IN HEALTH CARE WORKERS (SEROLOGICAL TEST),"Sero-prevalence and Sero-conversion Study of Health Care Workers and Their Households, Democratic Republic of the Congo"
NCT04699097,Completed,Observational,,Kayseri City Hospital,Other,1-Jul-20,1-Nov-20,1-Sep-20,CASE-ONLY,105,AZITHROMYCIN ADVERSE REACTION,TURKEY,ALL,"1 Year to 18 Years   (Child, Adult)",AZITHROMYCIN,EFFECT OF AZITROMYCIN ON VENTRICLE REPOLARIZATION,Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization
NCT04699227,Recruiting,Interventional,Not Applicable,Derek Yellon,Other,23-Apr-20,30-Apr-21,30-Apr-21,PREVENTION,20,COVID,UNITED KINGDOM,ALL,"18 Years to 80 Years   (Adult, Older Adult)",CUFF APPLICATION WITH INFLATION,PRIMARY ENDPOINT,"CAN REMOTE ISCHAEMIC CONDITIONING REDUCE INFLAMMATORY MARKERS IN COVID-19 PATIENTS - A MULTI-SITE, RANDOMISED PILOT STUDY"
NCT04699578,Recruiting,Observational,,"University of Campania ""Luigi Vanvitelli""",Other,28-Dec-20,1-May-22,31-Dec-21,COHORT,230,COVID,ITALY,FEMALE,"18 Years and older   (Adult, Older Adult)",COVID-19 POSITIVE,PRETERM BIRTH RATE,Impact of COVID-19 Infection on the Course of Pregnancy and Fetal-neonatal Outcomes
NCT04699851,Recruiting,Interventional,Not Applicable,Laval University,Other,18-Nov-20,18-May-21,18-Apr-21,PREVENTION,1200,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",TAILORED RECOMMENDATIONS,IMPROVEMENT IN MASK WEARING BEHAVIOR,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens
NCT04699903,Not yet recruiting,Observational,,Rapid Pathogen Screening,Industry,28-Dec-20,5-Feb-21,22-Jan-21,COHORT,215,"SARS-COV2, COVID",UNITED STATES,ALL,"1 Year and older   (Child, Adult, Older Adult)",POC SARS-COV-2 IGG ANTIBODY TEST,PPA (POSITIVE PERCENT AGREEMENT) AND NPA (NEGATIVE PERCENT AGREEMENT) OF POC COMPARED TO SARS-COV-2 REFERENCE PCR,"Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 IgG Antibody Test in Fingerstick Whole Blood"
NCT04699916,Not yet recruiting,Interventional,Not Applicable,University of Chile,Other,4-Jan-21,31-Dec-21,30-Jun-21,TREATMENT,44,SEDATION COMPLICATION,,ALL,"18 Years and older   (Adult, Older Adult)",EEG BASED PROTOCOL FOR DEEP SEDATION,VENTILATOR FREE DAYS,EEG-based Protocol to Guide Deep Sedation Decreases the Days of Mechanical Ventilation in COVID-19 Patients: Randomized Clinical Trial
NCT04699942,Not yet recruiting,Interventional,Not Applicable,Dr. David Maslove,Other,4-Jan-21,1-Jul-21,1-Jul-21,SUPPORTIVE CARE,23,HYPOXEMIA,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",CONVENTIONAL (LOW FLOW) OXYGEN DELIVERY VIA NASAL CANNULA,OXYGEN FLOW REQUIRED TO ACHIEVE SPO2 >96%.,Pilot Study to Evaluate the Revoxa™ System in Hypoxic Patients
NCT04700137,Enrolling by invitation,Interventional,Not Applicable,"St. Luke's Health System, Boise, Idaho",Other,18-Jan-21,17-Jan-22,17-Jan-22,TREATMENT,660,COVID,UNITED STATES,ALL,"12 Years and older   (Child, Adult, Older Adult)",CARING CONTACTS PLUS INTRODUCTORY PHONE CALL (CC+),LONELINESS AS MEASURED BY THE NATIONAL INSTITUTES OF HEALTH (NIH) TOOLBOX SOCIAL RELATIONSHIP SCALE FOR LONELINESS,"Investigating the Mental Health Impact of COVID-19 and Comparing the Effectiveness of Two Caring Contact Interventions on Patients, Providers, and Staff of St. Luke's Health System"
NCT04700163,Recruiting,Interventional,Phase 1,Rockefeller University,Other,11-Jan-21,15-Apr-22,15-Jun-21,TREATMENT,15,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",C144-LS AND C-135-LS,GRADE 2 AND HIGHER ADVERSE EVENTS 4 WEEKS AFTER ADMINISTRATION.,"A Phase 1, Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of a Combination of Two Anti-SARS-CoV-2 mAbs (C144-LS and C135-LS) in Healthy Volunteers"
NCT04700254,Completed,Observational,,"Chania General Hospital ""St. George""",Other,28-Dec-20,11-Jan-21,11-Jan-21,CASE-CONTROL,150,DIABETES MELLITUS,GREECE,ALL,"18 Years to 85 Years   (Adult, Older Adult)",DASS QUESTIONNAIRE,DASS (DEPRESSION),"The Effect of COVID-19 National Lockdown on People With Diabetes Mellitus Regarding Their Anxiety, Depression and Eating Attitudes, in Relation to Adjusted Work and Family Conditions"
NCT04700462,Recruiting,Interventional,Not Applicable,Johns Hopkins University,Other,5-Feb-21,30-Oct-21,30-Oct-21,PREVENTION,250,COVID,UNITED STATES,ALL,"60 Years and older   (Adult, Older Adult)",SM-EMA,CHANGE IN KNOWLEDGE TEST SCORE AS ASSESSED BY A QUESTIONNAIRE,Optimizing Tailored-feedback Message to Promote Adherence Behavior to Prevent COVID-19 in African Americans
NCT04701489,Enrolling by invitation,Interventional,Not Applicable,University of Minnesota,Other,14-Jan-21,21-Jun-21,21-Apr-21,OTHER,30,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SPLENIC ULTRASOUND,BETWEEN-ARM CHANGE OF IL-6 LEVELS FROM BASELINE TO END OF TREATMENT BETWEEN GROUPS,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19
NCT04701502,Completed,Interventional,Phase 2,Catalysis SL,Industry,9-Nov-20,15-Feb-21,15-Feb-21,SUPPORTIVE CARE,60,COVID,BULGARIA,ALL,"18 Years and older   (Adult, Older Adult)",VIUSID,CLINICAL IMPROVEMENT,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19
NCT04701515,Recruiting,Observational,,Methodist Health System,Other,10-Jun-20,31-Dec-22,31-Dec-22,COHORT,500,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CHART REVIEW,HEART FAILURE,Cardiovascular Manifestations of COVID-19
NCT04701528,Recruiting,Interventional,Phase 2,Leiden University Medical Center,Other,15-Nov-20,25-Oct-22,25-Mar-22,TREATMENT,20,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",VOCLOSPORIN,TIME TO VIRAL CLEARANCE OF SARS-COV-2,An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID Study
NCT04701606,Not yet recruiting,Interventional,Phase 2/Phase 3,Shin Poong Pharmaceutical Co. Ltd.,Industry,15-Feb-21,30-Sep-21,30-Sep-21,TREATMENT,402,COVID,PHILIPPINES,ALL,"19 Years and older   (Adult, Older Adult)",ARTECOM® (PYRONARIDINE-ARTESUNATE),PROPORTION OF PARTICIPANTS WITH CLINICAL IMPROVEMENT AS DEFINED BY AN IMPROVEMENT OF CATEGORIES ON THE WHO ORDINAL SCALE OF CLINICAL STATUS UNTIL DAYS 28.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (Artecom®) in COVID-19 Patients"
NCT04701658,Recruiting,Interventional,Phase 2,Eli Lilly and Company,Industry,1-Feb-21,7-Aug-21,7-Jun-21,TREATMENT,3000,COVID,UNITED STATES,ALL,"12 Years and older   (Child, Adult, Older Adult)",BAMLANIVIMAB,PERCENTAGE OF PARTICIPANTS WHO EXPERIENCE COVID-19 RELATED HOSPITALIZATION OR DEATH,"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls"
NCT04701710,Completed,Interventional,Phase 1/Phase 2,Maria de los Angeles Peral de Bruno,Other,15-Oct-20,31-Dec-20,18-Dec-20,PREVENTION,300,COVID,ARGENTINA,ALL,18 Years to 60 Years   (Adult),IVERMECTIN / IOTA-CARRAGEENAN,PEARSON'S CHI-SQUARE AND PROPORTION TEST.,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents
NCT04701892,Recruiting,Observational,,Universitair Ziekenhuis Brussel,Other,19-Jan-21,23-Jan-21,23-Jan-21,COHORT,200,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",INDICATORS OF CENTRAL SENSITISATION,SYMPTOMS OF CENTRAL SENSITISATION,Central Sensitisation in Post Covid-19 Infection Patients: a Prospective Cohort Study
NCT04701905,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,30-Apr-20,30-Apr-21,30-Apr-21,CASE-ONLY,450,COVID PANDEMIC,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE ANALYSIS OF THE MANAGEMENT OF NEUROSURGICAL PATHOLOGIES IN A HEALTH CRISIS SITUATION OF THE COVID-19 PANDEMIC,The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19
NCT04701944,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,21-Apr-20,21-Apr-21,21-Apr-21,CASE-ONLY,54,COVID,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",,A RETROSPECTIVE REVIEW OF THE MEDICAL RECORDS OF PREGNANT WOMEN WITH COVID-19 AT THE UNIVERSITY HOSPITALS OF STRASBOURG,Clinical Study of Pregnant Women With COVID-19: A Retrospective Review of Medical Records at Strasbourg University Hospitals
NCT04701996,Recruiting,Observational,,"Institute of Tropical Medicine, Belgium",Other,23-Sep-20,31-Dec-21,20-Nov-21,COHORT,1600,COVID,"CONGO, THE DEMOCRATIC REPUBLIC OF THE",ALL,"1 Month to 99 Years   (Child, Adult, Older Adult)",SEROLOGICAL SURVEILLANCE,TO PREDICT AND MONITOR THE TRANSMISSION OF SARS-COV-2 IN A RURAL SUB SAHARAN SETTING.,Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo
NCT04702178,Recruiting,Interventional,Phase 1/Phase 2,University of Saskatchewan,Other,21-Jan-21,23-Feb-21,22-Oct-21,PREVENTION,108,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",COVAC-2,"OCCURRENCE OF ADVERSE EVENTS (AES) FROM THE FIRST INJECTION TO DAY 28, IN ALL PARTICIPANTS, IN ALL GROUPS","A Randomized, Observer-Blind, Dose-Escalation Phase 1/2 Clinical Trial of COVAC Vaccines in Healthy Adults"
NCT04702295,Not yet recruiting,Observational,,University of Pisa,Other,21-Feb-21,23-Aug-21,23-Feb-21,COHORT,250,CONNECTIVE TISSUE DISEASES,,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,INCIDENCE OF ADVERSE EVENTS (ANY TYPE),COVID Vaccination in Rare and Complex Connective Tissue Diseases: ERN ReCONNET Multicentre Prospective Cohort Study
NCT04702945,Recruiting,Observational [Patient Registry],,University of British Columbia,Other,1-Mar-20,31-Dec-23,31-Dec-22,COHORT,200000,COVID,CANADA,ALL,"Child, Adult, Older Adult",,CONFIRMED COVID-19 DIAGNOSIS,Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) - Population-based Registry of Suspected and Confirmed COVID-19 Cases
NCT04703036,Recruiting,Interventional,Early Phase 1,Baylor College of Medicine,Other,11-Jan-21,31-Dec-21,31-Dec-21,OTHER,64,COVID,UNITED STATES,ALL,"55 Years to 85 Years   (Adult, Older Adult)",GLYCINE,CHANGE IN GLUTATHIONE CONCENTRATIONS,Randomized Trial of Supplementing Glycine and N-acetylcysteine vs. Placebo in COVID-19
NCT04703114,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,21-Feb-21,21-Dec-21,21-Oct-21,DIAGNOSTIC,80,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD COUNT,INTERFERON RESPONSE,Study of the Immunological and Virological Response of Patients Infected With SARS-CoV-2 and Presenting an Asymptomatic or Pauci-symptomatic Form
NCT04703140,Recruiting,Interventional,Not Applicable,CMC Ambroise Paré,Other,11-Feb-21,11-Sep-22,11-Aug-22,DIAGNOSTIC,350,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",RAPID DIAGNOSTIC TEST VS PCR,"COMPARAISON OF THE PERFORMANCE OF THE DIAGNOSTIC PERFORMANCE (SENSITIVITY, SENSIBILITY) OF RT-LAMP TEST USING THE RT-PCR TEST AS A REFERENCE.",Evaluation of the Performance of COVIDISC Rapid Test for Diagnosis of SARS-CoV-2
NCT04703205,Recruiting,Interventional,Phase 2,Kitasato University,Other,16-Sep-20,31-Mar-21,31-Mar-21,TREATMENT,240,COVID,JAPAN,ALL,"20 Years and older   (Adult, Older Adult)",IVERMECTIN 3 MG,COVID-19 PCR TEST (SARS-COV-2 NUCLEIC ACID DETECTION) PERIOD UNTIL THE COVID-19 PCR TEST (SARS-COV-2 NUCLEIC ACID DETECTION) BECOMES NEGATIVE,"A Placebo-controlled, Randomized, Double-blind Study in COvid-19 Patients With iveRmectin; An inVEstigator iniTiaTEd Trial"
NCT04703270,Recruiting,Observational,,"St George's, University of London",Other,4-Jan-21,3-Jan-23,3-Jan-23,CASE-CONTROL,1200,CORONAVIRUS INFECTION,UNITED KINGDOM,FEMALE,"18 Years and older   (Adult, Older Adult)",,ANTIBODY CONCENTRATIONS IN MATERNAL AND CORD BLOOD IN PREGNANT WOMEN IN ENGLAND AND IN INFANT BLOOD IF MOTHERS ARE RTPCR POSITIVE FOR SARS-COV-2,Understanding COVID-19 Infection in Pregnant Women and Their Babies
NCT04703400,Completed,Observational,,"Clinica Universitaria Reina Fabiola, Universidad Catolica de Cordoba",Other,15-Aug-20,3-Jan-21,1-Oct-20,COHORT,195,SURGICAL EDUCATION,ARGENTINA,ALL,20 Years to 30 Years   (Adult),ANONYMOUS SURVEY,DEMOGRAPHIC VARIABLES,Analysis of the Impact on Surgical Residency Programs in Times of Pandemic in Argentina: A Cross-sectional Study
NCT04703452,Recruiting,Observational,,Universitair Ziekenhuis Brussel,Other,19-Jan-21,22-Jan-21,22-Jan-21,CASE-ONLY,100,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",INDICATORS OF CENTRAL SENSITISATION,SYMPTOMS OF CENTRAL SENSITISATION,Central Sensitisation in Post Covid-19 Infection Patients: a Cross-sectional Study
NCT04703478,Not yet recruiting,Interventional,Not Applicable,University of Salamanca,Other,20-Jan-21,20-Apr-21,20-Apr-21,SUPPORTIVE CARE,20,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BREATHING EXERCISE,RATING OF PERCEIVED EXERTION (BORG SCALE),RespiraConNosotros: Creation and Implementation of a Mobile Application for the Rehabilitation of Patients With Respiratory Sequelae of the SARS-CoV-2 (COVID-19)
NCT04703608,Recruiting,Interventional,Phase 3,London School of Hygiene and Tropical Medicine,Other,22-Jan-21,22-Jul-21,22-Mar-21,TREATMENT,1200,COVID,GAMBIA,ALL,"5 Years and older   (Child, Adult, Older Adult)",IVERMECTIN,COHORT 1 INDEX CASE: PERCENTAGE OF PATIENTS WITH COVID-19 ASSOCIATED MILD DISEASE/MODERATE PNEUMONIA PROGRESSING TO SEVERE PNEUMONIA [TIME FRAME 14 DAYS],Prevention and Treatment for COVID -19 Associated Severe Pneumonia in The Gambia: a Single-Blinded Randomised Clinical Trial (PaTS-COVID)
NCT04703777,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,4-Apr-20,4-Apr-21,4-Apr-21,CASE-ONLY,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,"RETROSPECTIVE STUDY ON THE RELATIONSHIP BETWEEN SOCIAL STATUS AND USE OF HEALTHCARE SERVICES DURING THE CONFINEMENT PERIOD LINKED TO THE COVID-19 EPIDEMIC IN BAS-RHIN, FRANCE","Retrospective Study on the Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic in Bas-Rhin, France"
NCT04703790,Not yet recruiting,Observational,,Columbia University,Other,21-Feb-21,22-Aug-21,22-Aug-21,OTHER,1200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,INTENTION TO GET VACCINATED FOR COVID-19,Acceptability Across Two Time Periods of a SARS-CoV-2 Vaccine Among a Representative Sample of Adults Within the United States
NCT04703907,Recruiting,Interventional,Not Applicable,University Medicine Greifswald,Other,3-Dec-20,21-Aug-21,21-Aug-21,TREATMENT,60,STRESS AND ANXIETY,GERMANY,ALL,"19 Years to 65 Years   (Adult, Older Adult)",AURICULAR STIMULATION,ANXIETY,"Auricular Stimulation (AS) vs. ""Waiting List"" for Relief of Stress and Anxiety in Health Care Workers During COVID-19 Pandemic - a Prospective Controlled Investigation"
NCT04704388,Recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,1-Jun-20,21-Jan-21,21-Jan-21,COHORT,830,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,POST-INTENSIVE CARE SYNDROME (PICS),Study Project Comparing the Sequelae of SARS-CoV-2 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care
NCT04704466,Recruiting,Observational,,"Centre Hospitalier Universitaire, Amiens",Other,7-Jan-21,21-Jul-21,21-Jun-21,COHORT,150,HEAD AND NECK CANCER,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,VARIATION OF DELAY (IN DAYS) BETWEEN THE FIRST CANCER CONSULTATION AND THE BEGINNING OF THE FIRST LINE OF TREATMENT,Observational Study Evaluating the Impact of the Covid-19 Pandemic on the Management of Patients With Head and Neck Cancer in the Maxillofacial Surgery Department
NCT04704544,Not yet recruiting,Interventional,Not Applicable,University of Alabama at Birmingham,Other,1-Mar-21,30-Nov-22,30-Nov-22,TREATMENT,320,RHEUMATIC DISEASES,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELE-RHEUMATOLOGY,PATIENT SATISFACTION,Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis
NCT04705116,Not yet recruiting,Observational [Patient Registry],,Pregistry,Industry,15-Jan-21,31-Dec-25,31-Dec-25,COHORT,5000,COVID,UNITED STATES,FEMALE,18 Years to 50 Years   (Adult),COVID-19 VACCINE,OBSTETRIC OUTCOMES,COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)
NCT04705597,Not yet recruiting,Interventional,Phase 2,"BioAge Labs, Inc.",Industry,21-Feb-21,22-Apr-21,22-Feb-21,TREATMENT,132,COVID,UNITED STATES,ALL,"60 Years and older   (Adult, Older Adult)",BGE-175,PROPORTION OF PARTICIPANTS WHO HAVE DIED OR PROGRESSED TO RESPIRATORY FAILURE,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Patients Over 60 Years of Age With COVID-19"
NCT04705753,Completed,Interventional,Phase 2/Phase 3,University of Crete,Other,1-Apr-20,15-Oct-20,15-Oct-20,TREATMENT,20,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",CRETAN IAMA,NUMBER OF PATIENTS WITH SYMPTOM RESOLUTION,"Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial"
NCT04705766,Not yet recruiting,Observational [Patient Registry],,"University of California, San Francisco",Other,21-Mar-21,22-Mar-21,22-Mar-21,COHORT,2000,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",URINE COLLECTION,"CONTINUOUS, QUANTITATIVE KIT SCORE",The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY
NCT04705831,Recruiting,Interventional,Phase 4,IMMUNOe Research Centers,Industry,30-Dec-20,22-Jan-21,22-Jan-21,TREATMENT,40,POST-VIRAL FATIGUE SYNDROME,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",RUCONEST,NEUROPSYCHOLOGICAL MEASURES (BRIEF-A),"A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection"
NCT04705844,Not yet recruiting,Interventional,Phase 3,Ology Bioservices,Industry,21-Feb-21,22-Apr-21,22-Mar-21,TREATMENT,1444,MILD TO MODERATE COVID,,ALL,"40 Years to 80 Years   (Adult, Older Adult)",ADALIMUMAB,"ESTABLISH WHETHER TREATMENT WITH ADALIMUMAB IS ASSOCIATED WITH A LOWER RATE OF PROGRESSION TO SEVERE DISEASE AS DEFINED BY SEVERE ILLNESS OR CRITICAL ILLNESS, OR DEATH IN OUTPATIENT SUBJECTS WITH COVID-19","Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19"
NCT04706039,Not yet recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,21-Jan-21,21-Mar-21,21-Mar-21,DIAGNOSTIC,3000,COVID,FRANCE,ALL,"6 Years and older   (Child, Adult, Older Adult)",PERFORMANCE EVALUATION (SENSITIVITY AND SPECIFICITY) FOR COVID-19 DIAGNOSIS OF THE VOCUS PTR-TOF PROCESS,SENSITIVITY OF THE COVID-19 DIAGNOSTIC USING THE VOCUS PTR-TOF PROCESS.,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air
NCT04706143,Not yet recruiting,Observational,,Assiut University,Other,15-Jan-21,1-Aug-21,1-Jun-21,COHORT,100,COVID VACCINES,,ALL,"25 Years to 65 Years   (Adult, Older Adult)",COVID-19 VACCINES,MEASURE IMMUNE CELL ACTIVATION INDUCED BY THE VACCINE,"T Cell, Antibody and Cytokine Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians"
NCT04706156,Recruiting,Observational,,Masaryk University,Other,27-Jan-21,31-Mar-21,28-Feb-21,ECOLOGIC OR COMMUNITY,1540,ORAL MANIFESTATIONS,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 VACCINE,ORAL SIDE EFFECTS,Oral Side Effects of COVID-19 Vaccine: A Multicenter Cross-sectional Study
NCT04706260,Recruiting,Observational,,"University Hospital, Strasbourg, France",Other,14-Apr-20,14-Apr-21,14-Apr-21,CASE-CONTROL,600,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,RETROSPECTIVE EVALUATION OF THE CLINICAL EVOLUTION AND BECOMING OF ADULT PATIENTS INFECTED WITH COVID-19 HOSPITALIZED AT THE UNIVERSITY HOSPITALS OF STRASBOURG FROM THE EMERGENCY STRUCTURE,Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at the University Hospitals of Strasbourg : A Retrospective Observational Study
NCT04706299,Recruiting,Interventional,Not Applicable,The Cleveland Clinic,Other,12-Jan-21,1-Apr-21,1-Apr-21,PREVENTION,20,PREVENTION OF COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",RESISTANCE EXERCISE,EVALUATE THE EFFECTS OF WEARING A SURGICAL FACE MASK WHILE PERFORMING RESISTANCE EXERCISE ON AVERAGE PEAK FORCE AND TOTAL WORK PERFORMED.,"Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing"
NCT04706325,Recruiting,Observational,,Kocaeli Derince Education and Research Hospital,Other,1-Jan-21,15-May-21,1-May-21,CASE-CONTROL,100,ACUTE KIDNEY INJURY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",ACUTE KIDNEY INJURY,KDIGO,INVESTIGATION OF RISK FACTORS RELATED TO COVID-19 RELATED KIDNEY DAMAGE: A PROSPECTIVE OBSERVATIONAL STUDY
NCT04706390,Recruiting,Observational,,University of Bergen,Other,12-Jan-21,12-Jan-24,12-Jan-22,COHORT,2500,COVID,NORWAY,ALL,"20 Years to 100 Years   (Adult, Older Adult)",COVID-19 VACCINE,IMMUNE RESPONSES,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination
NCT04706403,Not yet recruiting,Interventional,Not Applicable,"University of Massachusetts, Worcester",Other,21-Jan-21,26-Dec-21,1-Jun-21,PREVENTION,3000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HEALTHCARE PROVIDERS' COMMUNICATION ABOUT THE COVID-19 VACCINE,INTENT TO BE VACCINATED AGAINST COVID-19.,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available"
NCT04706416,"Active, not recruiting",Interventional,Phase 1,Quantinosis.ai LLC,Industry,14-Nov-20,15-Jan-21,15-Jan-21,TREATMENT,50,CORONAVIRUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",N-ACETYL GLUCOSAMINE (NAG),RATE OF INTUBATION,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
NCT04706533,Recruiting,Observational,,University of Michigan,Other,23-Mar-20,21-Jun-21,21-Jun-21,COHORT,2000,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BIOMARKERS OF INFLAMMATION,"DEATH, NEED FOR MECHANICAL VENTILATION OR NEED FOR DIALYSIS","Prospective Observational Study Examining Clinical Characteristics, Inflammatory Markers, Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor"
NCT04707339,Recruiting,Observational,,Princess Alexandra Hospital NHS Trust,Other,30-Jan-20,30-Jan-21,31-Oct-20,COHORT,200,APPENDICITIS ACUTE,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",APPENDICECTOMY,NEGATIVE APPENDICECTOMY RATE,Management of Acute Appendicitis at District General Hospital
NCT04707534,Recruiting,Interventional,Phase 4,University of Oklahoma,Other,21-Jan-21,21-Jun-21,21-May-21,TREATMENT,300,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,WORLD HEALTH ORGANIZATION ORDINAL SCALE AT DAY 28,Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19
NCT04707664,Not yet recruiting,Interventional,Phase 2,"Partner Therapeutics, Inc.",Industry,21-Feb-21,21-Jun-21,21-Jun-21,TREATMENT,400,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SARGRAMOSTIM,"COVID-19-RELATED EMERGENCY ROOM VISIT OR COVID-19- RELATED HOSPITALIZATION, OR DEATH (ANY CAUSE)",A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19
NCT04707703,Not yet recruiting,Interventional,Phase 3,"Jeffrey Jenks, MD, MPH",Other,21-Jan-21,22-Mar-21,22-Jan-21,PREVENTION,162,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ISAVUCONAZONIUM INJECTION [CRESEMBA],THE INCIDENCE OF SARS-COV-2-ASSOCIATED INVASIVE ASPERGILLOSIS AT TIME OF ICU DISCHARGE,Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients
NCT04707742,Completed,Interventional,Not Applicable,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana,Other,15-Jun-20,18-Nov-20,18-Nov-20,PREVENTION,84,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",BETADINE© BUCAL 100 MG/ML,EFFECT OF 5 DIFFERENT MOUTHWASHES ON THE SARS-COV2 VIRAL LOAD.,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients
NCT04707820,Recruiting,Interventional,Not Applicable,"University Hospital, Rouen",Other,16-Apr-20,10-Jun-21,10-Jun-21,DIAGNOSTIC,80,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",ELISPOT,EVOLUTION OF THE NUMBER OF GAMMA INTERFERON (IFN) PRODUCING T LYMPHOCYTES IN RESPONSE TO THE S PROTEIN,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection
NCT04707833,Recruiting,Interventional,Not Applicable,"University Hospital, Rouen",Other,26-Nov-20,1-Dec-23,1-Dec-23,DIAGNOSTIC,385,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years to 80 Years   (Adult, Older Adult)",SEROLOGICAL TESTING FOR COVID-19 INFECTION,EVALUATION OF IMMUNOLOGICAL ABBOTT ARCHITECT SARS-COV-2 IGG ASSAY,Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen
NCT04708158,Not yet recruiting,Interventional,Phase 3,Genova Inc.,Industry,21-Jan-21,21-Jun-21,21-May-21,TREATMENT,385,COVID,,ALL,"20 Years and older   (Adult, Older Adult)",NOVAFERON,TIME TO CLINICAL IMPROVEMENT,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon vs. Placebo in Hospitalized Adult Patients With ModerateCOVID-19"
NCT04708236,Recruiting,Interventional,Phase 1/Phase 2,"Oryn Therapeutics, LLC",Industry,21-Apr-21,21-Jul-21,21-May-21,TREATMENT,18,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ORTD-1 LOW DOSE,INCIDENCE OF ADVERSE EVENTS,"A Blinded, Controlled, Escalating Dose Study of ORTD-1 for Treatment of Hospitalized Patients With SARS-CoV-2 (COVID-19) Related Pneumonia."
NCT04708327,Not yet recruiting,Interventional,Phase 2,"Cytocom, Inc.",Industry,21-Apr-21,22-Apr-21,22-Apr-21,TREATMENT,75,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",NALTREXONE HYDROCHLORIDE,PROPORTION OF PATIENTS WHO DEMONSTRATE PROGRESSION OF COVID-19 DISEASE,"A Randomized, Placebo-controlled, Phase 2 Study to Evaluate Safety and Efficacy of CYTO-205 (Low-dose Naltrexone) in Adult Patients With Mild COVID-19 Infection Who Are at High Risk for Disease Progression"
NCT04708340,Not yet recruiting,Interventional,Phase 1/Phase 2,"Reven Pharmaceuticals, Inc.",Industry,5-Mar-21,23-Feb-21,22-Oct-21,TREATMENT,237,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",REJUVEINIX (RJX) ACTIVE COMPARATOR,SAFETY AS MEASURED BY DLTS AND DRUG RELATED SAE'S,"A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19"
NCT04708457,Not yet recruiting,Interventional,Not Applicable,Australian and New Zealand Intensive Care Research Centre,Other,1-Feb-21,31-Jan-22,1-Dec-21,TREATMENT,12,MECHANICAL VENTILATION COMPLICATION,AUSTRALIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",VV-ECMO,NUMBER OF PARTICIPANTS WHO HAVE SARI AND HAVE BEEN MECHANICALLY VENTILATED FOR AT LEAST 5 DAYS.,"A Pilot Feasibility RCT of Early ECMO to DE-sedate, Extubate, and Mobilise in Severe Acute Respiratory Infection"
NCT04708912,Recruiting,Observational,,Basaksehir Cam & Sakura Şehir Hospital,Other,15-Dec-20,1-Feb-21,20-Jan-21,CASE-CONTROL,100,COVID,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",OBSERVATION,DETERMINATION OF PERIPHERAL BLOOD RNA MICROARRAY ASSAY,TUSEB-Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19)
NCT04709003,Recruiting,Observational,,Clalit Health Services,Other,23-Dec-20,22-Jun-21,22-Jun-21,COHORT,4504,COVID,ISRAEL,ALL,"18 Years to 120 Years   (Adult, Older Adult)",SEROLOGIC TEST,COVID-19 VACCINE EFFECTIVENESS (VE),Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI): A Prospective Cohort Study
NCT04709068,Recruiting,Observational,,Current Health,Industry,8-Feb-21,1-Jul-21,19-Mar-21,COHORT,2050,COVID,UNITED STATES,ALL,"21 Years and older   (Adult, Older Adult)",CURRENT HEALTH,HOSPITALIZATION,Risk Stratification and Early Alerting Regarding COVID-19 Hospitalization
NCT04709120,Recruiting,Observational [Patient Registry],,Eurasian Association of Therapists,Other,11-Jan-21,31-Dec-21,31-Mar-21,COHORT,2500,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",,DEATH,Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
NCT04709146,Not yet recruiting,Interventional,Not Applicable,"HaEmek Medical Center, Israel",Other,1-Mar-21,30-Jun-22,28-Feb-22,DIAGNOSTIC,70,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",AUDIO-VESTIBULAR EVALUATION,SENSONEURAL HEARING LEVEL - PTA,The Influence of Covid-19 on the Audio-vestibular System
NCT04709172,Recruiting,Interventional,Phase 4,Meiji Pharma Spain S.A.,Industry,5-Jan-21,30-Sep-21,5-Apr-21,TREATMENT,30,COVID PNEUMONIA,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",CEFDITOREN PIVOXIL 400MG,EVOLUTION OF PATIENT STATUS,"Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia"
NCT04709302,Recruiting,Observational [Patient Registry],,Medical University of Graz,Other,21-Feb-21,22-Dec-21,22-Jun-21,COHORT,342,COVID,NIGERIA,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19,NUMBER OF PATIENTS DEVELOPING ACUTE RESPIRATORY DISTRESS SYNDROME,"COVID-19 and Its Effects on Endothelium in HIV-Positive Patients in Sub-Saharan Africa: Cardiometabolic Risk, Thrombosis and Vascular Function"
NCT04709328,Not yet recruiting,Interventional,Phase 2/Phase 3,Sinocelltech Ltd.,Industry,1-Mar-21,1-Dec-21,1-Oct-21,TREATMENT,690,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SCTA01,PROPORTION OF PARTICIPANTS WHO EXPERIENCE COVID-19 RELATED HOSPITALIZATION (DEFINED AS AT LEAST 24 HOURS OF ACUTE CARE) OR DEATH (ALL CAUSE) UP TO DAY 29.,"An Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in High-Risk Outpatients With COVID-19 (MAOP3 Trial)"
NCT04709744,Completed,Observational,,Mansoura University,Other,1-Apr-20,30-Dec-20,25-Dec-20,CASE-ONLY,38,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VITAMIN D,LEVEL OF SERUM VITAMIN D IN SLE INFECTED WITH COVID-19,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic
NCT04709835,Not yet recruiting,Interventional,Phase 2,Hoffmann-La Roche,Industry,15-Jan-21,15-Feb-21,15-Feb-21,TREATMENT,220,COVID,BULGARIA,ALL,18 Years to 64 Years   (Adult),AT-527,CHANGE FROM BASELINE IN THE AMOUNT OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) VIRUS RNA,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Otherwise Healthy Non-Hospitalized Adult Patients With Mild or Moderate COVID-19"
NCT04710199,Not yet recruiting,Interventional,Phase 2,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla,Other,21-Feb-21,21-Oct-21,21-Aug-21,TREATMENT,40,VIRUS DISEASES,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",MARAVIROC EXPERIMENTAL GROUP,EVALUATE THE EFFICACY OF MARAVIROC IN SARS-COV-2 INFECTED PATIENTS HOSPITALIZED FOR COVID-19 USING THE ORDINAL SCALE.,Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19
NCT04710303,Not yet recruiting,Interventional,Phase 1,"ImmunityBio, Inc.",Industry,21-Feb-21,22-Apr-21,22-Apr-21,TREATMENT,35,COVID,,ALL,18 Years to 50 Years   (Adult),HAD5-S-FUSION+N-ETSD VACCINE,INCIDENCE OF MAAES AND SAES,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a City of a Prophylactiv COVID-19 Vaccination Using a 2nd Generation (E1/E2b/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)"
NCT04710316,Not yet recruiting,Interventional,Not Applicable,"Institut National de la Santé Et de la Recherche Médicale, France",Other,30-Jan-21,30-Sep-22,30-Apr-22,SCREENING,450,COVID,MALI,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 SCREENING BY MOLECULAR BIOLOGY,INCIDENCE RATE OF POSITIVE SARS-COV-2 RT-PCR IN BAMAKO HOSPITAL DEPARTMENTS DURING THE STUDY,"Étude de l'épidémie de SARS-CoV-2 Dans Les Services Hospitaliers de Bamako, Mali"
NCT04710329,Completed,Observational,,Sisli Hamidiye Etfal Training and Research Hospital,Other,16-Jan-21,10-Feb-21,25-Jan-21,COHORT,78,"RESPIRATORY DISTRESS SYNDROME, ADULT",TURKEY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",ASCORBIC ACID,SHORT TERM MORTALITY,"High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients, A Retrospective Cohort Study"
NCT04710381,Not yet recruiting,Interventional,Phase 4,University Hospital Ostrava,Other,1-Feb-21,30-Jun-21,31-May-21,PREVENTION,100,COVID,CZECHIA,ALL,18 Years to 60 Years   (Adult),IMUNOR,PREVENTION OF COVID-19 DISEASE,"Pilot, Monocentre, Phase-IV Clnical Trial Assessing the Clinical Effect of Per Oral Immunomodulation Treatment Using the IMUNOR® Preparation in the Prevention of COVID-19 Disease"
NCT04710394,Recruiting,Interventional,Not Applicable,Washington University School of Medicine,Other,11-Jan-21,11-Mar-22,11-Mar-22,TREATMENT,240,ANOSMIA,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",SMELL TRAINING,UNIVERSITY OF PENNSYLVANIA SMELL IDENTIFICATION TEST (UPSIT),Efficacy of Bimodal Visual-Olfactory Training in Participants With COVID-19 Resultant Hyposmia or Anosmia Using Participant-Preferred Scents
NCT04710771,Completed,Observational,,Sialkott College of Physical Therapy,Other,23-Nov-20,29-Jan-21,15-Jan-21,COHORT,30,COVID,PAKISTAN,ALL,"40 Years to 80 Years   (Adult, Older Adult)",PRONE LYING POSITION,PAO2,Effect of Prone Positioning and Alternate Nostril Breathing Technique in Patients With COVID-19: A Prospective Cohort Study.
NCT04710836,Recruiting,Observational,,Nottingham University Hospitals NHS Trust,Other,3-Dec-20,31-Aug-32,31-Aug-32,COHORT,500,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF PARTICIPANTS WITH SYMPTOMS AT PRESENTATION TO THE RESEARCH CLINIC,The Nottingham Recovery From COVID-19 Research Platform Assessment Clinic
NCT04711863,Recruiting,Interventional,Phase 2,Asan Medical Center,Other,16-Jan-21,31-Jul-21,31-May-21,TREATMENT,400,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,"KOREA, REPUBLIC OF",ALL,"18 Years to 85 Years   (Adult, Older Adult)",FLUVOXAMINE,CLINICAL DETERIORATION,"Fluvoxamine for Adults With Mild to Moderate COVID-19: A Single-blind, Randomized, Placebo-controlled Trial"
NCT04711954,Recruiting,Observational [Patient Registry],,Erasmus Medical Center,Other,1-Nov-20,1-Nov-22,1-Nov-21,COHORT,2000,HIV,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,PREVALENCE COVID19,COVID-19 in People Living With HIV in Light of the 90-90-90 Goals: A Netherlands/Ukraine Research Collaboration.
NCT04712045,Completed,Interventional,Not Applicable,University of Oxford,Other,1-Aug-20,12-Dec-20,12-Dec-20,PREVENTION,67,COVID,UNITED KINGDOM,ALL,"Child, Adult, Older Adult",NEW PPE,PROPORTION OF PARTICIPANTS AND SIMULATED PATIENTS WITH CONTAMINATION AS ASSESSED BY ULTRAVIOLET LIGHT,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic
NCT04712110,Recruiting,Interventional,Phase 1/Phase 2,Takeda,Industry,24-Feb-21,4-Apr-22,4-Apr-22,PREVENTION,200,PREVENTION OF INFECTION DISEASE CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV2),JAPAN,ALL,"20 Years and older   (Adult, Older Adult)",TAK-019,PERCENTAGE OF PARTICIPANTS WITH REPORTED SOLICITED LOCAL ADVERSE EVENTS (AES) FOR 7 DAYS FOLLOWING EACH VACCINATION,"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-019 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)"
NCT04712175,Not yet recruiting,Observational,,Centre Hospitalier Universitaire de Nīmes,Other,21-Jan-21,21-Jul-21,21-Jul-21,CASE-CONTROL,250,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",NASOPHARYNGEAL SAMPLING,DETECTION OF SARS-COV-2 ON NASOPHARYNGEAL SAMPLES (GOLD STANDARD),Validation Diagnostique de la détection Rapide du Virus SARS-CoV-2 Dans Des échantillons Salivaires Par spectrométrie de Masse
NCT04712279,Not yet recruiting,Interventional,Phase 2/Phase 3,Corpometria Institute,Other,25-Jan-21,20-Apr-21,21-Mar-21,TREATMENT,294,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN 0.6MG/KG/DAY,WORLD HEALTH ORGANIZATION (WHO) CLINICAL PROGRESSION SCALE [0 TO 10; 0 = UNINFECTED; 10 = DEATH],High-Dose Ivermectin for Mild-to-Moderate COVID-19 - The (HD)IVACOV Trial
NCT04712292,Recruiting,Observational,,Matteo Rottoli,Other,8-Sep-20,28-Feb-21,31-Jan-21,COHORT,2000,COLORECTAL NEOPLASMS MALIGNANT,ITALY,ALL,"Child, Adult, Older Adult",SURGICAL PROCEDURE FOR CANCER,ONCOLOGIC STAGE ACCORDING TO TNM CLASSIFICATION,"Impact of the Healthcare Lockdown Due to COVID-19 Pandemic on the Diagnosis, Treatment and Outcomes of Patients Affected by Colorectal Cancer Requiring Surgery: Results From a Retrospective Multicentric Study in Northern Italy"
NCT04712344,Recruiting,Interventional,Phase 2,University of Erlangen-Nürnberg Medical School,Other,18-Jan-21,21-Sep-21,21-Sep-21,TREATMENT,58,SEVERE COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 CONVALESCENT PLASMA,CHANGE IN SOFA SCORE FROM BASELINE VISIT,Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19
NCT04712357,Recruiting,Interventional,Not Applicable,Universidade Federal do Ceara,Other,9-Nov-20,23-Jan-21,22-Jan-21,TREATMENT,219,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN C 500 MG ORAL TABLET,"THE TIME TO RECOVERY, DEFINED AT DAY 7 DAYS FOLLOW UP AFTER ENROLLMENT, ON WHICH A PATIENT MET THE CRITERIA FOR CATEGORY 1, 2, OR 3 ON THE EIGHT-CATEGORY ORDINAL SCALE.","Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19"
NCT04713111,Completed,Interventional,Not Applicable,4YouandMe,Other,4-May-20,30-Nov-20,30-Nov-20,SCREENING,383,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",LIFESTYLE (MEDITATION),STUDY RETENTION,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices
NCT04713150,Recruiting,Observational,,Boston Children's Hospital,Other,5-Oct-20,21-Nov-21,21-Sep-21,COHORT,75,CHILD DEVELOPMENT,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,MATERNAL STRESS ASSOCIATED WITH A SARS-COV-2 DIAGNOSIS IN PREGNANCY.,HEALthy Brain and Child Development Study - COVID-19 Supplement
NCT04713163,Not yet recruiting,Observational [Patient Registry],,University of Manitoba,Other,21-Jan-21,21-Dec-21,21-Apr-21,COHORT,200,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVID19 VACCINE,NASAL T CELL RESPONSES,Prospective Evaluation of COVID-19 Vaccine Induced Immunity
NCT04713176,Not yet recruiting,Interventional,Phase 3,Daewoong Pharmaceutical Co. LTD.,Industry,18-Jan-21,30-Jun-21,30-Jun-21,TREATMENT,1120,SEVERE COVID,,ALL,"19 Years and older   (Adult, Older Adult)",DWJ1248 WITH REMDESIVIR,RATE OF MOTARLLITY OR ECMO PATIENTS,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients"
NCT04713488,"Active, not recruiting",Interventional,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,15-Jan-21,31-Jul-21,20-Jul-21,PREVENTION,110,COVID PREVENTION,RUSSIAN FEDERATION,ALL,"18 Years to 111 Years   (Adult, Older Adult)",SPUTNIK LIGHT,CHANGING OF ANTIBODY LEVELS AGAINST THE SARS-COV-2 GLYCOPROTEIN S,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso"
NCT04713540,Recruiting,Observational,,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,Other,1-Jan-21,1-May-21,1-Apr-21,COHORT,58,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,GLASKOW COMA SCALE,The Intensive Care Rehabilitation Experiences of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients of Pandemic Hospital in Turkey
NCT04713553,Recruiting,Interventional,Phase 3,BioNTech SE,Industry,15-Feb-21,24-Apr-21,24-Apr-21,PREVENTION,1530,SARS-COV2 INFECTION,UNITED STATES,ALL,"12 Years to 50 Years   (Child, Adult)",BNT162B2,"GEOMETRIC MEAN RATIO (GMR) OF SARS-COV-2 FULL-LENGTH S-BINDING OR S1-BINDING ANTIBODY LEVELS BETWEEN US LOTS (ARMS 1, 2 AND 3) IN PARTICIPANTS WITHOUT EVIDENCE OF INFECTION DURING THE STUDY","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE"
NCT04713852,Completed,Observational,,Jessa Hospital,Other,13-Mar-20,31-Dec-20,30-Sep-20,COHORT,116,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",,MORTALITY,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients: a Longitudinal Single-center Study
NCT04713878,Completed,Interventional,Not Applicable,Kanuni Sultan Suleyman Training and Research Hospital,Other,8-May-20,15-Jul-20,30-Jun-20,TREATMENT,21,CORONAVIRUS DISEASE 2019 (COVID) PNEUMONIA,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MESENCHYMAL STEM CELLS,CHANGE OF CLINICAL SYMPTOMS AS RESPIRATORY DISTRESS OR NEED FOR OXYGEN SUPPORT,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia
NCT04714008,Recruiting,Observational,,Nantes University Hospital,Other,1-Dec-20,31-Dec-22,31-Dec-22,ECOLOGIC OR COMMUNITY,180000,GAMBLING,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,TRAJECTORIES OF GAMBLING BEHAVIORS ACROSS TIME BEFORE AND DURING THE PANDEMICS,Impact of the COVID-19 Pandemic on Online Gambling in France and Sweden
NCT04714125,Recruiting,Observational,,University of Sao Paulo General Hospital,Other,19-Jun-20,1-Jun-22,1-Feb-21,COHORT,250,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",,COMPOSITE OUTCOME,Prognostic Value of Flow-mediated Dilation in Hospitalized Patients With SARS-CoV-2 Infection: an Observational Prospective Study
NCT04714138,Recruiting,Observational,,Groupe Hospitalier du Havre,Other,5-Jan-21,15-Mar-21,20-Feb-21,COHORT,190,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,HEALTH-RELATED QUALITY OF LIFE,Remote Evaluation of Quality of Life and Functional Capacities in Patients Hospitalised for COVID-19: a Prospective Observational Study
NCT04714333,Enrolling by invitation,Observational,,British Columbia Cancer Agency,Other,6-May-20,5-May-21,5-May-21,COHORT,1000,COVID,CANADA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",,COLLECT BREATH SAMPLES FROM COVID-19 POSITIVE PATIENTS AT TIME OF DIAGNOSIS AND POST RECOVERY,Detection of COVID-19 by Volatile Organic Compounds in Exhaled Breath (VOCs) - a Pilot Study
NCT04714515,Completed,Observational,,University of Sargodha,Other,20-Feb-20,20-Apr-20,30-Mar-20,COHORT,150,COVID,CHINA,ALL,"20 Years to 80 Years   (Adult, Older Adult)",MONTELUKAST,PATIENTS ADMITTANCE TO ICU,Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
NCT04715243,Recruiting,Interventional,Not Applicable,Sultan Qaboos University,Other,21-Jan-21,30-Jul-21,30-Apr-21,TREATMENT,360,ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID,OMAN,ALL,"18 Years and older   (Adult, Older Adult)",HIGH FLOW NASAL CANNULA (HFNC),RATE OF ENDOTRACHEAL INTUBATION,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients"
NCT04715295,Recruiting,Interventional,Phase 4,Yaounde Central Hospital,Other,5-Oct-20,5-Sep-21,30-May-21,TREATMENT,200,COVID,CAMEROON,ALL,"18 Years and older   (Adult, Older Adult)",DOXYCYCLINE TABLETS,CLINICAL,"Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19"
NCT04715360,Recruiting,Interventional,Phase 1/Phase 2,Hayandra Peduli Foundation,Other,29-Dec-20,27-Dec-21,29-Nov-21,TREATMENT,30,COVID,INDONESIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",AUTOLOGOUS ACTIVATED PLATELET-RICH PLASMA,"EFFECT OF AAPRP ON PRO-INFLAMMATORY CYTOKINES PLASMA LEVEL (IL-6, IL-1B, TNFA, IFN GAMMA, MCP-1) BEFORE AND AFTER INTERVENTION COMPARED TO CONTROL.",Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
NCT04715438,Recruiting,Observational,,University Medical Center Groningen,Other,8-Jan-21,23-Apr-21,21-Jul-21,COHORT,873,CANCER,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",,IMMUNE RESPONSE TO VACCINATION AGAINST COVID-19 MEASURED AS ANTIBODY RESPONSE EXPRESSED AS GEOMETRIC MEAN CONCENTRATION: ARBITRARY UNITS (AU)/ML,Vaccination Against cOvid In CancEr
NCT04715477,Recruiting,Observational,,Derince Training and Research Hospital,Other,17-Jan-21,15-Apr-21,1-Apr-21,CASE-CONTROL,100,ANXIETY,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL ANXIETY DEPRESSION MEASURE,INTENSIVE CARE ANXIETY,Intensive Care Anxiety in SARS-CoV-2 (COVID 19) Patients
NCT04715607,Recruiting,Interventional,Not Applicable,"Rigshospitalet, Denmark",Other,22-Jan-21,30-Mar-21,5-Mar-21,DIAGNOSTIC,22000,SARS-COV INFECTION,DENMARK,ALL,"16 Years to 120 Years   (Child, Adult, Older Adult)",SEQUENCE OF TESTING.,SARS-COV-2 DETECTION RATES FOR OROPHARYNGEAL SWABS (OPS) COMPARED WITH NASOPHARYNGEAL SWABS AND SALIVA COLLECTION.,"Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting"
NCT04715763,Not yet recruiting,Interventional,Phase 2,University of Hawaii,Other,1-Feb-21,31-Dec-22,31-Jan-22,TREATMENT,40,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TELMISARTAN ORAL PRODUCT,DURATION OF HOSPITALIZATION,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Treatment of COVID-19 in Hospitalized Patients"
NCT04715815,Not yet recruiting,Observational,,Prince of Songkla University,Other,21-Feb-21,22-Jun-21,21-Dec-21,COHORT,30,CHRONIC PAIN,,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION (ONLY INTERVIEW),TO EXPLAIN HOW THE COVID-19 AFFECTS CHRONIC PAIN PATIENTS IN TERMS OF PAIN AND PAIN MANAGEMENT.,Effects of COVID-19 on Chronic Pain Patients in Terms of Pain and Pain Management
NCT04715854,"Active, not recruiting",Interventional,Not Applicable,"Laboratory of Movement, Condorcet, Tournai, Belgium",Other,19-Feb-21,1-Jul-21,1-Apr-21,SUPPORTIVE CARE,15,HYPOXEMIC RESPIRATORY FAILURE,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",MASK,CHANGE IN PAO2 AND PACO2,Comparison of the Addition of an Aerosol Mask Above Nasal Canula on Oxygenation in Hypoxemic Failure
NCT04715919,Recruiting,Observational,,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,Other,15-Jan-21,1-Jun-21,1-Jun-21,COHORT,80,COVID,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CHEST COMPUTED TOMOGRAPHY,STRUCTURAL CHANGE IN LUNG,"Long Term Outcomes in Patients With Coronavirus Disease-19 (COVID-19) on Pulmonary Functions, Exercise Capacity, Lung Structure and Quality of Life"
NCT04715932,Recruiting,Interventional,Phase 2,Montreal Heart Institute,Other,18-Feb-21,21-May-21,21-May-21,TREATMENT,216,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",HESPERIDIN,PROPORTION OF SUBJECTS WITH COVID-19 SYMPTOMS.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)"
NCT04715997,Recruiting,Interventional,Phase 1/Phase 2,"Genexine, Inc.",Industry,30-Dec-20,30-Mar-22,30-May-21,PREVENTION,170,SARS-COV2,"KOREA, REPUBLIC OF",ALL,18 Years to 55 Years   (Adult),GX-19N,INCIDENCE OF SOLICITED ADVERSE EVENTS,"A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects"
NCT04716023,Recruiting,Observational,,Imperial College London,Other,23-Aug-19,2-Feb-22,22-Aug-21,CASE-ONLY,42,COPD,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",,RESPIRATORY RESISTANCE AT 5HZ - 20HZ (R5-R20) (KPA/L/S) RELATED TO AIRTRAPPING AS DETERMINED BY QUANTITATIVE CT (EXPIRATORY PHASE LOW ATTENUATION AREA <856 HU (%LAA <856 HU),Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19
NCT04716088,Completed,Observational,,The University Clinic of Pulmonary and Allergic Diseases Golnik,Other,18-Nov-20,22-Dec-20,2-Dec-20,CASE-ONLY,36,SARS-COV2 RAPID ANTIGEN TEST,SLOVENIA,ALL,"18 Years to 65 Years   (Adult, Older Adult)",RAPID ANTIGEN TEST FOR SARS COV2,SARS COV2 INFECTION,Usefulness of Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19 in the Hospital: a Pilot Study
NCT04716179,Recruiting,Interventional,Not Applicable,I.M. Sechenov First Moscow State Medical University,Other,18-Jan-21,18-May-21,18-May-21,BASIC SCIENCE,88,COVID,RUSSIAN FEDERATION,MALE,"18 Years to 65 Years   (Adult, Older Adult)",SPERM TEST,SEMEN QUALITY ANALYSIS - MOTILITY,Prospective Two-arm Study of Fertility in Men With COVID-19
NCT04716426,Recruiting,Interventional,Not Applicable,University of Nove de Julho,Other,28-Jan-21,21-Apr-21,21-Feb-21,PREVENTION,100,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TETRACYCLINE HYDROCHLORIDE 3%,COVID-19 CONTAMINATION RATE.,Use of APT™ T3X to Decrease the COVID-19 Contamination Rate in Humans
NCT04716465,Recruiting,Observational,,Moens Maarten,Other,19-Jan-21,23-Jan-21,23-Jan-21,COHORT,200,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",DYSAUTONOMIA,HEART RATE VARIABILITY,Dysautonomia in Patients Post COVID-19 Infection
NCT04716543,Not yet recruiting,Observational,,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),Other,21-Mar-21,22-Mar-21,22-Mar-21,COHORT,5400,INFLUENZA -LIKE ILLNESS,,ALL,"6 Months and older   (Child, Adult, Older Adult)",ILI AND COVID-19 DETECTION,PREVALENCE OF SARS-COV-2 RNA IN RESPIRATORY SAMPLES COLLECTED FROM INFLUENZA-LIKE ILLNESS PATIENTS FROM COHORT STUDY 2020-2021,One-health Approach in Epidemiological Investigation of SARS-CoV-2 in Laos
NCT04716556,"Active, not recruiting",Interventional,Not Applicable,Istituto Superiore di Sanità,Other,16-Jul-20,21-May-21,21-May-21,TREATMENT,474,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,NUMBER OF PATIENTS WHO MEET INVASIVE MECHANICAL VENTILATION OR DEATH,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial
NCT04716569,Recruiting,Interventional,Phase 2/Phase 3,South Valley University,Other,20-Jan-21,25-Feb-21,20-Feb-21,TREATMENT,150,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",INTRANASAL IVERMECTIN SPRAY,PROGRESSION OF COVID 19 CLINICAL PICTURE,"Faculty of Medicine ,South Valley University"
NCT04716647,Completed,Interventional,Not Applicable,Aarogyam UK,Other,9-Oct-20,18-Dec-20,12-Dec-20,SUPPORTIVE CARE,28,COVID,UNITED KINGDOM,ALL,"20 Years to 70 Years   (Adult, Older Adult)",AYURVEDA,TIME TO CLINICAL RECOVERY,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19
NCT04716907,Not yet recruiting,Observational,,CMC Ambroise Paré,Other,1-Feb-21,1-Feb-22,1-Feb-22,CASE-CONTROL,36,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SINGLE-NUCLEOTIDE POLYMORPHISMS (SNP) WITHIN THE TCRA/D REGION,GENETIC PREDISPOSITION TO SEVERE FORMS OF COVID-19,Thymic Function in Patients With COVID-19
NCT04716972,Not yet recruiting,Observational,,The Royal Wolverhampton Hospitals NHS Trust,Other,1-Apr-21,1-Dec-21,1-Dec-21,COHORT,200,COVID,,ALL,"Child, Adult, Older Adult",SURVEY,ACCEPTABILITY OF VACCINE STUDIES IN THE CARE HOME SETTING THROUGH FEEDBACK QUESTIONNAIRE WITH LOOSE THEMES AND NO UNIQUE MEASUREMENTS.,Evaluating the Impact of COVID-19 on Research in Care Homes
NCT04716985,Recruiting,Interventional,Not Applicable,AGIR à Dom,Other,22-Jan-21,22-Dec-22,22-Jul-21,PREVENTION,450,SARS-COV2,FRANCE,ALL,"60 Years and older   (Adult, Older Adult)",MOLECULAR HYDROGEN,CHANGE IN THE INCIDENCE RATE OF THE ONSET OF CLINICAL WORSENING,"Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care. Double-blind, Randomized, Comparative Study"
NCT04716998,Recruiting,Interventional,Phase 1/Phase 2,BonusBio Group Ltd,Industry,21-Jan-21,22-Jan-21,22-Jan-21,TREATMENT,35,COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",MESENCURE,SAFETY OF MESENCURE,A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19
NCT04717011,Recruiting,Observational,,Igenomix,Industry,21-Feb-21,21-Jul-21,21-Jul-21,CASE-ONLY,100,SARS-COV2,SPAIN,MALE,"18 Years to 65 Years   (Adult, Older Adult)",PCR TEST,SARS-COV-2 SEMEN RESULT,Case Series Biomedical Study to Detect the Presence of SARS-CoV-2 in Semen of Patients Diagnosed With COVID-19 Disease
NCT04717024,Recruiting,Observational,,Nanowear Inc.,Industry,15-Sep-20,31-Dec-21,31-Dec-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL STUDY - NO INTERVENTION,HOSPTIALIZED PATIENT DATA,The Nanowear Wearable Covid-19 Observational and Analysis Trend
NCT04717089,Recruiting,Observational,,Tuen Mun Hospital,Other,10-Feb-20,30-Jun-21,31-Jan-21,CASE-CONTROL,300,OVERNIGHT INTENSIVE RECOVERY,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",OVERNIGHT INTENSIVE RECOVERY / EXTENDED RECOVERY,TOTAL NUMBER OF ICU BED DAYS SPARED,The Rapid Conversion of Ordinary Recovery Beds to an Overnight Intensive Recovery (OIR) to Alleviate the High Pressure on Postoperative Intensive Care Demands During COVID-19 Pandemics in a Local Tertiary Hospital: a Multi-perspective Value-based Analysis
NCT04718220,Not yet recruiting,Interventional,Not Applicable,Washington University School of Medicine,Other,21-Feb-21,22-Nov-21,22-Nov-21,DIAGNOSTIC,420,COVID,,FEMALE,"Child, Adult, Older Adult",ANTIBODY TESTING FOR SARS-COV-2 IGG,RATE OF PRETERM DELIVERY,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19"
NCT04718285,Not yet recruiting,Interventional,Phase 2,Bahçeşehir University,Other,30-Jan-21,30-May-21,30-Apr-21,TREATMENT,380,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",MONTELUKAST ORAL TABLET,HOSPITALIZED PATIENT RATES,"A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment"
NCT04718467,Not yet recruiting,Interventional,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,Other,1-Feb-21,15-Mar-22,15-May-21,PREVENTION,4000,COVID,CHINA,ALL,"18 Years to 85 Years   (Adult, Older Adult)",RECOMBINANT COVID-19 VACCINE (SF9 CELLS),THE INCIDENCE OF ADVERSE REACTION (AR),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 to 85 Years Old"
NCT04718480,Recruiting,Interventional,Phase 2,SigmaDrugs Research Ltd.,Industry,27-Nov-20,21-Dec-21,21-Aug-21,TREATMENT,100,COVID,HUNGARY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",PLACEBO,TIME TO CLINICAL RECOVERY AFTER TREATMENT,"A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients"
NCT04718506,Recruiting,Interventional,Not Applicable,Universidad de Murcia,Other,12-Jan-21,12-Dec-21,12-Jun-21,TREATMENT,56,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",EXERCISE,CHANGES IN SUBJECT CLINICAL STATUS,"Rehabilitation for Post-COVID-19 Syndrome Through a Multicomponent, Educational and Supervised Exercise Intervention [RECOVE]"
NCT04718519,Completed,Observational,,Yale-NUS College,Other,22-Jun-20,11-Oct-20,11-Oct-20,COHORT,1288,CORONAVIRUS,SINGAPORE,MALE,"21 Years to 70 Years   (Adult, Older Adult)",FACTORS PROMOTING RESILIENCE,SELF-RATED WELL-BEING,Individual and Institutional Resilience in Migrant Workers During the COVID-19 Pandemic
NCT04719182,"Active, not recruiting",Observational,,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,1-Sep-20,1-Jul-21,1-Jan-21,COHORT,1000,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",ADJUNCTIVE THERAPIES,MORTALITY,Practice of Adjunctive Treatments in Intensive Care Unit Patients With Coronavirus Disease 2019 (PRoAcT-COVID) - an Observational Study in the Netherlands
NCT04719208,Recruiting,Interventional,Not Applicable,Augusta University,Other,6-Oct-20,21-Jun-21,21-May-21,PREVENTION,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",WATER (E) MOUTH RINSE WITH THE SOLUTION PROVIDED,CHANGE IN ORAL SARS-COV-2 LOAD IN ORAL CAVITY OF COVID-19 PATIENT USING PROPHYLACTIC MOUTH RINSE,Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse
NCT04719234,Completed,Interventional,Not Applicable,Bursa Yüksek İhtisas Education and Research Hospital,Other,15-Jun-20,1-Dec-20,1-Dec-20,DIAGNOSTIC,60,LUNG ULTRASOUND,TURKEY,ALL,"18 Years to 85 Years   (Adult, Older Adult)",LUNG ULTRASONOGRAPHY,RELATIONSHIP BETWEEN THORACIC CT IMAGING RESULTS AND LUS RESULTS,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virüs (COVID-19) Pneumonia
NCT04720118,Recruiting,Observational [Patient Registry],,Towson University,Other,21-Feb-21,21-May-21,21-Apr-21,OTHER,150,PARKINSON DISEASE,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION,MEASURE OF THE RELATIONSHIP BETWEEN LOCUS OF CONTROL AND QUALITY OF LIFE,Does Locus of Control Affect Satisfaction and Quality of Life During COVID - 19?
NCT04720235,Recruiting,Interventional,Not Applicable,Lucira Health Inc,Industry,9-Dec-20,30-Mar-21,9-Mar-21,DIAGNOSTIC,500,COVID,UNITED STATES,ALL,"14 Years to 75 Years   (Child, Adult, Older Adult)",LUCIRA COVID-19 ALL-IN-ONE TEST KIT,COVID-19 PREVALENCE RATE / EXPECTED VALUES COUNTS,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects
NCT04720378,Not yet recruiting,Interventional,Phase 1,"Noveome Biotherapeutics, formerly Stemnion",Industry,21-Feb-21,21-Aug-21,21-Aug-21,TREATMENT,12,CYTOKINE RELEASE SYNDROME,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",ST266,INCIDENCE AND SEVERITY OF TREATMENT-EMERGENT ADVERSE EVENTS,"A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection"
NCT04720404,Recruiting,Interventional,Not Applicable,Radboud University,Other,23-Jun-20,22-Feb-21,22-Feb-21,PREVENTION,220,MINDFULNESS,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",MINDFULNESS-BASED STRESS REDUCTION,"SOMATOFORM SYMPTOMS, ANXIETY, DEPRESSION",Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP)
NCT04720612,Not yet recruiting,Interventional,Phase 2,McGill University Health Centre/Research Institute of the McGill University Health Centre,Other,21-Feb-21,22-Jan-21,21-Jul-21,TREATMENT,200,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",OMALIZUMAB,INCIDENCE OF DEATH,COVID-19 Immunologic Antiviral Therapy With Omalizumab - An Adaptive Phase II Randomized-Controlled Clinical Trial
NCT04720794,Completed,Interventional,Not Applicable,Lucira Health Inc,Industry,25-Sep-20,20-Oct-20,20-Oct-20,DIAGNOSTIC,101,COVID,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",LUCIRA COVID-19 ALL-IN-ONE TEST KIT,COVID-19 PREVALENCE RATE / EXPECTED VALUES COUNTS,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay
NCT04721236,Recruiting,Interventional,Not Applicable,Catherine Klersy,Other,19-Nov-20,19-May-22,19-Nov-21,TREATMENT,300,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",HYPERIMMUNE PLASMA,CLINICAL IMPROVEMENT (EFFICACY),COVID-19 Wave II Study for Assessing the Early Use of Hyperimmune Plasma for the Treatment of COVID-19 Patients Needing Non-invasive or Invasive Mechanical Ventilation
NCT04721444,Recruiting,Observational,,Royal Marsden NHS Foundation Trust,Other,1-Mar-21,1-Jan-23,1-Aug-22,COHORT,1500,LUNG CANCER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",MACHINE LEARNING CLASSIFICATION OF PARENCHYMAL LUNG CHANGE CAUSE,DEVELOPMENT OF A MACHINE LEARNING MODEL TO DISTINGUISH PARENCHYMAL LUNG CHANGES,Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence
NCT04721457,Recruiting,Interventional,Phase 4,King Abdulaziz University,Other,3-Jan-21,30-Jun-21,28-Feb-21,PREVENTION,120,SARS-COV2,SAUDI ARABIA,ALL,"18 Years and older   (Adult, Older Adult)",DISTILLED WATER,CHANGE IN SARS-COV-2 VIRAL LOAD (QUANTITATIVE REAL-TIME REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION (QRT-PCR)),The Efficacy of Pre-procedural Mouth Rinses on SARS-CoV-2 Saliva Viral Load: A Randomized Control Clinical Trial
NCT04721535,Not yet recruiting,Interventional,Phase 3,Daewoong Pharmaceutical Co. LTD.,Industry,21-Jan-21,21-Jul-21,21-Apr-21,PREVENTION,1012,COVID,,ALL,"19 Years and older   (Adult, Older Adult)",DWJ1248,PERCENTAGE OF SUBJECTS WITH COVID-19,A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
NCT04723290,Completed,Interventional,Not Applicable,Grand Hôpital de Charleroi,Other,20-Jun-20,31-Dec-20,31-Oct-20,DIAGNOSTIC,4000,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL TESTS FOR SARS COV-2,SEROLOGICAL TESTS TO KNOW THE LEVEL OF ANTIBODIES AGAINST SARS COV-2,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members
NCT04723394,Recruiting,Interventional,Phase 3,AstraZeneca,Industry,28-Jan-21,27-May-22,30-Jun-21,TREATMENT,1700,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",AZD7442,A COMPOSITE OF EITHER SEVERE COVID-19 OR DEATH FROM ANY CAUSE THROUGH DAY 29.,"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults"
NCT04723407,Not yet recruiting,Observational,,"University Hospital, Limoges",Other,1-Feb-21,1-Mar-22,1-Jan-22,COHORT,950,RHEUMATISM,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRES,POST-TRAUMATIC STRESS,Assessment of the Psychological Impact of the COVID19 (SARS-CoV-2) Pandemic on Patients With Chronic Inflammatory Rheumatism According to a Management Strategy in the Rheumatology Department of Limoges University Hospital
NCT04723446,Not yet recruiting,Interventional,Not Applicable,Queen Mary University of London,Other,1-Feb-21,1-Jan-22,1-Jul-21,OTHER,40,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",CORSODYL® ALCOHOL FREE -0.2 % CHLORHEXIDINE DIGLUCONATE,VIRAL LOAD CHANGES IN THE SALIVA WITHIN GROUPS,Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study
NCT04723459,Recruiting,Interventional,Not Applicable,South Valley University,Other,23-Jan-21,28-Feb-21,19-Feb-21,PREVENTION,150,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN IMPREGNATED MASK,NUMBER OF PERSONS IN EACH GROUP WHO COMPLAIN OF ANY SUSPECTED SYMPTOMS,Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
NCT04723524,Recruiting,Interventional,Phase 2,University of Karachi,Other,22-Sep-20,21-Aug-21,21-Jun-21,TREATMENT,300,COVID,PAKISTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)","JINHUA QINGGAN (JHQG) GRANULES, TRADITIONAL CHINESE MEDICINE",CHANGE IN PRIMARY SYMPTOM (COUGH),"Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Effectiveness and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID 19 Patients"
NCT04723537,Recruiting,Interventional,Phase 2/Phase 3,RedHill Biopharma Limited,Industry,21-Feb-21,21-Sep-21,21-Sep-21,TREATMENT,310,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",PART A: UPAMOSTAT 200 MG,PART A - DETERMINATION OF THE SAFETY AND TOLERABILITY OF TWO DOSE LEVELS AND SELECTION OF AN UPAMOSTAT DOSE FOR PART B,"Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease"
NCT04723550,Recruiting,Interventional,Not Applicable,Wenwen Yin,Other,5-Jan-21,5-Jan-22,5-Nov-21,HEALTH SERVICES RESEARCH,120,TYPE 2 DIABETES MELLITUS,CHINA,ALL,18 Years to 55 Years   (Adult),HOSPITAL TELEMEDICINE MANAGEMENT SYSTEM,GLUCOSE CONTROL (HBA1C LEVELS),Impact of Telemedicine on Young and Middle-aged Obese Patients With Type 2 Diabetes Mellitus During COVID-19 Pandemic
NCT04723563,Enrolling by invitation,Interventional,Phase 4,Frederick Health,Other,22-Feb-21,29-May-21,1-May-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",HEPARIN,NEED FOR MECHANICAL VENTILATION AT DAY 28,INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia
NCT04723576,Recruiting,Interventional,Not Applicable,RAND,Other,3-Dec-20,30-Nov-23,22-Feb-21,HEALTH SERVICES RESEARCH,2132,HEALTHY,UNITED STATES,ALL,"Child, Adult, Older Adult",STRESS FIRST AID,POSTTRAUMATIC STRESS DISORDER (PTSD),Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
NCT04723589,Not yet recruiting,Interventional,Phase 2,University of Alabama at Birmingham,Other,1-Feb-21,1-Dec-21,1-Dec-21,TREATMENT,40,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",THAWED PLASMA,NUMBER OF PARTICIPANTS COMPLETING PLASMA INFUSION FOR COVID-19,Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)
NCT04723602,Recruiting,Interventional,Phase 1,Albert B. Sabin Vaccine Institute,Other,6-Jan-21,6-Dec-21,6-Dec-21,PREVENTION,32,EBOLA VIRUS DISEASE,UNITED STATES,ALL,18 Years to 50 Years   (Adult),CAD3-MARBURG,SAFETY OF EBOLA AND MARBURG VACCINES ASSESSED BY CLINICAL OBSERVATION.,"Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development"
NCT04723706,Not yet recruiting,Observational,,Henry Ford Health System,Other,1-Feb-21,1-Mar-22,1-Feb-22,COHORT,150,"HEMATOLOGIC DISORDERS AND BONE MARROW FAILURE, HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) OR CELLULAR THERAPY (CART)",UNITED STATES,ALL,"18 Years to 80 Years   (Adult, Older Adult)",COVID-19 SEROLOGY IGG,ESTIMATE RANGE FOR COVID-19 SEROLOGY IGG IN SCT AND CART PATIENTS POST VACCINE,Immunological Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
NCT04724395,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,21-Jan-21,23-Jan-21,23-Jan-21,COHORT,800,COVID,FRANCE,ALL,"18 Years to 70 Years   (Adult, Older Adult)",HOSPITALIZATION,"POST-ACUTE COVID-19 DISABILITY FROM THE CARE PROVIDER'S PERSPECTIVE, 9 MONTHS AFTER HOSPITALIZATION",Prospective Multicenter Cohort Study to Evaluate Disability Following Hospitalization in People of Working-age Surviving COVID-19
NCT04724434,Enrolling by invitation,Observational,,Hegau-Bodensee-Klinikum Singen,Other,4-Dec-20,26-Jun-21,21-Jun-21,COHORT,400,SARS-COV2 POSITIVE PATIENTS,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,RATE OF HOSPITALIZATION,Single Center Prospective Controlled Follow-up Study of COVID-19 Patients in the District Konstanz (FSC19-KN)
NCT04724538,Recruiting,Interventional,Phase 1/Phase 2,National Medical Research Radiological Centre of the Ministry of Health of Russia,Other,15-Oct-20,15-Mar-21,10-Feb-21,TREATMENT,15,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",99MTC-PERTECHNETATE,DOSIMETRY. TRANSITION COEFFICIENTS CALCULATION OF COUNT RATE TO ABSOLUTELY ACTIVITY OF 99MTC-PERTECHNETATE IN ROI.,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia
NCT04724616,Recruiting,Interventional,Not Applicable,Medical University of Vienna,Other,6-Jan-21,21-Jun-21,21-Jun-21,PREVENTION,60,COVID,AUSTRIA,ALL,3 Years to 6 Years   (Child),EDUCATIONAL PROGRAM (CARTOON),CHANGE OF EMOTIONAL OUTCOME,CARTOON: CoronAviRus educaTional prOgram fOr childreN to Promote Knowledge and Hygiene Measures and Dispel Fear During the COVID- 19 Pandemic
NCT04724629,Recruiting,Interventional,Phase 3,University of Sao Paulo,Other,5-Jan-21,30-Jul-21,31-Mar-21,TREATMENT,60,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",IXEKIZUMAB,ORDINAL SCALE OF SEVEN WORLD HEALTH ORGANIZATION (WHO) CATEGORIES OF IL-17 INHIBITOR VERSUS LOW DOSE IL-2 VERSUS INDIRECT IL-6 INHIBITOR (COLCHICINE) VERSUS STANDARD TREATMENT IN THE TREATMENT OF SEVERE COVID-19,"Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19"
NCT04724642,Recruiting,Observational,,Tel-Aviv Sourasky Medical Center,Other,28-Dec-20,28-Dec-21,28-May-21,CASE-ONLY,110,ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF SIDE EFFECTS IN PATIENTS,"Efficacy and Safety of COVID-19 Vaccine in Patients After Allogeneic Hamatopoietic Cell Transplantation, CAR-T Therapy and With Primary Immune Deficiency - a Post Marketing Prospective Cohort Study"
NCT04724681,Recruiting,Interventional,Not Applicable,University Hospital Bispebjerg and Frederiksberg,Other,1-Feb-21,31-Dec-21,31-Dec-21,PREVENTION,800,CLINICAL DETERIORATION,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",WARD CSS,CUMULATIVE DURATION OF DEVIATING VITAL SIGNS: SPO2 < 85% MIN-1,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection
NCT04724707,Recruiting,Observational [Patient Registry],,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Other,11-Sep-20,22-Dec-21,21-Dec-21,COHORT,900,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",,DEATH,An Open Multicenter Observational Study (Registry) of Patients Recovered From Novel Coronavirus Infection (COVID-19) With Involvement of the Cardiovascular System or With Baseline Severe Cardiovascular Diseases
NCT04724720,Recruiting,Interventional,Phase 2,Northwell Health,Other,19-Jan-21,21-Dec-21,21-Dec-21,TREATMENT,84,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FAMOTIDINE,CUMULATIVE INCIDENCE OF SYMPTOM RESOLUTION,"A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19"
NCT04724850,Not yet recruiting,Observational,,Juan Fernando Masa Jiménez,Other,1-Feb-21,1-Jul-23,1-Jul-22,COHORT,5000,CORONAVIRUS DISEASE 2019,,ALL,"Child, Adult, Older Adult",,TO DETERMINE THE EFFECTIVENESS OF THE PHARMACOLOGICAL TREATMENTS USED FOR HOSPITALIZED PATIENTS WITH COVID-19 IN CLINICAL PRACTICE ASSESSED IN TERMS OF MORTALITY.,Observational Study About the Characteristics and Evolution of Patients Diagnosed With COVID-19 in Extremadura
NCT04725084,Completed,Observational,,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,Other,1-Jul-20,15-Dec-20,15-Dec-20,COHORT,300,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2),FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",USE OF HIGH FLOW NASAL CANNULA ALONE,REFRACTORY HYPOXEMIA,Comparison of Non-invasive Oxygenation Strategies in ICU Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
NCT04725097,Recruiting,Observational,,Mayo Clinic,Other,10-Dec-20,30-Aug-21,31-Jul-21,COHORT,10000,COVID,INDIA,ALL,"18 Years to 89 Years   (Adult, Older Adult)",,COVID 19 DETECTION,Rapid Throughput Screening for Human COVID-19 Infection: A ECG Study
NCT04725110,Not yet recruiting,Interventional,Phase 2,University of Minnesota,Other,21-Mar-21,24-Mar-21,21-Mar-21,TREATMENT,250,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",INSTILLED T3,CHANGE EXTRAVASCULAR LUNG WATER INDEX,"Phase II Trial of Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 ARDS - A Multi-Site, Randomized, Double-blinded, Placebo-Controlled Clinical Trial"
NCT04726098,Recruiting,Interventional,Phase 4,Manuel Taboada Muñiz,Other,15-Jan-21,31-Dec-22,30-Jun-21,TREATMENT,198,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE HIGH DOSE,PERCENTAGE OF PATIENTS WITH TREATMENT FAILURE AT DAY 11,Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19
NCT04726111,Recruiting,Interventional,Not Applicable,Hopital Foch,Other,30-Dec-20,30-Aug-21,30-Jul-21,OTHER,200,COVID,FRANCE,FEMALE,"18 Years and older   (Adult, Older Adult)",SPECIMENS SPECIFIC FOR THE STUDY,PLACENTAL HISTOLOGICAL EVALUATION,COVID-19 and Pregnancy: Placental and Immunological Impacts
NCT04726137,Not yet recruiting,Observational,,PENTA Foundation,Other,30-Mar-21,30-Apr-22,31-Jul-21,COHORT,1150,SARS-COV2 ANTIBODIES IN CHILDREN AND ADOLESCENTS LIVING WITH HIV,,ALL,"up to 24 Years   (Child, Adult)",,NUMBER OF PARTICIPANTS WITH PRESENCE OF SARS-COV-2 ANTIBODIES ASSESSED BY SEROLOGY TESTS,European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Protocol
NCT04726150,Not yet recruiting,Observational [Patient Registry],,"University Hospital, Antwerp",Other,21-Apr-21,26-Apr-21,23-Apr-21,COHORT,250,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",ILR IMPLANTATION,PERCENTAGE OF ATHLETES WITH LGE ON CMR,Effect of CoVid-19 and Exercise on Myocardial Fibrosis and Ventricular Arrhythmias (CovidEx)
NCT04726163,Recruiting,Interventional,Not Applicable,"University Hospital, Strasbourg, France",Other,29-Jan-21,14-Jun-21,14-Jun-21,OTHER,60,"DIABETIC PATIENT (TYPE 1,2, MODY, SECONDARY) OR WITH CORTICOSTEROID-INDUCED DIABETES FOLLOWING INITIATION OF CORTICOSTEROID TREATMENT",FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",CONTINUOUS BLIND GLUCOSE MEASUREMENT DEVICE (FREE STYLE PRO),PERCENTAGE OF TIME SPENT IN THE RANGE 70-180 MG / DL (TIR),Tele-expertise for Glycemic Control Monitoring in Patients With Diabetes Hospitalized for Covid-19 Infection
NCT04726176,Recruiting,Observational,,Vrije Universiteit Brussel,Other,30-Jan-21,1-Jul-21,1-Jul-21,COHORT,40,COVID,BELGIUM,ALL,"40 Years to 76 Years   (Adult, Older Adult)",EXPOSURE TO COVID-19,BRAIN SCANS,COVID-19 and Brain Health
NCT04726371,Recruiting,Interventional,Not Applicable,Massachusetts General Hospital,Other,8-Jan-21,22-Oct-21,22-Oct-21,HEALTH SERVICES RESEARCH,5350,INTELLECTUAL DISABILITY,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",GENERIC BEST PRACTICES,NEW COVID-19 GROUP HOME INCIDENCE AT BASELINE,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings
NCT04726865,Completed,Observational,,University of Jordan,Other,1-Oct-20,31-Dec-20,20-Dec-20,OTHER,415,THE EFFECT OF COVID PANDEMIC,JORDAN,ALL,18 Years to 24 Years   (Adult),NASER AL-HUSBAN,PSYCHOLOGICAL STRESS AND ACADEMIC RESULTS,Effects of COVID-19 Pandemic on Medical Students in Jordanian Universities: A Multi-center Cross-sectional Study
NCT04727294,Recruiting,Observational,,HealthTree Foundation,Other,22-Jan-21,21-Dec-21,21-Jun-21,COHORT,1500,MULTIPLE MYELOMA,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",QUESTIONNAIRE,COVID-19 DIAGNOSIS AND TREATMENT,"Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey"
NCT04727372,Completed,Observational [Patient Registry],,Islamia University of Bahawalpur,Other,23-Jan-21,23-Feb-21,23-Feb-21,OTHER,986,"SOCIAL ACCEPTANCE, SOCIAL ANXIETY",PAKISTAN,ALL,"16 Years and older   (Child, Adult, Older Adult)",QUESTIONNAIRE,DEMOGRAPHICS (AGE),Social Acceptability of COVID-19 Vaccines in Pakistan: Fear and Social Trends
NCT04727424,Recruiting,Interventional,Phase 3,Cardresearch,Other,19-Jan-21,1-Mar-22,1-Feb-22,TREATMENT,2724,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",FLUVOXAMINE MALEATE 100 MG [LUVOX],"TO EVALUATE THE EFFECT OF FLUVOXAMINE, IVERMECTIN AND METFORMIN IN REDUCING NEED FOR EMERGENCY CARE AND OBSERVATION FOR MORE THAN 12 HOURS DUE TO THE WORSENING OF COVID-19;","A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin and Metformin in Reducing Hospitalization of Patients With Mild COVID-19 and a High Risk of Complications"
NCT04727762,Recruiting,Observational,,University of Valencia,Other,4-Feb-21,30-Mar-21,1-Mar-21,COHORT,500,FACE MASK SQUEEZE,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,GENERIC HEALTH,Population Impact on the Continued Use of the Mask Due to the Avoidance of COVID-19
NCT04727775,Recruiting,Interventional,Phase 1,Astana Medical University,Other,25-Nov-20,20-Mar-21,25-Jan-21,TREATMENT,300,COMPLICATION OF MEDICAL CARE,KAZAKHSTAN,ALL,"18 Years and older   (Adult, Older Adult)",FAVIPIRAVIR,OUTCOME WITHOUT COMLICATIONS,A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19
NCT04728347,Recruiting,Interventional,Phase 2,"Arcturus Therapeutics, Inc.",Industry,4-Jan-21,22-Jun-21,22-Jun-21,TREATMENT,106,SARS-COV2,SINGAPORE,ALL,"21 Years to 80 Years   (Adult, Older Adult)",ARCT-021,PERCENTAGES OF PARTICIPANTS REPORTING SOLICITED LOCAL ADVERSE EVENTS,"A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021"
NCT04728594,Completed,Interventional,Not Applicable,Geisinger Clinic,Other,15-Jan-21,20-Jan-21,17-Jan-21,PREVENTION,9656,VACCINATION REFUSAL,UNITED STATES,ALL,"Child, Adult, Older Adult",SOCIAL PROOF,NUMBER OF EMPLOYEES WHO SCHEDULED VACCINATION APPOINTMENTS AFTER 2 DAYS,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers
NCT04728698,Not yet recruiting,Interventional,Phase 2,"Sorrento Therapeutics, Inc.",Industry,21-Mar-21,21-Sep-21,21-Sep-21,TREATMENT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVI-MSC,MORTALITY AT DAY 28,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
NCT04728802,Not yet recruiting,Interventional,Phase 3,"Applied Biology, Inc.",Industry,1-Feb-21,30-Dec-21,30-Sep-21,TREATMENT,600,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",PROXALUTAMIDE,TREATMENT EFFICACY OF PROXALUTAMIDE RELATIVE TO STANDARD OF CARE ARM AS ASSESSED BY THE COVID-19 ORDINAL SCALE,Proxalutamide Treatment for Hospitalized COVID-19 Patients
NCT04728828,Recruiting,Observational,,Centre Hospitalier de Cornouaille,Other,25-Jan-21,15-Aug-23,15-Feb-23,COHORT,500,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGICAL COVID-19 VACCINE IMMUNOGENICITY,ANTIBODY SYNTHESIS INDUCED AFTER COVID-19 VACCINATION (POSITIVE OR NEGATIVE),Immune Response After COVID19 Vaccination in a Multicenter Cohort of In-center Haemodialysis Patients in France
NCT04728880,Recruiting,Observational,,Mansoura University,Other,26-Jan-21,30-May-21,31-Mar-21,COHORT,300,"PNEUMONIA, VIRAL",EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",REMDESIVIR,CHANGE FROM BASELINE IN PULSE RATE,Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
NCT04728906,Not yet recruiting,Interventional,Not Applicable,Rumah Sakit Pusat Angkatan Darat Gatot Soebroto,Other,5-Mar-21,19-Dec-21,19-Oct-21,TREATMENT,10,MYOCARDIAL INFARCTION,,ALL,40 Years to 60 Years   (Adult),HEART PATCH SEEDED WITH AUTOLOGOUS CARDIOMYOCYTES AND AMNION EPITHELIAL STEM CELLS,CHANGE OF THE ISCHEMIC BURDEN (%),Targeted-cell Therapy Using Epithelial Stem Cells and Patients' Cardiomyocytes Loaded in Amnion Bilayer to Regenerate Myocardial Infarction Post COVID-19 Complication
NCT04728919,Recruiting,Observational,,Tampere University Hospital,Other,15-Jan-21,15-Jan-24,15-Jan-22,CASE-CONTROL,80,COVID,FINLAND,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,VIRAL LOAD OF SARS-COV-2 FROM DIFFERENT SAMPLE SITES,Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection
NCT04728958,Not yet recruiting,Interventional,Not Applicable,University of Sheffield,Other,21-Jul-21,22-Sep-21,22-Apr-21,TREATMENT,219,WELLBEING,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",GRATITUDE,CHANGE IN ANXIETY LEVEL,Studying the Effect of Written Reflective Tasks With Healthcare Staff Working During the COVID-19 Health Pandemic
NCT04729075,Completed,Observational [Patient Registry],,Northwell Health,Other,19-Jan-21,19-Jan-21,19-Jan-21,COHORT,1800,"ARDS, HUMAN",UNITED STATES,ALL,"Child, Adult, Older Adult",ARDS AND COVID19 TREATMENTS,INDEX HOSPITAL SURVIVAL,"Towards Precision Medicine for COVID-19 ARDS - An Analysis of the NorthCARDS (Northwell Health COVID-19 ARDS) Dataset to Identify Associations Between Patient-level Factors, Inpatient Treatment and Clinical Trajectories on Mechanical Ventilation Liberation and Survival"
NCT04729140,Recruiting,Interventional,Phase 4,"Max Health, Subsero Health",Other,28-Dec-20,28-Mar-22,28-Dec-21,TREATMENT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN TABLETS,DECREASED ADMISSION RATE TO THE HOSPITAL SECONDARY TO RESPIRATORY ILLNESS RELATED TO COVID-19,A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS)
NCT04729153,Not yet recruiting,Observational,,Assiut University,Other,21-Feb-21,22-Mar-21,22-Feb-21,CASE-CONTROL,100,COVID,,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DAAD COMPOUND,EVALUATE THE EFFECT OF DAADS ON COVID -19,Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity
NCT04729374,Recruiting,Observational,,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,Other,27-Jan-21,31-Dec-23,31-Dec-23,COHORT,200,SARS-COV2,CHINA,ALL,18 Years to 59 Years   (Adult),,CONCENTRATION OF ANTI-SARS-COV-2 NEUTRALIZING ANTIBODY IN SERUM,"Longidutinal, Dynamic Analysis of COVID-19 Vaccine Induced Adaptive Immune Responses"
NCT04729452,Recruiting,Observational,,Lucy Jones,Other,1-Jun-20,1-Dec-23,1-Oct-23,COHORT,200,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD TEST,DETERMINATION OF KEY PROTECTIVE CELLULAR IMMUNE PARAMETERS,Characterisation of the Immune Response to SARS-CoV-2 Infection
NCT04729491,Completed,Interventional,Phase 2/Phase 3,Corpometria Institute,Other,30-Jun-20,7-Oct-20,15-Sep-20,TREATMENT,138,COVID,BRAZIL,MALE,"18 Years and older   (Adult, Older Adult)",DUTASTERIDE 0.5 MG,POSITIVITY RATE OF RTPCR-SARS-COV-2 (QUALITATIVE ANALYSIS),Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial)
NCT04729595,Not yet recruiting,Interventional,Phase 2/Phase 3,Adamis Pharmaceuticals Corporation,Industry,1-May-21,30-Jan-22,30-Dec-21,TREATMENT,310,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",TEMPOL,PRIMARY OUTCOME MEASURE,"A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) on Preventing COVID-19 Related Hospitalization in Subjects With COVID-19 Infection"
NCT04730206,Not yet recruiting,Interventional,Phase 3,KU Leuven,Other,21-Mar-21,23-May-21,22-May-21,TREATMENT,1306,COVID,,ALL,"50 Years and older   (Adult, Older Adult)",CAMOSTAT,ALL-CAUSE UNPLANNED HOSPITAL ADMISSION FOR AT LEAST 24 HOURS OR DEATH,The DAWN Camostat Trial: the Efficacy of Camostat for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial
NCT04730284,Recruiting,Interventional,Not Applicable,Chinese University of Hong Kong,Other,25-Aug-20,31-Mar-22,30-Sep-21,OTHER,20,CORONAVIRUS,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",HEALTH SUPPLEMENTS,CHANGES IN GUT MICROBIOME,Evaluation of a Synbiotic Formula in Patient With COVID-19
NCT04730323,Completed,Interventional,Phase 4,FMH College of Medicine and Dentistry,Other,12-May-20,12-Jun-20,12-Jun-20,TREATMENT,93,COVID,PAKISTAN,ALL,"16 Years to 85 Years   (Child, Adult, Older Adult)",TOCILIZUMAB,DECREASED MORTALITY IN PARTICIPANTS,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
NCT04730401,Recruiting,Interventional,Phase 2,Helsinki University Central Hospital,Other,27-Jan-21,31-Dec-21,31-Aug-21,TREATMENT,390,COVID,FINLAND,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA FROM COVID-19 DONORS,SAFETY (SAE),"Randomized, Double-Blind, Placebo-Controlled Study of Convalescent Plasma in the Treatment of Covid-19"
NCT04730427,Recruiting,Interventional,Phase 1,"Genexine, Inc.",Industry,21-Jan-21,22-Apr-21,21-May-21,TREATMENT,40,COVID,"KOREA, REPUBLIC OF",ALL,"19 Years and older   (Adult, Older Adult)",GX-I7,"INCIDENCE RATE, CHARACTERISTICS, AND SEVERITY OF ADVERSE REACTIONS",A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19
NCT04730661,Recruiting,Interventional,Not Applicable,"University Hospital, Rouen",Other,21-Dec-20,28-Dec-21,21-Dec-21,SCREENING,146,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SIT TO STAND TEST,"PROPORTION OF LATE HOSPITALIZATIONS, WITHIN 48 HOURS OF FIRST DISCHARGE FROM EMERGENCY DEPARTMENT, AND MOTIVATED BY WORSENING SYMPTOMS SECONDARY TO SARS-COV2 INFECTION.",Efficacy of the Sit to Stand Test (STST) in the Decision to Hospitalize a Patient Consulting the Emergency Department for COVID 19 (Coronavirus Infectious Disease)
NCT04730856,Not yet recruiting,Interventional,Phase 3,Hospital Universitario Infanta Leonor,Other,29-Jan-21,31-Jul-21,1-Jun-21,TREATMENT,600,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",TINZAPARIN,REDUCTION OF SUSPICION OF SYSTEMIC THROMBOTIC SYMPTOMATIC EVENTS,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)
NCT04730895,Not yet recruiting,Interventional,Phase 1/Phase 2,Kafrelsheikh University,Other,21-Feb-21,23-Dec-21,21-Apr-21,PREVENTION,360,COVID VACCINE,,MALE,18 Years to 40 Years   (Adult),ORAL 13 CIS RETINOIC ACID,ASSESS THE EFFICACY OF THE CANDIDATE ORAL AND AEROSOLIZED ISOTRETINOIN FOR PROVIDING COMPLETE PROTECTION AGAINST COVID-19 IN ADULTS AGED 18 YEARS AND OLDER.,(Isotretinoin (13- Cis-Retinoic Acid) Versus Spike Protein Based Vaccine
NCT04730934,Completed,Observational [Patient Registry],,Kars State Hospital,Other,1-Jan-21,25-Feb-21,25-Feb-21,COHORT,1360,FIBROMYALGIA,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",PERCEIVED STRESS SCALE,PHYSICAL ACTIVITY,Evaluation of the Physical and Emotional Effects of the COVID-19 Pandemic on Fibromyalgia Patients
NCT04731051,Not yet recruiting,Interventional,Phase 1/Phase 2,King Hussein Cancer Center,Other,21-Mar-21,21-Sep-21,21-Sep-21,TREATMENT,28,2019 NOVEL CORONAVIRUS,JORDAN,ALL,"18 Years and older   (Adult, Older Adult)",HCQ01,"PROPORTION OF PARTICIPANTS WHO IMPROVE BY AT LEAST ONE LEVEL LOWER ON THE 11-POINT WORLD HEALTH ORGANIZATION ORDINAL SCALE FOR CLINICAL IMPROVEMENT (WHO-OSCI), WHERE PATIENTS ARE SCORED ON A SCALE OF 0-10 WITH 0 BEING UNINFECTED AND 10 BEING DEAD .","A Pilot, Randomized, Open-label Trial to Determine the Feasibility, Safety, Efficacy, and Pharmacokinetics of Nebulized HCQ01 for the Treatment of Patients With COVID-19 and Cancer"
NCT04731116,Recruiting,Interventional,Phase 1/Phase 2,Rabin Medical Center,Other,10-Jan-21,30-Apr-22,31-Dec-21,TREATMENT,40,COVID,ISRAEL,ALL,"18 Years and older   (Adult, Older Adult)",CANNABIDIOL,SERUM C-REACTIVE PROTEIN (CRP) LEVEL,Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection
NCT04731324,Recruiting,Interventional,Phase 1,Cadila Healthcare Limited,Industry,5-Jan-21,30-Dec-21,22-Oct-21,TREATMENT,42,HEALTHY,INDIA,ALL,18 Years to 55 Years   (Adult),ZYIL1 CAPSULE,INCIDENCE AND SEVERITY OF ADVERSE EVENT OF ZYIL1 FOLLOWING A SINGLE ORAL DOSE IN HEALTHY SUBJECTS,"A Phase 1, Prospective Open Label, Single Dose, Single Arm Study of ZYIL1 Administered Via Oral Route to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Adult Human Subjects"
NCT04731870,Not yet recruiting,Observational,,East Carolina University,Other,21-Feb-21,23-Jan-21,23-Jan-21,COHORT,632,CORONAVIRUS,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",SURVEY RESEARCH,COVID-19 VACCINE CONFIDENCE (SURVEY TO BE DEVELOPED BY STUDY TEAM),Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines Among a Cross-section of US Healthcare Providers and Key At-risk Subgroups in the Rural South
NCT04732468,Not yet recruiting,Interventional,Phase 1,"ImmunityBio, Inc.",Industry,21-Feb-21,22-Apr-21,22-Apr-21,TREATMENT,65,COVID,UNITED STATES,ALL,18 Years to 55 Years   (Adult),HAD5-S-FUSION+N-ETSD (SUSPENSION FOR INJECTION),INCIDENCE OF MAAES AND SAES,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers"
NCT04732637,Not yet recruiting,Observational,,Datar Cancer Genetics Limited,Industry,26-Feb-21,31-Aug-21,31-May-21,COHORT,300,COVID,INDIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)","TEST AT HOME'S PROPRIETARY ""LOLLIPOP"" BUCCAL CAVITY SWAB",CONCORDANCE BETWEEN BUCCAL CAVITY SWAB AND CONTEMPORARY NASAL SWAB.,Evaluating the Use of Flavour-stimulated Oral Fluids Collection for Severe Acute Respiratory Syndrome Coronavirus 2 Detection by Reverse Transcriptase Polymerase Chain Reaction and Enzyme Linked Immunosorbent Assay - a Concordance Study.
NCT04732663,Not yet recruiting,Observational,,University of Alberta,Other,21-Feb-21,22-Feb-21,22-Feb-21,CASE-CONTROL,225,COVID,CANADA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NO INTERVENTION,PEAK OXYGEN UPTAKE (VO2PEAK),Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19
NCT04732702,Recruiting,Observational,,University of Cologne,Other,29-Oct-20,30-Apr-21,31-Jan-21,COHORT,30,MOTHER-CHILD INTERACTION,GERMANY,ALL,6 Months to 9 Months   (Child),NO INTERVENTION,ANALYSIS OF THE MOTHER-CHILD-INTERACTION,"Effects of Contact Restrictions During the COVID-19 Pandemic on Newborns and Their Parents in Terms of Mother-infant Interaction, Parental Well-being, Expression and Methylation of Candidate Genes of Stress Signaling Pathways"
NCT04732767,Not yet recruiting,Observational,,Atrium Health,Other,20-Jan-21,30-Jun-21,30-Jun-21,COHORT,50,COVID,,FEMALE,"18 Years and older   (Adult, Older Adult)",,PRESENCE OF COVID-19 IGG ANTIBODIES BY IMMUNOASSAY IN MATERNAL AND CORD BLOOD SAMPLES.,Prospective Study of Maternal and Umbilical Cord Blood Collection to Evaluate for Presence of COVID-19 Antibody Response in COVID-19 Positive Women
NCT04732819,Recruiting,Interventional,Not Applicable,Brown University,Other,4-Jan-21,19-Apr-21,19-Apr-21,HEALTH SERVICES RESEARCH,22500,COVID VACCINES,UNITED STATES,ALL,"Child, Adult, Older Adult",HIGH TOUCH MULTI-PRONGED BEHAVIORAL INTERVENTION,PATIENT VACCINE COUNTS,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities
NCT04732858,"Active, not recruiting",Observational,,Assistance Publique - Hôpitaux de Paris,Other,1-Mar-20,1-Jun-21,31-Aug-20,ECOLOGIC OR COMMUNITY,50,COVID,FRANCE,ALL,"18 Years to 75 Years   (Adult, Older Adult)",CROSS SECTIONAL E-SURVEY ON SURGEONS EXPOSED TO ANY EDUCATIONAL INTERVENTION,KIRKPATRICK LEVEL 3 ON A 5-MODALITIES LIKERT SCALE,"Educational Interventions to Integrate Surgical Staff Within Medical Units During the COVID-19 Pandemic: EDUCOVID Cross-sectional, E-survey"
NCT04732949,Recruiting,Interventional,Phase 3,Synairgen Research Ltd.,Industry,12-Jan-21,1-Sep-21,1-Jun-21,TREATMENT,610,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SNG001,TIME TO HOSPITAL DISCHARGE,"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19"
NCT04733105,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,21-Feb-21,21-May-21,21-May-21,OTHER,530,ACUTE RESPIRATORY FAILURE,,ALL,"18 Years and older   (Adult, Older Adult)",,DAY-28 MORTALITY,Pronostic Value of Type I ANTi-Interferon Antibodies in Patients With COVID-19 Acute Respiratory Failure: a Multicenter Observational Study
NCT04733170,Not yet recruiting,Observational,,Vatic Ltd.,Industry,15-Feb-21,31-Aug-21,31-Aug-21,CASE-ONLY,600,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",KNOWNOW SARS-COV-2 RAPID ANTIGEN TEST,ASSESS CLINICAL DIAGNOSTIC PERFORMANCE OF THE KNOWNOW SARS-COV-2 RAPID ANTIGEN TEST,Clinical Performance Evaluation of KnowNow SARS-CoV-2 Test for the Detection of COVID-19 Antigen
NCT04733625,Completed,Interventional,Not Applicable,Kasr El Aini Hospital,Other,15-Sep-20,17-Dec-20,17-Dec-20,TREATMENT,56,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",CHOLECALCIFEROL,DEATH OR NEED FOR INTUBATION,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection
NCT04733651,Not yet recruiting,Interventional,Phase 2,Nepal Health Research Council,Other,20-Feb-21,15-Aug-21,20-May-21,TREATMENT,250,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",HOSPITAL STANDARD OF CARE FOR COVID-19,"DISEASE PROGRESSION, DEFINED AS WHO CLINICAL PROGRESSION SCALE SCORE OF ≥ 6, AT ANY TIME FROM DAY 1 TO DAY 28","A Randomized, Open-labelled and Controlled Clinical Trial to Investigate the Clinical Efficacy of Isoquercetin in the Treatment of Mild-to-moderate Hospitalised COVID-19 Patients"
NCT04733677,Not yet recruiting,Observational,,Wake Forest University Health Sciences,Other,21-Feb-21,21-Jun-21,21-Jun-21,COHORT,200,COVID,UNITED STATES,ALL,"Child, Adult, Older Adult",,PERCENTAGE OF SUCCESSFUL FITS,User Experience of the OSR M1 Reusable Elastomeric Air Purifying Respirator in Non-Clinical Settings
NCT04733729,Recruiting,Observational [Patient Registry],,Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne,Other,1-Mar-20,31-Dec-21,30-Jan-21,COHORT,3000,COVID INFECTION IN HEMATOLOGICAL MALIGNANCIES PATIENTS,ITALY,ALL,"18 Years to 99 Years   (Adult, Older Adult)",,EPIDEMIOLOGY OF COVID-19 INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES,Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey
NCT04733807,Recruiting,Observational,,University of Roma La Sapienza,Other,28-Jan-21,1-Feb-22,31-Jul-21,ECOLOGIC OR COMMUNITY,600,COVID,ITALY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",BNT162B2 MRNA COVID-19 VACCINE,SERUM IGM AND IGG ANTIBODIES LEVELS IN RESPONSE TO VACCINE,SARS-Cov-2 Antibodies Response to BNT162b2 mRNA Vaccine to Prevent Covid-19
NCT04733833,Recruiting,Interventional,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,Industry,26-Jan-21,30-Jun-22,30-Jun-22,TREATMENT,30,SEVERE COVID,ISRAEL,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VB-201 + STANDARD OF CARE,ASSESS THE SAFETY AND TOLERABILITY OF VB-201,"A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19"
NCT04733846,Not yet recruiting,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,21-Feb-21,21-Mar-21,21-Mar-21,COHORT,9,EYE TRAUMA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION,VISUAL ACUITY (SNELLEN SCALE),Corneal Wounds Repair Emergencies During COVID-19 : 10/0 Absorbable Polyglactin Sutures as a Valuable Strategy
NCT04734171,Completed,Interventional,Not Applicable,Columbia University,Other,2-Apr-20,16-Apr-20,16-Apr-20,PREVENTION,1200,COVID,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DIGITAL SOCIAL ACTIVITY VIDEO INTERVENTION,CHANGE IN TOTAL STIGMA SCORE 2 WEEKS AFTER THE INTERVENTION,"COVID-19 and Its Implications on Social Activity, Loneliness and Stigma"
NCT04734223,Completed,Observational,,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,Other,1-Apr-20,31-Dec-20,31-Dec-20,CASE-CONTROL,436,NEUROIMAGING,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",NEUROIMAGING FINDINGS IN PATIENTS WITH COVID-19,FREQUENCY OF ACUTE THROMBOEMBOLISM IN COVID-19 PATIENTS UNDERGOING NEUROIMAGING,Correlation of Neuroimaging Findings With Clinical Presentation and Laboratory Data in Patients With COVID-19: A Single Center Study
NCT04734561,Not yet recruiting,Interventional,Not Applicable,Universidad Complutense de Madrid,Other,8-Feb-21,30-Jul-22,30-Jul-22,TREATMENT,88,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",INSPIRATORY MUSCLE TRAINING GROUP,HEALTH-RELATED QUALITY OF LIFE,"Effects of Respiratory Muscle Training on Quality of Life, Physical and Pulmonary Function and Psychological Status in Patients Who Have Had COVID-19 Disease"
NCT04734678,Recruiting,Observational,,Ain Shams University,Other,1-Dec-20,1-Jun-21,1-Mar-21,COHORT,84,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",TOCILIZUMAB,PATIENTS' CLINICAL STATUS IMPROVEMENT USING SIX CATEGORY SCALE,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
NCT04734717,Enrolling by invitation,Interventional,Not Applicable,Somogy Megyei Kaposi Mór Teaching Hospital,Other,12-Jan-21,12-Apr-21,12-Apr-21,TREATMENT,2,COVID,HUNGARY,ALL,"20 Years to 65 Years   (Adult, Older Adult)",NEUROLOGY TEST,EQ5D-5L,Coordination and Locomotor Problems in Patients With Covid-19 Virus
NCT04734860,Not yet recruiting,Interventional,Phase 2,"Sorrento Therapeutics, Inc.",Industry,21-Mar-21,21-Nov-21,21-Sep-21,TREATMENT,500,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVI-AMG,PROPORTION OF SUBJECTS WHO HAVE REMAINED OUT OF THE HOSPITAL OR EMERGENCY ROOM THROUGH DAY 29,"A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms"
NCT04734873,Recruiting,Interventional,Phase 3,"Corvus Pharmaceuticals, Inc.",Industry,21-Feb-21,30-Jan-22,30-Dec-21,TREATMENT,1000,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",CPI-006 2 MG/KG + SOC,TO COMPARE THE PROPORTION OF PARTICIPANTS ALIVE AND RESPIRATORY FAILURE FREE OF CPI-006 PLUS SOC VERSUS PLACEBO PLUS SOC,"Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients"
NCT04734886,Recruiting,Interventional,Not Applicable,"Örebro University, Sweden",Other,27-Nov-20,31-Dec-21,30-Aug-21,BASIC SCIENCE,400,COVID,SWEDEN,ALL,18 Years to 60 Years   (Adult),L. REUTERI DSM 17938 + VITAMIN D,SARS-COV-2 SPECIFIC ANTIBODIES,Exploratory Study on the Effects of Probiotic Supplementation on SARS-CoV-2 Antibody Response in Healthy Adults
NCT04734912,Recruiting,Interventional,Not Applicable,Johannes Gutenberg University Mainz,Other,13-Jan-21,31-Dec-21,15-Jun-21,SUPPORTIVE CARE,500,ENDOSCOPY,GERMANY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",GASTROSCOPY IN TRANSNASAL TECHIQUE,QUESTIONNAIRE,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic
NCT04735588,Not yet recruiting,Observational,,Gruppo Italiano Malattie EMatologiche dell'Adulto,Other,21-Apr-21,23-Oct-21,22-Jan-21,CASE-ONLY,140,IMMUNE THROMBOCYTOPENIA,,ALL,"18 Years and older   (Adult, Older Adult)",,NUMBER OF ITP PATIENTS IN WHICH COVID-19 OCCURS,"IMMUNE THROMBOCYTOPENIA (ITP) AND COVID-19: National Retrospective and Prospective Observational Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP"
NCT04735744,Not yet recruiting,Observational,,Radboud University,Other,15-Feb-21,1-Jan-24,17-Jul-22,COHORT,1315,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PATIENTS RECOVERING FROM COVID19 RECEIVE USUAL CARE BY ALLIED HEALTH PROFESSIONALS,PARTICIPATION,Evaluation of Allied Healthcare in Patients Recovering From COVID-19
NCT04735757,Recruiting,Observational,,VU University Medical Center,Other,3-Feb-21,19-Jan-23,19-Jan-23,CASE-CONTROL,40,DIAPHRAGM DISEASE,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",CONTRAST-ENHANCED MRI,TISSUE CHARACTERISTICS OF THE DIAPHRAGM,"Effects of COVID-19-infection and Mechanical Ventilation on Movement and Tissue Characteristics of the Diaphragm, Visualized by Magnetic Resonance Imaging: a Proof-of-concept Study"
NCT04736004,Not yet recruiting,Observational,,Duke University,Other,15-Mar-21,30-Apr-22,30-Apr-22,CASE-CONTROL,500,CARDIAC INVOLVEMENT WITH COVID,UNITED STATES,ALL,18 Years to 30 Years   (Adult),,RATE OF DEFINITE MYOCARDITIS AS MEASURED BY CMR (CARDIAC MAGNETIC RESONANCE IMAGING),Hearts of Athletes Study: Prospective Evaluation of Athletes for Cardiac Involvement With COVID-19
NCT04736524,Recruiting,Observational,,Texas Cardiac Arrhythmia Research Foundation,Other,15-Jan-21,22-Mar-21,22-Mar-21,COHORT,500,IGM AND IGG IN BLOOD,UNITED STATES,ALL,"16 Years to 85 Years   (Child, Adult, Older Adult)",RAPID ANTIBODY TEST,POST-VACCINATION IMMUNE RESPONSE,Immune Response Following COVID-19 Vaccination (IFVAC)
NCT04736680,Not yet recruiting,Observational,,Hospital General de Niños Pedro de Elizalde,Other,1-Mar-21,1-Sep-21,1-Sep-21,COHORT,667,TELEHEALTH,,ALL,"1 Month to 18 Years   (Child, Adult)",,PREVALENCE OF MISSED APPOINTMENTS,"Pediatric Virtual Visits as a Strategy for Access to Care During the COVID-19 Pandemic in a Pediatric Hospital. Missed Appointments Rates, Associated Factors, Generation and Validation of Predictive Models"
NCT04736732,Recruiting,Observational,,Institut de Recherches Cliniques de Montreal,Other,1-Jan-21,12-Dec-23,1-Jan-23,COHORT,570,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",MEDICAL FOLLOW-UP,EVALUATE THE SHORT- AND LONG-TERM END-ORGAN COMPLICATIONS POST-COVID-19 IN RELATION TO THE SEVERITY OF THE ACUTE COVID-19 INFECTION.,The IRCM POST-COVID-19 (IPCO) Clinic: A Multidisciplinary Approach to Evaluate Short and Long-term Complications of COVID-19
NCT04736901,Recruiting,Observational,,Ain Shams University,Other,1-Dec-20,1-Jun-21,1-Apr-21,COHORT,90,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ENOXAPARIN,CHANGE IN CLOTTING FACTORS LEVEL,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19
NCT04737161,Not yet recruiting,Interventional,Phase 1,Stanford University,Other,21-Mar-21,22-Sep-21,22-Sep-21,TREATMENT,20,ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years to 75 Years   (Adult, Older Adult)",T REGULATORY CELLS,THE NUMBER OF PARTICIPANTS THAT EXPERIENCE THE OCCURRENCE OF INFUSION ASSOCIATED ADVERSE EVENTS (AES),A Phase 1 Study to Assess the Safety of Living Related Donor Derived T Regulatory Cell Therapy in Subjects With COVID 19 Induced Acute Respiratory Distress Syndrome (ARDS)
NCT04737486,Recruiting,Interventional,Phase 1,"Vasomune Therapeutics, Inc.",Industry,16-Dec-20,1-Jun-21,12-Feb-21,TREATMENT,48,COVID-ASSOCIATED ARDS,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",AV-001,PARTICIPANTS EXPERIENCING DRUG-RELATED ADVERSE EVENTS,"A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects"
NCT04738032,Completed,Observational,,Mayo Clinic,Other,26-Aug-20,7-Jan-21,7-Jan-21,OTHER,76,TYPE2 DIABETES,UNITED STATES,ALL,"18 Years to 70 Years   (Adult, Older Adult)",DIGITAL STORYTELLING INTERVENTION,DIABETES SELF-MANAGEMENT BEHAVIORS,Stories for Change: Digital Storytelling Intervention for Diabetes Self-Management in the COVID-19 Pandemic
NCT04738045,Recruiting,Interventional,Phase 4,Ahmed Essam,Other,1-Nov-20,1-Apr-21,28-Feb-21,TREATMENT,90,COVID,EGYPT,ALL,"18 Years to 80 Years   (Adult, Older Adult)",REMDESIVIR,PROPORTION OF CURED PATIENTS IN THE INTERVENTIONAL GROUP VERSUS THE PROPORTION OF CURED PATIENTS IN THE CONTROL GROUP,Comparative Therapeutic Efficacy and Safety of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients
NCT04738136,Not yet recruiting,Interventional,Phase 2,SolAeroMed Inc.,Industry,15-Feb-21,31-Dec-21,31-May-21,TREATMENT,30,COVID,,ALL,"18 Years to 80 Years   (Adult, Older Adult)",S-1226,TREATMENT EMERGENT ADVERSE EFFECTS,"A Randomized, Open-Label, Controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy Of S-1226 In Hospitalized Subjects With Moderate Severity Covid-19 Bronchiolitis/Pneumonia"
NCT04738175,Not yet recruiting,Interventional,Phase 1/Phase 2,"Sorrento Therapeutics, Inc.",Industry,21-Apr-21,21-Nov-21,21-Nov-21,TREATMENT,209,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVI-AMG,"INCIDENCE OF ADVERSE EVENTS BY TYPE, FREQUENCY, SEVERITY, AND CAUSALITY (SAFETY)","A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19"
NCT04738331,Recruiting,Observational,,"University Hospital, Montpellier",Other,1-Feb-21,30-Jun-22,20-May-22,OTHER,10000000,COVID,FRANCE,ALL,"Child, Adult, Older Adult",,DETECTING CO-FACTORS ASSOCIATED WITH CT VALUES,Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database : CovPCR
NCT04738435,Recruiting,Observational,,Hospital Italiano de Buenos Aires,Other,5-Jan-21,1-Mar-21,1-Mar-21,COHORT,600,COVID,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF EVENTS SUPPOSEDLY ATTRIBUTED TO VACCINES AND IMMUNIZATIONS AFTER SPUTNIK V,"Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina"
NCT04738695,Recruiting,Observational,,Sciensano,Other,1-Feb-21,31-Mar-22,31-Mar-22,COHORT,3036,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",POINT-OF-CARE RAPID ANTI-SARS-COV-2 ANTIBODY TEST (ORIENT GENE BIOTECH) AND DRY BLOOD SPOT COLLECTION (EUROIMMUN),CHANGE OF SEROPREVALENCE OF ANTI-SARS-COV-2 ANTIBODIES AMONG NURSING HOME RESIDENTS AND STAFF IN BELGIUM,SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents in Belgium
NCT04738721,Recruiting,Observational [Patient Registry],,Medipol University,Other,5-Feb-21,15-Apr-21,5-Apr-21,OTHER,87,"ASSESSMENT, SELF",TURKEY,ALL,18 Years to 22 Years   (Adult),EVALUATION,PHYSICAL ACTIVITY,Comparison of Physical Activity and Physical Fitness Parameters of Young Adults Before and After COVID-19 Quarantine
NCT04738760,Recruiting,Observational,,Ain Shams University,Other,1-Dec-20,1-Jun-21,1-Apr-21,COHORT,150,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,DURATION OF HOSPITALIZATION,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients
NCT04739020,Recruiting,Interventional,Not Applicable,Johann Wolfgang Goethe University Hospital,Other,18-Jan-21,31-Dec-21,30-Jun-21,DIAGNOSTIC,525,SARS-COV2 INFECTION,GERMANY,ALL,"6 Years and older   (Child, Adult, Older Adult)",RESP-AER-METER,AEROSOL CONCENTRATION IN PCR SARS-COV-2 POSITIVE AND NEGATIVE PARTICIPANTS,Measurement of Respiratory Aerosols in PCR SARS-CoV-2 Positive and Negative Children and Adults
NCT04739345,Recruiting,Observational,,Ain Shams University,Other,1-Dec-20,1-Jul-21,1-Apr-21,COHORT,50,COVID,EGYPT,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,CHANGE IN PATIENTS' CLINICAL STATUS,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection
NCT04739410,Completed,Interventional,Phase 4,FMH College of Medicine and Dentistry,Other,1-May-20,30-Jun-20,30-Jun-20,TREATMENT,50,COVID,PAKISTAN,ALL,"18 Years to 75 Years   (Adult, Older Adult)",IVERMECTIN,RESOLUTION OF SYMPTOMS,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
NCT04739449,Not yet recruiting,Interventional,Not Applicable,University of Michigan,Other,10-Feb-21,22-Jan-21,21-Oct-21,HEALTH SERVICES RESEARCH,100,SARS-COV INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)","COACHING, CLEANING, COMMUNICATION, COLLABORATION",SURFACE CONTAMINATION WITH SARS-COV-2,"'4C' Intervention to Reduce SARS-CoV-2 Transmission: Coaching, Cleaning, Communication and Collaboration"
NCT04739462,Recruiting,Interventional,Not Applicable,University of Minnesota,Other,3-Feb-21,22-Feb-21,22-Feb-21,PREVENTION,248,PREGNANCY COMPLICATIONS,UGANDA,FEMALE,"18 Years and older   (Adult, Older Adult)",MHEALTH PLATFORM,CHANGE IN PRE- TO POST-INTERVENTION KNOWLEDGE,mHealth for Improvement of Access to Maternal Health Services in the Era of COVID-19 Pandemic (SMS Maama Project)
NCT04740125,Completed,Observational,,"General Administration of Military Health, Tunisia",Other,1-May-20,30-Nov-20,31-Jul-20,OTHER,368,HEALTH CARE WORKERS,TUNISIA,ALL,"18 Years to 70 Years   (Adult, Older Adult)",,STRESS-COVID,"PSYCHOLOGICAL IMPACT, STRESS FACTORS AND BEHAVIOURS IN HEALTH CARE PROFESSIONALS DURING THE COVID-19 PANDEMIC IN TUNISIA"
NCT04740320,Recruiting,Observational [Patient Registry],,Imperial College London,Other,15-Dec-20,21-May-21,21-May-21,COHORT,250,COVID,UNITED KINGDOM,ALL,18 Years to 30 Years   (Adult),,PARTICIPANTS ENROLLED,Screening Protocol for a Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain
NCT04740372,Recruiting,Observational,,Oslo University Hospital,Other,20-Nov-20,21-Nov-21,21-Jun-21,OTHER,350,"COVID, PATIENT REPORTED OUTCOME MEASURES, QUALITY OF LIFE",NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION. METHOD STUDY. PSYCHOMETRIC TESTING,VALIDATED COVID-19 SPECIFIC QUESTIONNAIRE,"Development of an International Questionnaire to Assess Patient-reported Quality of Life Related to COVID-19 Disease, the Oslo COVID-19 Quality of Life Questionnaire (QLQ) - ## © Phase III of Questionnaire Development"
NCT04740489,Not yet recruiting,Observational,,Ant Shepherd,Other,1-Feb-21,1-Jun-22,1-Jun-22,COHORT,30,HEART DISEASES,,ALL,"18 Years and older   (Adult, Older Adult)",PHASE 3 CARDIAC REHABILITATION,PSYCHOSOCIAL HEALTH AND WELLBEING,"A Pilot Study Examining Participants Psychosocial Health, Physical Activity and Staff Experiences: Is Adapted Home-based Phase 3 Cardiac Rehabilitation Feasible and Beneficial?"
NCT04740658,Not yet recruiting,Observational,,"University Hospital, Toulouse",Other,1-Feb-21,1-Jul-21,1-Jul-21,COHORT,9600,COVID,FRANCE,ALL,"Child, Adult, Older Adult",NO INTERVENTION,DEATH OCCURRENCE WITHIN ONE YEAR OF FOLLOW UP,Effect of Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents During and After the Epidemic Period
NCT04741061,Recruiting,Interventional,Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",Other,19-Feb-21,31-Jan-22,31-Dec-21,PREVENTION,6000,COVID PREVENTION,RUSSIAN FEDERATION,ALL,"18 Years to 111 Years   (Adult, Older Adult)",SPUTNIK LIGHT,INCIDENCE AND SEVERITY OF ADVERSE EVENTS IN STUDY SUBJECTS,"A Phase III, Randomized, Double-blind, Placebo-controlled International Multicenter Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Vector Vaccine in the Parallel Assignment of the Subjects in Prophylactic Treatment for SARS-СoV-2 Infection"
NCT04741178,Recruiting,Observational,,Morgagni Pierantoni Hospital,Other,20-Mar-20,31-Dec-21,2-Jan-21,COHORT,600,COVID,ITALY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",,CT EVIDENCE OF PECULIAR PATTERNS IN COVID-19 PNEUMONIA,PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis
NCT04741282,Not yet recruiting,Interventional,Not Applicable,Iran University of Medical Sciences,Other,15-Feb-21,15-Jun-21,15-Jun-21,SUPPORTIVE CARE,52,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",PULMONARY TELEREHABILITATION,FUNCTIONAL CAPACITY,Effect of Pulmonary Tele-rehabilitation With and Without Progressive Muscle Relaxation Program in Covid-19 Patients After Hospital Discharge: Randomized Clinical Trial
NCT04741386,Not yet recruiting,Observational [Patient Registry],,University Medical Center Groningen,Other,1-Feb-21,31-Dec-22,5-Apr-22,COHORT,850,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 VACCINATION,THE ANTIBODY BASED IMMUNE RESPONSE TO VACCINATION AGAINST COVID-19 AS COMPARED TO CONTROLS,"The Immune-response and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant - A Prospective, Controlled, Multicenter Cohort Study by the RECOVAC Consortium"
NCT04741412,Recruiting,Observational [Patient Registry],,University Hospital Erlangen,Other,3-Jun-20,31-May-21,31-May-21,COHORT,230,HYPOHIDROTIC ECTODERMAL DYSPLASIA,GERMANY,ALL,"Child, Adult, Older Adult",,AGE-DEPENDENCE OF SARS-COV-2 INFECTION,"SARS-CoV-2 Infections in Children and Adolescents: Course of COVID-19, Immune Responses, Complications and Long-term Consequences in Entire Households With Members Younger Than 18 Years"
NCT04742049,Recruiting,Interventional,Not Applicable,Hacettepe University,Other,28-Dec-20,21-Mar-21,21-Mar-21,TREATMENT,30,CYSTIC FIBROSIS,TURKEY,ALL,8 Years to 14 Years   (Child),TELEREHABILITATION-BASED,1 MINUTE SIT TO STAND TEST (STS) REPETITIONS,"The Effects of Telerehabilitation on Peripheral Muscle Function, Physical Activity Level and Sleep Quality in Pediatric Cystic Fibrosis Patients Having Social Isolation Due to Pandemic"
NCT04742569,Recruiting,Observational,,"ClinOne, Inc.",Industry,21-Dec-20,21-Dec-21,21-Jun-21,COHORT,2352,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,"THE PRIMARY OUTCOME OF INTEREST ARE PERFORMANCE OF THE BIOSTICKER, A MEDICAL GRADE MULTI-PARAMETER WEARABLE BIOSENSOR.",Wearable Diagnostic for Detection of COVID-19 Infection
NCT04742595,Recruiting,Interventional,Early Phase 1,M.D. Anderson Cancer Center,Other,18-Dec-20,31-Mar-22,31-Mar-22,TREATMENT,16,COVID-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES,PROPORTION OF PATIENTS WHO RECEIVE AT LEAST ONE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPECIFIC CYTOTOXIC T LYMPHOCYTES INFUSION,"Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients With Cancer"
NCT04742712,Recruiting,Observational,,Portsmouth Hospitals NHS Trust,Other,27-Oct-20,1-Dec-21,1-Nov-21,COHORT,40,SARS-COV INFECTION,UNITED KINGDOM,ALL,"16 Years and older   (Child, Adult, Older Adult)",CORONACHECK DEVICE,PRESENCE OF SARS-COV-2 INFECTION IN THOSE WITH HIGH CLINICAL SUSPICION AND/OR A POSITIVE RT-PCR SWAB.,A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 - FIND SARS CoV-2 Covid-19
NCT04742725,Not yet recruiting,Interventional,Phase 2,"Prothione, LLC",Other,15-Feb-21,26-Mar-21,16-Mar-21,TREATMENT,200,CORONAVIRUS DISEASE 2019 (COVID),,ALL,"18 Years and older   (Adult, Older Adult)",PLACEBO,PERCENTAGE OF SUBJECTS REPORTING EACH SEVERITY RATING ON AN 8-POINT ORDINAL SCALE ON DAY 29 CLINICAL STATUS IS ASSESSED BY THE INVESTIGATOR USING AN 8-CATEGORY ORDINAL SCALE,"A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)"
NCT04742738,Recruiting,Interventional,Phase 1/Phase 2,"SK Bioscience Co., Ltd.",Industry,20-Jan-21,22-Apr-21,21-Aug-21,PREVENTION,260,COVID (HEALTHY VOLUNTEERS),"KOREA, REPUBLIC OF",ALL,"19 Years to 85 Years   (Adult, Older Adult)",GBP510 ADJUVANTED WITH ALUM (RBD 10ΜG/DOSE) - STAGE 1,OCCURRENCE OF IMMEDIATE SYSTEMIC REACTIONS - STAGE 1,"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults"
NCT04742842,Not yet recruiting,Interventional,Phase 1,University of Sydney,Other,15-Feb-21,31-Dec-22,30-Jun-22,PREVENTION,150,SARS-COV2 COVID,AUSTRALIA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",COVIGEN 0.8 MG ID OR PLACEBO ID,FREQUENCY OF SOLICITED LOCAL REACTOGENICITY AES,"A Phase I, Double-blind, Dose-ranging, Randomised, Placebo-controlled Trial to Study the Safety and Immunogenicity of a DNA-based Vaccine Against COVID-19 (COVIGEN) in Healthy Participants Aged 18 to 75 Years Old"
NCT04742946,Not yet recruiting,Interventional,Not Applicable,Universidad de Granada,Other,15-Feb-21,30-Sep-21,30-May-21,TREATMENT,237,COVID,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",STANDARD PHYSIOTHERAPY PROGRAM,FUNCTIONAL CAPACITY,Telerehabilitation Intervention in Patients With Covid-19 After Hospital Discharge to Improve Functional Capacity and Quality of Life. Study Protocol for a Multicenter Randomized Clinical Trial
NCT04743011,Not yet recruiting,Interventional,Phase 1/Phase 2,UPECLIN HC FM Botucatu Unesp,Other,15-Feb-21,31-Dec-21,30-Jul-21,TREATMENT,50,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",HEPARIN SODIUM,CHANGE IN ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) > 1.5,Nebulized Enriched Heparin to Treat no Critical Patients With Sars-Cov-2 - Triple Blind Clinical Trial
NCT04743232,Recruiting,Interventional,Not Applicable,Erasmus Medical Center,Other,1-Mar-21,31-Jan-22,31-Dec-21,SCREENING,1000,COVID,NETHERLANDS,ALL,"18 Years and older   (Adult, Older Adult)",DECISION TOOL FOR CLINICIANS,ICU-ADMISSIONS,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or COVID-19 Pandemic Resuscitation Plans and Decisions on Escalation and Limitation of Treatment
NCT04743349,Recruiting,Interventional,Not Applicable,Meyer Children's Hospital,Other,26-Jan-21,31-Oct-21,31-Oct-21,TREATMENT,200,COVID,ITALY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",STEAM INHALATIONS,REDUCTION IN VIRAL SHEDDING,Steam Inhalations in Asymptomatic and Paucisymptomatic COVID-19 Patients
NCT04743388,Recruiting,Observational [Patient Registry],,National and Kapodistrian University of Athens,Other,4-Jan-21,22-Apr-21,21-Nov-21,COHORT,600,COVID,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",BNT162B2,NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2,Study of the Kinetics of Antibodies Against SARS-CoV-2 and of Cellular Subpopulations of the Immune System in Volunteers Receiving the BNT162b2 Vaccine or Other Approved Vaccine Against SARS-CoV-2
NCT04743401,Not yet recruiting,Interventional,Phase 1/Phase 2,VA Office of Research and Development,U.S. Fed,1-Apr-21,31-Mar-23,30-Sep-22,SUPPORTIVE CARE,60,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELE-EXERGAMING TABLET,EXERCISE DROPOUT RATE,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients
NCT04743609,Not yet recruiting,Observational,,Association Clinique Thérapeutique Infantile du val de Marne,Other,1-Feb-21,11-Jan-23,11-Jul-21,COHORT,1600,RSV INFECTION,FRANCE,ALL,up to 24 Months   (Child),NASOPHARYNGEAL SAMPLES,RSV PROVEN,"Ambulatory Respiratory Tract Infection Survey, Burden of Respiratory Syncitial Virus in the Era of Covid-19"
NCT04743908,Not yet recruiting,Interventional,Not Applicable,University of Chicago,Other,21-Feb-21,23-Dec-21,23-Dec-21,PREVENTION,2400,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",SOCIAL NETWORK STRATEGY + COVID-19 MESSAGING,TOTAL NUMBER OF TESTS AMONG NETWORK MEMBERS REFERRED FOR COVID TESTING (NETWORK TESTED),Community Network-driven COVID-19 Testing of Vulnerable Populations in the Central US (C3)
NCT04743947,Recruiting,Observational,,"Heinrich-Heine University, Duesseldorf",Other,21-Dec-20,31-Dec-25,31-Dec-24,COHORT,400,CHRONIC KIDNEY DISEASE STAGE 5 ON DIALYSIS,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",NO INTERVENTION; OBSERVATIONAL STUDY,SARS-COV-2- ANTIBODY- TITER,Observational Study on the Effects of SARS-CoV-2 Vaccination in Dialysis and Kidney Transplant Patients
NCT04744415,Recruiting,Observational [Patient Registry],,Heart Care Foundation,Other,9-Nov-20,9-Feb-21,9-Feb-21,COHORT,4000,MANAGEMENT AND EPIDEMIOLOGY OF PATIENTS ADMITTED IN ICU,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",EPIDEMIOLOGY OF ADMISSIONS,IMPACT THAT COVID-19 INFECTION MAY HAVE HAD ON THE IN-HOSPITAL MORTALITY,Epidemiology of the Hospitalizations in the Italian Coronary Care Unit Network at the Time of Covid19
NCT04745351,Not yet recruiting,Interventional,Phase 3,Gilead Sciences,Industry,21-Feb-21,21-Aug-21,21-Jul-21,TREATMENT,1116,COVID,,ALL,"12 Years and older   (Child, Adult, Older Adult)",REMDESIVIR,COMPOSITE OF ALL-CAUSE MORTALITY OR INVASIVE MECHANICAL VENTILATION (IMV) THROUGH DAY 29,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19"
NCT04745377,Recruiting,Observational,,Hellenic Cooperative Oncology Group,Other,12-Jan-21,31-Jan-22,30-Aug-21,CASE-CONTROL,300,CANCER,GREECE,ALL,"18 Years and older   (Adult, Older Adult)",IGG NEUTRALISING ANTIBODY TITERS TO S1 AND S2 PROTEINS OF SARS-COV-2 VIRUS,CLINICAL OUTCOME POST VACCINATION,Mapping the Responses to COVID-19 Vaccination in Patients With Cancer - the ReCOVer Study
NCT04745416,Completed,Observational,,Hospital General de Mexico,Other,1-Jan-20,25-Jan-21,31-Dec-20,COHORT,30,"LEUKEMIA, ACUTE",MEXICO,ALL,"18 Years and older   (Adult, Older Adult)",,OVERALL SURVIVAL,"Clinical Characteristics of Patients With Hematological Cancer Diagnosed and Severe Acute Respiratory Syndrome Coronavirus 2 Infection at the Hospital de Alta Especialidad de Ixtapaluca and the Hospital General de México ""Dr. Eduardo Liceaga"""
NCT04745442,Completed,Interventional,Phase 2,Maimónides Biomedical Research Institute of Córdoba,Other,27-Apr-20,15-Jan-21,20-Dec-20,TREATMENT,48,COVID,SPAIN,ALL,"18 Years to 85 Years   (Adult, Older Adult)",ANTITHROMBIN + BEST AVAILABLE TREATMENT,COMBINED VARIABLE: MORTALITY OR WORSENING RATE WITH NEED FOR NON-INVASIVE MECHANICAL VENTILATION OR WITH NEED FOR INVASIVE MECHANICAL VENTILATION,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
NCT04745533,Not yet recruiting,Observational,,Juan Fernando Masa Jiménez,Other,15-Feb-21,30-Jun-21,30-Apr-21,COHORT,3000,SARS-COV INFECTION,,ALL,"18 Years and older   (Adult, Older Adult)",ANTIGEN DETECTION TEST,SENSITIVITY OF THE ANTIGEN DETECTION TEST USED IN THE STUDY OF CONTACTS OF COVID-19 PATIENTS.,Diagnostic Efficacy of the SARS-CoV2 Antigen Detection Test for the COVID-19 Contact Study
NCT04745611,Recruiting,Observational [Patient Registry],,Maastricht University,Other,12-Dec-20,21-Sep-21,21-Sep-21,CASE-ONLY,400,COVID INFECTION,NETHERLANDS,ALL,"Child, Adult, Older Adult",MRI,CHANGE IN PARTICIPATION,Neurological and Neuropsychological Sequelae of COVID-19 Infection
NCT04745923,Recruiting,Observational,,Hacettepe University,Other,20-Jan-21,30-Mar-21,28-Feb-21,CASE-CONTROL,28,COVID,TURKEY,ALL,"18 Years to 65 Years   (Adult, Older Adult)",,FEAR OF COVID-19,Fear of COVID-19 and Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic
NCT04746066,"Active, not recruiting",Observational,,Società Italiana Talassemie ed Emoglobinopatie,Other,31-Mar-20,30-Dec-21,30-Dec-21,OTHER,10000,HAEMOGLOBINOPATHIES,ITALY,ALL,"Child, Adult, Older Adult",,NUMBER OF PATIENTS WITH COVID 19 INFECTION,Observational Study Multicentric Phamacological no Profit for the Treatment of Patients With Hemoglobinopathies and Rare Inherited Anemia Affected by Covid 19
NCT04746092,Recruiting,Observational,,Tel-Aviv Sourasky Medical Center,Other,6-Jan-21,24-May-22,24-May-22,CASE-CONTROL,550,CLL,ISRAEL,ALL,"18 Years to 100 Years   (Adult, Older Adult)",,CAPABILITY OF HAEMATO-ONCOLOGY PATIENTS TO GENERATE ANTIBODIES AGAINST COVID-19 AFTER INFECTION AND VACCINATION.,The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 After Infection and Vaccination
NCT04746183,Recruiting,Interventional,Phase 1/Phase 2,University of Liverpool,Other,3-Jul-20,31-Dec-21,22-Jun-21,TREATMENT,200,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",CST-2: EIDD-2801,MASTER PROTOCOL: DOSE-FINDING/PHASE I,AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment
NCT04746339,Not yet recruiting,Interventional,Phase 4,Brazilian Clinical Research Institute,Other,21-Feb-21,21-Dec-21,21-Aug-21,PREVENTION,1000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",APIXABAN 2.5 MG,NUMBER OF DAYS ALIVE AND OUT OF HOSPITAL OR EMERGENCY DEPARTMENT,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial
NCT04746365,Completed,Interventional,Phase 4,Elaraby Hospital,Other,6-Dec-20,6-Feb-21,31-Jan-21,TREATMENT,300,COVID,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",IVERMECTIN,REDUCTION IN THE WHO ORDINAL SCALE OF CLINICAL STATUS BY AT LEAST TWO POINTS,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial"
NCT04746430,Not yet recruiting,Interventional,Phase 4,General Practitioners Research Institute,Other,21-Feb-21,22-Mar-21,22-Feb-21,TREATMENT,2000,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,HOSPITALIZATION/DEATH,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study: an Open-label Randomized Controlled Trial
NCT04746443,Recruiting,Observational,,King Khalid University,Other,8-Dec-20,8-Mar-21,8-Mar-21,CASE-ONLY,40,COVID,SAUDI ARABIA,ALL,18 Years to 30 Years   (Adult),NOT APPLICABLE (NA),EVENT IMPACT SCALE - REVISED,Impact of Covid-19 Affliction on Psychological and Mental Health of the College Students: Cross-Sectional Survey
NCT04746521,Recruiting,Observational,,"University of Campania ""Luigi Vanvitelli""",Other,21-Mar-21,22-Dec-21,22-Jan-21,OTHER,100,COVID,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",MULTITEST 6 COLOR TBNK AND BD LYOTUBES,DETECTION OF CELLULAR-MEDIATED IMMUNE RESPONSE,DEtection of Cellular-MEdiated immuniTy in COVID-19 Patients and Subjects Who undeRgone vAccination Program
NCT04747132,Completed,Interventional,Not Applicable,"Universidad Iberoamericana A.C., Mexico",Other,20-Jul-20,16-Nov-20,20-Oct-20,HEALTH SERVICES RESEARCH,110,EFFECTIVENESS,MEXICO,ALL,"60 Years and older   (Adult, Older Adult)",TELEGERIATRIC INTERVENTION,VISUAL ANALOG SCALE OF THE EUROPEAN QUALITY OF LIFE QUESTIONNAIRE,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency
NCT04747158,Completed,Interventional,Phase 2/Phase 3,Angelica Samudio,Other,10-Aug-20,10-Jan-21,10-Dec-20,TREATMENT,350,SARS-COV2 INFECTION,PARAGUAY,ALL,"18 Years and older   (Adult, Older Adult)",CONVALESCENT PLASMA,OVERALL SURVIVAL (30-DAY MORTALITY),COVID-19 Convalescent Plasma Therapy
NCT04747249,Not yet recruiting,Interventional,Not Applicable,Centre Francois Baclesse,Other,21-Mar-21,22-Mar-21,21-Aug-21,TREATMENT,115,SOLID CARCINOMA,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",PSYCHOLOGICAL SUPPORT,PROPORTION OF PATIENTS WITH IMPROVEMENT IN POST-TRAUMATIC STRESS SYMPTOMS,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19
NCT04747366,Recruiting,Observational [Patient Registry],,"Charite University, Berlin, Germany",Other,6-Nov-20,30-Nov-25,1-Nov-25,COHORT,750,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,CHANGES IN PATIENT-REPORTED QUALITY OF LIFE RECORDED WITH THE HELP OF THE EUROPEAN QUALITY OF LIFE 5 DIMENSIONS 5 LEVEL VERSION (EQ5D5L) QUESTIONNAIRE,"National Pandemic Cohort Network - High-resolution Platform (HAP) Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity"
NCT04747405,Not yet recruiting,Interventional,Not Applicable,Centre Hospitalier Metropole Savoie,Other,22-Feb-21,22-Aug-22,22-Jun-22,OTHER,100,INTENSIVE CARE UNIT SYNDROME,,ALL,"18 Years and older   (Adult, Older Adult)",THERAPY GROUP,PREVALENCE OF POST TRAUMATIC STRESS SYNDROME,Evaluation of Psychological Impact of Group Therapy for Patients Who Have Been Hospitalized in Intensive Care During COVID-19 Pandemic: Exploratory Study
NCT04747522,Recruiting,Observational,,Oslo University Hospital,Other,22-Jan-21,30-Jun-21,30-Jun-21,COHORT,150,KIDNEY TRANSPLANT INFECTION,NORWAY,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 VACCINE,CELLULAR IMMUNOLOGICAL RESPONSE,SARS-CoV-2 Cellular and Humoral Immune Response Following Vaccination of Kidney Transplant Recipients and Healthy Controls
NCT04747574,Recruiting,Interventional,Phase 1,Tel-Aviv Sourasky Medical Center,Other,25-Sep-20,25-Mar-21,25-Feb-21,TREATMENT,30,SARS-COV2,ISRAEL,ALL,"18 Years to 85 Years   (Adult, Older Adult)",EXO-CD24,PRIMARY SAFETY ENDPOINT: ADVERSE EVENTS,A Phase I Feasibility Study to Evaluate the Safety of CD24-Exosomes in Patients With Moderate/Severe COVID-19 Infection
NCT04747678,Enrolling by invitation,Observational [Patient Registry],,Menoufia University,Other,3-Feb-21,1-Mar-21,28-Feb-21,CASE-CROSSOVER,200,COVID,EGYPT,ALL,"16 Years to 80 Years   (Child, Adult, Older Adult)",IVERMECTIN,ALL ADVERSE EFFECTS WILL BE COLLECTED FROM PEOPLE USED IVERMECTIN IN BETWEEN SEPTEMBER 2020 TO DECEMBER 2020,Tolerability and Adverse Effects of Using Multiple Doses of Ivermectin in Egypt During Covid 19 Pandemic
NCT04747756,Not yet recruiting,Interventional,Not Applicable,"University of California, Riverside",Other,21-Mar-21,22-Dec-21,22-Dec-21,OTHER,80,HIV,UNITED STATES,ALL,"50 Years and older   (Adult, Older Adult)",VIRTUAL VILLAGE,CHANGE IN DEPRESSION AFTER PILOT TESTING VIRTUAL VILLAGE,A Solution to Halt Further Isolation of People Aging With HIV During the COVID-19 Pandemic
NCT04747769,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,21-Feb-21,21-Oct-21,21-Apr-21,CASE-ONLY,50,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,QUALITATIVE AND QUANTITATIVE PARAMETERS OBTAINED BY IN SILICO MODELING OF INTRA-PULMONARY VASCULAR REMODELING IN 3D AT 2-4 MONTHS.,Modélisation in Silico du TDM Thoracique et séquelles du COVID-19
NCT04747782,Recruiting,Observational,,Dr. Andrew Baker,Other,23-Mar-20,31-Dec-21,1-Oct-21,COHORT,200,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)","NO INTERVENTIONS PERFORMED. JUST COLLECTING DATA, BLOOD SAMPLES AND POST-MORTEM BIOPSIES.",DEATH IN ICU,COVID-19 Longitudinal Biomarkers in Lung Injury
NCT04747821,Enrolling by invitation,Interventional,Phase 4,Butantan Institute,Other,17-Feb-21,22-Feb-21,21-May-21,PREVENTION,30000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ADSORBED COVID-19 (INACTIVATED) VACCINE,INCIDENCE OF COVID-19 CASES AFTER TWO-DOSES IMMUNIZATION SCHEDULE IN CLUSTERS IN THE FIRST QUARTER OF STUDY,A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
NCT04747990,Not yet recruiting,Observational,,University of Cagliari,Other,1-Mar-21,1-Sep-21,1-Jul-21,COHORT,600,ACUTE PANCREATITIS,,ALL,"16 Years and older   (Child, Adult, Older Adult)",EARLY DEFINITIVE TREATMENT,MORTALITY,coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis
NCT04748120,Enrolling by invitation,Interventional,Not Applicable,The Cleveland Clinic,Other,28-Dec-20,28-Sep-21,28-Jun-21,TREATMENT,50,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",OPERATIVE MANAGEMENT,RATE OF PULMONARY COMPLICATIONS,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients
NCT04748172,Recruiting,Observational,,Sheba Medical Center,Other,21-Feb-21,22-Feb-21,22-Feb-21,CASE-CONTROL,200,FERTILITY ISSUES,ISRAEL,FEMALE,18 Years to 42 Years   (Adult),SARS-COV-2 VIRUS VACCINES,DELTA IN AMH LEVELS,The Effect of COVID -19 mRNA Vaccine on Ovarian Reserve
NCT04748185,Recruiting,Observational,,Mayo Clinic,Other,18-Jan-21,30-Jan-23,30-Jan-23,COHORT,650,MONOCLONAL B-CELL LYMPHOCYTOSIS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,HUMORAL IMMUNOGENICITY,Immunogenicity and Safety of Commercially Available Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients With Hematologic Malignancies and Associated Precursor Conditions
NCT04748289,Not yet recruiting,Interventional,Not Applicable,Emanuela Keller,Other,1-Feb-21,31-Jan-23,31-Jan-23,DIAGNOSTIC,1000,CLINICAL DECISION SUPPORT SYSTEM,,ALL,"Child, Adult, Older Adult",ICU COCKPIT SOFTWARE TESTING,VERIFICATION OF ICU COCKPIT SOFTWARE FOR REMOTE MONITORING OF ISOLATED PATIENTS,Integrated Platform for Multimodal Patient Monitoring and Therapy Support in ICU Patients: Interventional Study With First ICU Cockpit Software Applications
NCT04748471,Not yet recruiting,Interventional,Phase 2,Assistance Publique - Hôpitaux de Paris,Other,10-Feb-21,25-Jan-23,1-Jul-21,PREVENTION,180,PREVENTION OF COVID,,ALL,"18 Years and older   (Adult, Older Adult)",MRNA-1273,TITERS OF ANTI-SARS-COV-2 SPIKE IGG IMMUNOGLOBULIN IN SERA,A Phase II Trial Assessing Immunogenicity and Safety of SARS-CoV-2 Vaccine mRNA-1273 in Volunteers Aged of 65 Years or More Compared to Participants 18-45 Years Old
NCT04748536,Recruiting,Interventional,Phase 1,Immune Regulation Ltd.,Industry,29-Jan-21,5-Apr-21,5-Apr-21,TREATMENT,18,HEALTHY VOLUNTEER,UNITED KINGDOM,ALL,"18 Years to 65 Years   (Adult, Older Adult)",IRL201104,NUMBER OF SUBJECTS WITH TEAES AND NUMBER OF EVENTS WILL BE SUMMARISED BY TREATMENT,"A Randomised, Double-blind, Placebo-controlled, Parallel Group Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of IRL201104 to Support a Future COVID-19 Patient Study"
NCT04748588,Not yet recruiting,Interventional,Phase 4,University of Calgary,Other,1-Feb-21,31-Mar-23,31-Jan-23,TREATMENT,648,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",BAMLANIVIMAB,REQUIREMENT FOR MECHANICAL VENTILATION OR IN-HOSPITAL DEATH,Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients
NCT04748614,Not yet recruiting,Observational,,Kocaeli Derince Education and Research Hospital,Other,15-Feb-21,30-Mar-21,15-Mar-21,COHORT,500,COST OF ICU,,ALL,"18 Years and older   (Adult, Older Adult)",COST,COST OF ICU,"Comparative ICU Cost, Hospital Stay and Mortality Analysis Before and After COVID 19"
NCT04748757,Not yet recruiting,Interventional,Phase 2,Lawson Health Research Institute,Other,21-Mar-21,22-Dec-21,22-Mar-21,TREATMENT,60,CORONAVIRUS INFECTION,CANADA,ALL,"19 Years and older   (Adult, Older Adult)",RECOMBINANT HUMAN ANNEXIN A5,ENROLLMENT,"Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial"
NCT04748783,Not yet recruiting,Interventional,Phase 2,"University of North Carolina, Chapel Hill",Other,21-Mar-21,22-Mar-21,22-Mar-21,TREATMENT,180,COVID,UNITED STATES,ALL,"18 Years to 65 Years   (Adult, Older Adult)",WATER,CHANGE IN REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) BASELINE TO 15 MIN,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus
NCT04749121,Completed,Interventional,Not Applicable,Bangkok Metropolitan Administration Medical College and Vajira Hospital,Other,1-Apr-20,5-Feb-21,5-Feb-21,PREVENTION,20,COVID,THAILAND,ALL,18 Years to 60 Years   (Adult),UVC IRRADIATION,FIT TEST,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:"
NCT04749173,Recruiting,Interventional,Phase 1,Daewoong Pharmaceutical Co. LTD.,Industry,21-Nov-20,30-Jun-21,28-Mar-21,TREATMENT,24,COVID,"KOREA, REPUBLIC OF",ALL,19 Years to 55 Years   (Adult),DWRX2003,INCIDENCE OF TREATMENT-EMERGENT ADVERSE EVENTS,"A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers"
NCT04750018,Recruiting,Observational,,Chen-Pin Chou,Other,3-Jul-20,1-Jun-21,28-Sep-20,COHORT,600,COVID,TAIWAN,FEMALE,"30 Years to 80 Years   (Adult, Older Adult)",SURGERY,BREAST CANCER,Influence of Co-Vid 19 Pandemic on Screening Mammography in a Single Institution
NCT04750265,Recruiting,Interventional,Not Applicable,"Charite University, Berlin, Germany",Other,11-Feb-21,21-Sep-21,21-Aug-21,TREATMENT,20,COVID,GERMANY,ALL,"18 Years to 100 Years   (Adult, Older Adult)",ROBOTIC ASSISTED EARLY MOBILIZATION,LEVEL OF MOBILIZATION,"Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19: an Interventional Randomized, Controlled Feasibility Study (ROBEM II Study)"
NCT04750278,Not yet recruiting,Interventional,Phase 2/Phase 3,"Foresee Pharmaceuticals Co., Ltd.",Industry,21-Feb-21,22-Aug-21,22-Apr-21,TREATMENT,403,SEVERE TO CRITICAL CORONAVIRUS (COV) DISEASE 2019 (COVID) WITH ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS),,ALL,"18 Years to 65 Years   (Adult, Older Adult)",FP-025 100 MG,THE PROPORTION OF PATIENTS ALIVE AND NOT REQUIRING NON-INVASIVE OR INVASIVE VENTILATION,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)"
NCT04750317,Completed,Interventional,Phase 2,I.M. Sechenov First Moscow State Medical University,Other,11-May-20,1-Sep-20,1-Aug-20,TREATMENT,414,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",TOFACITINIB,DEATH,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia
NCT04750330,Not yet recruiting,Observational,,Maastricht University,Other,21-Apr-21,31-Mar-22,31-Mar-22,CASE-CONTROL,600,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",,COVID-19 SEVERITY,Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection
NCT04750343,Recruiting,Interventional,Phase 1/Phase 2,"SK Bioscience Co., Ltd.",Industry,3-Feb-21,22-Jun-21,21-Jul-21,PREVENTION,320,COVID (HEALTHY VOLUNTEERS),"KOREA, REPUBLIC OF",ALL,"19 Years to 85 Years   (Adult, Older Adult)",GBP510 ADJUVANTED WITH AS03 (RBD 10ΜG/DOSE) - STAGE 1,OCCURRENCE OF IMMEDIATE SYSTEMIC REACTIONS - STAGE 1,"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults"
NCT04750356,Recruiting,Observational,,"University College, London",Other,27-Jan-21,31-Dec-24,31-Dec-24,COHORT,6000,SARS-COV INFECTION,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,SARS-COV-2 SUSCEPTIBILITY IN HEALTHCARE WORKERS AND PATIENTS,"SARS-CoV-2 Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity"
NCT04750369,Recruiting,Observational,,"University Health Network, Toronto",Other,1-Apr-20,31-Mar-21,31-Mar-21,CASE-CONTROL,400,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",,PREDICTIVE ACCURACY OF BIOMARKERS FOR RISK STRATIFICATION,Enhanced Triage for COVID-19 to Validate the Rapid Acute Lung Injury Diagnostic (RALI-Dx) Test
NCT04750629,Not yet recruiting,Observational,,Lumos Diagnostics,Industry,8-Feb-21,26-Mar-21,28-Feb-21,OTHER,100,SARS-COV2,UNITED STATES,ALL,"1 Year and older   (Child, Adult, Older Adult)",POC COVIDX™ RAPID ANTIGEN TEST,SENSITIVITY OF SARS-COV-2 ANTIGEN IN NASAL SWAB AS COMPARED TO A HIGH-SENSITIVE SARS-COV-2 RT-PCR GRANTED EMERGENCY USE AUTHORIZATION (EUA) BY THE FDA,"Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 CoviDx™ Rapid Antigen Test"
NCT04750720,Recruiting,Interventional,Not Applicable,Centre Hospitalier Régional d'Orléans,Other,27-Aug-20,27-Nov-22,27-Nov-22,OTHER,170,COVID,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SAMPLING BY VENIPUNCTURE,PRESENCE OF SPECIFIC ANTI-SARS-COV-2 ANTIBODIES,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.
NCT04750759,Recruiting,Interventional,Phase 2,Charité Research Organisation GmbH,Other,3-Feb-21,30-Jun-21,30-Jun-21,TREATMENT,40,COVID,GERMANY,ALL,"18 Years to 70 Years   (Adult, Older Adult)",NICLOSAMIDE + CAMOSTAT,TREATMENT EMERGENT NUMBER OF ADVERSE EVENTS,"A Randomized, Single Blind, Placebo-controlled, Multiple Dose, Parallel-arm Study to Investigate the Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat to Treat COVID-19 (""NICCAM"")"
NCT04751227,Completed,Observational,,King Faisal Specialist Hospital & Research Center,Other,22-Nov-20,30-Jan-21,30-Jan-21,COHORT,8,CRITICAL ILLNESS,SAUDI ARABIA,ALL,"18 Years to 90 Years   (Adult, Older Adult)",MODAFINIL,MEDIAN CHANGE IN OF GLASGOW COMA SCALE (GCS),Modafinil for Wakefulness in the Critical Care Units and COVID-19 Patients at a Tertiary Care Saudi Hospital
NCT04751474,"Active, not recruiting",Interventional,Not Applicable,Saglik Bilimleri Universitesi,Other,1-Feb-21,31-Mar-21,1-Mar-21,BASIC SCIENCE,93,MOTIVATION,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",MOTIVATIONAL MESSAGES,OPTIMISTIC LEVEL ASSESSED BY THE LIFE ORIENTATION TEST,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction of Intensive Care Nurses During the Covid-19 Pandemic : A Randomized Controlled Study"
NCT04751604,Recruiting,Interventional,Not Applicable,University Hospital Schleswig-Holstein,Other,1-Feb-21,21-Dec-21,21-Sep-21,OTHER,840,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",NICOTINAMIDE,FREQUENCY OF COMPLETE SYMPTOM RESOLUTION AFTER 2 WEEKS OF DIETARY SUPPLEMENTATION,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19
NCT04751617,Enrolling by invitation,Interventional,Not Applicable,University of Rzeszow,Other,1-Jan-21,31-Mar-21,31-Jan-21,TREATMENT,60,COVID,POLAND,ALL,"18 Years and older   (Adult, Older Adult)",PULMONARY REHABILITATION,CHANGE IN THE QUALITY OF LIFE,"Impact of Pulmonary Rehabilitation on Quality of Life, Body Composition and Respiratory Function of Patients With a History of COVID-19"
NCT04751630,Not yet recruiting,Interventional,Not Applicable,Universitat Internacional de Catalunya,Other,1-May-21,1-Feb-22,1-Oct-21,TREATMENT,78,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC EXERCISE,UPPER LIMB STRENGTH CHANGE,Effects of a Structured Online Therapeutic Exercise Program on Physical Performance in COVID-19 Patients at Discharge Time.
NCT04751643,Not yet recruiting,Interventional,Not Applicable,Hospices Civils de Lyon,Other,21-Feb-21,22-Nov-21,22-Sep-21,TREATMENT,132,INTENSIVE CARE UNITS,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",THERAPEUTIC PLASMA EXCHANGE : 3 SESSIONS IN 3 CONSECUTIVE DAYS (DAY 1 TO DAY 3),USE OF INTUBATION AND INVASIVE VENTILATION (IV) BETWEEN DAY 0 (INCLUSION VISIT) AND DAY 10,Assessment of Therapeutic Plasma Exchange to Improve Respiratory Function by Alleviating Cytokine Storm During Severe Covid-19 Infections Randomised Open-label Controlled Trial
NCT04751669,Not yet recruiting,Interventional,Not Applicable,Fundació Institut Germans Trias i Pujol,Other,1-Apr-21,31-Dec-21,31-Oct-21,TREATMENT,300,COVID,SPAIN,ALL,"18 Years to 80 Years   (Adult, Older Adult)",VITAMIN AND TRACE ELEMENTS,NEED FOR HOSPITAL ADMISSION,"Efficacy of Micronutrient Dietary Supplementation in Reducing Hospital Admissions for COVID-19: A Double-blind, Placebo-controlled, Randomized Clinical Trial"
NCT04751682,Not yet recruiting,Interventional,Phase 1,Bharat Biotech International Limited,Industry,1-Mar-21,30-Nov-21,1-May-21,PREVENTION,175,SARS-COV INFECTION,INDIA,ALL,18 Years to 60 Years   (Adult),BBV154 VACCINE,INCIDENCE OF IMMEDIATE ADVERSE EVENTS.,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers"
NCT04751695,Not yet recruiting,Interventional,Not Applicable,Izmir Bakircay University,Other,21-Feb-21,21-Apr-21,21-Mar-21,SCREENING,20,COVID VACCINE,TURKEY,MALE,"35 Years to 65 Years   (Adult, Older Adult)",CORONOVAC VACCINE,CHANGE OF THE LEVELS OF OXIDATIVE STRESS PARAMETER 1,"Comparison of Oxidative Stress Parameters, Trace, Element and Quality of Life Levels in Healthy Men Before and After Covid-19 Vaccines"
NCT04751721,Not yet recruiting,Interventional,Not Applicable,Izmir Bakircay University,Other,21-Feb-21,21-Apr-21,21-Mar-21,SCREENING,20,COVID VACCINE,TURKEY,FEMALE,"35 Years to 65 Years   (Adult, Older Adult)",CORONOVAC VACCINE,CHANGE OF THE LEVELS OF OXIDATIVE STRESS PARAMETER 1,"Comparison of Oxidative Stress Parameters, Trace, Element and Quality of Life Levels in Healthy Women Before and After Covid-19 Vaccines"
NCT04751734,Enrolling by invitation,Observational,,"Institute of Agrochemistry and Food Technology, National Research Council",Other,16-Jan-21,21-Dec-21,21-Dec-21,CASE-CONTROL,150,COVID VACCINES,SPAIN,FEMALE,"18 Years and older   (Adult, Older Adult)",COVID VACCINES,ANTIBODIES,"Impact of Maternal COVID-19 Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health"
NCT04752085,Recruiting,Observational,,I.M. Sechenov First Moscow State Medical University,Other,1-Nov-20,21-Oct-21,21-Mar-21,COHORT,300,COVID,RUSSIAN FEDERATION,ALL,"18 Years and older   (Adult, Older Adult)",CHITOTRIOSIDASE ACTIVITY,NEED IN BIOLOGICAL THERAPY OR/AND RESPIRATORY SUPPORT,Prognosis and Course of COVID-19 Infection in Hospitalised Patients
NCT04752839,Not yet recruiting,Observational [Patient Registry],,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Other,21-Feb-21,21-May-21,21-Mar-21,OTHER,300,PSYCHOLOGICAL STRESS,SPAIN,ALL,"Child, Adult, Older Adult",,GENERAL ANXIETY DISORDER (GAD7) SCORE.,Evaluation of the Psychosocial Impact on Health Professionals Exposed During the COVID 19 Coronavirus Pandemic
NCT04753242,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,8-Dec-20,30-Jun-21,30-Jun-21,COHORT,150,COVID,AUSTRIA,ALL,"18 Years and older   (Adult, Older Adult)",,STRUCTURAL AND PROCESS QUALITY OF COVID-19 RELATED PSYCHOSOCIAL CONSULTATION AND LIAISON (CL) SERVICES S,"Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals - an International Online Survey of Psychosomatic, Psychiatric and Psychological Consultation and Liaison (C&L) Services"
NCT04753346,Not yet recruiting,Observational,,Ankara University,Other,15-Feb-21,1-Jan-23,1-Jan-23,OTHER,240,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",PHYSICAL ACTIVITY LEVEL,PEAK OXYGEN UPTAKE,Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19 and Investigation of Factors Affecting Physical Capacity
NCT04753463,Not yet recruiting,Observational,,Medical University of Bialystok,Other,15-Feb-21,15-Mar-21,28-Feb-21,COHORT,130,SARS-COV2,POLAND,ALL,25 Years to 35 Years   (Adult),SURVEY,QUESTIONNAIRE ASSESSING THE INCIDENCE OF DISTURBANCE OF COVID-19 PANDEMIC ON OPHTHALMOLOGY TRAINING PROGRAMS AMONG RESIDENTS,Assessment of the Impact of COVID-19 Pandemic on Residents Training and Mental Health in Poland
NCT04753476,Recruiting,Interventional,Phase 2,Stem Cell and Cancer Research Indonesia,Other,8-Jun-20,8-Aug-21,8-Jun-21,TREATMENT,48,COVID,INDONESIA,ALL,"Child, Adult, Older Adult",INJECTION OF SECRETOME-MSCS,CHANGE IN PATIENTS CLINICAL MANIFESTATION,The Effect of Secretome of Hypoxia-Mesenchymal Stem Cells in Improving Survival of Severe Covid-19 Patients
NCT04753619,Recruiting,Interventional,Phase 2,University of Baghdad,Other,3-Jan-21,3-May-21,3-May-21,TREATMENT,150,COVID,IRAQ,ALL,"18 Years and older   (Adult, Older Adult)",NICLOSAMIDE ORAL TABLET,PERCENTAGE OF CURE OF THE PATIENT,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management (Randomized Controlled Clinical Trial)
NCT04753632,Not yet recruiting,Observational,,Universidad de Granada,Other,15-Feb-21,15-Jun-21,15-May-21,CASE-CONTROL,60,CEREBRAL PALSY,,ALL,"18 Years and older   (Adult, Older Adult)",,"QUESTIONNAIRE OF KNOWLEDGE, ATTITUDES AND PRACTICE TOWARDS COVID-19",Assessment of the Biopsychosocial Status of People With Cerebral Palsy and Related Diseases and Their Caregivers During the COVID-19 Pandemic
NCT04753645,"Active, not recruiting",Interventional,Not Applicable,BRAC University,Other,19-Sep-20,21-May-21,21-May-21,PREVENTION,3840,HYGIENE PRACTICES AND KNOWLEDGE,BANGLADESH,ALL,"10 Years and older   (Child, Adult, Older Adult)",HANDWASHING STATIONS AT THE PUBLIC PLACES,DAILY HANDWASHING FREQUENCY,The Effect of Public Handwashing Stations on Health Behaviour and Outcomes During COVID-19
NCT04753762,Recruiting,Observational,,"Central Hospital, Nancy, France",Other,1-Mar-20,1-Nov-22,1-Jan-22,OTHER,50,COVID VIRUS DISEASE,FRANCE,ALL,"18 Years to 79 Years   (Adult, Older Adult)",,TO CHARACTERIZE CARDIAC INVOLVEMENT BY CARDIAC TTE IMAGING DURING 4 MONTHS AFTER CONFIRMED COVID-19 INFECTION,Multimodal IMAgery (Echocardiography and Cardiac MRI) Characterization of Cardiac Damage and Severity After COVID-19 Infection
NCT04754113,Not yet recruiting,Interventional,Not Applicable,"Southeast University, China",Other,7-Feb-21,27-Feb-21,20-Feb-21,TREATMENT,10,COVID,CHINA,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PRONE POSITION,VENTILATION-PERFUSION (V/Q) MISMATCH,Effect of Prone Position on Lung Ventilation and Perfusion Matching in Non-intubated Patients With COVID-19 Pneumonia
NCT04754594,Not yet recruiting,Interventional,Phase 2/Phase 3,BioNTech SE,Industry,15-Feb-21,8-Jan-23,8-Jan-23,PREVENTION,4000,SARS-COV2 INFECTION,UNITED STATES,FEMALE,"18 Years and older   (Adult, Older Adult)",BNT162B2,PERCENTAGE OF MATERNAL PARTICIPANTS REPORTING: LOCAL REACTIONS,"A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER"
NCT04754633,Completed,Observational,,Seyhmus Kavak,Other,1-Jul-20,20-Jul-20,20-Jul-20,CASE-CONTROL,764,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,CURRENT STUDY EVALUATING THE SUCCESS OF THE GUIDELINES RECOMMENDED BY RSNA AND BSTI IN DETECTING COVID-19 DISEASE,Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines: Correlation Between Radiologists
NCT04754698,Recruiting,Interventional,Not Applicable,University of Sao Paulo General Hospital,Other,9-Feb-21,23-Mar-21,21-Sep-21,PREVENTION,2067,RHEUMATIC DISEASE,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",CORONAVAC,IMMUNOGENICITY,Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS
NCT04755972,Recruiting,Interventional,Not Applicable,"Clinical Hospital Center, Split",Other,29-Jan-21,29-Aug-21,29-Jul-21,PREVENTION,40,CORONAVIRUS INFECTION,CROATIA,ALL,"18 Years and older   (Adult, Older Adult)",INHALATION OF N-ACETYLCYSTEINE,DIFFERENCE BETWEEN 4 ARMS REGARDING VENTILATOR-ASSOCIATED PNEUMONIA RATE,Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2
NCT04756128,Enrolling by invitation,Interventional,Phase 2,HealthPartners Institute,Other,25-Jan-21,31-Dec-21,31-Dec-21,TREATMENT,164,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COLCHICINE 0.6 MG,"PROGRESSION OF COVID-19 FROM ""MODERATE"" CLASSIFICATION TO ""SEVERE/CRITICAL""",Impact of Colchicine and Low-dose Naltrexone on COVID-19 Disease Progression and Clinical Course in Hospitalized Patients
NCT04756141,Not yet recruiting,Interventional,Not Applicable,Mayo Clinic,Other,15-Feb-21,28-Jan-22,28-Jan-22,DIAGNOSTIC,20,DIABETES MELLITUS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",CONTINUOUS GLUCOSE MONITOR (CGM),CGM ACCURACY - MEAN ABSOLUTE RELATIVE DIFFERENCE (MARD),Continuous Glucose Monitor (CGM) Use in COVID-19 Patients
NCT04756193,Recruiting,Observational,,University of Louisville,Other,1-Apr-21,31-Dec-22,31-Dec-22,COHORT,250,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","POINT OF CARE ULTRASOUND INCLUDING ECHOCARDIOGRAPHY, LUNG ULTRASOUND, VASCULAR ULTRASOUND","ECHOCARDIOGRAPHIC STRAIN MEASUREMENTS OF THE LEFT, RIGHT HEART",Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound
NCT04756271,Recruiting,Interventional,Phase 3,Zagazig University,Other,11-Feb-21,21-Aug-21,21-Aug-21,PREVENTION,140,VACCINE ADVERSE REACTION,EGYPT,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 NEUTRALIZING ANTIBODY TITER,INCIDENCE OF ADVERSE REACTIONS,Safety and Immunogenicity of SARS-Cov-2 Inactivated Vaccine in Zagazig University Hospital Health-care Workers
NCT04756323,"Active, not recruiting",Interventional,Phase 2,"Beijing Minhai Biotechnology Co., Ltd",Industry,27-Oct-20,28-Feb-22,30-Jun-21,PREVENTION,1000,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",MEDIUM DOSAGE INACTIVATED SARS-COV-2 VACCINE,THE SEROPOSITIVE RATES OF SARS-COV-2 NEUTRALIZING ANTIBODY,"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial"
NCT04756466,Recruiting,Interventional,Not Applicable,Biosearch S.A.,Industry,1-Jan-21,31-Dec-21,30-Apr-21,OTHER,314,SARS COV-2 INFECTION,SPAIN,ALL,"60 Years and older   (Adult, Older Adult)",PLACEBO,INCIDENCE OF SARS COV-2 INFECTION.,"Multicenter, Randomized, Double-blind Parallel Group Pilot Study to Evaluate the Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly"
NCT04756479,Completed,Observational,,Brugmann University Hospital,Other,1-Mar-20,30-Jun-20,30-Jun-20,CASE-ONLY,160,COVID,BELGIUM,ALL,70 Years and older   (Older Adult),,ALL-CAUSE MORTALITY DURING HOSPITAL ADMISSION (ADMISSION UP TO DISCHARGE TIME),Predictors of Intrahospital Mortality in Older Patients Admitted Due to COVID-19 in the COVID-19 AGEBRU Study
NCT04756518,Recruiting,Observational,,East Suffolk and North Essex NHS Foundation Trust,Other,6-Jul-20,1-Jul-21,1-Jul-21,COHORT,785,COVID,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",,SPECIFICITY AND SENSITIVITY OF USING AI-BASED IMAGE ANALYTICAL MODELLING FOR DIAGNOSIS OF COVID-19.,Rapid Diagnosis of COVID-19 Positive Patients With Artificial Intelligence (AI) Algorithm Using Clinical and Image Analytical Parameters to Evaluate the Lymphocyte Subsets in the Peripheral Blood
NCT04756609,Not yet recruiting,Interventional,Not Applicable,Assistance Publique - Hôpitaux de Paris,Other,12-Feb-21,1-Jun-21,1-Jun-21,SCREENING,104000,SARS-COV INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",SYSTEMATIC OFFER OF NURSE-DRIVEN SARS-COV-2 SCREENING COMBINED WITH USUAL PRACTICE,PROPORTION OF PATIENTS TESTED POSITIVE FOR SARS-COV2 AMONGST THE FLOW OF CONSULTING ADULTS,Evaluation of the Benefit of a Systematic Offer of Nurse-Driven SARS-Cov2 Screening by Rapid Testing in Emergency Departments in the Paris Metropolitan Area
NCT04756674,Not yet recruiting,Observational,,University of Nottingham,Other,9-Feb-21,30-Apr-23,1-Oct-22,COHORT,36,COVID,,ALL,"40 Years and older   (Adult, Older Adult)",NO INTERVETION WILL BE USED,THE DIFFERENCE IN MITOCHONDRIAL FUNCTION BETWEEN COVID-19 INFECTION AND CONTROL GROUP,Investigating the Impact of COVID-19 Infection on Skeletal Muscle
NCT04756817,Recruiting,Observational,,G.Gennimatas General Hospital,Other,13-Feb-21,30-Sep-21,30-Aug-21,COHORT,500,"IMMUNOGENICITY, VACCINE",GREECE,ALL,85 Years to 100 Years   (Older Adult),,IMMUNOGENICITY AFTER THE FIRST DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE,Immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in Elderly People Over 85 Years of Age: Real World Data From Greece
NCT04756830,Not yet recruiting,Interventional,Phase 4,D'Or Institute for Research and Education,Other,21-Feb-21,23-Jun-21,21-Jul-21,PREVENTION,1200,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",ADSORBED COVID-19 (INACTIVATED) VACCINE,FREQUENCY OF LOCAL AND SYSTEMIC ADVERSE REACTIONS IN THE FIRST 7 DAYS AFTER IMMUNIZATION,An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up
NCT04756856,Not yet recruiting,Interventional,Not Applicable,IRCCS Policlinico S. Matteo,Other,1-Mar-21,1-Dec-21,1-Dec-21,SUPPORTIVE CARE,50,SARCOPENIA,,ALL,"18 Years and older   (Adult, Older Adult)",MUSCLE-TARGET ORAL NUTRITIONAL SUPPLEMENTATION,PHYSICAL PERFORMANCE - CHAIR-STAND,Impact of a Muscle-targeted Nutritional Therapy in the Recovery of Post-discharge COVID19 Patients Suffering From Sarcopenia
NCT04756869,"Active, not recruiting",Observational,,University of Michigan,Other,28-Apr-20,23-Jan-21,16-Jan-21,COHORT,226,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 MONITORING USING WEARABLE SENSORS AND SMARTPHONE TECHNOLOGY,FEASIBILITY OF WEARING FITBIT WATCH,Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology
NCT04757207,Not yet recruiting,Observational,,GULIN FINDIKOGLU,Other,22-Feb-21,1-May-21,1-May-21,COHORT,1000,SEDENTARY BEHAVIOR,TURKEY,ALL,"17 Years to 40 Years   (Child, Adult)",SURVEY,INTERNATIONAL PHYSICAL ACTIVITY SCORE (SHORT FORM) MET-MIN/WEEK,The Effect of Pandemia on Making Exercise In University Students of Turkey
NCT04757272,Completed,Observational,,Zagazig University,Other,1-May-20,30-Jan-21,30-Jan-21,COHORT,753,CORONAVIRUS INFECTION,EGYPT,ALL,"21 Years to 80 Years   (Adult, Older Adult)",,INCIDENCE OF CHRONIC HEPATITIS C AMONG COVID-19 HOSPITALIZED PATIENTS.,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?
NCT04757285,Completed,Observational [Patient Registry],,Alexandria University,Other,10-May-20,30-Oct-20,30-Oct-20,COHORT,90,PSYCHOLOGICAL STRESS,EGYPT,ALL,24 Years to 37 Years   (Adult),,EVALUATION OF PSYCHOLOGICAL STRESS,Evaluation of Serum Copeptin and Psychological Stress Level Among Healthcare Providers During COVID-19 Pandemic
NCT04757298,Recruiting,Interventional,Not Applicable,University of Illinois at Urbana-Champaign,Other,12-Feb-21,31-Dec-22,30-Jan-22,PREVENTION,670,COVID TESTING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",NAVIGATION SERVICES,COMPLETION OF COVID-19 TEST,Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community
NCT04757792,Completed,Observational,,Benha University,Other,6-Jun-20,11-Feb-21,1-Feb-21,CASE-ONLY,475,COVID DISEASE,EGYPT,ALL,"Child, Adult, Older Adult",FILE INQUIRY,MORTALITY RATE,Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
NCT04757818,Recruiting,Interventional,Not Applicable,Dentaid SL,Industry,4-Feb-21,25-Mar-21,25-Mar-21,OTHER,140,SARS-COV2 INFECTION,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",0.07% CETYLPYRIDINIUM CHLORIDE (CPC) IN MOUTHWASH,SARS-COV-2 VIRAL LOAD,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%"
NCT04757831,Not yet recruiting,Observational,,Duke University,Other,15-Feb-21,15-Feb-26,15-Feb-26,COHORT,1000000,COVID; MIS-C,,ALL,"up to 21 Years   (Child, Adult)",,"DESCRIBE THE INCIDENCE OF NON-SEVERE AND SEVERE COVID-19, INCLUDING MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C).",A Prospective Study of COVID-19 and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)
NCT04757857,Recruiting,Interventional,Phase 4,Hospital Alemão Oswaldo Cruz,Other,29-Sep-20,30-Apr-21,28-Feb-21,TREATMENT,1000,COVID,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",RIVAROXABAN 10 MG,VENOUS THROMBOEMBOLIC EVENTS (VTE),"Randomized, Pragmatic, Open Controlled Multicentre Study, Evaluating the Use of Rivaroxaban in Mild or Moderate COVID-19 Patients"
NCT04757870,Not yet recruiting,Observational,,Dr. Servet Akar,Other,1-Mar-21,31-Dec-21,30-Jun-21,OTHER,1790,COVID,,ALL,"Child, Adult, Older Adult",FREQUENCY,OCCURENCE,Determination of the Macro Scale Risk Factors in COVID19 Occurrence and Mortality
NCT04757883,Not yet recruiting,Observational,,"University Hospital, Strasbourg, France",Other,1-Mar-21,1-Mar-23,1-Mar-23,COHORT,100,KIDNEY TRANSPLANT RECIPIENTS,,ALL,"18 Years and older   (Adult, Older Adult)",STUDY OF THE SYNTHESIS OF ANTIBODIES DIRECTED AGAINST SARS,THE PRIMARY ENDPOINT WILL BE THE RATE OF KIDNEY TRANSPLANT PATIENTS WITH NEUTRALIZING ANTIBODIES DIRECTED AGAINST THE SPIKE PROTEIN OF THE SARS COV-2 VIRUS AFTER THE 2ND INJECTION OF THE VACCINE.,Immunological Follow-up After COVID 19 Vaccination in Kidney Transplant Recipients
NCT04758039,Completed,Observational [Patient Registry],,University of Chile,Other,13-Mar-20,10-Jul-20,10-Jul-20,COHORT,395,CORONAVIRUS INFECTION,CHILE,ALL,"18 Years and older   (Adult, Older Adult)",,IN HOSPITAL MORTALITY,Clinical Characteristics and In-hospital Death During the First 100 Days of the COVID-19 Pandemic in Chile: A Prospective Cohort Study From a University Hospital
NCT04758273,"Active, not recruiting",Interventional,Phase 1,"Beijing Minhai Biotechnology Co., Ltd",Industry,7-Oct-20,28-Feb-22,30-Jun-21,PREVENTION,180,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",MEDIUM DOSAGE INACTIVATED SARS-COV-2 VACCINE,INCIDENCE OF ADVERSE REACTIONS/EVENTS,"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial"
NCT04758286,Completed,Interventional,Not Applicable,Benha University,Other,1-Jul-20,11-Feb-21,1-Feb-21,TREATMENT,209,COVID,EGYPT,ALL,"Child, Adult, Older Adult",EMERGENCY SURGICAL PROCEDURES,QUESTIONNAIRE,Protocol for Anesthesia for Emergency Surgery
NCT04758299,Not yet recruiting,Interventional,Not Applicable,Barry Dewitt,Other,21-Feb-21,21-Mar-21,21-Mar-21,OTHER,1000,COVID TESTING,,ALL,"18 Years and older   (Adult, Older Adult)",DECISION SCIENCE-BASED DESIGN,CHOICE OF ACTION TO TAKE WITH NEGATIVE TEST,At Home Self-testing Kits for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) : A Randomized Trial Assessing How Consumers Interpret and Act on Test Results
NCT04758962,Recruiting,Interventional,Phase 1,GlaxoSmithKline,Industry,15-Feb-21,9-May-22,11-Jun-21,PREVENTION,40,VIRUS DISEASES,UNITED STATES,ALL,18 Years to 50 Years   (Adult),1 ΜG COV2 SAM (LNP),NUMBER OF PARTICIPANTS WITH AT LEAST 1 SOLICITED ADMINISTRATION SITE EVENT DURING 7-DAY FOLLOW-UP PERIOD AFTER FIRST VACCINATION (FIRST VACCINATION OCCURS ON DAY 1),"A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age"
NCT04760132,Recruiting,Interventional,Phase 4,"Jens D Lundgren, MD",Other,8-Feb-21,31-Dec-24,31-Dec-24,OTHER,10000,SARS-COV INFECTION,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",COMIRNATY - BIONTECH MANUFACTURING GMBH,ASSESSMENT OF THE EFFECTIVENESS OF CITIZENS BEING VACCINATED WITH ONE OF THE SARS-COV-2 VACCINES,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines
NCT04760184,Not yet recruiting,Observational,,Uppsala University,Other,1-Apr-21,31-Dec-21,30-Jun-21,COHORT,30,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",AUTOLOGOUS STEM CELL TRANSPLANTATION,OVERALL SURVIVAL,Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden - a Retrospective Cohort Study
NCT04760418,Not yet recruiting,Interventional,Not Applicable,University of Kentucky,Other,1-Mar-21,1-Aug-22,1-Aug-22,TREATMENT,6,PTSD,,ALL,"18 Years and older   (Adult, Older Adult)",CONCURRENT TREATMENT OF PTSD AND SUBSTANCE USE DISORDERS USING PROLONGED EXPOSURE (COPE),PTSD CHECKLIST FOR DSM-5 (PCL-5),"Evaluating the Impact of Trauma, Trauma-Focused Therapy Services, and COVID-19 Among Patients in the University of Kentucky SMART Clinic"
NCT04760561,Not yet recruiting,Interventional,Not Applicable,Damanhour University,Other,20-Feb-21,20-Apr-21,20-Mar-21,SUPPORTIVE CARE,82,PRONE POSITION,,ALL,"18 Years to 75 Years   (Adult, Older Adult)",PRONE POSITION GROUP,OXYGENATION INDEX,Effects of Self-prone Positioning on Oxygenation and Physiological Outcomes Among Awake Non-intubated Patients With COVID-19
NCT04760639,Recruiting,Observational,,Medical University of South Carolina,Other,16-Dec-20,16-Apr-21,16-Mar-21,COHORT,100,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",BREATH TEST,PROVIDE AN ADEQUATE SAMPLE AND COMPARE THE SIGNALS GIVEN FROM THE TWO GROUPS.,Breath Test Feasibility Trial for COVID-19 Infection Diagnosis
NCT04760704,Not yet recruiting,Observational,,"University Hospital, Lille",Other,21-Feb-21,23-May-21,23-May-21,CASE-CONTROL,250,COVID VACCINE,FRANCE,ALL,"40 Years and older   (Adult, Older Adult)",SPECIFIC ANTIBODY AND CELLULAR IMMUNE RESPONSE AFTER ANTI-SARS-COV-2 VACCINE ADMINISTRATION,COMPARISON OF SPECIFIC CELLULAR RESPONSE AFTER ANTI-SARS-COV-2 BNT162B2 MRNA VACCINE,Evaluation of the Immunogenicity of mRNA BNT162b2 (COMIRNATY®) Vaccine in Elderly Subjects by Monitoring the Specific Cellular and Humoral Response.
NCT04760730,Not yet recruiting,Interventional,Phase 1/Phase 2,R-Pharm,Industry,17-Mar-21,31-Dec-21,1-May-21,PREVENTION,100,COVID,,ALL,"18 Years to 100 Years   (Adult, Older Adult)",AZD1222,ANTIBODY SEROCONVERSION RATE (≥ 4 FOLD INCREASE FROM BASELINE) AGAINST SARS-COV-2 SPIKE PROTEIN 29 DAYS POST SECOND VACCINATION,A Phase I/II Single-Blinded Randomised Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID-19
NCT04760743,"Active, not recruiting",Interventional,Phase 1,"SK Bioscience Co., Ltd.",Industry,17-Dec-20,22-Apr-21,21-Apr-21,PREVENTION,50,COVID (HEALTHY VOLUNTEERS),"KOREA, REPUBLIC OF",ALL,19 Years to 55 Years   (Adult),NBP2001 ADJUVANTED WITH ALUM (RBD 30ΜG/DOSE),OCCURRENCE OF IMMEDIATE SYSTEMIC REACTIONS,"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years"
NCT04760795,Recruiting,Observational,,Centre Hospitalier Universitaire de Saint Etienne,Other,15-Nov-20,21-Jun-21,21-Jun-21,CASE-ONLY,118,PSYCHIATRIC DISORDER,FRANCE,ALL,65 Years and older   (Older Adult),PTSD CHECK LIST (PCL) SCALE,ANALYSIS POST TRAUMATIC STRESS DISORDER MEASURED BY PTSD CHECK LIST (PCL) RESULTS,"Stress, Personality, Attachment and Coping During the Covid Crisis."
NCT04760821,Recruiting,Interventional,Phase 2,"Ministry of Health, Brazil",Other,10-Dec-20,30-Apr-21,30-Apr-21,TREATMENT,80,ACUTE RESPIRATORY DISTRESS SYNDROME,BRAZIL,ALL,"18 Years and older   (Adult, Older Adult)",TRIMETAZIDINE,HIGH-SENSITIVITY CARDIAC TROPONIN,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for Moderate to Severe Acute Respiratory Syndrome Caused by SARS-CoV-2
NCT04760990,Recruiting,Observational,,"University Hospital, Basel, Switzerland",Other,1-Feb-21,23-Dec-21,23-Dec-21,COHORT,1400,MULTIPLE SCLEROSIS,SWITZERLAND,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION,INCIDENCE OF SEVERE COVID-19 AS DEFINED BY THE WHO CLINICAL PROGRESSION SCALE (SCORE 6-9),An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
NCT04761107,Recruiting,Observational,,Icahn School of Medicine at Mount Sinai,Other,21-Feb-21,26-Feb-21,23-Feb-21,OTHER,15240,COVID INFECTION,UNITED STATES,ALL,"40 Years and older   (Adult, Older Adult)",,PROPORTION OF PATIENTS WITH A NEW DIAGNOSIS OF GU,Mitigating Risk of COVID-19 for Clinical Management of Genitourinary Diseases
NCT04761510,Completed,Interventional,Not Applicable,University of Haifa,Other,14-Sep-20,14-Jan-21,14-Jan-21,TREATMENT,60,"STRESS DISORDERS, POST-TRAUMATIC",ISRAEL,ALL,"18 Years to 65 Years   (Adult, Older Adult)",MINDFULNESS-SOS FOR REFUGEES,HARVARD TRAUMA QUESTIONNAIRE ACCORDING TO DSM-5 (HTQ-5),Mindfulness-SOS: Stress Reduction for Refugees
NCT04761692,Not yet recruiting,Interventional,Not Applicable,Charles Drew University of Medicine and Science,Other,1-Oct-21,31-Dec-26,31-Oct-26,HEALTH SERVICES RESEARCH,570,COVID,UNITED STATES,ALL,65 Years and older   (Older Adult),FULL VEPMP INTERVENTION,"PREVALENCE OF VACCINATION UPTAKE FOR COVID-19, INFLUENZA, AND PNEUMONIA USING VACCINATION HISTORY SELF REPORT",Improving Vaccine Acceptance and Uptake Among Underresourced African American and Latinx Older Adults: A Multidisciplinary and Culturally Based Training Program for Minority Churches
NCT04761718,Not yet recruiting,Observational,,Delta University for Science and Technology,Other,1-Mar-21,30-May-21,30-May-21,COHORT,300,COVID EPIDEMIC LOCKDOWN IMPACT,,ALL,"6 Years to 18 Years   (Child, Adult)",,PRE LOCKDOWN ASSESSMENT FOR PHYSICAL ACTIVITY,Covid-19 Epidemic Lockdown Impact on Psychomotor Performance in Egyptian Children
NCT04761822,Not yet recruiting,Interventional,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NIH,21-Mar-21,21-Jun-21,21-May-21,TREATMENT,3400,SARS-COV INFECTION,UNITED STATES,ALL,"18 Years to 69 Years   (Adult, Older Adult)",MODERNA COVID-19 VACCINE,PROPORTION OF PARTICIPANTS WHO EXPERIENCE A SYSTEMIC ALLERGIC REACTION TO EITHER DOSE OF THE PFIZER-BIONTECH COVID-19 VACCINE,Systemic Allergic Reactions to SARS-CoV-2 Vaccination
NCT04761874,Completed,Observational,,University of Minnesota,Other,1-Dec-19,29-Sep-20,29-Jun-20,COHORT,296,"STROKE, ACUTE",UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",TELESTROKE,GUIDELINE-BASED INPATIENT STROKE CARE,TELEstroke to CAre for STroke Patients at a Comprehensive Stroke Center During the COVID-19 Pandemic
NCT04761913,Not yet recruiting,Observational,,Anglia Ruskin University,Other,21-Feb-21,21-Dec-21,21-Sep-21,CASE-ONLY,100,PAEDIATRIC INFLAMMATORY MULTISYSTEM SYNDROME TEMPORALLY ASSOCIATED WITH SARS-COV2,,ALL,3 Months to 16 Years   (Child),,BLOOD BIOMARKER ASSOCIATED WITH A CYTOKINE STORM - PRO-BETA NATRIURETIC PEPTIDE (MEASURED IN PG/ML).,Investigating Cytokine Storm Biomarkers in Children Presenting to Acute Paediatric Services (Non-intensive Care) With Paediatric Inflammatory Multisystem Syndrome During the Covid-19 Pandemic. An Observation Study
NCT04762056,Not yet recruiting,Observational,,Gaziosmanpasa Taksim Research and Education Hospital,Other,20-Feb-21,30-May-21,30-May-21,OTHER,26,POST INTENSIVE CARE UNIT SYNDROME,TURKEY,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CHELSEA CRITICAL CARE PHYSICAL ASSESSMENT TOOL,CHELSEA CRITICAL CARE PHYSICAL ASSESSMENT TOOL (CPAX),Validation of Chelsea Physical Assessment Tool (CPAx) in COVID-19 Patients for Assessing Functional Status After Intensive Care Unit Discharge
NCT04762173,"Active, not recruiting",Interventional,Not Applicable,Penn State University,Other,6-Nov-20,3-Jun-21,3-Jun-21,TREATMENT,584,STRESS,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",ONLINE SELF-HELP INTERVENTION,CHANGE IN STRESS,Self-Help for Stress Related to COVID-19
NCT04762186,Not yet recruiting,Interventional,Phase 1/Phase 2,Universitätsklinikum Köln,Other,1-Apr-21,1-Dec-22,1-Sep-22,TREATMENT,51,MODERATE COVID-INFECTION,GERMANY,ALL,"18 Years to 99 Years   (Adult, Older Adult)","IMP 1,000 PLUS SOC",PHASE I: DOSE-LIMITING TOXICITIES,A Randomized Phase I/II Trial to Analyse Safety and Efficacy of Adoptive SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
NCT04762628,"Active, not recruiting",Interventional,Not Applicable,Saisei Pharma,Industry,27-Oct-20,10-Jan-22,1-Nov-21,TREATMENT,600,COVID,UKRAINE,ALL,"18 Years and older   (Adult, Older Adult)",MAF CAPSULES 148 MG,THE TIME TO BASIC CLINICAL IMPROVEMENT AND TO RECOVERY DEFINED AS THE FOLLOWING,"Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation"
NCT04762680,Recruiting,Interventional,Phase 2,"Sanofi Pasteur, a Sanofi Company",Industry,21-Feb-21,22-Sep-21,22-Sep-21,PREVENTION,720,COVID (HEALTHY VOLUNTEERS),UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SARS-COV-2 RECOMBINANT PROTEIN VACCINE FORMULATION 1,PRESENCE OF IMMEDIATE ADVERSE EVENTS,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine With AS03 Adjuvant in Adults 18 Years of Age and Older
NCT04762693,Recruiting,Observational,,"Clinica Universidad de Navarra, Universidad de Navarra",Other,11-Nov-20,1-Nov-21,1-Oct-21,COHORT,300,COVID,SPAIN,ALL,"13 Years to 99 Years   (Child, Adult, Older Adult)",HYFE COUGH TRACKER,CORRELATION BETWEEN REGISTERED COUGHS PER PERSON-HOUR AND INCIDENCE OF RESPIRATORY DISEASES,"Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks: An Exploratory Observational Study in Navarra, Spain"
NCT04762771,Recruiting,Interventional,Phase 1/Phase 2,Baptist Health South Florida,Other,1-Dec-20,1-Nov-21,1-Nov-21,TREATMENT,75,COVID,UNITED STATES,ALL,"18 Years to 99 Years   (Adult, Older Adult)",COLCHICINE,MORTALITY,Open-label (Unblinded) Randomization to Treatment of Colchicine Plus Current Care Per Institution Treating Physicians vs. Current Care Per Institution Treating Physicians (Control Arm)
NCT04763213,Completed,Observational,,Kahramanmaras Sutcu Imam University,Other,1-Jan-18,31-Dec-19,31-Dec-19,OTHER,276,MYOCARD INFARCTUS,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",CORONARY ANGIOGRAPHY,PREDICTIVE FACTORS FOR NON ST ELEVATED MI BLOOD PRARAMETERS PREDICTIVE FACTORS FOR NON ST ELEVETED MI,New Predictors in Determining the Need for Invasive Treatment in Non-STEMI During the COVID-19 Pandemic: A Retrospective Study
NCT04763304,Completed,Interventional,Not Applicable,Hospital Italiano de Buenos Aires,Other,1-Sep-20,18-Nov-20,29-Oct-20,PREVENTION,60,PERSONAL PROTECTIVE EQUIPMENT,ARGENTINA,ALL,"18 Years and older   (Adult, Older Adult)",GOWN PERSONAL PROTECTIVE EQUIPMENT (PPE-G) SUIT,MEAN WITHIN-PARTICIPANT DIFFERENCE IN SELF-CONTAMINATION BETWEEN PPE-G AND PPE-C SUITS,"Self-contamination Following Removal of Two Personal Protective Equipment Suits: a Randomized, Controlled, Crossover Simulation Trial"
NCT04763395,Recruiting,Observational,,Sohag University,Other,29-Jan-21,1-Mar-21,20-Feb-21,CASE-ONLY,100,LIVER FUNCTION TESTS ABNORMALITIES,EGYPT,ALL,"Child, Adult, Older Adult",NO INTERVENTION,PERCENTAGE OF LIVER FUNCTION TESTS ABNORMALITIES IN EGYPTIAN PATIENTS WHO INFECTED WITH COVID19 -TO EVALUATE IF LIVER FUNCTION TEST ABNORMALITIES ARE RELATED TO THE SEVERITY OF THE COVID19.,Liver Function Test Abnormalities in COVID-19 Egyptian Patients
NCT04763681,Recruiting,Interventional,Not Applicable,York University,Other,1-Jan-21,31-Aug-21,31-Aug-21,TREATMENT,140,POSTTRAUMATIC STRESS DISORDER,CANADA,ALL,18 Years to 64 Years   (Adult),"COUPLE HOPES GUIDED, INTERNET-DELIVERED, SELF-HELP INTERVENTION",PTSD CHECKLIST FOR DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS-5 (PCL-5) WITH CHANGE MEASURED AS MEAN CHANGE FROM BASELINE,"Expanding a Randomized Controlled Trial of a Couple Internet-Delivered PTSD Intervention to Reach Military Members, Veterans, and First Responders With COVID-19-Related Trauma Exposure"
NCT04764032,Recruiting,Observational,,University of Glasgow,Other,2-Sep-20,30-Apr-21,31-Mar-21,COHORT,150,COVID,UNITED KINGDOM,ALL,"17 Years and older   (Child, Adult, Older Adult)",ECHOCARDIOGRAPHY,THE PREVALENCE OF RV DYSFUNCTION IN VENTILATED PATIENTS WITH COVID-19,Right Ventricular Dysfunction in Ventilated Patients With COVID-19
NCT04764422,Not yet recruiting,Interventional,Phase 1/Phase 2,Mahidol University,Other,21-Mar-21,23-Apr-21,22-Apr-21,PREVENTION,460,COVID,THAILAND,ALL,"18 Years to 75 Years   (Adult, Older Adult)",NORMAL SALINE,FREQUENCY OF SOLICITED REPORTABLE LOCAL ADVERSE EVENT AFTER FIRST VACCINATION,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand"
NCT04764721,Not yet recruiting,Interventional,Not Applicable,"Central Hospital, Nancy, France",Other,12-Apr-21,12-May-22,12-Apr-22,DIAGNOSTIC,50,COVID,,ALL,"18 Years to 65 Years   (Adult, Older Adult)",18F-FDG PET-CT,TO CHARACTERIZE THE CHANGES IN BRAIN METABOLISM IN 18F-FDG PET-CT IN PATIENTS ENROLLED IN NEUROCOG-STUDY IN THE HOSPITAL OF NANCY,Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Young Subjects With Sequelae Psycho-cognitive Disorders in the Aftermath of Severe Covid-19
NCT04764747,Recruiting,Observational,,Kufa University,Other,1-Nov-20,21-Apr-21,21-Apr-21,COHORT,400,COVID,IRAQ,ALL,"18 Years to 95 Years   (Adult, Older Adult)",,TIME TO CLINICAL IMPROVEMENT,Evaluating Effectiveness of Convalescent Plasma and Factors Influencing Therapeutic Outcome in Hospitalized Patients With COVID-19
NCT04764773,Recruiting,Observational,,Sohag University,Other,1-May-20,31-Mar-21,28-Feb-21,CASE-CONTROL,250,CORONAVIRUS INFECTION,EGYPT,ALL,"Child, Adult, Older Adult",NO INTERVENTION,PERCENTAGE OF PATIENT WHO HAD PERSISTENT SYMPTOMS AFTER RECOVERY OF ACUTE COVID19,"Persistence of Symptoms After Improvement of Acute COVID19 Infection in Sohag Governorate, Egypt, A Longitudinal Study"
NCT04764981,Enrolling by invitation,Interventional,Not Applicable,Universidade do Estado do Pará,Other,21-May-21,1-May-24,22-May-21,TREATMENT,350,COVID,BRAZIL,ALL,"18 Years to 65 Years   (Adult, Older Adult)",ESSENCE OILS,TO ASSESS THE EFFECTIVENESS OF OLFACTORY TRAINING THERAPY IN THE TREATMENT OF PERSISTENT OLFACTORY DYSFUNCTIONS AFTER COVID-19,Clinical Outcomes of Olfactory Training for Treatment of Olfactory Dysfunction After COVID-19
NCT04765215,Not yet recruiting,Observational,,Asoc. Prof. Erdoğan Selçuk Şeber,Other,31-Mar-21,31-Mar-22,31-Jul-21,CASE-CONTROL,291,IS THE CORONOVAC VACCINE EFFECTIVE IN PATIENTS RECEIVING CHEMOTHERAPY,,ALL,"18 Years to 90 Years   (Adult, Older Adult)",CORONOVAC,ANTIBODY LEVELS ABOVE THE DEFINED CUT-OFF,Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.
NCT04765254,Recruiting,Observational,,Cairo University,Other,20-Feb-21,10-Apr-21,20-Mar-21,CASE-CONTROL,300,COVID,EGYPT,ALL,"30 Years and older   (Adult, Older Adult)",NO INTERVENTION AS IT IS AN OBSERVATIONAL STUDY,INVESTIGATION OF BAD PROGNOSIS CAUSE FOR COVID-19 DIABETIC PATIENTS,Clinical Features of Diabetic Patients With COVID-19 Infection
NCT04765371,Not yet recruiting,Interventional,Phase 3,Centre Hospitalier René Dubos,Other,21-Mar-21,21-Oct-21,21-Oct-21,TREATMENT,220,CORONAVIRUS INFECTION,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DEXAMETHASONE,MORTALITY ASSESSMENT AT D28,"Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study"
NCT04765384,Not yet recruiting,Interventional,Phase 2,Janssen Vaccines & Prevention B.V.,Industry,26-Feb-21,20-Jun-23,16-Jan-23,PREVENTION,824,HEALTHY,SOUTH AFRICA,FEMALE,18 Years to 40 Years   (Adult),AD26.COV2.S,GROUPS 1-10: NUMBER OF PARTICIPANTS WITH SOLICITED LOCAL ADVERSE EVENTS (AES),"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants"
NCT04765436,Recruiting,Interventional,Phase 1,Providence Therapeutics Holdings Inc.,Industry,14-Jan-21,14-Feb-22,30-Apr-21,PREVENTION,60,COVID VACCINE,CANADA,ALL,18 Years to 64 Years   (Adult),PTX-COVID19-B,OCCURRENCE OF ADVERSE EVENTS (AES) DURING THE FOLLOW-UP AFTER EACH VACCINATION,"A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64"
NCT04765449,Not yet recruiting,Interventional,Phase 1,Thomas Jefferson University,Other,30-Mar-21,29-Feb-24,31-Aug-23,TREATMENT,24,COVID,UNITED STATES,ALL,70 Years and older   (Older Adult),CYTOTOXIC T LYMPHOCYTES,SAFETY OF COVID-19-SPECIFIC CTLS: INFUSION REACTIONS,Third-Party Covid-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With Covid-19 Infection
NCT04765475,Not yet recruiting,Interventional,Not Applicable,Johns Hopkins Bloomberg School of Public Health,Other,21-Feb-21,22-Sep-21,22-Feb-21,PREVENTION,600,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",MOTIVATIONAL INTERVIEWING,TESTING: PROPORTION TESTED FOR COVID-19,Protecting Native Families From COVID-19 (PROTECT)
NCT04765540,"Active, not recruiting",Interventional,Not Applicable,The Behavioural Insights Team,Other,3-Jan-21,30-May-21,1-May-21,PREVENTION,860,HAND WASHING,BANGLADESH,ALL,"Child, Adult, Older Adult",LOW INTENSITY NUDGES,AVERAGE HANDWASHING STATION SOAP PEDAL PRESSES PER DAY (IN WEEKS 1 TO 3),The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh
NCT04765839,"Active, not recruiting",Interventional,Not Applicable,Mayo Clinic,Other,12-Feb-21,22-Mar-21,22-Mar-21,SUPPORTIVE CARE,90,VACCINE PREVENTABLE DISEASE,UNITED STATES,ALL,"18 Years to 101 Years   (Adult, Older Adult)","EDUCATIONAL, CULTURALLY APPROPRIATE COVID-19 MESSAGES",COVID-19 ATTITUDES,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations
NCT04766294,Recruiting,Observational,,Sohag University,Other,25-Apr-20,1-Apr-21,15-Mar-21,OTHER,70,COVID,EGYPT,ALL,"19 Years to 70 Years   (Adult, Older Adult)",,"MEASUREMENT OF MATRIX METALLOPROTEINASE-7 ""MMP-7"" SERUM LEVEL (PG/ML) AS A BIOMARKER OF MACROPHAGE ACTIVATION","Is the Severity of COVID-19 in Obese and Diabetic Patients Linked to High Serum Levels of MMP-7, MMP-9, TGF-β and PDGF Macrophage Activation Markers?"
NCT04766333,Not yet recruiting,Interventional,Not Applicable,"Rutgers, The State University of New Jersey",Other,21-Mar-21,22-Aug-21,22-Feb-21,HEALTH SERVICES RESEARCH,2000,COVID,,ALL,"4 Years and older   (Child, Adult, Older Adult)",HEALTHCARE WORKER FOCUSED OUTREACH,NUMBER OF PARTICIPANTS WHO COMPLETE COVID-19 TESTING,NJ HEROES TOO (New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations)
NCT04766788,"Active, not recruiting",Observational,,University of Michigan,Other,3-Sep-20,21-Aug-21,21-May-21,COHORT,2494,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)","WEARABLE DEVICES, SALIVA SAMPLES, SURVEY MEASURES",FEASIBILITY OF WEARING FITBIT DEVICE,Monitoring Beliefs and Physiological Measures in Students at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology
NCT04766931,Not yet recruiting,Interventional,Phase 1,Frontier Biotechnologies Inc.,Industry,21-Mar-21,21-Dec-21,21-Aug-21,TREATMENT,32,COVID,UNITED STATES,ALL,18 Years to 60 Years   (Adult),FB2001,THE MAXIMUM TOLERABLE DOSE (MTD),"A Two-part, Phase I/II, Multi-center, Double-Blind, Randomized, Vehicle-controlled Study of the Safety and Efficacy of FB2001 in Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Infection"
NCT04766983,Recruiting,Observational,,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",Other,22-Jan-21,30-Apr-22,31-Jan-22,COHORT,100,VENTILATOR ASSOCIATED PNEUMONIA,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",BRONCHOALVEOLAR LAVAGE,INCIDENCE OF VAP,Cohort Study to Evaluate the Incidence of Ventilator-associated Pneumonia by Means of Bronchoalveolar Lavage in Patients With Severe SARS-CoV-2 Infection
NCT04767087,Recruiting,Interventional,Phase 2/Phase 3,Sohaib Ashraf,Other,5-Feb-21,15-Jul-21,15-Jun-21,PREVENTION,1000,COVID,PAKISTAN,ALL,"18 Years and older   (Adult, Older Adult)",HONEY,SARS-COV-2 INFECTION RATE,Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial
NCT04767477,Not yet recruiting,Interventional,Not Applicable,Universidade Federal de Pernambuco,Other,28-Mar-21,21-Aug-21,21-Jun-21,TREATMENT,60,COVID,BRAZIL,ALL,"18 Years to 75 Years   (Adult, Older Adult)",FACE-TO-FACE REHABILITATION,MAXIMUM FUNCTIONAL CAPACITY,Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol
NCT04767958,Not yet recruiting,Interventional,Not Applicable,Ottawa Heart Institute Research Corporation,Other,16-Feb-21,31-Jul-22,28-Feb-22,DIAGNOSTIC,2500,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",SPARTAN COVID-19 PLATFORM,SENSITIVITY OF POC TESTING AS COMPARED TO CORE LAB TESTING,"The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing to Optimize Patient Care, Resource Allocation and Safety for Frontline Staff"
NCT04768153,Recruiting,Observational,,University Hospital Center of Martinique,Other,29-Jun-20,29-Dec-21,29-Jun-21,COHORT,700,CANCER,MARTINIQUE,ALL,"18 Years and older   (Adult, Older Adult)",SEROLOGY,EVALUATION OF PSYCHIATRIC DISORDERS,Prioritising Prevention of COVID-19 in Persons With Cancer in the French West Indies: Monitoring Psychological Impact to Optimize Healthcare Delivery Strategies in Unique Public Health Circumstances
NCT04768179,Not yet recruiting,Interventional,Phase 2/Phase 3,Makerere University,Other,19-Feb-21,30-Sep-21,30-Jun-21,TREATMENT,490,COVID,,ALL,18 Years to 64 Years   (Adult),3-DAYIVM 200 MCG/KG/DAY/14-DAY 75MGASA/DAY + STANDARD OF CARE (INTERVENTION 1),SARS COV 2 VIRAL CLEARANCE,A Randomized Clinical Trial to Investigate Safety & Efficacy of Low-dose Aspirin / Ivermectin Combination Therapy in Management of COVID-19 Patients
NCT04768244,Recruiting,Observational,,"Institute of Agrochemistry and Food Technology, National Research Council",Other,1-Apr-20,21-Dec-21,21-Dec-21,CASE-CONTROL,100,COVID,SPAIN,FEMALE,18 Years to 45 Years   (Adult),MATERNAL SARS-COV-2 INFECTION,SARS-COV-2 RNA,"Impact of Maternal SARS-CoV-2 Infection and Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health (MilkCORONA)"
NCT04768257,Not yet recruiting,Observational,,University of Alcala,Other,21-Apr-21,1-Dec-22,1-Jul-22,COHORT,195,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PHYSICAL ACTIVITY,CHANGE IN PHYSICAL ACTIVITY (PA) PATTERNS (STEPS/DAY) FROM BASELINE (AT HOSPITAL DISCHARGE OR PATIENT'S HOME) AT 12 WEEKS AND 6 MONTHS,Physical Activity Post Coronavirus (COVID-19). A Longitudinal Study
NCT04768413,Recruiting,Observational [Patient Registry],,Fundación Universitaria de Ciencias de la Salud,Other,1-Jun-20,30-Jun-21,30-Apr-21,COHORT,200,RHEUMATOID ARTHRITIS,COLOMBIA,ALL,"18 Years and older   (Adult, Older Adult)",TELECONSULTATION EITHER BY PHONE OR BY COMPUTER CONSULTATION. QUANTITATIVE AND QUALITATIVE APPROACHES TO ANALYSIS,EVALUATION OF THE IMPLEMENTATION OF A NON-FACE-TO-FACE MULTIDISCIPLINARY CONSULTATION MODEL IN A POPULATION OF RHEUMATOID ARTHRITIS,Evaluation of a Non-face to Face Multidisciplinary Health Care Model in a Population With Rheumatoid Arthritis Highly Vulnerable to the 2019 Novel Coronavirus Disease
NCT04768998,Recruiting,Observational,,Goethe University,Other,4-Nov-20,23-Sep-21,21-Mar-21,COHORT,6550,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV2),GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",OBSERVATIONAL OF DIFFERENT COURSES OF SARS-COV-2 INFECTION IN DIFFERENT PHASES (ACUTE VS. POST-ACUTE) AND SETTINGS,LONGITUDINAL COLLECTION OF DATA AND BIOMATERIAL,Intersectoral Platform (SÜP) of the National Pandemic Cohort Network (NAPKON)
NCT04769154,Not yet recruiting,Observational [Patient Registry],,American University of Beirut Medical Center,Other,21-Feb-21,23-Feb-21,23-Feb-21,COHORT,100,AIRWAY MANAGEMENT,,ALL,"18 Years and older   (Adult, Older Adult)",,THE SUCCESS RATE OF ENDOTRACHEAL INTUBATION AT FIRST ATTEMPT,Airway Management in the Intensive Care and Regular Hospital Units During COVID-19 Pandemic: A Prospective Observational Study
NCT04769245,Recruiting,Observational,,Acibadem University,Other,18-Feb-21,1-Jun-21,1-Apr-21,CASE-ONLY,40,COVID,TURKEY,ALL,"18 Years to 75 Years   (Adult, Older Adult)",,MORTALITY RATE,The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection
NCT04769258,Not yet recruiting,Observational [Patient Registry],,Italian Group for the study of Inflammatory Bowel Disease (IG-IBD),Other,1-Mar-21,1-Jun-22,1-Mar-22,CASE-CONTROL,1380,INFLAMMATORY BOWEL DISEASES,,ALL,"18 Years and older   (Adult, Older Adult)",PFIZER COMIRNATY VACCINE,QUANTITATIVE SERUM TITER OF IGM AND IGG AGAINST SARS-COV-2,Effectiveness and Safety of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease Treated With Immunomodulatory or Biological Drugs
NCT04769284,Completed,Observational,,Yolanda Marcen Roman,Other,12-Feb-21,21-Feb-21,20-Feb-21,OTHER,332,"STRESS, PSYCHOLOGICAL",SPAIN,ALL,"Child, Adult, Older Adult",MENTAL HEALTH STUDENT,MODIFIED VERSION OF EPP-10 RELATED TO COVID-19 (EPP-10-C),Psychological State of University Students of Health Sciences During COVID-19
NCT04769297,"Active, not recruiting",Interventional,Phase 4,Limbic Medical,Other,15-Apr-20,21-Apr-21,21-Apr-21,TREATMENT,30,ACUTE STRESS DISORDER,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",SUBLINGUAL MICRO-DOSE KETAMINE,PATIENT SELF-REPORTED OUTCOME MEASURE,"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic"
NCT04769349,Recruiting,Observational,,University of Southern California,Other,29-Jan-21,15-Dec-22,15-Dec-21,COHORT,800,HOUSING,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",,LIFE SATISFACTION,Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness
NCT04769700,Recruiting,Observational,,Instituto Mexicano del Seguro Social,Other,1-Jan-21,1-Jun-21,1-Jun-21,COHORT,250,"BREAST FEEDING, EXCLUSIVE",MEXICO,FEMALE,"18 Years and older   (Adult, Older Adult)",EDINBURGH POSTNATAL DEPRESSION SCALE,POST-PARTUM DEPRESSION FREQUENCY,"Post-partum Depression, Breastfeeding Adherence, and Fear in Women Giving Birth During the COVID-19 Pandemic."
NCT04769999,Completed,Interventional,Not Applicable,University of Oxford,Other,4-Jun-20,30-Oct-20,16-Oct-20,TREATMENT,14,POST TRAUMATIC STRESS DISORDER,UNITED KINGDOM,ALL,"18 Years and older   (Adult, Older Adult)",SIMPLE COGNITIVE TASK,CHANGE IN THE NUMBER OF INTRUSIVE MEMORIES OF TRAUMATIC EVENT,"Reducing Intrusive Memories of Work-Related Traumatic Events, Including Events During the COVID-19 Pandemic, in NHS Staff Using a Brief Cognitive Task Intervention"
NCT04770467,Not yet recruiting,Interventional,Phase 2,"Brii Biosciences, Inc.",Industry,21-Feb-21,22-Oct-21,22-Oct-21,TREATMENT,56,COVID,CHINA,ALL,"18 Years and older   (Adult, Older Adult)",BRII-196 AND BRII-198,INCIDENCE OF ADVERSE EVENTS (AES),"A Phase 2, Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients"
NCT04770649,Recruiting,Observational,,Persephone Biosciences,Industry,21-Apr-21,23-Dec-21,22-Dec-21,COHORT,10000,VACCINE RESPONSE IMPAIRED,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 VACCINE,DETERMINE WHETHER THE MICROBIOME COMPOSITION CAN PREDICT EFFECTIVENESS OF VACCINE.,VOICES: Vaccine Observation to Include All Communities for Equitable Science
NCT04770740,Not yet recruiting,Interventional,Phase 2,Canisius-Wilhelmina Hospital,Other,22-Feb-21,1-Oct-21,1-Jun-21,OTHER,40,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",VITAMIN K2 IN THE FORM OF MENAQUINONE-7 (MK-7),PLASMA DESMOSINE LEVELS,"A Phase 2, Double Blind, Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Effects of Oral Vitamin K2 Supplementation in COVID-19"
NCT04771000,Recruiting,Interventional,Phase 2,Noorik Biopharmaceuticals AG,Industry,8-Feb-21,31-Oct-21,31-Jul-21,TREATMENT,150,COVID,SPAIN,ALL,"50 Years to 80 Years   (Adult, Older Adult)",AMBRISENTAN,CHANGE IN SPO2/FIO2 FROM BASELINE TO THE TIME-WEIGHTED AVERAGE OBTAINED ON DAY 3,"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19"
NCT04771013,Recruiting,Interventional,Phase 2,Universidad Católica de Honduras,Other,10-Feb-21,21-May-21,21-May-21,TREATMENT,20,COVID,HONDURAS,ALL,"21 Years and older   (Adult, Older Adult)",THYMIC PEPTIDES,TIME TO PARTICIPANT RESPONSE,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras"
NCT04771052,Enrolling by invitation,Observational,,Université de Sherbrooke,Other,1-Sep-20,21-Apr-21,21-Apr-21,CASE-CONTROL,128,COVID,CANADA,ALL,"Child, Adult, Older Adult",COVID REHABILITATION PROGRAM FOR THE ELDERLY (CORE),LENGTH OF STAY,Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly: the CORE Trial in Response to the Pandemic
NCT04771117,Completed,Observational,,Instituto Mexicano del Seguro Social,Other,1-May-20,1-Dec-20,1-Aug-20,COHORT,4004,HEALTH BEHAVIOR,MEXICO,ALL,"16 Years and older   (Child, Adult, Older Adult)",FEAR OF COVID-19 SCALE,RISK FACTORS,Defiances to Face COVID-19 Pandemic in Mexico
NCT04771351,Not yet recruiting,Interventional,Phase 2,"Sorrento Therapeutics, Inc.",Industry,21-Mar-21,21-Sep-21,21-Jul-21,TREATMENT,280,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",COVI-AMG,PROPORTION OF SUBJECTS WHO ARE ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 29,"A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adult Patients With COVID-19"
NCT04771559,Not yet recruiting,Interventional,Not Applicable,Bezmialem Vakif University,Other,1-Mar-21,1-Jul-21,1-Jun-21,OTHER,1000,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",COVID-19 ANTIBODY TEST,ANTIBODY LEVELS,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients
NCT04771585,Recruiting,Interventional,Not Applicable,Fraunhofer-Institute of Toxicology and Experimental Medicine,Other,15-Mar-21,31-Jan-22,31-Jan-22,BASIC SCIENCE,30,HEALTHY,GERMANY,ALL,"18 Years to 80 Years   (Adult, Older Adult)",COMMUNITY MASK,TO COMPARE THE EMITTED SMALL PARTICLE FRACTION BETWEEN VARIOUS RESPIRATORY ACTIVITIES.,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of SARS-Co-V-2
NCT04771598,Not yet recruiting,Interventional,Not Applicable,Tokat Gaziosmanpasa University,Other,25-Feb-21,30-Jul-21,30-Jun-21,SUPPORTIVE CARE,52,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",BREATHING EXERCISE WITH THE PHONE APPLICATION,6 MINUTE WALKING TEST,THE EFFECT OF BREATHING EXERCISE AFTER COVID-19 PNEUMONIA: A Randomised Controlled Study
NCT04771611,Not yet recruiting,Interventional,Phase 2,"James L. Kirkland, MD, PhD",Other,21-Mar-21,23-Jun-21,22-Dec-21,TREATMENT,150,COVID,UNITED STATES,ALL,"18 Years and older   (Adult, Older Adult)",FISETIN,SERIOUS ADVERSE EVENTS,COVFIS-HOME: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND DECREASE COMPLICATIONS IN AT-RISK OUTPATIENTS
NCT04771624,Recruiting,Observational,,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,Other,30-Oct-20,30-Jul-21,30-Apr-21,COHORT,100,COVID,TURKEY,ALL,"18 Years and older   (Adult, Older Adult)",,NEUROPSYCHOLOGICAL TEST SCORES,May Covid-19 Impair Executive Functions?
NCT04772404,Not yet recruiting,Observational,,Universidad de Granada,Other,1-Mar-21,15-Jun-21,15-May-21,COHORT,100,HEALTHY,SPAIN,ALL,"18 Years and older   (Adult, Older Adult)",,KNOWLEDGE OF COVID,"Repercussion of the COVID-19 Pandemic on Physical Activity, Psychological State and Sleep"
NCT04772586,Recruiting,Observational,,Brugmann University Hospital,Other,1-Sep-20,1-Mar-22,1-Mar-22,CASE-ONLY,120,SARCOPENIA,BELGIUM,ALL,"60 Years and older   (Adult, Older Adult)",,INDICATION OF MECHANICAL VENTILATION,Sarcopenia and Mechanical Ventilation in Older Patient Admitted With COVID-19 Infection
NCT04772703,Recruiting,Observational,,University Hospital Hradec Kralove,Other,23-Nov-20,30-Jul-21,28-Feb-21,COHORT,10,COVID,CZECHIA,ALL,"18 Years and older   (Adult, Older Adult)",COMET ASSAY,SINGLE-STRANDED DNA BREAKS,DNA Damage in Critically Ill Patients With SARS-CoV-2 Infection With Organ Failure
NCT04772820,Not yet recruiting,Interventional,Not Applicable,Brigham and Women's Hospital,Other,1-Mar-21,30-Jun-22,1-Dec-21,SUPPORTIVE CARE,60,MALNUTRITION,UNITED STATES,ALL,75 Years and older   (Older Adult),TELEPHONE-BASED COACHING,PHYSICAL ACTIVITY - SELF REPORT,The SOCIAL Study: Feasibility of Remote Home Support Coaches to Decrease the Physical and Psychological Impact of Social Distancing on Older Adults
NCT04772833,Recruiting,Observational,,Maimónides Biomedical Research Institute of Córdoba,Other,5-Jun-20,31-Dec-21,31-Dec-21,COHORT,50,COVID,SPAIN,ALL,"Child, Adult, Older Adult",AUTOPSY,HISTOPATHOLOGICAL AND ULTRA-STRUCTURAL FINDINGS,"Observational, Multicenter, Cross-sectional Study at National Level to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19 in Spain"
NCT04772859,Not yet recruiting,Interventional,Not Applicable,Universidad de Sonora,Other,21-Feb-21,21-Jul-21,21-Feb-21,PREVENTION,54,CHILDHOOD OBESITY,,ALL,9 Years to 12 Years   (Child),ONLINE LIFESTYLE INTERVENTION,CHANGE IN BMI Z-SCORE,Evaluation of a 4-month Online Lifestyle Intervention on the BMI Z-score of Mexican School Children During COVID-19 Pandemic: Randomized Controlled Pilot Trial
NCT04773067,Recruiting,Interventional,Phase 2,"United Biomedical Inc., Asia",Industry,30-Jan-21,30-Jun-22,30-Jun-21,PREVENTION,3850,COVID,TAIWAN,ALL,"12 Years to 85 Years   (Child, Adult, Older Adult)",UB-612,GEOMETRIC MEAN TITER (GMT) OF SARS-COV-2 NEUTRALIZAING ANTIBODY,"A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers"
NCT04773665,Not yet recruiting,Interventional,Phase 1/Phase 2,VBI Vaccines Inc.,Industry,21-Mar-21,22-Jun-21,22-Jun-21,PREVENTION,780,COVID,CANADA,ALL,"18 Years and older   (Adult, Older Adult)",VBI-2902A,RATE AND SEVERITY OF LOCAL AND SYSTEMIC SOLICITED ADVERSE EVENTS,"A Phase 1/2, Randomized, Observer-Blind, Dose-Escalation, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidate (VBI-2902a) in Healthy Adults"
NCT04773756,Completed,Interventional,Phase 4,Alexandria University,Other,1-Nov-20,12-Dec-20,30-Nov-20,TREATMENT,54,COVID,EGYPT,ALL,"12 Years to 90 Years   (Child, Adult, Older Adult)",SOFOSBUVIR 400 MG/ DACLATASVIR 60MG,EVALUATE THE COMBINED EFFECT OF SOFOSBUVIR AND DACLATASVIR IN TREATMENT OF PATIENTS WITH MILD-MODERATE COVID-19.,Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study)
NCT04773899,Not yet recruiting,Interventional,Not Applicable,"University Hospital, Angers",Other,9-Apr-21,9-Jun-22,9-Apr-22,DIAGNOSTIC,75,COVID,,ALL,"18 Years and older   (Adult, Older Adult)",PROCEDURE : MULTIMODAL MICROVASCULAR ASSESSMENT AT STUDY INCLUSION,ENDOTHELIAL FUNCTION MEASURED BY NEAR-INFRARED SPECTROSCOPY (NIRS),L'Étude de la Dysfonction endothéliale Dans la Maladie à COVID-19 Chez Des Patients en Soins Critiques.
NCT04775017,Recruiting,Observational,,"Charite University, Berlin, Germany",Other,1-Jan-21,21-Dec-21,21-Dec-21,COHORT,1000,INTENSIVE CARE UNIT DELIRIUM,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",,INCIDENCE OF DELIRIUM,Delirium in Covid-19: Germany-wide Covid-19 Intensive Register
NCT04775056,Not yet recruiting,Observational,,Humanity & Health Medical Group Limited,Other,15-Mar-21,31-Mar-22,31-Dec-21,COHORT,30000,SUBJECTS RECEIVED COVID VACCINES,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",,IMMUNOGENICITY INDEX-SEROCONVERSION RATES OF NEUTRALIZING ANTIBODY,"A Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of Vaccines Against COVID-19 in the Real World"
NCT04775069,Not yet recruiting,Interventional,Phase 4,Humanity & Health Medical Group Limited,Other,15-Mar-21,31-Mar-22,31-Dec-21,PREVENTION,900,CHRONIC LIVER DISEASE,HONG KONG,ALL,"18 Years and older   (Adult, Older Adult)",BNT162B2,ANTIBODY RESPONSE,"A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines"
NCT04775134,Recruiting,Observational,,Universitaire Ziekenhuizen Leuven,Other,31-Jan-21,31-Jan-22,31-Jan-22,COHORT,75,COVID,BELGIUM,ALL,"18 Years and older   (Adult, Older Adult)",LUNG BIOPSY,REVERSE TRANSCRIPTASE-PCR,Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma
NCT04775407,Recruiting,Interventional,Not Applicable,"Anders Fink-Jensen, MD, DMSci",Other,18-Jan-21,1-Sep-22,1-Mar-22,DIAGNOSTIC,1400,COVID,DENMARK,ALL,"18 Years and older   (Adult, Older Adult)",BLOOD SAMPLING,THE INCIDENCE OF POSITIVE SEROLOGICAL COVID-19 TEST RESULT,"COVID-19 Serological Testing of Patients With a Diagnosis of Schizophrenia, Schizoaffective Disorder or Bipolar Affective Disorder From the Catchment Area of the Capital Region of Denmark"
NCT04775563,Recruiting,Observational,,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",Other,1-Feb-21,1-Oct-21,30-Aug-21,OTHER,740,COVID,MEXICO,ALL,"18 Years To 99 Years   (Adult, Older Adult)",COVID-19 VACCINE HESITANCY SCALE IN RHEUMATIC DISEASES,MEASURE THE PHENOMENON OF VACCINE HESITANCY AMONG RHEUMATIC DISEASES PATIENTS,COVID-19 Vaccine Hesitancy Among Mexican Rheumatic Diseases Patients
NCT04775784,Recruiting,Observational,,IRCCS San Raffaele,Other,17-Dec-20,20-Dec-22,20-Sep-22,COHORT,300,COVID TESTING,ITALY,ALL,"18 Years and older   (Adult, Older Adult)",DETERMINATION OF SARS-COV2 PRESENCE IN CNS,DETERMINATION OF SARS-COV-2 PRESENCE IN THE CNS,Determination of SARS-Cov-2 Virus in Central Nervous System
NCT04775966,Completed,Observational,,"University Hospital, Montpellier",Other,15-Jan-21,15-Feb-21,15-Feb-21,COHORT,8477,SLEEP APNEA SYNDROMES,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",,DIFFERENCE IN POSITIVE AIRWAY PRESSURE(PAP)-ADHERENCE DURING THE FIRST LOCKDOWN VERSUS CORRESPONDING 2019 WEEKS (H/DAYS),CPAP Observance During the COVID 19 Pandemic
NCT04776005,Not yet recruiting,Observational,,Assistance Publique - Hôpitaux de Paris,Other,21-Mar-21,22-Dec-21,22-Sep-21,COHORT,500,SOLID TUMOR,FRANCE,ALL,"18 Years and older   (Adult, Older Adult)",DATA COLLECTION,SARS-COV-2 VACCINE RESPONSE AT 12 MONTHS,"Multicenter, Observational Study of Anti-Sars-Cov2 Vaccine Efficacy in Patients With Malignant Pathologies Treated in the University Hospitals of AP-HP. Nord"
NCT04776044,Not yet recruiting,Interventional,Phase 2,Atriva Therapeutics GmbH,Industry,21-Mar-21,22-Mar-21,21-Dec-21,TREATMENT,220,COVID,GERMANY,ALL,"18 Years and older   (Adult, Older Adult)",ATR-002,CLINICAL SEVERITY STATUS ON A 7-POINT ORDINAL SCALE,"RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19"
NCT04776174,Not yet recruiting,Interventional,Not Applicable,Centre Hospitalier Intercommunal Creteil,Other,1-Mar-21,22-Jan-21,30-Oct-21,DIAGNOSTIC,40,COVID,,ALL,1 Year To 10 Years    (Child),ULTRASOUND USING THE TELEROBOTIC MELODY SYSTEM,NUMBER OF NORMAL AND ABNORMAL STANDARD AND TELEROBOTIC ULTRASOUND EXAMINATIONS,Crossover Comparison of the Efficacy and Tolerance of Telerobotic vs Standard Ultrasound Exam in Children
NCT04776317,Not yet recruiting,Interventional,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NIH,15-Mar-21,19-Sep-22,19-Sep-22,PREVENTION,130,COVID,UNITED STATES,ALL,"18 Years To 99 Years   (Adult, Older Adult)",CHADV68-S,FREQUENCY BY GRADE OF SOLICITED LOCAL REACTOGENICITY ADVERSE EVENTS (AES),"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults"
